{"meta":{"query_hash":"072571263395","filters":{"topic":"Advanced Breast Cancer Therapies"},"cohort_total":898,"direct_labels_cover":3,"predictions_cover":898,"exported":898,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/072571263395","api":"https://metacan.xera.ac/api/v1/cohort?topic=Advanced+Breast+Cancer+Therapies"},"results":[{"id":"W1464936406","doi":"10.1056/nejmoa1505270","title":"Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1586,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Fulvestrant; Palbociclib; Medicine; Internal medicine; Oncology; Breast cancer; Hazard ratio; Exemestane; Clinical endpoint; Neutropenia; Placebo; Cancer; Metastatic breast cancer; Clinical trial; Estrogen receptor; Confidence interval; Chemotherapy; Tamoxifen; Pathology","score_opus":0.01997212785007568,"score_gpt":0.31165148999418874,"score_spread":0.29167936214411305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1464936406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91929716,0.024866242,0.0009521561,0.051789504,0.0014034068,0.00029061505,0.000018890045,0.000028293292,0.0013537516],"genre_scores_gemma":[0.9890461,0.0012549615,0.0015085726,0.0014679994,0.0061086533,0.0000048085344,0.000007000406,0.000038072892,0.00056383805],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981056,0.000082433755,0.000636236,0.00017522585,0.0006857328,0.00031478517],"domain_scores_gemma":[0.9981199,0.00012340935,0.0003827993,0.0001706558,0.0005168239,0.0006864169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067184056,0.00022217665,0.00075138285,0.00028097944,0.000021984835,0.0000052583514,0.00013994484,0.000077751734,0.00024538962],"category_scores_gemma":[0.00022930863,0.0001471731,0.00007247949,0.00037737627,0.0001554161,0.0002570841,0.000021285437,0.00055162347,0.000008279507],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020430107,0.00016789256,0.031466927,0.000030854255,0.00022682396,0.00059479417,0.006825725,0.0004662494,0.029050795,0.00009651361,0.007599422,0.90304387],"study_design_scores_gemma":[0.50852937,0.007221652,0.26907587,0.004791268,0.00047371624,0.013611411,0.0051153153,0.00009457081,0.0028999653,0.0031846114,0.18439244,0.0006098035],"about_ca_topic_score_codex":0.00025250425,"about_ca_topic_score_gemma":0.0000857758,"teacher_disagreement_score":0.9024341,"about_ca_system_score_codex":0.00039674118,"about_ca_system_score_gemma":0.000586676,"threshold_uncertainty_score":0.60015446},"labels":[],"label_agreement":null},{"id":"W1506161303","doi":"10.1158/1538-7445.sabcs14-p4-01-12","title":"Abstract P4-01-12: Circulating tumor cells (CTC) and endothelial cells (CEC) changes in HER2 negative metastatic breast cancer (MBC) patients treated with first line weekly paclitaxel and bevacizumab: Preliminary results of a prospective cohort from the French Breast Cancer","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre d'expertise et de recherche en infrastructures urbaines","funders":"","keywords":"Medicine; Bevacizumab; Internal medicine; Circulating tumor cell; Metastatic breast cancer; Oncology; Cancer; Prospective cohort study; Cohort; Breast cancer; Gastroenterology; Chemotherapy; Metastasis","score_opus":0.04347094340345074,"score_gpt":0.32966811734128276,"score_spread":0.286197173937832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1506161303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766154,0.0028525828,0.000005323433,0.002510928,0.00010754163,0.0032791623,0.014449224,0.00004019457,0.00013959063],"genre_scores_gemma":[0.9960077,0.0012571798,0.00020632266,0.00010171302,0.0003809777,0.0016631756,0.00007143079,0.0001133172,0.00019823108],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958078,0.0002929138,0.00063137774,0.0010771616,0.001296182,0.0008945508],"domain_scores_gemma":[0.9964235,0.00086254545,0.0004363396,0.00056356826,0.0012787061,0.00043533408],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00074824126,0.00052057486,0.0009335074,0.0002713002,0.00023502066,0.000067968955,0.0002694904,0.000114440154,0.00018722127],"category_scores_gemma":[0.00015256749,0.00035319882,0.000057798017,0.00081017637,0.0010990249,0.00030916673,0.00020250815,0.0008760336,0.000002971088],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043964107,0.0010603823,0.8752999,0.0008683296,0.0013858055,0.00023925104,0.02098086,0.00086976093,0.025993615,0.000004044938,0.00066381786,0.028670156],"study_design_scores_gemma":[0.016240964,0.0014559777,0.950964,0.0030325123,0.00023725344,0.000049355727,0.0024271978,0.00022407576,0.02471776,0.00012535475,0.00013171599,0.00039384209],"about_ca_topic_score_codex":0.20295706,"about_ca_topic_score_gemma":0.08670198,"teacher_disagreement_score":0.11625508,"about_ca_system_score_codex":0.001418132,"about_ca_system_score_gemma":0.0011002442,"threshold_uncertainty_score":0.999892},"labels":[],"label_agreement":null},{"id":"W1516639348","doi":"10.1158/1538-7445.sabcs14-s6-04","title":"Abstract S6-04: Fulvestrant 500 mg versus anastrozole as first-line treatment for advanced breast cancer: Overall survival from the Phase II ‘FIRST’ study","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Fulvestrant; Anastrozole; Medicine; Hazard ratio; Internal medicine; Clinical endpoint; Metastatic breast cancer; Oncology; Breast cancer; Phases of clinical research; Cancer; Confidence interval; Tamoxifen; Randomized controlled trial; Clinical trial","score_opus":0.19792366326965274,"score_gpt":0.4825408365740193,"score_spread":0.28461717330436653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1516639348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9669524,0.00575466,0.00008393194,0.018990139,0.0011907225,0.004205298,0.002449838,0.00012796043,0.0002450562],"genre_scores_gemma":[0.99054044,0.001483498,0.00016632256,0.00020362154,0.002480222,0.0037633658,0.00018344028,0.00014201886,0.0010370534],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99537706,0.00014557596,0.00055726035,0.0010447609,0.0015512054,0.001324122],"domain_scores_gemma":[0.9960897,0.00083226396,0.0001779851,0.0011865714,0.00094528665,0.000768225],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00078860525,0.0005482918,0.0008196499,0.00015757066,0.0008155288,0.00008781837,0.0005850175,0.00013435118,0.00093482697],"category_scores_gemma":[0.00016670652,0.00038294692,0.0002341526,0.0005106236,0.000408856,0.00047365765,0.00018189961,0.0006485844,0.000047681366],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29995108,0.013885095,0.014606713,0.00027113297,0.004843694,0.0004956904,0.015615872,0.0095262015,0.017667612,0.0002446168,0.0053586396,0.6175336],"study_design_scores_gemma":[0.32766333,0.045826964,0.07309281,0.0012804263,0.0009770858,0.00005562262,0.02059683,0.00054513646,0.011352847,0.0011132292,0.51586205,0.0016336472],"about_ca_topic_score_codex":0.025401779,"about_ca_topic_score_gemma":0.018889831,"teacher_disagreement_score":0.6159,"about_ca_system_score_codex":0.003031794,"about_ca_system_score_gemma":0.0019874019,"threshold_uncertainty_score":0.9999785},"labels":[],"label_agreement":null},{"id":"W1538330154","doi":"10.1158/1538-7445.sabcs14-ot3-1-06","title":"Abstract OT3-1-06: A phase 2 single-arm study to evaluate the clinical activity, safety and tolerability of enzalutamide (ENZA) with trastuzumab in patients with advanced human growth factor receptor 2 (HER2)-positive breast cancer","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Tolerability; Medicine; Enzalutamide; Oncology; Internal medicine; Clinical endpoint; Metastatic breast cancer; Cancer; Breast cancer; Clinical trial; Androgen receptor; Adverse effect; Prostate cancer","score_opus":0.11846389618430828,"score_gpt":0.46990363913841154,"score_spread":0.3514397429541033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1538330154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928631,0.0002896975,0.000038684226,0.0011925345,0.00007620041,0.004762527,0.0006457721,0.00003485335,0.000096594624],"genre_scores_gemma":[0.9988544,0.00004375173,0.00012310848,0.00010133918,0.00016314475,0.00056510203,0.000018395012,0.000084276835,0.000046500365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99476796,0.00078644574,0.0007085804,0.0010115699,0.0019303022,0.00079511123],"domain_scores_gemma":[0.99569976,0.00051982293,0.00022399152,0.00072404975,0.0022378522,0.0005945475],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020606187,0.0004077154,0.0010141168,0.00024354736,0.00020563442,0.00004394233,0.00034224856,0.00009705918,0.00023373569],"category_scores_gemma":[0.00025499417,0.00025284674,0.0000665676,0.0009807236,0.00095173466,0.00038053512,0.00019791501,0.0011476915,0.000004263567],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.103802085,0.012971005,0.72764856,0.00015724186,0.0004834588,0.000018851235,0.008669234,0.00014106423,0.006717322,0.000006033107,0.000051278803,0.13933389],"study_design_scores_gemma":[0.027866965,0.016043477,0.94856507,0.0007108848,0.00007597226,0.000004544898,0.0024875687,0.000005580057,0.0037648685,0.00003135161,0.00014259992,0.00030113687],"about_ca_topic_score_codex":0.0028441611,"about_ca_topic_score_gemma":0.0049385987,"teacher_disagreement_score":0.22091652,"about_ca_system_score_codex":0.0021567165,"about_ca_system_score_gemma":0.0013279646,"threshold_uncertainty_score":0.9999924},"labels":[],"label_agreement":null},{"id":"W1558355135","doi":"10.1002/cncr.28010","title":"Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trial","year":2013,"lang":"en","type":"article","venue":"Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Cambridge Memorial Hospital","funders":"National Cancer Institute; Sanofi; Celgene; AstraZeneca; Chugai Pharmaceutical; Amgen; Pfizer; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Medicine; Exemestane; Everolimus; Breast cancer; Internal medicine; Quality of life (healthcare); Placebo; Discontinuation; Oncology; Hazard ratio; Clinical endpoint; Randomized controlled trial; Aromatase inhibitor; Cancer; Gynecology; Confidence interval; Tamoxifen; Pathology","score_opus":0.020378568400534335,"score_gpt":0.32305479761711253,"score_spread":0.3026762292165782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1558355135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756876,0.0071183774,0.00015556536,0.0019103126,0.00032945818,0.014164103,0.0003590973,0.00006433075,0.00021115124],"genre_scores_gemma":[0.9931617,0.0007479032,0.00020783607,0.0004826764,0.00012108634,0.00488855,0.00009903063,0.00008871853,0.00020253341],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948435,0.0007858044,0.001959938,0.00060323835,0.0011014676,0.000706083],"domain_scores_gemma":[0.9949683,0.0010053581,0.0020155762,0.0007468846,0.0009558858,0.00030802426],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009022833,0.0005987433,0.0042617084,0.00021500004,0.000089040026,0.000016728794,0.00028834434,0.00016335852,0.0006801174],"category_scores_gemma":[0.00025074364,0.0003277659,0.00029462037,0.00079847977,0.00076957844,0.000318853,0.00003102625,0.00045314746,0.0000029453165],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9749988,0.0008079759,0.002267929,0.0002862708,0.0013425515,0.00000810393,0.0017683479,0.0021732259,0.00011537971,0.000048865433,0.00006404693,0.016118556],"study_design_scores_gemma":[0.980668,0.0025174469,0.013511142,0.00082005764,0.0005086347,0.0000073915435,0.0009953533,0.00044303635,0.000069037655,0.00001857325,0.000084474916,0.00035684224],"about_ca_topic_score_codex":0.0098994635,"about_ca_topic_score_gemma":0.0012755153,"teacher_disagreement_score":0.01747406,"about_ca_system_score_codex":0.0010506966,"about_ca_system_score_gemma":0.0020972476,"threshold_uncertainty_score":0.99991745},"labels":[],"label_agreement":null},{"id":"W1563433484","doi":"10.1158/1538-7445.sabcs14-s2-03","title":"Abstract S2-03: Preoperative window of opportunity study of the PI3K inhibitor pictilisib (GDC-0941) plus anastrozole vs anastrozole alone in patients with ER+, HER2-negative operable breast cancer (OPPORTUNE study)","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Anastrozole; Medicine; Clinical endpoint; Breast cancer; Internal medicine; Oncology; Aromatase inhibitor; Population; PTEN; Cancer; PI3K/AKT/mTOR pathway; Aromatase; Clinical trial; Apoptosis; Biology","score_opus":0.08048488932397262,"score_gpt":0.3796009434621001,"score_spread":0.2991160541381275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1563433484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99212843,0.00020367371,0.0000041955263,0.00085950067,0.00018722977,0.005789906,0.0004655711,0.00002765304,0.00033381267],"genre_scores_gemma":[0.9978823,0.000029248638,0.000058729016,0.000093592644,0.0001917158,0.0010464278,0.00001791401,0.00009167683,0.0005883751],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940134,0.0006916618,0.00090550934,0.0008339037,0.002631456,0.00092406373],"domain_scores_gemma":[0.9943984,0.0001534338,0.00043131088,0.0011369488,0.0032693467,0.0006105192],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013833287,0.00046956033,0.0011714606,0.00041985864,0.0002166694,0.000036680365,0.00063288445,0.00011679732,0.0004882816],"category_scores_gemma":[0.0002125373,0.00031757876,0.000087185945,0.001777373,0.0008107105,0.0005680986,0.0004146736,0.0013399877,0.000004357222],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018134661,0.0062054847,0.946979,0.00017295305,0.0005854211,0.000048003145,0.018804185,0.003543704,0.0008668035,0.0000024275223,0.0004187262,0.004238634],"study_design_scores_gemma":[0.023602864,0.005019256,0.91818357,0.0007648626,0.000089438705,0.000004280038,0.046020497,0.000031086558,0.0059251823,0.000009555364,0.00009057825,0.00025885238],"about_ca_topic_score_codex":0.03396218,"about_ca_topic_score_gemma":0.016997142,"teacher_disagreement_score":0.028795449,"about_ca_system_score_codex":0.0017890893,"about_ca_system_score_gemma":0.0043101846,"threshold_uncertainty_score":0.99992764},"labels":[],"label_agreement":null},{"id":"W1619197792","doi":"10.1096/fasebj.28.1_supplement.972.2","title":"Fluorescent biosensors for probing CDK4/cyclin D activity and developing non‐ATP pocket Inhibitors for melanoma, lung cancer and lymphoma (972.2)","year":2014,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Division of Arctic Sciences; CNIB","keywords":"Kinase; Cancer research; Biosensor; Anaplastic lymphoma kinase; Melanoma; Chemistry; Lung cancer; Biology; Biochemistry; Medicine; Oncology","score_opus":0.015913775216802952,"score_gpt":0.2909827353572502,"score_spread":0.2750689601404473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1619197792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683896,0.0016465277,0.023223184,0.005393326,0.00036995055,0.0009175386,0.000020858413,0.00002638253,0.000012647735],"genre_scores_gemma":[0.9886744,0.00022912615,0.009036417,0.00071087887,0.0010760552,0.00009824664,0.0000029099112,0.0000521265,0.00011980916],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988527,0.00004690463,0.00026662802,0.0002458945,0.00017853835,0.00040931476],"domain_scores_gemma":[0.99903667,0.00025967986,0.00024139025,0.00014902395,0.00014407374,0.00016918487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057507213,0.00022362445,0.00035798864,0.00009723866,0.0005035666,0.00006485798,0.000086486085,0.000076537435,0.000004967661],"category_scores_gemma":[0.00011012295,0.00014869338,0.00008807255,0.00008597708,0.00014090355,0.00016213808,0.000046100733,0.00016852828,2.2568456e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026099954,0.000060736988,0.009512924,0.00050446484,0.00038015033,0.000006908846,0.0030446423,0.00004900664,0.4679066,0.0001445167,0.0002347472,0.5155453],"study_design_scores_gemma":[0.015822655,0.00061472185,0.041593745,0.001941577,0.0005279143,0.0013707554,0.0010112436,0.011213429,0.91473705,0.0009117107,0.009629784,0.0006254247],"about_ca_topic_score_codex":0.000028611677,"about_ca_topic_score_gemma":0.000025584079,"teacher_disagreement_score":0.5149199,"about_ca_system_score_codex":0.0002686741,"about_ca_system_score_gemma":0.00018726356,"threshold_uncertainty_score":0.606354},"labels":[],"label_agreement":null},{"id":"W1647473915","doi":"10.1158/1538-7445.sabcs14-p2-09-01","title":"Abstract P2-09-01: MBC alliance: Coordinating metastatic research from lab bench to clinical trials","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Alliance; Clinical trial; Metastatic breast cancer; Medicine; General partnership; Translational research; Breast cancer; Family medicine; Cancer; Political science; Business; Internal medicine; Pathology; Finance","score_opus":0.7263462525258191,"score_gpt":0.6603201260117515,"score_spread":0.06602612651406758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1647473915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94537646,0.01671634,0.0006522832,0.026668271,0.001396635,0.003995407,0.00036263504,0.00017860637,0.004653382],"genre_scores_gemma":[0.977847,0.0010192228,0.008155072,0.00088277005,0.004752304,0.0015863235,0.00007365438,0.00017612854,0.0055075306],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.987753,0.0036838353,0.0015917155,0.0012765698,0.0039132135,0.0017816955],"domain_scores_gemma":[0.98482746,0.00826671,0.00023386131,0.0013290159,0.0034938352,0.0018491152],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","insufficient_payload"],"category_scores_codex":[0.047249004,0.0003371663,0.0014970797,0.00051307137,0.00035436387,0.00018394303,0.0008402082,0.00023658789,0.0026171925],"category_scores_gemma":[0.02619841,0.0002802993,0.00025620582,0.0021087932,0.00081483327,0.00031689843,0.00050565676,0.0030343153,0.0013325568],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012009952,0.00095328887,0.016626203,0.00042347584,0.001214318,0.0007272527,0.0043383488,0.00027150696,0.06518497,0.0005192628,0.14148292,0.7562485],"study_design_scores_gemma":[0.02424858,0.003628984,0.061276384,0.0033878998,0.00023235021,0.00004176137,0.015758092,0.0002897585,0.04785792,0.020042414,0.8220126,0.0012232317],"about_ca_topic_score_codex":0.0046668835,"about_ca_topic_score_gemma":0.00055789837,"teacher_disagreement_score":0.75502527,"about_ca_system_score_codex":0.0016720549,"about_ca_system_score_gemma":0.003485088,"threshold_uncertainty_score":0.9999649},"labels":[],"label_agreement":null},{"id":"W1933865299","doi":"10.1158/1538-7445.sabcs14-s6-03","title":"Abstract S6-03: Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: A New York cancer consortium trial","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Fulvestrant; Medicine; Internal medicine; Metastatic breast cancer; Cancer; Breast cancer; Oncology; Estrogen receptor; Bortezomib; Clinical endpoint; Progression-free survival; Randomized controlled trial; Chemotherapy; Multiple myeloma","score_opus":0.09604018843932562,"score_gpt":0.4197523491040481,"score_spread":0.32371216066472247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1933865299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97140336,0.0067227497,0.000059244336,0.0088808825,0.00043517607,0.011121683,0.0012631393,0.000044333236,0.00006943496],"genre_scores_gemma":[0.9906082,0.00092268974,0.00063812104,0.00019034978,0.0008158382,0.006028437,0.00013867144,0.00010815645,0.0005495473],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99361235,0.0008460599,0.0015984898,0.00088808074,0.0020208578,0.0010341712],"domain_scores_gemma":[0.99630916,0.0007930686,0.00051208277,0.0005897427,0.0009532419,0.00084272487],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0038940918,0.0004849357,0.0021523186,0.0010599953,0.000109716304,0.00005170021,0.00031157956,0.0001659784,0.0004862427],"category_scores_gemma":[0.0007857559,0.000355501,0.00015919327,0.0024169413,0.00070898735,0.00044334398,0.00009657615,0.00094762247,0.000009501242],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93694395,0.0030239287,0.000037062673,0.00016919163,0.0004610344,0.00021232365,0.0035208643,0.000261794,0.036851108,0.000039662606,0.004089758,0.014389328],"study_design_scores_gemma":[0.9690336,0.00926738,0.0005276885,0.0027459306,0.00020375047,0.00001925436,0.0017366438,0.000038294696,0.014559901,0.0001460813,0.0013075332,0.00041396663],"about_ca_topic_score_codex":0.0494237,"about_ca_topic_score_gemma":0.012798494,"teacher_disagreement_score":0.036625206,"about_ca_system_score_codex":0.0027059028,"about_ca_system_score_gemma":0.008336491,"threshold_uncertainty_score":0.9998897},"labels":[],"label_agreement":null},{"id":"W1966051563","doi":"10.1093/annonc/mdu165.112","title":"Standard Clinical Practice of Folfirinox in Advanced/Metastatic Pancreatic Cancer (Pc) Patients: A Canadian Registry","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Windsor Regional Hospital; Sunnybrook Health Science Centre; Ottawa Hospital","funders":"","keywords":"Medicine; FOLFIRINOX; Gemcitabine; Regimen; Internal medicine; Population; Performance status; Pancreatic cancer; Surgery; Cancer; Irinotecan","score_opus":0.06692371531196874,"score_gpt":0.4597018881989226,"score_spread":0.3927781728869539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966051563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97173744,0.002205025,0.00030522494,0.010674815,0.00037456205,0.0006259355,0.00012332769,0.000016665508,0.013936974],"genre_scores_gemma":[0.98428315,0.0011004743,0.0090355035,0.0052474122,0.00009342885,0.000061742445,0.00001636571,0.000028410961,0.00013349747],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99776816,0.0003084601,0.00093637087,0.00029858074,0.00027627722,0.00041212948],"domain_scores_gemma":[0.9967637,0.0010002445,0.00069117855,0.00042952842,0.00083913474,0.00027622143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092860224,0.00016243232,0.0009900978,0.00020205959,0.000023172144,0.0000022421323,0.00014848306,0.0001339113,0.00011935008],"category_scores_gemma":[0.0036443085,0.00015011558,0.000112554706,0.0002775623,0.00031097172,0.00016152106,0.000030409703,0.00029885775,0.0000054456054],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048144525,0.0007269983,0.22266549,0.00028520654,0.00028324605,0.000059840684,0.0004670216,0.00012635555,0.00010096646,0.0006139491,0.0015000615,0.7683564],"study_design_scores_gemma":[0.0096394615,0.009873881,0.22552782,0.0006734664,0.00022417816,0.000040856496,0.00065076636,0.00004685585,0.0008325824,0.0016363114,0.75061977,0.00023405832],"about_ca_topic_score_codex":0.01661333,"about_ca_topic_score_gemma":0.030338628,"teacher_disagreement_score":0.7681224,"about_ca_system_score_codex":0.00022745469,"about_ca_system_score_gemma":0.0014930243,"threshold_uncertainty_score":0.9899351},"labels":[],"label_agreement":null},{"id":"W1969593381","doi":"10.1158/0008-5472.sabcs-705","title":"A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy.","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Breast cancer; Internal medicine; Oncology; Medicine; Anthracycline; Interim analysis; Cancer; Estrogen receptor; Clinical trial","score_opus":0.23614154314008903,"score_gpt":0.5082386485427101,"score_spread":0.272097105402621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969593381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98348993,0.010726906,0.00006307365,0.002176883,0.00002121969,0.0025033012,0.0009800646,0.000018372193,0.000020236195],"genre_scores_gemma":[0.9975132,0.0008588859,0.00012873442,0.00024419712,0.00006943756,0.0008610078,0.00003620618,0.0000358885,0.0002524945],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9950574,0.0012443408,0.0010450968,0.0005968033,0.0015294459,0.0005269211],"domain_scores_gemma":[0.9960226,0.0011086488,0.0005848133,0.00060425024,0.0015044103,0.0001752664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032076666,0.00032143036,0.002367101,0.0007716664,0.00015501777,0.000019306874,0.000241891,0.00009604525,0.00070273277],"category_scores_gemma":[0.00027276317,0.00015980103,0.0003985969,0.0029794823,0.000614729,0.00018448949,0.00004405151,0.00044500045,2.0411231e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32044944,0.006253886,0.08359875,0.00020283219,0.12580927,0.00005528335,0.013216435,0.008139691,0.103550166,0.000022059688,0.000052212552,0.33865],"study_design_scores_gemma":[0.138456,0.038710102,0.5918273,0.0009861408,0.10765092,0.000011286033,0.0017467764,0.017349664,0.10221215,0.00014536004,0.00012355612,0.0007807556],"about_ca_topic_score_codex":0.008197206,"about_ca_topic_score_gemma":0.0006944039,"teacher_disagreement_score":0.50822854,"about_ca_system_score_codex":0.0003888959,"about_ca_system_score_gemma":0.0011948685,"threshold_uncertainty_score":0.9984073},"labels":[],"label_agreement":null},{"id":"W1977694976","doi":"10.1185/03007995.2013.836078","title":"Health-related quality of life and disease symptoms in postmenopausal women with HR<sup>+</sup>, HER2<sup>−</sup>advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy","year":2013,"lang":"en","type":"article","venue":"Current Medical Research and Opinion","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Sunnybrook Health Science Centre; University of Toronto","funders":"European Society for Medical Oncology; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Exemestane; Discontinuation; Internal medicine; Breast cancer; Quality of life (healthcare); Placebo; Confidence interval; Aromatase inhibitor; Hazard ratio; Oncology; Cancer; Aromatase","score_opus":0.04616009174512354,"score_gpt":0.38911583257544025,"score_spread":0.3429557408303167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977694976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96490365,0.02315901,0.0000878684,0.0095363185,0.00007043043,0.0020046455,0.00014025738,0.0000753813,0.000022443344],"genre_scores_gemma":[0.9839678,0.014505247,0.00010067845,0.00021432825,0.00016451396,0.0007404685,0.00016306776,0.0000763113,0.00006758552],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9942485,0.00054129737,0.00086874823,0.00088323187,0.002143086,0.0013151207],"domain_scores_gemma":[0.99492234,0.000593586,0.00023292302,0.0005159455,0.0005684496,0.003166772],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010587248,0.00046007056,0.0011416029,0.00036454346,0.00017477239,0.0000416088,0.0002233853,0.00017114448,0.0005079255],"category_scores_gemma":[0.00045965106,0.00031647866,0.0000363794,0.0009217344,0.0013646664,0.00038357385,0.00011427269,0.0010494099,0.0000057254497],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15906431,0.0016688114,0.091959104,0.0022633632,0.00053563307,0.00008261343,0.004328646,0.00043825147,0.00010549658,0.00027775092,0.0002398226,0.7390362],"study_design_scores_gemma":[0.12066018,0.019978782,0.82193995,0.009521037,0.00005086361,0.00016256218,0.0061669266,0.01587536,0.000025980064,0.00078739197,0.0036099765,0.0012209994],"about_ca_topic_score_codex":0.0026803939,"about_ca_topic_score_gemma":0.00008361019,"teacher_disagreement_score":0.7378152,"about_ca_system_score_codex":0.0008861318,"about_ca_system_score_gemma":0.002743139,"threshold_uncertainty_score":0.9999287},"labels":[],"label_agreement":null},{"id":"W1978882188","doi":"10.1158/0008-5472.sabcs-09-47","title":"CIRG/TORI 010: 10-Month Analysis of a Randomized Phase II Trial of Motesanib Plus Weekly Paclitaxel as First Line Therapy in HER2-Negative Metastatic Breast Cancer (MBC).","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Medicine; Metastatic breast cancer; Internal medicine; Placebo; Breast cancer; Gastroenterology; Surgery; Urology; Cancer; Pathology","score_opus":0.07820365543155519,"score_gpt":0.4614026070120939,"score_spread":0.38319895158053874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978882188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97333235,0.010296633,0.00036939656,0.009751879,0.00016448187,0.0048087775,0.0007460802,0.000043639953,0.00048678034],"genre_scores_gemma":[0.98848754,0.00746448,0.00037418632,0.00020925957,0.00041147904,0.001281475,0.00005156684,0.00005975406,0.0016602734],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9942613,0.00090820604,0.001393618,0.0007611898,0.0018070036,0.0008686429],"domain_scores_gemma":[0.99532944,0.0012671117,0.0005776515,0.00086714095,0.0016372512,0.00032142582],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029758636,0.00043376046,0.0032353417,0.0016298734,0.00015970255,0.00002323349,0.00043133958,0.00015353071,0.003783912],"category_scores_gemma":[0.0010193518,0.00033778948,0.0007442036,0.004686898,0.000948242,0.00023090067,0.000080435886,0.00072697573,0.000004903433],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.880442,0.002992902,0.00009156089,0.00014429943,0.0050259577,0.00004993098,0.0049411664,0.0016391453,0.010820803,0.00012773216,0.0001624072,0.09356206],"study_design_scores_gemma":[0.9641602,0.00877448,0.0017088932,0.00084433594,0.0015282051,0.000007885701,0.00108313,0.0024378889,0.01613283,0.0019494515,0.0009785609,0.00039415987],"about_ca_topic_score_codex":0.017513787,"about_ca_topic_score_gemma":0.002475323,"teacher_disagreement_score":0.0931679,"about_ca_system_score_codex":0.0012760779,"about_ca_system_score_gemma":0.0017311949,"threshold_uncertainty_score":0.99990743},"labels":[],"label_agreement":null},{"id":"W1982234365","doi":"10.1007/s10549-013-2814-5","title":"Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2","year":2013,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute","keywords":"Exemestane; Everolimus; Medicine; Hazard ratio; Breast cancer; Aromatase inhibitor; Internal medicine; Oncology; Clinical endpoint; Cancer; Discontinuation; Randomized controlled trial; Aromatase; Confidence interval","score_opus":0.04306472712332436,"score_gpt":0.37923311203474724,"score_spread":0.33616838491142287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982234365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9582352,0.017123027,0.000005770353,0.020751903,0.00012053884,0.0029264921,0.00031956992,0.00007970315,0.0004377954],"genre_scores_gemma":[0.9519284,0.039322812,0.000120286386,0.00036523968,0.00031596282,0.005701724,0.000030822244,0.00010306595,0.0021116848],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9960511,0.00013699649,0.0005227815,0.0009925616,0.0008387579,0.0014578489],"domain_scores_gemma":[0.9980678,0.00015138976,0.000101921345,0.0006216341,0.0004464838,0.0006108033],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002437991,0.0005544001,0.0008547506,0.0005607702,0.00018647916,0.00007703256,0.00020763592,0.0001722094,0.0026984208],"category_scores_gemma":[0.000013207205,0.00041958116,0.000103894,0.0010105869,0.00040007354,0.00045828888,0.000101367434,0.0005294255,0.00008859225],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01259774,0.0014234479,0.12633033,0.00010074438,0.0002642671,0.0003860451,0.0011002474,0.00041914516,0.002371127,0.00006846062,0.00006158234,0.8548769],"study_design_scores_gemma":[0.029489515,0.0021968368,0.9574912,0.0011834204,0.000025187666,0.00076018396,0.00077221193,0.0003588604,0.0015442495,0.0010404993,0.004639955,0.0004978422],"about_ca_topic_score_codex":0.07359025,"about_ca_topic_score_gemma":0.019564226,"teacher_disagreement_score":0.854379,"about_ca_system_score_codex":0.0037585446,"about_ca_system_score_gemma":0.0010310241,"threshold_uncertainty_score":0.9998256},"labels":[],"label_agreement":null},{"id":"W1984252859","doi":"10.1158/0008-5472.sabcs13-p6-10-03","title":"Abstract P6-10-03: Comparative efficacy of everolimus in combination with exemestane and chemotherapy for advanced breast cancer in terms of progression-free survival","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Everolimus; Medicine; Exemestane; Oncology; Internal medicine; Breast cancer; Randomized controlled trial; Progression-free survival; Hazard ratio; Cancer; Meta-analysis; Chemotherapy; Tamoxifen; Confidence interval","score_opus":0.05116332335270693,"score_gpt":0.4282500882082477,"score_spread":0.3770867648555408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984252859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99376774,0.0010412065,0.00002957952,0.0020716,0.00003718182,0.002734405,0.00009498917,0.000012696334,0.0002105792],"genre_scores_gemma":[0.9973083,0.00040986604,0.0006614352,0.000026169708,0.000043903197,0.001355826,0.0000124641365,0.000036675618,0.00014535812],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99812776,0.000069191934,0.0003886645,0.00036467172,0.00061635056,0.00043336596],"domain_scores_gemma":[0.99840057,0.0003625103,0.00017530634,0.00034332252,0.00061003916,0.000108238826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041892135,0.00018144851,0.0005878524,0.00031799026,0.00003646637,0.000011313275,0.00019213412,0.00007823402,0.0003403419],"category_scores_gemma":[0.000046439498,0.0001373683,0.000034441182,0.00056112575,0.00050435157,0.0002474471,0.000049178427,0.00029266722,9.354739e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036769457,0.0016211127,0.2395188,0.0017515251,0.00020182751,0.00001219621,0.0058205584,0.00044734537,0.23519146,0.00019114956,0.00017006985,0.47830448],"study_design_scores_gemma":[0.022462567,0.00078064075,0.94156325,0.002100148,0.000008291883,0.0000058247583,0.0005788158,0.00017022592,0.03137996,0.0006695316,0.00013256194,0.00014816076],"about_ca_topic_score_codex":0.0012175618,"about_ca_topic_score_gemma":0.0010473174,"teacher_disagreement_score":0.7020444,"about_ca_system_score_codex":0.000348469,"about_ca_system_score_gemma":0.00027390532,"threshold_uncertainty_score":0.5601717},"labels":[],"label_agreement":null},{"id":"W1995407080","doi":"10.1158/1538-7445.am10-22","title":"Abstract 22: Cyclin E amplification, a novel mechanism of resistance to trastuzumab in HER2 amplified breast cancer","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Manitoba","funders":"","keywords":"Trastuzumab; Cancer research; Breast cancer; Biology; Cyclin-dependent kinase; Medicine; Cancer; Oncology; Molecular biology; Cell cycle; Internal medicine","score_opus":0.0666644245371635,"score_gpt":0.41886504942162406,"score_spread":0.3522006248844606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995407080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863596,0.00064676895,0.0015064032,0.008026312,0.00035551592,0.0014835312,0.0005088543,0.00006546903,0.0010475247],"genre_scores_gemma":[0.99448353,0.00017686772,0.0018572137,0.00030102322,0.00044069576,0.0012426354,0.000013073596,0.000085103784,0.0013998367],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9967086,0.00004934668,0.0006004645,0.00073533657,0.0010717657,0.00083449465],"domain_scores_gemma":[0.99732894,0.00017196866,0.00014404596,0.0009013746,0.0010662072,0.0003874552],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010460608,0.00025217002,0.0005286654,0.000566368,0.00011821261,0.000031136515,0.0004736572,0.00019167659,0.0018266954],"category_scores_gemma":[0.00019731914,0.00023944168,0.00007625419,0.0014560117,0.00032212536,0.0001645255,0.000091247144,0.0012262912,0.000039836938],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023875826,0.0003436419,0.0028029478,0.0002893816,0.000060415587,0.000015314732,0.0009913512,0.000055425495,0.9705885,0.0050437483,0.00052353257,0.016898176],"study_design_scores_gemma":[0.005646467,0.0001711697,0.71887404,0.0016549242,0.000033744815,0.000055951237,0.0012449268,0.000028011425,0.24628897,0.004435396,0.02097319,0.00059324043],"about_ca_topic_score_codex":0.0037221112,"about_ca_topic_score_gemma":0.013557258,"teacher_disagreement_score":0.7242995,"about_ca_system_score_codex":0.00075405824,"about_ca_system_score_gemma":0.0012369673,"threshold_uncertainty_score":0.9990858},"labels":[],"label_agreement":null},{"id":"W1996349796","doi":"10.1158/1538-7445.am10-3487","title":"Abstract 3487: Synergy with combined inhibition of upstream EGFR-HER2 and downstream RAF-MEK nodes in breast cancer cells with activating RAS and RAF mutations","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Lapatinib; MAPK/ERK pathway; Cancer research; MEK inhibitor; Epidermal growth factor receptor; EGFR inhibitors; Kinase; Receptor tyrosine kinase; Chemistry; Cancer; Biology; Medicine; Breast cancer; Cell biology; Internal medicine; Trastuzumab","score_opus":0.019074516940063083,"score_gpt":0.340723013421331,"score_spread":0.3216484964812679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996349796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964581,0.0003666976,0.000029992252,0.002012685,0.00003695246,0.0006042578,0.00011898307,0.00003257352,0.0003397385],"genre_scores_gemma":[0.9982464,0.00038025,0.00063981605,0.000058908445,0.00011295486,0.00035899883,0.000020616955,0.00005733683,0.00012473192],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981899,0.000056980753,0.00026967743,0.00045744723,0.00054612383,0.00047982647],"domain_scores_gemma":[0.9986092,0.0002628041,0.00014065798,0.0002868012,0.00050356943,0.00019697697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003143197,0.00022625377,0.0003932591,0.000338084,0.0001500023,0.00004101853,0.000078747355,0.00010958407,0.00022545383],"category_scores_gemma":[0.000025450412,0.00016788195,0.000021909775,0.00063097535,0.0009704876,0.0003113055,0.000050798535,0.0008045113,0.0000011431422],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004201743,0.0002357957,0.10847461,0.0004641913,0.00013871999,0.000052309773,0.0014942242,0.00034553275,0.828897,0.00009772819,0.000022207762,0.055575956],"study_design_scores_gemma":[0.009499429,0.0004491431,0.5214426,0.0022381577,0.000050421204,0.00013504257,0.0029251867,0.00011090432,0.46242633,0.00021259343,0.0001889692,0.00032118906],"about_ca_topic_score_codex":0.007454646,"about_ca_topic_score_gemma":0.004558092,"teacher_disagreement_score":0.412968,"about_ca_system_score_codex":0.00020840067,"about_ca_system_score_gemma":0.000610162,"threshold_uncertainty_score":0.9991548},"labels":[],"label_agreement":null},{"id":"W2003187570","doi":"10.1158/0008-5472.sabcs13-p2-15-01","title":"Abstract P2-15-01: Impact of adjuvant trastuzumab (AT) on survival in metastatic (M1) her2 positive breast cancer","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Trastuzumab; Breast cancer; Internal medicine; Cohort; Oncology; Cancer; Hazard ratio; Surgery; Confidence interval","score_opus":0.0664768558664194,"score_gpt":0.44115381458796615,"score_spread":0.37467695872154677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003187570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913747,0.002959221,0.00001041828,0.0017770078,0.00015288359,0.0015124289,0.0007588572,0.000035376765,0.0014191502],"genre_scores_gemma":[0.99727017,0.0005212726,0.000062311105,0.00011697125,0.00024748768,0.00082920125,0.000037032976,0.00009916256,0.0008163798],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99610853,0.00024464657,0.00054277206,0.0006384169,0.001337791,0.0011278496],"domain_scores_gemma":[0.9976041,0.00047242848,0.00016193427,0.0005842458,0.0007566577,0.00042065224],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000670465,0.00036460563,0.0008561657,0.0005469729,0.00011216542,0.000030851006,0.0003056831,0.00010813986,0.01370561],"category_scores_gemma":[0.000084944775,0.00027947236,0.00023199299,0.0009129923,0.0005083751,0.00028592336,0.00011280689,0.0009530297,0.00017920167],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017207947,0.002048063,0.11641869,0.0010351418,0.0019884696,0.00044206268,0.0053890175,0.003493003,0.5012422,0.00016402753,0.0046489416,0.34592244],"study_design_scores_gemma":[0.0042060013,0.00080463727,0.97311765,0.0011775711,0.00003844986,0.00005211601,0.0008182819,0.00008864681,0.018935906,0.0002755751,0.0002013716,0.00028382408],"about_ca_topic_score_codex":0.04427532,"about_ca_topic_score_gemma":0.00375228,"teacher_disagreement_score":0.85669893,"about_ca_system_score_codex":0.004560989,"about_ca_system_score_gemma":0.0015546974,"threshold_uncertainty_score":0.9999657},"labels":[],"label_agreement":null},{"id":"W2004836183","doi":"10.1158/0008-5472.sabcs10-p3-14-15","title":"Abstract P3-14-15: Lapatinib Plus Capecitabine in Trastuzumab Pre-Treated HER2- Positive Metastatic Breast Cancer: The Canadian Lapatinib Expanded Access Program Experience","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Northeast Cancer Centre; Hôpital Charles-Le Moyne; Regional Municipality of Durham; CancerCare Manitoba; BC Cancer Agency","funders":"","keywords":"Lapatinib; Medicine; Capecitabine; Trastuzumab; Internal medicine; Metastatic breast cancer; Taxane; Oncology; Breast cancer; Cancer; Progressive disease; Gastroenterology; Tyrosine-kinase inhibitor; Chemotherapy; Colorectal cancer","score_opus":0.06690299879045916,"score_gpt":0.4538422047316935,"score_spread":0.3869392059412343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004836183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854515,0.0010900181,0.000007663044,0.0066655097,0.0003700742,0.0042613083,0.0007018936,0.00013400528,0.0013180209],"genre_scores_gemma":[0.9886551,0.0002573407,0.00024353692,0.00041819614,0.00046679404,0.009045812,0.000094336974,0.00012326459,0.0006956567],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9948443,0.00026110542,0.0006358687,0.0009748804,0.0014648894,0.0018189482],"domain_scores_gemma":[0.99639094,0.00038149272,0.0001812722,0.0009495547,0.0012467416,0.00085001177],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008996317,0.0004926821,0.000721668,0.00057488214,0.00065998675,0.00031011575,0.0010294691,0.00021011716,0.003268576],"category_scores_gemma":[0.00021599648,0.00036031794,0.00012889589,0.002002373,0.0012884374,0.0005871975,0.00016461272,0.0024160368,0.000028675873],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074675996,0.0013156044,0.12044249,0.00055840187,0.000645867,0.0009067784,0.030671157,0.00063687854,0.04983987,0.00016947881,0.0011406098,0.7862053],"study_design_scores_gemma":[0.007386359,0.0005372255,0.95497733,0.0010054522,0.00008167127,0.00028080124,0.0036010765,0.00063658925,0.023021825,0.00017619909,0.007571676,0.00072381424],"about_ca_topic_score_codex":0.6377947,"about_ca_topic_score_gemma":0.88357395,"teacher_disagreement_score":0.8345348,"about_ca_system_score_codex":0.002814785,"about_ca_system_score_gemma":0.0051798937,"threshold_uncertainty_score":0.99988544},"labels":[],"label_agreement":null},{"id":"W2005692436","doi":"10.1158/0008-5472.sabcs13-s5-04","title":"Abstract S5-04: Primary results of ROSE/TRIO-12, a randomized placebo controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Translational Research in Oncology","funders":"","keywords":"Ramucirumab; Docetaxel; Medicine; Metastatic breast cancer; Oncology; Internal medicine; Clinical endpoint; Breast cancer; Response Evaluation Criteria in Solid Tumors; Cancer; Taxane; Placebo; Interim analysis; Phases of clinical research; Progression-free survival; Chemotherapy regimen; Chemotherapy; Randomized controlled trial; Pathology","score_opus":0.09301979136539842,"score_gpt":0.4564439374470701,"score_spread":0.36342414608167173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005692436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96592534,0.003099991,0.00018905273,0.0107403165,0.00021007203,0.01868512,0.000698545,0.000034508605,0.00041708138],"genre_scores_gemma":[0.98466676,0.00095769024,0.0004599885,0.00046454638,0.000514185,0.0120516475,0.000072544935,0.00007592729,0.00073669746],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99404067,0.00091007823,0.0018034836,0.0006128261,0.0018497114,0.0007832158],"domain_scores_gemma":[0.9925353,0.004184495,0.000750727,0.00076230854,0.0015280375,0.00023911854],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007431141,0.00035512823,0.0022977353,0.0005539141,0.00014755639,0.000040643004,0.00041091262,0.000117471354,0.0036131528],"category_scores_gemma":[0.0020483728,0.00022945745,0.00036165514,0.0009978515,0.00063741853,0.0002524266,0.00008589358,0.0007739776,0.000013213796],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83026934,0.0007965082,0.000009395342,0.00030306057,0.00058187236,0.0000058768464,0.0016636165,0.0010906177,0.05750937,0.000010869386,0.0010823086,0.10667718],"study_design_scores_gemma":[0.98387706,0.0015462358,0.00085412414,0.0013174854,0.00017474328,0.000010498146,0.00039784878,0.00196348,0.008909264,0.00039128374,0.00035105456,0.00020691237],"about_ca_topic_score_codex":0.007243609,"about_ca_topic_score_gemma":0.0009530058,"teacher_disagreement_score":0.15360774,"about_ca_system_score_codex":0.00093862106,"about_ca_system_score_gemma":0.0017095704,"threshold_uncertainty_score":0.99936724},"labels":[],"label_agreement":null},{"id":"W2008621188","doi":"10.1158/0008-5472.sabcs-09-201","title":"Sunitinib (SU) in Combination with Trastuzumab (T) for the Treatment of Advanced Breast Cancer (ABC): Activity and Safety Results from a Phase II Study.","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Taxane; Internal medicine; Breast cancer; Lapatinib; Sunitinib; Cancer; Neutropenia; Pharmacokinetics; Metastatic breast cancer; Dosing; Clinical endpoint; Trastuzumab; Pharmacology; Oncology; Gastroenterology; Clinical trial; Chemotherapy","score_opus":0.06576479026102895,"score_gpt":0.43729516599548707,"score_spread":0.37153037573445813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008621188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850115,0.0022886673,0.00014122334,0.007257513,0.000044844237,0.0038059605,0.0013754994,0.000022847811,0.00005193275],"genre_scores_gemma":[0.9961876,0.0019793084,0.00013913511,0.000044285833,0.00013808343,0.0011907003,0.000039651528,0.000028068054,0.00025311208],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981115,0.00013847095,0.00029444855,0.00048635926,0.0005386067,0.00043063224],"domain_scores_gemma":[0.99825346,0.0006255316,0.00012260288,0.00043150247,0.0004503301,0.00011654881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042161084,0.00020745103,0.0004634358,0.00017548689,0.0002868061,0.000017871263,0.00012497428,0.000055720295,0.00005055744],"category_scores_gemma":[0.000045144665,0.0001315449,0.00004579344,0.00055225944,0.00028565185,0.00016848007,0.000021915896,0.00024467436,2.487876e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10417625,0.0048762457,0.0011979466,0.000027110143,0.00019489911,0.0000142207955,0.008186115,0.00019294782,0.022743827,0.000031211464,0.000015534271,0.85834366],"study_design_scores_gemma":[0.2215268,0.052279197,0.6644914,0.00095343555,0.00025632442,0.0000217097,0.010262128,0.00076491927,0.039035562,0.0004894658,0.009494362,0.00042466988],"about_ca_topic_score_codex":0.005285217,"about_ca_topic_score_gemma":0.004321747,"teacher_disagreement_score":0.85791904,"about_ca_system_score_codex":0.0011124176,"about_ca_system_score_gemma":0.0004969799,"threshold_uncertainty_score":0.7989702},"labels":[],"label_agreement":null},{"id":"W2012297324","doi":"10.1111/joim.12065","title":"Endocrine therapy: is the first generation of targeted drugs the last?","year":2013,"lang":"en","type":"review","venue":"Journal of Internal Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Lapatinib; Medicine; Everolimus; Trastuzumab; Tamoxifen; Targeted therapy; Breast cancer; Oncology; Hormonal therapy; Internal medicine; Endocrine system; Aromatase inhibitor; Cancer; Cancer research; PI3K/AKT/mTOR pathway; Estrogen receptor; Hormone; Signal transduction; Biology","score_opus":0.05816350002380269,"score_gpt":0.35939058904160787,"score_spread":0.30122708901780515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012297324","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002550541,0.98640305,0.00034125158,0.010275136,0.0015855427,0.0007880292,0.000009788064,0.00000850082,0.00033362108],"genre_scores_gemma":[0.0006762083,0.98828036,0.00020217776,0.0031719569,0.0067031663,0.000036517136,0.00000685419,0.00007245971,0.0008503336],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964475,0.00017315167,0.0018999836,0.00019947757,0.0010122313,0.00026764817],"domain_scores_gemma":[0.9949731,0.00053304125,0.0029497724,0.00057138526,0.00083571393,0.00013697315],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00076521444,0.00046958795,0.002272687,0.00029682575,0.00008355309,0.000016838616,0.00074385386,0.000121478384,0.0013698436],"category_scores_gemma":[0.00029102588,0.00016839866,0.0007507685,0.00035207195,0.0004543631,0.00012311105,0.000068979105,0.0012564891,0.000020593903],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017083662,0.0000677475,0.000022777078,0.0015237356,0.0016380465,0.000044530563,0.0012889248,0.0000014976788,0.00015704616,0.000031284424,0.021777386,0.9732762],"study_design_scores_gemma":[0.0018384765,0.0011638259,0.00003905965,0.024375256,0.001081359,0.003361342,0.000284866,0.000012549952,0.00029096752,0.000062556035,0.9673655,0.00012421161],"about_ca_topic_score_codex":0.00008197987,"about_ca_topic_score_gemma":0.000006096554,"teacher_disagreement_score":0.973152,"about_ca_system_score_codex":0.0002169677,"about_ca_system_score_gemma":0.0002954637,"threshold_uncertainty_score":0.999543},"labels":[],"label_agreement":null},{"id":"W2015569024","doi":"10.1158/0008-5472.sabcs11-s6-2","title":"S6-2: Patient-Reported Predictors of Early Treatment Discontinuation: NCIC JMA.27/E1Z03 Quality of Life Study of Postmenopausal Women with Primary Breast Cancer Randomized to Exemestane or Anastrozole.","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Anastrozole; Exemestane; Discontinuation; Internal medicine; Quality of life (healthcare); Breast cancer; Randomized controlled trial; Aromatase inhibitor; Adverse effect; Oncology; Cancer; Physical therapy; Tamoxifen","score_opus":0.09674473056512146,"score_gpt":0.39480204656842566,"score_spread":0.2980573160033042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015569024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99306786,0.00073746045,0.000046917598,0.00021930759,0.0001222082,0.0052655274,0.0003399317,0.000033573786,0.00016721056],"genre_scores_gemma":[0.99603605,0.00014350202,0.0003113403,0.00005835691,0.000108266286,0.0027704237,0.000015550013,0.00006628755,0.00049021374],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.994898,0.000704099,0.0013705941,0.0005979475,0.0017629319,0.0006664101],"domain_scores_gemma":[0.99570227,0.0003047169,0.00077085086,0.00087261596,0.001865485,0.00048409018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012499653,0.0003418455,0.0018531461,0.00042151686,0.00006784157,0.000008560715,0.0002444723,0.00007869219,0.0009014477],"category_scores_gemma":[0.00017496501,0.00021562129,0.00009172315,0.0010836689,0.00068869727,0.0002377647,0.00011734539,0.0002443892,0.0000014710029],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6639763,0.0037850868,0.24908224,0.0003081965,0.003009033,0.000039961702,0.03601006,0.000041836873,0.022321634,0.000014767196,0.000027621694,0.02138326],"study_design_scores_gemma":[0.14645275,0.023346065,0.8062164,0.00064336625,0.00033182724,0.000013843194,0.013111149,0.0000021077622,0.009515713,0.0000127198,0.00008251529,0.0002715309],"about_ca_topic_score_codex":0.012673489,"about_ca_topic_score_gemma":0.0009385885,"teacher_disagreement_score":0.55713415,"about_ca_system_score_codex":0.0011778069,"about_ca_system_score_gemma":0.002497129,"threshold_uncertainty_score":0.9939012},"labels":[],"label_agreement":null},{"id":"W2018755246","doi":"10.1158/0008-5472.sabcs13-p1-14-05","title":"Abstract P1-14-05: Is there a correlation between androgen receptor (AR) expression in metastatic breast cancer (MBC) ER+/Her2- and response to anti-estrogen treatment?","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Estrogen receptor; Metastatic breast cancer; Breast cancer; Antiestrogen; Internal medicine; Oncology; Cancer; Estrogen; Immunohistochemistry; Antiandrogen; Endocrine system; Androgen receptor; Gynecology; Gastroenterology; Prostate cancer; Hormone","score_opus":0.06780505961093732,"score_gpt":0.4060702453788812,"score_spread":0.3382651857679439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018755246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810181,0.008557733,0.00004601785,0.00745965,0.00009679523,0.0021826182,0.0005141851,0.0000548939,0.00006995114],"genre_scores_gemma":[0.99308664,0.002514436,0.00053583103,0.00019186076,0.00029013032,0.0017922556,0.00003453908,0.00009784624,0.001456438],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968793,0.00035448663,0.00042716227,0.0007368078,0.00076834345,0.0008339276],"domain_scores_gemma":[0.9980063,0.00043030642,0.00011031899,0.0005280668,0.00039849215,0.0005265184],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006840495,0.00033861515,0.00059600995,0.0004816004,0.00019181597,0.000083749816,0.00016792137,0.00014838103,0.0037647292],"category_scores_gemma":[0.000087414395,0.00026691888,0.00008060535,0.0007846674,0.0002314775,0.00040637748,0.000104272214,0.00048468192,0.00018939722],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006899281,0.0003758616,0.37025988,0.00025068448,0.00039937004,0.000093367205,0.006447795,0.00018053508,0.34213868,0.0000055662554,0.0034863383,0.26946265],"study_design_scores_gemma":[0.005448701,0.00073751784,0.8867882,0.0015179344,0.00007491408,0.000045292993,0.0015693859,0.000051422598,0.08005397,0.00017074394,0.02312991,0.00041201923],"about_ca_topic_score_codex":0.006122877,"about_ca_topic_score_gemma":0.00020066467,"teacher_disagreement_score":0.5165283,"about_ca_system_score_codex":0.0015825809,"about_ca_system_score_gemma":0.0007195314,"threshold_uncertainty_score":0.9999783},"labels":[],"label_agreement":null},{"id":"W2027306043","doi":"10.1158/0008-5472.sabcs13-p6-05-07","title":"Abstract P6-05-07: Discordance in estrogen receptor, progesterone receptor and HER-2/neu status between primary and metastatic breast cancer: A systematic review","year":2013,"lang":"en","type":"review","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Oncology; Breast cancer; Metastatic breast cancer; Internal medicine; Estrogen receptor; Interquartile range; Gynecology; Cancer; Progesterone receptor; Metastasis","score_opus":0.11986107829085137,"score_gpt":0.4504060065157053,"score_spread":0.33054492822485393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027306043","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019185813,0.97918934,0.0000044516632,0.0011034892,0.00016282962,0.015654555,0.0018567876,0.00007618285,0.00003380793],"genre_scores_gemma":[0.00007020622,0.97898763,0.0006758483,0.0001658688,0.00036092062,0.018311303,0.00035371815,0.00030607844,0.0007684307],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9918337,0.0011541896,0.0020602457,0.0016319806,0.0015473441,0.0017725527],"domain_scores_gemma":[0.99539334,0.0009348113,0.0009287433,0.0012674326,0.00053943554,0.0009362712],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0021421623,0.0011129285,0.0069809137,0.0006289875,0.00018592404,0.00016909884,0.00056344515,0.00030532907,0.0005798369],"category_scores_gemma":[0.0002814669,0.0008166881,0.00029956887,0.0013543906,0.00084057084,0.0005150186,0.00042839264,0.0023818526,0.00014389778],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059816295,0.00006600544,0.00025266298,0.59974706,0.0006084374,0.000030437188,0.00011590691,9.0485315e-8,0.000037884063,0.0000068921663,0.00040637542,0.39866844],"study_design_scores_gemma":[0.0012402993,0.00020535736,0.0005348016,0.8296257,0.0018208917,0.0002635767,0.00011378553,4.5030816e-7,0.00000889599,0.00002290434,0.16543539,0.0007279387],"about_ca_topic_score_codex":0.0019770432,"about_ca_topic_score_gemma":0.000113194124,"teacher_disagreement_score":0.39794052,"about_ca_system_score_codex":0.0031723096,"about_ca_system_score_gemma":0.0030129987,"threshold_uncertainty_score":0.9999197},"labels":[],"label_agreement":null},{"id":"W2028598713","doi":"10.1158/0008-5472.sabcs10-p5-13-09","title":"Abstract P5-13-09: Feasibility of a Randomized Controlled Trial of Vitamin D vs. Placebo in Recently Diagnosed Breast Cancer Patients","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Breast cancer; Randomized controlled trial; Population; Placebo; Internal medicine; Cohort; Cancer; Vitamin D and neurology; vitamin D deficiency; Clinical trial","score_opus":0.03860766003565889,"score_gpt":0.4033578890759887,"score_spread":0.3647502290403298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028598713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841205,0.0005422868,0.0000043513433,0.0013330884,0.00074898574,0.012436249,0.00025365737,0.000024122248,0.00053677126],"genre_scores_gemma":[0.99335057,0.0008509916,0.00007062574,0.00005129086,0.00035199427,0.005006742,0.000018097253,0.000054545708,0.00024516697],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99500215,0.0006855282,0.001435896,0.0005920306,0.0015615298,0.0007228712],"domain_scores_gemma":[0.9941951,0.0025360335,0.00055339816,0.00072036154,0.0017244015,0.00027068934],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00487598,0.00029772794,0.0027404819,0.0005260946,0.00006264651,0.000015667993,0.00035370074,0.00031491803,0.0018678474],"category_scores_gemma":[0.0032221265,0.00022327778,0.0004542732,0.0007385196,0.0011276607,0.0001697195,0.00009944219,0.0015788123,0.0000065837676],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90754837,0.001692219,0.041503552,0.0003457737,0.00029615033,0.000010023878,0.00067215256,0.000020031097,0.034098323,0.000024422932,0.00010504757,0.013683925],"study_design_scores_gemma":[0.88493854,0.00034592964,0.106086984,0.00059245306,0.00008366138,0.0000016566131,0.00011865149,0.000032414762,0.007391139,0.00013906813,0.00010743865,0.00016209182],"about_ca_topic_score_codex":0.0057994835,"about_ca_topic_score_gemma":0.0034048513,"teacher_disagreement_score":0.064583436,"about_ca_system_score_codex":0.0005883049,"about_ca_system_score_gemma":0.0015499007,"threshold_uncertainty_score":0.9990446},"labels":[],"label_agreement":null},{"id":"W2037157828","doi":"10.1016/j.clbc.2013.08.011","title":"Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor–Positive Breast Cancer in BOLERO-2","year":2013,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Sunnybrook Health Science Centre; University of Toronto","funders":"Novartis Pharmaceuticals Corporation; Pfizer","keywords":"Exemestane; Medicine; Everolimus; Breast cancer; Oncology; Internal medicine; Hormone receptor; Aromatase; Cancer; Gynecology","score_opus":0.009278835326357648,"score_gpt":0.29030447419732325,"score_spread":0.2810256388709656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037157828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910856,0.001120382,0.00007765364,0.0044627916,0.00013912808,0.0021523968,0.0007610025,0.0000572924,0.00014378663],"genre_scores_gemma":[0.9951111,0.0019133729,0.0012568219,0.0007944156,0.00020308446,0.00034792852,0.00005430928,0.00012411407,0.00019485231],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958433,0.00022625139,0.0013524643,0.0010643717,0.0007022753,0.00081136276],"domain_scores_gemma":[0.9968758,0.000566213,0.00061326986,0.00058341346,0.0008674758,0.0004938205],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032448434,0.0006147909,0.0016720043,0.00022027137,0.00006607875,0.00002466077,0.00022155228,0.0002878138,0.0008007568],"category_scores_gemma":[0.00007202429,0.000448456,0.00011045789,0.00092842156,0.0011545754,0.00052574574,0.00010255322,0.00088589726,0.0000127642625],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051632203,0.0014542472,0.6972159,0.000103746315,0.00031579201,0.00003263195,0.00049324706,0.0001156204,0.0002500658,0.000011137947,0.00006593342,0.24830945],"study_design_scores_gemma":[0.03665011,0.002062334,0.95734006,0.0025517894,0.00015443093,0.00008428402,0.00023313607,0.000061892526,0.00009766408,0.000032967633,0.0002018912,0.0005294398],"about_ca_topic_score_codex":0.008351845,"about_ca_topic_score_gemma":0.0027818724,"teacher_disagreement_score":0.26012412,"about_ca_system_score_codex":0.00060380547,"about_ca_system_score_gemma":0.0005425698,"threshold_uncertainty_score":0.99979675},"labels":[],"label_agreement":null},{"id":"W2039057822","doi":"10.1158/0008-5472.sabcs10-p1-09-02","title":"Abstract P1-09-02: Health Care Costs Incurred by Post-Menopausal Women with Hormone-Positive Breast Cancer Following the Initial Diagnosis of Metastasis","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada)","funders":"","keywords":"Medicine; Chemotherapy; Breast cancer; Cancer; Internal medicine; Oncology; Retrospective cohort study; Cohort; Population; Metastasis; Metastatic breast cancer; Surgery","score_opus":0.030991878451271195,"score_gpt":0.41523695897847773,"score_spread":0.3842450805272065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039057822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96735394,0.016496105,0.0000095552205,0.010114904,0.000266459,0.0016323669,0.003832938,0.00005249501,0.0002412646],"genre_scores_gemma":[0.99447846,0.0011297492,0.00009943796,0.0006851809,0.00045000535,0.0028993494,0.00009358094,0.0001113017,0.000052951105],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9958571,0.00022880324,0.00045007587,0.00063763664,0.0015684853,0.0012578996],"domain_scores_gemma":[0.99690485,0.00046241752,0.00022735106,0.00067695795,0.0011934047,0.0005350188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092780055,0.00035804074,0.00071454444,0.00024968464,0.0004961926,0.00006569002,0.0004727093,0.00012842742,0.0006237852],"category_scores_gemma":[0.00008546927,0.00024222412,0.000078244426,0.00088758237,0.0007979986,0.00032315275,0.00016462883,0.0016123471,0.000009491063],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010518249,0.00044367547,0.010510577,0.0004373346,0.0017745727,0.00010901482,0.018287793,0.000016249232,0.2790207,0.000046294386,0.0026768548,0.67615867],"study_design_scores_gemma":[0.020743748,0.010807004,0.6330692,0.003224741,0.0005378641,0.0002692218,0.05796592,0.000007183781,0.24315134,0.000088272136,0.028454717,0.0016807807],"about_ca_topic_score_codex":0.017274914,"about_ca_topic_score_gemma":0.0041229855,"teacher_disagreement_score":0.67447793,"about_ca_system_score_codex":0.00213403,"about_ca_system_score_gemma":0.0027333766,"threshold_uncertainty_score":0.98926914},"labels":[],"label_agreement":null},{"id":"W2042379375","doi":"10.1158/0008-5472.sabcs-09-4095","title":"A Phase II Study (FINDER 2) Comparing Three Dosing Regimens of Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer.","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Fulvestrant; Medicine; Tolerability; Discontinuation; Breast cancer; Internal medicine; Dosing; Cancer; Hazard ratio; Oncology; Urology; Estrogen receptor; Gastroenterology; Confidence interval; Adverse effect","score_opus":0.05101035564151347,"score_gpt":0.40964159348978224,"score_spread":0.3586312378482688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042379375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99336326,0.0023210533,0.000063370615,0.0015225792,0.000060053444,0.0022576903,0.000109090375,0.00006006647,0.00024285342],"genre_scores_gemma":[0.9982447,0.00012535925,0.0004893696,0.000110523,0.00018186333,0.00066014344,0.000011705751,0.000066662986,0.00010966916],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.996165,0.00017358862,0.00050639,0.0007693284,0.0011624113,0.0012232774],"domain_scores_gemma":[0.9981096,0.00009157116,0.00017617647,0.00059845747,0.00066332886,0.0003608865],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00067052146,0.0003597926,0.00086802646,0.00046989231,0.00025789186,0.00002786255,0.00030958827,0.00008800767,0.0002404822],"category_scores_gemma":[0.000021177795,0.0003026488,0.000042580148,0.0014016408,0.0004176653,0.00031924594,0.0001057531,0.0009177161,0.0000032221003],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07034595,0.007356373,0.049993075,0.00015811619,0.00063562475,0.0002946219,0.017474812,0.0013336906,0.5663816,0.00015138478,0.000029488485,0.28584528],"study_design_scores_gemma":[0.13631271,0.09339905,0.61763525,0.0070761214,0.00026405143,0.00042012671,0.034469213,0.00032266768,0.107019305,0.00085344404,0.00057422277,0.0016538285],"about_ca_topic_score_codex":0.0013994161,"about_ca_topic_score_gemma":0.00075188,"teacher_disagreement_score":0.56764215,"about_ca_system_score_codex":0.0021916595,"about_ca_system_score_gemma":0.0011037332,"threshold_uncertainty_score":0.99994254},"labels":[],"label_agreement":null},{"id":"W2044602856","doi":"10.1158/1535-7163.targ-13-c232","title":"Abstract C232: B-raf/Mek/Erk Pathway inhibition induces GPNMB expression and sensitizes melanoma cells to the antibody-drug conjugate glembatumumab vedotin.","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Vemurafenib; Trametinib; Dabrafenib; Melanoma; Medicine; Cancer research; Selumetinib; Antibody-drug conjugate; MAPK/ERK pathway; Targeted therapy; MEK inhibitor; Cancer; Kinase; Antibody; Immunology; Internal medicine; Monoclonal antibody; Biology; KRAS; Metastatic melanoma","score_opus":0.014183342169906209,"score_gpt":0.27512767143708655,"score_spread":0.26094432926718036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044602856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98159945,0.0073465896,0.0012173381,0.007618462,0.00041329162,0.0013002575,0.00006327642,0.00013635457,0.0003049724],"genre_scores_gemma":[0.9875133,0.0005709292,0.0011642381,0.009893807,0.00030467391,0.00019466277,0.00003884936,0.00011319187,0.0002063312],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977912,0.0000927783,0.00042115513,0.0005901267,0.0005303192,0.00057442195],"domain_scores_gemma":[0.9985475,0.00008325983,0.00021370541,0.00063615886,0.00027286133,0.00024654932],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001903578,0.00045390456,0.00046652,0.000120318095,0.00024223141,0.00013211824,0.00016438923,0.0001614926,0.00017336616],"category_scores_gemma":[0.000011028894,0.0003262165,0.00012431543,0.00027167427,0.00020138112,0.00021292275,0.00011787222,0.00045125114,0.00008942506],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022982324,0.00007046556,0.00018471098,0.00008197627,0.00016336582,0.00006402659,0.0016657838,0.00012154382,0.9495526,0.00005478407,0.00017524733,0.047635697],"study_design_scores_gemma":[0.0018051427,0.00015804403,0.0077951928,0.0005097687,0.00011920649,0.00006122769,0.0007280115,0.00011445908,0.9654017,0.00048208714,0.022401834,0.00042329676],"about_ca_topic_score_codex":0.00032781193,"about_ca_topic_score_gemma":0.0000433341,"teacher_disagreement_score":0.0472124,"about_ca_system_score_codex":0.00015013154,"about_ca_system_score_gemma":0.00015712202,"threshold_uncertainty_score":0.999919},"labels":[],"label_agreement":null},{"id":"W2046396781","doi":"10.1158/0008-5472.sabcs13-ot2-6-11","title":"Abstract OT2-6-11: PENELOPE: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy (GBG-78/BIG1-13)","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Palbociclib; Medicine; Internal medicine; Oncology; Clinical endpoint; Breast cancer; Taxane; Letrozole; Cancer; Placebo; Hormonal therapy; Clinical trial; Tamoxifen; Metastatic breast cancer; Pathology","score_opus":0.01863472530708059,"score_gpt":0.3456849310833449,"score_spread":0.3270502057762643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046396781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873219,0.0021169598,0.00002924693,0.0013163297,0.00024475748,0.00798451,0.0007410038,0.00014189005,0.00010338344],"genre_scores_gemma":[0.9886157,0.000719589,0.0006700908,0.00045962812,0.0008095187,0.0075503085,0.00015832928,0.00035745814,0.0006594054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9906913,0.00062936055,0.001151646,0.0018011304,0.0036960973,0.002030446],"domain_scores_gemma":[0.9949234,0.00029500976,0.000543077,0.0012440741,0.0021459348,0.00084846735],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016133075,0.00096292974,0.0013140624,0.0006439184,0.00047443918,0.00021713827,0.00057443377,0.00028588824,0.0034465103],"category_scores_gemma":[0.00006248579,0.00071728235,0.00014904646,0.0014121961,0.00070012454,0.0012192467,0.00028850918,0.0023491622,0.00010236513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09564058,0.0063037667,0.702984,0.00026269295,0.00082780974,0.00031952318,0.0055616694,0.00042878382,0.018611744,0.000001605974,0.00046381366,0.16859406],"study_design_scores_gemma":[0.082173936,0.00549025,0.9041033,0.001589961,0.00015258329,0.00001966026,0.002129056,0.00004569836,0.0032051,0.000016600658,0.00018483934,0.00088902685],"about_ca_topic_score_codex":0.030779213,"about_ca_topic_score_gemma":0.004775558,"teacher_disagreement_score":0.20111935,"about_ca_system_score_codex":0.0032001003,"about_ca_system_score_gemma":0.0018903003,"threshold_uncertainty_score":0.99995244},"labels":[],"label_agreement":null},{"id":"W2047310369","doi":"10.1158/0008-5472.sabcs11-pd01-09","title":"PD01-09: Identifying Novel Mechanisms of Resistance to Lapatinib in ERBB2+ Breast Cancer Cells through Whole Genome Mutational Analysis.","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Lapatinib; SKBR3; Trastuzumab; Breast cancer; Cancer research; Cancer; Biology; Genetics; Medicine","score_opus":0.1400050392613686,"score_gpt":0.42376446790017974,"score_spread":0.28375942863881115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047310369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9064207,0.0057882927,0.07391758,0.004054624,0.00047102984,0.0026019835,0.0031340502,0.00010951704,0.0035022083],"genre_scores_gemma":[0.9809766,0.00017346344,0.015378951,0.0003423584,0.00016922572,0.0007909029,0.000047685004,0.00006845874,0.0020523705],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99651515,0.00011717022,0.00058897876,0.0007140493,0.001273561,0.0007911071],"domain_scores_gemma":[0.99786144,0.000116081195,0.00016536856,0.0006050876,0.0010103887,0.00024163895],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008159952,0.00023912189,0.00065349555,0.00081752107,0.00012410042,0.000023387793,0.00041445874,0.00011463811,0.002713258],"category_scores_gemma":[0.000049083985,0.0002328692,0.00015748742,0.0033833561,0.0002622037,0.0002913429,0.0001633933,0.000514535,0.00004878044],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022308307,0.00031503264,0.004088568,0.0003677259,0.0006640771,0.000054781918,0.009796062,0.0011393083,0.9768679,0.002523392,0.00009288597,0.0018594147],"study_design_scores_gemma":[0.006388263,0.00028551352,0.4182937,0.0015422347,0.0004759592,0.000024625459,0.0058593405,0.0001518197,0.5451548,0.014069023,0.0068872334,0.0008674337],"about_ca_topic_score_codex":0.0051829247,"about_ca_topic_score_gemma":0.0072615054,"teacher_disagreement_score":0.4317131,"about_ca_system_score_codex":0.00093926815,"about_ca_system_score_gemma":0.0007180252,"threshold_uncertainty_score":0.9981984},"labels":[],"label_agreement":null},{"id":"W2052792754","doi":"10.2174/1568009043332989","title":"Novel Approaches for Targeted Cancer Therapy","year":2004,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"National Institute of Neurological Disorders and Stroke; Canadian Institutes of Health Research","keywords":"Cancer; Cancer therapy; Targeted therapy; Medicine; Internal medicine","score_opus":0.18711714940376617,"score_gpt":0.41402475167517727,"score_spread":0.2269076022714111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052792754","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004326785,0.9823189,0.0029307879,0.0004048204,0.005124669,0.00627876,0.0025708135,0.00030524164,0.00006172036],"genre_scores_gemma":[0.000011614112,0.97611964,0.0021639871,0.00015585836,0.0036525237,0.015237819,0.0012812013,0.00046043054,0.0009169336],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953982,0.00006285639,0.0011289913,0.00155639,0.00063448516,0.0012190307],"domain_scores_gemma":[0.99718875,0.00014216654,0.00096153916,0.00093533116,0.00032628851,0.00044590764],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00024211507,0.0014712153,0.0037638803,0.00039273873,0.00022749389,0.00005198357,0.00058822014,0.00039388755,0.00046449315],"category_scores_gemma":[0.000041398944,0.001137911,0.0015809748,0.00066768937,0.00026697156,0.00020234166,0.00010405832,0.0010599759,0.000030310528],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022042824,0.00046954546,0.000009277798,0.044843324,0.001194346,0.0000027440778,0.00035019292,0.00006383635,0.000010804549,0.00015819265,0.0015425204,0.9511348],"study_design_scores_gemma":[0.0041185985,0.0000721308,0.000014195351,0.04086665,0.0014738258,0.000029315841,0.0000255461,0.00001878041,0.00011002129,0.0001677132,0.95198965,0.0011135533],"about_ca_topic_score_codex":0.00016433894,"about_ca_topic_score_gemma":0.000047615253,"teacher_disagreement_score":0.95044714,"about_ca_system_score_codex":0.0024795742,"about_ca_system_score_gemma":0.004196882,"threshold_uncertainty_score":0.9998037},"labels":[],"label_agreement":null},{"id":"W2055922098","doi":"10.1158/1538-7445.am2011-4718","title":"Abstract 4718: A randomized phase 2 study of the cyclin-dependent kinase (CDK) inhibitor dinaciclib (SCH 727965) in patients with advanced breast cancer","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"","keywords":"Capecitabine; Medicine; Internal medicine; Taxane; Anthracycline; Clinical endpoint; Febrile neutropenia; Neutropenia; Oncology; Breast cancer; Cancer; Chemotherapy; Randomized controlled trial; Colorectal cancer","score_opus":0.04744629479669468,"score_gpt":0.3890347226297202,"score_spread":0.34158842783302557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055922098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922856,0.00095667323,0.0000062823447,0.00028957898,0.00027609698,0.0055706846,0.00016557291,0.000038655267,0.00041085074],"genre_scores_gemma":[0.9968253,0.00015347516,0.00007044991,0.00007434295,0.00016435093,0.002353672,0.000006335496,0.00009353253,0.00025854885],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9955237,0.00043491612,0.00074586895,0.0007178161,0.0017488346,0.0008288755],"domain_scores_gemma":[0.997192,0.00023434016,0.00031725882,0.0009737439,0.0010168584,0.00026576276],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011237769,0.00035909124,0.0010287159,0.00037298584,0.00016461036,0.000019907458,0.00049441255,0.00010851932,0.0011643353],"category_scores_gemma":[0.0001640924,0.00021644111,0.00014315499,0.0010673995,0.00070353824,0.00029368163,0.00022008896,0.0010483686,0.000009004763],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5912575,0.009855495,0.3109728,0.00033767748,0.00055055565,0.00008781201,0.007851465,0.0001057653,0.009817908,0.000028637352,0.000054814926,0.06907954],"study_design_scores_gemma":[0.44839045,0.0013578201,0.5297429,0.0012410077,0.00012829376,0.000005433564,0.0027569912,0.000009046897,0.015851151,0.000100496305,0.00010230547,0.0003140949],"about_ca_topic_score_codex":0.0047415756,"about_ca_topic_score_gemma":0.0018593835,"teacher_disagreement_score":0.2187701,"about_ca_system_score_codex":0.0007902361,"about_ca_system_score_gemma":0.0007026792,"threshold_uncertainty_score":0.9997487},"labels":[],"label_agreement":null},{"id":"W2056003586","doi":"10.3747/co.20.1394","title":"Cost-Effectiveness of Lapatinib plus Letrozole in her2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer in Canada","year":2013,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"GlaxoSmithKline (Canada); University of Toronto","funders":"","keywords":"Letrozole; Anastrozole; Lapatinib; Medicine; Trastuzumab; Metastatic breast cancer; Oncology; Breast cancer; Internal medicine; Quality-adjusted life year; Tamoxifen; Cost effectiveness; Gynecology; Cancer","score_opus":0.05515859164215883,"score_gpt":0.38077441046277666,"score_spread":0.32561581882061785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056003586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903509,0.0049490496,0.00026021453,0.0008392536,0.00068018696,0.0021935718,0.00041938468,0.000014469064,0.00029297563],"genre_scores_gemma":[0.99790245,0.00034570316,0.00020044416,0.00011255711,0.00006807603,0.0012348556,0.00008473825,0.000031425312,0.000019776311],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979301,0.00047956588,0.00048398215,0.00037174928,0.0002544974,0.00048006745],"domain_scores_gemma":[0.9987191,0.000395151,0.00022464052,0.0001986421,0.00030980574,0.00015266838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023832999,0.0002506999,0.00091624085,0.00019708737,0.000023895518,0.0000039560296,0.00012782124,0.00006765771,0.00044936646],"category_scores_gemma":[0.000051983712,0.00023194717,0.0000564624,0.00047959393,0.0001730461,0.0001511992,0.0000615841,0.00044662264,0.000013140583],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052067577,0.0015120314,0.31345877,0.0006713387,0.00028646245,0.00010915058,0.0018514572,0.0016110188,0.019876897,0.00013323537,0.0004612056,0.6548217],"study_design_scores_gemma":[0.009535571,0.00046711342,0.9819489,0.0010164141,0.00006258077,0.00007034077,0.0011452901,0.0006299702,0.0030956601,0.000084031184,0.0016894066,0.00025471783],"about_ca_topic_score_codex":0.6374742,"about_ca_topic_score_gemma":0.55586743,"teacher_disagreement_score":0.6684901,"about_ca_system_score_codex":0.006989166,"about_ca_system_score_gemma":0.0029729565,"threshold_uncertainty_score":0.99682283},"labels":[],"label_agreement":null},{"id":"W2057272791","doi":"10.1038/nrd4504","title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","year":2015,"lang":"en","type":"review","venue":"Nature Reviews Drug Discovery","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1762,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Consortium canadien en neurodégénérescence associée au vieillissement; Cancer Research UK; F. Hoffmann-La Roche; Bristol-Myers Squibb","keywords":"Kinase; Cyclin; Cancer research; Targeted therapy; Cancer; Cyclin-dependent kinase; Cancer therapy; Medicine; Oncology; Biology; Internal medicine; Cell biology; Cell cycle","score_opus":0.042037177351789655,"score_gpt":0.3749503544363558,"score_spread":0.3329131770845662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057272791","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000222447,0.9945078,0.0000011438442,0.0003870101,0.0021968589,0.00249143,0.00006908089,0.000021480715,0.0003029697],"genre_scores_gemma":[0.000006733282,0.99478847,0.00009716828,0.00036999912,0.0019964972,0.0005244651,0.000072460716,0.0001069475,0.0020372898],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966142,0.0005270289,0.001276178,0.00063889363,0.00054262934,0.00040107046],"domain_scores_gemma":[0.9973902,0.00029827975,0.0012790399,0.00076875545,0.00013867476,0.00012504132],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001453065,0.00070518354,0.003629227,0.00017965345,0.00005727589,0.000024039564,0.00037892556,0.0005657483,0.000037403064],"category_scores_gemma":[0.00014850046,0.00036493895,0.0006378672,0.00034153965,0.00023977339,0.00024205963,0.0001103486,0.0021598728,0.000004475456],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009292194,0.00006569819,0.000031139345,0.015286203,0.00014323449,0.000016167438,0.0001783307,2.2073151e-7,0.0000025028114,0.00010352045,0.0069237286,0.97715634],"study_design_scores_gemma":[0.00060889125,0.000033853066,0.000016241562,0.02576526,0.00040647434,0.000042010583,0.00009752568,1.8294006e-7,0.0000023072719,0.00005654718,0.97264415,0.00032654236],"about_ca_topic_score_codex":0.000059301314,"about_ca_topic_score_gemma":0.0000940298,"teacher_disagreement_score":0.97682977,"about_ca_system_score_codex":0.0013702958,"about_ca_system_score_gemma":0.0012567464,"threshold_uncertainty_score":0.99988025},"labels":[],"label_agreement":null},{"id":"W2058828565","doi":"10.3892/ol.2014.1957","title":"PD-0332991 induces G1 arrest of colorectal carcinoma cells through inhibition of the cyclin-dependent kinase-6 and retinoblastoma protein axis","year":2014,"lang":"en","type":"article","venue":"Oncology Letters","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal Neurological Institute and Hospital","funders":"","keywords":"Retinoblastoma; Retinoblastoma protein; Cancer research; Cell cycle; Oncogene; Cyclin-dependent kinase 4; Kinase; Cyclin-dependent kinase 2; Cyclin; Apoptosis; Protein kinase A; Biology; Cell biology; Genetics; Gene","score_opus":0.009919380703938926,"score_gpt":0.2511371488966866,"score_spread":0.24121776819274765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058828565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990043,0.000078054465,0.00015248667,0.0080135465,0.00029218374,0.00067988207,0.000014565712,0.00002251697,0.0007037808],"genre_scores_gemma":[0.99635667,0.00000534678,0.0014992412,0.0018526304,0.00015914456,0.00006371258,0.000004463291,0.000023787856,0.000034995064],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986792,0.00021057854,0.00035806623,0.00028198154,0.0002369812,0.00023315521],"domain_scores_gemma":[0.99907815,0.0001463534,0.00037388556,0.00027468987,0.000073859104,0.000053068263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022765934,0.00017085257,0.0004351674,0.000058875667,0.00006354353,0.0000033335718,0.00010378107,0.00013379805,0.00002310537],"category_scores_gemma":[0.00006945518,0.0001276578,0.00008093372,0.00013300139,0.0007842285,0.00007913848,0.00008449333,0.0002906885,0.0000038318385],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073046586,0.00024981206,0.0048953244,0.0001277802,0.00004581085,0.000017171727,0.001220726,0.000012322254,0.9890959,0.00012737267,0.00012035809,0.003356919],"study_design_scores_gemma":[0.004466112,0.0009512766,0.054509055,0.0001965732,0.00007314405,0.00005938949,0.00042052832,0.000011841034,0.9373493,0.00023667004,0.001603717,0.00012237328],"about_ca_topic_score_codex":0.00014491548,"about_ca_topic_score_gemma":0.00007478632,"teacher_disagreement_score":0.051746618,"about_ca_system_score_codex":0.00014809052,"about_ca_system_score_gemma":0.00008488655,"threshold_uncertainty_score":0.5205734},"labels":[],"label_agreement":null},{"id":"W2058966918","doi":"10.1158/1538-7445.am2014-1409","title":"Abstract 1409: The BP1 homeobox gene is dysregulated in triple negative breast cancer","year":2014,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Triple-negative breast cancer; Cancer research; Gene knockdown; Biology; Breast cancer; Small hairpin RNA; Cell culture; Cancer; Molecular biology; Genetics","score_opus":0.057266059045237704,"score_gpt":0.40912095228014733,"score_spread":0.35185489323490965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058966918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9662595,0.004697222,0.000044362652,0.025536427,0.00033524973,0.0012882786,0.00019736237,0.000074193405,0.001567422],"genre_scores_gemma":[0.99265635,0.0009880422,0.00008749922,0.001332248,0.0009146209,0.0008173053,0.000010390755,0.000081460676,0.0031120868],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9967687,0.00021993347,0.00036895036,0.00060822145,0.0010456861,0.0009885231],"domain_scores_gemma":[0.9979019,0.00033046943,0.00010015972,0.0007629824,0.0006458902,0.0002585791],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011253395,0.00026230648,0.00045871935,0.00032289038,0.00025140817,0.00005519934,0.00043608533,0.00015021897,0.004055247],"category_scores_gemma":[0.00012796414,0.00018124854,0.0001023657,0.0014281728,0.00065768283,0.00018917256,0.0001290647,0.0011242651,0.00009902704],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007878905,0.00049243605,0.035950363,0.00051229284,0.0006575274,0.00013728364,0.009471556,0.0009905013,0.21586215,0.00040170862,0.018275758,0.70936954],"study_design_scores_gemma":[0.009810058,0.00024046598,0.81213653,0.001043735,0.000053487554,0.00011934549,0.001268183,0.0011841652,0.12059056,0.0029794823,0.050011195,0.0005627631],"about_ca_topic_score_codex":0.010046555,"about_ca_topic_score_gemma":0.0022171652,"teacher_disagreement_score":0.77618617,"about_ca_system_score_codex":0.0011185657,"about_ca_system_score_gemma":0.00075625116,"threshold_uncertainty_score":0.9968552},"labels":[],"label_agreement":null},{"id":"W2060696690","doi":"10.1016/j.lungcan.2013.11.020","title":"Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Merck Sharp and Dohme","keywords":"Medicine; Erlotinib; Internal medicine; Neutropenia; Oncology; Lung cancer; Adverse effect; Surgery; Cancer; Epidermal growth factor receptor; Chemotherapy","score_opus":0.009580312840794003,"score_gpt":0.29764311509174984,"score_spread":0.2880628022509558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060696690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876316,0.0019296771,0.000042812306,0.00029463525,0.0013122166,0.008305837,0.000054279706,0.00004602,0.0003828831],"genre_scores_gemma":[0.9952396,0.000084775595,0.00012295715,0.00022967938,0.00029147314,0.003122915,0.000009540511,0.0000962286,0.0008027866],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99724704,0.00018983484,0.0007124066,0.0005867099,0.00071611285,0.0005478832],"domain_scores_gemma":[0.9980309,0.00020152151,0.00050788047,0.00072053855,0.00036090292,0.00017826323],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002262297,0.00043293575,0.0010677825,0.00014633904,0.00009520655,0.000024827374,0.00029705415,0.00010769865,0.00057089824],"category_scores_gemma":[0.000053139604,0.00026987723,0.00016413817,0.00045985938,0.00018318785,0.00021516421,0.000128974,0.0004563308,0.000004706781],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27739123,0.004462022,0.6978638,0.0005351587,0.0008956105,0.000017955967,0.007144295,0.0013355599,0.0018449744,0.0000050929784,0.0003264945,0.008177772],"study_design_scores_gemma":[0.8903041,0.0009852032,0.09665453,0.0009962561,0.0011059281,7.2337247e-7,0.001571974,0.00090176857,0.0068712416,0.000006985354,0.00013727175,0.00046401576],"about_ca_topic_score_codex":0.005714357,"about_ca_topic_score_gemma":0.0018638256,"teacher_disagreement_score":0.6129129,"about_ca_system_score_codex":0.0007136589,"about_ca_system_score_gemma":0.00034427518,"threshold_uncertainty_score":0.9999753},"labels":[],"label_agreement":null},{"id":"W2063756018","doi":"10.1158/0008-5472.sabcs11-p3-16-01","title":"P3-16-01: Safety Profile and Clinical Activity of Single-Agent BKM120, a Pan-Class I PI3K Inhibitor, for the Treatment of Patients with Metastatic Breast Carcinoma.","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Adverse effect; Gastroenterology; Metastatic breast cancer; Cancer; Oncology","score_opus":0.16235293003586573,"score_gpt":0.4113457694450203,"score_spread":0.2489928394091546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063756018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99391943,0.0015400292,0.0005341687,0.00033917022,0.000099983874,0.0028113236,0.00059711566,0.000012526669,0.00014625593],"genre_scores_gemma":[0.99777985,0.00032834543,0.0008771156,0.000018829347,0.00011569816,0.0005567015,0.000018208855,0.000042518022,0.00026273515],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979846,0.0002015122,0.0004000668,0.00039702674,0.00059149886,0.00042531578],"domain_scores_gemma":[0.9977903,0.0006299391,0.00020248805,0.00051032467,0.0007019507,0.00016501304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000515746,0.00019252143,0.0005628458,0.00010605624,0.00012014634,0.0000070464653,0.00012810012,0.00005851504,0.00014846592],"category_scores_gemma":[0.00006372654,0.000109222696,0.00012119273,0.00028242441,0.0009256686,0.00009407778,0.00005611237,0.00019139971,0.0000013516357],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04970901,0.004986425,0.28392038,0.00063313585,0.0011568049,0.000007319444,0.0026183964,0.000002100454,0.005678876,0.000057523546,0.00011032334,0.6511197],"study_design_scores_gemma":[0.017279157,0.01688466,0.8900426,0.0003497566,0.0005076271,0.000012295285,0.0009432242,0.00007369209,0.0683413,0.000108289125,0.0052411063,0.00021631157],"about_ca_topic_score_codex":0.0010779224,"about_ca_topic_score_gemma":0.0003827787,"teacher_disagreement_score":0.6509034,"about_ca_system_score_codex":0.00058217417,"about_ca_system_score_gemma":0.00047870586,"threshold_uncertainty_score":0.44539723},"labels":[],"label_agreement":null},{"id":"W2065803223","doi":"10.1158/0008-5472.sabcs11-pd05-05","title":"PD05-05: Meta Analysis of Discordant HER2 Status in Matched Primary and Metastatic Breast Cancer.","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Internal medicine; Breast cancer; Primary tumor; Metastatic breast cancer; Cancer; Disease; Meta-analysis; Metastasis","score_opus":0.15646634666622575,"score_gpt":0.4306198504474446,"score_spread":0.27415350378121883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065803223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9662706,0.030309618,0.00019906631,0.0010815992,0.000059735044,0.00080420496,0.0007026266,0.000030301473,0.00054220925],"genre_scores_gemma":[0.9931665,0.0039364207,0.0013873322,0.00018320327,0.000037771984,0.00063455116,0.000024265495,0.000049570946,0.00058037834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972148,0.00024093421,0.00045264378,0.0005414277,0.0007810294,0.00076916337],"domain_scores_gemma":[0.9984597,0.0001666274,0.00012766775,0.0005637418,0.00038280617,0.0002994733],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007592156,0.0002292008,0.0013319426,0.0009849049,0.000060187213,0.000014616614,0.00019536514,0.000042869557,0.0027633575],"category_scores_gemma":[0.000031619067,0.00017487607,0.00023646887,0.0025768816,0.00059500796,0.00020597508,0.00015970989,0.00045246343,0.0000029989353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014950726,0.0022530628,0.4315757,0.004256603,0.22074223,0.0009694173,0.02377432,0.000550583,0.15224671,0.0014965815,0.0004180703,0.146766],"study_design_scores_gemma":[0.0033968845,0.0003151666,0.9523518,0.00021137466,0.026542021,0.000054712782,0.002845602,0.00018710908,0.012239196,0.0008000884,0.0006797157,0.000376317],"about_ca_topic_score_codex":0.029451676,"about_ca_topic_score_gemma":0.0075268312,"teacher_disagreement_score":0.52077615,"about_ca_system_score_codex":0.0005526829,"about_ca_system_score_gemma":0.00070741307,"threshold_uncertainty_score":0.99814826},"labels":[],"label_agreement":null},{"id":"W2073042319","doi":"10.1158/1078-0432.ccr-08-2790","title":"Therapeutic Efficacy of Seliciclib in Combination with Ionizing Radiation for Human Nasopharyngeal Carcinoma","year":2009,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Nasopharyngeal carcinoma; Cancer research; Apoptosis; Cell cycle; Cell cycle checkpoint; Cyclin-dependent kinase; Radiation therapy; Biology; Medicine; Immunology; Internal medicine; Biochemistry","score_opus":0.21045845608325892,"score_gpt":0.5280816959434151,"score_spread":0.3176232398601562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073042319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99208903,0.0022919197,0.00036668568,0.0035992449,0.000062408435,0.0013613548,0.0000059357185,0.000027439162,0.0001960015],"genre_scores_gemma":[0.998515,0.00012519506,0.00039219527,0.00032882713,0.00031607106,0.00013599561,0.000024819894,0.000025975522,0.00013590367],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980082,0.00020625645,0.00053383806,0.000358148,0.0005141895,0.00037938697],"domain_scores_gemma":[0.9981607,0.0008242,0.00012525964,0.00029581302,0.00047579332,0.000118211894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015617076,0.00011465066,0.0004149213,0.00023681692,0.000097668824,0.000012243975,0.00014466642,0.00011242839,0.000040839102],"category_scores_gemma":[0.00021645236,0.0000937943,0.000088881694,0.0005583314,0.00025064417,0.00010581637,0.000016928567,0.0005126846,0.0000021288088],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01098661,0.0014402163,0.2499705,0.00018121298,0.00008191381,0.000013308012,0.00066565804,0.00009110597,0.012927293,0.0034687899,0.000079397105,0.720094],"study_design_scores_gemma":[0.016416278,0.0046791327,0.9674552,0.0002476948,0.000031229236,0.0000034922032,0.00010538186,0.00035188292,0.006308078,0.003206744,0.0010855836,0.00010930978],"about_ca_topic_score_codex":0.00015459555,"about_ca_topic_score_gemma":0.00006871824,"teacher_disagreement_score":0.7199847,"about_ca_system_score_codex":0.0002965847,"about_ca_system_score_gemma":0.00036932793,"threshold_uncertainty_score":0.38248205},"labels":[],"label_agreement":null},{"id":"W2077037832","doi":"10.1016/j.clbc.2013.10.016","title":"Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer","year":2013,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Merck","keywords":"Medicine; Capecitabine; Oncology; Breast cancer; Randomized controlled trial; Internal medicine; Cancer; Colorectal cancer","score_opus":0.020141642534631344,"score_gpt":0.34714416053795083,"score_spread":0.3270025180033195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077037832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98297477,0.0006048027,0.000022731218,0.006465147,0.0033848945,0.0055604433,0.00071920716,0.00007835169,0.00018963379],"genre_scores_gemma":[0.9945513,0.00033025912,0.00021991113,0.00082812837,0.0014447834,0.002057454,0.00003394544,0.0001203025,0.00041393057],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945728,0.00045939718,0.0020746216,0.0009873607,0.0010948529,0.0008109654],"domain_scores_gemma":[0.9956139,0.00082028715,0.0010821486,0.0011191678,0.0008877214,0.00047678538],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00071021845,0.0006379546,0.0022662873,0.0001544913,0.00015692062,0.000025836296,0.000470214,0.00030427618,0.0022231296],"category_scores_gemma":[0.00042312435,0.00038411943,0.0006500065,0.0006852327,0.0012292736,0.00046618175,0.00027146772,0.0009508395,0.000022185362],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.766441,0.004497262,0.02904811,0.00006999733,0.0004461997,0.0000061336295,0.0001158161,0.000086061715,0.00024197875,0.000022084947,0.00012342993,0.19890197],"study_design_scores_gemma":[0.8377685,0.0018618488,0.15759577,0.0008721678,0.0004719827,0.000009660178,0.000104565945,0.00007627709,0.0002527585,0.00006646404,0.0004982018,0.00042180854],"about_ca_topic_score_codex":0.0011631994,"about_ca_topic_score_gemma":0.00036159248,"teacher_disagreement_score":0.19848016,"about_ca_system_score_codex":0.00059282983,"about_ca_system_score_gemma":0.00074766466,"threshold_uncertainty_score":0.99986106},"labels":[],"label_agreement":null},{"id":"W2080994407","doi":"10.1038/cdd.2010.173","title":"The 12th international conference on differentiation therapy: targeting the aberrant growth, differentiation and cell death programs of cancer cells","year":2011,"lang":"en","type":"article","venue":"Cell Death and Differentiation","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Eli Lilly and Company; Bristol-Myers Squibb; Eisai; Celgene; Samuel Waxman Cancer Research Foundation","keywords":"Differentiation therapy; Cellular differentiation; Programmed cell death; Cancer research; Cancer; Cell growth; Cancer cell; Biology; Apoptosis; Cell biology; Gene; Genetics","score_opus":0.032540339692004504,"score_gpt":0.25986909124932783,"score_spread":0.22732875155732332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080994407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99207276,0.0019012521,0.0029609103,0.00032675176,0.00053900987,0.00083541026,0.00002043381,0.000052351246,0.0012911115],"genre_scores_gemma":[0.99246967,0.0064159404,0.00024299028,0.00009856735,0.00015180057,0.00014587546,0.00012318874,0.00003542397,0.00031652368],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983244,0.00009793397,0.0004379769,0.00040014627,0.00042395465,0.00031559812],"domain_scores_gemma":[0.9987657,0.00010088181,0.00046420313,0.00026320782,0.00029406144,0.00011195112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016994664,0.00031142158,0.00029459165,0.00009266667,0.00033334136,0.0000972933,0.00017738638,0.00011589585,0.00013669614],"category_scores_gemma":[0.000016576745,0.00018021911,0.00009560692,0.00010112104,0.00013060398,0.0001652405,0.0000633241,0.00023921463,0.0000026149992],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002432743,0.0011919981,0.40616706,0.0003417716,0.00040045922,0.0000025449513,0.0077482816,0.0000063832667,0.4663941,0.0078664115,0.00005712843,0.10739111],"study_design_scores_gemma":[0.0034551753,0.00044010818,0.6717441,0.00015811688,0.00022767913,0.0000030508472,0.0007302353,0.0042537395,0.31354633,0.0049954914,0.00015122534,0.00029476127],"about_ca_topic_score_codex":0.00022013027,"about_ca_topic_score_gemma":0.000039688934,"teacher_disagreement_score":0.26557702,"about_ca_system_score_codex":0.000067571054,"about_ca_system_score_gemma":0.000045903136,"threshold_uncertainty_score":0.7349122},"labels":[],"label_agreement":null},{"id":"W2083337020","doi":"10.1016/j.ejmech.2009.11.020","title":"Radiosynthesis and radiopharmacological evaluation of cyclin-dependent kinase 4 (Cdk4) inhibitors","year":2009,"lang":"en","type":"article","venue":"European Journal of Medicinal Chemistry","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Chemistry; Radiosynthesis; Kinase; Cyclin-dependent kinase 4; Cyclin-dependent kinase; Stereochemistry; Cancer research; Biochemistry; Cyclin-dependent kinase 2; Protein kinase A; Cell cycle; In vivo; Cell; Genetics","score_opus":0.025558618042140015,"score_gpt":0.30731265734872437,"score_spread":0.2817540393065844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083337020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98557496,0.008617912,0.00020656029,0.0017733913,0.0001328624,0.00010473475,0.000002169078,0.000011942927,0.0035754826],"genre_scores_gemma":[0.99729574,0.00030806405,0.0008620592,0.00029488484,0.001165548,4.770135e-7,0.0000014170517,0.000016462856,0.00005537941],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99779725,0.0002323267,0.0006579721,0.00016159414,0.0009859508,0.00016490252],"domain_scores_gemma":[0.99852484,0.00008690938,0.00055211183,0.00014653537,0.00040310048,0.00028650954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002683527,0.00016206679,0.00042883842,0.00006471749,0.000033619817,0.0000055832897,0.00012781454,0.00003839624,0.0003211172],"category_scores_gemma":[0.0006134375,0.00012094,0.0001095233,0.00009854066,0.00017480814,0.00007486597,0.000017987039,0.00040947038,0.0000017892086],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011710094,0.00016137198,0.00047091555,0.000073780975,0.00009262375,0.00061761873,0.00022727648,0.000050564144,0.7461198,0.0000011885298,0.00017597337,0.25083786],"study_design_scores_gemma":[0.014578913,0.0018110028,0.05237609,0.0014754458,0.0015351784,0.008386068,0.0009754653,0.00018199884,0.9157561,0.00016305457,0.0025069697,0.00025371727],"about_ca_topic_score_codex":3.8150333e-7,"about_ca_topic_score_gemma":1.8311601e-8,"teacher_disagreement_score":0.25058416,"about_ca_system_score_codex":0.00014167838,"about_ca_system_score_gemma":0.00014102286,"threshold_uncertainty_score":0.49317902},"labels":[],"label_agreement":null},{"id":"W2091031746","doi":"10.1158/0008-5472.sabcs12-p2-10-02","title":"Abstract P2-10-02: Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with ER+ early breast cancer (EBC): An ABCSG study","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Vancouver Coastal Health","funders":"","keywords":"Medicine; Anastrozole; Internal medicine; Breast cancer; Oncology; Tamoxifen; Population; Aromatase inhibitor; Hormonal therapy; Cancer; Gynecology","score_opus":0.09064113353943677,"score_gpt":0.44428192924448795,"score_spread":0.3536407957050512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091031746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920509,0.00256015,0.000028590552,0.00016031548,0.00024358231,0.0030056331,0.0019141829,0.000018551264,0.00001813008],"genre_scores_gemma":[0.99611247,0.0014127274,0.0001523622,0.000012310335,0.00047130405,0.0017143108,0.000013993926,0.00006709838,0.000043441443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950549,0.00086661224,0.0010850456,0.0006264758,0.001407051,0.0009599187],"domain_scores_gemma":[0.99570197,0.00086368906,0.00083738036,0.00095044443,0.0013626791,0.00028384535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039643846,0.00031302462,0.00078068563,0.00025110616,0.0001360879,0.000021422122,0.00051342626,0.00010839857,0.00030909717],"category_scores_gemma":[0.0004493096,0.00020590608,0.000086726664,0.00090936816,0.0009136604,0.000555063,0.00013970313,0.0010569817,9.976994e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030547565,0.0014824292,0.88806784,0.0002613504,0.00034506878,0.0000035885673,0.0071967994,0.0000791365,0.004425769,0.000005796821,0.000015848664,0.06756884],"study_design_scores_gemma":[0.0059616533,0.004655781,0.97338027,0.0010545058,0.00009826927,0.0000063611883,0.0033091314,0.000013252968,0.011151002,0.00010016725,0.000079970036,0.0001896251],"about_ca_topic_score_codex":0.0054104785,"about_ca_topic_score_gemma":0.0014037784,"teacher_disagreement_score":0.08531247,"about_ca_system_score_codex":0.00047898444,"about_ca_system_score_gemma":0.0010400001,"threshold_uncertainty_score":0.83966064},"labels":[],"label_agreement":null},{"id":"W2105314246","doi":"10.1093/annonc/mdu371","title":"Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer","year":2014,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; Ontario Clinical Oncology Group; University of Toronto","funders":"","keywords":"Exemestane; Everolimus; Medicine; Breast cancer; Oncology; Adverse effect; Internal medicine; Hazard ratio; Scopus; Cancer; Gynecology; Aromatase; MEDLINE; Confidence interval","score_opus":0.03922142997361332,"score_gpt":0.3289051840635258,"score_spread":0.2896837540899125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105314246","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.099143505,0.0005422569,0.0010984847,0.8923642,0.00017650568,0.002742109,0.0012102304,0.00014862485,0.0025740708],"genre_scores_gemma":[0.085492566,0.00019708015,0.0111933965,0.88875365,0.0036525324,0.0029311662,0.00049613544,0.00044883927,0.0068346458],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99676883,0.00007936613,0.0005427129,0.0008354374,0.0006095141,0.0011641256],"domain_scores_gemma":[0.9963824,0.0003434058,0.0009292308,0.00075984595,0.0013400635,0.0002450492],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024415884,0.0007343066,0.002191717,0.00024845888,0.00008630379,0.000013895219,0.00036600948,0.00079031073,0.00050582015],"category_scores_gemma":[0.000014711411,0.00048249055,0.00011520167,0.00021055121,0.0007362413,0.00014602317,0.00005169607,0.0009849361,0.0000044090334],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2458003,0.001079023,0.0066680303,0.0036831556,0.0065321554,0.0011909843,0.0022700927,0.00014712922,0.0005593224,0.00013933459,0.6310617,0.10086879],"study_design_scores_gemma":[0.014079243,0.05343049,0.00800995,0.00097077846,0.00048930664,0.0015925573,0.00017977775,0.000012182089,0.0006592017,0.0004591758,0.9193678,0.000749518],"about_ca_topic_score_codex":0.00021203369,"about_ca_topic_score_gemma":0.00065190636,"teacher_disagreement_score":0.28830615,"about_ca_system_score_codex":0.0004122861,"about_ca_system_score_gemma":0.0013641468,"threshold_uncertainty_score":0.99976265},"labels":[],"label_agreement":null},{"id":"W2112620415","doi":"10.1093/annonc/mdr593","title":"The sequential use of endocrine treatment for advanced breast cancer: where are we?","year":2012,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Fulvestrant; Tamoxifen; Breast cancer; Oncology; Endocrine system; Aromatase; Internal medicine; Metastatic breast cancer; Cancer; Gynecology; Hormone","score_opus":0.3123031055212625,"score_gpt":0.498874483100001,"score_spread":0.18657137757873848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112620415","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000034607183,0.9892171,0.00004938906,0.006102568,0.0006064354,0.002084974,0.0018134156,0.000024870174,0.00006666167],"genre_scores_gemma":[0.000091519905,0.99546033,0.00080218265,0.00011138085,0.0007053146,0.0012368108,0.000083793384,0.000090382746,0.0014182604],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99778,0.00016555535,0.00091880985,0.00034973613,0.00019470019,0.0005911849],"domain_scores_gemma":[0.9962096,0.0008204091,0.0016425769,0.00062849344,0.00054252153,0.00015635598],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001531598,0.00047481616,0.002979573,0.00011847318,0.00007823671,0.0000052452406,0.00021754848,0.00026042532,0.00012060488],"category_scores_gemma":[0.000029709416,0.00028274796,0.0008992505,0.00017271045,0.0003487479,0.000115809955,0.000066034634,0.0002021241,0.0000042220295],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012527753,0.00037905044,0.000039206916,0.007895939,0.0016253218,0.000012615432,0.00006021626,0.0000051879106,0.000023058952,0.00012007225,0.0007201126,0.98786646],"study_design_scores_gemma":[0.001921057,0.0016309666,0.000027543365,0.0062410356,0.0020207965,0.0004032482,0.00006843288,6.671987e-7,0.00013857402,0.000036857957,0.9873152,0.00019566457],"about_ca_topic_score_codex":0.00012356794,"about_ca_topic_score_gemma":0.00031767794,"teacher_disagreement_score":0.9876708,"about_ca_system_score_codex":0.00038243507,"about_ca_system_score_gemma":0.0010243217,"threshold_uncertainty_score":0.99996245},"labels":[],"label_agreement":null},{"id":"W2124253025","doi":"10.1002/14651858.cd011093.pub2","title":"Fulvestrant for hormone-sensitive metastatic breast cancer","year":2017,"lang":"en","type":"review","venue":"Cochrane Database of Systematic Reviews","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fulvestrant; Medicine; Breast cancer; Metastatic breast cancer; Oncology; Internal medicine; Clinical trial; Cancer; Gynecology; Estrogen receptor","score_opus":0.2315875720099776,"score_gpt":0.4659018755320151,"score_spread":0.23431430352203753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124253025","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[2.677458e-7,0.9575696,0.0035247023,0.000054082117,0.0003873184,0.025239138,0.013116199,0.00003962221,0.00006906354],"genre_scores_gemma":[0.0000020184839,0.98260826,0.0050032414,0.000056002948,0.00040377205,0.009369243,0.0018842394,0.00018414458,0.00048905495],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9929422,0.00072043884,0.0041867737,0.00090518896,0.0006860481,0.0005593361],"domain_scores_gemma":[0.9880177,0.001091503,0.00633444,0.0035988726,0.0006480424,0.00030949074],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0029172949,0.0011647063,0.017329045,0.0003140882,0.00015053415,0.00004719873,0.0007185169,0.00018290043,0.00008943945],"category_scores_gemma":[0.0016551432,0.0007084299,0.0023851108,0.000258825,0.0002912215,0.00028438243,0.00011738413,0.00039349057,0.00013795336],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007079056,0.000089382855,5.7123216e-8,0.7787028,0.001204001,0.000048852664,0.00005670206,1.1006948e-7,0.000016918024,0.00007099488,0.00047053065,0.21926887],"study_design_scores_gemma":[0.00091155316,0.00008420487,6.443039e-7,0.6968354,0.018227454,0.0020207134,0.000045125536,0.000009440769,0.000003748497,0.0000063155953,0.28143314,0.00042228223],"about_ca_topic_score_codex":0.00005110482,"about_ca_topic_score_gemma":0.000010806086,"teacher_disagreement_score":0.28096262,"about_ca_system_score_codex":0.00030134435,"about_ca_system_score_gemma":0.00083214644,"threshold_uncertainty_score":0.9995367},"labels":[],"label_agreement":null},{"id":"W2132468839","doi":"10.1158/0008-5472.sabcs12-s1-5","title":"Abstract S1-5: PIK3CA mutations are linked to PgR expression: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) pathology study.","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Neuroblastoma RAS viral oncogene homolog; HRAS; KRAS; Medicine; Internal medicine; Oncology; Exemestane; Hazard ratio; Mutation; Breast cancer; Tamoxifen; Cancer; Cancer research; Genetics; Gene; Biology; Colorectal cancer; Confidence interval","score_opus":0.11909862924820123,"score_gpt":0.469012708659068,"score_spread":0.3499140794108668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132468839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990308,0.002247305,0.00031739855,0.0035684917,0.00038577217,0.0020746137,0.00010787042,0.00011605818,0.0008745307],"genre_scores_gemma":[0.99173224,0.00005584472,0.002127659,0.0004151234,0.0012060202,0.0021983106,0.000058731068,0.000074273106,0.0021317902],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9965765,0.00021875893,0.00039964396,0.00054264633,0.001248987,0.0010134461],"domain_scores_gemma":[0.99725115,0.00035435447,0.00011357714,0.00061551447,0.00102111,0.00064429524],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009554866,0.00024024815,0.00042741257,0.00044032946,0.00034840556,0.000031184747,0.00028465217,0.00013119057,0.0024747564],"category_scores_gemma":[0.0005966826,0.00020599423,0.00007927822,0.00072043657,0.00024898496,0.00028774247,0.00020860917,0.0008282575,0.0005006551],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003770897,0.004066219,0.21434584,0.00036180313,0.00027098693,0.00062246795,0.031362507,0.00045307534,0.6329301,0.00019046827,0.009909281,0.10171636],"study_design_scores_gemma":[0.0039675236,0.00047901904,0.93378586,0.00042348108,0.000035562938,0.0000945669,0.0091568725,0.000019140743,0.009848176,0.00018727948,0.041683044,0.00031948148],"about_ca_topic_score_codex":0.00014092086,"about_ca_topic_score_gemma":0.00010244731,"teacher_disagreement_score":0.71944,"about_ca_system_score_codex":0.0007042219,"about_ca_system_score_gemma":0.00044234868,"threshold_uncertainty_score":0.9984371},"labels":[],"label_agreement":null},{"id":"W2137086876","doi":"10.1007/s00280-006-0371-x","title":"A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers","year":2006,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Pharmacokinetics; Tolerability; Vomiting; Nausea; Pharmacology; Medicine; Pharmacodynamics; Internal medicine; Adverse effect","score_opus":0.014082082024975417,"score_gpt":0.3399569902318229,"score_spread":0.3258749082068475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137086876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98722386,0.005970396,0.000009887723,0.004569295,0.0004243007,0.0016836717,0.000024380879,0.000019336634,0.000074863456],"genre_scores_gemma":[0.99572873,0.0009572572,0.000036868463,0.0025309052,0.000297813,0.00028895854,0.0000017706755,0.000030209958,0.00012746743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983423,0.00013894898,0.00050777907,0.00047535737,0.00017268807,0.00036292538],"domain_scores_gemma":[0.9994088,0.00010255971,0.00014744187,0.00019442687,0.00005090484,0.000095869145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022572573,0.0002425443,0.00055544154,0.00011629866,0.00006967789,0.0000054184966,0.00011209546,0.00008350555,0.000578973],"category_scores_gemma":[0.000004927361,0.0001943348,0.000048121186,0.00026500603,0.0002736015,0.000066911394,0.00004226215,0.0003470185,5.084114e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02071145,0.0068129366,0.69242436,0.0007011351,0.00018382396,0.00007871524,0.0055317003,0.0012591338,0.23172835,0.0000090959,0.00030064318,0.040258642],"study_design_scores_gemma":[0.20210555,0.0051672654,0.59560555,0.00036590916,0.00037830835,0.00016381031,0.0025518842,0.0035157746,0.16943356,0.0003724453,0.019534297,0.00080566877],"about_ca_topic_score_codex":0.0016790844,"about_ca_topic_score_gemma":0.0019383185,"teacher_disagreement_score":0.1813941,"about_ca_system_score_codex":0.00025123043,"about_ca_system_score_gemma":0.000107453714,"threshold_uncertainty_score":0.7924743},"labels":[],"label_agreement":null},{"id":"W2144067295","doi":"10.1200/jop.2011.000496","title":"Development of a Multidisciplinary, Multicampus Subspecialty Practice in Endocrine Cancers","year":2012,"lang":"en","type":"article","venue":"Journal of Oncology Practice","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Nutrition, Metabolism and Diabetes","funders":"Mayo Clinic","keywords":"Subspecialty; Medicine; Multidisciplinary approach; Clinical Practice; Clinical trial; Intensive care medicine; Endocrine system; MEDLINE; Oncology; Family medicine; Internal medicine; Hormone","score_opus":0.03742990464055773,"score_gpt":0.42124949502059444,"score_spread":0.3838195903800367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144067295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9558687,0.008986786,0.0019067659,0.017475953,0.0021312693,0.000650554,0.0000031909465,0.000019950903,0.012956827],"genre_scores_gemma":[0.6050369,0.00046940517,0.39325067,0.0005645366,0.0005624677,0.000010712708,0.0000010366539,0.000021426764,0.00008284773],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99757785,0.00026868936,0.0011069775,0.0001393639,0.00048454592,0.00042259617],"domain_scores_gemma":[0.994548,0.0021029562,0.0020589612,0.00019055646,0.00084036007,0.00025911926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002228787,0.00017311684,0.00066497456,0.00028740545,0.00005764721,0.000004441811,0.000142302,0.00009898067,0.0000866535],"category_scores_gemma":[0.0049025794,0.00014612431,0.00009012742,0.00032453466,0.00014293163,0.001495896,0.0000822453,0.0008233192,0.000012115516],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04941273,0.011009409,0.042800654,0.0002451662,0.001868375,0.003269832,0.073635794,0.0004280142,0.042538796,0.00050919637,0.000561252,0.7737208],"study_design_scores_gemma":[0.008854054,0.0011816839,0.052216586,0.0001808099,0.0004259475,0.016682198,0.020804336,0.000018404273,0.00684221,0.000021803215,0.89260316,0.00016883042],"about_ca_topic_score_codex":0.000050806142,"about_ca_topic_score_gemma":0.00007706775,"teacher_disagreement_score":0.89204186,"about_ca_system_score_codex":0.0019642643,"about_ca_system_score_gemma":0.002353058,"threshold_uncertainty_score":0.59587765},"labels":[],"label_agreement":null},{"id":"W2144498495","doi":"10.1634/theoncologist.2012-0342","title":"Analysis of Regional Timelines To Set Up a Global Phase III Clinical Trial in Breast Cancer: The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Experience","year":2013,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; World Bank Group; GlaxoSmithKline","keywords":"Medicine; Trastuzumab; Institutional review board; Lapatinib; Clinical trial; Breast cancer; Interquartile range; Randomized controlled trial; Informed consent; Internal medicine; Cancer; Surgery; Alternative medicine","score_opus":0.1228155068648815,"score_gpt":0.4756288442860815,"score_spread":0.35281333742119997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144498495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980798,0.00034491208,0.0011247726,0.015718354,0.00018209624,0.0015938869,0.00016655435,0.000026531652,0.00004488048],"genre_scores_gemma":[0.99633753,0.00047928802,0.0008307553,0.0010379591,0.00026600293,0.0008022986,0.00003496645,0.000009123079,0.00020209556],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984274,0.00019124943,0.0006315945,0.0003066978,0.00022804196,0.00021500974],"domain_scores_gemma":[0.9987829,0.00034102474,0.0002646164,0.0003656036,0.00014105193,0.00010483939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031701737,0.00017623855,0.0006837583,0.000064273976,0.00008320784,0.00001564968,0.00017737722,0.00007381519,0.00044962266],"category_scores_gemma":[0.000099201585,0.000081170176,0.00014145211,0.00076300366,0.00051085936,0.00007228844,0.000049717833,0.00009236022,0.0000031011232],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25806212,0.0022734688,0.02676769,0.000014432714,0.0016210757,0.00002063676,0.010265158,0.035782613,0.0001339712,0.000079614845,0.00082447374,0.66415477],"study_design_scores_gemma":[0.40481713,0.01963179,0.3605564,0.0003005687,0.0053868196,0.0002775337,0.028208096,0.17046171,0.00014055194,0.0001273858,0.009267543,0.00082446064],"about_ca_topic_score_codex":0.0039367476,"about_ca_topic_score_gemma":0.001568009,"teacher_disagreement_score":0.6633303,"about_ca_system_score_codex":0.00041466294,"about_ca_system_score_gemma":0.00029858443,"threshold_uncertainty_score":0.5951211},"labels":[],"label_agreement":null},{"id":"W2149472508","doi":"10.1007/s10637-007-9090-3","title":"A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pyrogenesis (Canada)","funders":"","keywords":"Pharmacokinetics; Cmax; Medicine; Tolerability; Bioavailability; Nausea; Adverse effect; Pharmacology; Pharmacodynamics; Maximum tolerated dose; Cyclin-dependent kinase; Dysgeusia; Toxicity; Refractory (planetary science); Oral administration; Internal medicine; Cancer; Cell cycle","score_opus":0.02381757120153434,"score_gpt":0.3125895757310258,"score_spread":0.2887720045294915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149472508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99842745,0.00018604213,0.000027656662,0.00022170936,0.00003795378,0.0010016882,0.000034996592,0.000016560318,0.000045946497],"genre_scores_gemma":[0.99652064,0.0000032587611,0.003044,0.00023208099,0.000038377053,0.000018089575,0.00004956705,0.000028801973,0.00006521206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979231,0.000059397396,0.00073050655,0.00032976677,0.0007341933,0.00022306241],"domain_scores_gemma":[0.99866176,0.00015856882,0.00046899423,0.0001868535,0.00022210837,0.00030171647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002651473,0.00023327688,0.0005150862,0.000320833,0.000044104276,0.000011711831,0.00006114042,0.000043691714,0.000019406725],"category_scores_gemma":[0.0001732399,0.00019140812,0.00002964168,0.00027423547,0.0003147099,0.00026694709,0.000056706274,0.0001594493,8.600413e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042515352,0.03188136,0.5890997,0.00095567445,0.0007533231,0.0003367946,0.05403939,0.00016305072,0.10178633,0.00022555562,0.00005582016,0.17818765],"study_design_scores_gemma":[0.070072934,0.030680021,0.86363727,0.0014752777,0.00028430173,0.000079537116,0.0101579325,0.000052332627,0.021212295,0.0018300643,0.000097437034,0.00042057372],"about_ca_topic_score_codex":0.00046189275,"about_ca_topic_score_gemma":0.00021734372,"teacher_disagreement_score":0.2745376,"about_ca_system_score_codex":0.0001169715,"about_ca_system_score_gemma":0.00039167592,"threshold_uncertainty_score":0.78053963},"labels":[],"label_agreement":null},{"id":"W2149989622","doi":"10.1200/jco.2014.59.3160","title":"<i>PIK3CA</i> Genotype and Treatment Decisions in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer","year":2015,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Genotyping; Personalized medicine; Breast cancer; Exome sequencing; Precision medicine; Multiplex; Genotype; Exome; Epidermal growth factor receptor; Human Epidermal Growth Factor Receptor 2; Oncology; Bioinformatics; Internal medicine; Cancer; Mutation; Genetics; Gene; Pathology; Biology","score_opus":0.13853819431666028,"score_gpt":0.468478089078549,"score_spread":0.3299398947618887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149989622","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1442967,0.004819925,0.00006459507,0.84603,0.002828291,0.00065267243,0.0005024784,0.000019343033,0.0007860266],"genre_scores_gemma":[0.10490509,0.016330432,0.006874147,0.81825113,0.05041287,0.000078893514,0.0001433906,0.00026987726,0.002734164],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99469304,0.0007989374,0.0029188194,0.00047584416,0.0006054802,0.00050786743],"domain_scores_gemma":[0.99211967,0.0033581224,0.00255814,0.00028229476,0.0011286109,0.0005531548],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0010737097,0.0004635044,0.0036035127,0.00033539534,0.00005792151,0.000014677385,0.00023316043,0.0017168705,0.00046766913],"category_scores_gemma":[0.0010629498,0.00031471354,0.000574933,0.00016954663,0.00049236976,0.00017319924,0.00008496034,0.0038954376,0.000017126704],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009074041,0.0012950079,0.034508906,0.0000403373,0.0017344647,0.006216509,0.00045123795,0.0000056332055,0.00023404526,0.000011111942,0.3036513,0.6427774],"study_design_scores_gemma":[0.014434765,0.010068456,0.16561647,0.00056608906,0.00065147656,0.002283842,0.000054747612,0.000002327609,0.000040270617,0.00053467555,0.80543804,0.00030886376],"about_ca_topic_score_codex":0.00031255384,"about_ca_topic_score_gemma":0.00024138876,"teacher_disagreement_score":0.6424685,"about_ca_system_score_codex":0.0019378446,"about_ca_system_score_gemma":0.003831393,"threshold_uncertainty_score":0.9999305},"labels":[],"label_agreement":null},{"id":"W2151082560","doi":"10.1093/annonc/mdu456","title":"Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":568,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Sunnybrook Health Science Centre; University of Toronto","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Exemestane; Human Epidermal Growth Factor Receptor 2; Everolimus; Oncology; Internal medicine; Hormone receptor; Breast cancer; Cancer research; Cancer; Aromatase","score_opus":0.0499435101726918,"score_gpt":0.36322891224759973,"score_spread":0.31328540207490796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151082560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9635448,0.0010103785,0.0018412368,0.018064544,0.00110147,0.0016632943,0.009624958,0.00018496097,0.0029643856],"genre_scores_gemma":[0.98797923,0.0007705692,0.0058335247,0.0025021895,0.0012266365,0.00023928525,0.0007613286,0.00011531145,0.0005719418],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963523,0.00034000204,0.0010547343,0.0009007655,0.00046185628,0.00089029764],"domain_scores_gemma":[0.99520177,0.0015893435,0.00093934534,0.0005474329,0.001334639,0.0003874701],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004370143,0.0005397518,0.001643782,0.00017600498,0.00019358737,0.000013467547,0.00034251978,0.0003844004,0.00032229803],"category_scores_gemma":[0.0005505847,0.0005082938,0.00034985936,0.00020993894,0.00048013846,0.00038048037,0.00011302243,0.00042092978,0.000023680182],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11369114,0.0013905811,0.0026928787,0.00023183295,0.0022187307,0.000031478543,0.0052713505,0.00037000424,0.3965859,0.002771002,0.014460493,0.4602846],"study_design_scores_gemma":[0.091790006,0.020049527,0.5504739,0.0008658407,0.00043815226,0.00007336158,0.001137575,0.0003817494,0.18713245,0.008502736,0.1371137,0.0020409902],"about_ca_topic_score_codex":0.0020701678,"about_ca_topic_score_gemma":0.00031558325,"teacher_disagreement_score":0.54778105,"about_ca_system_score_codex":0.00046703013,"about_ca_system_score_gemma":0.0004472021,"threshold_uncertainty_score":0.99973685},"labels":[],"label_agreement":null},{"id":"W2152377119","doi":"10.1200/jco.2010.28.9918","title":"Do We Have to Change the Way Targeted Drugs Are Developed?","year":2010,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pharmacology; Intensive care medicine","score_opus":0.1740761113745458,"score_gpt":0.4673023573426959,"score_spread":0.29322624596815006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152377119","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035893947,0.00498674,0.00014836834,0.9818713,0.0077634505,0.00063441356,0.000025706328,0.000021479113,0.0009591123],"genre_scores_gemma":[0.0032522313,0.002053442,0.007857998,0.9190873,0.06406877,0.00004932172,0.0000094857705,0.0001078,0.003513663],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943702,0.00067076524,0.0030122872,0.00042185828,0.00092633045,0.00059850904],"domain_scores_gemma":[0.98937684,0.0039387825,0.004289565,0.00065960264,0.0012752941,0.00045991832],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.003266876,0.00043196577,0.0031762638,0.00027507692,0.00008788683,0.000022203456,0.00080815115,0.003738131,0.00079308223],"category_scores_gemma":[0.0036822143,0.00023873786,0.00093110034,0.00020756152,0.00045442348,0.000116579904,0.00018850823,0.018216396,0.00016970382],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014189001,0.00014936185,0.0008388785,0.00005223573,0.00049049663,0.0022639195,0.00058575254,4.9300326e-7,0.000014490263,0.0000037981881,0.56513983,0.42904183],"study_design_scores_gemma":[0.0035193404,0.0029550567,0.0150168175,0.0006034641,0.00047035114,0.0011984438,0.00028173972,0.0000012527513,0.000025709796,0.00064097246,0.9750345,0.0002523752],"about_ca_topic_score_codex":0.0000135457285,"about_ca_topic_score_gemma":0.00006520728,"teacher_disagreement_score":0.42878944,"about_ca_system_score_codex":0.00035916854,"about_ca_system_score_gemma":0.0019525385,"threshold_uncertainty_score":0.9975552},"labels":[],"label_agreement":null},{"id":"W2154488022","doi":"10.1158/1078-0432.ccr-10-1869","title":"Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study","year":2011,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"National Cancer Institute","keywords":"Gefitinib; Tamoxifen; Medicine; Internal medicine; Breast cancer; Placebo; Oncology; Metastatic breast cancer; Cancer; Epidermal growth factor receptor; Pathology","score_opus":0.13883671522188215,"score_gpt":0.4788527990782955,"score_spread":0.34001608385641335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154488022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98969537,0.00049830537,0.00006760738,0.0009855692,0.00008682843,0.008258254,0.00016100558,0.000042589567,0.00020445786],"genre_scores_gemma":[0.9938689,0.00038654945,0.0007393058,0.00019030785,0.0000983465,0.0041954643,0.000046065205,0.00008356496,0.00039149923],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939038,0.0019153656,0.0011090155,0.00087610906,0.0013857849,0.00080991624],"domain_scores_gemma":[0.9961843,0.0015342967,0.0003012376,0.0005018764,0.0011270313,0.00035124805],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0044364934,0.00034541675,0.0015813182,0.0004962795,0.00014903475,0.000023822453,0.00028404957,0.00011005324,0.00093057903],"category_scores_gemma":[0.00057592895,0.00021243704,0.000091665155,0.001548803,0.001072644,0.00032452206,0.00014939754,0.0013985039,0.0000126741825],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7565652,0.013974532,0.16972232,0.0000515158,0.00048405628,0.00012357348,0.004356192,0.000007261037,0.000013548714,0.000023391105,0.00006166049,0.05461674],"study_design_scores_gemma":[0.6195373,0.019548357,0.35802475,0.00073074026,0.0001569466,0.0000060415337,0.0014426537,0.00006467284,0.000050962288,0.00011004003,0.000068013804,0.00025951254],"about_ca_topic_score_codex":0.005320702,"about_ca_topic_score_gemma":0.0047229286,"teacher_disagreement_score":0.18830244,"about_ca_system_score_codex":0.0008296515,"about_ca_system_score_gemma":0.0012194231,"threshold_uncertainty_score":0.9999827},"labels":[],"label_agreement":null},{"id":"W2155477677","doi":"10.1016/j.breast.2015.04.006","title":"One step forward, two steps back: The story of everolimus in advanced breast cancer","year":2015,"lang":"en","type":"article","venue":"The Breast","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Manitoba; University of Toronto; CancerCare Manitoba","funders":"","keywords":"Medicine; Everolimus; Bevacizumab; Breast cancer; Drug; Anticancer drug; Cancer; Cancer drugs; Clinical trial; Intensive care medicine; Oncology; Internal medicine; Pharmacology; Chemotherapy","score_opus":0.025772968564792453,"score_gpt":0.2992484553007128,"score_spread":0.27347548673592037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155477677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9511024,0.008741053,0.00077276333,0.03120629,0.00075131666,0.0020697378,0.0005211357,0.00013351899,0.004701822],"genre_scores_gemma":[0.9965506,0.00008942587,0.00048920995,0.000991199,0.000436177,0.00012393511,0.000009436557,0.000067436,0.0012425712],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99793047,0.0002484674,0.00038598082,0.00032655324,0.0006106314,0.0004978706],"domain_scores_gemma":[0.9981452,0.00017557073,0.00024828993,0.00091882906,0.0003206211,0.0001914729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077586016,0.00027438664,0.0005394118,0.00009897187,0.00009396816,0.000010585248,0.00043675664,0.00006899049,0.0002657269],"category_scores_gemma":[0.000035686335,0.00016860153,0.000121235076,0.00046218283,0.00043565643,0.00020146664,0.0001323105,0.0005643997,0.000079908285],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013698952,0.00074672006,0.036215927,0.00021699458,0.0005869627,0.000023681043,0.0065408098,0.0037125037,0.008076578,0.0009417019,0.0013621515,0.927877],"study_design_scores_gemma":[0.026976887,0.00044452646,0.9292787,0.0014985618,0.00044310908,0.002456787,0.010044995,0.0007310857,0.0015958125,0.0017264528,0.024045223,0.0007579004],"about_ca_topic_score_codex":0.0010731723,"about_ca_topic_score_gemma":0.00088707305,"teacher_disagreement_score":0.92711914,"about_ca_system_score_codex":0.00043870558,"about_ca_system_score_gemma":0.00042729563,"threshold_uncertainty_score":0.6875371},"labels":[],"label_agreement":null},{"id":"W2156785084","doi":"10.1016/j.ijrobp.2014.05.174","title":"Population-Based Analysis of the Impact and Generalizability of the Nsabp B24 Study on Endocrine Therapy (ET) for Ductal Carcinoma in Situ (DCIS) of the Breast","year":2014,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Institutes of Health; Breast Cancer Research Foundation","keywords":"Medicine; Generalizability theory; Breast cancer; Ductal carcinoma; Population; Cohort; Radiation therapy; Internal medicine; Oncology; Cancer; Gynecology","score_opus":0.02141761027247571,"score_gpt":0.3660888138781245,"score_spread":0.3446712036056488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156785084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956705,0.00011602641,0.0008021953,0.0024034136,0.00038259864,0.00048349195,0.00012104473,0.0000028878,0.000017827015],"genre_scores_gemma":[0.999221,0.000013877595,0.00015968239,0.0003378942,0.00022705643,0.000011224345,0.000013759065,0.000012205607,0.0000032670969],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981862,0.0005526654,0.00070257403,0.00015407734,0.00029044953,0.00011404489],"domain_scores_gemma":[0.99675506,0.0006632405,0.0016674325,0.00029166034,0.000591124,0.00003146859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006622578,0.00014443051,0.0005574531,0.00015319017,0.00004142071,0.0000043970335,0.00035778584,0.00006571345,0.000010644955],"category_scores_gemma":[0.00032550097,0.00007364921,0.00043503082,0.00038250367,0.00022030792,0.00007474908,0.000043463155,0.0002186147,5.674083e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011490269,0.0007185638,0.94680893,0.000005825873,0.00091602677,2.9806358e-7,0.0006349306,0.020900471,0.013429684,0.0007087997,0.0000044066164,0.014723055],"study_design_scores_gemma":[0.005538029,0.0008422295,0.9807253,0.000027304388,0.00024521042,0.000022536193,0.000091296155,0.0043670563,0.0058212425,0.0022187622,0.000045843502,0.00005518048],"about_ca_topic_score_codex":0.00024354347,"about_ca_topic_score_gemma":0.000112173235,"teacher_disagreement_score":0.033916395,"about_ca_system_score_codex":0.00036136663,"about_ca_system_score_gemma":0.0002998951,"threshold_uncertainty_score":0.30033275},"labels":[],"label_agreement":null},{"id":"W2213285461","doi":"10.3747/co.22.2700","title":"Does CDKN2A Loss Predict Palbociclib Benefit?","year":2015,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"U.S. Food and Drug Administration; Incyte; Pfizer","keywords":"Palbociclib; CDKN2A; Medicine; Letrozole; Kinase; Breast cancer; Estrogen receptor; Oncology; Cancer research; Internal medicine; Cyclin-dependent kinase; Regulator; Cancer; Pharmacology; Metastatic breast cancer; Cell cycle; Biology; Tamoxifen; Cell biology","score_opus":0.10587410463903617,"score_gpt":0.4210296053006268,"score_spread":0.3151555006615906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2213285461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9481123,0.011948814,0.0022081332,0.015402758,0.012856684,0.0010217516,0.00008169131,0.00055862864,0.007809221],"genre_scores_gemma":[0.99296767,0.00037276268,0.001504694,0.00067237223,0.002605607,0.00014624865,0.00008432585,0.00005211238,0.0015942332],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986894,0.000045733068,0.00027791352,0.0003330209,0.0002625489,0.00039138686],"domain_scores_gemma":[0.9988502,0.00007457826,0.000117630545,0.0003487918,0.00023606146,0.0003726978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019045144,0.00018584698,0.00042489285,0.00008724277,0.000041652867,0.0000072754556,0.00013977772,0.0001265516,0.0002289397],"category_scores_gemma":[0.00012252446,0.000113970396,0.00008539782,0.00015138744,0.00023963486,0.0001006231,0.00008542221,0.0003140747,0.00017730714],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013604957,0.00082797965,0.20785847,0.00012147327,0.00011596296,0.00011468043,0.0014901775,0.00002382707,0.00033277343,0.0012726285,0.005420593,0.78106093],"study_design_scores_gemma":[0.0051172916,0.0007941881,0.013414149,0.0000891159,0.00008721908,0.00016233536,0.00038658828,0.00009170363,0.00047397384,0.0047710123,0.9744493,0.00016315379],"about_ca_topic_score_codex":0.000011851342,"about_ca_topic_score_gemma":0.0000340232,"teacher_disagreement_score":0.96902865,"about_ca_system_score_codex":0.00046939173,"about_ca_system_score_gemma":0.00038340324,"threshold_uncertainty_score":0.46475777},"labels":[],"label_agreement":null},{"id":"W2223384622","doi":"10.1158/1538-7445.sabcs14-p1-13-07","title":"Abstract P1-13-07: A phase III study of fulvestrant 500 mg versus 250 mg in postmenopausal Chinese women with advanced breast cancer and disease progression following failure on prior antiestrogen or aromatase inhibitor therapy: Supporting superior clinical benefit for the","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Fulvestrant; Medicine; Internal medicine; Hazard ratio; Breast cancer; Tolerability; Antiestrogen; Aromatase inhibitor; Oncology; Clinical endpoint; Cancer; Population; Adverse effect; Randomized controlled trial; Tamoxifen; Gynecology; Confidence interval","score_opus":0.08213161146119569,"score_gpt":0.47809687708098275,"score_spread":0.39596526561978707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2223384622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873041,0.0036963117,0.0000027408107,0.00207198,0.00025434513,0.006018468,0.00059673394,0.000051960815,0.000003345516],"genre_scores_gemma":[0.99458784,0.0003800688,0.00016697857,0.00007388946,0.0004945265,0.004114616,0.00003545408,0.00011636139,0.000030284551],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.995692,0.00014508041,0.00085773424,0.00091270916,0.0013163512,0.0010761075],"domain_scores_gemma":[0.9969039,0.000731577,0.0002950662,0.00071782764,0.00044733647,0.0009043195],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017568299,0.00045517745,0.0009144425,0.00024941994,0.00029642772,0.00007262754,0.00033347597,0.000113491755,0.000099331315],"category_scores_gemma":[0.0003744051,0.00025247876,0.00009256327,0.000671712,0.00044058866,0.00038830264,0.0001312173,0.00075971545,0.0000012161013],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5363599,0.0040834467,0.12478325,0.00035280298,0.0007998056,0.00057216734,0.009517965,0.00021875768,0.014419053,0.0000044461135,0.000043213753,0.30884516],"study_design_scores_gemma":[0.3575541,0.05573043,0.4885982,0.0043665767,0.0003822289,0.000084284875,0.08806805,0.0003313418,0.0022354804,0.00011869487,0.0013329486,0.0011976486],"about_ca_topic_score_codex":0.00062523736,"about_ca_topic_score_gemma":0.00098721,"teacher_disagreement_score":0.36381495,"about_ca_system_score_codex":0.00059443683,"about_ca_system_score_gemma":0.0023514952,"threshold_uncertainty_score":0.9999927},"labels":[],"label_agreement":null},{"id":"W2226239069","doi":"10.1158/1538-7445.sabcs14-p3-05-15","title":"Abstract P3-05-15: Divergent activation of AKT1 and AKT2 isoforms downstream of PI3K mutation impacts response of breast cancer cells to estradiol and PI3K inhibitors","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"PI3K/AKT/mTOR pathway; AKT2; Protein kinase B; AKT1; Cancer research; Estrogen receptor; Breast cancer; Fulvestrant; Biology; Endocrinology; Estrogen; Phosphorylation; Internal medicine; Medicine; Cancer; Signal transduction; Cell biology","score_opus":0.05796178867786553,"score_gpt":0.3945458219769818,"score_spread":0.33658403329911624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2226239069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962287,0.0012082248,0.000045807938,0.0012202789,0.00011056605,0.00082932034,0.0002980253,0.000013654887,0.000045403583],"genre_scores_gemma":[0.9988598,0.00049530383,0.00024876976,0.000037300786,0.0001365753,0.00009191274,0.000009502519,0.000032436077,0.00008836497],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978489,0.00009741598,0.00044803,0.00033378994,0.0008845746,0.0003872721],"domain_scores_gemma":[0.9977922,0.00021238155,0.00023563358,0.00029915065,0.001029982,0.0004306888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009720987,0.00018260533,0.0004370212,0.0004564749,0.000054344982,0.000011956182,0.00010723638,0.000109077424,0.00010325773],"category_scores_gemma":[0.0002141585,0.00014981009,0.00004660472,0.0006094206,0.00042642388,0.00029057864,0.00008857596,0.0002599903,0.0000015947247],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017348597,0.00014068547,0.012143855,0.0006371396,0.00011536814,0.000008485433,0.00481878,0.0004224265,0.90343183,0.000010186249,0.00047243517,0.060450185],"study_design_scores_gemma":[0.0023804305,0.0008272827,0.31738988,0.00096691045,0.00002712505,0.000024363562,0.0018560229,0.000026399288,0.6760754,0.00009140156,0.00021722697,0.000117551375],"about_ca_topic_score_codex":0.005131324,"about_ca_topic_score_gemma":0.00013142318,"teacher_disagreement_score":0.30524603,"about_ca_system_score_codex":0.0005341642,"about_ca_system_score_gemma":0.0009880378,"threshold_uncertainty_score":0.7757061},"labels":[],"label_agreement":null},{"id":"W2226900876","doi":"10.1200/jco.2014.32.26_suppl.152","title":"Everolimus plus exemestane in patients with advanced invasive lobular carcinoma: Efficacy and safety results from BOLERO-2.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Everolimus; Exemestane; Internal medicine; Hazard ratio; Population; Oncology; Gastroenterology; Urology; Breast cancer; Cancer; Aromatase; Confidence interval","score_opus":0.035515576600396746,"score_gpt":0.3611832219876269,"score_spread":0.3256676453872302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2226900876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99561286,0.00048376748,0.00037281206,0.0022906607,0.00044915828,0.0003313466,0.000015591575,0.000009261755,0.00043451466],"genre_scores_gemma":[0.98822874,0.000236064,0.00926096,0.0016756892,0.00052105414,0.0000023629384,0.000014621233,0.000026522055,0.000033986464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964413,0.0003946815,0.0021432405,0.0003296851,0.00040630723,0.00028476844],"domain_scores_gemma":[0.99304116,0.004062223,0.0017142479,0.0003015,0.00047958997,0.00040130856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013073091,0.00020076451,0.0017089769,0.000115156494,0.00003267694,0.0000055257383,0.00014960744,0.00028081273,0.000020686048],"category_scores_gemma":[0.0051572863,0.00013780448,0.00011880269,0.00013969243,0.00030191924,0.00018239672,0.0000613336,0.00096370204,0.0000045552956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23351786,0.0014028283,0.38408518,0.000024626079,0.00026255954,0.00044353484,0.0005298232,0.00050441653,0.000083587904,0.000028046341,0.00008221775,0.37903532],"study_design_scores_gemma":[0.11173183,0.015924565,0.8579216,0.00029300185,0.00015260428,0.000048189875,0.00008444629,0.000036199355,0.000032489537,0.00022820446,0.013422095,0.00012475891],"about_ca_topic_score_codex":0.00003767013,"about_ca_topic_score_gemma":0.000096970194,"teacher_disagreement_score":0.47383645,"about_ca_system_score_codex":0.0003121679,"about_ca_system_score_gemma":0.0009265749,"threshold_uncertainty_score":0.6174126},"labels":[],"label_agreement":null},{"id":"W2240057089","doi":"10.5539/cco.v5n1p31","title":"GPCRs, at the Crossroad of Distortions in Extracellular Microenvironment and Intracellular Energetics Homeostasis, a New Model for 21st Century Cancer Therapeutics","year":2016,"lang":"en","type":"article","venue":"Cancer and Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"G protein-coupled receptor; Biology; Carcinogenesis; Intracellular; Cancer cell; Signal transduction; Tumor microenvironment; Extracellular; Systems biology; Cancer; Receptor; Malignant transformation; Cell; Cell biology; Cell signaling; Computational biology; Neuroscience; Bioinformatics; Cancer research; Genetics","score_opus":0.06168148902612671,"score_gpt":0.38743528173658265,"score_spread":0.32575379271045596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240057089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7794016,0.19203871,0.0073388144,0.019961063,0.00035276372,0.00066483684,0.00020691448,0.0000119352335,0.00002337244],"genre_scores_gemma":[0.7621513,0.2323742,0.0011774565,0.0013132651,0.00026495632,0.00017322283,0.000007927623,0.000032538952,0.0025051227],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99853915,0.00005697757,0.0006244947,0.00036714514,0.000111884336,0.00030036614],"domain_scores_gemma":[0.9988194,0.0004599777,0.00023936907,0.00026058877,0.00004583259,0.00017481536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000273767,0.00017198404,0.00054290233,0.00003100963,0.00007519706,0.0000039193874,0.00008797481,0.00021086447,0.00008204659],"category_scores_gemma":[0.000040413976,0.00010140553,0.00011089752,0.00005818592,0.000931812,0.00004097625,0.00008175168,0.00017812745,7.0667966e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018696357,0.0003052875,0.045218684,0.00006147316,0.00022304613,0.0000040666937,0.00057882705,0.00012368485,0.027398583,0.0004111324,0.00020635124,0.92359924],"study_design_scores_gemma":[0.017582143,0.0013625936,0.06282547,0.0003170234,0.0009460325,0.000026641786,0.00050508376,0.0018398984,0.006542506,0.0018345433,0.9058179,0.00040015695],"about_ca_topic_score_codex":0.000100709956,"about_ca_topic_score_gemma":0.0009103953,"teacher_disagreement_score":0.92319906,"about_ca_system_score_codex":0.00045782307,"about_ca_system_score_gemma":0.0004168577,"threshold_uncertainty_score":0.41351977},"labels":[],"label_agreement":null},{"id":"W2247411625","doi":"10.1200/jco.2012.30.15_suppl.512","title":"Effects of everolimus (EVE) on disease progression in bone and bone markers (BM) in patients (pts) with bone metastases (mets).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Bone remodeling; N-terminal telopeptide; Denosumab; Everolimus; Bone resorption; Clinical endpoint; Bisphosphonate; Bone mineral; Endocrinology; Osteoporosis; Oncology; Clinical trial; Osteocalcin; Alkaline phosphatase","score_opus":0.03234412571618997,"score_gpt":0.413646612018509,"score_spread":0.381302486302319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247411625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925442,0.0054587694,0.000023863175,0.0011461437,0.00028379518,0.00046449393,0.000003952917,0.0000049623195,0.000069842186],"genre_scores_gemma":[0.99616957,0.00043420185,0.0022268682,0.0008674681,0.0002397505,0.000013657557,0.0000026508187,0.000023777686,0.000022055468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99668294,0.00061794365,0.0016815795,0.00018919099,0.000490037,0.000338289],"domain_scores_gemma":[0.995452,0.0021111774,0.0015463002,0.00016154227,0.00017024542,0.00055875955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021566227,0.00018665957,0.0016547799,0.0003095832,0.000015808711,0.00000267985,0.000060533486,0.0001708626,0.000022990836],"category_scores_gemma":[0.0023958003,0.00011889452,0.00015778233,0.00021078138,0.00029441845,0.00023250363,0.000049357564,0.0007305812,0.0000019783388],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.085643806,0.0065294025,0.64626956,0.00019764974,0.00012926705,0.0006296425,0.00008607396,0.000009513338,0.00011543902,0.000012164217,0.00008091712,0.26029655],"study_design_scores_gemma":[0.0329428,0.013236923,0.94908714,0.0012774245,0.0002941935,0.00007459458,0.000042882602,0.000010142871,0.00017254204,0.00009157,0.0026618976,0.000107866974],"about_ca_topic_score_codex":0.000008579303,"about_ca_topic_score_gemma":0.0000118540775,"teacher_disagreement_score":0.30281758,"about_ca_system_score_codex":0.00019264016,"about_ca_system_score_gemma":0.0003858705,"threshold_uncertainty_score":0.48483777},"labels":[],"label_agreement":null},{"id":"W2268138802","doi":"10.1038/nrclinonc.2015.236","title":"Academic research sheds light on issues that matter to patients","year":2016,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Université de Montréal","funders":"","keywords":"Medicine; Breast cancer; Adjuvant; Oncology; Adjuvant chemotherapy; Disease; Stage (stratigraphy); Clinical trial; Intensive care medicine; Internal medicine; Cancer","score_opus":0.34109635688056944,"score_gpt":0.6409072574456448,"score_spread":0.29981090056507537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2268138802","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004345879,0.96356773,0.0000054637385,0.017810242,0.0029641811,0.0064479304,0.000051862142,0.00006678044,0.009081445],"genre_scores_gemma":[0.0000016351116,0.96304727,0.0009875519,0.019619687,0.0058391457,0.0011223292,0.00009040044,0.00020308465,0.0090888785],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9877718,0.0047167707,0.0033896985,0.001829904,0.0011250069,0.001166795],"domain_scores_gemma":[0.9899773,0.0053522736,0.0013292471,0.0019151438,0.0005254794,0.000900552],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.007272292,0.00094407535,0.009605443,0.00064920617,0.00011243537,0.000015496556,0.0011954486,0.0068376716,0.0025094158],"category_scores_gemma":[0.0068620606,0.0004953885,0.0018877763,0.0008924757,0.00037799607,0.00009618589,0.0005401394,0.014560132,0.03022259],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028337757,0.00032949992,0.00036101034,0.006689002,0.00018865983,0.000037048554,0.000016472728,1.6309795e-9,1.5577122e-7,0.00009704879,0.13431317,0.85768455],"study_design_scores_gemma":[0.0011771967,0.0022450394,0.00037584017,0.074613556,0.0005589182,0.000044745248,0.0000016648546,6.792653e-9,7.4311123e-7,0.00015879086,0.9203862,0.00043727693],"about_ca_topic_score_codex":0.0000020403131,"about_ca_topic_score_gemma":0.0000038650055,"teacher_disagreement_score":0.8572473,"about_ca_system_score_codex":0.0015408475,"about_ca_system_score_gemma":0.0009692609,"threshold_uncertainty_score":0.9997498},"labels":[],"label_agreement":null},{"id":"W2269518340","doi":"10.2139/ssrn.2287636","title":"Subcellular Localization and Functional Activity of the Cyclin-Dependent Kinase Inhibitor p21 WAF1/CIP1","year":2009,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Cell biology; Subcellular localization; Kinase; Cyclin-dependent kinase; Chemistry; Cancer research; Biology; Biochemistry; Cell cycle; Cell; Cytoplasm","score_opus":0.007449252720182192,"score_gpt":0.23734530295920936,"score_spread":0.22989605023902718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2269518340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94384956,0.004301343,0.048774164,0.002537145,0.00020315706,0.0001894351,0.0000022222184,0.00001903164,0.00012396071],"genre_scores_gemma":[0.9979818,0.0007590403,0.000043750573,0.00023786585,0.0004082209,0.0000020299979,0.0000022460217,0.000014889343,0.00055017276],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984628,0.00006802855,0.00021854728,0.00016133754,0.0003930101,0.00069630693],"domain_scores_gemma":[0.99941593,0.000022022827,0.00018942378,0.00017393468,0.00012210938,0.000076550816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004824066,0.00013516765,0.00019924111,0.000068474976,0.00016048567,0.000012087014,0.000067993315,0.000070785056,0.000027758399],"category_scores_gemma":[0.0000472786,0.000093851835,0.00009636632,0.00015761175,0.00008431237,0.00015039628,0.000019796873,0.00096639874,0.000002116535],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040335823,0.0008159042,0.02077987,0.000061821665,0.00046715085,0.00002052017,0.00045008998,0.0012886178,0.62343067,0.031230286,0.00006598377,0.3173555],"study_design_scores_gemma":[0.017703567,0.004468696,0.19590542,0.00056746905,0.0007389917,0.008671909,0.0025010887,0.0018182882,0.4286597,0.33224407,0.0058760187,0.00084478594],"about_ca_topic_score_codex":0.000015043265,"about_ca_topic_score_gemma":0.00006446488,"teacher_disagreement_score":0.3165107,"about_ca_system_score_codex":0.0006615188,"about_ca_system_score_gemma":0.00092169683,"threshold_uncertainty_score":0.41985753},"labels":[],"label_agreement":null},{"id":"W2275911521","doi":"10.1200/jco.2012.30.15_suppl.559","title":"Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Exemestane; Everolimus; Anastrozole; Hazard ratio; Internal medicine; Aromatase inhibitor; Letrozole; Clinical endpoint; Interim analysis; Progression-free survival; Breast cancer; Oncology; Population; Cancer; Randomized controlled trial; Tamoxifen; Confidence interval; Chemotherapy","score_opus":0.07042906341995182,"score_gpt":0.46638610420318527,"score_spread":0.39595704078323346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275911521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98406804,0.0007380778,0.00023104035,0.011354074,0.002202441,0.0009641104,0.00014632811,0.000012400124,0.00028347707],"genre_scores_gemma":[0.9916926,0.00022866923,0.0027782887,0.0024393674,0.0025043923,0.000054946868,0.0000042853026,0.00003560059,0.00026182042],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996006,0.00030129362,0.0025578937,0.00019028258,0.00043809926,0.0005064172],"domain_scores_gemma":[0.9931341,0.0012960196,0.0038315207,0.00035158216,0.00090263964,0.00048416763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029048477,0.00020335962,0.0018278902,0.000081108716,0.000058924034,0.0000034684408,0.00027416906,0.0002585684,0.00010154957],"category_scores_gemma":[0.000939713,0.00010827658,0.00027197337,0.00023217479,0.00039662872,0.0002615234,0.000049028247,0.00071188185,0.0000014573701],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72810733,0.0034437221,0.0010231823,0.000020883066,0.00075461296,0.000013188295,0.0003289932,0.000046125577,0.0024237975,0.000030029503,0.0008234362,0.26298472],"study_design_scores_gemma":[0.7021199,0.06587335,0.05328062,0.0002468354,0.0007891543,0.0007983108,0.0005252707,0.000016770382,0.0012489981,0.00018648135,0.17472717,0.00018712926],"about_ca_topic_score_codex":0.00001465127,"about_ca_topic_score_gemma":0.000014526218,"teacher_disagreement_score":0.2627976,"about_ca_system_score_codex":0.00040798838,"about_ca_system_score_gemma":0.0020737099,"threshold_uncertainty_score":0.44153908},"labels":[],"label_agreement":null},{"id":"W2290950904","doi":"10.1016/s1470-2045(15)00613-0","title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1822,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Calgary","funders":"University of California, Los Angeles; Novartis; Daiichi-Sankyo; Pfizer; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline; U.S. Department of Defense","keywords":"Fulvestrant; Palbociclib; Metastatic breast cancer; Medicine; Placebo; Internal medicine; Oncology; Gynecology; Cancer; Breast cancer; Estrogen receptor","score_opus":0.12359904773172471,"score_gpt":0.4149209742192354,"score_spread":0.2913219264875107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2290950904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96481967,0.0021749714,0.0005811652,0.007998017,0.0006042545,0.022109782,0.0015490246,0.0000544999,0.000108610315],"genre_scores_gemma":[0.9884078,0.0026320722,0.00058915414,0.00017176497,0.00052436313,0.0073074047,0.000062323445,0.00005784004,0.0002472751],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962571,0.0008829798,0.0010010242,0.0005819036,0.0005457136,0.00073124445],"domain_scores_gemma":[0.9924019,0.004889149,0.0013844419,0.00080094807,0.0003689285,0.0001546299],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059271476,0.0005879899,0.0035984502,0.00020126272,0.00016044178,0.000013609078,0.00041842132,0.00012750113,0.00020939013],"category_scores_gemma":[0.00012076191,0.0002531136,0.0011333455,0.00051390927,0.0008510839,0.00009407445,0.000030168732,0.00016547665,0.0000023859664],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92660457,0.0028472736,0.0000849642,0.000044828284,0.018238919,0.000019354926,0.0023965596,0.00054804207,0.009399512,0.00011149618,0.000034896064,0.03966961],"study_design_scores_gemma":[0.9468176,0.014563386,0.0010726503,0.00014022375,0.008859046,0.00002253284,0.00046385848,0.0006455318,0.02638,0.000036872534,0.0007420401,0.00025628845],"about_ca_topic_score_codex":0.00039338408,"about_ca_topic_score_gemma":0.0005001402,"teacher_disagreement_score":0.03941332,"about_ca_system_score_codex":0.0010323165,"about_ca_system_score_gemma":0.0009422986,"threshold_uncertainty_score":0.99999213},"labels":[],"label_agreement":null},{"id":"W2296942186","doi":"10.1200/jco.2015.33.18_suppl.lba502","title":"PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Fulvestrant; Palbociclib; Medicine; Metastatic breast cancer; Internal medicine; Goserelin; Clinical endpoint; Oncology; Breast cancer; Interim analysis; Tolerability; Cancer; Gynecology; Tamoxifen; Clinical trial; Adverse effect","score_opus":0.12490245384450548,"score_gpt":0.4693961585716095,"score_spread":0.344493704727104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2296942186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99142057,0.00078722555,0.00005910977,0.0049602245,0.00021045886,0.0024250338,0.00005452728,0.00001521389,0.00006763446],"genre_scores_gemma":[0.99233747,0.0013149625,0.004834241,0.0006063688,0.0005061004,0.00023381753,0.0000050446956,0.000059535116,0.000102459],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957074,0.0006184732,0.00192642,0.0004193924,0.0008372167,0.0004911132],"domain_scores_gemma":[0.9940129,0.0013265074,0.0027231604,0.00025342102,0.0009862756,0.000697761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019816512,0.00039451465,0.0028617608,0.00024015228,0.00003775841,0.000017671435,0.00018575898,0.00017150486,0.00007843775],"category_scores_gemma":[0.00023870269,0.00020507367,0.00008488177,0.00035471338,0.00078289775,0.0003336707,0.000034464098,0.0010887937,8.1218e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8186631,0.007367932,0.0057429066,0.000040638177,0.0017420787,0.0006571252,0.0030987642,0.000022390714,0.001536369,0.000008522107,0.000012245684,0.16110788],"study_design_scores_gemma":[0.66150737,0.28378028,0.048710357,0.0005600611,0.00038900485,0.0014317615,0.0019047624,0.000010213095,0.0008728873,0.000046885627,0.00057278096,0.00021360202],"about_ca_topic_score_codex":0.00018419589,"about_ca_topic_score_gemma":0.00033254418,"teacher_disagreement_score":0.27641237,"about_ca_system_score_codex":0.00040349682,"about_ca_system_score_gemma":0.003907904,"threshold_uncertainty_score":0.8362661},"labels":[],"label_agreement":null},{"id":"W2308811910","doi":"10.1158/1557-3125.advbc-ia18","title":"Abstract IA18: Targeting the androgen receptor in multiple breast cancer subtypes","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Androgen receptor; Tamoxifen; Breast cancer; Cancer research; Estrogen receptor; Androgen; Estrogen receptor alpha; Internal medicine; Endocrinology; Cancer; Endocrine system; Medicine; Biology; Prostate cancer; Hormone","score_opus":0.04010799196918155,"score_gpt":0.36241512016223965,"score_spread":0.32230712819305807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2308811910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96630996,0.013702746,0.000047777154,0.01778647,0.00014817904,0.0013751206,0.00005752814,0.000055503253,0.0005167115],"genre_scores_gemma":[0.9957222,0.0007597507,0.00029923112,0.0006318148,0.00033011503,0.001718071,0.000016378013,0.00008192538,0.0004405439],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99715006,0.0001748334,0.00031755923,0.0005084752,0.00092094776,0.00092812494],"domain_scores_gemma":[0.99850374,0.00016024955,0.0000697487,0.00050495064,0.0005501323,0.00021120337],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007128043,0.00022064053,0.00030542538,0.00021293972,0.00020968674,0.00007528151,0.0003495679,0.00011506286,0.004197958],"category_scores_gemma":[0.0001408473,0.00015582964,0.000101422906,0.0008114612,0.00034516712,0.0001876074,0.00014206175,0.0009175171,0.00023594288],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060693204,0.00014034534,0.107905984,0.00016637455,0.00016157386,0.00008164825,0.0008033476,0.00046367673,0.7637448,0.0000528657,0.0030499373,0.122822545],"study_design_scores_gemma":[0.0060889884,0.00016533506,0.54148114,0.0012001802,0.00004374135,0.00008082552,0.0025226732,0.0010122332,0.36978963,0.000895,0.075924575,0.0007956843],"about_ca_topic_score_codex":0.01910673,"about_ca_topic_score_gemma":0.00079130806,"teacher_disagreement_score":0.43357512,"about_ca_system_score_codex":0.0006560101,"about_ca_system_score_gemma":0.00048150335,"threshold_uncertainty_score":0.9967123},"labels":[],"label_agreement":null},{"id":"W2312914698","doi":"10.1158/0008-5472.sabcs10-p2-09-16","title":"Abstract P2-09-16: Effect of Continuous Statistically Standardized qPCR and IHC ER and PR on Disease-Free Survival in NCIC CTG MA.12","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Calgary; Queen's University; University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Tamoxifen; Breast cancer; Immunohistochemistry; Oncology; Proportional hazards model; Placebo; Randomization; Cancer; Gynecology; Clinical trial; Pathology","score_opus":0.028941889105593206,"score_gpt":0.39891292314582,"score_spread":0.3699710340402268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2312914698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994116,0.0018569281,0.00007555682,0.0011279514,0.00016379387,0.0010627535,0.00046016392,0.000026906304,0.0011099395],"genre_scores_gemma":[0.9985125,0.00035235367,0.00024076289,0.00004527329,0.00018803056,0.00019523218,0.000013863917,0.00005133365,0.00040066394],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974802,0.00020335156,0.00029219931,0.00046879266,0.0009942553,0.00056121557],"domain_scores_gemma":[0.99736863,0.0013286985,0.00006636365,0.0005479031,0.00027066318,0.00041776063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016091948,0.00020840508,0.0005795188,0.00022983883,0.000076485696,0.000034956985,0.00016803147,0.00010092599,0.00048532832],"category_scores_gemma":[0.0015012689,0.00016372158,0.0000424993,0.00020699587,0.00083466043,0.00008986857,0.00012711875,0.00094590895,0.000005101724],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.082772836,0.00033173562,0.28402892,0.0031620373,0.00029035308,0.00064012886,0.0006911215,0.000010983704,0.19512062,0.0021831251,0.001250858,0.4295173],"study_design_scores_gemma":[0.0151948,0.0014399237,0.9580163,0.0008301335,0.000057614656,0.000015342493,0.00012549765,0.000022945445,0.015081018,0.0023645796,0.0065870923,0.000264804],"about_ca_topic_score_codex":0.0006675443,"about_ca_topic_score_gemma":0.001259118,"teacher_disagreement_score":0.6739873,"about_ca_system_score_codex":0.00021823712,"about_ca_system_score_gemma":0.0004354784,"threshold_uncertainty_score":0.6676372},"labels":[],"label_agreement":null},{"id":"W2313479654","doi":"10.1093/annonc/mdw139","title":"Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":178,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Pfizer","keywords":"Fulvestrant; Palbociclib; Medicine; Placebo; Internal medicine; Quality of life (healthcare); Breast cancer; Metastatic breast cancer; Oncology; Cancer; Confidence interval; Anastrozole; Gynecology; Estrogen receptor; Tamoxifen","score_opus":0.08696416881545778,"score_gpt":0.3862310724140349,"score_spread":0.29926690359857716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313479654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819459,0.0010101834,0.00009091135,0.014183859,0.00009787821,0.0016788972,0.0008087656,0.000030442008,0.00015317975],"genre_scores_gemma":[0.9971638,0.0007366595,0.0006337848,0.0010247955,0.00007119131,0.00025160363,0.000033438748,0.000034730543,0.00005000457],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9966678,0.00077837217,0.001290485,0.00042075952,0.00043380295,0.00040877587],"domain_scores_gemma":[0.9953089,0.0020848333,0.0013986196,0.0004727977,0.00056800287,0.00016689581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054383307,0.0003088017,0.0016333046,0.00009506706,0.000039202023,0.0000037933455,0.00017253398,0.00012823178,0.00022630984],"category_scores_gemma":[0.0005261194,0.00015410711,0.00019497356,0.00034040958,0.0007033798,0.00014611703,0.00004213138,0.00019683554,0.0000029688554],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41611362,0.0020526682,0.26299283,0.00007141413,0.0041976776,0.000087467924,0.0068239407,0.000026896792,0.015286267,0.00007891057,0.0003376536,0.29193068],"study_design_scores_gemma":[0.10531777,0.00754232,0.8771815,0.00041224103,0.0002500655,0.00002196959,0.0014644979,0.0000023655084,0.0068202917,0.00038911434,0.00035971083,0.00023820206],"about_ca_topic_score_codex":0.011347513,"about_ca_topic_score_gemma":0.0025615022,"teacher_disagreement_score":0.6141886,"about_ca_system_score_codex":0.00019517302,"about_ca_system_score_gemma":0.0009843336,"threshold_uncertainty_score":0.995236},"labels":[],"label_agreement":null},{"id":"W2313680460","doi":"10.1097/cco.0000000000000015","title":"Personalized medicine for metastatic breast cancer","year":2013,"lang":"en","type":"review","venue":"Current Opinion in Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Servier; Bristol-Myers Squibb","keywords":"Medicine; Trastuzumab; PI3K/AKT/mTOR pathway; Metastatic breast cancer; Targeted therapy; Breast cancer; Clinical trial; Personalized medicine; Oncology; Cancer; Cancer research; Internal medicine; Bioinformatics; Signal transduction; Biology; Genetics","score_opus":0.2890610038731495,"score_gpt":0.5493149128190961,"score_spread":0.2602539089459466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313680460","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[4.0357563e-7,0.98142314,0.00071608764,0.002122727,0.010939541,0.004272798,0.00037519433,0.0000591997,0.00009091788],"genre_scores_gemma":[3.4487073e-7,0.98603916,0.000947546,0.000114368915,0.0033224248,0.008344784,0.0007372107,0.00011155149,0.00038263362],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970631,0.0002569653,0.0011230832,0.0007058385,0.00027560172,0.00057542196],"domain_scores_gemma":[0.99765277,0.0007607606,0.0007150629,0.0003919327,0.0002488588,0.00023058712],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036537024,0.0006097362,0.003940299,0.00052463263,0.000050008886,0.000006698751,0.00025702338,0.0002884196,0.0021537906],"category_scores_gemma":[0.00013718613,0.00042521307,0.00045712775,0.00044838598,0.00042699144,0.00007966779,0.00006728255,0.00070886244,0.00007323084],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014361089,0.00023389985,0.000010681232,0.05038419,0.00026410274,0.0000019580002,0.00016938591,4.4125795e-7,4.6219606e-7,0.0006276487,0.009596931,0.9385667],"study_design_scores_gemma":[0.00507909,0.00037564486,0.000018680652,0.048042785,0.0008695868,0.0005316512,0.00008389634,0.000015696096,4.6773888e-8,0.00026986038,0.9443861,0.00032694967],"about_ca_topic_score_codex":0.00005188065,"about_ca_topic_score_gemma":0.000005898418,"teacher_disagreement_score":0.93823975,"about_ca_system_score_codex":0.0017560298,"about_ca_system_score_gemma":0.0016751639,"threshold_uncertainty_score":0.99982},"labels":[],"label_agreement":null},{"id":"W2313872863","doi":"10.1158/0008-5472.sabcs11-p1-17-01","title":"P1-17-01: Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial.","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Exemestane; Medicine; Clinical endpoint; Internal medicine; Interim analysis; Breast cancer; Oncology; Metastatic breast cancer; Randomized controlled trial; Clinical trial; Cancer; Tamoxifen","score_opus":0.1443047070812785,"score_gpt":0.4505939564901019,"score_spread":0.3062892494088234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313872863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91146314,0.04158066,0.00014615146,0.0043604043,0.0013444329,0.020482209,0.015529741,0.00022672761,0.0048665465],"genre_scores_gemma":[0.8965335,0.06375357,0.0029996193,0.00032519663,0.0014575713,0.020794507,0.0024233034,0.0004153291,0.011297439],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.993668,0.0005348014,0.0012564684,0.0013737628,0.0015927162,0.0015742523],"domain_scores_gemma":[0.9947658,0.00085708493,0.00056862977,0.0013738623,0.0015999184,0.00083470065],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011121929,0.0008243,0.0026291416,0.00052868965,0.0006287951,0.00006499673,0.0008681673,0.00028113852,0.004550249],"category_scores_gemma":[0.00030092915,0.0006638293,0.0002640783,0.0013738746,0.0015464043,0.00064375123,0.0004725359,0.00066211255,0.000047704933],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82549864,0.0065992908,0.0000031201864,0.00010624369,0.0015891193,0.0002679716,0.0027266059,0.000022225835,0.024238614,0.00024323646,0.0015746265,0.13713028],"study_design_scores_gemma":[0.89646,0.050178137,0.000033286477,0.0007528122,0.0005796412,0.00010741664,0.0006550519,0.0000618339,0.031880222,0.00030706832,0.018368952,0.000615602],"about_ca_topic_score_codex":0.013951934,"about_ca_topic_score_gemma":0.00085507234,"teacher_disagreement_score":0.13651468,"about_ca_system_score_codex":0.004329725,"about_ca_system_score_gemma":0.0031267053,"threshold_uncertainty_score":0.9995813},"labels":[],"label_agreement":null},{"id":"W2314002099","doi":"10.1158/1538-7445.am10-3684","title":"Abstract 3684: Developing STAT3 protein inhibitors as adjuvant therapeutics: Promising synergistic effects in human cancers","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"STAT3; Cancer research; STAT protein; Venetoclax; Cyclin D1; Cancer; Leukemia; Cancer cell; Medicine; Survivin; Cell cycle; Biology; Signal transduction; Immunology; Cell biology; Internal medicine; Chronic lymphocytic leukemia","score_opus":0.06123415778194602,"score_gpt":0.4353586659263953,"score_spread":0.3741245081444493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314002099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992719,0.0017650228,0.00008893061,0.0014731773,0.0003717966,0.0023877511,0.0000074100913,0.00010493192,0.0010819632],"genre_scores_gemma":[0.99589443,0.00007967112,0.00092765206,0.00022738417,0.00066498155,0.001411446,0.00001092985,0.000117355594,0.00066616916],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965129,0.00013100456,0.00045753643,0.0006918602,0.0010529216,0.0011537964],"domain_scores_gemma":[0.99837595,0.00023084892,0.00011763825,0.0005591457,0.0004355209,0.0002808985],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010438063,0.00031697267,0.00049666467,0.0005362011,0.0003129387,0.00008039488,0.0003106985,0.00020352572,0.0003148997],"category_scores_gemma":[0.00024709076,0.00028281676,0.00007403581,0.00083594257,0.00055539864,0.00022044974,0.000112134505,0.0021197658,0.00004918758],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005146994,0.000065097185,0.002944631,0.00084103685,0.0000795805,0.0002239787,0.0010937535,0.000044902747,0.920098,0.0009714138,0.000027967579,0.07309496],"study_design_scores_gemma":[0.003781154,0.00035535303,0.035822958,0.004226575,0.000025108147,0.0000176585,0.0005669883,0.00003801056,0.9400726,0.0045667696,0.0100266235,0.0005001867],"about_ca_topic_score_codex":0.006858867,"about_ca_topic_score_gemma":0.0039556087,"teacher_disagreement_score":0.07259477,"about_ca_system_score_codex":0.002241527,"about_ca_system_score_gemma":0.0028864734,"threshold_uncertainty_score":0.9999624},"labels":[],"label_agreement":null},{"id":"W2318534181","doi":"10.1158/0008-5472.sabcs12-p1-07-13","title":"Abstract P1-07-13: Prognostic relevance of statistically standardized estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) in tamoxifen(TAM)-treated NCIC CTG MA.14 patients","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; Queen's University; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Hazard ratio; Oncology; Proportional hazards model; Biomarker; Estrogen receptor; Progesterone receptor; Tamoxifen; Gynecology; Cancer; Confidence interval; Biology","score_opus":0.04751012845281061,"score_gpt":0.37770389612705385,"score_spread":0.33019376767424324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318534181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900925,0.0037368382,0.00008242001,0.0005762109,0.00028728376,0.0033420816,0.001573471,0.000115525465,0.00019367602],"genre_scores_gemma":[0.9916876,0.0009234361,0.0047772904,0.00006738453,0.0004269704,0.0011115931,0.0003528294,0.00019833572,0.00045454837],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99355465,0.0005393471,0.0011863498,0.0009713023,0.0018710238,0.0018773461],"domain_scores_gemma":[0.9956277,0.000903177,0.00039607112,0.00068596087,0.0014954333,0.00089167483],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013170983,0.00059203064,0.0011857533,0.00048151313,0.00024315395,0.00006252625,0.00038505232,0.000331614,0.0030706252],"category_scores_gemma":[0.0020968292,0.00053337275,0.00012139324,0.0007235067,0.0010496883,0.0006552989,0.00022539537,0.0012864032,0.0001299805],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061198897,0.0011762339,0.80445814,0.0015140163,0.0002879155,0.000017025524,0.0014640853,0.0000030740932,0.1312839,0.00026677284,0.0014720298,0.05193694],"study_design_scores_gemma":[0.011159769,0.001976431,0.86259604,0.0022961367,0.00008718792,0.000010632097,0.00033136443,0.0000053753747,0.10785937,0.00023520124,0.0126484735,0.0007940043],"about_ca_topic_score_codex":0.0010450097,"about_ca_topic_score_gemma":0.00015523225,"teacher_disagreement_score":0.05813792,"about_ca_system_score_codex":0.0015478232,"about_ca_system_score_gemma":0.0006308351,"threshold_uncertainty_score":0.9997118},"labels":[],"label_agreement":null},{"id":"W2321231905","doi":"10.1093/annonc/mdt084.1","title":"Predicting Risk for Late Metastasis: the PAM50 Risk of Recurrence (ROR) Score After 5 Years of Endocrine Therapy in Postmenopausal Women with Hr+ Early Breast Cancer: a Study On 1,478 Patients from the Abcsg-8 Trial","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Metastasis; Retrospective cohort study; Cancer","score_opus":0.04042241227615178,"score_gpt":0.34329314301862135,"score_spread":0.30287073074246956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2321231905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99339867,0.00069574034,0.0000061629353,0.0008041875,0.00015128059,0.0036881226,0.0012310694,0.0000103321245,0.0000144426585],"genre_scores_gemma":[0.99699324,0.0006944408,0.00012923325,0.0003118911,0.00013705598,0.001687978,0.000007726704,0.000030760384,0.000007697711],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978767,0.00046658533,0.00062118826,0.0003133772,0.00035476114,0.0003673905],"domain_scores_gemma":[0.9970804,0.00097310345,0.00094228116,0.0004613211,0.00047857338,0.00006435764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006079126,0.00020799176,0.00073922466,0.00009174504,0.000043343352,0.0000058309893,0.00026189766,0.000060672286,0.00008422525],"category_scores_gemma":[0.00016257445,0.00011363342,0.00007708075,0.00025019512,0.0002869114,0.00011052809,0.00005459683,0.0003196428,0.0000013396867],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.119896665,0.0014762318,0.5673466,0.0000115846415,0.00089855323,0.0000033206366,0.009328895,0.000040171348,0.00013696974,0.0000016527044,0.00002028725,0.3008391],"study_design_scores_gemma":[0.039793786,0.039222375,0.91770065,0.0001578957,0.00015642552,0.0000017244755,0.0020420232,0.000009383787,0.000302488,0.00030727035,0.00021389741,0.00009206155],"about_ca_topic_score_codex":0.007633042,"about_ca_topic_score_gemma":0.00065859075,"teacher_disagreement_score":0.3503541,"about_ca_system_score_codex":0.00006819741,"about_ca_system_score_gemma":0.00019899363,"threshold_uncertainty_score":0.9989752},"labels":[],"label_agreement":null},{"id":"W2328376199","doi":"10.1093/annonc/mdu329.5","title":"Overall Survival (Os) Endpoint: an Incomplete Evaluation of Metastatic Breast Cancer (Mbc) Treatment Outcome","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Metastatic breast cancer; Oncology; Internal medicine; Clinical endpoint; Outcome (game theory); Breast cancer; Overall survival; Gynecology; Cancer; Clinical trial","score_opus":0.2909496066262447,"score_gpt":0.5014498677820636,"score_spread":0.21050026115581888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328376199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98934126,0.000524409,0.0005857758,0.0060749147,0.00030084516,0.0005739279,0.00020293865,0.00002918139,0.0023667333],"genre_scores_gemma":[0.99708635,0.00011411983,0.001482328,0.00087211555,0.0001853451,0.00009130288,0.000050303377,0.00002703647,0.00009111286],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99790287,0.00048911537,0.00057927344,0.00027523897,0.00047548529,0.00027802473],"domain_scores_gemma":[0.9980519,0.00020777734,0.00044757858,0.00040662833,0.00075128884,0.00013487431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011478758,0.00019580167,0.00089823065,0.00014458518,0.000030501007,0.0000025900922,0.00010821188,0.00007218367,0.00086514966],"category_scores_gemma":[0.00009520346,0.00015619125,0.00014894072,0.000113742586,0.0001746512,0.00012850559,0.000027788481,0.00008528531,0.000008643709],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025727013,0.001662992,0.029227853,0.00014642267,0.000825818,0.0000074057957,0.0010768079,0.0013964486,0.014528745,0.0021366265,0.000062244224,0.94635594],"study_design_scores_gemma":[0.021014865,0.013761905,0.8902577,0.00013957053,0.0015503273,0.00015767323,0.00046670795,0.0052712266,0.01449641,0.009474933,0.042980164,0.00042846997],"about_ca_topic_score_codex":0.0010705305,"about_ca_topic_score_gemma":0.00066558266,"teacher_disagreement_score":0.94592744,"about_ca_system_score_codex":0.00027243985,"about_ca_system_score_gemma":0.00039317235,"threshold_uncertainty_score":0.9472782},"labels":[],"label_agreement":null},{"id":"W2332561578","doi":"10.1158/1538-7445.am2011-2242","title":"Abstract 2242: A randomized phase 2 study of the cyclin-dependent kinase (CDK) inhibitor Dinaciclib (SCH 727965) in patients with non-small cell lung cancer (NSCLC)","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Erlotinib; Internal medicine; Oncology; Lung cancer; Cancer; Epidermal growth factor receptor","score_opus":0.04515505282875971,"score_gpt":0.3741909476857539,"score_spread":0.3290358948569942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332561578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896937,0.0015586358,0.000019708077,0.00013839925,0.00029474805,0.0071945307,0.00006661883,0.000029469822,0.0010042123],"genre_scores_gemma":[0.9963182,0.00017072723,0.000083332285,0.00006837576,0.0001986277,0.0025120268,0.0000058135724,0.0001002537,0.0005426005],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957128,0.00041839245,0.0007529001,0.00072010315,0.001532054,0.000863754],"domain_scores_gemma":[0.9973046,0.0002813141,0.00032484691,0.0009751073,0.0008431598,0.00027097933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013544043,0.0003677038,0.0010042749,0.00039000052,0.00016481352,0.000024385528,0.000546972,0.00012595845,0.0007231013],"category_scores_gemma":[0.00013369603,0.00022637355,0.00015478942,0.00091703725,0.00050669664,0.00019142877,0.00024941692,0.0011673183,0.000007696131],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.368388,0.010353391,0.5767279,0.00077573577,0.0005284897,0.00011625047,0.016966974,0.00010069866,0.014000589,0.000008655019,0.00011761735,0.0119156595],"study_design_scores_gemma":[0.5985436,0.0017895614,0.3217152,0.001882352,0.00027872087,0.000001623766,0.0036080899,0.000052359548,0.071558565,0.0000422303,0.00009373029,0.00043397435],"about_ca_topic_score_codex":0.008110246,"about_ca_topic_score_gemma":0.0019371451,"teacher_disagreement_score":0.25501275,"about_ca_system_score_codex":0.0007798997,"about_ca_system_score_gemma":0.0009624697,"threshold_uncertainty_score":0.99849486},"labels":[],"label_agreement":null},{"id":"W2340356624","doi":"10.1158/1538-7445.sabcs15-p5-09-06","title":"Abstract P5-09-06: Patient education for targeted therapies with apps","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Tamoxifen; Patient education; Breast cancer; Health professionals; Schedule; Oncology; Family medicine; Health care; Medical education; Cancer; Internal medicine; Computer science","score_opus":0.05530587403857739,"score_gpt":0.4068275192339474,"score_spread":0.35152164519537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2340356624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9731025,0.008939403,0.0011043295,0.013336385,0.00021015796,0.002009247,0.000084391395,0.000095654264,0.00111795],"genre_scores_gemma":[0.9910591,0.00046059184,0.0013394193,0.00027818122,0.0005450501,0.0024024749,0.000019378005,0.0000660629,0.0038297197],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983068,0.000038923452,0.00017947354,0.00037578444,0.00056897773,0.0005300041],"domain_scores_gemma":[0.9982583,0.00020377467,0.00006566134,0.00040260112,0.0008881315,0.00018154678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025758325,0.00015102042,0.00021050304,0.000185156,0.00015466646,0.000022323231,0.00013402048,0.00006594976,0.00061769667],"category_scores_gemma":[0.000082499304,0.00008546077,0.000051971794,0.0002842049,0.00028857013,0.00016670156,0.000026579399,0.00019105093,0.00005647418],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022560384,0.00017625377,0.0022243594,0.00014678153,0.00012305501,0.0000028930917,0.00088216213,0.000002878098,0.23534313,0.00035841862,0.0039310176,0.754553],"study_design_scores_gemma":[0.0040383684,0.0014806074,0.031317867,0.0017083086,0.000032085514,0.000023369304,0.0028471472,0.0000026299567,0.26942933,0.0035747425,0.685175,0.0003705636],"about_ca_topic_score_codex":0.00013601665,"about_ca_topic_score_gemma":0.00005046166,"teacher_disagreement_score":0.75418246,"about_ca_system_score_codex":0.00057306624,"about_ca_system_score_gemma":0.0012471644,"threshold_uncertainty_score":0.6763345},"labels":[],"label_agreement":null},{"id":"W2344659104","doi":"10.1016/j.jval.2015.03.1128","title":"Overall survival in post-menopausal women with hr+/her2- metastatic breast cancer treated with 1st-line endocrine therapy vs. Chemotherapy","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Metastatic breast cancer; Hazard ratio; Internal medicine; Proportional hazards model; Breast cancer; Chemotherapy; Oncology; Cancer; Medical record; Gynecology; Confidence interval","score_opus":0.041236051209525615,"score_gpt":0.3246524755579592,"score_spread":0.28341642434843356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344659104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98099476,0.0025391444,0.00009978252,0.014329064,0.000098218414,0.0015850405,0.00012308787,0.00013184606,0.00009905533],"genre_scores_gemma":[0.9900952,0.0014932678,0.0022945434,0.0048979707,0.0002208714,0.000424827,0.0000519289,0.00016989354,0.0003514811],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965194,0.00033525622,0.0006522185,0.00065483846,0.0007168416,0.0011214691],"domain_scores_gemma":[0.9982281,0.0001116937,0.0002916232,0.00052380917,0.00028296208,0.0005618515],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007097023,0.00051369274,0.0011566305,0.00035896123,0.00004928245,0.000023214001,0.00017841018,0.00005863659,0.0002446533],"category_scores_gemma":[0.000017413706,0.00035474097,0.000023916113,0.0008754974,0.00016632823,0.00023803422,0.000021217244,0.00047849314,0.000007845645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23576987,0.0056194663,0.48670542,0.001175026,0.0016377987,0.0015155751,0.025723444,0.04563328,0.006070546,0.00041032975,0.00013598321,0.18960327],"study_design_scores_gemma":[0.12197338,0.036581427,0.81924134,0.0023789594,0.000067166045,0.001961894,0.0038120204,0.002252501,0.0014976808,0.0006855437,0.0080281645,0.0015199066],"about_ca_topic_score_codex":0.042528685,"about_ca_topic_score_gemma":0.0021534052,"teacher_disagreement_score":0.33253595,"about_ca_system_score_codex":0.0022618384,"about_ca_system_score_gemma":0.0020272164,"threshold_uncertainty_score":0.99989045},"labels":[],"label_agreement":null},{"id":"W2394805951","doi":"10.1158/1538-7445.sabcs15-p5-14-01","title":"Abstract P5-14-01: A meta-analysis of clinical benefit rates for fulvestrant 500 mg versus alternative therapies for treatment of postmenopausal, estrogen receptor-positive advanced breast cancer","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Fulvestrant; Medicine; Internal medicine; Oncology; Anastrozole; Odds ratio; Breast cancer; Clinical trial; Cancer; Confidence interval; Randomized controlled trial; Progression-free survival; Gynecology; Estrogen receptor; Tamoxifen; Overall survival","score_opus":0.2738566685408791,"score_gpt":0.534350758404024,"score_spread":0.26049408986314493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2394805951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9442551,0.027037663,0.0005728326,0.0053980686,0.00034464546,0.0038925335,0.018403275,0.00003683792,0.000059027414],"genre_scores_gemma":[0.98325574,0.0072755287,0.0026692846,0.000057302106,0.00046343284,0.0052857366,0.00012848001,0.000105632695,0.0007588284],"study_design_codex":"meta_analysis","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996097,0.00016165077,0.0011327158,0.00093037286,0.00085012085,0.0008281221],"domain_scores_gemma":[0.99207854,0.0035910707,0.0006366216,0.0007112103,0.0026769456,0.00030559071],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009126856,0.00044667692,0.0025651339,0.00049578625,0.00014285021,0.000017324079,0.00033635256,0.00017477525,0.0016110118],"category_scores_gemma":[0.00017287896,0.00026916072,0.001597936,0.00074785255,0.0008505039,0.00024205347,0.000046013516,0.00014997646,0.0000037309167],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10227852,0.0012856807,0.0029602519,0.00025030418,0.30127695,0.00000771251,0.0014290803,0.000445911,0.29836082,0.0009883859,0.000089907466,0.29062647],"study_design_scores_gemma":[0.05322834,0.01984051,0.060616586,0.0005605598,0.10456747,0.000007826504,0.0020153238,0.00011273202,0.7456618,0.0017695387,0.010613474,0.0010058418],"about_ca_topic_score_codex":0.0013850823,"about_ca_topic_score_gemma":0.0006964381,"teacher_disagreement_score":0.44730097,"about_ca_system_score_codex":0.00083180965,"about_ca_system_score_gemma":0.0008885935,"threshold_uncertainty_score":0.99997604},"labels":[],"label_agreement":null},{"id":"W2399066128","doi":"10.1158/1538-7445.sabcs15-p4-13-14","title":"Abstract P4-13-14: Time on treatment of everolimus, fulvestrant, and capecitabine for the treatment of HR+/HER2- metastatic breast cancer: A retrospective claims study in the US","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Capecitabine; Discontinuation; Fulvestrant; Everolimus; Internal medicine; Metastatic breast cancer; Regimen; Oncology; Aromatase inhibitor; Cancer; Hazard ratio; Tolerability; Breast cancer; Anastrozole; Aromatase; Adverse effect; Tamoxifen; Confidence interval","score_opus":0.07351609551178608,"score_gpt":0.41901837090530686,"score_spread":0.3455022753935208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2399066128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840651,0.005530533,0.000011958121,0.0048422795,0.00006142753,0.0044937516,0.000918534,0.00001185286,0.00006456495],"genre_scores_gemma":[0.9895163,0.006521015,0.000034835444,0.000033356162,0.00021405978,0.0030595066,0.0000042926513,0.00004432877,0.00057226216],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976305,0.000190139,0.00040354917,0.00048270065,0.000761807,0.0005313302],"domain_scores_gemma":[0.9975001,0.001202,0.00015003297,0.00066015153,0.00038459265,0.000103102204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056554575,0.0002892784,0.0006976743,0.00019735092,0.00013280539,0.000014463444,0.00020432725,0.00004934951,0.00033096963],"category_scores_gemma":[0.000031291707,0.00012074196,0.00013590856,0.0004173517,0.00054764736,0.00007895393,0.000016717026,0.00013358127,0.000004474236],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030290961,0.011059548,0.18172954,0.00029776862,0.0032752855,0.000111132715,0.02266437,0.0001687297,0.07572103,0.00013212588,0.0001575703,0.6743919],"study_design_scores_gemma":[0.018416638,0.013342535,0.95265764,0.00038717926,0.00029789747,0.000029413603,0.0020133792,0.000021133781,0.010616567,0.00042428882,0.0016391416,0.00015415814],"about_ca_topic_score_codex":0.0074629453,"about_ca_topic_score_gemma":0.00413925,"teacher_disagreement_score":0.77092814,"about_ca_system_score_codex":0.0017564174,"about_ca_system_score_gemma":0.00042499293,"threshold_uncertainty_score":0.99914646},"labels":[],"label_agreement":null},{"id":"W2405407273","doi":"10.1158/1538-7445.sabcs15-p5-14-02","title":"Abstract P5-14-02: Clinical predictors of benefit from fulvestrant in advanced breast cancer: A meta-analysis of randomized controlled trials","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Princess Margaret Cancer Centre; CancerCare Manitoba; University of Toronto","funders":"","keywords":"Fulvestrant; Medicine; Internal medicine; Oncology; Breast cancer; Metastatic breast cancer; Tamoxifen; Clinical endpoint; Hazard ratio; Randomized controlled trial; Meta-analysis; Cancer; Adverse effect; Confidence interval; Gynecology","score_opus":0.19746940196252744,"score_gpt":0.49732033457268743,"score_spread":0.29985093261016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2405407273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9486453,0.03771289,0.00018525074,0.004776219,0.00030667218,0.00442687,0.0037448222,0.000035995345,0.00016597785],"genre_scores_gemma":[0.9844963,0.011126313,0.00026187027,0.00007446046,0.00036735655,0.0030258682,0.00002686592,0.00005914889,0.0005618436],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98902816,0.002356594,0.0048936964,0.0009216172,0.002022556,0.00077738165],"domain_scores_gemma":[0.9755142,0.019490063,0.0017775646,0.0010729535,0.001763991,0.00038127528],"candidate_categories":["metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.019523356,0.00043606918,0.017366115,0.0013710931,0.00004903723,0.00001562535,0.00048968795,0.00029247082,0.009162274],"category_scores_gemma":[0.005670966,0.0002237051,0.0060977195,0.0016695827,0.0013450616,0.00022194251,0.00009475815,0.0006367394,0.0000059296035],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5967882,0.00049844646,0.016715383,0.00011683766,0.2916876,0.000022484222,0.00031006872,0.0005932182,0.06052848,0.00011948838,0.000043203447,0.032576557],"study_design_scores_gemma":[0.6626693,0.00030034635,0.13636768,0.0008242782,0.18075898,0.000002603073,0.0002527504,0.000092087284,0.016724952,0.0013252645,0.00029174722,0.00038997878],"about_ca_topic_score_codex":0.0056343065,"about_ca_topic_score_gemma":0.0020495523,"teacher_disagreement_score":0.1196523,"about_ca_system_score_codex":0.0004325837,"about_ca_system_score_gemma":0.0012313935,"threshold_uncertainty_score":0.9972221},"labels":[],"label_agreement":null},{"id":"W2408477660","doi":"10.1158/1538-7445.sabcs15-p1-10-20","title":"Abstract P1-10-20: Importance of the patient voice in drug development: Early-stage breast cancer and measurement gaps concerning the treatment experience","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Asymptomatic; Stage (stratigraphy); Internal medicine; Cancer; Disease; Oncology; Physical therapy","score_opus":0.09652163825045382,"score_gpt":0.3756239939993864,"score_spread":0.2791023557489326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2408477660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856483,0.009470956,0.0000053248214,0.0032938102,0.000119886245,0.0010453211,0.00008021266,0.000017581733,0.0003186135],"genre_scores_gemma":[0.99490213,0.0016037262,0.000034607543,0.00011007924,0.00010699059,0.0014062646,8.4288433e-7,0.000036478123,0.0017988859],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969477,0.00012133796,0.00044641463,0.00049379107,0.0013496015,0.00064114475],"domain_scores_gemma":[0.99840915,0.00018593365,0.00019122889,0.0005762297,0.0004822783,0.0001551726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068824855,0.00023588623,0.00031772157,0.00009902368,0.00025917724,0.000024012294,0.00030599293,0.00005400627,0.00065272994],"category_scores_gemma":[0.00006587286,0.00011077306,0.00005950497,0.00043026675,0.0007736049,0.00015976498,0.00012875919,0.0002773053,0.000007660431],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016630117,0.00025461824,0.56747407,0.00018430752,0.0001913361,0.000029565985,0.032181915,0.00004673826,0.12547891,0.00005340795,0.00020713916,0.27223498],"study_design_scores_gemma":[0.0027290997,0.00011742568,0.74620557,0.001896329,0.000015486276,0.000011364972,0.0027704267,0.0000035331695,0.15764268,0.000030462674,0.088369444,0.00020819549],"about_ca_topic_score_codex":0.0033860991,"about_ca_topic_score_gemma":0.0063227587,"teacher_disagreement_score":0.2720268,"about_ca_system_score_codex":0.0023689263,"about_ca_system_score_gemma":0.0011390131,"threshold_uncertainty_score":0.7146935},"labels":[],"label_agreement":null},{"id":"W2461531801","doi":"10.1200/jco.2012.30.27_suppl.104","title":"Safety of everolimus for women over age 65 with advanced breast cancer (BC): 12.5-month follow-up of BOLERO-2.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; University of Calgary","funders":"","keywords":"Medicine; Everolimus; Exemestane; Internal medicine; Adverse effect; Tolerability; Breast cancer; Rash; Placebo; Population; Aromatase inhibitor; Oncology; Cancer; Aromatase","score_opus":0.058077749685863794,"score_gpt":0.43203815264828915,"score_spread":0.3739604029624254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2461531801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912322,0.0014586101,0.0015433414,0.0020639354,0.0018642938,0.0005428104,0.00010342939,0.0000116310885,0.0011797504],"genre_scores_gemma":[0.98739207,0.000677807,0.008397038,0.0011068463,0.0015187924,0.00003419975,0.0000029019789,0.00004965981,0.0008206582],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99608624,0.00017993672,0.0024853523,0.000200488,0.00050048216,0.0005474869],"domain_scores_gemma":[0.9934777,0.0015762445,0.0033310412,0.00030903178,0.0007618096,0.00054415886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020587898,0.00023472002,0.0025388284,0.00012897601,0.000032389682,0.0000021168116,0.00022212346,0.00032248424,0.00036658626],"category_scores_gemma":[0.00065615005,0.00015693795,0.0005213632,0.00015770305,0.00045554273,0.00033245803,0.000049428763,0.0006218717,0.0000013852466],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2253658,0.0027381263,0.22250392,0.00032615318,0.0022740744,0.00006453985,0.0013996781,0.00026185557,0.0030544843,0.0001926666,0.00065134536,0.5411674],"study_design_scores_gemma":[0.052293032,0.016042631,0.7990797,0.0005410296,0.00057610305,0.00033470173,0.0005813028,0.000016770997,0.00053971855,0.00038067633,0.12941328,0.00020106108],"about_ca_topic_score_codex":0.00004304769,"about_ca_topic_score_gemma":0.0001292218,"teacher_disagreement_score":0.57657576,"about_ca_system_score_codex":0.00047701088,"about_ca_system_score_gemma":0.001388533,"threshold_uncertainty_score":0.6399744},"labels":[],"label_agreement":null},{"id":"W2474470599","doi":"10.1200/jco.2014.32.15_suppl.2527","title":"A phase 1 dose-escalation study of BBI503, a first-in-class cancer stemness kinase inhibitor in adult patients with advanced solid tumors.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Internal medicine; Cancer; Pharmacokinetics; Gastroenterology; Nausea; Toxicity; Discontinuation; Oncology; Pharmacology","score_opus":0.041501006961884884,"score_gpt":0.4388185764004371,"score_spread":0.39731756943855223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2474470599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99718255,0.00009132319,0.00014435635,0.001112017,0.0006051712,0.00076751556,0.0000053816057,0.0000074263903,0.00008426206],"genre_scores_gemma":[0.998029,0.000048897306,0.0008640885,0.0004872302,0.00047557274,0.000045478704,0.000002258185,0.000030375702,0.000017107111],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953849,0.0004522425,0.0030204302,0.0002857316,0.00056308304,0.00029364304],"domain_scores_gemma":[0.99474984,0.0010971992,0.0026717808,0.0002448944,0.0009869068,0.00024939972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013292986,0.00020786142,0.0020943296,0.00028387018,0.000024889467,0.0000039846564,0.00015875802,0.00020270303,0.0000382522],"category_scores_gemma":[0.0017242725,0.00014539192,0.00014726825,0.00037564815,0.00016942123,0.00025528463,0.00003966211,0.0008702304,0.0000015834753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046664186,0.024370639,0.6087297,0.000090507114,0.00013315798,0.00016524828,0.0009423372,0.0016099554,0.0001438236,0.000009528474,0.000016923806,0.31712398],"study_design_scores_gemma":[0.14471775,0.062007457,0.78900146,0.0010915658,0.00014533056,0.00001820989,0.00077938626,0.00055623485,0.00013281513,0.00006460653,0.0013345267,0.00015066481],"about_ca_topic_score_codex":0.00010448715,"about_ca_topic_score_gemma":0.002709101,"teacher_disagreement_score":0.31697333,"about_ca_system_score_codex":0.00040828975,"about_ca_system_score_gemma":0.0008063878,"threshold_uncertainty_score":0.5928911},"labels":[],"label_agreement":null},{"id":"W2474699717","doi":"10.1634/theoncologist.2016-0097","title":"Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":246,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; AstraZeneca; Pfizer","keywords":"Medicine; Palbociclib; Fulvestrant; Neutropenia; Placebo; Metastatic breast cancer; Internal medicine; Adverse effect; Febrile neutropenia; Oncology; Common Terminology Criteria for Adverse Events; Breast cancer; Cancer; Chemotherapy; Estrogen receptor","score_opus":0.009780463777112593,"score_gpt":0.29616004749887154,"score_spread":0.2863795837217589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2474699717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98201805,0.00049047207,0.0053257626,0.0030710162,0.00004696229,0.008514379,0.0003606701,0.00007728184,0.00009541795],"genre_scores_gemma":[0.99254215,0.00044800062,0.0014856479,0.00021976637,0.000040355484,0.0049997875,0.000036464357,0.00005300854,0.00017481748],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99547243,0.0015627366,0.001007919,0.00073442305,0.0005777818,0.00064473005],"domain_scores_gemma":[0.99534905,0.0028727467,0.0007854419,0.0005480141,0.00026828324,0.0001764918],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001637433,0.00053853006,0.0027820186,0.00036830205,0.00013999983,0.000030405226,0.00027838966,0.00007535746,0.00029839991],"category_scores_gemma":[0.00019845543,0.00024887366,0.00016241241,0.0012771174,0.00093293976,0.00032975874,0.000051799645,0.00037786967,0.0000072603143],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.922018,0.0041006897,0.010059341,0.0000107019305,0.005557809,0.00015909175,0.008550045,0.0008919238,0.0021198953,0.000012757032,0.0000019427885,0.046517815],"study_design_scores_gemma":[0.86781025,0.0032054796,0.111497134,0.00036665506,0.0024774289,0.000012691158,0.013169265,0.00072004594,0.0002259359,0.00015139133,0.000011074955,0.00035265417],"about_ca_topic_score_codex":0.0032583743,"about_ca_topic_score_gemma":0.017618505,"teacher_disagreement_score":0.10143779,"about_ca_system_score_codex":0.0020841865,"about_ca_system_score_gemma":0.0003142217,"threshold_uncertainty_score":0.99999636},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W2484610442","doi":"10.1158/1538-7445.am2016-271","title":"Abstract 271: Influence of autophagy modulation on synergistic interactions of lapatinib and mTOR targeted agents in HER2-amplified lapatinib resistant breast cancer models in vitro and in vivo","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Simon Fraser University; University of British Columbia; Centre for Drug Research and Development; BC Cancer Agency","funders":"","keywords":"Lapatinib; Autophagy; mTORC1; In vivo; PI3K/AKT/mTOR pathway; Pharmacology; Cancer research; Breast cancer; Cancer; Medicine; Chemistry; Signal transduction; Biology; Apoptosis; Internal medicine; Trastuzumab; Biochemistry","score_opus":0.073837779111058,"score_gpt":0.40294037148538847,"score_spread":0.3291025923743305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2484610442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977108,0.000525022,0.0000389651,0.00059600134,0.000042114963,0.00059697765,0.00039757587,0.000010507688,0.00008202616],"genre_scores_gemma":[0.99878526,0.00056133687,0.00012048959,0.000035315028,0.000036010442,0.00033199374,0.000004513114,0.000029669705,0.000095434465],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980388,0.0001317222,0.0005524475,0.00041649793,0.00047989894,0.00038060782],"domain_scores_gemma":[0.9987736,0.00036895383,0.00016084148,0.00027969756,0.00030364376,0.00011327223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046767856,0.00016314162,0.00043146804,0.0006546564,0.00003176203,0.000008301353,0.000106183405,0.00008756166,0.00016145063],"category_scores_gemma":[0.00019684972,0.00013058605,0.000024868747,0.0005790373,0.0003109913,0.0002736081,0.000060781105,0.00034178325,7.067023e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008369692,0.00019859208,0.01944904,0.0003581914,0.000028574541,0.000020719432,0.0010421247,0.009435169,0.94070673,0.00010736482,0.000008774494,0.02027502],"study_design_scores_gemma":[0.003858493,0.000111635534,0.8796274,0.0032187377,0.0000064742235,0.0000033660974,0.0002022782,0.002366828,0.109305345,0.001125185,0.000036602025,0.00013764156],"about_ca_topic_score_codex":0.011511523,"about_ca_topic_score_gemma":0.004717308,"teacher_disagreement_score":0.86017835,"about_ca_system_score_codex":0.00069542095,"about_ca_system_score_gemma":0.00032071347,"threshold_uncertainty_score":0.99507093},"labels":[],"label_agreement":null},{"id":"W2504241715","doi":"10.1158/1538-7445.am2016-2269","title":"Abstract 2269: Comparative effectiveness of everolimus + endocrine therapy vs endocrine monotherapy among postmenopausal women with HR+/HER2- advanced breast cancer: a multicountry retrospective chart review","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Exemestane; Oncology; Breast cancer; Cancer; Aromatase inhibitor; Hazard ratio; Everolimus; Retrospective cohort study; Metastatic breast cancer; Gynecology; Aromatase; Confidence interval","score_opus":0.03510198508118839,"score_gpt":0.3965643395908768,"score_spread":0.3614623545096884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2504241715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95193213,0.039953697,0.000057688747,0.0022844407,0.00015843287,0.0044901716,0.00070425175,0.00013153271,0.00028764052],"genre_scores_gemma":[0.9107776,0.082425065,0.00012364352,0.0003317128,0.0003424899,0.0054524653,0.000015042295,0.0001588532,0.00037308224],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9943631,0.0005384166,0.00067378505,0.0012041389,0.0016384698,0.0015820438],"domain_scores_gemma":[0.9949281,0.00074960367,0.0004122328,0.0010705643,0.0023278142,0.0005116344],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010813317,0.000682501,0.0019114844,0.00036109844,0.0002142967,0.000026998618,0.00050179753,0.00010369357,0.0023166644],"category_scores_gemma":[0.00007054434,0.00042893225,0.00013363876,0.0011684258,0.0014035082,0.0005899241,0.00010476735,0.00083930336,0.000027061304],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.095521785,0.001004226,0.09129258,0.0034115466,0.0019860794,0.00019863728,0.0013018711,0.000052563708,0.68461955,0.00010209731,0.00017018752,0.120338894],"study_design_scores_gemma":[0.019305125,0.0037354298,0.802028,0.01743684,0.000058269678,0.00014484463,0.00029595642,0.000003976282,0.15223147,0.00015902432,0.004027636,0.00057340297],"about_ca_topic_score_codex":0.001616894,"about_ca_topic_score_gemma":0.00019185072,"teacher_disagreement_score":0.71073544,"about_ca_system_score_codex":0.00340216,"about_ca_system_score_gemma":0.0010754485,"threshold_uncertainty_score":0.99981624},"labels":[],"label_agreement":null},{"id":"W2552099557","doi":"10.1056/nejmoa1607303","title":"Palbociclib and Letrozole in Advanced Breast Cancer","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2948,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Palbociclib; Letrozole; Medicine; Breast cancer; Oncology; Estrogen receptor; Internal medicine; Cancer; Gynecology; Metastatic breast cancer; Tamoxifen","score_opus":0.011200091486167083,"score_gpt":0.2938672739258823,"score_spread":0.2826671824397152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552099557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91193944,0.009777937,0.0008421389,0.07656315,0.00043190067,0.00011328807,0.000005248427,0.000012170823,0.00031470144],"genre_scores_gemma":[0.9916431,0.0030844898,0.00058356934,0.0008941771,0.0029728308,0.0000022862505,4.089476e-7,0.000020953352,0.00079821143],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988539,0.00003828682,0.00042943787,0.00013363456,0.0003243392,0.00022037406],"domain_scores_gemma":[0.99905056,0.00014301664,0.00023253041,0.00012376091,0.00014552486,0.000304625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035837057,0.0001431355,0.0005025183,0.0002087968,0.000018209628,0.0000025661427,0.00007182988,0.00004555265,0.00051312445],"category_scores_gemma":[0.00013938847,0.000071711984,0.000035895253,0.00015968962,0.00015462794,0.00018270579,0.000015507238,0.00018578238,0.0000014515691],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029827098,0.000026976053,0.118402265,0.000025402262,0.00005012645,0.00016782862,0.00045550146,0.000005555706,0.04259667,0.00005585585,0.00043587745,0.83479524],"study_design_scores_gemma":[0.26870084,0.0018070694,0.55257094,0.006024655,0.00017374186,0.010927969,0.0004457327,0.000010731168,0.0019111919,0.0025829463,0.15459836,0.00024582844],"about_ca_topic_score_codex":0.00007498018,"about_ca_topic_score_gemma":0.000096009775,"teacher_disagreement_score":0.8345494,"about_ca_system_score_codex":0.00012076279,"about_ca_system_score_gemma":0.00016086774,"threshold_uncertainty_score":0.5618353},"labels":[],"label_agreement":null},{"id":"W2554177440","doi":"10.1634/theoncologist.2016-0185","title":"Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2– Advanced Breast Cancer","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); University of Calgary; Nova Scotia Cancer Centre; BC Cancer Agency; Dalhousie University; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Fulvestrant; Palbociclib; Medicine; Exemestane; Letrozole; Everolimus; Oncology; Breast cancer; Internal medicine; Sunitinib; Adverse effect; Combination therapy; Cancer; Metastatic breast cancer; Tamoxifen","score_opus":0.0302134003723064,"score_gpt":0.3549598303514997,"score_spread":0.3247464299791933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554177440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92547876,0.012167003,0.009296892,0.0470726,0.00082302047,0.0039506545,0.00032139802,0.00017733725,0.00071230636],"genre_scores_gemma":[0.9916287,0.00495423,0.0004943271,0.00037309533,0.00031162598,0.0009760051,0.0000069401976,0.0000337899,0.0012212644],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989354,0.000055645232,0.00028397446,0.00022571003,0.00018981742,0.00030947715],"domain_scores_gemma":[0.9982805,0.00078162993,0.00023992502,0.0004236275,0.00023086897,0.000043406897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015092726,0.00021533298,0.00035632498,0.00003457707,0.000179521,0.00001328643,0.0001774557,0.000044395514,0.00017426308],"category_scores_gemma":[0.000020514906,0.00008241984,0.00010464321,0.00012170002,0.00046100444,0.00013260791,0.000015580456,0.000053728894,0.0000046026757],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047039273,0.0005985061,0.00057016494,0.00002269685,0.00031750323,0.0000036598433,0.0009105768,0.0000646412,0.29233745,0.0033190649,0.000043637643,0.69710815],"study_design_scores_gemma":[0.055180207,0.029470026,0.16254427,0.00057934405,0.0007687004,0.00039031636,0.010250924,0.00012793405,0.5457477,0.01623028,0.17794314,0.000767135],"about_ca_topic_score_codex":0.00029930382,"about_ca_topic_score_gemma":0.0003813544,"teacher_disagreement_score":0.69634104,"about_ca_system_score_codex":0.0005279523,"about_ca_system_score_gemma":0.00029277624,"threshold_uncertainty_score":0.33609834},"labels":[],"label_agreement":null},{"id":"W2558360748","doi":"10.1016/s0140-6736(16)32389-3","title":"Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":602,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"AstraZeneca","keywords":"Anastrozole; Fulvestrant; Medicine; Internal medicine; Hazard ratio; Breast cancer; Oncology; Clinical endpoint; Population; Placebo; Aromatase inhibitor; Metastatic breast cancer; Cancer; Gynecology; Randomized controlled trial; Estrogen receptor; Tamoxifen; Confidence interval; Pathology","score_opus":0.06965433626529506,"score_gpt":0.38860102750416464,"score_spread":0.3189466912388696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558360748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9596859,0.00080249726,0.004818618,0.024364254,0.0024950951,0.0041280705,0.0027238356,0.0002158706,0.00076583936],"genre_scores_gemma":[0.9843453,0.0010352365,0.002020671,0.0008446562,0.008925488,0.0017934239,0.00024302432,0.00009358166,0.00069859996],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997995,0.00007944641,0.00043653537,0.0005049037,0.00038931164,0.0005947708],"domain_scores_gemma":[0.99815446,0.00032216348,0.00028556777,0.0007148891,0.00031163968,0.00021126951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004040473,0.00033797565,0.00077093946,0.00008745256,0.00016115405,0.00004206971,0.0004919766,0.00010068194,0.0004099207],"category_scores_gemma":[0.000061371175,0.00019703813,0.00021281061,0.00015561297,0.00026039936,0.00054010836,0.000046297857,0.00020770768,0.000026821928],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8069151,0.0002674431,0.00003374582,0.000012570863,0.0004969152,0.0000046554196,0.00023828556,0.000019584722,0.073625706,0.00033980294,0.00086096226,0.11718522],"study_design_scores_gemma":[0.9508999,0.0018762061,0.00055315753,0.0001904401,0.00022892508,0.000035722733,0.00021382669,0.00005480605,0.010701737,0.00014299649,0.034803916,0.00029838269],"about_ca_topic_score_codex":0.0000725434,"about_ca_topic_score_gemma":0.000049989423,"teacher_disagreement_score":0.14398478,"about_ca_system_score_codex":0.00032760113,"about_ca_system_score_gemma":0.00018887593,"threshold_uncertainty_score":0.80349815},"labels":[],"label_agreement":null},{"id":"W2559499796","doi":"10.1182/blood.v110.11.1507.1507","title":"A High Throughput Screen Identified Cyproheptadine That Decreases D-Type Cyclins, Arrests Cells in the G1 Phase, and Induces Apoptosis in Multiple Myeloma and Leukemia Cells.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cyproheptadine; Cancer research; Viability assay; Cyclin B; Cyclin; Cyclin D; Cyclin D1; Cyclin B1; Cyclin D3; Apoptosis; Cell cycle checkpoint; Cyclin A; Cell cycle; Cell growth; Biology; Cyclin E; Cyclin-dependent kinase 1; Molecular biology; Biochemistry","score_opus":0.026885064577257478,"score_gpt":0.29046616117431256,"score_spread":0.2635810965970551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559499796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99331015,0.005368345,0.00008250782,0.00020812941,0.0001361311,0.0007157819,0.000028253415,0.000048035792,0.00010266735],"genre_scores_gemma":[0.9962132,0.00096686906,0.00199446,0.00046009003,0.00020521643,0.000028352933,0.000038463004,0.000038787806,0.00005453482],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982903,0.00007458583,0.00037951954,0.0004890308,0.00031963844,0.00044692194],"domain_scores_gemma":[0.9988661,0.000428638,0.00013601886,0.00037637367,0.000046464185,0.00014642124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004804901,0.00028387355,0.0004461187,0.00022974082,0.00008700489,0.000050667546,0.00016280283,0.00014748695,0.000020781732],"category_scores_gemma":[0.00010130851,0.00021411467,0.000043599626,0.0004639594,0.00022002436,0.00023074892,0.0000745067,0.00032017817,0.0000050526314],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029261592,0.002144348,0.20390272,0.0002478264,0.00025268507,0.00043749937,0.0045768623,0.000015408046,0.7217068,0.00008200815,0.00017232838,0.063535355],"study_design_scores_gemma":[0.017122928,0.00031901788,0.30498576,0.00031818904,0.00017098259,0.00007867797,0.0015998107,0.000019470392,0.67389256,0.00028727425,0.0009223882,0.00028295195],"about_ca_topic_score_codex":0.0018490433,"about_ca_topic_score_gemma":0.0018639001,"teacher_disagreement_score":0.101083055,"about_ca_system_score_codex":0.00007223155,"about_ca_system_score_gemma":0.0000860075,"threshold_uncertainty_score":0.8731343},"labels":[],"label_agreement":null},{"id":"W2570267880","doi":"10.1158/1557-3265.pmccavuln16-a25","title":"Abstract A25: COTI-2, a novel small molecule that is effective against multiple human cancer cell lines in vitro and in vivo","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute","funders":"","keywords":"In vivo; Cancer; Flow cytometry; In silico; Cancer cell; In vitro; Cell growth; Cell culture; Apoptosis; PI3K/AKT/mTOR pathway; Cancer research; Viability assay; Pharmacology; Drug discovery; Chemistry; Biology; Biochemistry; Molecular biology; Genetics","score_opus":0.2372363984106822,"score_gpt":0.5182743531454814,"score_spread":0.2810379547347992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570267880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98962355,0.004789803,0.000012840923,0.0022442713,0.0002186467,0.0015039287,0.00015209499,0.00002780879,0.0014270435],"genre_scores_gemma":[0.99417824,0.0026288787,0.00022490163,0.0008079141,0.00054942624,0.0008259242,0.0000068620607,0.00007327125,0.00070456555],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.996861,0.0001662916,0.00060799654,0.0009329207,0.0005819548,0.0008498761],"domain_scores_gemma":[0.9971136,0.001106635,0.00022809132,0.00086838583,0.00032122715,0.00036206495],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017805863,0.0002874504,0.0007968669,0.00019514396,0.00029373897,0.000093761235,0.00046459842,0.00029864756,0.00021829651],"category_scores_gemma":[0.0007696811,0.0002539955,0.00013915595,0.00018629589,0.0010363302,0.00022751128,0.0003749411,0.0016105416,0.000009647074],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005908849,0.00096272305,0.4368486,0.0004817093,0.000098404074,0.0001691986,0.00069122505,0.000027642433,0.49043512,0.000004037358,0.00020843481,0.06416403],"study_design_scores_gemma":[0.013210117,0.00025357355,0.72447836,0.0009195543,0.000020934827,0.0000023801604,0.00028565075,0.00043380447,0.25692034,0.00008027341,0.0030976296,0.000297339],"about_ca_topic_score_codex":0.020102873,"about_ca_topic_score_gemma":0.033046197,"teacher_disagreement_score":0.28762978,"about_ca_system_score_codex":0.00066062465,"about_ca_system_score_gemma":0.0004437834,"threshold_uncertainty_score":0.99999124},"labels":[],"label_agreement":null},{"id":"W2571322812","doi":"10.15562/tcp.32","title":"Molecular Genetics in Breast Cancer: Signaling Pathways and Tumor Biology","year":2016,"lang":"en","type":"article","venue":"The Cancer Press","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Breast cancer; Biology; Cancer genetics; Signal transduction; Cancer; Molecular genetics; Computational biology; Genetics; Cancer research; Gene","score_opus":0.020469202253363437,"score_gpt":0.2902598421868009,"score_spread":0.26979063993343744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571322812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94818985,0.04414428,0.0009400246,0.0058756387,0.00016727005,0.00034683678,0.00017149761,0.00004567408,0.00011891849],"genre_scores_gemma":[0.995407,0.0027385466,0.00015409503,0.001160894,0.00023717231,0.000235001,0.0000010669037,0.00003407632,0.00003213747],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99903214,0.000062103434,0.00018116536,0.00030031457,0.00010644766,0.00031782573],"domain_scores_gemma":[0.9993856,0.00006834213,0.00007950526,0.00031716816,0.00006695439,0.00008243079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000118938886,0.00015845719,0.00024997845,0.000039207152,0.000040172086,0.000008024637,0.00016166722,0.000047927657,0.00011139385],"category_scores_gemma":[0.000009238971,0.00008680443,0.000033026732,0.00008676016,0.00024081732,0.00004614087,0.00008586434,0.00011851171,0.0000015929581],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005020328,0.000026962565,0.02902821,0.000058418682,0.00010594138,0.00003112635,0.0005142055,0.00025712387,0.7220506,0.0006298373,0.000023844843,0.24677166],"study_design_scores_gemma":[0.01284787,0.00028663143,0.12586176,0.0025325788,0.00040772776,0.0005893148,0.00034281478,0.0008329299,0.813374,0.014201078,0.027679102,0.0010442148],"about_ca_topic_score_codex":0.00063743565,"about_ca_topic_score_gemma":0.00005742909,"teacher_disagreement_score":0.24572745,"about_ca_system_score_codex":0.00014711062,"about_ca_system_score_gemma":0.00010946718,"threshold_uncertainty_score":0.3539782},"labels":[],"label_agreement":null},{"id":"W2576787462","doi":"10.1016/j.breast.2017.01.001","title":"Corrigendum to “3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)” [Breast 31 (February 2017) 244–259]","year":2017,"lang":"en","type":"erratum","venue":"The Breast","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Breast cancer; Regret; Oncology; Internal medicine; Cancer","score_opus":0.08359641699928291,"score_gpt":0.37835754730210835,"score_spread":0.29476113030282547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2576787462","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001958971,0.021910263,0.0035774342,0.51783067,0.2889641,0.013245911,0.10420978,0.0016819315,0.046620976],"genre_scores_gemma":[0.009758273,0.0019855532,0.0059733195,0.014588641,0.050323937,0.0031609724,0.0049740197,0.001020322,0.908215],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99352026,0.00010326257,0.0014867451,0.0017985003,0.0014831948,0.0016080342],"domain_scores_gemma":[0.9901458,0.00016141476,0.0015355848,0.0030604126,0.0042878506,0.00080895185],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006753935,0.0016263364,0.0020240461,0.00048926426,0.0009793392,0.0002330295,0.002478316,0.0008548757,0.00094997336],"category_scores_gemma":[0.00030571944,0.0012233574,0.0008615423,0.00030729696,0.00088900793,0.00029911002,0.00066393137,0.0016807662,0.0003460679],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00632065,0.00019023003,0.00041431183,0.00027789065,0.0012719365,0.00010302751,0.00019505755,0.00010127838,0.000616601,0.00011922882,0.83157134,0.15881847],"study_design_scores_gemma":[0.0057468377,0.0001986957,0.037184615,0.004044004,0.0009375226,0.016965747,0.0004912684,0.0004910149,0.00007233116,0.00061652175,0.9317133,0.0015381488],"about_ca_topic_score_codex":0.0037588319,"about_ca_topic_score_gemma":0.0014834583,"teacher_disagreement_score":0.86159396,"about_ca_system_score_codex":0.0012485272,"about_ca_system_score_gemma":0.002680759,"threshold_uncertainty_score":0.9999633},"labels":[],"label_agreement":null},{"id":"W2587349694","doi":"10.18192/uojm.v7i1.1563","title":"Triple Negative Breast Cancer: A review of common therapeutic Targets and Current Treatment options.","year":2017,"lang":"en","type":"review","venue":"University of Ottawa Journal of Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Triple-negative breast cancer; Carboplatin; Breast cancer; Oncology; Internal medicine; Cancer; Chemotherapy; Clinical trial; Bevacizumab; Adjuvant; Cancer research; Cisplatin","score_opus":0.07844334886115388,"score_gpt":0.38858899830040344,"score_spread":0.31014564943924955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587349694","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000066722832,0.99640155,0.00008867666,0.002112736,0.0003028422,0.00072327675,0.00017403666,0.0000051035076,0.00018510102],"genre_scores_gemma":[0.000065579814,0.999031,0.00030393925,0.000053743708,0.00027437208,9.181893e-7,0.000021009386,0.000022456346,0.0002269848],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981198,0.00020641004,0.00084171887,0.00019830416,0.00046039093,0.0001734225],"domain_scores_gemma":[0.9949319,0.00018057643,0.003642988,0.00039263084,0.0006249269,0.00022702607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047732724,0.00035808724,0.0040304027,0.00038311793,0.000095185474,0.000002009673,0.00031086663,0.000109528955,0.0004267416],"category_scores_gemma":[0.00006551004,0.00024137138,0.00052489736,0.0001760103,0.0008322882,0.00012474057,0.000046091962,0.00041348446,9.3385097e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015366565,0.00020096896,0.0000807927,0.044488028,0.0012890478,0.000070284616,0.0002982682,2.0561338e-7,0.0000013316653,0.000050272563,0.0006689443,0.9526982],"study_design_scores_gemma":[0.0038160656,0.00080677617,0.0003412815,0.27000585,0.0066304635,0.0010429614,0.00013891124,7.7828145e-7,0.0000014385943,0.000030861967,0.7170753,0.00010930577],"about_ca_topic_score_codex":0.000241836,"about_ca_topic_score_gemma":0.00002983435,"teacher_disagreement_score":0.9525889,"about_ca_system_score_codex":0.00049328647,"about_ca_system_score_gemma":0.00084544136,"threshold_uncertainty_score":0.9842839},"labels":[],"label_agreement":null},{"id":"W2587481440","doi":"10.1093/annonc/mdw435.05","title":"Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER + /HER2– advanced breast cancer (ABC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; BC Cancer Agency","funders":"","keywords":"Medicine; Palbociclib; Letrozole; Internal medicine; Breast cancer; Hazard ratio; Oncology; Fulvestrant; Clinical endpoint; Population; Progression-free survival; Biomarker; Cancer; Metastatic breast cancer; Gynecology; Gastroenterology; Estrogen receptor; Tamoxifen; Clinical trial; Chemotherapy; Confidence interval; Biology","score_opus":0.08366119973742049,"score_gpt":0.4202396635614648,"score_spread":0.3365784638240443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587481440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987764,0.00077876495,0.00036059003,0.0088437665,0.00008195139,0.0011515433,0.00050498295,0.000034848395,0.00047955045],"genre_scores_gemma":[0.9969664,0.00017459488,0.00096181716,0.0011083595,0.00014840132,0.00040813402,0.00002659814,0.000060097005,0.00014560453],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975509,0.00024928025,0.00061295443,0.0004977193,0.00047609696,0.00061304995],"domain_scores_gemma":[0.9973814,0.00066634355,0.0007045812,0.0005958146,0.00046770467,0.00018417586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030753156,0.0003745634,0.0013164085,0.00017570471,0.000060960465,0.000006324073,0.00026471206,0.00012897597,0.0004504886],"category_scores_gemma":[0.00003776427,0.00017189197,0.000060137845,0.0005486053,0.0010833478,0.00022406579,0.00005079239,0.00019849326,0.000003280539],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76842713,0.0014800467,0.008628198,0.00003697808,0.0015915841,0.00014115642,0.0014944504,0.00017620572,0.060329996,0.000018162098,0.00017527469,0.15750079],"study_design_scores_gemma":[0.6938983,0.052608836,0.20947905,0.0015993504,0.0005640784,0.00026253963,0.0051577967,0.000052128675,0.024215208,0.00020595606,0.01122682,0.00072989444],"about_ca_topic_score_codex":0.0014956984,"about_ca_topic_score_gemma":0.0026723405,"teacher_disagreement_score":0.20085086,"about_ca_system_score_codex":0.00029616785,"about_ca_system_score_gemma":0.00096879713,"threshold_uncertainty_score":0.7009551},"labels":[],"label_agreement":null},{"id":"W2588439324","doi":"10.1093/annonc/mdw365.04","title":"Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naïve postmenopausal patients with ER+ HER2- metastatic breast cancer (MBC): results from PALOMA-2","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Letrozole; Palbociclib; Medicine; Quality of life (healthcare); Metastatic breast cancer; Breast cancer; Internal medicine; Placebo; Oncology; Cancer; Tamoxifen; Alternative medicine","score_opus":0.08483000578050044,"score_gpt":0.411805459225645,"score_spread":0.32697545344514456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588439324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872426,0.00082339946,0.000029038756,0.0058517526,0.000051908126,0.0009852311,0.004865133,0.00002580132,0.00012517419],"genre_scores_gemma":[0.99816006,0.00026987222,0.00069261674,0.00043061216,0.00003159263,0.000060365695,0.00026404695,0.000050525512,0.000040330404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99635386,0.000536705,0.0015030826,0.00052159105,0.0005291158,0.00055564655],"domain_scores_gemma":[0.99586505,0.0007154665,0.001932113,0.00060437893,0.0005772865,0.0003056791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039960054,0.00039797425,0.0022403332,0.00025416978,0.000034300512,0.0000022966206,0.00014940138,0.00011793055,0.00012130102],"category_scores_gemma":[0.00010518281,0.00022359463,0.00014056942,0.00040665737,0.00047180778,0.00013169622,0.000032883272,0.00017362871,0.0000040879318],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33318773,0.011303241,0.5267341,0.00021900235,0.005157058,0.000072042836,0.0048354683,0.0017854291,0.007080564,0.000061202096,0.0003610119,0.10920312],"study_design_scores_gemma":[0.05816354,0.03908925,0.8992811,0.00084592187,0.000103542356,0.000011007192,0.00027444528,0.0000115368575,0.0018207225,0.000082737424,0.000108010056,0.00020822014],"about_ca_topic_score_codex":0.04493201,"about_ca_topic_score_gemma":0.0069079883,"teacher_disagreement_score":0.37254694,"about_ca_system_score_codex":0.0010636314,"about_ca_system_score_gemma":0.0018876127,"threshold_uncertainty_score":0.96142787},"labels":[],"label_agreement":null},{"id":"W2588818478","doi":"10.1093/annonc/mdw365.39","title":"Impact of palbociclib plus fulvestrant on patient reported general health status compared with fulvestrant alone in HR +, HER2- metastatic breast cancer","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Fulvestrant; Medicine; Palbociclib; Visual analogue scale; Metastatic breast cancer; Placebo; Breast cancer; Cancer; Anxiety; Internal medicine; Physical therapy; Oncology; Alternative medicine; Tamoxifen; Psychiatry","score_opus":0.09186327907846892,"score_gpt":0.42821981872231596,"score_spread":0.33635653964384704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588818478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901846,0.0009659481,0.00014193419,0.0072702602,0.00008737549,0.0007274769,0.00045919043,0.000027306785,0.00013590245],"genre_scores_gemma":[0.9967617,0.00086224213,0.0012764399,0.0008662745,0.000051099418,0.000070869835,0.00002924756,0.000042824966,0.000039302802],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971548,0.00022208955,0.001062625,0.00041836908,0.0004039639,0.00073818344],"domain_scores_gemma":[0.9976486,0.00016805987,0.0010125341,0.0004503466,0.00037510955,0.00034532996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028985232,0.00030686462,0.0014517236,0.00025312311,0.000027623597,0.000002522042,0.00009797103,0.0000801543,0.00021347697],"category_scores_gemma":[0.000034421784,0.00018064489,0.00017116757,0.00033133177,0.00039098706,0.0001027345,0.000021712358,0.00019182316,0.000002080318],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.067249775,0.004906418,0.20420584,0.00047072125,0.0027833441,0.00082230254,0.0051035914,0.005661082,0.03986259,0.00014702532,0.00078587804,0.6680014],"study_design_scores_gemma":[0.01749166,0.022308448,0.9521517,0.001073195,0.00009071039,0.0005048109,0.00035619643,0.000058989488,0.0044824923,0.00018253682,0.0010337669,0.00026548086],"about_ca_topic_score_codex":0.0087877745,"about_ca_topic_score_gemma":0.0018465162,"teacher_disagreement_score":0.74794585,"about_ca_system_score_codex":0.000628144,"about_ca_system_score_gemma":0.0028256082,"threshold_uncertainty_score":0.9978128},"labels":[],"label_agreement":null},{"id":"W2589217865","doi":"10.1200/jco.2013.31.15_suppl.557","title":"Characterization of patients who received prior chemotherapy for advanced breast cancer (ABC) in BOLERO-2.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Exemestane; Breast cancer; Everolimus; Internal medicine; Clinical endpoint; Metastatic breast cancer; Oncology; Cancer; Aromatase inhibitor; Chemotherapy; Randomized controlled trial; Aromatase","score_opus":0.04429092118661206,"score_gpt":0.42472936744359124,"score_spread":0.3804384462569792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589217865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880395,0.00010437122,0.00059623754,0.009634042,0.0007755409,0.0007557942,0.000028446018,0.0000057596785,0.000060291102],"genre_scores_gemma":[0.99000835,0.0010837045,0.004737734,0.0031438586,0.000715915,0.000060137067,0.000010142611,0.000033813994,0.00020632373],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971418,0.00012553977,0.0021011368,0.00017326802,0.00023530847,0.00022298316],"domain_scores_gemma":[0.9954904,0.00051233947,0.002407067,0.0001479392,0.0012632961,0.0001789881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006544994,0.00013836168,0.0014023843,0.00013015677,0.0000184585,0.000003831788,0.00013663904,0.00025706185,0.00032516665],"category_scores_gemma":[0.00056551874,0.00010379239,0.00026373388,0.00014978033,0.00014512952,0.0003178047,0.0000166035,0.0003949231,0.0000027469846],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011562173,0.0011922674,0.20473467,0.000057014047,0.00014092412,0.0000027609922,0.00019459179,0.000013877772,0.02424683,0.0000072178623,0.00008098314,0.7577667],"study_design_scores_gemma":[0.02305687,0.0034841516,0.9543131,0.00031300905,0.000055570035,0.000015057208,0.000047545473,0.00007949194,0.001849501,0.00021267809,0.016483044,0.000089978676],"about_ca_topic_score_codex":0.00001744472,"about_ca_topic_score_gemma":0.000016138232,"teacher_disagreement_score":0.7576767,"about_ca_system_score_codex":0.00023008214,"about_ca_system_score_gemma":0.00068692496,"threshold_uncertainty_score":0.42325306},"labels":[],"label_agreement":null},{"id":"W2590364524","doi":"10.1200/jco.2013.31.15_suppl.553","title":"Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Cambridge Memorial Hospital","funders":"","keywords":"Medicine; Exemestane; Discontinuation; Quality of life (healthcare); Breast cancer; Internal medicine; Adverse effect; Cancer; Clinical endpoint; Aromatase inhibitor; Oncology; Randomized controlled trial; Tamoxifen","score_opus":0.05542602667405326,"score_gpt":0.4080886539194081,"score_spread":0.3526626272453548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590364524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98833245,0.0006724506,0.00010129142,0.009597497,0.0008715365,0.00018559945,0.0000062485265,0.000012556383,0.0002203476],"genre_scores_gemma":[0.99405605,0.00019919744,0.0015496656,0.002193587,0.0019247115,0.000016243674,0.000004223422,0.000019089055,0.000037229234],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975172,0.0001882102,0.0015547066,0.00022751009,0.00031860496,0.00019372796],"domain_scores_gemma":[0.99683946,0.000736209,0.001569497,0.000102891776,0.0005454183,0.00020650218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020679149,0.00014813339,0.0011878113,0.00010885613,0.00006130996,0.000011341282,0.00006290063,0.00021252948,0.00023851446],"category_scores_gemma":[0.0003000582,0.000110881665,0.00021027023,0.00014058374,0.00025079973,0.000379697,0.00004148119,0.000856585,0.000009177782],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003347323,0.0013192348,0.115905434,0.000014990159,0.00040707283,0.00014172817,0.0008803825,0.000096036165,0.003909369,0.000053046948,0.0004083394,0.87351704],"study_design_scores_gemma":[0.008911243,0.0017514757,0.9733382,0.00016720252,0.00012810867,0.00021053046,0.0006875794,0.00018669432,0.0000517125,0.0030342056,0.011422179,0.00011090269],"about_ca_topic_score_codex":0.0001654941,"about_ca_topic_score_gemma":0.000052940413,"teacher_disagreement_score":0.8734061,"about_ca_system_score_codex":0.00022257741,"about_ca_system_score_gemma":0.0007041218,"threshold_uncertainty_score":0.4521623},"labels":[],"label_agreement":null},{"id":"W2591339827","doi":"10.1200/jco.2012.30.34_suppl.319","title":"Use of iPad technology to determine cancer patient-reported preferences for and understanding of pharmacogenetic testing (PGT).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer; Malignancy; Internal medicine; Interim; Oncology; Breast cancer; Test (biology); Family medicine","score_opus":0.5311195014013987,"score_gpt":0.5382484923085379,"score_spread":0.007128990907139143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591339827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99179703,0.0016401664,0.004175872,0.0014676235,0.0005691263,0.0003049987,0.000007940178,0.000006399245,0.000030818184],"genre_scores_gemma":[0.9464369,0.00021766289,0.05265099,0.00038295734,0.00027441687,0.000011553125,2.8574294e-7,0.000013083156,0.00001215593],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976176,0.00007765374,0.0017934332,0.000116877985,0.00017174456,0.00022268441],"domain_scores_gemma":[0.99430245,0.0025088463,0.0022859797,0.00010510579,0.0005701337,0.00022750608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078444555,0.000103555496,0.0010546127,0.00021264654,0.000021459715,0.0000017471689,0.00007230307,0.0001783464,0.000021781409],"category_scores_gemma":[0.0038860098,0.000075565724,0.00011354406,0.00021206486,0.0002846446,0.00012106427,0.00004853254,0.00026601722,1.2356672e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027950422,0.0003690722,0.45767486,0.00007866275,0.0003465262,0.0000113813085,0.00017955195,0.000035853438,0.032171648,0.000025217549,0.000047805774,0.5062644],"study_design_scores_gemma":[0.0334415,0.08053268,0.69481486,0.0030158383,0.004709248,0.0027067135,0.0028435846,0.00060725084,0.1098908,0.007930417,0.05882342,0.00068368175],"about_ca_topic_score_codex":0.00001047766,"about_ca_topic_score_gemma":0.000013195022,"teacher_disagreement_score":0.5055807,"about_ca_system_score_codex":0.00011473225,"about_ca_system_score_gemma":0.0005211334,"threshold_uncertainty_score":0.46521974},"labels":[],"label_agreement":null},{"id":"W2591741565","doi":"10.1158/1538-7445.sabcs16-p6-09-20","title":"Abstract P6-09-20: Clinical utility of PgR with various cutpoints using 3 commercial assays relative to 15yr survival","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia; Alberta Health Services","funders":"","keywords":"Tamoxifen; Medicine; Breast cancer; Oncology; Cohort; Internal medicine; Cancer; Immunohistochemistry; Hormonal therapy; Estrogen receptor; Adjuvant therapy; Estrogen; Gynecology","score_opus":0.3464387059699872,"score_gpt":0.5525184117322334,"score_spread":0.20607970576224616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591741565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98550487,0.0003015559,0.0017354072,0.002757853,0.00044753912,0.0009804181,0.00012829909,0.00003452485,0.008109554],"genre_scores_gemma":[0.9958174,0.000060459348,0.0026391742,0.00010084792,0.00068853673,0.000055167147,0.00000693307,0.00005863862,0.0005727921],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99655694,0.00030091807,0.000535922,0.00062085496,0.0012677418,0.00071761984],"domain_scores_gemma":[0.9961011,0.00057611306,0.0002736354,0.0013778048,0.0012151842,0.00045617452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002531418,0.00022125948,0.0007390946,0.00016208261,0.0005308398,0.000053308908,0.00054768205,0.0001887384,0.00066007563],"category_scores_gemma":[0.0011179713,0.00017950239,0.00012732855,0.00026378268,0.0014541118,0.00030275292,0.00032667222,0.0013780516,0.00004400245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020959077,0.00078695564,0.73804736,0.0003930559,0.00080046966,0.00028136623,0.00239254,0.000093206996,0.021878816,0.00032549727,0.0008503464,0.21319133],"study_design_scores_gemma":[0.0035692728,0.00063177315,0.9833832,0.0007149513,0.00005898261,0.00001624885,0.000270411,0.000119745746,0.004064065,0.00064953696,0.006307166,0.00021467858],"about_ca_topic_score_codex":0.004917332,"about_ca_topic_score_gemma":0.0028090624,"teacher_disagreement_score":0.24533582,"about_ca_system_score_codex":0.0004147515,"about_ca_system_score_gemma":0.0014239148,"threshold_uncertainty_score":0.74335676},"labels":[],"label_agreement":null},{"id":"W2592784720","doi":"10.1158/1538-7445.sabcs16-p4-22-10","title":"Abstract P4-22-10: Evaluation of the effects of palbociclib (PAL) + letrozole (LET) on QTc","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Palbociclib; Medicine; Letrozole; QT interval; Dosing; Internal medicine; Breast cancer; Clinical trial; Cancer; Pharmacology; Oncology; Metastatic breast cancer; Tamoxifen","score_opus":0.14008148373842555,"score_gpt":0.49721510235534105,"score_spread":0.3571336186169155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592784720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98637146,0.0024363028,0.0000037353961,0.0015685139,0.00030002368,0.0010776012,0.000016127246,0.00001126972,0.008214985],"genre_scores_gemma":[0.9977598,0.00015855256,0.000022659377,0.00006189196,0.00029281792,0.0002333865,0.0000025021163,0.00003062819,0.001437713],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969879,0.00018974153,0.00023373871,0.00027059522,0.0019685547,0.00034951404],"domain_scores_gemma":[0.9969641,0.00035293112,0.00024031418,0.0012843721,0.0010676776,0.00009062213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016474903,0.00012307195,0.0002881742,0.00011724564,0.00025888986,0.000019415505,0.0004906123,0.00008436777,0.0008423175],"category_scores_gemma":[0.0017763362,0.000083565596,0.000113427806,0.00016948234,0.0006370128,0.00010652414,0.00012943221,0.00044337544,0.00002917227],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017389932,0.00027057368,0.017671702,0.0013189228,0.0002506534,0.0000078632065,0.0007057459,0.00014951196,0.6724765,0.00039986448,0.001934756,0.30307493],"study_design_scores_gemma":[0.0033678953,0.00030583583,0.44381586,0.0013252525,0.000059504386,0.0000016509299,0.00006648504,0.000060604438,0.5464215,0.00079818384,0.0037020643,0.00007514607],"about_ca_topic_score_codex":0.0005799029,"about_ca_topic_score_gemma":0.00008813082,"teacher_disagreement_score":0.42614418,"about_ca_system_score_codex":0.00042611288,"about_ca_system_score_gemma":0.00069611415,"threshold_uncertainty_score":0.9222785},"labels":[],"label_agreement":null},{"id":"W2592880966","doi":"10.1158/1538-7445.sabcs16-p4-22-03","title":"Abstract P4-22-03: Palbociclib in combination with endocrine therapy in treatment-naive and previously treated elderly women with HR+, HER2– advanced breast cancer: a pooled analysis from randomized phase 2 and 3 studies","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Palbociclib; Fulvestrant; Medicine; Letrozole; Internal medicine; Breast cancer; Metastatic breast cancer; Cancer; Clinical endpoint; Neutropenia; Oncology; Randomized controlled trial; Placebo; Gastroenterology; Gynecology; Chemotherapy; Estrogen receptor; Tamoxifen; Pathology","score_opus":0.04410407231845639,"score_gpt":0.42231124401593967,"score_spread":0.3782071716974833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592880966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9720466,0.022391194,0.0000082173665,0.0023968196,0.000019741065,0.002855717,0.00017954258,0.000039217208,0.00006292352],"genre_scores_gemma":[0.94885373,0.046031497,0.00011327958,0.000047675403,0.00006574609,0.004533134,0.000039969225,0.000057854395,0.00025709506],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970297,0.0003010282,0.00044089815,0.00085883384,0.0005683754,0.0008011431],"domain_scores_gemma":[0.99778014,0.00054427894,0.00030057775,0.0006109314,0.00050253107,0.0002615208],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006047475,0.00043529758,0.0018151037,0.00066252373,0.00029443204,0.00012428465,0.00017708143,0.00007810912,0.00020164362],"category_scores_gemma":[0.000088083674,0.0002766118,0.00006576499,0.0007433656,0.0011226458,0.0004825323,0.000054966178,0.0004052376,9.901012e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3924493,0.0008133489,0.17141455,0.000116449446,0.0063336845,0.000364613,0.00843737,0.000087816195,0.0071969796,0.000011558873,0.0000031094337,0.41277122],"study_design_scores_gemma":[0.57328576,0.0034680506,0.41264024,0.0011592787,0.00063526095,0.000023753035,0.0037740998,0.00018169792,0.0039498494,0.00035999974,0.0001203566,0.00040164482],"about_ca_topic_score_codex":0.02496292,"about_ca_topic_score_gemma":0.020114264,"teacher_disagreement_score":0.41236958,"about_ca_system_score_codex":0.0014161698,"about_ca_system_score_gemma":0.00038507508,"threshold_uncertainty_score":0.9999686},"labels":[],"label_agreement":null},{"id":"W2592927667","doi":"10.1158/1538-7445.sabcs16-p1-01-01","title":"Abstract P1-01-01: Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Metastatic breast cancer; Internal medicine; Circulating tumor cell; Oncology; Progression-free survival; Breast cancer; Cancer; Adjuvant; Clinical trial; Chemotherapy; Metastasis","score_opus":0.11514751256542281,"score_gpt":0.4960428507092594,"score_spread":0.3808953381438366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592927667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920654,0.00057430513,0.0000053624585,0.0024440999,0.00048205582,0.0024693115,0.0013041681,0.0000187641,0.00063651643],"genre_scores_gemma":[0.99798447,0.0005628152,0.00006149961,0.00022335832,0.00039189702,0.0003969651,0.000019548255,0.00006544465,0.0002940112],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957973,0.00046033828,0.0010743664,0.00067935634,0.0012593898,0.00072925264],"domain_scores_gemma":[0.9964548,0.0009938411,0.00067400147,0.0010094715,0.0006096523,0.0002582529],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016385696,0.00031331132,0.00092525594,0.00017564702,0.0003593535,0.00008086625,0.00053103274,0.000085383814,0.00039776647],"category_scores_gemma":[0.00083348964,0.00020626739,0.00021629535,0.00030963673,0.0012219124,0.00033194103,0.00028080895,0.0012266011,0.0000045679485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.077613175,0.0022735232,0.8652611,0.00017356448,0.00041911824,0.00006467776,0.0007626403,0.000029915731,0.0019449915,0.000009652568,0.00024069002,0.051206946],"study_design_scores_gemma":[0.146301,0.0005318903,0.84969544,0.00054930156,0.000047822632,0.000012154922,0.0002299836,0.000045804012,0.0018629848,0.00011608428,0.00042935327,0.00017816598],"about_ca_topic_score_codex":0.006683263,"about_ca_topic_score_gemma":0.00059427053,"teacher_disagreement_score":0.06868782,"about_ca_system_score_codex":0.00041391488,"about_ca_system_score_gemma":0.0007413612,"threshold_uncertainty_score":0.99993134},"labels":[],"label_agreement":null},{"id":"W2592994249","doi":"10.1158/1538-7445.sabcs16-p4-22-06","title":"Abstract P4-22-06: Treatment postprogression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Palbociclib; Fulvestrant; Medicine; Metastatic breast cancer; Internal medicine; Hazard ratio; Breast cancer; Progression-free survival; Cancer; Oncology; Chemotherapy; Placebo; Gynecology; Tamoxifen; Confidence interval; Pathology","score_opus":0.050303170002198555,"score_gpt":0.41754668635269787,"score_spread":0.36724351635049934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592994249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840457,0.0055672918,0.0000027050598,0.0067293444,0.0001395991,0.0021806115,0.00026503127,0.00007445018,0.0009952715],"genre_scores_gemma":[0.9868677,0.006844601,0.0002350339,0.0001210393,0.0003517101,0.004179331,0.000020934543,0.00014630433,0.0012333489],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99469316,0.00017933609,0.0006360347,0.0011925352,0.0012877784,0.0020111797],"domain_scores_gemma":[0.9969857,0.00016605525,0.0002993352,0.0014731621,0.00047171855,0.0006040607],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006308164,0.00057461445,0.0010581805,0.00052660384,0.00045917038,0.00015940075,0.00062813895,0.00017465769,0.0009257027],"category_scores_gemma":[0.00007978477,0.00042365037,0.00009265084,0.00056939595,0.0008335046,0.00055374054,0.00015601351,0.0010701827,0.000026322323],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.087089576,0.0009949948,0.14186561,0.000719488,0.0003507771,0.0034552386,0.0050334106,0.0008152225,0.17425863,0.00004814939,0.00009595171,0.58527297],"study_design_scores_gemma":[0.022172,0.0013546643,0.94865525,0.0053851814,0.000024467423,0.0000812374,0.001881893,0.000045041947,0.012678602,0.00019475218,0.0070000477,0.00052686123],"about_ca_topic_score_codex":0.0139015475,"about_ca_topic_score_gemma":0.013434012,"teacher_disagreement_score":0.80678964,"about_ca_system_score_codex":0.007236811,"about_ca_system_score_gemma":0.0021543705,"threshold_uncertainty_score":0.9999876},"labels":[],"label_agreement":null},{"id":"W2593142478","doi":"10.1158/1538-7445.sabcs16-p2-08-02","title":"Abstract P2-08-02: Progression-free survival results in patient subgroups from a Phase 3 randomized trial of fulvestrant 500 mg vs anastrozole for hormone receptor-positive advanced breast cancer (FALCON)","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Anastrozole; Fulvestrant; Medicine; Internal medicine; Clinical endpoint; Hazard ratio; Oncology; Metastatic breast cancer; Breast cancer; Progression-free survival; Randomized controlled trial; Cancer; Estrogen receptor; Tamoxifen; Confidence interval; Chemotherapy","score_opus":0.048925185894192355,"score_gpt":0.4243854917778676,"score_spread":0.37546030588367524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593142478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9682123,0.003519246,0.00012835472,0.0069492864,0.0008730391,0.008442379,0.0115365125,0.00005192475,0.0002869568],"genre_scores_gemma":[0.98913604,0.001889905,0.0014043453,0.000052887965,0.0011202686,0.0057772924,0.00037197614,0.00011324162,0.00013404897],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941031,0.0004437886,0.0013590083,0.0011133208,0.001736371,0.0012444311],"domain_scores_gemma":[0.9940842,0.001447574,0.0009313138,0.0017039168,0.0013588695,0.00047412186],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025384894,0.0004959966,0.0018790928,0.0003777785,0.00044376397,0.00010061804,0.0008775282,0.0002610248,0.0003054218],"category_scores_gemma":[0.0016205184,0.00040261346,0.00040464694,0.00034453633,0.0014373244,0.00055282953,0.0002781275,0.00097145163,0.0000073301535],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7204437,0.00096116576,0.00013779549,0.000121698744,0.0003451331,0.000048035185,0.0009899647,0.000037186295,0.08671026,0.000034971414,0.00032488888,0.1898452],"study_design_scores_gemma":[0.93065906,0.002658262,0.010330671,0.00238008,0.000108681015,0.0000054362204,0.00066193566,0.0001135661,0.05064107,0.0005314855,0.0014930853,0.00041667017],"about_ca_topic_score_codex":0.0071724453,"about_ca_topic_score_gemma":0.0015416088,"teacher_disagreement_score":0.21021535,"about_ca_system_score_codex":0.00095627294,"about_ca_system_score_gemma":0.001385605,"threshold_uncertainty_score":0.9998426},"labels":[],"label_agreement":null},{"id":"W2593434036","doi":"10.1158/1538-7445.sabcs16-p3-12-01","title":"Abstract P3-12-01: Value-based approach to treatment of HER2-positive breast cancer: Examining the evidence","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Pertuzumab; Trastuzumab; Capecitabine; Lapatinib; Metastatic breast cancer; Nice; Breast cancer; Oncology; Internal medicine; Regimen; Cancer; Cost effectiveness; Colorectal cancer","score_opus":0.24476797528306762,"score_gpt":0.46907792851226093,"score_spread":0.2243099532291933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593434036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9598462,0.01036104,0.0006126073,0.019520095,0.0003107576,0.0031051592,0.00036372908,0.00006824749,0.0058121914],"genre_scores_gemma":[0.9947484,0.0010632575,0.0006397467,0.00024166626,0.0006959176,0.0015853931,0.0000064493825,0.00006525088,0.00095392135],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969062,0.00016659629,0.00031638768,0.0006731886,0.0011587413,0.00077884295],"domain_scores_gemma":[0.99676174,0.0005206559,0.00020292707,0.001566837,0.0006176943,0.00033015673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086499867,0.00028089806,0.0005163796,0.00017646658,0.0007356122,0.00010692457,0.0007171687,0.000097843935,0.0002787635],"category_scores_gemma":[0.00017098585,0.00018474442,0.00012426908,0.00027043535,0.0008876861,0.00023248189,0.00013550706,0.0003967469,0.000022040796],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010193211,0.0010225092,0.057231016,0.00063322484,0.00067441474,0.000078133366,0.005375427,0.0038842259,0.121724874,0.0002470744,0.00053800934,0.7983979],"study_design_scores_gemma":[0.0032577468,0.0013707351,0.89815795,0.003287243,0.00012181712,0.00003973764,0.0011892777,0.0003348156,0.08671444,0.00007368781,0.005125689,0.0003268857],"about_ca_topic_score_codex":0.014880006,"about_ca_topic_score_gemma":0.00039453054,"teacher_disagreement_score":0.8409269,"about_ca_system_score_codex":0.001645974,"about_ca_system_score_gemma":0.0014199552,"threshold_uncertainty_score":0.99167997},"labels":[],"label_agreement":null},{"id":"W2594198507","doi":"10.1158/1538-7445.sabcs16-p6-09-15","title":"Abstract P6-09-15: Mechanism of drug resistance in relation to sites of metastases: Meta-analyses of randomized controlled trials in advanced breast cancer","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Oncology; Internal medicine; Breast cancer; Randomized controlled trial; Metastatic breast cancer; Hazard ratio; Targeted therapy; Endocrine system; Cancer; Meta-analysis; Clinical trial; Confidence interval; Hormone","score_opus":0.2132482164782858,"score_gpt":0.5060859911771813,"score_spread":0.29283777469889555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594198507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9375136,0.04759633,0.00035672353,0.0047121528,0.00015311842,0.0077069527,0.0011698555,0.000017494232,0.0007737697],"genre_scores_gemma":[0.99186623,0.0020928304,0.0021602032,0.000034729783,0.00007557204,0.002832921,0.00001475352,0.000042917232,0.0008798622],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99150324,0.0023102637,0.0032867691,0.000606083,0.0017347505,0.000558878],"domain_scores_gemma":[0.9888915,0.005470876,0.0024972989,0.0011495567,0.0018225242,0.00016824831],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.024122508,0.00034320226,0.009297279,0.001308559,0.00009219779,0.000025887999,0.00053526234,0.0001321944,0.0013808875],"category_scores_gemma":[0.013673617,0.00023040806,0.0013335424,0.00076167047,0.0005849883,0.0003764073,0.00012223968,0.0005355525,0.0000024022174],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.432409,0.00027166557,0.00079063204,0.00078915927,0.0065498236,0.000018667315,0.0014033074,0.0014194964,0.55203867,0.0016942816,0.00008212884,0.0025331741],"study_design_scores_gemma":[0.42545044,0.0001237991,0.022775304,0.003105944,0.005494428,0.000002430859,0.0009580801,0.000094825424,0.5316457,0.009779674,0.0001832685,0.00038608912],"about_ca_topic_score_codex":0.007479482,"about_ca_topic_score_gemma":0.012171401,"teacher_disagreement_score":0.054352608,"about_ca_system_score_codex":0.00044429672,"about_ca_system_score_gemma":0.0009010013,"threshold_uncertainty_score":0.999532},"labels":[],"label_agreement":null},{"id":"W2594353641","doi":"10.1158/1538-7755.disp16-b47","title":"Abstract B47: Combating cancer with combination therapy in underserved populations","year":2017,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Hospital for Sick Children","funders":"","keywords":"Combination therapy; Medicine; Cancer; Cancer therapy; Metastasis; Drug; Pharmacology; Internal medicine","score_opus":0.20635351269125105,"score_gpt":0.4524718444106933,"score_spread":0.24611833171944228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594353641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9693766,0.006710498,0.0027320583,0.01872919,0.00068982656,0.0011479561,0.000014492668,0.00009615284,0.00050318375],"genre_scores_gemma":[0.9936864,0.0011473084,0.0033241143,0.000627848,0.00014924715,0.00053770025,0.00010275501,0.000042419986,0.0003822159],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980752,0.00022316638,0.00059450796,0.0005140422,0.0001451939,0.0004478828],"domain_scores_gemma":[0.99807066,0.00018052974,0.0008903819,0.000592693,0.00015299929,0.00011274465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010150074,0.0002617166,0.000586893,0.00017069766,0.00037232105,0.000019388484,0.00019962923,0.00020848648,0.00033570649],"category_scores_gemma":[0.00021848241,0.00022092683,0.000129724,0.00011861735,0.00036595733,0.00043135375,0.000035308443,0.0002840137,0.0000067944898],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011111585,0.00014284557,0.8384174,0.000057995716,0.00029010256,0.0000062276417,0.00009414299,0.00025340397,0.0018152702,0.0008680737,0.0001280282,0.15681535],"study_design_scores_gemma":[0.005446892,0.00021821224,0.9795047,0.00089208427,0.000067437606,0.000008717387,0.00011775214,0.00061380246,0.00033627078,0.011917163,0.0006504975,0.00022647172],"about_ca_topic_score_codex":0.0038036401,"about_ca_topic_score_gemma":0.006804661,"teacher_disagreement_score":0.15658887,"about_ca_system_score_codex":0.00056590635,"about_ca_system_score_gemma":0.00023772375,"threshold_uncertainty_score":0.9009134},"labels":[],"label_agreement":null},{"id":"W2594478488","doi":"10.1158/1538-7445.sabcs16-pd2-07","title":"Abstract PD2-07: 10-year follow-up and biomarker discovery for adjuvant endocrine therapy; results of the TEAM trial","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Exemestane; Medicine; Internal medicine; Oncology; Breast cancer; Hazard ratio; Tamoxifen; Clinical endpoint; Adjuvant therapy; Cancer; Randomized controlled trial; Confidence interval","score_opus":0.144528455159949,"score_gpt":0.45249150022353896,"score_spread":0.30796304506358996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594478488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834711,0.0032265864,0.000015619764,0.006585219,0.0007242721,0.002633764,0.00044947604,0.000019851126,0.002874101],"genre_scores_gemma":[0.9832999,0.0011470997,0.00008364352,0.00007100961,0.0007063914,0.0004883784,0.000011654728,0.00004903417,0.014142871],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99790156,0.00007414542,0.00034648197,0.000445439,0.00069963856,0.0005327571],"domain_scores_gemma":[0.99763876,0.00037811953,0.00022454203,0.0012093412,0.00042017136,0.00012907309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009900681,0.00017766883,0.00040426207,0.00010181462,0.00047198145,0.00009682329,0.00047719548,0.00007667332,0.00016272008],"category_scores_gemma":[0.0010205032,0.00010825621,0.00017028903,0.00011358783,0.00087053835,0.00027312915,0.00020998894,0.00032347927,0.0000065843847],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53397787,0.00026966532,0.0025726287,0.00030762597,0.0004894239,0.000010856917,0.00057330367,0.000002500672,0.2390546,0.00022931704,0.016740903,0.2057713],"study_design_scores_gemma":[0.30490217,0.0019216237,0.15431234,0.0009572227,0.00007057471,0.000016856726,0.00059162144,0.000018552684,0.18253754,0.0016236738,0.35269397,0.00035384018],"about_ca_topic_score_codex":0.0009086582,"about_ca_topic_score_gemma":0.00017789984,"teacher_disagreement_score":0.3359531,"about_ca_system_score_codex":0.00016697473,"about_ca_system_score_gemma":0.0005519549,"threshold_uncertainty_score":0.441456},"labels":[],"label_agreement":null},{"id":"W2595420534","doi":"10.1200/jco.2015.33.15_suppl.e11502","title":"Treatment patterns and characteristics of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Metastatic breast cancer; Exemestane; Internal medicine; Breast cancer; Everolimus; Oncology; Odds ratio; Cancer; Anastrozole; Gynecology; Tamoxifen","score_opus":0.08902011211839758,"score_gpt":0.43607617497690004,"score_spread":0.34705606285850243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595420534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928728,0.0003558637,0.00021274122,0.0058159516,0.00042366848,0.00016824093,0.000071813956,0.000007054649,0.00007188101],"genre_scores_gemma":[0.9944063,0.0008766451,0.0028772242,0.0009988388,0.00068370544,0.000012703919,0.0000022104584,0.00002758548,0.000114805945],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99753976,0.00024600068,0.0014456537,0.00017185474,0.0003339597,0.00026277348],"domain_scores_gemma":[0.9959104,0.0006921882,0.0018162547,0.00016192274,0.00084211334,0.00057712826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010064646,0.00018013432,0.0017212111,0.00009206013,0.000019000163,0.000006180329,0.00008823923,0.00011459127,0.00013609265],"category_scores_gemma":[0.00039066313,0.00010878028,0.00006464581,0.00008242804,0.0002397524,0.00014085959,0.00003106852,0.0003760547,0.0000019264132],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027407927,0.0014604719,0.34839404,0.00007613026,0.0015391806,0.00062758056,0.0014728688,0.000012839339,0.00060582324,0.0000075859634,0.000024502833,0.61837107],"study_design_scores_gemma":[0.013688861,0.04858762,0.92668307,0.00023991446,0.0006606524,0.003300351,0.0010263649,0.000015216691,0.000044897362,0.00007335588,0.0055695716,0.000110146604],"about_ca_topic_score_codex":0.0001584308,"about_ca_topic_score_gemma":0.00009425726,"teacher_disagreement_score":0.6182609,"about_ca_system_score_codex":0.00059805537,"about_ca_system_score_gemma":0.0019673284,"threshold_uncertainty_score":0.4435931},"labels":[],"label_agreement":null},{"id":"W2597559961","doi":"10.1200/jco.2013.31.15_suppl.tps652","title":"A randomized, multicenter, double-blind phase III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(–) breast cancer who have not received any prior systemic anticancer treatment for advanced disease.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Palbociclib; Medicine; Letrozole; Internal medicine; Adverse effect; Oncology; Regimen; Progression-free survival; Neutropenia; Placebo; Clinical endpoint; Fulvestrant; Breast cancer; Phases of clinical research; Metastatic breast cancer; Clinical trial; Cancer; Tamoxifen; Chemotherapy","score_opus":0.11242801869707363,"score_gpt":0.46402493767064373,"score_spread":0.3515969189735701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597559961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777557,0.0028468396,0.00062121195,0.0024083075,0.0012508186,0.014792606,0.00028803517,0.000022815884,0.00001362202],"genre_scores_gemma":[0.98907983,0.0025010614,0.0014652093,0.00026502437,0.0013376292,0.004925261,0.000019306404,0.00010625047,0.0003004022],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99351853,0.0007002747,0.0036316798,0.00064514106,0.00071659725,0.00078774657],"domain_scores_gemma":[0.98692024,0.005527679,0.004279453,0.00066069444,0.0017752852,0.0008366449],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015623702,0.0006479161,0.005289396,0.00021480052,0.00017345384,0.000030285266,0.00035194916,0.0002687221,0.00010294222],"category_scores_gemma":[0.00032730564,0.0003532574,0.0007465121,0.0001899483,0.00079379877,0.0004538206,0.000042039937,0.00036937345,0.0000012949995],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83080167,0.015929285,0.0015333407,0.00015456682,0.0065648123,0.000055034438,0.0037985458,0.0019168841,0.00086831144,0.0000071505438,0.000023303113,0.13834712],"study_design_scores_gemma":[0.8426484,0.135306,0.004013411,0.00044830012,0.0044935844,0.00006590013,0.0074810274,0.0028263293,0.000521268,0.000010912571,0.0018966314,0.00028824],"about_ca_topic_score_codex":0.0008043702,"about_ca_topic_score_gemma":0.00086965674,"teacher_disagreement_score":0.13805887,"about_ca_system_score_codex":0.0031358209,"about_ca_system_score_gemma":0.0031640937,"threshold_uncertainty_score":0.99989194},"labels":[],"label_agreement":null},{"id":"W2598145223","doi":"10.1200/jco.2013.31.15_suppl.558","title":"Clinical management and resolution of stomatitis in BOLERO-2.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cambridge Memorial Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Stomatitis; Exemestane; Internal medicine; Everolimus; Surgery; Placebo; Breast cancer; Cancer; Tamoxifen","score_opus":0.10342428957402121,"score_gpt":0.48924493115082496,"score_spread":0.38582064157680374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598145223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892418,0.0015455976,0.00069579383,0.005263756,0.0006258806,0.00023332196,7.255194e-7,0.0000049498935,0.0023882184],"genre_scores_gemma":[0.96042275,0.0027792137,0.03466777,0.0014225546,0.00045513647,0.0000045972997,4.0762853e-7,0.000009428091,0.00023812788],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99653006,0.0003292524,0.0026490511,0.00012832279,0.00021808053,0.00014524942],"domain_scores_gemma":[0.99701524,0.0010703052,0.0013396664,0.000141781,0.00023745406,0.00019553292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025851298,0.00007742159,0.0011382034,0.00012928068,0.000009049208,0.0000022786458,0.00008656465,0.00022172938,0.0001398368],"category_scores_gemma":[0.0009213222,0.000057169495,0.00019223017,0.00009858198,0.0003198782,0.00013312123,0.00005407069,0.0005902931,0.000010666293],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012799519,0.0007461868,0.23539126,0.000049173294,0.00017025511,0.00013274254,0.00004560337,0.000009593931,0.000052224485,0.00026293856,0.001067382,0.7607927],"study_design_scores_gemma":[0.00830365,0.0049709175,0.95403206,0.00023165994,0.000092113645,0.0001673085,0.00016602594,0.00013364303,0.00001274617,0.002441167,0.029402288,0.000046392608],"about_ca_topic_score_codex":0.000024484725,"about_ca_topic_score_gemma":0.000021176307,"teacher_disagreement_score":0.7607463,"about_ca_system_score_codex":0.00007444468,"about_ca_system_score_gemma":0.00020622637,"threshold_uncertainty_score":0.25645626},"labels":[],"label_agreement":null},{"id":"W2598366105","doi":"10.1200/jco.2014.32.15_suppl.e12530","title":"Triple-negative breast cancer: A population-based description of clinical-pathologic correlates and survival outcomes as a function of age at diagnosis.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Breast cancer; Cohort; Population; Internal medicine; Lymph node; Cancer; Triple-negative breast cancer; Pathological; Sentinel lymph node; Oncology","score_opus":0.12195619415490133,"score_gpt":0.45864133994610723,"score_spread":0.3366851457912059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598366105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915036,0.00041278312,0.0015588651,0.0036649434,0.002399781,0.00026980505,0.000022949565,0.000012515756,0.00015473417],"genre_scores_gemma":[0.99512553,0.000603384,0.0021991744,0.0013530708,0.0005579118,0.000014353978,0.000006415388,0.000019850933,0.00012028525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943318,0.0011767923,0.0036430722,0.00025690228,0.0004026775,0.00018875387],"domain_scores_gemma":[0.9850663,0.008780156,0.0049644317,0.00020805295,0.00071725156,0.00026379246],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0043119458,0.00018831657,0.002742572,0.00015946211,0.000044538712,0.0000038661005,0.00011050523,0.00047042643,0.00019764226],"category_scores_gemma":[0.0092349965,0.0001299663,0.00061174313,0.00016535807,0.00052862626,0.00014879611,0.000045356115,0.0007043374,0.0000030167664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014087669,0.000844048,0.7941861,0.000052761752,0.00029410227,0.00003851328,0.000050355102,0.0001240204,0.000087363675,0.00008619018,0.000054646964,0.19009425],"study_design_scores_gemma":[0.0151519,0.010745796,0.9692544,0.00022524071,0.00068551284,0.00010732465,0.00008718474,0.00027174462,0.000027362763,0.0024226145,0.0009189126,0.0001020182],"about_ca_topic_score_codex":0.00022839935,"about_ca_topic_score_gemma":0.00033735484,"teacher_disagreement_score":0.18999222,"about_ca_system_score_codex":0.0001680512,"about_ca_system_score_gemma":0.00047694778,"threshold_uncertainty_score":0.99911064},"labels":[],"label_agreement":null},{"id":"W2602672885","doi":"10.1200/jco.2013.31.15_suppl.564","title":"Competing risks of death in NCIC CTG MA.27 adjuvant exemestane versus anastrozole.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Hamilton Health Sciences; University of Toronto; Juravinski Cancer Centre; Sunnybrook Health Science Centre; McMaster University; Queen's University","funders":"","keywords":"Medicine; Exemestane; Anastrozole; Internal medicine; Letrozole; Breast cancer; Oncology; Cancer; Adjuvant therapy; Tamoxifen","score_opus":0.25716147792904726,"score_gpt":0.5203012545906464,"score_spread":0.2631397766615991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602672885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98969084,0.0011071577,0.00043239314,0.003941975,0.0015343662,0.00021342379,0.0000020823006,0.000008552268,0.003069233],"genre_scores_gemma":[0.9765553,0.00041354453,0.021430928,0.000715353,0.00078366353,0.0000035842686,0.0000013152659,0.0000206416,0.00007569822],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99610555,0.00035545934,0.0026791687,0.00017218191,0.00037094447,0.0003167015],"domain_scores_gemma":[0.9942792,0.0024930837,0.0021499894,0.00021674509,0.00053980947,0.00032118935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019805073,0.00015222529,0.001771822,0.00017394953,0.000017104201,0.0000039918364,0.0002013112,0.00026548476,0.00044177772],"category_scores_gemma":[0.0024850639,0.00011322775,0.00033698796,0.00016862317,0.00025304413,0.00016315034,0.00006014425,0.0011829047,0.000027771532],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019438995,0.0015960679,0.4189761,0.00007111562,0.00042825632,0.0007554542,0.0002639489,0.0002601045,0.0017662289,0.00022669314,0.00033963297,0.5558774],"study_design_scores_gemma":[0.025568042,0.013005771,0.9352214,0.00038083762,0.00020549029,0.0003802774,0.0009919779,0.00025326366,0.00023688635,0.0006796974,0.022948423,0.00012795052],"about_ca_topic_score_codex":0.00013439133,"about_ca_topic_score_gemma":0.00006331283,"teacher_disagreement_score":0.5557495,"about_ca_system_score_codex":0.0002587363,"about_ca_system_score_gemma":0.0009283238,"threshold_uncertainty_score":0.51391983},"labels":[],"label_agreement":null},{"id":"W2602982162","doi":"10.1200/jco.2012.30.15_suppl.516","title":"Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the TEAM pathology study.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Oncology; Internal medicine; Exemestane; Cohort; Chemotherapy; Breast cancer; Tamoxifen; Multivariate analysis; Cancer","score_opus":0.09514570156451081,"score_gpt":0.47282625460287575,"score_spread":0.37768055303836495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602982162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99555516,0.0007961195,0.00087314594,0.00067520817,0.0011640849,0.0006575885,0.000017178647,0.000007217502,0.00025429743],"genre_scores_gemma":[0.99089473,0.00013818343,0.0069119744,0.00046131184,0.0014961063,0.00003173901,0.0000041285193,0.000019252037,0.00004255804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99560815,0.0013830825,0.0022366743,0.00016462263,0.00032274605,0.0002847011],"domain_scores_gemma":[0.9940532,0.0031826792,0.0018771371,0.00031785504,0.0003681716,0.00020099299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010375561,0.00013512453,0.0011335247,0.000105853185,0.0000401237,0.0000028608915,0.00023874221,0.00041000382,0.000029234598],"category_scores_gemma":[0.0054330877,0.000083979205,0.00032214227,0.00012132557,0.0003058129,0.00021398632,0.00002797763,0.0012995248,0.0000035709047],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024966888,0.011501771,0.78777814,0.000018990879,0.0003320925,0.00010129165,0.0045314305,0.000012959678,0.00991817,0.00007476951,0.00022449567,0.16053899],"study_design_scores_gemma":[0.014326379,0.040403742,0.9325377,0.000036191264,0.0004363628,0.000893076,0.0025468285,0.000022906912,0.0003109269,0.0007567204,0.007660228,0.0000689665],"about_ca_topic_score_codex":0.000038558315,"about_ca_topic_score_gemma":0.000021565198,"teacher_disagreement_score":0.16047002,"about_ca_system_score_codex":0.00016105949,"about_ca_system_score_gemma":0.0005223439,"threshold_uncertainty_score":0.6504306},"labels":[],"label_agreement":null},{"id":"W2603848217","doi":"10.1200/jco.2013.31.15_suppl.e17564","title":"Should adjuvant zoledronic acid be used in early-stage, endocrine-sensitive breast cancer?","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Breast cancer; Adjuvant; Endocrine system; Oncology; Gynecology; Adverse effect; Internal medicine; Cancer; Hormone","score_opus":0.14093288341092883,"score_gpt":0.47818790494957014,"score_spread":0.3372550215386413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603848217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.953071,0.00080858974,0.00016782692,0.0433247,0.0012085111,0.00038607512,0.000021542499,0.000021232143,0.0009905443],"genre_scores_gemma":[0.9881583,0.00066270854,0.0018880657,0.006787262,0.0019265314,0.000023702536,0.000001759762,0.000041685154,0.0005099854],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9958825,0.00040402552,0.00238303,0.0002898957,0.00051464577,0.00052589545],"domain_scores_gemma":[0.99574804,0.0011961135,0.0015365817,0.00027082537,0.00070749363,0.0005409157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012089644,0.00024385551,0.0020568757,0.00022083257,0.00003180542,0.00001213386,0.00021907307,0.00033715027,0.0008356886],"category_scores_gemma":[0.0007643535,0.00017805747,0.00047046362,0.00024109035,0.00036695975,0.0003704357,0.000080033555,0.0019870123,0.000053321746],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008461749,0.0017282484,0.41486794,0.000054224318,0.00072250556,0.0029676564,0.0006090846,0.00015371245,0.005064284,0.00014871823,0.0011066572,0.5641152],"study_design_scores_gemma":[0.015455263,0.004095067,0.94132304,0.00025120866,0.00017795412,0.001693897,0.00054809696,0.00013943342,0.001004503,0.00035954962,0.03475767,0.00019429205],"about_ca_topic_score_codex":0.0005007094,"about_ca_topic_score_gemma":0.0004705344,"teacher_disagreement_score":0.5639209,"about_ca_system_score_codex":0.00062218413,"about_ca_system_score_gemma":0.001948934,"threshold_uncertainty_score":0.9150204},"labels":[],"label_agreement":null},{"id":"W2604788765","doi":"10.1200/jco.2009.27.15_suppl.6026","title":"A phase II randomized study of oral seliciclib in patients with previously treated nasopharyngeal carcinoma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Clinical endpoint; Dosing; Phases of clinical research; Nasopharyngeal carcinoma; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Oncology; Randomized controlled trial; Surgery; Adverse effect; Clinical trial; Radiation therapy","score_opus":0.05884612129321212,"score_gpt":0.44401686566541854,"score_spread":0.38517074437220644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604788765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99721706,0.0002863245,0.00002752,0.0008777463,0.00016624921,0.0012154507,0.0000018082757,0.000008948355,0.00019890105],"genre_scores_gemma":[0.99751073,0.000032299948,0.0014023492,0.0007969475,0.0001841561,0.000007841068,0.0000026527916,0.000015964137,0.000047048972],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952675,0.00088271743,0.0029579306,0.00019998488,0.00044444352,0.00024741574],"domain_scores_gemma":[0.995718,0.0009343779,0.0022495196,0.00020839598,0.00062661944,0.00026309968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024554895,0.0001864549,0.0035926397,0.00021504718,0.000025235915,0.000002514292,0.00015010206,0.00018089116,0.00005025004],"category_scores_gemma":[0.0012270692,0.000110799905,0.00032241544,0.00026911494,0.0002023921,0.00014364965,0.000023713263,0.0007234352,9.351101e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55094737,0.03631116,0.26274395,0.000007969608,0.00036657977,0.0003193495,0.0007175529,0.000016388307,0.000022519316,0.000004067366,0.000030580235,0.14851253],"study_design_scores_gemma":[0.5135035,0.15111138,0.33434814,0.00006838202,0.00045775576,0.00003673942,0.000104245664,0.000023943954,0.000020214391,0.000055098335,0.00021287563,0.000057696554],"about_ca_topic_score_codex":0.000042031235,"about_ca_topic_score_gemma":0.000041997635,"teacher_disagreement_score":0.14845483,"about_ca_system_score_codex":0.00015578468,"about_ca_system_score_gemma":0.00065655704,"threshold_uncertainty_score":0.4518289},"labels":[],"label_agreement":null},{"id":"W2606772776","doi":"10.1007/s10549-016-3898-5","title":"UK Breast Cancer Research Symposium 2016: Submitted Abstracts","year":2016,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Breast cancer; Medicine; Oncology; Cancer; Gynecology; Internal medicine","score_opus":0.07096547379454653,"score_gpt":0.40906914589680904,"score_spread":0.3381036721022625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606772776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89483213,0.008947524,0.0000160032,0.08871019,0.00027885192,0.002150591,0.0023495797,0.0001716699,0.0025434522],"genre_scores_gemma":[0.96237254,0.017007617,0.00007776119,0.00013365292,0.0013498272,0.002158217,0.000023697141,0.000115075505,0.01676162],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99427295,0.00027601566,0.00046718423,0.0011817777,0.0017420796,0.0020600033],"domain_scores_gemma":[0.99573535,0.000451243,0.00010109304,0.0009053769,0.0016079461,0.0011989969],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009005492,0.00048723785,0.00063899567,0.0006460431,0.0006257914,0.00011496027,0.0002736587,0.00021002292,0.002651949],"category_scores_gemma":[0.00002920848,0.0002890415,0.00013740256,0.0008609552,0.001307655,0.0003116082,0.00020190749,0.0005374291,0.00027963202],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0145878205,0.0015046054,0.1021234,0.00017957992,0.0012293314,0.0005836897,0.00059379655,0.000006745909,0.11483024,0.00041470362,0.00438159,0.7595645],"study_design_scores_gemma":[0.015959892,0.0017896135,0.89790684,0.002470157,0.00013364459,0.0020763364,0.0004585173,0.0000071215013,0.028648302,0.0012440719,0.048673842,0.00063165737],"about_ca_topic_score_codex":0.016449613,"about_ca_topic_score_gemma":0.0018341709,"teacher_disagreement_score":0.79578346,"about_ca_system_score_codex":0.0034106441,"about_ca_system_score_gemma":0.0019165486,"threshold_uncertainty_score":0.9999562},"labels":[],"label_agreement":null},{"id":"W2608878607","doi":"10.1016/j.breast.2017.04.007","title":"New agents for endocrine resistance in breast cancer","year":2017,"lang":"en","type":"review","venue":"The Breast","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Université de Sherbrooke","funders":"","keywords":"Endocrine system; Breast cancer; Medicine; Disease; Acquired resistance; Estrogen receptor; Oncology; Metastatic breast cancer; Internal medicine; Blockade; Estrogen; Cancer; Bioinformatics; Cancer research; Receptor; Hormone; Biology","score_opus":0.11168353010337549,"score_gpt":0.43499997076240043,"score_spread":0.32331644065902493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2608878607","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000012112455,0.99003863,0.00012863008,0.0041824584,0.0004998502,0.0024037021,0.0014024485,0.00006891845,0.0012741628],"genre_scores_gemma":[0.000018284836,0.9592597,0.00066655595,0.00022951722,0.0020742705,0.0009138942,0.00010829066,0.00017882511,0.03655066],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976088,0.00007774052,0.0006449205,0.0006323348,0.00034536666,0.00069083937],"domain_scores_gemma":[0.9973205,0.00014859166,0.00064470817,0.0015443267,0.000119232405,0.00022269676],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024020424,0.0006373418,0.0021619855,0.0001696281,0.0001876916,0.00005325686,0.0008360185,0.00017568815,0.00042801056],"category_scores_gemma":[0.00003322209,0.000401954,0.00057383435,0.00023125601,0.00016216765,0.00012875754,0.00013672671,0.0005485251,0.00006860969],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004923716,0.00004417746,0.000039623625,0.0076238257,0.00029706382,0.00004069607,0.00006422161,4.3857494e-7,5.4301523e-7,0.00031015885,0.004619459,0.9864674],"study_design_scores_gemma":[0.0017985927,0.000014915161,0.0013841976,0.03184737,0.0008828851,0.0020561244,0.00001036398,7.9918834e-7,4.4125832e-7,0.00040653205,0.96123797,0.00035980463],"about_ca_topic_score_codex":0.0005159534,"about_ca_topic_score_gemma":0.0006150549,"teacher_disagreement_score":0.9861076,"about_ca_system_score_codex":0.0006374191,"about_ca_system_score_gemma":0.0012282158,"threshold_uncertainty_score":0.99984324},"labels":[],"label_agreement":null},{"id":"W2610190179","doi":"","title":"Horizon Scanning in Oncology: Results of the 26th Prioritisation – 1st quarter 2016","year":2016,"lang":"en","type":"article","venue":"","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Medicine; Medical physics; Geography","score_opus":0.015524312216507853,"score_gpt":0.2967901348737938,"score_spread":0.28126582265728595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610190179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92179483,0.00039259624,0.0025621385,0.037171077,0.0005211049,0.0006721619,0.000021189242,0.00007205926,0.036792867],"genre_scores_gemma":[0.99559826,0.000026293563,0.0010435745,0.00019396661,0.00011792986,0.0000125888255,0.0000011007613,0.000009453834,0.0029968263],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9992695,0.000044877022,0.00025024908,0.0001485101,0.0001424925,0.00014439432],"domain_scores_gemma":[0.99944633,0.00010665099,0.000106544394,0.0002450136,0.000064345215,0.00003111229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020024087,0.00007044856,0.00016459008,0.00005615923,0.000018660881,0.0000017114224,0.00006599138,0.000060354236,0.00006114076],"category_scores_gemma":[0.00010116344,0.000033648317,0.000036649384,0.00012363019,0.00010282693,0.00009740331,0.000021722766,0.00006884643,0.000014493237],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015244504,0.00010375288,0.020271154,0.0000220395,0.000029545621,0.000006592797,0.0011373354,0.0000029850842,0.16724826,0.0007315407,0.0018408415,0.8070815],"study_design_scores_gemma":[0.02094485,0.001842215,0.76898694,0.0019127736,0.000048794565,0.00007162368,0.0015219006,0.00002440967,0.089721546,0.0022820137,0.11240162,0.0002413278],"about_ca_topic_score_codex":0.0001391041,"about_ca_topic_score_gemma":0.00019628234,"teacher_disagreement_score":0.8068402,"about_ca_system_score_codex":0.00019810366,"about_ca_system_score_gemma":0.00015285064,"threshold_uncertainty_score":0.13721386},"labels":[],"label_agreement":null},{"id":"W2610230715","doi":"10.1093/annonc/mdx137.004","title":"Ribociclib + letrozole vs placebo + letrozole in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC) and a high disease burden","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Metastatic breast cancer; Internal medicine; Tolerability; Breast cancer; Letrozole; Progression-free survival; Oncology; Clinical endpoint; Inflammatory breast cancer; Cancer; Surgery; Clinical trial; Adverse effect; Chemotherapy","score_opus":0.01767865693688511,"score_gpt":0.3340196490867851,"score_spread":0.3163409921499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610230715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96645004,0.0016014252,0.000029234652,0.029085724,0.0001249207,0.00094235374,0.00054946734,0.00004714135,0.0011697189],"genre_scores_gemma":[0.9943715,0.0015829043,0.0009758345,0.0015804784,0.00031278713,0.00048386693,0.00003210337,0.000073994466,0.0005865796],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976069,0.00016617768,0.00044744142,0.00065611495,0.0003200116,0.0008034008],"domain_scores_gemma":[0.99759454,0.0002016818,0.00063012325,0.00061950454,0.00045352327,0.00050065067],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029274524,0.00041643664,0.0010741067,0.00019150971,0.00022823988,0.000028712893,0.0002899405,0.00017750586,0.0002444698],"category_scores_gemma":[0.00014085046,0.00035716122,0.0000538445,0.00017530593,0.0011271407,0.00054885296,0.00018475985,0.00043133198,0.000012980712],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31715685,0.001993043,0.06857412,0.00035285484,0.0017221356,0.0008963699,0.009330658,0.00046006596,0.0406915,0.0007365417,0.0010823915,0.55700344],"study_design_scores_gemma":[0.02043516,0.010773469,0.95337516,0.00056684285,0.000111533016,0.00011614264,0.0018623432,0.000040986022,0.0028743143,0.00092426897,0.008396072,0.0005236797],"about_ca_topic_score_codex":0.0032706424,"about_ca_topic_score_gemma":0.00052912626,"teacher_disagreement_score":0.8848011,"about_ca_system_score_codex":0.00049862626,"about_ca_system_score_gemma":0.00061625696,"threshold_uncertainty_score":0.99988806},"labels":[],"label_agreement":null},{"id":"W2618745366","doi":"","title":"LibGuides: Vancouver Referencing Guide: Drug Database Monographs","year":2012,"lang":"en","type":"libguides","venue":"","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Database; Computer science; World Wide Web; History","score_opus":0.029812777942083,"score_gpt":0.30576054118768914,"score_spread":0.27594776324560616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2618745366","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014603914,0.10941426,0.009134058,0.0029019434,0.022783404,0.0041803396,0.0031121178,0.0039640693,0.8430494],"genre_scores_gemma":[0.0024767464,0.0062495456,0.100072116,0.0097425105,0.00974345,0.00033643437,0.0047662356,0.0007856178,0.8658273],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953851,0.00009022719,0.0012193781,0.001053969,0.0010411437,0.001210146],"domain_scores_gemma":[0.9958645,0.00024333112,0.0005668111,0.0021902951,0.0004776857,0.000657363],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000546762,0.0010404044,0.0015138965,0.0006831268,0.00016997305,0.0000505513,0.00055305206,0.0005221315,0.006423646],"category_scores_gemma":[0.0002239626,0.00083990203,0.0004931705,0.0005679648,0.000237049,0.0006646182,0.00037751475,0.0013297744,0.0004058905],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017789743,0.00013137293,0.00045200976,0.00087987207,0.00052513805,0.00009869836,0.00031913182,0.0000020938542,0.00027884747,0.00017800611,0.95888764,0.038069285],"study_design_scores_gemma":[0.0016204617,0.00007421414,0.00013117232,0.0017712892,0.00066138676,0.00015303832,0.000917738,0.000012826148,0.0017111561,0.00027725086,0.9917777,0.0008917473],"about_ca_topic_score_codex":0.0013004836,"about_ca_topic_score_gemma":0.0013687941,"teacher_disagreement_score":0.10316471,"about_ca_system_score_codex":0.00051535416,"about_ca_system_score_gemma":0.00085693336,"threshold_uncertainty_score":0.9994052},"labels":[],"label_agreement":null},{"id":"W2621569204","doi":"10.1200/jco.2017.35.15_suppl.1039","title":"Palbociclib (PAL) + letrozole (L) as first-line (1L) therapy (tx) in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Efficacy and safety across patient (pt) subgroups.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Palbociclib; Internal medicine; Hazard ratio; Letrozole; Breast cancer; Population; Progression-free survival; Oncology; Metastatic breast cancer; Adverse effect; Cancer; Estrogen receptor; Gynecology; Tamoxifen; Confidence interval; Overall survival","score_opus":0.05956333864583405,"score_gpt":0.44140055268790485,"score_spread":0.38183721404207077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621569204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.975585,0.0019699142,0.00007804808,0.019317193,0.0014688353,0.0009643887,0.00028932485,0.00003114521,0.0002961705],"genre_scores_gemma":[0.98540217,0.007611708,0.0024310912,0.0024080535,0.0018557056,0.000050439878,0.000018047085,0.0000953416,0.0001274463],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99362797,0.0007300078,0.0033259091,0.0007355045,0.0007006247,0.0008799851],"domain_scores_gemma":[0.9898938,0.0029345814,0.0046233833,0.00058999506,0.0011074132,0.000850827],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001659558,0.00059113133,0.0029126022,0.00015110783,0.000589102,0.00006197654,0.000567164,0.00069492176,0.0008185481],"category_scores_gemma":[0.0029539112,0.00045034292,0.0005912484,0.00017982532,0.0014644656,0.00081266824,0.00024938962,0.0022429316,0.000027517064],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058486402,0.0025291655,0.23522209,0.000048947626,0.0011042081,0.00033419905,0.0027554664,0.000064958236,0.002778734,0.00011327433,0.00016009006,0.6964025],"study_design_scores_gemma":[0.04743824,0.014801263,0.91213685,0.00069343916,0.00012018461,0.0003865578,0.0006213062,0.00001492297,0.0034379933,0.0005544699,0.01931052,0.0004842658],"about_ca_topic_score_codex":0.0007026301,"about_ca_topic_score_gemma":0.00074299384,"teacher_disagreement_score":0.6959182,"about_ca_system_score_codex":0.0010108674,"about_ca_system_score_gemma":0.0009978823,"threshold_uncertainty_score":0.99979484},"labels":[],"label_agreement":null},{"id":"W2622248187","doi":"10.1200/jco.2017.35.15_suppl.tps1115","title":"A randomized, open-label, multicentre, phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy based treatment strategy in patients with hormone receptor positive/HER2-negative metastatic breast cancer in a real world setting.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Metastatic breast cancer; Discontinuation; Palbociclib; Internal medicine; Chemotherapy; Breast cancer; Oncology; Clinical endpoint; Cancer; Clinical trial; Surgery","score_opus":0.1789631524317453,"score_gpt":0.5420921992405614,"score_spread":0.3631290468088161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622248187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98975956,0.00022580707,0.00002374366,0.0037769303,0.0003194882,0.005478611,0.00011588323,0.000010656211,0.0002893243],"genre_scores_gemma":[0.98970985,0.00061611726,0.0083808,0.0002698046,0.00030233042,0.00046443677,0.0000149769085,0.00006232053,0.00017938056],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99309415,0.0022916887,0.0028062572,0.00057571335,0.0006315728,0.00060063094],"domain_scores_gemma":[0.98908645,0.005084348,0.004249875,0.00048036544,0.00068818935,0.00041077676],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0029919734,0.000512642,0.004192127,0.00029079188,0.00015143135,0.000068620684,0.00036661455,0.00010785065,0.00021574553],"category_scores_gemma":[0.0012342698,0.00031491325,0.0002751718,0.00023891414,0.00043700598,0.0004339969,0.000069493646,0.00065225613,0.000003238316],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58747965,0.029979058,0.057930365,0.000008066002,0.0021817426,0.0005177359,0.00094714825,0.00029617615,0.000025320413,0.0000022657446,0.0000055234673,0.32062694],"study_design_scores_gemma":[0.66347474,0.081225835,0.25109953,0.00031147877,0.0010980295,0.000011526497,0.00083000166,0.0016721202,0.000028137638,0.000020563828,0.00004041747,0.00018765098],"about_ca_topic_score_codex":0.00498223,"about_ca_topic_score_gemma":0.012631654,"teacher_disagreement_score":0.32043928,"about_ca_system_score_codex":0.0037807499,"about_ca_system_score_gemma":0.0037569476,"threshold_uncertainty_score":0.9999303},"labels":[],"label_agreement":null},{"id":"W2622249265","doi":"10.1200/jco.2017.35.15_suppl.1038","title":"Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada)","funders":"","keywords":"Medicine; Letrozole; Clinical endpoint; Progression-free survival; Internal medicine; Interim analysis; Breast cancer; Cancer; Oncology; Gynecology; Surgery; Clinical trial; Chemotherapy; Tamoxifen","score_opus":0.07992102643971791,"score_gpt":0.4703164477870385,"score_spread":0.39039542134732064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622249265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9654848,0.0008416828,0.0001728349,0.028787129,0.0019617043,0.0007914337,0.0011013139,0.000017787617,0.0008413428],"genre_scores_gemma":[0.9865843,0.0034454342,0.0054706833,0.0008140694,0.003242832,0.00003138653,0.000059255042,0.000055538938,0.00029648468],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930441,0.0006318178,0.004568368,0.000548163,0.0007155026,0.0004920851],"domain_scores_gemma":[0.9864713,0.0030485897,0.007893722,0.00071155454,0.0013465636,0.0005282951],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002551384,0.00038526495,0.003284866,0.0002118796,0.0001467044,0.00001939773,0.000609776,0.00063874014,0.00037118458],"category_scores_gemma":[0.006399938,0.00030385534,0.0006853683,0.00022419696,0.0010469052,0.0005913508,0.00015769481,0.0018905372,0.000013550317],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7065898,0.006002137,0.0050517037,0.000013265318,0.0010312635,0.0004636919,0.00049174216,0.00018997036,0.001957858,0.000012193107,0.001078551,0.27711782],"study_design_scores_gemma":[0.6779444,0.03216398,0.25216252,0.0009988614,0.000585327,0.00013054842,0.00045106793,0.00033290006,0.0023384078,0.0011849663,0.0313055,0.00040153743],"about_ca_topic_score_codex":0.0016827115,"about_ca_topic_score_gemma":0.001843817,"teacher_disagreement_score":0.2767163,"about_ca_system_score_codex":0.00065910927,"about_ca_system_score_gemma":0.0016657922,"threshold_uncertainty_score":0.99994135},"labels":[],"label_agreement":null},{"id":"W2622352423","doi":"10.1200/jco.2017.35.15_suppl.1050","title":"Predictors of prolonged benefit from palbociclib (PAL) plus fulvestrant (F) in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer (ABC) in PALOMA-3.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Palbociclib; Population; Breast cancer; Fulvestrant; Gastroenterology; Cancer; Gynecology; Estrogen receptor; Metastatic breast cancer; Confidence interval","score_opus":0.04091000471739364,"score_gpt":0.3839514400226887,"score_spread":0.3430414353052951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622352423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907335,0.0010063841,0.000029906101,0.005935906,0.00071668247,0.00084334286,0.00051413226,0.000019899242,0.00020021558],"genre_scores_gemma":[0.9931638,0.0016986049,0.0033430818,0.00041821512,0.0011036148,0.0001062499,0.0000123454065,0.00007678651,0.000077298086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99356717,0.000570712,0.00362777,0.000635653,0.0007825023,0.00081618415],"domain_scores_gemma":[0.9909303,0.0017732969,0.005184137,0.0005609247,0.0008932919,0.00065804593],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013039184,0.00050458737,0.003541534,0.00030000327,0.00013515244,0.000023404757,0.00064490194,0.00045726413,0.000398425],"category_scores_gemma":[0.0015330993,0.00036910162,0.0003305221,0.00023593109,0.0012360672,0.0007161253,0.00013037673,0.002055459,0.0000035350693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21746027,0.0026830395,0.60317296,0.00011985093,0.001750405,0.0011953664,0.004154432,0.00014639793,0.033793923,0.00005999125,0.000074227755,0.13538916],"study_design_scores_gemma":[0.04004905,0.012701365,0.9410118,0.0011983812,0.00014887165,0.000095840565,0.0009954724,0.000012066741,0.0022694566,0.0005563383,0.00063116127,0.00033022277],"about_ca_topic_score_codex":0.001733663,"about_ca_topic_score_gemma":0.0032223521,"teacher_disagreement_score":0.33783883,"about_ca_system_score_codex":0.0016868764,"about_ca_system_score_gemma":0.001967957,"threshold_uncertainty_score":0.9998761},"labels":[],"label_agreement":null},{"id":"W2623152276","doi":"10.1200/jco.2017.35.15_suppl.1020","title":"Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: Results from MONALEESA-2.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada)","funders":"","keywords":"Letrozole; Medicine; Internal medicine; Hazard ratio; Quality of life (healthcare); Placebo; Oncology; Breast cancer; Nausea; Context (archaeology); Cancer; Confidence interval; Tamoxifen","score_opus":0.07319948994419362,"score_gpt":0.4246753327745315,"score_spread":0.3514758428303379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623152276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799111,0.0009767376,0.000067488,0.014968965,0.00032198065,0.0007429061,0.0025420904,0.000030998857,0.0004377206],"genre_scores_gemma":[0.99094146,0.0009964688,0.0061630984,0.0008256714,0.0006697022,0.000031147698,0.000071077906,0.000089029534,0.00021234335],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99001694,0.0015944621,0.00590371,0.00069197326,0.0010652386,0.0007276897],"domain_scores_gemma":[0.97404915,0.0034750127,0.017769698,0.00075086526,0.0028271629,0.0011281266],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00262479,0.0005645419,0.0053396914,0.00020267873,0.0002763853,0.000017569222,0.0005911092,0.0005763082,0.00044088348],"category_scores_gemma":[0.00337562,0.00038073552,0.00033953876,0.00028087752,0.0022116594,0.00068032026,0.00011997331,0.0018325315,0.0000064942537],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6339304,0.0053367033,0.19128886,0.00017297007,0.008813576,0.00019482602,0.0039874404,0.00010539132,0.033546325,0.00009808981,0.00061732956,0.12190811],"study_design_scores_gemma":[0.053013287,0.042129997,0.89933,0.0008409229,0.00025956507,0.00009156877,0.00095197296,0.000004873394,0.0024099834,0.0002045105,0.0004131346,0.00035015048],"about_ca_topic_score_codex":0.0059921923,"about_ca_topic_score_gemma":0.0007014086,"teacher_disagreement_score":0.7080412,"about_ca_system_score_codex":0.0011653554,"about_ca_system_score_gemma":0.0035928579,"threshold_uncertainty_score":0.99986446},"labels":[],"label_agreement":null},{"id":"W2659827805","doi":"10.1200/jco.2017.35.15_suppl.e12538","title":"Real world experience with exemestane and everolimus for advanced HR-positive breast cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Exemestane; Everolimus; Internal medicine; Metastatic breast cancer; Breast cancer; Cohort; Oncology; Adverse effect; Population; Cancer; Progression-free survival; Toxicity; Letrozole; Aromatase inhibitor; Chemotherapy; Aromatase","score_opus":0.08937730650384973,"score_gpt":0.5096555776797362,"score_spread":0.4202782711758865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2659827805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979849,0.00050329586,0.0009626646,0.015858797,0.0008610622,0.00039366807,0.000027523272,0.000012082007,0.0015319097],"genre_scores_gemma":[0.97744113,0.0013451233,0.017778793,0.0013175589,0.0013461501,0.000034636738,8.9659494e-7,0.000027652946,0.00070804614],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980661,0.00007521534,0.0010551758,0.0002563092,0.0002587778,0.000288378],"domain_scores_gemma":[0.9953505,0.0009842234,0.002213257,0.0003059529,0.0007381422,0.00040792036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007214122,0.00016880568,0.0012972628,0.000069800306,0.00017996828,0.000019746361,0.00022055903,0.00014439937,0.000045985627],"category_scores_gemma":[0.0005955244,0.00011156541,0.00017590744,0.000051145435,0.0008338769,0.00039098877,0.00005378771,0.0005223156,7.6451573e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062055815,0.00042183057,0.15472671,0.000038306902,0.00037636491,0.00046236007,0.0004726999,0.000017358838,0.0010132034,0.00023938356,0.00010998778,0.78006595],"study_design_scores_gemma":[0.019206231,0.009166507,0.9497355,0.00047778,0.00029281015,0.0015271504,0.00032563848,0.000042021074,0.00032996095,0.0005552138,0.01818363,0.0001575318],"about_ca_topic_score_codex":0.00007693442,"about_ca_topic_score_gemma":0.00041369098,"teacher_disagreement_score":0.79500884,"about_ca_system_score_codex":0.00020620019,"about_ca_system_score_gemma":0.001083088,"threshold_uncertainty_score":0.45495054},"labels":[],"label_agreement":null},{"id":"W2692549261","doi":"10.1200/jco.2017.35.15_suppl.e12534","title":"Safety results of the Canadian Expanded Access Program (EAP) of palbociclib (PAL) plus letrozole (L) in postmenopausal patients (pts) with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) deemed appropriate candidates for first-line (1L) endocrine therapy (ET) with L.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; Pfizer (Canada); Hôpital du Saint-Sacrement; Ottawa Hospital","funders":"","keywords":"Medicine; Neutropenia; Internal medicine; Adverse effect; Hazard ratio; Gastroenterology; Palbociclib; Expanded access; Surgery; Toxicity; Cancer; Breast cancer; Metastatic breast cancer; Confidence interval","score_opus":0.055903277375688704,"score_gpt":0.42061661476255563,"score_spread":0.36471333738686695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2692549261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983355,0.00023782003,0.00005651813,0.0115152635,0.00041380932,0.0029721141,0.0012012294,0.000013572363,0.00023470633],"genre_scores_gemma":[0.993662,0.0010507506,0.0039383355,0.0005504325,0.00038863363,0.00017998142,0.00007097888,0.00007660135,0.000082290724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948726,0.0005195153,0.0027129934,0.0005150607,0.00069534354,0.00068446307],"domain_scores_gemma":[0.9887412,0.0013311072,0.006197451,0.0005650316,0.0026259518,0.0005392358],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011551903,0.00046606222,0.0024020127,0.00021677109,0.0003488529,0.00003516428,0.0008168508,0.00031102594,0.000059279275],"category_scores_gemma":[0.0016831309,0.0002652096,0.0002935981,0.00027111277,0.0012969268,0.0006382944,0.00012183455,0.0011329949,5.001379e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32540855,0.0036509035,0.39576048,0.00013713702,0.0020640218,0.000062547755,0.0017512365,0.0003146796,0.001374321,0.000073253505,0.00011883488,0.26928404],"study_design_scores_gemma":[0.09225549,0.030544806,0.8690707,0.0008060008,0.00019247175,0.000051900544,0.0002067385,0.000034036842,0.004260378,0.00017431536,0.0020981273,0.00030503864],"about_ca_topic_score_codex":0.03258354,"about_ca_topic_score_gemma":0.28960943,"teacher_disagreement_score":0.4733102,"about_ca_system_score_codex":0.001237645,"about_ca_system_score_gemma":0.0046484126,"threshold_uncertainty_score":0.99998003},"labels":[],"label_agreement":null},{"id":"W2702886506","doi":"10.1200/jco.2016.34.15_suppl.507","title":"PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Palbociclib; Letrozole; Clinical endpoint; Internal medicine; Hazard ratio; Breast cancer; Cancer; Progression-free survival; Adverse effect; Oncology; Gynecology; Randomized controlled trial; Metastatic breast cancer; Confidence interval; Tamoxifen; Overall survival","score_opus":0.042529828937183864,"score_gpt":0.4039353674576152,"score_spread":0.36140553852043134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2702886506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98768896,0.00045862864,0.0006532563,0.009098107,0.00039943805,0.0008593499,0.0003846194,0.000028078506,0.00042956098],"genre_scores_gemma":[0.98785156,0.0004029858,0.008559393,0.0015151217,0.0013207215,0.00007192846,0.000019634785,0.00007880771,0.00017983715],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937519,0.0005156895,0.0034467625,0.0005861861,0.0009906038,0.00070886494],"domain_scores_gemma":[0.9911332,0.0024188978,0.004347284,0.00056135963,0.0008681803,0.0006710397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017106001,0.00044950237,0.0037825154,0.0002602124,0.00005036652,0.000009453734,0.00035852558,0.00032970143,0.00022596327],"category_scores_gemma":[0.00034227464,0.0002303586,0.00016499464,0.00044716243,0.001026989,0.00046769623,0.00006609793,0.0010794522,0.0000041183766],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76490504,0.005309836,0.0108516775,0.000028242934,0.0011628541,0.0011225679,0.000470172,0.00010573128,0.008204206,0.0000059740437,0.00010390133,0.20772977],"study_design_scores_gemma":[0.7184447,0.09296251,0.17567958,0.0015429009,0.0004322712,0.0007056424,0.00062257366,0.000009048992,0.00055673515,0.000094314106,0.008605695,0.00034402026],"about_ca_topic_score_codex":0.00031072673,"about_ca_topic_score_gemma":0.00087480474,"teacher_disagreement_score":0.20738575,"about_ca_system_score_codex":0.0010525141,"about_ca_system_score_gemma":0.003917209,"threshold_uncertainty_score":0.93937504},"labels":[],"label_agreement":null},{"id":"W2719623628","doi":"10.1634/theoncologist.2017-0072","title":"Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Cancer Research UK; AstraZeneca; American Society of Clinical Oncology; Pfizer","keywords":"Palbociclib; Fulvestrant; Medicine; Goserelin; Anastrozole; Internal medicine; Oncology; Breast cancer; Adverse effect; Neutropenia; Placebo; Letrozole; Gynecology; Cancer; Metastatic breast cancer; Chemotherapy; Tamoxifen","score_opus":0.022065930195343083,"score_gpt":0.3371386426214998,"score_spread":0.3150727124261567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2719623628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813605,0.0003978201,0.0000052089695,0.015161294,0.00006601561,0.0016484973,0.00005621009,0.00008880354,0.0012156677],"genre_scores_gemma":[0.9970024,0.0005228762,0.0007079193,0.00041459233,0.00012415356,0.0007225432,0.0000076279034,0.000048999114,0.0004488642],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982732,0.000068380075,0.0002704791,0.0004886982,0.00035996462,0.00053931016],"domain_scores_gemma":[0.99841225,0.00011125685,0.00038226662,0.0008507885,0.00009553602,0.00014789033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029951823,0.0003219509,0.00049763237,0.000053138687,0.0003886244,0.00006266612,0.0002871,0.000060885395,0.000028358754],"category_scores_gemma":[0.000037761514,0.00015319734,0.000016383947,0.00010683305,0.000988199,0.00018077697,0.00007025772,0.00037680252,0.0000025231554],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2487009,0.0007418265,0.0403353,0.00007491041,0.0001767207,0.0003994837,0.002023934,0.000091349866,0.007364981,0.000108116816,0.000022493701,0.69996],"study_design_scores_gemma":[0.037270974,0.014761856,0.93988013,0.0009472894,0.000036160684,0.00029353547,0.0007724527,0.000022479193,0.0024956432,0.00015028828,0.0030810444,0.00028812257],"about_ca_topic_score_codex":0.00018742996,"about_ca_topic_score_gemma":0.00072567974,"teacher_disagreement_score":0.89954484,"about_ca_system_score_codex":0.00034486214,"about_ca_system_score_gemma":0.00024477823,"threshold_uncertainty_score":0.62472063},"labels":[],"label_agreement":null},{"id":"W2737220576","doi":"10.1200/jco.2013.31.15_suppl.574","title":"Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney study—NCT00811369.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Toronto; Sunnybrook Health Science Centre; McMaster University; Grand River Hospital; Ottawa Hospital; BC Cancer Agency; Health Sciences Centre; Ontario Clinical Oncology Group; University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; N-terminal telopeptide; Placebo; Bone remodeling; Gastroenterology; Vandetanib; Fulvestrant; Breast cancer; Oncology; Urology; Endocrinology; Cancer; Estrogen receptor; Pathology; Receptor; Osteocalcin","score_opus":0.042590186934656354,"score_gpt":0.416951622254952,"score_spread":0.37436143532029564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737220576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820804,0.0013833382,0.00028737227,0.004015795,0.0008220334,0.011172659,0.00006939799,0.000019662535,0.00014932778],"genre_scores_gemma":[0.9916905,0.00096770335,0.0038850787,0.00059545913,0.0009629298,0.0011400959,0.000005617282,0.00007840818,0.00067417],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9877896,0.0028981774,0.0069085388,0.000547124,0.0010746586,0.0007819037],"domain_scores_gemma":[0.9842143,0.0070188334,0.0062697083,0.00040751387,0.0013016114,0.00078801706],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0086894985,0.00059381797,0.010887748,0.00048233572,0.00009050779,0.000020153899,0.00028455962,0.00034453813,0.0012399572],"category_scores_gemma":[0.002449098,0.000329905,0.0006248206,0.00048015043,0.00095970003,0.00047751344,0.00009111355,0.001588056,0.000008502156],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8904309,0.025639623,0.00011986358,0.000044899476,0.00577399,0.0016416765,0.0023377086,0.00006775845,0.00274305,0.000007950653,0.00013329157,0.07105928],"study_design_scores_gemma":[0.8276131,0.16180006,0.0022730085,0.00032798454,0.0025972733,0.001969507,0.0026245362,0.00016106258,0.00004382086,0.00012404777,0.00018029936,0.00028531512],"about_ca_topic_score_codex":0.00036117225,"about_ca_topic_score_gemma":0.0002809496,"teacher_disagreement_score":0.13616043,"about_ca_system_score_codex":0.001057411,"about_ca_system_score_gemma":0.0068222987,"threshold_uncertainty_score":0.9999153},"labels":[],"label_agreement":null},{"id":"W2738407951","doi":"10.1200/jco.2017.35.15_suppl.9518","title":"A phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with <i>BRAF V600</i>-mutant solid tumors and melanoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; MEK inhibitor; Response Evaluation Criteria in Solid Tumors; Oncology; Internal medicine; Melanoma; Palbociclib; Clinical endpoint; Pharmacokinetics; Pharmacology; Cancer; Phases of clinical research; Kinase; Cancer research; MAPK/ERK pathway; Clinical trial","score_opus":0.1003029350503233,"score_gpt":0.4806479685953801,"score_spread":0.38034503354505683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738407951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99550736,0.00022937171,0.00008583411,0.002328311,0.00033450243,0.001393553,0.000005874338,0.000015770107,0.000099423574],"genre_scores_gemma":[0.99632955,0.00013117638,0.0025886146,0.00046262113,0.00037058504,0.000031780248,0.0000055195273,0.00004436374,0.00003580387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99563324,0.00069021684,0.0021249864,0.000443356,0.00077772106,0.00033048645],"domain_scores_gemma":[0.99376434,0.001001414,0.0037825028,0.0003453311,0.0007577923,0.00034860233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004094806,0.00030352146,0.0017969575,0.00022829039,0.00029757188,0.000056867902,0.00019105013,0.00019902554,0.000021123426],"category_scores_gemma":[0.0019484033,0.00019532963,0.000106306536,0.00016575873,0.00050097704,0.00064402935,0.00009245918,0.00095414405,9.2822637e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05393999,0.012202702,0.5625945,0.000021687889,0.00033956356,0.00023400996,0.0015401201,0.000010835224,0.00054465624,0.00001209576,0.000010995851,0.36854887],"study_design_scores_gemma":[0.16744934,0.17692932,0.65281045,0.0003325726,0.00023899808,0.00023354377,0.00068785046,0.00036414032,0.00020739375,0.0002470575,0.00031481875,0.0001844955],"about_ca_topic_score_codex":0.000050540566,"about_ca_topic_score_gemma":0.00019856327,"teacher_disagreement_score":0.36836436,"about_ca_system_score_codex":0.00019270221,"about_ca_system_score_gemma":0.0009849626,"threshold_uncertainty_score":0.79653114},"labels":[],"label_agreement":null},{"id":"W2740470992","doi":"10.1158/1538-7445.am2017-lb-103","title":"Abstract LB-103: Landscape of somatic ERBB2 Mutations: Findings from AACR GENIE and comparison to ongoing ERBB2 mutant basket study","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Missense mutation; Cohort; Neratinib; Indel; Cancer; Medicine; Breast cancer; Oncology; Exome; Colorectal cancer; Germline mutation; Internal medicine; Mutation; Genetics; Exome sequencing; Biology; Gene; Single-nucleotide polymorphism; Genotype","score_opus":0.12130764087997967,"score_gpt":0.4710490454831226,"score_spread":0.34974140460314296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740470992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99470294,0.0017653353,0.00007661668,0.0013783993,0.00012795631,0.0013303127,0.00010276756,0.000035619745,0.00048004297],"genre_scores_gemma":[0.99834645,0.000089816924,0.00072825793,0.0000539208,0.00022904521,0.00029200115,0.000013874774,0.00004678647,0.00019983824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758285,0.000078067475,0.000433331,0.0004960211,0.0008999476,0.0005097505],"domain_scores_gemma":[0.9978996,0.0003997148,0.00016224658,0.0008715713,0.00037600705,0.00029084724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007395583,0.00019438169,0.0005652034,0.0002768291,0.00049445155,0.00013263983,0.00038801596,0.00007473189,0.0005525453],"category_scores_gemma":[0.000518306,0.00017134285,0.000052940155,0.00021889502,0.0002807661,0.00023464898,0.00023644924,0.00048507756,0.00004414265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014782046,0.00056422886,0.7560088,0.00042249841,0.0004473529,0.0001074087,0.016126465,0.00014075269,0.17820558,0.000028811519,0.00046598318,0.046003893],"study_design_scores_gemma":[0.0037501128,0.0005213914,0.957725,0.00087031076,0.00007340177,0.000007067525,0.008832856,0.00023342871,0.026485385,0.00047715555,0.00082319224,0.00020068903],"about_ca_topic_score_codex":0.0035850576,"about_ca_topic_score_gemma":0.0016627631,"teacher_disagreement_score":0.20171618,"about_ca_system_score_codex":0.00023702244,"about_ca_system_score_gemma":0.00031837088,"threshold_uncertainty_score":0.69871587},"labels":[],"label_agreement":null},{"id":"W2740617618","doi":"10.1158/1538-7445.am2017-2558","title":"Abstract 2558: MYC-dependent transformation model of triple-negative breast cancer in vivo","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Breast cancer; Cancer research; Myoepithelial cell; Triple-negative breast cancer; PI3K/AKT/mTOR pathway; In vivo; Cancer; Medicine; Biology; Pathology; Internal medicine; Signal transduction; Immunohistochemistry; Cell biology","score_opus":0.10417180535879887,"score_gpt":0.44607321248032406,"score_spread":0.34190140712152517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740617618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982653,0.0010556233,0.00039199606,0.006352412,0.00023261122,0.0013624929,0.0010516148,0.000033405933,0.006866824],"genre_scores_gemma":[0.99594706,0.0015273845,0.000122006444,0.000055197797,0.00018868853,0.00050838373,0.0000032011985,0.000040894494,0.0016071887],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99762547,0.00005219452,0.00040458742,0.00035625522,0.0009862784,0.0005752373],"domain_scores_gemma":[0.9983003,0.0000674902,0.00018213179,0.00064726186,0.0006256943,0.00017708182],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00073069707,0.00018085151,0.00042166858,0.00032461467,0.00023694354,0.00004201182,0.00040042214,0.00012479661,0.0013025231],"category_scores_gemma":[0.00008504387,0.00015920671,0.00008786894,0.00020381286,0.00046771034,0.00060695235,0.00006608356,0.00067537616,0.000010553961],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00953592,0.00046580864,0.013977648,0.0012827833,0.00027978193,0.000043494103,0.010276032,0.010488369,0.6834433,0.00086371053,0.00040947594,0.26893365],"study_design_scores_gemma":[0.018613148,0.000250717,0.326381,0.0031519192,0.000067537476,0.000036458943,0.002607861,0.0125008365,0.6294856,0.005511171,0.0007978317,0.0005959099],"about_ca_topic_score_codex":0.008207396,"about_ca_topic_score_gemma":0.0035950097,"teacher_disagreement_score":0.31240335,"about_ca_system_score_codex":0.00097173813,"about_ca_system_score_gemma":0.0010039748,"threshold_uncertainty_score":0.9996104},"labels":[],"label_agreement":null},{"id":"W2741548122","doi":"10.1158/1538-7445.am2017-ct046","title":"Abstract CT046: Phase I dose escalation study of the CDK4/6 inhibitor palbociclib in combination with the MEK inhibitor PD-0325901 in patients with <i>RAS</i> mutant solid tumors","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Palbociclib; Medicine; Tolerability; Pharmacokinetics; Pharmacology; Neutropenia; Leukopenia; Internal medicine; Oncology; Cancer; Adverse effect; Chemotherapy","score_opus":0.03961281957013143,"score_gpt":0.3934869420847642,"score_spread":0.3538741225146328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741548122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945274,0.00009063914,0.0000039934775,0.0017952949,0.000108196,0.0032701546,0.000025853451,0.000014752112,0.00016368742],"genre_scores_gemma":[0.99914885,0.000013100607,0.000011664957,0.00005532538,0.00013279397,0.0005014245,0.000008985514,0.000051028223,0.00007685698],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99689496,0.00021693282,0.00042374228,0.00043394917,0.0015275052,0.0005029211],"domain_scores_gemma":[0.99781156,0.00015458213,0.00035742883,0.0009637959,0.0006121269,0.000100482685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097117637,0.00021822835,0.0003967361,0.00022080349,0.0003884332,0.000070805894,0.00045074854,0.000068764806,0.000044711065],"category_scores_gemma":[0.00016555151,0.000115571966,0.000037079113,0.00059812004,0.00063144823,0.00038629273,0.00015216149,0.00086457253,0.0000029796013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016433854,0.005776777,0.9221536,0.00018864333,0.00010972538,0.000055796594,0.0093281,0.0003983154,0.01872931,0.000029238268,0.00008696723,0.026709707],"study_design_scores_gemma":[0.030944163,0.0022182395,0.94528025,0.0009467469,0.000019930416,0.0000018633273,0.0028282087,0.000047710102,0.017381372,0.00007578694,0.00010936627,0.00014634035],"about_ca_topic_score_codex":0.001179266,"about_ca_topic_score_gemma":0.0041332147,"teacher_disagreement_score":0.026563369,"about_ca_system_score_codex":0.00058786577,"about_ca_system_score_gemma":0.00046283688,"threshold_uncertainty_score":0.4712888},"labels":[],"label_agreement":null},{"id":"W2742102900","doi":"10.1158/1538-7445.am2017-ct047","title":"Abstract CT047: Phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumors","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Veliparib; PARP inhibitor; Medicine; Neutropenia; Febrile neutropenia; Mucositis; Internal medicine; Oncology; Nausea; Pharmacology; Chemotherapy; Poly ADP ribose polymerase; Chemistry","score_opus":0.044301939687582274,"score_gpt":0.40816896319788265,"score_spread":0.36386702351030037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2742102900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949269,0.0001091747,0.000005705046,0.0014572837,0.00010681183,0.0032359716,0.000017256552,0.000014185543,0.0001266865],"genre_scores_gemma":[0.9990239,0.000012614266,0.000021189453,0.00003075683,0.000102545535,0.000673059,0.000009064618,0.000045261895,0.0000816231],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972517,0.0001709726,0.00038425744,0.00041986335,0.0012984705,0.00047476948],"domain_scores_gemma":[0.9979058,0.00013493797,0.00033987412,0.00094308075,0.00058943836,0.000086852975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007318069,0.00020309578,0.00037818728,0.00020753157,0.0003759463,0.00005668284,0.000432634,0.00006341492,0.000029472187],"category_scores_gemma":[0.00017770742,0.000109566594,0.000031612784,0.00056725804,0.00055454543,0.00045251093,0.00014302149,0.00080582715,0.0000024261544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016276645,0.0045039877,0.8973666,0.00015068737,0.00007384797,0.00002216059,0.005303443,0.0008040093,0.009312685,0.000029504028,0.000051668136,0.06610481],"study_design_scores_gemma":[0.028354567,0.0024643384,0.95508116,0.000928075,0.000015947706,8.666835e-7,0.0021435523,0.000046242985,0.010646518,0.000049506638,0.0001370452,0.00013216103],"about_ca_topic_score_codex":0.000819723,"about_ca_topic_score_gemma":0.003080738,"teacher_disagreement_score":0.06597265,"about_ca_system_score_codex":0.00060366705,"about_ca_system_score_gemma":0.00038757277,"threshold_uncertainty_score":0.4467996},"labels":[],"label_agreement":null},{"id":"W2754512231","doi":"10.1016/j.ejca.2017.08.018","title":"Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Princess Margaret Cancer Centre; University of Toronto; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Palbociclib; Hormone receptor; Oncology; Breast cancer; Medicine; Cancer; Internal medicine; Gynecology; Metastatic breast cancer","score_opus":0.017561565929232806,"score_gpt":0.32859981764821466,"score_spread":0.31103825171898186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754512231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96639556,0.015992502,0.001013598,0.0116970595,0.00062900624,0.00041459338,0.0003438225,0.000028428458,0.0034854081],"genre_scores_gemma":[0.99365216,0.003415322,0.0009362759,0.00056061783,0.0007546583,0.000013807314,0.000005127997,0.000059694725,0.00060233683],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977138,0.00025825572,0.0007528625,0.00033068017,0.00052920147,0.00041520633],"domain_scores_gemma":[0.9969998,0.00004816796,0.0012726971,0.0006206857,0.0007297901,0.00032887663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008257446,0.0002770283,0.0008525792,0.00031427795,0.00019004778,0.000067939895,0.00046983585,0.00003950723,0.00074513734],"category_scores_gemma":[0.00012329483,0.000228567,0.000379959,0.0003889242,0.00027385823,0.0005471529,0.00009171447,0.0006016766,0.00001568761],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007941932,0.00018813257,0.22472988,0.000027702254,0.0018169679,0.0005128873,0.0010149797,0.0006587655,0.012390415,0.000010206617,0.00045330526,0.7502548],"study_design_scores_gemma":[0.0063904235,0.00022963002,0.9734665,0.00046963312,0.00072542665,0.000103102444,0.00022170212,0.000081946746,0.0012074197,0.000019809628,0.01685659,0.00022781256],"about_ca_topic_score_codex":0.00020074502,"about_ca_topic_score_gemma":0.00028376927,"teacher_disagreement_score":0.750027,"about_ca_system_score_codex":0.00052480417,"about_ca_system_score_gemma":0.00029450585,"threshold_uncertainty_score":0.93206924},"labels":[],"label_agreement":null},{"id":"W2757886480","doi":"10.1200/jco.2013.31.15_suppl.e11574","title":"Breast cancer biomarker discordance between primary and sites of metastasis: A systematic review.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Biomarker; Breast cancer; Oncology; Cancer; Internal medicine; Metastasis; Primary tumor; Brain metastasis; Lymph node; Lung cancer; Disease","score_opus":0.1098867776772774,"score_gpt":0.4728457450860793,"score_spread":0.3629589674088019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2757886480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7824226,0.18564305,0.0006302619,0.02885798,0.0004527456,0.0015112688,0.00005470485,0.000014869104,0.00041251906],"genre_scores_gemma":[0.9646113,0.023890086,0.0062925816,0.004374223,0.0005973767,0.000050328374,0.0000026221394,0.00002505389,0.00015644768],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9957035,0.00048299722,0.0030697153,0.00016651115,0.0003879019,0.00018933872],"domain_scores_gemma":[0.99359477,0.0018052896,0.003309895,0.00024181862,0.0007495715,0.00029866895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024395941,0.00015999384,0.0035007652,0.00009096864,0.00001949837,0.0000051320067,0.0001598321,0.00014853026,0.0001856456],"category_scores_gemma":[0.0011760846,0.000094596595,0.0003899286,0.00016828194,0.00035037688,0.00025034434,0.000060569,0.00049128453,0.0000075559838],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002509795,0.0012840912,0.32168767,0.21162856,0.0064664544,0.00016212121,0.0001440926,0.0000012894427,0.0039007168,0.00007341352,0.0033073262,0.44883448],"study_design_scores_gemma":[0.004496435,0.0020567249,0.9231367,0.06209475,0.00454832,0.0018427502,0.000108910615,0.000008683342,0.00007206689,0.00040809903,0.0010728536,0.00015372215],"about_ca_topic_score_codex":0.000030883246,"about_ca_topic_score_gemma":0.000005823226,"teacher_disagreement_score":0.601449,"about_ca_system_score_codex":0.00011351896,"about_ca_system_score_gemma":0.0006498823,"threshold_uncertainty_score":0.38575372},"labels":[],"label_agreement":null},{"id":"W2761532450","doi":"10.1093/annonc/mdx365.025","title":"PFS/TTP as a potential surrogate for OS in HR+, HER2– MBC","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Internal medicine; Progression-free survival; Surrogate endpoint; Oncology; Clinical endpoint; Randomized controlled trial; Pearson product-moment correlation coefficient; Overall survival; Statistics","score_opus":0.10834300483768006,"score_gpt":0.47686343894957156,"score_spread":0.3685204341118915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761532450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94744956,0.0010694994,0.00042765902,0.03981147,0.0005289486,0.00067635387,0.000022530297,0.000029825376,0.0099841375],"genre_scores_gemma":[0.9945482,0.00017946586,0.001597896,0.0019730371,0.00028800505,0.000074321055,0.000007263872,0.000022630005,0.0013091743],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99903107,0.0000368679,0.00027293633,0.0002179521,0.00011608584,0.00032508044],"domain_scores_gemma":[0.9989167,0.00008860956,0.00027288488,0.00041280664,0.00022031993,0.00008867256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030917823,0.00011667745,0.00047949198,0.00009211257,0.000076957665,0.000006893733,0.00019586239,0.00014685665,0.00014027089],"category_scores_gemma":[0.00030426568,0.00010790372,0.00012131402,0.00003711762,0.00024331744,0.00012038632,0.00006120693,0.00013051265,0.000026880547],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009258564,0.00091726746,0.0079266345,0.00020073762,0.0002815812,0.00040012848,0.00086808746,0.000059122387,0.035460018,0.0016565513,0.002367715,0.9406036],"study_design_scores_gemma":[0.022936337,0.012787003,0.124536425,0.00036787678,0.00011492007,0.00047271396,0.0007858233,0.00021576935,0.07064698,0.027955463,0.73873264,0.00044803802],"about_ca_topic_score_codex":0.00027863367,"about_ca_topic_score_gemma":0.00026292496,"teacher_disagreement_score":0.94015557,"about_ca_system_score_codex":0.000044763914,"about_ca_system_score_gemma":0.0002584353,"threshold_uncertainty_score":0.4400186},"labels":[],"label_agreement":null},{"id":"W2762084864","doi":"10.1093/annonc/mdx365.052","title":"The CAN BEAR study: A systematic review and meta-analysis investigating adverse events (AEs) of targeted agents added to endocrine therapy (ET) in patients (pts) with hormone-receptor positive (HR+) metastatic breast cancer (MBC)","year":2017,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Internal medicine; Meta-analysis; Oncology; Adverse effect; Odds ratio; Cochrane Library; Confidence interval; Randomized controlled trial; Targeted therapy; Metastatic breast cancer; Breast cancer; Pharmacology; Cancer","score_opus":0.19634231387762996,"score_gpt":0.4687768820763335,"score_spread":0.27243456819870354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762084864","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025327923,0.9835898,0.000002977693,0.001578377,0.000031241405,0.01087524,0.0013631204,0.0000108303075,0.000015612743],"genre_scores_gemma":[0.010714697,0.983974,0.00036180177,0.0013995181,0.000015190599,0.0031663792,0.00015684075,0.00008439655,0.00012718416],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99400204,0.002104994,0.0020522883,0.0006688908,0.00067837496,0.00049341767],"domain_scores_gemma":[0.9933616,0.0005622978,0.0037878787,0.0010541624,0.00097033964,0.00026372523],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013550124,0.000725695,0.011234751,0.0004907456,0.00011766311,0.000008711744,0.00052201975,0.00009984031,0.00006606352],"category_scores_gemma":[0.000473695,0.00039032765,0.0010401931,0.0009757303,0.00026502192,0.0001274281,0.0001592652,0.00040602373,0.000003432112],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010931683,0.002660308,0.0010310977,0.25477913,0.58778834,0.000070341805,0.0033122804,0.000020866875,0.000003351116,0.000011084824,0.00014797765,0.14908206],"study_design_scores_gemma":[0.006416238,0.009262152,0.0074032797,0.0758507,0.887188,0.000071840586,0.0009777328,0.0000026653656,0.000008652016,0.000018410687,0.011901028,0.0008992614],"about_ca_topic_score_codex":0.0012416624,"about_ca_topic_score_gemma":0.0011057912,"teacher_disagreement_score":0.2993997,"about_ca_system_score_codex":0.00025430636,"about_ca_system_score_gemma":0.0007979941,"threshold_uncertainty_score":0.99985486},"labels":[],"label_agreement":null},{"id":"W2762098071","doi":"10.1093/annonc/mdx365.086","title":"EarLEE-1: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), high-risk, early breast cancer (EBC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Letrozole; Internal medicine; Breast cancer; Oncology; Exemestane; Anastrozole; Placebo; Tamoxifen; Docetaxel; Gastroenterology; Cancer; Surgery; Pathology","score_opus":0.0632172734733662,"score_gpt":0.40724478441418716,"score_spread":0.34402751094082096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762098071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99018806,0.0005555224,0.000055816792,0.0014652512,0.00014782693,0.0034020378,0.004075063,0.000027772938,0.00008264497],"genre_scores_gemma":[0.99603945,0.0016802108,0.0009221195,0.00013582151,0.00019761642,0.00069739536,0.000114628696,0.000085761276,0.00012697525],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9972201,0.0003369376,0.0008703409,0.00059864647,0.0004332202,0.0005407606],"domain_scores_gemma":[0.99454314,0.00042773702,0.002263978,0.0006823313,0.0018716651,0.00021115795],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019383804,0.00049100706,0.001822895,0.0001933682,0.00024562492,0.000011277765,0.00030057257,0.00013962509,0.00022140895],"category_scores_gemma":[0.00010912088,0.0003555594,0.00024455466,0.0001331931,0.00066927803,0.00035431472,0.00006460523,0.00020350002,0.0000023044902],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08846752,0.03398091,0.2790337,0.00010079005,0.0056315553,0.000025982767,0.020702852,0.0000101240275,0.024924064,0.00009075206,0.0002917296,0.54674006],"study_design_scores_gemma":[0.062142886,0.13143376,0.72143334,0.00011181955,0.00025616243,0.0000054434604,0.00087041844,0.0000021481037,0.082682885,0.000115700415,0.00068926736,0.0002561517],"about_ca_topic_score_codex":0.016405163,"about_ca_topic_score_gemma":0.0009650771,"teacher_disagreement_score":0.5464839,"about_ca_system_score_codex":0.0002661141,"about_ca_system_score_gemma":0.00031794442,"threshold_uncertainty_score":0.9998896},"labels":[],"label_agreement":null},{"id":"W2762169730","doi":"10.1093/annonc/mdx365.054","title":"PALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor−positive (ER+)/human epidermal growth factor receptor 2−negative (HER2–) first-line advanced breast cancer (ABC) receiving palbociclib + letrozole (P+L)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Calgary; University of Alberta","funders":"","keywords":"Medicine; Neutropenia; Internal medicine; Palbociclib; Gastroenterology; Anemia; Breast cancer; Adverse effect; Progression-free survival; Metastatic breast cancer; Febrile neutropenia; Chemotherapy regimen; Cancer; Chemotherapy","score_opus":0.03672575176968415,"score_gpt":0.35281412984469135,"score_spread":0.3160883780750072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762169730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832835,0.00018205146,0.000070903254,0.012801374,0.00036014608,0.0012559793,0.0011915399,0.00006858458,0.00078588584],"genre_scores_gemma":[0.99552673,0.000591468,0.0011848757,0.0014448446,0.00046180596,0.00028125753,0.00016289063,0.00013393204,0.00021219031],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963205,0.00028340274,0.0009277845,0.0009315094,0.00051608647,0.0010207469],"domain_scores_gemma":[0.9958321,0.00031201745,0.0014657272,0.0008624936,0.0011537378,0.00037391428],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028053898,0.0006285187,0.0015104924,0.0002589655,0.000447911,0.000039036146,0.0005945101,0.00032277833,0.0011113855],"category_scores_gemma":[0.00025894993,0.0005416599,0.00021302995,0.0002284132,0.0006785164,0.0008799238,0.00025050848,0.000701226,0.000035905738],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008106437,0.0012067221,0.83036476,0.00016647181,0.0005197397,0.000058403926,0.0018065813,0.00006315256,0.004348075,0.00007672845,0.00031788048,0.15296504],"study_design_scores_gemma":[0.014347156,0.005598323,0.95444655,0.00094498653,0.000080929785,0.000031369265,0.00026082539,0.000007708372,0.020675905,0.00012934642,0.002919121,0.00055776606],"about_ca_topic_score_codex":0.0029489591,"about_ca_topic_score_gemma":0.0026149375,"teacher_disagreement_score":0.15240727,"about_ca_system_score_codex":0.00057698134,"about_ca_system_score_gemma":0.0003264208,"threshold_uncertainty_score":0.99980175},"labels":[],"label_agreement":null},{"id":"W2762790960","doi":"10.1093/annonc/mdx375.004","title":"Palbociclib in advanced breast cancer: A cost-utility analysis","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Palbociclib; Letrozole; Medicine; Cost effectiveness; Breast cancer; Statistics; Cancer; Internal medicine; Risk analysis (engineering); Mathematics; Metastatic breast cancer; Tamoxifen","score_opus":0.09860095043635311,"score_gpt":0.4710322987665924,"score_spread":0.3724313483302393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762790960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9704193,0.0010531438,0.00013648439,0.023654772,0.00015358531,0.00040900498,0.000117510215,0.000045949,0.0040102648],"genre_scores_gemma":[0.99708664,0.00076772436,0.00046304322,0.0013057113,0.00008847376,0.0000991356,0.000009734553,0.00002076942,0.00015877718],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99863046,0.00006915903,0.00040384638,0.00034171698,0.00017727178,0.00037753306],"domain_scores_gemma":[0.9981808,0.000096147225,0.0004556584,0.0008158245,0.00031252555,0.0001390634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035805805,0.00015571273,0.0008995085,0.00022603695,0.00007210098,0.0000073180777,0.00026500548,0.00014253503,0.00034078344],"category_scores_gemma":[0.0001472912,0.00014177196,0.0002195332,0.00028273347,0.0003899467,0.00018897928,0.00008726039,0.00021728661,0.0000052911446],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019609728,0.00028932895,0.4230461,0.000033102693,0.00046645588,0.000045815003,0.00020741756,0.00009415566,0.00096439733,0.000079353966,0.00008684473,0.572726],"study_design_scores_gemma":[0.0030873425,0.0003480125,0.96318763,0.000059816146,0.00021126145,0.000026557786,0.00013971748,0.00022586458,0.0017060562,0.0006148805,0.030274691,0.000118135904],"about_ca_topic_score_codex":0.0010246082,"about_ca_topic_score_gemma":0.0031274436,"teacher_disagreement_score":0.5726079,"about_ca_system_score_codex":0.000100197314,"about_ca_system_score_gemma":0.00030125462,"threshold_uncertainty_score":0.5781293},"labels":[],"label_agreement":null},{"id":"W2763742548","doi":"10.1093/annonc/mdx440.008","title":"MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham","funders":"","keywords":"Medicine; Internal medicine; Fulvestrant; Breast cancer; Metastatic breast cancer; Oncology; Hazard ratio; Letrozole; Anastrozole; Aromatase inhibitor; Tolerability; Cancer; Adverse effect; Estrogen receptor; Tamoxifen; Confidence interval","score_opus":0.07265391653121518,"score_gpt":0.46237463407396856,"score_spread":0.3897207175427534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763742548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981782,0.0005692566,0.00008566192,0.0131718395,0.00028596944,0.0010842283,0.00023402247,0.000034532175,0.0027524817],"genre_scores_gemma":[0.99382925,0.0006746919,0.0015120076,0.002877653,0.0003238357,0.00036788834,0.000031325202,0.000053355187,0.00032997015],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99866825,0.00003461873,0.00028735635,0.00033715295,0.00025059943,0.0004220072],"domain_scores_gemma":[0.997819,0.00012325047,0.00045679073,0.0005493736,0.00090561464,0.00014597907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013418864,0.00021107946,0.0005933876,0.00007805915,0.00019091438,0.000010822815,0.0002651799,0.00013787556,0.00023298369],"category_scores_gemma":[0.00006859337,0.00015986168,0.000112224094,0.000054743225,0.00045639795,0.0002404933,0.000047940644,0.00015518957,0.000007987154],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027965829,0.0008945694,0.07376616,0.000059267702,0.0003084221,0.000015489259,0.0003483929,0.000015216659,0.0009073412,0.00018529112,0.00029070754,0.8952433],"study_design_scores_gemma":[0.024670811,0.015360501,0.7958494,0.00023200385,0.00006325604,0.000059991296,0.00012806132,0.000012912985,0.010444754,0.0019181758,0.15093897,0.00032117552],"about_ca_topic_score_codex":0.00018867648,"about_ca_topic_score_gemma":0.000060763134,"teacher_disagreement_score":0.89492214,"about_ca_system_score_codex":0.00006147865,"about_ca_system_score_gemma":0.00045545943,"threshold_uncertainty_score":0.651897},"labels":[],"label_agreement":null},{"id":"W2763755836","doi":"10.1093/annonc/mdx365.011","title":"Impact of prior treatment on palbociclib plus letrozole (P+L) efficacy and safety in patients (pts) with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2–) first-line advanced breast cancer (ABC): A PALOMA-2 subgroup analysis","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; McGill University Health Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Palbociclib; Adverse effect; Neutropenia; Progression-free survival; Letrozole; Adjuvant; Discontinuation; Oncology; Chemotherapy; Gastroenterology; Surgery; Gynecology; Clinical trial; Metastatic breast cancer; Breast cancer; Cancer; Tamoxifen","score_opus":0.03404481043125903,"score_gpt":0.37548382599165103,"score_spread":0.341439015560392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763755836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950495,0.00024743343,0.000032269225,0.0018349276,0.000057186277,0.0012498625,0.0013599568,0.00003297155,0.00013589977],"genre_scores_gemma":[0.99795794,0.0008036816,0.00062020094,0.00012303222,0.00009915631,0.00012391512,0.00015223272,0.00006912645,0.00005068729],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973693,0.0002032666,0.0007776,0.0006891328,0.00035782752,0.00060287095],"domain_scores_gemma":[0.99673265,0.0004046143,0.0012876517,0.0006472747,0.0006318159,0.00029601593],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016841156,0.00052318635,0.0018662338,0.0003901312,0.00021865794,0.0000139376025,0.00023529341,0.0002135127,0.00027175763],"category_scores_gemma":[0.00014878802,0.00038048296,0.0003494539,0.0003620693,0.0006761618,0.00030604383,0.00008275562,0.00025875674,0.0000027563592],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040786482,0.0026509285,0.7422572,0.00007223418,0.0039880513,0.00002284177,0.0018048303,0.0005437943,0.0015554827,0.000033847362,0.000016946544,0.20626736],"study_design_scores_gemma":[0.028270554,0.021477548,0.94166094,0.00032005733,0.00044603393,0.000007235686,0.00008568119,0.000027729404,0.007224362,0.000022892022,0.0001553683,0.0003015737],"about_ca_topic_score_codex":0.0046992954,"about_ca_topic_score_gemma":0.0019867562,"teacher_disagreement_score":0.20596579,"about_ca_system_score_codex":0.0011261656,"about_ca_system_score_gemma":0.00038443223,"threshold_uncertainty_score":0.9998647},"labels":[],"label_agreement":null},{"id":"W2764130147","doi":"10.1093/annonc/mdx365.024","title":"Is PFS a more relevant endpoint than OS in 1L HR+, HER2– MBC? A systematic literature review","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Internal medicine; Metastatic breast cancer; Progression-free survival; Oncology; Randomized controlled trial; Clinical endpoint; Cancer; Breast cancer; Chemotherapy","score_opus":0.08035043177986463,"score_gpt":0.44206763810045724,"score_spread":0.3617172063205926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2764130147","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.082303025,0.6794276,0.000086991364,0.2247926,0.0005795966,0.0041342033,0.000090644935,0.00008772042,0.008497595],"genre_scores_gemma":[0.8370624,0.12723525,0.0019262003,0.030499589,0.00034032273,0.00045157745,0.000027154494,0.000071242066,0.0023862615],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99819875,0.00017075235,0.0007010252,0.00032536229,0.00025330568,0.00035081763],"domain_scores_gemma":[0.9975734,0.00013617071,0.00073153013,0.0011082052,0.00032634838,0.00012438856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074079674,0.00022345538,0.0014353647,0.00012854162,0.000062051375,0.000014455662,0.00032300246,0.00019385682,0.000087610424],"category_scores_gemma":[0.00082266424,0.00016583902,0.00021726587,0.0001380732,0.00019636861,0.00016633628,0.00009815619,0.00035481068,0.00002938777],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038263372,0.0023561097,0.010339021,0.76184887,0.001573501,0.0056645973,0.022057539,0.000005193399,0.0064623016,0.0023802763,0.019936403,0.16354984],"study_design_scores_gemma":[0.0077338694,0.0057948236,0.04802591,0.72186893,0.0006060136,0.0028749546,0.0013702204,0.00008063966,0.0062951758,0.00393103,0.20061834,0.00080006185],"about_ca_topic_score_codex":0.00004129226,"about_ca_topic_score_gemma":0.000061987645,"teacher_disagreement_score":0.7547594,"about_ca_system_score_codex":0.000093519026,"about_ca_system_score_gemma":0.00020495645,"threshold_uncertainty_score":0.6762719},"labels":[],"label_agreement":null},{"id":"W2765083464","doi":"10.1016/j.ctrv.2017.09.009","title":"Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis","year":2017,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Hôpital Charles-Le Moyne; Université de Sherbrooke","funders":"European Society for Medical Oncology","keywords":"Medicine; Internal medicine; Odds ratio; Meta-analysis; Adverse effect; Oncology; Breast cancer; Cochrane Library; Neutropenia; Randomized controlled trial; Metastatic breast cancer; Relative risk; Confidence interval; Cancer; Chemotherapy","score_opus":0.0726883789844289,"score_gpt":0.3747771327808193,"score_spread":0.30208875379639044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765083464","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000090542046,0.9686185,0.000025225369,0.0001662707,0.000017384742,0.022846809,0.008217924,0.000010232986,0.000007124629],"genre_scores_gemma":[0.00022391696,0.9780358,0.00042262246,0.00017166225,0.000018183284,0.02013714,0.00068921933,0.00008564412,0.00021581506],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9952284,0.0012266118,0.0017844525,0.00080374954,0.00058966037,0.00036714002],"domain_scores_gemma":[0.9925276,0.00016617763,0.0050883074,0.001587285,0.0004419337,0.00018870279],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.00048788375,0.0010957387,0.015648916,0.00036965543,0.000093853734,0.0000061641476,0.00032355115,0.00006579875,0.00043063663],"category_scores_gemma":[0.000042604534,0.00044194935,0.0018175436,0.0012396018,0.00016138752,0.00015899238,0.000045064935,0.0002228163,0.0000062035347],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070292375,0.00072163175,0.0007300777,0.37820297,0.36760175,0.000009038443,0.0002733438,0.00001568837,2.0077094e-7,9.80349e-7,0.000067132656,0.25167426],"study_design_scores_gemma":[0.0026087298,0.0012816519,0.002086985,0.13584504,0.8169974,0.0000131993,0.000016263983,4.1214065e-7,0.0000017280817,6.348132e-7,0.040767472,0.0003805084],"about_ca_topic_score_codex":0.000958985,"about_ca_topic_score_gemma":0.0003710978,"teacher_disagreement_score":0.44939563,"about_ca_system_score_codex":0.00090267323,"about_ca_system_score_gemma":0.00033459658,"threshold_uncertainty_score":0.99980325},"labels":[],"label_agreement":null},{"id":"W2765692744","doi":"10.1007/s10549-017-4523-y","title":"Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial","year":2017,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; Occupational Cancer Research Centre","funders":"Novartis Institutes for BioMedical Research; Astex Pharmaceuticals; Novartis Pharmaceuticals Corporation","keywords":"Letrozole; Medicine; Breast cancer; Hazard ratio; Discontinuation; Internal medicine; Placebo; Metastatic breast cancer; Clinical endpoint; Population; Nausea; Oncology; Cancer; Surgery; Randomized controlled trial; Tamoxifen; Confidence interval","score_opus":0.02442456894890639,"score_gpt":0.33779852049377096,"score_spread":0.3133739515448646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765692744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97781515,0.0017454729,0.000011739339,0.01317404,0.000058843416,0.005613049,0.0011104251,0.00002578348,0.00044546818],"genre_scores_gemma":[0.99110836,0.0022877785,0.00016281969,0.00011732995,0.00033138948,0.0053844466,0.00006526524,0.00006995089,0.00047268308],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9959686,0.0005324702,0.00042824034,0.0008109722,0.0012487998,0.0010109306],"domain_scores_gemma":[0.99771863,0.0004314923,0.0002696999,0.00075107865,0.0005240965,0.00030502523],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006893151,0.00051209214,0.0011781619,0.00030483078,0.0005719981,0.00019364765,0.000326626,0.00011531783,0.00017663796],"category_scores_gemma":[0.00003834832,0.00027311788,0.00011037821,0.00043432624,0.0014745956,0.00047349767,0.00008684689,0.00060115213,0.0000085216825],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78852683,0.0019244672,0.12041657,0.000030095962,0.00068005355,0.00014002006,0.0013477139,0.000021187716,0.000055690096,0.00004768188,0.000050661612,0.08675903],"study_design_scores_gemma":[0.45775914,0.0031941012,0.53737205,0.0005170451,0.000087398155,0.00005627532,0.00037930653,0.000014476672,0.0001583034,0.00007414258,0.00017652732,0.00021124503],"about_ca_topic_score_codex":0.056619767,"about_ca_topic_score_gemma":0.021735895,"teacher_disagreement_score":0.41695547,"about_ca_system_score_codex":0.0014364925,"about_ca_system_score_gemma":0.0006818007,"threshold_uncertainty_score":0.9999721},"labels":[],"label_agreement":null},{"id":"W2768609007","doi":"10.1200/jco.2017.35.31_suppl.133","title":"Health-related quality of life of postmenopausal women with hormone receptor–positive, HER2- advanced breast cancer treated with ribociclib + letrozole: Results from MONALEESA-2.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Letrozole; Medicine; Quality of life (healthcare); Internal medicine; Breast cancer; Hazard ratio; Placebo; Nausea; Oncology; Cancer; Confidence interval; Tamoxifen","score_opus":0.06706628399460873,"score_gpt":0.4317828630791085,"score_spread":0.3647165790844998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768609007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759236,0.0021900123,0.00006806372,0.019779606,0.00026357808,0.0004116295,0.00087234477,0.00001813838,0.0004730112],"genre_scores_gemma":[0.99076,0.0017101729,0.005889203,0.00088492193,0.00044133374,0.000014005914,0.000029491703,0.000053620202,0.00021724559],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9927867,0.0007965266,0.004686381,0.00043753744,0.0008045066,0.0004883431],"domain_scores_gemma":[0.9811413,0.0018727923,0.013741243,0.000702935,0.0017161677,0.000825554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027403915,0.0003390468,0.004111041,0.00012558847,0.00012435696,0.000009668839,0.00042014185,0.00039295224,0.00015208012],"category_scores_gemma":[0.0016444918,0.0002191647,0.0002176315,0.00019874112,0.001335488,0.0003760559,0.00007552838,0.001211512,0.0000034776633],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5991886,0.0034828086,0.15037982,0.00008720315,0.004215641,0.00018028666,0.00086373277,0.00022979677,0.01048308,0.000029221654,0.00035756576,0.2305022],"study_design_scores_gemma":[0.053269427,0.03631629,0.906439,0.000794077,0.00022605916,0.00015973106,0.00045561808,0.000009073591,0.00043262684,0.00008921632,0.0016065926,0.00020228559],"about_ca_topic_score_codex":0.00311747,"about_ca_topic_score_gemma":0.00051085884,"teacher_disagreement_score":0.75605917,"about_ca_system_score_codex":0.0006294455,"about_ca_system_score_gemma":0.003810543,"threshold_uncertainty_score":0.8937277},"labels":[],"label_agreement":null},{"id":"W2782174022","doi":"10.18438/b8sh4k","title":"Journal Update from EBLIP9","year":2017,"lang":"en","type":"article","venue":"Evidence Based Library and Information Practice","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Concordia University","funders":"","keywords":"Computer science; Library science; Information retrieval; Data science; World Wide Web","score_opus":0.016947692788883997,"score_gpt":0.29812695419537066,"score_spread":0.2811792614064867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2782174022","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.037402358,0.004877515,0.023794517,0.9179592,0.0009475004,0.00043265856,0.00003870347,0.00019858118,0.014348971],"genre_scores_gemma":[0.6904551,0.0064957393,0.062628575,0.23919408,0.0008036685,0.000015820911,0.000065993074,0.000019554705,0.0003215182],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992449,0.00005611712,0.00026600074,0.00008368044,0.00022622386,0.00012307081],"domain_scores_gemma":[0.9983475,0.00045362694,0.0005849151,0.00038285193,0.00007322227,0.00015787008],"candidate_categories":["scholarly_communication"],"consensus_categories":[],"category_scores_codex":[0.00023885454,0.000097086995,0.00012669899,0.000080292884,0.00045334137,0.00082882005,0.00017017941,0.000050399598,0.0008617216],"category_scores_gemma":[0.0018280305,0.000079859696,0.00003336744,0.000051136583,0.000089079054,0.33114326,0.00006692508,0.00029070597,0.00012686175],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014842006,0.00011086832,0.015180565,0.00020574582,0.000214369,0.00012665673,0.0006844725,0.00008730132,0.0007629105,0.043117695,0.01019403,0.91447335],"study_design_scores_gemma":[0.0011042091,0.00014505404,0.06030484,0.0005049352,0.000058879323,0.00022331125,0.00026318975,0.0005484077,0.0022811915,0.0004939978,0.93397015,0.00010181967],"about_ca_topic_score_codex":0.000005259778,"about_ca_topic_score_gemma":1.0619928e-8,"teacher_disagreement_score":0.92377615,"about_ca_system_score_codex":0.000011048531,"about_ca_system_score_gemma":0.00021091312,"threshold_uncertainty_score":0.9435247},"labels":[],"label_agreement":null},{"id":"W2783341375","doi":"10.1093/annonc/mdx797","title":"Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Pfizer","keywords":"Palbociclib; Medicine; Letrozole; Fulvestrant; Internal medicine; Hazard ratio; Breast cancer; Oncology; Metastatic breast cancer; Cancer; Placebo; Gynecology; Gastroenterology; Confidence interval; Estrogen receptor; Tamoxifen; Pathology","score_opus":0.04509901211439402,"score_gpt":0.41487364688864137,"score_spread":0.3697746347742473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2783341375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961059,0.0005201312,0.000010741634,0.0020171923,0.00004422741,0.00045741434,0.00010496189,0.0000024416368,0.0007369582],"genre_scores_gemma":[0.99760926,0.00018288408,0.0014878295,0.0006441201,0.000025915031,0.000027600609,0.0000025467816,0.000007816274,0.000012059503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989488,0.00015095704,0.0004656621,0.0001334499,0.00018088814,0.00012020573],"domain_scores_gemma":[0.9987439,0.00015369692,0.0004379182,0.0002442329,0.00039454713,0.000025724581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002811744,0.00008547995,0.00043774044,0.00004241518,0.000023982111,9.1334135e-7,0.00008674542,0.000041258132,0.000053028394],"category_scores_gemma":[0.000027396947,0.000045520082,0.00005416133,0.00013843286,0.0009645617,0.00005048328,0.000049529128,0.00008606859,1.5239742e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029814614,0.0010695856,0.85853416,0.00011866621,0.00053100043,0.0000013029043,0.0012482626,0.000032588883,0.00074336416,0.0020690297,0.000059696256,0.13261087],"study_design_scores_gemma":[0.004143289,0.0022583788,0.98442596,0.00026531162,0.0001620981,0.000010527746,0.0011604421,0.000008719469,0.004352129,0.0015742062,0.0015904316,0.000048496557],"about_ca_topic_score_codex":0.00008948827,"about_ca_topic_score_gemma":0.00031075868,"teacher_disagreement_score":0.13256237,"about_ca_system_score_codex":0.000009790336,"about_ca_system_score_gemma":0.00011240554,"threshold_uncertainty_score":0.35539678},"labels":[],"label_agreement":null},{"id":"W2784121544","doi":"10.1016/j.ejca.2017.12.010","title":"Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis","year":2018,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Health Sciences Centre; CancerCare Manitoba; University of Toronto; Sunnybrook Health Science Centre; University of Manitoba; Western University","funders":"","keywords":"Phosphoinositide 3-kinase; Medicine; Oncology; Breast cancer; Meta-analysis; Cancer; Internal medicine; PI3K/AKT/mTOR pathway; Biology; Signal transduction; Genetics","score_opus":0.04518991375417572,"score_gpt":0.364431768677626,"score_spread":0.31924185492345025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2784121544","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000005583087,0.99671566,0.000033392014,0.0008746823,0.00020192127,0.0017191566,0.0002802154,0.000020268659,0.00014911244],"genre_scores_gemma":[0.000074019335,0.996654,0.00037850995,0.0012683141,0.00043673126,0.00019085918,0.000008132563,0.00017770725,0.0008117765],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99379253,0.0013142328,0.0031303293,0.0005767001,0.0007370378,0.00044917053],"domain_scores_gemma":[0.9938584,0.00015231027,0.004117709,0.000727008,0.00074830215,0.00039624717],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001987333,0.0008534836,0.013082633,0.00083064364,0.000057905814,0.000045098077,0.00044177443,0.00008154421,0.0008357495],"category_scores_gemma":[0.00014580195,0.0005289186,0.0034351589,0.0017210444,0.00018754389,0.00025994604,0.00011058966,0.00089419814,0.000020733707],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000890615,0.00006319668,0.000014294381,0.7050606,0.15028846,0.0008071809,0.000108224485,0.000009574626,9.0882025e-7,0.000002226123,0.00038019483,0.1431761],"study_design_scores_gemma":[0.0005273898,0.000100181045,0.000025402045,0.23266804,0.59640265,0.0010987818,0.000017667677,3.4020388e-7,0.0000018420694,0.0000014591593,0.168833,0.0003232379],"about_ca_topic_score_codex":0.000041483345,"about_ca_topic_score_gemma":0.000054766486,"teacher_disagreement_score":0.47239256,"about_ca_system_score_codex":0.0007089711,"about_ca_system_score_gemma":0.0006176705,"threshold_uncertainty_score":0.9997162},"labels":[],"label_agreement":null},{"id":"W2789321069","doi":"10.1007/s12325-018-0689-x","title":"Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Breast cancer; Internal medicine; Metastatic breast cancer; Oncology; Rheumatology; Cancer; Gynecology","score_opus":0.009575853979504405,"score_gpt":0.3136427364288696,"score_spread":0.3040668824493652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789321069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98913455,0.0076597566,0.00022144371,0.00047971046,0.00043281686,0.0005843742,0.00008388464,0.00006573368,0.0013377554],"genre_scores_gemma":[0.9896583,0.006946116,0.0016869424,0.00037752566,0.00061767676,0.00031329837,0.0000061606806,0.000066314984,0.00032767528],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99826133,0.0000611878,0.00049866166,0.00042867564,0.00023592608,0.00051423983],"domain_scores_gemma":[0.9988773,0.000071280825,0.00028107953,0.00045852826,0.00018276031,0.00012907882],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018688911,0.00028333944,0.0006071555,0.00016814188,0.000047177567,0.000009784717,0.00023760785,0.000056477656,0.0017098881],"category_scores_gemma":[0.000013125659,0.00024085103,0.00006104541,0.0002381165,0.0006209588,0.000572067,0.000032345706,0.00016966289,0.000028901031],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008065622,0.00037225705,0.1449889,0.00024339947,0.0006077224,0.000024311717,0.013891216,0.0018778536,0.023289166,0.0007715704,0.000042971904,0.805825],"study_design_scores_gemma":[0.056149796,0.0099353995,0.578052,0.003294029,0.00024426624,0.00047384138,0.012667853,0.002724492,0.12937197,0.028958727,0.17504069,0.0030869462],"about_ca_topic_score_codex":0.00068430725,"about_ca_topic_score_gemma":0.0005523176,"teacher_disagreement_score":0.8027381,"about_ca_system_score_codex":0.00052362337,"about_ca_system_score_gemma":0.0001719507,"threshold_uncertainty_score":0.99920267},"labels":[],"label_agreement":null},{"id":"W2790167050","doi":"10.1007/s12282-018-0848-6","title":"Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials","year":2018,"lang":"en","type":"review","venue":"Breast Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Metastatic breast cancer; Oncology; Meta-analysis; Internal medicine; Surgical oncology; Breast cancer; Randomized controlled trial; Hormone receptor; Clinical trial; Cancer","score_opus":0.11919238198668243,"score_gpt":0.46894878344409596,"score_spread":0.34975640145741355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790167050","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000053534102,0.89979935,0.00026907047,0.0012957574,0.00039932068,0.03490573,0.0631998,0.000070021895,0.000007406556],"genre_scores_gemma":[0.0002958484,0.9577268,0.00033265012,0.0009753031,0.00066625385,0.03640195,0.0026428606,0.00027699445,0.00068136334],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98039544,0.0054715825,0.010074032,0.0020036432,0.0011935048,0.0008617935],"domain_scores_gemma":[0.97794944,0.0067896824,0.010252461,0.0014661278,0.0027484542,0.0007938157],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaepi_narrow","metaepi_broad"],"category_scores_codex":[0.008802658,0.0021451868,0.05386239,0.0009131357,0.00020323314,0.000065421176,0.00041758383,0.0004979909,0.0020387636],"category_scores_gemma":[0.0021497984,0.001219602,0.01087757,0.0014001239,0.0007743857,0.00026688128,0.00015429017,0.00048351358,0.000022398704],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052333895,0.0024528163,0.0000010030769,0.27387184,0.57427406,0.00001524216,0.00015250957,0.000002445373,0.0000025121622,0.000011755119,0.0001722834,0.09670964],"study_design_scores_gemma":[0.121723786,0.0016815535,0.0000024662056,0.064463876,0.805566,0.00014685778,0.000033763456,0.000013721925,0.0000052062455,0.000010328478,0.005527967,0.0008244875],"about_ca_topic_score_codex":0.0017995633,"about_ca_topic_score_gemma":0.00027888952,"teacher_disagreement_score":0.23129193,"about_ca_system_score_codex":0.001658302,"about_ca_system_score_gemma":0.0016458137,"threshold_uncertainty_score":0.9991289},"labels":[],"label_agreement":null},{"id":"W2790250024","doi":"10.1158/1538-7445.sabcs17-ot3-05-04","title":"Abstract OT3-05-04: A randomized, open-label, multi-center phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment strategy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer in a real world setting (PADMA)","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palbociclib; Internal medicine; Oncology; Metastatic breast cancer; Breast cancer; Population; Discontinuation; Chemotherapy; Randomization; Hazard ratio; Cancer; Randomized controlled trial; Progression-free survival; Surgery; Confidence interval","score_opus":0.15398987287476085,"score_gpt":0.49702976487793793,"score_spread":0.3430398920031771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790250024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824352,0.000691628,0.000028473989,0.0009520141,0.00011805575,0.014659782,0.00084646227,0.000057172056,0.00021117966],"genre_scores_gemma":[0.9856343,0.00050170464,0.0021224967,0.00009629767,0.00022657815,0.010620892,0.00014287082,0.00017782018,0.00047700474],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99324584,0.0013697738,0.0010189092,0.0013855897,0.0013980989,0.001581817],"domain_scores_gemma":[0.99625593,0.0011215516,0.0004250602,0.0006975982,0.0010937861,0.00040605158],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016566626,0.00079000223,0.0018214785,0.00080756797,0.0003292164,0.00016401714,0.0003836674,0.000071657676,0.0008813775],"category_scores_gemma":[0.00011777402,0.0005640833,0.00011697784,0.001698574,0.00072558864,0.00045069394,0.00012308356,0.00064254855,0.000017935332],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7348509,0.022210438,0.026819719,0.000075352444,0.0019495251,0.00021995802,0.007036232,0.0004123199,0.0020837937,0.000002810839,0.000026052261,0.2043129],"study_design_scores_gemma":[0.90781516,0.021891847,0.05996639,0.0012849725,0.00025318054,0.0000039765887,0.0033339048,0.0024555915,0.002409525,0.000010228857,0.000052057323,0.00052319496],"about_ca_topic_score_codex":0.04156261,"about_ca_topic_score_gemma":0.05541593,"teacher_disagreement_score":0.20378971,"about_ca_system_score_codex":0.010527216,"about_ca_system_score_gemma":0.0026586675,"threshold_uncertainty_score":0.99968106},"labels":[],"label_agreement":null},{"id":"W2790385254","doi":"10.1158/1538-7445.sabcs17-ot3-05-02","title":"Abstract OT3-05-02: BYLieve: A phase 2 study of alpelisib with fulvestrant or letrozole for treatment of <i>PIK3CA</i> mutant, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2<i>–</i>) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase (CDK)4/6 inhibitor therapy","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Fulvestrant; Letrozole; Medicine; Aromatase inhibitor; Internal medicine; Oncology; Cancer; Metastatic breast cancer; Breast cancer; Estrogen receptor; Aromatase","score_opus":0.06258979464817743,"score_gpt":0.42228201938771043,"score_spread":0.359692224739533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790385254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98218507,0.0030932536,0.000073543655,0.00094634836,0.00027615917,0.008615672,0.0046366197,0.000095227944,0.00007812502],"genre_scores_gemma":[0.98916787,0.0014335272,0.0011315914,0.00014253554,0.0014278787,0.0060253954,0.00007954911,0.00027360918,0.00031803624],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99344546,0.0003757075,0.0012312781,0.0015337261,0.0019269033,0.0014869013],"domain_scores_gemma":[0.9940882,0.0006088927,0.0007841623,0.0009683499,0.002955083,0.00059531257],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052271027,0.00093415804,0.0016921521,0.0005461192,0.0005363459,0.00007323373,0.00043169718,0.00023805484,0.0011206907],"category_scores_gemma":[0.00008343095,0.0006348911,0.00027732473,0.0010476861,0.001689901,0.0005561458,0.00008552951,0.00059085095,0.000010687007],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18156907,0.01063111,0.0029827817,0.0003049499,0.0015185998,0.00014035717,0.0099797025,0.000021179,0.59192884,0.000007756569,0.00015512493,0.2007605],"study_design_scores_gemma":[0.05790029,0.060939584,0.029108183,0.0018328748,0.00018084,0.000036994486,0.004884804,0.000008860823,0.843198,0.000031799376,0.0011633984,0.00071437465],"about_ca_topic_score_codex":0.0023088346,"about_ca_topic_score_gemma":0.001135822,"teacher_disagreement_score":0.25126913,"about_ca_system_score_codex":0.0019297285,"about_ca_system_score_gemma":0.0014015338,"threshold_uncertainty_score":0.9997924},"labels":[],"label_agreement":null},{"id":"W2790694922","doi":"10.1158/1538-7445.sabcs17-ot3-05-06","title":"Abstract OT3-05-06: EarLEE-2: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), intermediate-risk, early breast cancer (EBC)","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Letrozole; Internal medicine; Exemestane; Anastrozole; Oncology; Tamoxifen; Breast cancer; Placebo; Adjuvant therapy; Aromatase inhibitor; Gynecology; Cancer; Pathology","score_opus":0.055043549115642465,"score_gpt":0.41281874523035256,"score_spread":0.3577751961147101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790694922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984402,0.0014719238,0.0000403115,0.0003509059,0.00017864809,0.0062973867,0.0071574952,0.00005911574,0.000042234686],"genre_scores_gemma":[0.99365,0.0018740661,0.00024930044,0.000048618236,0.00069853436,0.0028362551,0.00020426077,0.0001822611,0.00025670382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99513036,0.00045709783,0.00090482715,0.0010141488,0.001390287,0.0011032557],"domain_scores_gemma":[0.99361414,0.000632573,0.00072940486,0.0007091915,0.003879768,0.00043490835],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041842696,0.00062931806,0.0013322543,0.00048644037,0.00035333788,0.000037685084,0.00038878864,0.00013199517,0.0012278792],"category_scores_gemma":[0.000116975905,0.00044998428,0.00022276271,0.0007561387,0.0012896471,0.00044795702,0.00009896557,0.0005761079,0.0000146368075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.119947664,0.019383516,0.3950163,0.00029676277,0.004988421,0.00002812627,0.050276548,0.000007085537,0.11991409,0.000020544456,0.00088344386,0.28923747],"study_design_scores_gemma":[0.049661722,0.0437831,0.7777028,0.0004004027,0.00013000904,0.0000024769863,0.002204255,0.0000033339543,0.12506923,0.000045047887,0.00061712874,0.00038050784],"about_ca_topic_score_codex":0.016335525,"about_ca_topic_score_gemma":0.0015899842,"teacher_disagreement_score":0.38268647,"about_ca_system_score_codex":0.0014077083,"about_ca_system_score_gemma":0.00072661525,"threshold_uncertainty_score":0.9997952},"labels":[],"label_agreement":null},{"id":"W2790923252","doi":"10.1007/s12325-018-0676-2","title":"Current Treatment Patterns Among Postmenopausal Women with HR+/HER2− Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Regimen; Fulvestrant; Internal medicine; Metastatic breast cancer; Discontinuation; Oncology; Aromatase inhibitor; Breast cancer; Cancer; Tamoxifen","score_opus":0.138153164960228,"score_gpt":0.4640211901505986,"score_spread":0.3258680251903706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790923252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944996,0.0029646535,0.00008810465,0.00031223273,0.00024691687,0.00167049,0.000097785174,0.000058744445,0.0000614564],"genre_scores_gemma":[0.99340826,0.0033877133,0.0007375742,0.0004428974,0.00023398954,0.0016702559,0.00004120013,0.000057807094,0.00002031143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973209,0.00077528943,0.0004756796,0.00046212994,0.0003749043,0.00059109094],"domain_scores_gemma":[0.9981653,0.0002982569,0.00053413154,0.0006087972,0.00021839835,0.00017512035],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005564214,0.00038341052,0.0006700498,0.00020161907,0.00014914747,0.000022935086,0.00025377463,0.000049191825,0.00039040417],"category_scores_gemma":[0.000022594571,0.00027675438,0.00002466845,0.00048699797,0.00033445132,0.0012195886,0.00003433356,0.0004911606,0.000004327729],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006943347,0.0062993183,0.6720209,0.000023310758,0.00017649675,0.00004982068,0.016407961,0.00025743095,0.00017256368,0.000010378328,2.4011436e-7,0.2976382],"study_design_scores_gemma":[0.012300286,0.019155232,0.9513284,0.00017775231,0.000044132874,0.00007294109,0.011714633,0.0000790237,0.00011512689,0.00032769146,0.004404585,0.00028022102],"about_ca_topic_score_codex":0.0058408617,"about_ca_topic_score_gemma":0.07452022,"teacher_disagreement_score":0.297358,"about_ca_system_score_codex":0.0021534378,"about_ca_system_score_gemma":0.00048414068,"threshold_uncertainty_score":0.99996847},"labels":[],"label_agreement":null},{"id":"W2790928047","doi":"10.1158/1538-7445.sabcs17-p3-15-02","title":"Abstract P3-15-02: Treat ER+ight Canadian prospective observational study in HR+ advanced breast cancer: <i>2nd interim analysis</i>","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada); Windsor Regional Hospital; Cambridge Memorial Hospital; BC Cancer Agency; Ottawa Hospital; Hôpital du Sacré-Cœur de Montréal; Grand River Hospital","funders":"","keywords":"Medicine; Palbociclib; Exemestane; Letrozole; Fulvestrant; Interim analysis; Internal medicine; Breast cancer; Oncology; Cancer; Metastatic breast cancer; Tamoxifen; Clinical trial","score_opus":0.13054642356143598,"score_gpt":0.4649339112295577,"score_spread":0.3343874876681217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790928047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861146,0.001846538,0.000018693563,0.004960457,0.00027061338,0.00227553,0.0005575155,0.000071366674,0.0038846426],"genre_scores_gemma":[0.99333644,0.00021012218,0.00013883576,0.0004998616,0.0009798927,0.00196205,0.000059886075,0.00008625865,0.0027266396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99553025,0.0001684361,0.0005771667,0.0011210358,0.0012423493,0.0013607797],"domain_scores_gemma":[0.99647796,0.00012848307,0.00012911245,0.00082680886,0.0017326925,0.00070495135],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00080329966,0.00039685974,0.00079627516,0.0014785015,0.00038687483,0.000085480766,0.0004858081,0.00014992716,0.0057959496],"category_scores_gemma":[0.00009095068,0.00035769626,0.0001576414,0.0042674798,0.0006529276,0.00047019223,0.000122019475,0.0009977359,0.000081867795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044689137,0.0006096984,0.92421967,0.00008916222,0.0011370544,0.0002227163,0.0033807706,0.0002672606,0.011876375,0.00010301812,0.0008198918,0.052805483],"study_design_scores_gemma":[0.0038323808,0.0006092806,0.98130125,0.00028327986,0.00016444719,0.000018820261,0.0019790023,0.000083507155,0.003265791,0.00020886536,0.007902461,0.00035089932],"about_ca_topic_score_codex":0.30932143,"about_ca_topic_score_gemma":0.8237663,"teacher_disagreement_score":0.5144449,"about_ca_system_score_codex":0.0058529885,"about_ca_system_score_gemma":0.0034095363,"threshold_uncertainty_score":0.9998875},"labels":[],"label_agreement":null},{"id":"W2791378653","doi":"10.1158/1538-7445.sabcs17-p5-20-15","title":"Abstract P5-20-15: Dosing patterns and economic burden of drug wastage among postmenopausal women with HR+/HER2- metastatic breast cancer receiving palbociclib","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Palbociclib; Medicine; Dosing; Metastatic breast cancer; Breast cancer; Cancer; Adverse effect; Regimen; Internal medicine; Oncology","score_opus":0.030252377590410134,"score_gpt":0.3630037483925001,"score_spread":0.33275137080208994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791378653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950953,0.001366652,0.0000310341,0.0015586611,0.00014173205,0.00077755534,0.0006131034,0.000054250933,0.0003616812],"genre_scores_gemma":[0.99667424,0.0006499456,0.00025403628,0.00009476406,0.00084860425,0.00040329123,0.000013313218,0.00012630493,0.0009354903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969538,0.00013850135,0.00044754584,0.00070679677,0.00067471585,0.0010786486],"domain_scores_gemma":[0.99809223,0.00023254001,0.00022733392,0.000554059,0.00045959858,0.00043424085],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00091549894,0.00032946252,0.0006486151,0.00033072746,0.00024282583,0.00008114941,0.00027295866,0.00007177756,0.0032356132],"category_scores_gemma":[0.000024241443,0.00026922638,0.000040047606,0.0003301661,0.0011880064,0.0004324569,0.0001701641,0.0006127868,0.000018706805],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013250622,0.00029418108,0.49965152,0.0030966634,0.0021903366,0.0002524697,0.04174731,0.00061592076,0.24370559,0.000059203554,0.0006098101,0.19452639],"study_design_scores_gemma":[0.006848712,0.0012876724,0.9368247,0.0039628525,0.00015334663,0.00017523782,0.013608749,0.00021815965,0.03361671,0.0002299421,0.0023626664,0.0007112702],"about_ca_topic_score_codex":0.017330876,"about_ca_topic_score_gemma":0.005760132,"teacher_disagreement_score":0.43717316,"about_ca_system_score_codex":0.0014068485,"about_ca_system_score_gemma":0.0008111513,"threshold_uncertainty_score":0.999976},"labels":[],"label_agreement":null},{"id":"W2791439302","doi":"10.1158/1538-7445.sabcs17-p3-07-08","title":"Abstract P3-07-08: Temozolomide as a targeted therapy strategy for triple negative breast cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Temozolomide; Breast cancer; Triple-negative breast cancer; O-6-methylguanine-DNA methyltransferase; Cancer research; Methyltransferase; Medicine; Population; Cancer; Synthetic lethality; Oncology; DNA methylation; Chemotherapy; Methylation; DNA repair; Internal medicine; Biology; Gene; Gene expression; Genetics","score_opus":0.11708995324075429,"score_gpt":0.46327633522660916,"score_spread":0.3461863819858549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791439302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9690984,0.010711406,0.00024326518,0.0097277835,0.0007570316,0.004422969,0.0010345136,0.00022812861,0.0037765007],"genre_scores_gemma":[0.9836129,0.0018578861,0.00044860394,0.0009533494,0.003192093,0.0029908344,0.000033756543,0.00014905276,0.0067615225],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963728,0.00012134999,0.0004217083,0.0008326348,0.00094005326,0.0013114376],"domain_scores_gemma":[0.9962451,0.00034170868,0.00014813982,0.00064197124,0.002173196,0.00044989813],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007793408,0.00036068316,0.00057739206,0.00031632322,0.00048264145,0.00008436392,0.0004058825,0.00021113749,0.012499688],"category_scores_gemma":[0.00016263168,0.0002939396,0.00018051943,0.00084270904,0.0010414193,0.00032459645,0.00007091085,0.0007460173,0.0003417477],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034947447,0.00040015916,0.002350436,0.00028854463,0.0009131897,0.000048766484,0.0024233703,0.000062811385,0.341118,0.00039401386,0.021350695,0.5957025],"study_design_scores_gemma":[0.030755423,0.005039443,0.15427864,0.0013011076,0.000101044425,0.00018095445,0.004344782,0.0003169241,0.5981532,0.013083319,0.1911375,0.0013076717],"about_ca_topic_score_codex":0.0062973336,"about_ca_topic_score_gemma":0.0011316336,"teacher_disagreement_score":0.59439486,"about_ca_system_score_codex":0.0010861611,"about_ca_system_score_gemma":0.0025352933,"threshold_uncertainty_score":0.9999513},"labels":[],"label_agreement":null},{"id":"W2791840917","doi":"10.1093/annonc/mdy012","title":"Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Pfizer","keywords":"Letrozole; Medicine; Palbociclib; Quality of life (healthcare); Breast cancer; Internal medicine; Metastatic breast cancer; Oncology; Placebo; Gynecology; Cancer; Tamoxifen","score_opus":0.20865205586815688,"score_gpt":0.47838773484195324,"score_spread":0.26973567897379636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791840917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98895216,0.0007303304,0.000017215383,0.007543191,0.0003710347,0.00071976206,0.00037336678,0.00002406064,0.0012688758],"genre_scores_gemma":[0.99783486,0.00008854597,0.00017357415,0.0014735014,0.00027327528,0.000012331269,0.00008898679,0.000019860687,0.0000350877],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99650645,0.00057509076,0.0019380964,0.00029052875,0.00037641358,0.00031342244],"domain_scores_gemma":[0.9945548,0.0012502773,0.0026855615,0.00072024914,0.0006350526,0.00015401498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011197617,0.00017602537,0.0012184251,0.00008383189,0.00004937645,0.0000015220354,0.00016251377,0.0001986275,0.00016181973],"category_scores_gemma":[0.0023051593,0.000114097755,0.00031558413,0.00028437574,0.0006398166,0.00004664585,0.00004947964,0.00023956738,0.0000069414855],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7630915,0.0022885134,0.010296394,0.00005512231,0.0023482782,0.000014641993,0.009777103,0.000089233785,0.010344913,0.00017175624,0.00960608,0.19191645],"study_design_scores_gemma":[0.1866594,0.09808912,0.69042104,0.00034472888,0.00011831466,0.000015685035,0.0010478346,0.000040663697,0.012251964,0.0019897446,0.008766989,0.00025452],"about_ca_topic_score_codex":0.0093646515,"about_ca_topic_score_gemma":0.00026880298,"teacher_disagreement_score":0.68012464,"about_ca_system_score_codex":0.00012188323,"about_ca_system_score_gemma":0.0013824047,"threshold_uncertainty_score":0.9972321},"labels":[],"label_agreement":null},{"id":"W2792282698","doi":"10.1158/1538-7445.sabcs17-p5-21-03","title":"Abstract P5-21-03: Palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Efficacy and safety updates with longer follow-up across patient subgroups","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; BC Cancer Agency","funders":"","keywords":"Palbociclib; Medicine; Internal medicine; Population; Progression-free survival; Breast cancer; Estrogen receptor; Metastatic breast cancer; Letrozole; Clinical endpoint; Cancer; Gynecology; Gastroenterology; Oncology; Randomized controlled trial; Overall survival; Tamoxifen","score_opus":0.032542310586138413,"score_gpt":0.3694373333917152,"score_spread":0.33689502280557676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792282698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98542374,0.00457476,0.000030195986,0.0045589185,0.0003404313,0.0030677058,0.0015757872,0.00014518536,0.00028327174],"genre_scores_gemma":[0.9909325,0.0046517346,0.00041659668,0.00061461877,0.001042936,0.0012948088,0.0002049803,0.0002627839,0.00057901896],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99333334,0.00038021128,0.00091565517,0.0016846902,0.0015619814,0.002124111],"domain_scores_gemma":[0.99530363,0.0007230273,0.00040196086,0.0008222758,0.0019750344,0.0007740977],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00069781236,0.00087498594,0.0011938978,0.00036808194,0.0010184398,0.00014799993,0.0005119735,0.0003360303,0.0048482637],"category_scores_gemma":[0.00020209358,0.0006998837,0.00017516504,0.0013652913,0.0023250058,0.000841472,0.00028616085,0.001610183,0.00015548266],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11987945,0.0017258947,0.19546431,0.000540608,0.0021767567,0.00022823867,0.041782975,0.000138982,0.16463552,0.00021345213,0.0012251819,0.47198862],"study_design_scores_gemma":[0.037744362,0.0066158753,0.66030604,0.002827488,0.000063307365,0.000092914706,0.0043964195,0.000018870769,0.27423763,0.00027494412,0.011873296,0.0015488492],"about_ca_topic_score_codex":0.006925947,"about_ca_topic_score_gemma":0.0039391466,"teacher_disagreement_score":0.47043976,"about_ca_system_score_codex":0.002193628,"about_ca_system_score_gemma":0.00076766853,"threshold_uncertainty_score":0.999687},"labels":[],"label_agreement":null},{"id":"W2792709310","doi":"10.1158/1538-7445.sabcs17-p2-09-10","title":"Abstract P2-09-10: Comprehensive gene expression biomarker analysis of CDK 4/6 and endocrine pathways from the PALOMA-2 study","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Palbociclib; Biomarker; Internal medicine; Cyclin-dependent kinase; Oncology; Cancer; Medicine; Letrozole; Gene expression; Cancer research; Biology; Gene; Breast cancer; Cell cycle; Metastatic breast cancer; Genetics","score_opus":0.16357835949288654,"score_gpt":0.4464824614363966,"score_spread":0.28290410194351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792709310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991542,0.0064306785,0.00005636231,0.0004949097,0.00007952829,0.0007822442,0.00023939053,0.0000289635,0.00034594414],"genre_scores_gemma":[0.9984945,0.00039400253,0.00024358623,0.0000913603,0.00036109856,0.00016793697,0.000040383482,0.000032912256,0.00017421426],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9975461,0.00022180927,0.0003381852,0.0005346266,0.0009132777,0.00044603314],"domain_scores_gemma":[0.99726576,0.00062598864,0.000116544004,0.0008533265,0.0009666858,0.00017167364],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040744516,0.00018926643,0.0005208577,0.0003183708,0.00024552262,0.000029155432,0.00026926261,0.000055172804,0.002297647],"category_scores_gemma":[0.000104043356,0.000120813434,0.00010247701,0.0011910415,0.0008176706,0.000090210415,0.00026719074,0.0003180536,0.000021200856],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023324792,0.00026012104,0.065214835,0.000035187506,0.0018912404,0.000057178666,0.002715105,0.000009198168,0.8846685,0.0000068663953,0.00072349806,0.042085737],"study_design_scores_gemma":[0.0022532416,0.00040029237,0.8372033,0.00013490683,0.0003555641,0.0000036915035,0.0037029702,0.000067683446,0.1507226,0.00011249066,0.0049205674,0.00012266637],"about_ca_topic_score_codex":0.0033699367,"about_ca_topic_score_gemma":0.00055159273,"teacher_disagreement_score":0.7719885,"about_ca_system_score_codex":0.00014041107,"about_ca_system_score_gemma":0.00016770768,"threshold_uncertainty_score":0.9986144},"labels":[],"label_agreement":null},{"id":"W2793113650","doi":"10.1016/j.breast.2018.02.027","title":"Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer","year":2018,"lang":"en","type":"article","venue":"The Breast","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Hôpital Charles-Le Moyne; Université de Sherbrooke","funders":"European Society for Medical Oncology; Pfizer","keywords":"Medicine; Palbociclib; Metastatic breast cancer; Oncology; Internal medicine; Breast cancer; Hormone receptor; Endocrine system; Hazard ratio; Population; Cancer; Gynecology; Hormone; Confidence interval","score_opus":0.02977192552836007,"score_gpt":0.32005924517608986,"score_spread":0.2902873196477298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793113650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881784,0.0012760721,0.00004628848,0.007372625,0.00012061888,0.0021253054,0.0005081773,0.0002204363,0.00015212057],"genre_scores_gemma":[0.9940368,0.00047333864,0.0031149464,0.0008754068,0.00023432645,0.00056905067,0.00004544403,0.00009100414,0.00055970263],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99771935,0.00029089398,0.00044707002,0.00055186136,0.00040861467,0.0005822276],"domain_scores_gemma":[0.99847144,0.0002200084,0.00023477124,0.00046741412,0.00037506875,0.00023129837],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002381084,0.00044811674,0.0006418603,0.000148575,0.00020975443,0.000073155905,0.00018331467,0.00006166001,0.0002805695],"category_scores_gemma":[0.000029398456,0.00027744897,0.00008165856,0.00073636963,0.0010539086,0.0003732956,0.00008985537,0.00042115175,0.000026228758],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045639273,0.002866199,0.122770116,0.00012774717,0.0019412616,0.00018830544,0.0153914085,0.000047492602,0.04088756,0.00066753215,0.0008714989,0.7686016],"study_design_scores_gemma":[0.009939946,0.0010637274,0.9770486,0.00070796633,0.0001254041,0.002213112,0.0008566384,0.00067213847,0.0052960464,0.0004905947,0.0011657579,0.00042010026],"about_ca_topic_score_codex":0.004076275,"about_ca_topic_score_gemma":0.00063407375,"teacher_disagreement_score":0.85427845,"about_ca_system_score_codex":0.0002333187,"about_ca_system_score_gemma":0.00015567514,"threshold_uncertainty_score":0.99996775},"labels":[],"label_agreement":null},{"id":"W2793303753","doi":"10.1158/1538-7445.sabcs17-p4-12-08","title":"Abstract P4-12-08: Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Palbociclib; Letrozole; Statistics; Breast cancer; Cost effectiveness; Medicine; Oncology; Econometrics; Mathematics; Cancer; Internal medicine; Metastatic breast cancer; Aromatase","score_opus":0.05739803345899822,"score_gpt":0.4316350572997205,"score_spread":0.37423702384072227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793303753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98256034,0.005571507,0.0001755796,0.006286653,0.0002278478,0.0018561289,0.0010867092,0.000120568904,0.0021146857],"genre_scores_gemma":[0.993681,0.0021716258,0.00031181853,0.00042149826,0.00090250844,0.0013947912,0.000087276465,0.00008391932,0.0009455385],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99515957,0.0002548955,0.0006093082,0.0011553396,0.0013364765,0.0014844323],"domain_scores_gemma":[0.9965099,0.0002901403,0.00016757674,0.0009704153,0.0014961051,0.0005658826],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012338152,0.0003918554,0.00091681164,0.0009347317,0.0003117424,0.000059229737,0.0004445025,0.00023101011,0.005910557],"category_scores_gemma":[0.00015628153,0.0003589956,0.00025443477,0.003758089,0.0012346182,0.00040666203,0.00019041322,0.001268068,0.00019334337],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023120316,0.0007306808,0.13925779,0.00020817814,0.001994706,0.00012412503,0.0031587621,0.00015636586,0.2642487,0.00008388023,0.0021114836,0.56480503],"study_design_scores_gemma":[0.0052558244,0.00036653705,0.954506,0.0004359354,0.00019137752,0.000016864558,0.00088365783,0.0002495651,0.025679464,0.00018195066,0.011796863,0.00043596394],"about_ca_topic_score_codex":0.0073467963,"about_ca_topic_score_gemma":0.008172477,"teacher_disagreement_score":0.8152482,"about_ca_system_score_codex":0.0023845625,"about_ca_system_score_gemma":0.0011118527,"threshold_uncertainty_score":0.9998862},"labels":[],"label_agreement":null},{"id":"W2793879924","doi":"10.1158/1538-7445.sabcs17-p3-12-04","title":"Abstract P3-12-04: Efficacy of extended adjuvant aromatase inhibitors in subgroups of women with early breast cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Letrozole; Internal medicine; Breast cancer; Oncology; Anastrozole; Tamoxifen; Hazard ratio; Exemestane; Aminoglutethimide; Gynecology; Cancer; Aromatase; Confidence interval","score_opus":0.036412960105669766,"score_gpt":0.3754610829437527,"score_spread":0.33904812283808294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793879924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961284,0.0016836341,0.000008874661,0.0005824681,0.00011125345,0.0008462607,0.0002857971,0.000031906544,0.00032140687],"genre_scores_gemma":[0.99842113,0.00023310394,0.00014267018,0.00004795636,0.000489818,0.00041586353,0.000009874653,0.00007403664,0.00016556634],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99656725,0.00010328935,0.0005444458,0.00054188643,0.0011912298,0.0010519138],"domain_scores_gemma":[0.9977507,0.0001786634,0.00020764502,0.0007039514,0.00079250784,0.00036651638],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009063332,0.0002512821,0.00070064573,0.0005447982,0.00007134873,0.000013953975,0.0003152117,0.0001203785,0.0014959933],"category_scores_gemma":[0.00007411373,0.00019617996,0.000060846232,0.0011058154,0.0014098586,0.00022438739,0.000111309215,0.00061239727,0.000016777365],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049909238,0.0014113615,0.15608585,0.0013260902,0.00048688368,0.00019472039,0.012499164,0.000077809076,0.49543992,0.00010257383,0.0005250627,0.28194135],"study_design_scores_gemma":[0.006357614,0.0012855962,0.8913106,0.0019658285,0.00002048402,0.000031247713,0.0011142418,0.00000769059,0.0965786,0.00013017569,0.0009905932,0.00020736172],"about_ca_topic_score_codex":0.008631103,"about_ca_topic_score_gemma":0.0019695035,"teacher_disagreement_score":0.7352247,"about_ca_system_score_codex":0.0013803721,"about_ca_system_score_gemma":0.0012870096,"threshold_uncertainty_score":0.99941677},"labels":[],"label_agreement":null},{"id":"W2794034349","doi":"10.1097/cad.0000000000000589","title":"Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer","year":2018,"lang":"en","type":"article","venue":"Anti-Cancer Drugs","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Pfizer","keywords":"Palbociclib; Letrozole; Medicine; QT interval; Placebo; Breast cancer; Dosing; Internal medicine; Anesthesia; Cardiology; Metastatic breast cancer; Cancer; Aromatase","score_opus":0.011148312293442708,"score_gpt":0.2969571145477851,"score_spread":0.2858088022543424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794034349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98971677,0.00024974372,0.000030144496,0.00657366,0.00082655344,0.0012860192,0.0001219217,0.00011580779,0.0010793727],"genre_scores_gemma":[0.99166965,0.00020405576,0.00023239286,0.00589342,0.00085728744,0.00037705005,0.000018680024,0.00011685358,0.0006306297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99705786,0.00016622567,0.00060535595,0.00077777175,0.0006781246,0.0007146837],"domain_scores_gemma":[0.99782765,0.00035352423,0.0003338466,0.00082712126,0.00048042682,0.00017743271],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041634933,0.00047840708,0.00077956996,0.00011764595,0.00019686586,0.000044079825,0.0003576662,0.00013471064,0.0009499173],"category_scores_gemma":[0.00009548712,0.00027739588,0.00016263242,0.00048710406,0.0007804992,0.0002420727,0.00010303826,0.0006472432,0.0002588575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021319052,0.0005854408,0.71183366,0.00013629877,0.00036834934,0.000013210312,0.0013431718,0.000037645346,0.0014166278,0.000051828873,0.0010144014,0.26188034],"study_design_scores_gemma":[0.017593395,0.0050704014,0.9452544,0.0031541095,0.00015871364,0.00000770648,0.00016195286,0.000102797756,0.004946396,0.000058996913,0.022865187,0.00062598294],"about_ca_topic_score_codex":0.00037955982,"about_ca_topic_score_gemma":0.00020454943,"teacher_disagreement_score":0.26125434,"about_ca_system_score_codex":0.00039095464,"about_ca_system_score_gemma":0.00028554664,"threshold_uncertainty_score":0.9999678},"labels":[],"label_agreement":null},{"id":"W2794108628","doi":"10.1158/1538-7445.sabcs17-ot3-05-03","title":"Abstract OT3-05-03: POLARIS: Palbociclib (P) in hormone receptor-positive (HR+) advanced breast cancer: A prospective multicenter noninterventional study","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Tolerability; Oncology; Population; Palbociclib; Cancer; Clinical trial; Metastatic breast cancer; Gynecology; Adverse effect","score_opus":0.03918688413333515,"score_gpt":0.42678278171469725,"score_spread":0.3875958975813621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794108628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985454,0.0050070677,0.00003537925,0.0034769818,0.0004687288,0.0036916533,0.0005796696,0.00011093292,0.0011755407],"genre_scores_gemma":[0.99358815,0.00044651603,0.00030533248,0.00022275123,0.0012923564,0.0024779441,0.000030429619,0.00012492633,0.0015115865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951447,0.00027607023,0.0006636622,0.0011746653,0.0014502193,0.0012906347],"domain_scores_gemma":[0.99673474,0.00015844437,0.00019106473,0.0006323466,0.0018912628,0.00039212353],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010360575,0.00042945644,0.0006769784,0.0005701129,0.00034772273,0.00008206369,0.00042665107,0.00017097195,0.00275381],"category_scores_gemma":[0.0001240644,0.00038961763,0.00018323793,0.001305244,0.00087338674,0.00056550174,0.0002680137,0.001492909,0.00028496273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045726188,0.0057747466,0.6158477,0.0002850836,0.0013774034,0.00034243774,0.014912729,0.00003552816,0.15697381,0.00013216987,0.0023848428,0.15620732],"study_design_scores_gemma":[0.014742723,0.002095862,0.9620239,0.0013938653,0.00004793368,0.000037476093,0.005426253,0.000030365507,0.011185809,0.00015621749,0.0024405366,0.00041901562],"about_ca_topic_score_codex":0.004196627,"about_ca_topic_score_gemma":0.004200084,"teacher_disagreement_score":0.3461762,"about_ca_system_score_codex":0.003255925,"about_ca_system_score_gemma":0.0008144802,"threshold_uncertainty_score":0.9998556},"labels":[],"label_agreement":null},{"id":"W2794342932","doi":"10.1158/1538-7445.sabcs17-pd3-12","title":"Abstract PD3-12: <i>PIK3CA</i> alterations and benefit with neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: Correlative analyses of the phase III ExteNET trial","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Neratinib; Medicine; Trastuzumab; Breast cancer; Oncology; Internal medicine; Clinical endpoint; Placebo; Population; Cancer; Randomized controlled trial; Pathology","score_opus":0.09401084786466163,"score_gpt":0.4463718082474957,"score_spread":0.3523609603828341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794342932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99221057,0.0032485179,0.00012676627,0.0014017787,0.0001544727,0.0020381613,0.0005887647,0.000023305733,0.00020767],"genre_scores_gemma":[0.9961899,0.0007632466,0.00011507071,0.00033225227,0.00058264786,0.0013315191,0.000015488546,0.00006019349,0.00060969044],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9972838,0.00015235471,0.000501354,0.0005783929,0.00088728045,0.0005968039],"domain_scores_gemma":[0.9980415,0.00023906541,0.0001977135,0.0005989011,0.0007208684,0.00020193688],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00046561292,0.00030134874,0.0005900761,0.00027700816,0.00025626906,0.000059948714,0.00023043183,0.00010932637,0.0011031972],"category_scores_gemma":[0.00002580715,0.00018771131,0.00009992154,0.0008598555,0.0013121538,0.0002486539,0.000051780666,0.0006788119,0.0000026386708],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59339654,0.0023810435,0.09149704,0.00025002446,0.00093109545,0.00011352913,0.011167898,0.0021125306,0.13156705,0.000116860836,0.00031274685,0.16615361],"study_design_scores_gemma":[0.2425966,0.007292726,0.6149693,0.0021912586,0.00015328643,0.000031057047,0.0011005885,0.0011033945,0.126846,0.00019561099,0.0028641662,0.0006560261],"about_ca_topic_score_codex":0.0095669525,"about_ca_topic_score_gemma":0.009696918,"teacher_disagreement_score":0.52347225,"about_ca_system_score_codex":0.00039632656,"about_ca_system_score_gemma":0.0011353584,"threshold_uncertainty_score":0.9998099},"labels":[],"label_agreement":null},{"id":"W2798042703","doi":"10.1007/s10549-018-4769-z","title":"Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2","year":2018,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Novartis Institutes for BioMedical Research; Astex Pharmaceuticals; Novartis Pharmaceuticals Corporation","keywords":"Letrozole; Medicine; Breast cancer; Internal medicine; Quality of life (healthcare); Placebo; Oncology; Cancer; Gynecology; Tamoxifen; Pathology","score_opus":0.04369723222632609,"score_gpt":0.35752007979006534,"score_spread":0.31382284756373924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2798042703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96076685,0.0030071284,0.000011285446,0.0055495007,0.000036550075,0.0019632918,0.028387142,0.00008716918,0.00019106058],"genre_scores_gemma":[0.99505913,0.0018338662,0.0007865796,0.00009954956,0.0002683534,0.00082115096,0.0005018841,0.00012007847,0.0005094138],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99437726,0.0006046666,0.0012006185,0.0012101217,0.0013196543,0.0012876703],"domain_scores_gemma":[0.9945971,0.00047211102,0.00093587994,0.00067310187,0.002241488,0.001080327],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043291118,0.0006944181,0.0018035079,0.0003537786,0.0004336368,0.00002958878,0.00021356184,0.00017501124,0.00083828444],"category_scores_gemma":[0.000051827992,0.00046917598,0.00008435336,0.0010884125,0.0022087789,0.00038264898,0.000097643715,0.00045573225,0.0000103628245],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5038301,0.0044635558,0.16225286,0.00034935764,0.008691511,0.000055557983,0.010257141,0.000022406948,0.14267428,0.000154016,0.00028012687,0.16696912],"study_design_scores_gemma":[0.034497175,0.018199015,0.9151814,0.0009948385,0.00009049653,0.00006360989,0.0015254251,0.000005507058,0.028799728,0.000086432156,0.000105933934,0.00045046763],"about_ca_topic_score_codex":0.10572122,"about_ca_topic_score_gemma":0.0041860417,"teacher_disagreement_score":0.7529285,"about_ca_system_score_codex":0.0026967924,"about_ca_system_score_gemma":0.0016536424,"threshold_uncertainty_score":0.999776},"labels":[],"label_agreement":null},{"id":"W2800064122","doi":"10.2147/bctt.s162841","title":"Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2&amp;ndash; metastatic breast cancer","year":2018,"lang":"en","type":"article","venue":"Breast Cancer Targets and Therapy","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"European Society for Medical Oncology","keywords":"Medicine; Internal medicine; Oncology; Progression-free survival; Breast cancer; Metastatic breast cancer; Surgical oncology; Univariate analysis; Chemotherapy; Cancer; Multivariate analysis","score_opus":0.019619746385943236,"score_gpt":0.34409609196033636,"score_spread":0.32447634557439314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800064122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9166056,0.02758124,0.0014564967,0.04038302,0.0023944392,0.0070269867,0.0036038358,0.00047559376,0.00047281853],"genre_scores_gemma":[0.96671087,0.0043704207,0.010808546,0.004757958,0.004615893,0.004430783,0.00020091631,0.0005439519,0.0035606397],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9958261,0.00018260007,0.0006744507,0.0011623414,0.00093730964,0.0012171606],"domain_scores_gemma":[0.99748033,0.00010477083,0.00031975404,0.00075288897,0.00072189927,0.000620346],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006597387,0.0007495466,0.0011554576,0.0003004104,0.00033426684,0.00011344293,0.00039607362,0.00018167542,0.0032275093],"category_scores_gemma":[0.000035434587,0.00057040696,0.00023158884,0.00053189165,0.00038591266,0.00039530714,0.00017876661,0.00031649022,0.000060473023],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03221702,0.0010209316,0.018705662,0.00028067516,0.0007809425,0.000058220943,0.0013246848,0.000053560736,0.026757471,0.00012957866,0.000933313,0.91773796],"study_design_scores_gemma":[0.072107196,0.003969986,0.6126287,0.005813252,0.0005348212,0.0015368074,0.0004408966,0.0011081313,0.007802419,0.0068312185,0.2836801,0.0035464633],"about_ca_topic_score_codex":0.0018905484,"about_ca_topic_score_gemma":0.0009052662,"teacher_disagreement_score":0.9141915,"about_ca_system_score_codex":0.0003506285,"about_ca_system_score_gemma":0.00060510146,"threshold_uncertainty_score":0.99967474},"labels":[],"label_agreement":null},{"id":"W2800306828","doi":"10.2147/cmar.s162714","title":"Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2&amp;minus; metastatic breast cancer?","year":2018,"lang":"en","type":"article","venue":"Cancer Management and Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"European Society for Medical Oncology","keywords":"Medicine; Metastatic breast cancer; Internal medicine; Oncology; Progression-free survival; Hazard ratio; Clinical endpoint; Breast cancer; Cancer; Observational study; Randomized controlled trial; Quality of life (healthcare); Chemotherapy; Confidence interval","score_opus":0.09342696169412701,"score_gpt":0.42938135925798293,"score_spread":0.3359543975638559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800306828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89229256,0.017325517,0.00075534906,0.0771761,0.0014504887,0.0046191956,0.0006359024,0.00022815945,0.005516742],"genre_scores_gemma":[0.95396125,0.015487886,0.0025692862,0.0008089445,0.0017123102,0.0016289604,0.00006112376,0.0001738062,0.023596458],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99542844,0.00020407312,0.0004940477,0.00095857645,0.0017334234,0.001181418],"domain_scores_gemma":[0.9978943,0.00016375807,0.00012349196,0.0009840584,0.00047653491,0.00035788288],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014002213,0.0004000786,0.00065347593,0.0005814801,0.00032967806,0.00009273484,0.000488827,0.000098493285,0.0015132375],"category_scores_gemma":[0.000057375863,0.00030831108,0.000108805776,0.0009923371,0.0008813149,0.00023594529,0.0007922411,0.00064572075,0.000036320682],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018978443,0.0016816827,0.26077873,0.006371411,0.002584489,0.0011122916,0.010810448,0.000113332055,0.0011776374,0.0031830177,0.018345105,0.6748634],"study_design_scores_gemma":[0.017488146,0.0009268698,0.6985187,0.0043390333,0.0003071595,0.000065458305,0.003243999,0.0012652463,0.0008961385,0.0061309934,0.26580456,0.0010137099],"about_ca_topic_score_codex":0.0026541052,"about_ca_topic_score_gemma":0.0066420506,"teacher_disagreement_score":0.6738497,"about_ca_system_score_codex":0.000683955,"about_ca_system_score_gemma":0.0002237395,"threshold_uncertainty_score":0.9999369},"labels":[],"label_agreement":null},{"id":"W2804105316","doi":"10.1016/s1470-2045(18)30292-4","title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1011,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Astex Pharmaceuticals; Novartis","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Hormone receptor; Endocrine system; Hormone therapy; Gynecology; Cancer; Hormone","score_opus":0.03244725651231038,"score_gpt":0.37153790821677674,"score_spread":0.33909065170446634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804105316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97346145,0.0015196329,0.0019472756,0.013647632,0.00068910193,0.0068775667,0.0005947945,0.00023187489,0.0010306442],"genre_scores_gemma":[0.9709054,0.0009339511,0.0040883077,0.0053974106,0.008384014,0.008894483,0.00008738841,0.00013810645,0.0011709216],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99719924,0.00025978073,0.00048521534,0.0005944814,0.00035137596,0.0011099178],"domain_scores_gemma":[0.9977175,0.0005559595,0.00039516098,0.00062710536,0.0004687953,0.00023548215],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006434701,0.0004429968,0.0014350833,0.00008500854,0.00029959783,0.000023697841,0.00038420217,0.00012429779,0.00073072256],"category_scores_gemma":[0.000058295213,0.00026549594,0.00010939832,0.0002980472,0.000845491,0.00017937215,0.00005855953,0.00036739043,0.000025171805],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78637385,0.00059524464,0.000034802553,0.000027036938,0.000775877,0.000017088369,0.0016092253,0.000018225448,0.06990329,0.00012868957,0.0014614916,0.13905516],"study_design_scores_gemma":[0.751824,0.026331494,0.0011577785,0.0000683643,0.0001533673,0.00025642593,0.00031961038,0.000091082424,0.00536067,0.00025483992,0.2138532,0.00032915318],"about_ca_topic_score_codex":0.000055663295,"about_ca_topic_score_gemma":0.00006673896,"teacher_disagreement_score":0.2123917,"about_ca_system_score_codex":0.0011012761,"about_ca_system_score_gemma":0.0008761207,"threshold_uncertainty_score":0.99997973},"labels":[],"label_agreement":null},{"id":"W2804378061","doi":"10.1158/1078-0432.ccr-18-0613","title":"Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Genentech","keywords":"Fulvestrant; Breast cancer; Cancer; Medicine; Internal medicine; Oncology; Hormone receptor; Phases of clinical research; Hormone; Metastatic breast cancer; Toxicity; Estrogen receptor","score_opus":0.06313931023451126,"score_gpt":0.4699763740301713,"score_spread":0.40683706379566004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804378061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946063,0.0002791872,0.000026658292,0.0012595656,0.00010767035,0.0033023236,0.00026857198,0.000027271635,0.00012244718],"genre_scores_gemma":[0.99807674,0.00023415161,0.00040502351,0.000119059085,0.00018328287,0.0007289858,0.000038765134,0.000070357055,0.00014363784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952964,0.00064403086,0.00094886986,0.00089403463,0.0014825922,0.0007340545],"domain_scores_gemma":[0.9960667,0.0005037224,0.00030247789,0.0005637462,0.0022746082,0.00028874693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013350891,0.00031116934,0.0009033605,0.0004294661,0.0001590629,0.000015788068,0.00028221466,0.00014699694,0.0003376637],"category_scores_gemma":[0.00021780406,0.00022901324,0.000051747527,0.0020155532,0.0014472777,0.0003595022,0.00013298423,0.0012114606,0.000006302949],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15315293,0.031115556,0.62847304,0.00008868419,0.0003267944,0.000041084768,0.004075808,0.00006818168,0.00060131965,0.00001706926,0.00014374571,0.1818958],"study_design_scores_gemma":[0.0948814,0.0651626,0.83507276,0.0011496327,0.000048259335,0.0000020555588,0.0021188206,0.000046374116,0.0010119313,0.00005936733,0.00019122503,0.0002555989],"about_ca_topic_score_codex":0.0046783807,"about_ca_topic_score_gemma":0.009776035,"teacher_disagreement_score":0.20659971,"about_ca_system_score_codex":0.0007832727,"about_ca_system_score_gemma":0.0008360128,"threshold_uncertainty_score":0.93388885},"labels":[],"label_agreement":null},{"id":"W2805079852","doi":"10.1200/jco.2018.36.15_suppl.1023","title":"Treatment effect of palbociclib (PAL) plus endocrine therapy (ET) by prognostic and intrinsic subtype: A joint analysis of PALOMA2 and PALOMA3.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Oncology; Palbociclib; Fulvestrant; Letrozole; Adjuvant; Progression-free survival; Overall survival; Cancer; Gynecology; Metastatic breast cancer; Tamoxifen","score_opus":0.068602060323931,"score_gpt":0.4536442761604686,"score_spread":0.3850422158365376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805079852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913188,0.00623949,0.00015585673,0.001636641,0.00017294247,0.00034984524,0.000011719292,0.0000067446376,0.00010794795],"genre_scores_gemma":[0.99203527,0.0060404525,0.0012123921,0.0003471147,0.000290107,0.000008365645,0.000004269031,0.000017387943,0.00004461614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969433,0.00057264516,0.0017888946,0.00022573816,0.0002653556,0.00020407567],"domain_scores_gemma":[0.9939011,0.0033795869,0.0018612377,0.00021075869,0.00038626156,0.00026106028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013102927,0.00020697116,0.002828447,0.00026286684,0.000024764333,0.0000044416965,0.00007409764,0.00016541254,0.00006901183],"category_scores_gemma":[0.00143637,0.00011943168,0.0004378214,0.0003302376,0.00077119813,0.00006801655,0.000039166236,0.00030632224,8.092849e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016219726,0.00079686684,0.48675108,0.00005496025,0.0052512214,0.00012897965,0.0003781864,0.0000027892206,0.004243119,0.000035965044,0.000046907564,0.4860902],"study_design_scores_gemma":[0.031759817,0.11103984,0.83631593,0.0001304514,0.004184593,0.00045124075,0.00008888541,0.00015987914,0.0061611785,0.00018533753,0.009396604,0.0001262751],"about_ca_topic_score_codex":0.00006572439,"about_ca_topic_score_gemma":0.00007334266,"teacher_disagreement_score":0.48596394,"about_ca_system_score_codex":0.000112278845,"about_ca_system_score_gemma":0.00044572717,"threshold_uncertainty_score":0.48702827},"labels":[],"label_agreement":null},{"id":"W2805363969","doi":"10.1200/jco.2018.36.18_suppl.lba1006","title":"Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) <i>v</i> FULV in patients (pts) with estrogen receptor (ER)-positive, <i>PIK3CA</i> -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Ottawa Hospital","funders":"","keywords":"Fulvestrant; Medicine; Metastatic breast cancer; Internal medicine; Clinical endpoint; Hazard ratio; Adverse effect; Oncology; Population; Randomized controlled trial; Cancer; Breast cancer; Placebo; Progression-free survival; Estrogen receptor; Confidence interval; Overall survival; Pathology","score_opus":0.03734654690843785,"score_gpt":0.40994934581902676,"score_spread":0.3726027989105889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805363969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99365985,0.0006191469,0.00204773,0.0010591304,0.0006323796,0.0012548037,0.000618031,0.000020696363,0.00008823501],"genre_scores_gemma":[0.9846236,0.00045284233,0.011885368,0.002072985,0.00073524856,0.000049507686,0.00006752134,0.00007147663,0.000041429776],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99148303,0.0010232623,0.0048173578,0.0007548712,0.0012805605,0.000640911],"domain_scores_gemma":[0.9905584,0.0017229781,0.004367364,0.0006211866,0.0020005018,0.00072956836],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018116436,0.0005527406,0.0047313278,0.00049826584,0.00008938895,0.000017377994,0.0004916049,0.00029259827,0.00086597615],"category_scores_gemma":[0.00047030253,0.0003550783,0.00060374313,0.0015288823,0.000854985,0.00048450188,0.00010811608,0.0012577017,0.0000074860277],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.346207,0.05063626,0.21446921,0.000069356545,0.014167136,0.0011001617,0.0015146991,0.00062426075,0.0035777267,0.0000033059396,0.00022247298,0.36740842],"study_design_scores_gemma":[0.35552537,0.2011365,0.4123382,0.0012530391,0.018017508,0.000310423,0.003674246,0.00021969364,0.0020531167,0.000071781884,0.0045250743,0.000875049],"about_ca_topic_score_codex":0.0004930017,"about_ca_topic_score_gemma":0.0018537589,"teacher_disagreement_score":0.36653337,"about_ca_system_score_codex":0.0007446855,"about_ca_system_score_gemma":0.0031993552,"threshold_uncertainty_score":0.99989015},"labels":[],"label_agreement":null},{"id":"W2806677947","doi":"10.1007/s12325-018-0701-5","title":"Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2− Metastatic Breast Cancer","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Palbociclib; Medicine; Dosing; Metastatic breast cancer; Oncology; Breast cancer; Internal medicine; Cancer; Medical prescription; Pharmacology","score_opus":0.012626847874048403,"score_gpt":0.326261645675861,"score_spread":0.31363479780181264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806677947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808433,0.017135147,0.00021195762,0.00084081705,0.00023741715,0.00040258834,0.000081869584,0.000027681375,0.00021919873],"genre_scores_gemma":[0.9829231,0.014971898,0.0013042939,0.00031983867,0.0002692041,0.00006859788,0.0000051522998,0.000047056215,0.00009089116],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986202,0.00006600119,0.0004382982,0.00038245379,0.00014397364,0.0003490567],"domain_scores_gemma":[0.99928576,0.00010731335,0.00019274493,0.00029478187,0.0000459542,0.00007346001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020704619,0.0002329119,0.0005301544,0.00019991596,0.000033003274,0.000010937969,0.00013342148,0.000038494796,0.0004054399],"category_scores_gemma":[0.0000063018533,0.00020222987,0.0000497283,0.00017845599,0.000313176,0.00047737447,0.000033938464,0.00016971095,0.000004636841],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020022772,0.0001260128,0.3597183,0.00018502086,0.000099973506,0.000025617637,0.0068022623,0.00067053223,0.0066823587,0.00021343683,0.000005612558,0.62346864],"study_design_scores_gemma":[0.042440135,0.0013808224,0.808657,0.0045704218,0.00011720416,0.0004303828,0.01169066,0.003211909,0.06691362,0.0126644615,0.046148222,0.0017751664],"about_ca_topic_score_codex":0.0024299326,"about_ca_topic_score_gemma":0.003251343,"teacher_disagreement_score":0.62169343,"about_ca_system_score_codex":0.00021078963,"about_ca_system_score_gemma":0.00008293381,"threshold_uncertainty_score":0.8246695},"labels":[],"label_agreement":null},{"id":"W2806730227","doi":"10.1200/jco.2018.36.15_suppl.tps1107","title":"BYLieve: A phase II study of alpelisib (ALP) with fulvestrant (FUL) or letrozole (LET) for treatment of <i>PIK3CA</i> mutant, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2<i>–</i>) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Fulvestrant; Letrozole; Medicine; Human Epidermal Growth Factor Receptor 2; Epidermal growth factor receptor; Internal medicine; Mutant; Hormone receptor; Pharmacology; Receptor; Oncology; Endocrinology; Cancer; Estrogen receptor; Biology; Genetics","score_opus":0.06887970135663998,"score_gpt":0.4446081298824254,"score_spread":0.37572842852578536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806730227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907134,0.0011186046,0.00041226487,0.002734671,0.00085184164,0.0032791647,0.00078968157,0.000034010056,0.00006633355],"genre_scores_gemma":[0.9840088,0.0008672683,0.0107258735,0.00077906944,0.0029629536,0.0003589323,0.000016310902,0.00013982413,0.00014099531],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99249333,0.0007939471,0.0040574255,0.0008420009,0.0010475738,0.00076572644],"domain_scores_gemma":[0.9888062,0.0019560826,0.0053303186,0.0005286824,0.0027086386,0.0006700787],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001047008,0.00077856105,0.003943603,0.00031575543,0.0002653057,0.00002041031,0.00035131807,0.00044713705,0.00041653172],"category_scores_gemma":[0.00045219783,0.0004723087,0.00073834165,0.00042097952,0.0012905216,0.0005027448,0.00007336203,0.00074502337,0.0000035129196],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40935823,0.040084768,0.005516414,0.000079620935,0.0034601777,0.00040723145,0.0052284054,0.000023486666,0.07002686,0.000008693278,0.00013853621,0.46566755],"study_design_scores_gemma":[0.17685908,0.62281084,0.047439,0.0012761856,0.00126165,0.00041350085,0.0033982864,0.000017658253,0.14081398,0.0000818532,0.0049546584,0.00067327387],"about_ca_topic_score_codex":0.0001550676,"about_ca_topic_score_gemma":0.000344355,"teacher_disagreement_score":0.5827261,"about_ca_system_score_codex":0.000896963,"about_ca_system_score_gemma":0.001968414,"threshold_uncertainty_score":0.99977285},"labels":[],"label_agreement":null},{"id":"W2806800866","doi":"10.1200/jco.2018.36.15_suppl.1031","title":"Serum PD-L1 and outcomes in CCTG MA.31 phase 3 trial of anti-HER2 therapy in first-line HER2+ metastatic breast cancer patients (trastuzumab arm only).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Queen's University","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Metastatic breast cancer; Oncology; Lapatinib; Taxane; Breast cancer; Univariate analysis; Cancer; Multivariate analysis","score_opus":0.0924004381767024,"score_gpt":0.4892809865557027,"score_spread":0.3968805483790003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806800866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891702,0.00047889384,0.00004892523,0.007942063,0.001535191,0.00067214575,0.00006515065,0.0000069930406,0.00008045899],"genre_scores_gemma":[0.99380785,0.002154015,0.0012232984,0.0017271853,0.00095995,0.000013671458,0.00000282376,0.00003371747,0.00007746055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951158,0.00042401912,0.0033062268,0.00030201173,0.0004696931,0.00038225064],"domain_scores_gemma":[0.9952009,0.0015837788,0.0021505512,0.00022929405,0.0005526165,0.00028291595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002059495,0.0002685775,0.002753068,0.00031788473,0.000031210508,0.0000069034318,0.00020508177,0.00026185214,0.00033929409],"category_scores_gemma":[0.0010047156,0.00018462702,0.00032375864,0.0003046934,0.00055173784,0.00022258739,0.000053255866,0.0008877919,0.000003558504],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15971236,0.01524041,0.4684873,0.0000407016,0.0004774428,0.00014210487,0.00034905592,0.000016523802,0.000064572174,0.000008115807,0.00007365398,0.35538775],"study_design_scores_gemma":[0.27726308,0.038062938,0.67900103,0.00022622803,0.00013896837,0.000120887555,0.00011490197,0.000049345606,0.00007863614,0.00038085584,0.0044334605,0.00012964832],"about_ca_topic_score_codex":0.0002108512,"about_ca_topic_score_gemma":0.001328805,"teacher_disagreement_score":0.3552581,"about_ca_system_score_codex":0.00033322992,"about_ca_system_score_gemma":0.0015168865,"threshold_uncertainty_score":0.7528871},"labels":[],"label_agreement":null},{"id":"W2807968494","doi":"10.3747/co.25.4000","title":"Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Redrawing the Lines","year":2018,"lang":"en","type":"review","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"BC Cancer Foundation; BC Cancer Agency; St. Michael's Hospital; University of Alberta; University of Calgary","funders":"","keywords":"Metastatic breast cancer; Medicine; Hormone receptor; Cancer; HER2 negative; Cancer research; Breast cancer; Hormone; Receptor; Oncology; Internal medicine","score_opus":0.14666920903289835,"score_gpt":0.47064312104842904,"score_spread":0.3239739120155307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807968494","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018415489,0.991124,0.00019552824,0.001612894,0.0034710935,0.0022318878,0.0007931765,0.00012233826,0.0004306741],"genre_scores_gemma":[0.000014186686,0.9924836,0.0009674824,0.00020108683,0.004170634,0.0012642039,0.00026893753,0.00015031252,0.0004795366],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99625313,0.00076936465,0.0010010405,0.0008666282,0.00040212026,0.0007077095],"domain_scores_gemma":[0.9964107,0.0009826771,0.0010600792,0.00072956056,0.00057672604,0.00024020673],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000476827,0.00082538,0.0031671736,0.00023004433,0.0002620099,0.000029317363,0.0005002182,0.00030536522,0.0005026489],"category_scores_gemma":[0.00017075661,0.00049516227,0.00069682434,0.0007323255,0.000998961,0.000121528676,0.00023083301,0.0013530314,0.00031026808],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024529075,0.0002922557,0.000009135697,0.004289627,0.0010690922,0.000022088967,0.0004998047,3.41896e-7,0.0000026557245,0.000044885597,0.0062590726,0.98726577],"study_design_scores_gemma":[0.0012429885,0.0005303153,0.00006669701,0.016778177,0.003559792,0.00097367517,0.00017024667,0.000005069829,0.000004705223,0.00011366245,0.9761125,0.0004421792],"about_ca_topic_score_codex":0.00007644126,"about_ca_topic_score_gemma":0.0000481067,"teacher_disagreement_score":0.98682356,"about_ca_system_score_codex":0.0018191857,"about_ca_system_score_gemma":0.0018324926,"threshold_uncertainty_score":0.99975},"labels":[],"label_agreement":null},{"id":"W2808476554","doi":"10.3747/co.25.3752","title":"Overcoming Endocrine Resistance in Hormone Receptor–Positive Breast Cancer","year":2018,"lang":"en","type":"review","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Breast cancer; Hormone receptor; Endocrine system; Hormone; Cancer; Bioinformatics; Resistance (ecology); Receptor; Cancer research; Internal medicine; Oncology; Computational biology; Biology","score_opus":0.11271090704222667,"score_gpt":0.4602473066929266,"score_spread":0.34753639965069993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808476554","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004715362,0.9936611,0.000047401536,0.00047335698,0.0023092495,0.0014179441,0.0006170364,0.00008002044,0.0013467217],"genre_scores_gemma":[0.00001896006,0.9945809,0.00071930216,0.0000917707,0.0025556788,0.00086697517,0.00027419574,0.00012269581,0.0007694914],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967419,0.00031304487,0.0009645012,0.0009168097,0.00029606445,0.00076769706],"domain_scores_gemma":[0.99799216,0.00029879145,0.00066866504,0.0005646863,0.00025251118,0.00022316483],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024328707,0.0006747395,0.0030972003,0.00040631628,0.00007110754,0.000011820616,0.00030401707,0.000361887,0.00048590984],"category_scores_gemma":[0.00007634879,0.00057386677,0.0003991751,0.00066461123,0.00038481984,0.00011597172,0.0001774159,0.0012399813,0.00017274029],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000605547,0.0003643452,0.000095460826,0.0069526057,0.00022143665,0.00008800289,0.00019474489,6.735113e-8,0.0000053313615,0.00011618981,0.004595387,0.98676085],"study_design_scores_gemma":[0.0021043324,0.00019249329,0.00044739517,0.03394066,0.00062066485,0.000386757,0.000023963421,6.390087e-7,0.0000021104418,0.000070470865,0.96175987,0.0004506324],"about_ca_topic_score_codex":0.00003972318,"about_ca_topic_score_gemma":0.00028177415,"teacher_disagreement_score":0.98631024,"about_ca_system_score_codex":0.004445275,"about_ca_system_score_gemma":0.0014612237,"threshold_uncertainty_score":0.9996713},"labels":[],"label_agreement":null},{"id":"W2808681954","doi":"10.3747/co.25.4159","title":"Progress in Breast Cancer—Can We Do Better?","year":2018,"lang":"en","type":"editorial","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Breast cancer; Malignancy; Cancer; Oncology; Internal medicine","score_opus":0.03939711881591096,"score_gpt":0.42460746923756604,"score_spread":0.3852103504216551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808681954","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030059658,0.041809328,0.00001343363,0.007897743,0.9450958,0.00084674277,0.0010035994,0.00013495638,0.00019243853],"genre_scores_gemma":[0.0013596078,0.0060310545,0.00026822576,0.00013699962,0.99042875,0.0009147329,0.0005208123,0.00014338044,0.00019644776],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967247,0.00015162899,0.0006469877,0.00095470506,0.0006967268,0.0008252064],"domain_scores_gemma":[0.99781126,0.0002635997,0.00048219427,0.0006281759,0.00055528944,0.00025949586],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025289092,0.0005771951,0.0013956906,0.00040223394,0.000060026807,0.000024159628,0.00042383705,0.0011235412,0.000644395],"category_scores_gemma":[0.00007376516,0.00051699666,0.0001744724,0.00036946058,0.0007361188,0.00007402193,0.0001948667,0.0019752728,0.00007340538],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080824253,0.00038077624,0.011460677,0.00047877245,0.00008865862,0.00007207595,0.00034278075,1.6753805e-7,0.0000041392773,0.0000048239326,0.48661068,0.4997482],"study_design_scores_gemma":[0.0049644946,0.00054276054,0.0035660695,0.0026355209,0.00019515773,0.00007477446,0.00006731874,0.000005738212,0.000009680581,0.00033906818,0.9871647,0.00043474356],"about_ca_topic_score_codex":0.00003601422,"about_ca_topic_score_gemma":0.00021641166,"teacher_disagreement_score":0.500554,"about_ca_system_score_codex":0.0027991761,"about_ca_system_score_gemma":0.0025393346,"threshold_uncertainty_score":0.99972814},"labels":[],"label_agreement":null},{"id":"W2810456709","doi":"10.1158/1538-7445.am2018-ct046","title":"Abstract CT046: A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) in <i>PIK3CA</i>-mutated locally advanced or metastatic solid tumors","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; KRAS; Internal medicine; Clinical endpoint; Cancer; Oncology; Adverse effect; Colorectal cancer; Cancer research; Clinical trial","score_opus":0.09041560544615307,"score_gpt":0.47746959028198604,"score_spread":0.387053984835833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810456709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938324,0.0008775415,0.000054574517,0.0010347423,0.00027696678,0.0034886058,0.0001256778,0.000059007576,0.00025049638],"genre_scores_gemma":[0.9972872,0.00008840018,0.00026330145,0.0003030618,0.0003623564,0.0008723594,0.0000109572975,0.000100232035,0.0007121224],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9951777,0.00043062284,0.0009076819,0.00075270137,0.0016832202,0.001048115],"domain_scores_gemma":[0.9967213,0.00040640248,0.00025972005,0.0010837443,0.0012245607,0.0003042537],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014992445,0.00035696354,0.00082562835,0.00047112207,0.0002371915,0.000036787176,0.0006138328,0.000079262216,0.0012883645],"category_scores_gemma":[0.00072846434,0.0002301273,0.000107535976,0.002575423,0.001032656,0.0002772288,0.00025720662,0.0010499225,0.00003465731],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061749604,0.014303262,0.0072346064,0.0013959401,0.0010392893,0.0013864699,0.019187547,0.00121517,0.6516757,0.00003083884,0.0042693336,0.23651226],"study_design_scores_gemma":[0.123646505,0.02381974,0.041782588,0.0069473498,0.00035213766,0.00020206414,0.049482986,0.0011496131,0.73720163,0.0006254407,0.013426678,0.0013632731],"about_ca_topic_score_codex":0.0016305783,"about_ca_topic_score_gemma":0.005003737,"teacher_disagreement_score":0.235149,"about_ca_system_score_codex":0.000682861,"about_ca_system_score_gemma":0.0018854687,"threshold_uncertainty_score":0.9996246},"labels":[],"label_agreement":null},{"id":"W2810702595","doi":"10.1007/s12325-018-0740-y","title":"Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2− Metastatic Breast Cancer","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Internal medicine; Breast cancer; Rheumatology; Metastatic breast cancer; Oncology; Cancer; Cardiac function curve; Hematology; Heart failure","score_opus":0.010532308368372332,"score_gpt":0.3003753413487511,"score_spread":0.2898430329803788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810702595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96987593,0.028937865,0.00019184836,0.00017438714,0.00023597437,0.00044010163,0.000016544589,0.000033439344,0.000093903574],"genre_scores_gemma":[0.98903054,0.00829147,0.0020696553,0.00013835057,0.0001387368,0.00026994766,0.0000018424608,0.000034838515,0.000024608713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987227,0.000067650915,0.00030329326,0.00032138888,0.000230355,0.00035461056],"domain_scores_gemma":[0.9993064,0.0000896223,0.00015473246,0.0002316264,0.0001457894,0.00007184925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018473386,0.00021818154,0.0005703177,0.00017156918,0.000035366393,0.0000070119154,0.000072377064,0.00004202541,0.00008483167],"category_scores_gemma":[0.000011116575,0.00016079843,0.000015101789,0.0004013248,0.00030070535,0.00041088052,0.000017265154,0.00015238888,0.0000017096107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077732624,0.00016709478,0.5747075,0.00015509289,0.00018487936,0.000018353972,0.002562458,0.000081821614,0.034986887,0.000057046065,3.8126362e-7,0.37930524],"study_design_scores_gemma":[0.0058397506,0.0042458554,0.96668196,0.00077660364,0.000047910074,0.000117292504,0.0035253812,0.000027149268,0.015538285,0.0018043949,0.0010696719,0.00032572675],"about_ca_topic_score_codex":0.00022956695,"about_ca_topic_score_gemma":0.00014367429,"teacher_disagreement_score":0.3919745,"about_ca_system_score_codex":0.0002308274,"about_ca_system_score_gemma":0.00008356076,"threshold_uncertainty_score":0.65571696},"labels":[],"label_agreement":null},{"id":"W2883737490","doi":"10.1016/j.ejca.2018.05.017","title":"Palbociclib plus endocrine therapy in older women with HR+/HER2– advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Pfizer","keywords":"Palbociclib; Medicine; Oncology; Gynecology; Internal medicine; Breast cancer; Pooled analysis; Endocrine system; Cancer; Obstetrics; Meta-analysis; Metastatic breast cancer; Hormone","score_opus":0.027011779279007546,"score_gpt":0.3734886352205431,"score_spread":0.34647685594153554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883737490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97716475,0.019496417,0.00026904128,0.0018558616,0.00038716977,0.00046916478,0.000040754643,0.00002377454,0.0002930451],"genre_scores_gemma":[0.98259205,0.013845214,0.0008700392,0.0011275003,0.0010668127,0.00004366139,0.000001730293,0.000089281035,0.00036368766],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99614716,0.00062076777,0.0016473158,0.00038943038,0.0006727776,0.0005225818],"domain_scores_gemma":[0.99598795,0.00024617242,0.0015205102,0.00042788824,0.0015253929,0.00029210866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014320994,0.00037342764,0.0020720372,0.00056567247,0.000060575665,0.000015224908,0.000309823,0.000034432695,0.0008754083],"category_scores_gemma":[0.00011592094,0.00024338561,0.0003789539,0.0013699332,0.00064031297,0.00023166297,0.000052713618,0.00047380946,0.0000032638895],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1717423,0.00046015493,0.15488887,0.00009198276,0.0231355,0.0006567061,0.009110575,0.0017624015,0.004779463,0.0000046642585,0.00018868456,0.6331787],"study_design_scores_gemma":[0.13136226,0.0032955764,0.8513944,0.0012383622,0.0022054787,0.0001645025,0.0026298787,0.00008277286,0.0012035127,0.000015589523,0.0060590343,0.00034859046],"about_ca_topic_score_codex":0.000044606582,"about_ca_topic_score_gemma":0.00022518155,"teacher_disagreement_score":0.69650555,"about_ca_system_score_codex":0.0005180611,"about_ca_system_score_gemma":0.00050149794,"threshold_uncertainty_score":0.99249774},"labels":[],"label_agreement":null},{"id":"W2884436796","doi":"10.1093/jnci/djy109","title":"Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer","year":2018,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"David Geffen School of Medicine, University of California, Los Angeles; BC Cancer Agency; Robert H. Lurie Comprehensive Cancer Center; Russian Science Foundation; Peter MacCallum Cancer Centre; Feinberg School of Medicine; Pfizer","keywords":"Palbociclib; Fulvestrant; Letrozole; Medicine; Internal medicine; Adverse effect; Breast cancer; Oncology; Placebo; Neutropenia; Metastatic breast cancer; Cancer; Gynecology; Chemotherapy; Tamoxifen","score_opus":0.027288105385752402,"score_gpt":0.36134952051147684,"score_spread":0.33406141512572446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884436796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866924,0.0014390096,0.0026837487,0.006968287,0.0009356426,0.0007090327,0.0004291667,0.000011495578,0.0001311971],"genre_scores_gemma":[0.9960771,0.0007040705,0.00107663,0.0010773725,0.0007460051,0.00007810971,0.000022601002,0.000026684413,0.00019142007],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978353,0.000048166134,0.00071925286,0.00021283007,0.0009467016,0.00023774366],"domain_scores_gemma":[0.9959149,0.00009608547,0.0009783916,0.00017569764,0.0027512945,0.00008364695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003569367,0.00020924499,0.00063439226,0.00052044785,0.00011264205,0.000012860622,0.00029190333,0.00005963685,0.0002193108],"category_scores_gemma":[0.00007673799,0.00013270683,0.0002936128,0.0014122417,0.00033713723,0.0004707954,0.000026959257,0.00024181523,3.7510858e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04854534,0.0011526992,0.66370845,0.00019898987,0.0091997385,0.000017563443,0.0011433174,0.040055875,0.031345256,0.0016819333,0.00021174162,0.2027391],"study_design_scores_gemma":[0.014627555,0.0004976145,0.96851885,0.00061329565,0.00085766416,0.00012659354,0.00003337826,0.00045141217,0.009840694,0.00039417553,0.0038653172,0.00017345134],"about_ca_topic_score_codex":0.000117769734,"about_ca_topic_score_gemma":0.0020156715,"teacher_disagreement_score":0.3048104,"about_ca_system_score_codex":0.0010259256,"about_ca_system_score_gemma":0.0010557992,"threshold_uncertainty_score":0.5411627},"labels":[],"label_agreement":null},{"id":"W2884677707","doi":"10.4212/cjhp.v50i1.2001","title":"Erratum in the Cancer Drug Manual, 2nd Edition","year":2018,"lang":"en","type":"erratum","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Library science; Computer science","score_opus":0.01927315215147469,"score_gpt":0.3259891020944077,"score_spread":0.306715949942933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884677707","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07785076,0.1597614,0.000034698336,0.40361336,0.2981175,0.003342661,0.0009280609,0.000052286436,0.05629931],"genre_scores_gemma":[0.7766817,0.0052063107,0.00012801774,0.021294937,0.09209251,0.00013821173,0.00020193587,0.0003388191,0.10391752],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997441,0.00018776281,0.0006693042,0.0002642232,0.0007529741,0.0006847615],"domain_scores_gemma":[0.9975765,0.000072981806,0.000747976,0.0005100506,0.0005726327,0.00051989476],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000913976,0.00042161948,0.00061388424,0.00042615473,0.0003453531,0.00014324195,0.001150624,0.00014533759,0.0012132258],"category_scores_gemma":[0.00010197429,0.00024516947,0.00029942262,0.00044101145,0.0006423341,0.00032928673,0.000028052546,0.0031650204,0.000038105158],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011641195,0.000043372136,0.0005520587,0.00007412116,0.00024307198,0.00077054166,0.004784637,0.000007875347,0.0000111961635,0.000030050207,0.98949903,0.0038676106],"study_design_scores_gemma":[0.0017001707,0.00029814077,0.0045101955,0.0010918843,0.00038419483,0.00061075075,0.0010858774,0.000011122183,0.00007540404,0.0017376407,0.98819816,0.00029643177],"about_ca_topic_score_codex":0.03146327,"about_ca_topic_score_gemma":0.12778819,"teacher_disagreement_score":0.69883096,"about_ca_system_score_codex":0.0012251061,"about_ca_system_score_gemma":0.0065630074,"threshold_uncertainty_score":0.9997721},"labels":[],"label_agreement":null},{"id":"W2886228434","doi":"10.1158/1078-0432.ccr-18-0717","title":"Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in <i>PIK3CA</i> -Mutant Lung Squamous Cell Carcinoma","year":2018,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"PI3K/AKT/mTOR pathway; In vivo; Cancer research; Medicine; Mutant; Lung cancer; Biology; Oncology; Signal transduction; Cell biology; Genetics; Gene","score_opus":0.09080625717076041,"score_gpt":0.46307274969746887,"score_spread":0.37226649252670846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886228434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980966,0.0029880286,0.00028248093,0.0126877725,0.0005556707,0.0014956068,0.00003734817,0.000066081506,0.0009210225],"genre_scores_gemma":[0.9928765,0.00014561391,0.00033716555,0.002634074,0.0023849637,0.000551278,0.0000074866543,0.0000751474,0.000987733],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99397856,0.0016973577,0.0010050832,0.0009262534,0.0012298526,0.0011629193],"domain_scores_gemma":[0.9945619,0.0031270918,0.00014919759,0.0008242658,0.00088539504,0.0004521242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009045387,0.00026679834,0.0005510381,0.00029189506,0.00039737817,0.000063338804,0.00036069247,0.00021978283,0.0005974892],"category_scores_gemma":[0.0031535472,0.00018983262,0.00015334546,0.0014330853,0.0011469955,0.00016037283,0.00036699596,0.0016118517,0.00026230243],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052441876,0.0007824435,0.045749903,0.00028526882,0.000034069224,0.0005214685,0.0050234552,0.000073485855,0.84458375,0.00007107117,0.006939474,0.043493725],"study_design_scores_gemma":[0.010687978,0.007134661,0.104433626,0.00085648976,0.00004795302,0.000051861025,0.0048558516,0.0008342374,0.7343206,0.000901828,0.13509443,0.0007804747],"about_ca_topic_score_codex":0.0008138866,"about_ca_topic_score_gemma":0.000713124,"teacher_disagreement_score":0.12815496,"about_ca_system_score_codex":0.00077980297,"about_ca_system_score_gemma":0.0013067562,"threshold_uncertainty_score":0.7741149},"labels":[],"label_agreement":null},{"id":"W2886537460","doi":"10.1158/1557-3125.advbc17-b35","title":"Abstract B35: Palbociclib treatment activates FAK and use of palbociclib in combination with the FAK inhibitor PF-562,271 enhances antitumor activity in ER-positive breast cancer cells","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Palbociclib; Cancer research; Cyclin-dependent kinase; Cyclin-dependent kinase 2; Kinase; Estrogen receptor; Tyrosine kinase; Cell cycle; Signal transduction; Medicine; Cancer; Chemistry; Breast cancer; Biology; Cell biology; Internal medicine; Metastatic breast cancer","score_opus":0.03597418242534653,"score_gpt":0.3689667991293732,"score_spread":0.3329926167040267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886537460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935029,0.0011364344,0.000079644095,0.0034481746,0.00006505522,0.0015069505,0.00015146926,0.000020998885,0.00008834749],"genre_scores_gemma":[0.9979176,0.0009430627,0.00012210914,0.00011796118,0.00011686564,0.0005814399,0.000009477269,0.00006034005,0.00013116501],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99727577,0.00029549413,0.00029125332,0.00063545565,0.00083096453,0.0006710774],"domain_scores_gemma":[0.99848294,0.00031393365,0.00017292534,0.0004167439,0.00047365515,0.00013980153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043109964,0.00031583782,0.0005234125,0.00036572755,0.0001499436,0.000068095906,0.00016275472,0.00011982028,0.00010069448],"category_scores_gemma":[0.000030718606,0.00021481568,0.00006438558,0.0009772839,0.0010681743,0.00041527516,0.00009600972,0.00052889803,0.000003461842],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048747,0.0006365816,0.027758405,0.00014181451,0.00017828506,0.00012112174,0.0020795672,0.00007240768,0.8898296,0.000036349058,0.000027135195,0.07424408],"study_design_scores_gemma":[0.0034791445,0.00070540496,0.28577107,0.0006843583,0.000025723946,0.000011313352,0.00044739424,0.00008113577,0.708317,0.00004875232,0.00026226733,0.00016643744],"about_ca_topic_score_codex":0.014520728,"about_ca_topic_score_gemma":0.008706363,"teacher_disagreement_score":0.25801268,"about_ca_system_score_codex":0.0009374273,"about_ca_system_score_gemma":0.0005626749,"threshold_uncertainty_score":0.99204165},"labels":[],"label_agreement":null},{"id":"W2886803370","doi":"10.1158/1538-7445.am2018-ct009","title":"Abstract CT009: Results of a dose- and regimen-finding Phase Ib study of HDM201 in combination with ribociclib in patients with locally advanced or metastatic liposarcoma","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Regimen; Neutropenia; Internal medicine; Liposarcoma; Adverse effect; Phases of clinical research; Gastroenterology; Oncology; Chemotherapy; Sarcoma; Pathology","score_opus":0.07042861192374962,"score_gpt":0.4342547883557902,"score_spread":0.36382617643204057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886803370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997083,0.00022289639,0.000023882125,0.00015493846,0.000020334308,0.0023417815,0.000034225934,0.000011180802,0.000107761385],"genre_scores_gemma":[0.99886096,0.00003722354,0.00073300034,0.000014395985,0.000018848208,0.00021121706,0.000013263383,0.000036850633,0.00007425307],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975448,0.00015894398,0.0005083592,0.00043364125,0.00094119756,0.0004130462],"domain_scores_gemma":[0.9981839,0.00027143082,0.00024336285,0.00038954467,0.0008000718,0.00011166365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008610472,0.00017285331,0.0005095165,0.00060601527,0.00005304526,0.0000106545385,0.00014366415,0.00004123467,0.00003544415],"category_scores_gemma":[0.00018818231,0.00011827877,0.000013165785,0.0012581578,0.0005054069,0.00026449072,0.00005810239,0.00037667263,8.9819247e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3616083,0.012612462,0.37807223,0.0010228673,0.0003790984,0.00018942558,0.021260278,0.00016874284,0.014594328,0.000046985064,0.000023970617,0.21002132],"study_design_scores_gemma":[0.1335966,0.030367838,0.8189775,0.0023500514,0.000036103942,0.000004683766,0.0051592146,0.000067016,0.009114835,0.000083447034,0.00006378146,0.00017893536],"about_ca_topic_score_codex":0.0011823019,"about_ca_topic_score_gemma":0.0040891953,"teacher_disagreement_score":0.44090527,"about_ca_system_score_codex":0.00032689908,"about_ca_system_score_gemma":0.0004500513,"threshold_uncertainty_score":0.48232684},"labels":[],"label_agreement":null},{"id":"W2887054120","doi":"10.1080/15384101.2018.1502567","title":"Targeting the cell cycle in breast cancer: towards the next phase","year":2018,"lang":"en","type":"review","venue":"Cell Cycle","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":201,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research; Campbell Family Institute for Breast Cancer Research","keywords":"Cell cycle; Biology; Cancer; Breast cancer; Cancer research; Cancer cell; Cell growth; Bioinformatics; Genetics","score_opus":0.04549567917826845,"score_gpt":0.35113561988146674,"score_spread":0.3056399407031983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887054120","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038485526,0.9921027,0.000044922894,0.0009123238,0.00065216207,0.0014815831,0.00015478309,0.000083298495,0.004183414],"genre_scores_gemma":[0.0021270188,0.99300617,0.00014140953,0.0006408623,0.0021284304,0.00044085897,0.000065484805,0.00017309323,0.0012766598],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972908,0.00023856007,0.0007128424,0.00063860376,0.00040954383,0.00070963625],"domain_scores_gemma":[0.9980075,0.00019502264,0.0004968338,0.0010389243,0.00010810335,0.00015362393],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005314622,0.00060390827,0.0013568529,0.00010915541,0.00024457969,0.00006673859,0.0007369223,0.00025238068,0.00095967617],"category_scores_gemma":[0.000023373344,0.00031851212,0.000450327,0.0006068804,0.00035675184,0.00012877003,0.00020610858,0.0009977552,0.0002980816],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007733277,0.00023345523,0.000006809446,0.0050901663,0.00007238646,0.00003327311,0.0006136101,0.000028750348,0.00006195686,0.0000046361656,0.0017099144,0.9920677],"study_design_scores_gemma":[0.0014991874,0.000062371866,0.000012899258,0.004392952,0.00053564133,0.00010629592,0.00035349603,0.0001336942,0.00010237145,0.000063125386,0.99237084,0.00036709255],"about_ca_topic_score_codex":0.000590821,"about_ca_topic_score_gemma":0.000028914925,"teacher_disagreement_score":0.9917006,"about_ca_system_score_codex":0.0004933094,"about_ca_system_score_gemma":0.0007215854,"threshold_uncertainty_score":0.99995357},"labels":[],"label_agreement":null},{"id":"W2887418167","doi":"10.1007/s12325-018-0764-3","title":"Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2− Advanced Breast Cancer","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Internal medicine; Chemotherapy; Breast cancer; Cancer; Oncology","score_opus":0.010342238505599505,"score_gpt":0.30675490596671456,"score_spread":0.29641266746111505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887418167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98804027,0.010096108,0.00023176482,0.00023040774,0.00027351675,0.00069071027,0.000033228756,0.00011566725,0.00028832673],"genre_scores_gemma":[0.97843075,0.018336248,0.0013805168,0.00011350868,0.0006455783,0.0007704451,0.0000032029313,0.00007880127,0.00024095569],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982836,0.00003754068,0.00026211143,0.0005649099,0.00023905995,0.0006127285],"domain_scores_gemma":[0.9991217,0.000046884285,0.00013931867,0.0003857046,0.00011837007,0.00018797569],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0000685967,0.0003800976,0.00047451118,0.00012052905,0.00010897556,0.000023330442,0.000110047906,0.00006582771,0.00017591445],"category_scores_gemma":[0.0000032722337,0.00027096467,0.00002347792,0.00026296003,0.0003632782,0.00070172345,0.000023380706,0.00014913554,0.0000035624273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037058415,0.000120380806,0.5219996,0.000023448998,0.0000866458,0.00001963271,0.0018570848,0.00005038866,0.003997079,0.000009477653,1.451993e-7,0.4681303],"study_design_scores_gemma":[0.010533057,0.00442122,0.95668447,0.0005381519,0.000022093365,0.00015211248,0.001581198,0.000023179013,0.016547905,0.00022803867,0.008846211,0.00042236233],"about_ca_topic_score_codex":0.00022230687,"about_ca_topic_score_gemma":0.00033736034,"teacher_disagreement_score":0.46770793,"about_ca_system_score_codex":0.0007535913,"about_ca_system_score_gemma":0.00008104995,"threshold_uncertainty_score":0.99997425},"labels":[],"label_agreement":null},{"id":"W2887856562","doi":"10.1016/j.clbc.2018.07.007","title":"Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Pfizer (Canada); Ottawa Hospital","funders":"MedImmune; AbbVie; Puma Biotechnology; Novartis; Pfizer; Eli Lilly and Company","keywords":"Palbociclib; Medicine; Letrozole; Neutropenia; Metastatic breast cancer; Breast cancer; Adverse effect; Internal medicine; Oncology; Febrile neutropenia; Expanded access; Fulvestrant; Cancer; Estrogen receptor; Chemotherapy; Tamoxifen","score_opus":0.03019194093956165,"score_gpt":0.38807140220821973,"score_spread":0.3578794612686581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887856562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938944,0.00035210088,0.00020489129,0.0011472872,0.00018440829,0.0031305873,0.0009715686,0.00004640237,0.000068374844],"genre_scores_gemma":[0.9955575,0.0003736052,0.00082996377,0.00021876779,0.00035619855,0.0023960508,0.000029282559,0.00009543888,0.00014323337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99700683,0.00015471825,0.0009878307,0.0007904835,0.0004946551,0.00056546007],"domain_scores_gemma":[0.9967917,0.00038068616,0.00079759565,0.0004958756,0.001278122,0.0002560248],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024795404,0.00045352383,0.0014414935,0.00017349474,0.000084954154,0.000014922662,0.00021468675,0.00013927299,0.00025343226],"category_scores_gemma":[0.000026473377,0.00031613203,0.00008384534,0.00070497365,0.00083682063,0.00038581045,0.000053101572,0.00016289247,0.0000017948705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17755687,0.011916586,0.51450604,0.00013697309,0.0015193967,0.000013588206,0.0051750406,0.00014982629,0.0049090395,0.000024052642,0.000028014267,0.28406456],"study_design_scores_gemma":[0.05312357,0.04021123,0.8981829,0.0006791081,0.00026672386,0.000039177903,0.003507238,0.00003558154,0.003402768,0.00007271128,0.0001304994,0.00034844826],"about_ca_topic_score_codex":0.0019433198,"about_ca_topic_score_gemma":0.002440752,"teacher_disagreement_score":0.38367692,"about_ca_system_score_codex":0.0010164502,"about_ca_system_score_gemma":0.0005904843,"threshold_uncertainty_score":0.9999291},"labels":[],"label_agreement":null},{"id":"W2888058824","doi":"10.3747/co.25.4139","title":"Endocrine Therapy for Breast Cancer in the Primary Care Setting","year":2018,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Fulvestrant; Medicine; Breast cancer; Hormonal therapy; Hormone therapy; Hormone; Cancer; Estrogen; Oncology; Estrogen receptor; Bioinformatics; Internal medicine; Intensive care medicine","score_opus":0.06367879973306502,"score_gpt":0.43528313567770344,"score_spread":0.37160433594463843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888058824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8953147,0.06003037,0.0013371046,0.029039256,0.0047483165,0.004199962,0.00053234736,0.00016702671,0.004630906],"genre_scores_gemma":[0.9914351,0.0008242972,0.000785703,0.002819507,0.0031742244,0.00082016835,0.000057368758,0.000032885735,0.000050720508],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990042,0.000068721645,0.00020194631,0.00025030013,0.00012795857,0.00034691484],"domain_scores_gemma":[0.99926406,0.00015115851,0.000087659995,0.00023108152,0.00022109589,0.000044965138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001454188,0.00014077187,0.00026657293,0.000069601236,0.00008433065,0.00000607837,0.00015232098,0.00004840778,0.00015949308],"category_scores_gemma":[0.000016346294,0.00009146646,0.000069682945,0.00014833231,0.0001937464,0.000052188057,0.00002860492,0.00021222983,0.000007799286],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001094443,0.0001740899,0.03092695,0.00012583451,0.00002534018,0.0000059719305,0.0038283917,0.0000015069285,0.0012815142,0.00009360289,0.00053491,0.96190745],"study_design_scores_gemma":[0.006791184,0.0008122613,0.26816216,0.00018023654,0.00003573624,0.0002440619,0.0017252261,0.000031457992,0.0005653232,0.00025633923,0.7210585,0.00013753],"about_ca_topic_score_codex":0.000018927634,"about_ca_topic_score_gemma":0.000111933114,"teacher_disagreement_score":0.96176994,"about_ca_system_score_codex":0.0005111938,"about_ca_system_score_gemma":0.00034459564,"threshold_uncertainty_score":0.3729894},"labels":[],"label_agreement":null},{"id":"W2891105830","doi":"10.1200/jco.2018.36.15_suppl.12031","title":"Role of serum thymidine kinase-1 (TK1) activity in patients (pts) with hormone receptor positive (HR+) advanced breast cancer (ABC) treated with endocrine therapy (ET) in the EFECT trial.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Fulvestrant; Cancer; Clinical endpoint; Randomization; Breast cancer; Oncology; Progression-free survival; Exemestane; Gastroenterology; Randomized controlled trial; Gynecology; Chemotherapy; Aromatase; Estrogen receptor","score_opus":0.034244122088055357,"score_gpt":0.4042840549857932,"score_spread":0.37003993289773784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891105830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99201334,0.00056274614,0.00001877437,0.0057025827,0.00016688657,0.0010859619,0.0000533372,0.000009340942,0.00038701494],"genre_scores_gemma":[0.99629164,0.0011694293,0.0006719266,0.0011581059,0.00057672674,0.00004980356,0.000004118951,0.000039571136,0.000038681035],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99620277,0.0010998866,0.0014273855,0.00031950057,0.0005608753,0.0003895719],"domain_scores_gemma":[0.9953986,0.0012624696,0.0019962376,0.00030863704,0.0008602643,0.00017381094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016356055,0.00029309202,0.0018310981,0.00021019987,0.000039451803,0.0000067565397,0.00025041,0.0001912799,0.00011603658],"category_scores_gemma":[0.0003291843,0.00014940582,0.00020710751,0.0005908721,0.00056794577,0.00032628782,0.000031822892,0.0011073644,0.0000021365702],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48460865,0.0048687547,0.16001251,0.0000077149725,0.0003507861,0.00006879735,0.00038185867,0.000028370041,0.003462895,0.0000094251345,0.000025303487,0.34617493],"study_design_scores_gemma":[0.1624989,0.077900484,0.754133,0.00029885303,0.000107203334,0.00010439683,0.00024613037,0.000009456547,0.0026918428,0.000041803298,0.0018360955,0.0001318359],"about_ca_topic_score_codex":0.0002840585,"about_ca_topic_score_gemma":0.00086940615,"teacher_disagreement_score":0.5941205,"about_ca_system_score_codex":0.00041581318,"about_ca_system_score_gemma":0.0010581707,"threshold_uncertainty_score":0.6092593},"labels":[],"label_agreement":null},{"id":"W2892488632","doi":"10.1200/jco.2018.36.30_suppl.268","title":"An interprofessional pathway for patients initiating treatment with palbociclib: Optimization of toxicity monitoring.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Neutropenia; Palbociclib; Toxicity; Internal medicine; Breast cancer; Cancer; Metastatic breast cancer","score_opus":0.10546826391672033,"score_gpt":0.4904770058813342,"score_spread":0.3850087419646139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892488632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9762441,0.000041431413,0.021977685,0.00039155464,0.0009653765,0.00024184037,0.000009273729,0.000007848527,0.0001209242],"genre_scores_gemma":[0.8677758,0.000027772256,0.13042891,0.00019469402,0.0015239582,0.000008296432,0.0000046318996,0.000016520373,0.000019430508],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99809295,0.00016189004,0.0012562247,0.00012980719,0.00022040769,0.0001386995],"domain_scores_gemma":[0.9958472,0.00092703855,0.0017490753,0.00012269214,0.0011742339,0.00017975063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064130116,0.000104224426,0.0007885324,0.000065355925,0.00004328817,0.0000027219428,0.00008261515,0.00016486683,0.000039069517],"category_scores_gemma":[0.0006602577,0.00006259738,0.00016111854,0.00006853746,0.00020178898,0.00016806778,0.000013785454,0.0001961553,5.9068543e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027653,0.004015854,0.54749405,0.000027192411,0.0003047485,0.0000128337215,0.0005042398,0.0002914915,0.0005172329,0.000015137258,0.000011228117,0.41915298],"study_design_scores_gemma":[0.05532763,0.46736896,0.45292908,0.0013554773,0.0005510484,0.00010758378,0.0012932528,0.003246857,0.012072068,0.00047489195,0.0050020227,0.00027110163],"about_ca_topic_score_codex":0.000003737433,"about_ca_topic_score_gemma":0.0000051899433,"teacher_disagreement_score":0.46335313,"about_ca_system_score_codex":0.00018717161,"about_ca_system_score_gemma":0.0010080681,"threshold_uncertainty_score":0.25526467},"labels":[],"label_agreement":null},{"id":"W2892968865","doi":"10.1200/jco.2018.36.30_suppl.73","title":"Underutilization of GnRH analogues (G) and exemestane (E) in young patients with early-stage breast cancer (BC) in Ontario.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Tamoxifen; Exemestane; Breast cancer; Population; Internal medicine; Gynecology; Adjuvant; Oncology; Adjuvant therapy; Stage (stratigraphy); Cancer; Oophorectomy; Surgery; Hysterectomy","score_opus":0.06466246384608657,"score_gpt":0.41658067563930484,"score_spread":0.35191821179321825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892968865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982491,0.00009876135,0.000184703,0.0006126315,0.0002869824,0.0001543234,0.000005342314,0.0000026693372,0.00040545186],"genre_scores_gemma":[0.9978355,0.00014964858,0.0014488479,0.00025939848,0.00016694574,0.000002218525,0.000002355867,0.000012392579,0.00012268068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99800134,0.00013814284,0.0012875394,0.00015062183,0.00025281528,0.0001695419],"domain_scores_gemma":[0.9979533,0.00026453106,0.0010229673,0.000105145366,0.00052442483,0.00012960672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000723441,0.00010510107,0.0008988087,0.00017587366,0.000012819329,0.0000031133118,0.0000706722,0.00017254328,0.00014266401],"category_scores_gemma":[0.00019593388,0.00007332777,0.000058226367,0.00018713999,0.0004028549,0.00018514012,0.000025379437,0.0005090394,6.435358e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009040446,0.0006804729,0.9604511,0.000019004565,0.00007977822,0.00005533702,0.00064383115,0.000018526962,0.000025290221,0.000032239794,0.000007087655,0.02894687],"study_design_scores_gemma":[0.011387789,0.0057056486,0.9811814,0.00033357574,0.00006313122,0.00005573,0.00016507976,0.000025200552,0.000017123351,0.00016983273,0.0008334347,0.00006204586],"about_ca_topic_score_codex":0.019159947,"about_ca_topic_score_gemma":0.43517566,"teacher_disagreement_score":0.4160157,"about_ca_system_score_codex":0.0003975881,"about_ca_system_score_gemma":0.0011874922,"threshold_uncertainty_score":0.98737156},"labels":[],"label_agreement":null},{"id":"W2895166167","doi":"10.1111/ajco.13065","title":"Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2‐non‐amplified metastatic breast cancer","year":2018,"lang":"en","type":"article","venue":"Asia-Pacific Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nutrasource","funders":"","keywords":"Metastatic breast cancer; Breast cancer; Cyclin-dependent kinase 4; Palbociclib; Medicine; Context (archaeology); Oncology; Hormone receptor; Cancer; Internal medicine; Human Epidermal Growth Factor Receptor 2; Endocrine system; Cancer research; Hormone; Cell cycle; Biology; Cyclin-dependent kinase 2","score_opus":0.04894483337038611,"score_gpt":0.4177188545871236,"score_spread":0.36877402121673747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895166167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9650449,0.0051575718,0.0029205673,0.019893449,0.002950741,0.0015396795,0.001988202,0.000023292996,0.00048160125],"genre_scores_gemma":[0.9588398,0.0050009578,0.030228926,0.00021838251,0.005297036,0.000043848973,0.00010899388,0.000061296894,0.00020081202],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997646,0.0001714905,0.0012738486,0.0003560576,0.00027082372,0.00028181454],"domain_scores_gemma":[0.99605334,0.00071671535,0.0013964905,0.00036318798,0.0011722869,0.00029799348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005625828,0.00023027237,0.0013326918,0.00013643302,0.00010616308,0.000008399346,0.00014570054,0.00014709213,0.00009735394],"category_scores_gemma":[0.00013847077,0.00014804339,0.00016507643,0.00021219761,0.0005611424,0.00024457055,0.00004174935,0.00026129695,0.0000019221598],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031592075,0.0027558818,0.031076862,0.000035514742,0.0022866558,0.000018105911,0.0012085258,9.3001177e-7,0.00047799514,0.000019722007,0.0013163344,0.9292114],"study_design_scores_gemma":[0.028838402,0.038866002,0.38192356,0.0002757824,0.0017706224,0.0003306003,0.0040873024,0.000041787156,0.0003548801,0.000110270856,0.5431527,0.00024810564],"about_ca_topic_score_codex":0.000026878604,"about_ca_topic_score_gemma":0.000057523164,"teacher_disagreement_score":0.9289633,"about_ca_system_score_codex":0.00023999544,"about_ca_system_score_gemma":0.0007669813,"threshold_uncertainty_score":0.60370344},"labels":[],"label_agreement":null},{"id":"W2895682835","doi":"10.1111/ajco.13064","title":"Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm","year":2018,"lang":"en","type":"article","venue":"Asia-Pacific Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nutrasource","funders":"Novartis Australia","keywords":"Metastatic breast cancer; Tolerability; Medicine; Oncology; Breast cancer; Internal medicine; Endocrine system; Hormone receptor; Cyclin-dependent kinase; Hormone; Cancer; Cell cycle; Adverse effect","score_opus":0.07353694004946239,"score_gpt":0.4576646807170495,"score_spread":0.38412774066758715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895682835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96262217,0.0029217694,0.00020149937,0.028816132,0.0022876759,0.00084222725,0.0002666219,0.00001919828,0.0020227008],"genre_scores_gemma":[0.9932332,0.0029398866,0.0009093665,0.00023017313,0.0025062363,0.000024567047,0.0000052824407,0.00004110247,0.00011016603],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9956744,0.0009182644,0.002121757,0.00032708322,0.00051370653,0.0004447942],"domain_scores_gemma":[0.9927989,0.0030124462,0.0025429993,0.00039456473,0.0007937507,0.0004573241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013655958,0.0003693286,0.0018942928,0.00018362926,0.00010389094,0.00001126157,0.00024423146,0.00015176654,0.00047349048],"category_scores_gemma":[0.0005868984,0.00019108027,0.0010289946,0.00038274456,0.0013740305,0.0001572551,0.00003560613,0.00095595716,0.000048260983],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0281242,0.004142674,0.013463925,0.000014906539,0.0035886937,0.00009401977,0.001486126,0.000026662367,0.0010940142,0.0002814352,0.0053085126,0.9423748],"study_design_scores_gemma":[0.03088146,0.16626121,0.684053,0.0014934381,0.0025065544,0.0022686606,0.0032610681,0.00008225055,0.006289011,0.004339934,0.09792505,0.0006383245],"about_ca_topic_score_codex":0.00013760425,"about_ca_topic_score_gemma":0.00003514935,"teacher_disagreement_score":0.9417365,"about_ca_system_score_codex":0.0012327188,"about_ca_system_score_gemma":0.0025678403,"threshold_uncertainty_score":0.7792027},"labels":[],"label_agreement":null},{"id":"W2895782917","doi":"10.1016/j.breast.2018.10.001","title":"Targeting CDK4/6 pathways and beyond in breast cancer","year":2018,"lang":"en","type":"review","venue":"The Breast","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Palbociclib; Oncology; Metastatic breast cancer; Internal medicine; Fulvestrant; Breast cancer; Neutropenia; Cancer; Clinical trial; Disease; Adjuvant; Adjuvant therapy; Toxicity; Tamoxifen","score_opus":0.031651075078762796,"score_gpt":0.3233811829162637,"score_spread":0.2917301078375009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895782917","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007256066,0.9961859,0.0000142971085,0.0009697903,0.0002851361,0.00096702034,0.000671094,0.00008324252,0.00075098407],"genre_scores_gemma":[0.0002568453,0.99657786,0.00016903809,0.0003986687,0.0017351819,0.00028440898,0.00007643046,0.00014970274,0.0003518387],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99773127,0.00015692778,0.0006077922,0.00060750556,0.00031399698,0.0005825327],"domain_scores_gemma":[0.99860674,0.00013807557,0.0003584613,0.00061556575,0.00011085618,0.00017032544],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044158194,0.0005958364,0.0016663289,0.00018343871,0.00013638524,0.000036080295,0.00030939438,0.0002538797,0.0003703432],"category_scores_gemma":[0.000017902528,0.00035753896,0.00022366062,0.00046643362,0.0004249668,0.00011030886,0.0002044778,0.00070011924,0.00008757163],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010183547,0.000048390037,0.00013727562,0.004925418,0.00018156585,0.00003667861,0.00030931924,4.9235246e-7,0.0000069419775,0.00009897383,0.0004012427,0.9937519],"study_design_scores_gemma":[0.00096429355,0.000041022147,0.0010979339,0.02270943,0.000815168,0.009810731,0.0001933394,0.000014018559,8.500832e-7,0.00026704962,0.96354014,0.00054601015],"about_ca_topic_score_codex":0.00018986542,"about_ca_topic_score_gemma":0.00003129401,"teacher_disagreement_score":0.99320585,"about_ca_system_score_codex":0.00035283747,"about_ca_system_score_gemma":0.0004536115,"threshold_uncertainty_score":0.99988765},"labels":[],"label_agreement":null},{"id":"W2897693137","doi":"10.1016/j.ejca.2018.08.011","title":"Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer in PALOMA-3","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Pfizer","keywords":"Fulvestrant; Palbociclib; Medicine; Placebo; Metastatic breast cancer; Internal medicine; Oncology; Breast cancer; Cancer; Estrogen receptor; Gynecology; Pathology","score_opus":0.013393079931901707,"score_gpt":0.2695117375637357,"score_spread":0.256118657631834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897693137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928499,0.0035622946,0.00008919733,0.0012753739,0.00027617626,0.0005673544,0.0011565565,0.000022604621,0.00020053708],"genre_scores_gemma":[0.9965789,0.0006693455,0.0013621936,0.00021946293,0.00087642507,0.000048567814,0.000009026575,0.0001261895,0.000109893284],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99627435,0.000497719,0.0013310135,0.00044484745,0.00078519655,0.0006668615],"domain_scores_gemma":[0.9971424,0.00014813467,0.0012374172,0.00027759912,0.0008282378,0.00036622578],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00050219096,0.00046265608,0.001180836,0.00040497057,0.000069782596,0.00002432188,0.00033041782,0.000037982605,0.0012455652],"category_scores_gemma":[0.00007290272,0.00034392072,0.0001226499,0.0005847092,0.0005646978,0.0004525274,0.000057979956,0.00068340957,0.0000058935716],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12705773,0.0010724548,0.2061455,0.00035313176,0.0041470053,0.0018218745,0.05346061,0.0005657761,0.5123243,0.000042466214,0.00030787807,0.09270132],"study_design_scores_gemma":[0.0156688,0.003170993,0.95546424,0.0022526672,0.00017018846,0.00008497546,0.0015473212,0.000010190182,0.020798963,0.000065191074,0.00040923367,0.00035720607],"about_ca_topic_score_codex":0.0010355288,"about_ca_topic_score_gemma":0.0009871095,"teacher_disagreement_score":0.7493188,"about_ca_system_score_codex":0.0012841658,"about_ca_system_score_gemma":0.0005210609,"threshold_uncertainty_score":0.9999013},"labels":[],"label_agreement":null},{"id":"W2898186613","doi":"10.1093/annonc/mdy272.320","title":"Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Aromatase inhibitor; Tamoxifen; Oncology; Internal medicine; Breast cancer; Subgroup analysis; Antiestrogen; Gynecology; Hormone receptor; Aromatase; Cancer; Meta-analysis","score_opus":0.019010494655576235,"score_gpt":0.32799831450718436,"score_spread":0.3089878198516081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898186613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99388146,0.00029927853,0.00032256465,0.0021738121,0.00011109702,0.001541891,0.001187138,0.00008658924,0.000396137],"genre_scores_gemma":[0.9919068,0.00024028188,0.0049739517,0.0013942597,0.00033616825,0.00049354776,0.00027599226,0.00013039893,0.00024855102],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961649,0.0002623866,0.00088261446,0.0010105452,0.0007421037,0.00093742245],"domain_scores_gemma":[0.99622285,0.00027650394,0.0009242454,0.00062040926,0.0015674012,0.00038857435],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032743195,0.0006386821,0.0016948134,0.0005667283,0.00011784814,0.000017981798,0.00030021355,0.00028719727,0.0003394118],"category_scores_gemma":[0.000068054316,0.00045888682,0.00014297769,0.0019717817,0.001213209,0.0005722594,0.00012974264,0.00047660776,0.000021396096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33780545,0.009970537,0.40107328,0.0003514983,0.011420472,0.0006372312,0.015209179,0.0006743672,0.03361571,0.000035841404,0.0026008338,0.1866056],"study_design_scores_gemma":[0.025955072,0.04727373,0.8880179,0.0008583073,0.0010768991,0.000104692284,0.0015243334,0.00012930292,0.03086936,0.00007852515,0.0032401048,0.0008717966],"about_ca_topic_score_codex":0.0019094812,"about_ca_topic_score_gemma":0.010052384,"teacher_disagreement_score":0.4869446,"about_ca_system_score_codex":0.00062728784,"about_ca_system_score_gemma":0.00071185135,"threshold_uncertainty_score":0.99978626},"labels":[],"label_agreement":null},{"id":"W2898400750","doi":"10.1093/annonc/mdy272.355","title":"LUCY: A phase IIIb, real-world study of olaparib in HER2-negative metastatic breast cancer patients with a BRCA mutation","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Olaparib; Metastatic breast cancer; Oncology; Internal medicine; BRCA mutation; Breast cancer; Taxane; Cohort; Progression-free survival; Eribulin; Cancer; Chemotherapy","score_opus":0.05783370770299373,"score_gpt":0.43824251956716864,"score_spread":0.3804088118641749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898400750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996945,0.00004920366,0.00004301112,0.00088410324,0.000075073025,0.0010586673,0.00010363258,0.000015726748,0.0008255696],"genre_scores_gemma":[0.9984654,0.0000245015,0.00071499817,0.0004519059,0.000063256666,0.00015059934,0.000015692942,0.000026235779,0.00008737231],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99846494,0.00017692476,0.0005152583,0.0002841407,0.0002915542,0.0002671922],"domain_scores_gemma":[0.9980405,0.00014162183,0.0005272108,0.00022949214,0.000976282,0.00008492131],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022063885,0.00017418407,0.0007314996,0.00032119377,0.000030403633,0.0000022057752,0.0000922137,0.00004286405,0.00021791358],"category_scores_gemma":[0.00005677336,0.00013732933,0.00004070181,0.0006516313,0.0003514614,0.00014893856,0.000030193818,0.00013945474,0.0000032554967],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050979722,0.03568119,0.41861612,0.00028156044,0.0019248221,0.00016502706,0.053182274,0.0001529737,0.0011688733,0.0001491901,0.00031988817,0.43737838],"study_design_scores_gemma":[0.041693706,0.03626308,0.9118482,0.0003420896,0.00026880944,0.000022706468,0.00451758,0.00008016795,0.00366358,0.0004817116,0.0006189849,0.00019940338],"about_ca_topic_score_codex":0.005669982,"about_ca_topic_score_gemma":0.021539215,"teacher_disagreement_score":0.49323207,"about_ca_system_score_codex":0.00014215041,"about_ca_system_score_gemma":0.00037390663,"threshold_uncertainty_score":0.9963151},"labels":[],"label_agreement":null},{"id":"W2898447893","doi":"10.1093/annonc/mdy269.181","title":"Neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer: The phase II NeoRHEA trial","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Palbociclib; Medicine; Breast cancer; Oncology; Tamoxifen; Internal medicine; Letrozole; Estrogen receptor; Biomarker; Gene signature; Neoadjuvant therapy; Cancer; Metastatic breast cancer; Gene expression; Gene","score_opus":0.14732162359298423,"score_gpt":0.49262454327951327,"score_spread":0.34530291968652904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898447893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97856724,0.00044781427,0.0000060671987,0.01692814,0.00017514796,0.0031468826,0.00011049623,0.000019306723,0.0005989206],"genre_scores_gemma":[0.99790144,0.00041984432,0.00016478401,0.00055391056,0.0003374919,0.00041812478,0.000011728089,0.000040906118,0.00015179736],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9968562,0.0009549456,0.000639961,0.00042212888,0.0005527751,0.00057395635],"domain_scores_gemma":[0.996732,0.0007302902,0.00039116282,0.0005123969,0.0015066117,0.00012755397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011202649,0.00024458347,0.00090418034,0.00028469847,0.00016846432,0.000005730304,0.00030901746,0.00009888117,0.0005477652],"category_scores_gemma":[0.000117256095,0.00014956364,0.00009029394,0.00094397535,0.0014668511,0.00011447276,0.00012178276,0.00040774167,0.000004012354],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5536288,0.011589584,0.0052224565,0.0000144180185,0.0008733091,0.00005861751,0.00979142,0.000003767566,0.01545666,0.00009628931,0.0007026233,0.40256205],"study_design_scores_gemma":[0.41425538,0.43471336,0.059963714,0.000324189,0.000094582836,0.00013038152,0.012040459,0.000050489925,0.06762852,0.00045611474,0.010046977,0.0002958435],"about_ca_topic_score_codex":0.004448839,"about_ca_topic_score_gemma":0.0013350572,"teacher_disagreement_score":0.42312378,"about_ca_system_score_codex":0.00013440211,"about_ca_system_score_gemma":0.0007436508,"threshold_uncertainty_score":0.67253435},"labels":[],"label_agreement":null},{"id":"W2898479222","doi":"10.1093/annonc/mdy272.283","title":"Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 patient-reported outcomes (PROs)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Letrozole; Internal medicine; Clinical endpoint; Anastrozole; Hazard ratio; Aromatase inhibitor; Tamoxifen; Breast cancer; Quality of life (healthcare); Oncology; Goserelin; Progression-free survival; Placebo; Cancer; Randomized controlled trial; Gynecology; Chemotherapy; Confidence interval","score_opus":0.024362455649523745,"score_gpt":0.3395648336872037,"score_spread":0.3152023780376799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898479222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918844,0.00026382133,0.000053687556,0.003012594,0.00038034646,0.0024563107,0.0012710118,0.00009003177,0.0005877775],"genre_scores_gemma":[0.99255604,0.00017781726,0.0031666425,0.0024219304,0.000277392,0.00071083015,0.00023560536,0.00012864129,0.00032510044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99556786,0.00024715165,0.0013414343,0.0010188449,0.0008058116,0.0010189257],"domain_scores_gemma":[0.99554706,0.00031160156,0.0013461694,0.0006581913,0.0017316388,0.00040533932],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029464313,0.00070384436,0.0016254388,0.00034918697,0.00014587316,0.000017172279,0.0002789888,0.00035080357,0.00043150614],"category_scores_gemma":[0.00021758271,0.0005276681,0.0001427444,0.0007741531,0.0010415128,0.0006079802,0.00019615507,0.00052312814,0.00003930624],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15424679,0.01010034,0.40141222,0.000297032,0.002867276,0.00068029715,0.014536061,0.00008767319,0.042048488,0.000021863714,0.005273845,0.3684281],"study_design_scores_gemma":[0.030324863,0.039865423,0.8668067,0.001048132,0.00023164884,0.0001759937,0.0017329484,0.00003455131,0.053132784,0.00017169799,0.0055837315,0.00089153094],"about_ca_topic_score_codex":0.0012243431,"about_ca_topic_score_gemma":0.0019779133,"teacher_disagreement_score":0.4653945,"about_ca_system_score_codex":0.00057961687,"about_ca_system_score_gemma":0.0008468601,"threshold_uncertainty_score":0.9997175},"labels":[],"label_agreement":null},{"id":"W2898484591","doi":"10.1093/annonc/mdy424.009","title":"Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Palbociclib; Fulvestrant; Internal medicine; Hazard ratio; Clinical endpoint; Breast cancer; Metastatic breast cancer; Progression-free survival; Oncology; Cancer; Gastroenterology; Chemotherapy; Estrogen receptor; Confidence interval; Randomized controlled trial","score_opus":0.055907089637438304,"score_gpt":0.38229451582051993,"score_spread":0.32638742618308164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898484591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910492,0.0006602368,0.0002452614,0.004549977,0.00016002859,0.0008333277,0.0012138076,0.00008466542,0.0012035542],"genre_scores_gemma":[0.9926968,0.0006450943,0.0036746454,0.0017260934,0.00059951737,0.0002666404,0.00011083756,0.000107763444,0.00017259625],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.996276,0.0003923325,0.00078757043,0.0009204299,0.00057608954,0.0010475353],"domain_scores_gemma":[0.99675816,0.00048407874,0.0007599064,0.00047754898,0.0011084831,0.00041181117],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025670897,0.00062065804,0.0017882208,0.00028808656,0.00015428595,0.000016988331,0.00029742657,0.00029147472,0.0016604072],"category_scores_gemma":[0.0000698349,0.00046845913,0.00012054901,0.00061897177,0.0014161312,0.0005141898,0.00008107857,0.0005578412,0.000023195083],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22067377,0.0026226074,0.06603646,0.00020575573,0.0063370233,0.00045636084,0.03463684,0.00026482932,0.4933505,0.00033023139,0.0011129319,0.17397268],"study_design_scores_gemma":[0.020478053,0.016849397,0.89058965,0.0006006193,0.00015080199,0.000059217386,0.00405334,0.00001367031,0.0637643,0.00067541236,0.0019789313,0.0007866238],"about_ca_topic_score_codex":0.0056188935,"about_ca_topic_score_gemma":0.0036018535,"teacher_disagreement_score":0.8245532,"about_ca_system_score_codex":0.0008023793,"about_ca_system_score_gemma":0.00084008375,"threshold_uncertainty_score":0.9997767},"labels":[],"label_agreement":null},{"id":"W2898595037","doi":"10.1093/annonc/mdy272.322","title":"Clinical outcomes in patients (pts) with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC) with objective response (OR) or without objective response (non-OR) in PALOMA-2","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Letrozole; Breast cancer; Palbociclib; Estrogen receptor; Cancer; Phases of clinical research; Metastatic breast cancer; Progression-free survival; Gastroenterology; Oncology; Clinical trial; Gynecology; Overall survival; Tamoxifen","score_opus":0.04555222766477911,"score_gpt":0.4145697970891816,"score_spread":0.3690175694244025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898595037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99273103,0.000051518524,0.00006924578,0.0028476627,0.00027434144,0.002856746,0.0008111211,0.00007992479,0.00027841888],"genre_scores_gemma":[0.99093646,0.00010823942,0.0050498787,0.0019425221,0.00023220044,0.0006406248,0.000035188583,0.00016517723,0.0008897211],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99218655,0.002933056,0.001555799,0.0014121041,0.0007077113,0.0012048051],"domain_scores_gemma":[0.99091,0.004339755,0.0013342209,0.00068712013,0.002272421,0.00045647944],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015354481,0.00087002956,0.0026991474,0.0007343795,0.0001880497,0.000016335387,0.00040450448,0.00054774416,0.0008593179],"category_scores_gemma":[0.0021785453,0.00054423336,0.00021400723,0.0013160418,0.0023787557,0.00068794034,0.00017016286,0.0010666965,0.000033750905],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47718844,0.0017617218,0.49108842,0.000032173146,0.00069617515,0.0001354989,0.007520295,0.000007659732,0.00088376005,0.0000062113604,0.00006927109,0.020610388],"study_design_scores_gemma":[0.031099366,0.0697063,0.88351744,0.0009995493,0.00010136903,0.000095333104,0.004119912,0.000005055027,0.009161479,0.000054438326,0.00048922264,0.00065054547],"about_ca_topic_score_codex":0.0015425896,"about_ca_topic_score_gemma":0.00967302,"teacher_disagreement_score":0.44608906,"about_ca_system_score_codex":0.0014937691,"about_ca_system_score_gemma":0.003906384,"threshold_uncertainty_score":0.9997009},"labels":[],"label_agreement":null},{"id":"W2900959981","doi":"10.1038/s41467-018-07407-3","title":"Author Correction: The prognostic effects of somatic mutations in ER-positive breast cancer","year":2018,"lang":"en","type":"erratum","venue":"Nature Communications","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute for Health and Care Research","keywords":"Somatic cell; Confidence interval; Breast cancer; Depiction; Germline mutation; Mutation; Oncology; Statistics; Cancer; Computer science; Internal medicine; Medicine; Genetics; Biology; Mathematics; Philosophy; Linguistics; Gene","score_opus":0.012067474803539343,"score_gpt":0.33600435176069476,"score_spread":0.3239368769571554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900959981","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0063946513,0.5322051,0.0012727488,0.25581867,0.11581207,0.022964176,0.003232184,0.0010164116,0.061283946],"genre_scores_gemma":[0.9084819,0.0031273735,0.003054309,0.001538643,0.0022133412,0.003424979,0.002355626,0.00021660923,0.0755872],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99820775,0.00034100757,0.00048507206,0.00030377298,0.00039041205,0.0002719957],"domain_scores_gemma":[0.994777,0.0015525568,0.0005016093,0.0023449678,0.00074443506,0.00007940114],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00018819922,0.0003279568,0.00058896176,0.00029747613,0.00031160982,0.000021789692,0.0009367999,0.0007849694,0.00007891976],"category_scores_gemma":[0.00063540065,0.0002454257,0.00016855134,0.00094534294,0.00081353437,0.000102014106,0.00024803425,0.0037275753,0.000020204863],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003230551,0.0016261514,0.012929539,0.0018842003,0.0016024427,0.000020286261,0.009062151,0.000035492114,0.00046884074,0.0014225673,0.9257092,0.0449161],"study_design_scores_gemma":[0.0017185501,0.0002604578,0.7421759,0.012764745,0.0018081568,0.00043976808,0.00088096753,0.0018730075,0.00030191982,0.0009533699,0.23625103,0.00057215727],"about_ca_topic_score_codex":0.00021592007,"about_ca_topic_score_gemma":0.0028271717,"teacher_disagreement_score":0.9020873,"about_ca_system_score_codex":0.00047960182,"about_ca_system_score_gemma":0.00095288374,"threshold_uncertainty_score":0.9999998},"labels":[],"label_agreement":null},{"id":"W2902672529","doi":"10.1200/jco.18.01624","title":"Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":235,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal; Centre hospitalier de l'Université Laval; Institute of Cancer Research; Jewish General Hospital","funders":"Daiichi Sankyo Europe; Genentech; Astellas Pharma; Eisai; Cancer Research UK; GlaxoSmithKline; Public Health Agency; MacroGenics; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Genomic Health","keywords":"Letrozole; Palbociclib; Medicine; Breast cancer; Estrogen receptor; Internal medicine; Oncology; Urology; Cancer; Metastatic breast cancer; Tamoxifen","score_opus":0.14846606869792917,"score_gpt":0.5541645440786152,"score_spread":0.405698475380686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902672529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862159,0.00043560125,0.000100241254,0.008637832,0.0016923322,0.0027119848,0.000028003722,0.000013150994,0.00016494139],"genre_scores_gemma":[0.9899292,0.00037969823,0.0020972455,0.0025364002,0.0047532916,0.00020579745,0.000005529632,0.00003611048,0.000056708916],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9920538,0.0028789458,0.0035786985,0.00038364765,0.0006869244,0.0004179516],"domain_scores_gemma":[0.9935607,0.0030084532,0.0020285333,0.00022918219,0.00078598724,0.00038716657],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010036178,0.0002584928,0.0030379724,0.00034652159,0.00007740027,0.000013741028,0.00023091199,0.00029490548,0.0010804157],"category_scores_gemma":[0.0036501056,0.00018766848,0.0004905905,0.0004223569,0.00033164545,0.00022210946,0.00006935349,0.0011782276,0.000025031763],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5968614,0.0055863312,0.0035788966,0.0000017825931,0.0003575138,0.00014096267,0.002015172,0.000019574243,0.0006915145,0.00000942425,0.00009838524,0.39063898],"study_design_scores_gemma":[0.8181682,0.16226143,0.015893463,0.0002977987,0.00016882553,0.000101470796,0.0009026687,0.000069937945,0.00013810776,0.00036914696,0.0014776763,0.00015125272],"about_ca_topic_score_codex":0.00038101748,"about_ca_topic_score_gemma":0.00029235217,"teacher_disagreement_score":0.39048773,"about_ca_system_score_codex":0.0005966565,"about_ca_system_score_gemma":0.0019511017,"threshold_uncertainty_score":0.99983275},"labels":[],"label_agreement":null},{"id":"W2903411408","doi":"10.1016/j.breast.2018.11.008","title":"Why upfront use of CDK inhibitors for the treatment of advanced breast cancer may be wasteful, and how we can increase their value","year":2018,"lang":"en","type":"article","venue":"The Breast","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Medicine; Breast cancer; Value (mathematics); Cyclin-dependent kinase; Cancer; Oncology; Internal medicine","score_opus":0.02622463847702784,"score_gpt":0.2785753223596665,"score_spread":0.25235068388263865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903411408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8718514,0.0054755816,0.00044838028,0.11588358,0.0003826993,0.002293016,0.003569771,0.00006321545,0.00003237909],"genre_scores_gemma":[0.9956494,0.0011676073,0.00060627534,0.00086582836,0.00071894174,0.0003072888,0.000020655947,0.00007365879,0.000590359],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99856985,0.00009243961,0.0002959436,0.00035395077,0.00028426797,0.000403526],"domain_scores_gemma":[0.9979254,0.00043077065,0.00031995415,0.00079120556,0.0003725188,0.00016016279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016458484,0.0003709584,0.00058828504,0.00007911834,0.00019855196,0.000021678321,0.00019263502,0.00007798807,0.00006314633],"category_scores_gemma":[0.00002510962,0.00018299607,0.00018500672,0.0002192963,0.0010660535,0.00016006173,0.00006075264,0.000095236355,5.5677066e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01799609,0.0011257185,0.014765237,0.00039806098,0.0021491034,0.0000070643086,0.013907859,0.00027978103,0.053607658,0.00085227913,0.0038398176,0.8910713],"study_design_scores_gemma":[0.028565172,0.006617014,0.24141525,0.0027213085,0.0032855063,0.0032059818,0.016274173,0.0023492747,0.19054402,0.0011837315,0.502433,0.0014055632],"about_ca_topic_score_codex":0.0034150195,"about_ca_topic_score_gemma":0.0012827812,"teacher_disagreement_score":0.8896658,"about_ca_system_score_codex":0.00021883218,"about_ca_system_score_gemma":0.0001854679,"threshold_uncertainty_score":0.7462363},"labels":[],"label_agreement":null},{"id":"W2908699784","doi":"10.1007/s10549-018-05125-4","title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","year":2019,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":442,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Alberta","funders":"Pfizer","keywords":"Palbociclib; Letrozole; Medicine; Breast cancer; Oncology; Internal medicine; Placebo; Metastatic breast cancer; Hazard ratio; Estrogen receptor; Population; Cancer; Gynecology; Tamoxifen; Confidence interval; Pathology","score_opus":0.03527075155297768,"score_gpt":0.3551255762284284,"score_spread":0.3198548246754507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908699784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98144835,0.0040642996,0.000011958097,0.0083081005,0.00017972138,0.0035166403,0.0019718858,0.00011405681,0.00038499915],"genre_scores_gemma":[0.98547214,0.0070766956,0.00031836214,0.00023810772,0.0004247411,0.0026889471,0.00016927175,0.00016938821,0.0034423366],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99522376,0.00025440805,0.00051854574,0.001367177,0.0011167526,0.001519341],"domain_scores_gemma":[0.99732214,0.00027738616,0.00021367564,0.0006325006,0.0008238278,0.00073049305],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021749518,0.0007823654,0.0011380122,0.0004373759,0.00040341698,0.00008786599,0.0002521074,0.00019013009,0.0037290913],"category_scores_gemma":[0.000017549419,0.00055768644,0.00018130582,0.00086625334,0.00057100673,0.0005514957,0.00011066775,0.00064006733,0.00010342498],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09151347,0.002199138,0.37040186,0.00024331635,0.0023963968,0.00024878985,0.0040440946,0.000115409064,0.023884797,0.0005213197,0.000109807086,0.50432163],"study_design_scores_gemma":[0.081153944,0.010766721,0.8512605,0.0019123148,0.000101726735,0.000565167,0.0018589289,0.000052552423,0.047950212,0.0005147713,0.0027218508,0.0011413149],"about_ca_topic_score_codex":0.017501121,"about_ca_topic_score_gemma":0.0032049255,"teacher_disagreement_score":0.5031803,"about_ca_system_score_codex":0.0037282386,"about_ca_system_score_gemma":0.0012068853,"threshold_uncertainty_score":0.99968743},"labels":[],"label_agreement":null},{"id":"W2911146996","doi":"10.1080/23723556.2018.1558684","title":"Patient-derived xenografts: a promising resource for preclinical cancer research","year":2019,"lang":"en","type":"article","venue":"Molecular & Cellular Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"CDKN2A; Medicine; Cancer research; Head and neck squamous-cell carcinoma; Cancer; Cyclin D1; Kinase; Oncology; Head and neck cancer; Internal medicine; Cell cycle; Biology","score_opus":0.05900352730484567,"score_gpt":0.42412549389129833,"score_spread":0.3651219665864527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911146996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98048586,0.004654413,0.0049701757,0.004126427,0.0004068421,0.0031284606,0.000015069943,0.00010005757,0.0021126948],"genre_scores_gemma":[0.98001945,0.00003921441,0.014769286,0.0023619402,0.00040069805,0.0009401952,0.00007668096,0.00014473226,0.0012478044],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970761,0.00040025671,0.00047824025,0.00073385425,0.00048752583,0.00082400924],"domain_scores_gemma":[0.99810886,0.00037424912,0.00016075649,0.0006861294,0.0004258685,0.0002441364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000767624,0.00023332614,0.00062985736,0.00020008074,0.00012628784,0.00002005268,0.00020065389,0.00033951204,0.00030642844],"category_scores_gemma":[0.00027685988,0.00021846956,0.00023371605,0.0003371029,0.000290297,0.000056942197,0.0001610373,0.0006435766,0.00008616115],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026719857,0.00030187544,0.0004915801,0.00015793405,0.00018452926,0.00015235803,0.0008254565,0.00008555706,0.9217798,0.00014931035,0.00034424936,0.07285532],"study_design_scores_gemma":[0.00409924,0.002577056,0.000116833,0.0001473415,0.000073701056,0.00004392784,0.0004432806,0.00015302587,0.47397265,0.0003713355,0.5178205,0.00018114413],"about_ca_topic_score_codex":0.000048332506,"about_ca_topic_score_gemma":0.00001096029,"teacher_disagreement_score":0.5174762,"about_ca_system_score_codex":0.0005843552,"about_ca_system_score_gemma":0.00065494765,"threshold_uncertainty_score":0.89089304},"labels":[],"label_agreement":null},{"id":"W2917684283","doi":"10.1200/jco.2015.33.15_suppl.1544","title":"Somatic mutations in Luminal HER2 negative tumors from young breast cancer patients.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Multiplex ligation-dependent probe amplification; Sanger sequencing; Breast cancer; Medicine; Nonsense mutation; Germline mutation; Cancer research; Exome sequencing; Mutation; Cancer; Exon; Exome; Somatic cell; Internal medicine; Oncology; Gene; Genetics; Biology; Missense mutation","score_opus":0.09120939041578294,"score_gpt":0.45986588970284975,"score_spread":0.3686564992870668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917684283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903702,0.00024672312,0.00013271725,0.006709057,0.0016279734,0.00017923555,0.000032344593,0.000008924937,0.0006927947],"genre_scores_gemma":[0.9924154,0.000044824657,0.0045853076,0.0011582758,0.0016775483,0.000011480033,0.0000057676193,0.000019948826,0.000081440434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99688226,0.0003467565,0.0019605532,0.00016643209,0.00042295922,0.00022103068],"domain_scores_gemma":[0.99594367,0.0011731345,0.0015695249,0.00012588016,0.0007438329,0.00044397975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093603594,0.00013734723,0.0011990764,0.00013269405,0.000021607702,0.0000063045477,0.00013984386,0.00018640571,0.00021819644],"category_scores_gemma":[0.0020145245,0.00010269462,0.00021075833,0.00017773296,0.00027990487,0.00025101056,0.00003410191,0.0008561539,0.000024903908],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004523846,0.0017289722,0.8869779,0.00001110452,0.00023809528,0.00035152587,0.0016600214,0.00015626353,0.000030626255,0.000012876055,0.00037370628,0.10393508],"study_design_scores_gemma":[0.014926011,0.0027698996,0.9743725,0.00026793385,0.00018744082,0.00025074353,0.0016026773,0.0001150799,0.000034361216,0.003651326,0.0017233543,0.00009864097],"about_ca_topic_score_codex":0.0008063858,"about_ca_topic_score_gemma":0.00088492996,"teacher_disagreement_score":0.10383644,"about_ca_system_score_codex":0.0006645453,"about_ca_system_score_gemma":0.0025729528,"threshold_uncertainty_score":0.45643076},"labels":[],"label_agreement":null},{"id":"W2921192143","doi":"10.1634/theoncologist.2018-0711","title":"What Is Important When Making Treatment Decisions in Metastatic Breast Cancer? A Qualitative Analysis of Decision-Making in Patients and Oncologists","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Medicine; Metastatic breast cancer; Oncology; Clinical decision making; Qualitative research; Internal medicine; Intensive care medicine; Cancer; Sociology","score_opus":0.043849595869289194,"score_gpt":0.43253152101234943,"score_spread":0.3886819251430602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921192143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937626,0.0029164348,0.00023466867,0.0017049306,0.00015886816,0.0010065819,0.00010544432,0.000013739034,0.000096700365],"genre_scores_gemma":[0.9949348,0.0011792372,0.002950059,0.0007085901,0.000009592233,0.0001325896,0.000009735695,0.000019213316,0.000056193414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781483,0.00026384147,0.0008226384,0.000439849,0.00033666322,0.0003221672],"domain_scores_gemma":[0.99643373,0.0024257172,0.00049994874,0.00045314242,0.00013954703,0.000047925227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007887172,0.0002466203,0.0010966108,0.00059761625,0.000050607956,0.000029210963,0.00017632594,0.000078322155,0.00019898661],"category_scores_gemma":[0.00019582165,0.00015103756,0.00015252842,0.0012064966,0.0003129798,0.00021218378,0.00010996843,0.0001721672,0.000003833767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003582674,0.0007723554,0.61365795,0.000021202106,0.0011851373,0.000044623685,0.030742364,0.00089175394,0.0000780777,0.0001450996,0.000011885017,0.34886688],"study_design_scores_gemma":[0.005074163,0.0008309171,0.95917684,0.0011292411,0.0010158074,0.000010969624,0.02579295,0.0014365916,0.000026148009,0.0050988686,0.00023058662,0.00017692962],"about_ca_topic_score_codex":0.0011410326,"about_ca_topic_score_gemma":0.00819488,"teacher_disagreement_score":0.34868997,"about_ca_system_score_codex":0.0016850063,"about_ca_system_score_gemma":0.00026262432,"threshold_uncertainty_score":0.6159133},"labels":[],"label_agreement":null},{"id":"W2924412259","doi":"10.1186/s13058-019-1121-4","title":"The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours","year":2019,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Environmental Health Sciences; BC Cancer Agency; Cancerfonden; National Research Foundation Singapore; National Research Foundation; National Cancer Institute; Cancerföreningen i Stockholm; Vetenskapsrådet; Cancer Research UK; Breast Cancer Research Foundation","keywords":"Surgical oncology; Cyclin D1; Breast cancer; Medicine; Oncology; Gene duplication; Term (time); Internal medicine; Gene; Cancer research; Cyclin; Cancer; Biology; Genetics; Cell cycle","score_opus":0.04371438391225062,"score_gpt":0.3675796944166135,"score_spread":0.32386531050436285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2924412259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99265736,0.0019536463,0.00010744051,0.0029591648,0.0001282725,0.0017067876,0.0003126123,0.000027390519,0.00014734002],"genre_scores_gemma":[0.9983546,0.0005329306,0.0000790757,0.000032841588,0.00020685447,0.0004130589,0.00002433242,0.000043129825,0.00031319234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973913,0.00023330774,0.0003706266,0.0005054904,0.00086870795,0.00063061103],"domain_scores_gemma":[0.99806345,0.00039123907,0.00013119819,0.000564358,0.0006614457,0.00018832032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010205049,0.00018891341,0.00035275886,0.00024064371,0.00013550541,0.00003611019,0.00025216382,0.00010025622,0.00011107649],"category_scores_gemma":[0.000086550695,0.00013833477,0.000054249533,0.00066265406,0.00075047376,0.00017872873,0.00012578064,0.00063020625,0.000022395583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030034625,0.00017453564,0.9140866,0.00024521933,0.000072064235,0.000009421314,0.0005702597,0.000045351262,0.02856919,0.0001400294,0.000017483571,0.053066377],"study_design_scores_gemma":[0.0019467544,0.00017027136,0.9924832,0.00059703994,0.000025445766,0.0004986706,0.0003247081,0.0001910211,0.0032998913,0.0002906489,0.000050429077,0.00012191038],"about_ca_topic_score_codex":0.0010215736,"about_ca_topic_score_gemma":0.00042281364,"teacher_disagreement_score":0.0783966,"about_ca_system_score_codex":0.00048042237,"about_ca_system_score_gemma":0.0004465381,"threshold_uncertainty_score":0.56411284},"labels":[],"label_agreement":null},{"id":"W2924646294","doi":"10.1158/1538-7445.sabcs18-p6-18-04","title":"Abstract P6-18-04: Ribociclib with a non-steroidal aromatase inhibitor and goserelin in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESA-7 age subgroup analysis","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Goserelin; Breast cancer; Internal medicine; Letrozole; Tamoxifen; Anastrozole; Aromatase inhibitor; Cancer; Hazard ratio; Gynecology; Oncology; Metastatic breast cancer; Clinical endpoint; Gastroenterology; Clinical trial; Confidence interval","score_opus":0.017254391296530298,"score_gpt":0.32690857408632235,"score_spread":0.30965418278979207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2924646294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927754,0.0024348856,0.000029565688,0.0010655625,0.000048569134,0.0022561296,0.0010532977,0.0000671905,0.00026942673],"genre_scores_gemma":[0.9944891,0.0012503329,0.0008497579,0.00016758178,0.00025252212,0.0018811339,0.00012944968,0.00013693249,0.00084324233],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99505836,0.00018544953,0.00052678457,0.0013192464,0.0014749563,0.0014352311],"domain_scores_gemma":[0.99747205,0.00028589246,0.00023821357,0.0007448906,0.0006405733,0.0006183559],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00073346106,0.0005606233,0.0011543856,0.00079206383,0.00017759715,0.00010431807,0.00030796247,0.00017863556,0.0010474075],"category_scores_gemma":[0.000024380337,0.00043594712,0.00006413441,0.002606394,0.0007496147,0.0006606419,0.00017052391,0.0012859268,0.000037461763],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11789869,0.0010147238,0.26319113,0.0010082388,0.004002805,0.000870133,0.011221305,0.0026061418,0.55224186,0.000013117112,0.00037244966,0.0455594],"study_design_scores_gemma":[0.014555707,0.0028565428,0.96125114,0.0015442197,0.00018128585,0.00004830234,0.0039884755,0.00010237624,0.014203041,0.00004596369,0.0005424041,0.0006805176],"about_ca_topic_score_codex":0.0060776374,"about_ca_topic_score_gemma":0.0054694316,"teacher_disagreement_score":0.69806004,"about_ca_system_score_codex":0.0022880896,"about_ca_system_score_gemma":0.0007850008,"threshold_uncertainty_score":0.9998658},"labels":[],"label_agreement":null},{"id":"W2925092419","doi":"10.1056/nejmoa1811714","title":"Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Cancer Care Ontario","funders":"National Cancer Institute","keywords":"Anastrozole; Fulvestrant; Medicine; Oncology; Aromatase inhibitor; Metastatic breast cancer; Internal medicine; Aromatase; Breast cancer; Cancer; Tamoxifen; Estrogen receptor; Progression-free survival; Overall survival","score_opus":0.01613558606668913,"score_gpt":0.2899758635197193,"score_spread":0.2738402774530302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2925092419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97866154,0.0022694056,0.0011697472,0.01654592,0.0005755243,0.00024232031,0.0000090020585,0.000011365842,0.0005151956],"genre_scores_gemma":[0.9951838,0.00028013386,0.0013056392,0.0007308581,0.0018800212,0.0000020436157,0.0000036699894,0.00003085058,0.00058296794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830395,0.000066052,0.0005050509,0.00016106218,0.00066844956,0.00029541136],"domain_scores_gemma":[0.99887323,0.00011556769,0.00031761618,0.00018369095,0.00019293083,0.00031693387],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00048388424,0.00020573224,0.0008411653,0.00024700054,0.000014683976,0.00000574361,0.00011572479,0.00003224788,0.0010401143],"category_scores_gemma":[0.000027516084,0.00011773097,0.00005480228,0.00023764382,0.00009742473,0.00018351992,0.000010667605,0.00047699708,0.0000049071373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05306078,0.00036037006,0.45905972,0.00052781083,0.0013341474,0.0032895568,0.0057102004,0.010932099,0.027103428,0.00047684537,0.000871982,0.43727306],"study_design_scores_gemma":[0.3511469,0.0051061385,0.5920163,0.004897148,0.0005790354,0.017002843,0.0016921196,0.00029586544,0.00038554636,0.00054437923,0.02598504,0.0003487192],"about_ca_topic_score_codex":0.0006785398,"about_ca_topic_score_gemma":0.00032754824,"teacher_disagreement_score":0.43692434,"about_ca_system_score_codex":0.00022058669,"about_ca_system_score_gemma":0.0006379827,"threshold_uncertainty_score":0.99987304},"labels":[],"label_agreement":null},{"id":"W2942888026","doi":"10.1158/1538-7445.sabcs18-p4-13-13","title":"Abstract P4-13-13: Meta-analyses of visceral versus non-visceral metastases treated by AI &amp; SERD agents as 2nd line endocrine therapy (ET) for HR+ breast cancer (BC)","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Fulvestrant; Metastatic breast cancer; Hazard ratio; Medicine; Internal medicine; Oncology; Cancer; Breast cancer; Confidence interval; Estrogen receptor","score_opus":0.2967427410094357,"score_gpt":0.5427007026166639,"score_spread":0.24595796160722821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942888026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97095984,0.013729363,0.00010449559,0.0070727877,0.00040335354,0.0030598105,0.0037952594,0.00009723625,0.00077788025],"genre_scores_gemma":[0.9764827,0.003675288,0.00023204552,0.0009248964,0.0005309047,0.0018159754,0.0005704601,0.00021267943,0.015555082],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9945815,0.00027914732,0.0008827194,0.0011390938,0.0017210038,0.0013965205],"domain_scores_gemma":[0.99559796,0.0006343198,0.0003554234,0.0011746477,0.0017444494,0.0004931943],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00089471537,0.0006956401,0.0018697474,0.0005486537,0.00019631133,0.000093728944,0.0005822831,0.00016649335,0.018120086],"category_scores_gemma":[0.00011831898,0.000510365,0.00086052757,0.0010198347,0.0004405007,0.0004748164,0.00015005392,0.0008943814,0.00011538285],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07639739,0.0017364005,0.0081479335,0.0012169981,0.037370715,0.00007541552,0.00086513534,0.0033738478,0.78307056,0.00006306659,0.03067239,0.057010133],"study_design_scores_gemma":[0.05244205,0.003673318,0.030336652,0.00060222135,0.00509534,0.000088070745,0.00045981532,0.00040219145,0.7241886,0.00038063864,0.18084373,0.0014873625],"about_ca_topic_score_codex":0.049540635,"about_ca_topic_score_gemma":0.0028305694,"teacher_disagreement_score":0.15017132,"about_ca_system_score_codex":0.0007882183,"about_ca_system_score_gemma":0.0011319533,"threshold_uncertainty_score":0.9997348},"labels":[],"label_agreement":null},{"id":"W2943032579","doi":"10.3747/co.26.4163","title":"U.S. Prevalence of Endocrine Therapy–Naïve Locally Advanced or Metastatic Breast Cancer","year":2019,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Cancer; Population; Incidence (geometry); Internal medicine; Metastatic breast cancer; Guideline; Oncology; Endocrine system; Hormone therapy; Malignancy; Trastuzumab; Gynecology; Database; Hormone; Pathology","score_opus":0.07833034697528762,"score_gpt":0.4285420643182823,"score_spread":0.35021171734299467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943032579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9607325,0.03165428,0.00084158767,0.0017527749,0.002096943,0.0019255041,0.00023610612,0.000109706736,0.0006505801],"genre_scores_gemma":[0.9854454,0.009965816,0.0019690383,0.00039088892,0.00021983124,0.0003012592,0.00001526469,0.00005451283,0.0016380197],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982437,0.00009278913,0.00047378452,0.00044201166,0.00031136078,0.0004363802],"domain_scores_gemma":[0.9985094,0.0001923987,0.0003204167,0.0004698399,0.00035763372,0.00015028521],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012753619,0.00026648084,0.0007346899,0.00012653945,0.000026488375,0.0000033686072,0.00021695808,0.000051697603,0.0048052203],"category_scores_gemma":[0.000040352086,0.00018926268,0.00012719483,0.00027764865,0.00022716842,0.00014921892,0.00006987882,0.00029965417,0.00007580826],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006522197,0.0009345761,0.07472333,0.0012935188,0.00021137713,0.000026475564,0.0003522263,0.0001121925,0.0118042715,0.0001499536,0.00010939604,0.9037605],"study_design_scores_gemma":[0.049589437,0.00818423,0.4938647,0.003019955,0.00069354504,0.0022300824,0.00088504574,0.00069994736,0.024574777,0.0007223283,0.4144713,0.001064673],"about_ca_topic_score_codex":0.000018875247,"about_ca_topic_score_gemma":0.000014780037,"teacher_disagreement_score":0.90269583,"about_ca_system_score_codex":0.0002695506,"about_ca_system_score_gemma":0.0007526889,"threshold_uncertainty_score":0.99610454},"labels":[],"label_agreement":null},{"id":"W2943776805","doi":"10.1016/j.ejca.2019.04.002","title":"Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor–positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT)","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Fondazione Sandro Pitigliani; Associazione Italiana per la Ricerca sul Cancro","keywords":"Medicine; Exemestane; Internal medicine; Fulvestrant; Oncology; Breast cancer; Metastatic breast cancer; Aromatase inhibitor; Clinical trial; Cancer; Progression-free survival; Response Evaluation Criteria in Solid Tumors; Aromatase; Gastroenterology; Phases of clinical research; Chemotherapy; Estrogen receptor","score_opus":0.029615690545690812,"score_gpt":0.35564776025566963,"score_spread":0.32603206970997883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943776805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956984,0.0016939625,0.00007459067,0.00014330795,0.0003457795,0.0016747845,0.00027880483,0.0000034790855,0.000086888824],"genre_scores_gemma":[0.99944764,0.00023106953,0.00011634986,0.000017967326,0.00011273254,0.00001576488,0.000008154942,0.000034184686,0.000016150674],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99546736,0.0015837144,0.0012558257,0.00022835482,0.0012683657,0.00019639549],"domain_scores_gemma":[0.9946898,0.00038085782,0.002701393,0.0003370102,0.0017823115,0.000108629174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002767734,0.00021409689,0.0013109527,0.00028818514,0.00002276404,0.0000052092714,0.00019908606,0.000028394443,0.0002986301],"category_scores_gemma":[0.00033558707,0.00013279074,0.00042422873,0.0009705294,0.00019586612,0.00019942285,0.00003854383,0.00033723298,5.0302623e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71176827,0.0016552805,0.09876894,0.000047093952,0.0050914264,0.0000046927635,0.00065772893,0.005135714,0.009914324,0.0000011626596,0.000005186178,0.16695021],"study_design_scores_gemma":[0.39932787,0.00401275,0.5850966,0.0004851015,0.0070801293,0.0000016392439,0.00016082576,0.0007276001,0.0029969353,0.00000186156,0.000015012378,0.00009366906],"about_ca_topic_score_codex":0.00007400851,"about_ca_topic_score_gemma":0.00006009177,"teacher_disagreement_score":0.48632765,"about_ca_system_score_codex":0.00030426655,"about_ca_system_score_gemma":0.00067761523,"threshold_uncertainty_score":0.5415049},"labels":[],"label_agreement":null},{"id":"W2943834628","doi":"10.1158/1538-7445.sabcs18-pd2-04","title":"Abstract PD2-04: Baseline circulating <i>ESR1</i> mutation analysis in the randomised phase III EFECT study of fulvestrant versus exemestane in advanced hormone receptor positive breast cancer","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Exemestane; Fulvestrant; Medicine; Internal medicine; Oncology; Aromatase inhibitor; Breast cancer; Hazard ratio; Metastatic breast cancer; Cancer; Triptorelin; Estrogen receptor; Gynecology; Aromatase; Gastroenterology; Confidence interval; Hormone","score_opus":0.04074556143826198,"score_gpt":0.4134207069088296,"score_spread":0.3726751454705676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943834628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99214226,0.0024710146,0.00007447081,0.00060826924,0.000121658435,0.0041946117,0.00020643661,0.000023204231,0.00015804937],"genre_scores_gemma":[0.9980337,0.00041235314,0.00007980078,0.00006219454,0.00013617174,0.001078893,0.000094722905,0.000047908274,0.000054255917],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9956833,0.0006800523,0.0008456636,0.0007155524,0.001367898,0.0007075224],"domain_scores_gemma":[0.99698246,0.0013133193,0.00028066165,0.00064127083,0.0006456481,0.00013665012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028652686,0.00029897553,0.00094804744,0.0008662379,0.00010022454,0.00002728085,0.0003108155,0.000099656994,0.00076386146],"category_scores_gemma":[0.00017710845,0.00023017252,0.00018123828,0.0036386333,0.00017247898,0.00029347176,0.00004787712,0.00091103266,0.0000074520876],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2537874,0.0030794148,0.02447042,0.0003157564,0.0016282388,0.00028475325,0.015313587,0.025599722,0.5811372,0.000009960289,0.000026466285,0.094347104],"study_design_scores_gemma":[0.3758089,0.0027593737,0.57385427,0.00088859914,0.0007341235,0.000023306187,0.03233597,0.002871389,0.010109603,0.000025381712,0.0000551789,0.0005339303],"about_ca_topic_score_codex":0.008365841,"about_ca_topic_score_gemma":0.003451707,"teacher_disagreement_score":0.5710276,"about_ca_system_score_codex":0.0010135311,"about_ca_system_score_gemma":0.0005291214,"threshold_uncertainty_score":0.99823755},"labels":[],"label_agreement":null},{"id":"W2943879513","doi":"10.1158/1538-7445.sabcs18-pd2-05","title":"Abstract PD2-05: Biomarker analysis by baseline circulating tumor DNA alterations in the MONALEESA-3 study","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Fulvestrant; Hazard ratio; Medicine; Internal medicine; Oncology; Biomarker; Cancer; Cancer research; Confidence interval; Breast cancer; Biology; Genetics; Estrogen receptor","score_opus":0.08727560084411412,"score_gpt":0.44179070129384373,"score_spread":0.3545151004497296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943879513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99325603,0.001520526,0.0001109871,0.0026506258,0.0000627713,0.0014577262,0.000062654886,0.000026754682,0.0008519149],"genre_scores_gemma":[0.99790484,0.000026605429,0.000059113565,0.0004355386,0.00014788435,0.00050524354,0.00006001237,0.000031553904,0.00082918943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99709225,0.00036283652,0.00038121556,0.00050347135,0.0011223967,0.00053780974],"domain_scores_gemma":[0.99820364,0.00056473044,0.00007334243,0.00072376535,0.00032311655,0.0001114288],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002501681,0.00016488037,0.00035994963,0.00052495534,0.00016450448,0.00006968279,0.00029598805,0.00004115791,0.00198701],"category_scores_gemma":[0.0001690112,0.000117078635,0.00011504067,0.0025498297,0.0001116284,0.00015923636,0.000062103085,0.00061252824,0.00008087133],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012895658,0.0017073998,0.58719677,0.00020170526,0.001822448,0.0003078759,0.007101138,0.0025638884,0.3626253,0.00006429271,0.0030553713,0.032064237],"study_design_scores_gemma":[0.004015827,0.00031163773,0.96911883,0.00017931474,0.0002412655,0.000023568238,0.011450869,0.0042594676,0.0024485982,0.00011784041,0.0075262333,0.00030653155],"about_ca_topic_score_codex":0.0020749418,"about_ca_topic_score_gemma":0.0010501484,"teacher_disagreement_score":0.38192207,"about_ca_system_score_codex":0.00038751814,"about_ca_system_score_gemma":0.00028531742,"threshold_uncertainty_score":0.9989253},"labels":[],"label_agreement":null},{"id":"W2943901493","doi":"10.1158/1538-7445.sabcs18-p5-04-24","title":"Abstract P5-04-24: Molecular stratification of ER+/HER2- breast cancer cell lines to predict sensitivity to targeted agents","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"PI3K/AKT/mTOR pathway; Cancer research; Breast cancer; Tamoxifen; Estrogen receptor; Protein kinase B; Cyclin-dependent kinase; Targeted therapy; Palbociclib; Cell growth; Signal transduction; Medicine; Trastuzumab; Cancer; Internal medicine; Cell cycle; Biology; Oncology; Metastatic breast cancer; Cell biology; Genetics","score_opus":0.04704236855036565,"score_gpt":0.39613543442364596,"score_spread":0.3490930658732803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943901493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900005,0.0011848754,0.000435174,0.0043679825,0.00035986464,0.0020671287,0.00058320834,0.00006331309,0.0009379727],"genre_scores_gemma":[0.995826,0.000198921,0.00075496826,0.00048905145,0.00036153183,0.00039356708,0.000042285945,0.000080719954,0.0018529749],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967902,0.0001463912,0.0004006316,0.00069918507,0.0012511512,0.0007124928],"domain_scores_gemma":[0.9971149,0.000107607826,0.00011244359,0.0008242036,0.0013489134,0.00049193564],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007028776,0.00025277288,0.00046398802,0.00025348997,0.00007706755,0.000029895593,0.00023904149,0.00013527353,0.0022276675],"category_scores_gemma":[0.00007232168,0.0002360356,0.00009963656,0.0008560438,0.00012033111,0.00018190512,0.00012095222,0.0004571902,0.00018254064],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015308124,0.0001985916,0.009751336,0.00048381262,0.00010520345,0.000030033932,0.0005463493,0.00251603,0.9525966,0.000020642452,0.0021601075,0.030060504],"study_design_scores_gemma":[0.0013249347,0.0002910138,0.33438805,0.0006568424,0.00003155511,0.000011921668,0.00049404777,0.00018013606,0.65593266,0.000028723518,0.0063969037,0.00026321187],"about_ca_topic_score_codex":0.005998396,"about_ca_topic_score_gemma":0.00076132215,"teacher_disagreement_score":0.3246367,"about_ca_system_score_codex":0.00084005576,"about_ca_system_score_gemma":0.000835653,"threshold_uncertainty_score":0.9986844},"labels":[],"label_agreement":null},{"id":"W2943928304","doi":"10.1158/1538-7445.sabcs18-p2-13-03","title":"Abstract P2-13-03: The impact of neratinib with or without anti-diarrheal prophylaxis on health-related quality of life in HER2+ early-stage breast cancer: Analyses from the ExteNET and CONTROL trials","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Neratinib; Medicine; Internal medicine; Breast cancer; Placebo; Diarrhea; Oncology; Gastroenterology; Cancer; Trastuzumab; Pathology","score_opus":0.2077961484088687,"score_gpt":0.5178687893869703,"score_spread":0.3100726409781016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943928304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821714,0.008988797,0.000009443615,0.004065798,0.000059667087,0.0031286466,0.0015127634,0.000017155216,0.00004629725],"genre_scores_gemma":[0.9976703,0.0014290994,0.000024647372,0.00018805453,0.00020180695,0.0002766321,0.000012340772,0.00005164888,0.00014549252],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946702,0.0018392279,0.0012097845,0.000536327,0.0011205131,0.0006239514],"domain_scores_gemma":[0.99505424,0.0025034063,0.0008005469,0.00085259834,0.0005364034,0.0002527929],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004851822,0.00029988584,0.0018520964,0.0001879134,0.00013436457,0.000041411146,0.00032406455,0.00013107073,0.0010668363],"category_scores_gemma":[0.0005496653,0.00012853419,0.00016632283,0.00088248664,0.00076135306,0.0001380192,0.000049672864,0.0010145104,0.000004480151],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049357425,0.0002490806,0.87051946,0.00034231468,0.0011277654,0.000007159864,0.0025790369,0.0034289223,0.054188926,0.000012731177,0.00008165999,0.018105507],"study_design_scores_gemma":[0.011130925,0.0017689529,0.9825495,0.0010678507,0.00003281242,0.0000042552315,0.001155952,0.00015567822,0.0019245069,0.000040204206,0.00002507233,0.0001443229],"about_ca_topic_score_codex":0.3783088,"about_ca_topic_score_gemma":0.015329059,"teacher_disagreement_score":0.36297974,"about_ca_system_score_codex":0.00044229103,"about_ca_system_score_gemma":0.0032231635,"threshold_uncertainty_score":0.99984634},"labels":[],"label_agreement":null},{"id":"W2944045371","doi":"10.1158/1538-7445.sabcs18-pd6-05","title":"Abstract PD6-05: Withdrawn","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Medicine; Cancer; Breast cancer; Gerontology; Gynecology; Internal medicine","score_opus":0.07358829241651378,"score_gpt":0.4467943645613154,"score_spread":0.3732060721448016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944045371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97105736,0.002972583,0.00002055504,0.0036476792,0.00033460322,0.0007075642,0.000013648486,0.00008542772,0.021160578],"genre_scores_gemma":[0.98007244,0.00020583972,0.00020508283,0.0004308916,0.000523473,0.00014955312,0.0000073867004,0.00005251436,0.018352836],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979848,0.000034896573,0.00016127854,0.00038154758,0.0008209949,0.000616484],"domain_scores_gemma":[0.99869764,0.00011514926,0.00003382099,0.0005609504,0.00037485763,0.00021757769],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00043736745,0.00012698454,0.00024790078,0.00018666184,0.000091293485,0.000031054064,0.00019123913,0.000081168175,0.007107102],"category_scores_gemma":[0.00005430816,0.00010510199,0.00006368667,0.00045558595,0.00021907606,0.00014478275,0.00007432836,0.00066735176,0.0016714534],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027171888,0.00020152875,0.043276966,0.0007183586,0.00023344893,0.00017061092,0.0010126065,0.000099721125,0.7375992,0.0012362733,0.0116484305,0.20108567],"study_design_scores_gemma":[0.004630869,0.00054364046,0.17769067,0.0007828452,0.000018617242,0.00008213906,0.0008371775,0.000028822727,0.09610475,0.0013322325,0.7176053,0.00034296047],"about_ca_topic_score_codex":0.00033705254,"about_ca_topic_score_gemma":0.000034150566,"teacher_disagreement_score":0.7059568,"about_ca_system_score_codex":0.0004497577,"about_ca_system_score_gemma":0.00057655695,"threshold_uncertainty_score":0.9991059},"labels":[],"label_agreement":null},{"id":"W2944046125","doi":"10.1158/1538-7445.sabcs18-p5-03-11","title":"Abstract P5-03-11: Sensitivity to cell cycle inhibitors in taxane resistant breast cancer models","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Taxane; Cyclin-dependent kinase 1; Paclitaxel; Cancer research; SKBR3; Cell cycle; Cell cycle checkpoint; Biology; Breast cancer; Cancer; Medicine; Internal medicine","score_opus":0.04379726349217531,"score_gpt":0.3776442483570133,"score_spread":0.333846984864838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944046125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860913,0.0017629486,0.00002999311,0.006647312,0.0003184648,0.001505526,0.00030374806,0.00007659005,0.0032640928],"genre_scores_gemma":[0.99530536,0.0003018437,0.00017699182,0.00046990952,0.0005711636,0.00041131937,0.000010410841,0.0001067838,0.0026461922],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9960009,0.00017008546,0.00041239403,0.0008821142,0.0012976016,0.0012369109],"domain_scores_gemma":[0.9978249,0.00021012838,0.00008727259,0.00079638115,0.0005710766,0.0005102322],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012125908,0.0003051909,0.0005731191,0.00055172475,0.00011393253,0.000050090715,0.0002190081,0.00017311066,0.0011394887],"category_scores_gemma":[0.00004032005,0.00028231874,0.00010399792,0.0012444555,0.00018856596,0.00035367906,0.00020678376,0.0009779817,0.00031684956],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049367817,0.000367026,0.024849294,0.00073969946,0.00005897288,0.00035254107,0.0016088461,0.020837642,0.8946455,0.00013551845,0.0017751745,0.049692977],"study_design_scores_gemma":[0.014214709,0.0007137155,0.57807714,0.0063660746,0.00006323219,0.00014676314,0.004853681,0.0029496024,0.35122526,0.0016441172,0.037772715,0.00197298],"about_ca_topic_score_codex":0.022212377,"about_ca_topic_score_gemma":0.009998403,"teacher_disagreement_score":0.55322784,"about_ca_system_score_codex":0.0021770485,"about_ca_system_score_gemma":0.001081899,"threshold_uncertainty_score":0.9999629},"labels":[],"label_agreement":null},{"id":"W2944090377","doi":"10.1158/1538-7445.sabcs18-p6-17-29","title":"Abstract P6-17-29: Withdrawn","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of Calgary; University of Alberta","funders":"","keywords":"Medicine; Cancer; Breast cancer; Citation; Gerontology; Gynecology; Library science; Internal medicine; Computer science","score_opus":0.07313228600122833,"score_gpt":0.44365908483177796,"score_spread":0.3705267988305496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944090377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9538482,0.003675873,0.000023311568,0.0036138538,0.0002633262,0.0007789269,0.000016235204,0.00009514246,0.037685145],"genre_scores_gemma":[0.96351075,0.00021513728,0.00021748342,0.0004828555,0.00057536573,0.0001741969,0.000008858831,0.00005721889,0.034758154],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99778616,0.00003652329,0.00018077888,0.0004219181,0.0008945007,0.00068008935],"domain_scores_gemma":[0.9985799,0.00011478223,0.000039047478,0.00062292616,0.00039916154,0.0002441408],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00047481625,0.00014351892,0.00027625437,0.00020199454,0.00010207331,0.000035495133,0.00021716302,0.0000920807,0.010060325],"category_scores_gemma":[0.000049932616,0.00011938691,0.000071006914,0.00048923586,0.000244594,0.00015871557,0.00008359558,0.0007771111,0.0014361091],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034428446,0.00025921254,0.065090336,0.00078366254,0.00031541087,0.00014762908,0.0017663032,0.00018329335,0.7246135,0.0009372408,0.020946419,0.18151416],"study_design_scores_gemma":[0.004668202,0.00049345713,0.22060859,0.0008229144,0.000020584976,0.000050810668,0.00082591386,0.000032320822,0.07066108,0.0011519627,0.7002989,0.00036528098],"about_ca_topic_score_codex":0.0004225459,"about_ca_topic_score_gemma":0.00006295358,"teacher_disagreement_score":0.67935246,"about_ca_system_score_codex":0.00049547566,"about_ca_system_score_gemma":0.0006397611,"threshold_uncertainty_score":0.99934137},"labels":[],"label_agreement":null},{"id":"W2944121148","doi":"10.1158/1538-7445.sabcs18-p5-13-20","title":"Abstract P5-13-20: Overall survival of women with breast cancer treated with newly approved targeted drugs in Manitoba: A population based study","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Palbociclib; Pertuzumab; Fulvestrant; Population; Trastuzumab emtansine; Breast cancer; Cancer; Internal medicine; Cancer registry; Clinical trial; Oncology; Trastuzumab; Metastatic breast cancer; Tamoxifen","score_opus":0.031767779054204935,"score_gpt":0.34074401945450433,"score_spread":0.3089762404002994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944121148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959531,0.000234142,0.000010610447,0.0005047579,0.00005765355,0.0028438065,0.00012893573,0.00006125919,0.00020573594],"genre_scores_gemma":[0.99793816,0.000018184943,0.0001018247,0.000057630397,0.00013558562,0.0011496762,0.00005367362,0.00010737809,0.00043789978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99628836,0.00020302169,0.00040309117,0.0006978432,0.0014311337,0.00097653706],"domain_scores_gemma":[0.99803466,0.00014240447,0.00018062824,0.0006441689,0.00073504273,0.00026309997],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000764303,0.00032406455,0.0007563433,0.00052282243,0.000070702205,0.00003135522,0.0002343759,0.00010265574,0.0009623477],"category_scores_gemma":[0.000017408807,0.0002348221,0.000040747076,0.0012496397,0.0001312174,0.0002710946,0.000047633792,0.00066276925,0.000010280904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029541755,0.00073770166,0.93437624,0.00038237896,0.0002864884,0.00003927402,0.0018798754,0.003942145,0.022206187,0.000006609993,0.000011083028,0.0065902444],"study_design_scores_gemma":[0.016474824,0.0012793445,0.97427297,0.0006818142,0.000030774267,0.0000051146117,0.0053415806,0.0002189304,0.0013205016,0.000016406648,0.00008908493,0.00026863578],"about_ca_topic_score_codex":0.0664878,"about_ca_topic_score_gemma":0.025748266,"teacher_disagreement_score":0.04073953,"about_ca_system_score_codex":0.003369588,"about_ca_system_score_gemma":0.0011567797,"threshold_uncertainty_score":0.9999509},"labels":[],"label_agreement":null},{"id":"W2944152537","doi":"10.1158/1538-7445.sabcs18-p5-07-02","title":"Abstract P5-07-02: Not presented","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"","keywords":"Chatterjee; Medicine; Cancer; Breast cancer; Citation; Gerontology; Oncology; Library science; Internal medicine; Philosophy; Computer science","score_opus":0.10633973551445756,"score_gpt":0.46212629530816507,"score_spread":0.3557865597937075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944152537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752747,0.0022434525,0.000020907633,0.006964216,0.00033356453,0.0009793247,0.000030317986,0.00010564857,0.014047891],"genre_scores_gemma":[0.9737006,0.0002813616,0.00011524212,0.0004365707,0.0005849404,0.00021640558,0.000012467828,0.00006174042,0.024590684],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99745715,0.000049051716,0.00021231633,0.00046482682,0.0010784875,0.0007381838],"domain_scores_gemma":[0.99831367,0.00018794545,0.00004460927,0.00069849374,0.00049607997,0.0002591981],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005130758,0.00015327238,0.0002958199,0.00021693572,0.00009477107,0.00003407946,0.0002607037,0.00010334373,0.009459607],"category_scores_gemma":[0.00010767325,0.00013027394,0.00008469302,0.00043420287,0.0002241813,0.00017469219,0.00012047237,0.0008172595,0.0031328355],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032877557,0.0001836739,0.023580704,0.0005824596,0.00021670277,0.00010241333,0.0005631121,0.000089885645,0.88039464,0.0004946686,0.0070435884,0.083460405],"study_design_scores_gemma":[0.0050979163,0.00041543524,0.2281904,0.00073062454,0.000022140353,0.000043783723,0.00066595845,0.00006873721,0.26358286,0.0005353442,0.50030035,0.0003464226],"about_ca_topic_score_codex":0.00057867577,"about_ca_topic_score_gemma":0.000032442324,"teacher_disagreement_score":0.61681175,"about_ca_system_score_codex":0.00047494555,"about_ca_system_score_gemma":0.0005312506,"threshold_uncertainty_score":0.99764335},"labels":[],"label_agreement":null},{"id":"W2944211448","doi":"10.1158/1538-7445.sabcs18-p4-13-06","title":"Abstract P4-13-06: Real-world experience using exemestane and everolimus in patients with hormone receptor positive/HER2 negative breast cancer with and without prior CDK4/6 inhibitor exposure","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Exemestane; Aromatase inhibitor; Internal medicine; Breast cancer; Discontinuation; Oncology; Lapatinib; Anastrozole; Everolimus; Cancer; Trastuzumab; Tamoxifen","score_opus":0.024729142544929347,"score_gpt":0.35337555918933505,"score_spread":0.3286464166444057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944211448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99567324,0.0013809022,0.0000072983153,0.00037069284,0.0000592005,0.0021042074,0.0001700922,0.000039252525,0.00019510518],"genre_scores_gemma":[0.9973789,0.0006123264,0.00075757765,0.00012507335,0.00018935053,0.00036243125,0.0000138248015,0.00010703568,0.00045348614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967101,0.00011084881,0.0003288607,0.0009045557,0.0010931705,0.00085245323],"domain_scores_gemma":[0.99811506,0.00011454601,0.00016690533,0.00042452765,0.00080370024,0.00037525076],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002865276,0.0003857566,0.0006112063,0.00037200685,0.00019179318,0.00007511911,0.00014431619,0.000111431335,0.00025874408],"category_scores_gemma":[0.000022173352,0.00028530485,0.000024430112,0.0009270581,0.00080899004,0.0006377018,0.00012255258,0.0007739522,0.000005138941],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018112242,0.00017226687,0.93250906,0.0001978735,0.00012002836,0.000023915441,0.0049884873,0.000045992932,0.029741501,0.0000073000115,0.00001653718,0.014064795],"study_design_scores_gemma":[0.010662945,0.0009774036,0.979386,0.0022423828,0.000026249507,0.000024896874,0.0015856024,0.000027593409,0.0045231427,0.000010174579,0.00016140574,0.00037220283],"about_ca_topic_score_codex":0.0109037375,"about_ca_topic_score_gemma":0.0028503113,"teacher_disagreement_score":0.04687694,"about_ca_system_score_codex":0.0011290846,"about_ca_system_score_gemma":0.000673073,"threshold_uncertainty_score":0.9999599},"labels":[],"label_agreement":null},{"id":"W2944311490","doi":"10.1158/1538-7445.sabcs18-pd1-10","title":"Abstract PD1-10: Randomized phase II study comparing two different schedules of palbociclib plus second line endocrine therapy in women with estrogen receptor positive, HER2 negative advanced/metastatic breast cancer: CCTG MA38 (NCT02630693)","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre; Université du Québec à Montréal; Ontario Institute for Cancer Research","funders":"","keywords":"Palbociclib; Medicine; Tolerability; Internal medicine; Oncology; Population; Breast cancer; Metastatic breast cancer; Tamoxifen; Cancer; Adverse effect","score_opus":0.04480513330979158,"score_gpt":0.4114934981525055,"score_spread":0.36668836484271394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944311490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98681104,0.0044394284,0.000030455,0.0007003764,0.00016432958,0.007101096,0.00047213488,0.000065108994,0.00021605178],"genre_scores_gemma":[0.99228424,0.0013663248,0.00046113512,0.00008518745,0.00019728031,0.004000933,0.000045542405,0.00015205452,0.0014073029],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945344,0.00064645254,0.0010406247,0.0010319821,0.0013818468,0.0013647117],"domain_scores_gemma":[0.99641216,0.0009001187,0.00046598088,0.0008079837,0.0009818212,0.000431936],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011575861,0.0006438281,0.0025252358,0.00061594363,0.00019569756,0.000050679868,0.000476155,0.000063341286,0.0075263726],"category_scores_gemma":[0.00008017704,0.00046475016,0.00016689612,0.0010738805,0.0007782459,0.00040840183,0.00022851577,0.0011991701,0.000024005203],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.768616,0.0051160823,0.019360228,0.0006472517,0.0026654731,0.0001132938,0.008643947,0.0024678493,0.09285336,0.000062215186,0.000024793182,0.099429496],"study_design_scores_gemma":[0.84841585,0.009793452,0.04055681,0.0028944407,0.0001281551,0.000043396594,0.012579775,0.0005775742,0.08356029,0.0003270445,0.00030655105,0.00081668614],"about_ca_topic_score_codex":0.002305618,"about_ca_topic_score_gemma":0.00096372905,"teacher_disagreement_score":0.09861281,"about_ca_system_score_codex":0.0020243318,"about_ca_system_score_gemma":0.0010399708,"threshold_uncertainty_score":0.9997804},"labels":[],"label_agreement":null},{"id":"W2944338381","doi":"10.1158/1538-7445.sabcs18-p6-18-15","title":"Abstract P6-18-15: Ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled safety analysis","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Adverse effect; Letrozole; Fulvestrant; Anastrozole; Internal medicine; Common Terminology Criteria for Adverse Events; Breast cancer; Goserelin; Cancer; Placebo; Tamoxifen; Oncology; Gynecology; Pathology","score_opus":0.03212609355398043,"score_gpt":0.39309888290963524,"score_spread":0.3609727893556548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944338381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761034,0.0108198915,0.000040333587,0.006671712,0.00021700136,0.0025282847,0.0011212685,0.00013300455,0.0023650613],"genre_scores_gemma":[0.9759604,0.01794764,0.0004137555,0.00049517583,0.0004096788,0.0011003764,0.000150337,0.00014047006,0.0033821873],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99431604,0.00036673574,0.0007749698,0.0013233679,0.0016024569,0.0016164437],"domain_scores_gemma":[0.99629956,0.0005853753,0.00024782584,0.0010458941,0.0013410569,0.0004803089],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009317345,0.0005505413,0.0013565582,0.0011899092,0.00021735195,0.000070158625,0.00054203573,0.00019997543,0.01341924],"category_scores_gemma":[0.00009952738,0.00048616895,0.00037231404,0.004785461,0.00050000375,0.00057423284,0.00017785754,0.0016788385,0.00022277566],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040235337,0.0007938255,0.11120532,0.00021311718,0.0041383626,0.00015827677,0.002851621,0.002932361,0.4556781,0.000092991686,0.0007226132,0.38097808],"study_design_scores_gemma":[0.014968804,0.0006700472,0.9254397,0.0006804619,0.00015905077,0.000026565765,0.0014891124,0.00014210473,0.0441278,0.00021091141,0.011430141,0.00065526454],"about_ca_topic_score_codex":0.012572095,"about_ca_topic_score_gemma":0.0024250213,"teacher_disagreement_score":0.81423444,"about_ca_system_score_codex":0.002896655,"about_ca_system_score_gemma":0.0010606996,"threshold_uncertainty_score":0.999759},"labels":[],"label_agreement":null},{"id":"W2944341352","doi":"10.1007/s12282-019-00973-4","title":"A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer","year":2019,"lang":"en","type":"review","venue":"Breast Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"AstraZeneca; Amgen","keywords":"Fulvestrant; Medicine; Anastrozole; Internal medicine; Oncology; Odds ratio; Breast cancer; Cancer; Estrogen receptor; Tamoxifen","score_opus":0.16535441409755702,"score_gpt":0.46977204743553985,"score_spread":0.30441763333798283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944341352","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014619442,0.89119315,0.0012381419,0.0017806883,0.0008587731,0.007485361,0.097169064,0.00009562024,0.00003298287],"genre_scores_gemma":[0.00058446487,0.97453123,0.0036892742,0.0005931795,0.0017712737,0.0140007045,0.0019565136,0.00043765412,0.0024357212],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99194163,0.00027825867,0.0033783661,0.0022318528,0.00091436086,0.001255552],"domain_scores_gemma":[0.98994035,0.0020292965,0.0036969022,0.0014331732,0.0024436335,0.00045666954],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaepi_narrow","metaepi_broad"],"category_scores_codex":[0.00076825736,0.0018242936,0.01633313,0.00087064743,0.00016483484,0.000054540033,0.00080006383,0.0005747477,0.0018185732],"category_scores_gemma":[0.00006646948,0.0012904716,0.01145927,0.001534773,0.0005505283,0.00039091226,0.00014550364,0.0008002863,0.000013832656],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006846582,0.00033734413,0.00007016535,0.006064859,0.34583294,0.0000046188156,0.00017974098,0.00019776775,0.000038503345,0.00020175696,0.00015485192,0.64007086],"study_design_scores_gemma":[0.006168247,0.00069296267,0.0018894857,0.0035713217,0.54779863,0.00014503815,0.00011249976,0.00011712969,0.000057977915,0.00010951534,0.4380853,0.0012519229],"about_ca_topic_score_codex":0.0010632172,"about_ca_topic_score_gemma":0.000328568,"teacher_disagreement_score":0.6388189,"about_ca_system_score_codex":0.00084464875,"about_ca_system_score_gemma":0.0017747874,"threshold_uncertainty_score":0.9994502},"labels":[],"label_agreement":null},{"id":"W2944461353","doi":"10.1158/1538-7445.sabcs18-p6-18-14","title":"Abstract P6-18-14: Patient-reported outcomes with ribociclib-based therapy in hormone receptor-positive, HER2-negative advanced breast cancer: results from the phase III MONALEESA-2, -3, and -7 trials","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Letrozole; Internal medicine; Goserelin; Fulvestrant; Anastrozole; Breast cancer; Clinical endpoint; Oncology; Cancer; Placebo; Aromatase inhibitor; Metastatic breast cancer; Progression-free survival; Palbociclib; Clinical trial; Chemotherapy; Estrogen receptor; Aromatase; Pathology","score_opus":0.07544344919931267,"score_gpt":0.4165428332646931,"score_spread":0.34109938406538043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944461353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97550267,0.005920408,0.000014957708,0.010336431,0.00019288911,0.0044165286,0.0032345692,0.00008062898,0.00030094516],"genre_scores_gemma":[0.99291044,0.0036033683,0.00033806197,0.0007610497,0.0002452615,0.0013225002,0.00022866779,0.00011679967,0.00047385332],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9944504,0.00068419107,0.0011400618,0.0011758748,0.0015778738,0.00097162125],"domain_scores_gemma":[0.99324113,0.0037408378,0.00064793666,0.0009790645,0.0010523524,0.00033868037],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019076798,0.00052919786,0.0013949652,0.00028098747,0.00025433162,0.00008530543,0.0003413646,0.00019708538,0.0010706523],"category_scores_gemma":[0.00048980303,0.00032084962,0.00016222028,0.0010026606,0.00073457806,0.0003814069,0.00008836481,0.0012662114,0.000018657358],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26216808,0.0012746926,0.081058815,0.00006677047,0.0015732896,0.00015757045,0.00602162,0.0006228414,0.17598172,0.00001454323,0.0010530263,0.47000703],"study_design_scores_gemma":[0.14363165,0.0024592325,0.79055935,0.0017838785,0.00009035809,0.000017455688,0.0031862569,0.000080608115,0.05187332,0.00022834212,0.0054059178,0.00068362174],"about_ca_topic_score_codex":0.021617627,"about_ca_topic_score_gemma":0.0017576466,"teacher_disagreement_score":0.70950055,"about_ca_system_score_codex":0.000974378,"about_ca_system_score_gemma":0.001360949,"threshold_uncertainty_score":0.99992436},"labels":[],"label_agreement":null},{"id":"W2944565413","doi":"10.1158/1538-7445.sabcs18-p1-16-05","title":"Abstract P1-16-05: Prognosis and survival in metastatic breast cancer – Ten years in review, a population-based analysis","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Metastatic breast cancer; Breast cancer; Cohort; Internal medicine; Oncology; Cancer; Hormonal therapy; Systemic therapy; Population","score_opus":0.058699294286680234,"score_gpt":0.4305917263851753,"score_spread":0.37189243209849504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944565413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741677,0.019889768,0.0000067331557,0.004217606,0.00006616189,0.0013742001,0.00013272492,0.000022375842,0.00012274372],"genre_scores_gemma":[0.99441785,0.0038944536,0.00012371103,0.00036494038,0.000062143015,0.00080209324,0.000056633977,0.000040182334,0.0002380011],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742556,0.0002002263,0.00041807722,0.00055160385,0.00083247427,0.00057206105],"domain_scores_gemma":[0.99887854,0.00024717845,0.000093587,0.0003874962,0.0002259388,0.00016728354],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012378118,0.00018127722,0.0007291736,0.0009380693,0.000034004515,0.000026570353,0.00015417053,0.00006128664,0.0020534634],"category_scores_gemma":[0.00008314304,0.00016145893,0.00010114949,0.002953275,0.00010550696,0.00016135251,0.000048359532,0.000545936,0.0000173759],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043640388,0.00011378416,0.9416494,0.0013175566,0.00023603874,0.000039327628,0.00011653702,0.0006304586,0.00072356453,0.0000111139725,0.00006608563,0.054659754],"study_design_scores_gemma":[0.001912698,0.00004618982,0.9940492,0.0024420065,0.00014167906,0.000003906388,0.0001486333,0.0002649342,0.00009374459,0.00004996705,0.0006832699,0.00016378425],"about_ca_topic_score_codex":0.028746285,"about_ca_topic_score_gemma":0.016460191,"teacher_disagreement_score":0.054495968,"about_ca_system_score_codex":0.0011282206,"about_ca_system_score_gemma":0.0005423374,"threshold_uncertainty_score":0.9988588},"labels":[],"label_agreement":null},{"id":"W2944583748","doi":"10.1158/1538-7445.sabcs18-gs3-02","title":"Abstract GS3-02: PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; Université du Québec à Montréal","funders":"","keywords":"Palbociclib; Letrozole; Medicine; Oncology; Breast cancer; Internal medicine; Cancer; Metastatic breast cancer; Tamoxifen","score_opus":0.07886522984097512,"score_gpt":0.4758817732521635,"score_spread":0.3970165434111884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944583748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923299,0.0025806355,0.000025500356,0.0015892986,0.00006463347,0.003203893,0.0000138287905,0.000017586774,0.00017472699],"genre_scores_gemma":[0.99869907,0.0002045488,0.00013428285,0.00028008723,0.0001539724,0.00022044462,0.0000015093449,0.000035675115,0.00027043273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979646,0.00023816536,0.00027840948,0.00046882575,0.00066041254,0.00038955576],"domain_scores_gemma":[0.9983106,0.0005614605,0.00007350998,0.0004611882,0.0003612799,0.00023196192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009112315,0.00017197897,0.00056970585,0.00010441749,0.00011885589,0.000032168937,0.00014860569,0.000031778403,0.000058493268],"category_scores_gemma":[0.00010912438,0.00009710338,0.000032113625,0.00029417584,0.00059494475,0.00007643292,0.00015423787,0.0006276286,0.000012771585],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043150727,0.00029518286,0.96561515,0.00032717167,0.0002721543,0.000024925943,0.004761864,0.000014131347,0.0077913115,0.000032911543,0.000095901356,0.016454233],"study_design_scores_gemma":[0.006917417,0.0030611018,0.97896105,0.0006881917,0.000041872874,0.000016028212,0.004628081,0.000020507301,0.004340665,0.000033105218,0.0011655575,0.00012639316],"about_ca_topic_score_codex":0.00036407312,"about_ca_topic_score_gemma":0.00039191477,"teacher_disagreement_score":0.016327841,"about_ca_system_score_codex":0.000053853848,"about_ca_system_score_gemma":0.0002455314,"threshold_uncertainty_score":0.3959761},"labels":[],"label_agreement":null},{"id":"W2944626596","doi":"10.1158/1538-7445.sabcs18-p6-18-05","title":"Abstract P6-18-05: First-line ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled efficacy analysis","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Letrozole; Fulvestrant; Internal medicine; Anastrozole; Goserelin; Clinical endpoint; Breast cancer; Placebo; Cancer; Oncology; Palbociclib; Aromatase inhibitor; Metastatic breast cancer; Gastroenterology; Clinical trial; Estrogen receptor; Tamoxifen; Pathology","score_opus":0.04112823362356666,"score_gpt":0.40130150514590096,"score_spread":0.3601732715223343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944626596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97557974,0.009835265,0.00004051402,0.00983812,0.00023895157,0.0028071345,0.0006571993,0.00014902832,0.0008540767],"genre_scores_gemma":[0.9758398,0.018580783,0.0003517652,0.00047285232,0.0005308118,0.0012172752,0.00014265052,0.00015911715,0.0027049626],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99420005,0.00029006987,0.0008037767,0.0014172123,0.0016163441,0.0016725445],"domain_scores_gemma":[0.9959563,0.0008567771,0.00027353133,0.0011303613,0.0012603857,0.0005226196],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008239341,0.0006123773,0.001433778,0.0012885033,0.00024206242,0.000075475655,0.0005888096,0.00021185048,0.008769186],"category_scores_gemma":[0.00014588064,0.00053689873,0.00040982701,0.005049271,0.0005062198,0.0004891472,0.000190407,0.0017121217,0.00022899086],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05013338,0.0020997936,0.09604461,0.00037151124,0.0058360407,0.00032239326,0.004007349,0.0120333,0.3310335,0.00006772743,0.0013327955,0.4967176],"study_design_scores_gemma":[0.023736151,0.0012008271,0.91321784,0.00096951466,0.00020771794,0.00003368587,0.0008135601,0.00027069898,0.04854522,0.00017561075,0.010057411,0.00077176356],"about_ca_topic_score_codex":0.011512117,"about_ca_topic_score_gemma":0.0029616673,"teacher_disagreement_score":0.81717324,"about_ca_system_score_codex":0.002410765,"about_ca_system_score_gemma":0.00084096723,"threshold_uncertainty_score":0.99970824},"labels":[],"label_agreement":null},{"id":"W2944630738","doi":"10.1158/1538-7445.sabcs18-p1-09-03","title":"Abstract P1-09-03: Withdrawn","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Cancer; Medicine; Breast cancer; Citation; Physiology; Gerontology; Gynecology; Library science; Internal medicine; Computer science","score_opus":0.07370384215184818,"score_gpt":0.44462985283243156,"score_spread":0.3709260106805834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944630738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9589636,0.003819558,0.000016752323,0.003025737,0.00030093524,0.0007688081,0.000015763291,0.00009299182,0.032995865],"genre_scores_gemma":[0.9802437,0.0002527795,0.00022130871,0.00032309577,0.00054677407,0.0001775499,0.000008276581,0.000059943337,0.018166572],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977802,0.000040290743,0.00018079381,0.00042293323,0.0008966161,0.0006791414],"domain_scores_gemma":[0.9986259,0.00011976042,0.00003892588,0.00062245433,0.0003517745,0.00024119552],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00048039397,0.00014329562,0.00027636767,0.00020360104,0.00010433381,0.00003590992,0.00021827148,0.00009212019,0.008316664],"category_scores_gemma":[0.000052031966,0.00011914912,0.000070961854,0.0004806054,0.00025443273,0.0001603701,0.00008408049,0.0007436086,0.0027152505],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029662445,0.00023091743,0.056112573,0.00080355786,0.000269759,0.00015486869,0.0011928589,0.000116869574,0.70236576,0.0013138516,0.0069343685,0.22753839],"study_design_scores_gemma":[0.0052631223,0.0005747362,0.20392375,0.0009779929,0.000024218785,0.0000727085,0.0010491651,0.000035797842,0.112456314,0.0014749294,0.6737214,0.0004258827],"about_ca_topic_score_codex":0.00043507712,"about_ca_topic_score_gemma":0.000047067228,"teacher_disagreement_score":0.666787,"about_ca_system_score_codex":0.0005043678,"about_ca_system_score_gemma":0.00063422666,"threshold_uncertainty_score":0.99806124},"labels":[],"label_agreement":null},{"id":"W2944820163","doi":"10.1093/annonc/mdz100.006","title":"Pooled efficacy analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2: Advanced breast cancer (ABC)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Letrozole; Metastatic breast cancer; Clinical endpoint; Breast cancer; Progression-free survival; Fulvestrant; Goserelin; Cancer; Oncology; Surgery; Tamoxifen; Gastroenterology; Chemotherapy; Clinical trial","score_opus":0.05001327186555722,"score_gpt":0.41572173290215414,"score_spread":0.36570846103659693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944820163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800469,0.004140698,0.000086535074,0.013388561,0.00017893671,0.00073978194,0.00015589407,0.000042171047,0.001220491],"genre_scores_gemma":[0.9905939,0.005658937,0.00047076048,0.0025122436,0.00008356545,0.000080859856,0.00006730615,0.000047424983,0.00048497],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976187,0.00014785765,0.00086756184,0.0004950537,0.0003412348,0.0005295999],"domain_scores_gemma":[0.99762404,0.00047352235,0.0006009902,0.0006402058,0.0005215622,0.00013968072],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035652608,0.00030940777,0.0018457294,0.00067932816,0.000024268096,0.0000033203696,0.00025873,0.00016158762,0.0016117356],"category_scores_gemma":[0.00007552454,0.0002663311,0.00039992543,0.0014560041,0.0002205726,0.00016847586,0.00007491683,0.00031263122,0.000012639671],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026421351,0.0031905111,0.24227212,0.00026386208,0.0069364607,0.00010802309,0.002465045,0.040833928,0.04458454,0.00051858445,0.00015489488,0.63225067],"study_design_scores_gemma":[0.027083384,0.0038657167,0.9068779,0.00033113576,0.0007076567,0.00006378142,0.00037800588,0.0014454836,0.020067712,0.00027824217,0.03848544,0.0004155854],"about_ca_topic_score_codex":0.0011336916,"about_ca_topic_score_gemma":0.0016426767,"teacher_disagreement_score":0.66460574,"about_ca_system_score_codex":0.00021435732,"about_ca_system_score_gemma":0.00041416244,"threshold_uncertainty_score":0.9999789},"labels":[],"label_agreement":null},{"id":"W2944907268","doi":"10.1200/edbk_237419","title":"Redrawing the Lines: The Next Generation of Treatment in Metastatic Breast Cancer","year":2019,"lang":"en","type":"review","venue":"American Society of Clinical Oncology Educational Book","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; PI3K/AKT/mTOR pathway; Metastatic breast cancer; Estrogen receptor; Breast cancer; Targeted therapy; Cancer research; Cancer; Systemic therapy; Protein kinase B; Bioinformatics; Signal transduction; Oncology; Internal medicine; Biology","score_opus":0.37035670190059716,"score_gpt":0.553309647800282,"score_spread":0.18295294589968486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944907268","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003623383,0.9644868,0.00002817384,0.03284567,0.0004901957,0.0014980286,0.0000894912,0.000006283245,0.00019305505],"genre_scores_gemma":[0.00027519677,0.98673594,0.0028419588,0.0046524806,0.0014892492,0.0006824333,0.00010479285,0.00003832074,0.0031796056],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965833,0.00063936866,0.0018905522,0.00040285688,0.00026536433,0.00021859666],"domain_scores_gemma":[0.99001366,0.0066788946,0.0023936317,0.0005500053,0.00028872854,0.00007508669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085987244,0.00030278147,0.0029373765,0.000042113934,0.00005918668,0.0000049490786,0.0002793223,0.00016262583,0.0003663422],"category_scores_gemma":[0.00017645692,0.00015306177,0.0014152366,0.00038364192,0.0019067604,0.00007150884,0.00004649173,0.00055424724,0.000013175654],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006288623,0.0005983697,0.00053948525,0.0008685529,0.0011696588,2.852381e-7,0.0006610903,0.00003836268,0.0000045378556,0.0001049228,0.0017577204,0.99419415],"study_design_scores_gemma":[0.0007456899,0.00066683395,0.002071961,0.0014489947,0.002008512,0.000047258825,0.0010011252,0.00007936334,7.3341647e-7,0.00004157383,0.99176145,0.00012651831],"about_ca_topic_score_codex":0.0007290078,"about_ca_topic_score_gemma":0.000055562916,"teacher_disagreement_score":0.9940676,"about_ca_system_score_codex":0.0010674378,"about_ca_system_score_gemma":0.014241697,"threshold_uncertainty_score":0.99134666},"labels":[],"label_agreement":null},{"id":"W2946889769","doi":"10.1200/jco.2019.37.15_suppl.1040","title":"Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with <i>PIK3CA-</i>mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Fulvestrant; Internal medicine; Letrozole; Breast cancer; Oncology; Cohort; Regimen; Palbociclib; Cancer; Metastatic breast cancer; Estrogen receptor; Tamoxifen","score_opus":0.04594670903478027,"score_gpt":0.4199377363683728,"score_spread":0.3739910273335925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946889769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896103,0.00035185996,0.00004437201,0.00565608,0.0008523542,0.0019351438,0.00021606639,0.000039137172,0.0012946872],"genre_scores_gemma":[0.9939159,0.0010592884,0.0014062485,0.0026572559,0.0005437003,0.000059304624,0.00003947433,0.000107774846,0.00021105733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9924984,0.0012404566,0.0038061335,0.0007897616,0.0009421961,0.00072303746],"domain_scores_gemma":[0.9908598,0.0023980401,0.0037338727,0.0004679622,0.002011685,0.0005286314],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0015476277,0.0006155806,0.0031316401,0.00034687095,0.000098541226,0.000025088202,0.00045964436,0.00032607946,0.0004435975],"category_scores_gemma":[0.0009029121,0.0004241827,0.00041837056,0.0005535154,0.0004780933,0.0007811596,0.00014518113,0.0024097918,0.00002742538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22724655,0.016443843,0.6109777,0.000034922286,0.002235649,0.00060859066,0.0044836057,0.00031137775,0.0011735718,0.0000274503,0.00048729542,0.13596945],"study_design_scores_gemma":[0.10947354,0.061124317,0.8236007,0.00045456423,0.00013315662,0.0001445222,0.0012842589,0.000011839611,0.00050115923,0.000072659015,0.0028123318,0.00038694544],"about_ca_topic_score_codex":0.00065620133,"about_ca_topic_score_gemma":0.0009101126,"teacher_disagreement_score":0.212623,"about_ca_system_score_codex":0.0011431464,"about_ca_system_score_gemma":0.0010577901,"threshold_uncertainty_score":0.9998917},"labels":[],"label_agreement":null},{"id":"W2947012155","doi":"10.1200/jco.2019.37.15_suppl.tps3170","title":"Leeomic: A comprehensive proteomic analysis towards discovery of predictive patterns of protein expression to ribociclib sensitivity and resistance—A compLEEment-1 Canadian correlative sub-study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada); Grand River Hospital; Université Laval; University of Alberta; BC Cancer Agency; Ottawa Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Oncology; Proteome; Internal medicine; Population; Proteomics; Cancer; Letrozole; Metastatic breast cancer; Biomarker; Bioinformatics; Biology; Tamoxifen; Genetics","score_opus":0.05483441910059244,"score_gpt":0.4019711863863359,"score_spread":0.34713676728574344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947012155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99332047,0.00011249286,0.0032267666,0.0010391014,0.0002172082,0.0017908158,0.00016011181,0.0000043102505,0.00012875514],"genre_scores_gemma":[0.9961705,0.000025685016,0.0032908435,0.0002464102,0.00012522853,0.000016538459,0.0000060438706,0.000017685446,0.00010105551],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99607027,0.00091602246,0.0019567173,0.00032272527,0.00047413167,0.00026013554],"domain_scores_gemma":[0.9950521,0.00091573776,0.0023238037,0.00029801362,0.0009999638,0.0004103951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015205228,0.00020113705,0.0025018025,0.00042454785,0.000035968933,0.0000060266557,0.00011689247,0.00020204247,0.000035909838],"category_scores_gemma":[0.0007108091,0.0001519197,0.0004037865,0.00032931246,0.00022481983,0.00021718006,0.000099404846,0.0006778302,0.0000015400151],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023822088,0.0011852665,0.90122706,0.00015521493,0.003102848,0.00019672293,0.0018736392,0.00032035698,0.06309561,0.000027066944,0.000025960588,0.0049681785],"study_design_scores_gemma":[0.0076656514,0.010458077,0.96800154,0.00060636294,0.0009886931,0.000026943388,0.0027164037,0.000095851006,0.008987937,0.00010083628,0.00022343318,0.00012829085],"about_ca_topic_score_codex":0.003738108,"about_ca_topic_score_gemma":0.016960511,"teacher_disagreement_score":0.066774465,"about_ca_system_score_codex":0.00038783514,"about_ca_system_score_gemma":0.0015593835,"threshold_uncertainty_score":0.9464363},"labels":[],"label_agreement":null},{"id":"W2947072656","doi":"10.1200/jco.2019.37.15_suppl.1037","title":"Comparison of outcomes in a population-based cohort of women with metastatic breast cancer receiving anti-HER2 therapy with clinical trial outcomes.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; St. Michael's Hospital; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Cohort; Pertuzumab; Population; Randomized controlled trial; Metastatic breast cancer; Breast cancer; Cancer; Cancer registry; Trastuzumab; Retrospective cohort study; Oncology","score_opus":0.12778230212331326,"score_gpt":0.5199624051973608,"score_spread":0.39218010307404755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947072656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951288,0.0001579462,0.00017583944,0.002772878,0.00074288505,0.0009524303,0.000013535799,0.000008512975,0.000047158097],"genre_scores_gemma":[0.9930822,0.0001088631,0.005552458,0.000950776,0.0001975257,0.000024146093,0.0000026234045,0.000039196326,0.00004217739],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927665,0.0008277769,0.004965326,0.00030108783,0.00077447895,0.000364837],"domain_scores_gemma":[0.98754424,0.005470995,0.005665675,0.0003749823,0.00065408484,0.0002900064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052444553,0.00025922633,0.0058769383,0.000251085,0.000016528402,0.0000047818944,0.00023894623,0.00025147494,0.00034304833],"category_scores_gemma":[0.0009935931,0.00014490035,0.0004368839,0.00032399816,0.00033470092,0.00015827284,0.000021742053,0.0010746629,0.0000017026762],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17794767,0.0043707797,0.77774245,0.000053886153,0.0015657031,0.00003131941,0.00015436587,0.0010439194,0.000023520986,0.000006980616,0.000005674588,0.03705372],"study_design_scores_gemma":[0.13980477,0.022023104,0.8367144,0.00032603,0.00027823224,0.000035925765,0.00024815323,0.000111350426,0.000015629195,0.00003234267,0.0002829181,0.00012712929],"about_ca_topic_score_codex":0.00035222826,"about_ca_topic_score_gemma":0.0003072476,"teacher_disagreement_score":0.058971953,"about_ca_system_score_codex":0.00045469144,"about_ca_system_score_gemma":0.002809844,"threshold_uncertainty_score":0.5908864},"labels":[],"label_agreement":null},{"id":"W2947234394","doi":"10.1200/jco.2019.37.15_suppl.1018","title":"In-depth gene expression analysis of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Letrozole; Breast cancer; Oncology; Anastrozole; Hazard ratio; Palbociclib; Tamoxifen; Cancer; Progression-free survival; Population; Aromatase inhibitor; Metastatic breast cancer; Chemotherapy; Confidence interval","score_opus":0.053760651211555203,"score_gpt":0.43821853841543934,"score_spread":0.38445788720388413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947234394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969974,0.00044393408,0.00009550263,0.0009984607,0.00019329684,0.0010514181,0.000021686228,0.000006616651,0.00019168037],"genre_scores_gemma":[0.9966744,0.0004195472,0.0014268287,0.001044953,0.000287044,0.000049113572,0.000012926415,0.00003261819,0.00005256643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955834,0.000673539,0.0023228622,0.00034430178,0.0007358052,0.00034008475],"domain_scores_gemma":[0.99462575,0.0012908701,0.002907455,0.00037606657,0.0006318004,0.00016806446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018383464,0.00026664688,0.0025281485,0.00043234645,0.000028727718,0.0000070101923,0.00029101298,0.0002299069,0.0002786846],"category_scores_gemma":[0.00013953981,0.00013332652,0.0002747333,0.0010150865,0.00021749502,0.00034802486,0.000025443347,0.00090194534,9.417576e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44169945,0.0043707187,0.4722499,0.000009166718,0.0013266199,0.00010968258,0.0004892016,0.0013545313,0.0018566721,0.0000029820546,0.000008722303,0.07652238],"study_design_scores_gemma":[0.32610506,0.04393484,0.62689155,0.0002946643,0.00079313375,0.000030561954,0.00044049564,0.00008719533,0.0004971303,0.000017812328,0.00076428644,0.00014324472],"about_ca_topic_score_codex":0.00016048153,"about_ca_topic_score_gemma":0.0004311023,"teacher_disagreement_score":0.15464167,"about_ca_system_score_codex":0.00029319953,"about_ca_system_score_gemma":0.00091916294,"threshold_uncertainty_score":0.5436898},"labels":[],"label_agreement":null},{"id":"W2947381343","doi":"10.1200/jco.2019.37.15_suppl.1041","title":"Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Discontinuation; Internal medicine; Population; Letrozole; Breast cancer; Interim analysis; Hazard ratio; Cancer; Chemotherapy regimen; Adverse effect; Oncology; Confidence interval; Clinical trial; Tamoxifen","score_opus":0.12992821335902252,"score_gpt":0.5039471352598323,"score_spread":0.37401892190080976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947381343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98981476,0.00070510095,0.000026071591,0.0072509376,0.0009132257,0.0010348976,0.00014342827,0.0000030877068,0.00010847009],"genre_scores_gemma":[0.9983141,0.0003492466,0.00025108893,0.0005497081,0.0004513381,0.00001627738,0.0000096623035,0.00001665691,0.000041935607],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99490756,0.0010291196,0.003064105,0.0002193963,0.0005809675,0.00019885032],"domain_scores_gemma":[0.9921175,0.0028294814,0.0039951047,0.00059919566,0.00038802094,0.00007069831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014576886,0.00018768474,0.0016139161,0.00006749228,0.000036104913,0.0000035185362,0.00045554395,0.00013577788,0.00013305772],"category_scores_gemma":[0.00038977075,0.00008398024,0.0004199955,0.00024840646,0.00027672056,0.00010453116,0.000059498903,0.0005077093,0.0000015027985],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12686187,0.026198154,0.37525618,0.00004509062,0.0016547472,0.00004382568,0.012903607,0.0027390444,0.006205142,0.000048196624,0.00021157885,0.44783258],"study_design_scores_gemma":[0.08244193,0.027340233,0.8740312,0.00033591824,0.0004988083,0.000048425303,0.007352756,0.00021621127,0.0003057355,0.00017697515,0.0071683126,0.000083508065],"about_ca_topic_score_codex":0.0019792046,"about_ca_topic_score_gemma":0.002672599,"teacher_disagreement_score":0.498775,"about_ca_system_score_codex":0.00043323514,"about_ca_system_score_gemma":0.0004911428,"threshold_uncertainty_score":0.3424615},"labels":[],"label_agreement":null},{"id":"W2947470150","doi":"10.1038/s41523-019-0111-0","title":"SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer","year":2019,"lang":"en","type":"article","venue":"npj Breast Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":355,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Cancer Institute; National Institutes of Health; Berlin Institute of Health; Deutsche Forschungsgemeinschaft; Breast Cancer Research Foundation","keywords":"Breast cancer; Metastatic breast cancer; Medicine; Internal medicine; Oncology; Cancer; Targeted therapy; Endocrine system; Hormone; Bioinformatics; Cancer research; Biology","score_opus":0.03199847053610999,"score_gpt":0.3266311783684151,"score_spread":0.2946327078323051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947470150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8555619,0.004757583,0.041626986,0.035398535,0.0034451215,0.015423674,0.042905513,0.0006684224,0.00021225856],"genre_scores_gemma":[0.9636698,0.00041702192,0.0140328575,0.008036634,0.0028542865,0.007095453,0.00025972663,0.00036551885,0.0032686987],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99642265,0.0000752547,0.0005678834,0.001142463,0.0005840157,0.0012077534],"domain_scores_gemma":[0.9971489,0.00027224692,0.00026953797,0.0008337447,0.0009294971,0.0005461115],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003330502,0.00069022237,0.0011784435,0.0002346644,0.00016455895,0.000055853547,0.00022354143,0.00011707376,0.0023151648],"category_scores_gemma":[0.000029733721,0.0005862804,0.00044262104,0.0004129428,0.000120225835,0.00034725005,0.00007883855,0.00025947538,0.00004742214],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044037204,0.0011027297,0.060478505,0.0016505551,0.0033129773,0.00005403517,0.00097405526,0.008526247,0.23002377,0.00017080942,0.00830463,0.64136446],"study_design_scores_gemma":[0.06798769,0.002602294,0.6036634,0.0023821814,0.0017740197,0.005358204,0.0005842158,0.010026919,0.05992063,0.0006537287,0.241713,0.0033336992],"about_ca_topic_score_codex":0.0010602159,"about_ca_topic_score_gemma":0.0004112454,"teacher_disagreement_score":0.63803077,"about_ca_system_score_codex":0.0010542839,"about_ca_system_score_gemma":0.0008138126,"threshold_uncertainty_score":0.9996589},"labels":[],"label_agreement":null},{"id":"W2947559705","doi":"10.1200/jco.2019.37.15_suppl.3095","title":"A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada)","funders":"","keywords":"Gemcitabine; Medicine; Tolerability; Pharmacodynamics; Pharmacokinetics; Cancer; Bioavailability; Cervical cancer; Internal medicine; Pharmacology; Ovarian cancer; CHEK1; Oncology; Adverse effect; Cell cycle; Cell cycle checkpoint","score_opus":0.04307739164022831,"score_gpt":0.43836247018055424,"score_spread":0.3952850785403259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947559705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99353665,0.0002793826,0.000035455578,0.004215499,0.00059103844,0.0010616382,0.00000372557,0.0000070110864,0.00026961506],"genre_scores_gemma":[0.99763876,0.00017788343,0.0014091553,0.00032566086,0.0002967284,0.000035285644,0.0000044686058,0.000031214044,0.00008086199],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99625754,0.00029284685,0.0023430604,0.0002900143,0.00047801115,0.0003385318],"domain_scores_gemma":[0.9964205,0.00075240596,0.0020428968,0.00022723527,0.00037683663,0.00018011866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017822264,0.00021576716,0.0021748415,0.00043759338,0.000020739313,0.0000035930043,0.00017233595,0.00026559277,0.000098583674],"category_scores_gemma":[0.00051896734,0.0001514707,0.00015020753,0.0005438652,0.00026039672,0.0003851409,0.000041748997,0.0011805985,0.0000016564092],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.675197,0.020517169,0.16731729,0.00017513645,0.00017896057,0.0008494177,0.0007322447,0.00185759,0.0024749609,0.00011033132,0.00002602533,0.13056387],"study_design_scores_gemma":[0.65812325,0.17725766,0.15798052,0.0017147753,0.00008807395,0.000093195325,0.0002941782,0.00015180188,0.0006259621,0.0003207408,0.0031660956,0.0001837305],"about_ca_topic_score_codex":0.0002555614,"about_ca_topic_score_gemma":0.0061091464,"teacher_disagreement_score":0.15674049,"about_ca_system_score_codex":0.00064328546,"about_ca_system_score_gemma":0.0018369863,"threshold_uncertainty_score":0.6176796},"labels":[],"label_agreement":null},{"id":"W2947918745","doi":"10.1200/jco.2019.37.15_suppl.tps597","title":"NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Calgary","funders":"","keywords":"Medicine; Letrozole; Anastrozole; Internal medicine; Randomization; Goserelin; Breast cancer; Cancer; Oncology; Metastatic breast cancer; Adjuvant; Randomized controlled trial; Tamoxifen","score_opus":0.07142779416144623,"score_gpt":0.473287293458567,"score_spread":0.4018594992971208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947918745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907476,0.0017539237,0.000016350205,0.0040391525,0.0009501848,0.0018944193,0.00019399283,0.000022909462,0.00038150937],"genre_scores_gemma":[0.99357504,0.0031631659,0.00058183813,0.0009941148,0.0009964113,0.00008196153,0.000017517716,0.00007769076,0.0005122756],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99293005,0.0014380397,0.0036771519,0.0005919014,0.00077686977,0.00058598706],"domain_scores_gemma":[0.99203104,0.0024123513,0.003524623,0.00040469234,0.0011087293,0.0005185662],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013021932,0.00052286516,0.003795918,0.00034939332,0.00006679388,0.0000130178905,0.0003453752,0.00033614028,0.0020199688],"category_scores_gemma":[0.00044782757,0.0003666315,0.0006557614,0.00038995725,0.0004124349,0.00050688407,0.00008896377,0.0014849721,0.00003972575],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15137991,0.04532681,0.27014014,0.000040892228,0.00510747,0.0010072339,0.0123019675,0.000033230008,0.04076853,0.000106113905,0.00028739704,0.47350028],"study_design_scores_gemma":[0.15118839,0.11623946,0.7201489,0.00024039,0.00027483475,0.00032336797,0.0027865695,0.0000063981074,0.005527506,0.00018339716,0.002746741,0.00033405598],"about_ca_topic_score_codex":0.003197316,"about_ca_topic_score_gemma":0.0004733253,"teacher_disagreement_score":0.47316623,"about_ca_system_score_codex":0.0012719021,"about_ca_system_score_gemma":0.0017319339,"threshold_uncertainty_score":0.9998786},"labels":[],"label_agreement":null},{"id":"W2950284764","doi":"10.1056/nejm-jw.na41601","title":"ASCO 2016 Report — Breast Cancer","year":2016,"lang":"en","type":"article","venue":"Journal watch","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Letrozole; Medicine; Breast cancer; Tamoxifen; Internal medicine; Placebo; Oncology; Aromatase inhibitor; Cancer; Clinical trial; Gynecology; Alternative medicine; Pathology","score_opus":0.012297164422825788,"score_gpt":0.31389649310904677,"score_spread":0.30159932868622097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950284764","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4195193,0.0028004916,0.0074527636,0.5643797,0.0024807209,0.0002932598,0.000056099932,0.0001530485,0.0028646337],"genre_scores_gemma":[0.87494725,0.0044029416,0.0022328885,0.001978074,0.005694345,0.000028196908,0.0000018238266,0.00009010732,0.11062439],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987172,0.00002267521,0.00034982007,0.00019014973,0.000383575,0.0003365987],"domain_scores_gemma":[0.998871,0.00003383691,0.00022745521,0.00028398822,0.00030114176,0.00028254278],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024736702,0.00014490451,0.00027109488,0.000050810675,0.00010232038,0.000018641487,0.0000979166,0.00006562821,0.0027711927],"category_scores_gemma":[0.00004353064,0.00007411866,0.00013196848,0.00010447927,0.000073318486,0.00025829265,0.000027060785,0.00022958197,0.00013885282],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010967319,0.00014045178,0.11659723,0.000030386529,0.00037372313,0.003334986,0.00022051434,0.0000034131615,0.11361197,0.00003859469,0.06905224,0.6954998],"study_design_scores_gemma":[0.00416167,0.00012618818,0.20118935,0.0012382515,0.00012136833,0.13253103,0.00007469132,0.0000018088058,0.0078135505,0.002289987,0.65017635,0.00027574852],"about_ca_topic_score_codex":0.000033719596,"about_ca_topic_score_gemma":0.0000071009117,"teacher_disagreement_score":0.695224,"about_ca_system_score_codex":0.0004927819,"about_ca_system_score_gemma":0.00033383432,"threshold_uncertainty_score":0.9981404},"labels":[],"label_agreement":null},{"id":"W2950856878","doi":"10.1634/theoncologist.2019-0019","title":"Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Calgary; University of Alberta","funders":"Genentech; Pfizer","keywords":"Letrozole; Palbociclib; Medicine; Oncology; Internal medicine; Postmenopausal women; Randomized controlled trial; Breast cancer; Cancer; Gynecology; Tamoxifen; Metastatic breast cancer","score_opus":0.006386544342530553,"score_gpt":0.2729757012801935,"score_spread":0.26658915693766294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950856878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98973256,0.00049290544,0.00008447516,0.0046951137,0.00014689685,0.003255115,0.00009032962,0.000059280705,0.0014433402],"genre_scores_gemma":[0.99730515,0.000121712,0.00032462084,0.00076802936,0.000065835084,0.0006696353,0.000014380927,0.00003596873,0.00069464004],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99739134,0.0004888927,0.00063352083,0.00043752338,0.00051367184,0.00053506054],"domain_scores_gemma":[0.9975091,0.0006617699,0.00067869184,0.00090571615,0.00015841545,0.0000862832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009739283,0.00034076843,0.002030791,0.00016005232,0.0001025222,0.00001311234,0.00042904975,0.00011373512,0.0006128011],"category_scores_gemma":[0.000073513715,0.00014009922,0.00018804573,0.0016817419,0.0010853962,0.0001005537,0.00009426703,0.00041037754,0.0000066665225],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.948518,0.00038586618,0.03558128,0.00005046358,0.0024025873,0.000022024073,0.0010732216,0.0055027083,0.0011111214,0.00034836362,0.000006766729,0.004997637],"study_design_scores_gemma":[0.8193256,0.0031967727,0.16930538,0.0002681282,0.0023503406,0.00014658147,0.0032015536,0.00037833297,0.00038987453,0.00023373262,0.00082874217,0.0003749496],"about_ca_topic_score_codex":0.00071227626,"about_ca_topic_score_gemma":0.0014256554,"teacher_disagreement_score":0.13372411,"about_ca_system_score_codex":0.0007656435,"about_ca_system_score_gemma":0.00045777086,"threshold_uncertainty_score":0.67097425},"labels":[],"label_agreement":null},{"id":"W2953541197","doi":"10.1158/1538-7445.am2019-ct012","title":"Abstract CT012: Open-label, multicenter, Phase Ib study to assess safety, tolerability and efficacy of adavosertib monotherapy in patients with advanced solid tumors: Expansion cohorts","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; Princess Margaret Cancer Centre; University of Alberta","funders":"","keywords":"Medicine; Tolerability; Nausea; Internal medicine; Adverse effect; Response Evaluation Criteria in Solid Tumors; Oncology; Breast cancer; Cancer; Metastatic breast cancer; Gastroenterology; Progressive disease; Chemotherapy; Surgery","score_opus":0.08270640598563027,"score_gpt":0.46787021229216635,"score_spread":0.38516380630653607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953541197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99029714,0.00038054833,0.000026378935,0.00022393752,0.00008256066,0.0088450955,0.00004983468,0.000024400977,0.00007010332],"genre_scores_gemma":[0.99872667,0.0000809947,0.00046659057,0.0001123076,0.000034451958,0.00041437565,0.000019058834,0.00006970496,0.00007584873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966327,0.00021227759,0.0006317215,0.00085489365,0.0010394467,0.00062894943],"domain_scores_gemma":[0.997643,0.00029260264,0.00015566926,0.0008725238,0.0007247492,0.00031144702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009829456,0.00027688607,0.0008959692,0.0002857064,0.000089850044,0.000045403533,0.00039023274,0.0000565396,0.00025650417],"category_scores_gemma":[0.00012852486,0.0002204283,0.000023487333,0.00065610977,0.00016801119,0.0004338834,0.0002792318,0.0005213561,0.000008700663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1230488,0.015326385,0.6209832,0.00027446213,0.00013427809,0.000024331164,0.0031084232,0.0003862887,0.057864998,0.0000029734383,0.000009629161,0.17883627],"study_design_scores_gemma":[0.08103849,0.010491567,0.89339,0.0013225412,0.000014242274,8.737335e-7,0.0012606625,0.000040515388,0.011983981,0.000010612723,0.00020878096,0.00023774659],"about_ca_topic_score_codex":0.00091753044,"about_ca_topic_score_gemma":0.00051807554,"teacher_disagreement_score":0.27240682,"about_ca_system_score_codex":0.00061100285,"about_ca_system_score_gemma":0.00041304063,"threshold_uncertainty_score":0.8988805},"labels":[],"label_agreement":null},{"id":"W2955160320","doi":"10.1200/jco.2013.31.15_suppl.531","title":"Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Jewish General Hospital","funders":"","keywords":"Medicine; Anastrozole; Internal medicine; Clinical endpoint; Breast cancer; Population; Interim analysis; Oncology; Placebo; Cancer; Gastroenterology; Randomized controlled trial; Tamoxifen; Pathology","score_opus":0.031222375686134878,"score_gpt":0.4148741344509979,"score_spread":0.383651758764863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955160320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901281,0.00036876064,0.00009713767,0.007181797,0.00024725375,0.0019152318,0.0000032637597,0.0000074080262,0.000051069535],"genre_scores_gemma":[0.9967962,0.0002713354,0.0010293028,0.0013656059,0.00020583802,0.00025074664,5.974216e-7,0.000032299893,0.000048099155],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99544674,0.0011546862,0.002272697,0.00025209016,0.0005349405,0.00033886783],"domain_scores_gemma":[0.9950032,0.0013917283,0.002448135,0.00023499099,0.0007408939,0.00018105103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002349871,0.00024000561,0.0023747373,0.00021182203,0.00004244501,0.000007832685,0.0002145242,0.00011157095,0.00015787421],"category_scores_gemma":[0.00031563625,0.00012212482,0.00015610555,0.0004463576,0.00040417621,0.00034446304,0.000051232593,0.0010827288,6.1219504e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5761476,0.021110835,0.053227168,0.000024255976,0.00065251807,0.00014400989,0.004796501,0.0016546489,0.0035401576,0.00001280099,0.000013380186,0.33867612],"study_design_scores_gemma":[0.77248996,0.048986807,0.16807452,0.00064045645,0.00010659636,0.00021302338,0.007826984,0.00010676925,0.0007443997,0.00022813289,0.00043209965,0.00015027863],"about_ca_topic_score_codex":0.00046774955,"about_ca_topic_score_gemma":0.0005825081,"teacher_disagreement_score":0.33852586,"about_ca_system_score_codex":0.0005054233,"about_ca_system_score_gemma":0.0011932581,"threshold_uncertainty_score":0.4980106},"labels":[],"label_agreement":null},{"id":"W2955852147","doi":"10.1016/j.bmcl.2019.06.021","title":"Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma","year":2019,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Paraza Pharma (Canada)","funders":"SLAC National Accelerator Laboratory; Biological and Environmental Research; Basic Energy Sciences; National Institute of General Medical Sciences; Genentech; Office of Science; National Institutes of Health; U.S. Department of Energy","keywords":"Cyclin-dependent kinase 6; Chemistry; Palbociclib; Polar surface area; Pharmacology; Cell cycle; Cyclin-dependent kinase 1; Kinase; Cancer research; Potency; Cyclin-dependent kinase; Biochemistry; Cell; Cancer; Internal medicine; In vitro; Biology; Breast cancer; Medicine; Metastatic breast cancer","score_opus":0.010539804837653068,"score_gpt":0.2466546069151321,"score_spread":0.23611480207747904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955852147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9617356,0.00067395234,0.023395227,0.012738604,0.0002783838,0.0009619736,0.00002010616,0.00009820384,0.00009796939],"genre_scores_gemma":[0.99118876,0.000008806057,0.0038269872,0.0037531566,0.0007145245,0.000043857122,0.00002014311,0.000073095434,0.00037066865],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99823666,0.000018564677,0.00043458364,0.0004343792,0.0004548919,0.00042090839],"domain_scores_gemma":[0.9987813,0.00023584695,0.00021250722,0.00045983924,0.0001205943,0.00018989522],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025348633,0.00028269918,0.000547711,0.000057484925,0.00003435892,0.0000058599167,0.00019795596,0.0001219412,0.0007635402],"category_scores_gemma":[0.0001432198,0.0002469115,0.00013239835,0.00023535488,0.00019656702,0.000061897226,0.000030547744,0.000217186,0.0000279397],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020699392,0.00007309589,0.00034531302,0.00081562815,0.00013912865,0.00002591591,0.0002377925,0.0000134006295,0.99270374,0.0000034101108,0.0019212298,0.0016514119],"study_design_scores_gemma":[0.005412566,0.00046250538,0.00047939448,0.0005152643,0.00010992241,0.00035695784,0.0002746543,0.00009949373,0.985882,0.000021152473,0.006144035,0.00024204119],"about_ca_topic_score_codex":0.000004609593,"about_ca_topic_score_gemma":1.8396031e-7,"teacher_disagreement_score":0.029453183,"about_ca_system_score_codex":0.00019202258,"about_ca_system_score_gemma":0.00020583575,"threshold_uncertainty_score":0.99999833},"labels":[],"label_agreement":null},{"id":"W2967512896","doi":"10.1158/1535-7163.mct-19-0162","title":"eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Montreal Neurological Institute and Hospital; McGill University Health Centre","funders":"Canadian Institutes of Health Research; National Institute of General Medical Sciences; Government of Canada","keywords":"Palbociclib; Cancer research; Cancer; Cancer cell; Downregulation and upregulation; KRAS; Cell cycle; Cyclin D1; Estrogen receptor; Medicine; Cyclin-dependent kinase 6; Breast cancer; Pharmacology; Biology; Internal medicine; Metastatic breast cancer; Colorectal cancer","score_opus":0.012868211759400505,"score_gpt":0.28810024795350697,"score_spread":0.27523203619410647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967512896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9767664,0.013733928,0.00033990192,0.0070782998,0.00036696158,0.0012063286,0.00006484233,0.00008602164,0.00035728866],"genre_scores_gemma":[0.9888709,0.0005888571,0.0009312698,0.0073371404,0.000114620336,0.00031947027,0.0000108143695,0.0001270438,0.0016998617],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99761254,0.00016768998,0.0004221787,0.00070658466,0.0004885931,0.00060242414],"domain_scores_gemma":[0.9988005,0.00007258775,0.00013879528,0.00060712686,0.00016212498,0.0002188774],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025738103,0.0003850752,0.0005139207,0.0002676874,0.000065198954,0.00004417702,0.00011599959,0.00018956664,0.00018249893],"category_scores_gemma":[0.000012874537,0.0003900717,0.00009574805,0.00064266194,0.00012501309,0.00016792849,0.00009479607,0.0002500204,0.000030493786],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0090152435,0.00013748072,0.008792095,0.00023371662,0.00010205921,0.00010702276,0.0021224595,0.0012984711,0.969517,0.000042822277,0.00007958467,0.008552081],"study_design_scores_gemma":[0.008215709,0.00044493048,0.055355534,0.0013417696,0.00016286272,0.000024939884,0.0006117508,0.00022745677,0.86870587,0.00046610917,0.06360649,0.00083657884],"about_ca_topic_score_codex":0.00021974606,"about_ca_topic_score_gemma":0.0003294465,"teacher_disagreement_score":0.1008111,"about_ca_system_score_codex":0.0006617403,"about_ca_system_score_gemma":0.00026460527,"threshold_uncertainty_score":0.9998551},"labels":[],"label_agreement":null},{"id":"W2971188595","doi":"10.1111/tbj.13516","title":"Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer","year":2019,"lang":"en","type":"article","venue":"The Breast Journal","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Pfizer","keywords":"Palbociclib; Medicine; Letrozole; Fulvestrant; Internal medicine; Oncology; Hazard ratio; Metastatic breast cancer; Breast cancer; Placebo; Anastrozole; Gynecology; Cancer; Estrogen receptor; Tamoxifen; Confidence interval; Pathology","score_opus":0.011805215036039552,"score_gpt":0.27498591668400224,"score_spread":0.2631807016479627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971188595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938543,0.00078556687,0.00007416213,0.0036925804,0.00007027319,0.000985004,0.0004429567,0.00003019359,0.00006500329],"genre_scores_gemma":[0.9967767,0.0016207737,0.0006904492,0.00035390255,0.00025437181,0.000059228627,0.00001596189,0.00008512547,0.0001435026],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972604,0.00037256494,0.00065412704,0.00039261903,0.0005937145,0.00072657113],"domain_scores_gemma":[0.9978581,0.00032326084,0.0007553263,0.00033570567,0.00037822858,0.0003493785],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032824196,0.00045408393,0.0010776593,0.00021824703,0.00018807038,0.000037295074,0.0002682474,0.000029933783,0.0008489186],"category_scores_gemma":[0.000021608712,0.00027022543,0.000090233545,0.00072066457,0.0007302358,0.00035242716,0.000067864275,0.0008282469,0.000010875484],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12281762,0.000985008,0.4304381,0.00014457974,0.003204939,0.00009911321,0.027502848,0.00036693152,0.04740914,0.00007453143,0.00006971064,0.36688748],"study_design_scores_gemma":[0.019121284,0.0018357303,0.97082525,0.00025218425,0.000069667425,0.003788679,0.0027551325,0.000014991647,0.000854778,0.000043252927,0.00012182729,0.00031719045],"about_ca_topic_score_codex":0.00073940936,"about_ca_topic_score_gemma":0.00016922748,"teacher_disagreement_score":0.54038715,"about_ca_system_score_codex":0.0007005027,"about_ca_system_score_gemma":0.00030563027,"threshold_uncertainty_score":0.99997497},"labels":[],"label_agreement":null},{"id":"W2971211596","doi":"10.1007/978-3-030-20301-6_8","title":"Therapeutic Options for Metastatic Breast Cancer","year":2019,"lang":"en","type":"review","venue":"Advances in experimental medicine and biology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Breast cancer; Metastatic breast cancer; Cancer; Oncology; Disease; Immunotherapy; Internal medicine; CA15-3","score_opus":0.14766039077636345,"score_gpt":0.5051459061718745,"score_spread":0.35748551539551104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971211596","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000142439085,0.9961836,0.00024109836,0.0004533801,0.0007884171,0.0019665493,0.00016950943,0.000032117397,0.000151125],"genre_scores_gemma":[0.0003393791,0.9953656,0.0009257894,0.0007280939,0.00050276227,0.0016741625,0.00022334572,0.00006233958,0.00017853391],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982287,0.00008700494,0.00059183256,0.00060662034,0.00008400837,0.0004018176],"domain_scores_gemma":[0.9989411,0.00036728216,0.00026560435,0.00027859616,0.000044289845,0.00010313113],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012796346,0.00047739677,0.0022959444,0.00028182348,0.000049011156,0.0000035126661,0.00013177635,0.00016858937,0.00020072135],"category_scores_gemma":[0.000017969058,0.0002964671,0.00018032115,0.00023897688,0.0005332334,0.00012258666,0.000050788254,0.0002687431,0.0000058760897],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015830214,0.000107725034,0.000046043475,0.005505904,0.00020720852,0.000004120534,0.00012863342,5.1603934e-7,0.00017341752,0.0016897084,0.000016850838,0.9919616],"study_design_scores_gemma":[0.0025070582,0.0009353341,0.000008658295,0.009270872,0.0007402328,0.0005324833,0.00054351403,0.000005992938,0.000019653236,0.0005455677,0.98460037,0.00029028155],"about_ca_topic_score_codex":0.000034235385,"about_ca_topic_score_gemma":0.000011344333,"teacher_disagreement_score":0.99167126,"about_ca_system_score_codex":0.00023008593,"about_ca_system_score_gemma":0.00014469273,"threshold_uncertainty_score":0.99994874},"labels":[],"label_agreement":null},{"id":"W2972122997","doi":"10.1016/j.clbc.2019.08.009","title":"Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2","year":2019,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Daiichi Sankyo Europe; Genentech; Daiichi Sankyo Company; Plexxikon; PharmaMar; Eisai; MacroGenics; Amgen; Nippon Kayaku; Astellas Pharma; Mylan; Genomic Health; Novartis Pharma; Novartis; Pfizer; Ontario Brain Institute; Merck; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Palbociclib; Letrozole; Medicine; Breast cancer; Internal medicine; Oncology; Placebo; Metastatic breast cancer; Estrogen receptor; Progression-free survival; Odds ratio; Population; Adverse effect; Cancer; Gynecology; Tamoxifen; Chemotherapy; Pathology","score_opus":0.02003432836318951,"score_gpt":0.3391463333567022,"score_spread":0.31911200499351267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972122997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98208696,0.00020604377,0.00013568284,0.0012625989,0.00020136085,0.0026311653,0.013285343,0.00013441623,0.00005642586],"genre_scores_gemma":[0.9958948,0.000036649362,0.001937019,0.00048127695,0.00021078794,0.0005236281,0.0005466028,0.00020481762,0.00016440073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99217623,0.0009619843,0.0018659782,0.0019607928,0.0019445313,0.0010904855],"domain_scores_gemma":[0.99297684,0.0011866149,0.0017847229,0.0014170452,0.0019513624,0.00068341783],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000504741,0.0011030898,0.003372206,0.0005526862,0.00017064974,0.00004705692,0.0006458896,0.00041202188,0.002819317],"category_scores_gemma":[0.00012356679,0.0007506729,0.00047503668,0.0023286396,0.0010659083,0.00064227224,0.00023071963,0.0012600519,0.000021943513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19629699,0.0011872198,0.79006785,0.000076032884,0.004936942,0.000027711616,0.00073603133,0.0004532479,0.0008324634,0.0000052235328,0.000017284721,0.0053630173],"study_design_scores_gemma":[0.048805326,0.002743051,0.94168526,0.0014625533,0.0013195368,0.00000936448,0.00082971615,0.00006774623,0.0021196774,0.000010259782,0.000022560345,0.0009249426],"about_ca_topic_score_codex":0.0055562025,"about_ca_topic_score_gemma":0.001906997,"teacher_disagreement_score":0.15161744,"about_ca_system_score_codex":0.0018422935,"about_ca_system_score_gemma":0.0010485562,"threshold_uncertainty_score":0.99949443},"labels":[],"label_agreement":null},{"id":"W2972497118","doi":"10.5376/cge.2019.07.0005","title":"Clinical-Pathologic Factors Associated with Hormone Receptor Expression Predict Prognosis in Breast Cancer","year":2019,"lang":"en","type":"article","venue":"Cancer Genetics and Epigenetics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Breast cancer; Medicine; Tamoxifen; Internal medicine; Oncology; Estrogen receptor; Cancer; Progesterone receptor; Immunohistochemistry; Triple-negative breast cancer; Hormone receptor","score_opus":0.035519516129476875,"score_gpt":0.3174413172502501,"score_spread":0.28192180112077325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972497118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773603,0.020445073,0.000057188063,0.000507427,0.00034797235,0.0008662737,0.00030055692,0.000046922272,0.000068302885],"genre_scores_gemma":[0.9642311,0.033924293,0.00082487264,0.0002419365,0.00020088103,0.00017107185,0.000047767113,0.00007602369,0.00028207776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978768,0.00008677808,0.00052226725,0.00064794294,0.00034937804,0.0005168178],"domain_scores_gemma":[0.9988082,0.00008999387,0.0002615792,0.00034559754,0.00022171634,0.00027293753],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019694403,0.00034873578,0.00064912555,0.000105064675,0.00006256169,0.00002341262,0.0001391414,0.00028251117,0.00020141888],"category_scores_gemma":[0.00002439187,0.00026013656,0.00007792189,0.00033455592,0.00023236411,0.0000517711,0.00008856864,0.00036837402,0.0000050449744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039440213,0.00018834257,0.93529713,0.000049423612,0.00010511754,0.000008592226,0.00028588885,0.00031624586,0.0265069,0.000001637435,0.00006688454,0.03677944],"study_design_scores_gemma":[0.0034037102,0.0007510621,0.9858473,0.0006539536,0.00012210383,0.000007243583,0.00021013657,0.0002580517,0.00600358,0.000036028818,0.0023584794,0.00034834415],"about_ca_topic_score_codex":0.000049650786,"about_ca_topic_score_gemma":0.00007949186,"teacher_disagreement_score":0.05055018,"about_ca_system_score_codex":0.00019846484,"about_ca_system_score_gemma":0.00024928898,"threshold_uncertainty_score":0.9999851},"labels":[],"label_agreement":null},{"id":"W2974027076","doi":"10.1158/1078-0432.ccr-19-0751","title":"Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer","year":2019,"lang":"en","type":"letter","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Pfizer","keywords":"Palbociclib; Letrozole; Breast cancer; Biomarker; Cyclin-dependent kinase 4; Oncology; Metastatic breast cancer; Medicine; Internal medicine; Cancer; Fulvestrant; Cancer research; Biology; Estrogen receptor; Cell cycle; Tamoxifen; Cyclin-dependent kinase 2","score_opus":0.26475433294806805,"score_gpt":0.543597462485185,"score_spread":0.278843129537117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974027076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7325886,0.0048609637,0.000010541067,0.25901705,0.00015248002,0.0023318427,0.00097354985,0.000027898483,0.00003710277],"genre_scores_gemma":[0.83529115,0.019515313,0.00046802053,0.12995909,0.0021318973,0.005852422,0.00015249623,0.00039026674,0.006239331],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9926385,0.00190299,0.0012497002,0.0014055059,0.0015633607,0.0012399416],"domain_scores_gemma":[0.99421453,0.0030883828,0.00036892504,0.001086247,0.00086857367,0.0003733123],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022657602,0.00061009795,0.002020563,0.001290552,0.0000849119,0.00004746317,0.00025346526,0.00036986658,0.0010531091],"category_scores_gemma":[0.00031189877,0.0004168844,0.00019302197,0.0012682676,0.0009942503,0.00014672278,0.00016696451,0.0021165877,0.000024609657],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3665779,0.0017242212,0.037079785,0.001303355,0.0041125445,0.0046090023,0.0011482033,0.0001014053,0.035935614,0.0000014594102,0.02145264,0.5259539],"study_design_scores_gemma":[0.07245899,0.026963074,0.6071531,0.0081056785,0.0007516331,0.00049847347,0.0014263191,0.000054936554,0.013438523,0.0003090666,0.2669629,0.0018772952],"about_ca_topic_score_codex":0.005869604,"about_ca_topic_score_gemma":0.00056820206,"teacher_disagreement_score":0.5700733,"about_ca_system_score_codex":0.0022175156,"about_ca_system_score_gemma":0.0021167018,"threshold_uncertainty_score":0.99986005},"labels":[],"label_agreement":null},{"id":"W2974264218","doi":"10.1136/ijgc-2019-igcs.293","title":"293 Molecular determinants of CDK4 inhibitor activity in low-grade serous ovarian cancer","year":2019,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Western University; University of British Columbia","funders":"","keywords":"Palbociclib; Cyclin-dependent kinase 6; CDKN2A; Cancer research; Medicine; Ovarian cancer; Oncology; Internal medicine; Breast cancer; Cancer; Cell cycle; Cyclin D1","score_opus":0.017429251695311496,"score_gpt":0.3436476119863559,"score_spread":0.3262183602910444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974264218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948823,0.0009468513,0.00016602047,0.0019586473,0.0015947132,0.00023478131,0.000032179203,0.000008650404,0.00017587512],"genre_scores_gemma":[0.9977771,0.0002961862,0.0006302984,0.00075977284,0.00034442017,0.000024551879,9.929112e-7,0.000019581468,0.00014707334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820435,0.00006634647,0.0005809392,0.00021157914,0.00069371745,0.00024304695],"domain_scores_gemma":[0.9983941,0.00016136064,0.0006249311,0.00013362533,0.00056764425,0.00011835052],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022989669,0.00017460162,0.0005744183,0.00021869279,0.000012001222,0.000012360096,0.0003121919,0.00014083352,0.0017746689],"category_scores_gemma":[0.00016485057,0.00013323329,0.00019411759,0.00017182884,0.00009744554,0.00023014331,0.00007679849,0.00042846362,0.0000070891556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037974925,0.0007799952,0.65557253,0.000098955024,0.00036680466,0.00093295774,0.0002141251,0.0027390958,0.23728004,0.000087698805,0.000036315218,0.09809397],"study_design_scores_gemma":[0.00607301,0.00068080344,0.8543004,0.00090880244,0.00004924821,0.00022509189,0.000068531575,0.00037096985,0.13490584,0.0005239338,0.0016991185,0.00019424313],"about_ca_topic_score_codex":0.00019930981,"about_ca_topic_score_gemma":0.0001829387,"teacher_disagreement_score":0.19872786,"about_ca_system_score_codex":0.00082442316,"about_ca_system_score_gemma":0.00041323132,"threshold_uncertainty_score":0.9991378},"labels":[],"label_agreement":null},{"id":"W2977259025","doi":"10.1200/jco.2012.30.15_suppl.551","title":"Safety of everolimus for women over 65 years of age with advanced breast cancer (BC): 12.5-mo follow-up of BOLERO-2.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Everolimus; Exemestane; Internal medicine; Adverse effect; Tolerability; Rash; Breast cancer; Population; Aromatase inhibitor; Placebo; Oncology; Cancer; Aromatase","score_opus":0.054556429554377686,"score_gpt":0.4282402993348184,"score_spread":0.3736838697804407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977259025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995716,0.0009296508,0.000726629,0.0007279826,0.001030472,0.00037540196,0.0001006769,0.000006193748,0.00038699305],"genre_scores_gemma":[0.9901344,0.0006483031,0.0073538776,0.0005437561,0.000845151,0.00001826731,0.0000019402062,0.0000402729,0.00041404067],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963714,0.00015775,0.0024050714,0.00016722854,0.0004763425,0.00042222865],"domain_scores_gemma":[0.9936169,0.001548673,0.0035201004,0.00025289398,0.00068256917,0.00037889744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018291381,0.00018010123,0.002374892,0.00013412317,0.000016336518,0.0000011722867,0.00020918029,0.0002860726,0.00024105719],"category_scores_gemma":[0.000653986,0.00013197381,0.00048246724,0.00016016857,0.00049790845,0.0002378754,0.000047793554,0.00049553206,9.249495e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15423909,0.0025046407,0.22149757,0.00040938178,0.002253227,0.000041954496,0.0016726493,0.0002814148,0.007470098,0.00019037821,0.00036439757,0.6090752],"study_design_scores_gemma":[0.037370566,0.011385344,0.8977505,0.0005459036,0.00046835924,0.00018933232,0.000496292,0.000009099514,0.00081354595,0.00032271733,0.050503936,0.00014439478],"about_ca_topic_score_codex":0.00004604544,"about_ca_topic_score_gemma":0.00006217899,"teacher_disagreement_score":0.67625296,"about_ca_system_score_codex":0.0003122788,"about_ca_system_score_gemma":0.0010986554,"threshold_uncertainty_score":0.53817356},"labels":[],"label_agreement":null},{"id":"W2977936382","doi":"10.1093/annonc/mdz394.007","title":"Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Human Epidermal Growth Factor Receptor 2; Oncology; Internal medicine; Hormone receptor; Cancer; Breast cancer; Gynecology","score_opus":0.02761816145389646,"score_gpt":0.3378950834321779,"score_spread":0.31027692197828144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977936382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903712,0.00015466464,0.000013097653,0.0014226389,0.00017328534,0.0026282095,0.003786593,0.000031757463,0.0014185115],"genre_scores_gemma":[0.99846214,0.00016514034,0.00029247187,0.00028094134,0.00012225968,0.00009709583,0.00021822889,0.000073196534,0.00028854268],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9964244,0.00041996787,0.0011316751,0.0006444446,0.00078155764,0.0005979488],"domain_scores_gemma":[0.9950817,0.000482186,0.0018614336,0.00056864414,0.0018029959,0.00020303129],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002700688,0.0005145223,0.0017202827,0.00016197196,0.00009242746,0.0000048668867,0.00031427667,0.00023722708,0.0001778364],"category_scores_gemma":[0.00008384008,0.00032502593,0.00020037613,0.00043453055,0.0009177456,0.00033576158,0.000081326485,0.00042325392,0.00000279693],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83544904,0.006105245,0.014832257,0.00013524047,0.0022544647,0.000025972495,0.002566282,0.00012797727,0.11458172,0.00024092292,0.00012277965,0.02355808],"study_design_scores_gemma":[0.37806457,0.082518764,0.40718648,0.00054310623,0.00037397706,0.000037106176,0.00050075096,0.000009256731,0.12983832,0.000119671255,0.0003473076,0.00046067964],"about_ca_topic_score_codex":0.002292084,"about_ca_topic_score_gemma":0.00038134868,"teacher_disagreement_score":0.4573845,"about_ca_system_score_codex":0.00023940063,"about_ca_system_score_gemma":0.00062887487,"threshold_uncertainty_score":0.9999202},"labels":[],"label_agreement":null},{"id":"W2978530456","doi":"10.1093/annonc/mdz242.028","title":"Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Letrozole; Human Epidermal Growth Factor Receptor 2; Hormone receptor; Breast cancer; Oncology; Internal medicine; Cancer; Metastatic breast cancer; Tamoxifen","score_opus":0.0271541311051166,"score_gpt":0.3359975925979312,"score_spread":0.3088434614928146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978530456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98959535,0.00094010466,0.00017453125,0.0018413309,0.0002517162,0.0024367087,0.00455002,0.00005155772,0.00015869612],"genre_scores_gemma":[0.99675125,0.00022736013,0.0005985099,0.0008763103,0.00025475043,0.00022269752,0.00096430973,0.00006277237,0.000042041516],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9959519,0.000794418,0.0010187979,0.0008418243,0.00055126817,0.0008418082],"domain_scores_gemma":[0.9968139,0.00064174004,0.0010696388,0.0005135547,0.0006698811,0.0002912706],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003255793,0.0005408545,0.0019388184,0.00029172594,0.00017464322,0.000025356252,0.00030321453,0.00019586094,0.0006820558],"category_scores_gemma":[0.00006453883,0.00038812094,0.00028851404,0.00086908095,0.00053026737,0.0004429408,0.00012524563,0.0004879214,0.0000119217075],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39141044,0.0066167656,0.37120587,0.0002611362,0.016222218,0.00006695637,0.010440572,0.00044215267,0.020745318,0.00058031373,0.0011408121,0.18086745],"study_design_scores_gemma":[0.17168333,0.015361827,0.7997469,0.00032425605,0.0014009594,0.000010605649,0.004606343,0.000105833715,0.0041090604,0.000044732868,0.0019747638,0.00063140644],"about_ca_topic_score_codex":0.0059924037,"about_ca_topic_score_gemma":0.0012647557,"teacher_disagreement_score":0.428541,"about_ca_system_score_codex":0.00066783396,"about_ca_system_score_gemma":0.00024598723,"threshold_uncertainty_score":0.99985707},"labels":[],"label_agreement":null},{"id":"W2980789446","doi":"10.1200/jco.2019.37.27_suppl.210","title":"Utilizaton of patient reported outcomes measures (PROM) to characterize symptom burden and adherence associated with oral oncolytic therapy.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prom; Nausea; Patient-reported outcome; Internal medicine; Observational study; Confidence interval; Tolerability; Vomiting; Physical therapy; Adverse effect; Quality of life (healthcare)","score_opus":0.12815848778523778,"score_gpt":0.4335398399811503,"score_spread":0.30538135219591256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980789446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99536705,0.00034612324,0.000046727975,0.0029208234,0.00051554973,0.00053221965,0.0000040880605,0.000014131037,0.00025327026],"genre_scores_gemma":[0.9965598,0.00019124619,0.0012228834,0.0016187382,0.00014507506,0.000006952296,0.0000019149054,0.000025761186,0.00022762378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99648935,0.00031026383,0.0021387092,0.00024171273,0.00058355695,0.00023642827],"domain_scores_gemma":[0.9942644,0.0012381253,0.0029683765,0.00026460696,0.0009291412,0.0003353096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016484276,0.00018914747,0.0020991948,0.00011792332,0.000019911608,0.0000067877054,0.00013294833,0.0002564134,0.00012656944],"category_scores_gemma":[0.0025649702,0.00011422994,0.00022345434,0.00019149476,0.00015759682,0.0001231426,0.00004449085,0.00055685436,0.000003914471],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011655501,0.00068695063,0.6113727,0.000019727284,0.0012015149,0.00019112976,0.00052814506,0.0000146848215,0.0036033904,0.0000107697815,0.000031189113,0.37068427],"study_design_scores_gemma":[0.01269523,0.037198383,0.93234617,0.00047702747,0.0002362808,0.00028991565,0.00027796396,0.00001779201,0.00048447252,0.00009560368,0.0157452,0.00013596112],"about_ca_topic_score_codex":0.00003287349,"about_ca_topic_score_gemma":0.00002466717,"teacher_disagreement_score":0.3705483,"about_ca_system_score_codex":0.00016030156,"about_ca_system_score_gemma":0.0011403454,"threshold_uncertainty_score":0.46581617},"labels":[],"label_agreement":null},{"id":"W2990084298","doi":"10.1002/cncr.32631","title":"The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: A population‐based study in British Columbia from 2003 to 2013","year":2019,"lang":"en","type":"article","venue":"Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Metastatic breast cancer; Hormonal therapy; Internal medicine; Breast cancer; Oncology; Population; Cancer; Hormone; Systemic therapy","score_opus":0.019466736493661072,"score_gpt":0.30771077125905316,"score_spread":0.28824403476539207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990084298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911333,0.0025645194,0.000003119634,0.000449783,0.00014264749,0.0033045984,0.0023579772,0.000024979068,0.000019080324],"genre_scores_gemma":[0.9979732,0.00035269503,0.000083346284,0.00008144673,0.00012740884,0.0005101208,0.00008290237,0.00006140799,0.0007274811],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978424,0.00031941323,0.0005074229,0.0005444093,0.00039266035,0.00039372148],"domain_scores_gemma":[0.9987158,0.0003345895,0.0002598943,0.00030324917,0.00019911393,0.00018732894],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014769417,0.00031325113,0.0008951112,0.00012996132,0.00009543567,0.00006903994,0.0001241573,0.00006467303,0.0011509802],"category_scores_gemma":[0.000034483266,0.0002814501,0.000096543525,0.00050346786,0.000062241306,0.00016090651,0.000022395394,0.00020260109,0.00001830118],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003604375,0.000620515,0.9481719,0.000022261444,0.00074133725,0.000009917655,0.0030901565,0.00064472854,0.009561534,0.0000028518277,0.0005283658,0.03300202],"study_design_scores_gemma":[0.008684704,0.002711546,0.9860818,0.0007575787,0.00005978222,0.0000036099184,0.0011315806,0.000060946197,0.0001883961,0.000036531055,0.000020894498,0.00026264382],"about_ca_topic_score_codex":0.53812975,"about_ca_topic_score_gemma":0.11671804,"teacher_disagreement_score":0.42141172,"about_ca_system_score_codex":0.0025025015,"about_ca_system_score_gemma":0.0004652903,"threshold_uncertainty_score":0.99996376},"labels":[],"label_agreement":null},{"id":"W2990519743","doi":"10.1158/1078-0432.ccr-19-2350","title":"Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Metastatic breast cancer; Breast cancer; Chemotherapy; Oncology; Population; Cancer; Hormone therapy; Confidence interval; Gastroenterology","score_opus":0.04489257946605979,"score_gpt":0.42035268426264466,"score_spread":0.37546010479658487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990519743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845344,0.0020877593,0.000026594642,0.0026624145,0.00019113148,0.0017411994,0.008713028,0.00002900069,0.000014461921],"genre_scores_gemma":[0.9927157,0.0044765356,0.00021484653,0.000542264,0.000172659,0.00044406438,0.0005885556,0.000086422435,0.00075891416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99633706,0.00053682266,0.0006787686,0.00084283145,0.00083051086,0.0007740269],"domain_scores_gemma":[0.99729973,0.0010283367,0.00018442856,0.00048774536,0.0005186738,0.00048106353],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00063443615,0.0003335171,0.0010802664,0.00013713818,0.00006411563,0.000044081302,0.00013422886,0.000112340065,0.001239414],"category_scores_gemma":[0.00011308499,0.00022528584,0.000084681786,0.00025455223,0.00034653043,0.00016854372,0.00008297974,0.000646837,0.00005317841],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009308584,0.0010861063,0.8624397,0.00006374681,0.0005316766,0.000013990241,0.00025801387,0.0000019337695,0.00012267083,0.0000013734789,0.00017716637,0.12599507],"study_design_scores_gemma":[0.014284978,0.0023828028,0.9792819,0.00056889973,0.00009821387,9.1358214e-7,0.0003284276,0.000041771356,0.00008893948,0.000007916138,0.0026678145,0.00024739493],"about_ca_topic_score_codex":0.020079192,"about_ca_topic_score_gemma":0.0010289651,"teacher_disagreement_score":0.12574767,"about_ca_system_score_codex":0.0012173932,"about_ca_system_score_gemma":0.00046591964,"threshold_uncertainty_score":0.9996736},"labels":[],"label_agreement":null},{"id":"W2991396635","doi":"10.1101/857839","title":"The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Genentech; Eisai; Daiichi-Sankyo; Foundation Medicine; MacroGenics; Puma Biotechnology; Sanofi; Exelixis; Array BioPharma; Celldex Therapeutics; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Cancer research; KRAS; AKT1; Kinase; Breast cancer; Cyclin-dependent kinase 4; Cancer; MAPK/ERK pathway; CHEK1; Protein kinase B; Biology; Medicine; Internal medicine; Cell cycle; Cell cycle checkpoint; Signal transduction; Genetics; Cyclin-dependent kinase 2","score_opus":0.005653962234441214,"score_gpt":0.2147804532742148,"score_spread":0.2091264910397736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991396635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987399,0.0077282675,0.000074071366,0.00074789894,0.00040540725,0.00238667,0.0011951115,0.000060767266,0.0000028074192],"genre_scores_gemma":[0.99671775,0.0006648094,0.0017650203,0.00018145079,0.00016848226,0.00034118572,0.0000014883645,0.00014662028,0.000013185336],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715567,0.0001368768,0.0006732563,0.0009241214,0.0005690577,0.0005410177],"domain_scores_gemma":[0.9972469,0.00012390954,0.0006045607,0.0010259069,0.0007244707,0.00027425916],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038624348,0.0005666421,0.00093422225,0.0003121391,0.000097074124,0.00006476368,0.00029819994,0.00018490177,0.000014179225],"category_scores_gemma":[0.000074457486,0.00043370074,0.00007836621,0.0005225236,0.00021220489,0.0001285548,0.00035842275,0.00046400228,0.0000101752385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020596953,0.0008393175,0.6061659,0.0013809147,0.0015431395,0.00006861447,0.00029602967,0.00037056784,0.36799413,0.000113551745,0.00020001062,0.00043090442],"study_design_scores_gemma":[0.004192404,0.00023416328,0.97161543,0.001793452,0.00021587583,3.923116e-8,0.000026080497,0.0000073623173,0.02103318,0.0000012702163,0.00038459702,0.0004961672],"about_ca_topic_score_codex":0.00011930745,"about_ca_topic_score_gemma":0.000057307556,"teacher_disagreement_score":0.36544955,"about_ca_system_score_codex":0.00072173297,"about_ca_system_score_gemma":0.0006866478,"threshold_uncertainty_score":0.9998115},"labels":[],"label_agreement":null},{"id":"W2991469489","doi":"","title":"Horizon Scanning in Oncology 41st Prioritisation – 4th quarter 2019","year":2019,"lang":"en","type":"article","venue":"","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quarter (Canadian coin); Medical physics; Geography","score_opus":0.014972726889157224,"score_gpt":0.3011205637180434,"score_spread":0.28614783682888617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991469489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9493047,0.00036060554,0.0012129643,0.0028000989,0.0004271618,0.0004734951,0.0000015205916,0.00008164157,0.045337792],"genre_scores_gemma":[0.9907883,0.000018660283,0.0032889068,0.00060295255,0.00016361347,0.000015504964,0.00001357521,0.00001733643,0.005091146],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9992535,0.000025528194,0.00017808202,0.00020426881,0.0001307286,0.00020787146],"domain_scores_gemma":[0.99962926,0.00004368931,0.000048439295,0.00018436227,0.000043225416,0.00005100933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000119069,0.000090805996,0.00022885829,0.0001125889,0.000012944744,0.000005780685,0.000042192274,0.000082591105,0.00076537137],"category_scores_gemma":[0.000011699036,0.00008045851,0.000030458206,0.00013242777,0.000025871217,0.00014739369,0.000014481924,0.00015089982,0.00040540547],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009707338,0.00022650197,0.25924724,0.00009369542,0.000053855914,0.000055976012,0.0021685476,0.00008967941,0.08900893,0.0030600484,0.0019326851,0.6430921],"study_design_scores_gemma":[0.014773123,0.0047129844,0.71501666,0.00046436876,0.000041519506,0.00029427078,0.0045198314,0.0007617456,0.007351241,0.0013930862,0.25013518,0.0005359703],"about_ca_topic_score_codex":0.0002006712,"about_ca_topic_score_gemma":0.000100944795,"teacher_disagreement_score":0.64255613,"about_ca_system_score_codex":0.00031392326,"about_ca_system_score_gemma":0.000115128496,"threshold_uncertainty_score":0.83802795},"labels":[],"label_agreement":null},{"id":"W2999904492","doi":"10.1016/j.jcjo.2019.11.003","title":"Ribociclib-associated vortex keratopathy","year":2020,"lang":"en","type":"article","venue":"Canadian Journal of Ophthalmology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Dalhousie University; McMaster University","funders":"","keywords":"Vortex; Medicine; Ophthalmology; Physics; Mechanics","score_opus":0.034420069420384114,"score_gpt":0.28249395859818793,"score_spread":0.24807388917780382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999904492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813541,0.0020138493,0.00008143925,0.008639732,0.0004462254,0.000096737676,0.0000209503,0.000008045392,0.0073388834],"genre_scores_gemma":[0.99732673,0.0000025474349,0.0005291907,0.0013715645,0.00038098713,0.000001383797,0.0000047757867,0.000028968341,0.00035384807],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99893713,0.0000658924,0.00036933695,0.00013507775,0.0001304984,0.0003620762],"domain_scores_gemma":[0.99804246,0.00004198968,0.00024204186,0.00011419442,0.00030232838,0.0012570102],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014146694,0.00013164846,0.00044415783,0.00013935367,0.00006607873,0.000012097681,0.0001612302,0.000121128236,0.0023449871],"category_scores_gemma":[0.00045896342,0.0001216014,0.00013905256,0.00026099407,0.00014772068,0.00009354867,0.000008133211,0.000398215,0.000044378234],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094767206,0.00010587991,0.643205,0.000082448736,0.0009147453,0.33317515,0.003919687,0.00015091682,0.006820738,0.0007942999,0.0035969594,0.0062865377],"study_design_scores_gemma":[0.0060690776,0.0039853095,0.35963383,0.00018266814,0.00024666713,0.5951417,0.00083682226,0.000082326376,0.001807382,0.0021306158,0.029440995,0.00044260424],"about_ca_topic_score_codex":0.0003788386,"about_ca_topic_score_gemma":0.00004612196,"teacher_disagreement_score":0.28357115,"about_ca_system_score_codex":0.00022840893,"about_ca_system_score_gemma":0.0016961086,"threshold_uncertainty_score":0.998567},"labels":[],"label_agreement":null},{"id":"W3004787369","doi":"10.1200/jco.2020.38.4_suppl.491","title":"Eligibility for second-line therapy in patients with advanced hepatocellular carcinoma (aHCC): A BC Cancer population-based study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Sorafenib; Cabozantinib; Hepatocellular carcinoma; Internal medicine; Regimen; Regorafenib; Ramucirumab; Population; Oncology; Cancer; Surgery; Colorectal cancer","score_opus":0.1042699116533265,"score_gpt":0.45515339199039073,"score_spread":0.35088348033706424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004787369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920684,0.00042663154,0.0006563986,0.004902806,0.00035292417,0.0015464778,0.000020585001,0.000013210323,0.0000125554325],"genre_scores_gemma":[0.9899786,0.0000181766,0.0040567345,0.0052381363,0.00058998057,0.000059845326,0.0000116548645,0.000035528006,0.0000113224505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99668574,0.00027547855,0.0020477741,0.00034210106,0.00039022535,0.00025869824],"domain_scores_gemma":[0.99611366,0.0010382448,0.0014974698,0.00021787015,0.00078703446,0.0003457113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010146238,0.000204624,0.0016762894,0.000088158085,0.000033899916,0.000005052646,0.00016215922,0.00018364174,0.00018740968],"category_scores_gemma":[0.0009773955,0.00013891878,0.00028798956,0.00023240315,0.00007435956,0.00014028863,0.000017462426,0.0006751587,0.0000012383472],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060591456,0.0026333977,0.8403245,0.000040569415,0.00016952497,0.000050418355,0.00016512477,0.00049390143,0.00004393527,0.0000020420953,0.000018951452,0.09546617],"study_design_scores_gemma":[0.056417063,0.046282064,0.8922672,0.000056002344,0.00010077306,0.0000018611562,0.00009938511,0.0005942777,0.00010467125,0.00008125103,0.003868498,0.00012693902],"about_ca_topic_score_codex":0.000059019592,"about_ca_topic_score_gemma":0.00020944263,"teacher_disagreement_score":0.09533923,"about_ca_system_score_codex":0.000326976,"about_ca_system_score_gemma":0.0014764506,"threshold_uncertainty_score":0.56649435},"labels":[],"label_agreement":null},{"id":"W3005705527","doi":"10.1158/1538-7445.sabcs19-ot1-08-04","title":"Abstract OT1-08-04: A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients with <i>PIK3CA</i>-mutant solid tumors","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Palbociclib; Breast cancer; Cancer; Pharmacodynamics; Metastatic breast cancer; Phases of clinical research; Internal medicine; Adverse effect; Pharmacokinetics; Pharmacology; Oncology; Toxicity","score_opus":0.0470059046040869,"score_gpt":0.3988687330718152,"score_spread":0.3518628284677283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005705527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964173,0.00037753888,0.0000130760645,0.0004135531,0.000032065018,0.0025898525,0.000038201528,0.000035970967,0.00008246776],"genre_scores_gemma":[0.9992924,0.000034538283,0.000037015947,0.000054885302,0.00014079455,0.00034922332,0.000015095242,0.00006758429,0.000008484552],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99685705,0.00013971915,0.0005745491,0.000705726,0.0010439111,0.00067903136],"domain_scores_gemma":[0.99864715,0.00016122857,0.0001775135,0.00028576897,0.0004319133,0.00029639638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046742096,0.00027976854,0.0006627971,0.00050334027,0.00014021789,0.000032772183,0.00016164678,0.000083400504,0.00008362304],"category_scores_gemma":[0.00016287748,0.00023789301,0.000037942275,0.0015148959,0.00024712953,0.00029784182,0.00010085769,0.00091653,0.0000029194778],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030147092,0.0050387345,0.7494486,0.0008277988,0.00026893002,0.00044254088,0.04330603,0.00063109264,0.1483102,0.000019577757,0.000042668726,0.021516742],"study_design_scores_gemma":[0.056193847,0.015119419,0.87345064,0.0019358111,0.000058115067,0.000009970941,0.006702651,0.00044658326,0.045306187,0.00017317403,0.00012262785,0.00048097657],"about_ca_topic_score_codex":0.0015216324,"about_ca_topic_score_gemma":0.002312833,"teacher_disagreement_score":0.12400204,"about_ca_system_score_codex":0.00083728577,"about_ca_system_score_gemma":0.000412215,"threshold_uncertainty_score":0.9700995},"labels":[],"label_agreement":null},{"id":"W3005787166","doi":"10.1158/1538-7445.sabcs19-pd2-03","title":"Abstract PD2-03: CDK4/6 inhibitor-resistant ER+ breast cancer cell lines are hypersensitive to TTK inhibition","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Palbociclib; Cancer research; Cell cycle; Cyclin-dependent kinase 4; Growth inhibition; Breast cancer; Cancer; Cytotoxicity; Biology; Estrogen receptor; Cell growth; Medicine; Internal medicine; Oncology; Metastatic breast cancer; Cyclin-dependent kinase 2; In vitro; Genetics","score_opus":0.07521458282039346,"score_gpt":0.38430360908024463,"score_spread":0.3090890262598512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005787166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93430233,0.0047983634,0.00004992063,0.055523735,0.0003161676,0.0013845086,0.0010718923,0.00019784964,0.002355254],"genre_scores_gemma":[0.98995066,0.00074093364,0.0002206239,0.004068183,0.003538585,0.00053212,0.000036295045,0.00013608388,0.0007765433],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960869,0.00011864646,0.00044232642,0.00096035015,0.0013569015,0.0010349007],"domain_scores_gemma":[0.9967487,0.00014551506,0.00013551766,0.00045952472,0.0015255483,0.0009852094],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035876065,0.00037874104,0.0005947082,0.00020919974,0.00029111735,0.00007951747,0.0001957638,0.000180761,0.0021056344],"category_scores_gemma":[0.00013132316,0.00034383096,0.00015505911,0.0011001911,0.00031331638,0.0003158634,0.00020604522,0.0009580763,0.00041267893],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061464966,0.0001729767,0.0014096143,0.00067912677,0.00011279311,0.00039482914,0.002346132,0.00027649786,0.96266145,0.000031457137,0.010497864,0.015270781],"study_design_scores_gemma":[0.006868578,0.0009000591,0.12990719,0.0034963281,0.00011330773,0.00008744312,0.013533954,0.000106511034,0.75963587,0.00012541073,0.08409105,0.0011342796],"about_ca_topic_score_codex":0.0024107627,"about_ca_topic_score_gemma":0.0009964122,"teacher_disagreement_score":0.20302555,"about_ca_system_score_codex":0.001632359,"about_ca_system_score_gemma":0.00087513705,"threshold_uncertainty_score":0.99990135},"labels":[],"label_agreement":null},{"id":"W3005879958","doi":"10.1158/1538-7445.sabcs19-p1-19-06","title":"Abstract P1-19-06: Patient-reported outcomes, including work productivity, from the MONALEESA-7 trial of ribociclib plus endocrine therapy in patients with HR+/HER2− advanced breast cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Hazard ratio; Letrozole; Tamoxifen; Anastrozole; Internal medicine; Breast cancer; Oncology; Population; Quality of life (healthcare); Cancer; Palbociclib; Metastatic breast cancer; Gynecology; Confidence interval; Nursing","score_opus":0.09963595940985603,"score_gpt":0.39932718149679064,"score_spread":0.2996912220869346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005879958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977972,0.002422907,0.000010894703,0.014725704,0.00024713334,0.0041132267,0.00036849166,0.00007359104,0.00006606755],"genre_scores_gemma":[0.9965048,0.0004990333,0.00016315613,0.00062595255,0.00061123364,0.0013057964,0.00008193659,0.000120033095,0.00008805564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949075,0.00026550563,0.0008203518,0.0009852138,0.0021128177,0.00090861815],"domain_scores_gemma":[0.9969375,0.00054601434,0.00045716445,0.00087517744,0.00082875765,0.00035538553],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004782009,0.00043084144,0.0009650453,0.00018043665,0.00020632373,0.00003800214,0.00049384777,0.00010479867,0.0006059307],"category_scores_gemma":[0.00038966376,0.00027812237,0.00014554992,0.0017676314,0.0005289486,0.00035135826,0.00026755684,0.0012770777,0.00000634011],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16240463,0.00065538066,0.68678015,0.00008601873,0.00053987803,0.000049788796,0.002383306,0.00072407816,0.003018588,0.00000487939,0.00035568772,0.1429976],"study_design_scores_gemma":[0.08410944,0.0010238743,0.905658,0.00060126104,0.00004267219,0.0000025659392,0.00049535313,0.000007825285,0.003552541,0.000082573235,0.00410143,0.00032246643],"about_ca_topic_score_codex":0.0052317153,"about_ca_topic_score_gemma":0.0006284327,"teacher_disagreement_score":0.21887782,"about_ca_system_score_codex":0.0011168539,"about_ca_system_score_gemma":0.001331255,"threshold_uncertainty_score":0.9999671},"labels":[],"label_agreement":null},{"id":"W3005965296","doi":"10.1158/1538-7445.sabcs19-p2-08-23","title":"Abstract P2-08-23: A population-based study examining the epidemiology, treatment patterns and resource utilization by stage in Ontario patients with HER2+ breast cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada); Sunnybrook Health Science Centre; Mount Sinai Hospital","funders":"","keywords":"Breast cancer; Medicine; Stage (stratigraphy); Cohort; Epidemiology; Population; Health care; Cancer; Cancer registry; Internal medicine; Disease; Oncology; Demography; Gerontology; Environmental health","score_opus":0.1886495615662797,"score_gpt":0.4197485354254959,"score_spread":0.23109897385921618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005965296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99396473,0.00059327215,0.000050292085,0.003270452,0.000022621289,0.0018114634,0.0002304754,0.00003007774,0.00002659261],"genre_scores_gemma":[0.99794745,0.00003976632,0.00002508126,0.00069792947,0.00008066477,0.00076916703,0.00017036969,0.00004621544,0.00022334231],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978149,0.00033763752,0.00033346907,0.00058121706,0.00043609293,0.0004967169],"domain_scores_gemma":[0.99876386,0.00042011452,0.00012188193,0.00031413793,0.00016843619,0.0002115866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005043142,0.00022133217,0.00040003494,0.00010317841,0.00018273982,0.000024834702,0.0001284754,0.00006718587,0.00056026067],"category_scores_gemma":[0.00007288474,0.00014067192,0.0000242906,0.0003487932,0.000119908014,0.00010424255,0.000047255056,0.0005139439,0.0000025829675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021328665,0.00029804607,0.9666872,0.00005793458,0.00008948429,0.0000102423555,0.0033306507,0.0011180729,0.00005696768,0.0000016037678,0.000050792016,0.026166162],"study_design_scores_gemma":[0.0051239464,0.0009232798,0.98951787,0.00023475452,0.000028172532,7.689193e-7,0.0018486616,0.00013343227,0.000045466157,0.0000033568745,0.0020085254,0.0001317915],"about_ca_topic_score_codex":0.2807229,"about_ca_topic_score_gemma":0.35339835,"teacher_disagreement_score":0.07267546,"about_ca_system_score_codex":0.0018330128,"about_ca_system_score_gemma":0.000504158,"threshold_uncertainty_score":0.72406685},"labels":[],"label_agreement":null},{"id":"W3006105063","doi":"10.1158/1538-7445.sabcs19-p4-10-29","title":"Abstract P4-10-29: Identifying novel molecular markers of response to trastuzumab in metastatic breast cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; McMaster University; Ontario Institute for Cancer Research; CancerCare Manitoba; University of Toronto","funders":"","keywords":"Medicine; Trastuzumab; Oncology; Interquartile range; Internal medicine; Breast cancer; Metastatic breast cancer; Cancer; Proportional hazards model; Cohort; Retrospective cohort study","score_opus":0.12124993240982997,"score_gpt":0.450419966527099,"score_spread":0.32917003411726903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006105063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97795904,0.0027212233,0.0010296131,0.016529005,0.0000812713,0.0011107452,0.00027303508,0.00004127379,0.00025479292],"genre_scores_gemma":[0.9968744,0.00012378597,0.0012270623,0.00076114334,0.00011503874,0.0005126592,0.00000648533,0.00008856374,0.0002908421],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9965788,0.00020286947,0.0005223439,0.00063964725,0.0012616845,0.0007946591],"domain_scores_gemma":[0.9981048,0.00029613683,0.00010041041,0.00043269977,0.0005374366,0.0005285333],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012502484,0.00024356725,0.0005830238,0.0005237639,0.00006589133,0.000031486197,0.00036715,0.00007067706,0.002798118],"category_scores_gemma":[0.00043674256,0.00023569557,0.0001225803,0.0018693374,0.000251959,0.00018216604,0.00015481154,0.0006952922,0.000048550806],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032680444,0.00015459572,0.0012714196,0.00065749424,0.0002093726,0.0002282004,0.0019559034,0.001233402,0.93758106,0.000029117116,0.0004158305,0.023583129],"study_design_scores_gemma":[0.016396211,0.001375178,0.50854737,0.0042087045,0.00016235004,0.00011867134,0.0058033494,0.00050277886,0.4449353,0.00017373524,0.016854985,0.0009213894],"about_ca_topic_score_codex":0.001979669,"about_ca_topic_score_gemma":0.00025017274,"teacher_disagreement_score":0.50727594,"about_ca_system_score_codex":0.0011172709,"about_ca_system_score_gemma":0.001424346,"threshold_uncertainty_score":0.99811345},"labels":[],"label_agreement":null},{"id":"W3006147702","doi":"10.1158/1538-7445.sabcs19-p1-19-10","title":"Abstract P1-19-10: Safety and efficacy of abemaciclib plus endocrine therapy (ET) in elderly patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+, HER2-) advanced breast cancer: An age-specific subgroup analysis of MONARCH 2 and 3 trials","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Medicine; Internal medicine; Fulvestrant; Breast cancer; Letrozole; Anastrozole; Oncology; Metastatic breast cancer; Placebo; Tolerability; Adverse effect; Cancer; Tamoxifen; Pathology","score_opus":0.07795745802238126,"score_gpt":0.39759211947698336,"score_spread":0.3196346614546021,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006147702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986449,0.006685913,0.000044624652,0.0018049615,0.000033840937,0.002291267,0.002590389,0.000039625884,0.000060374394],"genre_scores_gemma":[0.98138565,0.017102586,0.00048316104,0.00009482146,0.00018111468,0.00027184232,0.0003361193,0.000096119504,0.000048561153],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99464715,0.00095745164,0.0012258599,0.0011083423,0.0012789917,0.00078223407],"domain_scores_gemma":[0.99577075,0.0014503584,0.0005784313,0.0004716167,0.0010960805,0.0006327772],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010553185,0.0004964029,0.002186894,0.000771704,0.00017530253,0.000042978896,0.00030976685,0.0001370951,0.0016040601],"category_scores_gemma":[0.00028564388,0.00039520793,0.00018007896,0.002294869,0.0011189174,0.00050357543,0.000125693,0.0008438066,0.0000015367148],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16770923,0.0011837819,0.17039102,0.00057100377,0.003310665,0.00005774184,0.013784127,0.00057831843,0.28366065,0.00011572104,0.0000953652,0.35854235],"study_design_scores_gemma":[0.024648454,0.0031285905,0.94808173,0.00036865685,0.00014155624,0.0000024170981,0.0009505365,0.00002800955,0.021657297,0.000024825882,0.00058589235,0.00038201694],"about_ca_topic_score_codex":0.004089509,"about_ca_topic_score_gemma":0.0006207783,"teacher_disagreement_score":0.7776907,"about_ca_system_score_codex":0.0007006781,"about_ca_system_score_gemma":0.00047935074,"threshold_uncertainty_score":0.99985},"labels":[],"label_agreement":null},{"id":"W3009891869","doi":"10.1158/1538-7445.sabcs19-gs4-01","title":"Abstract GS4-01: Ten-year results from NRG Oncology/NSABP B-42: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor+ breast cancer (BC) who have completed previous adjuvant therapy with an aromatase inhibitor (AI)","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Letrozole; Internal medicine; Clinical endpoint; Statistical significance; Breast cancer; Oncology; Placebo; Tamoxifen; Hormonal therapy; Randomized controlled trial; Cancer; Gastroenterology; Pathology","score_opus":0.09348842831903145,"score_gpt":0.4190237873823928,"score_spread":0.3255353590633614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009891869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9674463,0.0058664656,0.000041402633,0.00789256,0.00015551358,0.015957857,0.0022980347,0.00015795614,0.00018389184],"genre_scores_gemma":[0.9802397,0.007363395,0.0005800985,0.00092664064,0.001878732,0.0082702,0.00037167955,0.0002762556,0.00009328394],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98923606,0.0018617782,0.0024358067,0.0020531528,0.002561277,0.0018519189],"domain_scores_gemma":[0.99302596,0.0017402571,0.0011665873,0.0013851125,0.0014055484,0.0012765449],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.003400692,0.0010501936,0.0050441395,0.0005357411,0.0002289234,0.000121576144,0.0008168154,0.00037334996,0.00083611725],"category_scores_gemma":[0.00021415182,0.0006345237,0.00026379805,0.0011804751,0.0022461123,0.00058400707,0.00014646932,0.0027546866,0.000016645208],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9303123,0.0035478105,0.0014951584,0.00008600487,0.0029081758,0.0006092613,0.0036214504,0.00031531465,0.010736118,0.000010812082,0.00040813698,0.045949474],"study_design_scores_gemma":[0.9388886,0.03936064,0.012245902,0.0009854964,0.00018125647,0.000062473046,0.002397907,0.00032614497,0.0028837498,0.000034136785,0.001885753,0.00074795925],"about_ca_topic_score_codex":0.012562699,"about_ca_topic_score_gemma":0.0027909747,"teacher_disagreement_score":0.045201518,"about_ca_system_score_codex":0.0014281526,"about_ca_system_score_gemma":0.004652076,"threshold_uncertainty_score":0.9996106},"labels":[],"label_agreement":null},{"id":"W3010027759","doi":"10.1158/1538-7445.sabcs19-p1-19-16","title":"Abstract P1-19-16: Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor-positive/human epidermal growth factor receptor 2–negative advanced breast cancer: An updated analysis","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Palbociclib; Fulvestrant; Letrozole; Medicine; Internal medicine; Breast cancer; Cancer; Adverse effect; Oncology; Placebo; Metastatic breast cancer; Gynecology; Gastroenterology; Estrogen receptor; Tamoxifen; Pathology","score_opus":0.04543092689725916,"score_gpt":0.3934009876766021,"score_spread":0.34797006077934295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010027759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98399085,0.0015017312,0.0015859121,0.005876603,0.00003887989,0.002556836,0.004302535,0.00009883359,0.000047793743],"genre_scores_gemma":[0.9923069,0.0019663011,0.00048527814,0.00035265155,0.00019572912,0.00095913635,0.003529893,0.00011317407,0.00009092445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99510396,0.0004469365,0.00096363836,0.0012351144,0.0012420947,0.0010082473],"domain_scores_gemma":[0.9956978,0.00042654143,0.0005302416,0.00059661857,0.0021107513,0.0006380761],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00057442207,0.00051997846,0.0017481971,0.0015858293,0.00029240426,0.00005254203,0.00047438222,0.00015907132,0.0037429773],"category_scores_gemma":[0.00010699581,0.00044472402,0.00041230588,0.0078100245,0.0005913151,0.00069407845,0.00008124393,0.0008112977,0.0000031386685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0652649,0.0013204871,0.40309462,0.00029560097,0.019631514,0.000039093287,0.004431346,0.0024999564,0.39241943,0.00014421226,0.00014251047,0.11071635],"study_design_scores_gemma":[0.015060784,0.0016983665,0.9044274,0.0001368495,0.0012420662,0.0000021440726,0.0007570737,0.00040316378,0.07564925,0.000043242253,0.000114829,0.0004648008],"about_ca_topic_score_codex":0.003735833,"about_ca_topic_score_gemma":0.0032709753,"teacher_disagreement_score":0.5013328,"about_ca_system_score_codex":0.0018237237,"about_ca_system_score_gemma":0.00064903765,"threshold_uncertainty_score":0.99980044},"labels":[],"label_agreement":null},{"id":"W3010131774","doi":"10.1200/jco.2007.25.18_suppl.540","title":"Competing causes of death in NCIC CTG MA.17, a placebo-controlled trial of letrozole as extended adjuvant therapy for breast cancer patients","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Breast cancer; Letrozole; Internal medicine; Tamoxifen; Oncology; Clinical endpoint; Placebo; Cancer; Gynecology; Randomized controlled trial; Pathology","score_opus":0.07493129269012377,"score_gpt":0.47237840394125247,"score_spread":0.3974471112511287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010131774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99416894,0.0010103752,0.00033119234,0.0012149987,0.0012605633,0.0016053629,0.000028324337,0.0000062247577,0.0003740511],"genre_scores_gemma":[0.9945441,0.00054948137,0.0026709794,0.00092496263,0.0011671593,0.00003854572,0.0000020169725,0.000029863666,0.000072912],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944825,0.0003413902,0.0040964563,0.00020915852,0.0005034962,0.00036697864],"domain_scores_gemma":[0.9893103,0.0049698898,0.004256479,0.00017646365,0.0010590764,0.00022776896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004694337,0.00020210832,0.003102062,0.00027416064,0.000025570484,0.0000025320871,0.00019426788,0.00031096637,0.00014729559],"category_scores_gemma":[0.002412818,0.00013948925,0.00072435144,0.00016643612,0.00022338316,0.00010345889,0.00002924174,0.00062917685,7.172468e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74978924,0.0041737426,0.0624535,0.000036459653,0.0005426273,0.000046303503,0.0002110344,0.00005059779,0.0008646652,0.000036456935,0.000028190327,0.18176717],"study_design_scores_gemma":[0.6307483,0.02359963,0.34140506,0.00032871272,0.00023269198,0.00007541415,0.00025658976,0.000035208872,0.0006091306,0.00032476187,0.002279659,0.00010486478],"about_ca_topic_score_codex":0.00008697501,"about_ca_topic_score_gemma":0.00018386784,"teacher_disagreement_score":0.27895156,"about_ca_system_score_codex":0.00030022115,"about_ca_system_score_gemma":0.0017711733,"threshold_uncertainty_score":0.56882066},"labels":[],"label_agreement":null},{"id":"W3012012183","doi":"10.1200/jco.2013.31.15_suppl.e11580","title":"The impact of estrogen receptor (ER), progesterone receptor (PR), and HER-2 receptor status on treatment of patients with advanced breast cancer.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dr. H. Bliss Murphy Cancer Centre; Memorial University of Newfoundland","funders":"","keywords":"Medicine; Breast cancer; Oncology; Progesterone receptor; Cancer; Metastatic breast cancer; Internal medicine; Biopsy; Estrogen receptor; Metastasis; Gynecology; Retrospective cohort study","score_opus":0.038131964573218484,"score_gpt":0.4167874640582783,"score_spread":0.37865549948505983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012012183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99333644,0.0017671859,0.000010656385,0.0031644008,0.00056373107,0.0009277471,0.0001645223,0.000008652976,0.000056642228],"genre_scores_gemma":[0.9860175,0.0059727025,0.007078824,0.0001355729,0.0005202368,0.00006719995,0.000013401585,0.000051025847,0.00014349622],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996638,0.00031991297,0.0019163487,0.00025684954,0.0004557102,0.00041317058],"domain_scores_gemma":[0.99353045,0.0013572728,0.0030831483,0.00032005974,0.0011931175,0.00051594543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004632874,0.00029706868,0.0017809954,0.00008464137,0.00005700006,0.000008726158,0.00015015679,0.00022288808,0.0004174029],"category_scores_gemma":[0.00037352755,0.00013941465,0.0003770795,0.00016353236,0.0006241503,0.00020907851,0.000028970682,0.0004161484,0.000009338641],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031931717,0.0025325064,0.36232433,0.000022123455,0.0010826662,0.0000025989339,0.00018780722,0.000043657576,0.00109035,0.000006207715,0.0004203548,0.6003557],"study_design_scores_gemma":[0.022515282,0.10137631,0.8504299,0.00036292788,0.00023455592,0.000036575537,0.00028554408,0.000007911536,0.0008612295,0.00004588065,0.023690173,0.00015370679],"about_ca_topic_score_codex":0.00020044926,"about_ca_topic_score_gemma":0.00002464448,"teacher_disagreement_score":0.60020196,"about_ca_system_score_codex":0.0008214314,"about_ca_system_score_gemma":0.0015174614,"threshold_uncertainty_score":0.56851643},"labels":[],"label_agreement":null},{"id":"W3013041600","doi":"10.1158/1538-7445.sabcs19-pd2-10","title":"Abstract PD2-10: Predicting sensitivity to CDK4/6 inhibition in ER+/HER2- breast cancer cell lines","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Palbociclib; Growth inhibition; Cancer research; Cell cycle; Cell growth; Cell culture; Biology; Cancer; Oncology; Metastatic breast cancer; Medicine; Internal medicine; Breast cancer; Genetics","score_opus":0.07894707575200022,"score_gpt":0.40755050504777635,"score_spread":0.32860342929577613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013041600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9677968,0.0017162309,0.00010818535,0.027382182,0.00014623538,0.0010041452,0.00031404285,0.00013386772,0.0013983183],"genre_scores_gemma":[0.99472076,0.0004431218,0.00019264242,0.001603407,0.0019821527,0.00041702666,0.000022375563,0.00008516979,0.00053333363],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9968922,0.00015978208,0.00038131452,0.00073897437,0.0009482567,0.00087946595],"domain_scores_gemma":[0.9981338,0.00020292048,0.00007784058,0.00033157607,0.00066295493,0.0005909279],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000766309,0.00025582843,0.0004379247,0.00019173008,0.00014682134,0.000048316717,0.00010495494,0.00014315445,0.0023764828],"category_scores_gemma":[0.00018290234,0.00024600214,0.00008165978,0.0011022639,0.00016656134,0.00030857263,0.00017486657,0.00092352997,0.00015341045],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039367853,0.00021581289,0.021409394,0.00086585607,0.00005657916,0.00044918258,0.0033605054,0.0025130094,0.897564,0.000011175143,0.0033894675,0.06622825],"study_design_scores_gemma":[0.0065439497,0.00058724533,0.56204605,0.0031245488,0.000049099,0.00012098373,0.0036337858,0.001533076,0.4013757,0.0000896838,0.020080967,0.0008149188],"about_ca_topic_score_codex":0.008251705,"about_ca_topic_score_gemma":0.0039495816,"teacher_disagreement_score":0.54063666,"about_ca_system_score_codex":0.0012824489,"about_ca_system_score_gemma":0.0007242735,"threshold_uncertainty_score":0.9999992},"labels":[],"label_agreement":null},{"id":"W3013217853","doi":"10.1158/1538-7445.sabcs19-p3-11-10","title":"Abstract P3-11-10: Health-related quality of life (HRQoL) in monarcHER: Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in HR+, HER2+ advanced breast cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Fulvestrant; Trastuzumab; Breast cancer; Oncology; Metastatic breast cancer; Cancer; Quality of life (healthcare); Tamoxifen; Nursing","score_opus":0.1312244441150667,"score_gpt":0.44956472524661995,"score_spread":0.3183402811315532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013217853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97276604,0.014321448,0.00007895077,0.008639814,0.000113398346,0.0028828043,0.0009154551,0.00009714729,0.00018493886],"genre_scores_gemma":[0.99529904,0.0025284186,0.00069608825,0.00026637438,0.00016415022,0.00067593134,0.00005371875,0.00019310902,0.00012316629],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.992781,0.00048800473,0.0018360497,0.0012018504,0.002236285,0.0014568064],"domain_scores_gemma":[0.99633247,0.00047982697,0.00062907225,0.00074581744,0.0009851614,0.00082765904],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012103209,0.0006200169,0.0026709575,0.00049018336,0.00012042753,0.000025747262,0.0005197978,0.00028844504,0.0025640675],"category_scores_gemma":[0.00019674803,0.00050300045,0.0001957318,0.0026090853,0.0010319637,0.00033842953,0.0000905822,0.0016511793,0.0000062090694],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.71902287,0.0006137931,0.027887916,0.007939058,0.0006707172,0.00020151846,0.040645532,0.01303371,0.015491516,0.00006223025,0.00012310626,0.17430802],"study_design_scores_gemma":[0.3185347,0.02573662,0.50268126,0.015678262,0.00015442008,0.00010626426,0.09807881,0.0018152244,0.029369965,0.00013918408,0.0049011963,0.00280406],"about_ca_topic_score_codex":0.015792226,"about_ca_topic_score_gemma":0.030462228,"teacher_disagreement_score":0.47479337,"about_ca_system_score_codex":0.005626875,"about_ca_system_score_gemma":0.013179413,"threshold_uncertainty_score":0.99974215},"labels":[],"label_agreement":null},{"id":"W3013546657","doi":"10.1158/1538-7445.sabcs19-p3-11-01","title":"Abstract P3-11-01: An updated systematic review and meta-analysis of the safety and efficacy of phosphoinositide 3-kinase inhibitors (PI3Ki) in advanced breast cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Manitoba; Mount Sinai Hospital; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Meta-analysis; Oncology; Subgroup analysis; Breast cancer; Odds ratio; Randomized controlled trial; Cochrane Library; Confidence interval; Cancer","score_opus":0.07118330192338554,"score_gpt":0.40109474195991385,"score_spread":0.3299114400365283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013546657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7359572,0.24724884,0.00001041904,0.012498174,0.000026309435,0.0033671446,0.00082553294,0.000025291616,0.00004108567],"genre_scores_gemma":[0.9909502,0.007728117,0.000058507354,0.0008345512,0.000027785803,0.0002810004,0.000022209355,0.000037849073,0.000059760507],"study_design_codex":"systematic_review","study_design_gemma":"observational","domain_scores_codex":[0.9969415,0.00038055793,0.0009278301,0.0005546966,0.0008044515,0.00039097745],"domain_scores_gemma":[0.9979193,0.00024918976,0.0003742563,0.0006761127,0.00050080806,0.00028028706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010059918,0.0002581171,0.0024304253,0.0002447291,0.000080956444,0.000014086285,0.00027797432,0.00007620445,0.0008121901],"category_scores_gemma":[0.00020480782,0.00016338014,0.0003206066,0.0026029677,0.0004730816,0.00019590017,0.00015819707,0.00046047868,7.880381e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013854148,0.0012303015,0.04120283,0.55480754,0.1545678,0.00014945079,0.009051062,0.004400491,0.20845667,0.00043019533,0.00066957826,0.011179938],"study_design_scores_gemma":[0.012073465,0.00075023697,0.45225507,0.033796247,0.4109944,0.00006698373,0.003033873,0.0006570036,0.084285334,0.0000695753,0.00077160273,0.0012462137],"about_ca_topic_score_codex":0.0021303673,"about_ca_topic_score_gemma":0.0012300253,"teacher_disagreement_score":0.5210113,"about_ca_system_score_codex":0.00023042069,"about_ca_system_score_gemma":0.0003232703,"threshold_uncertainty_score":0.8892912},"labels":[],"label_agreement":null},{"id":"W3013585111","doi":"10.1158/1538-7445.sabcs19-p1-19-36","title":"Abstract P1-19-36: Exploratory analysis of TreatER+ight; a Canadian prospective real-world observational study in HR+ advanced breast cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Windsor Regional Hospital; Novartis (Canada); BC Cancer Agency; Kingston General Hospital; Ottawa Hospital; Jewish General Hospital; Saskatchewan Cancer Agency; Lions Gate Hospital; London Health Sciences Centre; Grand River Hospital; Quebec Breast Cancer Foundation","funders":"","keywords":"Medicine; Internal medicine; Observational study; Breast cancer; Combination therapy; Prospective cohort study; Cancer; Palbociclib; Oncology; Metastatic breast cancer","score_opus":0.20963694267995425,"score_gpt":0.458363410279256,"score_spread":0.24872646759930173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013585111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881834,0.001251533,0.000005329432,0.0065945657,0.0000754058,0.0019006551,0.0008863964,0.00005198984,0.0010507313],"genre_scores_gemma":[0.99613684,0.00034604987,0.00007658555,0.0005060112,0.00028759806,0.002008549,0.00006331741,0.00006878288,0.00050629],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962723,0.00016990596,0.00061976205,0.000884151,0.0011951705,0.000858694],"domain_scores_gemma":[0.99730307,0.0001506492,0.00015963634,0.0005332323,0.0010079101,0.00084548385],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00055767695,0.00030532156,0.0009236043,0.0016532957,0.00016125095,0.000029724884,0.0003517005,0.000089816436,0.0027481453],"category_scores_gemma":[0.00010345731,0.00028297884,0.00015984382,0.0070768604,0.00030064394,0.00036527365,0.0000830752,0.0007656423,0.000013499491],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040201466,0.00032215583,0.96428365,0.00015638939,0.0015122574,0.00019439087,0.008259877,0.0030794963,0.0068237646,0.00009989507,0.0002598537,0.010988134],"study_design_scores_gemma":[0.0031113646,0.00023818205,0.9891056,0.00018993259,0.00024228869,0.0000013144191,0.0038799227,0.00017556449,0.0013564057,0.00006166068,0.0013955763,0.000242178],"about_ca_topic_score_codex":0.34952587,"about_ca_topic_score_gemma":0.8286124,"teacher_disagreement_score":0.47908652,"about_ca_system_score_codex":0.0039545475,"about_ca_system_score_gemma":0.004338785,"threshold_uncertainty_score":0.9999622},"labels":[],"label_agreement":null},{"id":"W3013587102","doi":"10.1158/1538-7445.sabcs19-p4-10-11","title":"Abstract P4-10-11: PIK3CA status as a predictor of benefit from drugs targeting the PI3K/AKT/mTOR pathway: A meta-analysis of randomized trials","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"PI3K/AKT/mTOR pathway; Protein kinase B; Medicine; Hazard ratio; Oncology; Randomized controlled trial; Breast cancer; Cancer; Meta-analysis; Internal medicine; Pharmacology; Bioinformatics; Cancer research; Phosphorylation; Confidence interval; Signal transduction; Biology; Genetics","score_opus":0.20661264422578995,"score_gpt":0.4406368692390121,"score_spread":0.23402422501322212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013587102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9241227,0.05841069,0.00026746627,0.009948337,0.000107722335,0.003320543,0.0031696889,0.00006823834,0.000584611],"genre_scores_gemma":[0.9957444,0.00089244836,0.0005936426,0.00038966502,0.00054461823,0.0010880568,0.00014436075,0.00007068554,0.0005321045],"study_design_codex":"meta_analysis","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99288636,0.0014537843,0.0018750657,0.0006964622,0.002348971,0.0007393641],"domain_scores_gemma":[0.98768264,0.008574933,0.0009918698,0.00083066133,0.0014788698,0.00044101162],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00798032,0.00033878424,0.005454403,0.0004112367,0.00013452013,0.000040241783,0.0005199867,0.00014422645,0.01857991],"category_scores_gemma":[0.008584638,0.00019697228,0.002766185,0.001994965,0.0007599458,0.00014282891,0.00018946227,0.00055689603,0.000017414679],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2808578,0.00031733757,0.0006810519,0.00058398343,0.36544126,0.000038223305,0.022090271,0.00192472,0.314939,0.0005064959,0.0019725207,0.010647306],"study_design_scores_gemma":[0.22098778,0.00093930046,0.0026606012,0.00033522001,0.27895927,0.0000017304619,0.01030862,0.0017256805,0.43385646,0.0036647846,0.04571607,0.0008444859],"about_ca_topic_score_codex":0.008904525,"about_ca_topic_score_gemma":0.00020065125,"teacher_disagreement_score":0.11891746,"about_ca_system_score_codex":0.00023929072,"about_ca_system_score_gemma":0.0011169028,"threshold_uncertainty_score":0.99976647},"labels":[],"label_agreement":null},{"id":"W3013704572","doi":"10.1158/1538-7445.sabcs19-pd4-01","title":"Abstract PD4-01: First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic g<i>BRCA</i>-associated breast cancer: Planned subgroup analysis from the phase 3 BROCADE3 trial","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Veliparib; Medicine; Internal medicine; Metastatic breast cancer; Carboplatin; PARP inhibitor; Placebo; Breast cancer; Hazard ratio; Population; Oncology; Clinical endpoint; Cancer; Chemotherapy; Surgery; Randomized controlled trial; Confidence interval; Pathology; Cisplatin","score_opus":0.06192788902987865,"score_gpt":0.3858429995150197,"score_spread":0.32391511048514104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013704572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97974163,0.0018951005,0.00011700556,0.009719476,0.00016683867,0.0032082438,0.0049609127,0.0001019128,0.00008887143],"genre_scores_gemma":[0.9956532,0.0004688863,0.00016197936,0.000921022,0.00059136935,0.0012925976,0.0006870403,0.00012403177,0.000099839766],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9940756,0.00041594225,0.0008965442,0.0011943582,0.0021363327,0.0012812001],"domain_scores_gemma":[0.9959055,0.0014415722,0.00045214695,0.00072046404,0.0008791482,0.00060113316],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006568893,0.0005748168,0.0014112374,0.0003504583,0.00038509924,0.00009743234,0.00061266223,0.00017805379,0.001217667],"category_scores_gemma":[0.000647392,0.00040850943,0.00025302882,0.0043713534,0.0005758779,0.00039038406,0.00016193395,0.0018182448,0.000025676623],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69775,0.0027669915,0.20426567,0.00032960865,0.008551061,0.00025124243,0.012385001,0.023681251,0.0010430632,0.000015480391,0.0012813351,0.04767935],"study_design_scores_gemma":[0.30576926,0.004281536,0.6787453,0.0012306193,0.0013598293,0.000001950824,0.0026349179,0.0023446546,0.0010712418,0.00022689636,0.0014423523,0.00089142343],"about_ca_topic_score_codex":0.019670775,"about_ca_topic_score_gemma":0.023444546,"teacher_disagreement_score":0.47447965,"about_ca_system_score_codex":0.0022186413,"about_ca_system_score_gemma":0.0012696042,"threshold_uncertainty_score":0.9998367},"labels":[],"label_agreement":null},{"id":"W3013767050","doi":"10.1158/1538-7445.sabcs19-pd2-08","title":"Abstract PD2-08: Gene expression analysis and association with treatment response in postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer in the MONALEESA-3 study","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Fulvestrant; Medicine; Breast cancer; Estrogen receptor; Internal medicine; Oncology; Cancer; Hazard ratio; Lapatinib; Cancer research; Progression-free survival; Metastatic breast cancer; Endocrinology; Trastuzumab; Confidence interval; Chemotherapy","score_opus":0.023338589891249647,"score_gpt":0.3491227203401349,"score_spread":0.32578413044888527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013767050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99129725,0.0009742023,0.000012178395,0.004732564,0.0000122126185,0.002469488,0.00045628138,0.000020851909,0.000024946607],"genre_scores_gemma":[0.9973578,0.00053156633,0.00022585545,0.00017485033,0.00008336937,0.0014722993,0.00004334569,0.000044131848,0.00006679253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963536,0.00073097885,0.00030800098,0.0007077351,0.0013375649,0.0005620665],"domain_scores_gemma":[0.9981876,0.00058799237,0.00017472997,0.0003050997,0.00054656575,0.00019801126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007196618,0.00029226692,0.0005476186,0.00037569483,0.00016035378,0.00004689541,0.00015742778,0.000081750346,0.00012498052],"category_scores_gemma":[0.0000891561,0.00017470172,0.0000365755,0.0023278059,0.00014715674,0.0002718141,0.000054614655,0.0005828591,0.0000037271368],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.103197336,0.0010453563,0.8188128,0.000019802123,0.00074954424,0.00008762973,0.014033889,0.0011114839,0.049859226,4.0857194e-7,0.000015874783,0.011066635],"study_design_scores_gemma":[0.012323001,0.0051008533,0.9699569,0.0001839811,0.00016345149,0.0000016155361,0.0053321975,0.000020269632,0.0066730585,0.0000038578173,0.0000483175,0.0001925139],"about_ca_topic_score_codex":0.0031492133,"about_ca_topic_score_gemma":0.002719827,"teacher_disagreement_score":0.15114407,"about_ca_system_score_codex":0.002608773,"about_ca_system_score_gemma":0.00042780684,"threshold_uncertainty_score":0.71241295},"labels":[],"label_agreement":null},{"id":"W3014011642","doi":"10.1158/1538-7445.sabcs19-p1-19-46","title":"Abstract P1-19-46: A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients with <i>PIK3CA</i>-mutant HR+/HER2- breast cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Palbociclib; Medicine; Letrozole; Breast cancer; Pharmacodynamics; Cancer; Pharmacokinetics; Pharmacology; Metastatic breast cancer; Combination therapy; PI3K/AKT/mTOR pathway; Internal medicine; Chemistry; Signal transduction; Tamoxifen","score_opus":0.057163889637291375,"score_gpt":0.41684407488504693,"score_spread":0.3596801852477556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014011642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910077,0.00045891805,0.00006608725,0.0029367069,0.00003614783,0.005284391,0.00008962051,0.000058490932,0.000061933606],"genre_scores_gemma":[0.9975563,0.000049555867,0.00010525048,0.0003050473,0.00019586063,0.0016217801,0.00002899106,0.000114511466,0.000022649254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99521434,0.00043410473,0.0005107512,0.000966076,0.002045343,0.00082938554],"domain_scores_gemma":[0.9977713,0.0002196662,0.0002666242,0.00038497697,0.0010179156,0.000339467],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011364629,0.00042418795,0.00062488194,0.00032389053,0.0003048115,0.00010679811,0.00021550895,0.00009875916,0.00011696774],"category_scores_gemma":[0.00011650622,0.0002609482,0.000028774697,0.002245168,0.00048821484,0.00052264216,0.00009690307,0.0013692536,0.0000027998196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053869274,0.00203448,0.86466205,0.00022086862,0.00024318682,0.00006729672,0.013827002,0.0012019719,0.010455334,0.0000075254825,0.00001795046,0.05339304],"study_design_scores_gemma":[0.059777144,0.011457678,0.91623145,0.0012757566,0.00011035097,0.000021653535,0.006495438,0.001702289,0.0024392668,0.000031536136,0.00004561733,0.00041180354],"about_ca_topic_score_codex":0.0036193714,"about_ca_topic_score_gemma":0.0073152683,"teacher_disagreement_score":0.05298124,"about_ca_system_score_codex":0.0015055737,"about_ca_system_score_gemma":0.0013760488,"threshold_uncertainty_score":0.99998426},"labels":[],"label_agreement":null},{"id":"W3020482066","doi":"10.1016/s1470-2045(20)30112-1","title":"Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":261,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Eisai; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Trastuzumab; Fulvestrant; Internal medicine; Breast cancer; Oncology; Metastatic breast cancer; Cancer; Chemotherapy; Tamoxifen","score_opus":0.053427430914663586,"score_gpt":0.3829554564653619,"score_spread":0.3295280255506983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020482066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9714132,0.0021060328,0.0011998727,0.014284483,0.00019085883,0.008647365,0.001182818,0.000142461,0.00083290704],"genre_scores_gemma":[0.9861772,0.0015566782,0.005922321,0.002477188,0.0008035535,0.0027006485,0.00008627267,0.00018778129,0.000088363406],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957322,0.000600987,0.00082479435,0.0009859314,0.0007050584,0.0011510216],"domain_scores_gemma":[0.99727976,0.0006044228,0.00066100684,0.00061296887,0.00041300655,0.00042881985],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005428988,0.00074749405,0.0035109275,0.00011486896,0.00018095165,0.000046911315,0.0006968445,0.00024058255,0.00047478132],"category_scores_gemma":[0.000053845684,0.00044619758,0.00008638174,0.0009333872,0.0010338059,0.00034336827,0.0001165535,0.0010092055,0.000006258132],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8245567,0.00088629534,0.000033229513,0.00017025373,0.0011425564,0.00029071106,0.032222293,0.00035667288,0.006510944,0.000026758738,0.00007793835,0.13372564],"study_design_scores_gemma":[0.8765252,0.09846667,0.0005172402,0.0006340889,0.00034766452,0.00029773766,0.0147869345,0.00018796329,0.0025512544,0.000015410971,0.005072714,0.0005970846],"about_ca_topic_score_codex":0.00020723027,"about_ca_topic_score_gemma":0.0006096729,"teacher_disagreement_score":0.13312855,"about_ca_system_score_codex":0.0039141374,"about_ca_system_score_gemma":0.0041316296,"threshold_uncertainty_score":0.99990964},"labels":[],"label_agreement":null},{"id":"W3021157979","doi":"10.1101/2020.05.11.20093146","title":"Nilotinib in Patients with Advanced Parkinson’s Disease: A Randomized Phase 2A Study (NILO-PD)","year":2020,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Michael J. Fox Foundation for Parkinson's Research","keywords":"Tolerability; Placebo; Medicine; Internal medicine; Parkinson's disease; Nilotinib; Montreal Cognitive Assessment; Adverse effect; Disease; Dementia; Tyrosine kinase","score_opus":0.01805245375242769,"score_gpt":0.30709842235075296,"score_spread":0.28904596859832526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021157979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858254,0.001428481,0.0008574088,0.0012855171,0.0005031839,0.009507447,0.00014531791,0.000290683,0.00015655257],"genre_scores_gemma":[0.9942803,0.000077767654,0.0018634698,0.00055863993,0.00025173702,0.002331421,0.00031248506,0.00018698302,0.00013723137],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995461,0.00048051265,0.000984105,0.0014439264,0.0010570841,0.00057340803],"domain_scores_gemma":[0.9970802,0.00022390451,0.0005882099,0.0012505057,0.00026427433,0.0005928722],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050506456,0.00081489654,0.002540088,0.00029762526,0.00006184465,0.00003748832,0.00040968767,0.0001432454,0.00018796581],"category_scores_gemma":[0.00065746804,0.000618252,0.0003106206,0.00041235104,0.00024476886,0.00012282861,0.00039463025,0.0011750266,0.000033352313],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50318825,0.004156552,0.4760893,0.00042364208,0.00062180794,0.00037310174,0.0017007046,0.00021511689,0.000029140409,0.000009821523,0.000015212819,0.013177366],"study_design_scores_gemma":[0.55929714,0.0010784179,0.43372616,0.0009734742,0.0007231168,0.0000015081424,0.00020536361,0.00016349743,0.000038567305,0.0003779618,0.0028086235,0.00060616236],"about_ca_topic_score_codex":0.00003410239,"about_ca_topic_score_gemma":0.000027887838,"teacher_disagreement_score":0.056108914,"about_ca_system_score_codex":0.00029860466,"about_ca_system_score_gemma":0.00046417405,"threshold_uncertainty_score":0.9996269},"labels":[],"label_agreement":null},{"id":"W3024684302","doi":"10.1158/2159-8290.cd-19-1390","title":"The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":433,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Jewish General Hospital; Institute of Cancer Research","funders":"National Cancer Institute; Susan G. Komen; American Association for Cancer Research; U.S. Department of Defense","keywords":"Cancer research; Breast cancer; KRAS; AKT1; Cancer; Metastatic breast cancer; Cyclin-dependent kinase 4; CHEK1; Kinase; Biology; Estrogen receptor; Cyclin-dependent kinase 6; Medicine; Internal medicine; Cell cycle; Cyclin-dependent kinase; Cell cycle checkpoint; Signal transduction; PI3K/AKT/mTOR pathway; Cyclin-dependent kinase 2; Genetics; Colorectal cancer","score_opus":0.0073441719764131734,"score_gpt":0.23730301436625445,"score_spread":0.22995884238984127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024684302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796846,0.01323265,0.00008085025,0.005135528,0.0001349518,0.0009350092,0.00073473074,0.000019791012,0.000041913547],"genre_scores_gemma":[0.9970879,0.001155835,0.00017121143,0.00097605493,0.00018057885,0.0002195237,0.000022007129,0.00005121604,0.00013567928],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840885,0.000056720826,0.00037737752,0.00045501866,0.00036604327,0.00033599138],"domain_scores_gemma":[0.99909586,0.0000839889,0.00020993646,0.00025804515,0.00014959413,0.0002025877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008748005,0.00025712504,0.00047997924,0.00007493191,0.00007662762,0.000036367626,0.00013246098,0.000037693575,0.000023774268],"category_scores_gemma":[0.000027266064,0.0001741142,0.00004850549,0.0004282435,0.00019287475,0.00029205278,0.00009580595,0.0001483926,0.0000027448216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.069608785,0.00040976694,0.756654,0.00050881965,0.0009771134,0.00004664923,0.0067664194,0.0009471795,0.035151716,0.00013750725,0.0013204925,0.12747155],"study_design_scores_gemma":[0.0065882495,0.00043764428,0.98539144,0.0006679444,0.00015581629,0.0000022972943,0.0009065524,0.0000074607074,0.0044993926,0.000031616986,0.0010218214,0.00028973873],"about_ca_topic_score_codex":0.00021051723,"about_ca_topic_score_gemma":0.00065378833,"teacher_disagreement_score":0.22873747,"about_ca_system_score_codex":0.00037232946,"about_ca_system_score_gemma":0.00027964415,"threshold_uncertainty_score":0.7100171},"labels":[],"label_agreement":null},{"id":"W3025639243","doi":"","title":"Chance of reimbursement for ADD-ON therapies in Poland and in the world - review of the reimbursement recommendations","year":2019,"lang":"en","type":"article","venue":"PubMed","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Context (archaeology); Family medicine; Palbociclib; Breast cancer; Cancer; Health care; Political science; Internal medicine; Metastatic breast cancer; Geography","score_opus":0.0293871494264946,"score_gpt":0.3022018412704503,"score_spread":0.2728146918439557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025639243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65481806,0.10399069,0.000049296254,0.21384837,0.00062962173,0.02107761,0.00011424982,0.000021039028,0.0054510366],"genre_scores_gemma":[0.98829097,0.004369946,0.00018050685,0.0040232674,0.000037355465,0.0023173364,0.000007791861,0.000011613582,0.0007612234],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.999138,0.00007372285,0.00030665664,0.00014263387,0.00017067697,0.00016833309],"domain_scores_gemma":[0.9992488,0.0001775449,0.0001732502,0.0003437682,0.00004127149,0.000015380981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072183483,0.00008862934,0.0002610965,0.000082843086,0.000016061595,0.000002570898,0.00011631368,0.000016590902,0.0000374456],"category_scores_gemma":[0.000065697925,0.000048789898,0.000048577018,0.0002859094,0.000053186934,0.000038131053,0.000022323942,0.000100270205,3.1466388e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014162702,0.00061054283,0.10766446,0.005929291,0.0001870436,8.6904686e-7,0.0021595347,0.000011669029,0.0007578656,0.004052513,0.00332182,0.87388813],"study_design_scores_gemma":[0.0028410389,0.00011457803,0.83789116,0.0053449194,0.000045639572,0.000003149093,0.00046197933,0.000006085051,0.0019607544,0.00068312784,0.15055533,0.00009222155],"about_ca_topic_score_codex":0.00001605489,"about_ca_topic_score_gemma":0.0002065357,"teacher_disagreement_score":0.8737959,"about_ca_system_score_codex":0.000057407848,"about_ca_system_score_gemma":0.000019830082,"threshold_uncertainty_score":0.19895944},"labels":[],"label_agreement":null},{"id":"W3026173705","doi":"10.1016/j.annonc.2020.03.256","title":"156P Matching-adjusted indirect comparison (MAIC) of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2 ABC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Palbociclib; Medicine; Fulvestrant; Internal medicine; Oncology; Hazard ratio; Population; Breast cancer; Metastatic breast cancer; Cancer; Gynecology; Confidence interval; Estrogen receptor","score_opus":0.08939372414674518,"score_gpt":0.3920312772754311,"score_spread":0.3026375531286859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026173705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829188,0.0025234614,0.000055832017,0.011358102,0.00022030792,0.000915502,0.00078764604,0.000093787596,0.0011265879],"genre_scores_gemma":[0.9939931,0.0013801543,0.0026814963,0.001378731,0.00023999621,0.00010006951,0.00009068881,0.00008669924,0.00004903872],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99648404,0.0004202385,0.0012284035,0.00074324466,0.0004300791,0.00069399405],"domain_scores_gemma":[0.9969084,0.0008172171,0.0010320425,0.00025148765,0.00058377336,0.00040704198],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028349835,0.0005043608,0.0021026677,0.0002653902,0.00010621846,0.000009601825,0.00026918814,0.00037433053,0.00057680847],"category_scores_gemma":[0.0002963944,0.00049268187,0.00020404764,0.0007289189,0.0007434941,0.00039929477,0.00016658039,0.0007364436,0.000013557319],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060076047,0.0018230898,0.08619591,0.00088912895,0.0018678174,0.000099862824,0.028599339,0.00018063393,0.5433637,0.0005308284,0.0023203045,0.27405336],"study_design_scores_gemma":[0.032885775,0.012279285,0.6938216,0.0007072031,0.00025554126,0.00006358338,0.0068250727,0.000105143015,0.24708124,0.00049836835,0.0044912794,0.0009859112],"about_ca_topic_score_codex":0.001016565,"about_ca_topic_score_gemma":0.00038197663,"teacher_disagreement_score":0.6076257,"about_ca_system_score_codex":0.00026326493,"about_ca_system_score_gemma":0.00032865716,"threshold_uncertainty_score":0.99975246},"labels":[],"label_agreement":null},{"id":"W3026733513","doi":"10.1016/j.jval.2020.04.1588","title":"PCN87 COST-EFFECTIVENESS OF RIBOCILIB PLUS NONSTEROIDAL AROMATASE INHIBITOR (NSAI) IN HORMONE RECEPTOR–POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Discontinuation; Breast cancer; Internal medicine; Quality-adjusted life year; Population; Placebo; Oncology; Exemestane; Adverse effect; Hazard ratio; Cohort; Cancer; Cost effectiveness; Confidence interval; Pathology; Aromatase; Environmental health","score_opus":0.038519867999389855,"score_gpt":0.33232328371295655,"score_spread":0.2938034157135667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026733513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9421638,0.005877191,0.0001506296,0.033874772,0.00042785224,0.0068892105,0.01038784,0.00013464621,0.00009402401],"genre_scores_gemma":[0.99430335,0.00060252834,0.0014103877,0.0021044507,0.00036886797,0.00071918976,0.00033486122,0.00014329902,0.000013067214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939419,0.0015479408,0.0012432561,0.0012449211,0.00064224907,0.00137974],"domain_scores_gemma":[0.9962433,0.00055801775,0.0005976709,0.00043793969,0.0006635769,0.0014994958],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006770489,0.0006775025,0.001782431,0.00061811815,0.00023512947,0.00002051041,0.00029384854,0.00029038795,0.00016253594],"category_scores_gemma":[0.0003685732,0.00070928683,0.00018794835,0.0015491395,0.00042709234,0.0004774493,0.00009206677,0.0012441332,0.000021680178],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.106633805,0.0038317377,0.3769678,0.022689179,0.0016738339,0.0011592192,0.23066323,0.016591769,0.13834871,0.008975331,0.0012592217,0.09120618],"study_design_scores_gemma":[0.032435283,0.005325706,0.91140234,0.00942746,0.000057292124,0.00014966384,0.019134793,0.0010325958,0.017777719,0.00072821905,0.0008282554,0.001700681],"about_ca_topic_score_codex":0.5796829,"about_ca_topic_score_gemma":0.07378025,"teacher_disagreement_score":0.53443456,"about_ca_system_score_codex":0.011499385,"about_ca_system_score_gemma":0.0049670683,"threshold_uncertainty_score":0.9995358},"labels":[],"label_agreement":null},{"id":"W3026866758","doi":"10.1016/j.annonc.2020.03.241","title":"140O Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Genentech; PharmaMar; Eisai; Daiichi-Sankyo; Invitae; Puma Biotechnology; Incyte; BeiGene; AbbVie; Daiichi Sankyo Europe; U.S. Department of Defense; Sanofi; Cilag; Celldex Therapeutics; Amgen; Vifor Pharma; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Carboplatin; Veliparib; Breast cancer; Hazard ratio; Metastatic breast cancer; Oncology; Population; Triple-negative breast cancer; Progression-free survival; Cancer; Chemotherapy; Confidence interval; Cisplatin","score_opus":0.03757875422880337,"score_gpt":0.34769198966008097,"score_spread":0.3101132354312776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026866758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9618072,0.0015083454,0.00002819421,0.022861298,0.00019500409,0.0029514756,0.010475832,0.0000386819,0.00013394798],"genre_scores_gemma":[0.9943448,0.001180411,0.0003590753,0.0029848018,0.00024432762,0.00046649843,0.00031581608,0.000069036454,0.00003526559],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9959103,0.000707483,0.0012078991,0.00087934174,0.00057574484,0.0007192596],"domain_scores_gemma":[0.9958312,0.0015904983,0.0012042101,0.0002980686,0.00076134637,0.00031469302],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044320567,0.0005385271,0.0017887742,0.00016551456,0.00011024207,0.000016320626,0.0002495755,0.00024039099,0.00008562395],"category_scores_gemma":[0.00062517653,0.00040360968,0.000117706215,0.0011239477,0.0006872446,0.00038799612,0.000113295544,0.00088575814,0.0000026476912],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7957472,0.002103281,0.016457317,0.00004313749,0.0012974541,0.00007172878,0.026842395,0.0004677302,0.000752366,0.000023759862,0.00076272193,0.15543087],"study_design_scores_gemma":[0.4081727,0.010543737,0.5737582,0.0007537416,0.0002495481,0.000009203432,0.0043998477,0.00027556394,0.0008364144,0.00027799263,0.0002597113,0.00046332594],"about_ca_topic_score_codex":0.020050913,"about_ca_topic_score_gemma":0.009541632,"teacher_disagreement_score":0.55730087,"about_ca_system_score_codex":0.0008422974,"about_ca_system_score_gemma":0.00103865,"threshold_uncertainty_score":0.9998416},"labels":[],"label_agreement":null},{"id":"W3027243897","doi":"10.1016/j.jval.2020.04.1816","title":"PCN361 POOR PROGNOSTIC FACTORS AND THEIR IMPACT ON TREATMENT PATTERNS AND OUTCOMES FOR WOMEN WITH HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC) IN CANADA","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Medicine; Internal medicine; Oncology; Breast cancer; Chemotherapy; Cancer; Hormone receptor; Metastatic breast cancer; Endocrine system; Disease; Hormone","score_opus":0.026102601444537375,"score_gpt":0.29660249050752663,"score_spread":0.2704998890629893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027243897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98474896,0.0005402398,0.000035837416,0.008710127,0.000058953938,0.00270093,0.0031616252,0.000038436065,0.0000049080304],"genre_scores_gemma":[0.997111,0.0006007221,0.00025277285,0.0012390862,0.00007738468,0.00055619865,0.000066725814,0.00008188099,0.000014209887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99761033,0.000178471,0.00050104444,0.0006614966,0.00023943503,0.00080921536],"domain_scores_gemma":[0.9981593,0.0006940664,0.00027304178,0.00016102109,0.000081588885,0.0006309697],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000100759244,0.000585728,0.0011399916,0.00013271037,0.00012900557,0.000017637003,0.0000778677,0.000066525376,0.000055629185],"category_scores_gemma":[0.00007112488,0.00034786132,0.000049811886,0.00024998854,0.00009260604,0.0001722174,0.000025583693,0.00027588764,3.5114437e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003939558,0.00014686454,0.9560082,0.00034178517,0.0002121036,0.000010192992,0.011833834,0.00032254332,0.00039809535,0.000009261926,0.000011547672,0.02676601],"study_design_scores_gemma":[0.007036507,0.0050734407,0.98125154,0.00052733166,0.000012463254,0.000010365041,0.0045909206,0.00014607323,0.00093661435,0.000035375437,0.000053687472,0.0003257008],"about_ca_topic_score_codex":0.73157996,"about_ca_topic_score_gemma":0.24346751,"teacher_disagreement_score":0.48811242,"about_ca_system_score_codex":0.0056232875,"about_ca_system_score_gemma":0.001458526,"threshold_uncertainty_score":0.99989736},"labels":[],"label_agreement":null},{"id":"W3028188420","doi":"10.1016/j.jval.2020.04.1534","title":"PCN28 CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS (CDK4/6I) IN HORMONE RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED/METASTATIC BREAST CANCER (A/MBC): A SYSTEMATIC LITERATURE REVIEW OF REAL-WORLD EVIDENCE (RWE) STUDIES","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Palbociclib; Letrozole; Medicine; Fulvestrant; Metastatic breast cancer; Internal medicine; Oncology; Progression-free survival; Cyclin-dependent kinase 4; Cancer; Breast cancer; Aromatase; Gynecology; Estrogen receptor; Overall survival; Cyclin-dependent kinase 2; Cell cycle","score_opus":0.06409227364805688,"score_gpt":0.3774474890229369,"score_spread":0.31335521537488004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028188420","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16903083,0.7847116,0.00006600754,0.035606507,0.0005749862,0.008795224,0.0009953736,0.00017507758,0.000044406253],"genre_scores_gemma":[0.5461816,0.44405755,0.0035579808,0.004431884,0.00040893056,0.0010341865,0.00005583785,0.00014472762,0.00012729417],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99109393,0.0022356273,0.0032499954,0.0012246824,0.0012042096,0.0009915385],"domain_scores_gemma":[0.9943554,0.0015613709,0.0019302135,0.0006616168,0.000869434,0.00062200066],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017121735,0.00083757733,0.0034980737,0.00057946466,0.00014873953,0.000027988599,0.00038943053,0.00012843151,0.00012133209],"category_scores_gemma":[0.0021940994,0.00070408743,0.00030224747,0.002765805,0.00032746542,0.0007760971,0.00017935234,0.0012254275,0.00002183705],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032351185,0.00091922644,0.015104521,0.92844254,0.0007359446,0.0003805418,0.028843261,0.00071638636,0.01239996,0.00042750497,0.0010719293,0.0077230544],"study_design_scores_gemma":[0.0047917315,0.0018275068,0.027584046,0.95721537,0.00022161285,0.00009452595,0.0026530388,0.00013409129,0.0042413315,0.00029461118,0.00006964021,0.00087250327],"about_ca_topic_score_codex":0.0035898217,"about_ca_topic_score_gemma":0.0004483917,"teacher_disagreement_score":0.37715077,"about_ca_system_score_codex":0.0030204232,"about_ca_system_score_gemma":0.00087619614,"threshold_uncertainty_score":0.99954104},"labels":[],"label_agreement":null},{"id":"W3028527898","doi":"10.1016/j.annonc.2020.03.245","title":"144P Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Chugai Pharmaceutical; Genentech; Servier; Eisai; Daiichi-Sankyo; Daiichi Sankyo Europe; Université de Liège; Curtin University of Technology; Incyte; Gilead Sciences; FibroGen; Merck KGaA; Genomic Health; Ariad Pharmaceuticals; Amgen; Pfizer; Novartis Pharmaceuticals Corporation; PharmaMar; Celgene; BC Cancer Agency; Centro de Investigación Biomédica en Red de Cáncer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Quality of life (healthcare); Progression-free survival; Fulvestrant; Placebo; Breast cancer; Oncology; Cancer; Urology; Gastroenterology; Overall survival; Estrogen receptor; Pathology","score_opus":0.05540093340937784,"score_gpt":0.357927209976405,"score_spread":0.30252627656702713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028527898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96358484,0.003182079,0.000017356457,0.03152166,0.00006234762,0.0011122054,0.00017102849,0.00007122815,0.00027723052],"genre_scores_gemma":[0.98847985,0.0028262571,0.0004384653,0.0076829283,0.000071938164,0.00023774616,0.0000603802,0.00007047127,0.00013195173],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727726,0.00010443436,0.000996328,0.0007033699,0.00032273837,0.0005958432],"domain_scores_gemma":[0.9982556,0.00020876619,0.00054474745,0.0003424924,0.00034609067,0.00030229375],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017716427,0.0004535285,0.0014261508,0.00023860115,0.000046994144,0.0000077277045,0.00014633605,0.00023871024,0.00047285933],"category_scores_gemma":[0.000085705586,0.00034826656,0.00011128241,0.00064764736,0.00033842787,0.00024779118,0.00005368159,0.0004630585,0.000004030203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02567098,0.0013330231,0.627448,0.00018529498,0.00057710026,0.00106059,0.0027749666,0.0009827901,0.010564638,0.000037077483,0.000055417728,0.3293101],"study_design_scores_gemma":[0.030210564,0.014707459,0.9196525,0.00041988792,0.0000852758,0.0005438704,0.000853077,0.00025314974,0.01711579,0.0003913011,0.015195236,0.0005718771],"about_ca_topic_score_codex":0.0010995711,"about_ca_topic_score_gemma":0.0038644746,"teacher_disagreement_score":0.3287382,"about_ca_system_score_codex":0.00013419945,"about_ca_system_score_gemma":0.000430024,"threshold_uncertainty_score":0.99989694},"labels":[],"label_agreement":null},{"id":"W3029388691","doi":"10.1200/jco.2020.38.15_suppl.1009","title":"Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis","keywords":"Medicine; CDKN2A; Internal medicine; Oncology; Hazard ratio; Biomarker; Proportional hazards model; Breast cancer; Progression-free survival; Cancer; Cancer research; Genetics; Overall survival; Confidence interval; Biology","score_opus":0.17953858133133552,"score_gpt":0.5292489329331808,"score_spread":0.34971035160184527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029388691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90497404,0.0027555036,0.0014664335,0.088334754,0.0015112378,0.00040579433,0.0001235509,0.000016565096,0.0004121303],"genre_scores_gemma":[0.98478675,0.0010078921,0.0016304615,0.010427755,0.0019665766,0.000009180231,0.0000031648774,0.000024948504,0.0001432802],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9932967,0.0009886227,0.0045061014,0.00028003758,0.0006585292,0.0002700151],"domain_scores_gemma":[0.9896104,0.0028453795,0.0057434086,0.00033793537,0.0009085131,0.0005543634],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034263919,0.00021592817,0.004583086,0.00017768946,0.00005085235,0.0000055188734,0.0004183886,0.00030565646,0.001345437],"category_scores_gemma":[0.005324191,0.00012252762,0.002407877,0.0011169558,0.0004341407,0.00015826577,0.000089003915,0.0011935806,0.0000039889715],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07235031,0.0021609778,0.025650917,0.000048052785,0.016661238,0.00017287352,0.00048695688,0.002515065,0.01162719,0.00009707668,0.001059207,0.86717016],"study_design_scores_gemma":[0.1543045,0.013800586,0.5757003,0.00045302857,0.05038011,0.0004466321,0.0010530555,0.0034288927,0.0027423974,0.0006090085,0.19660082,0.00048068017],"about_ca_topic_score_codex":0.000031271655,"about_ca_topic_score_gemma":0.000051278832,"teacher_disagreement_score":0.86668944,"about_ca_system_score_codex":0.00019851624,"about_ca_system_score_gemma":0.0020823854,"threshold_uncertainty_score":0.99956745},"labels":[],"label_agreement":null},{"id":"W3029553330","doi":"10.1200/jco.2020.38.15_suppl.e13052","title":"Comparison of treatment-related adverse events (TRAE) of different CDK4/6 inhibitors (CDK4/6i) in metastatic breast cancer (MBC): A network meta-analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Palbociclib; Fulvestrant; Medicine; Internal medicine; Discontinuation; Hazard ratio; Oncology; Tolerability; Adverse effect; Randomized controlled trial; Metastatic breast cancer; Breast cancer; Cancer; Confidence interval; Estrogen receptor","score_opus":0.2817822888061318,"score_gpt":0.518897369908049,"score_spread":0.2371150811019172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029553330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806552,0.0070532225,0.00051242963,0.010506973,0.00058012526,0.0005141824,0.00006390657,0.000011621985,0.00010236596],"genre_scores_gemma":[0.9960393,0.0004976094,0.0022816765,0.00069821405,0.00037353463,0.000015808895,0.0000080947575,0.000028775345,0.000057027115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99190867,0.0010439408,0.005811443,0.00032520946,0.0005604759,0.000350242],"domain_scores_gemma":[0.99143237,0.001718993,0.005650922,0.00026499623,0.0004393145,0.0004934151],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012248409,0.0003303375,0.008333863,0.00026366,0.000022065022,0.000001528164,0.00022926276,0.0002665165,0.0009775865],"category_scores_gemma":[0.0004517203,0.0002071102,0.003402217,0.00094772386,0.00028765982,0.00012484058,0.00005752327,0.0008692937,0.0000038371313],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01504373,0.0064930436,0.6823711,0.00012023732,0.21948591,0.00021246074,0.0010801039,0.040963557,0.0004992471,0.00006522775,0.00018027326,0.0334851],"study_design_scores_gemma":[0.027476678,0.020225206,0.6453499,0.00017056253,0.298536,0.00010804747,0.0007968013,0.0034136116,0.0005584551,0.00052043283,0.002531723,0.00031255893],"about_ca_topic_score_codex":0.00015932666,"about_ca_topic_score_gemma":0.00043972628,"teacher_disagreement_score":0.079050094,"about_ca_system_score_codex":0.00044613506,"about_ca_system_score_gemma":0.0010729948,"threshold_uncertainty_score":0.9999356},"labels":[],"label_agreement":null},{"id":"W3030599412","doi":"10.1200/jco.2020.38.15_suppl.e19109","title":"Impact of oligometastatic disease on survival in ER positive breast cancer: A population-based analysis.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Metastasis; Population; Cancer; Disease","score_opus":0.09207549153834477,"score_gpt":0.5002953619202082,"score_spread":0.4082198703818634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030599412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98236245,0.00020814168,0.00061744626,0.016288614,0.0001750242,0.00014961256,0.00014004436,0.0000051436987,0.000053521122],"genre_scores_gemma":[0.99605364,0.000054316355,0.0008017603,0.002606423,0.00044661993,0.000003089234,0.000012864508,0.00001530702,0.0000059872423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99685985,0.00049574027,0.0018518562,0.000190289,0.00041350775,0.00018878565],"domain_scores_gemma":[0.995292,0.0018753618,0.0016580021,0.00014237675,0.00041090036,0.00062135473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085198303,0.00014730416,0.0020243537,0.00030887805,0.000012849246,0.0000031830484,0.000116878036,0.00009226449,0.00036113054],"category_scores_gemma":[0.0015583915,0.00010121848,0.0010583389,0.0007849545,0.00011018764,0.00008376485,0.000015092874,0.00060430175,0.0000027522474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03309071,0.001240812,0.8972577,0.000027081363,0.0019732858,0.0003699676,0.00006660893,0.030739846,0.00004605916,0.00002334506,0.000021148038,0.035143454],"study_design_scores_gemma":[0.007773588,0.0050873244,0.982537,0.000117654505,0.0015693984,0.000013071547,0.00003192025,0.0026252195,0.0000051158895,0.00011141824,0.00004917494,0.00007914632],"about_ca_topic_score_codex":0.0003548565,"about_ca_topic_score_gemma":0.00011724979,"teacher_disagreement_score":0.085279286,"about_ca_system_score_codex":0.00041375295,"about_ca_system_score_gemma":0.0022400026,"threshold_uncertainty_score":0.41275698},"labels":[],"label_agreement":null},{"id":"W3030929389","doi":"10.1200/jco.2020.38.15_suppl.1006","title":"Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with <i>PIK3CA-</i>mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Fulvestrant; Internal medicine; Metastatic breast cancer; Clinical endpoint; Cohort; Breast cancer; Letrozole; Oncology; Cancer; Clinical trial; Estrogen receptor; Tamoxifen","score_opus":0.03321510135610873,"score_gpt":0.362653915720541,"score_spread":0.3294388143644323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030929389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842789,0.00031368376,0.00007433689,0.00938916,0.0005155355,0.0036378454,0.0015463384,0.000110888606,0.00013331218],"genre_scores_gemma":[0.9913601,0.00034129107,0.0027399303,0.0032429388,0.0016543202,0.00015797863,0.00023477888,0.00020767805,0.000060956605],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.98782206,0.0019647002,0.0058027734,0.0015086016,0.0017328779,0.0011689875],"domain_scores_gemma":[0.9880124,0.0016651712,0.005297332,0.0005808758,0.0026030804,0.0018411686],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001518398,0.0011360635,0.004510754,0.00038896492,0.00021601158,0.000059332924,0.0005694659,0.00068718824,0.00019873753],"category_scores_gemma":[0.0018182918,0.0007830786,0.00051200436,0.0011275227,0.000920072,0.0012046183,0.00017708202,0.003626495,0.000029757228],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5402417,0.027088718,0.30202806,0.00018214593,0.0039657583,0.0048229913,0.0070875385,0.0004801276,0.007692686,0.00000677857,0.0024069094,0.1039966],"study_design_scores_gemma":[0.1659155,0.12879474,0.6912756,0.0013036043,0.0011372202,0.00029959762,0.0029229743,0.000024246296,0.00624718,0.00001844218,0.0009947314,0.0010661813],"about_ca_topic_score_codex":0.0006431667,"about_ca_topic_score_gemma":0.0009155005,"teacher_disagreement_score":0.3892475,"about_ca_system_score_codex":0.0017358252,"about_ca_system_score_gemma":0.0023299314,"threshold_uncertainty_score":0.999462},"labels":[],"label_agreement":null},{"id":"W3030967068","doi":"10.1200/jco.2020.38.15_suppl.tps3656","title":"An open-label, first-in-human, phase I trial of the safety and efficacy of daily PCLX-001.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; Spinal Cord Injury BC","funders":"","keywords":"Tolerability; Medicine; Pharmacokinetics; In vivo; Lymphoma; Cancer; Internal medicine; Oncology; Pharmacology; Cancer research; Adverse effect","score_opus":0.18668089231023494,"score_gpt":0.5238295491597984,"score_spread":0.33714865684956347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030967068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97909987,0.00036209665,0.00010054211,0.018825099,0.0005257128,0.0005303639,0.000011163477,0.0000034827196,0.00054168806],"genre_scores_gemma":[0.9947635,0.0003066024,0.0016703126,0.0022365192,0.0009677971,0.000001851816,0.0000016418129,0.000015483112,0.000036302674],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962306,0.00047775244,0.0026751633,0.00017828064,0.00028837626,0.00014984592],"domain_scores_gemma":[0.994958,0.0019517486,0.0022915956,0.0002550055,0.00025411267,0.0002895803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021657352,0.00011554863,0.0017454291,0.00004766219,0.000035146113,0.000004616389,0.0004589164,0.00020763963,0.00013590658],"category_scores_gemma":[0.0032990966,0.000070941125,0.0001370304,0.00017184546,0.00046296685,0.0001558533,0.00014008,0.00079347374,8.3991387e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66370803,0.015884962,0.0049993508,0.000079212004,0.0003704158,0.00014345489,0.0006464708,0.00006218008,0.0057952967,0.00033694413,0.00043506853,0.3075386],"study_design_scores_gemma":[0.7376835,0.10243385,0.054253925,0.00022874573,0.00035815287,0.00010163957,0.0001797092,0.0001343567,0.0003925374,0.0004218193,0.10370823,0.00010358727],"about_ca_topic_score_codex":0.000020116342,"about_ca_topic_score_gemma":0.000039021477,"teacher_disagreement_score":0.307435,"about_ca_system_score_codex":0.00005963399,"about_ca_system_score_gemma":0.0007413335,"threshold_uncertainty_score":0.3949565},"labels":[],"label_agreement":null},{"id":"W3031097250","doi":"10.1200/jco.2020.38.15_suppl.1054","title":"Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Ottawa","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Internal medicine; Fulvestrant; Breast cancer; Gastroenterology; Cancer; Surgery; Estrogen receptor","score_opus":0.1833542722929642,"score_gpt":0.45652984645030714,"score_spread":0.27317557415734295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031097250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853052,0.0022193925,0.00021015943,0.010816858,0.00007680632,0.0011403821,0.00007318443,0.000021104981,0.0001369149],"genre_scores_gemma":[0.9858561,0.0033436774,0.004868193,0.00536064,0.00038524976,0.00006944588,0.000017051643,0.00007564067,0.000023981689],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99381405,0.002124183,0.0020096123,0.0005586872,0.00096085254,0.00053259],"domain_scores_gemma":[0.9932329,0.003259623,0.0022382091,0.0002733292,0.0005663354,0.00042960324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028248364,0.0005151044,0.0033566998,0.00021102063,0.00007645656,0.000034525783,0.00029671603,0.00016124085,0.000103956765],"category_scores_gemma":[0.0005520821,0.00023043744,0.00019726365,0.0006220609,0.000540327,0.00057490944,0.00006597088,0.0016582946,8.011084e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29495794,0.0018768135,0.5652824,0.000051868214,0.0015086337,0.0019918636,0.0013188263,0.0017888526,0.00007341994,0.000067315814,0.00003840645,0.13104366],"study_design_scores_gemma":[0.12723036,0.037874777,0.82496727,0.0007071427,0.00070772227,0.0008674316,0.0008564089,0.00014636465,0.00008613689,0.000037608803,0.006154813,0.0003639714],"about_ca_topic_score_codex":0.0005364379,"about_ca_topic_score_gemma":0.0022833173,"teacher_disagreement_score":0.25968483,"about_ca_system_score_codex":0.00041305198,"about_ca_system_score_gemma":0.001746013,"threshold_uncertainty_score":0.9396966},"labels":[],"label_agreement":null},{"id":"W3032176512","doi":"10.1200/jco.2020.38.15_suppl.1055","title":"Updated results from the phase IIIb complement-1 study of ribociclib (RIB) plus letrozole (LET) in the treatment of HR+, HER2-advanced breast cancer (ABC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Neutropenia; Tolerability; Internal medicine; Population; Adverse effect; Phases of clinical research; Nausea; Febrile neutropenia; Gastroenterology; Surgery; Clinical trial; Chemotherapy","score_opus":0.1977987316976941,"score_gpt":0.5158389428914423,"score_spread":0.31804021119374815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032176512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9488155,0.0010713321,0.00006512568,0.048293687,0.00040273613,0.000852163,0.0003617176,0.000007947672,0.00012979034],"genre_scores_gemma":[0.99363995,0.0009103818,0.0006407808,0.0036822187,0.0010335146,0.00002331629,0.00002453164,0.000022961345,0.00002234853],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9941666,0.0010629299,0.003559469,0.0003021831,0.00062640005,0.00028239438],"domain_scores_gemma":[0.9926359,0.003165904,0.0031014401,0.00043140913,0.00045320878,0.00021214118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014367463,0.00023830167,0.0020821022,0.000059283768,0.000053666754,0.0000057142956,0.00047286492,0.00014524689,0.00026075315],"category_scores_gemma":[0.0005676479,0.00012132096,0.0003936889,0.0003707895,0.0003711835,0.000104773855,0.00005473066,0.00070784835,0.0000030997876],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22136688,0.032813553,0.06855508,0.000029344672,0.0031209907,0.0008337593,0.026449706,0.0024840664,0.0026150735,0.000036690224,0.0026757484,0.63901913],"study_design_scores_gemma":[0.27293903,0.087311015,0.44265822,0.00023238672,0.0014380643,0.00011762325,0.025272632,0.0004901163,0.00053140573,0.00016163582,0.16862017,0.00022771605],"about_ca_topic_score_codex":0.00086737116,"about_ca_topic_score_gemma":0.0011767414,"teacher_disagreement_score":0.6387914,"about_ca_system_score_codex":0.00035188664,"about_ca_system_score_gemma":0.0009924287,"threshold_uncertainty_score":0.4947325},"labels":[],"label_agreement":null},{"id":"W3035496509","doi":"10.1158/1078-0432.ccr-20-0224","title":"<i>ESR1</i> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Institute for Health and Care Research; Cancer Research UK; AstraZeneca","keywords":"Fulvestrant; Exemestane; Oncology; Breast cancer; Medicine; Internal medicine; Hormone receptor; Estrogen receptor; Oestrogen receptor; Cancer; Aromatase","score_opus":0.22071949580049685,"score_gpt":0.5247294331244319,"score_spread":0.304009937323935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035496509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97798914,0.0030203878,0.000041763444,0.016214779,0.00021181387,0.001432048,0.0009639049,0.000024559795,0.000101596575],"genre_scores_gemma":[0.99281496,0.0059971893,0.00009464566,0.00048564412,0.00022640312,0.00024363365,0.000047732636,0.00003396296,0.00005582886],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99549675,0.0013437537,0.0010978676,0.0007282161,0.00085764064,0.00047579652],"domain_scores_gemma":[0.99372023,0.0047102193,0.00031520682,0.00039277293,0.00044586207,0.00041570474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002543433,0.00024698715,0.0015920291,0.00023130586,0.00014598535,0.00002702932,0.0002068719,0.0001462723,0.0001766702],"category_scores_gemma":[0.0016608608,0.00017545343,0.00030082415,0.0018580816,0.0010424468,0.00012264449,0.00014276418,0.0010234263,0.0000013734758],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5414643,0.0021696768,0.075500466,0.00031150907,0.006865925,0.00008856709,0.0031481914,0.0011918319,0.054465927,0.0007898055,0.00041988664,0.31358388],"study_design_scores_gemma":[0.15152904,0.00911658,0.82649666,0.00078611815,0.0024591992,0.0000055886617,0.001549572,0.0024593978,0.0034700853,0.0002697023,0.0013311254,0.0005269199],"about_ca_topic_score_codex":0.0009857628,"about_ca_topic_score_gemma":0.00081670796,"teacher_disagreement_score":0.7509962,"about_ca_system_score_codex":0.00025737582,"about_ca_system_score_gemma":0.0006120249,"threshold_uncertainty_score":0.71547836},"labels":[],"label_agreement":null},{"id":"W3038115149","doi":"10.1097/md.0000000000020458","title":"Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition","year":2020,"lang":"en","type":"article","venue":"Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"NIHR Newcastle Biomedical Research Centre; Newcastle University; National Institute for Health and Care Research; Newcastle upon Tyne Hospitals NHS Foundation Trust; Medical Research Council; Versus Arthritis; Celgene; Gilead Sciences; University of Birmingham; Sanofi; University Hospitals Birmingham NHS Foundation Trust; Pfizer; Birmingham Biomedical Research Centre; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Tolerability; Rheumatoid arthritis; Internal medicine; Oncology; Adverse effect; Pharmacodynamics; Clinical endpoint; Arthritis; Clinical trial; Pharmacology; Pharmacokinetics","score_opus":0.013453254135202297,"score_gpt":0.252586854370478,"score_spread":0.23913360023527572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3038115149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6405696,0.016576558,0.08684027,0.2513233,0.0008480477,0.0016649362,0.000031391017,0.00063912186,0.0015067459],"genre_scores_gemma":[0.9888909,0.0005501729,0.00061404065,0.007865309,0.0018575873,0.000044291297,0.00007196062,0.00004724903,0.000058509315],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982518,0.000066031025,0.00046393432,0.00035476155,0.00053054903,0.0003329106],"domain_scores_gemma":[0.9991131,0.000117724,0.00015330783,0.0002530555,0.000104411316,0.00025840985],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026073158,0.00022805989,0.00042350052,0.000054573968,0.00015769605,0.00000952351,0.00009940429,0.000071119954,0.0010361283],"category_scores_gemma":[0.00041690725,0.00014809502,0.000065198066,0.00029110676,0.00028476218,0.000101511985,0.00006422766,0.00034942332,0.00011262152],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018665411,0.00013973426,0.0021599734,0.00027029758,0.00016260167,0.00069411343,0.006587405,0.00033767184,0.7547282,0.00028033307,0.010786389,0.22198677],"study_design_scores_gemma":[0.07829221,0.01106427,0.014672616,0.016202101,0.0004095849,0.004964744,0.018508164,0.013550997,0.330524,0.004761189,0.5044614,0.00258875],"about_ca_topic_score_codex":0.00007792689,"about_ca_topic_score_gemma":0.000018190922,"teacher_disagreement_score":0.493675,"about_ca_system_score_codex":0.000081013,"about_ca_system_score_gemma":0.000054171564,"threshold_uncertainty_score":0.99987704},"labels":[],"label_agreement":null},{"id":"W3042798355","doi":"10.3747/co.27.6131","title":"Willingness of Women with Early Estrogen Receptor–Positive Breast Cancer to Take Adjuvant CDK4/6 Inhibitors","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Sunnybrook Hospital; University of Manitoba; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Worry; Adjuvant; Breast cancer; Internal medicine; Oncology; Cancer; Drug; Estrogen receptor; Adjuvant therapy; Drug holiday; Gynecology; Pharmacology; Family medicine; Psychiatry; Anxiety","score_opus":0.04044553223216646,"score_gpt":0.35063219316010225,"score_spread":0.3101866609279358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042798355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894771,0.0015555486,0.000781337,0.006520035,0.00058964663,0.00067047734,0.00023164458,0.00007257183,0.00010165761],"genre_scores_gemma":[0.997047,0.00008828848,0.0008673588,0.0007605298,0.00086829264,0.00027621607,0.000020374597,0.000049889804,0.00002206151],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99835247,0.00006420322,0.0003422393,0.00043811032,0.00028458718,0.0005184094],"domain_scores_gemma":[0.9986109,0.00005349355,0.00021074396,0.00019360615,0.0003593814,0.00057187397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000094464165,0.00024660118,0.0007170222,0.00006889424,0.000043959022,0.0000055603155,0.00014343412,0.00008989117,0.00031189914],"category_scores_gemma":[0.000032547374,0.00019791085,0.000059701484,0.00044945194,0.00021448941,0.000094205396,0.00007418416,0.00030154595,0.00003702548],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014028699,0.00058145844,0.17765255,0.0003011195,0.00041213617,0.000042752185,0.024837734,0.00018940037,0.029550295,0.0001330755,0.0005085651,0.7517622],"study_design_scores_gemma":[0.017479952,0.01815267,0.473845,0.0022417733,0.0005348254,0.0003181332,0.007313756,0.00009154068,0.041759603,0.00009405727,0.43689677,0.0012718982],"about_ca_topic_score_codex":0.00006750407,"about_ca_topic_score_gemma":0.000012687874,"teacher_disagreement_score":0.7504903,"about_ca_system_score_codex":0.0009799082,"about_ca_system_score_gemma":0.0005592655,"threshold_uncertainty_score":0.807057},"labels":[],"label_agreement":null},{"id":"W3043576044","doi":"10.1097/md.0000000000020821","title":"Efficacy of fulvestrant 500 mg in Chinese postmenopausal women with advanced/recurrent breast cancer and factors associated with prolonged time-to-treatment failure","year":2020,"lang":"en","type":"article","venue":"Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CAE (Canada)","funders":"","keywords":"Fulvestrant; Medicine; Internal medicine; Oncology; Metastatic breast cancer; Anastrozole; Breast cancer; Cancer; Progression-free survival; Univariate analysis; Chemotherapy; Tamoxifen; Multivariate analysis","score_opus":0.010894782947802089,"score_gpt":0.26352061326016535,"score_spread":0.25262583031236324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043576044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819583,0.00082082354,0.000019119654,0.015585217,0.000026593569,0.0013521925,0.00012329874,0.000078037316,0.000036368147],"genre_scores_gemma":[0.99883217,0.0000450306,0.00015629307,0.0004797573,0.00012795834,0.00017140426,0.00006590773,0.000060050774,0.00006142843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982027,0.00004213619,0.00035165672,0.00050021184,0.0004449984,0.00045830783],"domain_scores_gemma":[0.998851,0.00010720416,0.00018981,0.00022133431,0.00013831802,0.0004923033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008463973,0.00043033302,0.001004101,0.00014747647,0.0000367555,0.000004297012,0.00008895851,0.00006551605,0.00033459743],"category_scores_gemma":[0.000078420984,0.00023042045,0.000019731131,0.0007431353,0.00025274872,0.000091524744,0.000025625355,0.0002226858,0.0000032823255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.065679066,0.001910421,0.632061,0.000563262,0.0018933425,0.0003630534,0.054292664,0.0010410342,0.09415713,0.0000055018613,0.000049769827,0.14798376],"study_design_scores_gemma":[0.02460335,0.017905284,0.95316195,0.0016540636,0.00018980402,0.000049772418,0.0010154427,0.0000865033,0.0004946915,0.0000048828647,0.000554417,0.00027985187],"about_ca_topic_score_codex":0.00008691225,"about_ca_topic_score_gemma":0.00024549058,"teacher_disagreement_score":0.32110092,"about_ca_system_score_codex":0.00044087032,"about_ca_system_score_gemma":0.00019187598,"threshold_uncertainty_score":0.93962735},"labels":[],"label_agreement":null},{"id":"W3045479122","doi":"10.1016/j.lfs.2020.118150","title":"RETRACTED: Inhibition of CD73 using folate targeted nanoparticles carrying anti-CD73 siRNA potentiates anticancer efficacy of Dinaciclib","year":2020,"lang":"en","type":"article","venue":"Life Sciences","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":25,"is_retracted":true,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Student Research Committee, Tabriz University of Medical Sciences; National Institute for Medical Research Development; Tabriz University of Medical Sciences","keywords":"Cancer research; Cancer; Cancer cell; Pharmacology; Medicine; Metastasis; Cyclin-dependent kinase; Tumor progression; Chemistry; Internal medicine; Cell cycle","score_opus":0.05372441218727718,"score_gpt":0.3177483954196212,"score_spread":0.264023983232344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045479122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957118,0.002011909,0.0005976496,0.0011449662,0.00015047594,0.00023068489,0.000016776728,0.00006283821,0.00007292148],"genre_scores_gemma":[0.9938385,0.00007916191,0.0055484404,0.00035140713,0.0001569919,0.0000021368116,0.0000033593399,0.00001630026,0.000003710916],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998188,0.0000512792,0.0004901631,0.00036371412,0.0005847738,0.0003220401],"domain_scores_gemma":[0.9990286,0.000096435186,0.0003621857,0.00015703542,0.00017488869,0.00018084586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027464787,0.00015707222,0.00044920773,0.000119605436,0.00013977208,0.000016282063,0.00013941995,0.00006732776,0.00008539163],"category_scores_gemma":[0.0004425352,0.00012981852,0.00010471449,0.0011245646,0.0007226165,0.00042122178,0.00006135505,0.00014558337,0.000002994632],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017691904,0.000073111965,0.042241145,0.00013157757,0.000043144628,0.0000072546545,0.0008758843,0.001239228,0.9531516,0.000095918454,0.000007755803,0.0019564948],"study_design_scores_gemma":[0.0013611163,0.00045374475,0.07605783,0.00043235757,0.000110160436,0.000012145105,0.0011069877,0.006250203,0.9137787,0.00019612684,0.00007048355,0.00017012353],"about_ca_topic_score_codex":0.00010941751,"about_ca_topic_score_gemma":0.0000015462243,"teacher_disagreement_score":0.03937284,"about_ca_system_score_codex":0.000029045066,"about_ca_system_score_gemma":0.00021345544,"threshold_uncertainty_score":0.52938455},"labels":[],"label_agreement":null},{"id":"W3047016083","doi":"10.29169/1927-5951.2020.10.01.8","title":"Current Trends in the Treatment of Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer","year":2020,"lang":"en","type":"article","venue":"Journal of Pharmacy and Nutrition Sciences","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Olaparib; Oncology; Cancer; Internal medicine; Drug; Pharmacology","score_opus":0.10359104761371045,"score_gpt":0.4269706839634786,"score_spread":0.32337963634976813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047016083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9682121,0.007402913,0.000021396172,0.024061844,0.00010420073,0.00010706173,0.00005526988,0.0000030399033,0.00003211885],"genre_scores_gemma":[0.9933486,0.0057039396,0.00013717254,0.0003127538,0.00048300816,0.000008441301,9.919873e-7,0.0000027712763,0.0000023304651],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99910975,0.000079211335,0.0003014501,0.00010379289,0.00029691486,0.00010889134],"domain_scores_gemma":[0.99943733,0.00007326964,0.00025736573,0.000026569935,0.00011700603,0.0000884343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013579367,0.00008628154,0.00023612584,0.00014807099,0.000081394035,0.000014169612,0.00009062539,0.000009647,0.0002790475],"category_scores_gemma":[0.000009030678,0.00004766907,0.00008041289,0.0004441367,0.00025784885,0.0003028503,0.0000050209646,0.000104406245,2.8558478e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003460214,0.0022703651,0.16094543,0.00022774936,0.00011007201,0.00003192225,0.021539655,0.000010363385,0.06451715,0.00017590933,0.00067502295,0.7460362],"study_design_scores_gemma":[0.045497477,0.01024041,0.6603825,0.0011339152,0.00035014402,0.00082567544,0.010456257,0.00038061125,0.22512491,0.0016079558,0.043557175,0.00044295148],"about_ca_topic_score_codex":0.00004473685,"about_ca_topic_score_gemma":0.000004956828,"teacher_disagreement_score":0.7455932,"about_ca_system_score_codex":0.000051138257,"about_ca_system_score_gemma":0.000052499683,"threshold_uncertainty_score":0.30553743},"labels":[],"label_agreement":null},{"id":"W3048905405","doi":"10.1007/s10549-020-05782-4","title":"Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials","year":2020,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Pfizer","keywords":"Palbociclib; Internal medicine; Oncology; Medicine; Breast cancer; Hazard ratio; Progression-free survival; Placebo; Population; Biomarker; Cancer; Gastroenterology; Metastatic breast cancer; Confidence interval; Biology; Chemotherapy; Pathology","score_opus":0.09056274542627094,"score_gpt":0.4249490110503013,"score_spread":0.3343862656240304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048905405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97313476,0.022314733,0.000011404952,0.0012672576,0.000007958247,0.0021776615,0.0010670881,0.000014521315,0.0000046451405],"genre_scores_gemma":[0.98605734,0.013207334,0.000052144802,0.000028104767,0.000032527303,0.00037748477,0.00019879329,0.000028022652,0.000018270033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99666184,0.0008094228,0.00078742846,0.00078338454,0.00053255365,0.00042534614],"domain_scores_gemma":[0.99748963,0.0010081826,0.00030196004,0.00030935832,0.0002120646,0.00067877385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006324627,0.00039148878,0.0023186367,0.0006288255,0.00007142277,0.000031810643,0.000044556364,0.00006763188,0.00004277963],"category_scores_gemma":[0.00014757928,0.00022142616,0.00022735339,0.0016232994,0.0006301384,0.00008500758,0.00006223249,0.0001253166,2.1082464e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03829015,0.0006537075,0.6438346,0.00009864701,0.010480312,0.000058327572,0.00023008333,0.0000027361662,0.00012237777,0.0000042091033,0.0000022280888,0.30622262],"study_design_scores_gemma":[0.03252613,0.010078354,0.9503384,0.00011428293,0.0060072197,0.000009304191,0.00006642728,0.00035586057,0.0002611518,0.000008992843,0.00007521734,0.00015865183],"about_ca_topic_score_codex":0.0020155276,"about_ca_topic_score_gemma":0.000539209,"teacher_disagreement_score":0.3065038,"about_ca_system_score_codex":0.00023380537,"about_ca_system_score_gemma":0.00027974052,"threshold_uncertainty_score":0.9029497},"labels":[],"label_agreement":null},{"id":"W3049532301","doi":"10.2217/fon-2020-0573","title":"POLARIS: a Prospective, Multicenter, Noninterventional Study Assessing Palbociclib in Hormone Receptor-Positive Advanced Breast Cancer","year":2020,"lang":"en","type":"article","venue":"Future Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer","keywords":"Palbociclib; Medicine; Metastatic breast cancer; Oncology; Internal medicine; Clinical trial; Breast cancer; Hormone receptor; Cancer; Clinical Practice; Gynecology; Family medicine","score_opus":0.015351142844713004,"score_gpt":0.35120742469913363,"score_spread":0.3358562818544206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049532301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.957333,0.005618417,0.000742047,0.032139767,0.0008703047,0.0022782097,0.00018166486,0.00017646742,0.00066008064],"genre_scores_gemma":[0.99217206,0.00011727988,0.0037246027,0.0018352087,0.0015894641,0.00037133228,0.000032623135,0.000058750426,0.00009869035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979001,0.00025110203,0.00046518634,0.0006530354,0.0002943464,0.00043618694],"domain_scores_gemma":[0.9990193,0.00008219909,0.00024552082,0.00018597613,0.00024429208,0.00022270557],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018159563,0.00029921246,0.00068734906,0.00011414451,0.00009224335,0.000022509977,0.00014950994,0.00018095339,0.00047898336],"category_scores_gemma":[0.000049981914,0.00027092703,0.00013715873,0.0004733921,0.00011429496,0.00034187484,0.00010519778,0.00075609813,0.00003273169],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020748599,0.0053407247,0.682323,0.00012850921,0.00081727526,0.00061542046,0.015293539,0.00006234835,0.051887587,0.00017504168,0.0007237517,0.2218842],"study_design_scores_gemma":[0.020954205,0.002313231,0.9533736,0.00023522253,0.00011657433,0.000108944245,0.013136749,0.00010972961,0.00044465292,0.000029091496,0.008897285,0.00028070048],"about_ca_topic_score_codex":0.00010460236,"about_ca_topic_score_gemma":0.00030479347,"teacher_disagreement_score":0.2710506,"about_ca_system_score_codex":0.0011206974,"about_ca_system_score_gemma":0.00034634597,"threshold_uncertainty_score":0.9999743},"labels":[],"label_agreement":null},{"id":"W3049702673","doi":"10.1016/j.ctrv.2020.102086","title":"Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis","year":2020,"lang":"en","type":"article","venue":"Cancer Treatment Reviews","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Palbociclib; Medicine; Fulvestrant; Tolerability; Metastatic breast cancer; Internal medicine; Oncology; Adverse effect; Neutropenia; Discontinuation; Breast cancer; Hazard ratio; Pharmacology; Cancer; Chemotherapy; Estrogen receptor; Confidence interval","score_opus":0.13815874616013846,"score_gpt":0.40500467243691196,"score_spread":0.2668459262767735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049702673","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.43160224,0.5591402,0.00021065399,0.0023414397,0.00024204282,0.005309591,0.0009912589,0.000067399786,0.000095163094],"genre_scores_gemma":[0.95754397,0.03928404,0.000516298,0.00017749456,0.0001043726,0.0019572796,0.00013778664,0.000056293673,0.00022249323],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.995777,0.00041952948,0.002153955,0.0007610099,0.00040322242,0.000485275],"domain_scores_gemma":[0.9972579,0.00010915861,0.0014986792,0.0006739383,0.00011239663,0.00034795495],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016001746,0.00074561714,0.0062432336,0.00023499932,0.000045557612,0.000003444625,0.00016876459,0.00009077136,0.0017030896],"category_scores_gemma":[0.000015188223,0.0004596861,0.0026526286,0.0015218586,0.000111002475,0.00010928664,0.000045099983,0.00015827555,0.000012997261],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018399357,0.0035098097,0.57568645,0.00092073984,0.206137,0.00005110854,0.003476573,0.0401513,0.0016121418,0.000025404133,0.000059601334,0.16652994],"study_design_scores_gemma":[0.023287954,0.0043512355,0.061735865,0.0011603336,0.8769237,0.000019107534,0.00076760806,0.0031558273,0.013248621,0.00010403957,0.0140893,0.0011564251],"about_ca_topic_score_codex":0.002328117,"about_ca_topic_score_gemma":0.0018471633,"teacher_disagreement_score":0.6707867,"about_ca_system_score_codex":0.0017069539,"about_ca_system_score_gemma":0.0002749288,"threshold_uncertainty_score":0.9997855},"labels":[],"label_agreement":null},{"id":"W3080596891","doi":"10.1200/jco.2009.27.15_suppl.1041","title":"Developing a prediction model for benefit from fulvestrant in heavily pretreated metastatic breast cancer (MBC) patients","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Fulvestrant; Medicine; Metastatic breast cancer; Chemotherapy; Internal medicine; Oncology; Tamoxifen; Percentile; Breast cancer; Cancer; Surgery","score_opus":0.14181232783530565,"score_gpt":0.47138593484849833,"score_spread":0.3295736070131927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080596891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9622804,0.00044924932,0.027121011,0.008887459,0.0005601488,0.00045164232,0.00020080798,0.000014886649,0.00003439509],"genre_scores_gemma":[0.9459931,0.00034927143,0.0502464,0.002830545,0.00048622786,0.000018028059,0.000021738402,0.00001865514,0.000035984176],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99698126,0.00009278107,0.0021404366,0.00022505638,0.00029053816,0.00026993267],"domain_scores_gemma":[0.9972381,0.00061247696,0.001173004,0.0001234561,0.00062524417,0.00022773299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007317484,0.00016412055,0.0012790083,0.00014401277,0.000029725232,0.0000060296943,0.000114884395,0.00020943559,0.00002415308],"category_scores_gemma":[0.00045658648,0.00012325152,0.0002688209,0.00015627853,0.00006845236,0.00022692756,0.0000114640525,0.0005407732,0.0000010265561],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022812702,0.0022894547,0.13936695,0.000035438996,0.0004936137,0.00006827121,0.0003900869,0.006708931,0.0003828643,0.000117873344,0.0000933041,0.8272405],"study_design_scores_gemma":[0.021397168,0.005401993,0.943196,0.00048910826,0.00040988522,0.000082440085,0.000056199267,0.017937474,0.00007856972,0.010092213,0.0007355926,0.00012335552],"about_ca_topic_score_codex":0.00005595122,"about_ca_topic_score_gemma":0.00012263874,"teacher_disagreement_score":0.82711715,"about_ca_system_score_codex":0.0006755176,"about_ca_system_score_gemma":0.0015567391,"threshold_uncertainty_score":0.50260514},"labels":[],"label_agreement":null},{"id":"W3080816877","doi":"10.1136/esmoopen-2020-000842","title":"Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis","year":2020,"lang":"en","type":"review","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Centre Intégré de Santé et de Services Sociaux des Laurentides; Hôpital Charles-Le Moyne","funders":"Seagen; Servier; G1 Therapeutics; Amgen; Pfizer; Genomic Health; Genentech; AstraZeneca; Eli Lilly and Company","keywords":"Meta-analysis; Breast cancer; Hormone receptor; Oncology; Medicine; Internal medicine; Cancer; HER2 negative; Hormone therapy; Endocrine system; Hormone; Metastatic breast cancer","score_opus":0.08004028103045263,"score_gpt":0.3948734691561016,"score_spread":0.314833188125649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080816877","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[6.003087e-7,0.97989976,0.000042381187,0.0020006832,0.00004563028,0.016607977,0.0011423236,0.000058596434,0.00020204388],"genre_scores_gemma":[0.0000230424,0.9816136,0.0021633664,0.00214371,0.00009817896,0.01232779,0.0006517644,0.00017325363,0.0008053048],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99441695,0.0013454071,0.0017578927,0.0013640758,0.00049226696,0.0006233921],"domain_scores_gemma":[0.99615574,0.0005835799,0.0015758731,0.0011316678,0.00021080027,0.0003423674],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.000558722,0.0012808921,0.01923513,0.0002778654,0.000120039535,0.00009009587,0.00072220026,0.00017898106,0.001264788],"category_scores_gemma":[0.000084441206,0.0008268571,0.002124327,0.0028599408,0.00013734306,0.00028248265,0.00025645416,0.000620795,0.00004976612],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053653866,0.0002815667,0.000023373676,0.3502613,0.39496216,0.00021525034,0.000115771,0.00003836142,2.9839578e-7,0.000019609437,0.00020635751,0.25333938],"study_design_scores_gemma":[0.0028995061,0.00032905003,0.00012621691,0.16166197,0.70894283,0.00012426988,0.000024577483,0.0000064449555,0.0000024011724,0.000019941506,0.12504053,0.00082223373],"about_ca_topic_score_codex":0.0015089113,"about_ca_topic_score_gemma":0.0002956774,"teacher_disagreement_score":0.3139807,"about_ca_system_score_codex":0.00084554916,"about_ca_system_score_gemma":0.00057788903,"threshold_uncertainty_score":0.9999943},"labels":[],"label_agreement":null},{"id":"W3081728205","doi":"10.1158/1557-3265.ovca19-b23","title":"Abstract B23: CDK4/6 and MEK inhibitor combination in low-grade serous ovarian cancer cell lines","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Western University; University of British Columbia","funders":"","keywords":"Palbociclib; Trametinib; CDKN2A; Cancer research; Cyclin-dependent kinase 6; MEK inhibitor; Ovarian cancer; Medicine; Cancer; Oncology; Cell cycle; Internal medicine; Biology; Cyclin-dependent kinase; Breast cancer; Kinase; MAPK/ERK pathway; Metastatic breast cancer; Genetics","score_opus":0.21134993783408693,"score_gpt":0.5066971788215023,"score_spread":0.2953472409874154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081728205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9529343,0.008666321,0.000027293387,0.036442168,0.0003489681,0.0009085091,0.00004740725,0.00007201865,0.0005529748],"genre_scores_gemma":[0.98999065,0.005346127,0.00025584293,0.002099905,0.0016336655,0.00027138783,0.00001571651,0.000062656494,0.00032406862],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9968819,0.00023085884,0.0007447647,0.0007389288,0.0007830695,0.0006204632],"domain_scores_gemma":[0.99787897,0.0007051983,0.00012551478,0.00030883378,0.00041478119,0.00056670146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011671941,0.00021600747,0.0005813172,0.000107613734,0.00010825242,0.000048679,0.00021938242,0.00024810486,0.00065735704],"category_scores_gemma":[0.00057333236,0.00019186785,0.000096188116,0.0006290027,0.0004826658,0.00023884473,0.00017423338,0.0014672057,0.00003826626],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013519173,0.0026761664,0.37414262,0.0036371355,0.00028914603,0.00059796206,0.004553046,0.00028914466,0.051701654,0.00033795126,0.006109953,0.542146],"study_design_scores_gemma":[0.022331052,0.0017717858,0.9042588,0.0015961174,0.000068230445,0.000011144119,0.0014509484,0.0017233294,0.021066103,0.0012440395,0.043831397,0.0006470926],"about_ca_topic_score_codex":0.002911651,"about_ca_topic_score_gemma":0.0017462737,"teacher_disagreement_score":0.54149896,"about_ca_system_score_codex":0.0003847703,"about_ca_system_score_gemma":0.0007098034,"threshold_uncertainty_score":0.7824144},"labels":[],"label_agreement":null},{"id":"W3082840399","doi":"10.1158/1538-7445.am2020-ct109","title":"Abstract CT109: A phase I/Ib study evaluating GDC-0077 plus fulvestrant in patients with <i>PIK3CA</i>-mutant, hormone receptor-positive/HER2-negative breast cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"","keywords":"Medicine; Fulvestrant; Adverse effect; Breast cancer; Pharmacokinetics; Pharmacodynamics; Internal medicine; Cancer; Cmax; Dysgeusia; Oncology; Pharmacology; Estrogen receptor; Gastroenterology","score_opus":0.08345085841686188,"score_gpt":0.4375639325702059,"score_spread":0.35411307415334403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082840399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894586,0.0011121215,0.000045438297,0.0033862973,0.00010216978,0.0046659783,0.0008544743,0.00010394217,0.00027095884],"genre_scores_gemma":[0.99702173,0.0002010174,0.00028760944,0.00047055242,0.0006073094,0.0011167148,0.000058403577,0.00015835173,0.00007828974],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99379194,0.0004247115,0.00068470737,0.0012582309,0.002535667,0.0013047323],"domain_scores_gemma":[0.99668014,0.00032539418,0.00023896387,0.00054754235,0.0014940439,0.0007139143],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00095221587,0.0005296465,0.00091041374,0.00031810888,0.00030163245,0.000087557775,0.00042634516,0.00013838398,0.0015884407],"category_scores_gemma":[0.00020851754,0.0004317038,0.00009596142,0.001999248,0.0005233398,0.00048116688,0.00017648685,0.001765272,0.00005748856],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19053428,0.008055026,0.24744466,0.0008114331,0.00207841,0.00078625133,0.058849305,0.0025554358,0.1705143,0.000018862815,0.0013057478,0.31704628],"study_design_scores_gemma":[0.073155984,0.010986438,0.89344275,0.0017135609,0.00016471284,0.000014198657,0.009677316,0.00038485913,0.009282675,0.000036861435,0.000299088,0.0008415508],"about_ca_topic_score_codex":0.0057702516,"about_ca_topic_score_gemma":0.0010000663,"teacher_disagreement_score":0.6459981,"about_ca_system_score_codex":0.0023285884,"about_ca_system_score_gemma":0.0020457383,"threshold_uncertainty_score":0.9998135},"labels":[],"label_agreement":null},{"id":"W3083626914","doi":"10.21873/anticanres.14486","title":"The Future of ER+/HER2− Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors","year":2020,"lang":"en","type":"review","venue":"Anticancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Essar Steel Algoma (Canada); Sault Area Hospital","funders":"","keywords":"Medicine; Breast cancer; Estrogen receptor; Cancer research; Metastatic breast cancer; Cancer; Oncology; PI3K/AKT/mTOR pathway; Targeted therapy; Internal medicine; Biology; Signal transduction","score_opus":0.10091865237952086,"score_gpt":0.4713960969521116,"score_spread":0.37047744457259074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083626914","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002203469,0.9871505,0.000008703567,0.008382258,0.0006876252,0.0026924855,0.000447391,0.000062080355,0.00054690195],"genre_scores_gemma":[0.0002007619,0.99373287,0.00015834568,0.00022221338,0.003321209,0.0010220656,0.00004195826,0.0002476109,0.0010529767],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938126,0.0007972266,0.0010734845,0.0009217507,0.002211575,0.00118335],"domain_scores_gemma":[0.9959037,0.0010111546,0.00047641114,0.0012638068,0.00093436753,0.00041057586],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0013339168,0.0006922792,0.0027732635,0.0003615784,0.00041226955,0.00008754111,0.00095214386,0.00026656073,0.00067517237],"category_scores_gemma":[0.00008868044,0.00039360314,0.0008008525,0.002513651,0.0014475702,0.00014165118,0.0003042307,0.0024425345,0.00010231003],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046968984,0.00011523341,0.000033320193,0.008520665,0.0015546856,0.0000772298,0.00023347534,3.448686e-7,0.00001634653,0.0006122308,0.0032408524,0.9851259],"study_design_scores_gemma":[0.0009363531,0.00030099237,0.0000765501,0.00875091,0.0005091036,0.00020196346,0.0004078002,0.000003856186,0.000048032733,0.00036780103,0.9880612,0.00033545546],"about_ca_topic_score_codex":0.0003908605,"about_ca_topic_score_gemma":0.000119155884,"teacher_disagreement_score":0.9848203,"about_ca_system_score_codex":0.000751164,"about_ca_system_score_gemma":0.004366972,"threshold_uncertainty_score":0.99985886},"labels":[],"label_agreement":null},{"id":"W3087827200","doi":"10.1016/j.annonc.2020.08.431","title":"329P Ribociclib (RIB) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) and resistance to prior endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Fulvestrant; Breast cancer; Hazard ratio; Goserelin; Placebo; Progression-free survival; Cancer; Surgery; Gastroenterology; Oncology; Tamoxifen; Chemotherapy; Confidence interval; Pathology","score_opus":0.07957722803001016,"score_gpt":0.40408118477772087,"score_spread":0.3245039567477107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087827200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9128686,0.004192913,0.000017697665,0.08110811,0.000033197557,0.001270405,0.0001004743,0.000015595808,0.0003930097],"genre_scores_gemma":[0.97684914,0.0032026507,0.0012097078,0.018331828,0.00008196643,0.00023676346,0.00000920836,0.000030056191,0.00004869521],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980434,0.0003657903,0.00056692486,0.00042650432,0.00024330482,0.000354083],"domain_scores_gemma":[0.9986581,0.00048827802,0.0002847112,0.00022264976,0.00019484777,0.00015140398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060142967,0.0002323368,0.0009572156,0.00011359735,0.00003608177,0.000009024226,0.00014675548,0.00007368742,0.00004511238],"category_scores_gemma":[0.0002301916,0.00015148582,0.0000466701,0.0004096763,0.00019661627,0.00015518018,0.00004985796,0.00026094483,0.0000010409839],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05709458,0.00089022296,0.27406648,0.00017993037,0.00020535724,0.000096844065,0.008449176,0.00007913356,0.003442782,0.0007045834,0.00048619215,0.65430474],"study_design_scores_gemma":[0.018901218,0.004266716,0.9018667,0.0002828139,0.000027865719,0.000028106577,0.0007383241,0.000005209932,0.0012822397,0.0005498043,0.07184275,0.00020826614],"about_ca_topic_score_codex":0.00018282187,"about_ca_topic_score_gemma":0.0014542734,"teacher_disagreement_score":0.6540965,"about_ca_system_score_codex":0.000069413414,"about_ca_system_score_gemma":0.00021056767,"threshold_uncertainty_score":0.6177412},"labels":[],"label_agreement":null},{"id":"W3087842901","doi":"10.1016/j.annonc.2020.08.438","title":"336P PI3K pathway biomarkers and clinical response in a phase I/Ib study of GDC-0077 in hormone receptor-positive/HER2-negative breast cancer (HR+/HER2– BC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"EMD Serono; Genentech; PharmaMar; Springworks Therapeutics; MacroGenics; Silverback Therapeutics; Cilag; Puma Biotechnology; Relay Therapeutics; Eisai; Celltrion; Syndax Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Servier; Calithera Biosciences; Unum Therapeutics; Amgen; Radius Health; Clovis Oncology; Les Laboratories Pierre Fabre; Genomic Health; Ipsen; Array BioPharma; Mersana Therapeutics; Karyopharm Therapeutics; NuCana; Pfizer; Incyte; Taiho Pharmaceutical; F. Hoffmann-La Roche; GlaxoSmithKline; Jounce Therapeutics; PTC Therapeutics; Celgene; Cancer Research Institute; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Sanofi","keywords":"Medicine; Palbociclib; Breast cancer; Internal medicine; Fulvestrant; Oncology; Cancer; Estrogen receptor; Metastatic breast cancer","score_opus":0.09332269885895235,"score_gpt":0.45202263202816667,"score_spread":0.35869993316921434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087842901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772983,0.0009935991,0.00001763991,0.020128896,0.00008922098,0.0010801798,0.00020803287,0.000020329147,0.0001637889],"genre_scores_gemma":[0.99663275,0.0009194398,0.0004030719,0.0017719377,0.00011370259,0.000092613554,0.0000080267855,0.00003572552,0.000022732936],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9964531,0.0012065663,0.0011234146,0.0005666968,0.0002632582,0.0003869679],"domain_scores_gemma":[0.99740934,0.001242065,0.0005147361,0.0002559614,0.0003198248,0.00025805202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001322533,0.0002630646,0.0013000605,0.00026501936,0.000027844313,0.0000035966546,0.00015656419,0.00023830548,0.00014370497],"category_scores_gemma":[0.0006705572,0.00024315233,0.00010726026,0.00070746784,0.00063117105,0.00013992302,0.00011755599,0.0004559295,0.000004306693],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36893982,0.012082076,0.15454006,0.00011139712,0.0011382772,0.0006280114,0.023010647,0.000025617604,0.04769891,0.000018207917,0.00077882165,0.39102814],"study_design_scores_gemma":[0.037785083,0.04352536,0.900819,0.0002776927,0.00008290809,0.00004345651,0.0101261595,0.00008172549,0.004797082,0.000076469325,0.0021220443,0.0002630072],"about_ca_topic_score_codex":0.0026114066,"about_ca_topic_score_gemma":0.0012794463,"teacher_disagreement_score":0.74627894,"about_ca_system_score_codex":0.00014892309,"about_ca_system_score_gemma":0.0006205011,"threshold_uncertainty_score":0.99154645},"labels":[],"label_agreement":null},{"id":"W3087968179","doi":"10.1002/jmrs.435","title":"Safety of palbociclib concurrent with palliative pelvic radiotherapy: discussion of a case of increased toxicity and brief review of literature","year":2020,"lang":"en","type":"review","venue":"Journal of Medical Radiation Sciences","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Palbociclib; Medicine; Radiation therapy; Toxicity; Oncology; Palliative care; Internal medicine; Cancer; Surgery; Metastatic breast cancer; Breast cancer","score_opus":0.032529664355575034,"score_gpt":0.40483334609819377,"score_spread":0.37230368174261874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087968179","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005125052,0.9954142,0.0011399711,0.0021555964,0.00010514096,0.00052565173,0.00013069896,0.0000025067939,0.000013740978],"genre_scores_gemma":[0.0037359823,0.9946904,0.0011685379,0.00020590657,0.00016978664,0.000003852936,0.000010304929,0.000012193498,0.0000030203744],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9951545,0.00048961764,0.0020020735,0.00023502328,0.0019799366,0.00013887289],"domain_scores_gemma":[0.993134,0.0008675997,0.0049548806,0.00015831721,0.0005356802,0.00034951273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025028226,0.0002527484,0.0030196633,0.00026254047,0.00003476833,0.0000068029253,0.00029623814,0.0001775666,0.00013897163],"category_scores_gemma":[0.0021821815,0.000115466995,0.0003734762,0.0012307157,0.0010847029,0.00017696327,0.000036269557,0.00052129955,5.5264373e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021141334,0.00015258242,0.00017748933,0.06097539,0.00031955345,0.00012878422,0.00096337294,7.8138794e-7,0.000015082575,0.000120613615,0.00006310732,0.9368718],"study_design_scores_gemma":[0.0051817833,0.003580246,0.00047644242,0.68978035,0.0018556021,0.0040534902,0.00047237286,0.000120740464,0.00012286774,0.000052323685,0.29406068,0.00024311888],"about_ca_topic_score_codex":0.000014571969,"about_ca_topic_score_gemma":0.0000031873828,"teacher_disagreement_score":0.9366287,"about_ca_system_score_codex":0.00010007352,"about_ca_system_score_gemma":0.002443706,"threshold_uncertainty_score":0.47086072},"labels":[],"label_agreement":null},{"id":"W3088162954","doi":"10.1016/j.annonc.2020.08.675","title":"561P Phase Ib study of ribociclib (R) + trametinib (T) in patients (pts) with metastatic/advanced solid tumours","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Internal medicine; Neutropenia; Oncology; Regimen; Phases of clinical research; Response Evaluation Criteria in Solid Tumors; Pharmacokinetics; Trametinib; Adverse effect; Gastroenterology; Urology; Chemotherapy; Kinase; MAPK/ERK pathway","score_opus":0.09530483402239531,"score_gpt":0.4358727483727366,"score_spread":0.3405679143503413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088162954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99548733,0.0001704823,0.00013382306,0.002620934,0.00004798458,0.0010550254,0.000036341207,0.000024517838,0.00042355558],"genre_scores_gemma":[0.99568284,0.000028196866,0.0024413075,0.0016899954,0.00003250965,0.00005793407,0.000018463257,0.000033832403,0.000014926802],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9981929,0.00016324656,0.00066197105,0.00033490598,0.00032600178,0.00032098364],"domain_scores_gemma":[0.9985592,0.00017567167,0.00047640677,0.0002483975,0.0003700705,0.00017028594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020674261,0.0002010713,0.0010650923,0.00014024334,0.000018509356,0.0000018457512,0.00015058422,0.000052812527,0.000087023625],"category_scores_gemma":[0.00022465445,0.0001644873,0.00007190748,0.00044012975,0.00019067347,0.00012038856,0.000041926265,0.0002276693,0.000004449949],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0737381,0.047153212,0.14385784,0.00044622654,0.0013640033,0.00041412713,0.033991367,0.0019889388,0.011195999,0.000112992166,0.00035899977,0.6853782],"study_design_scores_gemma":[0.25204152,0.3814205,0.25295347,0.00038996604,0.000724193,0.000039273316,0.029151423,0.00028561422,0.06813748,0.000492679,0.013560936,0.00080296857],"about_ca_topic_score_codex":0.000038933707,"about_ca_topic_score_gemma":0.000057650075,"teacher_disagreement_score":0.68457526,"about_ca_system_score_codex":0.000043722455,"about_ca_system_score_gemma":0.00020506937,"threshold_uncertainty_score":0.67075974},"labels":[],"label_agreement":null},{"id":"W3088465742","doi":"10.1016/j.annonc.2020.08.427","title":"325P Characteristics of patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer who achieved durable response in the phase III BROCADE3 study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Hazard ratio; Metastatic breast cancer; Population; Clinical endpoint; Gastroenterology; Veliparib; Cancer; Surgery; Randomized controlled trial; Confidence interval","score_opus":0.047831265155041415,"score_gpt":0.3822295165894681,"score_spread":0.33439825143442664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088465742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870751,0.000109872475,0.000046678026,0.010650349,0.000045036835,0.0014163238,0.0005714308,0.00001969015,0.00006553851],"genre_scores_gemma":[0.9959475,0.00008431148,0.00015562354,0.003513224,0.000034201275,0.00014329312,0.000034717737,0.00003527912,0.000051869156],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99746287,0.0007143056,0.00070307375,0.00032951203,0.0004250012,0.0003652548],"domain_scores_gemma":[0.997421,0.00067830464,0.0008128719,0.00027578222,0.0006896809,0.00012233127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005308831,0.0002499608,0.0010943239,0.000107977095,0.000053410964,0.000004671381,0.00023234289,0.00007548261,0.00010244288],"category_scores_gemma":[0.0005380123,0.00017225079,0.00007461671,0.0006759384,0.0002774684,0.00015650546,0.00004877125,0.00036202712,0.000002256476],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.454445,0.021151002,0.32092413,0.000284689,0.0019151936,0.00031074413,0.057541434,0.00025512377,0.005353295,0.000021928303,0.0004952287,0.13730222],"study_design_scores_gemma":[0.032124333,0.02290479,0.93600804,0.00022484736,0.00019416814,0.0000088341685,0.006285975,0.00004399588,0.00095918414,0.000046404002,0.0010203064,0.00017913345],"about_ca_topic_score_codex":0.00018938837,"about_ca_topic_score_gemma":0.00015302033,"teacher_disagreement_score":0.6150839,"about_ca_system_score_codex":0.00011496044,"about_ca_system_score_gemma":0.00043791888,"threshold_uncertainty_score":0.7024183},"labels":[],"label_agreement":null},{"id":"W3088595788","doi":"10.1016/j.annonc.2020.08.2246","title":"LBA18 Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Novartis Pharmaceuticals Canada","keywords":"Medicine; Internal medicine; Hazard ratio; Fulvestrant; Population; Aromatase inhibitor; Progression-free survival; Oncology; Breast cancer; Cancer; Chemotherapy; Aromatase; Confidence interval; Estrogen receptor","score_opus":0.07991196063309068,"score_gpt":0.3941266836991093,"score_spread":0.3142147230660186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088595788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9667387,0.0006272403,0.0005816248,0.015122763,0.00040726672,0.0029960393,0.0130619425,0.000099925295,0.0003645149],"genre_scores_gemma":[0.99323744,0.00050444243,0.0023517373,0.00196105,0.00086468965,0.00031161896,0.0005598092,0.00011579493,0.00009344345],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99521947,0.00046341182,0.0017263286,0.0011503765,0.0006241991,0.00081620266],"domain_scores_gemma":[0.9945413,0.001205764,0.0015307969,0.00051498745,0.0016799679,0.000527199],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040236735,0.0006492005,0.0023465354,0.00017299523,0.0001817939,0.000012748854,0.0004265599,0.0003403772,0.00047001278],"category_scores_gemma":[0.0005410875,0.00060410664,0.00039581023,0.0003969899,0.0004972441,0.00048656116,0.000148782,0.0005737379,0.000009442498],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24159445,0.008808338,0.0013303419,0.00020923077,0.004297984,0.00008973445,0.038624596,0.00012474469,0.5369629,0.00017438325,0.0052002165,0.16258307],"study_design_scores_gemma":[0.30276656,0.115603775,0.17382343,0.0007077349,0.0012645876,0.000041788153,0.024293598,0.00019526106,0.3626474,0.001175359,0.01537804,0.0021024542],"about_ca_topic_score_codex":0.0038546566,"about_ca_topic_score_gemma":0.0007044554,"teacher_disagreement_score":0.17431551,"about_ca_system_score_codex":0.00025135197,"about_ca_system_score_gemma":0.00054511917,"threshold_uncertainty_score":0.999641},"labels":[],"label_agreement":null},{"id":"W3088603564","doi":"10.1016/j.annonc.2020.08.429","title":"327P Treatment sequencing in HR+/HER2- locally advanced or metastatic breast cancer: A real-world retrospective study in France, Germany, Italy and Spain","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Pfizer Pharmaceuticals; Novartis Pharmaceuticals Canada; Celldex Therapeutics; Astellas Pharma; Eisai; Chugai Pharmaceutical; Celltrion; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Celltrion Healthcare; Daiichi-Sankyo; Pfizer; Genomic Health","keywords":"Medicine; Fulvestrant; Internal medicine; Breast cancer; Metastatic breast cancer; Oncology; Cancer; Clinical trial; First line treatment; Chemotherapy; Tamoxifen","score_opus":0.07734766725541938,"score_gpt":0.4071170968901116,"score_spread":0.32976942963469225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088603564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877275,0.0011953005,0.000048964008,0.008377798,0.00006048172,0.0015853612,0.000072958996,0.000042497206,0.0008891423],"genre_scores_gemma":[0.9947152,0.0014924455,0.0010637408,0.0020293542,0.00008860339,0.00032532602,0.000004138666,0.000041542513,0.00023961104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978508,0.00022405652,0.0006600978,0.0005778144,0.00023264925,0.00045461766],"domain_scores_gemma":[0.9989184,0.00017970995,0.0002916756,0.00024229064,0.00017461828,0.0001932847],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031401348,0.00030454973,0.0012990456,0.00028867106,0.000031446812,0.0000058128867,0.000109707355,0.00006949596,0.00013036357],"category_scores_gemma":[0.000066293585,0.00024638977,0.000071013426,0.000887784,0.00019483497,0.00017515723,0.000057785343,0.00027306555,0.000003620639],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014996217,0.0019506791,0.61522603,0.00031454308,0.00095230294,0.0034147108,0.02248003,0.0022301872,0.0076641375,0.00016131064,0.000035043817,0.33057484],"study_design_scores_gemma":[0.016754417,0.015782997,0.95693374,0.00039658856,0.00015264473,0.0001220224,0.0056774747,0.00070034375,0.00069342484,0.00030984127,0.002147424,0.00032907198],"about_ca_topic_score_codex":0.0052858917,"about_ca_topic_score_gemma":0.02512548,"teacher_disagreement_score":0.34170774,"about_ca_system_score_codex":0.0013116733,"about_ca_system_score_gemma":0.00108985,"threshold_uncertainty_score":0.9999988},"labels":[],"label_agreement":null},{"id":"W3088741547","doi":"10.1016/j.annonc.2020.08.2240","title":"LBA12 PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Samsung; Genentech; Servier; Astellas Pharma; Oncolytics Biotech; Eisai; Genomic Health; Teva Pharmaceutical Industries; Daiichi-Sankyo; PharmaMar; Celgene; G1 Therapeutics; Breast Cancer Research Foundation; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Hazard ratio; Breast cancer; Palbociclib; Internal medicine; Oncology; Adjuvant; Cancer; Interim analysis; Randomized controlled trial; Confidence interval; Metastatic breast cancer","score_opus":0.11069745047158958,"score_gpt":0.42758771260660927,"score_spread":0.3168902621350197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088741547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.940514,0.008926664,0.0009111699,0.04231039,0.0005200837,0.0058103655,0.00042310738,0.00010318224,0.00048103655],"genre_scores_gemma":[0.9781279,0.013758806,0.0014632781,0.003846942,0.001146983,0.0013606097,0.00006351192,0.00010335656,0.00012863432],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99694186,0.00028451532,0.0010882196,0.00056657114,0.00045815753,0.00066067016],"domain_scores_gemma":[0.99634063,0.0011147015,0.0009403337,0.00043473244,0.0008567125,0.00031288245],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042293876,0.0004649723,0.0030278203,0.00014751815,0.00006010896,0.000007888743,0.00027902646,0.00013212537,0.0006368259],"category_scores_gemma":[0.00016021538,0.00032518207,0.0005641842,0.00036568014,0.0006677156,0.00015184692,0.000042334425,0.0002820532,0.0000029494004],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74252677,0.001576935,0.000089647045,0.00007058984,0.0022144162,0.000056392488,0.0013032174,0.000021794103,0.014402935,0.00012589469,0.00039259184,0.23721884],"study_design_scores_gemma":[0.8674712,0.041179955,0.00020133833,0.00009674789,0.00025247378,0.000059573293,0.00023733081,0.00006507799,0.037485905,0.00014790751,0.052532334,0.0002701243],"about_ca_topic_score_codex":0.00061666017,"about_ca_topic_score_gemma":0.00008096313,"teacher_disagreement_score":0.23694871,"about_ca_system_score_codex":0.00006221413,"about_ca_system_score_gemma":0.000721764,"threshold_uncertainty_score":0.99992},"labels":[],"label_agreement":null},{"id":"W3088751416","doi":"10.1016/j.annonc.2020.08.411","title":"309P Real-world effectiveness of alpelisib (ALP) + fulvestrant (FUL) compared with standard treatment among patients (Pts) with hormone-receptor positive (HR+) human epidermal growth factor receptor-2 negative (HER2–) PIK3CA-mutated (Mut) advanced breast cancer (ABC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Internal medicine; Oncology; Cohort; Clinical endpoint; Fulvestrant; Progression-free survival; Metastatic breast cancer; Clinical trial; Cancer; Chemotherapy; Breast cancer; Estrogen receptor","score_opus":0.0303983865183438,"score_gpt":0.33920947785819866,"score_spread":0.30881109133985485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088751416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908143,0.00023378192,0.0002532295,0.0018711659,0.000101542486,0.002613426,0.0032327154,0.00011481841,0.00076501054],"genre_scores_gemma":[0.996872,0.00034453452,0.0012722395,0.00037709335,0.00012345947,0.00035260923,0.00048784225,0.000130586,0.000039622686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99607575,0.00063196593,0.0009123599,0.0009245471,0.0006789501,0.0007764519],"domain_scores_gemma":[0.9952048,0.00057578605,0.0011604213,0.00038260964,0.0021285054,0.0005478775],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001777766,0.0007688717,0.0023798195,0.00024030622,0.00016247013,0.000012677643,0.00024703474,0.00019516496,0.00027283563],"category_scores_gemma":[0.000052164934,0.00056436355,0.00023606278,0.0008188329,0.001156416,0.00048056175,0.000063939544,0.00039049573,0.0000051120983],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33047765,0.005813529,0.4314488,0.0010989376,0.008419983,0.0002661627,0.018662,0.002059139,0.09130357,0.00024137142,0.00043393893,0.10977493],"study_design_scores_gemma":[0.02985131,0.04018491,0.75838304,0.0008821545,0.00037571642,0.000017439792,0.0010807234,0.000021607411,0.16823693,0.000032869753,0.00037376964,0.0005595456],"about_ca_topic_score_codex":0.004458347,"about_ca_topic_score_gemma":0.0017302965,"teacher_disagreement_score":0.32693425,"about_ca_system_score_codex":0.0011430572,"about_ca_system_score_gemma":0.0007821899,"threshold_uncertainty_score":0.99968076},"labels":[],"label_agreement":null},{"id":"W3088817799","doi":"10.1016/j.annonc.2020.08.419","title":"317P Updated results from the Canadian sub-population of the phase IIIb CompLEEment-1 ribociclib + letrozole HR+ HER2- advanced breast cancer trial","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation; Novartis (Canada); Ottawa Hospital; BC Cancer Agency; Sunnybrook Health Science Centre; McGill University; Jewish General Hospital; University of Alberta; Grand River Hospital","funders":"Medac; Eisai; Amgen; Pfizer; Genomic Health; Genentech; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Medicine; Neutropenia; Internal medicine; Breast cancer; Letrozole; Population; Febrile neutropenia; Interim analysis; Chemotherapy regimen; Progression-free survival; Cancer; Surgery; Chemotherapy; Clinical trial; Tamoxifen","score_opus":0.10344704891642564,"score_gpt":0.4071122338212833,"score_spread":0.30366518490485767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088817799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8515085,0.00044254342,0.000017044458,0.14347875,0.00043266226,0.00093234313,0.0026437263,0.000023684053,0.00052074157],"genre_scores_gemma":[0.9879077,0.00009117167,0.000114994364,0.010827577,0.00055173185,0.000041026684,0.00040648598,0.000025422543,0.000033870234],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99813783,0.00022349403,0.00067502557,0.00030672783,0.00031198494,0.00034494782],"domain_scores_gemma":[0.99820846,0.00019523253,0.0005977893,0.00042555103,0.0003596087,0.00021337955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024820855,0.0001821431,0.0005712238,0.000047280744,0.00014614622,0.0000069486455,0.00030487287,0.00013452751,0.00029669522],"category_scores_gemma":[0.00019651404,0.000120150515,0.00015835486,0.0003792869,0.00028064454,0.00009676727,0.000060204802,0.00028059483,0.000005785925],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3097376,0.0011701873,0.013223731,0.00006457117,0.0012979247,0.000039326686,0.0050010527,0.0016225177,0.04874802,0.0005084392,0.026134767,0.5924519],"study_design_scores_gemma":[0.24192359,0.005468337,0.2315746,0.0002834929,0.00042701222,0.000026939797,0.0010890223,0.0007858807,0.031248014,0.00078842195,0.48592708,0.00045763957],"about_ca_topic_score_codex":0.13843568,"about_ca_topic_score_gemma":0.1747598,"teacher_disagreement_score":0.5919942,"about_ca_system_score_codex":0.00019624367,"about_ca_system_score_gemma":0.0008138465,"threshold_uncertainty_score":0.8673015},"labels":[],"label_agreement":null},{"id":"W3089021817","doi":"10.1016/j.annonc.2020.08.428","title":"326P Exploratory analysis of TreatER+ight: A Canadian prospective real-world observational study in HR+ advanced breast cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada); McGill University Health Centre; Ottawa Regional Cancer Foundation; BC Cancer Agency; Ottawa Hospital; University of Saskatchewan; London Health Sciences Centre; Grand River Hospital; Windsor Regional Hospital; McGill University; Jewish General Hospital","funders":"Pfizer Pharmaceuticals; Novartis Pharmaceuticals Canada; Genentech; Eisai; Invitae; Puma Biotechnology; Incyte; BeiGene; Astellas Pharma; Celldex Therapeutics; Mylan; Aptitude Health; Sirtex Medical; Genomic Health; Amgen; Pfizer; PharmaMar; Celgene; AstraZeneca; Eli Lilly and Company; Daiichi Sankyo Europe; U.S. Department of Defense","keywords":"Medicine; Observational study; Breast cancer; Real world evidence; Adverse effect; Oncology; Cancer; Exploratory research; Health care; Endocrine system; Internal medicine; Intensive care medicine","score_opus":0.19009863461993937,"score_gpt":0.4356159237488292,"score_spread":0.24551728912888982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089021817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98061556,0.00033732978,0.0000075653825,0.016548268,0.000054955042,0.00071750226,0.00033386605,0.00002095482,0.0013640109],"genre_scores_gemma":[0.9967513,0.00013383597,0.00021585291,0.002389946,0.00008836927,0.00023884217,0.000038467988,0.000023008932,0.00012038648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835736,0.00010974609,0.0005749539,0.00038893212,0.00024505574,0.00032396248],"domain_scores_gemma":[0.9985169,0.00007889921,0.00030729553,0.00024314522,0.000582377,0.00027136042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017924384,0.0001867375,0.001055342,0.00072152144,0.000030182126,0.0000023229293,0.00013947971,0.00007680193,0.00043222748],"category_scores_gemma":[0.000050692848,0.00017395751,0.00014252115,0.0023510975,0.00014374773,0.00016506824,0.000031789914,0.00017725342,0.0000028453985],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025089863,0.00057969417,0.9646018,0.00003760582,0.0017331162,0.000094266,0.007482557,0.0013962009,0.0011640628,0.00022765766,0.00014360911,0.02003042],"study_design_scores_gemma":[0.0027195439,0.0015065512,0.98934186,0.000043208172,0.00042206378,0.0000024344943,0.0022755489,0.0001497008,0.000889163,0.00008838116,0.002429421,0.00013213773],"about_ca_topic_score_codex":0.06470717,"about_ca_topic_score_gemma":0.63466024,"teacher_disagreement_score":0.5699531,"about_ca_system_score_codex":0.0004289946,"about_ca_system_score_gemma":0.0014466838,"threshold_uncertainty_score":0.94152105},"labels":[],"label_agreement":null},{"id":"W3091625009","doi":"10.1158/1078-0432.ccr-20-1068","title":"Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2− Advanced Breast Cancer","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Cancer Institute; Novartis","keywords":"Exemestane; Everolimus; Postmenopausal women; Clinical trial; Breast cancer; Phases of clinical research; Cancer","score_opus":0.10019270655209407,"score_gpt":0.48215270754783834,"score_spread":0.3819600009957443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091625009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98742867,0.0008096924,0.000050449118,0.009401512,0.0000712596,0.0020597863,0.000071542505,0.000034282926,0.000072788454],"genre_scores_gemma":[0.99681383,0.0011851933,0.00037509802,0.00049037184,0.0002376695,0.0007513501,0.000019603413,0.000060301383,0.00006654986],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963327,0.00040957972,0.0008477235,0.00073095376,0.001037917,0.00064111006],"domain_scores_gemma":[0.997913,0.0005532812,0.00022232092,0.00032100343,0.00055393885,0.00043648147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012664602,0.00024153288,0.0008582244,0.00024027692,0.000061821265,0.000019098432,0.00016642043,0.00016263471,0.00020449077],"category_scores_gemma":[0.00023657177,0.00018315786,0.000032470176,0.0013625787,0.0006971323,0.00031960823,0.00009174522,0.0010477935,0.0000024121537],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6187199,0.0025508236,0.055227485,0.00028256525,0.00009390579,0.000121661025,0.0015938865,0.00021364768,0.0042313933,0.0000421169,0.000018470682,0.31690416],"study_design_scores_gemma":[0.47767553,0.04208178,0.47381127,0.0013540116,0.000048688365,0.000028468094,0.0017116189,0.00095072674,0.0007245824,0.00032018268,0.0009080495,0.00038507834],"about_ca_topic_score_codex":0.0008234541,"about_ca_topic_score_gemma":0.00087765796,"teacher_disagreement_score":0.41858378,"about_ca_system_score_codex":0.0006232455,"about_ca_system_score_gemma":0.0011368308,"threshold_uncertainty_score":0.746896},"labels":[],"label_agreement":null},{"id":"W3092366929","doi":"10.1016/s0959-8049(20)30860-1","title":"Development of a multiplexed protein panel using a targeted proteomics approach for the study of CDK4/6 inhibitors resistance in hormone receptor positive breast cancer","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Breast cancer; Proteomics; Hormone receptor; Receptor; Cancer; Hormone; Oncology; Medicine; Computational biology; Cancer research; Bioinformatics; Internal medicine; Biology; Genetics; Gene","score_opus":0.05152386587998115,"score_gpt":0.2897392281280002,"score_spread":0.23821536224801904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092366929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98293334,0.0052402797,0.007863922,0.00097477005,0.0000774934,0.0027886522,0.000092141825,0.000008913664,0.000020457464],"genre_scores_gemma":[0.8942753,0.00004603902,0.10502948,0.000093695635,0.00035934412,0.000098065306,0.0000019862498,0.00006747106,0.000028634066],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99767864,0.00022183733,0.0011083821,0.00024055758,0.00050388003,0.00024668826],"domain_scores_gemma":[0.99764156,0.00004234328,0.0012730163,0.00016089635,0.00075644214,0.00012572003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000683069,0.00022876977,0.000618416,0.000115005685,0.00007329471,0.000009447386,0.00024594172,0.000027473705,0.000014236518],"category_scores_gemma":[0.000098487275,0.00015912527,0.00011382687,0.00046387938,0.000114973016,0.00012986285,0.00005938996,0.0003453949,1.7941065e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020819642,0.00056779216,0.0023754134,0.00030171455,0.0006638172,0.00001975642,0.035510466,0.0033812234,0.9166456,0.0000025548864,0.000040505707,0.019671522],"study_design_scores_gemma":[0.060907327,0.0037691456,0.35633245,0.006555001,0.0009299726,0.00007804191,0.045266014,0.0030958643,0.5174201,0.000010126773,0.004494292,0.0011416163],"about_ca_topic_score_codex":0.0000594125,"about_ca_topic_score_gemma":0.000046763675,"teacher_disagreement_score":0.39922547,"about_ca_system_score_codex":0.00035449574,"about_ca_system_score_gemma":0.0006143688,"threshold_uncertainty_score":0.648894},"labels":[],"label_agreement":null},{"id":"W3093031070","doi":"10.1007/s10549-020-05960-4","title":"A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer","year":2020,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada); University of Toronto; Sunnybrook Health Science Centre; Mount Sinai Hospital","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Breast cancer; Lumpectomy; Population; Cancer; Cohort; Internal medicine; Stage (stratigraphy); Cancer registry; Health care; Oncology; Gynecology; Mastectomy; Environmental health","score_opus":0.05523799174352821,"score_gpt":0.3646883773413735,"score_spread":0.30945038559784527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093031070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97030056,0.003371958,0.00016404425,0.004537173,0.000022595344,0.0031428442,0.018402893,0.000038299528,0.000019649362],"genre_scores_gemma":[0.9945652,0.0010658118,0.00023241877,0.00017356046,0.000113774026,0.0022750949,0.0011285843,0.00007488145,0.00037070806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976145,0.00011208339,0.00037417252,0.00075472385,0.00058101787,0.0005634792],"domain_scores_gemma":[0.9980905,0.00018593999,0.00022850244,0.0002378949,0.00072336267,0.0005338113],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00006829327,0.00043105843,0.0007491619,0.00012108755,0.00028862292,0.00004626133,0.00007696471,0.00009368711,0.0002961806],"category_scores_gemma":[0.000008156402,0.00030940564,0.000067635505,0.0003105329,0.00025048124,0.00014709895,0.00003408635,0.00015652087,7.480776e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02116931,0.0009788965,0.79873073,0.00011738545,0.0007367827,0.0000025726708,0.0021039033,0.00010965962,0.00019145284,0.0000099429835,0.00019753736,0.17565185],"study_design_scores_gemma":[0.019675862,0.0060832966,0.96507,0.00061965873,0.00023177337,0.000003474991,0.0006864874,0.00029127678,0.0029241194,0.000004030538,0.004116623,0.00029338934],"about_ca_topic_score_codex":0.3321175,"about_ca_topic_score_gemma":0.101124205,"teacher_disagreement_score":0.23099329,"about_ca_system_score_codex":0.004668796,"about_ca_system_score_gemma":0.0009085428,"threshold_uncertainty_score":0.9999358},"labels":[],"label_agreement":null},{"id":"W3093770202","doi":"10.1016/j.breast.2020.10.005","title":"Eligibility of real-world patients with metastatic breast cancer for clinical trials","year":2020,"lang":"en","type":"article","venue":"The Breast","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Metastatic breast cancer; Medicine; Oncology; Breast cancer; Clinical trial; Internal medicine; Cancer","score_opus":0.1608991240040951,"score_gpt":0.4737175903520319,"score_spread":0.31281846634793686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093770202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95235246,0.0005228962,0.0032722685,0.033426717,0.00031024136,0.004820675,0.004702808,0.00015947525,0.0004324372],"genre_scores_gemma":[0.995958,0.00006604001,0.0015011713,0.001587766,0.0005184594,0.00016345862,0.00004840152,0.00005102179,0.000105698986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763566,0.00035950224,0.00096350285,0.00038583737,0.00037482646,0.00028068846],"domain_scores_gemma":[0.9972525,0.0009839858,0.00058477494,0.00049019494,0.00045677138,0.00023175516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014998545,0.0002249035,0.0011411437,0.000037577316,0.000063291336,0.000009155899,0.00020167851,0.000037649374,0.00025939223],"category_scores_gemma":[0.00030366605,0.000119573655,0.00028836486,0.0003322924,0.00033523043,0.00008985563,0.000046595087,0.00019922423,0.0000075751113],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049559716,0.0009113979,0.6518237,0.0005597077,0.0016182458,0.0000032417718,0.0006738239,0.00006354742,0.0003401686,0.00046195628,0.001513782,0.29247072],"study_design_scores_gemma":[0.01177122,0.00054105074,0.9829289,0.0002197769,0.0010613695,0.00002854624,0.00014019683,0.00013681673,0.00025654255,0.00039194667,0.0023360394,0.0001876001],"about_ca_topic_score_codex":0.00028435566,"about_ca_topic_score_gemma":0.00010324022,"teacher_disagreement_score":0.3311052,"about_ca_system_score_codex":0.00007507264,"about_ca_system_score_gemma":0.00027398468,"threshold_uncertainty_score":0.4876072},"labels":[],"label_agreement":null},{"id":"W3095255326","doi":"","title":"PIK3CA exon 9 and 20 mutations analysis in breast cancers using PCR-HRM and PCR-ARMS: relations with clinicopathologic criteria","year":2012,"lang":"fr","type":"preprint","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre d'expertise et de recherche en infrastructures urbaines","funders":"","keywords":"Exon; Breast cancer; Polymerase chain reaction; Gene; Oncology; Medicine; Cancer research; Cancer; Internal medicine; Biology; Genetics","score_opus":0.02774301384608624,"score_gpt":0.29463965044535406,"score_spread":0.2668966365992678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095255326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83723605,0.020636389,0.12270639,0.013825181,0.00032210627,0.0010244446,0.00043761657,0.00013705528,0.0036747553],"genre_scores_gemma":[0.9044176,0.0020656541,0.09070852,0.0001182814,0.0000751364,0.00011364883,0.0006335124,0.00006854546,0.001799134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993008,0.0038837139,0.0009213816,0.0011079498,0.0003978008,0.0006811119],"domain_scores_gemma":[0.99422973,0.0015964537,0.0008309897,0.0015244299,0.0013872474,0.0004311711],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0040522297,0.0005559985,0.00096162374,0.0006685952,0.00046360315,0.00021551206,0.00037593307,0.00039755693,0.0003883728],"category_scores_gemma":[0.000512312,0.00056033785,0.00017052643,0.001506278,0.0012490914,0.00045329897,0.0005323629,0.00097174844,0.000012411608],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031371406,0.0009338772,0.8518915,0.0005761854,0.0011738158,0.000047049176,0.048730608,0.004132813,0.004821336,0.009215976,0.000021980975,0.07814113],"study_design_scores_gemma":[0.0033059267,0.0000038651033,0.9077377,0.0070736418,0.003130554,0.0004931372,0.0040622167,0.068058856,0.0009794291,0.0020089517,0.0020805662,0.0010652095],"about_ca_topic_score_codex":0.006227946,"about_ca_topic_score_gemma":0.012110262,"teacher_disagreement_score":0.07707592,"about_ca_system_score_codex":0.0008453025,"about_ca_system_score_gemma":0.00064010726,"threshold_uncertainty_score":0.9996848},"labels":[],"label_agreement":null},{"id":"W3095962378","doi":"10.1007/s11523-020-00770-6","title":"Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis","year":2020,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Western University","funders":"","keywords":"Medicine; Everolimus; Exemestane; Oncology; Internal medicine; Hazard ratio; Breast cancer; Odds ratio; Metastatic breast cancer; Meta-analysis; Confidence interval; Cancer; Aromatase","score_opus":0.06320616612665578,"score_gpt":0.4072449643067012,"score_spread":0.34403879818004546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095962378","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[1.7305048e-7,0.9902333,0.00003752101,0.0031635582,0.00006206219,0.0057341517,0.00056728837,0.00010092753,0.00010101706],"genre_scores_gemma":[0.00000979028,0.9894756,0.0008036016,0.0039913477,0.000066331144,0.0050462843,0.00015329572,0.00010566819,0.00034807378],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99528265,0.00092617463,0.0019107424,0.0010196128,0.00031769375,0.0005431447],"domain_scores_gemma":[0.99690664,0.00043365223,0.0013584365,0.0007986491,0.00017049446,0.000332102],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004822548,0.00086993625,0.026421996,0.0006029755,0.00004179889,0.000009506435,0.00030947212,0.00045775354,0.0013317664],"category_scores_gemma":[0.0001931611,0.0005859674,0.002451215,0.0025299636,0.00013603889,0.000093819544,0.0001345892,0.00091837696,0.00006076755],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046335652,0.000066282024,0.0000014784918,0.753356,0.16576034,0.00027475326,0.000055215507,0.000002554681,2.9106207e-7,0.000015500553,0.00003729704,0.080383964],"study_design_scores_gemma":[0.00047655706,0.0001154536,0.0000044282588,0.031006427,0.68319976,0.00081244344,0.000015328586,0.0000034638267,5.9509077e-8,0.000013305743,0.28403267,0.0003200739],"about_ca_topic_score_codex":0.00008153608,"about_ca_topic_score_gemma":0.00015853756,"teacher_disagreement_score":0.7223496,"about_ca_system_score_codex":0.0011751541,"about_ca_system_score_gemma":0.0009924308,"threshold_uncertainty_score":0.9996592},"labels":[],"label_agreement":null},{"id":"W3107639073","doi":"10.1158/2643-3249.lymphoma20-po-62","title":"Abstract PO-62: Overcoming venetoclax resistance in B-cell malignancies by antagonism of stromal TGF-beta-mediated drug resistance","year":2020,"lang":"en","type":"article","venue":"Blood Cancer Discovery","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Stromal cell; Cancer research; Tumor microenvironment; Stroma; Venetoclax; Drug resistance; Biology; Leukemia; Medicine; Immunology; Chemistry; Chronic lymphocytic leukemia; Tumor cells","score_opus":0.011651078915782424,"score_gpt":0.24598814918626805,"score_spread":0.23433707027048561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107639073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9431611,0.049305387,0.00009157681,0.003631234,0.00021472211,0.0006275087,0.0011996544,0.00009635348,0.0016725132],"genre_scores_gemma":[0.99378186,0.0013960039,0.0007637158,0.0012289538,0.00029475277,0.00013106177,0.00011687671,0.0001037713,0.0021829943],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969253,0.00005966875,0.0008462814,0.00078276155,0.000694793,0.00069119054],"domain_scores_gemma":[0.99844396,0.00016535053,0.00051247055,0.0005260691,0.00011026178,0.00024190104],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016837746,0.00046259598,0.0009495368,0.00010799146,0.000074625284,0.000046012254,0.00034288215,0.00014072002,0.00010709644],"category_scores_gemma":[0.000057444362,0.00046330263,0.00020631928,0.00057626626,0.00026005614,0.00064148154,0.00008921967,0.00047255756,0.00000875135],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052558403,0.00047719516,0.028291244,0.0024976756,0.00032654303,0.0002900848,0.002483865,0.00019270818,0.95404017,0.00027671075,0.0055216323,0.00034632548],"study_design_scores_gemma":[0.014389559,0.0002027899,0.072704695,0.0025920959,0.00039738938,0.000007444251,0.0011101484,0.000015042603,0.8653067,0.00027182695,0.041969292,0.001033062],"about_ca_topic_score_codex":0.00041798424,"about_ca_topic_score_gemma":0.0008791464,"teacher_disagreement_score":0.088733524,"about_ca_system_score_codex":0.00041536105,"about_ca_system_score_gemma":0.0008555792,"threshold_uncertainty_score":0.99978185},"labels":[],"label_agreement":null},{"id":"W3113432048","doi":"10.1158/0008-5472.can-20-2121","title":"Differential Regulation of Cancer Progression by CDK4/6 Plays a Central Role in DNA Replication and Repair Pathways","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Ste. Anne's Hospital; McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Cyclin-dependent kinase 6; Biology; Cancer research; Metastasis; Cancer; DNA repair; Tumor progression; Cell cycle; Kinase; Cyclin-dependent kinase; Cell biology; Genetics; DNA","score_opus":0.0540760209616148,"score_gpt":0.39717524057498826,"score_spread":0.3430992196133735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113432048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989128,0.006134547,0.00009994102,0.0035396619,0.00003492016,0.0008395365,0.00006790268,0.000060893108,0.00009462558],"genre_scores_gemma":[0.998088,0.00081949745,0.0001719771,0.0000864482,0.00024089274,0.00042590578,0.00004565455,0.00003011002,0.00009150016],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99814844,0.000101993086,0.00028793112,0.00051218754,0.00056148146,0.00038798276],"domain_scores_gemma":[0.99913055,0.00004519467,0.000094534014,0.00032521193,0.00019964406,0.00020483955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019511509,0.00011845409,0.00026964908,0.000101694946,0.000064618645,0.000011351387,0.00009269912,0.00009237032,0.0002655291],"category_scores_gemma":[0.00010987512,0.0001038803,0.000042355477,0.0004502714,0.00019584558,0.0001183576,0.000081330516,0.000327482,0.0000014533615],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001951305,0.000075902484,0.06762702,0.00031488852,0.000030905736,0.0000028532534,0.0018181925,0.000020440097,0.84275633,0.00010837363,0.00047752762,0.084816255],"study_design_scores_gemma":[0.0030594554,0.00043015095,0.35114205,0.00074393983,0.000024126823,0.0000034168963,0.0004561012,0.003417158,0.6333556,0.00033349777,0.0068734577,0.00016100741],"about_ca_topic_score_codex":0.0005370704,"about_ca_topic_score_gemma":0.00010363894,"teacher_disagreement_score":0.28351504,"about_ca_system_score_codex":0.0003337925,"about_ca_system_score_gemma":0.00026628398,"threshold_uncertainty_score":0.42361155},"labels":[],"label_agreement":null},{"id":"W3119468389","doi":"10.1016/j.cpccr.2021.100054","title":"Radiation recall dermatitis with abemaciclib developing a year after radiotherapy","year":2021,"lang":"en","type":"article","venue":"Current Problems in Cancer Case Reports","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York Central Hospital; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Erythema; Breast cancer; Radiation therapy; Palbociclib; Dermatology; Internal medicine; Rash; Oncology; Cancer; Surgery; Metastatic breast cancer","score_opus":0.027955013869902498,"score_gpt":0.3327928435657888,"score_spread":0.3048378296958863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119468389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8691486,0.114719845,0.011624324,0.0018747111,0.0011557604,0.0011120008,0.000018976882,0.00014316649,0.0002026123],"genre_scores_gemma":[0.9791497,0.0082751205,0.010042277,0.0006658743,0.00039807317,0.001147903,0.00005383667,0.00008556075,0.00018168424],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99818355,0.000049437615,0.00055402453,0.0005339387,0.0003197935,0.00035925698],"domain_scores_gemma":[0.99895835,0.000026388449,0.0002553177,0.00041673676,0.00021655016,0.00012666089],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016260026,0.00023600915,0.00039438362,0.0001341377,0.000048707287,0.000033768378,0.000024182691,0.00007574201,0.00030307044],"category_scores_gemma":[0.000026491412,0.00020922911,0.00006635139,0.00052050216,0.00006690826,0.0002501479,0.000024967267,0.0002863606,0.000002446755],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018662747,0.00024363917,0.3535191,0.0014199956,0.0002611655,0.09379495,0.0024808655,0.0009604597,0.0006530079,0.00004855833,0.00025573449,0.5461759],"study_design_scores_gemma":[0.007638624,0.00022729086,0.13159738,0.010525195,0.0002791636,0.30973533,0.0002808224,0.00024933874,0.010908522,0.0010985843,0.5260886,0.0013711413],"about_ca_topic_score_codex":0.000095933785,"about_ca_topic_score_gemma":0.0004950005,"teacher_disagreement_score":0.54480475,"about_ca_system_score_codex":0.00092160364,"about_ca_system_score_gemma":0.0009695612,"threshold_uncertainty_score":0.8532115},"labels":[],"label_agreement":null},{"id":"W3119695293","doi":"10.3390/curroncol28010051","title":"Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Breast cancer; Cancer; Tamoxifen; Internal medicine; Quality of life (healthcare); Oncology; Family medicine","score_opus":0.08518103629288318,"score_gpt":0.4011817121243497,"score_spread":0.3160006758314665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119695293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908352,0.005637376,0.000042097592,0.0012971322,0.00055273453,0.0005126914,0.0008522244,0.000008253729,0.00026230293],"genre_scores_gemma":[0.9961975,0.0023544072,0.0008630563,0.00007625265,0.00011093316,0.00019994723,0.00010249286,0.0000150126625,0.0000803721],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9992514,0.000026651993,0.00021497693,0.00021397577,0.00008085072,0.00021213872],"domain_scores_gemma":[0.9991426,0.00006715851,0.00015147692,0.00013060537,0.0003983608,0.00010978154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000019407036,0.000120911296,0.00046697503,0.00012069538,0.000029467512,0.0000014099104,0.0000364839,0.00005284446,0.000059886494],"category_scores_gemma":[0.000017555489,0.000103467515,0.00006400702,0.00018455916,0.00012859219,0.000041301104,0.000010478095,0.000032519754,4.0804892e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044490965,0.0007618816,0.096633546,0.00018543116,0.00011827972,0.0000012889101,0.0010618345,0.000010604655,0.0019971924,0.00008011362,0.00008594408,0.898619],"study_design_scores_gemma":[0.0150550585,0.0036069716,0.58367026,0.00050208264,0.0004166595,0.000024264267,0.0010831557,0.000058021906,0.023783721,0.00049831177,0.37105545,0.0002460673],"about_ca_topic_score_codex":0.0030884834,"about_ca_topic_score_gemma":0.039734975,"teacher_disagreement_score":0.8983729,"about_ca_system_score_codex":0.0003482204,"about_ca_system_score_gemma":0.00070670515,"threshold_uncertainty_score":0.9777874},"labels":[],"label_agreement":null},{"id":"W3120241209","doi":"10.1016/s1470-2045(20)30642-2","title":"Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":255,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Pfizer","keywords":"Palbociclib; Interim analysis; Medicine; Interim; Adjuvant; Oncology; Breast cancer; Internal medicine; Cancer; Endocrine system; Adjuvant therapy; Gynecology; Clinical trial; Metastatic breast cancer; History; Hormone","score_opus":0.08323415090640111,"score_gpt":0.4366332390939129,"score_spread":0.35339908818751176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120241209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98999834,0.0020011,0.00009647845,0.005373264,0.00011254498,0.0018247666,0.00012205065,0.000032776206,0.0004387046],"genre_scores_gemma":[0.995307,0.0011420229,0.00073792756,0.0017324683,0.00018952235,0.0005554744,0.000027404392,0.000037581958,0.00027055346],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976203,0.0005930369,0.0005600698,0.0004727787,0.00027039807,0.00048340502],"domain_scores_gemma":[0.9980815,0.00038248286,0.0003427133,0.0007828522,0.00030873172,0.0001017164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051448226,0.0002679033,0.0020042611,0.00018860037,0.00005438863,0.000022574235,0.00045337275,0.00005856576,0.0007633908],"category_scores_gemma":[0.000046250192,0.00016101394,0.00008946756,0.0013406936,0.00021735903,0.00011455419,0.0001839986,0.00036677983,0.0000040390814],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36422944,0.014669919,0.34328464,0.00006347106,0.011490245,0.0014763726,0.013415921,0.0003526935,0.022065891,0.00006431926,0.000081660066,0.22880541],"study_design_scores_gemma":[0.6183466,0.00550858,0.36107126,0.00018017301,0.0024921384,0.00024218507,0.0044778413,0.0007064948,0.0022354682,0.000037001588,0.0043912423,0.00031103558],"about_ca_topic_score_codex":0.001993514,"about_ca_topic_score_gemma":0.009135486,"teacher_disagreement_score":0.25411713,"about_ca_system_score_codex":0.00027803262,"about_ca_system_score_gemma":0.0004498715,"threshold_uncertainty_score":0.83585936},"labels":[],"label_agreement":null},{"id":"W3121771782","doi":"10.3390/curroncol28010066","title":"Real-World Palbociclib Use in HR+/HER2− Advanced Breast Cancer in Canada: The IRIS Study","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer","keywords":"Palbociclib; Fulvestrant; Medicine; Letrozole; Metastatic breast cancer; Internal medicine; Oncology; Breast cancer; Cancer; Progression-free survival; Gynecology; Aromatase; Chemotherapy; Estrogen receptor","score_opus":0.07953434867907955,"score_gpt":0.41215476955907643,"score_spread":0.3326204208799969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121771782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872189,0.0032003107,0.0000089411615,0.0066075893,0.0016680097,0.0008593668,0.00008553702,0.000029177023,0.0003221568],"genre_scores_gemma":[0.9969608,0.0010982114,0.000101673184,0.0006137128,0.00025920352,0.00044352657,0.000019281219,0.000039308565,0.00046427705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773526,0.0003280236,0.000531594,0.0005247525,0.0003132158,0.0005671745],"domain_scores_gemma":[0.9986342,0.00035695778,0.00015850943,0.00051909155,0.00019237504,0.0001388688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020943824,0.00025065243,0.0006667751,0.00013928136,0.000056750603,0.0000106713605,0.00018234907,0.000055279706,0.0005140338],"category_scores_gemma":[0.00008692668,0.00019441766,0.000056584962,0.00094849506,0.000101439,0.00013264026,0.00012390409,0.0007218679,0.0000059160852],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005313344,0.0007293481,0.7525848,0.00003179293,0.000047610116,0.0004764158,0.00095623505,0.00029513313,0.000215134,0.000035662164,0.00039110013,0.24370544],"study_design_scores_gemma":[0.005378945,0.00010516155,0.9079302,0.00018735677,0.000051037186,0.00007212929,0.0041348343,0.00008973165,0.00006370767,0.00004896303,0.08175801,0.0001799156],"about_ca_topic_score_codex":0.64007556,"about_ca_topic_score_gemma":0.9967023,"teacher_disagreement_score":0.35662672,"about_ca_system_score_codex":0.0052675037,"about_ca_system_score_gemma":0.00541706,"threshold_uncertainty_score":0.9985511},"labels":[],"label_agreement":null},{"id":"W3123647779","doi":"10.1002/onco.13684","title":"Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Pfizer","keywords":"Palbociclib; Medicine; Internal medicine; Neutropenia; Breast cancer; Oncology; Adverse effect; Hazard ratio; Tolerability; Cumulative incidence; Febrile neutropenia; Cancer; Gastroenterology; Gynecology; Metastatic breast cancer; Chemotherapy; Confidence interval; Cohort","score_opus":0.01612740092076149,"score_gpt":0.3158817434457096,"score_spread":0.2997543425249481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123647779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99029624,0.00034759572,0.0037328242,0.002554584,0.00006217592,0.0014397367,0.00147992,0.0000435363,0.0000433974],"genre_scores_gemma":[0.9955052,0.0003688488,0.0019794053,0.00025420618,0.000038758863,0.0002925017,0.001128467,0.00004849505,0.00038409152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975629,0.00028603183,0.00069763314,0.0005781936,0.0004595155,0.00041572747],"domain_scores_gemma":[0.9970128,0.0004657038,0.00069271616,0.0005393301,0.0011598748,0.00012957728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027691716,0.00034004837,0.0015661446,0.0005462464,0.00010825319,0.000014129873,0.00025255885,0.000088368404,0.00046843593],"category_scores_gemma":[0.00008919055,0.00023693588,0.0003267347,0.004427354,0.00042575982,0.00017502352,0.000058486898,0.00022674103,0.0000010473481],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10125609,0.0016871373,0.5510764,0.00011498919,0.037486285,0.000056881814,0.006944628,0.0043596677,0.18849908,0.0004143239,0.00006565797,0.10803885],"study_design_scores_gemma":[0.017235262,0.0020760037,0.9260155,0.00011591228,0.0035513751,0.000007995188,0.0010943786,0.00008162158,0.04946535,0.000030289979,0.000047910984,0.00027838486],"about_ca_topic_score_codex":0.00096760824,"about_ca_topic_score_gemma":0.0054420023,"teacher_disagreement_score":0.3749391,"about_ca_system_score_codex":0.00065559574,"about_ca_system_score_gemma":0.00029824258,"threshold_uncertainty_score":0.96619654},"labels":[],"label_agreement":null},{"id":"W3128758614","doi":"10.1038/s41523-021-00222-y","title":"Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies","year":2021,"lang":"en","type":"article","venue":"npj Breast Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"European Organisation for Research and Treatment of Cancer; University of Nottingham; National Institute for Health and Care Research; Cancer Research UK; AstraZeneca","keywords":"Medicine; Metastatic breast cancer; Oncology; Breast cancer; Endocrine system; Internal medicine; Hormone; Hormone receptor; Cancer; Endocrinology","score_opus":0.06251399066135013,"score_gpt":0.36516630094651714,"score_spread":0.30265231028516704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128758614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74400705,0.1751973,0.001821964,0.03315531,0.0017728184,0.0026799021,0.038073014,0.0006000972,0.0026925593],"genre_scores_gemma":[0.9857139,0.0041149515,0.0016719669,0.0012531747,0.00065343257,0.00089992746,0.00051587966,0.0002509452,0.004925836],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9955514,0.00025234214,0.0010378492,0.0011358225,0.0010271792,0.0009953725],"domain_scores_gemma":[0.9964921,0.00020106179,0.0006247841,0.00088395865,0.0013557753,0.00044234542],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016174302,0.00095064373,0.002503944,0.00025820482,0.00017956624,0.00006260722,0.00030131455,0.0001469837,0.012435566],"category_scores_gemma":[0.000017761113,0.00075744296,0.0010474471,0.0010984531,0.0004868236,0.0004995615,0.00011884111,0.00050963816,0.000036294303],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02496611,0.0013710344,0.005493799,0.00033121946,0.084310815,0.0002301357,0.001100582,0.0007383855,0.79407954,0.00007223996,0.006992655,0.08031347],"study_design_scores_gemma":[0.041563574,0.0010974364,0.16372077,0.0007034816,0.05548643,0.0019737321,0.0014622281,0.0005103799,0.71936333,0.00011696352,0.01146629,0.0025354158],"about_ca_topic_score_codex":0.010533616,"about_ca_topic_score_gemma":0.00040689166,"teacher_disagreement_score":0.24170685,"about_ca_system_score_codex":0.0009191453,"about_ca_system_score_gemma":0.0007737121,"threshold_uncertainty_score":0.99948764},"labels":[],"label_agreement":null},{"id":"W3129342924","doi":"10.2217/cer-2020-0272","title":"Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer","year":2021,"lang":"en","type":"article","venue":"Journal of Comparative Effectiveness Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Fulvestrant; Palbociclib; Hazard ratio; Oncology; Internal medicine; Breast cancer; Hormone receptor; Gynecology; Cancer; Confidence interval; Metastatic breast cancer; Estrogen receptor","score_opus":0.09824933317196574,"score_gpt":0.46670897891742386,"score_spread":0.3684596457454581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129342924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98722035,0.010221773,0.00041396948,0.0004665058,0.00023981798,0.0008151878,0.00009063562,0.000015048692,0.0005167365],"genre_scores_gemma":[0.997011,0.000862218,0.0017486772,0.000015175902,0.00017130014,0.000080872516,0.000009863199,0.000047221252,0.00005365565],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99374664,0.0028372246,0.00096873945,0.0004907884,0.001344164,0.00061246305],"domain_scores_gemma":[0.9903334,0.005130684,0.0006492436,0.00025287532,0.0033209731,0.0003128178],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020008122,0.00036865124,0.002078515,0.0006881967,0.00016885863,0.000043043077,0.00023386495,0.0001746836,0.00012903492],"category_scores_gemma":[0.00034112044,0.00031938154,0.00020661045,0.0018717414,0.0007754243,0.00054663356,0.00017549253,0.0017574077,0.0000062271743],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.121939614,0.002454155,0.13943395,0.0008614711,0.002173362,0.00036614054,0.020381404,0.0027419962,0.651737,0.00046466466,0.00008775824,0.05735853],"study_design_scores_gemma":[0.016665734,0.0021694163,0.67640847,0.002477426,0.000088611516,0.00021503161,0.011059156,0.00013978707,0.28964922,0.0007310045,0.0001469726,0.00024920658],"about_ca_topic_score_codex":0.00022564737,"about_ca_topic_score_gemma":0.00024268015,"teacher_disagreement_score":0.5369745,"about_ca_system_score_codex":0.0010674953,"about_ca_system_score_gemma":0.0010051174,"threshold_uncertainty_score":0.99992585},"labels":[],"label_agreement":null},{"id":"W3129522204","doi":"10.1158/1538-7445.sabcs20-ps4-48","title":"Abstract PS4-48: Development of a multiplexed protein panel using a targeted proteomics approach for the study of CDK4/6 inhibitors resistance in hormone receptor positive breast cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Breast cancer; Medicine; Cancer research; Cancer; Oncology; Proteomics; Cyclin-dependent kinase; Drug resistance; Internal medicine; Bioinformatics; Biology; Cell cycle","score_opus":0.10881384647906636,"score_gpt":0.38783894327230517,"score_spread":0.27902509679323884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129522204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98423797,0.0061371396,0.00069922913,0.0006879971,0.000060305727,0.007845654,0.00029721728,0.000017005512,0.000017495986],"genre_scores_gemma":[0.9587729,0.00008081429,0.034951873,0.00002476088,0.00019299187,0.0056852587,0.000027182488,0.000074608586,0.00018960993],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967136,0.00020682884,0.00077802414,0.00062346424,0.0010238701,0.0006542178],"domain_scores_gemma":[0.99704367,0.00019095966,0.00030209892,0.0004997513,0.001838623,0.00012487448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011893935,0.00025936076,0.0006331058,0.00025751215,0.00022613263,0.000020097543,0.00027581002,0.00012188753,0.000055074743],"category_scores_gemma":[0.00020825813,0.00020240727,0.00008952639,0.001376049,0.00033269424,0.00013050617,0.00015373368,0.00063432456,4.808672e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010100733,0.0013389109,0.0024758514,0.0008359963,0.00038773162,0.00001060164,0.012040606,0.0005851301,0.9633444,0.00000832068,0.00006894441,0.008802764],"study_design_scores_gemma":[0.009659833,0.00021744451,0.10625069,0.0018637436,0.00005599281,0.0000065340014,0.019979844,0.0004046236,0.86089,0.000033905853,0.00031187935,0.00032554506],"about_ca_topic_score_codex":0.0021602022,"about_ca_topic_score_gemma":0.0019220498,"teacher_disagreement_score":0.10377484,"about_ca_system_score_codex":0.0014022655,"about_ca_system_score_gemma":0.002523954,"threshold_uncertainty_score":0.8253929},"labels":[],"label_agreement":null},{"id":"W3129754483","doi":"10.1158/1538-7445.sabcs20-pd1-02","title":"Abstract PD1-02: A phase I/Ib study evaluating GDC-0077 + palbociclib (palbo) + fulvestrant in patients (pts) with <i>PIK3CA</i>-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC)","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Fulvestrant; Internal medicine; Palbociclib; Phases of clinical research; Breast cancer; Oncology; Progressive disease; Cancer; Pharmacology; Chemotherapy; Gastroenterology; Metastatic breast cancer; Tamoxifen","score_opus":0.07982276108933845,"score_gpt":0.4456599860075646,"score_spread":0.3658372249182262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129754483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878162,0.003423708,0.000059591457,0.0021738247,0.00023563586,0.004503892,0.0012274159,0.00010921111,0.00045050352],"genre_scores_gemma":[0.9936608,0.0008943562,0.00096669124,0.00032932247,0.00043033148,0.002775509,0.00016550375,0.0002571883,0.00052031066],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98994523,0.001232504,0.0012079178,0.0018982358,0.0036800192,0.0020360877],"domain_scores_gemma":[0.9936707,0.0008209297,0.00043105075,0.001134926,0.0031707783,0.00077158376],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022065814,0.00084883143,0.001469899,0.00056113803,0.0005006903,0.00018618918,0.0005288016,0.00017966404,0.00315458],"category_scores_gemma":[0.0004150563,0.0007094271,0.00020061314,0.0029758164,0.00077097653,0.000665637,0.0002712724,0.002290051,0.000082552295],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060780704,0.023956003,0.1345821,0.0013111121,0.0045200232,0.0033157703,0.031682145,0.0012743549,0.31554168,0.000042048378,0.0009449061,0.42204913],"study_design_scores_gemma":[0.10118425,0.013845286,0.7835203,0.0056576817,0.0007661844,0.0001840171,0.025843998,0.00023570305,0.06552742,0.00029367593,0.0009638802,0.0019776374],"about_ca_topic_score_codex":0.008438341,"about_ca_topic_score_gemma":0.005087265,"teacher_disagreement_score":0.6489382,"about_ca_system_score_codex":0.003248918,"about_ca_system_score_gemma":0.0035951498,"threshold_uncertainty_score":0.9995357},"labels":[],"label_agreement":null},{"id":"W3130048594","doi":"10.1158/1538-7445.sabcs20-pd1-05","title":"Abstract PD1-05: Latest findings from the breast cancer cohort in SUMMIT - a phase 2 ‘basket’ trial of neratinib + trastuzumab + fulvestrant for <i>HER2</i>-mutant, hormone receptor-positive, metastatic breast cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Neratinib; Medicine; Fulvestrant; Trastuzumab; Internal medicine; Metastatic breast cancer; Oncology; Breast cancer; Population; Cancer; Estrogen receptor","score_opus":0.06149143344151323,"score_gpt":0.40938022759496856,"score_spread":0.3478887941534553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130048594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9481121,0.010271217,0.00009444539,0.014802116,0.00058662455,0.003934314,0.022062585,0.0000517915,0.000084814856],"genre_scores_gemma":[0.9864882,0.0055679656,0.0003659766,0.00047286882,0.0014145866,0.0045582894,0.00049326004,0.00017395055,0.00046487697],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99424595,0.00040496158,0.0011575308,0.0012167448,0.0015865351,0.0013882965],"domain_scores_gemma":[0.9954897,0.0015127242,0.0003108562,0.0008512366,0.0014178362,0.00041763106],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014743609,0.00057868386,0.001361304,0.00025546522,0.0003544316,0.0001244556,0.0005444265,0.00021708121,0.0034169052],"category_scores_gemma":[0.00020928822,0.00044795996,0.0003552223,0.0016365161,0.0008028166,0.00040771702,0.00012631495,0.0014147748,0.000011238202],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17663613,0.0029898202,0.019868389,0.0005343219,0.0024037324,0.0003175645,0.0023777625,0.00036988655,0.6967809,0.00008911116,0.009424356,0.08820798],"study_design_scores_gemma":[0.30807862,0.0025477412,0.44832075,0.0063080927,0.0013846146,0.0003005224,0.0051605897,0.0005481493,0.20574988,0.0005451615,0.01925851,0.0017973698],"about_ca_topic_score_codex":0.01999763,"about_ca_topic_score_gemma":0.00867145,"teacher_disagreement_score":0.49103105,"about_ca_system_score_codex":0.001702981,"about_ca_system_score_gemma":0.004219898,"threshold_uncertainty_score":0.9997972},"labels":[],"label_agreement":null},{"id":"W3130064472","doi":"10.3390/cancers13040924","title":"Drug Resistance and Novel Therapies in Cancers in 2019","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Drug resistance; Medicine; Drug; Oncology; Resistance (ecology); Internal medicine; Pharmacology; Biology; Microbiology","score_opus":0.012577331665914682,"score_gpt":0.2752884038958085,"score_spread":0.2627110722298938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130064472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9211359,0.0676655,0.00025846306,0.0062749158,0.00041187686,0.00037216427,0.000037409205,0.000054278506,0.0037894659],"genre_scores_gemma":[0.98520905,0.0024852026,0.002482302,0.0019141242,0.00011554194,0.000082015664,0.000011746533,0.000040223415,0.007659797],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99884456,0.00002588267,0.00022895023,0.0003934523,0.00017475491,0.00033241222],"domain_scores_gemma":[0.99945265,0.000060144834,0.000059353362,0.00027352644,0.00006473019,0.00008958203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000115233415,0.00016772699,0.0003483118,0.00011902804,0.0000298614,0.000013087467,0.00006621583,0.00005600008,0.000101028556],"category_scores_gemma":[0.00003924465,0.00016897183,0.000035728972,0.000481258,0.00016305954,0.00013145481,0.00002784418,0.00024140737,0.0000030646968],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010353291,0.00031810984,0.40121135,0.002192496,0.0008450144,0.0023237087,0.06407005,0.01188976,0.28916556,0.013853195,0.0143604865,0.18941697],"study_design_scores_gemma":[0.02692271,0.00010957836,0.44525084,0.004195592,0.00007966763,0.00016325667,0.017765753,0.00050261675,0.027161201,0.003909197,0.4725533,0.0013862987],"about_ca_topic_score_codex":0.0014811814,"about_ca_topic_score_gemma":0.021627136,"teacher_disagreement_score":0.45819283,"about_ca_system_score_codex":0.0029379835,"about_ca_system_score_gemma":0.0014142778,"threshold_uncertainty_score":0.9962256},"labels":[],"label_agreement":null},{"id":"W3130306790","doi":"10.1158/1538-7445.sabcs20-pd3-08","title":"Abstract PD3-08: Tucatinib vs placebo in combination with trastuzumab and capecitabine for patients with locally advanced unresectable or HER2-positive metastatic breast cancer (HER2CLIMB): Outcomes by hormone receptor status","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Capecitabine; Internal medicine; Metastatic breast cancer; Pertuzumab; Oncology; Trastuzumab; Placebo; Breast cancer; Regimen; Progression-free survival; Neratinib; Cancer; Chemotherapy; Colorectal cancer; Pathology","score_opus":0.022968683255123783,"score_gpt":0.35649628121608185,"score_spread":0.33352759796095804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130306790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98451495,0.004218753,0.00041254482,0.004675151,0.000087580374,0.003682079,0.0022512367,0.000048634385,0.00010907915],"genre_scores_gemma":[0.98785055,0.0016904618,0.003276305,0.00032027447,0.00005481799,0.0039495747,0.00058189,0.00016250841,0.0021136398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960814,0.00017496501,0.0004695838,0.00090834993,0.0011635784,0.0012020873],"domain_scores_gemma":[0.9962441,0.00080517697,0.00018547343,0.00039954035,0.0019471857,0.0004185655],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041153413,0.00042948307,0.0008385863,0.00026718335,0.00023412732,0.00008536715,0.00015875166,0.0000996495,0.00066318526],"category_scores_gemma":[0.00019485952,0.00030445476,0.000050346684,0.0011001757,0.00042906485,0.0005001904,0.00006902812,0.0006878142,0.0000050197473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29292637,0.0075417953,0.3538521,0.002375686,0.0022658014,0.00020839168,0.00555739,0.00071699376,0.033961125,0.00010965909,0.0040195254,0.29646516],"study_design_scores_gemma":[0.08700212,0.007051147,0.8787103,0.0023846112,0.00017061799,0.00003529611,0.005419095,0.00009465665,0.010666272,0.00009133993,0.0074964636,0.0008780545],"about_ca_topic_score_codex":0.0017121912,"about_ca_topic_score_gemma":0.004481012,"teacher_disagreement_score":0.52485824,"about_ca_system_score_codex":0.0019439379,"about_ca_system_score_gemma":0.002202412,"threshold_uncertainty_score":0.99994075},"labels":[],"label_agreement":null},{"id":"W3130310298","doi":"10.1158/1538-7445.sabcs20-ps10-54","title":"Abstract PS10-54: Single-centre retrospective study of treatment choices and outcomes of metastatic breast cancer post-progression on the CDK4/6 inhibitor palbobiclib","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Palbociclib; Metastatic breast cancer; Breast cancer; Internal medicine; Oncology; Cancer; Primary tumor; Population; Fulvestrant; Surgery; Metastasis; Tamoxifen","score_opus":0.08547221319040686,"score_gpt":0.4308914046703316,"score_spread":0.3454191914799247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130310298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886636,0.004085472,4.859321e-7,0.0052030464,0.00012436745,0.0014119874,0.0003284237,0.000019536834,0.00016305101],"genre_scores_gemma":[0.99828416,0.00043388119,0.000044684613,0.00009048415,0.00014241638,0.0003461762,0.000007971767,0.00004481269,0.0006054347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99740195,0.0002477185,0.0003965092,0.00051997515,0.0010009651,0.0004328904],"domain_scores_gemma":[0.99738187,0.00046042236,0.00021129638,0.00055609277,0.0012363291,0.0001539714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003603136,0.00024978715,0.00066407514,0.00016715728,0.00016503528,0.000029060966,0.0001385073,0.000053247357,0.0008828429],"category_scores_gemma":[0.00016544099,0.0001448646,0.00010214117,0.00056500605,0.0003943428,0.000109285254,0.000109530265,0.00035828477,0.0000031460913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038018404,0.005054964,0.63290346,0.00045400372,0.0018801981,0.00012686999,0.009667104,0.00004357054,0.2574615,0.000110672576,0.000101184836,0.08839464],"study_design_scores_gemma":[0.0054059913,0.0024278387,0.880695,0.000995449,0.00016058434,0.000014289097,0.012836737,0.0000067893643,0.096823424,0.000082625826,0.00039771444,0.0001535554],"about_ca_topic_score_codex":0.0019496595,"about_ca_topic_score_gemma":0.002161591,"teacher_disagreement_score":0.24779154,"about_ca_system_score_codex":0.00099266,"about_ca_system_score_gemma":0.0005980851,"threshold_uncertainty_score":0.9666511},"labels":[],"label_agreement":null},{"id":"W3130327672","doi":"10.1158/1538-7445.sabcs20-ps5-12","title":"Abstract PS5-12: Preliminary correlative analysis of clinical outcomes with <i>PIK3CA</i> mutation (mut) status from a phase I/Ib study of GDC-0077 in patients (pts) with hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC)","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Fulvestrant; Medicine; Letrozole; Internal medicine; Palbociclib; Oncology; Cancer; Breast cancer; Estrogen receptor; Tamoxifen","score_opus":0.06948872393345283,"score_gpt":0.4526514672675588,"score_spread":0.38316274333410594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130327672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926915,0.0009329535,0.00020149861,0.00027124607,0.000083631996,0.0022588628,0.0034061307,0.000024949557,0.0001292044],"genre_scores_gemma":[0.9968963,0.0005097624,0.001074523,0.000072061965,0.000059887323,0.00061956415,0.00050915446,0.000091651455,0.00016707167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934495,0.0010601691,0.0013950622,0.0011234101,0.0021979294,0.0007739458],"domain_scores_gemma":[0.99279416,0.0021069853,0.0008726305,0.00076827814,0.0030790067,0.000378949],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008875223,0.00046433875,0.002046827,0.0007550576,0.000118989374,0.000027824502,0.00024885475,0.0001355489,0.0011422886],"category_scores_gemma":[0.00037150795,0.0003497618,0.00022155765,0.0034223446,0.00084575976,0.00042593083,0.00013405604,0.001187591,0.00000561411],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062896125,0.0117806,0.8479089,0.00014099124,0.012299168,0.000276515,0.017609745,0.0029524993,0.0010834521,0.0000036321285,0.0000672444,0.042981133],"study_design_scores_gemma":[0.033498265,0.007998224,0.9328558,0.0008011096,0.002115757,0.0000030341873,0.02013425,0.00017156743,0.0020515865,0.000026521337,0.00002331271,0.00032060008],"about_ca_topic_score_codex":0.032463904,"about_ca_topic_score_gemma":0.017106198,"teacher_disagreement_score":0.08494688,"about_ca_system_score_codex":0.001026265,"about_ca_system_score_gemma":0.0019275581,"threshold_uncertainty_score":0.99989545},"labels":[],"label_agreement":null},{"id":"W3130435961","doi":"10.1158/1538-7445.sabcs20-ps10-05","title":"Abstract PS10-05: Ribociclib + letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC): Expanded safety analysis of the phase IIIb CompLEEment-1 trial","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Tolerability; Letrozole; Clinical endpoint; Internal medicine; Discontinuation; Breast cancer; Adverse effect; Population; Goserelin; Metastatic breast cancer; Phases of clinical research; Oncology; Cancer; Clinical trial; Gastroenterology; Surgery; Tamoxifen","score_opus":0.04300735938034665,"score_gpt":0.39475965956004255,"score_spread":0.3517523001796959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130435961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888598,0.0009163095,0.000049346043,0.0019350043,0.0002456361,0.0024832506,0.0051843775,0.000042000494,0.0002842931],"genre_scores_gemma":[0.99698216,0.00047183354,0.00020102468,0.00019883492,0.00029916083,0.000714837,0.000649173,0.00009781945,0.0003851722],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99389714,0.00071063306,0.0010459248,0.001079041,0.0021201486,0.0011471385],"domain_scores_gemma":[0.9952194,0.00045149162,0.0005394824,0.00089981913,0.0025256579,0.0003641412],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006122468,0.0005139977,0.0014138393,0.0006196365,0.0004954206,0.000049018734,0.0004991338,0.00018702996,0.00552473],"category_scores_gemma":[0.00022312516,0.00038293874,0.0003872331,0.0042248755,0.0009614087,0.0004770316,0.00026432017,0.0012910743,0.0000075287003],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4001861,0.006580491,0.23116933,0.00038918876,0.010104039,0.00006181087,0.006893412,0.000888191,0.24234104,0.00019047954,0.0012473741,0.099948555],"study_design_scores_gemma":[0.12627411,0.0012789445,0.8098493,0.00064212165,0.00041146507,0.0000020497205,0.0014425573,0.00002256813,0.058774143,0.000049315244,0.0007599919,0.00049341813],"about_ca_topic_score_codex":0.003468128,"about_ca_topic_score_gemma":0.0025855475,"teacher_disagreement_score":0.57868,"about_ca_system_score_codex":0.0026850277,"about_ca_system_score_gemma":0.0011923754,"threshold_uncertainty_score":0.99986225},"labels":[],"label_agreement":null},{"id":"W3130745660","doi":"10.1158/1538-7445.sabcs20-ps14-07","title":"Abstract PS14-07: Ribociclib + letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC) and central nervous system metastases: Subgroup analysis of the phase IIIb CompLEEment-1 trial","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Grand River Hospital","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Letrozole; Goserelin; Metastatic breast cancer; Tolerability; Oncology; Cancer; Population; Adverse effect; Tamoxifen","score_opus":0.03512929365736709,"score_gpt":0.36558569335040264,"score_spread":0.33045639969303553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130745660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98844415,0.0019535972,0.00004318444,0.00076660526,0.00021507755,0.0024188063,0.006016886,0.000041451298,0.000100231],"genre_scores_gemma":[0.99788684,0.00030753983,0.00018520208,0.00009049815,0.00024939014,0.0006182885,0.00046835298,0.00008608161,0.00010779642],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943888,0.0008103529,0.00091653643,0.0010250137,0.0016668366,0.001192436],"domain_scores_gemma":[0.9962884,0.00036312008,0.00050824566,0.00070664694,0.0017093465,0.0004242246],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000520196,0.000495925,0.0014112048,0.00052559644,0.00043175856,0.000075723954,0.00039085068,0.00014545493,0.0014558324],"category_scores_gemma":[0.00013290865,0.00036513177,0.0002916956,0.0029207787,0.0008753813,0.0004669665,0.00024504247,0.0009936423,0.000004152464],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30133003,0.006311573,0.39551237,0.0017678264,0.017604832,0.00015005487,0.008956777,0.0011745079,0.18225817,0.00059415447,0.0007437561,0.08359596],"study_design_scores_gemma":[0.08533453,0.0011805173,0.88635737,0.0008756565,0.00074296,0.000005005796,0.0031588639,0.000051174018,0.021581572,0.000013520034,0.00025388013,0.0004449389],"about_ca_topic_score_codex":0.0061717113,"about_ca_topic_score_gemma":0.0022849806,"teacher_disagreement_score":0.49084502,"about_ca_system_score_codex":0.002413776,"about_ca_system_score_gemma":0.00083286996,"threshold_uncertainty_score":0.9998801},"labels":[],"label_agreement":null},{"id":"W3130950208","doi":"10.1158/1538-7445.sabcs20-ps7-19","title":"Abstract PS7-19: Pre/perimenopausal (preMeno) women receiving palbociclib (PAL) for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) in a real-world setting: Treatment patterns from POLARIS","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Anastrozole; Palbociclib; Exemestane; Letrozole; Breast cancer; Internal medicine; Cancer; Fulvestrant; Gynecology; Oncology; Metastatic breast cancer; Tamoxifen","score_opus":0.0535790946027976,"score_gpt":0.4034126591646535,"score_spread":0.34983356456185594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130950208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.976561,0.0032314775,0.00008740551,0.0059256614,0.00037980804,0.0035045506,0.009660068,0.0001984877,0.00045154063],"genre_scores_gemma":[0.9800336,0.004405329,0.0020336395,0.00040805896,0.0015786758,0.0075982856,0.00071507506,0.00032823725,0.0028991413],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9922172,0.00067815976,0.0011704215,0.0020866152,0.0013646093,0.0024829947],"domain_scores_gemma":[0.99445784,0.0015333145,0.0004596191,0.0009852074,0.0015266652,0.0010373589],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00083472976,0.0009105551,0.0015145444,0.000615567,0.0007080283,0.00017680445,0.00048759088,0.00033994814,0.0062752194],"category_scores_gemma":[0.00040125946,0.0008711087,0.00025732617,0.0012533736,0.00044292578,0.00076289923,0.00028111413,0.0014422669,0.00003228787],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01209414,0.0011948826,0.11593768,0.00047235127,0.0015561443,0.000169001,0.02521061,0.000064554355,0.74508876,0.00007399307,0.0007401913,0.097397685],"study_design_scores_gemma":[0.012692183,0.0013632883,0.7422492,0.0016893473,0.00007631985,0.000012734487,0.005379768,0.000020027948,0.23209357,0.0005850055,0.002925032,0.0009135367],"about_ca_topic_score_codex":0.060238685,"about_ca_topic_score_gemma":0.01664582,"teacher_disagreement_score":0.62631154,"about_ca_system_score_codex":0.014317796,"about_ca_system_score_gemma":0.0025396158,"threshold_uncertainty_score":0.999374},"labels":[],"label_agreement":null},{"id":"W3131078121","doi":"10.1158/1538-7445.sabcs20-pd2-07","title":"Abstract PD2-07: Alpelisib + letrozole in patients with <i>PIK3CA-</i>mutated, hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Letrozole; Cohort; Medicine; Fulvestrant; Internal medicine; Oncology; Breast cancer; Clinical endpoint; Cancer; Gynecology; Clinical trial; Estrogen receptor; Aromatase","score_opus":0.02330723514965225,"score_gpt":0.33720449396616314,"score_spread":0.31389725881651087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3131078121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984753,0.0016505627,0.000011445083,0.0015266354,0.00018143065,0.006219672,0.0048557175,0.00020561823,0.00059587636],"genre_scores_gemma":[0.9940321,0.000572697,0.00034845024,0.00020250528,0.00052985305,0.0022671293,0.00081063964,0.0003544774,0.0008821646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9894094,0.0009188697,0.0014628791,0.0025940253,0.0032075956,0.002407246],"domain_scores_gemma":[0.99246806,0.00046203536,0.00062198454,0.0012374407,0.004155494,0.0010549623],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007818726,0.0012091198,0.0017167107,0.00070963986,0.0006506703,0.00020951754,0.00060260814,0.00035126333,0.0013325678],"category_scores_gemma":[0.0002613997,0.0009673232,0.00020860955,0.0024848168,0.0009552364,0.0011602903,0.00027522023,0.0026660399,0.00008587512],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23534095,0.017528754,0.5130695,0.0008605627,0.0038753632,0.0033380783,0.021129582,0.0014970554,0.15747362,0.000023573604,0.0012781044,0.04458485],"study_design_scores_gemma":[0.06605369,0.0070348987,0.8333573,0.0030508924,0.00020348027,0.000053274634,0.0055900067,0.000009101493,0.082986206,0.000017622135,0.00027675612,0.0013668054],"about_ca_topic_score_codex":0.010331624,"about_ca_topic_score_gemma":0.006866797,"teacher_disagreement_score":0.32028776,"about_ca_system_score_codex":0.0039416337,"about_ca_system_score_gemma":0.0021655587,"threshold_uncertainty_score":0.99988204},"labels":[],"label_agreement":null},{"id":"W3131211776","doi":"10.1158/1538-7445.sabcs20-ot-28-01","title":"Abstract OT-28-01: HER2CLIMB-02: A randomized, double-blind, phase 3 study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Taxane; Capecitabine; Metastatic breast cancer; Internal medicine; Oncology; Placebo; Nausea; Gastroenterology; Breast cancer; Trastuzumab; Phases of clinical research; Cancer; Surgery; Clinical trial; Colorectal cancer; Pathology","score_opus":0.1485206845789407,"score_gpt":0.4857765730134932,"score_spread":0.3372558884345525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3131211776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708546,0.007678579,0.0012255735,0.0028431062,0.00033894574,0.015823744,0.0006634279,0.00012261127,0.00044940412],"genre_scores_gemma":[0.9660773,0.0012097438,0.0021203184,0.00024344267,0.00050513237,0.021192051,0.000069552465,0.00026210814,0.008320299],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934338,0.0005053278,0.0011727632,0.0013245387,0.0020146072,0.0015490085],"domain_scores_gemma":[0.9922964,0.002087468,0.0004568094,0.0012590557,0.0032771046,0.0006231596],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002283467,0.0006358415,0.0022939285,0.00048707126,0.00038286718,0.000112978545,0.0005398244,0.00014619404,0.0061279493],"category_scores_gemma":[0.00053698453,0.000408372,0.000265983,0.0023162828,0.0008106649,0.0004520295,0.0001856857,0.0010709921,0.000015183015],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92621094,0.004648824,0.00026257537,0.0023105964,0.0026074292,0.00051175314,0.0025147414,0.001652837,0.011469545,0.00004138429,0.00042448094,0.047344897],"study_design_scores_gemma":[0.93313926,0.0043282807,0.00022036156,0.002881852,0.0007499559,0.0003300779,0.016961806,0.00023402981,0.036579326,0.000109377615,0.0038535537,0.0006121118],"about_ca_topic_score_codex":0.0038196389,"about_ca_topic_score_gemma":0.015992666,"teacher_disagreement_score":0.046732787,"about_ca_system_score_codex":0.0010092964,"about_ca_system_score_gemma":0.0073188157,"threshold_uncertainty_score":0.9998368},"labels":[],"label_agreement":null},{"id":"W3131295993","doi":"10.1158/1538-7445.sabcs20-ps11-20","title":"Abstract PS11-20: Radiation therapy (RT) induced toxicity in advanced breast cancer (ABC) patients treated with CDK4/6 inhibitors (CDK4/6is)","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Palbociclib; Common Terminology Criteria for Adverse Events; Toxicity; Adverse effect; Cancer; Internal medicine; Radiation therapy; Breast cancer; Oncology; Surgery; Metastatic breast cancer","score_opus":0.045906522525190764,"score_gpt":0.3821999245497152,"score_spread":0.3362934020245244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3131295993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99076533,0.0040612984,0.000007126236,0.0026162032,0.0002403705,0.0014304003,0.00024024658,0.00010856105,0.0005304533],"genre_scores_gemma":[0.99419445,0.0028079092,0.0000843088,0.00044559993,0.00053568085,0.001124109,0.00015521196,0.000139358,0.0005133545],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99550587,0.00024756845,0.00055833993,0.0010350917,0.0014906806,0.0011624338],"domain_scores_gemma":[0.99697775,0.00017172738,0.00019040209,0.00073104736,0.0015153723,0.00041369727],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004348798,0.00044319234,0.0006787744,0.0005095495,0.00024746166,0.00007172677,0.0002558825,0.00025162092,0.0014094607],"category_scores_gemma":[0.000095787975,0.00037024522,0.00011230964,0.0023341107,0.00027215367,0.0005693372,0.00008613009,0.0012074669,0.000030273437],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055750185,0.00070256134,0.3233881,0.00013566022,0.00018155103,0.00013471881,0.00071106554,0.00027470686,0.2783296,0.000010402261,0.00018212791,0.3903745],"study_design_scores_gemma":[0.011224708,0.00043312335,0.70723575,0.00091316976,0.000018261722,0.000021138036,0.00030266377,0.000024009008,0.27568048,0.000051756895,0.0036954854,0.00039946174],"about_ca_topic_score_codex":0.002774464,"about_ca_topic_score_gemma":0.0028048402,"teacher_disagreement_score":0.38997504,"about_ca_system_score_codex":0.0026960208,"about_ca_system_score_gemma":0.0018224884,"threshold_uncertainty_score":0.99987495},"labels":[],"label_agreement":null},{"id":"W3131366900","doi":"10.1158/1538-7445.sabcs20-pd13-04","title":"Abstract PD13-04: Impact of tucatinib on health-related quality of life in patients with HER2+ metastatic breast cancer with stable and active brain metastases","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Capecitabine; Quality of life (healthcare); Visual analogue scale; Internal medicine; Metastatic breast cancer; Breast cancer; Oncology; Trastuzumab; Placebo; Cancer; Physical therapy; Colorectal cancer; Alternative medicine; Nursing; Pathology","score_opus":0.08995328600110802,"score_gpt":0.4578494692486977,"score_spread":0.36789618324758966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3131366900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99153477,0.002987099,0.000007859612,0.002543172,0.000019619829,0.0009443748,0.0018732167,0.000012111259,0.00007777737],"genre_scores_gemma":[0.99896806,0.00025364917,0.00021913956,0.00014640056,0.000019553281,0.00017964416,0.00007537258,0.000052867515,0.0000853176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99660355,0.00053699524,0.00063724676,0.0005089841,0.0011003516,0.0006129016],"domain_scores_gemma":[0.9968968,0.0006740057,0.000410186,0.00046844303,0.001201455,0.0003491319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009869718,0.00024975327,0.0010580227,0.00030139653,0.00007221194,0.000013941059,0.00011166961,0.00005026581,0.0009010313],"category_scores_gemma":[0.00026772934,0.000170884,0.00006917209,0.0012402707,0.0004818355,0.00021162115,0.00005122045,0.0006122696,0.00000119251],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051589552,0.002736231,0.8493803,0.0026719794,0.002646994,0.000040206654,0.004419778,0.002039604,0.006275617,0.000103038954,0.00030476248,0.077791914],"study_design_scores_gemma":[0.008791031,0.0014055462,0.98334974,0.0015489812,0.000031067793,0.0000068188465,0.0011748709,0.0000048416114,0.0034140928,0.00008484598,0.000030733452,0.00015740188],"about_ca_topic_score_codex":0.049736105,"about_ca_topic_score_gemma":0.007451818,"teacher_disagreement_score":0.13396946,"about_ca_system_score_codex":0.00097187737,"about_ca_system_score_gemma":0.0048339902,"threshold_uncertainty_score":0.98656607},"labels":[],"label_agreement":null},{"id":"W3131900383","doi":"10.1158/1538-7445.sabcs20-gs1-02","title":"Abstract GS1-02: Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Palbociclib; Medicine; Oncology; Breast cancer; Internal medicine; Clinical endpoint; Neoadjuvant therapy; Taxane; Chemotherapy; Cancer; Metastatic breast cancer; Randomized controlled trial","score_opus":0.015045762838866125,"score_gpt":0.31623281666239944,"score_spread":0.30118705382353333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3131900383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99000394,0.0015609883,0.00001911539,0.0014020725,0.00006208503,0.0041404804,0.0025681783,0.000055135213,0.00018802892],"genre_scores_gemma":[0.99402964,0.0025272742,0.0005992558,0.00027339344,0.000155906,0.0013548255,0.0005779062,0.00020450604,0.00027729786],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9941835,0.00048619072,0.00082784216,0.0014349318,0.0020657743,0.0010018],"domain_scores_gemma":[0.99522465,0.0007285168,0.0005099519,0.001138299,0.002015557,0.00038301825],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052922574,0.00069029606,0.0013779812,0.0003259988,0.00024043133,0.000075157535,0.0003370526,0.00012858259,0.00059070665],"category_scores_gemma":[0.000048800728,0.00046998562,0.000083226325,0.0014535569,0.00069282425,0.00050202274,0.00011317129,0.0015189671,0.000005910802],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7647334,0.009692059,0.16939853,0.0000912739,0.0021325422,0.0007701449,0.020020543,0.00036520997,0.0026577634,0.00000276867,0.00015736243,0.029978449],"study_design_scores_gemma":[0.21673515,0.01255266,0.749694,0.0014396504,0.000080924896,0.0000122103265,0.0029368412,0.000003889113,0.015746271,0.000022260734,0.0002925967,0.00048354108],"about_ca_topic_score_codex":0.03289821,"about_ca_topic_score_gemma":0.022994325,"teacher_disagreement_score":0.58029544,"about_ca_system_score_codex":0.0014286423,"about_ca_system_score_gemma":0.0017031926,"threshold_uncertainty_score":0.9997752},"labels":[],"label_agreement":null},{"id":"W3131964219","doi":"10.1158/1538-7445.sabcs20-ps17-31","title":"Abstract PS17-31: Investigating the estrogen receptor Y537S mutation in transgenic models of luminal B breast cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Breast cancer; Estrogen receptor; Mutant; Cancer; Cancer research; Estrogen receptor alpha; Context (archaeology); Biology; Metastatic breast cancer; Fulvestrant; Mutation; Progesterone receptor; Estrogen; Internal medicine; Endocrinology; Medicine; Genetics; Gene","score_opus":0.11769280712546626,"score_gpt":0.42336265375022286,"score_spread":0.3056698466247566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3131964219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821659,0.008572586,0.00007829614,0.007918033,0.0001377659,0.000536442,0.00015223591,0.000023721943,0.00041504673],"genre_scores_gemma":[0.9970515,0.00084795564,0.00052716536,0.00018873128,0.00044888526,0.00049304747,0.00002663933,0.00004826084,0.00036784785],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975368,0.00016137697,0.00042389904,0.00042151933,0.0008858657,0.0005705446],"domain_scores_gemma":[0.9983403,0.00020776727,0.0001021783,0.00040874246,0.000770886,0.00017011934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007361798,0.00016790043,0.00033594773,0.00016727355,0.00012776018,0.000024804249,0.0002254532,0.00010148078,0.0008841359],"category_scores_gemma":[0.00008711487,0.00013394994,0.00010072414,0.0011197657,0.0005091844,0.00023599023,0.000053589163,0.00081238005,0.00000942326],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093590305,0.00018076351,0.013381183,0.0007556959,0.00022194392,0.00006519393,0.006088673,0.009245171,0.8226677,0.0005789037,0.00043744288,0.14544141],"study_design_scores_gemma":[0.007465633,0.0002452371,0.18521677,0.0046876045,0.00013220163,0.00028066672,0.011522333,0.0027803862,0.7763286,0.007512519,0.0031908895,0.0006371086],"about_ca_topic_score_codex":0.0029142934,"about_ca_topic_score_gemma":0.0010951507,"teacher_disagreement_score":0.17183559,"about_ca_system_score_codex":0.0007161427,"about_ca_system_score_gemma":0.0024818073,"threshold_uncertainty_score":0.9680668},"labels":[],"label_agreement":null},{"id":"W3132319387","doi":"10.1158/1538-7445.sabcs20-ps11-11","title":"Abstract PS11-11: Targeted safety events from a phase I/Ib study evaluating GDC-0077 alone and in combination with endocrine therapy (ET) ± palbociclib (palbo) in patients (pts) with <i>PIK3CA</i>-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC)","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Rash; Neutropenia; Internal medicine; Fulvestrant; Adverse effect; Dysgeusia; Gastroenterology; Letrozole; Maculopapular rash; Surgery; Breast cancer; Toxicity; Cancer; Estrogen receptor; Tamoxifen","score_opus":0.049800809997383504,"score_gpt":0.4119863499116258,"score_spread":0.3621855399142423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132319387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98873985,0.003437529,0.00005826656,0.0020950146,0.0000789691,0.0044245576,0.0010714887,0.000051007988,0.000043338165],"genre_scores_gemma":[0.9939315,0.0021914297,0.00093517045,0.00024623054,0.000096050026,0.0018718175,0.00047168488,0.00016261278,0.00009351007],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9929256,0.0013846763,0.000871784,0.0013786368,0.0023188079,0.0011205159],"domain_scores_gemma":[0.9961203,0.00076461607,0.00036389023,0.00061450835,0.0017724638,0.0003642268],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014355885,0.0006205143,0.0011513152,0.00048732597,0.00025849888,0.00008621193,0.0002582633,0.00009681586,0.00090113876],"category_scores_gemma":[0.00019750658,0.0004924481,0.00006604809,0.0021674142,0.0003804192,0.00063665013,0.00015715354,0.0013153057,0.0000065412914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09088978,0.015120414,0.61922747,0.0002234868,0.0017583285,0.00079508644,0.017470434,0.0006240062,0.11176803,0.000010872175,0.00005532421,0.14205675],"study_design_scores_gemma":[0.09851531,0.0047763376,0.86904514,0.0017891444,0.00010794152,0.00002391682,0.005301229,0.0001425742,0.019506909,0.00015595062,0.000095050265,0.0005405289],"about_ca_topic_score_codex":0.022150131,"about_ca_topic_score_gemma":0.021460382,"teacher_disagreement_score":0.24981762,"about_ca_system_score_codex":0.0021393115,"about_ca_system_score_gemma":0.0015417585,"threshold_uncertainty_score":0.9997527},"labels":[],"label_agreement":null},{"id":"W3132362195","doi":"10.1158/1538-7445.sabcs20-ps10-14","title":"Abstract PS10-14: Efficacy and safety of palbociclib (PAL) in patients (pts) with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) with preexisting conditions: A post hoc analysis of PALOMA-2","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Spinal Cord Injury BC","funders":"","keywords":"Medicine; Neutropenia; Internal medicine; Adverse effect; Breast cancer; Cancer; Placebo; Palbociclib; Estrogen receptor; Oncology; Gastroenterology; Metastatic breast cancer; Toxicity; Pathology","score_opus":0.027895225363218656,"score_gpt":0.36227043587781,"score_spread":0.33437521051459135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132362195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914299,0.0012512116,0.000023080867,0.00057180825,0.000033819924,0.0013944011,0.0050669326,0.00003125573,0.00019758566],"genre_scores_gemma":[0.99701303,0.0006311422,0.0010563714,0.00006231019,0.00007608276,0.00039386598,0.0005816899,0.000088453824,0.000097031705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995852,0.0003721536,0.0007933709,0.00094883144,0.0012407601,0.0007928831],"domain_scores_gemma":[0.99402165,0.0008106961,0.00052558584,0.000518918,0.003783561,0.00033961347],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037418114,0.00042433437,0.0012223161,0.00068300305,0.00025041692,0.00002985165,0.00022169658,0.00015531995,0.0016537266],"category_scores_gemma":[0.000275563,0.00034873202,0.00013668314,0.002823471,0.0011928923,0.00040567943,0.00012826279,0.00077719026,0.0000025612412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03658844,0.0012971393,0.8148007,0.000948887,0.0054057976,0.00007001428,0.0065750014,0.00074113585,0.09243541,0.0002280648,0.000027939663,0.04088148],"study_design_scores_gemma":[0.012249249,0.0015742182,0.93539953,0.002540017,0.00035216054,0.000008975106,0.0021460736,0.000010442819,0.04529103,0.00002813831,0.000042588315,0.00035754777],"about_ca_topic_score_codex":0.0030851348,"about_ca_topic_score_gemma":0.002746425,"teacher_disagreement_score":0.120598875,"about_ca_system_score_codex":0.0010251001,"about_ca_system_score_gemma":0.0010688399,"threshold_uncertainty_score":0.99989647},"labels":[],"label_agreement":null},{"id":"W3132423864","doi":"10.1158/1538-7445.sabcs20-ps14-13","title":"Abstract PS14-13: National comprehensive cancer network (NCCN) recommendations for drugs without US food and drug administration (FDA) approval in metastatic breast cancer: A cross-sectional study","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Metastatic breast cancer; Internal medicine; Cancer; Breast cancer; Confidence interval; Odds ratio; Oncology; Food and drug administration; Drug; Gynecology; Pharmacology","score_opus":0.13906231479616854,"score_gpt":0.48505789769048585,"score_spread":0.3459955828943173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132423864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98257256,0.0047086137,0.000113938506,0.007871807,0.0005168333,0.0024436354,0.0015863522,0.000048821836,0.00013741611],"genre_scores_gemma":[0.9899178,0.00065313425,0.0010575978,0.00045023265,0.0011653799,0.005726731,0.0002397747,0.00007316643,0.0007161621],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962,0.0002473952,0.000640932,0.00090772886,0.0012526475,0.0007512847],"domain_scores_gemma":[0.99596983,0.000620952,0.00018618163,0.00029278192,0.0026739356,0.000256314],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010573813,0.00029813166,0.00052296073,0.00027212786,0.0005268069,0.00018393745,0.0001671538,0.000091010304,0.00072064955],"category_scores_gemma":[0.00010586787,0.00030107604,0.0001018886,0.0009566137,0.00034007008,0.00038417755,0.00010959247,0.00080129923,0.0000039950287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066428874,0.0014323053,0.9411146,0.0008125891,0.0012902032,0.00004309551,0.002842224,0.006298299,0.003220056,0.0005065182,0.0025667155,0.033230484],"study_design_scores_gemma":[0.008840928,0.00036684744,0.9747452,0.00043680766,0.00007427949,0.00011163536,0.0028904183,0.0005217389,0.0010336973,0.0014319702,0.009181521,0.00036493587],"about_ca_topic_score_codex":0.002158523,"about_ca_topic_score_gemma":0.015414804,"teacher_disagreement_score":0.033630595,"about_ca_system_score_codex":0.0014993764,"about_ca_system_score_gemma":0.0040478697,"threshold_uncertainty_score":0.99994415},"labels":[],"label_agreement":null},{"id":"W3132547876","doi":"10.1158/1538-7445.sabcs20-ps12-28","title":"Abstract PS12-28: Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab, and a taxane as first-line therapy for locally advanced/metastatic triple-negative breast cancer (TNBC)","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Atezolizumab; Taxane; Medicine; Triple-negative breast cancer; Internal medicine; Oncology; Metastatic breast cancer; Phases of clinical research; Chemotherapy; Population; Breast cancer; Cancer; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Immunotherapy; Pembrolizumab","score_opus":0.159363250679661,"score_gpt":0.5174108302588322,"score_spread":0.35804757957917116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132547876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764498,0.0115808295,0.00052564114,0.0036390685,0.00020745523,0.0058523226,0.0016436052,0.000054850294,0.00004641594],"genre_scores_gemma":[0.98910093,0.0038895553,0.00087956066,0.0002539302,0.00022699115,0.0047607035,0.00017271945,0.000119172844,0.0005964499],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99524,0.00038824938,0.0009063256,0.0010059273,0.0015679516,0.0008915842],"domain_scores_gemma":[0.99406344,0.0010937095,0.00043039152,0.0006797753,0.0033744413,0.00035822528],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017300153,0.00043470325,0.00103311,0.00039564192,0.0004011291,0.00006571679,0.00026476115,0.000104926796,0.0009832811],"category_scores_gemma":[0.0010621098,0.00038608807,0.0001602789,0.0013083717,0.00040541674,0.00038781465,0.00012537019,0.0006734577,0.000006141269],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05358638,0.008349481,0.002499994,0.0014484775,0.0012532958,0.00025249805,0.0064433264,0.000562357,0.08296684,0.00007003617,0.00033930325,0.842228],"study_design_scores_gemma":[0.53088355,0.042820748,0.10277728,0.0074001327,0.0007913897,0.0004627479,0.032468308,0.00761193,0.2604142,0.008157253,0.004159576,0.0020528582],"about_ca_topic_score_codex":0.0017758633,"about_ca_topic_score_gemma":0.0012216102,"teacher_disagreement_score":0.84017515,"about_ca_system_score_codex":0.00078069326,"about_ca_system_score_gemma":0.0023348394,"threshold_uncertainty_score":0.99992996},"labels":[],"label_agreement":null},{"id":"W3132700492","doi":"10.1158/1538-7445.sabcs20-pd2-04","title":"Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Letrozole; Internal medicine; Anastrozole; Oncology; Tamoxifen; Hazard ratio; Placebo; Randomized controlled trial; Progression-free survival; Goserelin; Breast cancer; Chemotherapy; Gynecology; Cancer; Confidence interval; Pathology","score_opus":0.04548641285416216,"score_gpt":0.3831915911177023,"score_spread":0.33770517826354013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132700492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97398114,0.0014520298,0.00001950444,0.003874824,0.00019844166,0.003986511,0.016093645,0.00012213484,0.00027179185],"genre_scores_gemma":[0.9897844,0.002641441,0.000436387,0.00027186956,0.0008125776,0.0010989856,0.0031795416,0.00024175775,0.0015330066],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9926095,0.0010157417,0.0011089017,0.0015359103,0.0023911914,0.0013387327],"domain_scores_gemma":[0.99251616,0.0013403117,0.0007095658,0.001099228,0.003793888,0.00054082676],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000545991,0.00083575514,0.0014437723,0.00020689059,0.00053057505,0.00011422022,0.0005767991,0.00019499093,0.0047983937],"category_scores_gemma":[0.00025504697,0.00049954845,0.00017359824,0.0013175082,0.0011415381,0.0007632026,0.00018073707,0.001515997,0.000011013807],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71170163,0.0027997182,0.0035125378,0.00004508739,0.0020362015,0.00010669242,0.0024721643,0.000055223354,0.25789618,0.000028927565,0.0009541477,0.018391483],"study_design_scores_gemma":[0.39738294,0.00911347,0.35705268,0.00088949956,0.0001568099,0.00001590127,0.00091311405,0.000009779624,0.2308801,0.00003576185,0.0027712404,0.0007786866],"about_ca_topic_score_codex":0.01599763,"about_ca_topic_score_gemma":0.0017163034,"teacher_disagreement_score":0.35354015,"about_ca_system_score_codex":0.0012442063,"about_ca_system_score_gemma":0.0023304445,"threshold_uncertainty_score":0.9997456},"labels":[],"label_agreement":null},{"id":"W3133383562","doi":"10.1158/1538-7445.sabcs20-ps10-37","title":"Abstract PS10-37: Real-world experience of patients treated for HER2-positive metastatic breast cancer at the centre hospitalier universitaire de Quebec: A retrospective cohort study","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Lapatinib; Metastatic breast cancer; Pertuzumab; Trastuzumab emtansine; Trastuzumab; Internal medicine; Breast cancer; Cancer; Retrospective cohort study; Oncology; Population; Cohort; Progression-free survival; Chemotherapy","score_opus":0.026404129970632552,"score_gpt":0.3778593476893832,"score_spread":0.3514552177187506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133383562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927371,0.0006311535,0.000008673063,0.0017193903,0.00010295003,0.002896848,0.0013644672,0.000031765467,0.0005076384],"genre_scores_gemma":[0.9854919,0.00034011566,0.000042751213,0.00007186116,0.00010400061,0.00083586253,0.00008963764,0.00006241186,0.01296149],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99692696,0.00024296157,0.00032409286,0.0007033623,0.001058636,0.0007439888],"domain_scores_gemma":[0.996078,0.00028073427,0.00017254936,0.00060435425,0.0026378252,0.00022651446],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040229547,0.00026185127,0.0005682027,0.00013248208,0.00038965806,0.00003177487,0.00025553902,0.00005591661,0.001611021],"category_scores_gemma":[0.000092207396,0.00020059301,0.00015305827,0.00113447,0.0006080936,0.00020463901,0.00017611374,0.00038231752,0.0000052874952],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027084725,0.00085911585,0.97422105,0.00011747789,0.0009369907,0.0001046181,0.009941854,0.000038624203,0.0034032655,0.00005718987,0.000983152,0.0066281958],"study_design_scores_gemma":[0.0031720977,0.00029270095,0.9625114,0.00032713116,0.00021506124,0.0000052330033,0.016183125,0.000011436331,0.016392734,0.000038905033,0.00066536345,0.00018479362],"about_ca_topic_score_codex":0.050465137,"about_ca_topic_score_gemma":0.08415988,"teacher_disagreement_score":0.03369474,"about_ca_system_score_codex":0.00604288,"about_ca_system_score_gemma":0.0012378267,"threshold_uncertainty_score":0.9993016},"labels":[],"label_agreement":null},{"id":"W3133509869","doi":"10.1056/nejmoa1911149","title":"Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":841,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Institutes for BioMedical Research; Astex Pharmaceuticals; Novartis","keywords":"Fulvestrant; Oncology; Medicine; Internal medicine; Interim analysis; Cancer; Breast cancer; Human Epidermal Growth Factor Receptor 2; Hormone receptor; Metastatic breast cancer; Clinical trial; Estrogen receptor","score_opus":0.011255360947923886,"score_gpt":0.2819309661319838,"score_spread":0.2706756051840599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133509869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773268,0.0032502492,0.00047620514,0.016823368,0.00085160346,0.0002809729,0.000007364144,0.000017414197,0.0009660087],"genre_scores_gemma":[0.9937384,0.000640539,0.00096230715,0.0008585639,0.002757485,0.0000028085663,0.0000038638177,0.00004065941,0.0009953774],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981186,0.00005779476,0.00056009943,0.00020489948,0.00071865,0.00033996717],"domain_scores_gemma":[0.9986746,0.00013879726,0.000368529,0.00022543961,0.00024319782,0.0003494432],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045434857,0.00023946416,0.0009082089,0.00022954617,0.00001855193,0.0000055903483,0.00014148769,0.000064292515,0.0009287264],"category_scores_gemma":[0.000039011888,0.00014073573,0.00006365944,0.00025988554,0.000109841654,0.00023852236,0.000013747856,0.0005963921,0.000005831987],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057521276,0.00020469372,0.36119646,0.00030065328,0.0005125848,0.001574342,0.0038114311,0.0062663504,0.036799833,0.00034764342,0.00037448478,0.53109026],"study_design_scores_gemma":[0.35098335,0.00427553,0.5875906,0.0053248745,0.00025846888,0.010234743,0.0010620969,0.00012150965,0.0005122765,0.0006100159,0.03867001,0.00035655554],"about_ca_topic_score_codex":0.00037267333,"about_ca_topic_score_gemma":0.00026468656,"teacher_disagreement_score":0.5307337,"about_ca_system_score_codex":0.00028891634,"about_ca_system_score_gemma":0.00063367333,"threshold_uncertainty_score":0.99998456},"labels":[],"label_agreement":null},{"id":"W3134027539","doi":"10.2217/fon-2020-1264","title":"CDK4/6 Inhibitors in HR+/HER2- Advanced/metastatic Breast Cancer: A Systematic Literature Review of Real-World Evidence Studies","year":2021,"lang":"en","type":"review","venue":"Future Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Medicine; Oncology; Metastatic breast cancer; Internal medicine; Breast cancer; Trastuzumab; Real world evidence; Cancer; Gynecology","score_opus":0.061872516632544144,"score_gpt":0.45566446360252355,"score_spread":0.39379194696997943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134027539","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000016964951,0.9889974,0.000002831855,0.0027600876,0.0022002012,0.005445968,0.00025892243,0.000072263254,0.00026060943],"genre_scores_gemma":[0.0000018595275,0.9905137,0.0018030489,0.001102822,0.0015964234,0.0035527851,0.00014392188,0.0001614059,0.0011240523],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99233884,0.0018674157,0.0031909521,0.0011733292,0.00070941966,0.0007200618],"domain_scores_gemma":[0.99288094,0.0016428994,0.0027765587,0.0013325098,0.0011365263,0.00023059375],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012666403,0.001164902,0.013878906,0.0008266321,0.000061719504,0.000016104834,0.00049156934,0.0004915995,0.00019832568],"category_scores_gemma":[0.00082208315,0.00081155077,0.0011318253,0.00390862,0.0003085603,0.00026108566,0.00024718206,0.001697328,0.000018028579],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006192512,0.00013220833,0.0000101737005,0.59887075,0.000842752,0.00084152207,0.00032803457,6.587494e-7,0.0000012619238,0.00009184145,0.0011600681,0.3976588],"study_design_scores_gemma":[0.0004992508,0.00019011767,0.0000105146955,0.5758204,0.0033596023,0.0020945303,0.00034519073,1.6288276e-7,7.59632e-7,0.000012788733,0.41734427,0.00032239876],"about_ca_topic_score_codex":0.000035774752,"about_ca_topic_score_gemma":0.0006079005,"teacher_disagreement_score":0.41618422,"about_ca_system_score_codex":0.003433783,"about_ca_system_score_gemma":0.003160235,"threshold_uncertainty_score":0.9994335},"labels":[],"label_agreement":null},{"id":"W3135561905","doi":"10.21203/rs.3.rs-236645/v1","title":"High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer","year":2021,"lang":"en","type":"preprint","venue":"Research Square","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Congressionally Directed Medical Research Programs; Manchester Biomedical Research Centre; National Institutes of Health; Fundació la Marató de TV3; Fundación Fero; Ipsen; Instituto de Salud Carlos III; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Generalitat de Catalunya; Fundación Científica Asociación Española Contra el Cáncer; National Institute for Health and Care Research; Horizon 2020 Framework Programme; Cancer Research UK; Agència de Gestió d'Ajuts Universitaris i de Recerca; Pfizer; Novartis Pharmaceuticals Corporation; Institute for Research in Biomedicine; Centres de Recerca de Catalunya; Genentech; Ministerio de Economía y Competitividad; Memorial Sloan-Kettering Cancer Center; European Commission; Breast Cancer Research Foundation; Eli Lilly and Company","keywords":"Cancer research; Breast cancer; Cancer; Oncology; Expression (computer science); Internal medicine; Medicine; Computer science","score_opus":0.03926612108891776,"score_gpt":0.38955948678827357,"score_spread":0.3502933656993558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135561905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94595754,0.038173944,0.00031681656,0.009049699,0.00058371056,0.0036444163,0.00207456,0.00011857544,0.00008076177],"genre_scores_gemma":[0.9879666,0.0027925838,0.0039204047,0.00012100288,0.0010213896,0.0027924357,0.0002966045,0.00016855416,0.0009204483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951159,0.0003863134,0.00058242644,0.0015077476,0.00129347,0.001114142],"domain_scores_gemma":[0.9965507,0.0004380825,0.0002425939,0.0011057296,0.0012362314,0.00042670243],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00087009056,0.0005154569,0.0010242655,0.0006397599,0.00023280016,0.00018611325,0.00032492913,0.0005706348,0.00020865434],"category_scores_gemma":[0.00032731023,0.00047066217,0.00020690938,0.00058101444,0.0005094906,0.00019092427,0.00094514835,0.0016327014,0.0000033833342],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0890793,0.00347796,0.39642996,0.12588283,0.0025325108,0.008310337,0.012237546,0.0008794709,0.20890093,0.00041249563,0.018659128,0.13319753],"study_design_scores_gemma":[0.026258634,0.0007145658,0.70827156,0.16089986,0.0001802596,0.00040142832,0.011666515,0.0003384245,0.052546322,0.0063800486,0.029505294,0.002837104],"about_ca_topic_score_codex":0.00086525053,"about_ca_topic_score_gemma":0.0021721728,"teacher_disagreement_score":0.31184158,"about_ca_system_score_codex":0.0014539007,"about_ca_system_score_gemma":0.0009192427,"threshold_uncertainty_score":0.9997745},"labels":[],"label_agreement":null},{"id":"W3136856529","doi":"10.1158/1538-7445.sabcs20-pd3-03","title":"Abstract PD3-03: Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Neratinib; Medicine; Oncology; Breast cancer; Internal medicine; Trastuzumab; Hazard ratio; Placebo; Stage (stratigraphy); Cancer; Confidence interval; Pathology","score_opus":0.04989331607234977,"score_gpt":0.4014012699091703,"score_spread":0.35150795383682054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136856529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924301,0.0015167537,0.00007973093,0.0013234881,0.00017278192,0.0022139258,0.0020817027,0.00001904443,0.00016247317],"genre_scores_gemma":[0.9974646,0.00030780025,0.000115927534,0.00011683846,0.0005077472,0.00053703063,0.00037495245,0.000050359326,0.0005247752],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954515,0.0010216071,0.0006989431,0.0006946639,0.0014882071,0.00064508594],"domain_scores_gemma":[0.99543047,0.0020200503,0.00029269207,0.0006969258,0.0013584158,0.00020143099],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012445445,0.00030011588,0.0014822041,0.00024011747,0.0001416727,0.00007457191,0.0002888818,0.000116211035,0.0025632796],"category_scores_gemma":[0.0003571397,0.00019789145,0.00033562645,0.0014672392,0.0006668738,0.00016576481,0.0000985641,0.00086616987,0.000005287855],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91062444,0.0014136229,0.06791645,0.00003695741,0.0029849575,0.00009270987,0.0014227935,0.0006495906,0.0026729954,0.000034486235,0.000058935813,0.012092031],"study_design_scores_gemma":[0.51139784,0.00028138646,0.4849312,0.00029746586,0.000389467,5.359977e-7,0.0001702392,0.000056570258,0.0021563303,0.000019624418,0.00015040039,0.00014895815],"about_ca_topic_score_codex":0.025758555,"about_ca_topic_score_gemma":0.0048241457,"teacher_disagreement_score":0.41701475,"about_ca_system_score_codex":0.00044439425,"about_ca_system_score_gemma":0.0012697257,"threshold_uncertainty_score":0.99834853},"labels":[],"label_agreement":null},{"id":"W3138361250","doi":"10.1016/s0960-9776(21)00144-2","title":"Efficacy of fulvestrant in hormone refractory metastatic breast cancer (mBC): a Canadian province experience","year":2021,"lang":"en","type":"article","venue":"The Breast","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Fulvestrant; Metastatic breast cancer; Oncology; Refractory (planetary science); Cancer; Internal medicine; Breast cancer; Gynecology; Tamoxifen","score_opus":0.0176664327392084,"score_gpt":0.2939968056899863,"score_spread":0.2763303729507779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138361250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98643327,0.0054211295,0.000070059694,0.0065250937,0.00011017128,0.000515768,0.00034213345,0.00003532127,0.00054704107],"genre_scores_gemma":[0.9982232,0.00018789244,0.00038180395,0.0005337117,0.00011169816,0.00008611904,0.000016537253,0.00003864852,0.0004204027],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99834424,0.00009446828,0.0003752439,0.00035148655,0.00033939848,0.0004951887],"domain_scores_gemma":[0.9987017,0.0000914914,0.00013102741,0.00062844175,0.00017609587,0.0002712486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015899095,0.00022376893,0.00042724752,0.000122979,0.00007500495,0.000014133841,0.0002260408,0.000049401715,0.0003815976],"category_scores_gemma":[0.000037995054,0.00016387603,0.0000909529,0.00054190756,0.00032180749,0.00015485109,0.000043217657,0.00030045625,0.000013334801],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067092776,0.0021297422,0.033244006,0.00052713254,0.0007399711,0.0026317767,0.021942923,0.00065888715,0.32717088,0.001322841,0.00031334095,0.6026092],"study_design_scores_gemma":[0.0039809337,0.000095815,0.97899956,0.0005601799,0.0001282493,0.00535712,0.0027642772,0.00008986685,0.0040344656,0.00011134636,0.0035816515,0.00029655948],"about_ca_topic_score_codex":0.077710874,"about_ca_topic_score_gemma":0.08190364,"teacher_disagreement_score":0.94575554,"about_ca_system_score_codex":0.00048624675,"about_ca_system_score_gemma":0.002208141,"threshold_uncertainty_score":0.9348492},"labels":[],"label_agreement":null},{"id":"W3141372695","doi":"10.1016/s1470-2045(21)00034-6","title":"Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":349,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Fulvestrant; Medicine; Aromatase inhibitor; Internal medicine; Oncology; Breast cancer; Cancer; Cohort; Regimen; Clinical endpoint; Clinical trial; Estrogen receptor; Aromatase","score_opus":0.05096464552649327,"score_gpt":0.3993410276253444,"score_spread":0.34837638209885113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3141372695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985802,0.0031666746,0.00016606828,0.004376505,0.0003509767,0.004251107,0.0006441794,0.000050389655,0.0011921296],"genre_scores_gemma":[0.991376,0.0007411645,0.0039223973,0.0013173176,0.00051705335,0.0016850181,0.00009132913,0.00006405955,0.00028565203],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99633604,0.00064129604,0.0009027992,0.0008396989,0.00046633842,0.00081383064],"domain_scores_gemma":[0.99749464,0.00036741773,0.00047514244,0.00081784587,0.0006364345,0.00020850061],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062193,0.00047564472,0.0023317635,0.00013221406,0.0000993648,0.00002923351,0.0004830911,0.00017981787,0.00043147217],"category_scores_gemma":[0.00005702757,0.0003730007,0.00008176919,0.00086486514,0.00045676847,0.00032783885,0.00036162676,0.00081046496,0.00003132568],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30301258,0.044008065,0.029386058,0.00028070403,0.0043626493,0.0027796414,0.06302731,0.0010093768,0.46720022,0.000084025094,0.00094824296,0.0839011],"study_design_scores_gemma":[0.3867896,0.011467324,0.5113239,0.0018806426,0.0013960887,0.0007895908,0.035435762,0.0015030922,0.043459345,0.00014063716,0.0044927737,0.0013212408],"about_ca_topic_score_codex":0.00082829245,"about_ca_topic_score_gemma":0.0026978345,"teacher_disagreement_score":0.48193786,"about_ca_system_score_codex":0.0012225263,"about_ca_system_score_gemma":0.0012237461,"threshold_uncertainty_score":0.9998722},"labels":[],"label_agreement":null},{"id":"W3148345241","doi":"10.1200/jco.20.03639","title":"Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":324,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Palbociclib; Oncology; Internal medicine; Lapatinib; Taxane; Breast cancer; Letrozole; Estrogen receptor; Hormone receptor; Aromatase inhibitor; Gynecology; Tamoxifen; Cancer; Trastuzumab; Metastatic breast cancer","score_opus":0.08584686499972378,"score_gpt":0.4566029099254679,"score_spread":0.37075604492574415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3148345241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9484771,0.0011307308,0.00029233444,0.047230765,0.0018223731,0.00065865467,0.00015989676,0.000009022399,0.00021911337],"genre_scores_gemma":[0.97644764,0.0033048005,0.0071878945,0.0050673992,0.0072172717,0.00005826026,0.0000049534247,0.000041606672,0.0006701474],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9962011,0.0010111831,0.0017768502,0.0003225135,0.0003736487,0.0003147351],"domain_scores_gemma":[0.98284024,0.012742495,0.002197641,0.00021225508,0.0016581522,0.0003492074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00223858,0.00020389582,0.001622408,0.00005865182,0.00015448769,0.000024411003,0.00017060582,0.00034899043,0.00017529611],"category_scores_gemma":[0.0067536877,0.00012932913,0.00042499896,0.00016098519,0.000638083,0.00015892205,0.00009182459,0.0012378985,0.0000040385285],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39613768,0.0012943911,0.03206012,0.00005085299,0.0029967765,0.00086382066,0.0019028095,0.000031434603,0.00029291608,0.0004960574,0.002871875,0.5610013],"study_design_scores_gemma":[0.17343986,0.019896468,0.77394915,0.00034006746,0.0015393525,0.0014328624,0.0013840641,0.00000641762,0.0013537881,0.010544686,0.015900506,0.00021280255],"about_ca_topic_score_codex":0.00038771302,"about_ca_topic_score_gemma":0.0011352276,"teacher_disagreement_score":0.741889,"about_ca_system_score_codex":0.00023075142,"about_ca_system_score_gemma":0.004112468,"threshold_uncertainty_score":0.8085283},"labels":[],"label_agreement":null},{"id":"W3150431332","doi":"","title":"Treatment Timing of Triple-Negative Breast Cancer","year":2020,"lang":"en","type":"article","venue":"Scholarship at UWindsor (University of Windsor)","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Medicine; Cancer; Oncology; Internal medicine","score_opus":0.0440538659612367,"score_gpt":0.27650631178727736,"score_spread":0.23245244582604066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3150431332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98990804,0.00044926678,0.00019379197,0.0072537805,0.00009347728,0.00048502223,0.00040419985,0.000072153736,0.0011402819],"genre_scores_gemma":[0.9954432,0.00011648452,0.0023771198,0.00025521987,0.00011766934,0.0000014121929,0.000020901767,0.000034209548,0.0016337308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984995,0.000083409905,0.00022884677,0.00044209356,0.00042437913,0.00032178234],"domain_scores_gemma":[0.99863815,0.00007219459,0.00032703837,0.000332367,0.00028503273,0.0003452253],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000092781054,0.00026289813,0.00068104634,0.0001563084,0.00017272883,0.000005496427,0.00025281997,0.0001494066,0.002014338],"category_scores_gemma":[0.00004979159,0.00027843937,0.0003002562,0.0005361796,0.00033050566,0.00042637263,0.0001235237,0.00025817746,0.000047763308],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022241056,0.00083657226,0.63834137,0.0006997168,0.0023008836,0.0003221841,0.03264698,0.00019835423,0.21257348,0.00022128575,0.00025530093,0.089362815],"study_design_scores_gemma":[0.015695076,0.0012591329,0.9127453,0.00040745197,0.00077196286,0.00012924576,0.006607608,0.00023835672,0.057108756,0.00014018989,0.004422826,0.00047410978],"about_ca_topic_score_codex":0.00036453403,"about_ca_topic_score_gemma":0.00010002968,"teacher_disagreement_score":0.27440393,"about_ca_system_score_codex":0.00043158428,"about_ca_system_score_gemma":0.00026293853,"threshold_uncertainty_score":0.9999668},"labels":[],"label_agreement":null},{"id":"W3157276232","doi":"10.1002/onco.13804","title":"Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2–, <i>PIK3CA</i>-Mutated Breast Cancer","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Fulvestrant; Medicine; Internal medicine; Oncology; Aromatase inhibitor; Breast cancer; Cohort; Letrozole; Metastatic breast cancer; Palbociclib; Cancer; Clinical trial; Estrogen receptor; Aromatase","score_opus":0.01295471819976937,"score_gpt":0.2979926871360865,"score_spread":0.28503796893631717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157276232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955664,0.00027745217,0.00023465442,0.00055153423,0.00010614859,0.0012077455,0.0005011473,0.00009691223,0.0014579635],"genre_scores_gemma":[0.9984083,0.000110595574,0.0005446876,0.00007887064,0.00006246689,0.000240272,0.00015030506,0.000056692174,0.00034779988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981046,0.00028481506,0.0003141922,0.0004337441,0.00047512248,0.00038752475],"domain_scores_gemma":[0.9980512,0.0002893925,0.00028862266,0.0005789495,0.0006499991,0.00014179647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018680576,0.00035180917,0.0008778638,0.000058592937,0.00013442097,0.000019445275,0.0001390151,0.00005895512,0.00014224571],"category_scores_gemma":[0.000010159527,0.00018063224,0.00008863102,0.0005900406,0.00087575294,0.00010315072,0.0000376518,0.00018855454,0.0000021837682],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04621675,0.0017135576,0.926801,0.000346537,0.0014652341,0.00031564242,0.0006918163,0.004451909,0.001982386,0.000083669736,0.000042898257,0.015888603],"study_design_scores_gemma":[0.016937004,0.0025511757,0.9616889,0.0011332133,0.0005651831,0.00006694893,0.00041395877,0.000031081512,0.015823733,0.000030050116,0.0005187061,0.00024009706],"about_ca_topic_score_codex":0.004953731,"about_ca_topic_score_gemma":0.009819921,"teacher_disagreement_score":0.03488785,"about_ca_system_score_codex":0.0012095186,"about_ca_system_score_gemma":0.0008011834,"threshold_uncertainty_score":0.7488592},"labels":[],"label_agreement":null},{"id":"W3160261501","doi":"10.1007/s40273-021-01028-3","title":"Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2− Advanced Breast Cancer: A Canadian Healthcare Perspective","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Breast cancer; Quality-adjusted life year; Tamoxifen; Discontinuation; Aromatase inhibitor; Cost effectiveness; Internal medicine; Oncology; Cost-effectiveness analysis; Health economics; Gynecology; Hazard ratio; Cancer; Public health; Confidence interval","score_opus":0.02113951258208011,"score_gpt":0.3660010550140271,"score_spread":0.34486154243194694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3160261501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985506,0.007833676,0.000023978118,0.0028661254,0.00031647008,0.0011343686,0.002183878,0.00003245006,0.00010303243],"genre_scores_gemma":[0.99719346,0.00087345234,0.00041493238,0.00089893566,0.00015305857,0.00028471352,0.00009669834,0.00006115026,0.00002360473],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983183,0.00014848389,0.0003828201,0.0005741424,0.00009467251,0.00048158504],"domain_scores_gemma":[0.99872655,0.00012848261,0.0001482064,0.00027068894,0.00022771822,0.0004983356],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020621004,0.0002823113,0.0006922943,0.00019607255,0.00007347887,0.000020470514,0.000091407834,0.00008893911,0.000099506746],"category_scores_gemma":[0.00002214965,0.00032274233,0.000060407183,0.00022217054,0.00017033328,0.00028290454,0.00006644679,0.0003329926,0.000005116569],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03937608,0.0013268515,0.2498177,0.0058398275,0.001793074,0.0015357491,0.01951557,0.008115441,0.5279966,0.0021092235,0.000185286,0.14238858],"study_design_scores_gemma":[0.06347408,0.000914296,0.48986787,0.0036610137,0.0004499546,0.0031246904,0.011343097,0.0036004605,0.41292453,0.0009161267,0.007833419,0.0018904618],"about_ca_topic_score_codex":0.07516361,"about_ca_topic_score_gemma":0.08030609,"teacher_disagreement_score":0.24005017,"about_ca_system_score_codex":0.0027301337,"about_ca_system_score_gemma":0.002630457,"threshold_uncertainty_score":0.99992245},"labels":[],"label_agreement":null},{"id":"W3162472509","doi":"10.3390/curroncol28030168","title":"Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer","year":2021,"lang":"en","type":"review","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Breast cancer; Targeted therapy; Hormone therapy; Endocrine system; Oncology; Internal medicine; Hormone receptor; Systemic therapy; Cancer; Clinical trial; Disease; Hormone","score_opus":0.08954103463427499,"score_gpt":0.4406341625788522,"score_spread":0.3510931279445772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162472509","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009496979,0.9950862,0.000020039319,0.00020968022,0.001276092,0.0014789394,0.0008732465,0.000029305736,0.00007680241],"genre_scores_gemma":[0.0002881508,0.9977448,0.00014569271,0.000028594724,0.0005839091,0.0006304941,0.00047940793,0.0000762223,0.000022703276],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971298,0.0005391874,0.00087399967,0.0007369452,0.0002671362,0.00045291838],"domain_scores_gemma":[0.99796057,0.00041007702,0.00072453846,0.00033207625,0.0003891684,0.00018357436],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022405863,0.0005976243,0.0035641252,0.00037120332,0.000037565333,0.000008053621,0.00016285102,0.00036150205,0.0004567161],"category_scores_gemma":[0.000059935384,0.00046858258,0.00033321453,0.00072545523,0.00033801683,0.0000753203,0.00012496674,0.0011260185,0.000007986253],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038517275,0.00075563934,0.00094786816,0.0038785602,0.0004106837,0.000019093522,0.0007253426,4.118418e-7,0.000008643485,0.000030698004,0.0004932665,0.9923446],"study_design_scores_gemma":[0.0037489168,0.0005663809,0.0056542307,0.024166934,0.0004499956,0.00019601655,0.00018676271,0.0000032803973,0.000014391606,0.000028100445,0.96458346,0.0004015319],"about_ca_topic_score_codex":0.000082992265,"about_ca_topic_score_gemma":0.000059760463,"teacher_disagreement_score":0.99194306,"about_ca_system_score_codex":0.0008067929,"about_ca_system_score_gemma":0.001583063,"threshold_uncertainty_score":0.9997766},"labels":[],"label_agreement":null},{"id":"W3164810856","doi":"10.3390/cancers13164163","title":"Efficacy of Fulvestrant in Women with Hormone-Resistant Metastatic Breast Cancer (mBC): A Canadian Province Experience","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan","funders":"Mach-Gaensslen Foundation of Canada","keywords":"Fulvestrant; Medicine; Metastatic breast cancer; Internal medicine; Oncology; Cancer; Breast cancer; Chemotherapy; Gynecology; Tamoxifen","score_opus":0.01206057694611545,"score_gpt":0.27197099234825245,"score_spread":0.259910415402137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164810856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931399,0.0046973904,0.00007617719,0.00096366205,0.00007542824,0.0004687838,0.00020545973,0.000025985957,0.00034718512],"genre_scores_gemma":[0.997463,0.000268372,0.0009588378,0.00065291877,0.000048513517,0.0003335473,0.0000071687277,0.000041640586,0.00022602013],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99824095,0.00003629359,0.0003212247,0.00043663516,0.00032609294,0.0006388211],"domain_scores_gemma":[0.99880964,0.000038260237,0.00012193636,0.00041058435,0.00017831358,0.00044129018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007820398,0.0002300461,0.00049451046,0.00015529951,0.000049252627,0.000013159472,0.00013367482,0.000041734926,0.00030661462],"category_scores_gemma":[0.000025404026,0.00019585658,0.000042776905,0.000694989,0.00029853743,0.00015025765,0.000017176175,0.00019524306,0.0000020473656],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.056178614,0.0006139934,0.02825443,0.001957438,0.0018677593,0.0093383165,0.07341235,0.022540431,0.48491544,0.00083361275,0.00036416412,0.31972346],"study_design_scores_gemma":[0.021256063,0.0012290016,0.89503765,0.0029130063,0.00024396121,0.00090627634,0.028700523,0.00030180157,0.027837275,0.0001058937,0.02029435,0.0011742199],"about_ca_topic_score_codex":0.11097994,"about_ca_topic_score_gemma":0.21654329,"teacher_disagreement_score":0.8667832,"about_ca_system_score_codex":0.0062294877,"about_ca_system_score_gemma":0.012283748,"threshold_uncertainty_score":0.9975854},"labels":[],"label_agreement":null},{"id":"W3166379207","doi":"10.1200/jco.2021.39.15_suppl.1060","title":"Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–), <i>PIK3CA</i>-mutated advanced breast cancer (ABC) from BYLieve.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Fulvestrant; Internal medicine; Cohort; Letrozole; Oncology; Palbociclib; Proportional hazards model; Gastroenterology; Cancer; Breast cancer; Metastatic breast cancer; Estrogen receptor; Aromatase","score_opus":0.03335397663975626,"score_gpt":0.39071425035157153,"score_spread":0.3573602737118153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166379207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99492675,0.00078598596,0.00007662345,0.0016388333,0.0006655499,0.00081099686,0.0009735459,0.000017131862,0.00010456242],"genre_scores_gemma":[0.9931012,0.0019549187,0.0032861892,0.00058686273,0.00077338034,0.000027411113,0.00014140528,0.000086354565,0.00004227599],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99279284,0.0008952053,0.004097967,0.0006444684,0.0010643122,0.000505187],"domain_scores_gemma":[0.9881216,0.0020593703,0.0056103407,0.00039754756,0.0033266863,0.00048443547],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007999029,0.00053990405,0.0030511706,0.00028930666,0.000077419754,0.0000136783465,0.0002756452,0.0005694204,0.0007254286],"category_scores_gemma":[0.0011253555,0.00038495768,0.000702941,0.00055487663,0.00048547162,0.00060155656,0.000074851225,0.0015771204,0.0000053250287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15747455,0.01305585,0.3923499,0.000045848235,0.0026675642,0.0002449813,0.001933744,0.00077422743,0.10976064,0.000021729898,0.00017030547,0.32150066],"study_design_scores_gemma":[0.049401946,0.029874904,0.8750042,0.0008783426,0.00018404884,0.00003614863,0.00027602882,0.000014239306,0.04373559,0.00017032133,0.00010215899,0.00032212396],"about_ca_topic_score_codex":0.0010148663,"about_ca_topic_score_gemma":0.0005253778,"teacher_disagreement_score":0.48265424,"about_ca_system_score_codex":0.0014187807,"about_ca_system_score_gemma":0.0020672285,"threshold_uncertainty_score":0.9998602},"labels":[],"label_agreement":null},{"id":"W3167855488","doi":"10.1016/j.annonc.2021.05.353","title":"Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":278,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Institutes for BioMedical Research; Astex Pharmaceuticals","keywords":"Medicine; Fulvestrant; Internal medicine; Hazard ratio; Population; Breast cancer; Placebo; Metastatic breast cancer; Progression-free survival; Clinical endpoint; Oncology; Cancer; Randomized controlled trial; Gastroenterology; Confidence interval; Chemotherapy; Estrogen receptor; Pathology","score_opus":0.04265747474552653,"score_gpt":0.3792816454752698,"score_spread":0.33662417072974327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167855488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741296,0.001107716,0.00034059896,0.017462157,0.00028477266,0.0041897413,0.0019420444,0.000054008935,0.00048931624],"genre_scores_gemma":[0.9915453,0.001140194,0.0014628555,0.0026229366,0.00039253492,0.0019744083,0.00048224715,0.00008174973,0.00029773495],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958178,0.0010875149,0.0011001948,0.00066806516,0.00047427905,0.00085214816],"domain_scores_gemma":[0.99573857,0.0017047094,0.0007825748,0.00037487227,0.0011708959,0.00022836895],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010634119,0.00048572817,0.0024569882,0.0001656542,0.00015134446,0.000018797724,0.00026064657,0.00023515282,0.00076749735],"category_scores_gemma":[0.0002773476,0.0003348687,0.00023085298,0.00044733097,0.0006769531,0.00032616456,0.0000541309,0.0004811682,0.0000029057103],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88463044,0.0018436967,0.000031040818,0.00005985728,0.0013590154,0.00009446558,0.004889777,0.000049624126,0.080750346,0.00071101484,0.0003530891,0.025227638],"study_design_scores_gemma":[0.951797,0.01434466,0.0045188684,0.0001513401,0.00021414047,0.00011496144,0.0025732752,0.000029207553,0.021381263,0.0011556804,0.0032570306,0.000462569],"about_ca_topic_score_codex":0.00034992173,"about_ca_topic_score_gemma":0.00019722579,"teacher_disagreement_score":0.06716657,"about_ca_system_score_codex":0.00047093973,"about_ca_system_score_gemma":0.0011820422,"threshold_uncertainty_score":0.99991035},"labels":[],"label_agreement":null},{"id":"W3169437264","doi":"10.1200/jco.2021.39.15_suppl.1001","title":"Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Hazard ratio; Fulvestrant; Internal medicine; Breast cancer; Placebo; Oncology; Cancer; Nuclear medicine; Surgery; Confidence interval; Estrogen receptor; Pathology","score_opus":0.052988043005200325,"score_gpt":0.41162090071855323,"score_spread":0.3586328577133529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169437264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98742354,0.0004345973,0.00010808136,0.008824598,0.0009879627,0.0007275337,0.0010298707,0.000025166577,0.0004386778],"genre_scores_gemma":[0.9933224,0.00066178467,0.0023576412,0.0015943925,0.0014457126,0.000019303541,0.00025401384,0.00007002164,0.00027473117],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99340266,0.00094629056,0.0034512659,0.0005744287,0.00112218,0.0005031691],"domain_scores_gemma":[0.9897849,0.0026986676,0.004036696,0.00060305226,0.0023560915,0.0005205969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013067559,0.0004348794,0.0027578138,0.00008102599,0.00009727649,0.000017338358,0.00035813675,0.0003911288,0.0004184484],"category_scores_gemma":[0.00077003014,0.00023655387,0.00038465072,0.0004078696,0.0007029335,0.00031249286,0.00006944861,0.0014387885,0.0000038305093],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8564014,0.008872553,0.018820211,0.0000140935235,0.0028447153,0.0011868684,0.00025004783,0.00032757872,0.001628015,0.000026247973,0.00038587814,0.10924241],"study_design_scores_gemma":[0.669721,0.052027438,0.2562574,0.00055891386,0.0018032257,0.0004673628,0.00037186185,0.000045752124,0.0009061275,0.00012006013,0.017391877,0.00032892782],"about_ca_topic_score_codex":0.0004965048,"about_ca_topic_score_gemma":0.00080602034,"teacher_disagreement_score":0.23743722,"about_ca_system_score_codex":0.0003538871,"about_ca_system_score_gemma":0.0037058475,"threshold_uncertainty_score":0.96463865},"labels":[],"label_agreement":null},{"id":"W3169955705","doi":"10.1200/jco.2021.39.15_suppl.1051","title":"Correlation between work productivity loss (WPL) and European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) domains from the MONALEESA-7 (ML-7) trial of premenopausal women with HR+/HER2- advanced breast cancer (ABC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Quality of life (healthcare); Cancer; Physical therapy; Correlation; Placebo; Gerontology; Internal medicine","score_opus":0.15065157392538775,"score_gpt":0.48617013079030325,"score_spread":0.3355185568649155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169955705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989005,0.0021728158,0.00089697423,0.0067898966,0.00026455405,0.0007205371,0.00013025822,0.0000052940686,0.0000146665925],"genre_scores_gemma":[0.9954726,0.0017428492,0.0011985475,0.00005187679,0.0014193028,0.0000228928,0.000012176852,0.000030488984,0.000049257484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960437,0.001297414,0.0016818886,0.00029452238,0.00048522282,0.00019725879],"domain_scores_gemma":[0.9922544,0.0026608794,0.0022428911,0.0002514689,0.0023893854,0.00020097331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030278342,0.00014776684,0.0013584243,0.000056869576,0.00008371376,0.000006398051,0.000087346176,0.00014428927,0.000039588747],"category_scores_gemma":[0.0024393518,0.000092519964,0.00006957847,0.00035756544,0.0008217081,0.00014371038,0.000050574166,0.0003564595,1.11942185e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12730537,0.0013480175,0.6580009,0.000082889244,0.0009084893,0.000009228469,0.0011489488,0.00019168241,0.0010522146,0.000040917963,0.00001115636,0.20990023],"study_design_scores_gemma":[0.04584252,0.011465308,0.939661,0.00042634024,0.00031966768,0.000018242723,0.000435725,0.0000037771306,0.0005539743,0.0004912371,0.0007053991,0.000076795266],"about_ca_topic_score_codex":0.0002920289,"about_ca_topic_score_gemma":0.00048790482,"teacher_disagreement_score":0.28166014,"about_ca_system_score_codex":0.0003906738,"about_ca_system_score_gemma":0.0018940669,"threshold_uncertainty_score":0.37728545},"labels":[],"label_agreement":null},{"id":"W3170117047","doi":"10.1200/jco.2021.39.15_suppl.e13020","title":"First-line treatment with a cyclin-dependent kinase 4/6 inhibitor combined with an aromatase inhibitor for hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: Population-based outcomes for patients treated in Alberta, Canada.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); University of Calgary","funders":"","keywords":"Palbociclib; Medicine; Internal medicine; Metastatic breast cancer; Aromatase inhibitor; Oncology; Population; Breast cancer; Progression-free survival; Proportional hazards model; Cancer; Hazard ratio; Gastroenterology; Aromatase; Chemotherapy; Confidence interval","score_opus":0.03958041499443192,"score_gpt":0.37131618201223004,"score_spread":0.3317357670177981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170117047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98371255,0.00008882043,0.00028921213,0.01104434,0.00040575396,0.0019966313,0.0024428815,0.000015184524,0.0000046279956],"genre_scores_gemma":[0.98482156,0.0000490344,0.011853478,0.0011913106,0.0004751326,0.0003767333,0.0010278634,0.00009127906,0.0001136107],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952252,0.00049773045,0.0025841554,0.0005866701,0.00057077,0.00053547864],"domain_scores_gemma":[0.9901471,0.0047523635,0.0023524342,0.00029142402,0.0017695993,0.0006870889],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004239327,0.0005266336,0.0027588569,0.00019577473,0.00017036845,0.000021174312,0.00014058416,0.00022529141,0.00009281761],"category_scores_gemma":[0.0010652515,0.00034280776,0.00034973823,0.0002863586,0.00016253171,0.00031951044,0.000020545316,0.00045828192,6.1245976e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11803287,0.011742741,0.84139,0.00013771828,0.00198719,0.00034910737,0.00023122679,0.0005090244,0.00019439215,0.000023201412,0.00020809672,0.025194405],"study_design_scores_gemma":[0.11003605,0.07056803,0.81376016,0.00046124728,0.0010250199,0.000068873305,0.00020909586,0.00022373753,0.002332834,0.000094949806,0.0007710747,0.00044889483],"about_ca_topic_score_codex":0.098157056,"about_ca_topic_score_gemma":0.66613585,"teacher_disagreement_score":0.5679788,"about_ca_system_score_codex":0.002674544,"about_ca_system_score_gemma":0.0044309595,"threshold_uncertainty_score":0.99990237},"labels":[],"label_agreement":null},{"id":"W3170157997","doi":"10.1007/s40273-021-01027-4","title":"Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis Pharmaceuticals Corporation","keywords":"Fulvestrant; Medicine; Hazard ratio; Oncology; Metastatic breast cancer; Discontinuation; Internal medicine; Breast cancer; Cancer; Progression-free survival; Quality-adjusted life year; Letrozole; Cost effectiveness; Gynecology; Estrogen receptor; Tamoxifen; Confidence interval; Overall survival","score_opus":0.033363795315044825,"score_gpt":0.35892055458306005,"score_spread":0.3255567592680152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170157997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893654,0.0022655602,0.000110901885,0.0030640094,0.000071515155,0.0034858768,0.0015902617,0.00001075433,0.000035704874],"genre_scores_gemma":[0.99349123,0.004223267,0.00077426597,0.0002332107,0.00006308567,0.0010041755,0.000059715803,0.00006248644,0.00008857745],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986291,0.000105291656,0.00039660715,0.00036977686,0.00012008043,0.0003791368],"domain_scores_gemma":[0.9978786,0.00038443774,0.00035000304,0.0002688288,0.00094448257,0.00017364272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015619643,0.00026826275,0.0008425147,0.00012998687,0.000055638604,0.000005965351,0.00009709642,0.000041888597,0.00010160802],"category_scores_gemma":[0.000012379984,0.00018082936,0.000052938045,0.00020328122,0.00018792959,0.0001282585,0.000008192493,0.00012313087,2.6180072e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36811277,0.005543308,0.054458577,0.002018291,0.005427297,0.000090230234,0.023612281,0.008519922,0.098980255,0.0005212603,0.0000030464864,0.43271276],"study_design_scores_gemma":[0.11635025,0.02564809,0.40633932,0.001770123,0.00051747565,0.00027522736,0.012583782,0.001593115,0.43226743,0.00019240518,0.0018410587,0.00062173547],"about_ca_topic_score_codex":0.03844422,"about_ca_topic_score_gemma":0.10078149,"teacher_disagreement_score":0.43209103,"about_ca_system_score_codex":0.0027735252,"about_ca_system_score_gemma":0.0027068595,"threshold_uncertainty_score":0.96795887},"labels":[],"label_agreement":null},{"id":"W3171910277","doi":"10.1200/jco.2021.39.15_suppl.tps1101","title":"SERENA-4: A phase 3 comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Palbociclib; Medicine; Fulvestrant; Anastrozole; Oncology; Internal medicine; Breast cancer; Metastatic breast cancer; Cancer; Aromatase inhibitor; Estrogen receptor; Tamoxifen","score_opus":0.08469489683910919,"score_gpt":0.4701901440886904,"score_spread":0.38549524724958123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171910277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822991,0.0017004281,0.0052476227,0.0040234188,0.0012557573,0.003460454,0.0019234655,0.00003175268,0.0000580178],"genre_scores_gemma":[0.9786606,0.00095308997,0.018166333,0.0004834411,0.0007075601,0.00045812535,0.0001611315,0.000108687964,0.00030102386],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941615,0.0005014726,0.003256836,0.0007146472,0.0006506214,0.00071494235],"domain_scores_gemma":[0.98501855,0.0058801505,0.0044274083,0.00046616947,0.0033529901,0.0008547122],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005605218,0.00057196413,0.0042675333,0.00013670528,0.0001436469,0.0000178814,0.00026371793,0.00034018807,0.00005965226],"category_scores_gemma":[0.0016119491,0.00042048265,0.0010546837,0.00023666587,0.00047059523,0.0003510643,0.000048236998,0.000609352,0.0000012871988],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6039305,0.006894081,0.030297799,0.000602596,0.003636068,0.00015946751,0.0012342263,0.0056346385,0.0005524847,0.000028230148,0.00015912452,0.3468708],"study_design_scores_gemma":[0.6832679,0.12141042,0.15637568,0.006972224,0.0069135865,0.00019155414,0.0050156303,0.004244287,0.004764929,0.00013946186,0.0097212605,0.0009830709],"about_ca_topic_score_codex":0.00005599745,"about_ca_topic_score_gemma":0.000495232,"teacher_disagreement_score":0.34588775,"about_ca_system_score_codex":0.0020248315,"about_ca_system_score_gemma":0.0058614514,"threshold_uncertainty_score":0.9998247},"labels":[],"label_agreement":null},{"id":"W3172867079","doi":"10.1200/jco.2021.39.15_suppl.1004","title":"Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; University of Toronto; Sunnybrook Health Science Centre","funders":"Roche","keywords":"Medicine; Internal medicine; Metastatic breast cancer; Clinical endpoint; Ven; Fulvestrant; Venetoclax; Oncology; Progression-free survival; Neutropenia; Estrogen receptor; Phases of clinical research; Gastroenterology; Cancer; Breast cancer; Chemotherapy; Randomized controlled trial; Leukemia","score_opus":0.08351404281916895,"score_gpt":0.45458919973083395,"score_spread":0.371075156911665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172867079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889971,0.0028072118,0.00032758247,0.0039674337,0.0018243779,0.001245712,0.0006287035,0.000017692504,0.00018419321],"genre_scores_gemma":[0.9763542,0.0022802462,0.019384513,0.00064377644,0.0008888216,0.00008345478,0.000037565867,0.00006664048,0.000260816],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9890728,0.0029750122,0.005952087,0.00068259734,0.00080663513,0.0005108664],"domain_scores_gemma":[0.9774518,0.015551008,0.004218464,0.0005236435,0.0017085187,0.00054655486],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0040547703,0.00045440262,0.005434746,0.00021129356,0.00006980739,0.000012547231,0.00035757048,0.00037086513,0.00086696993],"category_scores_gemma":[0.009666689,0.00033135363,0.000769686,0.0005776109,0.000801088,0.0003419219,0.00016108512,0.0019128467,0.0000069044113],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8209911,0.012926553,0.00022313859,0.000051111972,0.0042221257,0.0032754098,0.0014196356,0.0016833523,0.0022167005,0.000016698623,0.000111429705,0.15286277],"study_design_scores_gemma":[0.9292941,0.04906695,0.005844117,0.0012119503,0.0022194278,0.0005629414,0.0034885197,0.00021507136,0.0023079119,0.0003197209,0.0051266747,0.0003426163],"about_ca_topic_score_codex":0.0005051652,"about_ca_topic_score_gemma":0.0037272822,"teacher_disagreement_score":0.15252015,"about_ca_system_score_codex":0.0008969576,"about_ca_system_score_gemma":0.008731761,"threshold_uncertainty_score":0.9999139},"labels":[],"label_agreement":null},{"id":"W3174841530","doi":"10.1038/s41416-021-01415-9","title":"Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer","year":2021,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Breast cancer; Medicine; Oncology; Hormone receptor; Cancer; Internal medicine; Oestrogen receptor; Clinical trial; Hormone","score_opus":0.016977192218138756,"score_gpt":0.3431304860266393,"score_spread":0.32615329380850056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174841530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9453079,0.050459813,0.000015127818,0.0029757726,0.00012696936,0.0005888196,0.00041093284,0.0000037745244,0.00011086307],"genre_scores_gemma":[0.93452775,0.064472936,0.00037812252,0.00019007573,0.00029029476,0.00004283754,0.0000052818514,0.000023988829,0.0000687297],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975713,0.0006134402,0.0009903403,0.00022936653,0.00036187295,0.00023366504],"domain_scores_gemma":[0.9976595,0.0010093407,0.00066084316,0.00012302399,0.00042310773,0.00012418318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001188418,0.00018705065,0.0011589397,0.00015853015,0.000063185806,0.000031123967,0.00008051106,0.000076834505,0.00020275656],"category_scores_gemma":[0.00074254733,0.00014635357,0.00023169455,0.00047263814,0.00022911177,0.00023575817,0.000019996656,0.0005308268,1.5576875e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10442823,0.0007422061,0.0069034086,0.00006705061,0.0008556269,0.00045404208,0.0025214525,0.002828301,0.04404943,0.000016441492,0.00022676837,0.836907],"study_design_scores_gemma":[0.06949982,0.0003717647,0.91987824,0.0030936159,0.0001590407,0.0030048762,0.0010111041,0.00000943898,0.0022806155,0.00011920135,0.0004269653,0.00014528651],"about_ca_topic_score_codex":0.0017555741,"about_ca_topic_score_gemma":0.0010940653,"teacher_disagreement_score":0.91297483,"about_ca_system_score_codex":0.00044396342,"about_ca_system_score_gemma":0.0006084856,"threshold_uncertainty_score":0.59681255},"labels":[],"label_agreement":null},{"id":"W3176202523","doi":"10.3390/curroncol28030209","title":"First-Line Treatment with a Cyclin-Dependent Kinase 4/6 Inhibitor Plus an Aromatase Inhibitor for Metastatic Breast Cancer in Alberta","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Palbociclib; Aromatase inhibitor; Metastatic breast cancer; Progression-free survival; Oncology; Population; Breast cancer; Chemotherapy; Gastroenterology; Aromatase; Cancer","score_opus":0.06824487577042973,"score_gpt":0.3996845676383934,"score_spread":0.3314396918679636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176202523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724229,0.008832345,0.0016605821,0.010922035,0.001724863,0.0025567356,0.0017414691,0.00008902345,0.000050031853],"genre_scores_gemma":[0.9891177,0.00095408765,0.0034544514,0.0004184206,0.0014106723,0.003138944,0.00082886236,0.00011640588,0.000560451],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99766654,0.00012175757,0.0005651835,0.00078592333,0.0002546421,0.00060597324],"domain_scores_gemma":[0.99834937,0.00029254064,0.00021917709,0.00051673374,0.00025532002,0.00036685122],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012801096,0.0004229841,0.0009598635,0.00017345323,0.00009224231,0.000019262929,0.00010370493,0.00010719733,0.00029453717],"category_scores_gemma":[0.000055334942,0.00032621747,0.00013018074,0.00030652928,0.00014992316,0.00018377086,0.000055882883,0.000247016,0.000015828145],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021302868,0.016104009,0.01829845,0.0012413746,0.0008285731,0.0020162247,0.004310815,0.0025836637,0.0051175468,0.00028414937,0.00031861814,0.9275937],"study_design_scores_gemma":[0.21038032,0.026713308,0.021118816,0.004281808,0.003638777,0.0075591356,0.0044533717,0.011040477,0.03287123,0.0015641281,0.67371285,0.0026657933],"about_ca_topic_score_codex":0.00067383976,"about_ca_topic_score_gemma":0.040714644,"teacher_disagreement_score":0.9249279,"about_ca_system_score_codex":0.002417479,"about_ca_system_score_gemma":0.0016307429,"threshold_uncertainty_score":0.999919},"labels":[],"label_agreement":null},{"id":"W3186455232","doi":"10.1016/j.breast.2021.07.017","title":"Efficacy and safety of palbociclib in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2","year":2021,"lang":"en","type":"article","venue":"The Breast","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Pfizer","keywords":"Palbociclib; Letrozole; Medicine; Post-hoc analysis; Internal medicine; Oncology; Adverse effect; Placebo; Breast cancer; Fulvestrant; Cancer; Common Terminology Criteria for Adverse Events; Estrogen receptor; Metastatic breast cancer; Aromatase; Pathology","score_opus":0.007593714205128284,"score_gpt":0.26553065339647824,"score_spread":0.25793693919134997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3186455232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99308795,0.00031783018,0.00006936382,0.0006800983,0.000019684243,0.00077029236,0.0049469676,0.000029766663,0.00007807148],"genre_scores_gemma":[0.9978982,0.00004167126,0.0011917204,0.00009770059,0.000040210598,0.00006990723,0.00057711836,0.000050170045,0.000033286713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979592,0.00021033926,0.00054046937,0.00048298284,0.0004505729,0.00035642885],"domain_scores_gemma":[0.9975009,0.00034913182,0.00055892655,0.0004051561,0.0010463743,0.00013953718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000115792594,0.00033426422,0.0009069293,0.00021575292,0.0001435247,0.000012093243,0.00013427551,0.00006895677,0.00042550548],"category_scores_gemma":[0.00005799414,0.00022320607,0.000109183726,0.0013258503,0.00063010654,0.00024029631,0.00007271755,0.00025546085,0.000001042385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026712637,0.00083037297,0.9249026,0.00018795399,0.0041414523,0.000012671671,0.0038713787,0.00034643855,0.013137984,0.0003304095,0.0000027500942,0.025523318],"study_design_scores_gemma":[0.010667154,0.00064934324,0.9810894,0.0010444198,0.0009406217,0.000062181396,0.001155966,0.000016501739,0.0041008303,0.000024407866,0.0000045129136,0.00024466586],"about_ca_topic_score_codex":0.0004263951,"about_ca_topic_score_gemma":0.0003557553,"teacher_disagreement_score":0.056186765,"about_ca_system_score_codex":0.00019921355,"about_ca_system_score_gemma":0.00021892977,"threshold_uncertainty_score":0.9102079},"labels":[],"label_agreement":null},{"id":"W3196278183","doi":"10.1007/s10549-021-06334-0","title":"Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population","year":2021,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Tolerability; Letrozole; Internal medicine; Breast cancer; Adverse effect; Neutropenia; Metastatic breast cancer; Population; Oncology; Progression-free survival; Hazard ratio; Cancer; Confidence interval; Chemotherapy; Tamoxifen","score_opus":0.1592860876520025,"score_gpt":0.48420631349289217,"score_spread":0.32492022584088964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196278183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834991,0.0038192857,0.000039564773,0.001982508,0.00008175538,0.0032345324,0.0073152,0.000022285238,0.000005766582],"genre_scores_gemma":[0.9948252,0.0015552489,0.00017007338,0.000049275313,0.00027220475,0.0014736558,0.0015436109,0.000046286477,0.00006445213],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99732417,0.00018753976,0.00067551824,0.0006151013,0.00069027557,0.00050742435],"domain_scores_gemma":[0.9979581,0.00030384294,0.00028690894,0.00058762875,0.0006449293,0.0002185461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003107692,0.00029806857,0.00069186697,0.00016884474,0.00021978648,0.000025064031,0.00012121109,0.00007132734,0.00015330814],"category_scores_gemma":[0.00003344581,0.00020905456,0.00009190722,0.00054248946,0.00012862934,0.00026137556,0.00005074725,0.00016224757,4.125823e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19674814,0.016157044,0.19203506,0.00007896033,0.00073856633,0.000034746823,0.006042198,0.0009871738,0.014641053,0.00004556293,0.00001584264,0.5724757],"study_design_scores_gemma":[0.19737636,0.013101398,0.77412325,0.00064715696,0.00016592731,0.000063300446,0.00688328,0.0015841911,0.0050903684,0.00046785353,0.000222849,0.00027406254],"about_ca_topic_score_codex":0.046969295,"about_ca_topic_score_gemma":0.038366277,"teacher_disagreement_score":0.5820882,"about_ca_system_score_codex":0.0009750114,"about_ca_system_score_gemma":0.00034171896,"threshold_uncertainty_score":0.97918105},"labels":[],"label_agreement":null},{"id":"W3198529699","doi":"10.3138/canlivj-2021-0015","title":"Palbociclib-induced severe hepatitis: A case study and literature review","year":2021,"lang":"en","type":"article","venue":"Canadian Liver Journal","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University; Jewish General Hospital","funders":"","keywords":"Palbociclib; Medicine; Letrozole; Adverse effect; Aromatase inhibitor; Metastatic breast cancer; Breast cancer; Oncology; Leukopenia; Internal medicine; Cancer; Pharmacology; Toxicity; Aromatase","score_opus":0.018066090907034215,"score_gpt":0.2830940732307775,"score_spread":0.2650279823237433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198529699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74981785,0.24695851,0.000006732288,0.002367631,0.00019654818,0.00029795704,0.00002907447,0.000012425957,0.00031327445],"genre_scores_gemma":[0.9595809,0.029085044,0.0006022879,0.009270061,0.0005147458,0.000011751121,0.000008082801,0.000033148404,0.00089395454],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9989782,0.00011364721,0.00022049154,0.00021510044,0.00016985548,0.00030267946],"domain_scores_gemma":[0.998335,0.000024407356,0.00007164019,0.00022878988,0.00036632075,0.0009738606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015839253,0.00015632255,0.00031628224,0.00011481619,0.00022833257,0.00008844267,0.00005127445,0.00006162253,0.00060398865],"category_scores_gemma":[0.00009440963,0.00013925057,0.00007005389,0.000305009,0.000025988747,0.00019497702,0.000017942972,0.00058035034,0.000010266267],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022932392,0.0000618714,0.04130787,0.0005103375,0.00028593678,0.7992213,0.004435819,2.4957484e-7,0.00008933274,0.000015683047,0.0024329145,0.15161575],"study_design_scores_gemma":[0.0018947993,0.00025112284,0.025450211,0.0053595314,0.00029039997,0.93062544,0.0032783814,0.000006265025,0.000021478523,0.000048959857,0.032551896,0.00022150014],"about_ca_topic_score_codex":0.005883547,"about_ca_topic_score_gemma":0.08605805,"teacher_disagreement_score":0.21787347,"about_ca_system_score_codex":0.00030037202,"about_ca_system_score_gemma":0.001124035,"threshold_uncertainty_score":0.930619},"labels":[],"label_agreement":null},{"id":"W3199173589","doi":"10.1177/12034754211036603","title":"<i>JCMS</i> Abstracts 2021","year":2021,"lang":"en","type":"editorial","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Association of Gastroenterology","funders":"","keywords":"Medicine; Dermatology","score_opus":0.015501716819560616,"score_gpt":0.28946661817961866,"score_spread":0.273964901360058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199173589","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004869014,0.08675832,0.00004859934,0.0064741485,0.8999248,0.00013853174,0.000026024058,0.00001879801,0.0017417582],"genre_scores_gemma":[0.0027176263,0.036361896,0.00028470886,0.0010573025,0.9565274,0.0000021380206,0.00009817367,0.000095545765,0.0028551975],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99580234,0.00009102829,0.0016125469,0.00032452948,0.0017627368,0.00040679838],"domain_scores_gemma":[0.99126536,0.004732011,0.0015386209,0.0003596633,0.0015665487,0.00053778285],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009389807,0.00045126092,0.0025415642,0.0004944204,0.00006666633,0.000027078182,0.00011790213,0.00064374757,0.00070255104],"category_scores_gemma":[0.004977449,0.0003250089,0.0004239594,0.0002546876,0.00028847298,0.00011201781,0.0000367283,0.0019265161,0.000006295232],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009127674,0.000082666076,0.00010596184,0.00054177723,0.00054743467,0.029538121,0.00021787349,0.0000039043593,0.00063169806,0.0000010033228,0.9280833,0.03933348],"study_design_scores_gemma":[0.0010749256,0.00047213648,0.000035679404,0.0065475213,0.00075972395,0.025991816,0.0004224218,7.785602e-7,0.00012598102,0.00009868025,0.964224,0.00024637155],"about_ca_topic_score_codex":0.000028317156,"about_ca_topic_score_gemma":0.000007217869,"teacher_disagreement_score":0.05660261,"about_ca_system_score_codex":0.00016846397,"about_ca_system_score_gemma":0.002138495,"threshold_uncertainty_score":0.9999202},"labels":[],"label_agreement":null},{"id":"W3199192590","doi":"10.1200/jco.2020.39.28_suppl.269","title":"Clinical practice patterns for advanced breast cancer patients on CDK4/6 inhibitors receiving palliative radiation therapy.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Family medicine; Concomitant; Palliative care; Cancer; Radiation therapy; Internal medicine; Oncology; Nursing","score_opus":0.09959189659249712,"score_gpt":0.5173216568826743,"score_spread":0.41772976029017717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199192590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95440876,0.0017535476,0.0013068371,0.034074873,0.007361988,0.0006157014,0.00007888662,0.0000216368,0.0003777758],"genre_scores_gemma":[0.94869715,0.012267318,0.012146763,0.019922012,0.0066594426,0.00004465568,0.000021351456,0.00006370694,0.00017761509],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99453175,0.0009217576,0.0032268863,0.00041062507,0.00057457475,0.00033442752],"domain_scores_gemma":[0.98232347,0.009940092,0.0041189957,0.00025444847,0.00295289,0.00041008083],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002867822,0.0002309222,0.0016230687,0.00009260324,0.00007815051,0.000014540266,0.0001502574,0.00045463495,0.00016745851],"category_scores_gemma":[0.013806052,0.0001748124,0.0007731238,0.00019151303,0.00011891672,0.00039975284,0.000039296177,0.0013437025,0.000007376403],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017472493,0.0030680555,0.29732442,0.000021784994,0.0005953808,0.00008185568,0.0001416592,0.000051049836,0.00006664252,0.000021504478,0.0007131762,0.680442],"study_design_scores_gemma":[0.024458922,0.011086605,0.7506747,0.00041864882,0.0002594894,0.00008792116,0.0002837003,0.000026083198,0.0002801672,0.00018460669,0.2120819,0.00015724004],"about_ca_topic_score_codex":0.000009356468,"about_ca_topic_score_gemma":0.000024972007,"teacher_disagreement_score":0.68028474,"about_ca_system_score_codex":0.0004938351,"about_ca_system_score_gemma":0.0022572733,"threshold_uncertainty_score":0.99450105},"labels":[],"label_agreement":null},{"id":"W3201907175","doi":"10.1016/j.annonc.2021.08.2086","title":"LBA14 Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Anastrozole; Medicine; Palbociclib; Gynecology; Breast cancer; Interim analysis; Oncology; Internal medicine; Letrozole; HER2 negative; Cancer; Tamoxifen; Metastatic breast cancer; Clinical trial","score_opus":0.039736183941007086,"score_gpt":0.37963328158910387,"score_spread":0.3398970976480968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201907175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98986185,0.00041939903,0.00003496065,0.005686365,0.00012376733,0.0023452507,0.0011798306,0.000033641096,0.00031493668],"genre_scores_gemma":[0.99655277,0.00026847157,0.0004536032,0.0014602052,0.00006823347,0.00057822146,0.00013528578,0.0000815228,0.00040166877],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99519056,0.0010727246,0.0013179901,0.0009293685,0.00058383157,0.00090553495],"domain_scores_gemma":[0.99575704,0.00037541625,0.00092907785,0.0008859661,0.0017183262,0.00033419553],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007000038,0.00060708076,0.0027077287,0.00041026162,0.00018986956,0.000038706497,0.0006837357,0.00021805325,0.0013321463],"category_scores_gemma":[0.00013413887,0.00042980778,0.00014682423,0.0026456022,0.00073792296,0.0003399477,0.00041930124,0.00055357575,0.0000036769654],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38978308,0.03527281,0.12977698,0.00014383493,0.030210208,0.0010860093,0.027886704,0.0013383604,0.25073195,0.000050254297,0.0002507862,0.13346902],"study_design_scores_gemma":[0.2526017,0.08130139,0.57801634,0.0008922659,0.0038874357,0.00023411433,0.014302449,0.00023981066,0.0660727,0.00004013128,0.0014828147,0.0009288044],"about_ca_topic_score_codex":0.008085876,"about_ca_topic_score_gemma":0.008298001,"teacher_disagreement_score":0.4482394,"about_ca_system_score_codex":0.00044940272,"about_ca_system_score_gemma":0.0016424113,"threshold_uncertainty_score":0.99981534},"labels":[],"label_agreement":null},{"id":"W3202325290","doi":"10.1016/j.annonc.2021.08.403","title":"122MO Quality of life from the Penelope-B study on high-risk HR+/HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Palbociclib; Endocrine system; Oncology; Gynecology; Cancer; Breast cancer; Internal medicine; Metastatic breast cancer; Hormone","score_opus":0.0899429528670888,"score_gpt":0.4043247517342565,"score_spread":0.3143817988671677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202325290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933721,0.0005195817,0.000015049177,0.004251066,0.00007280906,0.0010259366,0.00049189414,0.000037712412,0.00021385535],"genre_scores_gemma":[0.99610054,0.00067803444,0.00024464622,0.0022780704,0.00016333938,0.00017538764,0.000047341786,0.000061018083,0.0002516332],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722844,0.0006899339,0.00062102394,0.0005161121,0.00057667604,0.00036778155],"domain_scores_gemma":[0.9964967,0.00061779405,0.00078712206,0.0007126063,0.0012278515,0.00015795733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002514182,0.00033380179,0.0012433107,0.000059001777,0.000084942825,0.00000896967,0.00021898907,0.000090388836,0.00050985924],"category_scores_gemma":[0.00010100637,0.00016787037,0.000089633824,0.00043206927,0.00035587716,0.0000994413,0.000052844476,0.00032193988,0.000004284769],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05402997,0.0043181186,0.88536304,0.00001903155,0.0018443778,0.00004910146,0.0024527123,0.00002751275,0.0005427711,0.000011429153,0.000103515995,0.051238444],"study_design_scores_gemma":[0.021728922,0.019956078,0.94932777,0.00015722803,0.00017993669,0.000012303359,0.0019762227,0.0000012525555,0.005162983,0.00002973092,0.0012728869,0.00019466023],"about_ca_topic_score_codex":0.02013402,"about_ca_topic_score_gemma":0.007103359,"teacher_disagreement_score":0.06396478,"about_ca_system_score_codex":0.000072073,"about_ca_system_score_gemma":0.00080664334,"threshold_uncertainty_score":0.986391},"labels":[],"label_agreement":null},{"id":"W3203491237","doi":"10.18192/uojm.v11is3.6079","title":"Conference Proceedings: Faculty of Medicine Research Day","year":2021,"lang":"fr","type":"article","venue":"University of Ottawa Journal of Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medical education; Medicine; Library science; Traditional medicine; Computer science","score_opus":0.0830772872893975,"score_gpt":0.3578980155445593,"score_spread":0.2748207282551618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203491237","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1639069,0.20034017,0.014003191,0.5359315,0.0062308484,0.00088873773,0.00018576474,0.000037527854,0.07847536],"genre_scores_gemma":[0.9540599,0.010637996,0.004933542,0.00031910953,0.0038478114,1.2376613e-7,0.000021916965,0.000042411393,0.026137182],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99527866,0.00032962437,0.0011117846,0.00034055274,0.0023318653,0.0006075369],"domain_scores_gemma":[0.9861672,0.0006554344,0.0015161905,0.00033120683,0.010704079,0.00062591495],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0043170815,0.00030142436,0.0017176892,0.0007959967,0.0001471063,0.0000040512427,0.0006713676,0.000269918,0.007387934],"category_scores_gemma":[0.0030618326,0.00026458842,0.00019981997,0.0013788759,0.006634661,0.00041074737,0.00018017266,0.001393964,0.000011791473],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038736686,0.0019499131,0.03905531,0.0076242993,0.004075386,0.007872351,0.10311309,0.00008316895,0.25694793,0.06409021,0.27702978,0.23428488],"study_design_scores_gemma":[0.025383556,0.006073424,0.022497265,0.034125637,0.0014385376,0.002806161,0.17871603,0.00011969559,0.013647883,0.0029085497,0.7120054,0.00027789455],"about_ca_topic_score_codex":0.0005199537,"about_ca_topic_score_gemma":0.00006173191,"teacher_disagreement_score":0.790153,"about_ca_system_score_codex":0.00049827533,"about_ca_system_score_gemma":0.0015339514,"threshold_uncertainty_score":0.9999806},"labels":[],"label_agreement":null},{"id":"W3204212303","doi":"10.1016/j.annonc.2021.08.622","title":"339TiP SOLTI-1502 ARIANNA: Targeting PAM50 HER2-enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative metastatic breast cancer","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; Oncolytics Biotech; Eisai; Daiichi-Sankyo; Astellas Pharma US; Roche; Seagen; Puma Biotechnology; Novartis; Les Laboratories Pierre Fabre; Eli Lilly and Company; AstraZeneca; Daiichi Sankyo Europe; Breast Cancer Research Foundation; Amgen; Pfizer","keywords":"Enzalutamide; Medicine; Androgen receptor; Internal medicine; Tamoxifen; Oncology; Breast cancer; Estrogen receptor; Cancer research; Prostate cancer; Population; Exemestane; Cancer; Endocrinology","score_opus":0.03930127710637511,"score_gpt":0.3517432248888993,"score_spread":0.3124419477825242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204212303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9581548,0.009678432,0.00066000014,0.027848253,0.00028095554,0.0008198929,0.00019140485,0.00008247799,0.0022838055],"genre_scores_gemma":[0.985467,0.0022895187,0.008336254,0.002983287,0.0002640854,0.00015827894,0.000076535835,0.00008102977,0.00034400175],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997098,0.0004631667,0.00070472463,0.00063311186,0.0003773139,0.00072363537],"domain_scores_gemma":[0.997163,0.00055880623,0.0005281518,0.0003587883,0.0011679492,0.00022327999],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053273677,0.00038362655,0.0012412635,0.00023096713,0.00007649878,0.000013234476,0.00015917994,0.00018429845,0.00057871355],"category_scores_gemma":[0.0003615214,0.00033306878,0.00013664653,0.0009802923,0.00043414521,0.00025935238,0.000102917016,0.00059315213,0.00002739798],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030749517,0.004711082,0.048377987,0.00061023055,0.004240095,0.0035356397,0.012897115,0.0010413761,0.32099137,0.0015123494,0.0038638103,0.5674694],"study_design_scores_gemma":[0.027086938,0.0077566584,0.71689975,0.0015280364,0.0006996823,0.0017388957,0.01243544,0.00014348637,0.1985917,0.003497619,0.028080905,0.0015409001],"about_ca_topic_score_codex":0.0014365937,"about_ca_topic_score_gemma":0.0012794464,"teacher_disagreement_score":0.66852176,"about_ca_system_score_codex":0.00035952363,"about_ca_system_score_gemma":0.0014617047,"threshold_uncertainty_score":0.99991214},"labels":[],"label_agreement":null},{"id":"W3204818878","doi":"10.1016/j.annonc.2021.08.537","title":"254P Impact of palbociclib-dose reduction on survival: A retrospective cohort study","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Novartis","keywords":"Medicine; Palbociclib; Retrospective cohort study; Cohort; Oncology; Reduction (mathematics); Gynecology; Internal medicine; Cancer; Breast cancer","score_opus":0.08496692943628022,"score_gpt":0.4594045357469845,"score_spread":0.3744376063107043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204818878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917792,0.00032035768,0.000015736796,0.0013522578,0.00029423117,0.00048618208,0.000022202881,0.000027489696,0.0057023424],"genre_scores_gemma":[0.99890983,0.00017949405,0.00015650879,0.00012605738,0.00017514771,0.00002952949,0.000014113017,0.000023608025,0.00038571216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986072,0.0002006411,0.00037059165,0.00030947514,0.00029404368,0.00021805905],"domain_scores_gemma":[0.9982622,0.000104200975,0.00029540993,0.0004215649,0.0008339678,0.00008263422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043985632,0.00014183274,0.000809317,0.00011452172,0.000026311789,0.0000019280646,0.00006638308,0.00010497727,0.00031005376],"category_scores_gemma":[0.0002983266,0.00012125979,0.00020460531,0.00036142473,0.00015503581,0.0000600471,0.000036956237,0.00020887106,0.000007503469],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049378285,0.004821592,0.89872104,0.00003923403,0.0018503299,0.0001627321,0.0019736923,0.000099368364,0.03942411,0.00029449305,0.00083532964,0.046840236],"study_design_scores_gemma":[0.002772657,0.014235653,0.9622591,0.000047381676,0.000097700184,0.00009455621,0.0014331844,0.0000038155354,0.017451307,0.0007700306,0.0007482507,0.00008637976],"about_ca_topic_score_codex":0.00026758856,"about_ca_topic_score_gemma":0.00004727143,"teacher_disagreement_score":0.06353803,"about_ca_system_score_codex":0.00022506808,"about_ca_system_score_gemma":0.0004612761,"threshold_uncertainty_score":0.49448308},"labels":[],"label_agreement":null},{"id":"W3204829131","doi":"10.1016/j.annonc.2021.08.516","title":"233P Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Quality of life (healthcare); Internal medicine; Cohort; Surgery","score_opus":0.08109988633338527,"score_gpt":0.40707448615225167,"score_spread":0.3259745998188664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204829131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903388,0.0012006781,0.000018521767,0.0069640735,0.000031671105,0.0008481861,0.00024371524,0.0000120173845,0.00034231643],"genre_scores_gemma":[0.99614435,0.0018102768,0.00037698494,0.0013117912,0.000041044805,0.000117542186,0.00006940389,0.0000338804,0.00009469171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962156,0.001411719,0.000999841,0.00038883253,0.00062242325,0.0003615866],"domain_scores_gemma":[0.99581146,0.0012899954,0.0014232759,0.00034397465,0.0010476481,0.00008365403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016089904,0.00027658322,0.0017769114,0.0001406495,0.000025805835,0.0000055648325,0.0001257571,0.00012772334,0.000077972916],"category_scores_gemma":[0.0003734002,0.00016626302,0.00008611049,0.00054264796,0.00022867617,0.00019770443,0.00002882104,0.000281161,2.016288e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044869974,0.002024865,0.91463614,0.00013453703,0.0007170165,0.000024377498,0.0015329199,0.00031706016,0.0026261401,0.00020390723,0.000029184208,0.032883856],"study_design_scores_gemma":[0.035934728,0.0045265914,0.95315033,0.00030583615,0.0000744188,0.000014810405,0.00078648835,0.000006640798,0.0041113426,0.00014000964,0.00077633065,0.00017244468],"about_ca_topic_score_codex":0.0026251706,"about_ca_topic_score_gemma":0.007876955,"teacher_disagreement_score":0.038514197,"about_ca_system_score_codex":0.00018946939,"about_ca_system_score_gemma":0.00077225536,"threshold_uncertainty_score":0.6780009},"labels":[],"label_agreement":null},{"id":"W3204843825","doi":"10.1016/j.annonc.2021.08.517","title":"234P Effect of palbociclib (PAL) + endocrine therapy (ET) on time to chemotherapy (TTC) across subgroups of patients (pts) with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): Post hoc analyses from PALOMA-2 (P2) and PALOMA-3 (P3)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Palbociclib; Internal medicine; Human Epidermal Growth Factor Receptor 2; Chemotherapy; Oncology; Endocrine system; Chemotherapy regimen; Endocrinology; Hormone receptor; Receptor; Hormone; Cancer; Metastatic breast cancer; Breast cancer","score_opus":0.026053341794756074,"score_gpt":0.3776716080813189,"score_spread":0.3516182662865628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204843825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98746353,0.0023143524,0.000041863852,0.0043069874,0.0001058251,0.0012654045,0.0042846315,0.000049549897,0.00016782478],"genre_scores_gemma":[0.9913093,0.0034013686,0.0017341347,0.0024441823,0.00016025908,0.00016171725,0.0005088225,0.00013088303,0.00014937269],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959976,0.00070557836,0.0009799949,0.0009406408,0.0006399704,0.0007362263],"domain_scores_gemma":[0.99488384,0.0012897941,0.0010427623,0.0005942093,0.0018411108,0.00034828484],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027724504,0.00070688257,0.0023222493,0.00021374747,0.00012533806,0.000014745141,0.00026290986,0.00024488714,0.001257185],"category_scores_gemma":[0.00018081626,0.0005469237,0.00030680056,0.00064413535,0.000718668,0.00028909248,0.00011460757,0.000398707,0.000013011805],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06365337,0.0016582991,0.04119324,0.00014281034,0.0020328052,0.0000390895,0.0035542913,0.00001733651,0.58213127,0.000012577724,0.00031056083,0.30525437],"study_design_scores_gemma":[0.016333286,0.025676616,0.46016195,0.00038437196,0.000079178906,0.000016434587,0.00028502606,0.0000023895866,0.49557477,0.000048451795,0.0010790995,0.00035841778],"about_ca_topic_score_codex":0.0010164325,"about_ca_topic_score_gemma":0.00026201006,"teacher_disagreement_score":0.4189687,"about_ca_system_score_codex":0.00020526587,"about_ca_system_score_gemma":0.00026195895,"threshold_uncertainty_score":0.9996982},"labels":[],"label_agreement":null},{"id":"W3205205784","doi":"10.3390/curroncol28050346","title":"Synaptotagmin 13 Is Highly Expressed in Estrogen Receptor-Positive Breast Cancer","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Estrogen receptor; Breast cancer; Cancer research; Kinase; Estrogen receptor alpha; Medicine; Biology; Estrogen; Internal medicine; Cancer; Oncology; Genetics","score_opus":0.05362191116699247,"score_gpt":0.39394818305138446,"score_spread":0.340326271884392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205205784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96190315,0.01680652,0.00025746576,0.016945597,0.0020269558,0.00044677514,0.0005300365,0.000089265675,0.0009942233],"genre_scores_gemma":[0.9923967,0.0023527022,0.0011512489,0.0017055797,0.0010293655,0.0004327948,0.0001845901,0.0000680256,0.0006789522],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99831337,0.00013720762,0.00034273052,0.00053152745,0.00020889545,0.00046625562],"domain_scores_gemma":[0.99896204,0.000116672076,0.00012795128,0.00032359269,0.0002886186,0.00018109214],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009339327,0.00023306589,0.0005651291,0.00011413064,0.000044996723,0.000008963256,0.00011556513,0.00016039082,0.0023255027],"category_scores_gemma":[0.000035999117,0.0002262098,0.00010854242,0.00031573727,0.00016139245,0.00010397638,0.00009712757,0.0004409224,0.000119040626],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017426132,0.0016203807,0.11628722,0.00019666956,0.00028875182,0.0003658356,0.0035721194,0.000031145755,0.090475045,0.0005258794,0.005404174,0.7794902],"study_design_scores_gemma":[0.0119479755,0.0004637677,0.16515686,0.0011556651,0.00022752532,0.00083226635,0.0016500058,0.00014971806,0.085541494,0.0005683266,0.7316377,0.0006686976],"about_ca_topic_score_codex":0.00007507188,"about_ca_topic_score_gemma":0.00010342984,"teacher_disagreement_score":0.77882147,"about_ca_system_score_codex":0.0009976077,"about_ca_system_score_gemma":0.00081895845,"threshold_uncertainty_score":0.99858654},"labels":[],"label_agreement":null},{"id":"W3207439319","doi":"10.26355/eurrev_202110_26892","title":"Clinical efficacy of palbociclib-based therapy in women with HR+/HER2- metastatic breast cancer in the real-world setting for Chinese women: a comparison with the IRIS study.","year":2021,"lang":"en","type":"article","venue":"PubMed","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palbociclib; Metastatic breast cancer; Internal medicine; Breast cancer; Oncology; Retrospective cohort study; Cancer; Progression-free survival; Chemotherapy; Gynecology","score_opus":0.03699043557846534,"score_gpt":0.3641136784565306,"score_spread":0.32712324287806527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207439319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98608327,0.00042438039,0.00011177853,0.009023338,0.000047887024,0.0041800733,0.00004583769,0.000030073692,0.00005334284],"genre_scores_gemma":[0.9839981,0.000043325206,0.0004910326,0.0019876184,0.00013425984,0.013185333,0.0000074344343,0.00005895384,0.00009389323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970291,0.000596379,0.0006843998,0.00046926778,0.0005068574,0.0007139797],"domain_scores_gemma":[0.99692667,0.0017626215,0.00037274638,0.0006338264,0.00018223317,0.000121902944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002362864,0.00029724807,0.00093131873,0.00013285322,0.00007499051,0.000030472744,0.0002728937,0.000036405138,0.00004249199],"category_scores_gemma":[0.00011542099,0.00013828123,0.00007663444,0.0014013582,0.00024886278,0.000081528146,0.000028209886,0.0004549858,3.0351848e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016184572,0.0021755958,0.7204314,0.0000829764,0.00042325165,0.000039382485,0.014662093,0.000931454,0.000015449592,0.0000035479643,0.000023982217,0.24502634],"study_design_scores_gemma":[0.021885913,0.0006569208,0.9590759,0.00010713702,0.00006750018,0.000011636122,0.017144445,0.00015342978,0.000024839605,0.000030223366,0.0006736564,0.00016838755],"about_ca_topic_score_codex":0.00042279952,"about_ca_topic_score_gemma":0.00563572,"teacher_disagreement_score":0.24485794,"about_ca_system_score_codex":0.00035628525,"about_ca_system_score_gemma":0.00037703072,"threshold_uncertainty_score":0.5638945},"labels":[],"label_agreement":null},{"id":"W3209520629","doi":"10.5281/zenodo.1038045","title":"Pharmacodb-1.0.0","year":2017,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Computer science","score_opus":0.05230730478141165,"score_gpt":0.33754757785062556,"score_spread":0.2852402730692139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209520629","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000043175085,0.00044834585,0.00018723978,0.0008489724,0.0003200244,0.0006656382,0.981512,0.0006110948,0.015363504],"genre_scores_gemma":[0.00035337752,0.0005000769,0.00011542925,0.00044593523,0.0008792945,6.8222214e-8,0.9935351,0.0019535068,0.002217214],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979063,0.00015638994,0.00028478992,0.0006047954,0.00056853396,0.00047916573],"domain_scores_gemma":[0.99729997,0.000015921236,0.00028843092,0.0014387897,0.00063738215,0.0003194778],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003882118,0.00030036375,0.00039729188,0.00030577258,0.0023930108,0.0005803758,0.0014603523,0.00017654127,0.047160435],"category_scores_gemma":[0.0005756277,0.00030386721,0.00011801084,0.00019134795,0.0003340741,0.00020645108,0.001316934,0.000808472,0.03281625],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002497623,0.00013365853,1.5134944e-7,0.00026816144,0.00015368713,0.00011357997,0.000056504676,0.0000018521723,0.0005296153,0.000017758575,0.9038939,0.09458137],"study_design_scores_gemma":[0.0013611881,0.00026036557,0.000061584404,0.0001930099,0.00013314375,0.00076687196,0.000032175023,0.000006513713,0.00014035631,0.000036357058,0.9967316,0.00027686165],"about_ca_topic_score_codex":0.000029600693,"about_ca_topic_score_gemma":3.1869664e-7,"teacher_disagreement_score":0.09430451,"about_ca_system_score_codex":0.00031822198,"about_ca_system_score_gemma":0.00001450574,"threshold_uncertainty_score":0.99994135},"labels":[],"label_agreement":null},{"id":"W3211800240","doi":"10.2217/cer-2021-0221","title":"Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points","year":2021,"lang":"en","type":"article","venue":"Journal of Comparative Effectiveness Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Fulvestrant; Nausea; Breast cancer; Quality of life (healthcare); Internal medicine; Oncology; Palbociclib; Cancer; Metastatic breast cancer; Estrogen receptor","score_opus":0.13336599440221616,"score_gpt":0.5031046785495277,"score_spread":0.3697386841473115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211800240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99289787,0.0050487677,0.00020702074,0.00025803663,0.00045959288,0.0006855835,0.0000330168,0.000014932761,0.00039515144],"genre_scores_gemma":[0.9986938,0.00016882205,0.0008228176,0.000014436327,0.00015347132,0.00007309835,0.000013435863,0.000041629497,0.000018450697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99316955,0.0028237423,0.0011924157,0.00045805454,0.0017434215,0.00061284564],"domain_scores_gemma":[0.9923293,0.0022208982,0.000838847,0.00045130213,0.0038049675,0.00035470873],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019679747,0.00031131622,0.0018712889,0.0007411913,0.00012207434,0.000033037206,0.00026843548,0.00014017698,0.0002968155],"category_scores_gemma":[0.0003321359,0.00026908919,0.00023239397,0.0018237956,0.00048603542,0.0005822902,0.000116465155,0.0014401878,0.00000477839],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09122621,0.004560722,0.47725222,0.00061468146,0.0016330197,0.0011097838,0.008230328,0.0051268814,0.2541439,0.00015728392,0.000035324258,0.15590966],"study_design_scores_gemma":[0.012139636,0.0030490153,0.60772955,0.0016362686,0.000071451934,0.00034588636,0.0058679515,0.00020969917,0.36806256,0.00029166156,0.00039767913,0.00019865869],"about_ca_topic_score_codex":0.000110590525,"about_ca_topic_score_gemma":0.00025276837,"teacher_disagreement_score":0.15571101,"about_ca_system_score_codex":0.0010096803,"about_ca_system_score_gemma":0.0015327646,"threshold_uncertainty_score":0.99997616},"labels":[],"label_agreement":null},{"id":"W3211935866","doi":"10.1016/j.breast.2021.11.007","title":"Development of novel agents for the treatment of early estrogen receptor positive breast cancer","year":2021,"lang":"en","type":"review","venue":"The Breast","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Breast cancer; Estrogen receptor; Oncology; Adjuvant; Disease; PI3K/AKT/mTOR pathway; Cancer; Internal medicine; Biomarker; Estrogen; Targeted therapy; Adjuvant therapy; Bioinformatics; Signal transduction","score_opus":0.08722767617663327,"score_gpt":0.38408548017142,"score_spread":0.2968578039947868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211935866","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003963775,0.9907098,0.0005272355,0.00037317802,0.00026896587,0.0028035839,0.004866866,0.000019180958,0.00003480341],"genre_scores_gemma":[0.00012161256,0.9926245,0.0037446353,0.000042586147,0.00050747703,0.0015221942,0.00030371273,0.00012468635,0.0010085944],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99801797,0.00006401984,0.0007761075,0.00039560534,0.00038482208,0.00036145296],"domain_scores_gemma":[0.9977466,0.0003111968,0.0007517708,0.00070259697,0.00039010574,0.00009775037],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016579927,0.0005248725,0.0018832046,0.00007496106,0.00014028446,0.000011306828,0.00034349455,0.00014839813,0.0002020957],"category_scores_gemma":[0.0000073805422,0.00025743173,0.0007690399,0.00032753887,0.00023432888,0.00003752548,0.00006577991,0.00014610373,0.000007030657],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039284074,0.00060772273,0.000021941145,0.0020542608,0.0040581487,0.0000015917915,0.001624895,0.0000024239755,0.00005954026,0.00012315046,0.000032276992,0.9910212],"study_design_scores_gemma":[0.002167902,0.00021571074,0.0011111631,0.017457703,0.004291148,0.0007991873,0.0003387973,0.0000031107224,0.00025989328,0.0000027598235,0.97304803,0.00030456766],"about_ca_topic_score_codex":0.00020595764,"about_ca_topic_score_gemma":0.000018745564,"teacher_disagreement_score":0.99071664,"about_ca_system_score_codex":0.0006953579,"about_ca_system_score_gemma":0.0015492371,"threshold_uncertainty_score":0.9999878},"labels":[],"label_agreement":null},{"id":"W3216161881","doi":"10.1158/1535-7163.mct-21-0411","title":"Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Ralaniten Analogs for the Treatment of Androgen Receptor–positive Prostate and Breast Cancers","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre","funders":"National Cancer Institute; National Institutes of Health","keywords":"Palbociclib; Prostate; Androgen receptor; Medicine; Cyclin-dependent kinase 4; Internal medicine; Kinase; Cancer research; Androgen; Oncology; Endocrinology; Prostate cancer; Pharmacology; Breast cancer; Biology; Cancer; Cyclin-dependent kinase 2; Hormone; Cell cycle; Metastatic breast cancer; Biochemistry","score_opus":0.014216953938682468,"score_gpt":0.2829275605301325,"score_spread":0.2687106065914501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216161881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96439373,0.02747552,0.0022384492,0.0037609315,0.00011995878,0.0015901598,0.0003721449,0.000022759985,0.000026316158],"genre_scores_gemma":[0.9924076,0.0050515146,0.0008475496,0.00082546147,0.00005994335,0.00050234154,0.00009767144,0.000056827448,0.0001510676],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988508,0.00006384664,0.00024912233,0.00033497036,0.00023695358,0.0002643063],"domain_scores_gemma":[0.9991388,0.00008333381,0.00014195357,0.00026666198,0.0003016198,0.00006765788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000074914264,0.00022786781,0.00036172586,0.00006668654,0.000068761714,0.000019228786,0.000054269272,0.000068521265,0.000013923838],"category_scores_gemma":[0.0000031644904,0.00015649419,0.00007772942,0.00027634038,0.00017123394,0.00005491212,0.000014248887,0.00009330179,2.8887308e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009864077,0.0011798249,0.063911475,0.00025026282,0.002729218,0.00020040254,0.008954732,0.0014686154,0.29033956,0.00039334162,0.0000079427555,0.62070054],"study_design_scores_gemma":[0.033198215,0.003910451,0.03355457,0.00071196054,0.0013832296,0.00022459951,0.0032050237,0.0013127973,0.9066275,0.00070921547,0.014561742,0.0006007402],"about_ca_topic_score_codex":0.00032827246,"about_ca_topic_score_gemma":0.00056559,"teacher_disagreement_score":0.6200998,"about_ca_system_score_codex":0.0005739084,"about_ca_system_score_gemma":0.0004183214,"threshold_uncertainty_score":0.6381648},"labels":[],"label_agreement":null},{"id":"W4200069316","doi":"10.1158/1078-0432.ccr-21-3032","title":"Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":263,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Cancer Institute; Novartis Institutes for BioMedical Research; Astex Pharmaceuticals; Novartis Pharmaceuticals Corporation","keywords":"Overall survival; Randomized controlled trial; Endocrine system; Clinical trial; Breast cancer; Cancer","score_opus":0.12727510173342405,"score_gpt":0.5170188085085538,"score_spread":0.3897437067751297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200069316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97959673,0.011444998,0.000018931836,0.0024137388,0.00093087705,0.005080567,0.0003406804,0.000052714415,0.000120745906],"genre_scores_gemma":[0.9586929,0.037614033,0.00033131253,0.0003170473,0.0008100839,0.0015091414,0.00017650137,0.00013137826,0.00041758866],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98894805,0.0035277414,0.002920198,0.0015717287,0.0017566711,0.001275609],"domain_scores_gemma":[0.9914144,0.005003305,0.00058074715,0.0009530833,0.0014626784,0.00058573374],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004591967,0.00059356855,0.0036760513,0.0003670712,0.00010677682,0.000046091114,0.00041135217,0.00027448818,0.0014615267],"category_scores_gemma":[0.0011455237,0.00044985552,0.00036353283,0.0012026199,0.002015034,0.00034224568,0.00027961252,0.0023050783,0.0000028689212],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8002751,0.0052463436,0.053089235,0.000058881607,0.00084181735,0.00023228052,0.000283044,0.000101707345,0.00092350703,0.00005458034,0.000032365893,0.13886115],"study_design_scores_gemma":[0.85868305,0.006350848,0.13048802,0.00041561585,0.000070674236,0.000011793826,0.00012646226,0.00025280245,0.00085772714,0.0001024411,0.0022464346,0.00039415582],"about_ca_topic_score_codex":0.00319495,"about_ca_topic_score_gemma":0.002516824,"teacher_disagreement_score":0.138467,"about_ca_system_score_codex":0.00060535036,"about_ca_system_score_gemma":0.0028770396,"threshold_uncertainty_score":0.99999666},"labels":[],"label_agreement":null},{"id":"W4200557046","doi":"10.1158/1078-0432.ccr-21-1291","title":"Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Discontinuation; Regimen; Medicine; Internal medicine; Gastroenterology; Toxicity; Surgery","score_opus":0.16442287932536198,"score_gpt":0.49352622930669265,"score_spread":0.3291033499813307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200557046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918659,0.0035811798,0.00018618433,0.00030511423,0.000051864165,0.0030231096,0.0009660341,0.000012957551,0.0000076862825],"genre_scores_gemma":[0.99807525,0.00041515456,0.0006571673,0.000016204363,0.00011405265,0.00027818204,0.00025847013,0.000043729142,0.00014181838],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99688625,0.00042733256,0.00096185924,0.0006423714,0.0007134746,0.000368703],"domain_scores_gemma":[0.99381006,0.003702614,0.000416724,0.0005081683,0.0013770337,0.00018537581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005895206,0.00023483028,0.0009709372,0.00007860696,0.00013047973,0.00001618069,0.00013128889,0.00009840094,0.00011210575],"category_scores_gemma":[0.0005845305,0.00011760478,0.00008201719,0.00040787034,0.0010574103,0.000058938618,0.00005613084,0.00029439796,1.425004e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22382987,0.019213928,0.5750394,0.00040380048,0.0034003097,0.000047250393,0.0065217353,0.000016344682,0.0016604917,0.0000040805007,0.000076124765,0.16978666],"study_design_scores_gemma":[0.2132986,0.065950565,0.570528,0.0013570987,0.0014247436,0.000003475367,0.0067238254,0.0009149091,0.13835292,0.00007864035,0.001005273,0.00036194758],"about_ca_topic_score_codex":0.000581437,"about_ca_topic_score_gemma":0.00071367115,"teacher_disagreement_score":0.16942471,"about_ca_system_score_codex":0.00007841765,"about_ca_system_score_gemma":0.0005221503,"threshold_uncertainty_score":0.47957838},"labels":[],"label_agreement":null},{"id":"W4205194661","doi":"10.1200/jco.21.01918","title":"Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Palbociclib; Discontinuation; Adjuvant; Breast cancer; Cancer; Endocrine system; Adjuvant therapy; Hormone","score_opus":0.0664875891783569,"score_gpt":0.410618722763568,"score_spread":0.3441311335852111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205194661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98257416,0.0021683623,0.000050981507,0.011081663,0.00047849282,0.0030320622,0.00055323716,0.000013091622,0.00004797255],"genre_scores_gemma":[0.994612,0.0019803825,0.00096708944,0.0007100919,0.000853266,0.0006542515,0.00002746208,0.000060266284,0.0001351837],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936079,0.0021840218,0.0024391022,0.0005190182,0.0007983013,0.00045165612],"domain_scores_gemma":[0.99177516,0.003392061,0.0030780584,0.00028641426,0.0012205752,0.0002477573],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013556717,0.00043768645,0.0024634362,0.0002168528,0.00025514053,0.000022289345,0.0002895877,0.00014821746,0.00016842782],"category_scores_gemma":[0.0004014097,0.00025216016,0.00030644637,0.00050764,0.00047004438,0.0002862653,0.00007595088,0.0010063364,6.719639e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12730892,0.015475596,0.45338717,0.000030240417,0.0029937383,0.00032735584,0.033775114,0.000068140675,0.004564296,0.00008756015,0.00037475795,0.3616071],"study_design_scores_gemma":[0.074182056,0.13530122,0.76734626,0.000082270366,0.00037302612,0.00020555382,0.019334247,0.000010013751,0.00044282764,0.000120511504,0.002367406,0.00023461302],"about_ca_topic_score_codex":0.00046920325,"about_ca_topic_score_gemma":0.0011101088,"teacher_disagreement_score":0.3613725,"about_ca_system_score_codex":0.00070613256,"about_ca_system_score_gemma":0.0012622944,"threshold_uncertainty_score":0.9999931},"labels":[],"label_agreement":null},{"id":"W4206303014","doi":"10.1007/s10549-021-06374-6","title":"Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population","year":2021,"lang":"en","type":"erratum","venue":"Breast Cancer Research and Treatment","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Letrozole; Breast cancer; Medicine; Oncology; Population; Cancer; Phase (matter); Internal medicine; Gynecology; Tamoxifen","score_opus":0.12615718773354898,"score_gpt":0.4729401635544931,"score_spread":0.3467829758209441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206303014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9659561,0.0065233577,0.000048063164,0.0015697195,0.0023151692,0.0072440486,0.016285688,0.000036370187,0.000021490376],"genre_scores_gemma":[0.9794485,0.0039138957,0.00009231493,0.000062783576,0.001416226,0.00379897,0.009319671,0.00011239448,0.0018352313],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9957611,0.0002819847,0.0010502915,0.001055687,0.0011356225,0.0007153434],"domain_scores_gemma":[0.9967254,0.00040926793,0.00060702674,0.0008653607,0.0010464151,0.0003465608],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004280546,0.0005862531,0.0013341745,0.00043264532,0.00030694364,0.000047019003,0.00021024243,0.000203257,0.00017494579],"category_scores_gemma":[0.000075709744,0.00042873374,0.00016667007,0.00085475214,0.00013389345,0.00026108266,0.00008374065,0.0005084349,6.3022924e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2418059,0.017305933,0.03574658,0.00020560889,0.0014310221,0.00003461191,0.0071594976,0.0013620041,0.0024281696,0.000007277837,0.0033670426,0.68914634],"study_design_scores_gemma":[0.24203098,0.039548825,0.68886817,0.005913395,0.00064807653,0.0001252143,0.011111314,0.0037425957,0.0011632867,0.00019454634,0.005728579,0.0009250274],"about_ca_topic_score_codex":0.13336775,"about_ca_topic_score_gemma":0.1221976,"teacher_disagreement_score":0.68822134,"about_ca_system_score_codex":0.0026039174,"about_ca_system_score_gemma":0.0007908949,"threshold_uncertainty_score":0.9998164},"labels":[],"label_agreement":null},{"id":"W4206311031","doi":"10.1016/s0002-9440(21)00400-4","title":"Meeting Abstracts","year":2021,"lang":"en","type":"article","venue":"American Journal Of Pathology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Computer science","score_opus":0.011547616010331517,"score_gpt":0.30021694776105395,"score_spread":0.28866933175072246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206311031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99191815,0.0011958616,0.0010461676,0.0025170143,0.00018813083,0.000019123045,0.0000011201871,0.000009250316,0.0031051612],"genre_scores_gemma":[0.9673655,0.00008829819,0.030376172,0.0017263023,0.00031687302,5.826773e-7,7.9437075e-7,0.000014019872,0.000111437315],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9992115,0.00006908903,0.00032433565,0.00009310253,0.00013637681,0.00016559043],"domain_scores_gemma":[0.9989461,0.000081638595,0.0004314006,0.00012915199,0.00030377338,0.000107980704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019596634,0.00007178823,0.00036594627,0.00006926103,0.000021155725,0.0000037280167,0.00005238189,0.000021676304,0.000072742674],"category_scores_gemma":[0.00023550297,0.000060236463,0.000096762255,0.00016892493,0.00021249258,0.000047149748,0.000017150667,0.00023796513,0.000011733236],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047596116,0.00023537823,0.017793652,0.000020051566,0.00018150247,0.03016496,0.0011560472,0.00023083143,0.34690064,0.00012614878,0.00010342972,0.60261136],"study_design_scores_gemma":[0.0052021057,0.004619754,0.38035503,0.00050534063,0.0003735061,0.3796277,0.012086591,0.000011634349,0.14372125,0.0023253977,0.07077021,0.00040147672],"about_ca_topic_score_codex":0.000003306072,"about_ca_topic_score_gemma":0.0000015754493,"teacher_disagreement_score":0.6022099,"about_ca_system_score_codex":0.000045702378,"about_ca_system_score_gemma":0.00020402407,"threshold_uncertainty_score":0.24563718},"labels":[],"label_agreement":null},{"id":"W4206666777","doi":"10.1016/j.annonc.2020.09.010","title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1356,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"European Society for Medical Oncology; Novo Nordisk Fonden; European School of Oncology","keywords":"Medicine; Guideline; Multidisciplinary approach; Breast cancer; Expert opinion; Clinical Practice; Medical physics; Intensive care medicine; Cancer; Family medicine; Internal medicine; Pathology","score_opus":0.24432670650973862,"score_gpt":0.5038172245427751,"score_spread":0.25949051803303647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206666777","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.089132726,0.0022070054,0.0023268422,0.89978594,0.0009911924,0.0007565736,0.00075224164,0.00011212671,0.003935363],"genre_scores_gemma":[0.8713511,0.0011448618,0.032872617,0.09117873,0.0022326873,0.00023732454,0.000080003534,0.000068837464,0.00083380786],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99878824,0.000024080562,0.00046885174,0.00028370472,0.00017636472,0.00025874667],"domain_scores_gemma":[0.997509,0.00015524433,0.00026959166,0.00014809758,0.0017565775,0.0001614998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012728851,0.00015351312,0.0004940691,0.00006230113,0.000033562334,0.0000030690658,0.0001540189,0.00010404027,0.00051113334],"category_scores_gemma":[0.00042906057,0.00013676929,0.00014340719,0.00011843767,0.00018397633,0.000055863995,0.000048565027,0.00011556831,0.000012733088],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010631848,0.0002442334,0.003230452,0.0001539783,0.00064310123,0.00004201241,0.00045000648,0.00093266775,0.031373143,0.0010729383,0.081463285,0.86976236],"study_design_scores_gemma":[0.0062320465,0.0015915838,0.0052161003,0.00011429311,0.00007166845,0.00017346091,0.00045107325,0.00086563744,0.012782208,0.0008456929,0.97147477,0.00018149505],"about_ca_topic_score_codex":0.000054598833,"about_ca_topic_score_gemma":0.00002896617,"teacher_disagreement_score":0.8900114,"about_ca_system_score_codex":0.00005726865,"about_ca_system_score_gemma":0.00039055568,"threshold_uncertainty_score":0.55965513},"labels":[],"label_agreement":null},{"id":"W4206837320","doi":"10.4212/cjhp.v75i1.3252","title":"Effectiveness and Safety of Palbociclib plus Endocrine Therapy in Hormone Receptor– Positive, HER2-Negative Metastatic Breast Cancer: Real-World Results","year":2022,"lang":"en","type":"article","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Palbociclib; Medicine; Metastatic breast cancer; Letrozole; Oncology; Internal medicine; Breast cancer; Progression-free survival; Fulvestrant; Cancer; Gynecology; Estrogen receptor; Chemotherapy; Tamoxifen","score_opus":0.015047557292914899,"score_gpt":0.308979468882827,"score_spread":0.2939319115899121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206837320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800289,0.005634434,0.000007004194,0.0116821695,0.00037711643,0.0008821296,0.001123525,0.0000071981867,0.0002575055],"genre_scores_gemma":[0.9971045,0.0021583214,0.00013015073,0.00027791515,0.00013441943,0.000046685953,0.000011612148,0.000043474825,0.000092902796],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99785095,0.00050290435,0.0006271655,0.00021662089,0.0004011722,0.0004012094],"domain_scores_gemma":[0.9981256,0.00042092902,0.0005524831,0.00019143427,0.00031476855,0.00039474704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087194634,0.00024019324,0.0006373297,0.00037178892,0.0002641841,0.00001847874,0.00026461156,0.000012202189,0.00023093706],"category_scores_gemma":[0.00005483584,0.00018129789,0.00012902035,0.00069973315,0.0003771163,0.0002302008,0.000044040746,0.00071644364,7.232936e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21354966,0.0015534604,0.19883762,0.00054691575,0.007794592,0.005406333,0.06224539,0.012988161,0.034841243,0.0014220066,0.002999022,0.4578156],"study_design_scores_gemma":[0.04417608,0.003095286,0.92970586,0.0005463298,0.00025206426,0.0011117639,0.0024590215,0.000084915235,0.011543946,0.0010214614,0.005569914,0.00043333115],"about_ca_topic_score_codex":0.115022965,"about_ca_topic_score_gemma":0.019156458,"teacher_disagreement_score":0.7308683,"about_ca_system_score_codex":0.0015414803,"about_ca_system_score_gemma":0.001764409,"threshold_uncertainty_score":0.9987414},"labels":[],"label_agreement":null},{"id":"W4210383073","doi":"10.3390/curroncol29020059","title":"Acknowledgment to Reviewers of Current Oncology in 2021","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Publishing; Clinical Oncology; Current (fluid); Quality (philosophy); Data science; Medical physics; Medical education; Oncology; Internal medicine; Computer science; Cancer","score_opus":0.15939989149235442,"score_gpt":0.48567606005704,"score_spread":0.32627616856468555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210383073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65733767,0.27048776,0.0020210282,0.014390693,0.035052903,0.0059748786,0.00016190318,0.000113072536,0.014460092],"genre_scores_gemma":[0.97059965,0.013667377,0.003784107,0.001868483,0.0026038995,0.0054657864,0.00029076423,0.00016244629,0.0015574567],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99785906,0.00033678787,0.0006711961,0.00041811727,0.00030746858,0.00040734242],"domain_scores_gemma":[0.99884707,0.00014287795,0.00025243996,0.00037990135,0.0001913074,0.00018639606],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00061718136,0.00018750204,0.0008312128,0.0003346898,0.00005476477,0.0000012615114,0.00022778097,0.00005325807,0.003420599],"category_scores_gemma":[0.00021119403,0.00018458322,0.00013430745,0.0006581165,0.00011236804,0.000035167635,0.00037376047,0.0006507549,0.00009742633],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083143363,0.0024031913,0.009771481,0.00029717505,0.000034691424,0.000022923985,0.0018515349,0.000121345365,0.0012066984,0.00043228065,0.008132052,0.9748952],"study_design_scores_gemma":[0.0029616333,0.002195022,0.0040420457,0.00021909094,0.00005833929,0.000042262698,0.0007435784,0.000027605189,0.00023790791,0.00020592836,0.9891191,0.00014744804],"about_ca_topic_score_codex":0.00000682569,"about_ca_topic_score_gemma":0.000047886897,"teacher_disagreement_score":0.9809871,"about_ca_system_score_codex":0.0027691927,"about_ca_system_score_gemma":0.0008833978,"threshold_uncertainty_score":0.9974904},"labels":[],"label_agreement":null},{"id":"W4210528277","doi":"10.1016/j.ymthe.2022.01.039","title":"Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer","year":2022,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; National Cancer Institute; National Institutes of Health; Colorado School of Mines; Terry Fox Foundation; University of Massachusetts Boston; Institute of Nutrition, Metabolism and Diabetes; National Institute of Diabetes and Digestive and Kidney Diseases; U.S. Department of Defense","keywords":"Prostate cancer; Androgen receptor; Castration; Cancer research; Androgen; Oncology; Internal medicine; Prostate; Cancer; Medicine; Biology; Hormone","score_opus":0.011604703365716099,"score_gpt":0.2641866233473651,"score_spread":0.252581919981649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210528277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912146,0.0033993237,0.000080395854,0.0040364936,0.00008840059,0.0009614255,0.00014095628,0.000018972067,0.00005946251],"genre_scores_gemma":[0.99791324,0.00008198172,0.000055569686,0.0010424936,0.000025013103,0.0007310252,0.000017459975,0.000033829332,0.000099408724],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986924,0.00025729474,0.00020586843,0.00022847655,0.00040854153,0.00020740049],"domain_scores_gemma":[0.9993382,0.000028918297,0.00021926466,0.00031991367,0.00006340449,0.000030260713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019316562,0.00014242186,0.0001921982,0.000038234346,0.00019633956,0.000010906405,0.000106588624,0.00002144958,0.0001907353],"category_scores_gemma":[0.0000136825865,0.00009301258,0.00009012962,0.0003456962,0.000115326926,0.00007295256,0.000056951914,0.0002924538,6.436453e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011408771,0.00011988449,0.0010619056,0.000014046336,0.000047391717,0.000020752846,0.0020111143,0.00065004895,0.98101646,0.000044197,0.00007833604,0.01379497],"study_design_scores_gemma":[0.0022750166,0.00017889125,0.0024703413,0.00007609354,0.000013452142,0.000037375426,0.0011763991,0.000057623143,0.9870853,0.0002733842,0.006239432,0.00011669383],"about_ca_topic_score_codex":0.00038176874,"about_ca_topic_score_gemma":0.00003767613,"teacher_disagreement_score":0.013678276,"about_ca_system_score_codex":0.00022460417,"about_ca_system_score_gemma":0.0001533039,"threshold_uncertainty_score":0.3792943},"labels":[],"label_agreement":null},{"id":"W4212771317","doi":"10.1158/1078-0432.ccr-21-0885","title":"Natural History and Characteristics of <i>ERBB2</i> -mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy; National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation; Unicancer; Vanderbilt University; Institut Gustave-Roussy; Puma Biotechnology; Princess Margaret Cancer Foundation; Memorial Sloan-Kettering Cancer Center; University of Texas MD Anderson Cancer Center; Cancer Prevention and Research Institute of Texas; American Association for Cancer Research","keywords":"Natural history; Retrospective cohort study; Metastatic breast cancer; Hormone; Cancer; Breast cancer","score_opus":0.11103847282270961,"score_gpt":0.4503884108544883,"score_spread":0.33934993803177865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212771317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.964132,0.019734174,0.000111758614,0.0009736484,0.00085029245,0.003031576,0.011079649,0.00006226854,0.000024615963],"genre_scores_gemma":[0.995563,0.0008420459,0.0005998186,0.00038419952,0.00055828237,0.001535566,0.00010386518,0.000065290114,0.00034797055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943569,0.0015428688,0.0010183741,0.0010174835,0.0014327354,0.00063164206],"domain_scores_gemma":[0.996413,0.0010980594,0.0003986371,0.00048627213,0.0013133622,0.00029067296],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0022240912,0.00033987642,0.0012395226,0.000279157,0.00047176227,0.000019524623,0.00026833257,0.00008400354,0.0009104467],"category_scores_gemma":[0.00055123016,0.00029246963,0.00020597145,0.0006583034,0.0014735045,0.00017901657,0.0003588285,0.0023150097,0.0000047027447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09940443,0.011445193,0.6339927,0.00030470744,0.0107035935,0.00976296,0.014015237,0.00009591322,0.03400801,0.00012674031,0.0039321017,0.18220845],"study_design_scores_gemma":[0.022079207,0.0034611614,0.9644031,0.00015148136,0.00070301007,0.00079587405,0.0037163463,0.0013044142,0.00009820196,0.00004895125,0.0028087161,0.00042952516],"about_ca_topic_score_codex":0.012944859,"about_ca_topic_score_gemma":0.0008010604,"teacher_disagreement_score":0.33041045,"about_ca_system_score_codex":0.0043915757,"about_ca_system_score_gemma":0.002977123,"threshold_uncertainty_score":0.9999867},"labels":[],"label_agreement":null},{"id":"W4213278392","doi":"10.3390/curroncol29020089","title":"Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Pfizer","keywords":"Palbociclib; Medicine; Aromatase inhibitor; Aromatase; Metastatic breast cancer; Breast cancer; Oncology; Letrozole; Internal medicine; Cancer","score_opus":0.07514612807142944,"score_gpt":0.45621330224507395,"score_spread":0.3810671741736445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213278392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98761624,0.008248474,0.00020095505,0.0013103356,0.00063163333,0.0012484831,0.0006945538,0.000044405806,0.0000049100727],"genre_scores_gemma":[0.9811893,0.016458174,0.000166359,0.00028660567,0.00039805027,0.00069054804,0.0007599778,0.00003974782,0.000011238804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99534273,0.0024572334,0.0008119233,0.00065585115,0.00028022673,0.00045202233],"domain_scores_gemma":[0.9968225,0.0018224415,0.00061042106,0.0004555609,0.000068297915,0.00022082769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011479591,0.00030572276,0.0014609848,0.00018829963,0.00025880084,0.000008974281,0.00016243808,0.00004610296,0.00023126841],"category_scores_gemma":[0.00003492725,0.00022385699,0.0002171733,0.00090544584,0.0001967911,0.00008199327,0.00012413567,0.00062021334,0.0000010510236],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061130426,0.0012330665,0.65328425,0.000060624076,0.0006833761,0.000035580753,0.0007659352,0.023854075,0.000009903053,0.000011178658,0.000009641623,0.31393933],"study_design_scores_gemma":[0.013281396,0.006742545,0.96733576,0.00028853866,0.00056953187,0.000030680574,0.00063292624,0.002844922,0.000015825233,0.00019454719,0.00787244,0.00019086254],"about_ca_topic_score_codex":0.011938582,"about_ca_topic_score_gemma":0.018692335,"teacher_disagreement_score":0.31405154,"about_ca_system_score_codex":0.0017082597,"about_ca_system_score_gemma":0.00066786323,"threshold_uncertainty_score":0.999214},"labels":[],"label_agreement":null},{"id":"W4220673086","doi":"10.1158/1538-7445.sabcs21-p5-13-25","title":"Abstract P5-13-25: <i>PIK3CA</i> registry: A noninterventional, descriptive, retrospective cohort study of <i>PIK3CA</i> mutations in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Fulvestrant; Internal medicine; Oncology; Population; Metastatic breast cancer; Cohort; Clinical endpoint; Clinical trial; Breast cancer; Cancer; Gynecology; Estrogen receptor","score_opus":0.028842267968597714,"score_gpt":0.3440795251232873,"score_spread":0.3152372571546896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220673086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855511,0.0007611051,0.00002077846,0.0007931713,0.00025692998,0.005734753,0.0061317375,0.00008975068,0.0006606482],"genre_scores_gemma":[0.991293,0.00016220959,0.00021762853,0.00009857456,0.00019813569,0.0065817437,0.0004625145,0.0001893292,0.00079684315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9922314,0.0007936625,0.0010743155,0.0015525649,0.003147449,0.0012006034],"domain_scores_gemma":[0.99441594,0.00031742605,0.00076732354,0.0008067778,0.0033012708,0.0003912734],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00092069275,0.0006291747,0.0012674776,0.0007672325,0.000933039,0.000057523994,0.00063733547,0.00013647048,0.003335125],"category_scores_gemma":[0.00020190897,0.0006034528,0.0002192152,0.002565391,0.0010476485,0.00072876015,0.00041377125,0.0022928312,0.000013624164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015399027,0.005535221,0.94737124,0.00017930756,0.0013458708,0.000058664533,0.008134374,0.00042688698,0.016899452,0.00009393803,0.0014548094,0.003101175],"study_design_scores_gemma":[0.014908497,0.0045581725,0.966324,0.0006053681,0.00010287579,0.000010526839,0.009603992,0.000004907634,0.002938427,0.000143193,0.00024134803,0.00055873644],"about_ca_topic_score_codex":0.016736425,"about_ca_topic_score_gemma":0.0029799899,"teacher_disagreement_score":0.018952683,"about_ca_system_score_codex":0.0072859,"about_ca_system_score_gemma":0.0010757627,"threshold_uncertainty_score":0.99964166},"labels":[],"label_agreement":null},{"id":"W4220682552","doi":"10.1158/1538-7445.sabcs21-p1-18-11","title":"Abstract P1-18-11: Analysis of first-line (1L) patients (pts) with de novo disease vs late relapse and all pts with vs without prior chemotherapy (CT) in the MONALEESA-3 (ML-3) trial","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Internal medicine; Adjuvant; Population; Cancer; Breast cancer; Fulvestrant; Placebo; Oncology; Nuclear medicine; Tamoxifen; Pathology","score_opus":0.05174704060359159,"score_gpt":0.38079660490958755,"score_spread":0.32904956430599597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220682552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99347466,0.0011166369,0.000023054927,0.0031730344,0.000032277905,0.0019052601,0.00020395491,0.000024197194,0.000046946265],"genre_scores_gemma":[0.9971157,0.00044438083,0.00014219909,0.00057193596,0.00011213668,0.001098766,0.00007083247,0.000070824906,0.00037323966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964775,0.00025239366,0.00038771244,0.0005960704,0.0016376218,0.0006486879],"domain_scores_gemma":[0.9982106,0.0003177456,0.00019517684,0.00070268725,0.00029379848,0.00028000545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011266944,0.000261609,0.00062955485,0.0005447016,0.0002498296,0.00003279768,0.0003730865,0.00003911704,0.00071687397],"category_scores_gemma":[0.00009446546,0.00017069589,0.00009939622,0.0018275278,0.0004504429,0.00013629312,0.000106844884,0.00078785187,8.807991e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2703381,0.0013411863,0.7063866,0.0002487299,0.0015075793,0.00027122852,0.00351819,0.0057936604,0.0004602605,0.000014694152,0.00012040442,0.009999352],"study_design_scores_gemma":[0.09035951,0.003570436,0.88486403,0.00034032806,0.00085185905,0.000017285927,0.000768327,0.00095181464,0.00032742816,0.00009314595,0.017498175,0.00035767345],"about_ca_topic_score_codex":0.0017360669,"about_ca_topic_score_gemma":0.003752914,"teacher_disagreement_score":0.1799786,"about_ca_system_score_codex":0.00073119707,"about_ca_system_score_gemma":0.0006848069,"threshold_uncertainty_score":0.7849267},"labels":[],"label_agreement":null},{"id":"W4220704364","doi":"10.1016/j.annonc.2022.03.003","title":"Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study","year":2022,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Partnership Against Cancer; University of Calgary","funders":"Dana-Farber Cancer Institute","keywords":"Medicine; Tamoxifen; Breast cancer; Oncology; Internal medicine; Adjuvant therapy; Adjuvant; Population; Endocrine system; Letrozole; Gynecology; Aromatase inhibitor; Cancer; Hormone","score_opus":0.04882049634006941,"score_gpt":0.36429950356094076,"score_spread":0.31547900722087135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220704364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.61663395,0.0030350958,0.000043051787,0.37375587,0.000151165,0.0026629951,0.0036368736,0.00006110168,0.000019886003],"genre_scores_gemma":[0.7847372,0.0037524127,0.0004092969,0.2049031,0.0014629085,0.0017596975,0.0023621889,0.00017493202,0.00043821603],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99637234,0.0006959398,0.00072597095,0.00093650125,0.0006159277,0.0006533091],"domain_scores_gemma":[0.99565417,0.0016150986,0.0010250421,0.0010309702,0.00055646675,0.00011826058],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041602977,0.00060038676,0.0022843608,0.00035076396,0.00023437294,0.000021591088,0.00052398565,0.00028154821,0.0010128025],"category_scores_gemma":[0.000037612437,0.0003758139,0.00029459118,0.0008218028,0.0004969032,0.00007744826,0.00016991838,0.0016563055,0.0000014733876],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10701708,0.0037085004,0.26330984,0.00010880198,0.066944875,0.0012038277,0.004762048,0.00028485284,0.00021979425,0.000021015534,0.17839515,0.3740242],"study_design_scores_gemma":[0.023465222,0.027408967,0.5523562,0.000051514013,0.0059395824,0.00006083017,0.0005454907,0.000026550682,0.00013193104,0.0002842258,0.38928148,0.0004480426],"about_ca_topic_score_codex":0.012565068,"about_ca_topic_score_gemma":0.00101278,"teacher_disagreement_score":0.3735762,"about_ca_system_score_codex":0.00013326127,"about_ca_system_score_gemma":0.00043863847,"threshold_uncertainty_score":0.9999004},"labels":[],"label_agreement":null},{"id":"W4220713221","doi":"10.1158/1538-7445.sabcs21-p1-18-05","title":"Abstract P1-18-05: Early changes in circulating tumor DNA and its effect on clinical outcomes in patients with advanced breast cancer receiving the CDK4/6 inhibitor palbociclib: Genotyping results from POLARIS","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Palbociclib; Medicine; Oncology; Internal medicine; Breast cancer; Cancer; Genotyping; Metastatic breast cancer; Genotype; Gene; Genetics; Biology","score_opus":0.06046124020476749,"score_gpt":0.3998349772114765,"score_spread":0.339373737006709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220713221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921611,0.0014765889,6.0232e-7,0.0032961548,0.0003592832,0.0019348514,0.000665445,0.000050170987,0.00005583217],"genre_scores_gemma":[0.9977231,0.00013875934,0.0000344267,0.00050365395,0.00039926582,0.0009936936,0.00003180456,0.000105771236,0.00006952062],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99532586,0.0007404321,0.0006594141,0.0009912138,0.0013555248,0.00092754763],"domain_scores_gemma":[0.9965827,0.0021716654,0.0002728173,0.0005414151,0.00022010122,0.0002113023],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0023696423,0.00033952316,0.00072859105,0.00038351014,0.00043688837,0.000058962887,0.00032352455,0.00009544671,0.00023428015],"category_scores_gemma":[0.0006541573,0.000242043,0.00007388831,0.00093952764,0.00022100232,0.00021924407,0.0003254549,0.0023392201,0.000004445982],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013767566,0.00020293111,0.8821059,0.000084191575,0.00012273318,0.00009128808,0.002246563,0.0002912823,0.005285304,0.0000028289817,0.00002082438,0.09577862],"study_design_scores_gemma":[0.011523192,0.0011742722,0.9839232,0.001215735,0.000019110767,0.0000047295744,0.00055004406,0.00005768899,0.001022632,0.000019734372,0.00022320182,0.00026648145],"about_ca_topic_score_codex":0.0056204624,"about_ca_topic_score_gemma":0.003223131,"teacher_disagreement_score":0.10181731,"about_ca_system_score_codex":0.0013434072,"about_ca_system_score_gemma":0.0003938959,"threshold_uncertainty_score":0.99996245},"labels":[],"label_agreement":null},{"id":"W4220714022","doi":"10.1158/1538-7445.sabcs21-p5-17-05","title":"Abstract P5-17-05: A phase I/Ib study of inavolisib (GDC-0077) in combination with fulvestrant in patients (pts) with <i>PIK3CA</i>-mutated hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Fulvestrant; Medicine; Metastatic breast cancer; Internal medicine; Breast cancer; Oncology; Cancer; Combination therapy; Phases of clinical research; Chemotherapy; Tamoxifen","score_opus":0.03702796251358815,"score_gpt":0.38047729758949195,"score_spread":0.3434493350759038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220714022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926511,0.00060325826,0.00001941563,0.00081497856,0.00007174717,0.0047997655,0.0008469396,0.000042886953,0.00014992824],"genre_scores_gemma":[0.995659,0.00014766061,0.00014114553,0.00009726762,0.000044124008,0.0034691775,0.00016343192,0.00012351717,0.00015465888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941124,0.0007491037,0.0007684721,0.0009339733,0.0024622544,0.000973835],"domain_scores_gemma":[0.9972701,0.00031571757,0.0003778552,0.00053869624,0.0012331728,0.00026444724],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011362222,0.00045414164,0.00094924355,0.0010049968,0.00024807532,0.00003679157,0.0003880574,0.00006600882,0.0009611892],"category_scores_gemma":[0.000053620966,0.00037575926,0.000057030084,0.0035524445,0.00052873336,0.00045411935,0.0001634622,0.0016587514,0.000003157633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28493676,0.079072446,0.37770993,0.0010185441,0.0026316673,0.0017298949,0.07713936,0.021250045,0.034089457,0.00006655589,0.0013787171,0.11897665],"study_design_scores_gemma":[0.11438126,0.022135062,0.83055985,0.001304154,0.00014751185,0.000044970966,0.025393203,0.00020568665,0.004892346,0.00007898236,0.00021443574,0.0006425073],"about_ca_topic_score_codex":0.02728062,"about_ca_topic_score_gemma":0.008312696,"teacher_disagreement_score":0.45284995,"about_ca_system_score_codex":0.003199042,"about_ca_system_score_gemma":0.0013262664,"threshold_uncertainty_score":0.9999521},"labels":[],"label_agreement":null},{"id":"W4220718209","doi":"10.3390/curroncol29030145","title":"The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Mohawk College; Trillium Health Centre","funders":"","keywords":"Palbociclib; Letrozole; Medicine; Fulvestrant; Metastatic breast cancer; Dosing; Oncology; Neutropenia; Breast cancer; Internal medicine; Febrile neutropenia; Progression-free survival; Cancer; Chemotherapy; Estrogen receptor; Tamoxifen","score_opus":0.06730224895111962,"score_gpt":0.44949894578347943,"score_spread":0.3821966968323598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220718209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971721,0.00060679606,0.000019159183,0.00032519654,0.00042993648,0.00065972947,0.00030030304,0.000012589973,0.000474146],"genre_scores_gemma":[0.9995085,0.00008736192,0.000091820475,0.000007756092,0.000051157665,0.00019079287,0.000026975302,0.000021733142,0.000013890534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984045,0.00028383525,0.0003591923,0.0002124593,0.00047234018,0.00026764348],"domain_scores_gemma":[0.9986238,0.00033695155,0.0004857899,0.00030355263,0.00019464889,0.000055264416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000270354,0.00016492329,0.0004847036,0.00016160808,0.00008488869,0.0000048110605,0.00021552356,0.0000149571,0.00012740944],"category_scores_gemma":[0.00002751556,0.00009413106,0.00007840073,0.00041106337,0.0002900182,0.00007604195,0.000119020406,0.00034565432,2.7242723e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010556106,0.0019737408,0.7798965,0.00008471664,0.0003162683,0.000009090072,0.0013758453,0.0033966873,0.00009114963,0.0008951575,0.000059773058,0.20134498],"study_design_scores_gemma":[0.008746844,0.003386825,0.9841641,0.00030409885,0.000070151764,0.0000053600434,0.0015884428,0.00013870052,0.00009528762,0.0010138475,0.0003851987,0.000101132835],"about_ca_topic_score_codex":0.0007584946,"about_ca_topic_score_gemma":0.00066918205,"teacher_disagreement_score":0.20426764,"about_ca_system_score_codex":0.00090225623,"about_ca_system_score_gemma":0.00071536703,"threshold_uncertainty_score":0.3838553},"labels":[],"label_agreement":null},{"id":"W4220719444","doi":"10.1158/1538-7445.sabcs21-pd2-05","title":"Abstract PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Indel; Medicine; Oncology; False discovery rate; Exact test; Internal medicine; Breast cancer; Logistic regression; Multiple comparisons problem; Gene; Cancer; Bioinformatics; Biology; Genetics; Single-nucleotide polymorphism; Genotype","score_opus":0.08569701664852465,"score_gpt":0.4448074994330611,"score_spread":0.35911048278453644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220719444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95300007,0.037911322,0.0000068423838,0.0064693093,0.0003743175,0.0015377263,0.0005626391,0.000054922966,0.00008287719],"genre_scores_gemma":[0.9931498,0.0022252933,0.00016886916,0.00041313746,0.00034805856,0.003189644,0.000020434316,0.00009932081,0.00038542334],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9958366,0.00030613068,0.00062256295,0.00072449207,0.0013833888,0.0011268393],"domain_scores_gemma":[0.9974649,0.0005979681,0.00023677188,0.00077112287,0.0007773809,0.00015188698],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018831263,0.00031669738,0.000697537,0.00031623908,0.00060500967,0.00002551111,0.0006301856,0.00007506697,0.0008368205],"category_scores_gemma":[0.00014890493,0.00024543586,0.00015139986,0.0014905118,0.00100097,0.00015911006,0.00048255504,0.0016083905,0.000008357244],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018646857,0.0007125485,0.15225981,0.0019255385,0.00082042126,0.0002669705,0.008952126,0.047691315,0.46546304,0.00023641625,0.0005398096,0.30248514],"study_design_scores_gemma":[0.011876828,0.00080615876,0.79592156,0.0014814679,0.00009107736,0.000111049456,0.03592975,0.00034017573,0.13181771,0.0009759137,0.019809665,0.000838641],"about_ca_topic_score_codex":0.00230842,"about_ca_topic_score_gemma":0.0016357359,"teacher_disagreement_score":0.64366174,"about_ca_system_score_codex":0.0027164249,"about_ca_system_score_gemma":0.0017147613,"threshold_uncertainty_score":0.99999976},"labels":[],"label_agreement":null},{"id":"W4220721699","doi":"10.1002/cam4.4635","title":"A <scp>WIN</scp> Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non‐small cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Waterloo Institute for Nanotechnology, University of Waterloo; University of California, San Diego; Fondation ARC pour la Recherche sur le Cancer; Pfizer","keywords":"Axitinib; Medicine; Avelumab; Palbociclib; Internal medicine; Oncology; Neutropenia; Lung cancer; Pembrolizumab; Cancer; Adverse effect; Gastroenterology; Immunotherapy; Chemotherapy; Breast cancer; Sunitinib; Metastatic breast cancer","score_opus":0.04458647732105899,"score_gpt":0.344888726281933,"score_spread":0.30030224896087404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220721699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95846593,0.03471703,0.0001427711,0.0014354553,0.0014639256,0.0025629369,0.000090669775,0.00015405938,0.0009672023],"genre_scores_gemma":[0.9842051,0.0023428537,0.00018426191,0.0021482033,0.0008883132,0.007132583,0.000034450604,0.00014919924,0.0029150143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962634,0.00015172019,0.00085649,0.0010504862,0.00076422445,0.0009137218],"domain_scores_gemma":[0.99803174,0.00033836864,0.00036728347,0.0006311314,0.0001708947,0.0004605771],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005750222,0.0005542085,0.0012120625,0.0004503583,0.0002960307,0.000013579772,0.00028272765,0.00006870525,0.0010057822],"category_scores_gemma":[0.00016210039,0.0005168735,0.00008323766,0.00097287167,0.00029166992,0.00023545361,0.0002631269,0.0010053696,0.0000028541883],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032417781,0.0034694762,0.6275522,0.0017791847,0.0007770605,0.0021460496,0.11653991,0.0023037794,0.06855245,0.000058152596,0.003699781,0.1698802],"study_design_scores_gemma":[0.2307845,0.010877389,0.2620382,0.0036314717,0.0020795679,0.00034313885,0.260333,0.004112643,0.013288308,0.00016510914,0.21105124,0.0012954084],"about_ca_topic_score_codex":0.0010602018,"about_ca_topic_score_gemma":0.0003830723,"teacher_disagreement_score":0.36551398,"about_ca_system_score_codex":0.0009765635,"about_ca_system_score_gemma":0.0005683642,"threshold_uncertainty_score":0.99990743},"labels":[],"label_agreement":null},{"id":"W4220729116","doi":"10.1158/1538-7445.sabcs21-ot2-11-05","title":"Abstract OT2-11-05: SERENA-6: A Phase III study to assess the efficacy and safety of AZD9833 (camizestrant) compared with aromatase inhibitors when given in combination with palbociclib or abemaciclib in patients with HR+/HER2- metastatic breast cancer with detectable <i>ESR1</i>m who have not experienced disease progression on first-line therapy","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Palbociclib; Medicine; Internal medicine; Metastatic breast cancer; Cancer; Oncology; Breast cancer; Aromatase inhibitor; Aromatase; Estrogen receptor; Fulvestrant; Cancer research","score_opus":0.061133145485971666,"score_gpt":0.4015729937799294,"score_spread":0.34043984829395774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220729116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884363,0.00023082654,0.00003718413,0.0015889762,0.000024928804,0.009077579,0.0005600829,0.000036888443,0.000007263597],"genre_scores_gemma":[0.9937757,0.000057829133,0.00014718756,0.00013528284,0.000030374598,0.005609354,0.000093116934,0.00010599001,0.000045120596],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9950516,0.00049942045,0.0005761858,0.0009099012,0.002216613,0.000746262],"domain_scores_gemma":[0.99765974,0.00045736475,0.00031671376,0.0006908473,0.00050036557,0.00037497544],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00082944025,0.0004661326,0.0008528636,0.00045374307,0.0004850019,0.00007073532,0.00036243538,0.000031478863,0.00020961485],"category_scores_gemma":[0.00003473227,0.0002473764,0.000030246825,0.0014517849,0.00052689563,0.0003310262,0.00012837828,0.00074027356,3.7048088e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54406345,0.010533551,0.39535627,0.00031733577,0.00030577497,0.00036061916,0.018463567,0.010701611,0.000661135,0.0000026959356,0.000036978985,0.019196995],"study_design_scores_gemma":[0.14758043,0.019544438,0.8121471,0.003740319,0.0001020815,0.000019335579,0.012229669,0.00035232407,0.0035788005,0.000006714266,0.0001884736,0.0005103305],"about_ca_topic_score_codex":0.002906113,"about_ca_topic_score_gemma":0.009669812,"teacher_disagreement_score":0.4167908,"about_ca_system_score_codex":0.0008114482,"about_ca_system_score_gemma":0.00090971554,"threshold_uncertainty_score":0.99999785},"labels":[],"label_agreement":null},{"id":"W4220734028","doi":"10.1158/1538-7445.sabcs21-p1-18-25","title":"Abstract P1-18-25: Real-world quality of life (QoL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC) treated with palbociclib: A patient-reported outcome (PRO) analysis from POLARIS","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Palbociclib; Medicine; Cancer; Internal medicine; Oncology; Quality of life (healthcare); Breast cancer; Metastatic breast cancer; Stage (stratigraphy); Disease; Cohort; Gynecology","score_opus":0.06712141622283398,"score_gpt":0.3906830873880279,"score_spread":0.32356167116519396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220734028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98560345,0.00063331967,0.000017524575,0.0008123421,0.00007794481,0.002866984,0.009542668,0.00012910223,0.00031664106],"genre_scores_gemma":[0.9952106,0.00017606924,0.00046799163,0.0001733592,0.00012576427,0.002051045,0.0012270261,0.00020131185,0.00036684689],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99060214,0.0011835217,0.0018710833,0.0016840021,0.0032714228,0.0013878365],"domain_scores_gemma":[0.9935759,0.00074119243,0.0014899212,0.0011367622,0.0023564952,0.0006997338],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00085691706,0.00076734973,0.0022197112,0.0017859284,0.0006172447,0.00005009765,0.000522652,0.00017861325,0.0073302994],"category_scores_gemma":[0.00024382953,0.0006276986,0.0003198264,0.007244298,0.00089251867,0.0005879827,0.00031161137,0.0020545486,0.0000064719497],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039228592,0.0013823854,0.9304577,0.00012983801,0.00432208,0.00004100278,0.0033131444,0.00038705338,0.0130191455,0.00001592625,0.00011352882,0.007589565],"study_design_scores_gemma":[0.013796323,0.0015914767,0.97530836,0.00026895327,0.0003777777,0.0000010522392,0.0024678162,0.000009699407,0.0053387284,0.000025039113,0.00011639727,0.00069834996],"about_ca_topic_score_codex":0.20246415,"about_ca_topic_score_gemma":0.018567426,"teacher_disagreement_score":0.18389672,"about_ca_system_score_codex":0.0044170297,"about_ca_system_score_gemma":0.0012435153,"threshold_uncertainty_score":0.99961746},"labels":[],"label_agreement":null},{"id":"W4220775282","doi":"10.1158/1538-7445.sabcs21-p1-18-29","title":"Abstract P1-18-29: Male patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) receiving palbociclib in the real-world: patient characteristics, treatment patterns, and outcomes from the POLARIS study","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Palbociclib; Medicine; Fulvestrant; Internal medicine; Breast cancer; Oncology; Cancer; Neutropenia; Metastatic breast cancer; Tamoxifen; Gynecology; Chemotherapy","score_opus":0.0380005638176461,"score_gpt":0.35891615054231046,"score_spread":0.32091558672466436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220775282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97972584,0.00064632524,0.0000019504862,0.0048669353,0.00022975504,0.004732837,0.009640424,0.00004917093,0.00010678865],"genre_scores_gemma":[0.99301916,0.001020999,0.00006014478,0.00055187254,0.00030436553,0.0042183213,0.00039388065,0.00013485174,0.0002963976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939756,0.0012918166,0.0007243211,0.0011172628,0.0018331164,0.0010578886],"domain_scores_gemma":[0.9965221,0.0013934155,0.00043291523,0.0008175134,0.0005644461,0.00026955374],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006426198,0.00061117706,0.0008905748,0.0002953374,0.0012927689,0.00013417778,0.0005358876,0.000077429875,0.0041690296],"category_scores_gemma":[0.00010783913,0.00036437743,0.00011865815,0.0008520159,0.00044916678,0.0003614641,0.0003587304,0.0015183993,0.000009052026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050805877,0.0015621942,0.89235973,0.000031385087,0.00059466803,0.00005602227,0.02489357,0.0000067914184,0.0012124149,0.0000062626923,0.00023449732,0.07396187],"study_design_scores_gemma":[0.0073483996,0.0022880586,0.97046125,0.00025171574,0.000088691944,0.000004216573,0.018029356,0.000001979318,0.00045816702,0.00002016258,0.0006433178,0.000404698],"about_ca_topic_score_codex":0.07741856,"about_ca_topic_score_gemma":0.01180495,"teacher_disagreement_score":0.07810149,"about_ca_system_score_codex":0.0032818215,"about_ca_system_score_gemma":0.00040872014,"threshold_uncertainty_score":0.9998808},"labels":[],"label_agreement":null},{"id":"W4220799525","doi":"10.1158/1538-7445.sabcs21-gs1-02","title":"Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gemcitabine; Carboplatin; Pembrolizumab; Internal medicine; Taxane; Hazard ratio; Population; Oncology; Placebo; Chemotherapy; Breast cancer; Clinical endpoint; Cancer; Confidence interval; Clinical trial; Cisplatin; Pathology","score_opus":0.1262927204348393,"score_gpt":0.45418967136191757,"score_spread":0.32789695092707827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220799525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96917444,0.00358739,0.00024284092,0.0028605857,0.0002840511,0.021393511,0.0022377016,0.00007533148,0.00014416089],"genre_scores_gemma":[0.97698516,0.0020826447,0.00038251258,0.00022238956,0.00026445038,0.01644774,0.00013063248,0.00018543402,0.0032990365],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99290794,0.0008699847,0.0017454905,0.0011480558,0.0021498566,0.0011786538],"domain_scores_gemma":[0.9939176,0.0016911651,0.0009143498,0.0009803864,0.0021449924,0.0003515392],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0039067436,0.0006102091,0.0024354546,0.00077557936,0.00044314563,0.000043568572,0.0007166004,0.00011029112,0.003982546],"category_scores_gemma":[0.00033373706,0.0004670956,0.0003975518,0.0019071177,0.0007633756,0.00024609556,0.00015682768,0.0011711118,0.000003143559],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90060246,0.0059038103,0.00007593008,0.00090854446,0.0025356617,0.000043206965,0.009969128,0.0020632348,0.005382361,0.000017801707,0.001529416,0.070968464],"study_design_scores_gemma":[0.94874775,0.009857583,0.0003060969,0.0007111226,0.00041923407,0.000066121225,0.004632633,0.00080929237,0.031282745,0.00012076498,0.0025976347,0.00044898893],"about_ca_topic_score_codex":0.0068490375,"about_ca_topic_score_gemma":0.0011270134,"teacher_disagreement_score":0.07051947,"about_ca_system_score_codex":0.0017737026,"about_ca_system_score_gemma":0.003694498,"threshold_uncertainty_score":0.9997781},"labels":[],"label_agreement":null},{"id":"W4220833656","doi":"10.1158/1538-7445.sabcs21-p4-10-01","title":"Abstract P4-10-01: Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05)","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Palbociclib; Breast cancer; Clinical endpoint; Quality of life (healthcare); Internal medicine; Adjuvant; Cancer; Randomized controlled trial; Interim analysis; Adjuvant therapy; Oncology; Metastatic breast cancer","score_opus":0.07693271054620061,"score_gpt":0.42274366292314197,"score_spread":0.34581095237694137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220833656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98574257,0.006339484,0.0000030303777,0.0042670597,0.00008363792,0.003082484,0.00027181,0.000013892637,0.00019605384],"genre_scores_gemma":[0.99369377,0.0031212033,0.000026977614,0.00022605775,0.0001734063,0.0025833282,0.00001079929,0.000039618386,0.00012483331],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948854,0.0015750967,0.00084410043,0.0004733232,0.0016353576,0.0005867458],"domain_scores_gemma":[0.9972234,0.0014479787,0.0003100697,0.0005593106,0.00032216377,0.00013711577],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004823742,0.00023386505,0.0012780001,0.0003236414,0.00011112184,0.000017810406,0.00037262673,0.000057471563,0.0012970705],"category_scores_gemma":[0.00022110964,0.00015061,0.00013146491,0.0010124524,0.00087332336,0.00012730072,0.00014039883,0.0010201954,5.83759e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92105585,0.0005913534,0.05016932,0.00026335032,0.00023484541,0.00003590445,0.004063926,0.00013481549,0.006317263,0.00010153125,0.000068293215,0.01696357],"study_design_scores_gemma":[0.60110056,0.0007572378,0.3946906,0.00019749394,0.000016675394,0.000015779135,0.0013507926,0.000018294364,0.0008765665,0.0002674695,0.000552077,0.00015645943],"about_ca_topic_score_codex":0.037440065,"about_ca_topic_score_gemma":0.0031766267,"teacher_disagreement_score":0.34452128,"about_ca_system_score_codex":0.00040977515,"about_ca_system_score_gemma":0.0013036891,"threshold_uncertainty_score":0.9996159},"labels":[],"label_agreement":null},{"id":"W4220840510","doi":"10.1158/1538-7445.sabcs21-p1-18-08","title":"Abstract P1-18-08: Effect of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy (≤6 mo or &amp;gt;6 mo) on alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), <i>PIK3CA</i>-mutated advanced breast cancer (ABC) from BYLieve","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Fulvestrant; Letrozole; Internal medicine; Cohort; Population; Aromatase inhibitor; Oncology; Gastroenterology; Cancer; Breast cancer; Tamoxifen","score_opus":0.028843720760742365,"score_gpt":0.34747679407936316,"score_spread":0.3186330733186208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220840510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98432857,0.0014615444,0.000013298616,0.0005377414,0.00025153952,0.004837456,0.008405619,0.00007829031,0.00008595612],"genre_scores_gemma":[0.9946194,0.00090804684,0.0002925384,0.00013610315,0.0003130959,0.0024587906,0.0008020615,0.00022330301,0.00024663063],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9924237,0.00084823056,0.0012969954,0.0013902445,0.0029284568,0.0011123704],"domain_scores_gemma":[0.99521196,0.001180612,0.0009380499,0.00068751234,0.0015910445,0.00039083103],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008640073,0.0007724357,0.0014877316,0.0007269929,0.00045525143,0.000041199317,0.0005608839,0.00023863382,0.004353371],"category_scores_gemma":[0.00023697874,0.00059987325,0.00021115188,0.0015879816,0.00063351786,0.0005671212,0.00024567384,0.0017750125,0.00001709773],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1922168,0.0022905488,0.04547438,0.00031110266,0.0008240541,0.000033793694,0.0045128143,0.0017196534,0.6236684,0.000013381983,0.00030521108,0.12862986],"study_design_scores_gemma":[0.029391918,0.00757267,0.5289239,0.0013090238,0.00005871015,0.000003480629,0.0005460039,0.00001623729,0.43129686,0.0000604436,0.00020913057,0.00061162363],"about_ca_topic_score_codex":0.008841119,"about_ca_topic_score_gemma":0.0010214077,"teacher_disagreement_score":0.48344952,"about_ca_system_score_codex":0.0032240152,"about_ca_system_score_gemma":0.00067854265,"threshold_uncertainty_score":0.9996453},"labels":[],"label_agreement":null},{"id":"W4220870634","doi":"10.1158/1538-7445.sabcs21-ot2-11-06","title":"Abstract OT2-11-06: SERENA-4: A Phase III comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive/HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Palbociclib; Medicine; Fulvestrant; Breast cancer; Internal medicine; Anastrozole; Cancer; Oncology; Letrozole; Aromatase inhibitor; Estrogen receptor; Tamoxifen; Pharmacology; Metastatic breast cancer","score_opus":0.062136053726374436,"score_gpt":0.41991301954510485,"score_spread":0.3577769658187304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220870634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9625297,0.0026262298,0.00065092853,0.0015170696,0.00036732896,0.014635491,0.01749407,0.00013020803,0.000048973452],"genre_scores_gemma":[0.97073257,0.0004830959,0.00091964466,0.00010287122,0.00031276842,0.024904743,0.0012276989,0.00027575044,0.0010408725],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9932403,0.0003426325,0.0011748315,0.0015945764,0.0018418375,0.0018058254],"domain_scores_gemma":[0.99342084,0.0016120134,0.0008881116,0.0010240481,0.0021796487,0.0008753582],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005140124,0.0008583432,0.0020022441,0.000428088,0.000973881,0.00006027488,0.0005947318,0.00014448013,0.000341806],"category_scores_gemma":[0.00018211514,0.00074660685,0.00045961916,0.0007654745,0.00067409285,0.0004534125,0.0001758693,0.00074397685,0.0000030938866],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76001376,0.004501785,0.018330216,0.0032646395,0.002790119,0.000071348884,0.010855427,0.04936475,0.0125114,0.00007677409,0.0008147333,0.13740508],"study_design_scores_gemma":[0.7683812,0.036472477,0.07767586,0.0106606735,0.0026969037,0.00003651586,0.0307045,0.011196697,0.045326587,0.00013183868,0.013497667,0.0032190937],"about_ca_topic_score_codex":0.002629724,"about_ca_topic_score_gemma":0.0019538698,"teacher_disagreement_score":0.13418598,"about_ca_system_score_codex":0.008041063,"about_ca_system_score_gemma":0.0036850632,"threshold_uncertainty_score":0.9994985},"labels":[],"label_agreement":null},{"id":"W4220871701","doi":"10.51731/cjht.2022.286","title":"Alpelisib (Piqray)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Fulvestrant; Medicine; Regimen; Family medicine; Metastatic breast cancer; Breast cancer; Oncology; Internal medicine; Cancer; Gynecology; Political science; Estrogen receptor; Health care","score_opus":0.024443423046101077,"score_gpt":0.29228039434484965,"score_spread":0.26783697129874856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220871701","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24462451,0.3965818,0.0015217363,0.35322034,0.0018196872,0.000679916,0.000080963866,0.00039448333,0.0010765694],"genre_scores_gemma":[0.99552864,0.00014176157,0.0017541872,0.0023644068,0.000018181887,0.000011701358,0.0000019435695,0.000019065536,0.00016013713],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99879175,0.00004460056,0.00041876247,0.00010653726,0.00021925746,0.00041906975],"domain_scores_gemma":[0.9991565,0.000026538635,0.0003408886,0.00024876907,0.00011535614,0.00011199414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004900216,0.00009743178,0.00035054056,0.00068164023,0.00038547334,0.000009078701,0.0002837391,0.000044293705,0.00024181424],"category_scores_gemma":[0.00019845,0.00008830191,0.000078128374,0.00043032688,0.00016931858,0.00007243564,0.00003215958,0.0007067811,0.0000041552375],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062474115,0.000018674487,0.004884629,0.00005039332,0.000049790953,0.00046440458,0.00039275317,0.0000968382,0.00010165469,0.0012492258,0.0043228995,0.9883063],"study_design_scores_gemma":[0.0007659733,0.0008960784,0.006125647,0.000071854796,0.000010968554,0.0035729883,0.00873405,0.000004219696,0.00026834093,0.0046546864,0.9748058,0.00008940592],"about_ca_topic_score_codex":0.0014971367,"about_ca_topic_score_gemma":0.00051780697,"teacher_disagreement_score":0.9882169,"about_ca_system_score_codex":0.0011734545,"about_ca_system_score_gemma":0.0042613978,"threshold_uncertainty_score":0.75595367},"labels":[],"label_agreement":null},{"id":"W4220884345","doi":"10.1158/1538-7445.sabcs21-p5-16-11","title":"Abstract P5-16-11: Ipatasertib (ipat) in combination with palbociclib (palbo) and fulvestrant (fulv) in patients (pts) with hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC)","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Palbociclib; Medicine; Breast cancer; Fulvestrant; Internal medicine; Cancer; Oncology; Aromatase inhibitor; Tamoxifen; Pharmacology; Metastatic breast cancer","score_opus":0.021763398283629904,"score_gpt":0.333341173949691,"score_spread":0.3115777756660611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220884345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918811,0.0014278764,0.000014087753,0.0027293765,0.000080839694,0.0024979953,0.0011160253,0.00004869995,0.00020402341],"genre_scores_gemma":[0.9952004,0.0007129211,0.00019918679,0.00023405142,0.00007357278,0.0029716496,0.00027213138,0.00011662288,0.00021944856],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99543554,0.0003496278,0.0004908787,0.0010077769,0.001652415,0.0010637471],"domain_scores_gemma":[0.99808115,0.00026344226,0.0002146046,0.00045127762,0.000668954,0.00032056822],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00067624875,0.00042511846,0.0006558651,0.00061641855,0.00036786363,0.00004867589,0.00027683185,0.00010367401,0.0006367594],"category_scores_gemma":[0.000047284124,0.00036038982,0.00004322584,0.0018492086,0.00065637974,0.0005706508,0.00018245091,0.0015438234,0.000005289515],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06312507,0.0025598612,0.74375445,0.000419018,0.0003097127,0.00024388278,0.010074151,0.0018556287,0.010879632,0.00014203394,0.00040829257,0.16622825],"study_design_scores_gemma":[0.024840565,0.0026860475,0.96216214,0.0010421715,0.000029137225,0.000028803539,0.0043264027,0.000041293686,0.0031786403,0.0002074161,0.00097057637,0.00048677996],"about_ca_topic_score_codex":0.014338842,"about_ca_topic_score_gemma":0.012435172,"teacher_disagreement_score":0.21840769,"about_ca_system_score_codex":0.003932191,"about_ca_system_score_gemma":0.0009246245,"threshold_uncertainty_score":0.9998915},"labels":[],"label_agreement":null},{"id":"W4220900778","doi":"10.1158/1538-7445.sabcs21-p1-18-03","title":"Abstract P1-18-03: Alpelisib + fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), <i>PIK3CA</i>-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + aromatase inhibitor (AI): 18-month follow-up of BYLieve Cohort A","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Fulvestrant; Rash; Internal medicine; Maculopapular rash; Letrozole; Clinical endpoint; Cohort; Oncology; Cancer; Hazard ratio; Breast cancer; Adverse effect; Confidence interval; Clinical trial; Estrogen receptor; Tamoxifen","score_opus":0.02095730569695405,"score_gpt":0.3205103256317687,"score_spread":0.29955301993481465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220900778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756997,0.00176156,0.000013089134,0.00082659815,0.00029148432,0.008000292,0.012964591,0.0001994234,0.0002432572],"genre_scores_gemma":[0.990268,0.0005061963,0.00033489053,0.000230071,0.00036319735,0.005417103,0.001995559,0.00040223118,0.00048273164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98882276,0.0009497318,0.0016823094,0.002271456,0.003995155,0.0022785973],"domain_scores_gemma":[0.9938414,0.00045842453,0.0009774852,0.0011982583,0.0024940749,0.001030333],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010111047,0.0012521251,0.0020879472,0.001041295,0.00080857024,0.00010293377,0.00077972544,0.00030920774,0.0035745907],"category_scores_gemma":[0.00016605688,0.0010451173,0.0002802589,0.0027981517,0.001371632,0.0010839863,0.00041496436,0.002987154,0.000022569446],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23034817,0.007281109,0.45213273,0.001194067,0.003092885,0.0009555421,0.0074374126,0.0015784798,0.26825225,0.000022485641,0.004446244,0.023258623],"study_design_scores_gemma":[0.0613809,0.009856927,0.75107574,0.0032612246,0.00034498723,0.00006363081,0.0027510459,0.000024690506,0.16895851,0.00003725624,0.00050489506,0.0017401786],"about_ca_topic_score_codex":0.015687486,"about_ca_topic_score_gemma":0.0026119787,"teacher_disagreement_score":0.29894304,"about_ca_system_score_codex":0.0054098247,"about_ca_system_score_gemma":0.0022337341,"threshold_uncertainty_score":0.999313},"labels":[],"label_agreement":null},{"id":"W4220902905","doi":"10.1158/1538-7445.sabcs21-p5-13-10","title":"Abstract P5-13-10: Elevated plasma IL-8 predicts for reduced outcomes in CCTG MA.38, a phase 2 randomized trial of palbociclib in ER+/HER2- metastatic breast cancer patients","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; BC Cancer Agency; Queen's University","funders":"","keywords":"Palbociclib; Medicine; Internal medicine; Breast cancer; Oncology; Metastatic breast cancer; Cancer; Biomarker; Gastroenterology; Urology","score_opus":0.07302284824606578,"score_gpt":0.4411081391265313,"score_spread":0.3680852908804655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220902905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844482,0.0006113017,0.000011219612,0.0020695506,0.0005213123,0.009224975,0.0029713307,0.000045071836,0.00009702653],"genre_scores_gemma":[0.9794329,0.00025622375,0.00013599804,0.0000886457,0.00017246319,0.018473553,0.00022031192,0.00011452459,0.0011053752],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99416745,0.0008277157,0.0013613931,0.0007716832,0.0017651174,0.00110664],"domain_scores_gemma":[0.9964744,0.0016299069,0.0004179012,0.00053803035,0.0006799317,0.000259867],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0032085157,0.00037907303,0.0018310419,0.0010217662,0.00016347656,0.000025459636,0.0004463067,0.000102994105,0.0032439684],"category_scores_gemma":[0.0010898623,0.00032753666,0.0003242439,0.0014473639,0.0004348678,0.00021324606,0.00018768015,0.0010291113,0.000005176815],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9557629,0.0037038834,0.00303588,0.0005215841,0.0005763029,0.000046964757,0.0018079515,0.0008134795,0.012598996,0.000025291656,0.00050655456,0.020600189],"study_design_scores_gemma":[0.97986406,0.0015399975,0.008665775,0.00043062377,0.00011573496,0.000006169655,0.000769052,0.0007709518,0.005856599,0.00043710542,0.0012341709,0.000309745],"about_ca_topic_score_codex":0.00319095,"about_ca_topic_score_gemma":0.00067670643,"teacher_disagreement_score":0.024101151,"about_ca_system_score_codex":0.0018979323,"about_ca_system_score_gemma":0.0018087605,"threshold_uncertainty_score":0.9999177},"labels":[],"label_agreement":null},{"id":"W4220961745","doi":"10.1158/1538-7445.sabcs21-p5-13-36","title":"Abstract P5-13-36: Germline <i>BRCA</i>1/2 and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"CHEK2; Medicine; Oncology; Internal medicine; Breast cancer; PALB2; Cancer; Germline; Hazard ratio; Germline mutation; Genetics; Mutation; Biology; Gene; Confidence interval","score_opus":0.03400871225458401,"score_gpt":0.3600987525816422,"score_spread":0.3260900403270582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220961745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907588,0.0022017285,0.000015486368,0.00091080624,0.00004123241,0.003040965,0.00290075,0.00007793443,0.00005230671],"genre_scores_gemma":[0.9930078,0.001365347,0.00007633718,0.00046945544,0.00020581069,0.0037593895,0.00018186828,0.00016224473,0.00077179587],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99538165,0.0007815801,0.00047105865,0.0010529903,0.0015382401,0.0007744911],"domain_scores_gemma":[0.9978896,0.00033459533,0.00027426603,0.0008187839,0.00045646654,0.00022632776],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007160738,0.0004647946,0.0008214943,0.00045125087,0.0005502923,0.00011662205,0.00038160838,0.00005978176,0.0042232135],"category_scores_gemma":[0.000012512113,0.00026603183,0.00008083436,0.0023236617,0.00040466493,0.0002891895,0.0001930996,0.0013083688,0.000002904945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03962599,0.0010666839,0.92213976,0.00003574793,0.0023967258,0.00014313134,0.004971493,0.0014211565,0.00059299066,0.000001326069,0.000036820904,0.027568176],"study_design_scores_gemma":[0.018253436,0.0022823163,0.97300005,0.00014747451,0.00039309677,0.000013937736,0.0034933786,0.00009503257,0.00059949054,0.000009580911,0.00136775,0.00034445658],"about_ca_topic_score_codex":0.29716343,"about_ca_topic_score_gemma":0.13728786,"teacher_disagreement_score":0.15987557,"about_ca_system_score_codex":0.00072853174,"about_ca_system_score_gemma":0.0007880806,"threshold_uncertainty_score":0.9999792},"labels":[],"label_agreement":null},{"id":"W4220967821","doi":"10.1158/1538-7445.sabcs21-p4-12-01","title":"Abstract P4-12-01: Adherence with adjuvant endocrine therapy with or without Palbociclib in the PALLAS trial","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Université Laval","funders":"","keywords":"Medicine; Palbociclib; Adjuvant; Internal medicine; Pill; Breast cancer; Cancer; Oncology; Metastatic breast cancer; Pharmacology","score_opus":0.1864431683296825,"score_gpt":0.4594538310750189,"score_spread":0.2730106627453364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220967821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877977,0.0026993433,0.000016987657,0.003875998,0.00011943497,0.0036366154,0.00003832651,0.000061739935,0.0017538941],"genre_scores_gemma":[0.9903112,0.00072490243,0.00016611209,0.00075411913,0.000490003,0.0061046067,0.00001657477,0.000084722924,0.0013477574],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99559826,0.00039777788,0.00032489546,0.0006317472,0.0021194192,0.00092789275],"domain_scores_gemma":[0.9983091,0.00042999172,0.000116955285,0.00081539364,0.00016403491,0.00016457678],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001063922,0.00028213684,0.0005134281,0.0002414124,0.00040774693,0.000060068836,0.00062555785,0.00003981493,0.0036518164],"category_scores_gemma":[0.000051659703,0.00014244001,0.000059216112,0.0011728201,0.00050244917,0.00014404864,0.000116561765,0.0017006507,0.000011177258],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8147645,0.0011558381,0.04115462,0.00016256409,0.00031102222,0.0017670406,0.0066712457,0.00041215908,0.016237434,0.00014028007,0.00066855515,0.11655472],"study_design_scores_gemma":[0.50894755,0.05224785,0.1348424,0.0011646702,0.00009969589,0.0014236607,0.026780939,0.00010400575,0.017005548,0.00059293624,0.25538394,0.0014067905],"about_ca_topic_score_codex":0.0022489242,"about_ca_topic_score_gemma":0.0031735187,"teacher_disagreement_score":0.30581695,"about_ca_system_score_codex":0.00046902453,"about_ca_system_score_gemma":0.0017579399,"threshold_uncertainty_score":0.99725896},"labels":[],"label_agreement":null},{"id":"W4220992683","doi":"10.1158/1538-7445.sabcs21-p5-13-03","title":"Abstract P5-13-03: Alpelisib + endocrine therapy (ET) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), <i>PIK3CA</i>-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i): Biomarker analyses from the Phase II BYLieve study","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Fulvestrant; Internal medicine; Cohort; Letrozole; Breast cancer; Oncology; Hazard ratio; Cancer; Clinical endpoint; Progression-free survival; Estrogen receptor; Confidence interval; Aromatase; Clinical trial; Chemotherapy","score_opus":0.05369898673042435,"score_gpt":0.40153964004033166,"score_spread":0.3478406533099073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220992683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786032,0.0038738053,0.00001005571,0.0021746685,0.00016122952,0.008491617,0.006384647,0.0001818741,0.00011892557],"genre_scores_gemma":[0.9895932,0.0010459181,0.00013776925,0.00049519684,0.00031808042,0.006484421,0.001225153,0.00032544826,0.00037478187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9898271,0.0019014355,0.001170183,0.0020546368,0.0032546874,0.0017919383],"domain_scores_gemma":[0.99470353,0.0008749891,0.00069230737,0.0012080878,0.0019176183,0.00060345116],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008924664,0.0011129811,0.0014876268,0.0006694332,0.0016478931,0.00014854371,0.0008869832,0.00013230389,0.003832078],"category_scores_gemma":[0.00012329144,0.0007320744,0.00021299381,0.0029175682,0.0009923375,0.000834865,0.00051720213,0.0024786585,0.000015324416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21901345,0.021406692,0.35030606,0.00009526564,0.005459756,0.00068720244,0.018684408,0.0010241513,0.2839743,0.0000049777927,0.0014335271,0.09791022],"study_design_scores_gemma":[0.08333506,0.014198046,0.8421112,0.0006719864,0.00023144227,0.000018263865,0.007903687,0.00001918476,0.049839817,0.000022409764,0.0005457181,0.0011031961],"about_ca_topic_score_codex":0.046280004,"about_ca_topic_score_gemma":0.005667158,"teacher_disagreement_score":0.49180514,"about_ca_system_score_codex":0.0035892553,"about_ca_system_score_gemma":0.0011718667,"threshold_uncertainty_score":0.9998227},"labels":[],"label_agreement":null},{"id":"W4221013240","doi":"10.1158/1538-7445.sabcs21-pd13-05","title":"Abstract PD13-05: Alpelisib + fulvestrant in patients with <i>PIK3CA</i>-mutated, HR+, HER2— advanced breast cancer (ABC) who received chemotherapy or endocrine therapy (ET) as immediate prior treatment: BYLieve Cohort C primary results and exploratory biomarker analyses","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Fulvestrant; Internal medicine; Cohort; Letrozole; Oncology; Clinical endpoint; Breast cancer; Cancer; Metastatic breast cancer; Palbociclib; Clinical trial; Tamoxifen","score_opus":0.06264451628072079,"score_gpt":0.4018803996710633,"score_spread":0.3392358833903425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221013240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98080397,0.008921751,0.0000031671211,0.0044255126,0.0001837952,0.0036991928,0.0014407139,0.00012269574,0.0003991901],"genre_scores_gemma":[0.9594129,0.032228008,0.00024291432,0.001466144,0.00017375332,0.004499974,0.00047998477,0.00025988612,0.0012364521],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99379647,0.0005054808,0.0008566523,0.0015518668,0.0019015792,0.0013879358],"domain_scores_gemma":[0.99707586,0.00039420626,0.00035653813,0.0009325587,0.00071393745,0.0005269204],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00082582084,0.00074099295,0.0012006825,0.00074003683,0.00052649394,0.000086620086,0.00039572886,0.00011610848,0.0010708636],"category_scores_gemma":[0.000049080394,0.0005307124,0.00013618499,0.0018915802,0.0007104851,0.0006471352,0.00015603962,0.0010503022,0.0000067491665],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2412988,0.0025478324,0.117960796,0.0002476465,0.0017943474,0.000845234,0.004023244,0.00079487805,0.04476993,0.0000030501346,0.00051182794,0.5852024],"study_design_scores_gemma":[0.064594984,0.0034801953,0.900712,0.00066673633,0.00008768478,0.00010513332,0.0018173762,0.000025802157,0.0107876295,0.00002918083,0.01695094,0.0007423185],"about_ca_topic_score_codex":0.004772349,"about_ca_topic_score_gemma":0.0009514683,"teacher_disagreement_score":0.7827512,"about_ca_system_score_codex":0.0031022609,"about_ca_system_score_gemma":0.0024615822,"threshold_uncertainty_score":0.9998423},"labels":[],"label_agreement":null},{"id":"W4221038606","doi":"10.1158/1538-7445.sabcs21-pd10-05","title":"Abstract PD10-05: Activity of atezolizumab (atezo) plus paclitaxel (pac) in metastatic triple-negative breast cancer (mTNBC) according to Burstein molecular subtype: Analysis of the IMpassion131 trial","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Atezolizumab; Medicine; Oncology; Internal medicine; Triple-negative breast cancer; Taxane; Clinical endpoint; Breast cancer; Population; Progression-free survival; Paclitaxel; Adjuvant; Cancer; Randomized controlled trial; Chemotherapy; Immunotherapy; Nivolumab","score_opus":0.08240046586389813,"score_gpt":0.4384546055163097,"score_spread":0.3560541396524116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221038606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99113,0.0010189853,0.00011067202,0.0036190492,0.00029839843,0.0024527635,0.0012339758,0.00001920018,0.0001169435],"genre_scores_gemma":[0.99737936,0.00009860799,0.00008409336,0.000104517945,0.00008845009,0.0018428488,0.00001228455,0.00006189353,0.00032796312],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.994838,0.0008564268,0.0007048966,0.0006836469,0.002100423,0.0008166242],"domain_scores_gemma":[0.9971921,0.00057456066,0.00042873542,0.0009368005,0.0006212101,0.0002466168],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018209848,0.00030027181,0.0012453693,0.0013837762,0.00024661815,0.000021125361,0.0006521174,0.00007239978,0.0014500826],"category_scores_gemma":[0.0004781017,0.000231004,0.00045358678,0.007427371,0.00037945554,0.00018056257,0.00055027264,0.0011598764,0.0000020623975],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20586778,0.0010947449,0.012277806,0.0005850623,0.0050902446,0.0001597734,0.0059122555,0.056087706,0.6317598,0.00020083194,0.00029557067,0.08066838],"study_design_scores_gemma":[0.10313149,0.0023397023,0.57223713,0.0012805836,0.0024216422,0.00004492801,0.018826472,0.0025969588,0.2942352,0.0010132923,0.0008352571,0.0010373568],"about_ca_topic_score_codex":0.030161329,"about_ca_topic_score_gemma":0.0019321705,"teacher_disagreement_score":0.5599593,"about_ca_system_score_codex":0.0035419657,"about_ca_system_score_gemma":0.0025956393,"threshold_uncertainty_score":0.9994627},"labels":[],"label_agreement":null},{"id":"W4221062043","doi":"10.1158/1538-7445.sabcs21-gs2-07","title":"Abstract GS2-07: Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) ≤ 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG S1007 (RxPONDER)","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; BC Cancer Agency","funders":"","keywords":"Taxane; Medicine; Post-hoc analysis; Internal medicine; Oncology; Breast cancer; Clinical trial; Cancer","score_opus":0.08411709192082865,"score_gpt":0.44281978933278765,"score_spread":0.358702697411959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221062043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96366364,0.004429146,0.00021610617,0.014863486,0.00027351378,0.012834055,0.0033512304,0.00015096916,0.00021785818],"genre_scores_gemma":[0.9750325,0.009546396,0.000919818,0.0015306487,0.0005960805,0.011300002,0.0004068489,0.00025594843,0.0004117555],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98634917,0.0054926323,0.0018985289,0.0022342093,0.00226281,0.0017626623],"domain_scores_gemma":[0.9887128,0.0073337005,0.0007974976,0.000952008,0.0012898096,0.0009141932],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008422742,0.00093902973,0.0036379148,0.0006476146,0.0005959822,0.00015693618,0.0005986177,0.00014947203,0.0024786384],"category_scores_gemma":[0.0010857391,0.0006694745,0.00034146666,0.0021309566,0.0025558823,0.00046743272,0.00027066647,0.0022887536,0.000025522748],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9275772,0.002222504,0.0008631721,0.000029677427,0.0023653796,0.000388196,0.006809665,0.00025020682,0.004421177,0.000048183214,0.00041387376,0.054610748],"study_design_scores_gemma":[0.9690314,0.0031075166,0.014964788,0.0012958903,0.00022119917,0.00007399097,0.001993194,0.00026978934,0.00722828,0.0002697584,0.0007330731,0.0008111222],"about_ca_topic_score_codex":0.03481241,"about_ca_topic_score_gemma":0.0014118693,"teacher_disagreement_score":0.05379963,"about_ca_system_score_codex":0.0018108842,"about_ca_system_score_gemma":0.0028140943,"threshold_uncertainty_score":0.9995757},"labels":[],"label_agreement":null},{"id":"W4221068906","doi":"10.1158/1538-7445.sabcs21-p5-16-10","title":"Abstract P5-16-10: RLY-2608: The first allosteric mutant- and isoform-selective inhibitor of PI3Kα, is efficacious as a single agent and drives regressions in combination with standard of care therapies in <i>PIK3CA</i> mutant breast cancer models","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Paraza Pharma (Canada)","funders":"","keywords":"Fulvestrant; PI3K/AKT/mTOR pathway; Allosteric regulation; Mutant; Pharmacology; Kinase; Cancer research; Estrogen receptor; Cancer; Chemistry; Breast cancer; Biology; Medicine; Receptor; Internal medicine; Signal transduction; Biochemistry","score_opus":0.030474278015578764,"score_gpt":0.33826035101037627,"score_spread":0.3077860729947975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221068906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794878,0.014276038,0.000013466615,0.0041686995,0.000039015024,0.0013658506,0.0004775513,0.000014133453,0.0001574924],"genre_scores_gemma":[0.9970653,0.0018746922,0.000034008757,0.0001157132,0.00003214385,0.00075742527,0.000009738374,0.00004780175,0.00006320005],"study_design_codex":"qualitative","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99757,0.00014983575,0.00037832558,0.0004554105,0.00099733,0.0004491028],"domain_scores_gemma":[0.9986358,0.00022442492,0.000192053,0.0003133837,0.0005364225,0.00009787112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040426542,0.00022258789,0.0005159195,0.00038391727,0.00027051542,0.000024769015,0.0001806145,0.00006624779,0.00020682902],"category_scores_gemma":[0.000025106083,0.00015534993,0.00004276572,0.0009549862,0.0006754475,0.00020488905,0.00020458212,0.0006250648,2.151109e-7],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06797569,0.0017518575,0.06807985,0.0025731793,0.0006977007,0.00020925333,0.3723898,0.005806835,0.22743255,0.00034753443,0.00027318433,0.25246257],"study_design_scores_gemma":[0.04963822,0.019008042,0.28937972,0.012785067,0.0002467805,0.00054860476,0.3012314,0.0013243634,0.31107455,0.005431622,0.007750957,0.0015806777],"about_ca_topic_score_codex":0.0052217576,"about_ca_topic_score_gemma":0.007807564,"teacher_disagreement_score":0.25088188,"about_ca_system_score_codex":0.0016231283,"about_ca_system_score_gemma":0.0006979418,"threshold_uncertainty_score":0.78937703},"labels":[],"label_agreement":null},{"id":"W4221104500","doi":"10.1158/1538-7445.sabcs21-pd15-01","title":"Abstract PD15-01: Impact of <i>ESR1</i> mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), <i>PIK3CA</i>-mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor (CDK4/6i) therapy in the BYLieve trial","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Cohort; Internal medicine; Fulvestrant; Oncology; Clinical endpoint; Hazard ratio; Progression-free survival; Clinical trial; Cancer; Estrogen receptor; Confidence interval; Breast cancer; Chemotherapy","score_opus":0.03477374645994236,"score_gpt":0.380465132983951,"score_spread":0.34569138652400866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221104500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98091173,0.0012751712,0.0000017493402,0.0024932332,0.00021600525,0.010299069,0.00463446,0.00006307619,0.00010551194],"genre_scores_gemma":[0.9844691,0.001589244,0.000084646475,0.0007225854,0.00040428666,0.01197755,0.00036273288,0.00023093002,0.0001589294],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9917757,0.0011844583,0.0011716649,0.0013590942,0.003038868,0.001470236],"domain_scores_gemma":[0.9958424,0.0012142587,0.00063273247,0.0008755479,0.0010913814,0.00034369208],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010218406,0.0008660675,0.0012631282,0.00089884194,0.0005031937,0.00010184012,0.0007248403,0.0001630496,0.0025181277],"category_scores_gemma":[0.00014471222,0.00055472524,0.00030804658,0.0021224916,0.0006627527,0.0005814531,0.00016278397,0.0026505494,0.000010042269],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8530101,0.0070142183,0.02100305,0.000100909456,0.0007441139,0.00024191877,0.013686916,0.0038707799,0.028954394,0.000028851317,0.0002550352,0.07108968],"study_design_scores_gemma":[0.18504576,0.027490726,0.74930835,0.0010718221,0.000032484983,0.000013709818,0.0020559027,0.00001434481,0.033733882,0.00009072225,0.00032106097,0.0008212306],"about_ca_topic_score_codex":0.005949234,"about_ca_topic_score_gemma":0.0012355885,"teacher_disagreement_score":0.7283053,"about_ca_system_score_codex":0.0047261687,"about_ca_system_score_gemma":0.0018994948,"threshold_uncertainty_score":0.9996904},"labels":[],"label_agreement":null},{"id":"W4221110320","doi":"10.1007/s11912-022-01251-x","title":"Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms: from Bench to Bedside","year":2022,"lang":"en","type":"review","venue":"Current Oncology Reports","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Bench to bedside; Kinase; Cancer research; Neuroendocrine tumors; Oncology; Internal medicine; Medical physics; Cell biology","score_opus":0.11412949759123805,"score_gpt":0.4438766195547126,"score_spread":0.32974712196347455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221110320","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027768703,0.9824869,0.000010874445,0.00034748012,0.010701692,0.0029135833,0.00011558126,0.0001718295,0.0004751982],"genre_scores_gemma":[0.00021662177,0.9940989,0.00022797631,0.0003226871,0.0013688705,0.0021208248,0.0011442183,0.00017700923,0.00032289064],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99392045,0.0004097866,0.0024121692,0.0017006391,0.00073520787,0.0008217242],"domain_scores_gemma":[0.9960408,0.0007101614,0.0014092181,0.0012871681,0.000074453885,0.00047816357],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035094604,0.00087744533,0.003958286,0.00084840326,0.000103970975,0.000019475367,0.00029064994,0.00020334363,0.0013467729],"category_scores_gemma":[0.00073799584,0.000801604,0.0006495068,0.00082249404,0.00012483711,0.00009805293,0.0006789355,0.0020979051,0.000071300725],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007185392,0.0007692302,0.0013544435,0.0022180646,0.00015827475,0.029383468,0.00012516844,0.000014656989,0.0000034942518,0.0000032618518,0.00157538,0.9643227],"study_design_scores_gemma":[0.00072988134,0.00056327827,0.00024244432,0.0058998056,0.0009970862,0.012620009,0.000070687776,4.777448e-7,0.000013424625,0.00013357041,0.9782548,0.00047454386],"about_ca_topic_score_codex":0.00020902282,"about_ca_topic_score_gemma":0.00024384653,"teacher_disagreement_score":0.9766794,"about_ca_system_score_codex":0.0026330682,"about_ca_system_score_gemma":0.0023235192,"threshold_uncertainty_score":0.99956614},"labels":[],"label_agreement":null},{"id":"W4221119482","doi":"10.1158/1538-7445.sabcs21-pd13-06","title":"Abstract PD13-06: Neoadjuvant giredestrant (GDC-9545) + palbociclib versus anastrozole + palbociclib in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer: Primary analysis of the randomized, open-label, phase II coopERA breast cancer study","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Anastrozole; Palbociclib; Medicine; Breast cancer; Estrogen receptor; Internal medicine; Oncology; Clinical endpoint; Cancer; Estrogen; Aromatase inhibitor; Tamoxifen; Metastatic breast cancer; Randomized controlled trial","score_opus":0.04047341895383786,"score_gpt":0.38535084469638503,"score_spread":0.34487742574254715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221119482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977898,0.0019318641,0.0000042573283,0.0038638795,0.00021716271,0.00725124,0.008550876,0.000073209885,0.00020953728],"genre_scores_gemma":[0.98734057,0.00081716647,0.00007791978,0.00029457622,0.00018131403,0.010208274,0.00022137685,0.0001906266,0.0006681474],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9904983,0.0018793148,0.0013131124,0.0016065963,0.0028028672,0.0018997855],"domain_scores_gemma":[0.9951998,0.0007683386,0.00068984204,0.0013484673,0.0013766179,0.00061695004],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024798526,0.0008274516,0.0027473595,0.0009994105,0.0012151902,0.00015527658,0.0016543169,0.0001485501,0.004658124],"category_scores_gemma":[0.00006791495,0.0005965365,0.00021639068,0.007535209,0.0015389692,0.00058924203,0.0012237207,0.0020652006,0.000005674179],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7757715,0.0097709,0.10041278,0.00015782307,0.015036322,0.00032188467,0.012555891,0.0072972034,0.03885184,0.000036179732,0.00024316942,0.03954451],"study_design_scores_gemma":[0.5252948,0.007711211,0.4476213,0.0007305355,0.0023305016,0.00006655743,0.011949826,0.00035293752,0.002546329,0.000024268562,0.0003925134,0.0009792899],"about_ca_topic_score_codex":0.07362477,"about_ca_topic_score_gemma":0.006190606,"teacher_disagreement_score":0.3472085,"about_ca_system_score_codex":0.005988935,"about_ca_system_score_gemma":0.0041645095,"threshold_uncertainty_score":0.99964863},"labels":[],"label_agreement":null},{"id":"W4223438198","doi":"10.1001/jamanetworkopen.2022.4361","title":"Evaluation of Information Theoretic Network Meta-analysis to Rank First-Line Anticancer Regimens for Hormone Receptor–Positive, <i>ERBB2</i>-Negative Metastatic Breast Cancer","year":2022,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institute on Minority Health and Health Disparities; National Cancer Institute","keywords":"Oncology; Internal medicine; Medicine; Randomized controlled trial; Regimen; Breast cancer; Metastatic breast cancer; Docetaxel; Meta-analysis; Cancer","score_opus":0.06664060781675794,"score_gpt":0.359539479326846,"score_spread":0.29289887151008803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223438198","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11288853,0.06107295,0.5061542,0.19832756,0.003039519,0.086528435,0.020094471,0.00051264337,0.011381716],"genre_scores_gemma":[0.9517658,0.00033744698,0.030166011,0.0057532615,0.00056847563,0.010079535,0.00086653203,0.00007702427,0.00038593065],"study_design_codex":"simulation_or_modeling","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9954319,0.00089980615,0.0009896567,0.00050902925,0.0015614398,0.0006081605],"domain_scores_gemma":[0.9955424,0.00075448095,0.0009500778,0.0007085487,0.0018456723,0.0001987989],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0065713623,0.00038149452,0.0017642294,0.00022580111,0.00049440004,0.00009522437,0.00052734296,0.000061686645,0.0048226467],"category_scores_gemma":[0.00023130061,0.00032309783,0.00068998866,0.002964625,0.00013009999,0.0007771154,0.00041935252,0.00029497428,0.000012696322],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009214236,0.00014047239,0.00028902627,0.00004783185,0.08832272,0.0000010616149,0.0018317275,0.85855716,0.000040161984,0.0014689197,0.008442781,0.031643923],"study_design_scores_gemma":[0.0243534,0.0026093165,0.031254694,0.00023225714,0.7277344,0.000058153833,0.0020966588,0.14193214,0.0005647206,0.025274914,0.0424136,0.0014757519],"about_ca_topic_score_codex":0.0006455811,"about_ca_topic_score_gemma":0.0002923279,"teacher_disagreement_score":0.83887726,"about_ca_system_score_codex":0.0008238024,"about_ca_system_score_gemma":0.0004749829,"threshold_uncertainty_score":0.9999221},"labels":[],"label_agreement":null},{"id":"W4223506793","doi":"10.1016/j.vhri.2022.01.007","title":"Pfizer and Palbociclib in China: Analyzing an Oncology Pay-for-Performance Plan","year":2022,"lang":"en","type":"article","venue":"Value in Health Regional Issues","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Palbociclib; China; Plan (archaeology); Oncology; Medicine; Internal medicine; Political science; Cancer; Geography","score_opus":0.07200149222268658,"score_gpt":0.39672897608055707,"score_spread":0.3247274838578705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223506793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9623302,0.009998621,0.00004781073,0.026774555,0.0001476256,0.0006031613,0.000013213027,0.000040213337,0.0000445823],"genre_scores_gemma":[0.9908402,0.0016974399,0.0038674776,0.0027493308,0.0002527906,0.00026546544,0.000063781474,0.000031095096,0.00023240679],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983904,0.00023886173,0.0004089208,0.00034529687,0.00022074154,0.00039581527],"domain_scores_gemma":[0.99935174,0.00016700837,0.00013912485,0.00017970816,0.000023806733,0.00013863717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009843087,0.00013930375,0.00044027207,0.00027064778,0.0001681283,0.0000053742324,0.00009417423,0.000051102117,0.00003479599],"category_scores_gemma":[0.0000313947,0.00012189077,0.000029426901,0.00030669954,0.00007740595,0.00012629868,0.000049424074,0.00039863188,0.0000010558015],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048627662,0.0006392336,0.7159057,0.0011257675,0.000052465686,0.000103088896,0.02138818,0.015316921,0.0002875999,0.005302106,0.00043143015,0.23458473],"study_design_scores_gemma":[0.006193376,0.003459641,0.60562646,0.00041826785,0.000011581382,0.00035819528,0.002932597,0.016175603,0.000054626194,0.005529821,0.3589266,0.00031320544],"about_ca_topic_score_codex":0.0017742214,"about_ca_topic_score_gemma":0.000221816,"teacher_disagreement_score":0.35849518,"about_ca_system_score_codex":0.00057604816,"about_ca_system_score_gemma":0.00034293006,"threshold_uncertainty_score":0.49705613},"labels":[],"label_agreement":null},{"id":"W4223953324","doi":"10.46747/cfp.6804e120","title":"Thérapies endocriniennes contre les cancers du sein et de la prostate","year":2022,"lang":"fr","type":"article","venue":"Canadian Family Physician","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Alberta Health Services; McGill University","funders":"","keywords":"Gynecology; Medicine; Prostate disease; Prostate; Cancer; Internal medicine","score_opus":0.010546759858392273,"score_gpt":0.2605600802046214,"score_spread":0.25001332034622914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223953324","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3278192,0.2596068,0.00023067035,0.04355918,0.0076265964,0.002609715,0.009116915,0.00039354453,0.34903738],"genre_scores_gemma":[0.8621561,0.0013167887,0.00024649713,0.12398808,0.0017415984,0.00048188338,0.000156936,0.00019360622,0.0097185215],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964014,0.00068203686,0.00033417772,0.0005906213,0.00037353902,0.0016182236],"domain_scores_gemma":[0.9979669,0.0003100207,0.00017439919,0.0004912491,0.00012348332,0.00093398796],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040032458,0.0004913411,0.00057827897,0.00030235812,0.0008278787,0.00008924708,0.00038659698,0.00009676461,0.00015586641],"category_scores_gemma":[0.000038877184,0.0006004624,0.00020745954,0.0005964146,0.00083307177,0.0002749571,0.0000991613,0.0009814258,0.000059950253],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0005327207,0.00025187302,0.004008813,0.00041216196,0.0013281202,0.004530634,0.01700885,0.015007266,0.008941258,0.06326298,0.06315301,0.8215623],"study_design_scores_gemma":[0.0022620766,0.00027813582,0.011227893,0.0003011419,0.00019283876,0.00009388665,0.037122022,0.00039296362,0.00026167507,0.002296871,0.9450003,0.00057021773],"about_ca_topic_score_codex":0.29093814,"about_ca_topic_score_gemma":0.065733805,"teacher_disagreement_score":0.88184726,"about_ca_system_score_codex":0.006999779,"about_ca_system_score_gemma":0.007861422,"threshold_uncertainty_score":0.9996447},"labels":[],"label_agreement":null},{"id":"W4226227245","doi":"10.4212/cjhp.v75i2.3285","title":"Correction to “Effectiveness and Safety of Palbociclib plus Endocrine Therapy in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Real-World Results”","year":2022,"lang":"en","type":"erratum","venue":"The Canadian Journal of Hospital Pharmacy","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Palbociclib; Metastatic breast cancer; Oncology; Medicine; Endocrine system; Breast cancer; Gynecology; Internal medicine; Hormone receptor; Cancer; Hormone","score_opus":0.015398595606861227,"score_gpt":0.3143781598627587,"score_spread":0.29897956425589745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226227245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6366325,0.08547548,0.00011674332,0.08714606,0.13739051,0.015329423,0.020995768,0.00011432321,0.016799197],"genre_scores_gemma":[0.9681132,0.018911647,0.00015342816,0.0007005334,0.001748291,0.00016483513,0.00015409738,0.00019275604,0.009861255],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9966115,0.0006678473,0.0010583057,0.00042309036,0.0006421642,0.000597144],"domain_scores_gemma":[0.9964667,0.00062065956,0.0011543905,0.0003317927,0.00071009144,0.0007163649],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010210037,0.00052966294,0.001364503,0.0009266122,0.00028482542,0.000042570253,0.00042022855,0.00005217975,0.00043586205],"category_scores_gemma":[0.00020629648,0.00041453206,0.00025492182,0.0011884383,0.00039772285,0.00027026125,0.000062197134,0.002267448,0.0000019553863],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.105936445,0.00070252497,0.011337133,0.0006679368,0.0069358167,0.0026693041,0.02743642,0.0039056202,0.0018465908,0.00009764265,0.5320876,0.30637696],"study_design_scores_gemma":[0.043008015,0.0077489065,0.572869,0.0063691563,0.0011325084,0.0018467443,0.0034278203,0.00014028963,0.0033374967,0.0004510182,0.35815105,0.0015179607],"about_ca_topic_score_codex":0.26295394,"about_ca_topic_score_gemma":0.13787398,"teacher_disagreement_score":0.5615319,"about_ca_system_score_codex":0.004111551,"about_ca_system_score_gemma":0.005237639,"threshold_uncertainty_score":0.99983066},"labels":[],"label_agreement":null},{"id":"W4226429142","doi":"","title":"","year":2022,"lang":"fr","type":"article","venue":"PubMed","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Natural Sciences and Engineering Research Council of Canada","funders":"","keywords":"Computer science","score_opus":0.024490882651775264,"score_gpt":0.24204439500133232,"score_spread":0.21755351234955705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226429142","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3915202,0.41890275,0.001064837,0.15501583,0.024878282,0.00617864,0.00043753276,0.00039561137,0.0016063268],"genre_scores_gemma":[0.87615824,0.00039418676,0.00043210768,0.01099503,0.00410022,0.06485327,0.000041071016,0.00014854598,0.042877313],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9929035,0.0007024153,0.00076304225,0.0009911767,0.0014092711,0.0032306178],"domain_scores_gemma":[0.9970342,0.000337164,0.00033535718,0.0010493844,0.00012308414,0.0011208367],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00187735,0.0005310151,0.0008261842,0.00029900647,0.0010492008,0.0000453716,0.00059169385,0.00009936103,0.0014196091],"category_scores_gemma":[0.0003041281,0.00065356947,0.00035204634,0.0014430544,0.000602377,0.0005490952,0.0009133497,0.0015409994,0.000017510936],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032851773,0.0011347359,0.035380326,0.00027866836,0.0006722687,0.0011245114,0.0026157647,0.0060095144,0.00014582384,0.004304066,0.0005532789,0.94449586],"study_design_scores_gemma":[0.006303842,0.00023725684,0.47248316,0.000025310172,0.00030430334,0.0019132859,0.0049669063,0.0000820284,0.0005047689,0.002028761,0.51074284,0.00040751882],"about_ca_topic_score_codex":0.0004867155,"about_ca_topic_score_gemma":0.000026865268,"teacher_disagreement_score":0.94408834,"about_ca_system_score_codex":0.00467749,"about_ca_system_score_gemma":0.00029710997,"threshold_uncertainty_score":0.9995915},"labels":[],"label_agreement":null},{"id":"W4229062082","doi":"10.1016/j.annonc.2022.03.185","title":"166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Oncology; Internal medicine; Tolerability; Adverse effect","score_opus":0.11293539615260782,"score_gpt":0.4609971678987615,"score_spread":0.34806177174615366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229062082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95276046,0.002110238,0.00074777403,0.016575413,0.000811781,0.0060186493,0.020261647,0.00013760637,0.0005764105],"genre_scores_gemma":[0.98857373,0.0004507674,0.0024640474,0.0016936099,0.00044919437,0.00407493,0.0009400461,0.00012747035,0.0012261982],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99522436,0.0004985984,0.0014026391,0.0011890905,0.0007207679,0.00096451846],"domain_scores_gemma":[0.9954918,0.0013631141,0.0010106764,0.00093177176,0.00081929186,0.00038334905],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00061176275,0.0006327445,0.0018323193,0.00036801255,0.000702266,0.000016137428,0.00045256747,0.00012396552,0.0014407753],"category_scores_gemma":[0.00054557977,0.00058605627,0.00034207114,0.0007022669,0.00036705876,0.00029910068,0.00033835997,0.0004610126,0.000011661571],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21665528,0.02613317,0.00037850105,0.00010720784,0.0039223777,0.0010049597,0.011357457,0.004961371,0.0017766709,0.00009273843,0.0017033375,0.7319069],"study_design_scores_gemma":[0.42824355,0.28429434,0.003568283,0.00045427223,0.0026402306,0.0012127458,0.024815636,0.0025036936,0.024825899,0.010627927,0.2151216,0.0016918222],"about_ca_topic_score_codex":0.007939098,"about_ca_topic_score_gemma":0.006312107,"teacher_disagreement_score":0.7302151,"about_ca_system_score_codex":0.001127165,"about_ca_system_score_gemma":0.0024543046,"threshold_uncertainty_score":0.99965906},"labels":[],"label_agreement":null},{"id":"W4229070154","doi":"10.1016/j.annonc.2022.03.280","title":"LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Population; Breast cancer; Hazard ratio; Cancer; Randomized controlled trial; Adjuvant; Oncology; Confidence interval","score_opus":0.039587239532819306,"score_gpt":0.35083410199658555,"score_spread":0.31124686246376626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229070154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98322123,0.00024958048,0.000014452983,0.010790661,0.0001734683,0.001933887,0.003380613,0.000033271685,0.00020282113],"genre_scores_gemma":[0.9953617,0.00013879535,0.00011894888,0.0015681471,0.00016699778,0.00028721406,0.00225289,0.00004916966,0.000056125504],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9968109,0.00048124255,0.0009496135,0.000519804,0.00079184776,0.00044660838],"domain_scores_gemma":[0.9973861,0.00050713966,0.0009942004,0.0005960998,0.00042989,0.00008658692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057282974,0.00034724482,0.0009344042,0.00012391958,0.0001805544,0.0000074179025,0.00036221958,0.000111513866,0.0002078585],"category_scores_gemma":[0.00005291309,0.00020064496,0.000093560164,0.0006109144,0.00028394198,0.00018754232,0.00007246582,0.0004810395,8.358498e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8962827,0.0065047685,0.0271697,0.0000235827,0.00074471446,0.00011651935,0.0025010358,0.0064038765,0.0011175672,0.000088509056,0.00031783254,0.0587292],"study_design_scores_gemma":[0.45897886,0.04733578,0.47787562,0.00020310453,0.00044901323,0.00008333495,0.0011418005,0.00027622332,0.0008370213,0.00031581146,0.01208211,0.0004213229],"about_ca_topic_score_codex":0.010530325,"about_ca_topic_score_gemma":0.00584239,"teacher_disagreement_score":0.45070592,"about_ca_system_score_codex":0.0002389065,"about_ca_system_score_gemma":0.00034844797,"threshold_uncertainty_score":0.99605864},"labels":[],"label_agreement":null},{"id":"W4229735891","doi":"10.1158/1538-7445.am2019-3088","title":"Abstract 3088: Farnesyl/geranylgeranyl transferase dual inhibitor thwarts mutant KRas-driven patient-derived pancreatic tumors","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"KRAS; Farnesyltransferase; Cancer research; Pancreatic cancer; Cancer; Prenylation; Carcinogenesis; PI3K/AKT/mTOR pathway; Protein kinase B; EGFR inhibitors; Biology; Medicine; Apoptosis; Epidermal growth factor receptor; Colorectal cancer; Internal medicine; Biochemistry","score_opus":0.03989486226974744,"score_gpt":0.351024661300706,"score_spread":0.31112979903095855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229735891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99125236,0.002437222,0.00003585881,0.001872207,0.0004930161,0.0023830193,0.00015676941,0.00019042855,0.001179116],"genre_scores_gemma":[0.9968466,0.000362134,0.00017950516,0.0004550197,0.0006993566,0.0006592327,0.00005610647,0.00016309864,0.0005789574],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99504817,0.0002003653,0.00065051345,0.0009746266,0.0017108155,0.0014154991],"domain_scores_gemma":[0.99730515,0.00038484496,0.00010845351,0.00091765064,0.00067071425,0.0006132075],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004893797,0.0004606097,0.0008461752,0.00042319528,0.0002695231,0.00008792316,0.00027802997,0.00020082224,0.0043351003],"category_scores_gemma":[0.0001247732,0.00039523348,0.0002369682,0.000804354,0.0004614687,0.00035795098,0.00009619682,0.0012758157,0.00061706605],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028926872,0.00028334136,0.0050342176,0.0005403906,0.00022737758,0.00046775994,0.0030571811,0.00020488535,0.9514222,0.00008420757,0.00025345694,0.03553228],"study_design_scores_gemma":[0.01239565,0.0020562445,0.039251823,0.0028602097,0.00011927066,0.0002906142,0.0041709724,0.00019421118,0.9027935,0.00043448547,0.03430641,0.0011265724],"about_ca_topic_score_codex":0.000621546,"about_ca_topic_score_gemma":0.00008992602,"teacher_disagreement_score":0.048628677,"about_ca_system_score_codex":0.0008340911,"about_ca_system_score_gemma":0.0010588306,"threshold_uncertainty_score":0.99985},"labels":[],"label_agreement":null},{"id":"W4231037796","doi":"10.1007/s40274-017-4376-y","title":"Addition of palbociclib to letrozole not cost effective in Canada","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics & Outcomes News","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Palbociclib; Letrozole; Quality of Life Research; Medicine; Public health; Internal medicine; Cancer; Breast cancer","score_opus":0.019636002678375175,"score_gpt":0.3615838674096126,"score_spread":0.34194786473123745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231037796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98291916,0.000053365107,0.00008355602,0.013102868,0.0006915862,0.0014322088,0.00026520653,0.000015847705,0.0014361945],"genre_scores_gemma":[0.9835968,0.000034116372,0.00043472418,0.015273453,0.00013074717,0.0002618617,0.000019751737,0.000033265387,0.00021526446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989159,0.000025381412,0.00037561147,0.0002788842,0.00010537056,0.00029883214],"domain_scores_gemma":[0.9988448,0.00015986993,0.00028385114,0.00047354237,0.000044528035,0.0001934219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011045319,0.0001900393,0.00057016034,0.00010000088,0.000071456896,0.000016996928,0.00024179326,0.00003094761,0.00032463574],"category_scores_gemma":[0.000083409934,0.00018928545,0.00008961616,0.000035604695,0.00004048243,0.00021170253,0.000086629494,0.00017952715,0.000039597966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012533326,0.000078967954,0.6835611,0.00008062492,0.00021235523,0.000035784567,0.0002753883,0.00080948236,0.011588238,0.00010760796,0.003343477,0.29865366],"study_design_scores_gemma":[0.0064808144,0.00006160827,0.8320439,0.00006214498,0.000054333294,0.000008953841,0.00016813715,0.00034149227,0.05411708,0.000064216525,0.106347926,0.0002494036],"about_ca_topic_score_codex":0.5895726,"about_ca_topic_score_gemma":0.75359654,"teacher_disagreement_score":0.29840428,"about_ca_system_score_codex":0.001423251,"about_ca_system_score_gemma":0.00048646823,"threshold_uncertainty_score":0.7718836},"labels":[],"label_agreement":null},{"id":"W4233437943","doi":"10.1016/j.annonc.2021.07.011","title":"Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’","year":2021,"lang":"en","type":"erratum","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Fulvestrant; Medicine; Oncology; Internal medicine; Cancer; Hormone receptor; Progression-free survival; Breast cancer; Metastatic breast cancer; Estrogen receptor; Epidermal growth factor receptor; Overall survival","score_opus":0.05281472117392018,"score_gpt":0.38073810267926245,"score_spread":0.3279233815053423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233437943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7840883,0.013654405,0.0013296513,0.07475217,0.029245682,0.0505024,0.03964064,0.0003725425,0.006414206],"genre_scores_gemma":[0.7423548,0.027159303,0.007761402,0.03174859,0.013995986,0.04743885,0.02967454,0.0018872367,0.097979285],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99254316,0.0016506985,0.0019952636,0.0013649088,0.0009360673,0.0015099029],"domain_scores_gemma":[0.993474,0.001330768,0.0018811745,0.00074911775,0.002068732,0.0004962119],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015432303,0.0011765147,0.005873055,0.00049790624,0.00022228844,0.000039604387,0.0006569717,0.00088177837,0.0012773297],"category_scores_gemma":[0.00047076333,0.0008351487,0.0004829239,0.00077764574,0.00079782883,0.0003149985,0.00012843756,0.0015996789,0.0000059956715],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88276243,0.0019932506,0.0000045348092,0.0002471267,0.002999646,0.00014984986,0.006274825,0.000025350791,0.010171249,0.00020178982,0.07773694,0.017432997],"study_design_scores_gemma":[0.8634213,0.02883288,0.0011178409,0.0008930301,0.00055399095,0.000107059845,0.002640124,0.000016287355,0.002037138,0.00037359403,0.098887645,0.0011190702],"about_ca_topic_score_codex":0.0010576702,"about_ca_topic_score_gemma":0.00057327526,"teacher_disagreement_score":0.09156508,"about_ca_system_score_codex":0.001307658,"about_ca_system_score_gemma":0.0034420583,"threshold_uncertainty_score":0.99963564},"labels":[],"label_agreement":null},{"id":"W4233519726","doi":"10.18438/eblip29591","title":"Journal Update from EBLIP10","year":2019,"lang":"en","type":"article","venue":"Evidence Based Library and Information Practice","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Concordia University","funders":"","keywords":"Computer science; Library science; Information retrieval; Data science; World Wide Web","score_opus":0.008630389436037604,"score_gpt":0.2610878494683742,"score_spread":0.2524574600323366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233519726","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27684462,0.012596305,0.029098673,0.6545195,0.0018280951,0.0012468759,0.000056563014,0.0004762159,0.023333155],"genre_scores_gemma":[0.5229483,0.0047264704,0.05696622,0.41399795,0.0004955387,0.000013957227,0.00012866166,0.000023843753,0.00069900614],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991775,0.000073672934,0.00028874818,0.00008859244,0.0002463955,0.00012505792],"domain_scores_gemma":[0.99860084,0.0006937173,0.0003003618,0.00020376168,0.00006611434,0.00013520556],"candidate_categories":["scholarly_communication","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020752633,0.000098094526,0.00013387519,0.0001161714,0.00007485679,0.00023506915,0.00008427542,0.000051531017,0.0028295217],"category_scores_gemma":[0.00046614103,0.00008058953,0.000033403663,0.00018194475,0.000031209285,0.23299214,0.000035894092,0.00030547552,0.00053976837],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028143592,0.0002506415,0.04057959,0.0007000497,0.00043671115,0.000099233905,0.0017697477,0.0008897935,0.004879455,0.12885043,0.01471976,0.778681],"study_design_scores_gemma":[0.0012108807,0.00018494639,0.0176164,0.00048455872,0.00004477041,0.00022425006,0.0005294854,0.00094023056,0.0026990538,0.0002586051,0.9756989,0.00010795561],"about_ca_topic_score_codex":0.0000019647616,"about_ca_topic_score_gemma":2.7818092e-9,"teacher_disagreement_score":0.9609791,"about_ca_system_score_codex":0.000013498896,"about_ca_system_score_gemma":0.00022625206,"threshold_uncertainty_score":0.99808204},"labels":[],"label_agreement":null},{"id":"W4235161998","doi":"10.1158/1538-7445.am2019-443","title":"Abstract 443: Blood-based genotyping and clinical outcomes in patients with advanced breast cancer receiving the CDK4/6 inhibitor palbociclib in real-world settings: Results from POLARIS","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Palbociclib; Oncology; Medicine; Genotyping; Breast cancer; Internal medicine; Cancer; Circulating tumor cell; Copy-number variation; Metastatic breast cancer; Genotype; Gene; Biology; Genetics; Metastasis","score_opus":0.034679735385543656,"score_gpt":0.39399517430360664,"score_spread":0.359315438918063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235161998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99049443,0.0009267264,0.0000015464074,0.0058126263,0.000230737,0.0017805193,0.0004810024,0.000051295054,0.00022111458],"genre_scores_gemma":[0.997574,0.0005229892,0.0003995236,0.00058501726,0.0002885249,0.0002298856,0.000043590153,0.00009598745,0.00026051755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995742,0.00032125704,0.0009013708,0.001035848,0.0010460766,0.0009534006],"domain_scores_gemma":[0.9963755,0.0018400088,0.0002827393,0.00082651863,0.00043125704,0.00024400183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017391193,0.00033983157,0.00076739595,0.000421137,0.0001501556,0.000068732224,0.0003225568,0.00017268822,0.00022895147],"category_scores_gemma":[0.00035607987,0.0002316546,0.00008716052,0.0010440125,0.00040947346,0.0003123509,0.00015926783,0.001856482,0.000013488213],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0092234835,0.000289839,0.95033616,0.00010519837,0.00014156524,0.000021735757,0.00062331697,0.00015704695,0.0011201239,0.0000043381983,0.00003711039,0.037940063],"study_design_scores_gemma":[0.018662652,0.00022249424,0.9767304,0.00249589,0.000032650492,8.031597e-7,0.00033429288,0.0000511286,0.00053050247,0.00004157947,0.0006230446,0.00027454912],"about_ca_topic_score_codex":0.018332567,"about_ca_topic_score_gemma":0.020681633,"teacher_disagreement_score":0.037665516,"about_ca_system_score_codex":0.0008077129,"about_ca_system_score_gemma":0.00082982157,"threshold_uncertainty_score":0.9971884},"labels":[],"label_agreement":null},{"id":"W4235233928","doi":"10.1139/bcb8005abst","title":"Abstracts of the 12th Annual CSBMCB/SCBBMC Winternational Symposium / Résumés du 12e Symposium international annuel d'hiver de la SCBBMC/CSBMCB","year":2002,"lang":"fr","type":"article","venue":"Biochemistry and Cell Biology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Biology","score_opus":0.006634002439364582,"score_gpt":0.24439799234634116,"score_spread":0.23776398990697659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235233928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8923812,0.02289015,0.00019062308,0.010812912,0.003392206,0.00026966922,0.0013900709,0.000047892416,0.068625264],"genre_scores_gemma":[0.9653574,0.0029287825,0.00028073875,0.00058858196,0.0021638246,0.000018435981,0.00009009512,0.000033347707,0.028538764],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980709,0.00013761812,0.0005099216,0.0005435382,0.00023158279,0.00050643616],"domain_scores_gemma":[0.99846756,0.00031986012,0.0003650193,0.00037004234,0.0002691126,0.00020841381],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029935,0.0003654586,0.00036170956,0.00005892019,0.00012077721,0.00002920425,0.0004977745,0.00054779625,0.0015987847],"category_scores_gemma":[0.000121011406,0.00031255223,0.00018784813,0.00011623294,0.0015738292,0.00013084893,0.00023923926,0.00049030996,0.000044494744],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039269123,0.0007399323,0.028168172,0.0004017041,0.00032871243,0.000054444165,0.0011900809,0.00019542038,0.95959246,0.0006563254,0.003604195,0.004675881],"study_design_scores_gemma":[0.0029148364,0.00018201511,0.009845086,0.0003886116,0.00016873237,0.0008722021,0.0006770267,0.00050166395,0.7107874,0.00033527723,0.27294475,0.00038240652],"about_ca_topic_score_codex":0.00007327824,"about_ca_topic_score_gemma":0.0000023745401,"teacher_disagreement_score":0.26934054,"about_ca_system_score_codex":0.00023378475,"about_ca_system_score_gemma":0.00017206302,"threshold_uncertainty_score":0.99993265},"labels":[],"label_agreement":null},{"id":"W4235292000","doi":"10.29169/1927-5951.2020.10.04.5","title":"Current Trends in the Treatment of Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer","year":2020,"lang":"en","type":"article","venue":"Journal of Pharmacy and Nutrition Sciences","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Olaparib; Breast cancer; Oncology; Cancer; Internal medicine; Drug; Pharmacology","score_opus":0.10359104761371045,"score_gpt":0.4269706839634786,"score_spread":0.32337963634976813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235292000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9682121,0.007402913,0.000021396172,0.024061844,0.00010420073,0.00010706173,0.00005526988,0.0000030399033,0.00003211885],"genre_scores_gemma":[0.9933486,0.0057039396,0.00013717254,0.0003127538,0.00048300816,0.000008441301,9.919873e-7,0.0000027712763,0.0000023304651],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99910975,0.000079211335,0.0003014501,0.00010379289,0.00029691486,0.00010889134],"domain_scores_gemma":[0.99943733,0.00007326964,0.00025736573,0.000026569935,0.00011700603,0.0000884343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013579367,0.00008628154,0.00023612584,0.00014807099,0.000081394035,0.000014169612,0.00009062539,0.000009647,0.0002790475],"category_scores_gemma":[0.000009030678,0.00004766907,0.00008041289,0.0004441367,0.00025784885,0.0003028503,0.0000050209646,0.000104406245,2.8558478e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003460214,0.0022703651,0.16094543,0.00022774936,0.00011007201,0.00003192225,0.021539655,0.000010363385,0.06451715,0.00017590933,0.00067502295,0.7460362],"study_design_scores_gemma":[0.045497477,0.01024041,0.6603825,0.0011339152,0.00035014402,0.00082567544,0.010456257,0.00038061125,0.22512491,0.0016079558,0.043557175,0.00044295148],"about_ca_topic_score_codex":0.00004473685,"about_ca_topic_score_gemma":0.000004956828,"teacher_disagreement_score":0.7455932,"about_ca_system_score_codex":0.000051138257,"about_ca_system_score_gemma":0.000052499683,"threshold_uncertainty_score":0.30553743},"labels":[],"label_agreement":null},{"id":"W4236986578","doi":"10.1158/1538-7445.sabcs16-ot2-01-01","title":"Abstract OT2-01-01: SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with <i>PIK3CA-</i>mutant tumors","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Calgary","funders":"","keywords":"Fulvestrant; Metastatic breast cancer; Medicine; Internal medicine; Estrogen receptor; Cancer; Aromatase inhibitor; Breast cancer; Oncology; Estrogen; Placebo; PI3K/AKT/mTOR pathway; Endocrinology; Cancer research; Aromatase; Biology; Pathology; Apoptosis; Biochemistry","score_opus":0.029655723474470718,"score_gpt":0.3682503041920291,"score_spread":0.3385945807175584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236986578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849516,0.00026431138,0.00005562265,0.00051090063,0.00018599848,0.011099363,0.0028618528,0.00003506762,0.000035292644],"genre_scores_gemma":[0.99538213,0.00007575689,0.00048387027,0.00009800621,0.00015186059,0.0034243022,0.00009525343,0.00017419884,0.000114644194],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9940724,0.00029878222,0.0009160822,0.0011643734,0.0022692555,0.0012791489],"domain_scores_gemma":[0.99466395,0.00041147016,0.0008479825,0.0014047192,0.0022098692,0.000462009],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006535408,0.0006841174,0.0012694142,0.00030883081,0.000813359,0.00010700598,0.00086232624,0.00010870788,0.00033252581],"category_scores_gemma":[0.00029164003,0.00040163053,0.00013428368,0.0008426287,0.0012224959,0.00068723137,0.00022198488,0.0009690504,0.0000029567846],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48658562,0.018022088,0.37377858,0.0012984949,0.0025783752,0.00020412591,0.010720789,0.0017901569,0.014303641,0.00002277561,0.00024797203,0.09044739],"study_design_scores_gemma":[0.19419792,0.013623812,0.7604734,0.004271916,0.0004104157,0.000008915224,0.0061097783,0.00005431722,0.01971378,0.00004177807,0.00022990978,0.0008640976],"about_ca_topic_score_codex":0.0051278304,"about_ca_topic_score_gemma":0.0047370717,"teacher_disagreement_score":0.3866948,"about_ca_system_score_codex":0.0016795407,"about_ca_system_score_gemma":0.0025436108,"threshold_uncertainty_score":0.99984354},"labels":[],"label_agreement":null},{"id":"W4237328149","doi":"10.1016/s0960-9776(13)70002-x","title":"Speakers' Abstracts","year":2013,"lang":"en","type":"article","venue":"The Breast","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Dermatology","score_opus":0.007845878108867157,"score_gpt":0.23814446719075277,"score_spread":0.2302985890818856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237328149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9178851,0.00047994798,0.00020115796,0.029041283,0.00020918646,0.00061008206,0.000009441717,0.00019712438,0.051366657],"genre_scores_gemma":[0.9937924,0.000005455927,0.00046285157,0.0014857014,0.00036448453,0.000028426548,0.0000039344286,0.00002019782,0.003836543],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9994022,0.000011503101,0.000116954936,0.00011376323,0.0001501058,0.00020544155],"domain_scores_gemma":[0.9994315,0.0000311714,0.000042697287,0.00033842068,0.00006590303,0.000090301466],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000065767825,0.000093885064,0.000116305695,0.000021327183,0.00005580217,0.000016630802,0.00009891365,0.000027570366,0.0017114251],"category_scores_gemma":[0.000010233767,0.000054109994,0.00004694827,0.00008336837,0.00010707055,0.00009897335,0.000024258297,0.00013054624,0.0024853451],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000443588,0.00025346864,0.009879481,0.00006677659,0.00025601065,0.000041303276,0.0015551174,0.00007929525,0.04386742,0.0014794272,0.009723544,0.93235457],"study_design_scores_gemma":[0.0009497686,0.000042514028,0.96083057,0.000058765225,0.00003655036,0.0026733354,0.00041994994,0.000032738142,0.0016350514,0.0020946886,0.031109573,0.000116482835],"about_ca_topic_score_codex":0.0002285136,"about_ca_topic_score_gemma":0.000004883638,"teacher_disagreement_score":0.9509511,"about_ca_system_score_codex":0.000038409784,"about_ca_system_score_gemma":0.00003183274,"threshold_uncertainty_score":0.9992011},"labels":[],"label_agreement":null},{"id":"W4238548979","doi":"10.1007/s40274-021-7747-3","title":"Ribociclib + NSAI may be cost effective for advanced breast cancer in Canada","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics & Outcomes News","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quality of Life Research; Breast cancer; Cancer; Medicine; Public health; Internal medicine","score_opus":0.015470597123697947,"score_gpt":0.3594825584680343,"score_spread":0.3440119613443363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238548979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89416945,0.002227797,0.00039345247,0.09276013,0.0026217217,0.004190009,0.0028549172,0.000086821725,0.0006956881],"genre_scores_gemma":[0.9278226,0.00071094936,0.0013202523,0.065233484,0.0003806139,0.0026840097,0.00012694873,0.00014107292,0.0015800727],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99798894,0.00005318517,0.00053939346,0.00062450935,0.00013408426,0.00065986835],"domain_scores_gemma":[0.9985474,0.00043037097,0.0002054696,0.00036767684,0.00015204276,0.00029703902],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011397402,0.00037992102,0.0008972899,0.00009210876,0.0000743772,0.000022561415,0.00017060796,0.00006075716,0.0008738179],"category_scores_gemma":[0.00003893663,0.00038477057,0.00020378869,0.00016954962,0.000043342196,0.0002585568,0.000074474665,0.00031456954,0.000010441732],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020126211,0.00015921802,0.46867624,0.00023617891,0.0006600135,0.00011946327,0.0002642372,0.0046405783,0.009581992,0.00016267311,0.0027686744,0.5107181],"study_design_scores_gemma":[0.031286996,0.000058083268,0.34919825,0.00016823706,0.00033097563,0.00022125647,0.0011848679,0.0018958282,0.053801876,0.00024810914,0.56058264,0.0010229108],"about_ca_topic_score_codex":0.30708125,"about_ca_topic_score_gemma":0.83416396,"teacher_disagreement_score":0.55781394,"about_ca_system_score_codex":0.004250716,"about_ca_system_score_gemma":0.002654016,"threshold_uncertainty_score":0.9998604},"labels":[],"label_agreement":null},{"id":"W4239051461","doi":"10.1093/annonc/mdy192","title":"4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1190,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Breast cancer; Oncology; Consensus conference; Medical physics; Cancer; Family medicine; Internal medicine","score_opus":0.1732144412306442,"score_gpt":0.5044417495037564,"score_spread":0.3312273082731122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239051461","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42829055,0.0036831053,0.0043884674,0.5386152,0.0048503843,0.0014604903,0.0011334703,0.00019594963,0.017382389],"genre_scores_gemma":[0.9264634,0.00070455426,0.037585355,0.02789001,0.0035547926,0.0002300996,0.000053049178,0.000063657935,0.0034550305],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987555,0.000024674284,0.00046328883,0.00027752935,0.00017629623,0.000302688],"domain_scores_gemma":[0.9957973,0.0001627991,0.00028808642,0.00022985782,0.0034166703,0.00010529627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021996052,0.00015511908,0.00044477012,0.000114963,0.0000537767,0.000003237762,0.00015657135,0.000120407836,0.0005638584],"category_scores_gemma":[0.00033413505,0.00013431528,0.00012288231,0.0001109935,0.00045818582,0.0000604044,0.00004703774,0.00008927345,0.000015609718],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007613084,0.00027914692,0.0027441785,0.00005978198,0.00049474416,0.000015143754,0.00023787949,0.00007795763,0.020901538,0.0011611584,0.06715311,0.89926225],"study_design_scores_gemma":[0.0051958403,0.0020204545,0.008253811,0.00015897595,0.00006097885,0.00030131667,0.00027859156,0.0003031187,0.020321958,0.0022413689,0.9606933,0.00017028948],"about_ca_topic_score_codex":0.00012287141,"about_ca_topic_score_gemma":0.0001589154,"teacher_disagreement_score":0.89909196,"about_ca_system_score_codex":0.00008342386,"about_ca_system_score_gemma":0.00041013784,"threshold_uncertainty_score":0.61738545},"labels":[],"label_agreement":null},{"id":"W4241446446","doi":"10.1634/theoncologist.2016-0469","title":"In Reply","year":2017,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Palbociclib; Oncology; Metastatic breast cancer; Breast cancer; Internal medicine; Gynecology; Cancer","score_opus":0.049334204669764445,"score_gpt":0.36627834033573087,"score_spread":0.3169441356659664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241446446","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002567742,0.0008561598,0.000012591568,0.96192014,0.00074424024,0.00044078287,0.000013158393,0.000055296743,0.03570087],"genre_scores_gemma":[0.0014251219,0.00006593848,0.00027093192,0.91190124,0.007374626,0.000108748194,0.000035249144,0.000046649257,0.0787715],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99884474,0.000072555755,0.00021596186,0.00030583804,0.00022647424,0.0003344011],"domain_scores_gemma":[0.9981056,0.00017748616,0.00026700858,0.0013818652,0.000044051674,0.000024032142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027541624,0.0002128576,0.0005005561,0.00006426072,0.00010274232,0.000023414825,0.0004885307,0.00037529235,0.0002984657],"category_scores_gemma":[0.0002096035,0.000126273,0.00010322287,0.000050244173,0.00062533806,0.000052045838,0.00009642079,0.002057682,0.00024930958],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013656117,0.000018853803,0.00013635286,0.000058635203,0.000040365096,0.003553787,0.00009491436,9.3663084e-7,0.00003253388,0.000016000296,0.98811585,0.0077952067],"study_design_scores_gemma":[0.0008376995,0.00015116595,0.0015169522,0.00015573167,0.000055193374,0.0004874148,0.000017945667,0.0000015213677,0.00004141497,0.0015030722,0.9950961,0.00013580572],"about_ca_topic_score_codex":0.00043873547,"about_ca_topic_score_gemma":0.000055952944,"teacher_disagreement_score":0.050018895,"about_ca_system_score_codex":0.00046393857,"about_ca_system_score_gemma":0.00025436745,"threshold_uncertainty_score":0.8939719},"labels":[],"label_agreement":null},{"id":"W4243762055","doi":"10.1200/jco.2013.31.26_suppl.151","title":"Characterization of patients who received prior chemotherapy for advanced breast cancer (ABC) in BOLERO-2.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Exemestane; Everolimus; Breast cancer; Internal medicine; Clinical endpoint; Metastatic breast cancer; Aromatase inhibitor; Oncology; Cancer; Surgery; Randomized controlled trial; Aromatase","score_opus":0.04429092118661206,"score_gpt":0.42472936744359124,"score_spread":0.3804384462569792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243762055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880395,0.00010437122,0.00059623754,0.009634042,0.0007755409,0.0007557942,0.000028446018,0.0000057596785,0.000060291102],"genre_scores_gemma":[0.99000835,0.0010837045,0.004737734,0.0031438586,0.000715915,0.000060137067,0.000010142611,0.000033813994,0.00020632373],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971418,0.00012553977,0.0021011368,0.00017326802,0.00023530847,0.00022298316],"domain_scores_gemma":[0.9954904,0.00051233947,0.002407067,0.0001479392,0.0012632961,0.0001789881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006544994,0.00013836168,0.0014023843,0.00013015677,0.0000184585,0.000003831788,0.00013663904,0.00025706185,0.00032516665],"category_scores_gemma":[0.00056551874,0.00010379239,0.00026373388,0.00014978033,0.00014512952,0.0003178047,0.0000166035,0.0003949231,0.0000027469846],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011562173,0.0011922674,0.20473467,0.000057014047,0.00014092412,0.0000027609922,0.00019459179,0.000013877772,0.02424683,0.0000072178623,0.00008098314,0.7577667],"study_design_scores_gemma":[0.02305687,0.0034841516,0.9543131,0.00031300905,0.000055570035,0.000015057208,0.000047545473,0.00007949194,0.001849501,0.00021267809,0.016483044,0.000089978676],"about_ca_topic_score_codex":0.00001744472,"about_ca_topic_score_gemma":0.000016138232,"teacher_disagreement_score":0.7576767,"about_ca_system_score_codex":0.00023008214,"about_ca_system_score_gemma":0.00068692496,"threshold_uncertainty_score":0.42325306},"labels":[],"label_agreement":null},{"id":"W4245477772","doi":"10.1200/jco.2012.30.27_suppl.102","title":"Effects of everolimus (EVE) on disease progression in bone and bone markers (BMs) in patients (pts) with bone metastases (mets).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Bone remodeling; N-terminal telopeptide; Bone resorption; Everolimus; Clinical endpoint; Bisphosphonate; Denosumab; Bone mineral; Exemestane; Osteoclast; Osteoporosis; Endocrinology; Oncology; Breast cancer; Urology; Cancer; Clinical trial; Aromatase; Osteocalcin; Alkaline phosphatase","score_opus":0.031168876565012042,"score_gpt":0.41234507384085245,"score_spread":0.3811761972758404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245477772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992539,0.005455646,0.000024568973,0.0011535204,0.0002826896,0.0004671287,0.000004006394,0.000005088143,0.00006837389],"genre_scores_gemma":[0.99606556,0.0004513317,0.0023005544,0.0008801759,0.00024096895,0.000013850065,0.0000026910457,0.000024156605,0.000020707623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966529,0.0006212312,0.0016921208,0.00019123219,0.0005007409,0.00034176203],"domain_scores_gemma":[0.99543273,0.0021135197,0.0015547231,0.00016302206,0.00017202031,0.00056398386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021909864,0.00018903,0.001662717,0.00031735297,0.000015984608,0.0000027590047,0.000062236606,0.00017300168,0.000023882412],"category_scores_gemma":[0.0024009605,0.00012060217,0.00015929565,0.00021440149,0.00029494244,0.0002398942,0.000050556013,0.0007361259,0.0000020451562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08354434,0.006459715,0.62847006,0.00019590877,0.00012834054,0.00061858335,0.00008623926,0.000010360559,0.00011357649,0.000012434835,0.00007840959,0.280282],"study_design_scores_gemma":[0.03287098,0.014665271,0.947855,0.0012747833,0.00029705075,0.000075796335,0.000043736323,0.000011078474,0.00013911078,0.000089707595,0.002567989,0.00010951531],"about_ca_topic_score_codex":0.000008792539,"about_ca_topic_score_gemma":0.000012355344,"teacher_disagreement_score":0.3193849,"about_ca_system_score_codex":0.0001946418,"about_ca_system_score_gemma":0.00038750627,"threshold_uncertainty_score":0.49180138},"labels":[],"label_agreement":null},{"id":"W4246209348","doi":"10.1093/annonc/mdz100.017","title":"Pooled safety analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2– advanced breast cancer (ABC)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Adverse effect; Letrozole; Neutropenia; Internal medicine; Common Terminology Criteria for Adverse Events; QT interval; Fulvestrant; Breast cancer; Surgery; Tamoxifen; Cancer; Oncology; Chemotherapy","score_opus":0.04222964193277495,"score_gpt":0.40370793800425586,"score_spread":0.3614782960714809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246209348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9744428,0.004508491,0.00017339516,0.017508848,0.00019960463,0.0007431111,0.00033793293,0.000041668085,0.0020441473],"genre_scores_gemma":[0.9864622,0.00910455,0.00057091203,0.0029523121,0.000078889956,0.00007698754,0.00009658195,0.000045421566,0.0006121541],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975478,0.00015579455,0.00094345916,0.00048624526,0.0003412557,0.0005254218],"domain_scores_gemma":[0.9976876,0.00038244834,0.0006117506,0.00062864996,0.0005539493,0.00013565137],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004182792,0.00030632835,0.0018783879,0.00062350853,0.000027167824,0.0000027995468,0.00024790506,0.00016642948,0.0022056517],"category_scores_gemma":[0.00005970527,0.00026406487,0.00038788683,0.0014066598,0.00022096171,0.00018631485,0.00007770828,0.0003120284,0.000010370547],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03438798,0.0020298741,0.29120705,0.0002836057,0.0067337314,0.0000947045,0.002163765,0.03921636,0.032612085,0.0007438734,0.00013999126,0.590387],"study_design_scores_gemma":[0.024151884,0.0037160038,0.8692198,0.00034411994,0.00071792427,0.00007604889,0.00054228486,0.0019327241,0.015705565,0.0004816766,0.08265498,0.00045697993],"about_ca_topic_score_codex":0.0014391403,"about_ca_topic_score_gemma":0.0029305553,"teacher_disagreement_score":0.58993,"about_ca_system_score_codex":0.00027331553,"about_ca_system_score_gemma":0.00045509895,"threshold_uncertainty_score":0.99998116},"labels":[],"label_agreement":null},{"id":"W4248668221","doi":"10.1158/1538-7445.sabcs18-p6-18-34","title":"Abstract P6-18-34: Treat ER+ight Canadian prospective observational study in HR+ advanced breast cancer: <i>3rd interim analysis</i>","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada); Lions Gate Hospital; Windsor Regional Hospital; Saskatchewan Cancer Agency; BC Cancer Agency; Kingston General Hospital; Ottawa Hospital; North York General Hospital","funders":"","keywords":"Medicine; Palbociclib; Exemestane; Fulvestrant; Letrozole; Everolimus; Internal medicine; Interim analysis; Breast cancer; Oncology; Adverse effect; Cancer; Anastrozole; Discontinuation; Metastatic breast cancer; Hazard ratio; Tamoxifen; Clinical trial; Confidence interval","score_opus":0.12552298573273044,"score_gpt":0.4553104924355075,"score_spread":0.329787506702777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248668221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98515487,0.0021038775,0.0000057797147,0.003918295,0.00026773408,0.0030722965,0.0005103005,0.0000650693,0.0049017947],"genre_scores_gemma":[0.9914081,0.0002672392,0.00007702036,0.0004147261,0.00036092996,0.0018789568,0.00008192987,0.000089449466,0.005421629],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99548244,0.00016234092,0.00057496026,0.0011467701,0.0013182627,0.0013152245],"domain_scores_gemma":[0.99708754,0.00015393253,0.00013253366,0.0008879689,0.0011094327,0.00062860263],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007620039,0.00040162564,0.0009044071,0.0014673948,0.00020488603,0.000078755766,0.00048243295,0.00015429297,0.008037632],"category_scores_gemma":[0.000057764995,0.0003638895,0.00018782426,0.0037530721,0.00024386426,0.000500283,0.00011547233,0.0011952012,0.0001463114],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027853544,0.00045813288,0.9609344,0.00012511302,0.000896632,0.00015250026,0.0019184407,0.0013186747,0.010711609,0.0000905687,0.00037413582,0.020234447],"study_design_scores_gemma":[0.0046798093,0.00035087942,0.98502105,0.0003222284,0.0001382072,0.000014543928,0.0026104555,0.0000895429,0.0013591766,0.0001387399,0.0049192784,0.00035610955],"about_ca_topic_score_codex":0.30611086,"about_ca_topic_score_gemma":0.6109985,"teacher_disagreement_score":0.30488768,"about_ca_system_score_codex":0.0074242637,"about_ca_system_score_gemma":0.0034399424,"threshold_uncertainty_score":0.9998813},"labels":[],"label_agreement":null},{"id":"W4250738875","doi":"10.1503/cmaj.045221","title":"Le Vioxx : lecons pour Sante Canada et la FDA","year":2005,"lang":"fr","type":"article","venue":"Canadian Medical Association Journal","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.004546910529998931,"score_gpt":0.25154752628363714,"score_spread":0.24700061575363821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250738875","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018293584,0.016559638,0.0007829919,0.90724987,0.005893271,0.00018527932,0.00028890732,0.000028198045,0.050718274],"genre_scores_gemma":[0.8099872,0.0016119424,0.0010177165,0.13181753,0.018370776,0.000011088154,0.000026508784,0.000094810974,0.037062436],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99539524,0.00058690377,0.0007086627,0.00025725347,0.0017613658,0.0012905699],"domain_scores_gemma":[0.99382085,0.0006631212,0.00038578117,0.0001735794,0.0005389234,0.004417728],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021979066,0.00027442432,0.00047705235,0.00018005724,0.00039372797,0.00010573083,0.0003040217,0.0005975027,0.01693793],"category_scores_gemma":[0.002594838,0.0003031366,0.00015471071,0.0002860476,0.00012682789,0.0003217225,0.000022065164,0.0025872614,0.00033791355],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00002467799,0.00008360616,0.01713527,0.00002936633,0.0005581071,0.0024569968,0.0005234596,0.00015286717,0.000031783045,0.0072482782,0.34619993,0.62555563],"study_design_scores_gemma":[0.0026497296,0.00003498181,0.02460402,0.00053272716,0.00007908918,0.003847785,0.001079398,0.00040513466,0.000035143068,0.00027368317,0.96618426,0.00027406917],"about_ca_topic_score_codex":0.7991006,"about_ca_topic_score_gemma":0.9964953,"teacher_disagreement_score":0.7916936,"about_ca_system_score_codex":0.009856644,"about_ca_system_score_gemma":0.13416433,"threshold_uncertainty_score":0.99994206},"labels":[],"label_agreement":null},{"id":"W4251532834","doi":"10.3747/co.v16i5.551","title":"Table Data Correction","year":2009,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Medicine; Table (database); Information retrieval; Data science; Computational biology; Data mining; Computer science; Biology","score_opus":0.17573896458593505,"score_gpt":0.4672816582780982,"score_spread":0.2915426936921631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251532834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4065765,0.10070796,0.1631978,0.057192378,0.095353104,0.004590889,0.00027492276,0.0028008732,0.16930553],"genre_scores_gemma":[0.98890954,0.00064107875,0.0033670976,0.0017532953,0.0023064082,0.000021652859,0.00054629147,0.000023877916,0.0024307745],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99933255,0.000023028286,0.00012915616,0.00023958518,0.00009057635,0.00018507714],"domain_scores_gemma":[0.9992955,0.000031659783,0.0000569596,0.00047890312,0.00006186199,0.000075147764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009625995,0.0000790945,0.00019400318,0.00004772387,0.00003892417,0.0000041258354,0.00013331424,0.000051759314,0.00022333948],"category_scores_gemma":[0.000082805214,0.00006990999,0.000017843326,0.00013990574,0.000042946624,0.000115421775,0.000040831077,0.00019580148,0.0000844565],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021121617,0.0003104129,0.0020740763,0.000008093079,0.000010439987,0.000008214773,0.00006619377,0.000004887422,0.0013008523,0.00010226576,0.022294935,0.97360843],"study_design_scores_gemma":[0.0012668037,0.00051434175,0.013110668,0.000037790818,0.0000406663,0.00019260145,0.00005728948,0.0008759938,0.0003585184,0.00035768858,0.9831186,0.00006901871],"about_ca_topic_score_codex":0.0000039212828,"about_ca_topic_score_gemma":0.0000074900354,"teacher_disagreement_score":0.9735394,"about_ca_system_score_codex":0.00014104367,"about_ca_system_score_gemma":0.00016061564,"threshold_uncertainty_score":0.2850847},"labels":[],"label_agreement":null},{"id":"W4255097239","doi":"10.21203/rs.3.rs-538054/v1","title":"Efficacy of Fulvestrant in Women with Hormone-Resistant Metastatic Breast Cancer (mBC): A Canadian Province Experience","year":2021,"lang":"en","type":"preprint","venue":"Research Square","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"Mach-Gaensslen Foundation of Canada; Saskatchewan Cancer Agency; University of Saskatchewan","keywords":"Fulvestrant; Metastatic breast cancer; Oncology; Medicine; Internal medicine; Breast cancer; Gynecology; Cancer; Estrogen receptor","score_opus":0.04034945561232564,"score_gpt":0.38227477023681605,"score_spread":0.3419253146244904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255097239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858479,0.008749582,0.00006180013,0.0018153402,0.00005034809,0.0025542087,0.0006895176,0.00003466379,0.00019662148],"genre_scores_gemma":[0.9955181,0.00085231214,0.0011085672,0.00007099895,0.000090988935,0.0020088023,0.000059953974,0.00009498534,0.00019531533],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9948564,0.0003483198,0.00058321434,0.0010225443,0.0016980113,0.0014914972],"domain_scores_gemma":[0.9965112,0.00020533336,0.00017694857,0.0012008236,0.001003842,0.0009018555],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007485639,0.0004337985,0.0010258951,0.00089523935,0.00011132091,0.00008229047,0.0004950856,0.00017931942,0.0004172731],"category_scores_gemma":[0.00016989376,0.0003566534,0.000100771904,0.0011639665,0.0007076765,0.00015151467,0.00030251849,0.0017641076,0.0000035419366],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.12888935,0.006609112,0.055876672,0.041987844,0.004340571,0.033275,0.21222302,0.012516001,0.13936496,0.0005753553,0.00028016683,0.36406195],"study_design_scores_gemma":[0.007163166,0.0014359311,0.93493706,0.015699787,0.00007754338,0.00025809451,0.035165947,0.00018721576,0.0024522615,0.00012793977,0.0016887676,0.0008063079],"about_ca_topic_score_codex":0.2840369,"about_ca_topic_score_gemma":0.26591313,"teacher_disagreement_score":0.8790604,"about_ca_system_score_codex":0.0044875043,"about_ca_system_score_gemma":0.016686803,"threshold_uncertainty_score":0.99988854},"labels":[],"label_agreement":null},{"id":"W4280651407","doi":"10.1158/1078-0432.ccr-21-3811","title":"VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital; Sunnybrook Health Science Centre","funders":"Roche","keywords":"Fulvestrant; Venetoclax; Internal medicine; Medicine; Metastatic breast cancer; Oncology; Cancer; Clinical endpoint; Breast cancer; Hazard ratio; Estrogen receptor; Randomized controlled trial; Confidence interval; Leukemia; Chronic lymphocytic leukemia","score_opus":0.11383709289944145,"score_gpt":0.5007041477483942,"score_spread":0.3868670548489528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280651407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98068357,0.0076432857,0.0000053402073,0.0060159555,0.00023014606,0.0041622682,0.0011654991,0.000024576137,0.00006934868],"genre_scores_gemma":[0.9959809,0.0024476522,0.000063398526,0.00018830273,0.00014852546,0.0009069135,0.000041426058,0.000056163375,0.00016670545],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9925726,0.0028211318,0.0016960829,0.0009939309,0.0012427707,0.00067346485],"domain_scores_gemma":[0.9943175,0.0039458456,0.00034037986,0.0005241305,0.0004872963,0.0003848924],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0077094906,0.00029685194,0.001665104,0.0004464665,0.00038692786,0.000021458049,0.00024379347,0.00008599925,0.00029194722],"category_scores_gemma":[0.0009939471,0.00024560108,0.00016795199,0.0009980707,0.0016539671,0.0001250778,0.0007560672,0.0014046265,0.0000010311812],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79553854,0.004352515,0.0032587335,0.00014339596,0.00097165257,0.00023252766,0.00415129,0.00021740331,0.0020090654,0.00003136621,0.000107663705,0.18898582],"study_design_scores_gemma":[0.8150595,0.014251287,0.15981013,0.00066272035,0.0005052732,0.00012513997,0.006206076,0.0007668412,0.0002502483,0.00016778464,0.0017784197,0.0004165972],"about_ca_topic_score_codex":0.0070374887,"about_ca_topic_score_gemma":0.0012244688,"teacher_disagreement_score":0.18856923,"about_ca_system_score_codex":0.0007795745,"about_ca_system_score_gemma":0.0014870804,"threshold_uncertainty_score":0.99999964},"labels":[],"label_agreement":null},{"id":"W4281660086","doi":"10.1200/jco.2022.40.16_suppl.526","title":"Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin versus placebo in hormone receptor–positive early-stage breast cancer (CCTG MA32).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; McMaster University; Sinai Health System; Université Laval","funders":"National Institutes of Health","keywords":"Medicine; Metformin; Placebo; Discontinuation; Internal medicine; Breast cancer; Cancer; Insulin","score_opus":0.15199529384254745,"score_gpt":0.4719469433412135,"score_spread":0.31995164949866606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281660086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99164414,0.0023082471,0.000053596003,0.0020585188,0.0011437527,0.0025438669,0.00004128642,0.0000073104798,0.00019925188],"genre_scores_gemma":[0.99386793,0.004136554,0.00064769073,0.00012854139,0.0005288087,0.00044805201,0.000008091076,0.000032484324,0.00020181762],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934038,0.0015945499,0.0035869274,0.0003179055,0.00064470916,0.00045211907],"domain_scores_gemma":[0.99095094,0.0052351877,0.003081943,0.00019300326,0.00026806231,0.00027084714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008873304,0.00025837263,0.0033711484,0.0004608378,0.00005250853,0.000010467572,0.0001924898,0.00019295233,0.00035592483],"category_scores_gemma":[0.0013546391,0.00019337739,0.00045457247,0.0004221943,0.0005364216,0.0004131257,0.00011560437,0.0013932717,8.183449e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89040387,0.0018781883,0.0079835225,0.0000104375395,0.0007984731,0.00022385678,0.0012789379,0.0002267679,0.00039240601,0.00006229228,0.000020621701,0.09672063],"study_design_scores_gemma":[0.9518716,0.012503176,0.031787258,0.00010495149,0.00033418828,0.000082611645,0.0012762777,0.00022752555,0.00045316407,0.000107476575,0.0010836881,0.00016809217],"about_ca_topic_score_codex":0.0009304571,"about_ca_topic_score_gemma":0.00087700575,"teacher_disagreement_score":0.096552536,"about_ca_system_score_codex":0.0005746124,"about_ca_system_score_gemma":0.0011822393,"threshold_uncertainty_score":0.7885701},"labels":[],"label_agreement":null},{"id":"W4281674598","doi":"10.1200/jco.2022.40.16_suppl.508","title":"Historical early treatment effects of adjuvant endocrine therapy for breast cancer in high-risk subgroups: Reanalysis of BIG 1-98, SOFT and TEXT.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Tamoxifen; Hazard ratio; Oncology; Adjuvant; Randomization; Relative risk; Clinical trial; Randomized controlled trial; Cancer; Gynecology; Confidence interval","score_opus":0.044655869791955564,"score_gpt":0.4023459941710787,"score_spread":0.3576901243791231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281674598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834745,0.010984999,0.000384266,0.0038286336,0.0008347721,0.00041625352,0.00005920502,0.0000049885216,0.000012401714],"genre_scores_gemma":[0.99003315,0.0073622507,0.0014810986,0.00022015652,0.000652404,0.000071581715,0.0000013908045,0.000025758043,0.00015220442],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996537,0.0005165494,0.0020927805,0.00023987233,0.0003777325,0.0002360438],"domain_scores_gemma":[0.99310684,0.003677561,0.0024900376,0.00021369028,0.0003139167,0.00019792456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012326705,0.0001780664,0.0025904495,0.0002996636,0.00004079859,0.0000016771842,0.0001367764,0.00011310692,0.000102420614],"category_scores_gemma":[0.0005944874,0.00012353095,0.0005678508,0.00027393986,0.00017859574,0.000056304023,0.00004695236,0.00053282274,1.552886e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019597154,0.0022729284,0.31597313,0.000051942145,0.0009894667,0.0001428761,0.0002316141,0.00014820108,0.0010810929,0.000022814605,0.000043749973,0.65944505],"study_design_scores_gemma":[0.034044065,0.040024687,0.9031892,0.00009093035,0.0010566353,0.00025361753,0.00009854653,0.000054633783,0.00048109333,0.0006296939,0.019965304,0.00011158401],"about_ca_topic_score_codex":0.001962844,"about_ca_topic_score_gemma":0.00025598853,"teacher_disagreement_score":0.65933347,"about_ca_system_score_codex":0.0012627458,"about_ca_system_score_gemma":0.0008830452,"threshold_uncertainty_score":0.50374454},"labels":[],"label_agreement":null},{"id":"W4281675779","doi":"10.1200/edbk_350358","title":"Personalizing Adjuvant Endocrine Therapy for Early-Stage Hormone Receptor–Positive Breast Cancer","year":2022,"lang":"en","type":"article","venue":"American Society of Clinical Oncology Educational Book","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Endocrine system; Breast cancer; Oncology; Medicine; Adjuvant; Internal medicine; Hormone receptor; Adjuvant therapy; Stage (stratigraphy); Medical prescription; Hormone; Cancer; Gynecology; Pharmacology; Biology","score_opus":0.0643257032058528,"score_gpt":0.455452952006897,"score_spread":0.3911272488010442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281675779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73914486,0.007985223,0.00054257043,0.24717085,0.00084720604,0.0016190002,0.0014992851,0.00006535246,0.0011256417],"genre_scores_gemma":[0.8313375,0.0064030774,0.04141217,0.081337854,0.0030540691,0.0027937684,0.00039291562,0.00011576233,0.033152893],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976862,0.00020899475,0.00081616844,0.00050306227,0.00041950564,0.00036605346],"domain_scores_gemma":[0.9958552,0.0023058224,0.000899176,0.0002450208,0.00047144463,0.00022334972],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000593927,0.00021057126,0.0009923996,0.000037474954,0.00026733833,0.0000040347527,0.00020334983,0.00006383384,0.0034870969],"category_scores_gemma":[0.00008988672,0.00020049466,0.0007596176,0.0002410704,0.001419528,0.000102032,0.00008556365,0.0005665125,0.000006131352],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013645458,0.00436691,0.13119511,0.000050401475,0.0022108795,0.0000029159146,0.0056721778,0.00011391884,0.0064873635,0.0012572884,0.06928519,0.7657124],"study_design_scores_gemma":[0.0041435165,0.003213997,0.41647825,0.000017364799,0.00008674155,0.00003688252,0.0040494557,0.000054905748,0.000107504435,0.0001491924,0.571485,0.0001771691],"about_ca_topic_score_codex":0.0006314559,"about_ca_topic_score_gemma":0.0000036891129,"teacher_disagreement_score":0.76553524,"about_ca_system_score_codex":0.000758532,"about_ca_system_score_gemma":0.0032650037,"threshold_uncertainty_score":0.9974238},"labels":[],"label_agreement":null},{"id":"W4281690006","doi":"10.1200/jco.2022.40.16_suppl.567","title":"Disparity between Ki67 measurements and tumor gene expression tests in patients with hormone-sensitive early breast cancer from the OPTIMA preliminary trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Institute for Health and Care Research","keywords":"Medicine; Breast cancer; Kappa; Oncology; Internal medicine; Adjuvant; Concordance; Cancer","score_opus":0.09464192110889556,"score_gpt":0.40750288461721096,"score_spread":0.3128609635083154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281690006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994426,0.0006912027,0.000059841263,0.0036872386,0.00039535246,0.00058916066,0.000116927826,0.0000059298995,0.000028323611],"genre_scores_gemma":[0.99573356,0.00006093085,0.002164358,0.0010988887,0.00086664216,0.000033206863,0.000008326513,0.000022629676,0.000011435187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967294,0.0008386898,0.0012359106,0.00025747943,0.00071298657,0.00022557605],"domain_scores_gemma":[0.9961551,0.001650182,0.0014320883,0.00019733704,0.00033690798,0.00022838068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016601357,0.00016028038,0.0010882257,0.000061314306,0.000110270514,0.000007862345,0.00017180746,0.00009891847,0.000048999715],"category_scores_gemma":[0.0005214705,0.000093439165,0.00012474894,0.00013861552,0.00022201995,0.00015893995,0.0001730225,0.0012441942,6.8500293e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22370681,0.0010997799,0.73086697,0.0000029222435,0.00023224905,0.00010938151,0.00023728583,0.000068608526,0.0001831962,2.0375053e-7,0.00014167931,0.043350935],"study_design_scores_gemma":[0.081914335,0.016271148,0.90054107,0.000115376126,0.00028291676,0.00004692049,0.0001496115,0.0000066346497,0.000051812454,0.00004889584,0.00047799575,0.00009331317],"about_ca_topic_score_codex":0.00018856364,"about_ca_topic_score_gemma":0.000029595858,"teacher_disagreement_score":0.1696741,"about_ca_system_score_codex":0.00036342704,"about_ca_system_score_gemma":0.00071083725,"threshold_uncertainty_score":0.54054743},"labels":[],"label_agreement":null},{"id":"W4281693510","doi":"10.1200/jco.2022.40.16_suppl.1018","title":"Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), <i>PIK3CA</i>-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Letrozole; Cohort; Internal medicine; Fulvestrant; Hazard ratio; Oncology; Breast cancer; Cancer; Gastroenterology; Estrogen receptor; Confidence interval; Aromatase","score_opus":0.031121113661462998,"score_gpt":0.39359984602320747,"score_spread":0.3624787323617445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281693510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878187,0.0013775295,0.00009664515,0.0072644744,0.00035893594,0.0024332737,0.00060649845,0.000018154133,0.000025787092],"genre_scores_gemma":[0.99435645,0.0024156808,0.0012803684,0.0011840356,0.00026049858,0.00027362347,0.0001362692,0.00006962487,0.000023422292],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9881776,0.0051851654,0.0037139861,0.00073477894,0.0016594937,0.00052899745],"domain_scores_gemma":[0.99063927,0.0033113288,0.0040130485,0.00047903953,0.0012579036,0.0002994023],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004858315,0.0005437459,0.0025909566,0.0006018536,0.00020333954,0.000026359501,0.00052517565,0.00020590138,0.00038291278],"category_scores_gemma":[0.0010459411,0.00033886472,0.00039272656,0.0015555219,0.00049638376,0.00053476315,0.00018833512,0.0018248635,6.0081373e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11455642,0.01760137,0.59073234,0.000018751243,0.0025508031,0.00024131365,0.0030786,0.00012455067,0.009228573,0.00000437244,0.00021028197,0.26165265],"study_design_scores_gemma":[0.07340799,0.031624496,0.8888697,0.00011999261,0.0003515235,0.00005174103,0.003014561,0.00005497303,0.0016826077,0.000044423803,0.00043467645,0.00034328506],"about_ca_topic_score_codex":0.00078936986,"about_ca_topic_score_gemma":0.0013058928,"teacher_disagreement_score":0.29813743,"about_ca_system_score_codex":0.0007383055,"about_ca_system_score_gemma":0.00083029683,"threshold_uncertainty_score":0.99990636},"labels":[],"label_agreement":null},{"id":"W4281719541","doi":"10.1200/jco.2022.40.16_suppl.1087","title":"Retrospective study to estimate the prevalence of HER2-low breast cancer (BC) and describe its clinicopathological characteristics.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Concordance; Internal medicine; Breast cancer; Oncology; Immunohistochemistry; Retrospective cohort study; Cancer; Gynecology","score_opus":0.09156177983517647,"score_gpt":0.49356996992915875,"score_spread":0.40200819009398225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281719541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870568,0.00052738044,0.00007130762,0.010457159,0.0011316488,0.000582517,0.00009158881,0.000010414551,0.00007120116],"genre_scores_gemma":[0.9956653,0.0004271124,0.00088139065,0.0019908312,0.00071595627,0.000043169366,4.1179348e-7,0.000019944988,0.00025588588],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99581593,0.00097261876,0.002090249,0.00030848265,0.0005627194,0.00025002274],"domain_scores_gemma":[0.99583083,0.0009794813,0.0019486155,0.0002649701,0.00069042406,0.00028567275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004821246,0.00016594077,0.0015293866,0.00007823759,0.00012317635,0.0000069630382,0.00033146612,0.0000958239,0.00054501306],"category_scores_gemma":[0.0025569275,0.00010187121,0.00023549602,0.00022039068,0.00034860533,0.000083927305,0.00032703596,0.0014590851,0.000003135168],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0115638515,0.0034792982,0.89146155,0.00007526506,0.0001990208,0.00049325364,0.0010165067,0.000055369524,0.00020979381,0.00004627719,0.00011254369,0.09128727],"study_design_scores_gemma":[0.0038995515,0.02086826,0.970317,0.00010384633,0.00043053727,0.0014620436,0.0006716056,0.000048686496,0.000014231354,0.00015489246,0.0019358055,0.00009352761],"about_ca_topic_score_codex":0.000019093633,"about_ca_topic_score_gemma":0.000016810181,"teacher_disagreement_score":0.09119374,"about_ca_system_score_codex":0.00029098635,"about_ca_system_score_gemma":0.0008153265,"threshold_uncertainty_score":0.63390803},"labels":[],"label_agreement":null},{"id":"W4281755040","doi":"10.1200/jco.2022.40.16_suppl.1052","title":"Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with <i>PIK3CA</i>-mutated, hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Genentech","keywords":"Medicine; Neutropenia; Adverse effect; Internal medicine; Letrozole; Gastroenterology; Toxicity; Phases of clinical research; Palbociclib; Fulvestrant; Common Terminology Criteria for Adverse Events; Pharmacology; Oncology; Cancer; Tamoxifen; Breast cancer; Metastatic breast cancer","score_opus":0.07703013949222451,"score_gpt":0.4674175886751332,"score_spread":0.3903874491829087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281755040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99624234,0.0005208917,0.00007789389,0.001155722,0.00010691685,0.0018346612,0.000041592226,0.0000086239925,0.000011356958],"genre_scores_gemma":[0.9958478,0.00138545,0.0019917404,0.00049671135,0.00006902681,0.00012836471,0.00001554361,0.0000562639,0.000009095041],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936648,0.0023717762,0.0023692206,0.000467103,0.0007572152,0.000369861],"domain_scores_gemma":[0.99487394,0.0018911354,0.0022327588,0.00020248405,0.0005866567,0.0002130389],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032380212,0.00033135246,0.0020193225,0.00046087123,0.00008174864,0.00001451691,0.00017767501,0.000087183915,0.00010339975],"category_scores_gemma":[0.00025313208,0.00022919034,0.00007596645,0.00073355425,0.00035725132,0.00049700204,0.00007350367,0.0013494841,1.2240423e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15981692,0.017521136,0.577219,0.000021495875,0.00033041614,0.00028960517,0.0033877864,0.00051807443,0.00019684983,0.0000023348966,0.0000011712361,0.24069524],"study_design_scores_gemma":[0.17943735,0.104913466,0.7110791,0.00033358074,0.0001183742,0.000158502,0.003265247,0.00040291323,0.000060869854,0.000045992143,0.000008537883,0.00017602903],"about_ca_topic_score_codex":0.0008936198,"about_ca_topic_score_gemma":0.0036072147,"teacher_disagreement_score":0.24051921,"about_ca_system_score_codex":0.00077565224,"about_ca_system_score_gemma":0.000954871,"threshold_uncertainty_score":0.9346111},"labels":[],"label_agreement":null},{"id":"W4281773151","doi":"10.1200/jco.2022.40.16_suppl.e13054","title":"Supporting patients with metastatic breast cancer during therapy with cyclin-dependent kinase 4/6 (CDK) inhibitors: A needs assessment.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Axdev Group (Canada)","funders":"","keywords":"Medicine; Palbociclib; Discontinuation; Oncology; Breast cancer; Internal medicine; Metastatic breast cancer; Cancer","score_opus":0.044849346532066625,"score_gpt":0.44294296556850393,"score_spread":0.3980936190364373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281773151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99270207,0.00039233657,0.00023989171,0.0051961853,0.000753102,0.00047770946,0.000042555865,0.000023690834,0.00017243749],"genre_scores_gemma":[0.9921145,0.00013773085,0.004309739,0.0022078082,0.00088948803,0.000066326174,0.000007053692,0.00006756599,0.00019983295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99526894,0.0005666636,0.0022029292,0.0002891507,0.0011970727,0.0004752646],"domain_scores_gemma":[0.99433196,0.00065599295,0.0036278705,0.00026458787,0.0006841692,0.00043543347],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001958476,0.00026985884,0.0015976223,0.00028196897,0.00019240045,0.00001630579,0.00023192517,0.000087328815,0.0010553251],"category_scores_gemma":[0.00014176698,0.0001691349,0.00029186154,0.00041404922,0.00022436724,0.00028837152,0.000105960295,0.0018434267,0.0000016555589],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03506455,0.004601592,0.8099456,0.000048371967,0.0016223677,0.0014208704,0.00041468095,0.0011266916,0.00048559584,0.000012169108,0.00009325237,0.14516428],"study_design_scores_gemma":[0.054470923,0.024407933,0.9045181,0.00022733703,0.00063712243,0.0025374405,0.0021790275,0.000031862608,0.00015726955,0.00008550223,0.010451276,0.00029614862],"about_ca_topic_score_codex":0.00005203875,"about_ca_topic_score_gemma":0.000033229404,"teacher_disagreement_score":0.14486812,"about_ca_system_score_codex":0.0008506786,"about_ca_system_score_gemma":0.0029356715,"threshold_uncertainty_score":0.99985784},"labels":[],"label_agreement":null},{"id":"W4282018015","doi":"10.1177/10781552221102884","title":"Cyclin-dependent kinase 4/6 inhibitor treatment use in women treated for advanced breast cancer: Integrating ASCO/NCODA patient-centered standards in a community pharmacy","year":2022,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal; AMT Die Casting (Canada)","funders":"Pfizer","keywords":"Medicine; Discontinuation; Fulvestrant; Internal medicine; Pharmacy; Breast cancer; Oncology; Palbociclib; Letrozole; Cancer; Metastatic breast cancer; Tamoxifen; Family medicine","score_opus":0.05411267099891534,"score_gpt":0.42878351827453065,"score_spread":0.3746708472756153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282018015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878926,0.0016685221,0.000079788675,0.0069442536,0.00091326504,0.0015419518,0.00081322587,0.000030213436,0.000116140145],"genre_scores_gemma":[0.9912757,0.0019081753,0.0025666514,0.0029239622,0.00024972475,0.0009117353,0.000024798994,0.000073836476,0.0000654033],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99461675,0.0021896386,0.0015002149,0.00031952985,0.00070659054,0.0006672698],"domain_scores_gemma":[0.9944581,0.0021192315,0.0019316445,0.00028834044,0.00087396725,0.0003287631],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024183197,0.0004009918,0.0011109115,0.0006104438,0.0003169956,0.00003701208,0.0002735182,0.000054446493,0.0003682253],"category_scores_gemma":[0.00093181396,0.0003563766,0.00020502332,0.0005746989,0.00010136362,0.0015759718,0.00015821104,0.0021742466,8.3117357e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22502494,0.012128496,0.02928368,0.00009799315,0.0008664372,0.0024478557,0.01580948,0.0029679518,0.054336768,0.0000046680084,0.00023335242,0.65679836],"study_design_scores_gemma":[0.19346718,0.014531605,0.0031224606,0.0006374167,0.000816307,0.00829841,0.052594554,0.0010179313,0.017151695,0.00005388142,0.7077116,0.00059696427],"about_ca_topic_score_codex":0.0024745732,"about_ca_topic_score_gemma":0.00075977936,"teacher_disagreement_score":0.7074782,"about_ca_system_score_codex":0.019891635,"about_ca_system_score_gemma":0.002806639,"threshold_uncertainty_score":0.99988884},"labels":[],"label_agreement":null},{"id":"W4282028151","doi":"10.1200/jco.2022.40.16_suppl.589","title":"Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Clinical endpoint; Anastrozole; Palbociclib; Internal medicine; Urology; Estrogen receptor; Breast cancer; Gastroenterology; Confidence interval; Phases of clinical research; Neoadjuvant therapy; Oncology; Gynecology; Cancer; Randomized controlled trial; Tamoxifen; Chemotherapy; Metastatic breast cancer","score_opus":0.0776512974025615,"score_gpt":0.4460083337624238,"score_spread":0.36835703635986233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282028151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98945165,0.0002108332,0.00008451539,0.007099514,0.0009800856,0.0015197621,0.00043578597,0.000011903413,0.00020597842],"genre_scores_gemma":[0.99696934,0.00016637833,0.0011574642,0.00084058405,0.00029925996,0.00023704986,0.000029126651,0.000046390498,0.00025440412],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.992408,0.0024037699,0.0029783465,0.0005210505,0.0011664566,0.00052239985],"domain_scores_gemma":[0.99217343,0.0029019127,0.0031745527,0.00039301472,0.00097408803,0.00038297934],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034302727,0.00039261373,0.0038704535,0.0004380152,0.00017237531,0.000037428876,0.001012891,0.00016497962,0.0016883301],"category_scores_gemma":[0.00073382375,0.00024965376,0.00036497376,0.001488851,0.0008055127,0.00032829374,0.000398332,0.0016653768,0.0000020734162],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87630767,0.009276284,0.043214034,0.000008457953,0.01667407,0.0008238595,0.0024685252,0.011870693,0.00030476454,0.000048255977,0.00007260808,0.038930755],"study_design_scores_gemma":[0.73440593,0.040397782,0.21210866,0.00014352394,0.004172539,0.00030432147,0.004439049,0.0021312744,0.000054664968,0.000032701424,0.0015164271,0.00029309661],"about_ca_topic_score_codex":0.0035114551,"about_ca_topic_score_gemma":0.0012706306,"teacher_disagreement_score":0.16889462,"about_ca_system_score_codex":0.0026276277,"about_ca_system_score_gemma":0.0044213524,"threshold_uncertainty_score":0.9999956},"labels":[],"label_agreement":null},{"id":"W4284666919","doi":"10.3390/curroncol29070377","title":"Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Triple-negative breast cancer; Breast cancer; Metastatic breast cancer; Immunotherapy; Oncology; Triple negative; Cancer; Disease; Internal medicine","score_opus":0.35067111665651585,"score_gpt":0.5225592737331444,"score_spread":0.17188815707662852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284666919","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010046753,0.987294,0.0017614258,0.00032745543,0.0037959686,0.0047030384,0.0020138784,0.000058658665,0.000035499175],"genre_scores_gemma":[0.0000032164894,0.99224865,0.00089292956,0.00004277638,0.0005461977,0.00467817,0.0011082948,0.00009651488,0.00038327443],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99767274,0.00016748603,0.0006998372,0.00073582534,0.00028068013,0.00044344013],"domain_scores_gemma":[0.9978405,0.00066123594,0.0007947412,0.00028921006,0.00013179267,0.00028252476],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017966,0.0006008293,0.002512165,0.000336434,0.0001512515,0.000014664421,0.00016328716,0.000121088764,0.00056234404],"category_scores_gemma":[0.000111284084,0.00048426058,0.0004243757,0.00037038166,0.00014484237,0.00010145727,0.00011900446,0.0006070935,0.0000076575625],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026784829,0.0012780253,0.000025142874,0.008382985,0.0009965462,0.0000036630217,0.00023818725,4.0664534e-7,3.6229721e-7,0.00025833168,0.0009178022,0.9876307],"study_design_scores_gemma":[0.010711551,0.0007727069,0.00014116812,0.00430276,0.007428654,0.00038528562,0.000059391034,0.000024987083,4.3979736e-7,0.00045411242,0.975367,0.0003519216],"about_ca_topic_score_codex":0.000042418553,"about_ca_topic_score_gemma":0.000022180293,"teacher_disagreement_score":0.98727876,"about_ca_system_score_codex":0.0028408954,"about_ca_system_score_gemma":0.0024066344,"threshold_uncertainty_score":0.9997609},"labels":[],"label_agreement":null},{"id":"W4285393349","doi":"10.3390/curroncol29070394","title":"Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer—A Literature Review","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Tamoxifen; Breast cancer; Adjuvant; Hormone therapy; Internal medicine; MEDLINE; Cancer; Gynecology; Life expectancy; Oncology; Adjuvant therapy; Population","score_opus":0.10871243085217636,"score_gpt":0.4658902644464685,"score_spread":0.35717783359429217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285393349","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007553035,0.98920894,0.000011514506,0.001722306,0.0021579645,0.004596165,0.001786295,0.00010660675,0.00040265548],"genre_scores_gemma":[0.000002863419,0.9915492,0.00025340836,0.00084229506,0.0012996733,0.0038334378,0.0018660468,0.00018380293,0.0001692836],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99475276,0.0012679988,0.0013576588,0.0012379556,0.0005258341,0.0008577679],"domain_scores_gemma":[0.9968947,0.00071270816,0.0011380574,0.0006942505,0.00028468488,0.00027556208],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004697294,0.0010752551,0.005303141,0.00053142157,0.00013207305,0.00002246308,0.00046466794,0.00032457346,0.002091356],"category_scores_gemma":[0.00016767898,0.0008402727,0.0008058455,0.0018740229,0.0002577965,0.00017659774,0.0002598742,0.0032185947,0.000041438147],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005313317,0.0007377264,0.000016627173,0.028159989,0.000421134,0.00032755377,0.0004756707,2.9463104e-7,0.000002738567,0.000029606312,0.0024136428,0.96688366],"study_design_scores_gemma":[0.0024848185,0.00076030474,0.00013235924,0.16111578,0.00063968217,0.0024689846,0.000051397386,7.105265e-7,0.000001242739,0.000023577704,0.8317543,0.0005668004],"about_ca_topic_score_codex":0.00007064263,"about_ca_topic_score_gemma":0.000026372527,"teacher_disagreement_score":0.9663169,"about_ca_system_score_codex":0.0039537973,"about_ca_system_score_gemma":0.0018483439,"threshold_uncertainty_score":0.9998698},"labels":[],"label_agreement":null},{"id":"W4286293830","doi":"10.1200/jco.2022.40.16_suppl.tps1118","title":"KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2- locally recurrent inoperable or metastatic breast cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Medicine; Metastatic breast cancer; Pembrolizumab; Internal medicine; Oncology; Breast cancer; Chemotherapy; Cancer; Placebo; Immunotherapy; Pathology","score_opus":0.07995130304151785,"score_gpt":0.4552754857975471,"score_spread":0.3753241827560293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286293830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900392,0.0006867844,0.00033093707,0.0027867358,0.0008484522,0.0051606544,0.0000287959,0.000012934615,0.000105496256],"genre_scores_gemma":[0.9962495,0.0002946383,0.00093239156,0.0013520758,0.00030386413,0.0005998916,0.0000060929156,0.000060855044,0.00020071573],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9910008,0.0022189398,0.004662701,0.00041939263,0.0012460637,0.00045210432],"domain_scores_gemma":[0.99105513,0.0028551337,0.0043870527,0.0003657563,0.000969257,0.00036769683],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005644348,0.00037761612,0.006356704,0.00042646768,0.0000928133,0.000011720943,0.00040193537,0.00013562432,0.0013882845],"category_scores_gemma":[0.00067685265,0.00022327958,0.0005789105,0.0005882421,0.00034762264,0.00019902158,0.000099648336,0.0018257734,0.0000016218902],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.862376,0.030326948,0.006744324,0.000054119,0.003276696,0.0003633017,0.0012831481,0.004446819,0.000006533595,0.000007578245,0.00007588446,0.09103866],"study_design_scores_gemma":[0.9208191,0.06873747,0.004758952,0.00018849249,0.0014997912,0.00028153067,0.0015658572,0.00063822215,0.0000058927926,0.00003778321,0.0012600934,0.0002068122],"about_ca_topic_score_codex":0.000225996,"about_ca_topic_score_gemma":0.0003878339,"teacher_disagreement_score":0.090831846,"about_ca_system_score_codex":0.0011314077,"about_ca_system_score_gemma":0.0051848963,"threshold_uncertainty_score":0.9995246},"labels":[],"label_agreement":null},{"id":"W4286298026","doi":"10.1200/jco.2022.40.16_suppl.1015","title":"Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/human epidermal growth factor receptor–negative (HR+/HER2−) advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Quality of life (healthcare); Internal medicine; Oncology; Aromatase inhibitor; Letrozole; Progression-free survival; Cancer; Breast cancer; Aromatase; Overall survival","score_opus":0.1017267633768129,"score_gpt":0.45310265736838784,"score_spread":0.35137589399157493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839031,0.0015223266,0.0008854741,0.008821865,0.001585905,0.0013533996,0.0017183934,0.00007314379,0.00013637572],"genre_scores_gemma":[0.99237895,0.00063880585,0.0040096794,0.0012184855,0.0011409529,0.0001512413,0.00022886466,0.00013522278,0.00009780482],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9878971,0.0025960186,0.006120849,0.00085867837,0.0017185679,0.00080877193],"domain_scores_gemma":[0.9811519,0.005855633,0.0095366575,0.0006342446,0.0017938215,0.0010277819],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023082036,0.00082832837,0.0064136083,0.00041247107,0.00037199247,0.000018603778,0.00057634903,0.00054251135,0.0012447654],"category_scores_gemma":[0.0014548217,0.00064947776,0.0010279004,0.00080352917,0.0011072656,0.0006408494,0.0002651133,0.0026384566,0.000009737322],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7401887,0.021490645,0.08936571,0.00066475547,0.013500589,0.00060698093,0.0070492476,0.012167806,0.036368515,0.00027328127,0.0024737427,0.075849995],"study_design_scores_gemma":[0.2169949,0.12536682,0.6168635,0.0009490689,0.002346189,0.00054015085,0.0052996553,0.00046105206,0.023405178,0.00062243274,0.0056130816,0.0015380093],"about_ca_topic_score_codex":0.0023069587,"about_ca_topic_score_gemma":0.0010874502,"teacher_disagreement_score":0.52749777,"about_ca_system_score_codex":0.0042826817,"about_ca_system_score_gemma":0.0052786036,"threshold_uncertainty_score":0.99966824},"labels":[],"label_agreement":null},{"id":"W4286510380","doi":"10.1016/j.ijrobp.2022.07.005","title":"Radiation Therapy With Cyclin-Dependent Kinase 4/6 Inhibitors: A Multi-institutional Safety and Toxicity Study","year":2022,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Dalhousie University","funders":"Pfizer","keywords":"Medicine; Toxicity; Internal medicine; Oncology; Propensity score matching; Retrospective cohort study; Acute toxicity; Gastroenterology","score_opus":0.021189867110090417,"score_gpt":0.33248292355114367,"score_spread":0.31129305644105326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286510380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9701699,0.0015534832,0.02275683,0.0029805389,0.0016219803,0.0006632801,0.00011934658,0.00004810185,0.00008652493],"genre_scores_gemma":[0.99408984,0.0005067615,0.0023265306,0.0012180669,0.0016548883,0.000048427293,0.000083633386,0.000030086218,0.00004173848],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99785703,0.000352891,0.0007107714,0.00030822432,0.00056495296,0.00020613869],"domain_scores_gemma":[0.9979492,0.00023453882,0.0009919206,0.00015214599,0.00053434726,0.00013785016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007240685,0.00024009724,0.000493631,0.00021754301,0.0002739841,0.0000230775,0.00025223586,0.00009192491,0.000107213076],"category_scores_gemma":[0.0001165674,0.00019197074,0.0001262424,0.00019787354,0.00022097758,0.00034777005,0.000095557196,0.0006461915,0.0000038486564],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007845227,0.0033414753,0.4585849,0.000005250859,0.0012906676,0.00019921319,0.0021127528,0.007967886,0.009600602,0.001736781,0.000047814494,0.5072674],"study_design_scores_gemma":[0.14253971,0.028567512,0.6309377,0.00012765394,0.0005658334,0.005646722,0.0037657516,0.0066742077,0.012838339,0.005026439,0.16211101,0.0011991396],"about_ca_topic_score_codex":0.00003624935,"about_ca_topic_score_gemma":0.000009275165,"teacher_disagreement_score":0.5060683,"about_ca_system_score_codex":0.0016069867,"about_ca_system_score_gemma":0.0007959031,"threshold_uncertainty_score":0.782834},"labels":[],"label_agreement":null},{"id":"W4293000937","doi":"10.54097/hset.v8i.1219","title":"The Combination Therapy in Breast Cancer Treatment","year":2022,"lang":"en","type":"article","venue":"Highlights in Science Engineering and Technology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Breast cancer; Medicine; Oncology; Combination therapy; Internal medicine; Metastatic breast cancer; Chemotherapy; Cancer; Drug resistance; Drug; Pharmacology","score_opus":0.007560513292599189,"score_gpt":0.2545620940950164,"score_spread":0.24700158080241721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293000937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9751927,0.0022782641,0.000017497048,0.02200071,0.00020475905,0.00018821555,0.000003302526,0.0000841202,0.000030389134],"genre_scores_gemma":[0.9980861,0.0013739571,0.00012728327,0.000027480752,0.0000135921555,0.0002949187,3.874461e-7,0.0000068466684,0.00006946109],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99932057,0.000006127148,0.00010237907,0.00019712061,0.00014377746,0.00023002118],"domain_scores_gemma":[0.99974066,0.000027621676,0.000022132781,0.00016288909,0.000023417784,0.000023248778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016255186,0.000078113175,0.00011084871,0.00046177773,0.00018338158,0.000009460597,0.00012810517,0.000024808056,0.00000616364],"category_scores_gemma":[0.000007839145,0.000051246654,0.000008365754,0.0013412981,0.00024118001,0.000056266847,0.000048561626,0.00013242035,9.876783e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026620837,0.0004451767,0.06833946,0.000011861398,0.000030917403,0.00010079476,0.0017582902,0.007821825,0.12989315,0.2886624,0.000013021256,0.5026569],"study_design_scores_gemma":[0.012105225,0.0018612723,0.55960035,0.0001499701,0.000014005777,0.0011044149,0.0016393024,0.02823236,0.056161072,0.0057232706,0.3327576,0.0006511541],"about_ca_topic_score_codex":0.000068314155,"about_ca_topic_score_gemma":0.0000211463,"teacher_disagreement_score":0.50200576,"about_ca_system_score_codex":0.00048341329,"about_ca_system_score_gemma":0.000085931424,"threshold_uncertainty_score":0.20897779},"labels":[],"label_agreement":null},{"id":"W4293104491","doi":"10.3390/curroncol29080462","title":"Palbociclib Induces the Apoptosis of Lung Squamous Cell Carcinoma Cells via RB-Independent STAT3 Phosphorylation","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Natural Science Foundation of China","keywords":"Palbociclib; Cancer research; Medicine; Cyclin-dependent kinase; Apoptosis; Tyrosine kinase; Cell cycle; Biology; Cancer; Internal medicine; Receptor; Breast cancer","score_opus":0.041472651596529436,"score_gpt":0.3402487918603457,"score_spread":0.29877614026381627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293104491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98855907,0.006137355,0.00097475876,0.00057718693,0.0022087742,0.0007378246,0.000048529626,0.000041788728,0.0007147171],"genre_scores_gemma":[0.9989387,0.000054711316,0.00013429507,0.00018639822,0.00019655137,0.00023860707,0.000050137438,0.00003290206,0.00016769973],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982138,0.00024072354,0.00042079928,0.00032842607,0.0004587344,0.00033749815],"domain_scores_gemma":[0.998781,0.00024296963,0.00038016797,0.0003759336,0.00012536749,0.00009452745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003317518,0.0001902269,0.00039626478,0.000113516544,0.00022673469,0.000005157189,0.00024605673,0.00007119942,0.0006238879],"category_scores_gemma":[0.000017722374,0.00015233237,0.00013200022,0.00028558023,0.00015211875,0.000058515918,0.00020686483,0.0005968339,0.000012026669],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038899514,0.011411394,0.07235255,0.0009041585,0.00020193568,0.000046901332,0.03874228,0.0012726084,0.23476012,0.00039067183,0.004982353,0.63104504],"study_design_scores_gemma":[0.028440582,0.004820396,0.029432723,0.000043263528,0.000866528,0.00012490618,0.014328651,0.0020201856,0.55610716,0.0011580812,0.36186928,0.0007882512],"about_ca_topic_score_codex":0.000078388024,"about_ca_topic_score_gemma":0.000009897358,"teacher_disagreement_score":0.63025683,"about_ca_system_score_codex":0.0007371264,"about_ca_system_score_gemma":0.0003183746,"threshold_uncertainty_score":0.6831135},"labels":[],"label_agreement":null},{"id":"W4293113495","doi":"10.14740/wjon1507","title":"Prospective Cohort Study of Palbociclib Treatment in Postmenopausal Patients With Unresectable and Metastatic Hormone Receptor-Positive Breast Cancer: Study Protocol for a CSPOR-BC Palbociclib Cohort Trial","year":2022,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Palbociclib; Medicine; Metastatic breast cancer; Clinical endpoint; Letrozole; Breast cancer; Oncology; Internal medicine; Fulvestrant; Cohort; Cancer; Clinical trial; Adverse effect; Prospective cohort study; Quality of life (healthcare); Estrogen receptor; Tamoxifen","score_opus":0.018559196159928133,"score_gpt":0.35757416340083137,"score_spread":0.33901496724090324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293113495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77578044,0.00006250835,0.000006817293,0.00024255982,0.00011535058,0.22358616,0.000117522024,0.000009022538,0.000079634185],"genre_scores_gemma":[0.7622476,0.0000054444035,0.00044037553,0.00004656752,0.00011835681,0.23690392,0.000009970895,0.000047687114,0.00018006537],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99661165,0.00061030354,0.0011257649,0.00045915195,0.00078558514,0.00040752967],"domain_scores_gemma":[0.9972768,0.00032965626,0.0013863292,0.00022893886,0.00060444046,0.0001738575],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009852118,0.00035100125,0.0016903111,0.00051410537,0.00018035813,0.000012870777,0.00016004052,0.000035107776,0.00019191777],"category_scores_gemma":[0.000033900258,0.00025127135,0.00008768734,0.000685379,0.0001461182,0.0001812566,0.00009352262,0.00045691867,2.2944378e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34056497,0.02150211,0.6244042,0.000021837131,0.0022304954,0.00013024129,0.0039016812,0.000096776945,0.00009036039,0.0000047556114,0.000047075908,0.007005499],"study_design_scores_gemma":[0.24889143,0.15335181,0.59045094,0.000045550336,0.00077503594,0.00009810227,0.00552095,0.000003442677,0.000025553729,0.000032444197,0.0006660619,0.00013865803],"about_ca_topic_score_codex":0.0008459596,"about_ca_topic_score_gemma":0.002032858,"teacher_disagreement_score":0.13184969,"about_ca_system_score_codex":0.002725769,"about_ca_system_score_gemma":0.0010590098,"threshold_uncertainty_score":0.999994},"labels":[],"label_agreement":null},{"id":"W4293113633","doi":"10.14740/wjon1511","title":"Prospective Cohort Study of Combination Therapy With Abemaciclib and Hormonal Therapy for Chemotherapy-Treated Patients With Hormone Receptor-Positive Metastatic Breast Cancer","year":2022,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Metastatic breast cancer; Oncology; Internal medicine; Hormonal therapy; Chemotherapy; Clinical endpoint; Prospective cohort study; Breast cancer; Combination therapy; Cancer; Adverse effect; Clinical trial","score_opus":0.010424662318231062,"score_gpt":0.2939140692354587,"score_spread":0.2834894069172276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293113633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938056,0.0015715979,0.00013731129,0.0010253037,0.000068354406,0.0032310898,0.000099239434,0.0000112477155,0.000050292587],"genre_scores_gemma":[0.9973094,0.00043194066,0.0011933626,0.0003473593,0.000059241982,0.00048726404,0.000020151738,0.000047455993,0.00010381128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983199,0.0001924714,0.00046402155,0.00025640943,0.00054504944,0.00022213205],"domain_scores_gemma":[0.99754125,0.0001714874,0.0009879222,0.00013264734,0.0010694627,0.00009724175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037000628,0.00023647753,0.0008473822,0.00030596362,0.00016009602,0.000008137042,0.00010559095,0.000025244253,0.00013925474],"category_scores_gemma":[0.000004897211,0.0001552795,0.000063157946,0.00049157493,0.00019316036,0.00015917761,0.0000186238,0.0003301299,8.905618e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10275504,0.0068169883,0.7746538,0.000010165693,0.003248092,0.000019902232,0.0028618905,0.00007225356,0.0017394872,0.000029605671,0.00007844194,0.10771435],"study_design_scores_gemma":[0.06107336,0.05815235,0.8770988,0.000038712184,0.00026063836,0.00021599133,0.0011626076,0.000010563433,0.0005406368,0.00008367836,0.0012138163,0.00014885719],"about_ca_topic_score_codex":0.00006941782,"about_ca_topic_score_gemma":0.000061087994,"teacher_disagreement_score":0.107565485,"about_ca_system_score_codex":0.0006731021,"about_ca_system_score_gemma":0.00029665406,"threshold_uncertainty_score":0.63321143},"labels":[],"label_agreement":null},{"id":"W4293168482","doi":"10.4324/9781003308195-2","title":"Crypto-Comprehension","year":2022,"lang":"en","type":"book-chapter","venue":"","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science; Programming language","score_opus":0.02504011619062775,"score_gpt":0.26814463872733346,"score_spread":0.24310452253670572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293168482","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002212458,0.002501444,0.0002557352,0.0008968057,0.00033198306,0.0003190268,0.00001579827,0.00023185469,0.9954252],"genre_scores_gemma":[0.00047101514,0.00027411352,0.0027419394,0.0022829825,0.00036767658,0.000016597101,0.000106785556,0.000116625335,0.99362224],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99894345,0.000004009319,0.00019740216,0.00032711186,0.00037207297,0.00015598098],"domain_scores_gemma":[0.99926484,0.000030411393,0.00008943884,0.00046291616,0.000058019283,0.000094406365],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000031065865,0.00025120663,0.00041197147,0.00011927677,0.000063578445,0.0000043357945,0.00007876216,0.00012635869,0.09862219],"category_scores_gemma":[0.0000034273962,0.00021807432,0.00016941185,0.000016287166,0.00006299479,0.000036302983,0.000109270375,0.0004699592,0.00044887027],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007655313,0.00004567168,0.000018319752,0.00018793163,0.0004184347,0.00038899362,0.00010538225,0.000011927334,0.0014636149,0.7098724,0.00968691,0.27703482],"study_design_scores_gemma":[0.00068154803,0.00016315939,0.000050715775,0.000098947596,0.000086930515,0.00021140109,0.000011609441,0.0000036563574,0.000078078425,0.015239853,0.9831663,0.00020785053],"about_ca_topic_score_codex":0.000009097324,"about_ca_topic_score_gemma":0.0000020900889,"teacher_disagreement_score":0.97347933,"about_ca_system_score_codex":0.00021761989,"about_ca_system_score_gemma":0.000091403694,"threshold_uncertainty_score":0.9022018},"labels":[],"label_agreement":null},{"id":"W4293213938","doi":"10.1177/10781552221122057","title":"Elevated transaminases and development of cardiomyopathy in a 32-year-old woman with metastatic breast cancer after treatment with ribociclib followed by palbociclib","year":2022,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Alberta Health Services","funders":"","keywords":"Palbociclib; Medicine; Discontinuation; Metastatic breast cancer; Breast cancer; Internal medicine; Cardiomyopathy; Heart failure; Adverse effect; Cancer; Oncology","score_opus":0.024529496821787684,"score_gpt":0.3570514982484372,"score_spread":0.3325220014266495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293213938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98861504,0.005447423,0.00029178517,0.0048722504,0.00008240023,0.00052884745,0.00008255432,0.000010515158,0.00006917127],"genre_scores_gemma":[0.98425275,0.00089404295,0.013365511,0.0010571451,0.000046794452,0.00021826853,0.000007014825,0.000044580356,0.0001139156],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978707,0.00042212577,0.00064480567,0.00024310872,0.000517052,0.0003022144],"domain_scores_gemma":[0.99812526,0.00038831634,0.00089428347,0.0001281356,0.00028133308,0.00018264727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006431807,0.00025571568,0.00083130854,0.00022969495,0.00008778083,0.0000091967495,0.00008803471,0.000024735971,0.00029603112],"category_scores_gemma":[0.00002120965,0.00017830105,0.0000670135,0.00037940044,0.00013850295,0.00045799508,0.00002727703,0.0004822327,5.301381e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33383125,0.008542422,0.28402412,0.0003316584,0.008935471,0.011721854,0.02412646,0.0006839895,0.05024991,0.0000042223414,0.00031192644,0.27723673],"study_design_scores_gemma":[0.14663266,0.018424954,0.058296006,0.0004493944,0.0060685365,0.04594554,0.024363337,0.00006417435,0.021042459,0.000007812963,0.67798567,0.00071945606],"about_ca_topic_score_codex":0.00013427333,"about_ca_topic_score_gemma":0.00009407804,"teacher_disagreement_score":0.67767376,"about_ca_system_score_codex":0.0012007118,"about_ca_system_score_gemma":0.0016497774,"threshold_uncertainty_score":0.7270906},"labels":[],"label_agreement":null},{"id":"W4293555019","doi":"10.3332/ecancer.2022.ed124","title":"CDK 4/6 inhibitors for adjuvant therapy in early breast cancer—Do we have a clear winner?","year":2022,"lang":"en","type":"editorial","venue":"ecancermedicalscience","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Government of Ontario","keywords":"Palbociclib; Medicine; Adjuvant; Breast cancer; Oncology; Cyclin-dependent kinase; Internal medicine; Cancer; Adjuvant therapy; Clinical trial; Pharmacology; Metastatic breast cancer; Cell cycle","score_opus":0.012900508948980514,"score_gpt":0.3166935721001164,"score_spread":0.30379306315113586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293555019","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009989487,0.041287355,0.0002515192,0.013044978,0.9266387,0.0042025917,0.0038760907,0.0003683317,0.0003409268],"genre_scores_gemma":[0.024206238,0.037471063,0.0007207575,0.0013395149,0.9258657,0.006234383,0.00022831798,0.00044330384,0.0034906848],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99116504,0.00016326635,0.0011878428,0.0021165386,0.0036960477,0.0016712903],"domain_scores_gemma":[0.99601245,0.00094726676,0.0007247402,0.001094696,0.00051609357,0.00070473633],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014238354,0.0009084402,0.001751061,0.0006659084,0.00042421595,0.00010501119,0.0013475015,0.0008389943,0.0022831715],"category_scores_gemma":[0.0007057174,0.00079875224,0.00043624145,0.001394379,0.0015441893,0.00039286184,0.00034898918,0.0026196307,0.000017508815],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004122457,0.0003516939,0.0013674144,0.00036886934,0.000118078715,0.00012326457,0.0023390234,0.000087890505,0.00035797164,0.000028237715,0.57569313,0.41504195],"study_design_scores_gemma":[0.006917529,0.0014512707,0.0024916155,0.0022126674,0.000071436276,0.000044266177,0.0005649991,0.00017368198,0.00012438984,0.00056720374,0.9845406,0.0008403733],"about_ca_topic_score_codex":0.0019510814,"about_ca_topic_score_gemma":0.00044327753,"teacher_disagreement_score":0.4142016,"about_ca_system_score_codex":0.003140513,"about_ca_system_score_gemma":0.006603423,"threshold_uncertainty_score":0.99968135},"labels":[],"label_agreement":null},{"id":"W4294897727","doi":"10.1126/sciadv.abq4293","title":"The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor–resistant ER <sup>+</sup> breast cancer with mitotic aberrations","year":2022,"lang":"en","type":"article","venue":"Science Advances","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Princess Margaret Cancer Centre; Jewish General Hospital; McGill University; University of Toronto; University Health Network","funders":"","keywords":"Mitosis; Spindle checkpoint; Breast cancer; Cancer research; Cancer; G2-M DNA damage checkpoint; Cell cycle checkpoint; Cell biology; Biology; Cell cycle; Spindle apparatus; Cell; Cell division; Genetics","score_opus":0.015891031830873915,"score_gpt":0.3055272050993999,"score_spread":0.289636173268526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294897727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974652,0.0100030545,0.00063799275,0.012381375,0.00036222674,0.0009943123,0.00016746411,0.00009238216,0.0007092138],"genre_scores_gemma":[0.9971106,0.00007395698,0.0009937426,0.0006893962,0.00013369646,0.00040648642,0.0000025879692,0.00002749219,0.0005620159],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99673116,0.00009621601,0.00044821526,0.00066637306,0.0014431359,0.0006149223],"domain_scores_gemma":[0.998117,0.00015145146,0.0003037182,0.0007915616,0.0004715899,0.00016465476],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.00088908453,0.00025675906,0.0003656365,0.0001419978,0.0016337947,0.000058305828,0.0005547844,0.000025697185,0.00035584907],"category_scores_gemma":[0.000060109258,0.00015979726,0.000105567444,0.0018018391,0.002269187,0.0007061137,0.00015578335,0.00038260283,0.00000430769],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005990239,0.0014327142,0.051243328,0.00037891738,0.00042335544,0.000030036119,0.013524137,0.055914156,0.6023208,0.0023232782,0.00015970017,0.26625934],"study_design_scores_gemma":[0.009790796,0.005612754,0.4273908,0.0009841952,0.0006925169,0.0010960364,0.05960984,0.010004805,0.32974347,0.012505533,0.14029737,0.00227184],"about_ca_topic_score_codex":0.00014564366,"about_ca_topic_score_gemma":0.00013544258,"teacher_disagreement_score":0.3761475,"about_ca_system_score_codex":0.00057149684,"about_ca_system_score_gemma":0.0013317444,"threshold_uncertainty_score":0.9996659},"labels":[],"label_agreement":null},{"id":"W4295816936","doi":"10.1016/j.annonc.2022.07.179","title":"144P Neoadjuvant giredestrant (GDC-9545) + palbociclib (P) vs anastrozole (A) + P in postmenopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Biomarker subgroup analysis of the randomised, phase II coopERA BC study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Daiichi Sankyo Europe; Daiichi-Sankyo; Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Anastrozole; Palbociclib; Internal medicine; Clinical endpoint; Breast cancer; Oncology; Stage (stratigraphy); Gynecology; Cancer; Urology; Gastroenterology; Metastatic breast cancer; Tamoxifen; Clinical trial","score_opus":0.023651441136603498,"score_gpt":0.3379894408180784,"score_spread":0.3143379996814749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295816936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99181426,0.00033356692,0.000017726006,0.003760935,0.00010419424,0.0023040392,0.0014759661,0.000038681912,0.00015061702],"genre_scores_gemma":[0.9976474,0.00010143531,0.0001301342,0.00079178024,0.00004335237,0.00090689183,0.00010258628,0.00006870666,0.00020768943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99555725,0.0011250229,0.0010563206,0.00072016363,0.0007267068,0.0008145503],"domain_scores_gemma":[0.99730563,0.00033002827,0.0008509262,0.00066161115,0.000605163,0.0002466389],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008443803,0.0004921917,0.00199681,0.00060424337,0.000282349,0.000011270257,0.000452392,0.00012448546,0.0014486429],"category_scores_gemma":[0.00004631377,0.00035042936,0.00024212559,0.0030595134,0.0006480937,0.00017630181,0.00024099059,0.0004995984,0.000001828073],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4060334,0.018957105,0.407265,0.000066630244,0.019023094,0.00044547487,0.019199228,0.0042643263,0.055000145,0.000023630098,0.00021766221,0.06950428],"study_design_scores_gemma":[0.10028226,0.03883723,0.8428031,0.00011237874,0.0018805997,0.00010949112,0.007874341,0.00028679724,0.006128867,0.000021045553,0.001222922,0.00044092865],"about_ca_topic_score_codex":0.008705151,"about_ca_topic_score_gemma":0.0020205127,"teacher_disagreement_score":0.4355381,"about_ca_system_score_codex":0.0006072159,"about_ca_system_score_gemma":0.00081263675,"threshold_uncertainty_score":0.9998948},"labels":[],"label_agreement":null},{"id":"W4296130406","doi":"10.1158/1557-3265.sarcomas22-a013","title":"Abstract A013: CDK2 and CDK4/6 inhibition in GIST: Mechanisms of response and resistance","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cyclin D1; Cancer research; Cyclin-dependent kinase; Palbociclib; Cyclin-dependent kinase 2; Cell cycle; GiST; Biology; Cell growth; Hyperphosphorylation; Kinase; Cell culture; Cell; Cell biology; Cancer; Biochemistry; Genetics","score_opus":0.1671865645841084,"score_gpt":0.511879329938308,"score_spread":0.34469276535419957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296130406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98740053,0.00462207,0.000049205944,0.0068596564,0.00008607569,0.00050380465,0.000067496556,0.00001777647,0.0003934052],"genre_scores_gemma":[0.9971324,0.00077591435,0.00066109747,0.00032611119,0.00007829299,0.00023811324,0.0000053118674,0.000026817585,0.0007559401],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9972596,0.00060487265,0.0005656284,0.00047871054,0.00074173254,0.00034941753],"domain_scores_gemma":[0.99779177,0.001414378,0.00011166679,0.00032450096,0.00018166608,0.00017599428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005622254,0.000106775326,0.00039082585,0.00025140762,0.00014850823,0.000011368088,0.00007963269,0.000080575424,0.00039953017],"category_scores_gemma":[0.00088853936,0.00010415441,0.000048931546,0.00050601544,0.0006497242,0.00008205772,0.00025817368,0.0010887322,0.0000021116214],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44169077,0.0022803375,0.0860861,0.0022871704,0.00028173285,0.0019092072,0.0039058311,0.00008833367,0.30136964,0.015813185,0.0031146407,0.14117305],"study_design_scores_gemma":[0.01041461,0.0024171956,0.9044039,0.0006833515,0.000023411945,0.000056121295,0.0021207384,0.00004153363,0.0077337413,0.045717355,0.026115915,0.00027210702],"about_ca_topic_score_codex":0.0002324452,"about_ca_topic_score_gemma":0.00032850818,"teacher_disagreement_score":0.81831783,"about_ca_system_score_codex":0.0002822567,"about_ca_system_score_gemma":0.00042538522,"threshold_uncertainty_score":0.473006},"labels":[],"label_agreement":null},{"id":"W4296131396","doi":"10.1158/1557-3265.sarcomas22-a019","title":"Abstract A019: Phase 1, first-in-human, dose-expansion study of oral TP-1287, a cyclin dependent kinase 9 (CDK9) inhibitor, in patients with sarcoma","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Sarcoma; Internal medicine; Cancer; Oncology; Synovial sarcoma; Neutropenia; Chemotherapy; Gastroenterology; Pathology","score_opus":0.13262587911092769,"score_gpt":0.5003120973935415,"score_spread":0.36768621828261383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296131396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957153,0.00046871006,0.0000028082934,0.0005525306,0.00022682213,0.002842667,0.00007103219,0.00003076118,0.00008934266],"genre_scores_gemma":[0.99846965,0.000052858883,0.000073895026,0.00012525878,0.00014878705,0.0008847288,0.000041144005,0.000073399366,0.00013025748],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99375343,0.00073109154,0.0013877614,0.00093827536,0.0023945984,0.00079485256],"domain_scores_gemma":[0.9974793,0.00066212454,0.00026475155,0.0008508223,0.0004216213,0.00032138024],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0032857666,0.0002702635,0.0009052093,0.00059657346,0.00023903137,0.000018142944,0.00044602357,0.00011723321,0.0010799558],"category_scores_gemma":[0.00034874005,0.00022978835,0.0001136744,0.0012142165,0.00038068008,0.00016339919,0.00051518675,0.0024709275,0.000008471774],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032180525,0.028511722,0.88938993,0.00014934198,0.000093655,0.0004903864,0.0011412087,0.00091263076,0.00041943407,0.0000059582762,0.00014632194,0.0465589],"study_design_scores_gemma":[0.0674361,0.015989142,0.9120143,0.00033744882,0.000029263949,0.0000023773753,0.002259578,0.000053878015,0.00027367898,0.00009707997,0.001269236,0.00023788527],"about_ca_topic_score_codex":0.005763538,"about_ca_topic_score_gemma":0.010374398,"teacher_disagreement_score":0.046321016,"about_ca_system_score_codex":0.001121917,"about_ca_system_score_gemma":0.00071855786,"threshold_uncertainty_score":0.99983317},"labels":[],"label_agreement":null},{"id":"W4296354869","doi":"10.3390/curroncol29090521","title":"Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Novartis Italia","keywords":"Medicine; Aromatase inhibitor; Breast cancer; Internal medicine; Oncology; Cancer; Adverse effect; Aromatase; Anastrozole; Letrozole; Gynecology","score_opus":0.05409704367183831,"score_gpt":0.4265244540488006,"score_spread":0.3724274103769623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296354869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99564755,0.00064852124,0.000022803819,0.00067281385,0.0004206724,0.0022624524,0.00019488332,0.000074598065,0.000055697892],"genre_scores_gemma":[0.99696463,0.0002518201,0.0010052515,0.00009244588,0.00008103238,0.0011866037,0.0003433362,0.000058151603,0.000016715898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99703026,0.00037619585,0.0010071032,0.0006671174,0.00042560708,0.00049370824],"domain_scores_gemma":[0.9985746,0.00013366087,0.00062769046,0.00032378975,0.00015020574,0.00019000923],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041218623,0.00032298185,0.0009698375,0.00045376192,0.00012623501,0.000029716766,0.00023156442,0.0000849821,0.000014473049],"category_scores_gemma":[0.000038030936,0.00029818097,0.00005690642,0.0007528282,0.00033513585,0.0005807745,0.00028961274,0.00074516603,4.1129974e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007008772,0.006456676,0.6880723,0.00013893285,0.000076174285,0.000053211388,0.0008649179,0.00005525747,0.00050930824,0.00002180151,0.000031252734,0.29671136],"study_design_scores_gemma":[0.02466433,0.0064954986,0.96556664,0.0002330465,0.0001002328,0.000023200968,0.0008112756,0.00042881013,0.000030118425,0.00006319274,0.0012945114,0.00028915817],"about_ca_topic_score_codex":0.00058491854,"about_ca_topic_score_gemma":0.0031415196,"teacher_disagreement_score":0.29642218,"about_ca_system_score_codex":0.001122752,"about_ca_system_score_gemma":0.0002956318,"threshold_uncertainty_score":0.999947},"labels":[],"label_agreement":null},{"id":"W4298111282","doi":"10.1111/bcp.15549","title":"Population pharmacokinetics and exposure–response of trilaciclib in extensive‐stage small cell lung cancer and triple‐negative breast cancer","year":2022,"lang":"en","type":"article","venue":"British Journal of Clinical Pharmacology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NeuroRx Research (Canada)","funders":"G1 Therapeutics","keywords":"Medicine; Population; Breast cancer; Lung cancer; Internal medicine; Oncology; Pharmacokinetics; Cancer; Triple-negative breast cancer; Adverse effect; Chemotherapy; Pharmacology","score_opus":0.03505273500487991,"score_gpt":0.4065309302285039,"score_spread":0.37147819522362396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298111282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97039497,0.02546979,0.000034343106,0.0019953453,0.0013039237,0.00048222116,0.0003002666,0.000008351549,0.00001077616],"genre_scores_gemma":[0.98312694,0.013356603,0.00043923143,0.002175457,0.00056237844,0.000046306137,0.00000300115,0.000033170716,0.0002569165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966643,0.0009899569,0.001487002,0.0002890526,0.00029350966,0.00027619273],"domain_scores_gemma":[0.9971058,0.0010519464,0.00114098,0.00006915634,0.00037832215,0.00025381416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017051036,0.0001679069,0.0010137288,0.00020954895,0.00008209228,0.000009640767,0.0001212883,0.00009209728,0.00089348486],"category_scores_gemma":[0.00022534642,0.0001880368,0.00014307183,0.00026025335,0.00026509303,0.00013566263,0.00012101754,0.0010618503,9.534375e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09067951,0.0013381501,0.5855143,0.00038677783,0.0006205064,0.0025461614,0.00076822436,0.0028858024,0.050515555,0.0000028600198,0.0017880134,0.26295415],"study_design_scores_gemma":[0.0338935,0.0009641222,0.9561363,0.00021465744,0.00050137454,0.002870645,0.00038023826,0.0009337359,0.0020482286,0.00004785327,0.0018222411,0.00018711199],"about_ca_topic_score_codex":0.00046532688,"about_ca_topic_score_gemma":0.000070319795,"teacher_disagreement_score":0.370622,"about_ca_system_score_codex":0.0001715486,"about_ca_system_score_gemma":0.00039397142,"threshold_uncertainty_score":0.97830325},"labels":[],"label_agreement":null},{"id":"W4299579271","doi":"10.24127/trb.v4i2.93","title":"tes1","year":2008,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thinkpath Engineering Services (Canada)","funders":"","keywords":"Computer science","score_opus":0.32981257590352336,"score_gpt":0.5881849640931794,"score_spread":0.2583723881896561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4299579271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9327611,0.047420677,0.0009516336,0.0007467913,0.00063796435,0.0006952291,0.00003219675,0.00011274077,0.016641708],"genre_scores_gemma":[0.9830225,0.010981526,0.0014464092,0.0013766087,0.0005148899,0.000047257017,0.0000109274515,0.0000921913,0.0025076815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974509,0.000100316545,0.00073687854,0.00042951576,0.00082142133,0.00046095363],"domain_scores_gemma":[0.99774426,0.00019810343,0.00058180664,0.0006579972,0.00041583777,0.00040198458],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045373247,0.00033313266,0.00095310615,0.0006220533,0.0002642117,0.00017748779,0.0014115905,0.000108796805,0.017984092],"category_scores_gemma":[0.00026151666,0.00028547674,0.00023499485,0.00094599026,0.00031064483,0.001703019,0.00048555434,0.0004943364,0.00007085251],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010754308,0.00045595795,0.7123198,0.00011798424,0.00042742136,0.00044537743,0.00038001072,0.000076774624,0.19216931,0.00007221993,0.03173469,0.060725044],"study_design_scores_gemma":[0.0017728711,0.000026196703,0.84673995,0.00050458027,0.000100457764,0.00063225237,0.00007231394,0.000016973256,0.054852787,0.0029241515,0.09198352,0.00037392264],"about_ca_topic_score_codex":0.00032070724,"about_ca_topic_score_gemma":0.000010332566,"teacher_disagreement_score":0.13731652,"about_ca_system_score_codex":0.00017848969,"about_ca_system_score_gemma":0.00029901872,"threshold_uncertainty_score":0.99995977},"labels":[],"label_agreement":null},{"id":"W4301035879","doi":"","title":"Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2&ndash; metastatic breast cancer","year":2018,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Metastatic breast cancer; Breast cancer; Oncology; Internal medicine; Medicine; Surrogate endpoint; Cancer; Progression-free survival; Cancer survival; Overall survival","score_opus":0.13750312567212555,"score_gpt":0.5600601352409399,"score_spread":0.42255700956881437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4301035879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96957517,0.01392202,0.0015056682,0.005184241,0.0020800994,0.005440016,0.00069494307,0.00017266729,0.0014251834],"genre_scores_gemma":[0.9844087,0.0017594352,0.007296409,0.001226447,0.0017057495,0.0012433924,0.00006637993,0.00035690068,0.0019366095],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9943805,0.00044232613,0.0013445076,0.0009921335,0.0017732491,0.0010673335],"domain_scores_gemma":[0.9955163,0.0003623441,0.0010591979,0.0010080733,0.0013048494,0.00074924657],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022444222,0.00068742794,0.0017801335,0.001011265,0.00032123463,0.0005810201,0.0022924943,0.00016617529,0.015990315],"category_scores_gemma":[0.00056547415,0.000558815,0.00034806956,0.0013633067,0.00036511477,0.0019379798,0.0012248876,0.0005183691,0.0000790651],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02930568,0.0023639956,0.22550577,0.0008716173,0.0014416964,0.00036063386,0.0008511294,0.00031170927,0.26510555,0.000074330375,0.011608415,0.46219948],"study_design_scores_gemma":[0.016261393,0.0005002827,0.89120865,0.009765087,0.0006514285,0.00032757223,0.00024826513,0.00054126,0.04488005,0.010148741,0.023806121,0.0016611493],"about_ca_topic_score_codex":0.0013287601,"about_ca_topic_score_gemma":0.00036139032,"teacher_disagreement_score":0.6657029,"about_ca_system_score_codex":0.00046364334,"about_ca_system_score_gemma":0.00075059413,"threshold_uncertainty_score":0.99968636},"labels":[],"label_agreement":null},{"id":"W4304585003","doi":"10.3390/cancers14204981","title":"HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study","year":2022,"lang":"en","type":"article","venue":"Cancers","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Polytechnique Montréal","funders":"","keywords":"Medicine; Palbociclib; Metastatic breast cancer; Internal medicine; Breast cancer; Retrospective cohort study; Oncology; Cohort; Cancer; Progression-free survival; Gynecology; Chemotherapy","score_opus":0.016092665859179168,"score_gpt":0.2964514760097352,"score_spread":0.280358810150556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304585003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909938,0.0003598909,0.000060139915,0.00028643323,0.00031352235,0.0039149546,0.0039526713,0.00006990809,0.000048702466],"genre_scores_gemma":[0.9972029,0.0005558852,0.00033927534,0.000095252,0.000046153058,0.0012535811,0.00012414418,0.000113830654,0.00026900796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966629,0.00020243677,0.00061943225,0.00074152474,0.0011970793,0.0005766227],"domain_scores_gemma":[0.99763,0.0003337526,0.0007576601,0.0006722753,0.00042625784,0.00018006469],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019170929,0.0005206262,0.0014886654,0.00018325057,0.00017909998,0.000010427577,0.00016739618,0.000021943495,0.00019825109],"category_scores_gemma":[0.000032663218,0.00030973583,0.0001506068,0.000517635,0.00026705523,0.00014214421,0.000071009876,0.00023178206,3.681556e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05314545,0.0015482676,0.92234576,0.00013297619,0.0045536333,0.000051996292,0.0043022046,0.010031049,0.000121158926,0.0000051656457,0.0000037049506,0.003758664],"study_design_scores_gemma":[0.07157965,0.011723349,0.90795416,0.00019058562,0.00068595575,0.000005692329,0.005629213,0.0001231497,0.0016101529,0.0000039809242,0.00016502518,0.00032908865],"about_ca_topic_score_codex":0.0187401,"about_ca_topic_score_gemma":0.02068364,"teacher_disagreement_score":0.018434195,"about_ca_system_score_codex":0.0077971527,"about_ca_system_score_gemma":0.0012657564,"threshold_uncertainty_score":0.99993545},"labels":[],"label_agreement":null},{"id":"W4306711477","doi":"10.1016/j.ejca.2022.10.003","title":"Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Genentech; Aptitude Health; Oncolytics Biotech; Eisai; Seagen; Bayer HealthCare; G1 Therapeutics; Silverback Therapeutics; Puma Biotechnology; BioTheranostics; Ipsen; OncoSec Medical; Syndax Pharmaceuticals; Mersana Therapeutics; Queen Mary University of London; Clovis Oncology; Mylan; MacroGenics; Celldex Therapeutics; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; Taiho Pharmaceutical; Ipsen Biopharmaceuticals; F. Hoffmann-La Roche; Radius Health; Amgen; Ariad Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Servier; Gilead Sciences; Baxalta; Foundation Medicine; Genomic Health; AbbVie; Revolution Medicines; Exelixis; Sanofi; Incyte; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Quality of life (healthcare); Breast cancer; Nausea; Population; Vinorelbine; Gemcitabine; Oncology; Eribulin; Metastatic breast cancer; Capecitabine; Cancer; Chemotherapy; Physical therapy; Colorectal cancer; Cisplatin","score_opus":0.05695953814471598,"score_gpt":0.39383531743827,"score_spread":0.336875779293554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306711477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768846,0.008865759,0.00018202867,0.011459462,0.0008557728,0.0010130854,0.00051293295,0.0000074808886,0.00021885199],"genre_scores_gemma":[0.9978086,0.00092167483,0.00018618171,0.0007649444,0.00019231546,0.000031412823,0.0000040668597,0.000046392448,0.000044412787],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937803,0.0023762868,0.0021647913,0.00020943406,0.0011605974,0.0003085677],"domain_scores_gemma":[0.9964573,0.00027345636,0.0025383746,0.0002876467,0.00029812072,0.00014510764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044186437,0.00022175345,0.0012995601,0.00030108466,0.00006620646,0.000007619773,0.00034120498,0.000015585758,0.000855952],"category_scores_gemma":[0.00018484573,0.00016287006,0.00025053206,0.0008511509,0.00019854328,0.00012465096,0.000040427065,0.00078739505,3.0735927e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7728052,0.0011598567,0.00083911774,0.00013841005,0.00074373104,0.00009506236,0.015902987,0.002586125,0.0008469902,0.00007353487,0.00031504105,0.20449392],"study_design_scores_gemma":[0.9161226,0.012233646,0.04986624,0.0008104125,0.00019929255,0.000110427594,0.0119191585,0.000060848834,0.0006769149,0.00014156308,0.0075399852,0.00031890217],"about_ca_topic_score_codex":0.0016028754,"about_ca_topic_score_gemma":0.00056685857,"teacher_disagreement_score":0.20417503,"about_ca_system_score_codex":0.0013372971,"about_ca_system_score_gemma":0.0018517073,"threshold_uncertainty_score":0.9372074},"labels":[],"label_agreement":null},{"id":"W4307911017","doi":"10.1016/s0959-8049(22)00883-8","title":"Optimal dosing of a novel PLK4 inhibitor nested in a phase II study of CFI-400945 in patients with Advanced/Metastatic Breast Cancer (MBC): Canadian Cancer Trials Group (CCTG) IND.237","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Occupational Cancer Research Centre; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network; Queen's University","funders":"Stand Up To Cancer; Ontario Institute for Cancer Research; Government of Ontario; American Association for Cancer Research","keywords":"Medicine; Neutropenia; Internal medicine; Cancer; Adverse effect; Dosing; Breast cancer; Clinical endpoint; Cohort; Surrogate endpoint; Cmax; Pharmacokinetics; Oncology; Clinical trial; Toxicity","score_opus":0.030776345458151153,"score_gpt":0.3292102583652843,"score_spread":0.2984339129071331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307911017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927105,0.003672752,0.00009566176,0.00047344388,0.00058635895,0.0014112953,0.0010055901,0.000009640361,0.000034778244],"genre_scores_gemma":[0.9978981,0.00011968245,0.0011426872,0.0002565867,0.00027023806,0.000120092634,0.00001312982,0.00013380828,0.00004564995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947074,0.0008458206,0.0022171447,0.0004250441,0.0012026144,0.0006019565],"domain_scores_gemma":[0.9960546,0.00011008509,0.0024079655,0.0003431263,0.00070094335,0.00038331735],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018424361,0.00042849514,0.0017090378,0.0012153053,0.00013731916,0.000016161239,0.00038431346,0.00002852493,0.00049978326],"category_scores_gemma":[0.0001205027,0.000355817,0.00015726051,0.0015877794,0.00014869068,0.00042287342,0.00012681283,0.00087156723,2.3948368e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06642862,0.014583667,0.35468912,0.0003816658,0.0017175341,0.0010702504,0.025424428,0.16945615,0.017064141,0.0000070142055,0.00018099838,0.3489964],"study_design_scores_gemma":[0.19386834,0.021714376,0.7629085,0.0049053626,0.00097175676,0.00016996806,0.010357223,0.0002580187,0.00094464805,0.0000044294293,0.0030698008,0.0008275863],"about_ca_topic_score_codex":0.018415665,"about_ca_topic_score_gemma":0.03865394,"teacher_disagreement_score":0.40821937,"about_ca_system_score_codex":0.0019111312,"about_ca_system_score_gemma":0.0019221376,"threshold_uncertainty_score":0.9998894},"labels":[],"label_agreement":null},{"id":"W4308354356","doi":"10.1177/17151635221135415","title":"AFPC CPERC 2022 Abstracts: Oral and Poster Presentations","year":2022,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Information retrieval; Computer science","score_opus":0.031081854763545667,"score_gpt":0.2948218582331299,"score_spread":0.2637400034695842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308354356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891406,0.0037803908,0.000036017656,0.0013608828,0.0019642136,0.00054533186,0.0010461226,0.000037566584,0.002088853],"genre_scores_gemma":[0.98824424,0.001190672,0.00023481037,0.0072512687,0.00049484055,0.000058018533,0.000070385264,0.00007141794,0.0023843236],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.99756247,0.00013699381,0.0004970737,0.00037702845,0.0005722439,0.00085420563],"domain_scores_gemma":[0.9970408,0.00006605463,0.00019959942,0.00022367797,0.0003036869,0.0021661443],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039604006,0.0003002316,0.00035011605,0.00032798472,0.0014489826,0.00010796652,0.0003033155,0.000030032747,0.0049810875],"category_scores_gemma":[0.000072627496,0.0003323678,0.000105020044,0.0005277563,0.00020764965,0.00036267066,0.000081036924,0.0010382652,0.000005915971],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018717875,0.00028401843,0.025721116,0.000510405,0.0014324299,0.311381,0.007853395,0.007266044,0.0314293,0.00010890264,0.08934529,0.5227963],"study_design_scores_gemma":[0.0031028446,0.0000878583,0.00062193256,0.0000081752205,0.00017800646,0.6743308,0.00011600988,0.00042558077,0.0010028433,0.000077842684,0.31967774,0.00037039263],"about_ca_topic_score_codex":0.024794044,"about_ca_topic_score_gemma":0.04748617,"teacher_disagreement_score":0.5224259,"about_ca_system_score_codex":0.0027869896,"about_ca_system_score_gemma":0.003944971,"threshold_uncertainty_score":0.99991286},"labels":[],"label_agreement":null},{"id":"W4309348334","doi":"10.1016/j.breast.2022.11.005","title":"Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3","year":2022,"lang":"en","type":"article","venue":"The Breast","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Pfizer","keywords":"Medicine; Palbociclib; Oncology; Human Epidermal Growth Factor Receptor 2; Hormone receptor; Internal medicine; Cancer; Chemotherapy; Breast cancer; Endocrine system; Hormone; Receptor; Metastatic breast cancer","score_opus":0.008396602502152975,"score_gpt":0.2926130271226839,"score_spread":0.2842164246205309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309348334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97950524,0.0010050156,0.000020387428,0.0016871507,0.00007338369,0.002063605,0.015523125,0.000086140695,0.00003594738],"genre_scores_gemma":[0.997541,0.00018793726,0.00024245033,0.00064725196,0.00017274747,0.00035261482,0.0005597355,0.00015193617,0.00014432464],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99644166,0.0005627931,0.0006152772,0.0007749618,0.0009469465,0.00065833254],"domain_scores_gemma":[0.99719906,0.00069077575,0.0006595519,0.0006972397,0.00048617192,0.00026722474],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025974947,0.0006858122,0.0013727057,0.00016135542,0.0004232109,0.000023011597,0.00042474776,0.00007051894,0.0017663816],"category_scores_gemma":[0.000030819316,0.00044639755,0.00022219429,0.00068982685,0.00054276775,0.00021945496,0.00019004884,0.0004551315,0.000013178276],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19052821,0.0009852503,0.050598305,0.00009928777,0.0021214793,0.000013614304,0.009181246,0.00015392018,0.44262877,0.0000128795555,0.00012914054,0.30354786],"study_design_scores_gemma":[0.024149943,0.010591491,0.8500681,0.0002390948,0.00014279221,0.000058405083,0.00053146033,0.0000122865695,0.11348709,0.00002261789,0.0001875722,0.0005091586],"about_ca_topic_score_codex":0.0014762514,"about_ca_topic_score_gemma":0.000036140347,"teacher_disagreement_score":0.79946977,"about_ca_system_score_codex":0.00044563357,"about_ca_system_score_gemma":0.0001022025,"threshold_uncertainty_score":0.9997988},"labels":[],"label_agreement":null},{"id":"W4311785325","doi":"10.3390/curroncol29120756","title":"CDK4/6 Inhibitors as Upfront Treatment in a Patient with Breast Cancer Presenting with a Clinical Critic Situation: A Case Report and Review of the Literature","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Metastatic breast cancer; Letrozole; Breast cancer; Chemotherapy; Clinical trial; Cancer; Oncology; Population; Intensive care medicine; Internal medicine; Tamoxifen","score_opus":0.11180652570880967,"score_gpt":0.48159012477873386,"score_spread":0.3697835990699242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311785325","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025216374,0.99219805,0.0000018527162,0.00073581707,0.00058464956,0.0037215217,0.00012887728,0.000016426438,0.00009118849],"genre_scores_gemma":[0.00027158327,0.9964196,0.000098515804,0.00014231614,0.0003071473,0.002526889,0.0001191174,0.000049150247,0.00006568003],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967111,0.00068421627,0.0012860051,0.0006760126,0.00035983563,0.00028285908],"domain_scores_gemma":[0.9974653,0.000331587,0.0012475782,0.00059514964,0.0002262764,0.00013409674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037959308,0.00044510464,0.002407432,0.00012945806,0.00008018386,0.000009059127,0.00009368934,0.00015191338,0.00014985037],"category_scores_gemma":[0.0001655586,0.00022356269,0.00029124232,0.00062158343,0.00027923033,0.00006132745,0.00013586582,0.0008536661,5.496506e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019269253,0.0007302531,0.0015054025,0.051649075,0.00029157146,0.030414188,0.00076579396,5.23729e-7,1.6957125e-8,0.000004844189,0.0000793765,0.91436625],"study_design_scores_gemma":[0.0010080948,0.0008635339,0.00010629693,0.124420464,0.0016400802,0.25540462,0.00011556011,8.6951775e-7,9.61165e-8,0.0000035412515,0.6162938,0.00014302839],"about_ca_topic_score_codex":0.000113682705,"about_ca_topic_score_gemma":0.0002945928,"teacher_disagreement_score":0.91422325,"about_ca_system_score_codex":0.0013489707,"about_ca_system_score_gemma":0.0029556358,"threshold_uncertainty_score":0.91166216},"labels":[],"label_agreement":null},{"id":"W4312557334","doi":"10.20517/cdr.2022.63","title":"Association between genome-wide epigenetic and genetic alterations in breast cancer tissue and response to HER2-targeted therapies in HER2-positive breast cancer patients: new findings and a systematic review","year":2022,"lang":"en","type":"review","venue":"Cancer Drug Resistance","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Université Laval; Centre hospitalier de l'Université Laval; Hôtel-Dieu de Québec","funders":"Fonds de Recherche du Québec - Santé; Fondation du cancer du sein du Québec; Université Laval","keywords":"Breast cancer; Epigenetics; Oncology; DNA methylation; Cancer; Genetic association; Medicine; Genome-wide association study; Population; Internal medicine; Bioinformatics; Biology; Gene; Genetics; Genotype; Single-nucleotide polymorphism; Gene expression","score_opus":0.011987418497592932,"score_gpt":0.30190014810543225,"score_spread":0.2899127296078393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312557334","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013735044,0.96923757,0.000016716298,0.0067448346,0.0001265915,0.00700707,0.0030824994,0.000040030514,0.0000096667945],"genre_scores_gemma":[0.0020678681,0.9872822,0.00023237176,0.0016461656,0.00019980838,0.0066344263,0.00015315281,0.00016753611,0.0016164576],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9942394,0.0013443263,0.0015839756,0.0013096449,0.0007701463,0.00075248955],"domain_scores_gemma":[0.9969532,0.000968304,0.0009127344,0.0005532425,0.00023106832,0.00038147083],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008345441,0.00091802335,0.0036670053,0.00062118855,0.00021081646,0.000116473544,0.00031067603,0.00023802627,0.0002513358],"category_scores_gemma":[0.00022516499,0.00084952824,0.00014823546,0.0015328998,0.000111350775,0.00022610922,0.00013864803,0.0007252508,0.000003164956],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015655609,0.0002275013,0.058814496,0.7144088,0.0017687512,0.0001354452,0.012465035,0.00001496601,0.00002737906,0.0000047468407,0.0010524677,0.20951484],"study_design_scores_gemma":[0.0021465588,0.00011542195,0.34200662,0.49698776,0.003561794,0.000063552725,0.00028240235,9.580012e-7,0.0000024267904,0.0000336163,0.15360521,0.0011936706],"about_ca_topic_score_codex":0.0016867964,"about_ca_topic_score_gemma":0.0046581947,"teacher_disagreement_score":0.28319213,"about_ca_system_score_codex":0.0046452754,"about_ca_system_score_gemma":0.001141437,"threshold_uncertainty_score":0.99939555},"labels":[],"label_agreement":null},{"id":"W4312648120","doi":"10.2139/ssrn.4236797","title":"Active Growth Signalling Promotes Senescence and Cancer Cell Sensitivity to CDK7 Inhibition","year":2022,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Senescence; Sensitivity (control systems); Signalling; Cell biology; Cell growth; Cancer; Signalling pathways; Chemistry; Signal transduction; Cancer research; Biology; Biochemistry; Genetics; Engineering","score_opus":0.0072701556072775255,"score_gpt":0.2482749886445063,"score_spread":0.24100483303722878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312648120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97665983,0.004165668,0.0155692585,0.0029938605,0.00010108933,0.00034956486,0.000015648435,0.00004308435,0.00010196854],"genre_scores_gemma":[0.99718434,0.0013156112,0.00029300558,0.00054651615,0.00029737,0.000041978717,0.000004056733,0.000033579705,0.00028352885],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99792683,0.00012653564,0.00016652781,0.0002690939,0.00034877314,0.0011622251],"domain_scores_gemma":[0.9994638,0.000048110418,0.00012588175,0.00008240407,0.0001390911,0.00014071625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007213362,0.00016024687,0.00022085333,0.000086570864,0.0004014969,0.000017791794,0.000043093012,0.000029815717,0.000074645104],"category_scores_gemma":[0.000025649133,0.00015441047,0.000056597422,0.00021793442,0.00003908087,0.00020839587,0.00007164261,0.0014185217,0.000002191264],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017644198,0.00020753693,0.0025153619,0.000049633258,0.00019516806,0.00009432163,0.0022307155,0.0004573298,0.8631735,0.0020415094,0.00001297438,0.12725757],"study_design_scores_gemma":[0.011141734,0.0076119322,0.0124858115,0.0005744339,0.0006169126,0.024911525,0.038709775,0.0013498344,0.7842151,0.113584876,0.0030659414,0.0017321239],"about_ca_topic_score_codex":0.00033763688,"about_ca_topic_score_gemma":0.0005121705,"teacher_disagreement_score":0.12552544,"about_ca_system_score_codex":0.0027419454,"about_ca_system_score_gemma":0.0013998704,"threshold_uncertainty_score":0.7170092},"labels":[],"label_agreement":null},{"id":"W4313202375","doi":"10.51731/cjht.2022.532","title":"Abemaciclib (Verzenio)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Family medicine; Breast cancer; Disease; Internal medicine; Oncology; Drug; Cancer; Pharmacology; Health care; Political science","score_opus":0.025378513830842764,"score_gpt":0.2975466509263467,"score_spread":0.2721681370955039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313202375","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33290577,0.3676483,0.0012613344,0.2938876,0.0019418225,0.0007271415,0.000093676084,0.00045151377,0.0010828432],"genre_scores_gemma":[0.9961506,0.00013042885,0.0014790678,0.002020645,0.000015701606,0.000012134211,0.0000019639974,0.000019228546,0.00017019533],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99878174,0.000044609118,0.0004226345,0.00010786157,0.00022101232,0.0004221243],"domain_scores_gemma":[0.99916714,0.000026263067,0.0003479878,0.00024382876,0.00010310537,0.00011167387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046870147,0.00009863815,0.0003551085,0.00063327176,0.00040460523,0.000008941166,0.00027715784,0.000043952852,0.00026399473],"category_scores_gemma":[0.00016685508,0.000089987196,0.000081675214,0.0004234388,0.00017328265,0.000074679636,0.000033445653,0.0007001894,0.0000046398495],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007147799,0.000020579093,0.006119993,0.000059509322,0.00005531777,0.00049839646,0.00041696426,0.00008333021,0.00012523589,0.0012493199,0.0034043784,0.9878955],"study_design_scores_gemma":[0.00091100275,0.00094641314,0.005880783,0.000073219875,0.000012537342,0.004506955,0.007982656,0.000005129905,0.0003678957,0.0052599637,0.973954,0.00009940596],"about_ca_topic_score_codex":0.0011115422,"about_ca_topic_score_gemma":0.00038119362,"teacher_disagreement_score":0.98779607,"about_ca_system_score_codex":0.0011735833,"about_ca_system_score_gemma":0.0039384225,"threshold_uncertainty_score":0.69865924},"labels":[],"label_agreement":null},{"id":"W4317470309","doi":"10.1016/j.ctarc.2023.100683","title":"Real-world treatment outcomes in HR+ HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors: Results from a reference center in Brazil","year":2023,"lang":"en","type":"article","venue":"Cancer Treatment and Research Communications","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Discontinuation; Internal medicine; Tolerability; Palbociclib; Neutropenia; Adverse effect; Breast cancer; Metastatic breast cancer; Gastroenterology; Oncology; Febrile neutropenia; Population; Cancer; Chemotherapy","score_opus":0.12236005037989336,"score_gpt":0.4448572747629137,"score_spread":0.3224972243830203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317470309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97928655,0.0012775573,2.4827094e-7,0.013480107,0.000032138312,0.0017250584,0.0028736715,0.00010348176,0.0012211805],"genre_scores_gemma":[0.9599045,0.031377587,0.00026768973,0.000053906253,0.00003918823,0.0033835438,0.0014780754,0.00005666325,0.0034388811],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99729985,0.00042688166,0.00053689594,0.0006253626,0.00043863995,0.00067235966],"domain_scores_gemma":[0.9972437,0.0007291593,0.00012712738,0.0013548741,0.00030058008,0.00024458425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022859326,0.0003671239,0.00066549535,0.00086003426,0.0002690401,0.000053814412,0.0002900218,0.00007063354,0.00007430273],"category_scores_gemma":[0.00003228012,0.00024026861,0.0000675152,0.0018406241,0.00048245428,0.000214705,0.0001802466,0.00034960156,0.000024087325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022514374,0.0023810188,0.9433503,0.00002304903,0.00045101426,0.00003817418,0.0030428735,0.00003096735,0.00014957086,0.0000369992,0.000104163424,0.04814039],"study_design_scores_gemma":[0.0190358,0.0007692844,0.97107404,0.0009284664,0.00009995203,0.0000025478082,0.00083196757,0.00015988262,0.00029040297,0.00009580205,0.00648171,0.0002301215],"about_ca_topic_score_codex":0.15041296,"about_ca_topic_score_gemma":0.23907973,"teacher_disagreement_score":0.08866677,"about_ca_system_score_codex":0.0031751837,"about_ca_system_score_gemma":0.00052027614,"threshold_uncertainty_score":0.97978693},"labels":[],"label_agreement":null},{"id":"W4318043123","doi":"10.3390/cancers15030717","title":"Drug Resistance and Novel Therapies in Cancers in 2020","year":2023,"lang":"en","type":"editorial","venue":"Cancers","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Drug resistance; Resistance (ecology); Intensive care medicine; Biology","score_opus":0.010945465987859983,"score_gpt":0.2900582756143241,"score_spread":0.2791128096264641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318043123","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005753373,0.038653493,0.000039313672,0.0023210929,0.950195,0.0011352294,0.00057634985,0.00023163168,0.0010945185],"genre_scores_gemma":[0.01058786,0.03226874,0.0014153427,0.00073176983,0.9161296,0.0014631416,0.00048632128,0.0006669536,0.036250293],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970806,0.00004593617,0.00054260995,0.00093533465,0.00069589005,0.0006996303],"domain_scores_gemma":[0.9982857,0.0006595999,0.00024242618,0.0005035159,0.00013574475,0.00017301041],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035182614,0.0005306837,0.0010721314,0.00037779714,0.000050946273,0.000031017906,0.0002481669,0.00048645496,0.00005097954],"category_scores_gemma":[0.0004321675,0.00053373456,0.00009364826,0.0009001967,0.00035390965,0.00014255558,0.0000750659,0.0013653632,0.000011083274],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020230883,0.000013972715,0.0005514364,0.0009212181,0.00017006251,0.00022106586,0.0033275613,0.0004468352,0.0003314675,0.000039749804,0.98781884,0.004134705],"study_design_scores_gemma":[0.005005749,0.00004444094,0.0012145714,0.0031889533,0.000045538298,0.0000020448801,0.0012273936,0.00003626034,0.000046489466,0.00028339258,0.9883912,0.00051395263],"about_ca_topic_score_codex":0.0061373883,"about_ca_topic_score_gemma":0.067221835,"teacher_disagreement_score":0.061084446,"about_ca_system_score_codex":0.010498566,"about_ca_system_score_gemma":0.0045027025,"threshold_uncertainty_score":0.9997114},"labels":[],"label_agreement":null},{"id":"W4318754916","doi":"10.1158/1535-7163.mct-22-0092","title":"Inhibition of the MNK1/2–eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer","year":2022,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont; University of Toronto; University Health Network; McGill University; Jewish General Hospital","funders":"Warren Y. Soper Charitable Trust; Fonds de Recherche du Québec - Santé; Fondation De Famille Alvin Segal; Jewish General Hospital; Canadian Institutes of Health Research; Cancer Research Society; Genome Canada; Faculty of Medicine, McGill University; McGill University","keywords":"Palbociclib; Cancer research; EIF4E; Clonogenic assay; Melanoma; Cancer; Survivin; Medicine; Downregulation and upregulation; Cell cycle; Breast cancer; Pharmacology; Biology; Cell; Translation (biology); Internal medicine; Messenger RNA; Metastatic breast cancer; Biochemistry","score_opus":0.0161072384513956,"score_gpt":0.28223943783779337,"score_spread":0.26613219938639776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318754916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98938763,0.005090491,0.00014116756,0.0039626453,0.00025089202,0.0006408972,0.00041816098,0.000032417232,0.00007570543],"genre_scores_gemma":[0.9962716,0.000523852,0.000057914396,0.0026108902,0.0000452057,0.000326265,0.000012686463,0.000056161854,0.00009542338],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99833226,0.00017284571,0.00027588152,0.00035748494,0.0005300393,0.00033149496],"domain_scores_gemma":[0.9992031,0.000031443153,0.00022397572,0.0003866735,0.00008537856,0.00006944235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015657373,0.00023220025,0.0003718808,0.00012026616,0.00013800731,0.000010400913,0.00014287382,0.000064953696,0.00027786684],"category_scores_gemma":[0.000005053443,0.00019418853,0.00010369093,0.0006329353,0.00019657976,0.00008378643,0.00018102555,0.00041366852,7.746919e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012564949,0.00031697535,0.1730133,0.00012870328,0.00032573933,0.000052560845,0.0010532427,0.0005447749,0.7707724,0.000056973215,0.000010904906,0.05246794],"study_design_scores_gemma":[0.007594282,0.00027509528,0.7422545,0.00031847812,0.00031575424,0.00015678638,0.00048811873,0.0009428002,0.24073619,0.00042697423,0.006033678,0.00045733128],"about_ca_topic_score_codex":0.0008740801,"about_ca_topic_score_gemma":0.00020623808,"teacher_disagreement_score":0.5692412,"about_ca_system_score_codex":0.00053224363,"about_ca_system_score_gemma":0.0002917324,"threshold_uncertainty_score":0.79187787},"labels":[],"label_agreement":null},{"id":"W4319461346","doi":"10.1158/1078-0432.ccr-22-2206","title":"<i>CCNE1</i> and <i>PLK1</i> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Associazione Italiana per la Ricerca sul Cancro; Università degli Studi di Napoli Federico II; AstraZeneca; Pfizer","keywords":"Palbociclib; Medicine; Capecitabine; Metastatic breast cancer; Oncology; Internal medicine; Breast cancer; Estrogen receptor; Cancer; Cancer research; Colorectal cancer","score_opus":0.21797034272938606,"score_gpt":0.5550666118599532,"score_spread":0.3370962691305671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319461346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91405797,0.007714196,0.000028714921,0.07436894,0.00063402014,0.0016798305,0.00042031112,0.00022911266,0.00086688716],"genre_scores_gemma":[0.96711177,0.015505255,0.0006805418,0.005665531,0.0012951879,0.0020412542,0.000024925097,0.00017408104,0.0075014713],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9943813,0.0006096604,0.0010192968,0.0011833084,0.0013853507,0.0014210698],"domain_scores_gemma":[0.99572194,0.0018903799,0.00011833382,0.0007702858,0.0005550521,0.0009439967],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004399402,0.00032262996,0.0009831757,0.0003978108,0.00018306753,0.000061347164,0.00040725656,0.00017423341,0.0005978863],"category_scores_gemma":[0.0009689299,0.00027964747,0.00014699817,0.0033017455,0.0008216057,0.00019991837,0.00039865894,0.0015077422,0.00029320043],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015441739,0.00065821386,0.439079,0.001419323,0.0004964862,0.0011755028,0.0020423292,0.00019460726,0.0049118875,0.0004958056,0.049524583,0.48456052],"study_design_scores_gemma":[0.009796588,0.00048757167,0.77668357,0.0020098756,0.0000964972,0.00003736836,0.0009172572,0.00015242651,0.0009301432,0.0036773016,0.2045538,0.00065762136],"about_ca_topic_score_codex":0.0010873859,"about_ca_topic_score_gemma":0.0077867326,"teacher_disagreement_score":0.4839029,"about_ca_system_score_codex":0.0004992488,"about_ca_system_score_gemma":0.0008191423,"threshold_uncertainty_score":0.99996555},"labels":[],"label_agreement":null},{"id":"W4321371142","doi":"10.3390/curroncol30020191","title":"Molecular Profile and Matched Targeted Therapy for Advanced Breast Cancer Patients","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Metastatic breast cancer; Oncology; Cancer; Targeted therapy; Clinical trial; Population","score_opus":0.04298048746458732,"score_gpt":0.3983618443786761,"score_spread":0.3553813569140888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321371142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897518,0.0044053514,0.00032136907,0.0023567164,0.0010372966,0.0015919738,0.00027940233,0.00019700106,0.000059086495],"genre_scores_gemma":[0.99415123,0.0015435256,0.00096715515,0.0005183743,0.00024793125,0.0019779229,0.00037202268,0.000071294715,0.00015052846],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988759,0.000034140045,0.00021216572,0.00035485212,0.00014109063,0.00038181015],"domain_scores_gemma":[0.99928,0.00006535476,0.00010960328,0.00016767917,0.00024670298,0.00013067348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007921708,0.00018250712,0.00038102924,0.00010978049,0.000065022075,0.0000055768223,0.00007091775,0.000088613095,0.00011133391],"category_scores_gemma":[0.000031529376,0.00015474852,0.00006841148,0.00025719756,0.00010631202,0.00006911895,0.000041476815,0.00013907782,0.000017559114],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021393273,0.00040082488,0.039864868,0.0001630464,0.0001037399,0.000006038829,0.00049201905,0.0000180796,0.025669688,0.00007736985,0.0009818387,0.93008316],"study_design_scores_gemma":[0.035664428,0.0023690134,0.58471435,0.00027951627,0.00013402534,0.000042088042,0.0004571905,0.0009319434,0.019044712,0.001526167,0.3542264,0.0006101467],"about_ca_topic_score_codex":0.0000044974086,"about_ca_topic_score_gemma":0.000002941976,"teacher_disagreement_score":0.92947304,"about_ca_system_score_codex":0.0001893494,"about_ca_system_score_gemma":0.00015955222,"threshold_uncertainty_score":0.6310461},"labels":[],"label_agreement":null},{"id":"W4321795635","doi":"10.1177/17588359231152843","title":"Quality of life with ribociclib <i>versus</i> abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"National Cancer Institute; Eli Lilly and Company; Novartis Institutes for BioMedical Research; Astex Pharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer","keywords":"Medicine; Breast cancer; Internal medicine; Quality of life (healthcare); Oncology; Placebo; Cancer; Hazard ratio; Clinical trial; Confidence interval; Alternative medicine; Pathology","score_opus":0.06506842105089145,"score_gpt":0.4343277424711693,"score_spread":0.36925932142027784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321795635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9652327,0.020579748,0.0015919852,0.008743074,0.00077906874,0.0014078253,0.00014351396,0.00030238126,0.0012197547],"genre_scores_gemma":[0.9763013,0.020397743,0.0014494754,0.00091786694,0.00023491305,0.00040719786,0.000070145594,0.00008733965,0.00013400936],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99522465,0.00042093146,0.0016197265,0.0007013065,0.0012333796,0.00080000097],"domain_scores_gemma":[0.995541,0.0020925368,0.0010243219,0.0006239654,0.00024849083,0.0004696841],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007325589,0.00052675727,0.00273952,0.00034013583,0.0000839114,0.0000038126923,0.00038231825,0.00038844178,0.0007616286],"category_scores_gemma":[0.00018144918,0.00038956545,0.00021482582,0.0015199974,0.0012260741,0.0002269644,0.00008118843,0.0005087343,0.000020808162],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04871656,0.0025943872,0.06100689,0.0006153692,0.00078433857,0.00012675341,0.0031698826,0.0035917878,0.0010382595,0.0005346287,0.00000866717,0.8778125],"study_design_scores_gemma":[0.25979108,0.060246203,0.3574496,0.0049495804,0.0017090956,0.00069327955,0.019948654,0.004180342,0.013287684,0.011104814,0.2636362,0.003003481],"about_ca_topic_score_codex":0.0006269435,"about_ca_topic_score_gemma":0.004144311,"teacher_disagreement_score":0.874809,"about_ca_system_score_codex":0.0008122512,"about_ca_system_score_gemma":0.0014035766,"threshold_uncertainty_score":0.99985564},"labels":[],"label_agreement":null},{"id":"W4322213255","doi":"10.14740/wjon1577","title":"Biomarker Research in World Journal of Oncology","year":2023,"lang":"en","type":"editorial","venue":"World Journal of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Biomedical Imaging and Bioengineering; National Cancer Institute; National Institutes of Health; Roswell Park Cancer Institute; U.S. Department of Defense","keywords":"Medicine; Biomarker; Oncology; Medical physics; Internal medicine","score_opus":0.10151259851599966,"score_gpt":0.4785332519702711,"score_spread":0.37702065345427144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322213255","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007942973,0.0093183685,0.000058864644,0.014495484,0.9654846,0.00038623292,0.000029885901,0.000018791208,0.00941347],"genre_scores_gemma":[0.0037093011,0.0050937813,0.003994281,0.00029775585,0.9682641,0.000021688002,0.000020617628,0.00023596635,0.018362531],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99099433,0.0018039484,0.003194704,0.00039620753,0.0024982556,0.0011125361],"domain_scores_gemma":[0.9789588,0.011932045,0.003678424,0.00047405975,0.0043880804,0.00056859676],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.011779304,0.00046331313,0.0032456121,0.00904298,0.000095565265,0.000029359577,0.0010169898,0.001096467,0.0007480378],"category_scores_gemma":[0.004212882,0.00037838463,0.0006246237,0.0033527876,0.000870494,0.00022969634,0.0002703659,0.010020073,0.000070043876],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0115219075,0.00066116045,0.00036026878,0.00018095829,0.00074275065,0.012896405,0.0003692518,0.000030477915,0.00063311507,0.00003150276,0.77198005,0.20059216],"study_design_scores_gemma":[0.011861902,0.0065276963,0.0011409238,0.0023340583,0.0002938797,0.0019515584,0.00043795313,0.0000037264385,0.000050895193,0.0014691239,0.97368795,0.0002403243],"about_ca_topic_score_codex":0.000071016126,"about_ca_topic_score_gemma":0.003413795,"teacher_disagreement_score":0.20170791,"about_ca_system_score_codex":0.007144959,"about_ca_system_score_gemma":0.013904288,"threshold_uncertainty_score":0.9998668},"labels":[],"label_agreement":null},{"id":"W4322769118","doi":"10.1158/1538-7445.sabcs22-pd18-10","title":"Abstract PD18-10: Treatment of HER2-positive (HER2+) hormone-receptor positive (HR+) metastatic breast cancer (mBC) with the novel combination of zanidatamab, palbociclib, and fulvestrant","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Health Sciences Centre; Zymeworks (Canada); Sunnybrook Health Science Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Fulvestrant; Palbociclib; Metastatic breast cancer; Trastuzumab; Tolerability; Internal medicine; Oncology; Pertuzumab; Combination therapy; Breast cancer; Cancer; Adverse effect; Estrogen receptor","score_opus":0.05721189662845406,"score_gpt":0.39040719515226985,"score_spread":0.3331952985238158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322769118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850174,0.002992366,0.000078166515,0.007251275,0.00005268499,0.0015890979,0.0027703564,0.000040529525,0.000208098],"genre_scores_gemma":[0.9950116,0.0028779,0.00016810665,0.000047460264,0.00010717356,0.0006291476,0.00015620183,0.000069243244,0.0009331505],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9974635,0.00012875277,0.00035788948,0.00049308455,0.0009843169,0.00057242584],"domain_scores_gemma":[0.9976682,0.0005460591,0.00021426268,0.00042390305,0.00096119125,0.00018638729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046622136,0.00028748353,0.00058890454,0.0002642807,0.00018540151,0.000028654802,0.00018553704,0.00007135646,0.00045768908],"category_scores_gemma":[0.000023360257,0.00018158804,0.000091802176,0.0010616431,0.0010496817,0.00020806571,0.00006337805,0.0002927738,0.000017178627],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013819257,0.0019323461,0.0032596362,0.0006652656,0.0027290042,0.00007650125,0.012311093,0.00029541907,0.8516481,0.0005857411,0.0012741006,0.11140354],"study_design_scores_gemma":[0.012370678,0.004731542,0.7710724,0.0012576679,0.00040946493,0.00008285384,0.0070779514,0.00015617955,0.20089085,0.00016916102,0.0014036146,0.00037766912],"about_ca_topic_score_codex":0.006143578,"about_ca_topic_score_gemma":0.0005115159,"teacher_disagreement_score":0.7678127,"about_ca_system_score_codex":0.0006294163,"about_ca_system_score_gemma":0.000689118,"threshold_uncertainty_score":0.92872924},"labels":[],"label_agreement":null},{"id":"W4322769163","doi":"10.1158/1538-7445.sabcs22-pd17-06","title":"Abstract PD17-06: Immunohistochemical markers and determinants of clinical response in the Penelope-B trial","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Palbociclib; Medicine; Oncology; Internal medicine; Proportional hazards model; Breast cancer; Hazard ratio; Estrogen receptor; Immunohistochemistry; Progesterone receptor; Cancer; Confidence interval; Metastatic breast cancer","score_opus":0.23591794451281867,"score_gpt":0.5581976815810864,"score_spread":0.32227973706826774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322769163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953573,0.0010395924,5.802685e-7,0.002266538,0.00013492185,0.0008790235,0.000015672802,0.000019172388,0.00028724663],"genre_scores_gemma":[0.99798363,0.0007589012,0.000043997337,0.000089770256,0.00024608354,0.00029552946,0.0000043016753,0.000024305036,0.0005534654],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99738806,0.00054819154,0.0005699172,0.0003333134,0.000714803,0.00044570214],"domain_scores_gemma":[0.9966731,0.0025134569,0.00008490641,0.00046301112,0.00015873127,0.00010676107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00784739,0.00010862614,0.00040768232,0.00024110326,0.00007301971,0.000013944159,0.00027479546,0.00012510063,0.00014569695],"category_scores_gemma":[0.002039119,0.0000758592,0.00008484715,0.0007243046,0.00075196836,0.000064771535,0.00012046583,0.0007868409,0.000030706695],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.759277,0.00025151233,0.03986401,0.00027488347,0.000073784984,0.0004048058,0.0016849631,0.0000034416473,0.0856254,0.000018601611,0.0030612901,0.10946034],"study_design_scores_gemma":[0.035747696,0.0010398315,0.9447674,0.00044772282,0.000014940024,0.000029216275,0.0018123549,0.000030390325,0.0041842815,0.00022231856,0.011576265,0.00012758511],"about_ca_topic_score_codex":0.00022531112,"about_ca_topic_score_gemma":0.000034945326,"teacher_disagreement_score":0.9049034,"about_ca_system_score_codex":0.00014454035,"about_ca_system_score_gemma":0.0007375122,"threshold_uncertainty_score":0.3418476},"labels":[],"label_agreement":null},{"id":"W4322769650","doi":"10.1158/1538-7445.sabcs22-p5-02-27","title":"Abstract P5-02-27: Serum thymidine kinase activity as a prognostic marker in women with metastatic breast cancer treated with two different schedules of palbociclib plus second-line endocrine therapy within the CCTG MA38 trial","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; BC Cancer Agency; Queen's University","funders":"","keywords":"Palbociclib; Medicine; Metastatic breast cancer; Internal medicine; Oncology; Dosing; Breast cancer; Cancer; Randomization; Gastroenterology; Clinical trial","score_opus":0.07700599130751773,"score_gpt":0.40800145374454355,"score_spread":0.3309954624370258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322769650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886899,0.0015165929,0.0000086931195,0.004510712,0.00013422078,0.00443759,0.0004930229,0.00012572802,0.00008355733],"genre_scores_gemma":[0.9910766,0.0010596144,0.000049914554,0.00012635962,0.0003083741,0.005499911,0.0000303986,0.00016507981,0.0016837437],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9950751,0.0005021184,0.00059974764,0.0008592718,0.0015874862,0.0013762627],"domain_scores_gemma":[0.99702185,0.0008067511,0.000326691,0.0008801724,0.00059816416,0.00036634927],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012668062,0.00057094934,0.0011177667,0.00059561135,0.00019963253,0.000070645736,0.00043707536,0.0000769128,0.002364404],"category_scores_gemma":[0.00011629929,0.0003089836,0.0000984426,0.0024547752,0.0008861826,0.00027323957,0.00014186042,0.0013127637,0.00002038048],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76563495,0.0019376853,0.06285584,0.0013388875,0.0026787356,0.001137461,0.0034579972,0.0026315951,0.076209426,0.00010984437,0.00008281762,0.08192472],"study_design_scores_gemma":[0.18719155,0.006329936,0.7037678,0.002926046,0.00019489505,0.00019647006,0.0045544417,0.000737308,0.09228408,0.0005544425,0.0004550575,0.0008080122],"about_ca_topic_score_codex":0.004095487,"about_ca_topic_score_gemma":0.006430631,"teacher_disagreement_score":0.64091194,"about_ca_system_score_codex":0.0013440882,"about_ca_system_score_gemma":0.0019789163,"threshold_uncertainty_score":0.9999362},"labels":[],"label_agreement":null},{"id":"W4322769656","doi":"10.1158/1538-7445.sabcs22-p5-02-22","title":"Abstract P5-02-22: Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving the Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib: Biomarker Results from POLARIS","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Palbociclib; Breast cancer; Biomarker; Oncology; Medicine; Internal medicine; Cancer; CDKN2A; Cancer research; Biology; Metastatic breast cancer; Genetics","score_opus":0.03956129808422907,"score_gpt":0.34768262221763374,"score_spread":0.30812132413340465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322769656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938485,0.0015699652,0.000012392687,0.0018345986,0.00020355817,0.001299809,0.00110828,0.00007429917,0.000048594247],"genre_scores_gemma":[0.9982606,0.00037110975,0.00025441407,0.00011268523,0.00035651913,0.0003693957,0.00013060737,0.00009363902,0.000051012303],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9964824,0.00020304263,0.00071395136,0.00076941284,0.0010524865,0.0007787416],"domain_scores_gemma":[0.99757236,0.00062761444,0.00028348208,0.00064243743,0.00066322903,0.00021086921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009669177,0.00028393627,0.0004752604,0.00045490966,0.00034553997,0.00006905319,0.0002367988,0.00009928147,0.00011562226],"category_scores_gemma":[0.00034665363,0.00021302179,0.00005932406,0.001477651,0.00038509522,0.00034813315,0.00022859618,0.0005468315,0.0000073143487],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010541238,0.00020940493,0.27301437,0.00024163109,0.00030916333,0.00010213329,0.0042548925,0.00081748725,0.4603639,0.000009271276,0.000069680194,0.25006685],"study_design_scores_gemma":[0.0069266935,0.00009689798,0.966624,0.0016270269,0.000033399032,0.000006074364,0.0010250913,0.00016230698,0.023113668,0.00007494942,0.000079739715,0.000230105],"about_ca_topic_score_codex":0.0062856916,"about_ca_topic_score_gemma":0.0017186465,"teacher_disagreement_score":0.69360965,"about_ca_system_score_codex":0.00073268125,"about_ca_system_score_gemma":0.0005953018,"threshold_uncertainty_score":0.9502127},"labels":[],"label_agreement":null},{"id":"W4322769985","doi":"10.1158/1538-7445.sabcs22-tc1-3-1","title":"Abstract TC1-3-1: Ki 67 Ki67 – a clinically relevant biomarker or just <i>nice to have</i> information?","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Oncology; Biomarker; Population; Cohort; Cancer; Clinical trial","score_opus":0.2118287432103727,"score_gpt":0.5158105906984785,"score_spread":0.30398184748810575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322769985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91635555,0.000941478,0.00040517803,0.061490513,0.0011676664,0.0035204382,0.00037616305,0.0008484211,0.01489459],"genre_scores_gemma":[0.97388107,0.0016718499,0.0012525707,0.0056179403,0.0009444754,0.0014676183,0.000112732,0.00012068343,0.014931092],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960961,0.000094263945,0.0007757151,0.00048663656,0.0014589616,0.0010883565],"domain_scores_gemma":[0.996575,0.0008184725,0.0001146289,0.00087756704,0.0009821211,0.0006322272],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0021591622,0.00023500394,0.00042671472,0.00065321603,0.000258181,0.00010056249,0.00040992707,0.00017322283,0.0016343822],"category_scores_gemma":[0.0017085136,0.00018133609,0.00012927753,0.0019795946,0.00028912604,0.00048635225,0.00030891673,0.0008367812,0.0041420213],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023538439,0.00025870127,0.013586423,0.0013916497,0.00047194355,0.0005120228,0.0043693623,0.00029238683,0.053374857,0.000191963,0.19899786,0.7030144],"study_design_scores_gemma":[0.0037357218,0.00054833165,0.13741407,0.0008054425,0.000031470157,0.000046902718,0.0030347272,0.00013474507,0.0028462657,0.00021258634,0.85084045,0.00034926413],"about_ca_topic_score_codex":0.0005406724,"about_ca_topic_score_gemma":0.00020599984,"teacher_disagreement_score":0.70266515,"about_ca_system_score_codex":0.0006105845,"about_ca_system_score_gemma":0.0014755772,"threshold_uncertainty_score":0.99927825},"labels":[],"label_agreement":null},{"id":"W4322770094","doi":"10.1158/1538-7445.sabcs22-p3-03-12","title":"Abstract P3-03-12: Risk of recurrence with adjuvant endocrine therapy in real world patients with hormone receptor positive/human epidermal growth factor receptor-negative early breast cancer: a US database analysis","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Oncology; Stage (stratigraphy); Cohort; Cancer; Medical record; Proportional hazards model; Adjuvant therapy; Adjuvant; Retrospective cohort study","score_opus":0.04564387843784488,"score_gpt":0.3743183163418518,"score_spread":0.3286744379040069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322770094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876327,0.0008039666,0.000019208754,0.00064727355,0.00006735947,0.0018031778,0.00871784,0.00010217845,0.00020632839],"genre_scores_gemma":[0.98904914,0.008288249,0.00034949082,0.000039042294,0.0002212681,0.00093825127,0.000641476,0.00012059942,0.00035250522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943207,0.00048654934,0.0007100922,0.0011787821,0.001977649,0.0013262535],"domain_scores_gemma":[0.9958717,0.0005886554,0.0004853884,0.00077959115,0.0017949913,0.0004796222],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006910203,0.00053481985,0.0011897177,0.0018994703,0.00027823038,0.000048112634,0.00045160152,0.000088420384,0.0013210204],"category_scores_gemma":[0.000105635685,0.0003913083,0.00016139467,0.0067281346,0.00094194413,0.0006300517,0.00016169748,0.0014563764,0.000029207516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022486158,0.000531179,0.9109944,0.00013759508,0.0018938924,0.00007998877,0.0015735979,0.000111432426,0.012711395,0.000013946898,0.0002452403,0.049221195],"study_design_scores_gemma":[0.008639654,0.0016029662,0.97647643,0.0009214185,0.00016235156,0.0000024096416,0.00028936952,0.000024333707,0.0112945065,0.00002431441,0.00013514221,0.00042712764],"about_ca_topic_score_codex":0.08881301,"about_ca_topic_score_gemma":0.020352658,"teacher_disagreement_score":0.06846035,"about_ca_system_score_codex":0.0012916689,"about_ca_system_score_gemma":0.00082150457,"threshold_uncertainty_score":0.9998539},"labels":[],"label_agreement":null},{"id":"W4322770969","doi":"10.1158/1538-7445.sabcs22-ot3-32-01","title":"Abstract OT3-32-01: OPTIMA, a prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in high clinical risk early breast cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics; University of Alberta","funders":"","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Population; Cancer; Randomized controlled trial; Gynecology; Interim analysis","score_opus":0.15514271317249284,"score_gpt":0.5186807093158099,"score_spread":0.36353799614331705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322770969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851573,0.0009782752,0.00020441154,0.001350875,0.00047812395,0.011070687,0.0005774093,0.00012260082,0.000060295286],"genre_scores_gemma":[0.98459446,0.007729764,0.00067053956,0.00007902718,0.0006720715,0.0060541984,0.00001600002,0.00008104021,0.00010288977],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.992119,0.0033697998,0.0013823978,0.0011326035,0.0011880798,0.00080810476],"domain_scores_gemma":[0.9756286,0.02166563,0.00032826437,0.00091613096,0.001018439,0.00044294124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018675512,0.00033400315,0.0017912625,0.00037370317,0.00024652726,0.000052061183,0.00042789688,0.0003115667,0.0003227975],"category_scores_gemma":[0.007492563,0.00021467867,0.0003442321,0.0018793935,0.0014841685,0.00015766616,0.00024888176,0.0017577321,0.000019362406],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73753655,0.0006144205,0.15173565,0.000056131947,0.0002714644,0.000023581679,0.00043632684,0.00008946386,0.0066414988,0.0000061510846,0.00021167258,0.10237708],"study_design_scores_gemma":[0.34811422,0.0004439646,0.6420991,0.00074433984,0.00005386749,0.0000039845186,0.000083354236,0.00013360573,0.007337325,0.0006536599,0.00018649067,0.00014611079],"about_ca_topic_score_codex":0.0040140525,"about_ca_topic_score_gemma":0.00036654077,"teacher_disagreement_score":0.49036342,"about_ca_system_score_codex":0.0004250409,"about_ca_system_score_gemma":0.0011024942,"threshold_uncertainty_score":0.8969839},"labels":[],"label_agreement":null},{"id":"W4322771176","doi":"10.1158/1538-7445.sabcs22-ot3-26-01","title":"Abstract OT3-26-01: CCTG MA40: DOUBLE-BLIND PLACEBO CONTROLLED PHASE III TRIAL OF FULVESTRANT AND IPATASERTIB FOR ADVANCED HER-2 NEGATIVE AND ESTROGEN RECEPTOR POSITIVE (ER+) BREAST CANCER POST FIRST LINE CDK 4/6 AND AROMATASE INHIBITOR THERAPY (FINER)","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Centre Hospitalier de l’Université de Montréal; University Health Network; Vancouver Hospital and Health Sciences Centre; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Fulvestrant; Medicine; Internal medicine; Oncology; Breast cancer; Anastrozole; Placebo; PTEN; Exemestane; Cancer; Palbociclib; Tolerability; Estrogen receptor; Metastatic breast cancer; PI3K/AKT/mTOR pathway; Adverse effect; Tamoxifen; Pathology; Biology","score_opus":0.076524905853375,"score_gpt":0.42588625224610077,"score_spread":0.34936134639272576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322771176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9651716,0.010381704,0.000018792995,0.0067547816,0.00024775974,0.009096194,0.008210961,0.00009967046,0.000018545625],"genre_scores_gemma":[0.9804875,0.012490725,0.00021288758,0.00012881962,0.0009722258,0.0048787924,0.00045804883,0.0001499391,0.00022101385],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963464,0.00013928351,0.0007930709,0.000983837,0.0007792804,0.0009580896],"domain_scores_gemma":[0.99646115,0.0012778216,0.000334582,0.00044267456,0.0009004393,0.0005833206],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010386297,0.00051893434,0.001299593,0.0004738345,0.0004126602,0.0000877385,0.00018298256,0.00022612973,0.00021171969],"category_scores_gemma":[0.00018570176,0.00041877662,0.00015208103,0.0006965728,0.0009982915,0.0003946955,0.00012479888,0.0006096154,0.000004275106],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7717799,0.000491057,0.00011100787,0.00038532607,0.0007173045,0.000043777283,0.0012794025,0.000038611746,0.1544534,0.000031843403,0.0003532659,0.0703151],"study_design_scores_gemma":[0.8830426,0.005250326,0.001549376,0.0012300805,0.00018093386,0.0000556044,0.0017529781,0.00015131835,0.10412068,0.00016187078,0.0020044888,0.000499758],"about_ca_topic_score_codex":0.0016012405,"about_ca_topic_score_gemma":0.00052295777,"teacher_disagreement_score":0.11126268,"about_ca_system_score_codex":0.00029038527,"about_ca_system_score_gemma":0.00081235066,"threshold_uncertainty_score":0.99982643},"labels":[],"label_agreement":null},{"id":"W4322771858","doi":"10.1158/1538-7445.sabcs22-p1-11-19","title":"Abstract P1-11-19: A real-world evidence study of treatment patterns in patients with HER2-positive metastatic breast cancer who have received at least 2-lines of therapy","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; AstraZeneca (Canada)","funders":"","keywords":"Medicine; Metastatic breast cancer; Pertuzumab; Trastuzumab; Discontinuation; Internal medicine; Oncology; Breast cancer; Cancer; Interquartile range","score_opus":0.13987231841483044,"score_gpt":0.4563584420705444,"score_spread":0.31648612365571394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322771858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99412733,0.0008223185,0.0000021766566,0.00093324564,0.00005566228,0.0032943971,0.0006799643,0.000036143712,0.000048757858],"genre_scores_gemma":[0.99241626,0.004413578,0.00001992851,0.000038644794,0.00009098333,0.0016305831,0.000041438543,0.00008780684,0.0012607494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99629384,0.00033649892,0.00061915064,0.00070784724,0.0013249019,0.0007177441],"domain_scores_gemma":[0.99716306,0.0005594397,0.0002951646,0.0006682147,0.0010759323,0.00023818611],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005529338,0.00035271636,0.0009230554,0.00078672473,0.00011660641,0.000015683954,0.00026475312,0.00005140679,0.0005723294],"category_scores_gemma":[0.000048660513,0.0002505041,0.00009086938,0.0016396382,0.0003600334,0.0002208913,0.00010945587,0.00031071744,0.0000061072074],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013489234,0.0015966014,0.9357432,0.00032854904,0.0006134749,0.00007049322,0.008431774,0.0012598325,0.0026872074,0.0000015713649,0.000066667024,0.03571136],"study_design_scores_gemma":[0.009747011,0.0031025745,0.9737838,0.003125408,0.000069274894,0.0000024493818,0.0037898053,0.00004166784,0.0060418793,0.000010489766,0.000082794446,0.00020286899],"about_ca_topic_score_codex":0.10921703,"about_ca_topic_score_gemma":0.12050145,"teacher_disagreement_score":0.03804054,"about_ca_system_score_codex":0.0026715384,"about_ca_system_score_gemma":0.0009004189,"threshold_uncertainty_score":0.9999947},"labels":[],"label_agreement":null},{"id":"W4322771875","doi":"10.1158/1538-7445.sabcs22-ot2-16-05","title":"Abstract OT2-16-05: Safety Analyses of NRG BR004: A Randomized, Double-blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-line HER2-Positive Metastatic Breast Cancer (MBC)","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Pertuzumab; Taxane; Metastatic breast cancer; Atezolizumab; Internal medicine; Oncology; Clinical endpoint; Placebo; Trastuzumab; Randomized controlled trial; Breast cancer; Ixabepilone; Interim analysis; Surgery; Cancer; Nivolumab; Pathology","score_opus":0.16414596421967279,"score_gpt":0.48526084246379503,"score_spread":0.3211148782441222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322771875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98166573,0.003095926,0.00050427334,0.003232642,0.000243857,0.008961517,0.0015988455,0.00010738313,0.0005898521],"genre_scores_gemma":[0.9889462,0.0051949234,0.00017367516,0.00006168582,0.00039883514,0.0034988823,0.00020553124,0.00013806866,0.00138219],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99305713,0.0005580283,0.0017591049,0.0010200847,0.002283108,0.0013225523],"domain_scores_gemma":[0.99409026,0.0023363365,0.0007221194,0.0008811377,0.0015499054,0.00042023355],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027658797,0.0006267137,0.0029532826,0.0015702106,0.00021496826,0.000039630748,0.0005210667,0.00019801655,0.0023353887],"category_scores_gemma":[0.00034604655,0.00042804398,0.0004217683,0.0043007075,0.00167154,0.0003122249,0.00017670663,0.0011156744,0.000018389972],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94478816,0.0014006825,0.00006106189,0.0011009749,0.0024659354,0.00053675217,0.0016423623,0.006517139,0.006360568,0.000050993913,0.00018641482,0.03488893],"study_design_scores_gemma":[0.9570276,0.0024564902,0.00041583378,0.0034188249,0.0006229374,0.00014212365,0.0016712296,0.00046962462,0.032871626,0.00011414278,0.0003469142,0.00044266082],"about_ca_topic_score_codex":0.03362893,"about_ca_topic_score_gemma":0.010239569,"teacher_disagreement_score":0.034446273,"about_ca_system_score_codex":0.0024696137,"about_ca_system_score_gemma":0.0038228189,"threshold_uncertainty_score":0.99981713},"labels":[],"label_agreement":null},{"id":"W4322772104","doi":"10.1158/1538-7445.sabcs22-ot1-01-01","title":"Abstract OT1-01-01: A randomised phase II trial of palbociclib and fulvestrant vs standard endocrine therapy in patients with ER positive HER2 negative breast cancer and ctDNA detected molecular relapse during adjuvant endocrine therapy (TRAK-ER)","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Fulvestrant; Palbociclib; Medicine; Oncology; Breast cancer; Internal medicine; Tamoxifen; Cancer; Estrogen receptor; Gynecology; Metastatic breast cancer","score_opus":0.023026925003652506,"score_gpt":0.36025714966292083,"score_spread":0.33723022465926833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322772104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98927844,0.0029481263,0.000008770118,0.0013500258,0.000089908914,0.0053441375,0.0008664076,0.000086866414,0.000027342858],"genre_scores_gemma":[0.9888157,0.0092014875,0.0000785381,0.00007335835,0.00016339497,0.0013938561,0.00005227082,0.00013617774,0.00008521936],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99567676,0.0003206144,0.0006792131,0.00089705846,0.0013416063,0.0010847341],"domain_scores_gemma":[0.99776137,0.0003997228,0.00024260028,0.0004677399,0.00074620405,0.00038236188],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00056502485,0.00050700293,0.0011229359,0.0006401296,0.00024080898,0.00004353309,0.00019357256,0.00010729272,0.00030026503],"category_scores_gemma":[0.00011267165,0.00038213114,0.00011775009,0.0012826691,0.00090397213,0.00029179655,0.00011244798,0.0009251368,0.0000011616462],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7654061,0.0008191662,0.008061619,0.00020214933,0.00071957224,0.00041497248,0.0032814087,0.000059821952,0.14379941,0.0000055442174,0.00001320626,0.07721705],"study_design_scores_gemma":[0.5240258,0.0068354136,0.31228843,0.00090389594,0.000042733183,0.000028763738,0.0004140056,0.00001746452,0.15490593,0.0001143709,0.000084659536,0.00033854067],"about_ca_topic_score_codex":0.0020675822,"about_ca_topic_score_gemma":0.00046134953,"teacher_disagreement_score":0.30422682,"about_ca_system_score_codex":0.00048503917,"about_ca_system_score_gemma":0.00065095007,"threshold_uncertainty_score":0.9998631},"labels":[],"label_agreement":null},{"id":"W4322772114","doi":"10.1158/1538-7445.sabcs22-ot1-03-04","title":"Abstract OT1-03-04: Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators’ choice of chemotherapy in previously-treated, inoperable or metastatic HR+/HER2– breast cancer: TROPION-Breast01","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Metastatic breast cancer; Vinorelbine; Eribulin; Internal medicine; Chemotherapy; Oncology; Breast cancer; Gemcitabine; Cancer","score_opus":0.07280313990434058,"score_gpt":0.42821128420626087,"score_spread":0.3554081443019203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322772114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98257494,0.0040609986,0.000012305415,0.009218251,0.00018462706,0.0027508345,0.0006924819,0.0002505664,0.000255022],"genre_scores_gemma":[0.9852503,0.008520773,0.00040225877,0.0008207526,0.00048823495,0.0017611746,0.00025233135,0.0002569314,0.0022472397],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99309325,0.00056792283,0.0011244488,0.0013264524,0.0018641358,0.0020237681],"domain_scores_gemma":[0.9960551,0.00070573215,0.000321119,0.0013489099,0.0008618649,0.00070721895],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001497059,0.0006987042,0.0015593681,0.0013007984,0.0002541547,0.00011384042,0.0009402231,0.00020733732,0.002909098],"category_scores_gemma":[0.00030939054,0.000563381,0.00021968616,0.005305398,0.00095694105,0.00061175885,0.00017452061,0.0014891076,0.00015487314],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019569699,0.0024633147,0.37010613,0.008425505,0.0019490479,0.0022021516,0.010770665,0.00063499145,0.42100537,0.00028099783,0.013357557,0.14923458],"study_design_scores_gemma":[0.036741473,0.0017874517,0.7128274,0.008836019,0.00039681027,0.0009498221,0.0057122777,0.00061628217,0.13500035,0.0009607819,0.094057545,0.0021137851],"about_ca_topic_score_codex":0.03442941,"about_ca_topic_score_gemma":0.0060344394,"teacher_disagreement_score":0.34272128,"about_ca_system_score_codex":0.0013515115,"about_ca_system_score_gemma":0.0031773627,"threshold_uncertainty_score":0.9996818},"labels":[],"label_agreement":null},{"id":"W4322772140","doi":"10.1158/1538-7445.sabcs22-her2-15","title":"Abstract HER2-15: HER2-15 Retrospective Study to Estimate the Prevalence and Describe the Clinicopathological Characteristics, Treatment Patterns, and Outcomes of HER2-Low Breast Cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Immunohistochemistry; Concordance; Internal medicine; Breast cancer; Trastuzumab; Oncology; Metastatic breast cancer; Cancer","score_opus":0.09410522239188455,"score_gpt":0.47343707429145787,"score_spread":0.3793318518995733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322772140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98593605,0.0013145203,0.0000056356816,0.009212748,0.00018456078,0.0024461558,0.00080021995,0.000069758906,0.000030347835],"genre_scores_gemma":[0.9928884,0.004211296,0.000022515775,0.00023511681,0.00023715022,0.0013172224,0.000006670167,0.000056124212,0.0010255108],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968921,0.00032034045,0.00046256324,0.0007545705,0.00086512655,0.00070533203],"domain_scores_gemma":[0.9978785,0.0005124871,0.00014610442,0.0007377717,0.00047551247,0.00024961602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014694883,0.00032455157,0.0006714619,0.0001312845,0.00035293496,0.00007954263,0.00033044355,0.00007959783,0.0005194903],"category_scores_gemma":[0.0002513596,0.0001701113,0.00008229662,0.00051142287,0.00074383477,0.00009453686,0.00033771122,0.0005788863,0.000022014476],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000987122,0.00036538905,0.9468783,0.00028204196,0.00017600818,0.00010518992,0.0039830455,0.000009016974,0.0008928125,0.000014321891,0.00010455636,0.046202194],"study_design_scores_gemma":[0.001443941,0.0010732323,0.9932605,0.000443303,0.000099747966,0.000037380003,0.0027384935,0.000017928003,0.00039290043,0.000068763155,0.00025773433,0.00016607615],"about_ca_topic_score_codex":0.0033570756,"about_ca_topic_score_gemma":0.0021614383,"teacher_disagreement_score":0.0463822,"about_ca_system_score_codex":0.0005574968,"about_ca_system_score_gemma":0.0002534146,"threshold_uncertainty_score":0.69369376},"labels":[],"label_agreement":null},{"id":"W4322774011","doi":"10.1158/1538-7445.sabcs22-her2-06","title":"Abstract HER2-06: HER2-06 Outcome analysis of HER2-zero or HER2-low hormone receptor-positive (HR+) breast cancer patients - characterization of the molecular phenotype in combination with molecular subtyping","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Breast cancer; Medicine; Oncology; Internal medicine; Cancer; Neoadjuvant therapy; Biomarker; Hormone receptor; Stage (stratigraphy); Trastuzumab; Biopsy; Pathology; Biology","score_opus":0.027486313822030494,"score_gpt":0.35326751890507757,"score_spread":0.3257812050830471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322774011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99565315,0.00034652397,0.0002741402,0.0016034553,0.0000884654,0.001414354,0.0005058687,0.000046281733,0.00006776063],"genre_scores_gemma":[0.99795717,0.00042597004,0.000055681332,0.00015376165,0.000043290027,0.00041140238,0.0005025981,0.000101860154,0.00034829509],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99599826,0.0003315709,0.00072768854,0.0006308487,0.001630966,0.00068069104],"domain_scores_gemma":[0.9970314,0.00013785502,0.00044309362,0.0006597362,0.001571649,0.00015624703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007000396,0.00032471586,0.00081520434,0.00092339475,0.0001253389,0.00002972043,0.00039107027,0.00017786567,0.00033034562],"category_scores_gemma":[0.00011819231,0.00024011989,0.00018908374,0.0062802983,0.0004367084,0.00023782816,0.00015780391,0.000620625,0.0000138891055],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033816653,0.00063446723,0.34818646,0.00050424127,0.0013310262,0.00003347304,0.0016547159,0.0024924895,0.62933785,0.00009115818,0.00003443458,0.01231802],"study_design_scores_gemma":[0.0028833493,0.00027262984,0.9242536,0.000949242,0.00023847392,0.0000013670852,0.0002804913,0.00029337147,0.07043578,0.00003711118,0.00011359792,0.00024098276],"about_ca_topic_score_codex":0.003277661,"about_ca_topic_score_gemma":0.0005261279,"teacher_disagreement_score":0.57606715,"about_ca_system_score_codex":0.0010340454,"about_ca_system_score_gemma":0.0005429728,"threshold_uncertainty_score":0.9791805},"labels":[],"label_agreement":null},{"id":"W4322774367","doi":"10.1158/1538-7445.sabcs22-p1-02-01","title":"Abstract P1-02-01: Comparing the efficacy of aromatase inhibitors vs tamoxifen in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic review and trial-level meta-analysis","year":2023,"lang":"en","type":"review","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada); McGill University Health Centre; Jewish General Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Tamoxifen; Hazard ratio; Meta-analysis; Randomized controlled trial; Population; Gynecology; Cancer; Confidence interval","score_opus":0.30001612865526334,"score_gpt":0.4709470240388539,"score_spread":0.17093089538359058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322774367","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031188605,0.9740133,0.0000030256376,0.00096056185,0.0001075335,0.01524543,0.0064508202,0.00007332587,0.00002711426],"genre_scores_gemma":[0.010523122,0.9774673,0.00004483735,0.00007056093,0.00039861005,0.010490763,0.00036385987,0.00024136595,0.00039956952],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9885633,0.003063868,0.0034551623,0.0015297366,0.0021651688,0.001222781],"domain_scores_gemma":[0.9903311,0.0045398325,0.0021188424,0.0015842242,0.0009344421,0.0004915708],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0048071085,0.0011526314,0.0143912565,0.0016535774,0.00037301058,0.00012686185,0.0010634369,0.00041284336,0.000875379],"category_scores_gemma":[0.0013133786,0.0007131563,0.002594414,0.005674301,0.0010107536,0.00031988192,0.00049659057,0.0026049253,0.000061384104],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004023718,0.0003785086,0.00006437499,0.83436257,0.14971283,0.000057328798,0.0011921065,0.000005366615,0.00009001542,0.000039278253,0.0010806205,0.008993306],"study_design_scores_gemma":[0.018310443,0.0008074786,0.0073786103,0.5257345,0.44189146,0.000060033453,0.00043772033,0.0000030123108,0.0001982771,0.000055543915,0.003163684,0.0019592165],"about_ca_topic_score_codex":0.010746417,"about_ca_topic_score_gemma":0.00086359197,"teacher_disagreement_score":0.30862805,"about_ca_system_score_codex":0.0019008056,"about_ca_system_score_gemma":0.0012417124,"threshold_uncertainty_score":0.9996961},"labels":[],"label_agreement":null},{"id":"W4322774598","doi":"10.1158/1538-7445.sabcs22-p4-09-12","title":"Abstract P4-09-12: Baseline and End-of-Treatment Biomarkers in Patients With PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From BYLieve Study Cohorts A and B","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Fulvestrant; Internal medicine; Oncology; Letrozole; Biomarker; Cancer; Breast cancer; Aromatase inhibitor; Cohort; Hazard ratio; Cancer research; Estrogen receptor; Biology; Confidence interval; Aromatase; Genetics","score_opus":0.034773631021361856,"score_gpt":0.3609850733321113,"score_spread":0.3262114423107494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322774598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99054754,0.001430706,0.0000051409743,0.00070470467,0.000085004576,0.0033149766,0.0037788749,0.000075337244,0.000057692392],"genre_scores_gemma":[0.9961656,0.0016613669,0.0003070235,0.00003368839,0.00012439431,0.001157536,0.00034616838,0.00010961055,0.00009461762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962465,0.00033595154,0.0005619695,0.0010605793,0.0009399859,0.0008549996],"domain_scores_gemma":[0.9975564,0.0006619407,0.00021925934,0.000397452,0.0007516335,0.00041330623],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004710117,0.00047621215,0.00089132757,0.0005824246,0.00023397758,0.000037523707,0.00014915502,0.00012531619,0.00062111],"category_scores_gemma":[0.00009994865,0.0003747846,0.000055492623,0.0010664192,0.00074438093,0.00036329526,0.00015220759,0.0004961952,0.000007735051],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01663383,0.0010139964,0.80496836,0.00011131674,0.0014241388,0.00007402144,0.004772804,0.000034251687,0.046684023,0.00000267163,0.00012903921,0.12415155],"study_design_scores_gemma":[0.018736161,0.0025465938,0.9640406,0.00068889663,0.000077930505,0.0000026515231,0.0021371858,0.000020559075,0.011259965,0.000035224406,0.00009806373,0.00035618077],"about_ca_topic_score_codex":0.022976859,"about_ca_topic_score_gemma":0.0035263987,"teacher_disagreement_score":0.15907222,"about_ca_system_score_codex":0.001512204,"about_ca_system_score_gemma":0.00049858104,"threshold_uncertainty_score":0.9998704},"labels":[],"label_agreement":null},{"id":"W4322774660","doi":"10.1158/1538-7445.sabcs22-p3-02-02","title":"Abstract P3-02-02: Real-World Time-to-Treatment Discontinuation in Hormone-Receptor-Positive Metastatic Breast Cancer Patients following CDK4/6 Inhibitor Treatment, Based on Observational Data Collected Through Patient-Partnered Research","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Discontinuation; Regimen; Medicine; Metastatic breast cancer; Breast cancer; Internal medicine; Medical record; Oncology; Observational study; Cancer; Cohort","score_opus":0.22782759749489598,"score_gpt":0.4755263896598825,"score_spread":0.2476987921649865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322774660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802502,0.00039034322,0.000007003149,0.006226706,0.0002596796,0.0052842447,0.0062194974,0.00015734263,0.0012050173],"genre_scores_gemma":[0.9790326,0.00051673135,0.00045740776,0.00019934127,0.00046640326,0.0058701425,0.0072722556,0.00018939291,0.0059957616],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9923704,0.00079514453,0.00080869667,0.0015500681,0.0028585724,0.0016170868],"domain_scores_gemma":[0.99530226,0.0015599971,0.00017867253,0.0012493961,0.0012694205,0.00044023222],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011472448,0.00053427496,0.00083190895,0.0014891183,0.0006206721,0.00014529807,0.00048509808,0.00012384231,0.0012252366],"category_scores_gemma":[0.00037870195,0.00044760722,0.00016512685,0.006125784,0.0002715261,0.00070269546,0.0002680278,0.0006512368,0.00063009094],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06597602,0.016243579,0.17737135,0.00038058747,0.004099212,0.0008405821,0.016575063,0.012476584,0.1893162,0.00012215789,0.08038054,0.43621814],"study_design_scores_gemma":[0.022211207,0.0066105938,0.9165721,0.003283782,0.00016591199,0.000001865727,0.0011909816,0.0056364266,0.022815797,0.0001335885,0.02042477,0.0009529564],"about_ca_topic_score_codex":0.014427866,"about_ca_topic_score_gemma":0.0059660655,"teacher_disagreement_score":0.7392008,"about_ca_system_score_codex":0.00968344,"about_ca_system_score_gemma":0.0027793716,"threshold_uncertainty_score":0.9997976},"labels":[],"label_agreement":null},{"id":"W4322774773","doi":"10.1158/1538-7445.sabcs22-p4-01-42","title":"Abstract P4-01-42: Pooled analysis of post-progression treatments after first-line ribociclib + endocrine therapy in patients with HR+/HER2− advanced breast cancer in the MONALEESA-2, -3, and -7 studies","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Oncology; Cancer; Propensity score matching; Adjuvant therapy; Targeted therapy; Randomized controlled trial","score_opus":0.04679614256199177,"score_gpt":0.43014768948204934,"score_spread":0.3833515469200576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322774773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792744,0.014632352,7.534545e-7,0.0040403507,0.000043912616,0.0014710082,0.00048741634,0.000031634554,0.000018209661],"genre_scores_gemma":[0.9836672,0.013790164,0.000042716147,0.00016424707,0.00006562582,0.0020070288,0.00008253346,0.000052074935,0.00012840409],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99682933,0.00016783897,0.00046275381,0.00061669416,0.0011875144,0.00073589553],"domain_scores_gemma":[0.99814874,0.00038919778,0.00014622972,0.0005019686,0.000693077,0.00012077427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005152065,0.00031840132,0.0007847037,0.0010645419,0.00011785082,0.0000213054,0.0002220771,0.00006994952,0.0002827014],"category_scores_gemma":[0.000058961585,0.00018509636,0.00010226506,0.0037913525,0.0004427245,0.00022950202,0.00011190789,0.00046837394,0.0000036920935],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014669141,0.0005363039,0.8062891,0.00017745247,0.0016876599,0.000114084934,0.0029041409,0.0008562667,0.0013802573,0.0000029675177,0.000013467504,0.17136917],"study_design_scores_gemma":[0.009656874,0.0007511919,0.9859512,0.0008842396,0.00023379347,0.0000024469173,0.0012875316,0.00006319381,0.0007849696,0.000046653164,0.00016427081,0.00017364463],"about_ca_topic_score_codex":0.0016159372,"about_ca_topic_score_gemma":0.007237524,"teacher_disagreement_score":0.17966211,"about_ca_system_score_codex":0.0005554004,"about_ca_system_score_gemma":0.00018581105,"threshold_uncertainty_score":0.7548011},"labels":[],"label_agreement":null},{"id":"W4322774970","doi":"10.1158/1538-7445.sabcs22-pd13-06","title":"Abstract PD13-06: PD13-06 Long-Term and Very-Long-Term Disease Control in Patients From BYLieve Study Cohort A With PIK3CA-Mutant, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Advanced Breast Cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Fulvestrant; Medicine; Internal medicine; Cohort; Oncology; Population; Hazard ratio; Cancer; Breast cancer; Adverse effect; Gastroenterology; Estrogen receptor; Confidence interval","score_opus":0.0275034566686928,"score_gpt":0.3540003620675184,"score_spread":0.3264969053988256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322774970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98414844,0.001843295,0.000023954019,0.0009716298,0.00020505696,0.006444731,0.0060757874,0.00022994455,0.00005714438],"genre_scores_gemma":[0.99277496,0.0013686839,0.0000434253,0.00021211489,0.0005679028,0.0034172554,0.0008522108,0.00027189928,0.00049154006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923449,0.000549923,0.0009299889,0.0019740353,0.0023114032,0.0018897589],"domain_scores_gemma":[0.99540883,0.00068905676,0.00036726423,0.00095082575,0.0013687778,0.0012152697],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006192245,0.0008938578,0.0014666658,0.0007976505,0.0005722904,0.00016386222,0.0005603213,0.00022481037,0.001542315],"category_scores_gemma":[0.00020135399,0.0007697782,0.00015394558,0.0016942753,0.0009988026,0.000944969,0.0003189401,0.0016235233,0.00012421656],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020408187,0.0012895751,0.9328421,0.0002830054,0.0010792946,0.0004426458,0.0017568204,0.000032422442,0.026296766,0.0000033081387,0.0003353995,0.015230496],"study_design_scores_gemma":[0.025780888,0.0011404245,0.9682932,0.0014912458,0.00018212636,0.0000049877563,0.00046200372,0.0000108042905,0.0017732154,0.000029857507,0.000033737975,0.0007975429],"about_ca_topic_score_codex":0.0030295649,"about_ca_topic_score_gemma":0.001981514,"teacher_disagreement_score":0.035451084,"about_ca_system_score_codex":0.002273749,"about_ca_system_score_gemma":0.00090670265,"threshold_uncertainty_score":0.9994753},"labels":[],"label_agreement":null},{"id":"W4322775130","doi":"10.1158/1538-7445.sabcs22-p4-03-30","title":"Abstract P4-03-30: Patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"","keywords":"Capecitabine; Medicine; Metastatic breast cancer; Internal medicine; Breast cancer; Oncology; Cancer; Colorectal cancer","score_opus":0.11628946331537403,"score_gpt":0.4670810383718094,"score_spread":0.3507915750564354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322775130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925943,0.0006531898,0.000002359042,0.0037870612,0.00015887278,0.0014093989,0.0012618132,0.000081928476,0.000051049632],"genre_scores_gemma":[0.9906826,0.0069302274,0.000023192451,0.00039497102,0.00015738806,0.001177803,0.00014775914,0.00008895705,0.000397075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99684227,0.00031273335,0.00056111853,0.000671176,0.0007806072,0.0008320878],"domain_scores_gemma":[0.9979017,0.00075909233,0.00018075272,0.0003770031,0.0004679015,0.00031359345],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000709227,0.00033042792,0.00080551463,0.00030506146,0.00014176822,0.000054964403,0.00013044884,0.000100638674,0.000945706],"category_scores_gemma":[0.00011935645,0.00022537787,0.0001014605,0.00062362093,0.0003837419,0.00011963845,0.00006448673,0.0006117804,0.000045511828],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013174986,0.0006088208,0.73274714,0.00004923328,0.00075951027,0.00025749634,0.0013828514,0.0000068646787,0.00026097454,0.000003921558,0.0000642007,0.26254147],"study_design_scores_gemma":[0.00542611,0.0012360548,0.9903715,0.0008575844,0.00005180982,0.000012829856,0.000875094,0.000028214316,0.000426821,0.000028805527,0.0004557217,0.00022945303],"about_ca_topic_score_codex":0.008509659,"about_ca_topic_score_gemma":0.0036262164,"teacher_disagreement_score":0.26231202,"about_ca_system_score_codex":0.0012903517,"about_ca_system_score_gemma":0.0007624097,"threshold_uncertainty_score":0.9999676},"labels":[],"label_agreement":null},{"id":"W4322775169","doi":"10.1158/1538-7445.sabcs22-pd11-09","title":"Abstract PD11-09: PD11-09 Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Sherbrooke; London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Internal medicine; Oncology; Triple-negative breast cancer; Tolerability; Cancer; Breast cancer; Adverse effect","score_opus":0.11298569127230479,"score_gpt":0.46541165906745285,"score_spread":0.35242596779514807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322775169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94549465,0.003607592,0.00034590805,0.011886025,0.00078778365,0.012124429,0.024771765,0.0006392801,0.00034258876],"genre_scores_gemma":[0.9696946,0.0037307618,0.00084229314,0.00023544308,0.0011733755,0.011984522,0.0027520754,0.00043817097,0.009148752],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9896407,0.00051553285,0.0016928668,0.0027446458,0.0025550618,0.002851208],"domain_scores_gemma":[0.99150527,0.0021747577,0.00056892936,0.0022254423,0.0023232005,0.0012024335],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016880493,0.0011721408,0.0019430363,0.0011103993,0.0011851179,0.00023230002,0.0010142437,0.0002755509,0.0023901367],"category_scores_gemma":[0.0011061162,0.0010128589,0.00040846822,0.0037556454,0.000774245,0.00079160783,0.0003869086,0.0013235663,0.00047990098],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21395047,0.016398452,0.0021260353,0.00090628694,0.0078004263,0.0030211147,0.013035951,0.007198283,0.031679973,0.000074506184,0.013127832,0.6906807],"study_design_scores_gemma":[0.6058969,0.030857371,0.042049915,0.0062543876,0.0027237893,0.00036697157,0.037992004,0.008471557,0.115661465,0.009982748,0.13481715,0.004925736],"about_ca_topic_score_codex":0.03908156,"about_ca_topic_score_gemma":0.024895715,"teacher_disagreement_score":0.68575495,"about_ca_system_score_codex":0.0047204616,"about_ca_system_score_gemma":0.0043946397,"threshold_uncertainty_score":0.9992322},"labels":[],"label_agreement":null},{"id":"W4322775479","doi":"10.1158/1538-7445.sabcs22-pd17-08","title":"Abstract PD17-08: Pooled gene expression analysis and association with treatment response in patients with HR+/HER2− advanced breast cancer in the MONALEESA-2, -3, and -7 trials","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Cancer; Cyclin-dependent kinase 6; Metastatic breast cancer; Progression-free survival; Gene expression; Gene; Palbociclib; Bioinformatics; Cyclin D1; Biology; Overall survival; Cell cycle; Genetics","score_opus":0.0491737236380621,"score_gpt":0.4054284037579695,"score_spread":0.3562546801199074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322775479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933321,0.0013517668,0.0000065907725,0.0034843134,0.000021124626,0.0014364895,0.00032315322,0.000026544136,0.00001793522],"genre_scores_gemma":[0.9965306,0.0015207932,0.00009927581,0.00006550755,0.00008160986,0.0012693551,0.000051689447,0.000035918416,0.00034523927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99667233,0.00076667615,0.00036555273,0.00054675236,0.0010814399,0.00056725624],"domain_scores_gemma":[0.99783915,0.0011855067,0.00018567564,0.00034614088,0.0003092758,0.0001342542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028756075,0.00022756447,0.0006714184,0.0007995483,0.00013929103,0.00005196795,0.00010733034,0.00010206608,0.00012625137],"category_scores_gemma":[0.00020077483,0.00012742533,0.000050706505,0.0024661664,0.00013212209,0.00019816606,0.0000415413,0.00036846142,0.0000028796383],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047321483,0.00019979662,0.8788164,0.000044248092,0.00053505274,0.000054183118,0.001994986,0.0011848898,0.019132312,9.3613636e-7,0.000024043457,0.050691616],"study_design_scores_gemma":[0.011276397,0.00059693935,0.9820651,0.00035638252,0.00019111714,0.000002291586,0.0008312302,0.00004155191,0.004248265,0.000020370671,0.00022509534,0.00014527295],"about_ca_topic_score_codex":0.001838001,"about_ca_topic_score_gemma":0.0029670147,"teacher_disagreement_score":0.10324863,"about_ca_system_score_codex":0.0016373477,"about_ca_system_score_gemma":0.0004028616,"threshold_uncertainty_score":0.5196254},"labels":[],"label_agreement":null},{"id":"W4322775512","doi":"10.1158/1538-7445.sabcs22-p5-02-14","title":"Abstract P5-02-14: Identification of mechanisms of acquired resistance to ribociclib plus endocrine therapy using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Oncology; Cancer","score_opus":0.2759882814859952,"score_gpt":0.47739272994277016,"score_spread":0.20140444845677496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322775512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919433,0.00473073,0.0006242416,0.0010209535,0.00003988145,0.0013950375,0.00021903244,0.000013423577,0.00001338149],"genre_scores_gemma":[0.9971616,0.0014058085,0.00097500684,0.000026328287,0.000075302945,0.0002426143,0.000021556947,0.00002749774,0.00006428477],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99761933,0.00036027483,0.0007553549,0.00033572718,0.00061275676,0.00031655558],"domain_scores_gemma":[0.9974238,0.0015043742,0.00029327115,0.00037069118,0.0003352286,0.00007260456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036952794,0.0001429296,0.00060398947,0.0003688858,0.000080492,0.000015177639,0.00013449237,0.000034134864,0.000051077648],"category_scores_gemma":[0.00072234205,0.0001023909,0.00006235719,0.0008177836,0.00023259025,0.00008477027,0.000050828494,0.000084,4.604183e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018151915,0.000057028403,0.0014574926,0.00038585122,0.00009003213,0.000015044589,0.002347489,0.0004072764,0.9625429,0.0004329468,0.000007787083,0.03044096],"study_design_scores_gemma":[0.004890579,0.000336734,0.08008513,0.0009434103,0.000042875654,0.00001364815,0.0033418117,0.00045080468,0.90451163,0.004872831,0.00037901616,0.00013154869],"about_ca_topic_score_codex":0.0012957155,"about_ca_topic_score_gemma":0.00028085333,"teacher_disagreement_score":0.07862764,"about_ca_system_score_codex":0.0003115489,"about_ca_system_score_gemma":0.00039330786,"threshold_uncertainty_score":0.41753796},"labels":[],"label_agreement":null},{"id":"W4322775514","doi":"10.1158/1538-7445.sabcs22-p3-01-03","title":"Abstract P3-01-03: Characterization of neutropenia in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer on palbociclib in a real-world setting: Results from POLARIS","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Palbociclib; Medicine; Fulvestrant; Neutropenia; Febrile neutropenia; Internal medicine; Breast cancer; Adverse effect; Cancer; Oncology; Aromatase inhibitor; Metastatic breast cancer; Estrogen receptor; Chemotherapy; Aromatase","score_opus":0.03499175233405395,"score_gpt":0.3568053691348744,"score_spread":0.32181361680082043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322775514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873933,0.00008884052,0.000002681608,0.003336697,0.00015538528,0.0021186126,0.006456815,0.00010739188,0.0003402523],"genre_scores_gemma":[0.99533534,0.0009068749,0.0001503172,0.00014302395,0.00033782996,0.0006234546,0.0018880824,0.00016513735,0.00044993],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9947756,0.00045144523,0.0010066574,0.001170608,0.0014402617,0.0011554614],"domain_scores_gemma":[0.9969798,0.0006027236,0.0005250807,0.0006172535,0.0009566218,0.00031853173],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006496667,0.00048762184,0.0009254887,0.0011816663,0.00018881403,0.00004613702,0.00037343943,0.00020140436,0.0007170348],"category_scores_gemma":[0.00020759717,0.00042814217,0.00009226966,0.003061795,0.0004076981,0.00064420654,0.0001536217,0.0014257026,0.00006133782],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058754984,0.0007402971,0.40384793,0.00019675172,0.00023954647,0.000050198774,0.0057045785,0.00013326001,0.48335135,0.000032093696,0.00028753476,0.046661474],"study_design_scores_gemma":[0.0136695,0.0007240431,0.944153,0.0019390828,0.00001531081,3.8864658e-7,0.00037489884,0.000022416212,0.038469825,0.000043550222,0.0002019738,0.00038601801],"about_ca_topic_score_codex":0.021664158,"about_ca_topic_score_gemma":0.0056153527,"teacher_disagreement_score":0.5403051,"about_ca_system_score_codex":0.002260127,"about_ca_system_score_gemma":0.00055097445,"threshold_uncertainty_score":0.999817},"labels":[],"label_agreement":null},{"id":"W4323050795","doi":"10.1158/1538-7445.sabcs22-p3-07-14","title":"Abstract P3-07-14: A phase II study of CFI-400945 in patients with advanced/metastatic cancer: Canadian Cancer Trials Group (CCTG) IND.237","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Sunnybrook Health Science Centre; Health Sciences Centre; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer; Internal medicine; Oncology; Breast cancer; Taxane; PTEN; Neutropenia; Cohort; Metastatic breast cancer; Chemotherapy","score_opus":0.15451503812154424,"score_gpt":0.49154997275969453,"score_spread":0.33703493463815026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323050795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880175,0.0035647594,0.0000049057066,0.0011476844,0.0004280161,0.0053187837,0.0012816099,0.000088381996,0.00014836018],"genre_scores_gemma":[0.9922545,0.0013306456,0.00009373636,0.00015774865,0.00028443986,0.004877385,0.00013106814,0.0001674944,0.0007029639],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99328965,0.0004894721,0.0012025059,0.00105185,0.002182394,0.0017841317],"domain_scores_gemma":[0.996089,0.00049855834,0.00042122044,0.0009224368,0.0012389594,0.0008298642],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026064627,0.00050392625,0.0016118686,0.0018971987,0.0003795212,0.000043328313,0.00054895703,0.00014194245,0.0018936733],"category_scores_gemma":[0.00052621047,0.00041312413,0.000120274264,0.004039265,0.00040069866,0.00042391464,0.00016976954,0.0012358356,0.000037701957],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02648998,0.004892707,0.23678258,0.0012008965,0.001568498,0.00051827455,0.010843016,0.0035438144,0.0068676346,0.000036174002,0.0033060592,0.70395035],"study_design_scores_gemma":[0.120348945,0.018689416,0.8165503,0.00494861,0.0004411965,0.0000057960556,0.011510979,0.00011647315,0.0038821425,0.0004038108,0.021720568,0.0013817486],"about_ca_topic_score_codex":0.25038227,"about_ca_topic_score_gemma":0.4676882,"teacher_disagreement_score":0.7025686,"about_ca_system_score_codex":0.0028763183,"about_ca_system_score_gemma":0.004096968,"threshold_uncertainty_score":0.99983203},"labels":[],"label_agreement":null},{"id":"W4323312545","doi":"10.3390/curroncol30030233","title":"Ki67 in Breast Cancer Assay: An Ad Hoc Testing Recommendation from the Canadian Association of Pathologists Task Force","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University Health Network; Nova Scotia Health Authority; Sunnybrook Health Science Centre; St. Michael's Hospital","funders":"","keywords":"Medicine; Breast cancer; Context (archaeology); Internal medicine; Oncology; Clinical trial; Guideline; Disease; Cancer; Task force; Adjuvant therapy; Family medicine; Gynecology; Pathology","score_opus":0.11814876663736101,"score_gpt":0.41595373633663346,"score_spread":0.29780496969927245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323312545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9595478,0.00085071515,0.00009739304,0.03601583,0.0016602516,0.0005296083,0.0008150896,0.00009898757,0.00038428206],"genre_scores_gemma":[0.99770534,0.00029495062,0.0003015487,0.0005720759,0.00034732543,0.00013390249,0.000559772,0.000020675323,0.000064392625],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987411,0.0002647092,0.00028354733,0.0002400022,0.00014169446,0.00032895443],"domain_scores_gemma":[0.9986909,0.00055289496,0.00026780026,0.00017261127,0.00021391612,0.000101881764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007547815,0.00011145961,0.00027103987,0.00013208807,0.0000873071,0.0000077578825,0.00010796533,0.00013835503,0.00012369934],"category_scores_gemma":[0.000483463,0.0000909533,0.00003229688,0.0005183097,0.00006105332,0.00010012694,0.00003152355,0.00032854013,0.000016379776],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060210707,0.000047326666,0.45328817,0.0000105311465,0.000015932788,0.0000057482403,0.0007964388,0.000039597286,0.00087404,0.000009522241,0.0006468506,0.5442056],"study_design_scores_gemma":[0.0013464736,0.00011866752,0.9422079,0.00012298423,0.000040783205,0.000011392685,0.00048642483,0.001403294,0.00003810111,0.0005796906,0.053551152,0.00009314488],"about_ca_topic_score_codex":0.02892205,"about_ca_topic_score_gemma":0.45865068,"teacher_disagreement_score":0.5441125,"about_ca_system_score_codex":0.0025781726,"about_ca_system_score_gemma":0.0007953212,"threshold_uncertainty_score":0.9775444},"labels":[],"label_agreement":null},{"id":"W4361204681","doi":"10.3390/cancers15072015","title":"Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer","year":2023,"lang":"en","type":"review","venue":"Cancers","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Fulvestrant; Exemestane; Metastatic breast cancer; Medicine; Everolimus; Oncology; Internal medicine; Palbociclib; Breast cancer; Cancer; Estrogen receptor; Clinical trial; Tamoxifen","score_opus":0.09731471734959683,"score_gpt":0.3832936032639684,"score_spread":0.28597888591437154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361204681","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000082990366,0.98390406,0.00033072088,0.000887413,0.0005504254,0.0038394078,0.010271621,0.00011526484,0.000018064324],"genre_scores_gemma":[0.00007864143,0.98284763,0.0015727817,0.00023128965,0.0012204136,0.012111973,0.00052262546,0.00016258696,0.001252053],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99787396,0.00006982713,0.00056737586,0.00072619657,0.00018469815,0.0005779613],"domain_scores_gemma":[0.99837124,0.00048523158,0.00037487564,0.00041291045,0.00016653724,0.00018919597],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013236358,0.00068660505,0.0017073863,0.00018775264,0.0001970436,0.00003787696,0.00013448084,0.00012567862,0.00010116714],"category_scores_gemma":[0.000038931186,0.00039416968,0.00052443595,0.0004666543,0.00033701424,0.000087857945,0.00006314897,0.00028412353,0.000020703854],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005688252,0.00004760286,0.0000042359798,0.0044567343,0.0029560558,0.00002132178,0.00035897642,0.000062815736,0.00008182565,0.00007548831,0.000479793,0.99088633],"study_design_scores_gemma":[0.002221581,0.00053530996,0.000046270034,0.012864773,0.0045945384,0.0003418791,0.00038082423,0.00003622735,0.000020561192,0.000053271848,0.97836745,0.000537323],"about_ca_topic_score_codex":0.00050886854,"about_ca_topic_score_gemma":0.0001111313,"teacher_disagreement_score":0.990349,"about_ca_system_score_codex":0.0043586898,"about_ca_system_score_gemma":0.0012349876,"threshold_uncertainty_score":0.99985105},"labels":[],"label_agreement":null},{"id":"W4361817471","doi":"10.1158/1078-0432.c.6530853","title":"Data from Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Discontinuation; Medicine; Regimen; Internal medicine; Gastroenterology","score_opus":0.0942066740050742,"score_gpt":0.359705631009887,"score_spread":0.2654989570048128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361817471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9589306,0.0011610951,0.0034418255,0.000095736876,0.0001070013,0.006998471,0.029185804,0.000075103715,0.000004335187],"genre_scores_gemma":[0.9735507,0.00012473977,0.0049958206,0.0000093984645,0.00009050487,0.00025751218,0.020727333,0.00011095143,0.00013308847],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99661255,0.00014023721,0.0011397508,0.0012204773,0.0005703347,0.00031666414],"domain_scores_gemma":[0.99514157,0.0013981323,0.0013199731,0.0015566585,0.00045015194,0.00013353731],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017152562,0.0006398161,0.0016693098,0.00013213184,0.000091136615,0.000025871854,0.00037256145,0.00017446064,0.00007577979],"category_scores_gemma":[0.00013289356,0.0003122094,0.00007437088,0.00018711603,0.00042958444,0.00009125466,0.0003541001,0.00023714044,2.3139395e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.384213,0.042111825,0.40092027,0.0018633254,0.03796522,0.00007642193,0.045222275,0.00025250379,0.0023631032,0.0000034276945,0.000300025,0.084708594],"study_design_scores_gemma":[0.33632553,0.04145375,0.48258293,0.004953748,0.015170986,0.000003593238,0.017916374,0.016672207,0.082903355,0.0002695246,0.00028891955,0.0014590843],"about_ca_topic_score_codex":0.0034176651,"about_ca_topic_score_gemma":0.0019578373,"teacher_disagreement_score":0.08324951,"about_ca_system_score_codex":0.0000683952,"about_ca_system_score_gemma":0.00021437657,"threshold_uncertainty_score":0.999933},"labels":[],"label_agreement":null},{"id":"W4361953411","doi":"10.1158/1078-0432.c.6529767.v1","title":"Data from Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR&lt;sup&gt;+&lt;/sup&gt;, HER2&lt;sup&gt;−&lt;/sup&gt; Advanced Breast Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Everolimus; Exemestane; Internal medicine; Tolerability; Breast cancer; Adverse effect; Oncology; Cancer; Gastroenterology; Aromatase","score_opus":0.028605135683123905,"score_gpt":0.31995296184845406,"score_spread":0.29134782616533017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361953411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9753703,0.0022033735,0.002310017,0.00279886,0.00063752924,0.007830229,0.007916881,0.0006006919,0.00033210625],"genre_scores_gemma":[0.9748542,0.002518013,0.0073130187,0.00044197086,0.0008010177,0.0019624468,0.010069428,0.000617045,0.0014228753],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98792857,0.0006587225,0.002919679,0.0038514445,0.0027464258,0.0018951666],"domain_scores_gemma":[0.99186563,0.00080326776,0.001767546,0.003687601,0.0010408255,0.0008351075],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0015458406,0.0021167416,0.0038431268,0.0015216104,0.00024114455,0.00017907283,0.0013877691,0.0011348862,0.00097101677],"category_scores_gemma":[0.0002708484,0.001809256,0.00016299615,0.0020323189,0.0008692048,0.0017700053,0.0015723958,0.0020283996,0.000030901596],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6724428,0.011829516,0.012787018,0.0028066076,0.0036288647,0.0014265674,0.013650067,0.038113706,0.048303563,0.00044590855,0.0010046542,0.19356072],"study_design_scores_gemma":[0.6697718,0.018248798,0.20864947,0.015210102,0.002239685,0.0005832768,0.0057648527,0.058428247,0.001821773,0.0049334797,0.007846504,0.006502015],"about_ca_topic_score_codex":0.0034925118,"about_ca_topic_score_gemma":0.010254425,"teacher_disagreement_score":0.19586246,"about_ca_system_score_codex":0.0026709477,"about_ca_system_score_gemma":0.002208966,"threshold_uncertainty_score":0.99994224},"labels":[],"label_agreement":null},{"id":"W4361958415","doi":"10.1158/1078-0432.c.6531065.v1","title":"Data from Natural History and Characteristics of &lt;i&gt;ERBB2&lt;/i&gt;-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy; National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation; Unicancer; Vanderbilt University; Institut Gustave-Roussy; Puma Biotechnology; Princess Margaret Cancer Foundation; Memorial Sloan-Kettering Cancer Center; University of Texas MD Anderson Cancer Center; Cancer Prevention and Research Institute of Texas; American Association for Cancer Research","keywords":"Breast cancer; Cancer; Medicine; Internal medicine; Metastatic breast cancer; Oncology; Endocrinology","score_opus":0.04720821073975694,"score_gpt":0.31361267979538016,"score_spread":0.2664044690556232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361958415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68770766,0.031134935,0.0074913334,0.00045734833,0.00262147,0.006293043,0.26376536,0.0004909884,0.000037847873],"genre_scores_gemma":[0.971014,0.0014541725,0.01306118,0.00016969813,0.0008792206,0.00064410677,0.011873023,0.00020134839,0.0007032417],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9939013,0.0004556935,0.0014237963,0.002444471,0.0011183686,0.0006563463],"domain_scores_gemma":[0.99475944,0.00055407383,0.0012835276,0.0019293171,0.0011703443,0.0003033189],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005411351,0.0011868405,0.002772471,0.00044999033,0.00020546261,0.000054770964,0.00067999266,0.0003525231,0.0004553226],"category_scores_gemma":[0.00038397437,0.0010166891,0.00025400647,0.00034072303,0.0008810585,0.00041539563,0.0013361516,0.001516953,0.000023947705],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07252108,0.015047228,0.07511255,0.0018700779,0.14013818,0.032666795,0.045989085,0.00043774993,0.5063272,0.0003730445,0.0129565075,0.09656048],"study_design_scores_gemma":[0.020255284,0.0006540019,0.94998693,0.0013432554,0.00752016,0.0008921853,0.0015327442,0.014669089,0.00019080455,0.00014947927,0.0012580698,0.0015479873],"about_ca_topic_score_codex":0.01690444,"about_ca_topic_score_gemma":0.00822542,"teacher_disagreement_score":0.8748744,"about_ca_system_score_codex":0.0041225813,"about_ca_system_score_gemma":0.0024849463,"threshold_uncertainty_score":0.9997004},"labels":[],"label_agreement":null},{"id":"W4361959406","doi":"10.1158/1078-0432.c.6529556","title":"Data from Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Hazard ratio; Internal medicine; Metastatic breast cancer; Breast cancer; Chemotherapy; Population; Oncology; Gastroenterology; Confidence interval; Cancer; Gynecology","score_opus":0.026917428408831514,"score_gpt":0.2995488053940495,"score_spread":0.272631376985218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361959406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66579336,0.00111844,0.0011959908,0.0012813649,0.0002600232,0.0013816021,0.32885706,0.00010918941,0.0000029535704],"genre_scores_gemma":[0.8032108,0.0048492714,0.005348806,0.0007125746,0.00024963016,0.00057419535,0.18395352,0.00030380255,0.00079740764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99654925,0.00017345097,0.00069372175,0.0015058254,0.0005443536,0.0005333783],"domain_scores_gemma":[0.9973058,0.00032834586,0.00045391507,0.0013946961,0.00019173903,0.00032548362],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011616536,0.00080170354,0.0016557086,0.00014870243,0.000044075245,0.00007321549,0.00027529872,0.0001632999,0.0006570065],"category_scores_gemma":[0.000038065507,0.0005571038,0.00006440469,0.0001028388,0.00012154876,0.00018786502,0.00051713944,0.000443453,0.000029387513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035594676,0.0009573185,0.94654137,0.00011049861,0.0033338547,0.00004487642,0.0006475139,0.000009428547,0.00006580457,3.3499333e-7,0.00049494853,0.044234585],"study_design_scores_gemma":[0.008690067,0.0003628147,0.9865487,0.0013397337,0.00094452687,9.798229e-7,0.0005991772,0.00027452706,0.000052223284,0.00001862802,0.00059481733,0.0005737676],"about_ca_topic_score_codex":0.1293229,"about_ca_topic_score_gemma":0.0076878867,"teacher_disagreement_score":0.14490354,"about_ca_system_score_codex":0.0011138838,"about_ca_system_score_gemma":0.00027892963,"threshold_uncertainty_score":0.999688},"labels":[],"label_agreement":null},{"id":"W4361959809","doi":"10.1158/1078-0432.c.6529533","title":"Data from A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Astellas Pharma; Pfizer","keywords":"Enzalutamide; Medicine; Cohort; Exemestane; Internal medicine; Population; Breast cancer; Placebo; Clinical endpoint; Oncology; Gastroenterology; Endocrinology; Prostate cancer; Cancer; Randomized controlled trial; Androgen receptor; Aromatase; Pathology","score_opus":0.0627104037941062,"score_gpt":0.38427953527354364,"score_spread":0.32156913147943744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361959809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9497958,0.0008860104,0.005831082,0.0011350642,0.000664946,0.031355668,0.009716147,0.0004451957,0.00017008017],"genre_scores_gemma":[0.9232367,0.00051655155,0.03616221,0.0006777129,0.0017301803,0.014230308,0.0169083,0.00066642393,0.005871595],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99249697,0.00095061614,0.0016891374,0.0021922102,0.0018523075,0.00081877905],"domain_scores_gemma":[0.99327636,0.0017996081,0.0015491802,0.0021277328,0.0009022701,0.00034483115],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002049508,0.0012098909,0.0059004775,0.00040282417,0.0001716176,0.000092696,0.0007037619,0.0004084358,0.001202363],"category_scores_gemma":[0.00084423035,0.00068402,0.00022201329,0.000494515,0.00047099873,0.0003568851,0.0010701382,0.001438501,0.000017160028],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97565603,0.0019282722,0.00093664357,0.000090624926,0.0053761904,0.00006495998,0.0013376855,0.00037328337,0.00017836114,0.0000024602516,0.00017207519,0.013883396],"study_design_scores_gemma":[0.97203416,0.006262832,0.0011699115,0.0042365524,0.0035569668,0.000011088296,0.0005155538,0.0111482395,0.000037037742,0.00006312771,0.000039608967,0.00092495134],"about_ca_topic_score_codex":0.0067777885,"about_ca_topic_score_gemma":0.0038416071,"teacher_disagreement_score":0.030331125,"about_ca_system_score_codex":0.0009758558,"about_ca_system_score_gemma":0.0027131,"threshold_uncertainty_score":0.99983615},"labels":[],"label_agreement":null},{"id":"W4362486236","doi":"10.1158/1535-7163.c.6543604","title":"Data from Inhibition of the MNK1/2–eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of Toronto; University Health Network; Jewish General Hospital; McGill University; Princess Margaret Cancer Centre; University of Manitoba; Hôpital Maisonneuve-Rosemont; Telesta Therapeutics (Canada)","funders":"","keywords":"Palbociclib; Cancer research; EIF4E; Clonogenic assay; Melanoma; Downregulation and upregulation; Cell cycle; Cancer; Survivin; Medicine; Breast cancer; Pharmacology; Biology; Cell; Translation (biology); Internal medicine; Messenger RNA; Biochemistry; Metastatic breast cancer","score_opus":0.0656322307284416,"score_gpt":0.33658947048184706,"score_spread":0.27095723975340547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362486236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803703,0.00064276165,0.00015031599,0.003826786,0.00054565613,0.0009165824,0.013342194,0.00009920729,0.00010618745],"genre_scores_gemma":[0.99686706,0.00078607304,0.00031472556,0.00021949274,0.00021943457,0.000101751975,0.0011146547,0.0000634643,0.00031335393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978912,0.0001056593,0.00042301824,0.00084811513,0.0004510112,0.00028102388],"domain_scores_gemma":[0.9978309,0.00015129341,0.0003678685,0.0014599692,0.00009416581,0.000095773525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023182831,0.0003327738,0.000700898,0.00014412058,0.00004169178,0.00002042339,0.00035677027,0.0002517736,0.0005401859],"category_scores_gemma":[0.000077787205,0.00023951962,0.00007152945,0.00029493275,0.00021830693,0.00018835519,0.0019889625,0.00067896384,0.00001306186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001962081,0.00047546654,0.8863425,0.0009898511,0.000816629,0.00007710225,0.0006563937,0.00008168386,0.07840675,0.000015904181,0.0009997045,0.029175892],"study_design_scores_gemma":[0.0024720684,0.00002183527,0.9863968,0.0018352574,0.0001369719,0.000012119833,0.0001366945,0.00086940185,0.0068863523,0.0008205304,0.00018271504,0.00022923862],"about_ca_topic_score_codex":0.020931216,"about_ca_topic_score_gemma":0.012595296,"teacher_disagreement_score":0.10005428,"about_ca_system_score_codex":0.00024788472,"about_ca_system_score_gemma":0.00036497173,"threshold_uncertainty_score":0.9855885},"labels":[],"label_agreement":null},{"id":"W4362593083","doi":"10.1158/1538-7445.am2023-3998","title":"Abstract 3998: Metronomic gemcitabine plus neratinib effectively inhibits the growth of human Her-2 positive breast cancer cells intracranially implanted into immunodeficient mice","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Neratinib; Gemcitabine; Lapatinib; Medicine; Breast cancer; Oncology; Cancer; Metastatic breast cancer; Internal medicine; In vivo; Cancer research; Trastuzumab; Biology","score_opus":0.03244288141759056,"score_gpt":0.38009187465678124,"score_spread":0.3476489932391907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362593083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99093634,0.0025842967,0.000047563368,0.0033030075,0.00033588093,0.0017100952,0.0006601727,0.00011773815,0.00030487723],"genre_scores_gemma":[0.99740833,0.00052623363,0.000057111294,0.00016195847,0.00054079114,0.0007461322,0.000071882256,0.00011552481,0.00037203354],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99627745,0.00030713435,0.0005991659,0.00071658567,0.0010578563,0.0010417884],"domain_scores_gemma":[0.9971196,0.0005994865,0.00022998558,0.0005577669,0.00128288,0.00021029357],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015016367,0.0003790346,0.0006996653,0.0005461696,0.0005495812,0.0000671847,0.00053675455,0.00015319412,0.00043798858],"category_scores_gemma":[0.000073708514,0.00028034707,0.00018653882,0.0017776279,0.00080817007,0.0002123308,0.00030267314,0.0011730632,0.00010409583],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002759465,0.00014157873,0.0009657821,0.00041375126,0.0004329045,0.00004524506,0.003376071,0.00038776067,0.97538245,0.00019374008,0.0005230874,0.015378194],"study_design_scores_gemma":[0.0050197816,0.0005181724,0.2833731,0.0011738545,0.00010284408,0.00006341914,0.0017630198,0.00018294982,0.70694774,0.00026290579,0.00021421383,0.00037799397],"about_ca_topic_score_codex":0.016726863,"about_ca_topic_score_gemma":0.000994032,"teacher_disagreement_score":0.2824073,"about_ca_system_score_codex":0.0019896738,"about_ca_system_score_gemma":0.001143245,"threshold_uncertainty_score":0.9999649},"labels":[],"label_agreement":null},{"id":"W4362664852","doi":"10.21203/rs.3.rs-2755862/v1","title":"Thrombotic risk in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with CDK 4/6 inhibitors: a meta-analysis","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Peking University Health Science Center; Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety; Peking University; National Natural Science Foundation of China; Peking University First Hospital","keywords":"Medicine; Internal medicine; Breast cancer; Oncology; Odds ratio; Meta-analysis; Randomized controlled trial; Cancer; Hazard ratio; Confidence interval; Gynecology","score_opus":0.07184095948394943,"score_gpt":0.37483455197727317,"score_spread":0.30299359249332375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362664852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97640324,0.0013437294,0.00014663488,0.001924567,0.000062850304,0.006010814,0.013667847,0.00033738575,0.000102920836],"genre_scores_gemma":[0.9915845,0.00049112394,0.001076391,0.000040383762,0.00032315968,0.0028018518,0.0024816534,0.00035407182,0.0008468992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9894848,0.0019641377,0.0010399339,0.0023416085,0.0035059124,0.0016636052],"domain_scores_gemma":[0.9922681,0.0008522853,0.0007764693,0.0015230437,0.003908525,0.0006716116],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010527398,0.0012011627,0.0037481112,0.0026349444,0.00045525184,0.00016636871,0.0005614814,0.0005806785,0.002061554],"category_scores_gemma":[0.00030359678,0.00080418604,0.0010246241,0.005206017,0.0009919867,0.00039747835,0.00067604706,0.004051049,0.000095882286],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00981448,0.0013831536,0.8171032,0.0008229592,0.16422622,0.000118777054,0.0030690334,0.0014582084,0.0002495749,0.000014448326,0.0004395986,0.0013003707],"study_design_scores_gemma":[0.0057357894,0.001884441,0.9620239,0.00092357845,0.026460804,0.0000029395542,0.0008598072,0.00004213481,0.0010405534,0.00012700688,0.00002028731,0.000878755],"about_ca_topic_score_codex":0.031155303,"about_ca_topic_score_gemma":0.0046606297,"teacher_disagreement_score":0.14492072,"about_ca_system_score_codex":0.0028934963,"about_ca_system_score_gemma":0.00085606903,"threshold_uncertainty_score":0.9994409},"labels":[],"label_agreement":null},{"id":"W4365512785","doi":"10.1158/1538-7445.am2023-ct065","title":"Abstract CT065: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pertuzumab; Medicine; Internal medicine; Capecitabine; Metastatic breast cancer; Oncology; Neratinib; Taxane; Trastuzumab; Progression-free survival; Breast cancer; Cancer; Colorectal cancer; Chemotherapy","score_opus":0.12400111099607009,"score_gpt":0.4907828270774674,"score_spread":0.3667817160813973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365512785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98537195,0.0012995903,0.000008688935,0.003335788,0.0001073554,0.009651089,0.00014940981,0.0000473046,0.000028855977],"genre_scores_gemma":[0.9864342,0.0010875628,0.000111849105,0.000057853224,0.000115519055,0.0115440255,0.000026403653,0.00009062186,0.0005319397],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99678624,0.00023173599,0.0005831274,0.0006706642,0.0009356103,0.0007926133],"domain_scores_gemma":[0.99805236,0.0006681332,0.00018678964,0.00036901914,0.00055822666,0.0001654769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015118613,0.0002859705,0.000742598,0.0007269868,0.000108299006,0.000039589744,0.00022173705,0.00007665129,0.0002452464],"category_scores_gemma":[0.00016675262,0.0002004617,0.00004930858,0.001802694,0.00040321372,0.00023599039,0.000046582445,0.00053936266,0.0000028656016],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6323249,0.0074402504,0.009390674,0.0007471565,0.00035171327,0.00024003223,0.012095788,0.0001418231,0.002213136,0.00004680412,0.00029163784,0.3347161],"study_design_scores_gemma":[0.7603738,0.032736428,0.1621168,0.0025061916,0.00007755279,0.00009651171,0.036445122,0.00075547275,0.0022234442,0.00050119095,0.0016196483,0.0005478511],"about_ca_topic_score_codex":0.0029809806,"about_ca_topic_score_gemma":0.0050704614,"teacher_disagreement_score":0.33416826,"about_ca_system_score_codex":0.00093978556,"about_ca_system_score_gemma":0.0016627045,"threshold_uncertainty_score":0.81745905},"labels":[],"label_agreement":null},{"id":"W4366236771","doi":"10.2217/fon-2022-1196","title":"Design of SERENA-6, a phase III switching trial of camizestrant in <i>ESR1</i> -mutant breast cancer during first-line treatment","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"AstraZeneca","keywords":"Medicine; Mutant; Breast cancer; Oncology; Cancer; Line (geometry); Internal medicine; Cancer research; Genetics; Biology; Gene","score_opus":0.030193153996958478,"score_gpt":0.354143198096221,"score_spread":0.32395004409926254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366236771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924985,0.0006492788,0.00067428825,0.0037417389,0.00074455386,0.0014309187,0.00011811462,0.0000761308,0.0000664811],"genre_scores_gemma":[0.9961213,0.0015233253,0.00069209165,0.000075106436,0.0010819458,0.00030982686,0.000022802165,0.00004334655,0.00013028056],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982646,0.00010749695,0.0006742477,0.00033734733,0.00021341039,0.00040291515],"domain_scores_gemma":[0.9989976,0.00017486858,0.00033683528,0.0002967924,0.0000882298,0.00010561754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021964467,0.0002560923,0.0010655327,0.00027657615,0.000047395544,0.000002387458,0.00010582764,0.00019496145,0.00013993385],"category_scores_gemma":[0.000015553143,0.00019795077,0.00012819466,0.000552772,0.00007630509,0.00006785778,0.000033074935,0.00021086777,0.0000035527237],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4075116,0.0029891457,0.0006983898,0.00039197406,0.0005624729,0.0008909811,0.007959361,0.0063223457,0.3861565,0.00004201126,0.000029566834,0.18644565],"study_design_scores_gemma":[0.88664687,0.0134319905,0.006895936,0.0010285741,0.0006137905,0.00075287104,0.0028862758,0.0016170022,0.0790986,0.00021456616,0.006299309,0.0005142461],"about_ca_topic_score_codex":0.0010661193,"about_ca_topic_score_gemma":0.0013173936,"teacher_disagreement_score":0.47913527,"about_ca_system_score_codex":0.000703231,"about_ca_system_score_gemma":0.00059380004,"threshold_uncertainty_score":0.8072198},"labels":[],"label_agreement":null},{"id":"W4366351020","doi":"10.1007/s11523-023-00957-7","title":"Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review","year":2023,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Medicine; Oncology; Metastatic breast cancer; Breast cancer; Internal medicine; Palbociclib; Targeted therapy; Chemotherapy; Cyclin-dependent kinase 4; Cancer; Clinical trial; Cell cycle; Cyclin-dependent kinase 2","score_opus":0.03738858245496208,"score_gpt":0.39182272420085024,"score_spread":0.35443414174588816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366351020","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011200283,0.9918593,0.0000015632882,0.0018384861,0.00086483045,0.0042597335,0.0007966116,0.00015060016,0.00011685925],"genre_scores_gemma":[0.000041744268,0.99503857,0.0002384123,0.0009730776,0.0005224151,0.0018581563,0.0006970182,0.00024599777,0.00038461125],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940795,0.00095016416,0.0024411222,0.0010974089,0.0005239445,0.0009078669],"domain_scores_gemma":[0.9967598,0.00051243586,0.0013481968,0.00086005457,0.00027404842,0.00024547655],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0010064911,0.0009881755,0.006519103,0.0013705028,0.000032549877,0.000009233269,0.0004903257,0.0012509655,0.00043305042],"category_scores_gemma":[0.00018757075,0.0007876815,0.00069641566,0.0036897622,0.00021452141,0.00012863848,0.00015814883,0.0023144416,0.000059610833],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068930216,0.00053455896,0.0001656713,0.066716775,0.0003871562,0.001690596,0.0003693348,0.000010495549,0.00007091243,0.00001712544,0.0010892336,0.92825884],"study_design_scores_gemma":[0.003495185,0.0003348967,0.00023252745,0.2431091,0.00030894656,0.00062428054,0.000043199634,0.0000031600723,0.000016203276,0.00006594577,0.7512399,0.0005266579],"about_ca_topic_score_codex":0.00038843002,"about_ca_topic_score_gemma":0.0005301843,"teacher_disagreement_score":0.92773217,"about_ca_system_score_codex":0.0023482323,"about_ca_system_score_gemma":0.002833559,"threshold_uncertainty_score":0.99998724},"labels":[],"label_agreement":null},{"id":"W4367299362","doi":"10.57264/cer-2023-0009","title":"Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant","year":2023,"lang":"en","type":"letter","venue":"Journal of Comparative Effectiveness Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Palbociclib; Medicine; Fulvestrant; Oncology; Breast cancer; Quality of life (healthcare); Internal medicine; Cancer; Gynecology; Metastatic breast cancer; Estrogen receptor","score_opus":0.12516054244642327,"score_gpt":0.46097057455155016,"score_spread":0.3358100321051269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367299362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816983,0.0009975946,0.00018426393,0.015180357,0.00009048636,0.0017116623,0.000108132415,0.000010644251,0.000018612507],"genre_scores_gemma":[0.99804187,0.0000827792,0.000268589,0.0010259787,0.00030179357,0.00013077544,0.000052303567,0.00008326011,0.000012670728],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9917998,0.0032938346,0.0015239781,0.00052209117,0.00227577,0.0005845483],"domain_scores_gemma":[0.98994297,0.0056283143,0.0017313792,0.00033446655,0.0022258654,0.00013699714],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0031210457,0.0004463019,0.0033151342,0.0019454446,0.00007150761,0.0000281827,0.00029351318,0.0002715703,0.000012021929],"category_scores_gemma":[0.00026172318,0.00031889544,0.00011639442,0.00176992,0.00084326847,0.00042064616,0.000086329805,0.003734494,7.269762e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020422526,0.00048114997,0.9652222,0.003232631,0.0007251785,0.00007249375,0.0023872608,0.0007311589,0.0007581877,0.0000038572425,0.00051331194,0.0054500415],"study_design_scores_gemma":[0.013928944,0.0030875346,0.96339774,0.015567221,0.00007486981,0.000009885292,0.00034562222,0.000022743867,0.002806656,0.0001348894,0.00033565486,0.00028825516],"about_ca_topic_score_codex":0.0004220865,"about_ca_topic_score_gemma":0.00028732416,"teacher_disagreement_score":0.016343603,"about_ca_system_score_codex":0.0007152284,"about_ca_system_score_gemma":0.0008096162,"threshold_uncertainty_score":0.9999263},"labels":[],"label_agreement":null},{"id":"W4367673953","doi":"10.1016/s1470-2045(23)00165-1","title":"Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Breast cancer; Adjuvant; Oncology; Internal medicine; Adjuvant therapy; Clinical trial; Population; Randomized controlled trial; Cancer; Disease; Family medicine","score_opus":0.1417651738107499,"score_gpt":0.42229626471409526,"score_spread":0.2805310909033454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367673953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9483764,0.004214671,0.0000058971286,0.044738073,0.00029925507,0.0020597943,0.00011193667,0.00004199385,0.00015193765],"genre_scores_gemma":[0.9399581,0.036449205,0.00048446015,0.020023955,0.0007423542,0.0013796786,0.000005794815,0.00005497021,0.00090149796],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9982173,0.00033308918,0.00045240272,0.00023884718,0.00031865344,0.00043974235],"domain_scores_gemma":[0.9980632,0.00061212754,0.00028772248,0.00072768907,0.00022967781,0.00007959246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012634086,0.00015288919,0.000998684,0.000070985174,0.000026358051,0.0000024516412,0.000388247,0.00006244437,0.000286785],"category_scores_gemma":[0.000413069,0.00007543413,0.000059427803,0.0009241734,0.00030018625,0.00008622047,0.00016389354,0.0002896641,0.000026497075],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.488188,0.0006352367,0.06775841,0.011872752,0.00050489546,0.00016132803,0.00798961,0.0005933936,0.020470565,0.00018086641,0.028376663,0.3732683],"study_design_scores_gemma":[0.041759577,0.007264873,0.69051933,0.032640632,0.0002503318,0.0003656922,0.00040130274,0.000035187073,0.0011559378,0.0002093011,0.2250547,0.00034315395],"about_ca_topic_score_codex":0.00030280635,"about_ca_topic_score_gemma":0.00033202037,"teacher_disagreement_score":0.6227609,"about_ca_system_score_codex":0.00036766723,"about_ca_system_score_gemma":0.0007534164,"threshold_uncertainty_score":0.31400946},"labels":[],"label_agreement":null},{"id":"W4376613563","doi":"10.1016/j.esmoop.2023.101385","title":"196P Efficacy and safety of first-line (1L) ribociclib (RIB) + letrozole (LET) in patients (pts) with de novo metastatic disease and late recurrence from (neo)adjuvant therapy (tx) in MONALEESA (ML)-2","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Bristol-Myers Squibb; Samsung; Genentech; Daiichi-Sankyo; Eisai; Novartis Pharmaceuticals Corporation; Ascentage Pharma; Argenx; Syndax Pharmaceuticals; Mirati Therapeutics; Les Laboratories Pierre Fabre; TG Therapeutics; AstraZeneca; Novocure; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Amgen; Pfizer; G1 Therapeutics; Ipsen Biopharmaceuticals; Celgene; Carrick Therapeutics; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Letrozole; Adjuvant; Gastroenterology; Progression-free survival; Surgery; Chemotherapy; Cancer; Breast cancer; Oncology; Aromatase","score_opus":0.026123771770422327,"score_gpt":0.30380116496314485,"score_spread":0.27767739319272255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376613563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963526,0.0010162477,0.0000720266,0.0010103657,0.000031437412,0.0012581489,0.00018739965,0.00002216628,0.00004961351],"genre_scores_gemma":[0.99688107,0.0011855836,0.0012467206,0.00025029355,0.000018537597,0.00009477494,0.00017797656,0.000036713383,0.00010834618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998528,0.00009649734,0.00037482023,0.00042836845,0.00025608233,0.00031625174],"domain_scores_gemma":[0.9990242,0.00026640415,0.00014203406,0.00032438737,0.00005921795,0.00018375998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029024802,0.0002232645,0.0005431257,0.00014349594,0.00005049654,0.000023039118,0.00019570661,0.000032961987,0.00008335834],"category_scores_gemma":[0.000110382425,0.00017625473,0.000025073452,0.00045325558,0.000162618,0.00023023617,0.00017126485,0.00020765407,0.0000064915307],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013841379,0.0005434913,0.904622,0.00009566041,0.00014451532,0.00017461719,0.0020711436,0.00056932657,0.00010850825,0.000027187347,0.000015724496,0.07778643],"study_design_scores_gemma":[0.020239163,0.00046912444,0.97495186,0.00083247724,0.00004844478,0.000003235158,0.00010907207,0.0006591027,0.00023278005,0.0007004515,0.0015616176,0.0001926936],"about_ca_topic_score_codex":0.001828255,"about_ca_topic_score_gemma":0.0015023616,"teacher_disagreement_score":0.07759374,"about_ca_system_score_codex":0.00012137389,"about_ca_system_score_gemma":0.00011849666,"threshold_uncertainty_score":0.71874595},"labels":[],"label_agreement":null},{"id":"W4376613634","doi":"10.1016/j.esmoop.2023.101463","title":"124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 window of opportunity trial","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Genentech; PharmaMar; Eisai; Clovis Oncology; Eli Lilly and Company; AstraZeneca; Les Laboratories Pierre Fabre; Seagen; Relay Therapeutics; Gilead Sciences; Veracyte; Pfizer; Oncolytics Biotech","keywords":"Medicine; Triple-negative breast cancer; Breast cancer; Internal medicine; Oncology; Clinical trial; Cancer; Gastroenterology","score_opus":0.045698589555339356,"score_gpt":0.33968918892926603,"score_spread":0.2939905993739267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376613634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98370695,0.0002906602,0.000025061521,0.003321425,0.00042685974,0.0042964993,0.004393747,0.000055851793,0.003482973],"genre_scores_gemma":[0.996002,0.00072599726,0.0010405775,0.00015385155,0.000265596,0.00030814175,0.00018456971,0.00007381825,0.0012454579],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9963028,0.00048227038,0.0013298839,0.0006946429,0.0006680019,0.0005224072],"domain_scores_gemma":[0.99673015,0.0007773441,0.0010404015,0.0005581248,0.0005935574,0.00030043803],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012658192,0.00042588823,0.0015368343,0.00033076058,0.00008948881,0.00002085219,0.00045905137,0.00024289126,0.000600427],"category_scores_gemma":[0.0006973567,0.00038970762,0.00017203503,0.0011398759,0.00078103004,0.00044242293,0.00038157884,0.00049680483,0.000005800787],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5962059,0.0026477645,0.029385928,0.0007472857,0.0025560975,0.00021001049,0.023919115,0.00017512194,0.012334273,0.0003860713,0.0061469236,0.32528552],"study_design_scores_gemma":[0.16866201,0.003455836,0.74089503,0.0027055074,0.00031656,0.000045228786,0.0068776575,0.00007394297,0.07218148,0.0020466386,0.002032208,0.00070789206],"about_ca_topic_score_codex":0.028172225,"about_ca_topic_score_gemma":0.004991609,"teacher_disagreement_score":0.7115091,"about_ca_system_score_codex":0.00026834873,"about_ca_system_score_gemma":0.0011682317,"threshold_uncertainty_score":0.99985546},"labels":[],"label_agreement":null},{"id":"W4376613897","doi":"10.1016/j.esmoop.2023.101392","title":"203P Clinical effectiveness of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer (mBC) by ER expression level: Subgroup analysis from phase IIIb LUCY trial","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University of British Columbia","funders":"Yonsei University College of Medicine; Merck Sharp and Dohme; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Universitat de Barcelona; Medizinischen Hochschule Hannover; Hacettepe Üniversitesi; Gilead Sciences; Merck; AstraZeneca","keywords":"Medicine; Olaparib; Internal medicine; Oncology; Metastatic breast cancer; Taxane; Eribulin; Breast cancer; Population; Vinorelbine; Cancer; Chemotherapy; Cisplatin","score_opus":0.09030039216248577,"score_gpt":0.4620253913515751,"score_spread":0.37172499918908936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376613897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991773,0.00019397383,0.0020339608,0.00039315745,0.000379581,0.0024888767,0.002565276,0.000065816,0.0001063567],"genre_scores_gemma":[0.99650145,0.00012567769,0.001018785,0.0001412924,0.00015380647,0.00067990256,0.00091910554,0.00006944981,0.00039054162],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9958963,0.0012665768,0.0010191711,0.00084404706,0.0005295793,0.00044431622],"domain_scores_gemma":[0.99659795,0.001871342,0.00046898404,0.00063060736,0.00020432027,0.00022681824],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018321518,0.00035969313,0.0018209332,0.0003511031,0.000076141034,0.000043537675,0.0004932146,0.00015613061,0.0015824522],"category_scores_gemma":[0.0003462522,0.00029531153,0.00033909536,0.0021995823,0.00024969265,0.00044681603,0.00030923134,0.00045742962,0.0000438105],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.573763,0.008731153,0.20300484,0.0004560358,0.0149379205,0.0006818562,0.0040092524,0.0020743539,0.042827312,0.000041308896,0.0029481852,0.14652476],"study_design_scores_gemma":[0.27956122,0.0011364571,0.65490687,0.0014038612,0.0026001886,0.000008785502,0.0010097334,0.0010929841,0.055703375,0.0010235632,0.00092016865,0.0006327903],"about_ca_topic_score_codex":0.03620589,"about_ca_topic_score_gemma":0.0026621176,"teacher_disagreement_score":0.45190203,"about_ca_system_score_codex":0.00028136527,"about_ca_system_score_gemma":0.0003257047,"threshold_uncertainty_score":0.9999499},"labels":[],"label_agreement":null},{"id":"W4377287000","doi":"10.1101/2023.05.19.541369","title":"Deconstructing the contributions of heterogeneity to combination treatment of hormone sensitive breast cancer","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal; University of Saskatchewan","funders":"","keywords":"Fulvestrant; Palbociclib; Breast cancer; Oncology; Estrogen receptor; Pharmacodynamics; Cancer; Medicine; Internal medicine; Hormone receptor; Pharmacokinetics; Pharmacology; Metastatic breast cancer","score_opus":0.021110568006991,"score_gpt":0.28670520228592,"score_spread":0.265594634278929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377287000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888219,0.0013280337,0.0022040452,0.0017964055,0.0005105832,0.0014505943,0.003734219,0.00015310608,0.0000011158971],"genre_scores_gemma":[0.9974029,0.00042081674,0.0014207666,0.00007254466,0.00024153246,0.00035672696,0.0000012212512,0.00008094184,0.0000025222303],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980684,0.000107935615,0.00058263226,0.0005447459,0.00034373743,0.00035255856],"domain_scores_gemma":[0.99666727,0.00014705377,0.0006090269,0.00087494345,0.00152314,0.0001785425],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002759643,0.00037960822,0.0008297181,0.00022456549,0.00011764853,0.00001844054,0.00016034812,0.00022153412,0.0000074981726],"category_scores_gemma":[0.000121939906,0.00031082646,0.00021602085,0.00054782245,0.00024752071,0.000055861638,0.00016746367,0.00024287,0.0000073804913],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042087762,0.00029154719,0.018215192,0.00016983514,0.0010908273,0.000019616504,0.00008462965,0.00035725028,0.97889286,0.00036353662,0.000017305594,0.00007653745],"study_design_scores_gemma":[0.0012401477,0.00014878681,0.4113623,0.00037914937,0.0003261753,2.1557487e-7,0.000024764602,0.0001118262,0.5861087,0.0000032507937,0.000103321814,0.00019137881],"about_ca_topic_score_codex":0.0005447901,"about_ca_topic_score_gemma":0.000019695548,"teacher_disagreement_score":0.39314708,"about_ca_system_score_codex":0.0009271325,"about_ca_system_score_gemma":0.0006849565,"threshold_uncertainty_score":0.9999344},"labels":[],"label_agreement":null},{"id":"W4378347748","doi":"10.1038/s41389-023-00475-1","title":"CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer","year":2023,"lang":"en","type":"article","venue":"Oncogenesis","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"CIHR Skin Research Training Centre; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Cure Brain Cancer Foundation; Canadian Cancer Society; Government of Canada","keywords":"Triple-negative breast cancer; Cancer research; Breast cancer; Oncology; Medicine; Internal medicine; Cancer","score_opus":0.012991934623037008,"score_gpt":0.2912556387195237,"score_spread":0.2782637040964867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378347748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98941475,0.00366257,0.000019021336,0.005479235,0.00023159011,0.0007266867,0.000118211,0.00009415372,0.0002538002],"genre_scores_gemma":[0.9955271,0.001964341,0.00022773273,0.00033959385,0.00031421153,0.00037467387,0.000009989756,0.00004918607,0.0011931695],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99858946,0.00012563635,0.00026673486,0.0004100597,0.0002820507,0.00032604556],"domain_scores_gemma":[0.9991088,0.00031174085,0.00010193423,0.00027186246,0.00007574467,0.00012991461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027880556,0.00022673399,0.00043080523,0.00016845316,0.00013556829,0.000023864752,0.00008554607,0.00009849518,0.000095224736],"category_scores_gemma":[0.00008517003,0.00014761272,0.000059776452,0.00054244034,0.0003794984,0.00015941095,0.00013422285,0.00016107867,0.00000848669],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017941575,0.0002588162,0.21629949,0.0006830576,0.00040935425,0.00022456184,0.021597726,0.00018921247,0.19276267,0.00013379076,0.003002155,0.5464976],"study_design_scores_gemma":[0.020194411,0.00013337462,0.8700321,0.0011495199,0.00018427102,0.00023656106,0.0048472625,0.00048201447,0.09371262,0.00082080375,0.0077163703,0.0004907129],"about_ca_topic_score_codex":0.0009071639,"about_ca_topic_score_gemma":0.00028443057,"teacher_disagreement_score":0.6537326,"about_ca_system_score_codex":0.000113725546,"about_ca_system_score_gemma":0.00008395974,"threshold_uncertainty_score":0.6019472},"labels":[],"label_agreement":null},{"id":"W4378952203","doi":"10.1177/10781552231179190","title":"Implementation and evaluation of a shared care model between oncologists and pharmacists for breast cancer patients at a Canadian regional ambulatory cancer centre","year":2023,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacist; Ambulatory; Family medicine; Breast cancer; Medical prescription; Cancer; Pharmaceutical care; Ambulatory care; Pharmacy; Internal medicine; Health care; Nursing","score_opus":0.13863132179766358,"score_gpt":0.5167725657152309,"score_spread":0.3781412439175673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378952203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98271626,0.002544977,0.00001814257,0.012232703,0.00026006575,0.0009488573,0.0012077652,0.000009866206,0.00006137012],"genre_scores_gemma":[0.9953693,0.0018217602,0.0009980086,0.0012347985,0.00033990934,0.00009184398,0.0000792446,0.00002738717,0.000037717564],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982736,0.00020076292,0.00052405027,0.00021148336,0.0005065495,0.00028356814],"domain_scores_gemma":[0.99557924,0.0003931603,0.0010501496,0.00007086752,0.002577479,0.00032912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008886458,0.00015602069,0.0004034637,0.00027927308,0.0001349559,0.00000953646,0.00007190003,0.000071260874,0.00016033307],"category_scores_gemma":[0.00012648558,0.00014474342,0.00006551812,0.00017585204,0.0001039368,0.0005952712,0.000039472936,0.00022882497,7.3013433e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006740303,0.00014050482,0.35953078,0.00028711316,0.0010200714,0.000039696028,0.0069850967,0.0014015532,0.0040851664,0.0000057320954,0.0059370273,0.61382693],"study_design_scores_gemma":[0.09218881,0.0012378194,0.73637694,0.00036410792,0.009746476,0.0013337894,0.0071911225,0.014973507,0.0024196703,0.00018715336,0.13346548,0.00051510835],"about_ca_topic_score_codex":0.0027945007,"about_ca_topic_score_gemma":0.0055016414,"teacher_disagreement_score":0.6133118,"about_ca_system_score_codex":0.0030563425,"about_ca_system_score_gemma":0.0034831618,"threshold_uncertainty_score":0.79922295},"labels":[],"label_agreement":null},{"id":"W4379232529","doi":"10.3390/curroncol30060411","title":"HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of British Columbia; Dr. H. Bliss Murphy Cancer Centre; Sunnybrook Health Science Centre; McGill University Health Centre; Mount Sinai Hospital","funders":"Novartis Pharmaceuticals Canada; Astellas Pharma; Mylan; Genomic Health; Seagen; Gilead Sciences; Sanofi; Amgen; Pfizer; Myriad Genetics; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Palbociclib; Fulvestrant; Oncology; Internal medicine; Breast cancer; Cancer; Disease; Metastatic breast cancer; Bevacizumab; Life expectancy; Intensive care medicine; Tamoxifen; Population; Chemotherapy","score_opus":0.21358301662601772,"score_gpt":0.5293600720080169,"score_spread":0.3157770553819992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379232529","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000024112874,0.9824121,0.000013018125,0.0097232,0.0022162215,0.004972329,0.00028820965,0.0001580041,0.00021453011],"genre_scores_gemma":[0.0000011513797,0.9851329,0.00009512166,0.0015684732,0.0019528961,0.010309399,0.00042983587,0.00015914429,0.00035111784],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99614877,0.00044623064,0.0012968485,0.000933635,0.00039245107,0.00078207126],"domain_scores_gemma":[0.9972617,0.00067017425,0.0007527573,0.001011693,0.00013984765,0.00016383757],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048810727,0.0009021397,0.0040019886,0.00025978076,0.00010741472,0.000011993467,0.0005187531,0.00033757245,0.0003782249],"category_scores_gemma":[0.00010490128,0.0005195091,0.00079405255,0.0010440374,0.0001859208,0.00007193269,0.00011928435,0.00093213085,0.00024430235],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000068770256,0.0006128764,0.000029177085,0.040450837,0.00025055988,0.00014909245,0.00032058885,0.0000015710835,8.457811e-8,0.000015904017,0.0034781848,0.9546223],"study_design_scores_gemma":[0.00163073,0.0004004914,0.000066937864,0.1276812,0.0012078723,0.00078831636,0.00006108562,0.0000025028312,1.3238189e-7,0.000026879037,0.8677618,0.00037204803],"about_ca_topic_score_codex":0.00007691125,"about_ca_topic_score_gemma":0.000424692,"teacher_disagreement_score":0.9542503,"about_ca_system_score_codex":0.003479972,"about_ca_system_score_gemma":0.0015855742,"threshold_uncertainty_score":0.99972564},"labels":[],"label_agreement":null},{"id":"W4379281207","doi":"10.1200/jco.2023.41.16_suppl.e18623","title":"Real world evidence for continuing HER2-directed therapy for metastatic breast cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Pertuzumab; Trastuzumab; Metastatic breast cancer; Cohort; Breast cancer; Systemic therapy; Cancer; Internal medicine; Pharmacy; Oncology; Family medicine","score_opus":0.29597170892414887,"score_gpt":0.5694901139097674,"score_spread":0.2735184049856186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.907888,0.0043528555,0.004171305,0.0756117,0.005161095,0.0022779237,0.00012364371,0.00021607413,0.00019741524],"genre_scores_gemma":[0.9041307,0.01548109,0.06223017,0.0050768023,0.00826382,0.00041540372,0.000012804156,0.00013991301,0.0042493106],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9966795,0.00025617643,0.0020777106,0.000263276,0.00030886548,0.0004144729],"domain_scores_gemma":[0.984202,0.012244328,0.0018524948,0.00019207125,0.0012009203,0.0003081331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040952777,0.00018151478,0.0017860866,0.00022081187,0.000057800004,0.000011829958,0.00021338018,0.00014351639,0.000121606754],"category_scores_gemma":[0.0035210229,0.00012919755,0.00073296635,0.00043691063,0.00020595304,0.00019957944,0.000025497407,0.00049853866,0.000005816557],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041398343,0.00045488751,0.017301949,0.00010900986,0.00094934873,0.000098886434,0.0002147005,0.00008105501,0.0017839408,0.00009751217,0.006573515,0.9309369],"study_design_scores_gemma":[0.042251393,0.015102686,0.6108886,0.0018427497,0.0010319784,0.0004625342,0.0004099845,0.0016232535,0.00054968084,0.0041138227,0.32139248,0.0003308458],"about_ca_topic_score_codex":0.00006116442,"about_ca_topic_score_gemma":0.00023081218,"teacher_disagreement_score":0.930606,"about_ca_system_score_codex":0.0002767539,"about_ca_system_score_gemma":0.0015237546,"threshold_uncertainty_score":0.52685237},"labels":[],"label_agreement":null},{"id":"W4379281224","doi":"10.1200/jco.2023.41.16_suppl.e18798","title":"Canadian (CAN) real-world outcomes for relapsed/recurrent (R/R) metastatic triple-negative breast cancer (mTNBC) in the first-line or later (1L+) setting by early or late recurrence status.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Gilead Sciences (Canada)","funders":"","keywords":"Medicine; Internal medicine; Population; Taxane; Oncology; Triple-negative breast cancer; Breast cancer; Cancer","score_opus":0.1317608025608072,"score_gpt":0.48175530173972303,"score_spread":0.34999449917891584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7402819,0.00046262998,0.000098523364,0.2514483,0.0037387148,0.0020922173,0.0015403177,0.00004798005,0.0002894273],"genre_scores_gemma":[0.9663804,0.004741344,0.0042580585,0.016995622,0.0013178237,0.00033144144,0.00005519102,0.00011317254,0.0058069276],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9948651,0.00057561585,0.0027585705,0.00038670594,0.000511084,0.0009029142],"domain_scores_gemma":[0.9878113,0.008922705,0.0017907616,0.00029127754,0.0005583715,0.000625582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041631893,0.00032959218,0.0019107345,0.00046391346,0.00014369066,0.000029005045,0.00040393168,0.0002071917,0.0003332313],"category_scores_gemma":[0.0041998723,0.00017261089,0.0004218224,0.0009976793,0.00025593094,0.00023453086,0.000049858885,0.0015262767,0.000015196502],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030768879,0.00083648233,0.28856495,0.00019931926,0.0011987457,0.0013788436,0.003634173,0.00023149564,0.0000116088095,0.000055736025,0.02260837,0.6505114],"study_design_scores_gemma":[0.021345263,0.006748321,0.79352283,0.00070645794,0.00055763806,0.00018804807,0.00090177235,0.00043352428,0.000015735102,0.0015096366,0.17375849,0.00031226836],"about_ca_topic_score_codex":0.0197579,"about_ca_topic_score_gemma":0.54814416,"teacher_disagreement_score":0.6501991,"about_ca_system_score_codex":0.001194557,"about_ca_system_score_gemma":0.005400112,"threshold_uncertainty_score":0.9867696},"labels":[],"label_agreement":null},{"id":"W4379284089","doi":"10.1200/jco.2023.41.16_suppl.tps616","title":"lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Letrozole; Tamoxifen; Internal medicine; Anastrozole; Oncology; Exemestane; Fulvestrant; Breast cancer; Tolerability; Estrogen receptor; Hazard ratio; Adverse effect; Cancer; Gynecology; Confidence interval","score_opus":0.05948224414837465,"score_gpt":0.43914211620900123,"score_spread":0.37965987206062657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379284089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99576503,0.00019571703,0.000016702195,0.0022009131,0.0005079483,0.0010949636,0.00009175028,0.000021073565,0.00010592334],"genre_scores_gemma":[0.9972687,0.0007319758,0.0005293083,0.0005765178,0.0006804559,0.00004930615,0.000008693757,0.00006547293,0.00008959278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943778,0.00071938004,0.003065218,0.0004367348,0.00089977786,0.0005010751],"domain_scores_gemma":[0.9928982,0.0016771147,0.003361691,0.00034599603,0.0013832471,0.0003337226],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00095607596,0.00037909282,0.0030520235,0.0003126391,0.00004939062,0.0000074689033,0.0003275004,0.00019927966,0.00015616202],"category_scores_gemma":[0.00034075804,0.0002658832,0.00038421774,0.0007541048,0.0004969056,0.00030942485,0.00006762891,0.0011756244,0.0000061787223],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.088703945,0.019487202,0.52030766,0.000051472354,0.0019071617,0.00035133128,0.0024689788,0.00025432935,0.0008301105,0.0000072216185,0.0001676628,0.36546296],"study_design_scores_gemma":[0.09735624,0.062863156,0.8344183,0.0006800945,0.00028190322,0.000037619546,0.0013973088,0.000021529471,0.0017958774,0.000055736007,0.00089263124,0.00019961192],"about_ca_topic_score_codex":0.0034360385,"about_ca_topic_score_gemma":0.0007159912,"teacher_disagreement_score":0.36526334,"about_ca_system_score_codex":0.0003826539,"about_ca_system_score_gemma":0.001296968,"threshold_uncertainty_score":0.9999793},"labels":[],"label_agreement":null},{"id":"W4379284114","doi":"10.1200/jco.2023.41.16_suppl.tps1123","title":"INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–) <i>PIK3CA</i>-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Roche","keywords":"Medicine; Fulvestrant; Tolerability; Regimen; Internal medicine; Everolimus; Oncology; Pharmacology; Cancer; Adverse effect; Breast cancer; Estrogen receptor","score_opus":0.045631715074727526,"score_gpt":0.4278713048804936,"score_spread":0.38223958980576606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379284114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99337476,0.0003004527,0.00030333365,0.002750302,0.0007460605,0.002101949,0.00019089178,0.00006259278,0.00016966017],"genre_scores_gemma":[0.9935795,0.0015023332,0.0032736764,0.00080818275,0.0003649432,0.00012696687,0.0000368345,0.00012962506,0.00017790595],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99004984,0.0018085339,0.005019305,0.0008010998,0.0014387199,0.0008824929],"domain_scores_gemma":[0.9881695,0.0038013146,0.0043791793,0.00053035875,0.0023589353,0.0007607125],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0026900063,0.00069998915,0.004469831,0.00065411726,0.00010374166,0.000023546769,0.0005486154,0.00042165903,0.00022525544],"category_scores_gemma":[0.0015214863,0.00047406222,0.0004336855,0.002119811,0.0009520731,0.00072533387,0.00016894795,0.0023465052,0.000015762802],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48862943,0.039188243,0.04670381,0.0002097196,0.0035603186,0.0053414833,0.005423759,0.002351508,0.00088054244,0.00001545006,0.00074627134,0.4069495],"study_design_scores_gemma":[0.26491943,0.14398755,0.57463384,0.0018262834,0.0013916014,0.0007204055,0.0090349475,0.000233644,0.00035500654,0.00013356352,0.00211083,0.00065290934],"about_ca_topic_score_codex":0.0007017375,"about_ca_topic_score_gemma":0.0014349939,"teacher_disagreement_score":0.52793,"about_ca_system_score_codex":0.000989487,"about_ca_system_score_gemma":0.0033297008,"threshold_uncertainty_score":0.9999551},"labels":[],"label_agreement":null},{"id":"W4379284394","doi":"10.1200/jco.2023.41.16_suppl.1110","title":"Imbalance in treatment discontinuation without progression between experimental and control arms among randomized trials in advanced breast cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Randomized controlled trial; Hazard ratio; Internal medicine; Breast cancer; Discontinuation; Oncology; Odds ratio; Adverse effect; Progression-free survival; Cancer; Confidence interval; Overall survival","score_opus":0.12906726759457574,"score_gpt":0.547813829062053,"score_spread":0.41874656146747724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379284394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887911,0.0019381717,0.00017870065,0.0072731883,0.0004564368,0.0013052195,0.000013226561,0.000015833382,0.000028141794],"genre_scores_gemma":[0.99651194,0.0012592018,0.0009961124,0.00015622878,0.00081400713,0.0001923084,0.0000046995337,0.00001945011,0.00004608171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938239,0.0019730988,0.0034225157,0.00024184427,0.00027506013,0.00026358658],"domain_scores_gemma":[0.9918795,0.005139886,0.0025498779,0.0001090643,0.000113973234,0.00020770173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009299552,0.00018469816,0.0047581056,0.00023558203,0.000020379104,0.000008530418,0.000071548384,0.00022014542,0.00002622993],"category_scores_gemma":[0.0031021642,0.00011054117,0.00039762273,0.00021196871,0.00033725263,0.00022171206,0.00002061067,0.0004315196,0.0000015022811],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15038984,0.0004541914,0.5331496,0.00000608011,0.000189118,0.000102744336,0.00034536407,0.000052471583,0.0011005908,0.0000026476418,0.0000033786414,0.314204],"study_design_scores_gemma":[0.3307481,0.0024679801,0.6648275,0.00045612903,0.00016915395,0.000033750846,0.00034202286,0.00028373167,0.00034734965,0.000115859184,0.0001368525,0.00007154373],"about_ca_topic_score_codex":0.000078589685,"about_ca_topic_score_gemma":0.000104012826,"teacher_disagreement_score":0.31413245,"about_ca_system_score_codex":0.00044592711,"about_ca_system_score_gemma":0.00051350944,"threshold_uncertainty_score":0.45077384},"labels":[],"label_agreement":null},{"id":"W4379285726","doi":"10.1200/jco.2023.41.16_suppl.1075","title":"Impact of pathogenic germline <i>BRCA1/2</i> and <i>PALB2</i> mutations and tumor aneuploidy in patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Palbociclib; Oncology; Breast cancer; Cancer; Internal medicine; Germline; Metastatic breast cancer; Gene; Biology; Genetics","score_opus":0.03512793821252162,"score_gpt":0.40659574631437717,"score_spread":0.37146780810185553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379285726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99787503,0.00041411608,0.000017632747,0.0010993856,0.0000829174,0.00036047463,0.00011665959,0.000014420066,0.000019337116],"genre_scores_gemma":[0.9979398,0.0003163981,0.0011668373,0.0003204959,0.00016399044,0.000014204142,0.000013946257,0.000038863447,0.000025468564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733764,0.0002400309,0.0015225178,0.00025329273,0.00035969264,0.00028679843],"domain_scores_gemma":[0.99654436,0.00090278353,0.0014637479,0.00015362122,0.0005894615,0.0003460285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007998983,0.00022301966,0.00155218,0.00028311886,0.00003260363,0.0000068688064,0.00007261672,0.000103738595,0.00004231837],"category_scores_gemma":[0.00026887227,0.00013019002,0.0001530653,0.0006074347,0.000503435,0.00019977853,0.000032874534,0.00056571607,0.0000011683384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013811993,0.0011778503,0.93273664,0.00006783287,0.00065949315,0.00046406058,0.00018360683,0.00026969233,0.00039830038,0.0000020625198,0.0000534075,0.05017507],"study_design_scores_gemma":[0.0236214,0.0147055285,0.95944864,0.0003636346,0.00054624816,0.0007639756,0.0001285947,0.00006918872,0.000033331202,0.000049401526,0.00014205642,0.00012798759],"about_ca_topic_score_codex":0.00017425139,"about_ca_topic_score_gemma":0.00024239528,"teacher_disagreement_score":0.05004708,"about_ca_system_score_codex":0.00016454936,"about_ca_system_score_gemma":0.001101357,"threshold_uncertainty_score":0.5308995},"labels":[],"label_agreement":null},{"id":"W4379285819","doi":"10.1200/jco.2023.41.16_suppl.e13112","title":"Comparison of real-world outcomes over time in a large population-based cohort of patients with metastatic breast cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Metastatic breast cancer; Proportional hazards model; Oncology; Breast cancer; Internal medicine; Cohort; Population; Cancer; Log-rank test; Disease","score_opus":0.07430403723859035,"score_gpt":0.4999019569320717,"score_spread":0.4255979196934813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379285819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975667,0.000042201395,0.000054509117,0.0016426465,0.00023052232,0.00027801865,0.00009018705,0.000008911019,0.00008630457],"genre_scores_gemma":[0.99785846,0.000022344744,0.0015056115,0.00037060896,0.000078632635,0.0000068042727,0.000024932087,0.000020682215,0.00011191863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99634445,0.00025870756,0.0025030447,0.00014170361,0.0005432341,0.00020887682],"domain_scores_gemma":[0.9945584,0.0019266534,0.0027155648,0.00017317885,0.0004821591,0.00014403583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014004811,0.00013004093,0.0023371505,0.00034461258,0.000013747942,0.000001444321,0.000113050795,0.00009454937,0.0003418627],"category_scores_gemma":[0.0005154852,0.00008583761,0.00024541223,0.00052816106,0.00012215364,0.000087533066,0.000023344317,0.00043626927,0.0000036354247],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007026801,0.0020841397,0.97825074,0.00007010768,0.00047509634,0.000029967667,0.000057696678,0.0011498504,0.000013959484,0.00002109744,0.00014206195,0.01067847],"study_design_scores_gemma":[0.014664188,0.0022244079,0.98114806,0.00025707053,0.0003506266,0.0000028226602,0.00003177158,0.0007623793,0.000013270381,0.00007476103,0.00039957426,0.00007105942],"about_ca_topic_score_codex":0.0003816259,"about_ca_topic_score_gemma":0.0012380496,"teacher_disagreement_score":0.01060741,"about_ca_system_score_codex":0.00023887349,"about_ca_system_score_gemma":0.0008889893,"threshold_uncertainty_score":0.3743157},"labels":[],"label_agreement":null},{"id":"W4379285864","doi":"10.1200/jco.2023.41.16_suppl.tps1121","title":"TACTIVE-U: Phase 1b/2 umbrella study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER+ advanced or metastatic breast cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Fulvestrant; Metastatic breast cancer; Breast cancer; Internal medicine; Oncology; Cancer; Estrogen receptor; Palbociclib","score_opus":0.12521894117043925,"score_gpt":0.49614112231660895,"score_spread":0.3709221811461697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379285864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933914,0.00079951435,0.00013365959,0.0028016716,0.0003691913,0.002357291,0.0000644959,0.000036194982,0.000046611243],"genre_scores_gemma":[0.98773015,0.0011002038,0.0096775,0.00036323076,0.00038583,0.00036738178,0.0000068779486,0.00009907159,0.0002697616],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943423,0.0008368888,0.0029668147,0.0005145624,0.0007692203,0.0005701834],"domain_scores_gemma":[0.9940577,0.0013741485,0.003257406,0.0003463118,0.00056814245,0.00039625794],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016884872,0.00041384052,0.0031748626,0.00040443137,0.00007172554,0.000009614931,0.00027451702,0.0001828839,0.0003855373],"category_scores_gemma":[0.00078358984,0.0002564113,0.00036593698,0.0012287745,0.0003264082,0.00030908143,0.00006060113,0.000991637,0.000009997498],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23229568,0.042401925,0.21904401,0.00023437467,0.007242964,0.0013894129,0.0022030405,0.00084856723,0.008952607,0.00001419581,0.00011332382,0.4852599],"study_design_scores_gemma":[0.47073233,0.22529393,0.2639521,0.0028341855,0.0057194387,0.0009126097,0.015182048,0.00087220635,0.004602733,0.0002831889,0.008575032,0.0010401804],"about_ca_topic_score_codex":0.0002121098,"about_ca_topic_score_gemma":0.00022656024,"teacher_disagreement_score":0.48421973,"about_ca_system_score_codex":0.0005189302,"about_ca_system_score_gemma":0.0019084355,"threshold_uncertainty_score":0.9999888},"labels":[],"label_agreement":null},{"id":"W4379328967","doi":"10.1200/jco.2023.41.16_suppl.tps1115","title":"HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pertuzumab; Internal medicine; Metastatic breast cancer; Capecitabine; Oncology; Trastuzumab; Neratinib; Taxane; Progression-free survival; Breast cancer; Cancer; Colorectal cancer; Chemotherapy","score_opus":0.13449861670288013,"score_gpt":0.5150052673203316,"score_spread":0.3805066506174515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379328967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98800457,0.00032699524,0.00023955041,0.009618373,0.0003530867,0.0013780282,0.00002491787,0.000014566461,0.000039891696],"genre_scores_gemma":[0.995699,0.001135269,0.0016604451,0.0008230567,0.00020781554,0.00012611083,0.0000033881092,0.00003861251,0.00030631793],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99684244,0.00037636593,0.0018460777,0.0002655043,0.0003793102,0.00029029546],"domain_scores_gemma":[0.9941221,0.0032265189,0.001637346,0.0001730808,0.0006315704,0.00020940538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002353773,0.00019635941,0.0017336406,0.00024190191,0.00004164372,0.0000071329628,0.00014762445,0.00011957336,0.000080096965],"category_scores_gemma":[0.0010175187,0.00011728635,0.00014550469,0.00044393088,0.00025764204,0.00016662403,0.000022290033,0.0005365252,0.0000011957159],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23240605,0.015388002,0.021471262,0.00012806233,0.001007488,0.0006153982,0.0029874705,0.00014274767,0.00020869893,0.00005072334,0.00040357976,0.7251905],"study_design_scores_gemma":[0.34215328,0.26090294,0.36135116,0.00073604437,0.0005586186,0.002606437,0.020464242,0.00093293,0.00009983593,0.0009749238,0.008947102,0.00027249954],"about_ca_topic_score_codex":0.00011742412,"about_ca_topic_score_gemma":0.0005031635,"teacher_disagreement_score":0.724918,"about_ca_system_score_codex":0.00028555674,"about_ca_system_score_gemma":0.0020591815,"threshold_uncertainty_score":0.47827986},"labels":[],"label_agreement":null},{"id":"W4379329068","doi":"10.1200/jco.2023.41.16_suppl.1078","title":"Alpelisib + endocrine therapy in patients with <i>PIK3CA</i>-mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Letrozole; Fulvestrant; Internal medicine; Tolerability; Breast cancer; Cohort; Oncology; Cancer; Metastatic breast cancer; Adverse effect; Gynecology; Aromatase; Estrogen receptor","score_opus":0.0445158908315171,"score_gpt":0.4085474749493247,"score_spread":0.3640315841178076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379329068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99528533,0.00025733074,0.000016251848,0.002554107,0.00044063458,0.0010353997,0.0002981133,0.000017993965,0.00009482547],"genre_scores_gemma":[0.9970475,0.0012352617,0.00074947433,0.0005915819,0.00019857033,0.000031110438,0.00003210446,0.00004938699,0.00006503421],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99365383,0.0010631019,0.003377606,0.00042699743,0.0010206205,0.00045781338],"domain_scores_gemma":[0.9912144,0.0018809949,0.0043431013,0.0004202332,0.0018664269,0.0002748506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013100698,0.0003537413,0.0034107624,0.0005836113,0.00005895285,0.0000054116363,0.0004318578,0.00020249178,0.0003034782],"category_scores_gemma":[0.00071667414,0.00021012363,0.00070298836,0.0022137284,0.0006013599,0.00027375453,0.00011840626,0.0010811025,0.0000019527079],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029207012,0.0049030916,0.88539886,0.000018209132,0.006855586,0.000057333706,0.00092395546,0.0007475707,0.0024478515,0.000006372149,0.00022361141,0.06921055],"study_design_scores_gemma":[0.030114887,0.014665154,0.95150065,0.00016186123,0.0011055791,0.000012723436,0.00051751215,0.000021313936,0.0011843588,0.000034103818,0.00049679814,0.00018508047],"about_ca_topic_score_codex":0.00035639206,"about_ca_topic_score_gemma":0.00036771238,"teacher_disagreement_score":0.06902547,"about_ca_system_score_codex":0.00037211413,"about_ca_system_score_gemma":0.00070388056,"threshold_uncertainty_score":0.8568593},"labels":[],"label_agreement":null},{"id":"W4379329451","doi":"10.1200/jco.2023.41.16_suppl.1056","title":"Comparative overall survival of patients in trials of CKD4/6 inhibitors in combination with endocrine therapy in advanced breast cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Palbociclib; Fulvestrant; Internal medicine; Oncology; Breast cancer; Tamoxifen; Odds ratio; Adverse effect; Tolerability; Gynecology; Cancer; Metastatic breast cancer","score_opus":0.15844072831483,"score_gpt":0.505342744608513,"score_spread":0.346902016293683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379329451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962953,0.00027714405,0.00001229779,0.0021610176,0.00059981394,0.0005231952,0.00002730506,0.0000044896706,0.00009945105],"genre_scores_gemma":[0.9977004,0.0015728062,0.00039294927,0.00013358722,0.00014438275,0.000016839671,0.000007929523,0.000014413629,0.00001669902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942642,0.0010429136,0.0038515325,0.00017229396,0.00044825076,0.0002208132],"domain_scores_gemma":[0.9927357,0.003223677,0.0032473402,0.00011932349,0.000578994,0.000094966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003726553,0.00014896286,0.0031101834,0.000517547,0.000006739283,0.0000014351995,0.00012152003,0.0001417404,0.00004814917],"category_scores_gemma":[0.0011628746,0.00010312717,0.00019927748,0.0006883628,0.00021288163,0.00018646565,0.000027486523,0.000649746,6.460863e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051366944,0.002908468,0.80393195,0.000036862035,0.00013853176,0.000078688965,0.000611552,0.0016764586,0.00079378596,0.000050152958,0.000027956621,0.13837866],"study_design_scores_gemma":[0.064910956,0.009683793,0.9223898,0.00056969316,0.000024891202,0.000010789177,0.0004273569,0.000063390406,0.00075974996,0.00050372863,0.00057896925,0.000076875636],"about_ca_topic_score_codex":0.00026390544,"about_ca_topic_score_gemma":0.0013820934,"teacher_disagreement_score":0.13830179,"about_ca_system_score_codex":0.00031437073,"about_ca_system_score_gemma":0.0009624998,"threshold_uncertainty_score":0.4205404},"labels":[],"label_agreement":null},{"id":"W4379508645","doi":"10.1177/17588359231178125","title":"Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy <i>versus</i> endocrine therapy alone in patients with HR+/HER2− early breast cancer","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Genentech; PharmaMar; Novartis Institutes for BioMedical Research; Daewoong Pharmaceutical Company; Astellas Pharma; Eisai; Seagen; Mersana Therapeutics; Mylan; Syndax Pharmaceuticals; Clovis Oncology; Astex Pharmaceuticals; Merck KGaA; Taiho Pharmaceutical; F. Hoffmann-La Roche; Amgen; Radius Health; Daiichi Sankyo Europe; LEO Pharma; Gilead Sciences; Exelixis; Sanofi; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Letrozole; Internal medicine; Breast cancer; Clinical endpoint; Oncology; Anastrozole; Palbociclib; Metastatic breast cancer; Goserelin; Randomization; Cancer; Adjuvant therapy; Clinical trial; Tamoxifen; Gynecology","score_opus":0.0373529934834873,"score_gpt":0.3836976276393478,"score_spread":0.3463446341558605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379508645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980725,0.010088973,0.0010597844,0.0021966808,0.00080118305,0.0048710853,0.00011343597,0.0000717459,0.00007210241],"genre_scores_gemma":[0.96795684,0.028822115,0.00079624186,0.00072413473,0.00041012393,0.0010714,0.00008391463,0.00007604025,0.0000591705],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99580514,0.00049899664,0.0012368147,0.0006071044,0.0011874264,0.0006645039],"domain_scores_gemma":[0.9970915,0.0014662707,0.0005772582,0.0003942134,0.0002426967,0.00022809443],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00082490285,0.00042523065,0.0016587125,0.00042346836,0.000050497307,0.0000052146547,0.00030994372,0.00020442388,0.00052870647],"category_scores_gemma":[0.000118714794,0.0003113406,0.00010432195,0.0010592282,0.0011171214,0.0003305318,0.000067869594,0.0005880766,0.0000022450001],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.568946,0.0025650654,0.002403034,0.00003627621,0.00020886707,0.000073261464,0.0005420698,0.00008733958,0.0004594721,0.000076562595,0.0000061898318,0.42459586],"study_design_scores_gemma":[0.9492896,0.028877662,0.008946215,0.00027061565,0.00006929176,0.00003717082,0.0002623628,0.00024374641,0.0009863175,0.0006868613,0.010014846,0.00031529603],"about_ca_topic_score_codex":0.00016801676,"about_ca_topic_score_gemma":0.00015196434,"teacher_disagreement_score":0.42428055,"about_ca_system_score_codex":0.0002576988,"about_ca_system_score_gemma":0.0009079584,"threshold_uncertainty_score":0.99993384},"labels":[],"label_agreement":null},{"id":"W4379645953","doi":"10.1200/jco.2023.41.17_suppl.lba500","title":"Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Letrozole; Breast cancer; Clinical endpoint; Tolerability; Internal medicine; Anastrozole; Population; Oncology; Interim analysis; Goserelin; Cancer; Surgery; Gynecology; Randomized controlled trial; Tamoxifen; Adverse effect","score_opus":0.07422391342854126,"score_gpt":0.4508825997255233,"score_spread":0.37665868629698207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379645953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796555,0.0013468929,0.000003914434,0.017001314,0.00070820213,0.0008796942,0.0002164745,0.00002105465,0.0001669518],"genre_scores_gemma":[0.9886286,0.0067374185,0.0002820543,0.0024043492,0.0015526284,0.00004322954,0.000044253142,0.000036133333,0.0002712983],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99653333,0.00043116775,0.0019118183,0.00032472808,0.0004766503,0.00032230516],"domain_scores_gemma":[0.9946154,0.0030759147,0.0014416768,0.0003032858,0.0002831328,0.00028063636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011260228,0.0002321772,0.0015936447,0.00010696385,0.000058254853,0.000012916347,0.00017752228,0.00016462534,0.00007170611],"category_scores_gemma":[0.0004131212,0.00011629027,0.00021235568,0.0002736806,0.00033605134,0.0001691755,0.00004757347,0.0006973994,0.000009418523],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4239222,0.0022249676,0.073802985,0.0000025206498,0.0004818736,0.0004218074,0.00039284135,0.000006899409,0.000025714922,0.000002992803,0.00020546372,0.49850973],"study_design_scores_gemma":[0.3718432,0.02681236,0.57405925,0.00011451922,0.00012928319,0.000061589446,0.00009906081,0.0000045582055,0.000018760978,0.00011424717,0.026663654,0.00007953325],"about_ca_topic_score_codex":0.0010467157,"about_ca_topic_score_gemma":0.0002622869,"teacher_disagreement_score":0.50025624,"about_ca_system_score_codex":0.0003838703,"about_ca_system_score_gemma":0.0013702617,"threshold_uncertainty_score":0.47421795},"labels":[],"label_agreement":null},{"id":"W4379662208","doi":"10.1200/jco.2023.41.17_suppl.lba5507","title":"Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"ImmunoGen","keywords":"Medicine; Clinical endpoint; Tolerability; Internal medicine; Progression-free survival; Oncology; Fallopian tube; Chemotherapy; Ovarian cancer; Topotecan; Paclitaxel; Nausea; Randomized controlled trial; Urology; Surgery; Cancer; Adverse effect","score_opus":0.07782574795674795,"score_gpt":0.4396865665417338,"score_spread":0.36186081858498587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379662208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99103415,0.0002944711,0.00018222224,0.0055010235,0.0014905276,0.0012610498,0.000105080544,0.0000586459,0.00007281413],"genre_scores_gemma":[0.97247756,0.0006077314,0.023531301,0.0013517835,0.0015520679,0.00006133755,0.00004787898,0.00013125398,0.0002391149],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.990888,0.00080206036,0.0056918818,0.000706457,0.0012605642,0.0006510491],"domain_scores_gemma":[0.9894425,0.0025876216,0.0055725067,0.0007139587,0.00094201806,0.00074137055],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002992005,0.00054129696,0.0044248495,0.0005156022,0.00008704724,0.0000118328335,0.0004951949,0.0005935038,0.00024456985],"category_scores_gemma":[0.0032733306,0.00038702035,0.00036541832,0.0011483191,0.0009873849,0.00043320408,0.00011202579,0.0017031922,0.0000022039746],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44889256,0.015655339,0.026258014,0.00055029755,0.0028124163,0.011150309,0.0030929805,0.0007184833,0.37102717,0.00005489649,0.0019380894,0.11784944],"study_design_scores_gemma":[0.4491597,0.15520748,0.2704618,0.003712829,0.0011037582,0.001211523,0.0026286452,0.00009548066,0.053320304,0.0005868135,0.061349522,0.0011621373],"about_ca_topic_score_codex":0.00075935695,"about_ca_topic_score_gemma":0.00070788775,"teacher_disagreement_score":0.31770688,"about_ca_system_score_codex":0.00073341775,"about_ca_system_score_gemma":0.007889159,"threshold_uncertainty_score":0.99985814},"labels":[],"label_agreement":null},{"id":"W4379802500","doi":"10.3390/curroncol30060415","title":"Safety of CDK4/6 Inhibitors Combined with Radiotherapy in Patients with Metastatic Breast Cancer: A Review of the Literature","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de l'Est-de-l'Île-de-Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital Maisonneuve-Rosemont; University of Calgary; McGill University Health Centre","funders":"Pfizer Canada; Pfizer","keywords":"Medicine; Metastatic breast cancer; Radiation therapy; Oncology; Breast cancer; Internal medicine; Cancer; Clinical trial; Palbociclib","score_opus":0.04812967486991594,"score_gpt":0.4022585200143359,"score_spread":0.35412884514441995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379802500","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001237818,0.9939732,0.000007893957,0.0003881447,0.00056018756,0.0041308207,0.0007769134,0.000023294053,0.000015793268],"genre_scores_gemma":[0.000021918804,0.99868965,0.00016601114,0.00010597821,0.000107153544,0.0005031629,0.00026269013,0.00010095611,0.00004249933],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99707884,0.00048410645,0.0011748335,0.00044513287,0.00049126975,0.0003258474],"domain_scores_gemma":[0.9969848,0.00022762288,0.0015918333,0.0006575847,0.00044896101,0.00008919365],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030344128,0.00052780675,0.004061045,0.00027183592,0.000027002516,0.0000031670402,0.00031376904,0.000152151,0.000068058165],"category_scores_gemma":[0.00004403909,0.0002559372,0.00035152264,0.0020333,0.00036539175,0.000057808473,0.00006694455,0.0008217398,0.0000013711302],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012079494,0.00057336286,0.0025503642,0.21956544,0.0006642613,0.0000074991935,0.00018313379,0.0000013687711,8.693867e-8,0.00001943411,0.000162433,0.77506465],"study_design_scores_gemma":[0.0043717693,0.00091619045,0.001882958,0.46921462,0.0013290079,0.0000556909,0.000009794175,3.6500566e-7,3.2113792e-7,0.0000050329577,0.5220406,0.0001736493],"about_ca_topic_score_codex":0.000013423482,"about_ca_topic_score_gemma":0.000038521594,"teacher_disagreement_score":0.774891,"about_ca_system_score_codex":0.00090730994,"about_ca_system_score_gemma":0.0016719332,"threshold_uncertainty_score":0.9999893},"labels":[],"label_agreement":null},{"id":"W4381612716","doi":"10.1200/jco.22.02746","title":"AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"Sanofi","keywords":"Medicine; Internal medicine; Hazard ratio; Estrogen receptor; Oncology; Breast cancer; Fulvestrant; Cancer; Progression-free survival; Clinical endpoint; Gynecology; Clinical trial; Confidence interval; Chemotherapy","score_opus":0.08678585079797575,"score_gpt":0.4766479143054478,"score_spread":0.38986206350747205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381612716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893228,0.0006797048,0.00014645323,0.0051564714,0.0017244561,0.0024012031,0.00044147452,0.00007109533,0.00005634491],"genre_scores_gemma":[0.99009186,0.0020472312,0.0060176323,0.00029183464,0.0010986527,0.00021369403,0.000036884725,0.00011783496,0.00008439898],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98979944,0.0028525863,0.004720294,0.00072827697,0.0010401258,0.0008592951],"domain_scores_gemma":[0.9878008,0.005484255,0.0039475206,0.00034564198,0.0017940636,0.00062776514],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0029542702,0.00064222753,0.0058354577,0.00062150817,0.00017798254,0.000014833891,0.00043946493,0.00039476008,0.00073427794],"category_scores_gemma":[0.00277203,0.0005008311,0.0010838766,0.0011121281,0.0008647178,0.0004860281,0.000108334585,0.0019538607,0.000009822061],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76128936,0.006644517,0.01655972,0.000040427018,0.004131047,0.00026829797,0.0034174111,0.00020687778,0.013675268,0.000068805355,0.00025404894,0.1934442],"study_design_scores_gemma":[0.854488,0.09287938,0.026574029,0.0004284439,0.0008718411,0.00013779233,0.004264681,0.000059688115,0.017583072,0.0003408486,0.00179415,0.00057806674],"about_ca_topic_score_codex":0.00041848354,"about_ca_topic_score_gemma":0.0002241604,"teacher_disagreement_score":0.19286613,"about_ca_system_score_codex":0.0013530997,"about_ca_system_score_gemma":0.002196241,"threshold_uncertainty_score":0.99974436},"labels":[],"label_agreement":null},{"id":"W4382023148","doi":"10.3390/curroncol30070454","title":"Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Capecitabine; Medicine; Internal medicine; Metastatic breast cancer; Aromatase inhibitor; Oncology; Breast cancer; Regimen; Clinical endpoint; Retrospective cohort study; Adverse effect; Progression-free survival; Aromatase; Cancer; Chemotherapy; Randomized controlled trial; Colorectal cancer","score_opus":0.0781724674039042,"score_gpt":0.4118370089856422,"score_spread":0.333664541581738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382023148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9219159,0.017894093,0.0019299705,0.04048708,0.004600929,0.005384506,0.0069363853,0.0006635886,0.00018757282],"genre_scores_gemma":[0.9418095,0.024289673,0.005696667,0.00333292,0.007666088,0.009291405,0.0049453583,0.00045564785,0.0025127905],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977597,0.00010494039,0.0005094241,0.0006283141,0.00030847907,0.0006891476],"domain_scores_gemma":[0.99801636,0.0006077058,0.00028046212,0.000347742,0.00043874484,0.00030898242],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002396355,0.00041265236,0.0008883393,0.00025611502,0.00020448214,0.000017057506,0.0001718346,0.0001229628,0.00058557367],"category_scores_gemma":[0.00015776114,0.000343721,0.00020722317,0.00070098875,0.00029994364,0.00017596029,0.000079891804,0.0003591822,0.0002632903],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0268594,0.002464007,0.001062938,0.00045606462,0.0012445401,0.00013410753,0.004640814,0.00021306431,0.01662944,0.0003036404,0.051321685,0.8946703],"study_design_scores_gemma":[0.05414235,0.00805979,0.041071545,0.0008079985,0.0005320367,0.00047720352,0.001989034,0.0016067548,0.010397221,0.0022008528,0.87765265,0.0010625989],"about_ca_topic_score_codex":0.00014052373,"about_ca_topic_score_gemma":0.00011692046,"teacher_disagreement_score":0.8936077,"about_ca_system_score_codex":0.001112935,"about_ca_system_score_gemma":0.0006899988,"threshold_uncertainty_score":0.9999015},"labels":[],"label_agreement":null},{"id":"W4382989916","doi":"10.3390/books978-3-0365-7908-5","title":"Cancer Prevention with Molecular Target Therapies 3.0","year":2023,"lang":"en","type":"book","venue":"","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Deutsche Gesellschaft für Urologie; Astellas Pharma; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Canadian Dermatology Foundation; Japan Society for the Promotion of Science; Ministerstvo Školství, Mládeže a Tělovýchovy; AstraZeneca; Bristol-Myers Squibb; Universität Heidelberg; Pfizer; National Science Foundation","keywords":"Cancer; Medicine; Internal medicine","score_opus":0.01507194981185289,"score_gpt":0.2978450724852088,"score_spread":0.2827731226733559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382989916","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00072460563,0.032746986,0.030141747,0.005279535,0.00084525533,0.0034183848,0.00015580634,0.002116747,0.9245709],"genre_scores_gemma":[0.00024035916,0.00052419916,0.0051602293,0.0007842314,0.00041285573,0.00028285847,0.0002226892,0.00024536956,0.9921272],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99855876,0.000017161256,0.00021777928,0.00044492245,0.0004702425,0.00029112393],"domain_scores_gemma":[0.99910885,0.00002496771,0.00015680106,0.00044067053,0.00016997673,0.000098743374],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006390835,0.00037580574,0.0005590155,0.00015998821,0.000040661358,0.00001491361,0.000104991894,0.00021735395,0.0022259823],"category_scores_gemma":[0.000005012423,0.0002668198,0.00015473115,0.00012451841,0.00012642561,0.00006515127,0.000033922115,0.00034486334,0.00017239654],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009442857,0.0007668126,0.0022241327,0.0068761893,0.030357026,0.0036466245,0.003779448,0.001512571,0.015289896,0.058785662,0.2005714,0.6667474],"study_design_scores_gemma":[0.0026460069,0.0007126776,0.00050375296,0.0026486008,0.0005595208,0.00008504587,0.0001221284,0.000017224553,0.0022888032,0.03770018,0.9520168,0.00069931685],"about_ca_topic_score_codex":0.00002350197,"about_ca_topic_score_gemma":0.000059137175,"teacher_disagreement_score":0.75144535,"about_ca_system_score_codex":0.00037538176,"about_ca_system_score_gemma":0.0009359653,"threshold_uncertainty_score":0.9999784},"labels":[],"label_agreement":null},{"id":"W4383199379","doi":"10.1200/jco.23.00759","title":"Sequencing of Endocrine and Targeted Therapies in Hormone-Sensitive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Metastatic breast cancer; Breast cancer; Context (archaeology); Clinical trial; Cancer; Oncology; Population; Palbociclib; Letrozole; Targeted therapy; Internal medicine; Bioinformatics; Aromatase; Biology","score_opus":0.18503550709040315,"score_gpt":0.5029483626875648,"score_spread":0.31791285559716165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383199379","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024842964,0.9716289,0.000025044385,0.001337309,0.0008727614,0.00086973445,0.00030404195,0.00002866935,0.000090591406],"genre_scores_gemma":[0.010485186,0.9849924,0.002710377,0.00026475018,0.0012477514,0.0000379077,0.000014596021,0.000112113536,0.00013494103],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99229693,0.0012024617,0.0050702477,0.0004767012,0.0004703684,0.00048331212],"domain_scores_gemma":[0.98709565,0.005111291,0.006237058,0.00024140975,0.00094937504,0.000365214],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0015586386,0.00054613315,0.008476072,0.00059419003,0.000049138842,0.0000069316993,0.00024380138,0.0006291004,0.00014294476],"category_scores_gemma":[0.0024557377,0.00037982877,0.0010237863,0.00055425166,0.00073340227,0.00025296237,0.00012644046,0.0025073178,0.0000053740714],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023318408,0.00027371963,0.0006394114,0.0030273849,0.0019616685,0.00066013884,0.00042075285,0.0000034123254,0.0003573601,0.00004579838,0.00006898205,0.9902095],"study_design_scores_gemma":[0.049389794,0.025332103,0.17846563,0.08348509,0.0065108156,0.008110578,0.003528806,0.000016431059,0.0003498532,0.002147911,0.6403238,0.0023391675],"about_ca_topic_score_codex":0.00015812049,"about_ca_topic_score_gemma":0.00011951951,"teacher_disagreement_score":0.98787034,"about_ca_system_score_codex":0.0009578887,"about_ca_system_score_gemma":0.0032159663,"threshold_uncertainty_score":0.99986535},"labels":[],"label_agreement":null},{"id":"W4384965809","doi":"","title":"Highly sensitive determination of PIK3CA exon 9 and 20 hotspot mutations in breast tumors","year":2012,"lang":"en","type":"preprint","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre d'expertise et de recherche en infrastructures urbaines","funders":"","keywords":"Hotspot (geology); Exon; Cancer research; Computer science; Genetics; Medicine; Biology; Gene; Physics","score_opus":0.012612052769413216,"score_gpt":0.25349776415021646,"score_spread":0.24088571138080325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384965809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92160493,0.0012963612,0.060145058,0.008927925,0.00016674197,0.00090895605,0.00024349666,0.00012577749,0.0065807747],"genre_scores_gemma":[0.9650041,0.00017332447,0.033282563,0.00005553036,0.000028072925,0.00006240293,0.00046970224,0.000042043626,0.0008822954],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99701357,0.0014153778,0.0005057446,0.00047336982,0.0003195606,0.00027237224],"domain_scores_gemma":[0.99620336,0.000703039,0.0005176862,0.0008941359,0.001525372,0.0001563862],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017062814,0.00026853423,0.00048223024,0.0003383443,0.00009022313,0.000042059364,0.00020754563,0.00020031935,0.000034010485],"category_scores_gemma":[0.00036433476,0.0002889502,0.00010068514,0.00031443202,0.00035544182,0.00016353076,0.00037907835,0.00048716442,0.0000057958678],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005142776,0.0024893247,0.07746155,0.002037978,0.00025626874,0.00006303174,0.079338044,0.0001296517,0.10702667,0.020732071,0.000048096732,0.70990306],"study_design_scores_gemma":[0.0041101663,0.0000024355252,0.7601941,0.013416547,0.0003302074,0.0004972745,0.0017890343,0.01125257,0.20039077,0.0056422283,0.001367479,0.0010071781],"about_ca_topic_score_codex":0.0008028677,"about_ca_topic_score_gemma":0.0007858786,"teacher_disagreement_score":0.70889586,"about_ca_system_score_codex":0.00020158851,"about_ca_system_score_gemma":0.000243029,"threshold_uncertainty_score":0.99995625},"labels":[],"label_agreement":null},{"id":"W4385410847","doi":"10.1093/oncolo/oyad207","title":"Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"Genentech; Plexxikon; Eisai; Seagen; MacroGenics; Les Laboratories Pierre Fabre; Genomic Health; F. Hoffmann-La Roche; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Novartis Pharmaceuticals Corporation; Bayer; AstraZeneca; Eli Lilly and Company; Breast Cancer Alliance","keywords":"Medicine; Quality of life (healthcare); Breast cancer; Anxiety; Physical therapy; Diarrhea; Cancer; Internal medicine; Psychiatry","score_opus":0.022455856401611768,"score_gpt":0.3213516366995914,"score_spread":0.2988957802979796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385410847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973521,0.00039505633,0.000007713256,0.00062061474,0.000108802305,0.0008949436,0.0004753359,0.000087674955,0.000057749196],"genre_scores_gemma":[0.9990931,0.00014273038,0.00015250569,0.0001674084,0.000024715902,0.00012445543,0.0001404287,0.000031515716,0.00012314822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851173,0.00027231907,0.00035516088,0.00032098047,0.00024364582,0.0002961885],"domain_scores_gemma":[0.99796563,0.0012858508,0.00021863732,0.00032922276,0.000102702026,0.00009797418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003465032,0.00022182576,0.000651946,0.000073700874,0.00006767585,0.00000774061,0.00010378613,0.00009978061,0.000024683724],"category_scores_gemma":[0.00027180108,0.00013158824,0.00003992987,0.00048197727,0.00039938174,0.00008362803,0.00004954661,0.00016358386,0.000008850527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007687491,0.00030140724,0.9466318,0.00004758424,0.0002192121,0.000009280184,0.0007282849,0.00023357278,0.0007504971,0.000008776453,0.000011031897,0.04337107],"study_design_scores_gemma":[0.016332379,0.0006791661,0.98206836,0.0001756591,0.000051355513,0.0000012961624,0.00021107569,0.000073936375,0.00014058164,0.000076791184,0.00004866031,0.00014074512],"about_ca_topic_score_codex":0.016601516,"about_ca_topic_score_gemma":0.009424921,"teacher_disagreement_score":0.043230325,"about_ca_system_score_codex":0.00044147813,"about_ca_system_score_gemma":0.0001935476,"threshold_uncertainty_score":0.989947},"labels":[],"label_agreement":null},{"id":"W4385476617","doi":"10.1093/oncolo/oyad215","title":"A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Center for Advancing Translational Sciences; Conquer Cancer Foundation; National Cancer Institute; Memorial Sloan-Kettering Cancer Center; American Society of Clinical Oncology; Eli Lilly and Company","keywords":"Nausea; Medicine; Vomiting; Adverse effect; Dosing; Gastroenterology; Clinical endpoint; Pharmacokinetics; Internal medicine; Neutropenia; Anemia; Pharmacology; Peripheral edema; Toxicity; Clinical trial","score_opus":0.033547687745609484,"score_gpt":0.36931083232137035,"score_spread":0.33576314457576084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385476617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99626964,0.000028284154,0.00012577495,0.0004690259,0.00015584622,0.0026604314,0.00007402229,0.000092662274,0.00012429968],"genre_scores_gemma":[0.99890816,0.000006019239,0.0003679786,0.00012631115,0.00006931936,0.00025449492,0.00003512656,0.000036639598,0.00019593985],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99812055,0.00010734559,0.00058796053,0.00032133184,0.000585919,0.00027689108],"domain_scores_gemma":[0.9984214,0.0001596684,0.0004413792,0.00056797266,0.00028446404,0.0001251315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030628723,0.00020795179,0.0005813553,0.00015190965,0.00007663784,0.0000058456744,0.00018864608,0.000046354653,0.00003080634],"category_scores_gemma":[0.000174594,0.00013135561,0.00006262098,0.0005874577,0.00019605443,0.000067956236,0.00012014371,0.00014542686,0.000018765082],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14775212,0.06147178,0.22390875,0.00082764257,0.0012012367,0.0004337588,0.032926667,0.009820418,0.12013312,0.000088414585,0.00033948346,0.4010966],"study_design_scores_gemma":[0.07621856,0.0781263,0.79576796,0.0007571286,0.00045020747,0.00001709967,0.013115193,0.0001947545,0.0341489,0.00010573789,0.000645362,0.00045276937],"about_ca_topic_score_codex":0.000074503994,"about_ca_topic_score_gemma":0.00016966402,"teacher_disagreement_score":0.57185924,"about_ca_system_score_codex":0.00021436997,"about_ca_system_score_gemma":0.00015071833,"threshold_uncertainty_score":0.53565264},"labels":[],"label_agreement":null},{"id":"W4385690625","doi":"10.1200/jco.23.00126","title":"Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Palbociclib; Medicine; Oncology; Breast cancer; Internal medicine; Endocrine system; Hormone receptor; Cancer; Gynecology; Hormone; Metastatic breast cancer","score_opus":0.080194030517838,"score_gpt":0.4702822198798135,"score_spread":0.39008818936197553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385690625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957517,0.00017357012,0.000012718172,0.0028188308,0.00025574744,0.0008786935,0.000026149208,0.000010101891,0.0000725349],"genre_scores_gemma":[0.9971803,0.0011098507,0.00047944093,0.0004028571,0.0007025908,0.00003604611,0.000004588651,0.00003927898,0.00004504175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99622464,0.0007358238,0.0017605507,0.00023994457,0.00064587337,0.00039319374],"domain_scores_gemma":[0.99505097,0.0022062038,0.0017783092,0.000235327,0.00055651285,0.00017269964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00197719,0.00023266814,0.0017690061,0.00025619025,0.000028221706,0.000009214503,0.00024534584,0.00017652058,0.00011415576],"category_scores_gemma":[0.00050360744,0.00010143069,0.00025445136,0.00086677057,0.00032680173,0.00021355636,0.000028585022,0.0011763611,0.0000027568944],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39462605,0.0012987445,0.5360111,0.0000050119506,0.00036764267,0.00012437241,0.0007049103,0.00006235866,0.00004850855,0.0000012562873,0.00006735036,0.06668267],"study_design_scores_gemma":[0.17131658,0.057125356,0.7704671,0.00032551176,0.00007192705,0.00008553421,0.0002550009,0.000007637807,0.000009786694,0.00002493574,0.00021249926,0.00009811947],"about_ca_topic_score_codex":0.00039794575,"about_ca_topic_score_gemma":0.0006251216,"teacher_disagreement_score":0.23445599,"about_ca_system_score_codex":0.00037418195,"about_ca_system_score_gemma":0.001918721,"threshold_uncertainty_score":0.5110769},"labels":[],"label_agreement":null},{"id":"W4385749349","doi":"10.21203/rs.3.rs-3158114/v1","title":"Comparative overall survival of CKD4/6 inhibitors in combination with endocrine therapy in advanced breast cancer","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Neutropenia; Adverse effect; Discontinuation; Palbociclib; Breast cancer; Oncology; Combination therapy; Cancer; Metastatic breast cancer; Toxicity","score_opus":0.09714353197445472,"score_gpt":0.4449209688270008,"score_spread":0.34777743685254603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385749349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906066,0.0023050953,0.00003911843,0.0029028766,0.00022879537,0.0031991429,0.0003224459,0.00008067956,0.00031526675],"genre_scores_gemma":[0.9951442,0.0025037616,0.00023335806,0.000020775786,0.00015503883,0.0012143626,0.00021644466,0.000094417985,0.0004176561],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99571997,0.0005071768,0.0006074845,0.00078973937,0.0016202533,0.0007553732],"domain_scores_gemma":[0.99740165,0.00044459134,0.00022968199,0.0006424259,0.001132701,0.00014892136],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008404208,0.00039029773,0.0011768808,0.0012899092,0.00004743022,0.000023825552,0.0002867683,0.00018680934,0.00012569221],"category_scores_gemma":[0.0000681855,0.0003262668,0.0001056251,0.0013312773,0.00037446604,0.00016435364,0.00034593872,0.0020303258,0.000008763422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02830057,0.002646243,0.8535053,0.003880424,0.0005160903,0.00052904297,0.009620117,0.024969423,0.011189994,0.0008410127,0.00015835778,0.063843414],"study_design_scores_gemma":[0.013335566,0.0011232813,0.9652261,0.008599354,0.000009378132,0.00001541641,0.0027660101,0.00052156305,0.0054500615,0.0021371911,0.0004480862,0.00036794948],"about_ca_topic_score_codex":0.0059978194,"about_ca_topic_score_gemma":0.005820511,"teacher_disagreement_score":0.11172083,"about_ca_system_score_codex":0.0013398229,"about_ca_system_score_gemma":0.001099048,"threshold_uncertainty_score":0.99991894},"labels":[],"label_agreement":null},{"id":"W4385989336","doi":"10.1016/j.annonc.2023.08.003","title":"Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Principia Biopharma; ImmunoMedics; Sierra Oncology; Loxo Oncology; Chugai Pharmaceutical; AstraZeneca; Genentech; Amgen; Science Foundation Ireland; Seagen; G1 Therapeutics; Daiichi-Sankyo; MacroGenics; Silverback Therapeutics; FibroGen; Puma Biotechnology; Novartis Pharmaceuticals Corporation; F-star Therapeutics; Aminex Therapeutics; F. Hoffmann-La Roche; Genomic Health; Menarini Silicon Biosystems; BeiGene; University of Wisconsin Carbone Cancer Center; Sun Pharma; Five Prime Therapeutics; Array BioPharma; Merck KGaA; Memorial Sloan-Kettering Cancer Center; National Institutes of Health; Natera; BioMarin Pharmaceutical; Astellas Pharma; Eisai; Daiichi Sankyo Europe; University of Wisconsin-Madison; National Breast Cancer Foundation; Incyte; Servier; Gilead Sciences; Exelixis; Jounce Therapeutics; Breast Cancer Research Foundation; Apollomics; Sanofi; GlaxoSmithKline; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; Pfizer","keywords":"Fulvestrant; Neratinib; Medicine; Trastuzumab; Metastatic breast cancer; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Breast cancer; Cancer; Gastroenterology; Progressive disease; Chemotherapy; Tamoxifen","score_opus":0.09886301706774538,"score_gpt":0.4203931923658902,"score_spread":0.3215301752981448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385989336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9460942,0.00068729324,0.00075573404,0.047376875,0.00028228093,0.0014941402,0.0031379687,0.00006430534,0.000107204796],"genre_scores_gemma":[0.994646,0.0006848124,0.0013835597,0.002228401,0.00020000806,0.00043372292,0.00018455199,0.000041917952,0.00019702334],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977917,0.0002876837,0.00067198643,0.0004858026,0.00029737508,0.00046542977],"domain_scores_gemma":[0.9961937,0.00257448,0.0003888832,0.00035111076,0.00033949394,0.00015230414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058535323,0.0003044948,0.0013340295,0.00023446504,0.00015144225,0.000020508738,0.00017738387,0.0001173522,0.00023391374],"category_scores_gemma":[0.00021164422,0.00019802351,0.00043490267,0.0009174792,0.00048148658,0.000114390525,0.0000534442,0.00017771643,0.0000051006637],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13844086,0.0016490087,0.060437813,0.00018589337,0.03691323,0.00020032167,0.006295879,0.0003840712,0.009955742,0.00050935015,0.0041866666,0.74084115],"study_design_scores_gemma":[0.06414041,0.0043917843,0.90398335,0.00012781964,0.0050056167,0.00003570381,0.0033998657,0.0013301595,0.004241595,0.003174548,0.009728864,0.00044025524],"about_ca_topic_score_codex":0.0023312157,"about_ca_topic_score_gemma":0.0028457178,"teacher_disagreement_score":0.84354556,"about_ca_system_score_codex":0.00007405975,"about_ca_system_score_gemma":0.00035859874,"threshold_uncertainty_score":0.80751646},"labels":[],"label_agreement":null},{"id":"W4386000004","doi":"10.7287/peerj.15873v0.1/reviews/1","title":"Peer Review #1 of \"Prognostic and clinicopathological role of RACK1 for cancer patients: a systematic review and meta-analysis (v0.1)\"","year":2023,"lang":"en","type":"review","venue":"","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Meta-analysis; Cancer; Medicine; Oncology; Internal medicine; Psychology","score_opus":0.18087803615338305,"score_gpt":0.4597451726201375,"score_spread":0.27886713646675443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386000004","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[3.1374734e-7,0.9873279,0.00006777929,0.00065719226,0.000020719779,0.010930968,0.0009184575,0.000033168646,0.000043509197],"genre_scores_gemma":[0.0000017706609,0.98971754,0.0008535296,0.0009834284,0.000020127138,0.004967008,0.00025611007,0.00006496577,0.003135512],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9949408,0.00042478179,0.003042478,0.000649844,0.0006964963,0.00024558112],"domain_scores_gemma":[0.9931185,0.0015358281,0.0024288911,0.00072170957,0.0020591232,0.00013595128],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.002466767,0.000564836,0.020802671,0.00023677184,0.000024977193,0.0000063913803,0.00018532465,0.00019242539,0.00036405394],"category_scores_gemma":[0.0071235946,0.0002948287,0.0031782698,0.0010042867,0.00016587862,0.00005061087,0.0001234285,0.00022139166,0.000004560446],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000069276134,0.00007069599,0.00001720153,0.930511,0.052845553,0.0000013870396,0.000011499992,2.1135259e-8,2.3731092e-8,0.00003344287,0.00014562324,0.016356632],"study_design_scores_gemma":[0.00015275773,0.00014180935,0.0000057001307,0.36708772,0.58014166,0.000011828242,0.000009586109,7.153175e-7,9.541944e-8,0.000025380252,0.052278742,0.00014400165],"about_ca_topic_score_codex":0.000014011869,"about_ca_topic_score_gemma":0.000007747928,"teacher_disagreement_score":0.5634233,"about_ca_system_score_codex":0.000051616615,"about_ca_system_score_gemma":0.00014475288,"threshold_uncertainty_score":0.9999504},"labels":[],"label_agreement":null},{"id":"W4386000016","doi":"10.7287/peerj.15873v0.1/reviews/3","title":"Peer Review #3 of \"Prognostic and clinicopathological role of RACK1 for cancer patients: a systematic review and meta-analysis (v0.1)\"","year":2023,"lang":"en","type":"review","venue":"","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Meta-analysis; Oncology; Medicine; Internal medicine","score_opus":0.18087803615338305,"score_gpt":0.4597451726201375,"score_spread":0.27886713646675443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386000016","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[3.2678346e-7,0.98719764,0.00006286301,0.00066248735,0.000020607467,0.01106941,0.0009105937,0.000033417982,0.000042683558],"genre_scores_gemma":[0.0000016986583,0.98974824,0.00092367985,0.0009812142,0.000020733922,0.0050699026,0.00026142,0.00006531917,0.0029278055],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99491763,0.0004294131,0.0030435177,0.00065440615,0.00070696574,0.0002480739],"domain_scores_gemma":[0.99314827,0.0015454992,0.0024341252,0.00072893396,0.0020050348,0.00013815345],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0024930988,0.00056721794,0.020898277,0.00023715127,0.000025517365,0.000006482864,0.0001829887,0.00019735687,0.0003761877],"category_scores_gemma":[0.0068522114,0.0002968958,0.0031469832,0.0010226516,0.0001649215,0.000051022904,0.00012326313,0.00022005252,0.0000046251475],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000066217517,0.00006960962,0.000018017536,0.9312648,0.05216576,0.0000013791141,0.000011222995,2.3520908e-8,2.410921e-8,0.000033830584,0.00014321339,0.016285472],"study_design_scores_gemma":[0.00015450944,0.00014028126,0.000006217673,0.36018482,0.5858675,0.000011338689,0.000008774602,6.9041107e-7,9.833624e-8,0.000027980026,0.05345016,0.0001476043],"about_ca_topic_score_codex":0.000013746768,"about_ca_topic_score_gemma":0.000007286109,"teacher_disagreement_score":0.57108,"about_ca_system_score_codex":0.000051779592,"about_ca_system_score_gemma":0.00014810998,"threshold_uncertainty_score":0.9999483},"labels":[],"label_agreement":null},{"id":"W4386000975","doi":"10.7287/peerj.15873v0.1/reviews/2","title":"Peer Review #2 of \"Prognostic and clinicopathological role of RACK1 for cancer patients: a systematic review and meta-analysis (v0.1)\"","year":2023,"lang":"en","type":"review","venue":"","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Meta-analysis; Oncology; Peer review; Internal medicine; Medicine; Psychology; Political science; Law","score_opus":0.18087803615338305,"score_gpt":0.4597451726201375,"score_spread":0.27886713646675443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386000975","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[3.28391e-7,0.98720247,0.00006233222,0.00066286186,0.000020651154,0.011062713,0.00091195863,0.000033432458,0.0000432816],"genre_scores_gemma":[0.0000016940103,0.98968726,0.00090032443,0.00097564305,0.000020760051,0.0050574616,0.00026265436,0.000065335,0.0030288415],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9949115,0.00042912958,0.0030471473,0.0006550844,0.00070885755,0.00024830247],"domain_scores_gemma":[0.99311435,0.0015433714,0.0024459425,0.000729949,0.0020280792,0.00013829248],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0025003403,0.0005675571,0.020880822,0.0002371954,0.000025565312,0.0000064881137,0.00018500937,0.00019740645,0.00037355945],"category_scores_gemma":[0.0069163353,0.00029702645,0.0031408782,0.0010230972,0.00016515197,0.000051063074,0.00012336452,0.00022023913,0.000004635921],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000006639405,0.00007038079,0.000017288872,0.93006575,0.052422293,0.0000013774284,0.000011411487,2.3387228e-8,2.3437762e-8,0.000034428165,0.0001432644,0.017227143],"study_design_scores_gemma":[0.00015505108,0.00014054193,0.000006256271,0.35990047,0.5860003,0.000011446225,0.000008903038,6.944336e-7,9.635608e-8,0.00002750552,0.05360099,0.00014768941],"about_ca_topic_score_codex":0.000013724731,"about_ca_topic_score_gemma":0.0000073629835,"teacher_disagreement_score":0.5701653,"about_ca_system_score_codex":0.000051880157,"about_ca_system_score_gemma":0.00014854163,"threshold_uncertainty_score":0.9999482},"labels":[],"label_agreement":null},{"id":"W4386102828","doi":"10.1016/s0140-6736(23)01245-x","title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":427,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"MacroGenics; Puma Biotechnology; Mylan; Gilead Sciences; Amgen; Pfizer; Samsung; Genentech; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Metastatic breast cancer; Internal medicine; Oncology; Clinical endpoint; Breast cancer; Hazard ratio; Taxane; Cancer; Clinical trial; Confidence interval","score_opus":0.05675231104043848,"score_gpt":0.3583262430471858,"score_spread":0.3015739320067473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386102828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98604095,0.00041039998,0.00010100532,0.0068832207,0.00023021684,0.0042392835,0.0016838891,0.00014219519,0.00026884102],"genre_scores_gemma":[0.99497455,0.0005851753,0.0010647151,0.0007549887,0.0010214432,0.0008135875,0.00017319123,0.00009894355,0.00051340356],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997019,0.0005685259,0.00053036114,0.0006211954,0.00048114447,0.00077980594],"domain_scores_gemma":[0.99804157,0.0007137109,0.00033854294,0.00049232744,0.00019067238,0.00022315611],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054038723,0.00046634272,0.0015268932,0.00015308069,0.0002459273,0.00011146669,0.00039943022,0.00007708608,0.0003158367],"category_scores_gemma":[0.00017125034,0.0003028763,0.000063942854,0.00059733476,0.00040023867,0.00042240345,0.00018378593,0.00055169483,0.000025028628],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94078726,0.0011142844,0.0025577853,0.00017466581,0.0014224343,0.00012491741,0.0059954664,0.00002853279,0.02479061,0.0009918552,0.0015122038,0.020499988],"study_design_scores_gemma":[0.95043254,0.0021547268,0.040952995,0.0004428224,0.00030626325,0.000051993848,0.0010595332,0.00015266628,0.002365462,0.0006660592,0.0008348606,0.0005800706],"about_ca_topic_score_codex":0.0028741278,"about_ca_topic_score_gemma":0.00089205994,"teacher_disagreement_score":0.03839521,"about_ca_system_score_codex":0.0004470126,"about_ca_system_score_gemma":0.00021643593,"threshold_uncertainty_score":0.99994236},"labels":[],"label_agreement":null},{"id":"W4386175661","doi":"10.22259/2638-5074.0101005","title":"Patent and Publications Trends in Breast Cancer Chemotherapy","year":2018,"lang":"en","type":"article","venue":"Archives of Oncology and Cancer Therapy","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Instituto Mexicano del Seguro Social","keywords":"Breast cancer; Oncology; Chemotherapy; Medicine; Internal medicine; Cancer","score_opus":0.03782662346253245,"score_gpt":0.3540970565709901,"score_spread":0.31627043310845765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386175661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94868183,0.012939751,0.00010028112,0.034532856,0.00010985176,0.00022104854,0.000068146284,0.000033000077,0.0033132574],"genre_scores_gemma":[0.9572055,0.038241558,0.0007937243,0.0025031907,0.00024052165,0.00018796188,0.000006720497,0.000021798776,0.0007990237],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99916804,0.000044238517,0.0002091507,0.00027710223,0.00007721498,0.00022428109],"domain_scores_gemma":[0.999508,0.0000646221,0.000107340806,0.0001749218,0.000048181035,0.00009693355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000069440706,0.00014244669,0.00033874743,0.00024786766,0.000063642256,0.000005039023,0.000074494645,0.000069300455,0.00059877546],"category_scores_gemma":[0.000001835467,0.00011452282,0.00004016927,0.00022070705,0.0008607354,0.00008291512,0.000022606459,0.00013641977,4.5735018e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002347677,0.00016777606,0.15216757,0.0000123285445,0.00011788013,0.0000011828106,0.002766934,9.258698e-7,0.019425731,0.00036492455,0.000056284076,0.8225708],"study_design_scores_gemma":[0.00624828,0.00067029055,0.9026301,0.000075359916,0.000018422741,0.00006762621,0.00018044905,0.000070611146,0.0029686403,0.0014690777,0.08548038,0.00012076047],"about_ca_topic_score_codex":0.00043024894,"about_ca_topic_score_gemma":0.0003530658,"teacher_disagreement_score":0.82245004,"about_ca_system_score_codex":0.00004907998,"about_ca_system_score_gemma":0.00014556384,"threshold_uncertainty_score":0.6556171},"labels":[],"label_agreement":null},{"id":"W4386243741","doi":"10.1016/s1470-2045(23)00268-1","title":"Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; F. Hoffmann-La Roche; Roche; Amgen","keywords":"Anastrozole; Medicine; Palbociclib; Breast cancer; Internal medicine; Oncology; Clinical endpoint; Cancer; Gynecology; Regimen; Phases of clinical research; Tamoxifen; Clinical trial; Metastatic breast cancer","score_opus":0.07426775205635529,"score_gpt":0.41728094600258087,"score_spread":0.3430131939462256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386243741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683664,0.00046320446,0.00004193318,0.019490508,0.00060671597,0.0085103195,0.001736571,0.00030021626,0.00048416088],"genre_scores_gemma":[0.98655695,0.00099936,0.00046197322,0.0027637496,0.0016200216,0.005803074,0.000080385915,0.00019026933,0.0015242427],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99430805,0.0015478198,0.0010491076,0.0010776123,0.00055465405,0.0014627815],"domain_scores_gemma":[0.9969176,0.0007291394,0.00053082046,0.0010116998,0.00039308143,0.0004176573],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016871955,0.0007268942,0.0030235471,0.00025147173,0.00036554167,0.00012158496,0.0012008125,0.00024950158,0.0018955152],"category_scores_gemma":[0.00008326144,0.00045212975,0.00012304488,0.0013147942,0.00058739417,0.0005351139,0.00032860594,0.00095981744,0.00010631908],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.753777,0.00586485,0.033285487,0.00007570603,0.00213706,0.0012430885,0.010113242,0.0010976709,0.0133078825,0.00007240919,0.0015347411,0.17749085],"study_design_scores_gemma":[0.7934967,0.0070993756,0.1858438,0.00048994715,0.0006193965,0.00068320846,0.0061090803,0.0014693526,0.0004009867,0.00008582977,0.002944551,0.0007577357],"about_ca_topic_score_codex":0.013935042,"about_ca_topic_score_gemma":0.01143871,"teacher_disagreement_score":0.1767331,"about_ca_system_score_codex":0.0012993492,"about_ca_system_score_gemma":0.0017535195,"threshold_uncertainty_score":0.99979305},"labels":[],"label_agreement":null},{"id":"W4386329445","doi":"10.1186/s13058-023-01701-9","title":"Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant","year":2023,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Institutes for BioMedical Research; Astex Pharmaceuticals; Novartis Pharmaceuticals Corporation","keywords":"Fulvestrant; Medicine; Hazard ratio; Internal medicine; Breast cancer; Oncology; Population; Cancer; Placebo; Letrozole; Progression-free survival; Proportional hazards model; Chemotherapy; Tamoxifen; Confidence interval; Pathology","score_opus":0.05336560724581937,"score_gpt":0.374452246573516,"score_spread":0.32108663932769665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386329445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95826524,0.0012910726,0.000019141049,0.033467572,0.00059684145,0.0027820133,0.0030285749,0.00033212587,0.00021741615],"genre_scores_gemma":[0.9895198,0.0020324183,0.00010621014,0.0005598044,0.0022083865,0.0033256763,0.00029623994,0.0002563514,0.0016951464],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9922765,0.0005690175,0.0008161444,0.0014025911,0.0025222553,0.0024134924],"domain_scores_gemma":[0.99631375,0.0008754706,0.00023201383,0.0011658011,0.000803311,0.00060965144],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017668116,0.00067152746,0.0011180859,0.00046903122,0.0005214753,0.0001486669,0.00085282605,0.00025452365,0.0029811456],"category_scores_gemma":[0.0000915862,0.00046978088,0.00011544851,0.0031159085,0.000699996,0.0005356787,0.00036501756,0.0018826947,0.00011354021],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72309536,0.00094959006,0.05962095,0.00029348824,0.0015339534,0.0010604647,0.0065330197,0.014632791,0.014037741,0.00013371448,0.0016924815,0.17641643],"study_design_scores_gemma":[0.104939334,0.001253867,0.8776325,0.0016382817,0.000087972585,0.00024668104,0.0027292592,0.00077998557,0.00028512106,0.0006815232,0.008910979,0.00081449485],"about_ca_topic_score_codex":0.030604912,"about_ca_topic_score_gemma":0.017158197,"teacher_disagreement_score":0.8180115,"about_ca_system_score_codex":0.0036070799,"about_ca_system_score_gemma":0.0025607373,"threshold_uncertainty_score":0.9997754},"labels":[],"label_agreement":null},{"id":"W4386445019","doi":"10.1016/j.annonc.2023.08.011","title":"Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation; Novartis","keywords":"Medicine; Oncology; CDKN2A; Internal medicine; Breast cancer; Clinical trial; Cancer; Palbociclib; Biomarker; Progression-free survival; Placebo; Metastatic breast cancer; Pathology; Overall survival; Genetics; Biology","score_opus":0.14263278148074146,"score_gpt":0.499450519089931,"score_spread":0.35681773760918956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386445019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98069066,0.0021876819,0.00024314747,0.014229055,0.00027798864,0.00051460444,0.0008049851,0.00009322303,0.0009586388],"genre_scores_gemma":[0.9949136,0.002105489,0.00035449985,0.0014185632,0.0001799988,0.00012151399,0.00012750298,0.000029220942,0.00074962183],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997612,0.0002134636,0.0010944688,0.00034309283,0.00033816803,0.00039882088],"domain_scores_gemma":[0.9972306,0.0006535652,0.0008845429,0.000428665,0.0006409203,0.00016169764],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011245506,0.00020553153,0.0023412374,0.0008847318,0.00003554488,0.000002226201,0.00016846547,0.00015975742,0.0013991562],"category_scores_gemma":[0.00030613033,0.00017365378,0.0006152865,0.0023235334,0.00024700732,0.00010551305,0.000058181893,0.00014887287,0.00001343416],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012755961,0.00085969584,0.0023599167,0.00010086315,0.0098051615,0.00006356699,0.00070426444,0.002235409,0.15961307,0.0002517254,0.0015579914,0.8096924],"study_design_scores_gemma":[0.11044344,0.011792818,0.3226848,0.00079732586,0.026478792,0.00016755065,0.0038819897,0.005093062,0.2806086,0.0033003923,0.23339014,0.0013611006],"about_ca_topic_score_codex":0.00019515274,"about_ca_topic_score_gemma":0.000130931,"teacher_disagreement_score":0.80833125,"about_ca_system_score_codex":0.00007140097,"about_ca_system_score_gemma":0.00041179653,"threshold_uncertainty_score":0.9995137},"labels":[],"label_agreement":null},{"id":"W4386602801","doi":"10.32388/ewkufh","title":"Review of: \"Targeting Cancer Cell Signaling Using Precision Oncology Towards a Holistic Approach to Cancer Therapeutics\"","year":2023,"lang":"en","type":"peer-review","venue":"","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Cancer; Precision oncology; Medicine; Cancer research; Computational biology; Oncology; Internal medicine; Biology","score_opus":0.20853951999257384,"score_gpt":0.4641549480270235,"score_spread":0.2556154280344497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386602801","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002762324,0.96359867,0.008116483,0.01360185,0.0028664782,0.0038756286,0.0005537595,0.00019257831,0.0071669496],"genre_scores_gemma":[0.00007030773,0.87713873,0.031561267,0.046008695,0.0019211302,0.001258844,0.0004920844,0.0003567145,0.041192222],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949303,0.00027707792,0.0016738437,0.0011757778,0.0011108754,0.00083211664],"domain_scores_gemma":[0.99587125,0.0002984694,0.0011067003,0.00087198336,0.0015303404,0.00032128164],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014027348,0.0008497705,0.0033839522,0.00023259012,0.000105144136,0.000014580581,0.00053438504,0.00046918937,0.002207815],"category_scores_gemma":[0.00030616857,0.0006646742,0.0005741631,0.0011254187,0.000115547955,0.000092563816,0.00030910718,0.00091807713,0.000028718205],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023544005,0.00028319113,0.000010288742,0.3292833,0.00080524787,0.000017743705,0.00040973476,0.0007905328,0.0048766313,0.000008513354,0.21243758,0.45084178],"study_design_scores_gemma":[0.0005845481,0.00015810366,0.0000056312474,0.2230418,0.0026426418,0.000024186673,0.00010174503,0.00029407087,0.0008316855,0.000021996408,0.7717452,0.0005483738],"about_ca_topic_score_codex":0.006295322,"about_ca_topic_score_gemma":0.00016076757,"teacher_disagreement_score":0.55930763,"about_ca_system_score_codex":0.0025604556,"about_ca_system_score_gemma":0.0032999974,"threshold_uncertainty_score":0.99958044},"labels":[],"label_agreement":null},{"id":"W4386639869","doi":"10.26434/chemrxiv-2023-kzgfb","title":"Spy1-activated Cyclin Dependent Kinase 2 Shows Reduced Affinity for Current Synthetic Small Molecule Inhibitors of the CDK2-Cyclin Complex","year":2023,"lang":"en","type":"preprint","venue":"ChemRxiv","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Windsor","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Alliance de recherche numérique du Canada; Ontario Institute for Cancer Research","keywords":"Cyclin-dependent kinase; Cyclin-dependent kinase 2; Cyclin; Small molecule; Biology; Kinase; Cyclin A; CDK inhibitor; Cancer research; Cell cycle; Cell biology; Protein kinase A; Biochemistry; Cell","score_opus":0.0990356197157667,"score_gpt":0.3385206987463813,"score_spread":0.2394850790306146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386639869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99039066,0.0009841333,0.0008121063,0.0017195086,0.0023258165,0.0031759262,0.0001774077,0.00028691377,0.00012755039],"genre_scores_gemma":[0.9961328,0.000112426904,0.0015092696,0.000111417656,0.00060549425,0.0007528676,0.0002414049,0.00020126767,0.00033308516],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996795,0.00012482108,0.0009449244,0.0010259167,0.00052674545,0.00058256986],"domain_scores_gemma":[0.9966341,0.00028065254,0.0008312305,0.0016526205,0.00037421187,0.00022713064],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042073464,0.00064338173,0.0011282064,0.0001839094,0.00011886878,0.00002703526,0.0006543439,0.00039748754,0.000114713264],"category_scores_gemma":[0.0005566545,0.00051365216,0.00072781194,0.00030777935,0.00034107768,0.000032868567,0.0008512821,0.0011916744,0.000017502654],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010070744,0.00071213994,0.00074617425,0.0024755416,0.00047068027,0.00001608105,0.00048613845,0.000514398,0.9667147,0.00005028418,0.00049846136,0.026308367],"study_design_scores_gemma":[0.002315046,0.00009329704,0.0063216174,0.0019518263,0.00039705867,0.000013750591,0.00021452525,0.00020209192,0.9841737,0.0014071928,0.002404017,0.0005058525],"about_ca_topic_score_codex":0.00010926988,"about_ca_topic_score_gemma":0.00007822613,"teacher_disagreement_score":0.025802514,"about_ca_system_score_codex":0.00045395474,"about_ca_system_score_gemma":0.0005558301,"threshold_uncertainty_score":0.9997315},"labels":[],"label_agreement":null},{"id":"W4386708615","doi":"10.1158/1078-0432.ccr-23-0873","title":"Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco; National Institute of General Medical Sciences; University of California, San Francisco; National Institutes of Health; National Cancer Institute; St. Baldrick's Foundation; Rally Foundation","keywords":"Cancer research; Metastasis; Drug; Medicine; Osteosarcoma; Genome; Cancer; Oncology; Biology; Internal medicine; Pharmacology; Gene; Genetics","score_opus":0.423596895930628,"score_gpt":0.5438498985017948,"score_spread":0.12025300257116678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386708615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9494704,0.010581809,0.022115257,0.007556275,0.00040863937,0.007343544,0.00092444924,0.00044215086,0.0011574851],"genre_scores_gemma":[0.9766034,0.0027532827,0.010434537,0.0005956804,0.0010724147,0.00505296,0.0017105204,0.0001681844,0.001609007],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99227667,0.0014859389,0.0015639248,0.0014754063,0.0019324328,0.0012656243],"domain_scores_gemma":[0.9940622,0.0024058402,0.00031460222,0.0008802776,0.0018319737,0.0005051282],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.010424749,0.00038723485,0.0010460247,0.00025914505,0.0003963784,0.00007560125,0.00036178302,0.00038551138,0.00025846701],"category_scores_gemma":[0.0013700823,0.00034151573,0.0005133287,0.0016232674,0.0008603625,0.0004877006,0.00026888077,0.0014956098,0.00009216878],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05057494,0.009232031,0.0057337983,0.0043852553,0.0027861719,0.00009973347,0.0057770023,0.019508801,0.17873229,0.0007514916,0.046252977,0.6761655],"study_design_scores_gemma":[0.09491298,0.010407251,0.0097097345,0.0011842638,0.0026180882,0.00005393817,0.008662642,0.48144558,0.16245069,0.17429584,0.051125333,0.0031336646],"about_ca_topic_score_codex":0.000114724324,"about_ca_topic_score_gemma":0.000043186254,"teacher_disagreement_score":0.67303187,"about_ca_system_score_codex":0.00053044525,"about_ca_system_score_gemma":0.0011263796,"threshold_uncertainty_score":0.9999037},"labels":[],"label_agreement":null},{"id":"W4386784388","doi":"10.1016/j.annonc.2023.08.007","title":"VP3-2023: Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HR+/HER2- early breast cancer (EBC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"European Society for Medical Oncology","keywords":"Medicine; Internal medicine; Hospital Anxiety and Depression Scale; Quality of life (healthcare); Population; Anxiety; Aromatase inhibitor; Physical therapy; Breast cancer; Cancer; Psychiatry; Tamoxifen","score_opus":0.07369785635320222,"score_gpt":0.40994183603148554,"score_spread":0.33624397967828334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386784388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909701,0.0008989961,0.0000042003635,0.0046954188,0.00016425127,0.0021336975,0.001055798,0.000036051806,0.00004153483],"genre_scores_gemma":[0.9982123,0.00013500609,0.000040597657,0.0010473193,0.00005957481,0.00023845836,0.0001844914,0.000044381104,0.00003789452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995208,0.0008850989,0.0019820323,0.00052543666,0.000772844,0.00062657753],"domain_scores_gemma":[0.99686646,0.00043285525,0.0013917027,0.00065729883,0.00044990628,0.00020179976],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016895203,0.00033735385,0.0019777776,0.00049145153,0.000054341544,0.000004756998,0.0003439924,0.00019694759,0.000050021823],"category_scores_gemma":[0.00015992968,0.0002506856,0.000116362,0.001473489,0.00047195624,0.00019565677,0.00013502616,0.0005327771,0.000008837269],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14425719,0.031135326,0.6687716,0.0010693517,0.0013140513,0.0003872663,0.06493743,0.0008900916,0.0017138921,0.000048113074,0.0023064343,0.08316926],"study_design_scores_gemma":[0.07410918,0.018419068,0.89831525,0.00053919264,0.0000609196,0.000025152833,0.0076474748,0.00005411115,0.00029027465,0.000051691837,0.00025330216,0.00023440589],"about_ca_topic_score_codex":0.021560533,"about_ca_topic_score_gemma":0.013756418,"teacher_disagreement_score":0.22954363,"about_ca_system_score_codex":0.00023801436,"about_ca_system_score_gemma":0.0010701388,"threshold_uncertainty_score":0.9999945},"labels":[],"label_agreement":null},{"id":"W4387115725","doi":"10.1080/14737167.2023.2263167","title":"Is Palbociclib a cost-effective strategy in the second-line treatment of metastatic breast cancer in Iran?","year":2023,"lang":"en","type":"article","venue":"Expert Review of Pharmacoeconomics & Outcomes Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Health, British Columbia","keywords":"Palbociclib; Fulvestrant; Medicine; Metastatic breast cancer; Oncology; Breast cancer; Cost effectiveness; Internal medicine; Cancer; Gynecology; Statistics; Estrogen receptor; Mathematics; Risk analysis (engineering)","score_opus":0.11914498741705118,"score_gpt":0.578111293209492,"score_spread":0.4589663057924408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387115725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7293906,0.22576223,0.000007042822,0.029589932,0.00019959782,0.012993322,0.0010771785,0.00003390087,0.00094616134],"genre_scores_gemma":[0.6697261,0.31769556,0.00009667492,0.004502732,0.00014372359,0.0067479108,0.000048062066,0.00007175939,0.00096752594],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971155,0.0005969243,0.00092390325,0.00041661822,0.0003867281,0.0005603432],"domain_scores_gemma":[0.9979031,0.0011128888,0.00020547373,0.0005091459,0.00015967006,0.0001097403],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018285572,0.00027648773,0.001306398,0.00048751384,0.00003725557,0.00001059363,0.0003368846,0.000042471787,0.0028279885],"category_scores_gemma":[0.000051092975,0.00017875762,0.0002953693,0.0009940988,0.00021614661,0.00014883062,0.000066874294,0.0003362029,0.000046555633],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013541791,0.001606802,0.05949723,0.009583596,0.0010951898,0.0001643951,0.010333215,0.00021219795,0.009740177,0.0001281343,0.002534063,0.90375084],"study_design_scores_gemma":[0.05388539,0.003275377,0.53639346,0.017071389,0.0004442216,0.00027418646,0.014247093,0.0059505887,0.06012377,0.0011581912,0.30572253,0.0014538071],"about_ca_topic_score_codex":0.0009178628,"about_ca_topic_score_gemma":0.00042170388,"teacher_disagreement_score":0.902297,"about_ca_system_score_codex":0.00076003245,"about_ca_system_score_gemma":0.00030148323,"threshold_uncertainty_score":0.99808353},"labels":[],"label_agreement":null},{"id":"W4387341282","doi":"10.5489/cuaj.8594","title":"Erratum: 2023 CKCF consensus statement","year":2023,"lang":"en","type":"erratum","venue":"Canadian Urological Association Journal","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Statement (logic); Consensus conference; Scientific consensus; Political science; Computer science; Law; Library science; Biology; Climate change","score_opus":0.022970235663489103,"score_gpt":0.2784654134218947,"score_spread":0.2554951777584056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387341282","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00553047,0.015632784,0.00014978243,0.5616651,0.20975448,0.0025838483,0.0038708407,0.00089427823,0.19991837],"genre_scores_gemma":[0.00649561,0.0025065795,0.00040156505,0.018330798,0.013839502,0.00006861024,0.0012030824,0.00020839198,0.95694584],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960992,0.00025597538,0.00087949604,0.00047181733,0.0010254814,0.0012680361],"domain_scores_gemma":[0.99615914,0.00021866885,0.00097838,0.00027686197,0.0007847716,0.0015821856],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010770377,0.00044413473,0.000881329,0.00056268903,0.00042239425,0.00015079336,0.00025761378,0.0012547865,0.0020487655],"category_scores_gemma":[0.001583888,0.00038655224,0.0003630304,0.0005228337,0.00008885069,0.00005346091,0.000038220718,0.0039331713,0.0010772202],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000076652395,0.000024430843,0.0043875813,0.000025215075,0.0005924795,0.0011685375,0.00006465505,0.00002859526,0.0000068803183,0.000056199628,0.9897498,0.003819008],"study_design_scores_gemma":[0.0011030944,0.00030533966,0.04360542,0.00012461233,0.00021893259,0.0004590193,0.00013368552,0.00003962773,8.837525e-7,0.0034173916,0.9502481,0.0003438475],"about_ca_topic_score_codex":0.0018583022,"about_ca_topic_score_gemma":0.0049762237,"teacher_disagreement_score":0.7570275,"about_ca_system_score_codex":0.006971112,"about_ca_system_score_gemma":0.004815678,"threshold_uncertainty_score":0.9998586},"labels":[],"label_agreement":null},{"id":"W4387808212","doi":"10.1016/j.annonc.2023.09.657","title":"481P Second generation oral selective estrogen receptor degraders (SERDs) in breast cancer: A systematic review and meta-analysis of clinical trials","year":2023,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cochrane Library; Internal medicine; Oncology; Breast cancer; Meta-analysis; Adverse effect; Estrogen receptor; Nausea; Randomized controlled trial; Cancer","score_opus":0.6932043071277709,"score_gpt":0.6183950127801529,"score_spread":0.07480929434761807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387808212","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000045730398,0.99221134,0.000008498073,0.0019861204,0.00009933002,0.004255652,0.0013527453,0.000018453351,0.000022132725],"genre_scores_gemma":[0.000034233395,0.9963479,0.00032247746,0.0010478212,0.000120315446,0.0016007056,0.00023286766,0.000057344798,0.00023631428],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98698467,0.005917381,0.005797119,0.0006682166,0.00031375422,0.00031886564],"domain_scores_gemma":[0.99030703,0.0028220338,0.005526876,0.00054130115,0.0006392788,0.00016347134],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.010486491,0.00049325137,0.033323452,0.0008099254,0.000021841339,0.0000052992077,0.00021112307,0.0005768617,0.0006332017],"category_scores_gemma":[0.0022134092,0.0003262053,0.0041754767,0.0019775755,0.00022416918,0.000081986975,0.0000613086,0.0005102847,0.0000072392186],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011682606,0.00018802947,0.00001825254,0.5338112,0.3478371,0.0000116976935,0.000073217736,0.0000035685043,0.0000030040017,0.000034112694,0.00096086564,0.11694213],"study_design_scores_gemma":[0.0006695303,0.00059114356,0.000022967914,0.027857676,0.92762405,0.000070808164,0.000047940823,0.000011091531,0.0000061883993,0.000019794108,0.042823855,0.00025494536],"about_ca_topic_score_codex":0.00017860488,"about_ca_topic_score_gemma":0.0006648495,"teacher_disagreement_score":0.57978696,"about_ca_system_score_codex":0.00016200508,"about_ca_system_score_gemma":0.0014891634,"threshold_uncertainty_score":0.999919},"labels":[],"label_agreement":null},{"id":"W4387808506","doi":"10.1016/j.annonc.2023.09.572","title":"395P Interim analysis (IA) of the giredestrant (G) + ipatasertib (IPAT) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Internal medicine; Interim analysis; Population; Breast cancer; Phases of clinical research; Cancer; Gastroenterology; Oncology; Toxicity; Clinical trial","score_opus":0.0466354699439815,"score_gpt":0.4023210216354885,"score_spread":0.355685551691507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387808506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574894,0.000082776125,0.000052000225,0.00086397975,0.000055943594,0.0019565981,0.0011493386,0.000016046513,0.000074363976],"genre_scores_gemma":[0.9985671,0.00014823167,0.00033805586,0.000078586956,0.000008371701,0.0006377746,0.00014245458,0.00003301962,0.000046414087],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734837,0.00050147524,0.0009328025,0.00044176113,0.00039023702,0.00038534938],"domain_scores_gemma":[0.9977506,0.0003558519,0.00073848054,0.00045787822,0.00059438136,0.000102831844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029461016,0.00031665762,0.0012642083,0.0006291384,0.000055416553,0.0000033704443,0.00023372096,0.00008011975,0.00010624233],"category_scores_gemma":[0.000076071774,0.00022525196,0.00018790043,0.0023473536,0.00046006433,0.00014401623,0.000096940246,0.00020471204,0.0000016616249],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028972417,0.08454085,0.52058446,0.00024671928,0.0076821316,0.00016993601,0.028928785,0.024181284,0.0037629595,0.00006718688,0.000044548357,0.30081874],"study_design_scores_gemma":[0.048170794,0.06987012,0.85146964,0.0008431876,0.0012272018,0.000013629363,0.011544143,0.00042011307,0.01586293,0.00019369878,0.00008721431,0.00029732846],"about_ca_topic_score_codex":0.00819593,"about_ca_topic_score_gemma":0.010886143,"teacher_disagreement_score":0.3308852,"about_ca_system_score_codex":0.00049084495,"about_ca_system_score_gemma":0.0005797366,"threshold_uncertainty_score":0.99840856},"labels":[],"label_agreement":null},{"id":"W4387809013","doi":"10.1016/j.annonc.2023.09.478","title":"281P Cyclin-dependent kinase 4/6 inhibitors combined with endocrine therapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: A meta-analysis of randomized clinical trials","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"AstraZeneca; Amgen","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Hormonal therapy; Meta-analysis; Cancer","score_opus":0.22178342434744358,"score_gpt":0.48070566826926253,"score_spread":0.25892224392181895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96446365,0.0017543011,0.000514745,0.022771295,0.0003544198,0.0050966907,0.004806764,0.00011866387,0.00011946717],"genre_scores_gemma":[0.9919063,0.0024229886,0.0015057403,0.0011228953,0.0004514943,0.0017171531,0.0003796073,0.00008638862,0.00040746582],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99052405,0.0039263335,0.003367387,0.00080997485,0.00071414106,0.00065811165],"domain_scores_gemma":[0.9804986,0.0134405745,0.0030814759,0.0004794074,0.0021673858,0.00033253862],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007480951,0.0005568974,0.01017629,0.0008856165,0.000121876,0.000013065716,0.0002921616,0.0002949323,0.0013158836],"category_scores_gemma":[0.0023206568,0.00036462647,0.004544039,0.001247651,0.0011236218,0.00019803659,0.00008141921,0.0004308725,0.0000069862117],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5799559,0.0018831907,0.00584862,0.000093888266,0.34727776,0.00003562132,0.0011197206,0.000077845485,0.021435248,0.0005850411,0.001410655,0.040276516],"study_design_scores_gemma":[0.51449096,0.02891238,0.100610584,0.0001282582,0.14944644,0.000028830545,0.0007588169,0.00013350866,0.20070013,0.001960806,0.001751858,0.0010774239],"about_ca_topic_score_codex":0.00093541184,"about_ca_topic_score_gemma":0.00015794863,"teacher_disagreement_score":0.19783132,"about_ca_system_score_codex":0.00010911908,"about_ca_system_score_gemma":0.0005377582,"threshold_uncertainty_score":0.99988055},"labels":[],"label_agreement":null},{"id":"W4387809927","doi":"10.1016/j.annonc.2023.09.3100","title":"354TiP A phase III randomised open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy (ET) in patients with ER+/HER2– early breast cancer (BC) and an intermediate or high risk of recurrence (CAMBRIA-1)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"Seagen; Relay Therapeutics; Incyte; Daiichi-Sankyo; Pfizer; Genentech; Mersana Therapeutics; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Adjuvant therapy; Oncology; Tamoxifen; Fulvestrant; Breast cancer; Adjuvant; Aromatase inhibitor; Hazard ratio; Cancer; Trastuzumab; Surgery; Confidence interval","score_opus":0.06015312760793879,"score_gpt":0.4174183995271137,"score_spread":0.3572652719191749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99481696,0.00035768494,0.000026930944,0.0004298599,0.000086750915,0.0036346798,0.00060308626,0.000028067678,0.000015992258],"genre_scores_gemma":[0.99164736,0.007281641,0.00031035478,0.00018819899,0.00003448563,0.00041841317,0.00003757466,0.00005563058,0.000026324742],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9972595,0.0005017153,0.00083696085,0.0005382043,0.00043121673,0.00043241165],"domain_scores_gemma":[0.99733776,0.00031552464,0.00093317963,0.00047725302,0.00076819153,0.00016807439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068025524,0.0003573945,0.0018074181,0.00030753482,0.000043722,0.000010863411,0.00030485837,0.0000783125,0.0000694326],"category_scores_gemma":[0.000044654975,0.00021762658,0.000039863797,0.0006100984,0.00047413853,0.00031938977,0.00007534281,0.00028763738,2.6092718e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54979396,0.00840446,0.07871648,0.000045715635,0.000739402,0.00007690472,0.004965319,0.000027027354,0.00051543704,0.000007427303,0.000011957983,0.3566959],"study_design_scores_gemma":[0.3848279,0.08824291,0.5238347,0.00033002178,0.00008091751,0.000012999927,0.0008725025,0.000023049563,0.0014806157,0.00005630392,0.00006995223,0.00016814304],"about_ca_topic_score_codex":0.00721411,"about_ca_topic_score_gemma":0.004055997,"teacher_disagreement_score":0.4451182,"about_ca_system_score_codex":0.00005967927,"about_ca_system_score_gemma":0.00071650924,"threshold_uncertainty_score":0.9993969},"labels":[],"label_agreement":null},{"id":"W4387950431","doi":"10.1158/1078-0432.ccr-23-1079","title":"A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; Sierra Oncology; University of Pennsylvania; AstraZeneca","keywords":"Cancer research; Ovarian cancer; Medicine; Antibody-drug conjugate; Flow cytometry; Cancer; Antibody; Internal medicine; Immunology; Monoclonal antibody","score_opus":0.1463424974379257,"score_gpt":0.5155802340373745,"score_spread":0.3692377365994488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387950431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923175,0.0023942855,0.00005480585,0.003193916,0.00023085444,0.001152266,0.00009596987,0.00016209476,0.00039829058],"genre_scores_gemma":[0.9940658,0.0031592795,0.00047924853,0.0002581349,0.0005628123,0.00034701344,0.000030460104,0.00009604312,0.00100117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948737,0.00066174415,0.0007484986,0.0011712107,0.0012843434,0.0012605241],"domain_scores_gemma":[0.99653804,0.001715476,0.0002091971,0.0006103639,0.000386686,0.00054022024],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0038724411,0.00034313972,0.0009537619,0.00041168914,0.00033018528,0.00007269975,0.00028947814,0.00018041507,0.0002807312],"category_scores_gemma":[0.0008064861,0.00026264956,0.00010361005,0.0015037603,0.0012192358,0.00031616882,0.00033343452,0.0019180159,0.000030532865],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028528184,0.00032555315,0.6069339,0.0009736595,0.00021421297,0.0012416658,0.0012169853,0.0003290995,0.30773953,0.000062190615,0.0027964956,0.049638547],"study_design_scores_gemma":[0.022631556,0.0027962283,0.8587341,0.007377082,0.00010577534,0.000044518107,0.004288142,0.0035900795,0.06343932,0.0008642614,0.034828715,0.0013002608],"about_ca_topic_score_codex":0.0037466064,"about_ca_topic_score_gemma":0.0035614201,"teacher_disagreement_score":0.25180018,"about_ca_system_score_codex":0.00055488,"about_ca_system_score_gemma":0.0011031758,"threshold_uncertainty_score":0.9999826},"labels":[],"label_agreement":null},{"id":"W4388227085","doi":"10.2217/fon-2023-0407","title":"The Effects of Adding Palbociclib to Endocrine Therapy to Treat Advanced Breast Cancer: A Plain Language Summary of a Study Using the PALOMA-2 and PALOMA-3 Trial Results","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Palbociclib; Breast cancer; Medicine; Placebo; Internal medicine; Hormonal therapy; Cancer; Oncology; Clinical trial; Hormone therapy; Gynecology; Metastatic breast cancer; Alternative medicine; Pathology","score_opus":0.014905550092935559,"score_gpt":0.3629975390301803,"score_spread":0.34809198893724475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388227085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98532784,0.0036823929,0.000009881267,0.0060170926,0.0008389154,0.0037503275,0.00018857018,0.00007026504,0.00011471659],"genre_scores_gemma":[0.9955865,0.0010203924,0.0004382651,0.00059255166,0.0013901395,0.0005918635,0.0000145074555,0.000056798515,0.00030897153],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997941,0.00036849396,0.0005024696,0.00041256013,0.00031664502,0.00045881286],"domain_scores_gemma":[0.997316,0.0015957077,0.00026276527,0.0005530708,0.00012629811,0.0001461418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048353904,0.0002696359,0.00074429245,0.00016915437,0.00019247753,0.000009856762,0.00023502756,0.0000900822,0.000009641598],"category_scores_gemma":[0.00023875888,0.00014998247,0.000101597776,0.00083473494,0.0001435598,0.000048149646,0.00014579722,0.00024465617,0.000001576292],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18567732,0.00037113702,0.0015997727,0.00011423422,0.00035838495,0.00024649804,0.023440126,0.00006783451,0.14264259,0.000041515246,0.0006497366,0.6447908],"study_design_scores_gemma":[0.45625848,0.044733763,0.1876684,0.0016480498,0.0009226442,0.0006820232,0.11884111,0.00008835275,0.040615264,0.00013408092,0.1473428,0.0010650412],"about_ca_topic_score_codex":0.0003984303,"about_ca_topic_score_gemma":0.0009903532,"teacher_disagreement_score":0.6437258,"about_ca_system_score_codex":0.00019101087,"about_ca_system_score_gemma":0.0001966861,"threshold_uncertainty_score":0.6116108},"labels":[],"label_agreement":null},{"id":"W4388379556","doi":"10.1016/j.ejca.2023.113420","title":"Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Positive Living Society of British Columbia","funders":"Pfizer","keywords":"Palbociclib; Medicine; Placebo; Quality of life (healthcare); Breast cancer; Internal medicine; Oncology; Mood; Cancer; Physical therapy; Gynecology; Metastatic breast cancer; Clinical psychology","score_opus":0.01585629647036171,"score_gpt":0.2924184670737479,"score_spread":0.2765621706033862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388379556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952754,0.00055980944,0.000022989296,0.0012412369,0.00031858069,0.0023339132,0.00005177803,0.000092970055,0.00010334666],"genre_scores_gemma":[0.996861,0.0007866798,0.00016967511,0.00044509553,0.0002370082,0.00018650385,0.000005932197,0.00020979054,0.0010983617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950156,0.0013351305,0.0014053729,0.00044973145,0.0012694049,0.00052475784],"domain_scores_gemma":[0.99591464,0.0002537168,0.0020746489,0.0005108404,0.0010068262,0.00023931747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001198372,0.0005641021,0.0016294272,0.00036074885,0.00016538151,0.000073704,0.00032358585,0.000028396415,0.00024381262],"category_scores_gemma":[0.00011685582,0.00023772939,0.00018143818,0.0011553715,0.00032645598,0.0003248983,0.00004856148,0.00075091614,0.000009659617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.223209,0.0005770911,0.7400164,0.000011585385,0.0022862635,0.0011716795,0.0055135167,0.000766439,0.000057131012,8.170539e-7,0.00003727504,0.02635281],"study_design_scores_gemma":[0.23796481,0.0036112713,0.755142,0.0004951782,0.00055524945,0.00017209328,0.0013208926,0.000017167444,0.00018253567,0.000004079837,0.0002600881,0.00027467328],"about_ca_topic_score_codex":0.0024029517,"about_ca_topic_score_gemma":0.0014933491,"teacher_disagreement_score":0.026078137,"about_ca_system_score_codex":0.00025267378,"about_ca_system_score_gemma":0.00043857205,"threshold_uncertainty_score":0.96943235},"labels":[],"label_agreement":null},{"id":"W4388541367","doi":"10.1016/s0960-9776(23)00671-9","title":"PO107 TREATMENT PATTERNS AND CLINICAL OUTCOMES AMONG PATIENTS RECEIVING CDK4/6 INHIBITORS FOR HR+/HER2-ADVANCED/METASTATIC BREAST CANCER IN A SINGLE-CENTRE, CANADIAN REAL-WORLD SETTING USING AI-EXTRACTED DATA","year":2023,"lang":"en","type":"article","venue":"The Breast","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Oncology; Metastatic breast cancer; Internal medicine; Real world data; Breast cancer; Cancer; Gynecology; Data science","score_opus":0.06498576353557098,"score_gpt":0.3755091171562621,"score_spread":0.31052335362069117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388541367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98842674,0.00005727628,0.000043735305,0.0048223143,0.00050269463,0.0018407,0.0041271434,0.00013241102,0.000047003065],"genre_scores_gemma":[0.9972876,0.00010074471,0.0006152309,0.0004902464,0.00032398172,0.00009735924,0.00058787863,0.00013557484,0.00036140875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967474,0.0001926434,0.00087481533,0.00083858037,0.00034719662,0.0009993967],"domain_scores_gemma":[0.99745923,0.00063838065,0.00035839475,0.00090001797,0.00018754089,0.00045645045],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059750193,0.00047044258,0.00077745644,0.0004219824,0.00028767902,0.000077023,0.00030547584,0.00009529022,0.000061663195],"category_scores_gemma":[0.0001459679,0.00034902504,0.00013605946,0.0007436467,0.00020946149,0.00047611372,0.00017497975,0.00033607037,0.0000060576986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030549653,0.00022213632,0.77297515,0.000068698675,0.00022915736,0.00003444686,0.00046249418,0.0001323638,0.000039626866,0.0000026009295,0.00005556198,0.22547227],"study_design_scores_gemma":[0.005162057,0.00010576701,0.9880039,0.0011037668,0.00032589093,0.00006114801,0.0007561929,0.0036977595,0.00001427383,0.000042494557,0.0003841686,0.00034256696],"about_ca_topic_score_codex":0.17823991,"about_ca_topic_score_gemma":0.6592951,"teacher_disagreement_score":0.48105517,"about_ca_system_score_codex":0.0013692678,"about_ca_system_score_gemma":0.0004603727,"threshold_uncertainty_score":0.99989617},"labels":[],"label_agreement":null},{"id":"W4388775919","doi":"10.1177/17151635231207694","title":"AFPC CPERC 2023 Abstracts – Oral and Poster Presentations","year":2023,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Computer science; Medical physics","score_opus":0.049058594608043855,"score_gpt":0.3212007657541824,"score_spread":0.27214217114613853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388775919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99220026,0.0012051917,0.00002236687,0.0013918419,0.0016800317,0.0004472858,0.0005294952,0.000074267635,0.0024492608],"genre_scores_gemma":[0.9881781,0.002807893,0.00018615353,0.003406121,0.0007154699,0.000023955421,0.00007733798,0.00007419704,0.004530775],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9976454,0.00006871441,0.00047621076,0.000366847,0.00042848627,0.0010143836],"domain_scores_gemma":[0.99650043,0.0000901303,0.00015091371,0.00021435884,0.0004126114,0.0026315635],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034366,0.00031569562,0.00036082722,0.00043075564,0.00065475074,0.00014298772,0.00023280973,0.000058732476,0.0010359639],"category_scores_gemma":[0.00013535267,0.00032406615,0.0000994913,0.00083445024,0.0002412256,0.00042486572,0.000040486815,0.00061538164,0.00006254619],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007743271,0.00009152888,0.021624384,0.0007215839,0.0011225545,0.32956782,0.0041920673,0.0028475751,0.028258258,0.00006032569,0.14021616,0.47052342],"study_design_scores_gemma":[0.004585376,0.00007635409,0.0052133356,0.000052044714,0.00028242497,0.72457206,0.00008722165,0.0011350986,0.0032006677,0.00017057829,0.25997502,0.0006498476],"about_ca_topic_score_codex":0.022389488,"about_ca_topic_score_gemma":0.08839916,"teacher_disagreement_score":0.46987358,"about_ca_system_score_codex":0.0011635595,"about_ca_system_score_gemma":0.002935619,"threshold_uncertainty_score":0.99992114},"labels":[],"label_agreement":null},{"id":"W4389248415","doi":"10.1016/j.ctrv.2023.102666","title":"Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review","year":2023,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Protocol (science); Clinical trial; Breast cancer; Population; Metastatic breast cancer; Research design; Clinical study design; Internal medicine; Oncology; Cancer; Alternative medicine; Pathology","score_opus":0.5415218340859154,"score_gpt":0.6121691677018806,"score_spread":0.0706473336159652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389248415","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[2.9906283e-7,0.7496174,0.00001559435,0.00035092124,0.00022786729,0.2493046,0.0003696671,0.000078922574,0.00003474372],"genre_scores_gemma":[1.046977e-7,0.5825173,0.0002325772,0.00020493679,0.0002590075,0.41596815,0.00012670357,0.00012444147,0.0005667601],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9667934,0.0057250387,0.02505883,0.0012356902,0.0006204536,0.00056657323],"domain_scores_gemma":[0.9589699,0.0016023885,0.036888693,0.0018710742,0.00042806822,0.00023991159],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.016811524,0.0013456536,0.031672798,0.00040867992,0.00005858627,0.000031536478,0.0003503964,0.00030172785,0.00042975685],"category_scores_gemma":[0.0064845844,0.00073184527,0.0047154934,0.0015046019,0.00017544335,0.00017005687,0.00005517072,0.0005577294,0.00007385369],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065201355,0.00018987163,0.000026013868,0.51537216,0.0017109776,0.0000583216,0.00004524514,3.5216726e-7,3.741228e-7,0.0000051600537,0.00010544892,0.48242086],"study_design_scores_gemma":[0.0012834679,0.00022756522,0.00001554493,0.6150916,0.018349515,0.00021841346,0.000027668526,0.000001766803,4.7144377e-7,0.000010735668,0.36445123,0.0003220165],"about_ca_topic_score_codex":0.0007178752,"about_ca_topic_score_gemma":0.00044640456,"teacher_disagreement_score":0.48209885,"about_ca_system_score_codex":0.0021245703,"about_ca_system_score_gemma":0.0032128287,"threshold_uncertainty_score":0.9999294},"labels":[],"label_agreement":null},{"id":"W4389516746","doi":"10.1016/j.annonc.2023.09.3104","title":"Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; McGill University; Jewish General Hospital","funders":"Foundation Medicine; EMD Serono; Eisai; Sanofi; Seagen; Pfizer; Genentech; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Fulvestrant; Medicine; Tolerability; Metastatic breast cancer; Internal medicine; Palbociclib; Oncology; Aromatase inhibitor; Breast cancer; Estrogen receptor; Pharmacology; Cancer; Adverse effect; Tamoxifen","score_opus":0.13297165779521494,"score_gpt":0.45270710836088984,"score_spread":0.3197354505656749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389516746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92613524,0.0007519596,0.0010795747,0.06452105,0.0008843799,0.0032272444,0.0029900668,0.00012206767,0.0002884397],"genre_scores_gemma":[0.9900022,0.00048778424,0.003822147,0.0017618653,0.0014198459,0.0011696751,0.0009229024,0.00006312066,0.000350437],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99797916,0.0002945456,0.0006539547,0.00038821396,0.00029835434,0.00038575023],"domain_scores_gemma":[0.995493,0.003034315,0.0004770991,0.00040568502,0.00044866235,0.00014126493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011777219,0.00022980948,0.001065759,0.00009516345,0.00015188614,0.000008863858,0.00017518418,0.00008919129,0.00014460625],"category_scores_gemma":[0.00048835133,0.00013875478,0.00020215212,0.00036612235,0.00047300986,0.00014890787,0.00002921986,0.00016889643,0.0000058389755],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84356254,0.0006603628,0.0000014476074,0.000020868973,0.0011998876,0.00007924461,0.0017637811,0.00039206687,0.0003866178,0.00016604141,0.00093571295,0.15083143],"study_design_scores_gemma":[0.95641035,0.021139698,0.00013696248,0.000095760166,0.0008502646,0.00008118761,0.0012796264,0.00078203966,0.0012840043,0.0012867852,0.016486935,0.00016637743],"about_ca_topic_score_codex":0.00072671525,"about_ca_topic_score_gemma":0.0006478629,"teacher_disagreement_score":0.15066504,"about_ca_system_score_codex":0.000056221033,"about_ca_system_score_gemma":0.0006287525,"threshold_uncertainty_score":0.5658256},"labels":[],"label_agreement":null},{"id":"W4389617190","doi":"10.1038/s41467-023-44071-8","title":"Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial","year":2023,"lang":"en","type":"erratum","venue":"Nature Communications","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Triple-negative breast cancer; Carboplatin; Paclitaxel; Durvalumab; Medicine; Metastatic breast cancer; Oncology; Breast cancer; Triple negative; Randomized controlled trial; Internal medicine; Cancer; Chemotherapy; Cisplatin; Nivolumab; Immunotherapy","score_opus":0.027320491622520395,"score_gpt":0.3623504589377628,"score_spread":0.3350299673152424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389617190","genre_codex":"protocol","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026605852,0.2504058,0.02769668,0.22791116,0.071310595,0.34344813,0.03318964,0.009197986,0.010234152],"genre_scores_gemma":[0.199904,0.014174779,0.021145975,0.0016998107,0.0019730062,0.0852732,0.0041563977,0.0010964461,0.6705764],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99500734,0.0011099499,0.0011464013,0.0010191276,0.00085325347,0.0008639466],"domain_scores_gemma":[0.9889971,0.004429299,0.0015773845,0.0030082306,0.0016170345,0.0003709451],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011323361,0.0011129738,0.0033631476,0.00039699147,0.0014348358,0.00012615377,0.0010611269,0.0007388894,0.00011008202],"category_scores_gemma":[0.0020397848,0.000564189,0.0002507316,0.0018294746,0.0017325248,0.0002621256,0.00031120243,0.0036928141,0.0000020570865],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92812604,0.0006209392,0.0000023668326,0.0003856997,0.0049977372,0.00002321029,0.005569687,0.00012234872,0.0000080927875,0.00009812966,0.024002282,0.036043447],"study_design_scores_gemma":[0.8637225,0.009580523,0.000037249687,0.003921085,0.004907391,0.0007908775,0.005806454,0.009349694,0.000014165242,0.0001522731,0.100754544,0.000963211],"about_ca_topic_score_codex":0.00065336336,"about_ca_topic_score_gemma":0.025184263,"teacher_disagreement_score":0.6603423,"about_ca_system_score_codex":0.0015679697,"about_ca_system_score_gemma":0.0061164373,"threshold_uncertainty_score":0.9998652},"labels":[],"label_agreement":null},{"id":"W4389762740","doi":"10.25071/1708-6701.40467","title":"Reports from the 2023 CAML / ACBM Annual General Meeting","year":2023,"lang":"en","type":"article","venue":"CAML Review / Revue de l ACBM","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of Saskatchewan; Mount Allison University; McGill University; University of Calgary; University of Toronto; Memorial University of Newfoundland; Library and Archives Canada","funders":"","keywords":"Environmental science","score_opus":0.020194191407842736,"score_gpt":0.31129847037015224,"score_spread":0.2911042789623095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389762740","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32702675,0.5999881,0.00038545704,0.05936241,0.002373236,0.0030849483,0.00033851445,0.00094589527,0.0064946925],"genre_scores_gemma":[0.19884805,0.51418424,0.024771553,0.12156136,0.034168486,0.0033597064,0.0034762046,0.0011646493,0.09846573],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99753755,0.00016762243,0.0007323559,0.0005928847,0.00036176448,0.0006078435],"domain_scores_gemma":[0.99771947,0.00027075346,0.00038329954,0.001186874,0.00021692233,0.00022270142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001045477,0.00031724622,0.00080218166,0.0000569992,0.00016548624,0.000026389067,0.00027539322,0.000116383715,0.0003515076],"category_scores_gemma":[0.0013354437,0.00022972467,0.00030952692,0.0008076297,0.000110472814,0.00013316033,0.00017123143,0.00045669032,0.00040479956],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021136669,0.00014524526,0.042783577,0.008555945,0.0008707261,0.008915226,0.004111505,0.0001821607,0.022835141,0.0005605596,0.4382142,0.47261432],"study_design_scores_gemma":[0.00043406113,0.000054687567,0.0192825,0.008741662,0.0003533364,0.0014186507,0.00025118998,0.00005991018,0.00058226334,0.00052044983,0.9679849,0.00031634828],"about_ca_topic_score_codex":0.00022234913,"about_ca_topic_score_gemma":0.000045108467,"teacher_disagreement_score":0.52977073,"about_ca_system_score_codex":0.00020767776,"about_ca_system_score_gemma":0.00017534704,"threshold_uncertainty_score":0.93679},"labels":[],"label_agreement":null},{"id":"W4389916824","doi":"10.1177/17151635231219546","title":"OPEN Summit 2023 Abstracts–Poster and Oral Presentations","year":2023,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Summit; Medicine; Library science; Computer science; Geography; Cartography","score_opus":0.0689570310416718,"score_gpt":0.35103755730100766,"score_spread":0.2820805262593359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389916824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98650867,0.001292142,0.00002885983,0.0021266413,0.0019788546,0.000990652,0.00086040236,0.000072013325,0.0061417934],"genre_scores_gemma":[0.9846063,0.0024143038,0.00025743456,0.0038084744,0.000679955,0.000042076885,0.00009660617,0.00007633302,0.008018514],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99764544,0.00008338066,0.0005071506,0.00040449438,0.00038396008,0.0009755846],"domain_scores_gemma":[0.99648726,0.00010833006,0.00018355183,0.0002485147,0.0004024608,0.002569854],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047549943,0.00030937366,0.00040346012,0.00036834506,0.00075683114,0.00033692067,0.0005291437,0.000054182954,0.0013568873],"category_scores_gemma":[0.00014091036,0.00031725553,0.0000834712,0.00088289677,0.00022273709,0.0006719106,0.00012328474,0.00060048606,0.000064080385],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089409645,0.000090179696,0.031425472,0.00054281164,0.0011199996,0.24123235,0.002419839,0.001944803,0.008280253,0.00007847433,0.2714873,0.44048443],"study_design_scores_gemma":[0.00695434,0.000093254894,0.004460331,0.00006972898,0.00033278222,0.45082533,0.00011799139,0.0010549182,0.0031311251,0.00029146046,0.5318881,0.00078058883],"about_ca_topic_score_codex":0.043535247,"about_ca_topic_score_gemma":0.20370749,"teacher_disagreement_score":0.43970385,"about_ca_system_score_codex":0.001162892,"about_ca_system_score_gemma":0.0036746135,"threshold_uncertainty_score":0.99992794},"labels":[],"label_agreement":null},{"id":"W4390061897","doi":"10.1007/s10549-023-07185-7","title":"Survival, treatment patterns, and costs of HER2+ metastatic breast cancer patients in Ontario between 2005 to 2020","year":2023,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); Canadian Breast Cancer Network; Sunnybrook Hospital; Mount Sinai Hospital; Sunnybrook Health Science Centre","funders":"AstraZeneca Canada","keywords":"Medicine; Metastatic breast cancer; Trastuzumab; Breast cancer; Pertuzumab; Stage (stratigraphy); Internal medicine; Cohort; Cancer; Population; Oncology; Retrospective cohort study; Gynecology","score_opus":0.07276757750080395,"score_gpt":0.38936530344920967,"score_spread":0.31659772594840574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390061897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98968536,0.0008142581,0.0000033327613,0.004357342,0.000075557524,0.0017208931,0.0032481859,0.00003738156,0.000057714795],"genre_scores_gemma":[0.9922502,0.004453866,0.000058116944,0.00004300918,0.00013163587,0.0013180973,0.0001826527,0.00005779041,0.0015046563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99714714,0.00013928527,0.00040224363,0.0006978453,0.00069327425,0.00092019065],"domain_scores_gemma":[0.99847835,0.00018273074,0.000081984086,0.00034320328,0.00025602416,0.0006577041],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023827984,0.00038092624,0.0007973017,0.00044191335,0.00011965569,0.000035327368,0.00009450962,0.00006434898,0.00038877563],"category_scores_gemma":[0.0000074524046,0.00028404142,0.00007153296,0.0006195471,0.00017268598,0.00013107821,0.0001146642,0.00018568666,0.000019763993],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017341849,0.00063116156,0.7192997,0.000058298807,0.00051206397,0.00007708566,0.00090032694,0.000014741825,0.00006763003,0.000007526382,0.00005171093,0.2766456],"study_design_scores_gemma":[0.008512472,0.0016994751,0.98633915,0.00064140564,0.00012466106,0.00003361107,0.00045163385,0.000008421916,0.00038744925,0.0000357893,0.0015585686,0.00020734698],"about_ca_topic_score_codex":0.564486,"about_ca_topic_score_gemma":0.6606788,"teacher_disagreement_score":0.27643827,"about_ca_system_score_codex":0.00453064,"about_ca_system_score_gemma":0.00079970376,"threshold_uncertainty_score":0.9999612},"labels":[],"label_agreement":null},{"id":"W4390590466","doi":"10.1093/oncolo/oyad337","title":"CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Astellas Pharma; Ipsen; Clovis Oncology; Gilead Sciences; Eisai; Daiichi Sankyo Europe; Sanofi; Instituto de Salud Carlos III; Amgen; Pfizer; PharmaMar; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Oncolytics Biotech","keywords":"Medicine; Hazard ratio; Internal medicine; Chemotherapy; Breast cancer; Oncology; Confidence interval; Progression-free survival; Randomized controlled trial; Gastroenterology; Cancer","score_opus":0.05329712438884447,"score_gpt":0.4183184199007502,"score_spread":0.3650212955119057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390590466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96467733,0.0058220183,0.00012486681,0.0194639,0.0024494524,0.003920048,0.0004019475,0.00011351038,0.0030269483],"genre_scores_gemma":[0.9971221,0.0009329684,0.00021125365,0.00020207436,0.0002905832,0.0003199018,0.000010241024,0.000036680034,0.00087421463],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977093,0.00051464274,0.00069291936,0.00044444992,0.00033794562,0.0003007796],"domain_scores_gemma":[0.99636465,0.002631627,0.00038938344,0.000419434,0.00012472537,0.00007020368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095511734,0.00031069844,0.0009903804,0.00013292088,0.00018730354,0.00002051858,0.00020720364,0.00012307515,0.000095560295],"category_scores_gemma":[0.00069992687,0.00015431517,0.0002953032,0.00083760364,0.002111631,0.000129598,0.00010271064,0.00041540075,0.0000020467548],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88472486,0.00037288287,0.000028774997,0.00003359886,0.00072300696,0.000017382139,0.0027452963,0.00011012429,0.004771725,0.00014842991,0.00020309452,0.1061208],"study_design_scores_gemma":[0.9785029,0.0018507318,0.001930331,0.00067555584,0.00058082,0.000035683504,0.0017623387,0.0013512579,0.010536513,0.00096189,0.0015870341,0.00022492229],"about_ca_topic_score_codex":0.0016497537,"about_ca_topic_score_gemma":0.00042183572,"teacher_disagreement_score":0.10589588,"about_ca_system_score_codex":0.0004556652,"about_ca_system_score_gemma":0.0003698395,"threshold_uncertainty_score":0.7780393},"labels":[],"label_agreement":null},{"id":"W4390914920","doi":"10.1158/1538-7445.panca2023-pr12","title":"Abstract PR12: Targeting CDK7/9 in basal pancreatic cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cyclin-dependent kinase 7; Biology; Cancer research; Basal (medicine); Histone deacetylase; Cell biology; Kinase; Protein kinase A; Genetics; Gene; Histone; Cyclin-dependent kinase 2; Endocrinology","score_opus":0.08348506235782635,"score_gpt":0.46145680681395834,"score_spread":0.377971744456132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390914920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9053748,0.08257665,0.000052348638,0.006816582,0.0005587445,0.0008104577,0.00005057405,0.00017736385,0.0035824736],"genre_scores_gemma":[0.9908337,0.0028337066,0.0002598492,0.0002591331,0.0012575089,0.0010310232,0.000013101872,0.00009575178,0.0034162048],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971937,0.00008673688,0.00033899245,0.0005977754,0.0008576885,0.00092512456],"domain_scores_gemma":[0.9988694,0.00031866692,0.000028341175,0.00032199945,0.00023555351,0.00022601032],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001006278,0.00020370109,0.00036050205,0.00047770655,0.0001032206,0.00008116412,0.00019709302,0.00011465642,0.0044178637],"category_scores_gemma":[0.00016505804,0.00017176993,0.000085191445,0.001232022,0.00024787977,0.00023914038,0.00008710507,0.001225822,0.00018012071],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019342698,0.00023247406,0.053691644,0.004695553,0.00045345433,0.001776098,0.0045286254,0.0007258593,0.5118015,0.00094836304,0.02072627,0.39848593],"study_design_scores_gemma":[0.005978947,0.00051349576,0.26878065,0.018749185,0.00014191076,0.000077306264,0.0036102198,0.0024944185,0.13312624,0.007029616,0.5581509,0.0013471113],"about_ca_topic_score_codex":0.0034687095,"about_ca_topic_score_gemma":0.0006630893,"teacher_disagreement_score":0.5374246,"about_ca_system_score_codex":0.0015288551,"about_ca_system_score_gemma":0.0013741837,"threshold_uncertainty_score":0.9964922},"labels":[],"label_agreement":null},{"id":"W4390952294","doi":"10.21203/rs.3.rs-3782509/v1","title":"Acquired resistance to CDK4/6 inhibition is associated with dysregulation of multiple pathways including cyclin D-CDK4/6-RB, EGFR/HER, AKT/mTOR and IFN signaling","year":2024,"lang":"en","type":"preprint","venue":"Research Square","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"Genentech; Government of Ontario; AstraZeneca; National Institutes of Health; Pfizer","keywords":"Protein kinase B; PI3K/AKT/mTOR pathway; Cancer research; Signal transduction; Cell biology; Chemistry; Biology","score_opus":0.08750888868332644,"score_gpt":0.38355116234782743,"score_spread":0.296042273664501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390952294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988072,0.004595519,0.0011194985,0.002234388,0.00013031645,0.0025781281,0.0006623246,0.00022715167,0.0003807136],"genre_scores_gemma":[0.99430794,0.00010678591,0.0031904539,0.000091478374,0.00036384928,0.00040561997,0.00041120034,0.00016676045,0.0009559231],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9949609,0.00039632025,0.0007242229,0.0011662061,0.0019843357,0.0007680036],"domain_scores_gemma":[0.9962014,0.00077624066,0.00032560376,0.00075114047,0.0015948678,0.00035074327],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018469264,0.00046454553,0.00090675394,0.0008746901,0.00027507328,0.000119367905,0.00019354776,0.00048107587,0.00008904487],"category_scores_gemma":[0.001273618,0.00042291122,0.00015419436,0.0011389961,0.00033025898,0.00014787653,0.0009785638,0.0010524045,0.000014756631],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010438862,0.00070595497,0.013791937,0.016286852,0.0014389872,0.0005436805,0.023297975,0.0021643802,0.9041229,0.0006467812,0.0015783912,0.024983324],"study_design_scores_gemma":[0.013330867,0.0028342723,0.07230338,0.16108881,0.0006083954,0.00005487213,0.010306698,0.007052569,0.68978083,0.03682501,0.0033347178,0.0024795684],"about_ca_topic_score_codex":0.00017864208,"about_ca_topic_score_gemma":0.000521571,"teacher_disagreement_score":0.21434203,"about_ca_system_score_codex":0.001531142,"about_ca_system_score_gemma":0.000646808,"threshold_uncertainty_score":0.99982226},"labels":[],"label_agreement":null},{"id":"W4391095740","doi":"10.1200/jco.2024.42.3_suppl.129","title":"A first-in-human, open-label, phase I trial of daily oral zelenirstat, an NMT inhibitor, in patients with relapsed/refractory advanced cancer including gastrointestinal cancers.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Nausea; Tolerability; Internal medicine; Adverse effect; Gastroenterology; Cancer; Vomiting; Refractory (planetary science); Colorectal cancer; Oncology","score_opus":0.13944598514296183,"score_gpt":0.5023822377590372,"score_spread":0.3629362526160754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391095740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951681,0.00086126174,0.00015694895,0.0012293853,0.0014688922,0.0008732949,0.000025712709,0.000016875352,0.00019955335],"genre_scores_gemma":[0.9876557,0.00023568035,0.0105722295,0.00043002702,0.0009316355,0.000045561268,0.000008679332,0.000061436614,0.00005906311],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947895,0.00041352244,0.0032474932,0.00046791352,0.0006136034,0.0004679634],"domain_scores_gemma":[0.99590313,0.0009961572,0.0018582776,0.00028679537,0.00055663555,0.00039900694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023979987,0.000298775,0.0022167412,0.0004248633,0.000051359933,0.000022951135,0.00040047624,0.00022511357,0.00013753017],"category_scores_gemma":[0.0011457257,0.00022245238,0.00015679274,0.00051437627,0.00039915892,0.0009542356,0.00013633074,0.0019852319,0.0000015607363],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62790996,0.014664082,0.09050667,0.00021325995,0.00024608732,0.00160615,0.000623332,0.00063677615,0.0009810107,0.000081316044,0.00023879501,0.26229253],"study_design_scores_gemma":[0.6893762,0.21076094,0.071473084,0.005989053,0.00032326035,0.00017587554,0.00039057012,0.00038935812,0.00009841306,0.000547089,0.020117566,0.00035859706],"about_ca_topic_score_codex":0.00044302692,"about_ca_topic_score_gemma":0.003334667,"teacher_disagreement_score":0.26193395,"about_ca_system_score_codex":0.0017561903,"about_ca_system_score_gemma":0.0051758736,"threshold_uncertainty_score":0.9181777},"labels":[],"label_agreement":null},{"id":"W4391170098","doi":"10.1002/ctm2.1544","title":"Seize the engine: Emerging cell cycle targets in breast cancer","year":2024,"lang":"en","type":"review","venue":"Clinical and Translational Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Breast Cancer Research Foundation; Princess Margaret Cancer Foundation; American Society of Clinical Oncology; National Cancer Institute; Conquer Cancer Foundation","keywords":"Breast cancer; Medicine; Cancer; Internal medicine","score_opus":0.06372966994859343,"score_gpt":0.44211560120779897,"score_spread":0.37838593125920555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391170098","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000014033846,0.9757344,0.00018506321,0.022202827,0.00060982275,0.00060844957,0.00014183253,0.000044035045,0.0004595422],"genre_scores_gemma":[0.0009724808,0.99497193,0.00022488963,0.00085892953,0.0021318132,0.0001273614,0.000097091346,0.000063106345,0.00055240974],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976568,0.00009056034,0.0011277383,0.000515117,0.00034846144,0.0002612728],"domain_scores_gemma":[0.998694,0.0007021946,0.00014349977,0.00022364917,0.00005759779,0.00017906456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006003097,0.00038036346,0.0016119374,0.00014956566,0.000052300653,0.000006859993,0.00012339403,0.00024209186,0.00034132463],"category_scores_gemma":[0.00003898767,0.00019169207,0.0003080595,0.00040510067,0.000505165,0.000046445857,0.000025466396,0.0011969742,0.000018900335],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007069559,0.00006157792,0.00028146972,0.007910239,0.00019713628,0.0000447316,0.00016129755,0.000019627541,3.3764846e-7,0.0002182811,0.0003370791,0.9906975],"study_design_scores_gemma":[0.0018840323,0.000055743923,0.001711392,0.024124,0.0023510626,0.00020504711,0.00002573268,0.00070905226,8.0974054e-8,0.0019012444,0.96680045,0.00023216168],"about_ca_topic_score_codex":0.000024872019,"about_ca_topic_score_gemma":0.000014205008,"teacher_disagreement_score":0.99046534,"about_ca_system_score_codex":0.0000268133,"about_ca_system_score_gemma":0.0003814777,"threshold_uncertainty_score":0.7816976},"labels":[],"label_agreement":null},{"id":"W4391263220","doi":"10.1158/0008-5472.can-23-1749","title":"Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill Genome Centre; McGill University Health Centre; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Palbociclib; Cancer research; Senescence; Cyclin-dependent kinase 4; KRAS; Cancer; Telomere; Cancer cell; Biology; Cell cycle; Breast cancer; Medicine; Cyclin-dependent kinase 2; Cell biology; Internal medicine; Biochemistry","score_opus":0.08410937371333618,"score_gpt":0.4478843793961258,"score_spread":0.36377500568278964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391263220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9482028,0.044410724,0.00009690051,0.006415757,0.000115662115,0.0005061953,0.00002766548,0.00007268426,0.00015162636],"genre_scores_gemma":[0.99435115,0.004058786,0.00030783605,0.00012790652,0.00028812006,0.0002244876,0.0000025296063,0.000042868825,0.00059629855],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981624,0.00013368251,0.00016850942,0.00056323997,0.0004273354,0.0005448258],"domain_scores_gemma":[0.9991763,0.00026688346,0.00001799596,0.00017903668,0.000178056,0.00018168353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009481335,0.0001558317,0.00028465583,0.00026792192,0.000120239034,0.00007904604,0.00004591166,0.00007950949,0.00012426343],"category_scores_gemma":[0.00012421407,0.00013467764,0.000024194967,0.00067230035,0.00043230312,0.00022676868,0.00013347776,0.0006608791,0.0000057575958],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041682596,0.0000496844,0.15294307,0.0018155696,0.000083302395,0.0004328474,0.0029320517,0.000019394478,0.57237315,0.00025251674,0.00016749049,0.2685141],"study_design_scores_gemma":[0.004594979,0.000694505,0.5608381,0.016901307,0.0001268891,0.00074881135,0.003694637,0.012213993,0.35599583,0.00285683,0.040091425,0.0012427127],"about_ca_topic_score_codex":0.0033713959,"about_ca_topic_score_gemma":0.001817821,"teacher_disagreement_score":0.407895,"about_ca_system_score_codex":0.00042340212,"about_ca_system_score_gemma":0.0004234529,"threshold_uncertainty_score":0.5491995},"labels":[],"label_agreement":null},{"id":"W4391446028","doi":"10.1158/1538-7445.advbc23-ia16","title":"Abstract IA16: Creation and preliminary analyses of a full spectrum of breast cancers initiated de novo from normal human mammary cells","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Human breast; Medicine; Breast cancer; Cancer research; Cancer; Oncology; Biology; Internal medicine","score_opus":0.10337962413084463,"score_gpt":0.4532357359209101,"score_spread":0.3498561117900655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391446028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842817,0.01274023,0.00029298803,0.0008438394,0.000073715455,0.00033776218,0.00039876727,0.000047445144,0.00098353],"genre_scores_gemma":[0.9979457,0.0010340211,0.00037522567,0.000030669962,0.00026152094,0.000072300325,0.000055723136,0.00003904943,0.0001857781],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982956,0.000078375204,0.00033780135,0.00036027835,0.00053189107,0.00039604952],"domain_scores_gemma":[0.99900997,0.00018709165,0.00007928337,0.00031543372,0.0002471758,0.00016104752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034416284,0.0001548247,0.00035263487,0.00043069007,0.00006895323,0.000027462185,0.000154579,0.000100625206,0.0007258994],"category_scores_gemma":[0.000020642081,0.00014120908,0.00007704066,0.0006161163,0.0004240063,0.00022813,0.000091467606,0.0004399574,0.000004037135],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020694803,0.00007005565,0.0026589904,0.00094728364,0.00040660307,0.00016377709,0.0012261262,0.00021127136,0.9767872,0.00008988896,0.00018180438,0.015187502],"study_design_scores_gemma":[0.0018832356,0.0008877634,0.26637232,0.002635027,0.0001877363,0.00014865774,0.0009562423,0.00053583476,0.7242836,0.0013761749,0.0005074942,0.00022595642],"about_ca_topic_score_codex":0.010968915,"about_ca_topic_score_gemma":0.00049883936,"teacher_disagreement_score":0.26371333,"about_ca_system_score_codex":0.0005903075,"about_ca_system_score_gemma":0.0010624742,"threshold_uncertainty_score":0.99561715},"labels":[],"label_agreement":null},{"id":"W4391446094","doi":"10.1158/1538-7445.advbc23-a081","title":"Abstract A081: Real-world treatment patterns and clinical outcomes in patients with HER2+ metastatic breast cancer receiving systemic therapy in Ontario, Canada","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Systemic therapy; Medicine; Metastatic breast cancer; Breast cancer; Cancer; Oncology; Internal medicine; Intensive care medicine","score_opus":0.07777638033646204,"score_gpt":0.42533386187962047,"score_spread":0.3475574815431584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391446094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99493235,0.0016450628,0.0000014098558,0.0014460332,0.00028044684,0.0013615265,0.00020771191,0.000030742605,0.00009472951],"genre_scores_gemma":[0.9948597,0.0027243777,0.000027993432,0.00012370982,0.00009193775,0.0006931996,0.000023195911,0.00007295766,0.0013829218],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970387,0.00018248455,0.0005696986,0.00069247134,0.00080654485,0.0007100537],"domain_scores_gemma":[0.9986199,0.00049891794,0.00006869633,0.0003744923,0.00018777813,0.00025022373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055971555,0.0002999739,0.00072683004,0.00040449243,0.00006358543,0.0000615766,0.00013338459,0.000057785815,0.0007019004],"category_scores_gemma":[0.000015784904,0.00020128493,0.00006049877,0.0005529703,0.00013655142,0.00017495373,0.000040890798,0.0008681132,0.0000026236619],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013542474,0.00022862594,0.9022571,0.00022648633,0.00040448367,0.00029268983,0.00067220494,0.000050066265,0.000018815797,0.0000046914033,0.000046135377,0.09444447],"study_design_scores_gemma":[0.004816257,0.00035802025,0.9906552,0.0028243042,0.00003181094,0.000011555928,0.00026548537,0.000013998136,0.000030269443,0.000012988999,0.00078307925,0.00019705672],"about_ca_topic_score_codex":0.99612087,"about_ca_topic_score_gemma":0.9995218,"teacher_disagreement_score":0.094247416,"about_ca_system_score_codex":0.009767257,"about_ca_system_score_gemma":0.005244368,"threshold_uncertainty_score":0.99403405},"labels":[],"label_agreement":null},{"id":"W4391613717","doi":"10.1038/s41598-024-53151-8","title":"Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer","year":2024,"lang":"en","type":"review","venue":"Scientific Reports","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Endocrine system; Oncology; Breast cancer; Medicine; Cancer; Internal medicine; Overall survival; Bioinformatics; Biology; Hormone","score_opus":0.04112898038906376,"score_gpt":0.3723288790259778,"score_spread":0.331199898636914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391613717","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013428554,0.9797282,0.0000058690334,0.00009314219,0.0039670314,0.002332572,0.000049353617,0.00005398105,0.00034126153],"genre_scores_gemma":[0.0355346,0.9611636,0.00019069853,0.0000121416015,0.00013337492,0.00063819904,0.00032095917,0.00010508072,0.001901385],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99602014,0.00012629663,0.0013867677,0.0011838721,0.00085623,0.0004266803],"domain_scores_gemma":[0.99780923,0.00006473525,0.0009272568,0.00078375184,0.00031091552,0.00010408391],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006887299,0.0005270762,0.0024574648,0.0010195597,0.000040858333,0.000054006454,0.00013282624,0.00012241035,0.000098588345],"category_scores_gemma":[0.000018352752,0.00035984663,0.00024874046,0.0020399245,0.00040580763,0.00023770233,0.000064254506,0.000572711,0.000005730861],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038943088,0.0006425413,0.0023782528,0.009899927,0.000312722,0.001810276,0.0010653615,0.00010733858,0.0002441618,0.00008504171,0.00025318182,0.98281175],"study_design_scores_gemma":[0.0028449986,0.00031291918,0.002064616,0.07402441,0.0003700286,0.0021802383,0.0002396649,0.000016789125,0.00038636505,0.0010687897,0.91575646,0.00073472917],"about_ca_topic_score_codex":0.00024112183,"about_ca_topic_score_gemma":0.00055306667,"teacher_disagreement_score":0.98207706,"about_ca_system_score_codex":0.00074153545,"about_ca_system_score_gemma":0.0013590066,"threshold_uncertainty_score":0.9998854},"labels":[],"label_agreement":null},{"id":"W4391893409","doi":"10.1158/1078-0432.c.7077821.v1","title":"Data from Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach","year":2024,"lang":"en","type":"preprint","venue":"","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"University of California, San Francisco; National Institutes of Health; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco; National Cancer Institute; Rally Foundation","keywords":"Osteosarcoma; Metastasis; Cancer research; Genome; Drug; Cancer cell lines; Medicine; Computational biology; Biology; Cancer; Pharmacology; Internal medicine; Gene; Cancer cell; Genetics","score_opus":0.18609845142337977,"score_gpt":0.39411698563458925,"score_spread":0.20801853421120947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391893409","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20094311,0.04397243,0.70414984,0.002922443,0.00074436545,0.00987958,0.034269273,0.00077432557,0.0023446376],"genre_scores_gemma":[0.6012949,0.0005493905,0.28773114,0.00051415176,0.00076335407,0.0017929578,0.106427014,0.00023208439,0.0006950179],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99380034,0.00036616955,0.0014842463,0.0026877488,0.0010524015,0.0006091124],"domain_scores_gemma":[0.9956227,0.00039416106,0.0006086386,0.002540696,0.0005865841,0.00024723337],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015184189,0.0008782947,0.0014868852,0.00015845877,0.00012100445,0.00015169446,0.0006414788,0.0006187842,0.00034892166],"category_scores_gemma":[0.00015363825,0.00076418504,0.000440765,0.00026965106,0.00021255939,0.00051465014,0.0018869833,0.0014291955,0.000043507815],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02772396,0.013441533,0.00015837052,0.021398392,0.02166745,0.00011151941,0.014918549,0.10091907,0.44189104,0.001066416,0.034341037,0.32236266],"study_design_scores_gemma":[0.008087723,0.00030248435,0.000033010027,0.0005942546,0.0063542174,0.00001943274,0.0013144137,0.7038685,0.04806248,0.22816907,0.002067101,0.0011272887],"about_ca_topic_score_codex":0.0002600564,"about_ca_topic_score_gemma":0.000077321274,"teacher_disagreement_score":0.60294944,"about_ca_system_score_codex":0.0004559989,"about_ca_system_score_gemma":0.0008063076,"threshold_uncertainty_score":0.9994809},"labels":[],"label_agreement":null},{"id":"W4391893486","doi":"10.1158/1078-0432.c.7077821","title":"Data from Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach","year":2024,"lang":"en","type":"preprint","venue":"","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"University of California, San Francisco; National Institutes of Health; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco; National Cancer Institute; Rally Foundation","keywords":"Drug; Cancer research; Osteosarcoma; Drug response; Genome; Computational biology; Medicine; Biology; Pharmacology; Gene; Genetics","score_opus":0.18609845142337977,"score_gpt":0.39411698563458925,"score_spread":0.20801853421120947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391893486","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20094311,0.04397243,0.70414984,0.002922443,0.00074436545,0.00987958,0.034269273,0.00077432557,0.0023446376],"genre_scores_gemma":[0.6012949,0.0005493905,0.28773114,0.00051415176,0.00076335407,0.0017929578,0.106427014,0.00023208439,0.0006950179],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99380034,0.00036616955,0.0014842463,0.0026877488,0.0010524015,0.0006091124],"domain_scores_gemma":[0.9956227,0.00039416106,0.0006086386,0.002540696,0.0005865841,0.00024723337],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015184189,0.0008782947,0.0014868852,0.00015845877,0.00012100445,0.00015169446,0.0006414788,0.0006187842,0.00034892166],"category_scores_gemma":[0.00015363825,0.00076418504,0.000440765,0.00026965106,0.00021255939,0.00051465014,0.0018869833,0.0014291955,0.000043507815],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02772396,0.013441533,0.00015837052,0.021398392,0.02166745,0.00011151941,0.014918549,0.10091907,0.44189104,0.001066416,0.034341037,0.32236266],"study_design_scores_gemma":[0.008087723,0.00030248435,0.000033010027,0.0005942546,0.0063542174,0.00001943274,0.0013144137,0.7038685,0.04806248,0.22816907,0.002067101,0.0011272887],"about_ca_topic_score_codex":0.0002600564,"about_ca_topic_score_gemma":0.000077321274,"teacher_disagreement_score":0.60294944,"about_ca_system_score_codex":0.0004559989,"about_ca_system_score_gemma":0.0008063076,"threshold_uncertainty_score":0.9994809},"labels":[],"label_agreement":null},{"id":"W4392350553","doi":"10.1186/s12935-023-03195-z","title":"Targeting HER2-positive breast cancer cells by a combination of dasatinib and BMS-202: Insight into the molecular pathways","year":2024,"lang":"en","type":"article","venue":"Cancer Cell International","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Qatar University","keywords":"SKBR3; Dasatinib; Breast cancer; Cancer research; Medicine; Combination therapy; Cancer; Lapatinib; Protein kinase B; Tyrosine kinase; Epithelial–mesenchymal transition; Angiogenesis; PI3K/AKT/mTOR pathway; Cancer cell; Internal medicine; Signal transduction; Biology; Trastuzumab; Metastasis; Receptor; Cell biology","score_opus":0.006142587872453561,"score_gpt":0.26442122739555685,"score_spread":0.25827863952310326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392350553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81373644,0.13691191,0.011471342,0.018874256,0.0038673035,0.0013857683,0.001803553,0.0002085945,0.01174084],"genre_scores_gemma":[0.99540883,0.0021631776,0.0003936892,0.0008245044,0.0002596217,0.00016335903,0.000101612066,0.000042884883,0.0006422929],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99880195,0.000038950486,0.00027737732,0.00033384908,0.00038501035,0.00016286017],"domain_scores_gemma":[0.99929726,0.00009358738,0.00012156936,0.00013053679,0.0002888297,0.000068208006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011283613,0.00018148992,0.0001954441,0.00006403749,0.00006083268,0.000044854598,0.00014741499,0.00006494242,0.0005886881],"category_scores_gemma":[0.0000091276,0.00013904748,0.00007027237,0.00015683731,0.0001783365,0.00019894983,0.00007409857,0.00021117355,0.000004853241],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000261548,0.00013038158,0.00087146356,0.0002555127,0.00040339,0.000027032176,0.008606017,0.00028034157,0.9118618,0.0027970907,0.0013760066,0.073129445],"study_design_scores_gemma":[0.0027408833,0.00019609579,0.0040276563,0.0014850659,0.00025105686,0.000057092246,0.0017255723,0.015094213,0.8863495,0.0016585842,0.08593279,0.00048147512],"about_ca_topic_score_codex":0.0010679509,"about_ca_topic_score_gemma":0.000036137426,"teacher_disagreement_score":0.18167244,"about_ca_system_score_codex":0.00044642427,"about_ca_system_score_gemma":0.00018916884,"threshold_uncertainty_score":0.64457226},"labels":[],"label_agreement":null},{"id":"W4392977246","doi":"10.1056/nejmoa2305488","title":"Ribociclib plus Endocrine Therapy in Early Breast Cancer","year":2024,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":357,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Letrozole; Breast cancer; Anastrozole; Internal medicine; Goserelin; Oncology; Aromatase inhibitor; Cancer; Interim analysis; Clinical endpoint; Tamoxifen; Gynecology; Randomized controlled trial","score_opus":0.021500044059869907,"score_gpt":0.32886922496921145,"score_spread":0.30736918090934157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392977246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85687613,0.06951894,0.0006986659,0.069980524,0.0019380682,0.00023359772,0.000010891276,0.000052359213,0.00069084513],"genre_scores_gemma":[0.9798521,0.006856561,0.0003075865,0.0011402018,0.010567084,0.0000048748116,0.0000023303915,0.000044340955,0.0012249551],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983377,0.000054740136,0.0005807334,0.00018021483,0.00054951396,0.00029711888],"domain_scores_gemma":[0.99905115,0.00016968386,0.0001423911,0.0001609076,0.00016733258,0.00030856082],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045932087,0.00020725868,0.0006353599,0.00041905526,0.000020896328,0.000014143002,0.00013032989,0.000051503728,0.0010234177],"category_scores_gemma":[0.000053797394,0.0001245163,0.000096330616,0.0004530209,0.00012235984,0.00021055058,0.000013973591,0.0006702103,0.000007722351],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046598115,0.000050217386,0.019020978,0.00008612498,0.0002732495,0.00247529,0.0035536885,0.000086217995,0.009701113,0.00018571434,0.0020668546,0.95784074],"study_design_scores_gemma":[0.18661034,0.003976997,0.24941757,0.007831814,0.00029238898,0.031518772,0.0005243207,0.000235814,0.0017082844,0.0034762647,0.51403624,0.00037117332],"about_ca_topic_score_codex":0.00071903615,"about_ca_topic_score_gemma":0.000083533574,"teacher_disagreement_score":0.9574696,"about_ca_system_score_codex":0.000281453,"about_ca_system_score_gemma":0.0005545359,"threshold_uncertainty_score":0.9998898},"labels":[],"label_agreement":null},{"id":"W4393068335","doi":"10.1101/2024.03.18.585604","title":"The PRC2.1 Subcomplex Opposes G1 Progression through Regulation of CCND1 and CCND2","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"University of California, San Francisco; National Institutes of Health","keywords":"PRC2; Cyclin D1; Cell cycle; Cell biology; Biology; Palbociclib; Cancer research; Genetics; Gene; Epigenetics; EZH2; Cancer","score_opus":0.021047155572650408,"score_gpt":0.28281209647093186,"score_spread":0.26176494089828145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393068335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94157207,0.05087306,0.0006555703,0.0029128133,0.0013048423,0.0019403512,0.00014012311,0.00054885563,0.000052339787],"genre_scores_gemma":[0.98943925,0.001224903,0.008278724,0.00009541639,0.0005582312,0.00022575536,6.49081e-7,0.0001496638,0.0000273856],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997634,0.000095677766,0.0005380179,0.0007924541,0.0005312008,0.000408677],"domain_scores_gemma":[0.9976037,0.000119812066,0.00046189793,0.001159242,0.0005070219,0.00014830835],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004176873,0.0004773766,0.0006309864,0.00013150052,0.0001881218,0.00011858877,0.00025674148,0.00034762017,0.000020785128],"category_scores_gemma":[0.00013488138,0.00035109182,0.0001418989,0.0003775925,0.0004739899,0.00011838201,0.0006061122,0.0007226135,0.000012210949],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057799,0.00016939244,0.0040640333,0.0029259897,0.0005720147,0.00004269551,0.00010238125,0.00001616368,0.982299,0.008372528,0.00044166253,0.00041617014],"study_design_scores_gemma":[0.0018126434,0.00033295565,0.19289234,0.0067420425,0.0005614436,4.9497646e-7,0.000032102533,0.00056406285,0.7291023,0.0005716017,0.06648195,0.0009060439],"about_ca_topic_score_codex":0.000023520244,"about_ca_topic_score_gemma":0.000002028839,"teacher_disagreement_score":0.25319666,"about_ca_system_score_codex":0.00022319774,"about_ca_system_score_gemma":0.00053983874,"threshold_uncertainty_score":0.9998941},"labels":[],"label_agreement":null},{"id":"W4393087180","doi":"10.1158/1538-7445.am2024-3299","title":"Abstract 3299: Harnessing PIKfyve as a therapeutic vulnerability in neuroendocrine prostate cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Prostate cancer; Cancer; Medicine; Vulnerability (computing); Prostate; Oncology; Internal medicine; Computer science","score_opus":0.09684557134616648,"score_gpt":0.47790503663842276,"score_spread":0.3810594652922563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393087180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9281946,0.053327817,0.000023892373,0.015030407,0.00057266053,0.0012393399,0.000045661127,0.0002088123,0.0013568414],"genre_scores_gemma":[0.9908136,0.0025704352,0.000043336295,0.0005716504,0.00056376634,0.0014839038,0.000009267115,0.00011341427,0.0038306427],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996472,0.00018956223,0.0004065306,0.00088656234,0.00095464225,0.0010906861],"domain_scores_gemma":[0.99850535,0.00032639795,0.000039352835,0.00055664993,0.00031174635,0.00026052774],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00078532525,0.00027851813,0.00042302645,0.00050500367,0.00016175181,0.00016156732,0.0002368994,0.00006014716,0.0026406322],"category_scores_gemma":[0.0001340964,0.00022966746,0.000107766085,0.0015107231,0.00046959877,0.00036141582,0.000113897586,0.0017995368,0.0001328178],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00221864,0.00020912371,0.020722019,0.0018535398,0.00015848654,0.0017052924,0.0020020523,0.00035408096,0.18648729,0.00049161795,0.00040884578,0.78338903],"study_design_scores_gemma":[0.008159648,0.00096957677,0.3852145,0.009647763,0.0001408257,0.0006016692,0.00223825,0.0020302502,0.17285568,0.025636246,0.3911535,0.0013520638],"about_ca_topic_score_codex":0.0044364766,"about_ca_topic_score_gemma":0.0008995467,"teacher_disagreement_score":0.78203696,"about_ca_system_score_codex":0.001507561,"about_ca_system_score_gemma":0.0019051236,"threshold_uncertainty_score":0.9982711},"labels":[],"label_agreement":null},{"id":"W4393139269","doi":"10.1016/j.jbc.2024.106122","title":"Abstract 2210 To Die or Not to Die: Controlling Death in Breast and Ovarian Cancer Cells with a Novel Pathway Regulating Anticancer Drug","year":2024,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Ovarian cancer; Breast cancer; Drug; Anticancer drug; Medicine; Cancer research; Cancer; Oncology; Internal medicine; Pharmacology","score_opus":0.027177665474749816,"score_gpt":0.3021858219282277,"score_spread":0.27500815645347787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393139269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932826,0.0015237244,0.0006988807,0.0040345574,0.000085220796,0.00017581329,0.00007848857,0.00002455591,0.000096149146],"genre_scores_gemma":[0.99392927,0.0001698022,0.00424442,0.00077457813,0.0006957291,0.0000146282155,0.0000015229408,0.000023065228,0.00014697868],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986304,0.000010165343,0.00047181593,0.00031548584,0.00024540187,0.00032675514],"domain_scores_gemma":[0.9990968,0.00019529177,0.00013277543,0.00012313094,0.00013122318,0.00032074627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030627026,0.00022419637,0.00055368996,0.000057592817,0.00003767954,0.000045715264,0.000107252454,0.000109622015,0.0001430174],"category_scores_gemma":[0.00008344952,0.00012329798,0.0000748805,0.00016998364,0.000067675384,0.000079361256,0.00004536314,0.000484721,0.0000011201131],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068005947,0.000092000184,0.004774955,0.00020855799,0.00012030858,0.00062281766,0.00032733392,0.0008088776,0.9624063,0.000003052147,0.000009568076,0.023825645],"study_design_scores_gemma":[0.007287994,0.00066011766,0.22292955,0.008551239,0.00014059014,0.0026442998,0.0008884049,0.00066929724,0.7520314,0.00007317322,0.003436629,0.0006872998],"about_ca_topic_score_codex":0.000053893105,"about_ca_topic_score_gemma":0.000018487135,"teacher_disagreement_score":0.21815461,"about_ca_system_score_codex":0.00024467817,"about_ca_system_score_gemma":0.00022585937,"threshold_uncertainty_score":0.50279456},"labels":[],"label_agreement":null},{"id":"W4393260725","doi":"10.1007/s11523-024-01046-z","title":"Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Pfizer","keywords":"Palbociclib; Medicine; Breast cancer; Randomized controlled trial; Population; Metastatic breast cancer; Clinical trial; Oncology; Internal medicine; Cochrane Library; Cancer","score_opus":0.01904652755948039,"score_gpt":0.3726052928173543,"score_spread":0.35355876525787394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393260725","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008219356,0.9875009,0.00001821902,0.0004022144,0.0004722731,0.010755286,0.0005040405,0.0001788336,0.00016003582],"genre_scores_gemma":[0.000015259195,0.9896883,0.000740845,0.0012756571,0.00012071866,0.006838881,0.0004861807,0.00027765098,0.0005565155],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9952031,0.0005565082,0.0018899408,0.0010137692,0.0005370835,0.000799606],"domain_scores_gemma":[0.9971908,0.00030189386,0.0010857004,0.0008764153,0.00028123977,0.00026399316],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003870018,0.0010325114,0.008891428,0.0005581289,0.000042340856,0.000014924111,0.00034938948,0.0003358122,0.000520232],"category_scores_gemma":[0.00012119877,0.00062793173,0.0005419663,0.0016054258,0.00017709086,0.00013575258,0.000109747496,0.0012788747,0.0003295558],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000078820034,0.00028341956,0.00002151238,0.6856462,0.0008133145,0.00030627937,0.000065180306,7.202185e-7,5.2015295e-8,0.000014614569,0.0003061198,0.3124638],"study_design_scores_gemma":[0.00218852,0.00042549707,0.000049953487,0.7680913,0.015379649,0.0007696668,0.000025896423,0.0000016718159,4.0993246e-8,0.00003263458,0.21252668,0.00050848926],"about_ca_topic_score_codex":0.000021660435,"about_ca_topic_score_gemma":0.000056467332,"teacher_disagreement_score":0.3119553,"about_ca_system_score_codex":0.0024926732,"about_ca_system_score_gemma":0.0019738148,"threshold_uncertainty_score":0.9996172},"labels":[],"label_agreement":null},{"id":"W4393590190","doi":"10.5281/zenodo.6760819","title":"The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER+ breast cancer with mitotic aberrations","year":2022,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Princess Margaret Cancer Centre; Jewish General Hospital; McGill University; University of Toronto; University Health Network","funders":"","keywords":"Spindle checkpoint; Breast cancer; Mitosis; Cancer research; Spindle apparatus; Vulnerability (computing); Cancer; Biology; Cell biology; Computer science; Cell; Genetics; Cell division","score_opus":0.030162731746807253,"score_gpt":0.28849859320248517,"score_spread":0.2583358614556779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393590190","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016603247,0.0014474677,0.00017475983,0.0055442955,0.00023862033,0.0016383382,0.98784834,0.00028300763,0.0011648297],"genre_scores_gemma":[0.036740016,0.0010668071,0.00011674791,0.00086652674,0.00064285443,0.000004883018,0.9564805,0.0026552568,0.0014263826],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966874,0.00048722795,0.000572032,0.0006806339,0.0010616739,0.000511001],"domain_scores_gemma":[0.9967278,0.0000739333,0.0004774188,0.0014144601,0.0010994746,0.00020687841],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007469818,0.00036381363,0.00048308604,0.00022467718,0.0027718132,0.00029374484,0.0010203841,0.00012053501,0.06923291],"category_scores_gemma":[0.0001909556,0.00027134301,0.00014464666,0.0008771321,0.00060926046,0.00015732403,0.0008122584,0.000989265,0.0002708952],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019237597,0.00050952693,0.000004388837,0.00051352347,0.0006745448,0.000021399466,0.0005415406,0.00006207773,0.003607804,0.00009084222,0.96860933,0.02344124],"study_design_scores_gemma":[0.0011721422,0.0007309207,0.0013772068,0.00019513059,0.00024160903,0.0003077758,0.0004941254,0.000023520324,0.00037549465,0.000053467014,0.9947505,0.00027808425],"about_ca_topic_score_codex":0.00026675488,"about_ca_topic_score_gemma":0.000019660441,"teacher_disagreement_score":0.068962015,"about_ca_system_score_codex":0.0007986129,"about_ca_system_score_gemma":0.00009316831,"threshold_uncertainty_score":0.9999739},"labels":[],"label_agreement":null},{"id":"W4393803589","doi":"10.5281/zenodo.6760818","title":"The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER+ breast cancer with mitotic aberrations","year":2022,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Princess Margaret Cancer Centre; Jewish General Hospital; McGill University; University of Toronto; University Health Network","funders":"","keywords":"Spindle checkpoint; Mitosis; Cancer research; Breast cancer; Cancer; Medicine; Oncology; Biology; Internal medicine; Spindle apparatus; Cell biology; Cell; Genetics; Cell division","score_opus":0.030162731746807253,"score_gpt":0.28849859320248517,"score_spread":0.2583358614556779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393803589","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016603247,0.0014474677,0.00017475983,0.0055442955,0.00023862033,0.0016383382,0.98784834,0.00028300763,0.0011648297],"genre_scores_gemma":[0.036740016,0.0010668071,0.00011674791,0.00086652674,0.00064285443,0.000004883018,0.9564805,0.0026552568,0.0014263826],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966874,0.00048722795,0.000572032,0.0006806339,0.0010616739,0.000511001],"domain_scores_gemma":[0.9967278,0.0000739333,0.0004774188,0.0014144601,0.0010994746,0.00020687841],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007469818,0.00036381363,0.00048308604,0.00022467718,0.0027718132,0.00029374484,0.0010203841,0.00012053501,0.06923291],"category_scores_gemma":[0.0001909556,0.00027134301,0.00014464666,0.0008771321,0.00060926046,0.00015732403,0.0008122584,0.000989265,0.0002708952],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019237597,0.00050952693,0.000004388837,0.00051352347,0.0006745448,0.000021399466,0.0005415406,0.00006207773,0.003607804,0.00009084222,0.96860933,0.02344124],"study_design_scores_gemma":[0.0011721422,0.0007309207,0.0013772068,0.00019513059,0.00024160903,0.0003077758,0.0004941254,0.000023520324,0.00037549465,0.000053467014,0.9947505,0.00027808425],"about_ca_topic_score_codex":0.00026675488,"about_ca_topic_score_gemma":0.000019660441,"teacher_disagreement_score":0.068962015,"about_ca_system_score_codex":0.0007986129,"about_ca_system_score_gemma":0.00009316831,"threshold_uncertainty_score":0.9999739},"labels":[],"label_agreement":null},{"id":"W4394393852","doi":"10.6084/m9.figshare.1591559.v7","title":"CPD-CP2012","year":2015,"lang":"en","type":"dataset","venue":"Figshare","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science; Business","score_opus":0.07740393506992195,"score_gpt":0.3485299268235078,"score_spread":0.27112599175358587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394393852","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[9.491315e-8,0.0035503516,9.140471e-8,0.000116030584,0.0001595032,0.00032762234,0.9950954,0.00008963601,0.0006613026],"genre_scores_gemma":[8.713139e-7,0.000011046182,0.00005619268,0.0010941227,0.0013987412,0.00025713557,0.99568605,0.000045332352,0.0014504953],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99877596,0.000016453308,0.00017979738,0.00031869678,0.0004138466,0.00029523944],"domain_scores_gemma":[0.99851316,0.00003966068,0.0001474466,0.0007959804,0.00025111806,0.00025265853],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000026755559,0.00028787644,0.00043527115,0.00010055643,0.000028543427,0.000018227842,0.00023886382,0.00031571463,0.5693155],"category_scores_gemma":[0.00065529766,0.00025079187,0.00010483769,0.00012773271,0.000009259142,0.00007493115,0.00014446213,0.00049293967,0.036797855],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058299636,0.000034397868,3.2847623e-7,0.00064284407,0.00006231137,0.00013342325,0.0000070170536,5.222752e-7,0.0000010218329,6.814841e-8,0.9962658,0.002793933],"study_design_scores_gemma":[0.00065287296,0.00008758475,0.000044746925,0.0037244344,0.00006090263,0.000163438,0.000006742569,5.432294e-7,0.000021493192,0.000016295757,0.9949763,0.00024467084],"about_ca_topic_score_codex":0.000014338724,"about_ca_topic_score_gemma":0.000014030959,"teacher_disagreement_score":0.5325177,"about_ca_system_score_codex":0.00019904059,"about_ca_system_score_gemma":0.0004287047,"threshold_uncertainty_score":0.99999446},"labels":[],"label_agreement":null},{"id":"W4394396077","doi":"10.6084/m9.figshare.1591559.v5","title":"CPD-CP2012","year":2015,"lang":"en","type":"dataset","venue":"Figshare","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.07740393506992195,"score_gpt":0.3485299268235078,"score_spread":0.27112599175358587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394396077","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[9.491315e-8,0.0035503516,9.140471e-8,0.000116030584,0.0001595032,0.00032762234,0.9950954,0.00008963601,0.0006613026],"genre_scores_gemma":[8.713139e-7,0.000011046182,0.00005619268,0.0010941227,0.0013987412,0.00025713557,0.99568605,0.000045332352,0.0014504953],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99877596,0.000016453308,0.00017979738,0.00031869678,0.0004138466,0.00029523944],"domain_scores_gemma":[0.99851316,0.00003966068,0.0001474466,0.0007959804,0.00025111806,0.00025265853],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000026755559,0.00028787644,0.00043527115,0.00010055643,0.000028543427,0.000018227842,0.00023886382,0.00031571463,0.5693155],"category_scores_gemma":[0.00065529766,0.00025079187,0.00010483769,0.00012773271,0.000009259142,0.00007493115,0.00014446213,0.00049293967,0.036797855],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058299636,0.000034397868,3.2847623e-7,0.00064284407,0.00006231137,0.00013342325,0.0000070170536,5.222752e-7,0.0000010218329,6.814841e-8,0.9962658,0.002793933],"study_design_scores_gemma":[0.00065287296,0.00008758475,0.000044746925,0.0037244344,0.00006090263,0.000163438,0.000006742569,5.432294e-7,0.000021493192,0.000016295757,0.9949763,0.00024467084],"about_ca_topic_score_codex":0.000014338724,"about_ca_topic_score_gemma":0.000014030959,"teacher_disagreement_score":0.5325177,"about_ca_system_score_codex":0.00019904059,"about_ca_system_score_gemma":0.0004287047,"threshold_uncertainty_score":0.99999446},"labels":[],"label_agreement":null},{"id":"W4394396671","doi":"10.6084/m9.figshare.1591559.v10","title":"CPD-CP2012","year":2015,"lang":"en","type":"dataset","venue":"Figshare","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Environmental science","score_opus":0.07740393506992195,"score_gpt":0.3485299268235078,"score_spread":0.27112599175358587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394396671","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[9.491315e-8,0.0035503516,9.140471e-8,0.000116030584,0.0001595032,0.00032762234,0.9950954,0.00008963601,0.0006613026],"genre_scores_gemma":[8.713139e-7,0.000011046182,0.00005619268,0.0010941227,0.0013987412,0.00025713557,0.99568605,0.000045332352,0.0014504953],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99877596,0.000016453308,0.00017979738,0.00031869678,0.0004138466,0.00029523944],"domain_scores_gemma":[0.99851316,0.00003966068,0.0001474466,0.0007959804,0.00025111806,0.00025265853],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000026755559,0.00028787644,0.00043527115,0.00010055643,0.000028543427,0.000018227842,0.00023886382,0.00031571463,0.5693155],"category_scores_gemma":[0.00065529766,0.00025079187,0.00010483769,0.00012773271,0.000009259142,0.00007493115,0.00014446213,0.00049293967,0.036797855],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058299636,0.000034397868,3.2847623e-7,0.00064284407,0.00006231137,0.00013342325,0.0000070170536,5.222752e-7,0.0000010218329,6.814841e-8,0.9962658,0.002793933],"study_design_scores_gemma":[0.00065287296,0.00008758475,0.000044746925,0.0037244344,0.00006090263,0.000163438,0.000006742569,5.432294e-7,0.000021493192,0.000016295757,0.9949763,0.00024467084],"about_ca_topic_score_codex":0.000014338724,"about_ca_topic_score_gemma":0.000014030959,"teacher_disagreement_score":0.5325177,"about_ca_system_score_codex":0.00019904059,"about_ca_system_score_gemma":0.0004287047,"threshold_uncertainty_score":0.99999446},"labels":[],"label_agreement":null},{"id":"W4394408952","doi":"10.6084/m9.figshare.1591559","title":"CPD-CP2012","year":2015,"lang":"en","type":"dataset","venue":"Figshare","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Environmental science","score_opus":0.07740393506992195,"score_gpt":0.3485299268235078,"score_spread":0.27112599175358587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394408952","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[9.491315e-8,0.0035503516,9.140471e-8,0.000116030584,0.0001595032,0.00032762234,0.9950954,0.00008963601,0.0006613026],"genre_scores_gemma":[8.713139e-7,0.000011046182,0.00005619268,0.0010941227,0.0013987412,0.00025713557,0.99568605,0.000045332352,0.0014504953],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99877596,0.000016453308,0.00017979738,0.00031869678,0.0004138466,0.00029523944],"domain_scores_gemma":[0.99851316,0.00003966068,0.0001474466,0.0007959804,0.00025111806,0.00025265853],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000026755559,0.00028787644,0.00043527115,0.00010055643,0.000028543427,0.000018227842,0.00023886382,0.00031571463,0.5693155],"category_scores_gemma":[0.00065529766,0.00025079187,0.00010483769,0.00012773271,0.000009259142,0.00007493115,0.00014446213,0.00049293967,0.036797855],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058299636,0.000034397868,3.2847623e-7,0.00064284407,0.00006231137,0.00013342325,0.0000070170536,5.222752e-7,0.0000010218329,6.814841e-8,0.9962658,0.002793933],"study_design_scores_gemma":[0.00065287296,0.00008758475,0.000044746925,0.0037244344,0.00006090263,0.000163438,0.000006742569,5.432294e-7,0.000021493192,0.000016295757,0.9949763,0.00024467084],"about_ca_topic_score_codex":0.000014338724,"about_ca_topic_score_gemma":0.000014030959,"teacher_disagreement_score":0.5325177,"about_ca_system_score_codex":0.00019904059,"about_ca_system_score_gemma":0.0004287047,"threshold_uncertainty_score":0.99999446},"labels":[],"label_agreement":null},{"id":"W4394420017","doi":"10.6084/m9.figshare.1591559.v8","title":"CPD-CP2012","year":2015,"lang":"en","type":"dataset","venue":"Figshare","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.07740393506992195,"score_gpt":0.3485299268235078,"score_spread":0.27112599175358587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394420017","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[9.491315e-8,0.0035503516,9.140471e-8,0.000116030584,0.0001595032,0.00032762234,0.9950954,0.00008963601,0.0006613026],"genre_scores_gemma":[8.713139e-7,0.000011046182,0.00005619268,0.0010941227,0.0013987412,0.00025713557,0.99568605,0.000045332352,0.0014504953],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99877596,0.000016453308,0.00017979738,0.00031869678,0.0004138466,0.00029523944],"domain_scores_gemma":[0.99851316,0.00003966068,0.0001474466,0.0007959804,0.00025111806,0.00025265853],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000026755559,0.00028787644,0.00043527115,0.00010055643,0.000028543427,0.000018227842,0.00023886382,0.00031571463,0.5693155],"category_scores_gemma":[0.00065529766,0.00025079187,0.00010483769,0.00012773271,0.000009259142,0.00007493115,0.00014446213,0.00049293967,0.036797855],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058299636,0.000034397868,3.2847623e-7,0.00064284407,0.00006231137,0.00013342325,0.0000070170536,5.222752e-7,0.0000010218329,6.814841e-8,0.9962658,0.002793933],"study_design_scores_gemma":[0.00065287296,0.00008758475,0.000044746925,0.0037244344,0.00006090263,0.000163438,0.000006742569,5.432294e-7,0.000021493192,0.000016295757,0.9949763,0.00024467084],"about_ca_topic_score_codex":0.000014338724,"about_ca_topic_score_gemma":0.000014030959,"teacher_disagreement_score":0.5325177,"about_ca_system_score_codex":0.00019904059,"about_ca_system_score_gemma":0.0004287047,"threshold_uncertainty_score":0.99999446},"labels":[],"label_agreement":null},{"id":"W4394432639","doi":"10.6084/m9.figshare.1591559.v2","title":"CPD-CP2012","year":2015,"lang":"en","type":"dataset","venue":"Figshare","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.07740393506992195,"score_gpt":0.3485299268235078,"score_spread":0.27112599175358587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394432639","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[9.491315e-8,0.0035503516,9.140471e-8,0.000116030584,0.0001595032,0.00032762234,0.9950954,0.00008963601,0.0006613026],"genre_scores_gemma":[8.713139e-7,0.000011046182,0.00005619268,0.0010941227,0.0013987412,0.00025713557,0.99568605,0.000045332352,0.0014504953],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99877596,0.000016453308,0.00017979738,0.00031869678,0.0004138466,0.00029523944],"domain_scores_gemma":[0.99851316,0.00003966068,0.0001474466,0.0007959804,0.00025111806,0.00025265853],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000026755559,0.00028787644,0.00043527115,0.00010055643,0.000028543427,0.000018227842,0.00023886382,0.00031571463,0.5693155],"category_scores_gemma":[0.00065529766,0.00025079187,0.00010483769,0.00012773271,0.000009259142,0.00007493115,0.00014446213,0.00049293967,0.036797855],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058299636,0.000034397868,3.2847623e-7,0.00064284407,0.00006231137,0.00013342325,0.0000070170536,5.222752e-7,0.0000010218329,6.814841e-8,0.9962658,0.002793933],"study_design_scores_gemma":[0.00065287296,0.00008758475,0.000044746925,0.0037244344,0.00006090263,0.000163438,0.000006742569,5.432294e-7,0.000021493192,0.000016295757,0.9949763,0.00024467084],"about_ca_topic_score_codex":0.000014338724,"about_ca_topic_score_gemma":0.000014030959,"teacher_disagreement_score":0.5325177,"about_ca_system_score_codex":0.00019904059,"about_ca_system_score_gemma":0.0004287047,"threshold_uncertainty_score":0.99999446},"labels":[],"label_agreement":null},{"id":"W4394533324","doi":"10.6084/m9.figshare.1591559.v9","title":"CPD-CP2012","year":2015,"lang":"en","type":"dataset","venue":"Figshare","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.07740393506992195,"score_gpt":0.3485299268235078,"score_spread":0.27112599175358587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394533324","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[9.491315e-8,0.0035503516,9.140471e-8,0.000116030584,0.0001595032,0.00032762234,0.9950954,0.00008963601,0.0006613026],"genre_scores_gemma":[8.713139e-7,0.000011046182,0.00005619268,0.0010941227,0.0013987412,0.00025713557,0.99568605,0.000045332352,0.0014504953],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99877596,0.000016453308,0.00017979738,0.00031869678,0.0004138466,0.00029523944],"domain_scores_gemma":[0.99851316,0.00003966068,0.0001474466,0.0007959804,0.00025111806,0.00025265853],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000026755559,0.00028787644,0.00043527115,0.00010055643,0.000028543427,0.000018227842,0.00023886382,0.00031571463,0.5693155],"category_scores_gemma":[0.00065529766,0.00025079187,0.00010483769,0.00012773271,0.000009259142,0.00007493115,0.00014446213,0.00049293967,0.036797855],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058299636,0.000034397868,3.2847623e-7,0.00064284407,0.00006231137,0.00013342325,0.0000070170536,5.222752e-7,0.0000010218329,6.814841e-8,0.9962658,0.002793933],"study_design_scores_gemma":[0.00065287296,0.00008758475,0.000044746925,0.0037244344,0.00006090263,0.000163438,0.000006742569,5.432294e-7,0.000021493192,0.000016295757,0.9949763,0.00024467084],"about_ca_topic_score_codex":0.000014338724,"about_ca_topic_score_gemma":0.000014030959,"teacher_disagreement_score":0.5325177,"about_ca_system_score_codex":0.00019904059,"about_ca_system_score_gemma":0.0004287047,"threshold_uncertainty_score":0.99999446},"labels":[],"label_agreement":null},{"id":"W4394610160","doi":"10.3390/curroncol31040161","title":"Real-World Treatment Patterns and Clinical Outcomes among Patients Receiving CDK4/6 Inhibitors for Metastatic Breast Cancer in a Canadian Setting Using AI-Extracted Data","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; Pfizer (Canada)","funders":"","keywords":"Medicine; Palbociclib; Metastatic breast cancer; Internal medicine; Breast cancer; Oncology; Cancer; Chemotherapy","score_opus":0.15176959375757845,"score_gpt":0.500363996342458,"score_spread":0.3485944025848795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394610160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915134,0.0007003142,0.00014598526,0.0019262221,0.002504367,0.0012046839,0.0019251619,0.00005611077,0.000023756127],"genre_scores_gemma":[0.99746996,0.00048366602,0.00075661374,0.00014818605,0.00042906,0.00014383717,0.0004694925,0.000058941896,0.00004023968],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771583,0.00014830493,0.00069933996,0.0006910308,0.00014030568,0.0006052094],"domain_scores_gemma":[0.9984183,0.0005924213,0.0001552293,0.00035344512,0.00010321382,0.00037741274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044505057,0.00027660897,0.00068963354,0.00043343348,0.000084896514,0.000037188056,0.00012038953,0.00009110656,0.000058542395],"category_scores_gemma":[0.0001430591,0.00022655915,0.00009440784,0.000269261,0.00012277119,0.000292579,0.000085976324,0.00035775805,0.0000016023911],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000072413335,0.00019525604,0.61758363,0.00014290967,0.00017394102,0.000032595242,0.00027676305,0.0000074476693,0.000003364714,0.0000046768105,0.000054860728,0.3814521],"study_design_scores_gemma":[0.0031734793,0.00022023152,0.9684471,0.0010444875,0.00046849262,0.000022564522,0.00014807662,0.010215682,0.000003627458,0.000027348304,0.01602918,0.00019972728],"about_ca_topic_score_codex":0.21838792,"about_ca_topic_score_gemma":0.84460545,"teacher_disagreement_score":0.62621754,"about_ca_system_score_codex":0.0028158561,"about_ca_system_score_gemma":0.0014183103,"threshold_uncertainty_score":0.9238814},"labels":[],"label_agreement":null},{"id":"W4395012305","doi":"10.1097/jsm.0000000000001219","title":"2024 CASEM Poster Abstracts","year":2024,"lang":"en","type":"article","venue":"Clinical Journal of Sport Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.060960513183831826,"score_gpt":0.4358707834098986,"score_spread":0.37491027022606677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395012305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9140819,0.027639646,0.0002536505,0.040391862,0.009072664,0.00021044216,0.000003593908,0.00006469554,0.008281564],"genre_scores_gemma":[0.980155,0.00116035,0.0007063989,0.004784793,0.0084204,0.000001081293,0.000004732506,0.000041458836,0.004725779],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970812,0.00001042149,0.001843225,0.00022254896,0.00060179294,0.00024080908],"domain_scores_gemma":[0.9982874,0.00023326302,0.00036851378,0.0002525693,0.00032903478,0.0005292444],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016619777,0.00018230102,0.0008753081,0.00022648192,0.000021538577,0.000010674344,0.00013452157,0.00014101688,0.001719026],"category_scores_gemma":[0.00024019417,0.00010935584,0.00031540974,0.00025689587,0.00038043226,0.00016754461,0.00002412349,0.0011453116,0.00011302159],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050506075,0.00066998816,0.14969938,0.0008354083,0.001806287,0.080821194,0.00090446736,0.000019363488,0.0020506883,0.00047535126,0.08679935,0.6708679],"study_design_scores_gemma":[0.0035064097,0.0028660137,0.1954976,0.0046494645,0.00072056055,0.01957815,0.00031231332,0.000013053791,0.00022933751,0.0008176292,0.77166295,0.00014649713],"about_ca_topic_score_codex":0.0000069934167,"about_ca_topic_score_gemma":0.0000014895892,"teacher_disagreement_score":0.6848636,"about_ca_system_score_codex":0.000081960374,"about_ca_system_score_gemma":0.0003565919,"threshold_uncertainty_score":0.99919355},"labels":[],"label_agreement":null},{"id":"W4396532678","doi":"10.3390/jpm14050464","title":"Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy versus Endocrine Therapy Alone for HR-Positive, HER-2-Negative Early Breast Cancer: Meta-Analysis of Phase III Randomized Clinical Trials","year":2024,"lang":"en","type":"article","venue":"Journal of Personalized Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Universidade Federal do Pará; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior","keywords":"Medicine; Internal medicine; Breast cancer; Oncology; Fulvestrant; Meta-analysis; Randomized controlled trial; Clinical trial; Cancer; Estrogen receptor","score_opus":0.18428031887082622,"score_gpt":0.491908685514699,"score_spread":0.30762836664387283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396532678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45662332,0.4547837,0.02022103,0.050717786,0.0061965417,0.008629366,0.002402186,0.00017164752,0.00025443],"genre_scores_gemma":[0.9380857,0.050099205,0.002479879,0.0015025726,0.0056508738,0.00052442006,0.000112991205,0.00017834644,0.0013660116],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98788804,0.0026074725,0.0058634374,0.0008333611,0.0021010973,0.00070660625],"domain_scores_gemma":[0.9767317,0.01613099,0.0036557317,0.00056340866,0.0021709255,0.0007472269],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.013554404,0.00091310486,0.014258161,0.0016358148,0.00012835553,0.000045608685,0.00040358555,0.00020652128,0.0053352937],"category_scores_gemma":[0.0031618595,0.0005183696,0.008806534,0.0015619979,0.0014224946,0.00040519875,0.000045662782,0.0011070602,0.000002527213],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5882002,0.0009166055,0.000031694446,0.00011080441,0.3171798,0.0005376156,0.0035451606,0.000066894805,0.016134325,0.00013874423,0.0004875698,0.07265058],"study_design_scores_gemma":[0.719915,0.0059918985,0.00012737431,0.0005543032,0.2541118,0.00045204427,0.0013299469,0.0007980318,0.010678118,0.00034837864,0.00526671,0.00042643072],"about_ca_topic_score_codex":0.0008025945,"about_ca_topic_score_gemma":0.00003927952,"teacher_disagreement_score":0.4814624,"about_ca_system_score_codex":0.0005396497,"about_ca_system_score_gemma":0.0011203967,"threshold_uncertainty_score":0.9997268},"labels":[],"label_agreement":null},{"id":"W4396587639","doi":"10.1158/1538-7445.sabcs23-po2-20-04","title":"Abstract PO2-20-04: TACTIVE-U: phase 1b/2 umbrella study of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER–positive advanced or metastatic breast cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Ottawa Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Chimera (genetics); Proteolysis; Estrogen receptor; Medicine; Cancer research; Estrogen; Internal medicine; Chemistry; Cancer; Biochemistry; Breast cancer","score_opus":0.06529943656489028,"score_gpt":0.4349569742338259,"score_spread":0.3696575376689356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396587639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97742414,0.011829147,0.000071099836,0.0011211316,0.00015008972,0.0079134125,0.0012387831,0.00012435859,0.00012784252],"genre_scores_gemma":[0.9892557,0.0011534163,0.0010428561,0.000060013273,0.00022620217,0.0071145664,0.000057770747,0.000260411,0.00082906295],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.994407,0.00040960844,0.00086201285,0.0013892243,0.0016250759,0.0013070969],"domain_scores_gemma":[0.99754703,0.00041388816,0.00026386324,0.00065714814,0.00072509155,0.00039300247],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007066581,0.0006933752,0.0013210921,0.0008143085,0.00022503329,0.00008974851,0.00036788167,0.0001249557,0.0018701869],"category_scores_gemma":[0.00006413538,0.0004884922,0.00017642207,0.0027375922,0.0005374353,0.0005848879,0.00008992331,0.0012332385,0.000023770497],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10426983,0.016880339,0.02312871,0.0028848592,0.007917482,0.0013907608,0.014596216,0.0008993165,0.5770343,0.000058072397,0.00014240087,0.2507977],"study_design_scores_gemma":[0.21833114,0.041834064,0.087135665,0.032539647,0.0038871968,0.00047254117,0.042039663,0.0014846257,0.5626794,0.00031090018,0.0053522857,0.0039328383],"about_ca_topic_score_codex":0.0053410283,"about_ca_topic_score_gemma":0.0012646654,"teacher_disagreement_score":0.24686486,"about_ca_system_score_codex":0.0018497074,"about_ca_system_score_gemma":0.0021493216,"threshold_uncertainty_score":0.9997567},"labels":[],"label_agreement":null},{"id":"W4396587707","doi":"10.1158/1538-7445.sabcs23-po2-17-01","title":"Abstract PO2-17-01: Impact of the introduction of CDK4/6 inhibitors on treatment duration in patients with HR+, HER2– advanced breast cancer: Final analysis of TreatER+ight, a Canadian prospective, real-world, observational study","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada); McGill University Health Centre; Jewish General Hospital; BC Cancer Agency; Ottawa Hospital; Windsor Regional Hospital; London Health Sciences Centre; Grand River Hospital; Saskatchewan Cancer Agency","funders":"","keywords":"Cancer; Medicine; Breast cancer; Oncology; Duration (music); Internal medicine; Prospective cohort study; Art","score_opus":0.06125053355173842,"score_gpt":0.4109199862730255,"score_spread":0.3496694527212871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396587707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99590456,0.00023272302,8.238084e-7,0.0010199476,0.00008893922,0.0017862478,0.0008357267,0.000012518624,0.00011848938],"genre_scores_gemma":[0.99870515,0.000088669345,0.000018316025,0.0000059770473,0.00017890017,0.0004670296,0.000101871476,0.00003357507,0.00040054106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975367,0.0001131578,0.0005289762,0.0004979949,0.0009494003,0.00037375555],"domain_scores_gemma":[0.99830633,0.00008886677,0.00019613536,0.00046650151,0.0008127735,0.00012936586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002959682,0.00023440778,0.0005789447,0.0014317088,0.000082844956,0.000015717504,0.00013140943,0.000053176074,0.00045993607],"category_scores_gemma":[0.00002776856,0.00013954002,0.00018012497,0.004247064,0.00022145468,0.00021171037,0.000020698251,0.00029484503,7.695993e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005888198,0.0008251088,0.956666,0.00010173629,0.0018690504,0.000006710929,0.0017146971,0.012071075,0.0024228822,0.000039014452,0.000056659173,0.018338855],"study_design_scores_gemma":[0.0027293016,0.0017574605,0.99047816,0.0004451562,0.0003096614,8.6240067e-7,0.0002981282,0.00010207216,0.0036870209,0.000022046597,0.00006308984,0.00010702093],"about_ca_topic_score_codex":0.32590395,"about_ca_topic_score_gemma":0.50189704,"teacher_disagreement_score":0.17599308,"about_ca_system_score_codex":0.006799143,"about_ca_system_score_gemma":0.002382367,"threshold_uncertainty_score":0.99701357},"labels":[],"label_agreement":null},{"id":"W4396587723","doi":"10.1158/1538-7445.sabcs23-po2-18-09","title":"Abstract PO2-18-09: A phase 3 randomized open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy in patients with ER+/HER2– early breast cancer and an intermediate or high risk of recurrence (CAMBRIA 1)","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Cancer; Breast cancer; Endocrine system; Adjuvant; Oncology; Adjuvant therapy; Internal medicine; Open label; Randomized controlled trial; Hormone","score_opus":0.05914551455094619,"score_gpt":0.438484531426877,"score_spread":0.3793390168759308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396587723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863188,0.005053802,0.000027345177,0.0002490781,0.00013689646,0.0067085717,0.0014480328,0.00003974664,0.000017672794],"genre_scores_gemma":[0.98001534,0.017671822,0.00021100683,0.000024587294,0.000107952714,0.0017539556,0.00002740433,0.000115664516,0.00007229832],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956688,0.0005873807,0.00079000543,0.00094199454,0.0013050704,0.0007066949],"domain_scores_gemma":[0.99708325,0.000463589,0.00031256312,0.00069271,0.0011471251,0.00030076952],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014718818,0.00045733593,0.0016761941,0.00052268396,0.00010016516,0.00010974224,0.00048033384,0.00006640526,0.00044686126],"category_scores_gemma":[0.000059023212,0.00025779274,0.000049635404,0.0010637427,0.0009812282,0.0005950265,0.00010885341,0.00091635284,7.545378e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61380863,0.0036789319,0.033564962,0.00020754046,0.0009486159,0.00012744596,0.0038457788,0.000015059585,0.0012651719,0.000013650869,0.000009526526,0.34251466],"study_design_scores_gemma":[0.6088233,0.022571733,0.36131474,0.0028675762,0.0001271362,0.000016148066,0.0010119645,0.00007300365,0.0026658396,0.00012005708,0.00007318307,0.00033534045],"about_ca_topic_score_codex":0.031290416,"about_ca_topic_score_gemma":0.0054645236,"teacher_disagreement_score":0.34217933,"about_ca_system_score_codex":0.0003688586,"about_ca_system_score_gemma":0.0017899491,"threshold_uncertainty_score":0.9999874},"labels":[],"label_agreement":null},{"id":"W4396587780","doi":"10.1158/1538-7445.sabcs23-po3-02-05","title":"Abstract PO3-02-05: Racial and Ethnic Differences in Clinical Outcomes among North American Patients with Hormone Receptor-Positive, HER2-negative, Early Breast Cancer in the PALLAS Trial (AFT-05)","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Breast cancer; Medicine; Hormone receptor; Internal medicine; Oncology; Ethnic group; Cancer; Hormone; Clinical trial; Demography; Gynecology","score_opus":0.06929292016749988,"score_gpt":0.42962184328080993,"score_spread":0.36032892311331005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396587780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99313414,0.0015795536,0.0000035092207,0.0023795313,0.00031242703,0.0020733392,0.00038510654,0.00004561763,0.00008676599],"genre_scores_gemma":[0.99547154,0.0024996144,0.00003744311,0.00020873743,0.00058381277,0.00095363945,0.000020655885,0.000068222085,0.00015632348],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955031,0.0006510654,0.00068846234,0.00088049594,0.0013817593,0.00089510373],"domain_scores_gemma":[0.9972924,0.001563257,0.00015314312,0.00039359237,0.00033001072,0.0002676151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011542573,0.00037080227,0.00084541674,0.00042145682,0.0001441021,0.00013446345,0.00036491101,0.0001303789,0.00016754102],"category_scores_gemma":[0.0001932744,0.00022519525,0.00011975258,0.0018710591,0.0019861436,0.00035152477,0.000120166995,0.0021470876,0.00001138613],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030435052,0.00029868932,0.8134285,0.00006209356,0.00019504665,0.00008638094,0.0031253705,0.0000042359347,0.000024782305,0.0000070465435,0.00010451897,0.15222828],"study_design_scores_gemma":[0.01948381,0.0015250068,0.9770111,0.0005846834,0.00003648698,0.0000029585556,0.0008699107,0.00001038424,0.000013833621,0.00003592924,0.00016189113,0.00026404476],"about_ca_topic_score_codex":0.026069967,"about_ca_topic_score_gemma":0.0662224,"teacher_disagreement_score":0.16358256,"about_ca_system_score_codex":0.00060390285,"about_ca_system_score_gemma":0.0007057202,"threshold_uncertainty_score":0.9804155},"labels":[],"label_agreement":null},{"id":"W4396590627","doi":"10.1158/1538-7445.sabcs23-lbo1-04","title":"Abstract LBO1-04: Primary results from a phase 2a study of zanidatamab (zani) + palbociclib (palbo) + fulvestrant (fulv) in HER2+/HR+ metastatic breast cancer (mBC)","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Baker Hughes (Canada); Health Sciences Centre; Zymeworks (Canada); Ottawa Hospital; Jewish General Hospital","funders":"","keywords":"Palbociclib; Fulvestrant; Metastatic breast cancer; Medicine; Oncology; Internal medicine; Breast cancer; Cancer; Gynecology; Estrogen receptor","score_opus":0.10942888924298524,"score_gpt":0.4624104369764118,"score_spread":0.3529815477334266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396590627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97123957,0.015176897,0.000035690424,0.0035119895,0.00044914056,0.0024809088,0.006459786,0.00014975881,0.0004962378],"genre_scores_gemma":[0.9950115,0.0017266477,0.00024791044,0.0001664888,0.00067495304,0.0010449358,0.00028452187,0.00017344834,0.0006695885],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99354035,0.00038092994,0.0012094674,0.0015017979,0.0021203065,0.0012471329],"domain_scores_gemma":[0.99669176,0.0007981061,0.00020136137,0.0012896091,0.00056130165,0.0004578503],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016883892,0.0005323036,0.0011768413,0.0008605869,0.00014166176,0.00012729484,0.00064165494,0.00015710859,0.0020036395],"category_scores_gemma":[0.00016028111,0.00045301087,0.00017953258,0.0021301878,0.0005006033,0.0005593253,0.00024231958,0.001857345,0.00007348002],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04072535,0.010448983,0.0086749215,0.0036996154,0.0030547758,0.005563894,0.021867165,0.0006479814,0.4336855,0.00008759911,0.004832897,0.4667113],"study_design_scores_gemma":[0.13034178,0.0070319697,0.71585494,0.019914605,0.001393061,0.00038746314,0.031977475,0.0011619821,0.0462409,0.001959125,0.040994354,0.0027423217],"about_ca_topic_score_codex":0.03257549,"about_ca_topic_score_gemma":0.007913301,"teacher_disagreement_score":0.70718,"about_ca_system_score_codex":0.0016810164,"about_ca_system_score_gemma":0.002505337,"threshold_uncertainty_score":0.99979216},"labels":[],"label_agreement":null},{"id":"W4396590741","doi":"10.1158/1538-7445.sabcs23-gs01-12","title":"Abstract GS01-12: MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2- advanced breast cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham","funders":"","keywords":"Aromatase inhibitor; Aromatase; Medicine; Nonsteroidal; Breast cancer; Internal medicine; Oncology; Cancer","score_opus":0.10098032848230017,"score_gpt":0.43732577981712517,"score_spread":0.336345451334825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396590741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.950996,0.022683373,0.00015610714,0.012699214,0.0013190444,0.0031400535,0.0082613975,0.00022318431,0.00052162004],"genre_scores_gemma":[0.9825695,0.0069626,0.00048289122,0.00024990545,0.0027927002,0.0023192004,0.00033454772,0.00022021263,0.004068408],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994601,0.00012775326,0.00093254726,0.0012581018,0.001718584,0.0013619941],"domain_scores_gemma":[0.99645376,0.0009791143,0.00017894566,0.0009198727,0.0009800299,0.00048825308],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013145994,0.0005314612,0.00092272356,0.00054108846,0.00027341634,0.00010667632,0.00049672264,0.00025175003,0.0010892854],"category_scores_gemma":[0.00016832608,0.00044816447,0.0003447404,0.0008195234,0.00068001606,0.00042286929,0.00017553104,0.0011441051,0.00007230055],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18503141,0.0011011946,0.0015229726,0.0052161803,0.0013429691,0.0006426587,0.0031044693,0.003136728,0.2792018,0.0004371748,0.012451337,0.5068111],"study_design_scores_gemma":[0.08933482,0.0072832443,0.05440554,0.017397763,0.00026214868,0.00060982205,0.0014601749,0.0030045244,0.23719658,0.0038260035,0.58276796,0.0024513968],"about_ca_topic_score_codex":0.0027587956,"about_ca_topic_score_gemma":0.0012332739,"teacher_disagreement_score":0.5703167,"about_ca_system_score_codex":0.0010973809,"about_ca_system_score_gemma":0.002668971,"threshold_uncertainty_score":0.99982387},"labels":[],"label_agreement":null},{"id":"W4396590874","doi":"10.1158/1538-7445.sabcs23-gs03-03","title":"Abstract GS03-03: Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Aromatase inhibitor; Oncology; Breast cancer; Internal medicine; Nonsteroidal; Cancer; Adjuvant; Aromatase","score_opus":0.045699305010672396,"score_gpt":0.36555625623166677,"score_spread":0.3198569512209944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396590874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711479,0.0076363403,0.0000072244366,0.0041870764,0.0005577655,0.002695553,0.013586731,0.00010528082,0.000076124285],"genre_scores_gemma":[0.9939587,0.00063448376,0.000034337296,0.0001371725,0.0016048003,0.0019720723,0.001050826,0.000121767654,0.00048585367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942168,0.00037290872,0.00064327795,0.0013050963,0.0023340653,0.0011278604],"domain_scores_gemma":[0.9963515,0.0009872742,0.00014402057,0.0014016684,0.00046699392,0.0006485668],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005794891,0.00057141506,0.00093677477,0.0006135716,0.0002941878,0.0002759955,0.00066097896,0.00015842728,0.001607384],"category_scores_gemma":[0.00015025772,0.00036326452,0.00036813572,0.0022678461,0.00069334847,0.00048959104,0.00024948473,0.0010555699,0.00015344341],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23480561,0.0017410141,0.6880048,0.00028513657,0.005827406,0.0016199616,0.0029298419,0.0003946074,0.0006921807,0.000047213674,0.0013386094,0.062313635],"study_design_scores_gemma":[0.046501763,0.0012880753,0.94594496,0.0013437725,0.00099638,0.0000047604776,0.0005615363,0.00004414473,0.0005994306,0.00022914553,0.0020342914,0.00045175105],"about_ca_topic_score_codex":0.040054824,"about_ca_topic_score_gemma":0.020882118,"teacher_disagreement_score":0.25794017,"about_ca_system_score_codex":0.0025411367,"about_ca_system_score_gemma":0.0034047053,"threshold_uncertainty_score":0.9998819},"labels":[],"label_agreement":null},{"id":"W4396591215","doi":"10.1158/1538-7445.sabcs23-gs02-01","title":"Abstract GS02-01: Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Results from TROPION-Breast01","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Metastatic breast cancer; Oncology; Hormone receptor; Chemotherapy; Internal medicine; Breast cancer; Cancer; HER2 negative","score_opus":0.03609913088047207,"score_gpt":0.3900478600258503,"score_spread":0.3539487291453782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396591215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757166,0.0031392316,0.00022477644,0.0016020492,0.0001585043,0.011503009,0.007456364,0.00014117047,0.000058273905],"genre_scores_gemma":[0.9892939,0.0022101642,0.0011173517,0.00009293526,0.0003269887,0.005304718,0.0005937221,0.0002125197,0.00084773166],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9946902,0.000569016,0.0010420112,0.0012921803,0.001417865,0.0009887641],"domain_scores_gemma":[0.9943416,0.002304576,0.00032040503,0.00080503477,0.0018306457,0.00039769794],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011593654,0.00058816414,0.0017872556,0.0004752175,0.00027371015,0.000121530844,0.00038371698,0.000119340366,0.0010679429],"category_scores_gemma":[0.0003350566,0.00037785718,0.0002027383,0.0014549397,0.0006893601,0.0004396263,0.00007881701,0.0007616665,0.00001173262],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87252647,0.004119953,0.0009769979,0.00049388077,0.004689634,0.00005831167,0.008556309,0.00007519093,0.0063167503,0.000008752489,0.00078180764,0.10139593],"study_design_scores_gemma":[0.91859865,0.010662984,0.027070988,0.005089313,0.0012619859,0.000018734327,0.0044689667,0.00040636494,0.029486688,0.00024265608,0.0018183453,0.0008743125],"about_ca_topic_score_codex":0.023469565,"about_ca_topic_score_gemma":0.0012287856,"teacher_disagreement_score":0.10052162,"about_ca_system_score_codex":0.0012793115,"about_ca_system_score_gemma":0.0015952596,"threshold_uncertainty_score":0.9998673},"labels":[],"label_agreement":null},{"id":"W4396591583","doi":"10.1158/1538-7445.sabcs23-po5-04-11","title":"Abstract PO5-04-11: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) beyond progression in hormone receptor positive advanced breast cancer: a systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Meta-analysis; Breast cancer; Medicine; Hormone receptor; Cyclin-dependent kinase 4; Cancer; Oncology; Cancer research; Internal medicine; Kinase; Biology; Cell cycle; Cyclin-dependent kinase 2; Genetics","score_opus":0.09274614306301798,"score_gpt":0.4757449913275471,"score_spread":0.3829988482645291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396591583","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007658573,0.9787023,0.0000025270197,0.0034248235,0.00019097108,0.013844509,0.003536602,0.00012430303,0.000097344135],"genre_scores_gemma":[0.0005568676,0.97352713,0.00010850295,0.00023983713,0.00035138254,0.022395993,0.00034827084,0.00032995496,0.0021420792],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9893813,0.0013125128,0.0027268957,0.0024207816,0.002642964,0.0015155096],"domain_scores_gemma":[0.9947464,0.0006367022,0.0010870633,0.0016709828,0.0010696198,0.00078925857],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0034607213,0.0014756784,0.013207993,0.002382597,0.00023552791,0.00020890261,0.00073812297,0.0006208953,0.0010942785],"category_scores_gemma":[0.0002777699,0.0009510992,0.0025907715,0.0057912907,0.000543051,0.00040840395,0.00058375933,0.0032378847,0.00012806703],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002418772,0.00022218698,0.0000050734507,0.8149003,0.0676576,0.00045607256,0.0002154862,0.0000040482264,0.00010154077,0.000016419192,0.00053021265,0.11564921],"study_design_scores_gemma":[0.0009680349,0.0002084627,0.000025458892,0.43096954,0.5330498,0.00024434383,0.00021304715,0.0000021275787,0.000051886756,0.00003709397,0.033147912,0.001082248],"about_ca_topic_score_codex":0.0011382651,"about_ca_topic_score_gemma":0.00079650996,"teacher_disagreement_score":0.46539223,"about_ca_system_score_codex":0.003907565,"about_ca_system_score_gemma":0.0021394703,"threshold_uncertainty_score":0.99991626},"labels":[],"label_agreement":null},{"id":"W4396596413","doi":"10.1158/1538-7445.sabcs23-rf02-01","title":"Abstract RF02-01: A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab, and Pertuzumab in Hormone Receptor (HR)-Positive, HER2-Positive Metastatic Breast Cancer (ASPIRE)","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Pertuzumab; Palbociclib; Anastrozole; Medicine; Trastuzumab; Metastatic breast cancer; Oncology; Internal medicine; Breast cancer; Letrozole; Hormone receptor; Cancer; Tamoxifen","score_opus":0.052623292453304084,"score_gpt":0.4284209011597165,"score_spread":0.3757976087064124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396596413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9646608,0.024523083,0.00008176537,0.005360013,0.00036437876,0.0025801456,0.0021237994,0.00007828513,0.00022771175],"genre_scores_gemma":[0.99128455,0.005663423,0.0003805428,0.0001381462,0.00056833157,0.001164983,0.00008289881,0.00012986067,0.0005872482],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99563414,0.00029573904,0.0008054959,0.000990515,0.0012039999,0.001070124],"domain_scores_gemma":[0.9979426,0.00051844993,0.00014194548,0.00043557378,0.0005147762,0.00044665724],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00096638076,0.00045594812,0.00094662997,0.00083523855,0.00020525843,0.00008873552,0.0002592869,0.00014917622,0.0010347532],"category_scores_gemma":[0.000103237486,0.0003959885,0.00020002491,0.0013746308,0.00086965546,0.0004951184,0.00017552287,0.001277415,0.00001734158],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18932095,0.0035095308,0.00033193707,0.0011753453,0.0011178228,0.00045794673,0.006638361,0.000040014624,0.2856127,0.00009513725,0.0012996919,0.51040053],"study_design_scores_gemma":[0.6011938,0.04438296,0.12290286,0.025210671,0.001364985,0.00055333145,0.012703442,0.003727362,0.15861751,0.0006201962,0.025717877,0.0030050087],"about_ca_topic_score_codex":0.005341879,"about_ca_topic_score_gemma":0.00055436476,"teacher_disagreement_score":0.50739557,"about_ca_system_score_codex":0.0016945777,"about_ca_system_score_gemma":0.0012883182,"threshold_uncertainty_score":0.9998784},"labels":[],"label_agreement":null},{"id":"W4396597566","doi":"10.1158/1538-7445.sabcs23-po1-01-08","title":"Abstract PO1-01-08: The impact of drug-drug interactions between palbociclib and proton pump inhibitors on clinical outcomes of patients with hormone receptor positive, HER2-negative, early breast cancer: an exploratory analysis of the PALLAS study","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Palbociclib; Drug; Oncology; Cancer; Breast cancer; Hormone receptor; Internal medicine; Pharmacology; Metastatic breast cancer","score_opus":0.06028534070307063,"score_gpt":0.447671778744674,"score_spread":0.3873864380416034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396597566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939001,0.00037621977,0.0000015646941,0.0008382056,0.00009589719,0.0029333408,0.0018001237,0.000022216464,0.000032302607],"genre_scores_gemma":[0.99887294,0.00022422729,0.000010308121,0.000017148363,0.00014738596,0.00055559905,0.000024024986,0.000056046254,0.00009231361],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99634564,0.0007256971,0.0007678666,0.00054515176,0.001241733,0.0003739075],"domain_scores_gemma":[0.9964238,0.0012639633,0.00036573652,0.0007067259,0.0010368236,0.00020297905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012135594,0.00028060086,0.0008992599,0.0004733694,0.00016274797,0.00003902608,0.00033319253,0.000058165,0.00017509458],"category_scores_gemma":[0.00010714072,0.00014043409,0.00032428987,0.0019651933,0.0010755571,0.00032155332,0.0001503549,0.0010301687,0.0000018043984],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040000705,0.00091938785,0.96855223,0.00010048033,0.005966703,0.00000223201,0.008627767,0.00010378036,0.000770166,0.0000026796217,0.00010267483,0.010851829],"study_design_scores_gemma":[0.002117163,0.0014287898,0.98818374,0.00057992357,0.00064077287,2.8210692e-7,0.004201,0.00001162742,0.0026529746,0.00001630154,0.000036770693,0.00013066728],"about_ca_topic_score_codex":0.012960584,"about_ca_topic_score_gemma":0.0025240527,"teacher_disagreement_score":0.019631498,"about_ca_system_score_codex":0.00047671446,"about_ca_system_score_gemma":0.00069115264,"threshold_uncertainty_score":0.9936122},"labels":[],"label_agreement":null},{"id":"W4396599098","doi":"10.1158/1538-7445.sabcs23-po1-18-12","title":"Abstract PO1-18-12: Trial in progress: Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating locally advanced or ER+/HER2- metastatic breast cancer with an ESR1 mutation","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Open label; Randomized controlled trial; Oncology; Internal medicine","score_opus":0.10982656949936029,"score_gpt":0.4989883495578806,"score_spread":0.3891617800585203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396599098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97509897,0.0044698436,0.00026107265,0.0007609622,0.00014404078,0.018858127,0.0003520868,0.000033729124,0.000021147762],"genre_scores_gemma":[0.9911486,0.00045748247,0.0019282541,0.000026675996,0.00014881919,0.0059689567,0.000026884101,0.00009489966,0.00019945786],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963797,0.00054493564,0.0009475538,0.00069656386,0.0008846674,0.00054662046],"domain_scores_gemma":[0.99669707,0.001675844,0.0003181913,0.0004830385,0.0006562488,0.00016961455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002258076,0.0003127473,0.0012246255,0.00029705488,0.00015635496,0.000081464605,0.00037573616,0.00006298131,0.00015711633],"category_scores_gemma":[0.00040830852,0.0001789946,0.000063016574,0.0009298412,0.0007184418,0.00045924136,0.00013665887,0.0004797773,3.5829686e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7265538,0.003081444,0.00012698899,0.001166067,0.00062481174,0.000053313383,0.0034684911,0.00075202173,0.0042693377,0.000018519586,0.000005418699,0.2598798],"study_design_scores_gemma":[0.9703427,0.008873126,0.0014175908,0.0048110336,0.00043836402,0.000035219786,0.0045196284,0.0058713597,0.003337929,0.0000448469,0.00008905904,0.00021915023],"about_ca_topic_score_codex":0.001877733,"about_ca_topic_score_gemma":0.004096867,"teacher_disagreement_score":0.25966066,"about_ca_system_score_codex":0.0005528841,"about_ca_system_score_gemma":0.0015390607,"threshold_uncertainty_score":0.7299188},"labels":[],"label_agreement":null},{"id":"W4396599443","doi":"10.1158/1538-7445.sabcs23-ps09-08","title":"Abstract PS09-08: Genomic characterization of endocrine resistance in ER+HER2+ breast cancers in the POETIC Trial","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Endocrine system; Breast cancer; Oncology; Internal medicine; Cancer research; Cancer; Hormone","score_opus":0.05891477362471634,"score_gpt":0.40997220219079605,"score_spread":0.3510574285660797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396599443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98435026,0.0069957105,0.000018074317,0.0055937795,0.00033371066,0.0014648152,0.00013295653,0.00003072441,0.001079993],"genre_scores_gemma":[0.995834,0.0016776214,0.00003603602,0.00011426143,0.00063090737,0.00070734293,0.00003589447,0.000049645514,0.0009143205],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9975061,0.00018981642,0.0004893119,0.0004529062,0.00076903484,0.0005928498],"domain_scores_gemma":[0.9989921,0.0002465687,0.000066708686,0.0004546741,0.00016101255,0.000078931786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011246225,0.00017338089,0.0003600412,0.0005371485,0.000052345476,0.000047023193,0.00032079138,0.00007265606,0.000556878],"category_scores_gemma":[0.000066708955,0.00013277466,0.000075577846,0.0014617323,0.00029384473,0.00018386838,0.000049639413,0.00085005554,0.000025676949],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060076274,0.00030529613,0.0033364238,0.002159686,0.00014322349,0.000645593,0.007893395,0.000120929544,0.8298854,0.0015211382,0.0003708209,0.093541816],"study_design_scores_gemma":[0.042723455,0.00059641164,0.850142,0.006042553,0.00005714995,0.00013082886,0.0019129844,0.00015863264,0.018635526,0.0020600199,0.07698887,0.0005515399],"about_ca_topic_score_codex":0.0019468972,"about_ca_topic_score_gemma":0.0032889165,"teacher_disagreement_score":0.84680563,"about_ca_system_score_codex":0.0016667658,"about_ca_system_score_gemma":0.0013496171,"threshold_uncertainty_score":0.60974234},"labels":[],"label_agreement":null},{"id":"W4396599757","doi":"10.1158/1538-7445.sabcs23-ps17-06","title":"Abstract PS17-06: A phase I trial of the PI3K inhibitor (PI3Ki) copanlisib and fulvestrant in combination with continuous or intermittent abemaciclib in patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Fulvestrant; Medicine; Estrogen receptor; Internal medicine; Estrogen; Oncology; Cancer; Breast cancer","score_opus":0.033909403583169254,"score_gpt":0.3827888557235882,"score_spread":0.34887945214041893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396599757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99276197,0.0009279791,0.000017181766,0.0015374379,0.00016081014,0.0038886177,0.00063301384,0.000026166366,0.000046807458],"genre_scores_gemma":[0.998115,0.00018757701,0.00012522268,0.000058785885,0.000109539586,0.0011228548,0.00003330513,0.00007250612,0.00017520494],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99688524,0.00030888265,0.00053866603,0.000616197,0.0010868375,0.00056415936],"domain_scores_gemma":[0.99835014,0.00039792215,0.00017029358,0.00030991153,0.00060557004,0.000166156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062235864,0.00031298056,0.0006430632,0.00038894842,0.0000787328,0.0000682268,0.00019143158,0.000079977355,0.00025037583],"category_scores_gemma":[0.000085601554,0.00018021568,0.00006176701,0.0012698576,0.0008290303,0.00032921063,0.00007875581,0.00091239356,0.000003214166],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59384394,0.005920642,0.08311782,0.0022152013,0.0014095618,0.000413868,0.016560182,0.00012837892,0.009516003,0.00020229236,0.00036089006,0.2863112],"study_design_scores_gemma":[0.306239,0.014510238,0.6196814,0.02092695,0.00029658282,0.00008396334,0.0050791483,0.00017376852,0.031498533,0.0003238019,0.0004577479,0.00072884397],"about_ca_topic_score_codex":0.0030836074,"about_ca_topic_score_gemma":0.0022995826,"teacher_disagreement_score":0.5365636,"about_ca_system_score_codex":0.0010664511,"about_ca_system_score_gemma":0.0013103664,"threshold_uncertainty_score":0.7348982},"labels":[],"label_agreement":null},{"id":"W4396599772","doi":"10.1158/1538-7445.sabcs23-ps12-08","title":"Abstract PS12-08: MORPHEUS Hormone Receptor-Positive Breast Cancer: interim analysis of a Phase Ib/II, study of fulvestrant ± atezolizumab and abemaciclib triplet treatment in patients metastatic disease","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Fulvestrant; Atezolizumab; Medicine; Oncology; Internal medicine; Cancer; Interim analysis; Breast cancer; Metastatic breast cancer; Disease; Estrogen receptor; Clinical trial; Immunotherapy; Pembrolizumab","score_opus":0.06473927860091323,"score_gpt":0.4428545749237581,"score_spread":0.3781152963228449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396599772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98178726,0.011659133,0.000011382186,0.0004670576,0.00007971484,0.0020221348,0.003926032,0.000028195293,0.000019102463],"genre_scores_gemma":[0.9963484,0.002322857,0.000035891866,0.0000137065545,0.00005163495,0.00091622653,0.00014054103,0.00005224615,0.0001185298],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99684656,0.00021575516,0.0007304127,0.0007226726,0.0009422113,0.00054237555],"domain_scores_gemma":[0.9983277,0.00019942784,0.00014905802,0.00047641023,0.00047631963,0.00037112337],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003933934,0.0003243323,0.0010670363,0.001310321,0.00008484961,0.000030551153,0.00016561526,0.000042790838,0.0006640038],"category_scores_gemma":[0.000039875347,0.00025519138,0.00018928465,0.0024008031,0.00037829988,0.00021791313,0.00010323715,0.00035128722,0.000002737235],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09432938,0.025863348,0.13758278,0.0020365722,0.024141045,0.0009510635,0.030873464,0.0010380517,0.07925505,0.000042645188,0.00018144523,0.60370517],"study_design_scores_gemma":[0.030834652,0.0108151045,0.9406905,0.0016394982,0.0038292357,0.0000075636026,0.004573953,0.000981147,0.005958664,0.000057458165,0.00019699415,0.00041521512],"about_ca_topic_score_codex":0.0071628783,"about_ca_topic_score_gemma":0.0007351937,"teacher_disagreement_score":0.80310774,"about_ca_system_score_codex":0.0013131499,"about_ca_system_score_gemma":0.0007232288,"threshold_uncertainty_score":0.99999005},"labels":[],"label_agreement":null},{"id":"W4396599802","doi":"10.1158/1538-7445.sabcs23-ps12-09","title":"Abstract PS12-09: Capivasertib plus cyclin-dependent kinase 4/6 inhibitor and fulvestrant in hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: updated Phase 1b analysis from CAPItello-292","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean","funders":"","keywords":"Fulvestrant; Human Epidermal Growth Factor Receptor 2; Oncology; Internal medicine; Hormone receptor; Cancer research; Medicine; Cancer; Breast cancer; Epidermal growth factor receptor; Estrogen receptor","score_opus":0.03672440036031972,"score_gpt":0.3882298435116482,"score_spread":0.3515054431513285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396599802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95987153,0.024305426,0.00009739382,0.0043886034,0.0004171168,0.0017722193,0.008806712,0.00023954242,0.00010147757],"genre_scores_gemma":[0.9890935,0.0067544403,0.0003680808,0.0001577989,0.0010768845,0.00087564014,0.0009226927,0.00019735092,0.0005536417],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9931187,0.00045444167,0.0011437251,0.002039174,0.001643387,0.0016005613],"domain_scores_gemma":[0.99648416,0.00065542466,0.00022057978,0.0007618962,0.00086401385,0.001013914],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007464331,0.0008098437,0.0014825969,0.0016103865,0.00039791226,0.00025009722,0.00043434478,0.0003768489,0.004466275],"category_scores_gemma":[0.00013098844,0.00073880353,0.0003327942,0.0029002442,0.00093400344,0.00094733236,0.00022913897,0.0023430916,0.000099975914],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0105311675,0.0011456052,0.003635734,0.000383302,0.0031661897,0.00097358925,0.0064526945,0.00023313075,0.8846772,0.00006021711,0.00077245745,0.087968715],"study_design_scores_gemma":[0.05204157,0.0016721132,0.26227716,0.0035524145,0.0014829689,0.0000768678,0.005739734,0.00129963,0.66550756,0.0010307935,0.0027218421,0.0025973802],"about_ca_topic_score_codex":0.031086912,"about_ca_topic_score_gemma":0.004753761,"teacher_disagreement_score":0.25864142,"about_ca_system_score_codex":0.0037990573,"about_ca_system_score_gemma":0.0013554102,"threshold_uncertainty_score":0.9999585},"labels":[],"label_agreement":null},{"id":"W4396716258","doi":"10.14740/wjon1873","title":"Synergistic Effects of Neratinib in Combination With Palbociclib or Miransertib in Brain Cancer Cells","year":2024,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Kingston University","keywords":"Cancer research; Erlotinib; Trk receptor; Growth factor receptor; Epidermal growth factor receptor; Lapatinib; Tyrosine kinase; Medicine; Protein kinase B; Platelet-derived growth factor receptor; Fibroblast growth factor receptor; Biology; Cancer; Signal transduction; Fibroblast growth factor; Growth factor; Internal medicine; Cell biology; Receptor; Trastuzumab; Neurotrophic factors; Breast cancer","score_opus":0.013597459582180445,"score_gpt":0.3410543115128225,"score_spread":0.32745685193064206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396716258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809688,0.0063036187,0.0011133824,0.009931593,0.00092193147,0.00036779852,0.0000023272496,0.00001189164,0.00037869363],"genre_scores_gemma":[0.9963808,0.00017603696,0.001652361,0.0006601678,0.00014173538,0.000020969315,8.788958e-7,0.000023307179,0.0009437471],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988493,0.00014063285,0.0005133592,0.00012465462,0.00018895672,0.00018309541],"domain_scores_gemma":[0.9986187,0.0009199773,0.00021455139,0.00008236638,0.00009952484,0.00006483845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003193226,0.00011796308,0.00054760085,0.00057417346,0.000010174944,0.000005792387,0.00007418731,0.000059247628,0.00013199636],"category_scores_gemma":[0.000085656044,0.000078787205,0.0000502545,0.0006801649,0.00010248106,0.00010309036,0.000009698496,0.00042648945,0.0000016171194],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014403633,0.001394131,0.01800771,0.0022041993,0.00038000158,0.010059457,0.0053325756,0.0025722256,0.5005233,0.0011052453,0.0016132989,0.44240418],"study_design_scores_gemma":[0.111702606,0.03732531,0.23126839,0.03719298,0.0010628873,0.0023145904,0.0015203244,0.0039748913,0.33231416,0.0051206523,0.2350663,0.0011369071],"about_ca_topic_score_codex":0.00008996595,"about_ca_topic_score_gemma":0.004028477,"teacher_disagreement_score":0.44126728,"about_ca_system_score_codex":0.00049388164,"about_ca_system_score_gemma":0.00073424174,"threshold_uncertainty_score":0.3212849},"labels":[],"label_agreement":null},{"id":"W4396732203","doi":"10.1016/j.annonc.2024.04.013","title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":206,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham","funders":"Sanofi Genzyme; Gilead Sciences; Sanofi; Pfizer; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Medicine; Nonsteroidal; Aromatase inhibitor; Aromatase; Oncology; Internal medicine; Breast cancer; Cancer","score_opus":0.10355764462433985,"score_gpt":0.4507032766043178,"score_spread":0.34714563197997794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396732203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9699497,0.006044035,0.00015426046,0.016609192,0.0010126946,0.0011089736,0.003995148,0.000096662916,0.0010292949],"genre_scores_gemma":[0.9940402,0.0015698968,0.0011853217,0.0012661426,0.00092602364,0.00026540647,0.0002316016,0.00006865562,0.00044675503],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99761707,0.00011418178,0.00082726707,0.0005368493,0.0003815709,0.00052306673],"domain_scores_gemma":[0.9980429,0.0005983115,0.00030365074,0.00038373054,0.0004929525,0.00017850245],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045763326,0.00030619308,0.00097467296,0.00023674581,0.00005128216,0.000009920001,0.00020075748,0.00022502281,0.00015120069],"category_scores_gemma":[0.000094624316,0.0002667698,0.00029716163,0.00026371397,0.00039797803,0.00020993373,0.00006935806,0.0002962928,0.000014811579],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12974697,0.0009944886,0.0004032942,0.0007694232,0.0007908566,0.00030532226,0.0018215142,0.00025375804,0.05634258,0.00075923867,0.0033897758,0.8044228],"study_design_scores_gemma":[0.08314753,0.040765963,0.017282786,0.0030758132,0.00031995118,0.001933855,0.0012366142,0.001140657,0.25436413,0.008231947,0.58727336,0.0012273823],"about_ca_topic_score_codex":0.00040827345,"about_ca_topic_score_gemma":0.00010133577,"teacher_disagreement_score":0.8031954,"about_ca_system_score_codex":0.00013279184,"about_ca_system_score_gemma":0.0015382572,"threshold_uncertainty_score":0.9999784},"labels":[],"label_agreement":null},{"id":"W4397007282","doi":"10.1016/j.esmoop.2024.103202","title":"180O IMpassion132 double-blind randomised phase III trial of chemotherapy (CT) ± atezolizumab (atezo) for early-relapsing unresectable locally advanced or metastatic triple-negative breast cancer (aTNBC)","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Centre Hospitalier Universitaire Vaudois","keywords":"Atezolizumab; Medicine; Triple-negative breast cancer; Oncology; Chemotherapy; Breast cancer; Internal medicine; Radiology; Cancer; Immunotherapy","score_opus":0.05708297713041971,"score_gpt":0.4125401569395417,"score_spread":0.355457179809122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397007282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8632454,0.0050440496,0.051630482,0.007865353,0.004748684,0.061938513,0.001791524,0.00056030025,0.0031756721],"genre_scores_gemma":[0.97158366,0.0005237093,0.008018713,0.00034985403,0.00061118917,0.0060921283,0.00013424689,0.00027532305,0.0124111455],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99637425,0.00014644813,0.0011960629,0.00091765233,0.0005981247,0.0007674344],"domain_scores_gemma":[0.9973265,0.0007644138,0.00048376576,0.0006519535,0.00044250058,0.00033084975],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00086541,0.0006021477,0.0017883645,0.00031996417,0.00024088641,0.0002057528,0.0005886618,0.00010757648,0.0033584924],"category_scores_gemma":[0.00013996585,0.00042709967,0.00042665948,0.0009760837,0.00027191668,0.0010366847,0.00014768454,0.00042765515,0.00001631854],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81365657,0.00070852245,0.0000053820636,0.0003451538,0.0016306565,0.000086060536,0.0011717856,0.00019740325,0.0036164445,0.00020463469,0.0006075082,0.17776985],"study_design_scores_gemma":[0.9394705,0.002937281,0.000040624913,0.0022726632,0.0007023917,0.00016285872,0.0005249916,0.001789097,0.041234534,0.001089359,0.00925159,0.00052410207],"about_ca_topic_score_codex":0.003275558,"about_ca_topic_score_gemma":0.00039735602,"teacher_disagreement_score":0.17724575,"about_ca_system_score_codex":0.0005623738,"about_ca_system_score_gemma":0.002012115,"threshold_uncertainty_score":0.9998181},"labels":[],"label_agreement":null},{"id":"W4397007298","doi":"10.1016/j.esmoop.2024.103338","title":"280P Outcomes of women with early-stage triple-negative breast cancer (TNBC) in connection with age and other socio-demographic factors: A population based cohort study","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatoon Medical Imaging; University of Saskatchewan","funders":"","keywords":"Triple-negative breast cancer; Breast cancer; Cohort; Medicine; Connection (principal bundle); Demography; Population; Stage (stratigraphy); Oncology; Triple negative; Cancer; Gynecology; Internal medicine; Environmental health; Biology; Sociology","score_opus":0.019516205927045262,"score_gpt":0.31873658817177236,"score_spread":0.2992203822447271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397007298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966424,0.000037261198,0.00009984213,0.0002786221,0.000045611716,0.0026445314,0.00009055184,0.000054246855,0.00010692354],"genre_scores_gemma":[0.99866337,0.000003707052,0.00017422187,0.00012586422,0.000022461989,0.0005452536,0.000012717416,0.00005474106,0.00039766027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873626,0.0000977172,0.00023969868,0.00039964332,0.00028604435,0.00024063227],"domain_scores_gemma":[0.99941695,0.00010362136,0.00011781365,0.00021742583,0.000058704907,0.00008546464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003171542,0.00022299378,0.0005682621,0.00023945616,0.000054698292,0.000059726033,0.00009184486,0.000055022316,0.00029541992],"category_scores_gemma":[0.00001311905,0.00014436348,0.000026614307,0.00051363505,0.0001166744,0.00034189387,0.000033120567,0.000190729,7.695998e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027744968,0.00019190641,0.98711884,0.00007893323,0.00059266755,0.00005733407,0.008006629,0.000068151174,0.000030351903,0.00003730467,0.0000015319358,0.0010418718],"study_design_scores_gemma":[0.0065895105,0.00075355597,0.9857026,0.00035852907,0.000109510496,0.000007023989,0.006051147,0.000053218046,0.00005705751,0.00007071825,0.00006730762,0.00017985111],"about_ca_topic_score_codex":0.06010482,"about_ca_topic_score_gemma":0.017193783,"teacher_disagreement_score":0.042911038,"about_ca_system_score_codex":0.0003975071,"about_ca_system_score_gemma":0.00013268214,"threshold_uncertainty_score":0.9594534},"labels":[],"label_agreement":null},{"id":"W4397044878","doi":"10.2217/fon-2022-1228","title":"Disease landscape of advanced HER2-breast cancer patients by treatment line in three EU countries and USA","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Breast cancer; Disease; Oncology; Cancer; Internal medicine","score_opus":0.006321741113262881,"score_gpt":0.29921723161172464,"score_spread":0.29289549049846175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397044878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94101405,0.043284692,0.000022097367,0.013203815,0.00070823624,0.00054285955,0.00088669197,0.000045149736,0.0002923927],"genre_scores_gemma":[0.9934461,0.0042091385,0.0002642235,0.0007586793,0.0005508777,0.00019017041,0.00011175405,0.000033225082,0.00043579863],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990897,0.000026100226,0.00022466815,0.00030199075,0.00013414698,0.00022338846],"domain_scores_gemma":[0.9995112,0.000067702196,0.00006194259,0.00014892948,0.000073953874,0.0001362817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003392381,0.00018500937,0.00041099548,0.00009366224,0.000023721841,0.000005871514,0.000044820896,0.00010113715,0.00038229057],"category_scores_gemma":[0.0000067513784,0.00013332338,0.000044674773,0.00016299977,0.0001222804,0.000086456115,0.000024173962,0.00012172242,0.000006742005],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0082034925,0.0009738949,0.50423396,0.00061825867,0.00027279506,0.00018999311,0.0012646576,0.000054929875,0.001169469,0.0005101064,0.0016333557,0.48087507],"study_design_scores_gemma":[0.006751268,0.0015501672,0.45295918,0.00038518364,0.00017279063,0.00003150509,0.00022359371,0.00010016038,0.00025176187,0.0001888717,0.53720796,0.00017753472],"about_ca_topic_score_codex":0.00011273669,"about_ca_topic_score_gemma":0.0015033314,"teacher_disagreement_score":0.5355746,"about_ca_system_score_codex":0.00036752073,"about_ca_system_score_gemma":0.00030156056,"threshold_uncertainty_score":0.543677},"labels":[],"label_agreement":null},{"id":"W4398241184","doi":"10.1186/s12885-024-12269-8","title":"Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i","year":2024,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Medicine; Internal medicine; Oncology; Metastatic breast cancer; MEDLINE; Breast cancer; Population; Systematic review; Cancer","score_opus":0.04729688805729527,"score_gpt":0.3810714846895797,"score_spread":0.3337745966322844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398241184","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024092779,0.96756047,0.0004821682,0.0015592315,0.00029013134,0.0052663707,0.00046649502,0.000099582336,0.00018277597],"genre_scores_gemma":[0.33966,0.5689823,0.0078043337,0.0018987347,0.0011315449,0.024357382,0.00019785,0.00028527415,0.05568256],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9979543,0.00006869006,0.00073543476,0.00057367276,0.00031807477,0.0003498403],"domain_scores_gemma":[0.9984578,0.00039279746,0.00020924081,0.00060531794,0.00021573262,0.00011910606],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002178734,0.00042072052,0.0011821038,0.000231147,0.000028215076,0.000028382474,0.00010371008,0.000077902485,0.0005872775],"category_scores_gemma":[0.000052567077,0.0002586008,0.00024107516,0.00084622623,0.00006588785,0.00024389813,0.000020557398,0.00013105063,0.000011435609],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005049859,0.0003474662,0.014450627,0.9665648,0.0010543166,0.00031048714,0.0016526013,0.000076356024,0.00034506936,0.00008661475,0.00039059066,0.00967121],"study_design_scores_gemma":[0.00374037,0.0017542506,0.0050119986,0.97490513,0.0015570746,0.00009910724,0.000043200886,0.0002415894,0.0016679334,0.00006239041,0.010583371,0.0003335684],"about_ca_topic_score_codex":0.00026240924,"about_ca_topic_score_gemma":0.014681521,"teacher_disagreement_score":0.39857814,"about_ca_system_score_codex":0.0014199996,"about_ca_system_score_gemma":0.00046631636,"threshold_uncertainty_score":0.99998665},"labels":[],"label_agreement":null},{"id":"W4398256251","doi":"10.1158/1535-7163.mct-23-0564","title":"PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Telesta Therapeutics (Canada)","funders":"National Cancer Institute; National Institutes of Health; Susan G. Komen; Golfers Against Cancer; Cancer Prevention and Research Institute of Texas; Breast Cancer Research Foundation; Pfizer; Robert and Janice McNair Foundation; Susan G. Komen for the Cure","keywords":"Palbociclib; Gemcitabine; Breast cancer; Cancer research; Estrogen receptor; Cancer; Tamoxifen; Medicine; Internal medicine; Biology; Oncology; Metastatic breast cancer","score_opus":0.019532345515422503,"score_gpt":0.31857852558174427,"score_spread":0.2990461800663218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398256251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7095473,0.26607382,0.003448389,0.01734625,0.00041367792,0.0018497136,0.0010905114,0.000121329766,0.0001090088],"genre_scores_gemma":[0.98847514,0.003179417,0.0023107121,0.0032876306,0.00015004039,0.0010787648,0.000009754871,0.00015792111,0.0013505999],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979921,0.0001140185,0.0004559137,0.00063768344,0.00029667883,0.00050359697],"domain_scores_gemma":[0.99897057,0.00015948627,0.000109227425,0.00044591812,0.00016878446,0.00014601936],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023940353,0.0004322446,0.0006259494,0.0002709876,0.00005421392,0.000036339286,0.00011622522,0.00016716978,0.00020647177],"category_scores_gemma":[0.0000068505124,0.00036235797,0.00022517858,0.0005127311,0.00023117787,0.00007958041,0.000029304727,0.00019082124,0.0000017769263],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03305874,0.00043168696,0.010328052,0.0015867525,0.0030088087,0.00017412017,0.0076750284,0.00018274681,0.6909646,0.00083690963,0.00010842059,0.25164416],"study_design_scores_gemma":[0.0155347055,0.0021473942,0.04988849,0.004312242,0.0016619244,0.00019061132,0.0006711002,0.004851228,0.2506216,0.008608978,0.6600329,0.0014787897],"about_ca_topic_score_codex":0.00014881812,"about_ca_topic_score_gemma":0.00014101551,"teacher_disagreement_score":0.6599245,"about_ca_system_score_codex":0.0010919565,"about_ca_system_score_gemma":0.0009836067,"threshold_uncertainty_score":0.9998828},"labels":[],"label_agreement":null},{"id":"W4398379232","doi":"10.7910/dvn/ohwwnr/xx3aoo","title":"DSC_0060.nef","year":2016,"lang":"en","type":"dataset","venue":"Harvard Dataverse","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Geography","score_opus":0.015204411733121521,"score_gpt":0.2757435426895139,"score_spread":0.26053913095639236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398379232","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000056359627,0.0000109721295,0.00013978581,0.000056280867,0.00086858496,0.00041990637,0.99792975,0.00012603724,0.0004430219],"genre_scores_gemma":[0.000003957273,0.0006036676,0.00053725566,0.0016281662,0.001346358,0.00005850753,0.99257064,0.000060814455,0.0031906285],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99797004,0.000039308245,0.00034889625,0.0006446963,0.0005054961,0.0004915559],"domain_scores_gemma":[0.99692893,0.000069608344,0.0002225579,0.0023800782,0.000114867966,0.00028394183],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00013547366,0.0004496224,0.00065680325,0.0002199178,0.00007412752,0.000027145898,0.0004533382,0.00034412506,0.08883111],"category_scores_gemma":[0.00017343741,0.00033699875,0.00017910682,0.00013369817,0.00021384,0.00023463971,0.00031084364,0.00045850585,0.24079631],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004034326,0.00008486964,0.000007930706,0.0002307563,0.00021573431,0.0003871906,0.0000064919004,1.4311634e-7,0.00016625486,0.000017651024,0.99151254,0.006967026],"study_design_scores_gemma":[0.0020533283,0.00011756152,0.000054742955,0.0006056605,0.00032457407,0.00027239672,0.000018234177,4.2746197e-7,0.00011464186,0.0000613807,0.9959949,0.00038210847],"about_ca_topic_score_codex":0.00009758562,"about_ca_topic_score_gemma":0.000030544878,"teacher_disagreement_score":0.1519652,"about_ca_system_score_codex":0.0002668758,"about_ca_system_score_gemma":0.00030127107,"threshold_uncertainty_score":0.9999082},"labels":[],"label_agreement":null},{"id":"W4398389215","doi":"10.7910/dvn/8qpl75/mixrw2","title":"cly20141026_03.txt.gz","year":2021,"lang":"en","type":"dataset","venue":"Harvard Dataverse","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Natural Resources Canada","funders":"","keywords":"Physics","score_opus":0.016951781324690444,"score_gpt":0.27952914397366435,"score_spread":0.2625773626489739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398389215","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000151639,0.0000061669243,0.00009353847,0.000012801676,0.001110638,0.0003853846,0.9979304,0.00010641116,0.00033950948],"genre_scores_gemma":[0.000003007715,0.00095159624,0.0015652074,0.0024452282,0.0011952404,0.00005688452,0.9916629,0.00006840824,0.0020514964],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976134,0.000070819035,0.00042426694,0.00078067597,0.0005931669,0.0005176739],"domain_scores_gemma":[0.99677175,0.00006972024,0.00023376253,0.0024061308,0.0001965029,0.00032211194],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00015754993,0.000500726,0.000833299,0.00020485191,0.0000947809,0.000057294215,0.0003976887,0.0004096476,0.40589222],"category_scores_gemma":[0.00024604693,0.00048076175,0.00024313794,0.00024991162,0.0001840189,0.00021428667,0.0004196324,0.0008046854,0.54316235],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026700474,0.00016547318,0.000008614489,0.00043682972,0.0003388708,0.0013532703,0.000013420863,0.0000021179424,0.00016515475,0.00001065918,0.99436545,0.0028731292],"study_design_scores_gemma":[0.0017086864,0.00009275802,0.00007886986,0.0005445537,0.0005378284,0.0005991659,0.00010139025,0.0000029700043,0.00018089762,0.00001865554,0.99569434,0.0004399116],"about_ca_topic_score_codex":0.00026107364,"about_ca_topic_score_gemma":0.000093582166,"teacher_disagreement_score":0.13727011,"about_ca_system_score_codex":0.00027221604,"about_ca_system_score_gemma":0.0005739999,"threshold_uncertainty_score":0.9997644},"labels":[],"label_agreement":null},{"id":"W4398412772","doi":"10.7910/dvn/ohwwnr/npmq4z","title":"DSC_0012.nef","year":2016,"lang":"zh","type":"dataset","venue":"Harvard Dataverse","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"NACA airfoil; Geography; Meteorology","score_opus":0.016732134429281037,"score_gpt":0.27498549180225673,"score_spread":0.2582533573729757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398412772","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000030317962,0.000071524875,0.0007050681,0.00011401018,0.00400231,0.0010763758,0.99146485,0.0001988352,0.0023366814],"genre_scores_gemma":[0.00009542027,0.0040604305,0.00075272296,0.0025091392,0.0053001554,0.00012855958,0.9755674,0.00021602401,0.011370165],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.994128,0.0002214718,0.0010644485,0.0017371554,0.0012612052,0.0015877098],"domain_scores_gemma":[0.99236465,0.00033358796,0.0007628436,0.00532038,0.00031391057,0.0009046213],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0005009349,0.001313072,0.0016328339,0.0004784439,0.00029283055,0.000106791245,0.001488477,0.0008383448,0.30199558],"category_scores_gemma":[0.00060268387,0.0010601463,0.0004329905,0.00037165053,0.00079580466,0.00082410726,0.0010677027,0.0011937335,0.7346482],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015431864,0.0003596256,0.0000730234,0.0006763796,0.0009339464,0.0011558408,0.00007635132,0.0000012101679,0.00064790406,0.00031057332,0.97175586,0.022466103],"study_design_scores_gemma":[0.006530889,0.00039475798,0.00018209752,0.002843923,0.001117497,0.00035951956,0.00020924857,0.0000047115072,0.00017685068,0.00025196082,0.98674124,0.0011873137],"about_ca_topic_score_codex":0.0002400779,"about_ca_topic_score_gemma":0.000075815,"teacher_disagreement_score":0.43265262,"about_ca_system_score_codex":0.0008599874,"about_ca_system_score_gemma":0.00086338585,"threshold_uncertainty_score":0.9999621},"labels":[],"label_agreement":null},{"id":"W4398437430","doi":"10.7910/dvn/fmk6sq/jkfgm7","title":"657163_1_S1C.roi","year":2020,"lang":"en","type":"dataset","venue":"Harvard Dataverse","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Computer science","score_opus":0.019898095784446356,"score_gpt":0.27486502942745594,"score_spread":0.2549669336430096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398437430","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000029969044,0.000008145138,0.00009034064,0.00009258814,0.00072911254,0.00046971499,0.99816304,0.00016176183,0.00028228332],"genre_scores_gemma":[0.0000045395873,0.0004012022,0.0013136261,0.004849358,0.0014412834,0.000046743367,0.9912785,0.000065275,0.0005994648],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979096,0.000043462314,0.00037087247,0.0007124693,0.0005396038,0.00042396292],"domain_scores_gemma":[0.99752057,0.000053321055,0.00021367366,0.0017129086,0.0000923663,0.0004071905],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000088806664,0.00047242467,0.00076487416,0.00015238658,0.0000733137,0.000039154784,0.00047239417,0.00030552893,0.039363243],"category_scores_gemma":[0.00024026404,0.0004434511,0.00020046018,0.00024039252,0.00016148204,0.00019113703,0.00036814896,0.00081436906,0.3778503],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052395085,0.00008774696,0.0000051740803,0.00042899817,0.0002689679,0.0008897007,0.000021037582,0.0000012384154,0.0001103368,0.00001161642,0.99550974,0.0021415143],"study_design_scores_gemma":[0.0016895747,0.0001784624,0.000052086096,0.00026019025,0.0004819715,0.00024859782,0.000050036448,0.000004771354,0.00008358829,0.000023388242,0.99653095,0.00039637552],"about_ca_topic_score_codex":0.00010665042,"about_ca_topic_score_gemma":0.000022259612,"teacher_disagreement_score":0.33848703,"about_ca_system_score_codex":0.00020127199,"about_ca_system_score_gemma":0.000358456,"threshold_uncertainty_score":0.99980175},"labels":[],"label_agreement":null},{"id":"W4398456731","doi":"10.7910/dvn/ohwwnr/kczdzi","title":"DSC_0039.nef","year":2016,"lang":"en","type":"dataset","venue":"Harvard Dataverse","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Chemistry","score_opus":0.01537756097037153,"score_gpt":0.27599799752423065,"score_spread":0.26062043655385914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398456731","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000005594177,0.000011257574,0.00013451943,0.000055082146,0.0009270177,0.0004170665,0.9978697,0.00011814371,0.0004616414],"genre_scores_gemma":[0.000003711438,0.00063262926,0.0005348834,0.0016924401,0.0013601547,0.00005679554,0.99237865,0.00006100299,0.0032797446],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979568,0.000042101557,0.00035043876,0.00064812443,0.00050652213,0.0004959884],"domain_scores_gemma":[0.99692297,0.00007051758,0.00022304231,0.0023698846,0.00011915086,0.00029441304],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00013789962,0.0004520782,0.0006625226,0.00021508722,0.00007463901,0.000027490712,0.00044756976,0.00033892135,0.092842355],"category_scores_gemma":[0.0001867473,0.0003385897,0.00017774112,0.00013595953,0.0002105743,0.00023728644,0.0003036401,0.00045782002,0.24296932],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041571842,0.00008531582,0.000007939994,0.00023128043,0.00022952045,0.00039798353,0.000007092996,1.41822e-7,0.00015999163,0.000017788514,0.9917307,0.0067165177],"study_design_scores_gemma":[0.0021097611,0.00011754726,0.000057298104,0.00059406686,0.00032117704,0.0002754759,0.000019436537,4.228482e-7,0.00010886113,0.00005830221,0.9959537,0.00038399213],"about_ca_topic_score_codex":0.000093103554,"about_ca_topic_score_gemma":0.000029702682,"teacher_disagreement_score":0.15012696,"about_ca_system_score_codex":0.000266885,"about_ca_system_score_gemma":0.00031605424,"threshold_uncertainty_score":0.9999066},"labels":[],"label_agreement":null},{"id":"W4398490102","doi":"10.7910/dvn/8qpl75/io0l8q","title":"cly20141002_03.txt.gz","year":2021,"lang":"en","type":"dataset","venue":"Harvard Dataverse","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Natural Resources Canada","funders":"","keywords":"Computer science","score_opus":0.01704052934826819,"score_gpt":0.2790674637264745,"score_spread":0.26202693437820634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398490102","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012959346,0.000007822818,0.00009490048,0.000013723023,0.0010872717,0.00038738435,0.9979717,0.000106895124,0.00031732672],"genre_scores_gemma":[0.0000025864638,0.0009490585,0.0015330331,0.0024234192,0.0011906959,0.000058998838,0.99107265,0.00006789755,0.002701645],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976041,0.000071552444,0.00042557952,0.0007827824,0.0005970191,0.0005189915],"domain_scores_gemma":[0.99675703,0.00007062608,0.00023383662,0.0024204403,0.00019549213,0.00032257152],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00015809122,0.0005017858,0.0008353192,0.00020561159,0.00010886909,0.000057181656,0.00039913162,0.00040980455,0.44919884],"category_scores_gemma":[0.00024141111,0.00048185696,0.00024322525,0.0002513239,0.00018470285,0.00021503716,0.00041854123,0.00080608943,0.5229584],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026015358,0.0001643273,0.000008642931,0.00043488058,0.00033915983,0.0013526813,0.000013582794,0.0000017169307,0.00015356552,0.000011824324,0.99429286,0.0029666298],"study_design_scores_gemma":[0.0017087279,0.0000928925,0.000070356706,0.00054402486,0.00053842115,0.00059466483,0.00010565071,0.0000025635422,0.00017945452,0.000019252502,0.9957032,0.00044077725],"about_ca_topic_score_codex":0.00020226011,"about_ca_topic_score_gemma":0.00009097115,"teacher_disagreement_score":0.07375952,"about_ca_system_score_codex":0.0002772679,"about_ca_system_score_gemma":0.00057342165,"threshold_uncertainty_score":0.9997633},"labels":[],"label_agreement":null},{"id":"W4399280247","doi":"10.1200/jco.2024.42.16_suppl.e23184","title":"Understanding breast cancer (BC) from the patient (pt) perspective: A qualitative study of symptoms, impacts and health-related quality of life (HRQoL) in hormone receptor-positive, HER2-negative (HR+, HER2–) BC.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Roche","keywords":"Medicine; Breast cancer; Perspective (graphical); Quality of life (healthcare); Hormone receptor; Health related quality of life; Cancer; Oncology; Internal medicine; Hormone; Gerontology; Gynecology; Family medicine; Disease; Nursing","score_opus":0.22766241118193264,"score_gpt":0.5252653460637992,"score_spread":0.2976029348818665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399280247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95747495,0.01099136,0.00015438437,0.029811261,0.00054526195,0.0007185129,0.00016801663,0.000012178984,0.00012408785],"genre_scores_gemma":[0.99625224,0.0023402763,0.0003605388,0.00071765546,0.0002688049,0.000013042127,0.0000027878023,0.00003180384,0.000012878806],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.9909015,0.0038039063,0.003935479,0.00038477895,0.0006630692,0.00031124573],"domain_scores_gemma":[0.9845545,0.0107979635,0.0033002135,0.00021482585,0.0007556132,0.00037685814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005707482,0.00026230194,0.0025591594,0.00019185542,0.00006396244,0.000011878556,0.00015876912,0.0002715229,0.00011657764],"category_scores_gemma":[0.0023356038,0.00016636755,0.0003038387,0.00055778044,0.0007940757,0.0002286969,0.00008776822,0.0015977977,0.0000013097476],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07734206,0.00955299,0.176357,0.00031935194,0.01068927,0.00020710901,0.6671388,0.00021745176,0.00061540585,0.002912396,0.0013777477,0.053270377],"study_design_scores_gemma":[0.010570067,0.016169887,0.6556931,0.0012886274,0.00021301632,0.000037811955,0.31162447,0.000037565183,0.000019661578,0.0041568787,0.000057558824,0.00013132054],"about_ca_topic_score_codex":0.029852055,"about_ca_topic_score_gemma":0.006028796,"teacher_disagreement_score":0.47933614,"about_ca_system_score_codex":0.0023077358,"about_ca_system_score_gemma":0.0030120967,"threshold_uncertainty_score":0.9766082},"labels":[],"label_agreement":null},{"id":"W4399298523","doi":"10.1186/s12943-024-02029-4","title":"Genome-wide in vivo CRISPR screen identifies TGFβ3 as actionable biomarker of palbociclib resistance in triple negative breast cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research","keywords":"Palbociclib; CRISPR; Triple-negative breast cancer; Breast cancer; Biomarker; Biology; Cancer research; Computational biology; Cancer; Oncology; Bioinformatics; Medicine; Genetics; Gene; Metastatic breast cancer","score_opus":0.012494398962193527,"score_gpt":0.30875887565994264,"score_spread":0.29626447669774914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399298523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9130121,0.071035616,0.0013544775,0.007767603,0.0006793446,0.0012868609,0.0005951644,0.00013111795,0.0041377535],"genre_scores_gemma":[0.9897034,0.0014366455,0.000432786,0.0007682574,0.00010506571,0.00054722215,0.000014848839,0.0000957121,0.00689605],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99777573,0.000088375586,0.00052667456,0.00063156354,0.00049342326,0.0004842505],"domain_scores_gemma":[0.9990953,0.000087534296,0.00012687936,0.0003922001,0.00018489659,0.00011315898],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021772817,0.00030307728,0.00054799835,0.00048742737,0.00004090818,0.00003746166,0.00017232163,0.0001345877,0.00199229],"category_scores_gemma":[0.00006437851,0.00029475463,0.00016090012,0.0013799381,0.00020605598,0.0003349127,0.00006539388,0.00032793594,0.000015994112],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061527914,0.00031145947,0.04590951,0.0018371127,0.0011022836,0.0015640238,0.0041578924,0.0012932126,0.92111176,0.00078378926,0.0024312122,0.013344926],"study_design_scores_gemma":[0.006724762,0.000091273454,0.574456,0.004974938,0.00025831527,0.000061513245,0.0013656646,0.0002971992,0.35060054,0.006204538,0.054070238,0.00089503767],"about_ca_topic_score_codex":0.008056653,"about_ca_topic_score_gemma":0.009888419,"teacher_disagreement_score":0.5705113,"about_ca_system_score_codex":0.0010695329,"about_ca_system_score_gemma":0.00069510174,"threshold_uncertainty_score":0.99995047},"labels":[],"label_agreement":null},{"id":"W4399319966","doi":"10.1200/jco.2024.42.16_suppl.tps1127","title":"Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an <i>ESR1</i> mutation.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Metastatic breast cancer; Oncology; Breast cancer; Internal medicine; Open label; Randomized controlled trial; Cancer","score_opus":0.09312446749221592,"score_gpt":0.5052449030153938,"score_spread":0.4121204355231779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399319966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98335856,0.0021452953,0.00702011,0.0030123307,0.0005595067,0.0037541438,0.00010016472,0.00001369269,0.00003618683],"genre_scores_gemma":[0.97034407,0.00058439333,0.0278647,0.0005791471,0.00029771877,0.000117970034,0.0000038277267,0.00005151045,0.00015664632],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99504834,0.0009065743,0.0030431796,0.00033766532,0.0004230183,0.0002412232],"domain_scores_gemma":[0.98730356,0.008810398,0.0024642565,0.00028281446,0.00089312944,0.00024583688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035663764,0.00025163926,0.0029780199,0.00010735004,0.00007576405,0.000020400594,0.00033480205,0.00010256837,0.000063826476],"category_scores_gemma":[0.0021692154,0.0001222496,0.00020343882,0.0003148382,0.0005877096,0.0003666549,0.00009834825,0.000542061,2.484756e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61013144,0.0069831638,0.00023367708,0.00024004494,0.0020139795,0.00014808268,0.0009147819,0.0009500421,0.0005012355,0.00003241767,0.000012864946,0.37783825],"study_design_scores_gemma":[0.91822946,0.0610818,0.00238362,0.0019272771,0.0041933362,0.0009704955,0.0025550763,0.006958165,0.00027194998,0.00011175898,0.0011508012,0.00016623121],"about_ca_topic_score_codex":0.00007742294,"about_ca_topic_score_gemma":0.0004241325,"teacher_disagreement_score":0.37767202,"about_ca_system_score_codex":0.00017527153,"about_ca_system_score_gemma":0.0020608453,"threshold_uncertainty_score":0.49851942},"labels":[],"label_agreement":null},{"id":"W4399323727","doi":"10.1200/jco.2024.42.16_suppl.1055","title":"Impact of prior anticancer treatments on palbociclib (PAL) clinical outcomes in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC) in real-world settings.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Palbociclib; Medicine; Human Epidermal Growth Factor Receptor 2; Cancer; Oncology; Hormone receptor; Internal medicine; Breast cancer; Receptor; Cancer research; Epidermal growth factor receptor; Metastatic breast cancer; Gynecology","score_opus":0.049924082980505526,"score_gpt":0.4670128968005136,"score_spread":0.41708881382000806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399323727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934382,0.00028966612,0.000011552271,0.003532835,0.0009815068,0.0009931267,0.00040545553,0.00003243474,0.0003152541],"genre_scores_gemma":[0.9938991,0.0017139401,0.002620895,0.00067143317,0.0006905657,0.00004038583,0.000023400722,0.00010134444,0.00023890425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99196076,0.00106137,0.004699021,0.0007393958,0.00084526977,0.00069417123],"domain_scores_gemma":[0.9906196,0.0048258826,0.0027899423,0.00034736295,0.0008431961,0.00057399384],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0017071278,0.00057941175,0.0039964234,0.000617087,0.000056009823,0.000018014343,0.00029747694,0.00048956554,0.0005024944],"category_scores_gemma":[0.0014627627,0.0003625517,0.0010342507,0.0007875634,0.0007298567,0.00054987526,0.00007642387,0.0023425063,0.000014210783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035878018,0.0047746967,0.77035695,0.00005348728,0.0019056246,0.00018407629,0.00037528918,0.00003447064,0.00013545946,0.000027922244,0.00022401137,0.18605001],"study_design_scores_gemma":[0.032123897,0.026113147,0.9389545,0.0015788449,0.0002964665,0.000016939888,0.00009097455,0.000012381353,0.000087389424,0.00011439479,0.00029912012,0.00031194824],"about_ca_topic_score_codex":0.0008042983,"about_ca_topic_score_gemma":0.00068501575,"teacher_disagreement_score":0.18573807,"about_ca_system_score_codex":0.0025285839,"about_ca_system_score_gemma":0.0022600542,"threshold_uncertainty_score":0.9999591},"labels":[],"label_agreement":null},{"id":"W4399324232","doi":"10.1200/jco.2024.42.16_suppl.e13066","title":"Real-world experience with CDK4/6 inhibitors in the first-line palliative setting for HR+/HER2- advanced breast cancer.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Windsor; Western University","funders":"","keywords":"Medicine; Oncology; Breast cancer; Internal medicine; Cancer; Palbociclib; Cancer research; Metastatic breast cancer","score_opus":0.08438857424667509,"score_gpt":0.49997371258075923,"score_spread":0.41558513833408417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399324232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8604019,0.0030710963,0.0020170254,0.1297138,0.0024902395,0.0010657418,0.000041297444,0.000047199082,0.001151702],"genre_scores_gemma":[0.9839963,0.001301254,0.007262142,0.003961,0.0030827215,0.00013356624,0.0000021699643,0.000040988874,0.00021985844],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969152,0.00018482273,0.001810748,0.00031399404,0.00041505467,0.000360182],"domain_scores_gemma":[0.99400115,0.0042187185,0.0009883062,0.00020508195,0.000410426,0.0001763022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020818366,0.00021215573,0.0011133458,0.00016334341,0.000071511386,0.000020275344,0.00025224735,0.00016644478,0.000066009525],"category_scores_gemma":[0.00064721407,0.00011495883,0.0003095268,0.0005244928,0.00036376482,0.00026305858,0.000032694807,0.0011772136,0.0000025284946],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018525997,0.00079466903,0.1261166,0.0002348128,0.00041054713,0.001032002,0.005201259,0.0011113636,0.00019880578,0.00044790827,0.0010401318,0.8448859],"study_design_scores_gemma":[0.016150955,0.013617264,0.556943,0.0043331464,0.00044363816,0.0010438502,0.0051047564,0.0010491982,0.00031050254,0.0018173616,0.39880952,0.00037680037],"about_ca_topic_score_codex":0.000088585715,"about_ca_topic_score_gemma":0.0018500767,"teacher_disagreement_score":0.84450907,"about_ca_system_score_codex":0.0004912942,"about_ca_system_score_gemma":0.0015085251,"threshold_uncertainty_score":0.51144725},"labels":[],"label_agreement":null},{"id":"W4399324721","doi":"10.1200/jco.2024.42.16_suppl.tps1136","title":"INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–), <i>PIK3CA</i>-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Roche","keywords":"Fulvestrant; Medicine; Internal medicine; Hormone receptor; Oncology; Pharmacology; Cancer; Estrogen receptor; Breast cancer","score_opus":0.03719958490996564,"score_gpt":0.424430612596551,"score_spread":0.38723102768658535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399324721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99135935,0.0014177228,0.00075788604,0.0029011385,0.0010596003,0.0020177183,0.00020471514,0.000056454657,0.00022541547],"genre_scores_gemma":[0.9919713,0.0017041469,0.004642085,0.00077674974,0.00046661965,0.00011022088,0.000024209281,0.00013661763,0.00016800777],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9904431,0.0016282774,0.0049529443,0.0008614181,0.0013423086,0.0007719203],"domain_scores_gemma":[0.9901859,0.0037417659,0.00289668,0.00048048032,0.0019703573,0.0007248105],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0023490305,0.0007242153,0.004214766,0.0005864342,0.00008144795,0.00004031844,0.0004933448,0.00042428824,0.00030887456],"category_scores_gemma":[0.0010122032,0.00047362715,0.0004767337,0.0015360344,0.00095537154,0.0008813967,0.00013503438,0.0027854263,0.000010692508],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3970987,0.036708485,0.015661325,0.00035421824,0.004419593,0.0069065294,0.005409337,0.0011587766,0.00078370207,0.00003120595,0.00057622435,0.5308919],"study_design_scores_gemma":[0.3272342,0.26293916,0.37657893,0.00629079,0.0035476137,0.0024470878,0.0105975885,0.0005639889,0.00066965335,0.00027930294,0.007689112,0.001162549],"about_ca_topic_score_codex":0.0006620032,"about_ca_topic_score_gemma":0.0012523611,"teacher_disagreement_score":0.52972937,"about_ca_system_score_codex":0.0012195734,"about_ca_system_score_gemma":0.0042740237,"threshold_uncertainty_score":0.99977154},"labels":[],"label_agreement":null},{"id":"W4399361514","doi":"10.1016/j.esmoop.2024.103466","title":"Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Astellas Pharma; Chugai Pharmaceutical; Seagen; Gilead Sciences; Eisai; Daiichi Sankyo Europe; Sanofi; Novartis; Daiichi-Sankyo; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Oncology; Internal medicine; Breast cancer; Palbociclib; Hormone receptor; Docetaxel; Gynecology; Chemotherapy; Cancer; Metastatic breast cancer","score_opus":0.009595296794721674,"score_gpt":0.2882959797367978,"score_spread":0.27870068294207617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399361514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949076,0.0003192537,0.000015624395,0.00052739633,0.00007793376,0.003077234,0.0008431628,0.000039673057,0.00019208422],"genre_scores_gemma":[0.9959223,0.00049851986,0.0015042363,0.00012804972,0.000039525967,0.0010423553,0.0003218062,0.00011420055,0.00042900397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975926,0.0001686828,0.0005526677,0.0007367677,0.00048458288,0.00046468372],"domain_scores_gemma":[0.99882007,0.000110519984,0.00025481283,0.00040791312,0.00026351205,0.00014319042],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011244343,0.00049717433,0.00092856365,0.00027586837,0.0000460189,0.00005334048,0.00022227257,0.000073218755,0.0005695913],"category_scores_gemma":[0.000012175504,0.00032281392,0.000055206903,0.00088946876,0.00019498197,0.0005534291,0.00010798289,0.00029355998,0.000010557007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05374476,0.002419385,0.91795146,0.00007060065,0.000996154,0.000117419215,0.0029937674,0.00010458896,0.00021183101,0.000011143146,0.00004497852,0.021333907],"study_design_scores_gemma":[0.030489074,0.0067103663,0.95355105,0.0014772746,0.00023527241,0.0000054316192,0.00019031297,0.000023711911,0.006715605,0.000054188196,0.00018057603,0.00036714473],"about_ca_topic_score_codex":0.06031082,"about_ca_topic_score_gemma":0.01569804,"teacher_disagreement_score":0.04461278,"about_ca_system_score_codex":0.0010161917,"about_ca_system_score_gemma":0.00027071594,"threshold_uncertainty_score":0.9999224},"labels":[],"label_agreement":null},{"id":"W4399383641","doi":"10.1016/j.lfs.2024.122773","title":"Retraction notice to “Inhibition of CD73 using folate targeted nanoparticles carrying anti-CD73 siRNA potentiates anticancer efficacy of Dinaciclib” [Life Sci. 259 (2020) 118150]","year":2024,"lang":"en","type":"article","venue":"Life Sciences","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Notice; Chemistry; Pharmacology; Cancer research; Medicine; Political science","score_opus":0.03278688341935456,"score_gpt":0.3349154829166513,"score_spread":0.30212859949729676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399383641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99119884,0.0035692044,0.0019548933,0.0015207038,0.0011405611,0.00038382332,0.000022361799,0.00012469207,0.00008492397],"genre_scores_gemma":[0.9919968,0.000121598496,0.007202247,0.00025842167,0.00035515497,0.000006301383,0.0000037524237,0.000027420272,0.000028293323],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99747324,0.000072580464,0.00060138036,0.00056938035,0.00083254714,0.0004508957],"domain_scores_gemma":[0.9988126,0.00021115609,0.00023746392,0.00024651698,0.000240209,0.00025201947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007098762,0.00021341302,0.0004644298,0.0003310817,0.00022060375,0.0000615036,0.00015518129,0.000095198724,0.00010900378],"category_scores_gemma":[0.000672962,0.00017834728,0.00013739985,0.0019927844,0.00054478477,0.00074086175,0.00007268678,0.00020508886,0.000013785797],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001981768,0.000092876035,0.0068237786,0.00031523724,0.00007693365,0.000017799477,0.000852205,0.0064214673,0.98116297,0.00021269887,0.00005423132,0.003771637],"study_design_scores_gemma":[0.0011750681,0.00067997654,0.062309545,0.002311771,0.00036201352,0.000063561216,0.0021636293,0.022312228,0.9073563,0.0003881777,0.00049207493,0.00038565457],"about_ca_topic_score_codex":0.0002734174,"about_ca_topic_score_gemma":0.000008553943,"teacher_disagreement_score":0.07380666,"about_ca_system_score_codex":0.00009983572,"about_ca_system_score_gemma":0.00043361538,"threshold_uncertainty_score":0.7272791},"labels":[],"label_agreement":null},{"id":"W4399505359","doi":"10.1158/1538-8514.synthleth24-a014","title":"Abstract A014: Inhibiting eIF4E phosphorylation sensitizes triple-negative breast cancer to CDK4/6 inhibition","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Cancer; Phosphorylation; Breast cancer; Triple-negative breast cancer; Cancer research; Citation; Medicine; Library science; Internal medicine; Chemistry; Biochemistry; Computer science","score_opus":0.020628025765530616,"score_gpt":0.3142404357098953,"score_spread":0.29361240994436466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399505359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93502444,0.021148527,0.01715074,0.020807466,0.0014567398,0.001814815,0.00061564386,0.00080213015,0.001179499],"genre_scores_gemma":[0.98833,0.00067879196,0.0015157486,0.007794549,0.0007255871,0.0003328041,0.000050545645,0.00018957391,0.00038238996],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974227,0.00005876785,0.0005015363,0.0007503812,0.00065258343,0.0006140284],"domain_scores_gemma":[0.9987901,0.000081883925,0.00013317748,0.0003626198,0.0003865399,0.00024566564],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020997728,0.0004808651,0.00048101234,0.0002944673,0.0001574558,0.0001331043,0.00009097143,0.00019509126,0.0004828192],"category_scores_gemma":[0.000015415799,0.0004571843,0.00023900815,0.00088413694,0.00013291553,0.0002668196,0.000055381646,0.0005317724,0.00008607652],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008174363,0.00007051115,0.0003204238,0.00028803892,0.00061869755,0.00028452833,0.0020723564,0.0013887782,0.67169094,0.0003589346,0.00013083707,0.3219585],"study_design_scores_gemma":[0.0030046,0.00021094973,0.018310893,0.0035952923,0.00070962013,0.00032542803,0.0008154526,0.0022835727,0.949187,0.0019883069,0.018530054,0.0010388425],"about_ca_topic_score_codex":0.00058252877,"about_ca_topic_score_gemma":0.00011841089,"teacher_disagreement_score":0.32091966,"about_ca_system_score_codex":0.0010630592,"about_ca_system_score_gemma":0.00047188648,"threshold_uncertainty_score":0.999788},"labels":[],"label_agreement":null},{"id":"W4399667405","doi":"10.1200/jco.2024.42.16_suppl.3052","title":"Characterization of molecular response and progression in patients with metastatic HR+/HER2- breast cancer receiving endocrine therapy and CDK4/6 inhibitors using a high-sensitivity tumor-informed assay.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Metastatic breast cancer; Internal medicine; Breast cancer; Cancer; Endocrine system; Hormone","score_opus":0.04237718569485227,"score_gpt":0.4209714391097517,"score_spread":0.37859425341489944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399667405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963691,0.00056246814,0.00040433838,0.0020385925,0.0002744853,0.00032463935,0.000016220985,0.000007920954,0.0000022079466],"genre_scores_gemma":[0.99514896,0.0003864434,0.0040068957,0.000290992,0.00013178444,0.0000049466885,0.0000028778295,0.000023873628,0.000003257709],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99751604,0.00069276075,0.0011230872,0.0001814036,0.00031697328,0.00016972511],"domain_scores_gemma":[0.99733603,0.0011774686,0.00092666043,0.00008735249,0.0003261142,0.00014639103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020097967,0.00014575527,0.0009345732,0.00022802317,0.000020885864,0.000012244539,0.00003039629,0.00007628658,0.000013546621],"category_scores_gemma":[0.0006704526,0.00009401136,0.000070780865,0.00023203273,0.00023179584,0.00029753437,0.000031158575,0.00046792653,1.08708036e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05212504,0.00057914783,0.33096692,0.000170113,0.00032001964,0.00080842304,0.00032940885,0.000026780983,0.09352714,0.000007821553,0.0000014090091,0.5211378],"study_design_scores_gemma":[0.008317716,0.0042694113,0.98015904,0.0020143448,0.00014140047,0.00068049156,0.000051049086,0.00032757764,0.0036588737,0.000037585556,0.00024880082,0.0000937312],"about_ca_topic_score_codex":0.000035252244,"about_ca_topic_score_gemma":0.000021911703,"teacher_disagreement_score":0.6491921,"about_ca_system_score_codex":0.00019460937,"about_ca_system_score_gemma":0.001004041,"threshold_uncertainty_score":0.3833672},"labels":[],"label_agreement":null},{"id":"W4400151309","doi":"10.1016/j.annonc.2024.05.419","title":"504MO Phase I study of the PKMYT1 inhibitor lunresertib (lunre) in combination with FOLFIRI in advanced gastrointestinal (GI) cancers (MINOTAUR study)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; FOLFIRI; Gastrointestinal cancer; Internal medicine; Oncology; Cancer; Colorectal cancer; Irinotecan","score_opus":0.051749825533576294,"score_gpt":0.4110234841949122,"score_spread":0.35927365866133587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400151309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948487,0.0005807935,0.0000682841,0.002027052,0.00019368493,0.0018738697,0.00000879605,0.000027611746,0.00037117192],"genre_scores_gemma":[0.999179,0.00001712572,0.00024256352,0.00017003185,0.00005082561,0.00019505328,0.000003285092,0.00003072906,0.0001113681],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980144,0.00023545552,0.00064076367,0.00038462583,0.0003917244,0.00033305582],"domain_scores_gemma":[0.9988208,0.00025430546,0.00023564388,0.00036169123,0.00026174146,0.00006585585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049087894,0.0002075237,0.000643504,0.0003542003,0.000027461529,0.0000053525737,0.00019411513,0.000051782106,0.000030411795],"category_scores_gemma":[0.00017115436,0.0001463163,0.0000613738,0.0009105533,0.00019554509,0.00016050588,0.00007571856,0.0003906191,0.000001430661],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023300296,0.026533723,0.607747,0.0004201714,0.00038147857,0.0011783226,0.026311204,0.00289013,0.020882204,0.00015938572,0.00024464048,0.28995144],"study_design_scores_gemma":[0.07433026,0.14147808,0.7138572,0.003256435,0.00022509653,0.00032619687,0.049548686,0.0012440557,0.011851847,0.0005634695,0.002879985,0.00043873044],"about_ca_topic_score_codex":0.0010729011,"about_ca_topic_score_gemma":0.007083812,"teacher_disagreement_score":0.2895127,"about_ca_system_score_codex":0.00035087165,"about_ca_system_score_gemma":0.0007292664,"threshold_uncertainty_score":0.59666055},"labels":[],"label_agreement":null},{"id":"W4400691510","doi":"10.1007/978-3-031-58516-6_5","title":"Deconstructing the Contributions of Heterogeneity to Combination Treatment of Hormone-Sensitive Breast Cancer","year":2024,"lang":"en","type":"book-chapter","venue":"˜The œIMA volumes in mathematics and its applications","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal; University of Saskatchewan","funders":"","keywords":"Fulvestrant; Palbociclib; Breast cancer; Estrogen receptor; Oncology; Cancer; Pharmacodynamics; Internal medicine; Medicine; Hormone receptor; Pharmacokinetics; Metastatic breast cancer","score_opus":0.016928156435580835,"score_gpt":0.303568033826811,"score_spread":0.2866398773912302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400691510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38813666,0.20527534,0.09256196,0.046360448,0.0009916244,0.059538692,0.043389957,0.0005591034,0.1631862],"genre_scores_gemma":[0.98128223,0.0025380978,0.0016276023,0.00006810221,0.00014180812,0.0010141158,0.00005631181,0.00007211711,0.013199602],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9989993,0.000007657147,0.0004699942,0.00022155535,0.00017240735,0.00012907205],"domain_scores_gemma":[0.998716,0.00022304012,0.00030136912,0.0003804618,0.00032956354,0.000049553622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012053205,0.00020852874,0.00046294567,0.0001028872,0.00010022414,0.0000123244445,0.00009503531,0.000096374686,0.000015279942],"category_scores_gemma":[0.0000073338206,0.00013175514,0.00010909744,0.00010643138,0.0002241898,0.00002279875,0.000055327328,0.00013374478,0.000007967787],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009168127,0.00037651462,0.00007751414,0.0005474579,0.0009969604,0.0000024545266,0.0037573592,0.00006246,0.007768185,0.8979179,0.000065342756,0.08833613],"study_design_scores_gemma":[0.00740149,0.0014530838,0.007312906,0.005585798,0.0067403135,0.001700903,0.006782118,0.03125929,0.02074236,0.79050195,0.11863572,0.0018840793],"about_ca_topic_score_codex":0.000041067644,"about_ca_topic_score_gemma":0.000108858396,"teacher_disagreement_score":0.59314555,"about_ca_system_score_codex":0.00021141574,"about_ca_system_score_gemma":0.00008919267,"threshold_uncertainty_score":0.5372819},"labels":[],"label_agreement":null},{"id":"W4400901746","doi":"10.21203/rs.3.rs-4655101/v1","title":"A Canadian real world prospective observational study assessing the impact of hormone therapy ± targeted therapy in the treatment of HR+ HER2- advanced breast cancer","year":2024,"lang":"en","type":"preprint","venue":"Research Square","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada); Kingston Health Sciences Centre; McGill University Health Centre; Jewish General Hospital; BC Cancer Agency; Centre hospitalier universitaire de Québec; Ottawa Hospital; Windsor Regional Hospital; Western University; Ottawa Regional Cancer Foundation; Saskatchewan Cancer Agency","funders":"Gilead Sciences; University of Toronto; AstraZeneca; Eli Lilly and Company; Novartis Pharmaceuticals Canada; Breast Cancer Alliance","keywords":"Observational study; Breast cancer; Oncology; Hormone therapy; Medicine; Internal medicine; Cancer","score_opus":0.1344096755950791,"score_gpt":0.5003190854387544,"score_spread":0.36590940984367526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400901746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9597396,0.025950253,0.0000015998634,0.0042920215,0.00009648228,0.008436001,0.0010230899,0.000032862277,0.00042806193],"genre_scores_gemma":[0.9857508,0.009576809,0.000072973,0.000032815668,0.00036999694,0.0037033928,0.00012279804,0.00010087342,0.00026955115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99523413,0.0009221779,0.00065674615,0.00075806654,0.0016169299,0.0008119616],"domain_scores_gemma":[0.9963543,0.00062578195,0.0002604673,0.0011964847,0.0013688774,0.00019409129],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013830782,0.0005205816,0.0009382711,0.00090990245,0.0002098446,0.00010551486,0.0005710897,0.00016553169,0.00018488421],"category_scores_gemma":[0.000044887627,0.00026119332,0.0004197634,0.0022172628,0.0003941316,0.00011010724,0.00011652627,0.0014930975,0.00000234622],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0051048608,0.0037196132,0.8271873,0.00018033346,0.0025551727,0.00015200554,0.040614136,0.0027803748,0.0035269558,0.00011885223,0.00015811178,0.113902286],"study_design_scores_gemma":[0.0037155743,0.003461769,0.9799473,0.00071239995,0.000038927425,0.000010570326,0.008959229,0.00026222275,0.00030888364,0.0021954775,0.00018127983,0.00020636109],"about_ca_topic_score_codex":0.58256906,"about_ca_topic_score_gemma":0.21672194,"teacher_disagreement_score":0.3658471,"about_ca_system_score_codex":0.0061565805,"about_ca_system_score_gemma":0.007820262,"threshold_uncertainty_score":0.999984},"labels":[],"label_agreement":null},{"id":"W4401024204","doi":"10.1016/j.critrevonc.2024.104455","title":"The impact of previous therapy on overall-survival in registration clinical trials for 1st line metastatic breast cancer a systemic review","year":2024,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"American Society of Clinical Oncology; Conquer Cancer Foundation","keywords":"Clinical trial; Medicine; Breast cancer; Metastatic breast cancer; Oncology; Overall survival; Internal medicine; Cancer; Medical physics","score_opus":0.43042100573632724,"score_gpt":0.6349239968568318,"score_spread":0.20450299112050452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401024204","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00000816614,0.978354,0.00018771413,0.0043496354,0.0013945579,0.015188565,0.0003610605,0.00003870085,0.000117643416],"genre_scores_gemma":[0.00008941947,0.98724496,0.00041450342,0.00075435214,0.0006025063,0.010564273,0.00010221055,0.00013751262,0.000090246365],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97670954,0.010769233,0.010024606,0.0012329591,0.00036768385,0.00089598435],"domain_scores_gemma":[0.9664227,0.028986536,0.00264942,0.0012640806,0.0004049889,0.00027231892],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.023097899,0.0010622478,0.019655285,0.0003393588,0.000060397317,0.000022971142,0.00061797973,0.00091297575,0.00012997352],"category_scores_gemma":[0.031717494,0.00053361163,0.0039395574,0.00080887054,0.0008495528,0.00007690458,0.000091355294,0.0020842468,0.000056596444],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092270586,0.0006631865,0.000014816138,0.14487204,0.00074304396,0.00013262693,0.000024741434,5.0357744e-7,9.1859226e-7,0.00914777,0.002583688,0.840894],"study_design_scores_gemma":[0.0022849047,0.0018317553,0.000008654765,0.3867327,0.0034798014,0.0029410913,0.000009994407,0.000018742783,3.363061e-7,0.001675922,0.6006734,0.0003427446],"about_ca_topic_score_codex":0.000045956123,"about_ca_topic_score_gemma":0.000085896405,"teacher_disagreement_score":0.8405512,"about_ca_system_score_codex":0.001624974,"about_ca_system_score_gemma":0.0036509237,"threshold_uncertainty_score":0.9997115},"labels":[],"label_agreement":null},{"id":"W4401288399","doi":"10.1093/noajnl/vdae090.113","title":"RMTD-06 TREATMENT PATTERNS AND OUTCOMES OF HR+/HER2- BREAST CANCER WITH BRAIN METASTASES: A SINGLE-CENTER RETROSPECTIVE STUDY","year":2024,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Center (category theory); Cancer; Breast cancer; Retrospective cohort study; Oncology; Single Center; Internal medicine","score_opus":0.017465581968682885,"score_gpt":0.3331982587564331,"score_spread":0.31573267678775024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401288399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98666704,0.003778896,0.00033878844,0.0062888996,0.00041761826,0.0014741304,0.000663882,0.00017289307,0.00019783943],"genre_scores_gemma":[0.99711967,0.00047767733,0.00055134436,0.00092975056,0.000162877,0.00043858652,0.000014936724,0.00007105311,0.00023409596],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99798703,0.00017512553,0.0003802033,0.0007662223,0.00030826402,0.0003831788],"domain_scores_gemma":[0.9987983,0.00041472787,0.0001757225,0.00033912185,0.0001311145,0.00014099944],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011380146,0.00041337142,0.0009842605,0.00019729557,0.00007788333,0.000022471066,0.00009835464,0.00007230975,0.00016578844],"category_scores_gemma":[0.0000362287,0.0002695923,0.00010730307,0.00029085155,0.00035439208,0.00032651064,0.000058503687,0.00024753987,0.0000046811565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015238645,0.0018700106,0.8914991,0.00014240966,0.0010921536,0.0006962789,0.0021022856,0.00002679454,0.004697736,0.000053825963,0.00004022882,0.09625533],"study_design_scores_gemma":[0.012697828,0.018749198,0.9019023,0.0004115281,0.001164947,0.0020619063,0.0047149924,0.000028555773,0.0026669535,0.00017330621,0.054948855,0.00047958305],"about_ca_topic_score_codex":0.0002049289,"about_ca_topic_score_gemma":0.0020035158,"teacher_disagreement_score":0.095775746,"about_ca_system_score_codex":0.0005450764,"about_ca_system_score_gemma":0.00019366086,"threshold_uncertainty_score":0.9999756},"labels":[],"label_agreement":null},{"id":"W4401737373","doi":"10.21203/rs.3.rs-4770215/v1","title":"Steatotic liver disease in metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitor","year":2024,"lang":"en","type":"preprint","venue":"Research Square","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences North; Queen's University; University Health Network","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Proportional hazards model; Cancer; Population; Incidence (geometry); Cancer registry; Adverse effect; Stage (stratigraphy)","score_opus":0.061719056493859996,"score_gpt":0.3977860829477099,"score_spread":0.3360670264538499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401737373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9150374,0.07629195,0.000010102494,0.0042062993,0.000078948804,0.00315544,0.0009409369,0.00014948088,0.00012941776],"genre_scores_gemma":[0.98621994,0.009504748,0.00023331451,0.00008244684,0.00038082688,0.0017231994,0.00012445694,0.00017213007,0.0015589466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960917,0.00035678796,0.00035289768,0.0010973718,0.0012427523,0.0008584684],"domain_scores_gemma":[0.99781,0.0002238352,0.00007032742,0.0007605885,0.0005338517,0.0006013617],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039176614,0.0005155479,0.00077757094,0.0009190521,0.000086893015,0.00012891664,0.00018509223,0.00010094238,0.00059220963],"category_scores_gemma":[0.000051453044,0.00035837066,0.0001176584,0.0008223654,0.00049251126,0.000096511765,0.0005868832,0.002139056,0.000035932084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04220949,0.0025490199,0.5013772,0.038001284,0.0032245475,0.028717082,0.0048626517,0.0013843226,0.002224461,0.000691071,0.0006305263,0.3741283],"study_design_scores_gemma":[0.012544067,0.0014150935,0.9360864,0.033470973,0.00046521373,0.000632993,0.0012494099,0.003686356,0.0012455418,0.0037663635,0.00417676,0.0012607987],"about_ca_topic_score_codex":0.0032894495,"about_ca_topic_score_gemma":0.0005055934,"teacher_disagreement_score":0.43470922,"about_ca_system_score_codex":0.00087928283,"about_ca_system_score_gemma":0.0014153766,"threshold_uncertainty_score":0.9998868},"labels":[],"label_agreement":null},{"id":"W4401813121","doi":"10.1016/j.esmorw.2024.100064","title":"UK multicentre real-world data of the use of cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer","year":2024,"lang":"en","type":"article","venue":"ESMO Real World Data and Digital Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Wellcome Trust","keywords":"Metastatic breast cancer; Breast cancer; Oncology; Medicine; Cancer; Cancer research; Kinase; Cyclin-dependent kinase 4; Internal medicine; Biology; Cyclin-dependent kinase 2; Cell cycle; Genetics","score_opus":0.10088517780756026,"score_gpt":0.38920088669000413,"score_spread":0.28831570888244384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401813121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.945638,0.0024608576,0.00007173187,0.009304869,0.0012290851,0.0014182671,0.03624825,0.0000940827,0.0035348437],"genre_scores_gemma":[0.99556893,0.0009092592,0.0006252934,0.00021038835,0.00016141038,0.000015834545,0.0010157407,0.000035771056,0.0014573504],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979736,0.000085729494,0.00066309713,0.0006534533,0.00030547884,0.00031863552],"domain_scores_gemma":[0.9972916,0.0007228363,0.00026814453,0.001512049,0.00006720768,0.00013816614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024063892,0.00023167161,0.0006891269,0.00028583975,0.000030859053,0.0000479008,0.00052917283,0.000037277387,0.00006486668],"category_scores_gemma":[0.00013363748,0.00015799829,0.000053403222,0.0008036122,0.000664074,0.0008482072,0.0012392078,0.00031620936,0.0000045978604],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019849287,0.0006192854,0.35192397,0.000407017,0.00042458472,0.00039741327,0.00039287898,0.00006844801,0.00044023956,0.0007461641,0.0032117246,0.6393833],"study_design_scores_gemma":[0.0056080013,0.00036905461,0.67502236,0.00207942,0.00090822176,0.00026753568,0.0009619717,0.0036910889,0.0006757159,0.00048705214,0.30941525,0.00051433104],"about_ca_topic_score_codex":0.012199157,"about_ca_topic_score_gemma":0.11904993,"teacher_disagreement_score":0.638869,"about_ca_system_score_codex":0.00022482923,"about_ca_system_score_gemma":0.0005072878,"threshold_uncertainty_score":0.9943787},"labels":[],"label_agreement":null},{"id":"W4402259280","doi":"10.1200/jco.24.00110","title":"Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; F. Hoffmann-La Roche; Memorial Sloan-Kettering Cancer Center; Pfizer","keywords":"Medicine; Palbociclib; Tolerability; Internal medicine; Letrozole; Fulvestrant; Oncology; Adverse effect; Metastatic breast cancer; Breast cancer; Cancer; Tamoxifen","score_opus":0.11422356113720195,"score_gpt":0.4995596041199905,"score_spread":0.38533604298278856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402259280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9709053,0.008563452,0.0016972465,0.013268533,0.0024279007,0.0021487304,0.0008613866,0.00004840988,0.00007901316],"genre_scores_gemma":[0.96766007,0.0120251505,0.015162979,0.0015003603,0.0029284246,0.00017787784,0.000031271396,0.000111017194,0.00040285927],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99443,0.0006583909,0.0033650626,0.0005124278,0.0005227006,0.000511438],"domain_scores_gemma":[0.9893695,0.006472346,0.002221039,0.00021582175,0.0011949484,0.0005263125],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015532112,0.00043364664,0.0031503905,0.0002753265,0.00009927866,0.00002517621,0.00022961822,0.00025439786,0.00047514675],"category_scores_gemma":[0.0018431733,0.00028199426,0.00075443956,0.0003875135,0.0007597042,0.00054620346,0.0000610605,0.0011629671,0.0000029823943],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5114439,0.0033058336,0.00009960768,0.00019942228,0.002358499,0.00024330216,0.00068837905,0.0000127423955,0.021500474,0.00016045298,0.001166221,0.45882112],"study_design_scores_gemma":[0.76418346,0.15935107,0.0032929801,0.0011980734,0.001477531,0.0013903996,0.0009212791,0.0002302073,0.01637024,0.0016607139,0.049303327,0.00062069483],"about_ca_topic_score_codex":0.000069815294,"about_ca_topic_score_gemma":0.000030190482,"teacher_disagreement_score":0.45820042,"about_ca_system_score_codex":0.0004522088,"about_ca_system_score_gemma":0.00239171,"threshold_uncertainty_score":0.9999632},"labels":[],"label_agreement":null},{"id":"W4402266765","doi":"10.1158/1538-7445.pediatric24-b065","title":"Abstract B065: A phase 1 study of abemaciclib, a CDK 4/6 inhibitor, with radiation in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG)","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cyclin-dependent kinase; Glioma; Oncology; Cancer; Internal medicine; Cancer research; Cell cycle","score_opus":0.03209554356281608,"score_gpt":0.3941030076058603,"score_spread":0.36200746404304424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402266765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906582,0.0057942024,0.00003445754,0.0006018442,0.00008180386,0.0026131521,0.000047102083,0.00010135275,0.00006784044],"genre_scores_gemma":[0.9979699,0.0002365553,0.00009245568,0.000031545398,0.00055816496,0.0008736566,0.000028226372,0.000097332246,0.000112131216],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970503,0.00011764967,0.00041221376,0.0006530847,0.0011639367,0.00060285354],"domain_scores_gemma":[0.9986449,0.00021066178,0.000086054024,0.00052477245,0.0003150402,0.00021858168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005529971,0.00026653605,0.0005047147,0.000991303,0.000073735864,0.00006617524,0.0001923222,0.000078525016,0.00017082551],"category_scores_gemma":[0.000080744554,0.00019040343,0.00004506073,0.0024078914,0.00028507962,0.00031584591,0.00006529703,0.0008337172,0.000012609907],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024532063,0.009291617,0.35572866,0.00081122684,0.001583064,0.0027846992,0.013034372,0.00036034867,0.08661437,0.00006599104,0.00046767693,0.50472593],"study_design_scores_gemma":[0.08677943,0.013343244,0.85429883,0.0031564296,0.00021447333,0.00027041166,0.003352133,0.00010771643,0.036346406,0.00006411759,0.0015012601,0.00056556734],"about_ca_topic_score_codex":0.0028910888,"about_ca_topic_score_gemma":0.0013029155,"teacher_disagreement_score":0.50416034,"about_ca_system_score_codex":0.00055385026,"about_ca_system_score_gemma":0.0007703835,"threshold_uncertainty_score":0.77644265},"labels":[],"label_agreement":null},{"id":"W4402356242","doi":"10.1097/coc.0000000000001143","title":"Efficacy and Safety of Abemaciclib in Combination With Endocrine Therapy for HR+/HER2− Advanced or Metastatic Breast Cancer","year":2024,"lang":"en","type":"review","venue":"American Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Fulvestrant; Internal medicine; Oncology; Hazard ratio; Metastatic breast cancer; Breast cancer; Adverse effect; Combination therapy; Cancer; Confidence interval; Tamoxifen","score_opus":0.1099644072603908,"score_gpt":0.5343017928638563,"score_spread":0.42433738560346546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402356242","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002787821,0.99160737,0.00048498076,0.0024530378,0.000596529,0.0018970058,0.00012567603,0.000014007545,0.000033555843],"genre_scores_gemma":[0.0017717787,0.9847918,0.012222975,0.00040938982,0.0004468513,0.00014094797,0.000013054142,0.0000972501,0.00010591097],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99505913,0.0005764754,0.0032983078,0.00041333248,0.00031821834,0.00033451928],"domain_scores_gemma":[0.9899916,0.0049339165,0.004104994,0.00024949198,0.00046449873,0.00025547732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012800627,0.00043219858,0.007010828,0.00038169348,0.000021527841,0.000006823525,0.00021566778,0.00012680702,0.00006713907],"category_scores_gemma":[0.0004616702,0.00023364398,0.00057807425,0.0006964451,0.0010100802,0.00010787747,0.000039431074,0.0011244817,0.000001175006],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03825924,0.0010555057,0.00014672507,0.0029565166,0.0020440004,0.00024338019,0.00008218562,0.000008344392,0.0000015386861,0.00004859827,0.000031067593,0.9551229],"study_design_scores_gemma":[0.027056452,0.037322413,0.0018312464,0.018195415,0.0038365126,0.0041417847,0.00019811848,0.000007792783,0.0000013657403,0.00010101693,0.9070314,0.00027644058],"about_ca_topic_score_codex":0.000028081915,"about_ca_topic_score_gemma":0.000048612248,"teacher_disagreement_score":0.95484644,"about_ca_system_score_codex":0.00034049997,"about_ca_system_score_gemma":0.0033575331,"threshold_uncertainty_score":0.9527725},"labels":[],"label_agreement":null},{"id":"W4402428455","doi":"10.57264/cer-2024-0111","title":"A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib","year":2024,"lang":"en","type":"review","venue":"Journal of Comparative Effectiveness Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Palbociclib; Quality of life (healthcare); Clinical trial; Metastatic breast cancer; Breast cancer; Internal medicine; Randomized controlled trial; Oncology; Cancer; Physical therapy","score_opus":0.13816752987078193,"score_gpt":0.5181216320709223,"score_spread":0.37995410220014036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402428455","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023658324,0.9679128,0.00003393424,0.00008586799,0.000060044968,0.008013125,0.00020369173,0.000010792141,0.000021406266],"genre_scores_gemma":[0.06708774,0.93201876,0.000071686074,0.000013253139,0.000020484891,0.0006369369,0.000026722813,0.00009069682,0.000033724384],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9829451,0.009520236,0.004203045,0.00045999882,0.0023657517,0.00050591293],"domain_scores_gemma":[0.98669004,0.0033400345,0.004894536,0.0005849228,0.004222817,0.0002676518],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0071310857,0.00066223356,0.015615568,0.0012701357,0.00005356151,0.000014453085,0.00040203257,0.00016460041,0.000035984838],"category_scores_gemma":[0.0005246291,0.0003279745,0.0006976433,0.0030404022,0.0005002197,0.00022391453,0.000078984165,0.0018339896,0.0000041036174],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005264298,0.00093063316,0.014974251,0.95626676,0.006108862,0.000025510659,0.00027029798,0.000022445745,0.0000014902749,0.00002807143,0.0000057318302,0.01610164],"study_design_scores_gemma":[0.0051803566,0.002909251,0.0640571,0.9256127,0.0016368459,0.00006768248,0.00013405681,0.0000012891708,0.000005130011,0.000015019166,0.00013363035,0.00024694487],"about_ca_topic_score_codex":0.00018290684,"about_ca_topic_score_gemma":0.000027588687,"teacher_disagreement_score":0.049082845,"about_ca_system_score_codex":0.001730908,"about_ca_system_score_gemma":0.0039840196,"threshold_uncertainty_score":0.9999172},"labels":[],"label_agreement":null},{"id":"W4402490088","doi":"10.3390/curroncol31090397","title":"Therapeutic Prospects of Abemaciclib for Patients with Endometrial Cancer","year":2024,"lang":"en","type":"review","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Endometrial cancer; Cancer; Oncology; Bioinformatics; Internal medicine; Cancer research; Biology","score_opus":0.2070319121503156,"score_gpt":0.5123341317071216,"score_spread":0.30530221955680603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402490088","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033684486,0.98922443,0.00014906263,0.000039399813,0.00501958,0.0049297335,0.00045763617,0.000060257677,0.00008619375],"genre_scores_gemma":[0.00006347579,0.9947328,0.00033117022,0.000020900616,0.0015620094,0.0027416614,0.00025511812,0.00012515973,0.00016770017],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980957,0.000067039175,0.0006550002,0.000532948,0.00027659358,0.00037272027],"domain_scores_gemma":[0.99833965,0.00033999857,0.0005777573,0.0003300083,0.00030631595,0.000106283886],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012672966,0.00045670502,0.0027428498,0.00039767617,0.000027783248,0.0000069347843,0.00016998674,0.00025142255,0.00009166784],"category_scores_gemma":[0.00007130974,0.0002730867,0.0004846438,0.000590301,0.00019360302,0.000037115708,0.00005323079,0.00048401195,0.000016569658],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074005115,0.00059181504,0.00023445576,0.048199974,0.0010078325,0.0000032228813,0.00006201264,1.0528882e-7,3.0387443e-7,0.00022149699,0.0002460831,0.9486926],"study_design_scores_gemma":[0.004993511,0.0023838421,0.000030838895,0.017391447,0.0066682636,0.00001572237,0.0000048843735,9.5084687e-7,0.0000020863065,0.00012513767,0.9681464,0.00023693121],"about_ca_topic_score_codex":0.0000022958814,"about_ca_topic_score_gemma":0.0000053246617,"teacher_disagreement_score":0.9679003,"about_ca_system_score_codex":0.0008507413,"about_ca_system_score_gemma":0.001508163,"threshold_uncertainty_score":0.9999721},"labels":[],"label_agreement":null},{"id":"W4402558540","doi":"10.1016/j.annonc.2024.08.2251","title":"LBA13 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Loxo Oncology; Sociedad Española de Oncología Médica; PharmaMar; European Society for Medical Oncology; Eisai; Seagen; G1 Therapeutics; MacroGenics; Genentech; Veracyte; Pfizer; Incyte; Mersana Therapeutics; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Mylan; AstraZeneca; Novocure; Eli Lilly and Company; National Comprehensive Cancer Network; Medac; Jazz Pharmaceuticals; Puma Biotechnology; Bristol-Myers Squibb; American Society of Clinical Oncology; Amgen; Radius Health; Daiichi Sankyo Europe; Gilead Sciences; Merck KGaA; Exelixis; Sanofi; Celgene","keywords":"Medicine; Aromatase inhibitor; Breast cancer; Internal medicine; Nonsteroidal; Adjuvant; Oncology; Aromatase; Cancer; Gynecology","score_opus":0.03707574296529653,"score_gpt":0.3526388762594793,"score_spread":0.3155631332941828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828225,0.0016395081,0.000017913224,0.0110251,0.0010414018,0.0011075119,0.0020639,0.00007509697,0.00020711687],"genre_scores_gemma":[0.9963229,0.00012246885,0.00019992165,0.0020974353,0.0006431377,0.00019249372,0.00017128322,0.000066786044,0.00018360994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765116,0.00017290529,0.0006407839,0.00053071615,0.00049713376,0.0005072959],"domain_scores_gemma":[0.9984253,0.0004706433,0.00023564023,0.0004977246,0.00021178141,0.00015893033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029300753,0.00033657573,0.00093360746,0.00016140912,0.000057027155,0.00002806241,0.00027279474,0.00021645495,0.00035046096],"category_scores_gemma":[0.00006770218,0.00020968965,0.00017570343,0.0003445233,0.000412042,0.00027929872,0.000118916025,0.0005224523,0.00007053876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19278799,0.002315374,0.4338779,0.00022786866,0.0019665628,0.000708776,0.0068261093,0.00008050268,0.0006261596,0.0001948659,0.009541867,0.35084602],"study_design_scores_gemma":[0.09091541,0.006798746,0.87257886,0.00094815716,0.00024065818,0.000044591685,0.00074736075,0.00004051864,0.00074262364,0.0003070854,0.026213031,0.00042295328],"about_ca_topic_score_codex":0.0021408014,"about_ca_topic_score_gemma":0.0010738503,"teacher_disagreement_score":0.43870097,"about_ca_system_score_codex":0.0002584623,"about_ca_system_score_gemma":0.0007419027,"threshold_uncertainty_score":0.8550896},"labels":[],"label_agreement":null},{"id":"W4402560121","doi":"10.1016/j.annonc.2024.08.685","title":"618MO Phase Ib/II first-in-class novel combination trial of next generation CDK4-selective inhibitor PF-07220060 and next generation CDK2-selective inhibitor PF-07104091 in HR+ HER2- metastatic breast cancer and advanced solid tumors","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Medicine; Oncology; Internal medicine; Cancer research","score_opus":0.08902763781321484,"score_gpt":0.39765652122498907,"score_spread":0.30862888341177425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853114,0.00425516,0.0006065369,0.00696268,0.00070610305,0.0018555722,0.00016515197,0.00003879381,0.000098587385],"genre_scores_gemma":[0.9958478,0.0012534604,0.0009618109,0.00046533076,0.00073547004,0.00047789284,0.00011180226,0.00005992764,0.00008649903],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99720854,0.00019456969,0.0010646369,0.0007133288,0.00036182572,0.00045710083],"domain_scores_gemma":[0.99827087,0.00029190964,0.0004778974,0.00019708744,0.0006209196,0.00014131263],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00060044683,0.00038189124,0.0011179266,0.0006860185,0.00010973271,0.000033633325,0.000079164376,0.00022497741,0.00003639981],"category_scores_gemma":[0.00021627184,0.0003735927,0.000103115846,0.0008475415,0.00032411452,0.0010118029,0.0000655746,0.0004248228,0.0000013472134],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02716007,0.0033477903,0.00033803072,0.00045553848,0.00038389786,0.00006280436,0.006150781,0.0014109198,0.6196131,0.0008009996,0.00041703452,0.33985904],"study_design_scores_gemma":[0.22801189,0.038954157,0.009412819,0.0022757726,0.00064199814,0.00064345903,0.0025492816,0.10253969,0.6038931,0.0022608684,0.007417349,0.0013995913],"about_ca_topic_score_codex":0.000612414,"about_ca_topic_score_gemma":0.0028512413,"teacher_disagreement_score":0.33845943,"about_ca_system_score_codex":0.00055192393,"about_ca_system_score_gemma":0.0007983365,"threshold_uncertainty_score":0.9998716},"labels":[],"label_agreement":null},{"id":"W4402561493","doi":"10.1016/j.annonc.2024.08.184","title":"241P Overall survival and updated invasive disease free survival results from the Penelope-B trial investigating palbociclib vs placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after NACT","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Association of Schools and Colleges of Optometry; Chugai Pharmaceutical; Samsung; European Society for Medical Oncology; Astellas Pharma; Eisai; Genentech; Veracyte; Sociedad Española de Oncología Médica; BeiGene; Mylan; Japanese Breast Cancer Society; Les Laboratories Pierre Fabre; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; F. Hoffmann-La Roche; Relay Therapeutics; Seagen; Roche; Celgene; Novartis; Amgen; Novartis Pharmaceuticals Corporation; Pfizer","keywords":"Medicine; Palbociclib; Placebo; Oncology; Internal medicine; Breast cancer; Disease; Overall survival; Cancer; Surgery; Metastatic breast cancer; Pathology; Alternative medicine","score_opus":0.036486052286007,"score_gpt":0.32645242039347855,"score_spread":0.28996636810747156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9552502,0.0017760277,0.000013625067,0.0255366,0.000516859,0.0016190265,0.015202154,0.00005463149,0.000030862935],"genre_scores_gemma":[0.99513394,0.00064294256,0.00043630644,0.0014714613,0.0009241898,0.00034099523,0.00086028024,0.00007210569,0.00011780847],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9975679,0.00035604503,0.0005353261,0.00070311053,0.00041509976,0.00042255578],"domain_scores_gemma":[0.99593574,0.00241002,0.00032238747,0.000471406,0.00037407503,0.00048637483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050423807,0.00034400827,0.0006620839,0.00007557203,0.00013927126,0.000051339506,0.00017454034,0.00012457756,0.000053649845],"category_scores_gemma":[0.0011282302,0.0002267357,0.000087619366,0.00016360695,0.0006195271,0.00025873812,0.0001800977,0.00031141244,0.0000015898817],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7308762,0.00039277683,0.24179155,0.00023824809,0.0011184603,0.00012821234,0.0014658581,0.0000471629,0.0000634207,0.00025045383,0.0046263332,0.019001331],"study_design_scores_gemma":[0.08409897,0.0024729248,0.902609,0.00064075174,0.0007124688,0.0000028759528,0.00021592586,0.000056703848,0.00006531156,0.004348808,0.0044589024,0.00031737864],"about_ca_topic_score_codex":0.002105439,"about_ca_topic_score_gemma":0.002196226,"teacher_disagreement_score":0.66081744,"about_ca_system_score_codex":0.00007769461,"about_ca_system_score_gemma":0.0010261156,"threshold_uncertainty_score":0.9246014},"labels":[],"label_agreement":null},{"id":"W4402748292","doi":"10.1016/j.annonc.2024.09.010","title":"Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Institutes for BioMedical Research; Astex Pharmaceuticals; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Endocrine system; Oncology; Internal medicine; Genetic enhancement; Endocrinology; Gene; Hormone; Genetics","score_opus":0.20248340160230427,"score_gpt":0.425786403148013,"score_spread":0.22330300154570876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402748292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868577,0.009674806,0.000091548005,0.001782653,0.000039351162,0.0013671808,0.00014036796,0.00002098868,0.000025373132],"genre_scores_gemma":[0.9930303,0.003712984,0.0023058986,0.000536933,0.00011399189,0.00014080499,0.00010865798,0.000034068136,0.00001635015],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99785197,0.00049744756,0.00079721137,0.00035724894,0.00018750632,0.000308634],"domain_scores_gemma":[0.99783754,0.0014591205,0.00026819317,0.0002259068,0.00014724208,0.000062002124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062246074,0.0002672406,0.0010549887,0.00030252867,0.00005012461,0.000015488096,0.00006845716,0.000046681555,0.000056409233],"category_scores_gemma":[0.00015083191,0.00014878892,0.00007418193,0.00040571205,0.00022944354,0.00013548204,0.000021936774,0.00009247946,1.8301985e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025497584,0.0019728956,0.13778643,0.00016900511,0.0011654398,0.0007164853,0.0067541087,0.0006780623,0.12973228,0.00016547859,0.000013769806,0.69534844],"study_design_scores_gemma":[0.14809765,0.061592955,0.43297228,0.0020898504,0.0006333649,0.002760687,0.0039624716,0.010380643,0.31595954,0.0013386715,0.019018201,0.0011936643],"about_ca_topic_score_codex":0.0011868487,"about_ca_topic_score_gemma":0.00042660724,"teacher_disagreement_score":0.6941548,"about_ca_system_score_codex":0.00014556483,"about_ca_system_score_gemma":0.0004022712,"threshold_uncertainty_score":0.6067436},"labels":[],"label_agreement":null},{"id":"W4402801800","doi":"10.53539/squjs.splisspp34-44","title":"Cutting-Edge Approach to Targeted Therapy: Repositioning of Old Drugs in Combination with Standard Clinical Chemotherapeutics Potentiates a Propitious Novel Targeted Therapy for Human Pancreatic Cancer","year":2024,"lang":"en","type":"article","venue":"Maǧallaẗ ǧāmiʿaẗ al-Sulṭān Qābūs li-l-ʿulūm/Sultan Qaboos University journal for science","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Pancreatic cancer; Targeted therapy; Cancer therapy; Oncology; Combination therapy; Cancer; Pharmacology; Cancer research; Internal medicine","score_opus":0.029367763048112932,"score_gpt":0.3319781138248555,"score_spread":0.30261035077674253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402801800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91055644,0.0017958349,0.08084057,0.0025835375,0.0004655546,0.0032012637,0.0002009583,0.00016600697,0.00018983574],"genre_scores_gemma":[0.96155775,0.00057116157,0.035989508,0.0006837995,0.00018949182,0.00004844153,0.000041849387,0.000093153336,0.0008248332],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960803,0.00010110552,0.0008923838,0.001007192,0.0010552094,0.00086382194],"domain_scores_gemma":[0.996446,0.00024802855,0.0005839552,0.00044718664,0.0018601649,0.00041462606],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018077072,0.00047398955,0.00089608703,0.0011762638,0.0009666948,0.00025023986,0.00067156757,0.00017212324,0.000020115504],"category_scores_gemma":[0.00012758595,0.00040305188,0.00031028304,0.0027595325,0.00079120795,0.00084224035,0.00007603815,0.0006205279,8.5258483e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04064445,0.005016932,0.025548682,0.001344099,0.0028590213,0.0001552488,0.054330256,0.0063632433,0.68729764,0.016616253,0.0005363571,0.15928784],"study_design_scores_gemma":[0.19143829,0.04967779,0.14192154,0.01621177,0.0024630653,0.0021063488,0.054872185,0.116741285,0.31420326,0.009443857,0.093827784,0.0070928265],"about_ca_topic_score_codex":0.0001445364,"about_ca_topic_score_gemma":0.00002396456,"teacher_disagreement_score":0.37309435,"about_ca_system_score_codex":0.0013675358,"about_ca_system_score_gemma":0.0014575608,"threshold_uncertainty_score":0.9998421},"labels":[],"label_agreement":null},{"id":"W4402922384","doi":"10.3390/curroncol31100424","title":"Monitoring the Response of Cyclin-Dependent Kinase 4/6 Inhibitors with Mean Corpuscular Volume","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Mean corpuscular volume; Gastroenterology; Progression-free survival; Oncology; Metastatic breast cancer; Breast cancer; Proportional hazards model; Hormone receptor; Cancer; Overall survival; Hemoglobin","score_opus":0.05555381851868337,"score_gpt":0.3870709389838087,"score_spread":0.3315171204651253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402922384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96608865,0.027300907,0.0010242977,0.002007701,0.0029156865,0.0004283384,0.000010081616,0.00011358087,0.00011078073],"genre_scores_gemma":[0.9981207,0.00026144608,0.00033406023,0.000029070805,0.0007839725,0.000078116034,0.0000035217297,0.000038460355,0.00035063372],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99863476,0.00019010894,0.00029239838,0.00030127607,0.0003216309,0.00025983973],"domain_scores_gemma":[0.99902576,0.0002753633,0.000095893265,0.00037017485,0.0001310088,0.00010176857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000531384,0.00017091911,0.00033122321,0.00012848178,0.000057323276,0.000011080947,0.00012809594,0.00007677451,0.00005730107],"category_scores_gemma":[0.00008446618,0.00010467194,0.00010198849,0.00026431106,0.00029863062,0.000067119734,0.0000639787,0.0004325344,0.000037067293],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010135199,0.0006031583,0.06704549,0.0005702029,0.00045551898,0.00065057963,0.0060883644,0.00015627948,0.060998324,0.00025166618,0.0004239218,0.8526213],"study_design_scores_gemma":[0.0055033006,0.0044953437,0.07219358,0.003043847,0.000786682,0.0009813125,0.0040264437,0.00048286136,0.08422786,0.00043395808,0.82334536,0.0004794259],"about_ca_topic_score_codex":0.000013690615,"about_ca_topic_score_gemma":0.000007064042,"teacher_disagreement_score":0.85214186,"about_ca_system_score_codex":0.0004054109,"about_ca_system_score_gemma":0.00040313922,"threshold_uncertainty_score":0.42683977},"labels":[],"label_agreement":null},{"id":"W4402986924","doi":"10.1200/op.2024.20.10_suppl.92","title":"Adaptive learning to address gaps in metastatic breast cancer treatment with CDK 4/6 inhibitors.","year":2024,"lang":"en","type":"article","venue":"JCO Oncology Practice","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Axdev Group (Canada)","funders":"Pfizer","keywords":"Metastatic breast cancer; Breast cancer; Cyclin-dependent kinase; Medicine; Oncology; Cancer; Internal medicine; Cancer research","score_opus":0.031476512022942923,"score_gpt":0.3890009703745398,"score_spread":0.35752445835159685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402986924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6699917,0.038035225,0.0034486584,0.23830996,0.0028228601,0.0068136044,0.00022729383,0.0012708367,0.03907987],"genre_scores_gemma":[0.98146945,0.0005728339,0.011159242,0.0024313314,0.0004965685,0.0009419378,0.000011946976,0.00008486274,0.0028318504],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998228,0.00030210146,0.00028054236,0.00052230275,0.0002577242,0.00040931994],"domain_scores_gemma":[0.9982551,0.0010492767,0.00012983679,0.00020392996,0.00016787676,0.00019400213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032604442,0.00026564486,0.0005135952,0.00027136516,0.00007035374,0.000029124723,0.000066468114,0.00008953232,0.00028011386],"category_scores_gemma":[0.000104858176,0.00019474169,0.000055638284,0.00064574456,0.00010400704,0.00049237884,0.000041529718,0.00060200144,0.0001438907],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020996733,0.0016612957,0.003980065,0.00018801588,0.0020018793,0.008258186,0.023796225,0.0044045453,0.0039416263,0.00048069117,0.00061490934,0.9296758],"study_design_scores_gemma":[0.0055432315,0.008147184,0.0057960204,0.0009828522,0.0011841855,0.005758198,0.016654294,0.0005740366,0.000993276,0.000048337497,0.9539244,0.0003939903],"about_ca_topic_score_codex":0.0017231783,"about_ca_topic_score_gemma":0.0016712294,"teacher_disagreement_score":0.9533095,"about_ca_system_score_codex":0.0024556997,"about_ca_system_score_gemma":0.0011134585,"threshold_uncertainty_score":0.79413354},"labels":[],"label_agreement":null},{"id":"W4403153281","doi":"10.1210/jendso/bvae163.017","title":"8040 Precision-Engineered Activin and GDF Ligand Trap HS235: A Novel Lean Mass-Preserving Treatment for Obesity","year":2024,"lang":"en","type":"article","venue":"Journal of the Endocrine Society","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Trap (plumbing); Activin receptor; Chemistry; Ligand (biochemistry); Cell biology; Biology; Physics; Receptor; Transforming growth factor; Biochemistry","score_opus":0.02597886009649806,"score_gpt":0.31434716722073575,"score_spread":0.28836830712423767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403153281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9500971,0.010897341,0.025737738,0.01152537,0.0008792327,0.0006579713,0.000057499998,0.000053743453,0.000094015515],"genre_scores_gemma":[0.97646874,0.0010645264,0.018611617,0.00020167504,0.0009895447,0.000017293658,0.0000015130425,0.000047291993,0.0025977732],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989738,0.000013382388,0.00031119926,0.00017531283,0.00027839304,0.00024795035],"domain_scores_gemma":[0.99904054,0.00035752094,0.00013418922,0.00023213364,0.000119335215,0.000116287694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021455063,0.00019318335,0.0003805659,0.000043410313,0.00011618817,0.000044794866,0.00014903687,0.000042613996,0.00002195384],"category_scores_gemma":[0.000112028814,0.00011184384,0.0006019825,0.00016622418,0.000060605584,0.00021399124,0.00005411087,0.00030453657,6.1279167e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019187067,0.00097642664,0.0041765296,0.0011822577,0.005390523,0.00009446381,0.011078947,0.0014999844,0.7834648,0.0003466447,0.011587365,0.17828338],"study_design_scores_gemma":[0.032005053,0.0040899497,0.040683784,0.004844118,0.003108432,0.008045992,0.0063242996,0.019681064,0.42400637,0.011691718,0.4445321,0.0009871033],"about_ca_topic_score_codex":0.0000083108125,"about_ca_topic_score_gemma":0.000003319878,"teacher_disagreement_score":0.43294474,"about_ca_system_score_codex":0.00031365748,"about_ca_system_score_gemma":0.00016031358,"threshold_uncertainty_score":0.45608592},"labels":[],"label_agreement":null},{"id":"W4403227496","doi":"10.1016/j.cjca.2024.08.058","title":"THE RISK OF QTC PROLONGATION IN PATIENTS USING CYCLIN-DEPENDENT KINASE 4/6 IN ADVANCED BREAST CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS","year":2024,"lang":"en","type":"review","venue":"Canadian Journal of Cardiology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Prolongation; Meta-analysis; Breast cancer; Oncology; Internal medicine; Cardiology; Cancer","score_opus":0.03989452810546913,"score_gpt":0.3450875406558515,"score_spread":0.3051930125503824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403227496","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024382553,0.9970777,0.000035005738,0.0002031692,0.00015159027,0.0018220734,0.00045590303,0.0000018101733,0.000008921858],"genre_scores_gemma":[0.009925953,0.9896838,0.000050572395,0.000055876564,0.0000736945,0.00014321084,0.000011457449,0.000036752393,0.000018647885],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9959717,0.0011981279,0.0019921416,0.00028112825,0.00023236377,0.00032453943],"domain_scores_gemma":[0.9968284,0.00023104089,0.0019060696,0.00040804612,0.0003778908,0.00024855183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016643172,0.00035645306,0.008675745,0.0010698804,0.000044190274,0.000013857207,0.00022048817,0.00018690774,0.000008395573],"category_scores_gemma":[0.00039354505,0.00019668903,0.0016693791,0.000978617,0.00015242596,0.000073474745,0.000022086473,0.00078984327,7.687266e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009359666,0.000009637779,0.004554507,0.69366795,0.2290017,0.0003384478,0.00016176036,0.0017448838,1.8263674e-7,0.000016223676,0.000018076867,0.070393026],"study_design_scores_gemma":[0.0005125429,0.00009321727,0.0010390251,0.06776944,0.9233819,0.0007138236,0.000046820674,0.000006720658,7.06992e-8,0.000050226758,0.006193262,0.00019290281],"about_ca_topic_score_codex":0.0014037237,"about_ca_topic_score_gemma":0.008726233,"teacher_disagreement_score":0.6943802,"about_ca_system_score_codex":0.0010358334,"about_ca_system_score_gemma":0.0018419491,"threshold_uncertainty_score":0.80207455},"labels":[],"label_agreement":null},{"id":"W4403250931","doi":"10.2139/ssrn.4969633","title":"A First-in-Human Phase 1/2 Dose-Escalation Study of Mak683 (Eed Inhibitor) in Patients with Advanced Malignancies","year":2024,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"De-escalation; Medicine; Maximum tolerated dose; Oncology; Internal medicine; Cancer","score_opus":0.008059983410896046,"score_gpt":0.2883609029510119,"score_spread":0.2803009195401159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403250931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99382013,0.003575324,0.00017737546,0.0001987936,0.00026524154,0.0018478899,0.000013536763,0.000045243054,0.000056492456],"genre_scores_gemma":[0.99894595,0.0002753043,0.00014158899,0.000017746066,0.00020369481,0.00011175242,0.000037096506,0.00010493201,0.00016191886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960014,0.00010172289,0.0009893122,0.0005938741,0.0007684829,0.0015451689],"domain_scores_gemma":[0.99857885,0.000034363336,0.00058865384,0.0004377945,0.0002651125,0.0000952483],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0007245501,0.00047943392,0.00093239377,0.0008102914,0.00007083012,0.000031553067,0.00023349271,0.00019620721,0.00002018134],"category_scores_gemma":[0.000037311536,0.000395191,0.00013311853,0.00051464926,0.0000786692,0.00014591639,0.00020062765,0.0046690535,0.0000027627464],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03615585,0.026098901,0.7246969,0.0024212934,0.0032639692,0.00039134268,0.020394932,0.024670128,0.0033149656,0.0034108758,0.000012615742,0.15516827],"study_design_scores_gemma":[0.14023867,0.040017534,0.64261395,0.013845847,0.0010862948,0.0002701389,0.01775181,0.0003839767,0.00078207813,0.14106551,0.00017580512,0.0017684024],"about_ca_topic_score_codex":0.00018917328,"about_ca_topic_score_gemma":0.005480786,"teacher_disagreement_score":0.15339985,"about_ca_system_score_codex":0.0036185342,"about_ca_system_score_gemma":0.00232091,"threshold_uncertainty_score":0.99985},"labels":[],"label_agreement":null},{"id":"W4403632643","doi":"10.1530/erc-24-0282","title":"In memoriam: Charis Eng MD PhD (1962–2024)","year":2024,"lang":"en","type":"editorial","venue":"Endocrine Related Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Publishing; Associate editor; Editorial board; Library science; Medicine; Psychoanalysis; Psychology; Political science; Law; Computer science","score_opus":0.011688799290568132,"score_gpt":0.3285436245086093,"score_spread":0.31685482521804115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403632643","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018273026,0.10960509,0.000008227786,0.0025350968,0.8795527,0.0008140078,0.00040675883,0.0003863266,0.0065090284],"genre_scores_gemma":[0.0003342142,0.022590848,0.00013686012,0.00022373645,0.81579924,0.00073525996,0.00039831048,0.00040976837,0.15937178],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99513257,0.000083504885,0.0010239643,0.0013679941,0.0013015987,0.0010903908],"domain_scores_gemma":[0.9978693,0.0003437784,0.00030065447,0.000896837,0.00029666495,0.00029274976],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00023561863,0.0009231574,0.0015281959,0.00077145733,0.000065440596,0.000055602035,0.00036894224,0.00093869056,0.006699004],"category_scores_gemma":[0.00036957927,0.0008442727,0.000373372,0.0012465927,0.00015800784,0.0002479449,0.00020709394,0.005309713,0.00083876663],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005375747,0.000085090265,0.000035795325,0.0009627797,0.0007464297,0.002623309,0.0006985078,0.00007336947,0.00043431154,0.000065743065,0.9844649,0.009272219],"study_design_scores_gemma":[0.004193916,0.00017351583,0.000013003491,0.0032081786,0.0006815808,0.00014559316,0.00007181202,0.00004327071,0.00084463577,0.0009244877,0.9889608,0.00073922414],"about_ca_topic_score_codex":0.0019076283,"about_ca_topic_score_gemma":0.00029785142,"teacher_disagreement_score":0.15286276,"about_ca_system_score_codex":0.0033777156,"about_ca_system_score_gemma":0.0025757025,"threshold_uncertainty_score":0.9999392},"labels":[],"label_agreement":null},{"id":"W4403687451","doi":"10.51731/cjht.2024.1007","title":"Abemaciclib (Verzenio)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.02564525981457516,"score_gpt":0.3288999898054583,"score_spread":0.30325472999088315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403687451","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.057299446,0.7542902,0.0028155255,0.18231277,0.0015929395,0.00029361848,0.000024735766,0.0005642116,0.0008065006],"genre_scores_gemma":[0.9961571,0.0007010752,0.002027324,0.0008212622,0.00003837718,0.0000035479047,0.0000010985165,0.00002404999,0.00022612861],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989041,0.00001720729,0.00041220052,0.00012139127,0.00014151845,0.00040360182],"domain_scores_gemma":[0.9994075,0.000038789414,0.000120421115,0.00020094895,0.000109684996,0.00012270536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034056342,0.00011197804,0.00033406803,0.00074881176,0.000100196165,0.000033041833,0.0001710434,0.0001020889,0.00007689571],"category_scores_gemma":[0.0001850776,0.000087264045,0.00009356097,0.0004299285,0.00021855684,0.00014042458,0.000009458974,0.0005408228,0.000027891725],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015574344,0.0000045258626,0.000802457,0.00022528722,0.00006096605,0.00071303954,0.00023701722,0.0000044697085,0.00011518825,0.002434906,0.0027240168,0.99266255],"study_design_scores_gemma":[0.0003423339,0.00042421353,0.002525836,0.0010856555,0.000020472968,0.0038576075,0.0017423857,0.000015553402,0.00095910503,0.009755209,0.9791748,0.00009682717],"about_ca_topic_score_codex":0.00069171615,"about_ca_topic_score_gemma":0.00051315565,"teacher_disagreement_score":0.99256575,"about_ca_system_score_codex":0.0006618111,"about_ca_system_score_gemma":0.004273231,"threshold_uncertainty_score":0.7580528},"labels":[],"label_agreement":null},{"id":"W4403761092","doi":"10.1016/j.brachy.2024.08.016","title":"MPP02 Presentation Time: 4:09 PM","year":2024,"lang":"en","type":"article","venue":"Brachytherapy","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Presentation (obstetrics); Surgery","score_opus":0.012508853978834899,"score_gpt":0.31896491290540546,"score_spread":0.3064560589265706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403761092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80880463,0.08310647,0.027062004,0.029029105,0.002827536,0.0033968922,0.00005145058,0.0033880696,0.042333815],"genre_scores_gemma":[0.91569954,0.00083689456,0.007812449,0.002968238,0.0027550245,0.0002625048,0.0001045555,0.00018820625,0.06937256],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990609,0.000028470822,0.00018596867,0.00027554712,0.00024116709,0.00020788952],"domain_scores_gemma":[0.9995149,0.000076667886,0.000030581556,0.00024815535,0.000048631027,0.000081084334],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00010473975,0.00014704991,0.00023235168,0.00011257951,0.000043216958,0.000046781246,0.000057891793,0.00006194048,0.0017945755],"category_scores_gemma":[0.000013654959,0.000117869735,0.00011891793,0.00026162513,0.000056973127,0.00021649893,0.000009702332,0.00015517534,0.0010612482],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012919629,0.00011340599,0.0006976788,0.0001428891,0.00034913226,0.00014850222,0.001178484,0.000038224756,0.10312264,0.0016919373,0.005928441,0.8852967],"study_design_scores_gemma":[0.0069939657,0.0006725035,0.01492938,0.00046034803,0.00013640779,0.0007314491,0.0001441172,0.0047708927,0.024103958,0.006889341,0.93971807,0.00044955444],"about_ca_topic_score_codex":0.000010983817,"about_ca_topic_score_gemma":0.0000013997337,"teacher_disagreement_score":0.9337897,"about_ca_system_score_codex":0.00008088805,"about_ca_system_score_gemma":0.00008813177,"threshold_uncertainty_score":0.9997165},"labels":[],"label_agreement":null},{"id":"W4403763220","doi":"10.1016/j.ejca.2024.114974","title":"467 (PB455): IND.241: A Canadian Cancer Trials Group liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant ER +/HER2- metastatic breast cancer","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Oncology; Internal medicine; Breast cancer; Metastatic breast cancer; HER2 negative; Clinical trial; Cancer","score_opus":0.06766777546693979,"score_gpt":0.38378836128649385,"score_spread":0.31612058581955405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403763220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9145885,0.045107353,0.00017143947,0.024849797,0.007625398,0.0036197351,0.0017823051,0.000108021886,0.0021474601],"genre_scores_gemma":[0.9822699,0.0041523017,0.0011256414,0.0022414215,0.0067217937,0.0005409272,0.000021826256,0.00031169364,0.002614521],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939852,0.0006542857,0.002479883,0.0006031646,0.0012003321,0.0010771581],"domain_scores_gemma":[0.99651736,0.00031302145,0.00082126027,0.000459837,0.0005795292,0.0013090046],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003379093,0.0007191083,0.0018301287,0.0013473274,0.00013879254,0.00019166403,0.00038380484,0.000088197325,0.0032844888],"category_scores_gemma":[0.00033166495,0.0005069317,0.0006282374,0.0011461254,0.00013781739,0.0006072203,0.00005737267,0.00071974105,0.00006898477],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.30751207,0.00045346704,0.00055885466,0.0005643858,0.00474327,0.0072028846,0.010499435,0.002082072,0.015879622,0.0001202907,0.008507892,0.64187574],"study_design_scores_gemma":[0.11683011,0.008699938,0.017033476,0.011033551,0.002710171,0.0011591639,0.0014018458,0.00012446646,0.0031482407,0.00009270063,0.83645546,0.0013108774],"about_ca_topic_score_codex":0.033526365,"about_ca_topic_score_gemma":0.1535233,"teacher_disagreement_score":0.82794756,"about_ca_system_score_codex":0.0081085265,"about_ca_system_score_gemma":0.008011457,"threshold_uncertainty_score":0.9997382},"labels":[],"label_agreement":null},{"id":"W4403797757","doi":"10.1016/j.annonc.2024.07.638","title":"O5-2 WJOG (West Japan Oncology Group) Breast Cancer Consensus Meeting 2023","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"Daiichi-Sankyo; Kanazawa University","keywords":"Medicine; Oncology; Internal medicine; Breast cancer; Consensus conference; Clinical Oncology; Family medicine; Cancer; Gynecology","score_opus":0.07591772040298896,"score_gpt":0.4249526068402364,"score_spread":0.34903488643724745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403797757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71413386,0.037896615,0.00012561327,0.18254332,0.0035828764,0.0009222498,0.0004831222,0.00044387605,0.059868496],"genre_scores_gemma":[0.989284,0.0014473563,0.0012115459,0.00514893,0.0012504809,0.000119002405,0.000030403253,0.000073170864,0.0014351454],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978468,0.00016490158,0.00061037665,0.000507667,0.0002500126,0.0006202864],"domain_scores_gemma":[0.99818057,0.0006701571,0.00022339723,0.00032986625,0.00036521355,0.00023081196],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047558366,0.00027075908,0.0008773978,0.00026274114,0.000071915216,0.000010845533,0.00016866604,0.00033377833,0.0011611962],"category_scores_gemma":[0.0001113939,0.00023941026,0.00020879814,0.0004428892,0.00057418837,0.000079652644,0.00010080772,0.00048305583,0.0001846733],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017705283,0.00044587583,0.0034533103,0.00043004888,0.00079645327,0.0007040534,0.0011084062,0.0000686522,0.04596696,0.0019390637,0.012875117,0.93044156],"study_design_scores_gemma":[0.0024540364,0.0035457124,0.031279642,0.0007406476,0.0002648697,0.0031901489,0.0012983414,0.00025530634,0.0036021208,0.0014228071,0.9515885,0.00035787403],"about_ca_topic_score_codex":0.0009877436,"about_ca_topic_score_gemma":0.00088245526,"teacher_disagreement_score":0.9387134,"about_ca_system_score_codex":0.0003153081,"about_ca_system_score_gemma":0.0009795391,"threshold_uncertainty_score":0.99975187},"labels":[],"label_agreement":null},{"id":"W4403809602","doi":"10.3390/biomedicines12112471","title":"A Multicenter Physician Survey Evaluating the Use of Ki-67 in Breast Cancer Management in Canada","year":2024,"lang":"en","type":"article","venue":"Biomedicines","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Breast cancer; Family medicine; Adjuvant; Oncology; Clinical trial; Internal medicine; Cancer; Gynecology","score_opus":0.08150078033372031,"score_gpt":0.36704423163550537,"score_spread":0.28554345130178505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403809602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988508,0.003484111,0.00003587519,0.0065066935,0.00065896916,0.00060658506,0.00013310745,0.00001919281,0.00004745556],"genre_scores_gemma":[0.99770653,0.00020333183,0.00020630761,0.0013922837,0.00016318937,0.00008869875,0.000020485952,0.00002504909,0.00019412623],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986746,0.000087087144,0.0003392085,0.00024429164,0.00039963095,0.0002552012],"domain_scores_gemma":[0.9993586,0.00021944448,0.00005916938,0.00024119853,0.00007486282,0.000046705616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031133264,0.00014741605,0.00027237897,0.0001984423,0.000015956377,0.000008505694,0.00009616259,0.000021849464,0.00005902822],"category_scores_gemma":[0.000025933537,0.000091314585,0.000028897592,0.0008229217,0.00010051968,0.000085149695,0.000042662443,0.00013465609,0.0000018404853],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008103059,0.00009724513,0.48532087,0.0007316889,0.000252072,0.00018050491,0.0010560493,0.00037613974,0.0052710343,0.00002070913,0.0012688828,0.5046145],"study_design_scores_gemma":[0.0014035442,0.000038760798,0.9832275,0.0020488603,0.00005663707,0.0000102274835,0.0007384346,0.007938637,0.00010866364,0.000011887675,0.004322881,0.00009395551],"about_ca_topic_score_codex":0.8628788,"about_ca_topic_score_gemma":0.8222707,"teacher_disagreement_score":0.50452054,"about_ca_system_score_codex":0.00065392774,"about_ca_system_score_gemma":0.00047560252,"threshold_uncertainty_score":0.37237006},"labels":[],"label_agreement":null},{"id":"W4403875943","doi":"10.1080/14796694.2024.2418797","title":"Part 2 – Highlights of the San Antonio Breast Cancer Symposium 2023","year":2024,"lang":"en","type":"article","venue":"Future Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Air (Canada)","funders":"","keywords":"Medicine; Breast cancer; Oncology; Cancer; Internal medicine; Gynecology","score_opus":0.009030785945327625,"score_gpt":0.3010043440202266,"score_spread":0.29197355807489894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403875943","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14901873,0.056299575,0.00011240445,0.68792814,0.043157354,0.0017581496,0.0009116451,0.0005490917,0.060264934],"genre_scores_gemma":[0.95486116,0.0028083185,0.00045753023,0.0041847867,0.016843406,0.00022529428,0.000030679334,0.000105205094,0.020483628],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989617,0.000061355284,0.00023057799,0.000281812,0.00019751056,0.00026705553],"domain_scores_gemma":[0.9993311,0.00006201228,0.00007828958,0.0003510076,0.000094810166,0.00008274875],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009090865,0.00016124103,0.00035431204,0.00006536213,0.00005855503,0.000007071277,0.00015649562,0.00018580195,0.0016014499],"category_scores_gemma":[0.000004057012,0.00009333573,0.00013496255,0.00035579412,0.00019955447,0.000062167994,0.000059367583,0.0003007648,0.000046190078],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00302815,0.0007566421,0.009433852,0.0018823366,0.002124076,0.0006601471,0.005907121,0.00011037124,0.24350737,0.048079178,0.30896595,0.37554482],"study_design_scores_gemma":[0.0006937716,0.00016229645,0.019041814,0.0002992729,0.00015945769,0.00065984065,0.00017910794,0.000017035944,0.0040269666,0.00021429158,0.9744468,0.00009938169],"about_ca_topic_score_codex":0.00008631365,"about_ca_topic_score_gemma":0.00035602273,"teacher_disagreement_score":0.8058424,"about_ca_system_score_codex":0.00033650658,"about_ca_system_score_gemma":0.00058908726,"threshold_uncertainty_score":0.9993112},"labels":[],"label_agreement":null},{"id":"W4404070167","doi":"10.1038/s41467-024-53837-7","title":"Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer","year":2024,"lang":"en","type":"article","venue":"Nature Communications","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Imperial College London; Cancer Research UK","keywords":"Endocrine system; Palbociclib; Cancer; Breast cancer; Cancer research; Oncology; Medicine; Internal medicine; Bioinformatics; Hormone; Biology; Metastatic breast cancer","score_opus":0.018442548364937403,"score_gpt":0.3512481833683104,"score_spread":0.33280563500337296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404070167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8686094,0.10518221,0.00004336465,0.02472964,0.00014773487,0.00035780488,0.00012835638,0.000085951455,0.00071551884],"genre_scores_gemma":[0.98024297,0.018224653,0.00093846855,0.00025630434,0.000103134116,0.00012134313,0.000022952921,0.000020323288,0.00006983891],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99930733,0.00006143072,0.00017422366,0.00018514255,0.0001425136,0.00012937543],"domain_scores_gemma":[0.99902695,0.0001681296,0.00005579067,0.0005981542,0.000107008855,0.00004395221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010332769,0.00012026246,0.00021313794,0.00017926947,0.000053935262,0.000014425116,0.00012487706,0.00011434585,0.000053261618],"category_scores_gemma":[0.000017930108,0.000101407466,0.000045720066,0.00046674325,0.00022208753,0.00021909617,0.00009146591,0.0007558503,0.0000017803835],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040893242,0.00036609298,0.01357396,0.00019140448,0.00011910633,0.0000072162625,0.0012085376,0.0000035400474,0.7230489,0.0030964124,0.00023238835,0.2577435],"study_design_scores_gemma":[0.003518544,0.00019367835,0.5438137,0.0028663683,0.00008833859,0.00028865458,0.0005268974,0.00074263534,0.36086962,0.002124366,0.084520504,0.0004466843],"about_ca_topic_score_codex":0.00013334013,"about_ca_topic_score_gemma":0.00044946355,"teacher_disagreement_score":0.53023976,"about_ca_system_score_codex":0.00011169281,"about_ca_system_score_gemma":0.000118744996,"threshold_uncertainty_score":0.41352764},"labels":[],"label_agreement":null},{"id":"W4404417044","doi":"10.3390/curroncol31110529","title":"Correction: Alvarado-Miranda et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. Curr. Oncol. 2023, 30, 6097–6110","year":2024,"lang":"en","type":"erratum","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Capecitabine; Aromatase inhibitor; Aromatase; Human Epidermal Growth Factor Receptor 2; HER2 negative; Internal medicine; Metastatic breast cancer; Hormone receptor; Oncology; Second line; Cancer research; Breast cancer; Cancer; First line","score_opus":0.045414296236339025,"score_gpt":0.3958328626615461,"score_spread":0.3504185664252071,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404417044","genre_codex":"editorial","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013875617,0.36463445,0.0029661944,0.14560978,0.414045,0.016956044,0.04772904,0.0011739477,0.005497975],"genre_scores_gemma":[0.004297513,0.45688346,0.004954153,0.03542647,0.08289926,0.038560323,0.07567264,0.003094162,0.29821202],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932672,0.00044320358,0.0016271517,0.0022190243,0.0010343866,0.0014090757],"domain_scores_gemma":[0.99445003,0.0012399039,0.0012401843,0.0009563898,0.0013773052,0.00073617377],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00063838414,0.0017582176,0.0034063347,0.0006808011,0.00042511823,0.00012205905,0.00053338346,0.00083736976,0.0033569697],"category_scores_gemma":[0.00038276994,0.0015393324,0.0008990807,0.001116455,0.00076934963,0.0003602285,0.0002554802,0.004183975,0.00056824327],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.010674859,0.0017874484,0.000008238251,0.00077827164,0.0018067235,0.00016958846,0.0011910009,0.000036499012,0.00017245984,0.000030993036,0.77607965,0.20726423],"study_design_scores_gemma":[0.018557625,0.0071480554,0.00026123622,0.004577084,0.0013447913,0.0010334149,0.0006181964,0.0010959958,0.00021036006,0.00032830102,0.96350515,0.0013197811],"about_ca_topic_score_codex":0.00063990656,"about_ca_topic_score_gemma":0.0009113459,"teacher_disagreement_score":0.33114576,"about_ca_system_score_codex":0.005844509,"about_ca_system_score_gemma":0.0062086713,"threshold_uncertainty_score":0.99951637},"labels":[],"label_agreement":null},{"id":"W4404638136","doi":"10.3390/curroncol31120548","title":"Timing of Dose Reductions and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Cyclin-Dependent Kinase 4/6 Inhibitors","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Metastatic breast cancer; Oncology; Kinase; Cancer research; Cyclin-dependent kinase 4; Internal medicine; Palbociclib; Cancer; Cyclin-dependent kinase 2; Biology; Cell cycle; Genetics","score_opus":0.062111010126262134,"score_gpt":0.40254658744673144,"score_spread":0.3404355773204693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404638136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99422413,0.0031932278,0.000031039228,0.0008860783,0.0009963649,0.0004118522,0.00013610355,0.000047136047,0.0000740429],"genre_scores_gemma":[0.9991972,0.0002688978,0.00017308966,0.00001628886,0.00008974388,0.00011229824,0.000029467517,0.000027316453,0.000085690066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988691,0.000074998236,0.00033760397,0.0003086586,0.00018803723,0.0002215855],"domain_scores_gemma":[0.99945307,0.00011624015,0.00009457401,0.00012839037,0.00011003023,0.0000976965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010313541,0.00017689033,0.00050405966,0.00026436595,0.00002810852,0.0000070913343,0.00004097142,0.000045328743,0.00008419288],"category_scores_gemma":[0.000024333376,0.00012725656,0.00004613356,0.00028991723,0.0001904781,0.00010672297,0.000035111745,0.00024604317,0.0000028327438],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006793227,0.0011410307,0.70804507,0.00035356102,0.00023574394,0.000059400263,0.0010049602,0.000038544218,0.0009525246,0.000051249466,0.00003343666,0.2874052],"study_design_scores_gemma":[0.008720425,0.0010296598,0.98212826,0.001224514,0.0006263464,0.00016931247,0.0009820013,0.00025788078,0.0009327854,0.00011505627,0.0035262275,0.00028754296],"about_ca_topic_score_codex":0.00022762094,"about_ca_topic_score_gemma":0.00030148847,"teacher_disagreement_score":0.28711763,"about_ca_system_score_codex":0.0004058939,"about_ca_system_score_gemma":0.00023015117,"threshold_uncertainty_score":0.5189372},"labels":[],"label_agreement":null},{"id":"W4404910188","doi":"10.1016/s1470-2045(24)00673-9","title":"Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation; Novartis","keywords":"Fulvestrant; Medicine; Aromatase inhibitor; Internal medicine; Oncology; Breast cancer; Cancer; Cohort; Regimen; Letrozole; Clinical endpoint; Clinical trial; Aromatase; Estrogen receptor","score_opus":0.04917139460894078,"score_gpt":0.40713169796505505,"score_spread":0.3579603033561143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404910188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811374,0.005904372,0.00021628677,0.0044776783,0.00055282464,0.0056841844,0.00077655975,0.000103012266,0.0011476731],"genre_scores_gemma":[0.9929611,0.0007683119,0.0021479274,0.00077157415,0.00069297047,0.0022320142,0.000061397746,0.00007867787,0.00028600823],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965755,0.0004479014,0.000871974,0.00085337536,0.00045337464,0.0007979279],"domain_scores_gemma":[0.99812126,0.0004243607,0.00029024272,0.00066152686,0.00031087658,0.00019174353],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007599575,0.000497064,0.0020508766,0.00021770918,0.00008267037,0.00004594076,0.0005221373,0.00017746369,0.00033211272],"category_scores_gemma":[0.000030643325,0.000363483,0.0000838632,0.00091126765,0.0004961573,0.00040932934,0.0002843588,0.0009200115,0.000057657246],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34807602,0.030126702,0.011893955,0.0006788081,0.0062841885,0.002768998,0.10425737,0.0011140795,0.3129496,0.00019441107,0.0021512106,0.17950465],"study_design_scores_gemma":[0.44452175,0.03004186,0.41735268,0.0069658863,0.0031789937,0.0011764969,0.041754853,0.010601602,0.02500801,0.00040201703,0.016437111,0.0025587624],"about_ca_topic_score_codex":0.0010528511,"about_ca_topic_score_gemma":0.0015389051,"teacher_disagreement_score":0.40545872,"about_ca_system_score_codex":0.0014176738,"about_ca_system_score_gemma":0.00093308813,"threshold_uncertainty_score":0.9998817},"labels":[],"label_agreement":null},{"id":"W4404997121","doi":"10.1007/s40273-024-01456-x","title":"Cost-Effectiveness of Capivasertib as a Second-Line Therapy for Advanced Breast Cancer","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Fulvestrant; Medicine; Cost effectiveness; Anastrozole; Breast cancer; Quality of Life Research; Oncology; Health economics; Internal medicine; Cancer; Gynecology; Tamoxifen; Public health; Nursing; Risk analysis (engineering)","score_opus":0.04592795873233327,"score_gpt":0.4144842457790218,"score_spread":0.3685562870466885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404997121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768801,0.014069572,0.0022193524,0.0013676438,0.0011768946,0.0025088424,0.0013146094,0.00016497548,0.0002980263],"genre_scores_gemma":[0.9937248,0.0019897022,0.00061617355,0.0012279712,0.00048323005,0.0013197851,0.00006494873,0.00011025709,0.00046308912],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987959,0.000034963927,0.00034183223,0.00043110037,0.00007735636,0.000318818],"domain_scores_gemma":[0.9990498,0.00032750014,0.00009776441,0.00022999194,0.00014557216,0.00014937123],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026194338,0.00025630902,0.00050790433,0.00012972648,0.000042340915,0.000019386067,0.00012500111,0.00006343321,0.0014543959],"category_scores_gemma":[0.00000845968,0.0002360281,0.00022228036,0.00012534641,0.000093854454,0.00027352353,0.000024441275,0.0001753927,0.000029030967],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014661795,0.00019076992,0.00062612206,0.0016019436,0.000968779,0.000012867786,0.0003317553,0.0015295298,0.49987873,0.0007557258,0.00017005675,0.47927192],"study_design_scores_gemma":[0.011506229,0.00039742806,0.0024172824,0.0005323794,0.0001877629,0.00020396958,0.00010213925,0.0039067925,0.83413523,0.0016501812,0.14457925,0.00038135616],"about_ca_topic_score_codex":0.00004342953,"about_ca_topic_score_gemma":0.00000956667,"teacher_disagreement_score":0.47889057,"about_ca_system_score_codex":0.00037709597,"about_ca_system_score_gemma":0.0004270561,"threshold_uncertainty_score":0.99945843},"labels":[],"label_agreement":null},{"id":"W4405062917","doi":"10.7554/elife.97577.2","title":"The PRC2.1 Subcomplex Opposes G1 Progression through Regulation of CCND1 and CCND2","year":2024,"lang":"en","type":"preprint","venue":"eLife","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"PRC2; Cyclin D1; Palbociclib; Cell cycle; Biology; Cancer research; Cell growth; Cyclin D2; Cell biology; Genetics; Cancer; Gene; EZH2; Epigenetics; Breast cancer","score_opus":0.036329249021307755,"score_gpt":0.37022481920275296,"score_spread":0.3338955701814452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405062917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75449723,0.20853113,0.0010687757,0.021250207,0.0024779174,0.0033333066,0.00011903665,0.0005542489,0.008168177],"genre_scores_gemma":[0.9894183,0.0017355494,0.005995797,0.00018417001,0.0007450186,0.00012889774,0.000074098425,0.00006924199,0.0016488952],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985576,0.000051555002,0.0003338992,0.00039021613,0.00048032764,0.00018639794],"domain_scores_gemma":[0.99885494,0.00010455952,0.00024216386,0.0005512795,0.00018647336,0.000060615785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000215455,0.00023538602,0.0003903404,0.00005054617,0.00009398553,0.000038254188,0.00012616976,0.00016881638,0.00003092417],"category_scores_gemma":[0.00007431447,0.00014749212,0.00010064254,0.00010160556,0.000291181,0.000045123707,0.0005207053,0.0004682595,0.000009696674],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035440733,0.00039704665,0.005870647,0.007939265,0.0016088857,0.000061619285,0.008618967,0.00019065713,0.057389885,0.032086737,0.016820364,0.86547184],"study_design_scores_gemma":[0.003263967,0.0008357774,0.08468212,0.014475132,0.0007696197,0.00029569428,0.0013585627,0.0019227121,0.16366354,0.16248515,0.56519586,0.0010518451],"about_ca_topic_score_codex":0.000027574195,"about_ca_topic_score_gemma":0.000009804817,"teacher_disagreement_score":0.86442,"about_ca_system_score_codex":0.000082404236,"about_ca_system_score_gemma":0.00020014617,"threshold_uncertainty_score":0.6014554},"labels":[],"label_agreement":null},{"id":"W4405194826","doi":"10.1038/s41591-024-03349-0","title":"Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial","year":2024,"lang":"en","type":"erratum","venue":"Nature Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Oncology; Breast cancer; Medicine; Internal medicine; Cancer","score_opus":0.010698001452572279,"score_gpt":0.3575968906321315,"score_spread":0.34689888917955924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405194826","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0058097304,0.21536921,0.002106316,0.20132108,0.49588287,0.026377354,0.0033028089,0.0024641543,0.0473665],"genre_scores_gemma":[0.0551227,0.002311245,0.0015763817,0.020799132,0.045713022,0.0042837346,0.006376141,0.0013847714,0.8624329],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9929962,0.00030449437,0.0012434047,0.0020957384,0.002159311,0.0012008314],"domain_scores_gemma":[0.9963273,0.00035417004,0.0006890917,0.0010918193,0.0008955666,0.0006420498],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.00079629105,0.00165318,0.0035519858,0.001494455,0.00014633058,0.00009528536,0.00049518934,0.0018972805,0.0025198676],"category_scores_gemma":[0.00065173564,0.0010004637,0.00030142747,0.003183631,0.0008394286,0.0005439871,0.000102412705,0.010391291,0.00001687908],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20561992,0.00072957296,0.000032944234,0.0008563904,0.001348947,0.0019305433,0.0014937994,0.000008804562,0.00008530102,0.000014401912,0.6483286,0.13955078],"study_design_scores_gemma":[0.18354414,0.009355001,0.00026825492,0.019666519,0.0024609622,0.004246265,0.0025984633,0.00010614097,0.000050312625,0.00012217561,0.77645636,0.0011254178],"about_ca_topic_score_codex":0.0010853898,"about_ca_topic_score_gemma":0.009353722,"teacher_disagreement_score":0.8150664,"about_ca_system_score_codex":0.0025545333,"about_ca_system_score_gemma":0.00429286,"threshold_uncertainty_score":0.9996215},"labels":[],"label_agreement":null},{"id":"W4405234188","doi":"10.3390/curroncol31120581","title":"First-Line (1L) Treatment Decision Patterns and Survival of Hormone Receptor (HR)-Positive/HER2-Negative Advanced Breast Cancer (ABC) Patients in a Latin American (LATAM) Public Institution","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Oncology; Internal medicine; Breast cancer; Chemotherapy; Population; Hormone therapy; Cancer; Endocrine system; Disease; Clinical trial; Gynecology; Hormone","score_opus":0.04696573317374571,"score_gpt":0.3782863379829165,"score_spread":0.3313206048091708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405234188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903679,0.0033300577,0.0018563146,0.0015950167,0.0010592262,0.0008205359,0.00086736237,0.000058169106,0.00004544498],"genre_scores_gemma":[0.992013,0.0065426584,0.0007349598,0.000034575285,0.00019127355,0.0002594226,0.0001739841,0.00003312098,0.000017021543],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99823564,0.000109958004,0.00049209106,0.00054375664,0.00026345797,0.00035506743],"domain_scores_gemma":[0.998823,0.00035028957,0.00021507531,0.00020222773,0.00024054416,0.00016887725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011308839,0.00029620726,0.00069741014,0.0003130056,0.000061410814,0.000013394048,0.000077222205,0.00008926882,0.000071605056],"category_scores_gemma":[0.00009116822,0.00023951291,0.00008112468,0.00055463513,0.00038408182,0.00023695621,0.00007763057,0.00025820002,0.0000075651624],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018811364,0.00097599195,0.2649677,0.00007836201,0.000097571756,0.000012624482,0.0012559621,0.00004793566,0.00027051193,0.00008366354,0.000016101845,0.73031247],"study_design_scores_gemma":[0.007946477,0.0031245737,0.9724216,0.00093526684,0.0000966192,0.0000149497,0.00033745184,0.00055118604,0.00039933817,0.0001748963,0.013759801,0.0002378614],"about_ca_topic_score_codex":0.001103252,"about_ca_topic_score_gemma":0.0045026024,"teacher_disagreement_score":0.7300746,"about_ca_system_score_codex":0.0018139869,"about_ca_system_score_gemma":0.00033096224,"threshold_uncertainty_score":0.9767053},"labels":[],"label_agreement":null},{"id":"W4405579443","doi":"10.1177/17151635241305206","title":"OPEN Summit 2024 Abstracts–Poster and Oral Presentations","year":2024,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Summit; Library science; Computer science; World Wide Web; Geography; Cartography","score_opus":0.05094235696076765,"score_gpt":0.3473039835938807,"score_spread":0.29636162663311305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405579443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9353226,0.023642616,0.00023057566,0.0047884556,0.008992995,0.0019471971,0.0017327683,0.00012782669,0.02321499],"genre_scores_gemma":[0.9816995,0.002704565,0.00044132335,0.0036069637,0.0009870124,0.000032996457,0.00004017781,0.000083865976,0.010403564],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978506,0.000069683956,0.00049360294,0.00044886037,0.00034495263,0.0007923204],"domain_scores_gemma":[0.99690276,0.000102797036,0.00009666246,0.0002125335,0.00030421471,0.0023810253],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003795477,0.00032496106,0.00036748886,0.00031651123,0.00051685434,0.00074853614,0.00044091223,0.000053782944,0.0026837077],"category_scores_gemma":[0.00007449619,0.00031461302,0.00009571697,0.000542517,0.00022223627,0.00087968394,0.000088717425,0.00080177624,0.000031939024],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045908394,0.00006070438,0.0055475384,0.0008967189,0.0011680361,0.25290355,0.0021043024,0.0004883005,0.004509686,0.00016647969,0.16565357,0.56604207],"study_design_scores_gemma":[0.001808461,0.000047764068,0.00025927584,0.00009143424,0.00029045643,0.44610626,0.000034568675,0.0008141173,0.001614097,0.0001966956,0.54835546,0.00038140247],"about_ca_topic_score_codex":0.033292353,"about_ca_topic_score_gemma":0.1469002,"teacher_disagreement_score":0.56566066,"about_ca_system_score_codex":0.0016040776,"about_ca_system_score_gemma":0.0053218845,"threshold_uncertainty_score":0.9999306},"labels":[],"label_agreement":null},{"id":"W4405686098","doi":"10.25071/1708-6701.40496","title":"Reports from the 2024 CAML / ACBM Annual General Meeting","year":2024,"lang":"en","type":"article","venue":"CAML Review / Revue de l ACBM","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.013780685910959286,"score_gpt":0.3069288206959117,"score_spread":0.29314813478495244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405686098","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02706292,0.937175,0.0005776987,0.026384559,0.0021131043,0.0011343237,0.00014843197,0.00031060734,0.0050933515],"genre_scores_gemma":[0.23074846,0.47676417,0.036005616,0.099287085,0.04212886,0.0021569924,0.001147942,0.0010586131,0.110702254],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976791,0.00013664764,0.0007100985,0.0006635402,0.0003233364,0.00048724565],"domain_scores_gemma":[0.9981838,0.00024694303,0.00019370882,0.0010092858,0.00016072848,0.00020554564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081000506,0.00033528256,0.000725575,0.000049235772,0.000109271336,0.00006153544,0.00022688281,0.00011550426,0.0007328767],"category_scores_gemma":[0.00066304044,0.00022786256,0.00035743148,0.00048847176,0.00011017363,0.00018097159,0.00012374397,0.00062631606,0.0002027686],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010681155,0.00009865747,0.0067124995,0.015232207,0.0009228236,0.009841355,0.0032254725,0.000043811713,0.011010927,0.0016204087,0.2858344,0.6653506],"study_design_scores_gemma":[0.00017907527,0.00004711758,0.0015535498,0.019924372,0.00055957364,0.0033931055,0.00011616725,0.00009643029,0.0004930903,0.00072539307,0.9726537,0.00025846512],"about_ca_topic_score_codex":0.00015180199,"about_ca_topic_score_gemma":0.000031991392,"teacher_disagreement_score":0.68681926,"about_ca_system_score_codex":0.0002891438,"about_ca_system_score_gemma":0.00025842106,"threshold_uncertainty_score":0.92919654},"labels":[],"label_agreement":null},{"id":"W4405774694","doi":"10.1007/s10549-024-07578-2","title":"Steatotic liver disease in metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitor","year":2024,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Health Sciences North; University Health Network; University of Toronto; Regional Municipality of Durham; Princess Margaret Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Proportional hazards model; Cancer; Population; Hormonal therapy; Metastatic breast cancer","score_opus":0.05660394675775749,"score_gpt":0.3702484980170477,"score_spread":0.3136445512592902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405774694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9073315,0.083430275,0.00000660854,0.006478311,0.000043418306,0.0015302288,0.0010200054,0.00010109038,0.000058512916],"genre_scores_gemma":[0.96716356,0.02890796,0.000089254834,0.00008521225,0.00026045844,0.001919279,0.000036261783,0.000087789005,0.0014501975],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974081,0.000125941,0.0002460409,0.00083301635,0.00058908924,0.00079779234],"domain_scores_gemma":[0.99861634,0.00014252147,0.000032651904,0.00032564474,0.00019891789,0.000683918],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001342883,0.00042693017,0.0005166913,0.0004709333,0.00014857548,0.00013159508,0.000067754445,0.00003797389,0.0005606464],"category_scores_gemma":[0.000003868516,0.00026387532,0.00006199751,0.00073305884,0.0004942182,0.00028160147,0.000052226384,0.00029583016,0.000011940769],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018493244,0.0011672182,0.29040882,0.00055851846,0.001270542,0.0049827327,0.0007891967,0.000031523403,0.0009771592,0.00026349677,0.000056922956,0.68100065],"study_design_scores_gemma":[0.013432325,0.0018036806,0.9722588,0.0025742804,0.00027367196,0.0022091593,0.00032649885,0.00073843746,0.0010655778,0.00022351356,0.004648705,0.0004453414],"about_ca_topic_score_codex":0.012434334,"about_ca_topic_score_gemma":0.001957623,"teacher_disagreement_score":0.68184996,"about_ca_system_score_codex":0.0011020766,"about_ca_system_score_gemma":0.00079831283,"threshold_uncertainty_score":0.99998134},"labels":[],"label_agreement":null},{"id":"W4405883638","doi":"10.4103/mdj.mdj_21_24","title":"MIDEC 2024 Abstracts","year":2024,"lang":"fr","type":"article","venue":"Malaysian Dental Journal","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.01127924827418299,"score_gpt":0.2988835253411998,"score_spread":0.2876042770670168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405883638","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24336463,0.6251019,0.002359505,0.02214043,0.069085695,0.00036182156,0.000115299445,0.00018392813,0.03728677],"genre_scores_gemma":[0.8223535,0.0027039798,0.0016236812,0.00080341275,0.017316122,0.0000069537837,0.000008912701,0.0001376374,0.1550458],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971986,0.00007827001,0.0007005163,0.00039302028,0.0006711501,0.0009584354],"domain_scores_gemma":[0.99863017,0.000094073104,0.000130293,0.0002550462,0.0000767773,0.00081363454],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00044881896,0.0003953719,0.000412268,0.00033427653,0.00017272317,0.00053574314,0.00024939343,0.00021484627,0.02075814],"category_scores_gemma":[0.00004449886,0.00036914556,0.00042911636,0.0004375815,0.00030173623,0.00074217207,0.000078989,0.0018211945,0.008182235],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034371827,0.00030223004,0.006007462,0.0010387223,0.0013188513,0.046459448,0.0014319959,0.000882237,0.009875198,0.0018889288,0.037495863,0.89295536],"study_design_scores_gemma":[0.001503199,0.0004205068,0.02315631,0.008274229,0.0006118055,0.13638991,0.0027235178,0.0011496937,0.0027904387,0.003264462,0.8192098,0.0005061334],"about_ca_topic_score_codex":0.000033410462,"about_ca_topic_score_gemma":0.000017409136,"teacher_disagreement_score":0.8924492,"about_ca_system_score_codex":0.0011871285,"about_ca_system_score_gemma":0.00048370252,"threshold_uncertainty_score":0.999876},"labels":[],"label_agreement":null},{"id":"W4406119963","doi":"10.1200/jco.24.00994","title":"Fulvestrant Versus Anastrozole in Endocrine Therapy–Naïve Women With Hormone Receptor–Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Fulvestrant; Anastrozole; Medicine; Hazard ratio; Internal medicine; Oncology; Breast cancer; Gynecology; Cancer; Tamoxifen; Confidence interval","score_opus":0.08268262787253476,"score_gpt":0.4658087781659373,"score_spread":0.3831261502934025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406119963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978991,0.0013414031,0.00015624105,0.016509628,0.0014999287,0.00079760776,0.00003504007,0.000009696137,0.00065949594],"genre_scores_gemma":[0.9929465,0.0031162659,0.00075548305,0.0018785461,0.0010948867,0.000090548056,0.000005797216,0.000020495796,0.000091452705],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99579746,0.0007801879,0.0020678965,0.0003239473,0.0004886742,0.00054184604],"domain_scores_gemma":[0.9956764,0.0023887842,0.0011525092,0.00025699893,0.00031905816,0.00020624741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022700555,0.0002781506,0.0018861458,0.00024990295,0.000047159272,0.000013649537,0.0003268468,0.00017616285,0.00012553077],"category_scores_gemma":[0.00034498455,0.00016897665,0.00023527317,0.00047996262,0.00036816738,0.00024734702,0.00003585274,0.0017468994,0.0000014851593],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62574834,0.0028355848,0.0016990016,0.0000069699286,0.00039605083,0.00056458963,0.0004396322,0.00015222326,0.00067880633,0.00008374909,0.0000799466,0.36731508],"study_design_scores_gemma":[0.7459311,0.055997487,0.17283808,0.00029091063,0.0001297111,0.00025180378,0.0024364681,0.000027741959,0.000112722424,0.00022538935,0.021566845,0.00019175545],"about_ca_topic_score_codex":0.00017510151,"about_ca_topic_score_gemma":0.0004166941,"teacher_disagreement_score":0.36712334,"about_ca_system_score_codex":0.0008818881,"about_ca_system_score_gemma":0.002648023,"threshold_uncertainty_score":0.7589506},"labels":[],"label_agreement":null},{"id":"W4406146832","doi":"10.51731/cjht.25.1055","title":"Capivasertib (Truqap)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fulvestrant; Reimbursement; Medicine; Oncology; Metastatic breast cancer; Regimen; Internal medicine; Anastrozole; Cancer; Breast cancer; Tamoxifen; Political science","score_opus":0.01585888414316502,"score_gpt":0.3169227501187481,"score_spread":0.3010638659755831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406146832","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20674603,0.38522944,0.0054143895,0.39766547,0.0015048463,0.0005820321,0.000019428417,0.00035803436,0.0024803437],"genre_scores_gemma":[0.99391425,0.00031749287,0.0028156003,0.0026007467,0.000011159905,0.000003998662,8.3862426e-7,0.000010236037,0.00032569462],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989451,0.000020734651,0.00044227345,0.00010226759,0.000100339974,0.0003892583],"domain_scores_gemma":[0.9992021,0.000032142558,0.00021893905,0.00026218567,0.0001957329,0.00008890792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027347135,0.000105037376,0.0003867014,0.0008322359,0.00015153899,0.000012461089,0.00021469672,0.00010594918,0.000028169561],"category_scores_gemma":[0.00039159885,0.000086931956,0.0000731662,0.0004513633,0.00023706419,0.00007677359,0.0000123342725,0.0004215844,0.0000052672635],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039650255,0.0000117309855,0.007746908,0.00012868064,0.000066694665,0.00013716365,0.00011099695,0.000007452214,0.00013633164,0.0029691518,0.002604649,0.9860406],"study_design_scores_gemma":[0.001358287,0.00040391827,0.032327767,0.0009915346,0.000028261446,0.00068860356,0.003941304,0.0000044735284,0.00319675,0.016380701,0.9405682,0.0001101627],"about_ca_topic_score_codex":0.0020437376,"about_ca_topic_score_gemma":0.0019775745,"teacher_disagreement_score":0.98593044,"about_ca_system_score_codex":0.00070604467,"about_ca_system_score_gemma":0.0054433537,"threshold_uncertainty_score":0.96562755},"labels":[],"label_agreement":null},{"id":"W4406477227","doi":"10.1016/s0029-7437(05)70966-6","title":"10.1016/s0029-7437(05)70966-6","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Ablative case; Breast cancer; Medicine; Cancer; Oncology; Medical physics; Internal medicine; Radiation therapy","score_opus":0.007350754198806023,"score_gpt":0.2151808666961698,"score_spread":0.20783011249736377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406477227","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007027453,0.00036743155,0.0000072450507,0.0015199045,5.1237566e-7,0.00030095724,0.000015058009,0.00028486786,0.99680126],"genre_scores_gemma":[0.000298454,4.5954613e-7,0.0009154559,0.00033350993,0.00036614892,0.000037416765,0.000018330647,0.000051848867,0.9979784],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989509,0.00001987994,0.00018428941,0.0002758645,0.00023165761,0.00033742256],"domain_scores_gemma":[0.9992218,0.00003346386,0.00002886439,0.0004200749,0.00006032255,0.00023549897],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000068655354,0.00017701065,0.00027434024,0.00007717603,0.000055713903,0.00001332605,0.00012641812,0.00006341528,0.99836403],"category_scores_gemma":[0.00002609906,0.00016107883,0.00007599511,0.00022634481,0.00005631911,0.00009018488,0.000024690207,0.00014481238,0.9933619],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006074897,0.00006536119,3.0861804e-7,0.000012874959,0.00004279306,0.000019828187,0.000040035953,0.000037960377,0.00039582796,9.690623e-7,0.27366722,0.72510934],"study_design_scores_gemma":[0.0010072652,0.00032235807,0.000120146105,0.000064712614,0.000039725535,0.00011964271,0.0000032920652,0.000042830816,0.000536257,0.000023013097,0.9975429,0.00017783354],"about_ca_topic_score_codex":0.000014960555,"about_ca_topic_score_gemma":1.3154919e-7,"teacher_disagreement_score":0.7249315,"about_ca_system_score_codex":0.00009819971,"about_ca_system_score_gemma":0.00005038986,"threshold_uncertainty_score":0.6568604},"labels":[],"label_agreement":null},{"id":"W4406543261","doi":"10.1016/s0029-7437(12)70075-7","title":"10.1016/s0029-7437(12)70075-7","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medical prescription; Metabolism; Pharmacology; Medicine; Chemistry; Internal medicine","score_opus":0.007706351667295777,"score_gpt":0.21330267523682236,"score_spread":0.2055963235695266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406543261","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00067232765,0.00030370345,0.0000078166095,0.0010074931,4.6316273e-7,0.00030239442,0.00001441334,0.00028091372,0.9974105],"genre_scores_gemma":[0.00025331078,4.7013555e-7,0.00086533127,0.00028239263,0.00037500617,0.000037117366,0.000018730954,0.00005246733,0.9981152],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989457,0.000019326173,0.00018461134,0.00027524208,0.00023691621,0.0003381923],"domain_scores_gemma":[0.999228,0.00003304322,0.00002883347,0.00042068472,0.000053794538,0.00023563839],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00007684344,0.00017805718,0.00027209157,0.000078027115,0.00005610633,0.000013589326,0.00012523476,0.000063945066,0.9985614],"category_scores_gemma":[0.000025022116,0.00016262868,0.00007282303,0.00018469727,0.000056784913,0.000088792614,0.00002502306,0.00014723418,0.99311656],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006874215,0.00006620872,5.8809184e-7,0.000013279091,0.000045163724,0.000017170974,0.000037680737,0.000038280887,0.00041709654,7.405902e-7,0.22623628,0.7724401],"study_design_scores_gemma":[0.0010085176,0.0003091643,0.00018482318,0.000065126595,0.000040575072,0.000094605144,0.0000026730565,0.000040464125,0.0005110188,0.000019380002,0.9975435,0.00018016684],"about_ca_topic_score_codex":0.00001607927,"about_ca_topic_score_gemma":2.0863669e-7,"teacher_disagreement_score":0.7722599,"about_ca_system_score_codex":0.00009762751,"about_ca_system_score_gemma":0.00005145018,"threshold_uncertainty_score":0.66318053},"labels":[],"label_agreement":null},{"id":"W4406544084","doi":"10.1016/0960-4634(91)90190-q","title":"10.1016/0960-4634(91)90190-q","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Business; Computer science","score_opus":0.005519162806854488,"score_gpt":0.20136151829313026,"score_spread":0.19584235548627577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406544084","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013761679,0.00032905667,0.0000069508983,0.0012462111,0.0000023357609,0.00030231738,0.000015007912,0.00024130031,0.99648064],"genre_scores_gemma":[0.0005457285,5.030027e-7,0.00070195016,0.00031192598,0.00035920725,0.000035852074,0.000019106,0.00005102527,0.9979747],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989683,0.000019374284,0.0001796302,0.00027037878,0.00023189612,0.00033039952],"domain_scores_gemma":[0.99924,0.00003204454,0.000028016535,0.00041512842,0.000059464874,0.00022538265],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000073428346,0.00017268906,0.00026848158,0.000076143246,0.000055046366,0.00001355977,0.00012251259,0.00006238695,0.99785924],"category_scores_gemma":[0.000023918072,0.00015647424,0.00007390757,0.0002242983,0.00005591599,0.00008818372,0.000024196468,0.00014206338,0.992056],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006355857,0.00006576224,7.1445066e-7,0.000013674238,0.00004457348,0.000021004396,0.000039593637,0.00004593867,0.0005178823,9.058217e-7,0.029685935,0.96892846],"study_design_scores_gemma":[0.000991495,0.0002808383,0.00021367255,0.00006134311,0.00003991533,0.00008793322,0.0000029095397,0.0000396882,0.0005897872,0.00002029553,0.99749666,0.0001754425],"about_ca_topic_score_codex":0.000017328874,"about_ca_topic_score_gemma":1.4308061e-7,"teacher_disagreement_score":0.968753,"about_ca_system_score_codex":0.00009568861,"about_ca_system_score_gemma":0.00005290523,"threshold_uncertainty_score":0.6380834},"labels":[],"label_agreement":null},{"id":"W4406615869","doi":"10.3390/curroncol32010052","title":"Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2− Advanced Breast Cancer","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital; Western University","funders":"","keywords":"Palbociclib; Medicine; Internal medicine; Oncology; Metastatic breast cancer; Breast cancer; Cancer; Proportional hazards model; Exemestane; Progression-free survival; Cohort; Aromatase; Overall survival","score_opus":0.05844413702398454,"score_gpt":0.44538625974114293,"score_spread":0.3869421227171584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406615869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92270684,0.006415101,0.005590154,0.054063886,0.0029274686,0.0048346487,0.00017709596,0.00019974251,0.0030850598],"genre_scores_gemma":[0.9920281,0.0006129648,0.0015559937,0.0016440485,0.0005475066,0.0032378153,0.00003245138,0.000033370332,0.00030773337],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983751,0.0000688198,0.00040229489,0.00047705442,0.00019676595,0.00047997467],"domain_scores_gemma":[0.9987125,0.0004586296,0.00021476788,0.00032164768,0.00022805804,0.00006441838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021711845,0.00026094497,0.00048406987,0.0001875011,0.0001540547,0.000011574893,0.00021806001,0.00007507698,0.000045489727],"category_scores_gemma":[0.00006633165,0.00017192839,0.00007546205,0.00075770303,0.00027779743,0.0001225433,0.000055124645,0.00039212054,0.0000020929797],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003762428,0.00064897863,0.33088544,0.0003823713,0.00008819668,0.000022189395,0.009362566,0.00047702843,0.00034767386,0.0011098757,0.00079698866,0.6521163],"study_design_scores_gemma":[0.0127991615,0.0009016457,0.4263126,0.0026454576,0.00016612309,0.00003724677,0.0069354908,0.00068906357,0.0013399443,0.0009950505,0.5467493,0.00042895347],"about_ca_topic_score_codex":0.00014360268,"about_ca_topic_score_gemma":0.004511948,"teacher_disagreement_score":0.6516873,"about_ca_system_score_codex":0.00094048306,"about_ca_system_score_gemma":0.00047516206,"threshold_uncertainty_score":0.7011036},"labels":[],"label_agreement":null},{"id":"W4406615899","doi":"10.3390/curroncol32010053","title":"Systematic Review and Network Meta-Analysis on Treating Hormone Receptor-Positive Metastatic Breast Cancer After CDK4/6 Inhibitors","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; NOSM University; Health Sciences North; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Oncology; Internal medicine; Hazard ratio; Palbociclib; Fulvestrant; Trastuzumab; Metastatic breast cancer; Estrogen receptor; Breast cancer; Odds ratio; Population; Cancer; Confidence interval","score_opus":0.10560221540387417,"score_gpt":0.44592665900340334,"score_spread":0.3403244435995292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406615899","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[5.698442e-7,0.99179786,0.00012310484,0.000629451,0.00046733383,0.005764959,0.0010190322,0.000067379566,0.0001302909],"genre_scores_gemma":[0.000006487964,0.9874098,0.00036158075,0.0007708821,0.0004037417,0.009960715,0.00038537948,0.00008056169,0.0006208989],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99400264,0.0017740336,0.0020675822,0.0011160997,0.00041601429,0.0006236206],"domain_scores_gemma":[0.9952324,0.0015806978,0.0017490322,0.00083915755,0.0003293922,0.0002693034],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0008854106,0.0011030211,0.018620102,0.0005855756,0.000116566654,0.00002720913,0.00021735806,0.00026477242,0.00057015935],"category_scores_gemma":[0.00021733416,0.0006968626,0.0034253218,0.0020775704,0.00019591162,0.00008271,0.00015671006,0.00094375544,0.000042863878],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006167777,0.0001633752,0.0000033706,0.5977057,0.17106119,0.0000253669,0.00005001394,0.0000027488675,2.3575332e-8,0.000018622604,0.0006017427,0.23030618],"study_design_scores_gemma":[0.00030453183,0.00016777514,0.0000056579743,0.25172558,0.6404555,0.00011511272,0.000014562333,0.000001755495,4.86522e-8,0.000008680151,0.10686446,0.00033638],"about_ca_topic_score_codex":0.000019641877,"about_ca_topic_score_gemma":0.000027336284,"teacher_disagreement_score":0.46939427,"about_ca_system_score_codex":0.0013665273,"about_ca_system_score_gemma":0.00068889325,"threshold_uncertainty_score":0.99954826},"labels":[],"label_agreement":null},{"id":"W4406637964","doi":"10.1016/b978-0-7506-4581-2.50219-x","title":"10.1016/b978-0-7506-4581-2.50219-x","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Political science","score_opus":0.009724017621358738,"score_gpt":0.20477378087947543,"score_spread":0.19504976325811668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406637964","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[7.187507e-7,0.0020443487,0.000004274829,0.0005811235,0.000007730856,0.00073055795,0.00014359465,0.00034914623,0.9961385],"genre_scores_gemma":[0.0000013249088,0.0000013142039,0.00041858703,0.00032944634,0.0011940269,0.00004596608,0.0002015541,0.00029318573,0.9975146],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978371,0.000012897496,0.00044747375,0.00067533256,0.00054018706,0.0004869963],"domain_scores_gemma":[0.9982709,0.000060757837,0.00015793428,0.00094995135,0.00015305023,0.00040737522],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000091005975,0.000640535,0.00092305336,0.00030444094,0.000075478,0.00002469507,0.0002726144,0.00041586236,0.99846107],"category_scores_gemma":[0.000020256342,0.00061845366,0.00028752105,0.00007521844,0.00014945447,0.000079749225,0.00009231179,0.00060472114,0.9947809],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009315114,0.000032106895,1.3476215e-8,0.00005742618,0.00025443124,0.00011889978,0.000022848459,0.000010684495,0.000033529097,0.000055202843,0.017366646,0.9811167],"study_design_scores_gemma":[0.0009772753,0.00044417338,0.0000029861249,0.0006564837,0.00026190834,0.00022280749,6.8327057e-7,0.000004110641,0.000047546946,0.0005097469,0.99627286,0.00059941737],"about_ca_topic_score_codex":0.00001451213,"about_ca_topic_score_gemma":3.6890202e-7,"teacher_disagreement_score":0.98051727,"about_ca_system_score_codex":0.00029856514,"about_ca_system_score_gemma":0.00018888585,"threshold_uncertainty_score":0.9996267},"labels":[],"label_agreement":null},{"id":"W4406638052","doi":"10.1016/b978-0-7506-3993-4.50376-9","title":"10.1016/b978-0-7506-3993-4.50376-9","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.009738726441171856,"score_gpt":0.20472198896618082,"score_spread":0.19498326252500897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406638052","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[6.862457e-7,0.0018366737,0.000004227011,0.00056273036,0.00000782585,0.00074718066,0.00014146633,0.00036159108,0.9963376],"genre_scores_gemma":[0.0000012839248,4.6169347e-7,0.00041862315,0.000324998,0.0011885932,0.00004678198,0.00019880793,0.00029418542,0.9975263],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978253,0.000012918842,0.00044822533,0.0006874959,0.0005387611,0.0004872729],"domain_scores_gemma":[0.9982546,0.0000621999,0.00015856545,0.0009667274,0.00015180287,0.00040610327],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009442182,0.0006407616,0.00091758714,0.00030788901,0.00007596199,0.000024409213,0.00027572285,0.00040991334,0.9985786],"category_scores_gemma":[0.000020960011,0.0006236739,0.00028569845,0.00006618033,0.00015124575,0.00008042574,0.00009267125,0.000606552,0.9955594],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009518588,0.00003181941,1.4427381e-8,0.000047111316,0.00025055607,0.00011955076,0.000020226835,0.0000098641385,0.000033190543,0.00009091864,0.006197967,0.9922469],"study_design_scores_gemma":[0.0010002424,0.0004515156,0.0000035479686,0.000611762,0.00026245738,0.00022236927,6.0783753e-7,0.000003416656,0.00004519345,0.00057027565,0.99622834,0.00060025975],"about_ca_topic_score_codex":0.000013180732,"about_ca_topic_score_gemma":3.3720465e-7,"teacher_disagreement_score":0.99164665,"about_ca_system_score_codex":0.00030242847,"about_ca_system_score_gemma":0.00018841703,"threshold_uncertainty_score":0.99962145},"labels":[],"label_agreement":null},{"id":"W4406638053","doi":"10.1016/b978-0-7506-3993-4.50377-0","title":"10.1016/b978-0-7506-3993-4.50377-0","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Geology","score_opus":0.009737051898730103,"score_gpt":0.20460089069946577,"score_spread":0.19486383880073566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406638053","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[6.741091e-7,0.0018268719,0.000004312399,0.00056574686,0.00000775814,0.00075713627,0.00013642113,0.00036133622,0.99633974],"genre_scores_gemma":[0.0000012615363,4.6508316e-7,0.00041359256,0.00032684568,0.0011988032,0.000046804627,0.00019531959,0.0002939353,0.99752295],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978261,0.000012892095,0.00044774154,0.0006873329,0.00053811254,0.00048783224],"domain_scores_gemma":[0.9982559,0.00006240696,0.000158481,0.0009649447,0.00015169155,0.0004065834],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009423634,0.00064030435,0.00091596844,0.0003063478,0.00007594565,0.000024333134,0.00027538007,0.00040949666,0.9986543],"category_scores_gemma":[0.00002104035,0.00062332535,0.0002860144,0.00006561952,0.00015063216,0.00008034572,0.00009249707,0.00060618087,0.9957335],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093127915,0.000031252537,1.4110241e-8,0.000047120513,0.00024991552,0.000120649805,0.000020065867,0.000009836413,0.00003247039,0.000093377355,0.0059920233,0.992472],"study_design_scores_gemma":[0.0009748459,0.0004477878,0.0000033955919,0.00061105774,0.00026301373,0.0002257363,6.185613e-7,0.0000034151117,0.000046868405,0.00057093694,0.99625254,0.0005997646],"about_ca_topic_score_codex":0.000012859462,"about_ca_topic_score_gemma":3.2975188e-7,"teacher_disagreement_score":0.99187225,"about_ca_system_score_codex":0.00030190797,"about_ca_system_score_gemma":0.00018853616,"threshold_uncertainty_score":0.9996218},"labels":[],"label_agreement":null},{"id":"W4406638082","doi":"10.1016/b978-0-7506-3993-4.50384-8","title":"10.1016/b978-0-7506-3993-4.50384-8","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.009744169745317013,"score_gpt":0.20479457601045817,"score_spread":0.19505040626514114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406638082","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[6.8758266e-7,0.00186205,0.0000043392015,0.0005833568,0.000007735031,0.00074322295,0.00013957384,0.00036087458,0.99629813],"genre_scores_gemma":[0.0000012726655,4.5594686e-7,0.00041135788,0.00031841296,0.0011826118,0.000046730856,0.00019462146,0.0002934496,0.9975511],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978343,0.000012842577,0.00044712803,0.00068504165,0.0005355826,0.00048508545],"domain_scores_gemma":[0.9982588,0.000062692605,0.00015809602,0.00096400536,0.00015129063,0.00040507194],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000093726856,0.00063883467,0.00091527554,0.00030569534,0.000075920114,0.000024298553,0.00027548725,0.00040718203,0.99860173],"category_scores_gemma":[0.000021113814,0.00062147464,0.0002850977,0.00006552253,0.00015155421,0.00008019268,0.00009266424,0.00060495414,0.99551183],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009255825,0.00003171517,1.4518365e-8,0.00004697167,0.0002494508,0.000118481206,0.000020580454,0.000009722865,0.000033322693,0.00008932154,0.0059174765,0.99255735],"study_design_scores_gemma":[0.00096932705,0.00045086013,0.000003402629,0.00060960767,0.0002620976,0.00022186198,6.1809686e-7,0.0000034068564,0.000046438843,0.000549434,0.9962848,0.0005981337],"about_ca_topic_score_codex":0.00001436225,"about_ca_topic_score_gemma":3.6074735e-7,"teacher_disagreement_score":0.9919592,"about_ca_system_score_codex":0.00031491028,"about_ca_system_score_gemma":0.0001942752,"threshold_uncertainty_score":0.99962366},"labels":[],"label_agreement":null},{"id":"W4406638121","doi":"10.1016/b978-0-7506-3993-4.50389-7","title":"10.1016/b978-0-7506-3993-4.50389-7","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.009739361747796091,"score_gpt":0.2047647424902599,"score_spread":0.19502538074246378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406638121","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[6.949207e-7,0.0018643461,0.000004203378,0.00058741594,0.0000075512635,0.00074009167,0.00014033055,0.0003614326,0.99629396],"genre_scores_gemma":[0.0000012886866,4.38668e-7,0.00041820947,0.0003193927,0.0011789886,0.000045804594,0.00019604976,0.0002948743,0.99754494],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978384,0.000012801178,0.0004467237,0.00068422,0.00053411827,0.00048376774],"domain_scores_gemma":[0.9982621,0.000062254156,0.00015810809,0.0009623784,0.00015073702,0.00040441327],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009354736,0.0006375381,0.00091302715,0.00030480835,0.00007596218,0.000024113293,0.00027479968,0.00040639294,0.9985726],"category_scores_gemma":[0.000020967094,0.00062016683,0.00028465904,0.000065282846,0.00015134603,0.00007828532,0.00009258847,0.00060485303,0.9954761],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009271421,0.00003166461,1.4251396e-8,0.000046865018,0.00024879607,0.00011808022,0.000020014497,0.000009838241,0.00003312271,0.00009167623,0.006302653,0.99217016],"study_design_scores_gemma":[0.0009658368,0.0004486861,0.0000034002132,0.0006079013,0.00026183194,0.00022090547,6.226306e-7,0.0000034516474,0.00004607914,0.0005502754,0.9962941,0.00059690815],"about_ca_topic_score_codex":0.0000139832055,"about_ca_topic_score_gemma":3.485355e-7,"teacher_disagreement_score":0.9915732,"about_ca_system_score_codex":0.00030714218,"about_ca_system_score_gemma":0.00019021513,"threshold_uncertainty_score":0.99962497},"labels":[],"label_agreement":null},{"id":"W4406638251","doi":"10.1016/b978-0-7506-3993-4.50380-0","title":"10.1016/b978-0-7506-3993-4.50380-0","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Geology","score_opus":0.009754909090796654,"score_gpt":0.2048086079919144,"score_spread":0.19505369890111773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406638251","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[6.634652e-7,0.0018396949,0.0000046739365,0.0005756042,0.0000075984453,0.0007424091,0.00013680404,0.00036023368,0.99633235],"genre_scores_gemma":[0.0000013226439,4.4918627e-7,0.0004051998,0.0003249309,0.0011824465,0.000046684654,0.00019571511,0.00029325136,0.99755],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99783766,0.000012836856,0.00044646137,0.00068403076,0.0005346388,0.00048438105],"domain_scores_gemma":[0.9982632,0.0000626359,0.00015786718,0.0009622135,0.00014950166,0.0004045768],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000093287556,0.0006381711,0.00091291463,0.00030540518,0.000075818636,0.00002447001,0.00027446006,0.00040650682,0.9985579],"category_scores_gemma":[0.000020941929,0.0006209149,0.00028450537,0.0000654012,0.00015132278,0.000079891324,0.00009226168,0.00060309883,0.9954936],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009257767,0.00003070453,1.3716508e-8,0.000047391208,0.0002457241,0.000120056466,0.000020365533,0.000010503205,0.000033342385,0.00009147537,0.006168459,0.9923062],"study_design_scores_gemma":[0.00096862396,0.00045053865,0.0000032837736,0.00060904375,0.00026175118,0.0002254283,6.0482444e-7,0.0000034929892,0.000045820365,0.0005542407,0.99627966,0.0005975087],"about_ca_topic_score_codex":0.0000140720485,"about_ca_topic_score_gemma":3.4576271e-7,"teacher_disagreement_score":0.9917087,"about_ca_system_score_codex":0.00030619884,"about_ca_system_score_gemma":0.00019347902,"threshold_uncertainty_score":0.9996242},"labels":[],"label_agreement":null},{"id":"W4406638333","doi":"10.1016/b978-0-7506-3993-4.50392-7","title":"10.1016/b978-0-7506-3993-4.50392-7","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.009754147976603973,"score_gpt":0.2048297880740907,"score_spread":0.1950756400974867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406638333","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[6.9331645e-7,0.0018151313,0.0000042237207,0.00054911216,0.000007728036,0.00074415095,0.00014452207,0.00035943143,0.996375],"genre_scores_gemma":[0.000001312457,1.7827176e-7,0.0004207431,0.00031610028,0.0011731047,0.00004683219,0.00019914571,0.0002922115,0.99755037],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99778163,0.000012906294,0.00044705783,0.00068335375,0.00053601706,0.0005390469],"domain_scores_gemma":[0.998231,0.00006202178,0.00015838929,0.0009556609,0.00015141243,0.00044150653],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000103804654,0.0006373394,0.0009108224,0.00030609014,0.0000758973,0.000024155137,0.00027458827,0.00040778297,0.9986048],"category_scores_gemma":[0.000022591264,0.0006203437,0.0002838426,0.00006604347,0.00015097986,0.000078485326,0.00009224607,0.00060510053,0.995713],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009112042,0.000031399977,1.4553302e-8,0.000046654037,0.0002461621,0.00011692178,0.000019586738,0.000009952506,0.000032501142,0.00009159689,0.0020733455,0.9964207],"study_design_scores_gemma":[0.0009638586,0.00043789708,0.0000034478355,0.0006087082,0.00026137786,0.00022120806,6.248116e-7,0.000003484076,0.000044986657,0.0005662174,0.99629056,0.0005976373],"about_ca_topic_score_codex":0.0000128385445,"about_ca_topic_score_gemma":3.4978308e-7,"teacher_disagreement_score":0.995823,"about_ca_system_score_codex":0.00033136734,"about_ca_system_score_gemma":0.00020512805,"threshold_uncertainty_score":0.9996248},"labels":[{"model":"gemma","categories":["insufficient_payload"],"domain":null,"study_design":"not_applicable","genre":"other","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":["insufficient_payload"],"domain":null,"study_design":"design_other","genre":"other","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W4406638416","doi":"10.1016/b978-0-7506-3993-4.50302-2","title":"10.1016/b978-0-7506-3993-4.50302-2","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.010035262614998625,"score_gpt":0.20571502267140734,"score_spread":0.19567976005640872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406638416","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[6.9121353e-7,0.0018520803,0.0000042034862,0.0005536662,0.000007741817,0.0007559517,0.0001407798,0.0003614708,0.9963234],"genre_scores_gemma":[0.0000012436698,4.576682e-7,0.00040756748,0.00031994248,0.0011988891,0.000050172654,0.00020310098,0.00029112917,0.9975275],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978287,0.000013355492,0.00044715716,0.00068602816,0.0005387319,0.00048602984],"domain_scores_gemma":[0.99826103,0.00006213216,0.00015792892,0.0009650238,0.00015117088,0.00040270033],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0000973224,0.0006400978,0.0009190435,0.00030715758,0.000075532975,0.000024292958,0.00027478108,0.0004092032,0.9985842],"category_scores_gemma":[0.000020160836,0.0006231144,0.00028531582,0.00006588925,0.00015112964,0.00007946453,0.000096140124,0.0006048002,0.99551696],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008811998,0.000031588082,1.3311838e-8,0.000046338413,0.00024929253,0.00011558797,0.00002111794,0.0000092506125,0.000033488668,0.000091151414,0.006305826,0.99221516],"study_design_scores_gemma":[0.00093794015,0.00044882475,0.000003152339,0.00061365875,0.00026246556,0.00022184306,7.025515e-7,0.0000033200245,0.000045586392,0.0005756874,0.9962871,0.0005997324],"about_ca_topic_score_codex":0.000013011126,"about_ca_topic_score_gemma":3.2670283e-7,"teacher_disagreement_score":0.9916154,"about_ca_system_score_codex":0.00030583405,"about_ca_system_score_gemma":0.00019110269,"threshold_uncertainty_score":0.99962205},"labels":[],"label_agreement":null},{"id":"W4406638418","doi":"10.1016/b978-0-7506-3993-4.50318-6","title":"10.1016/b978-0-7506-3993-4.50318-6","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.009747319006887129,"score_gpt":0.2048151901831158,"score_spread":0.19506787117622867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406638418","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[6.6089825e-7,0.0018671643,0.0000041927506,0.00053318415,0.000007760722,0.00074336695,0.00013872563,0.0003609286,0.99634403],"genre_scores_gemma":[0.0000012927575,4.3850105e-7,0.0004032249,0.00032383858,0.0012097544,0.000046394896,0.00020427007,0.0002936695,0.9975171],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997834,0.000012919504,0.00044716295,0.00068502023,0.00053612114,0.00048477334],"domain_scores_gemma":[0.9982696,0.00006005134,0.0001583642,0.0009635523,0.00015202416,0.00039636428],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009466036,0.0006386347,0.0009131791,0.00030789146,0.00007751069,0.000024013898,0.00027539334,0.00040598924,0.9985817],"category_scores_gemma":[0.000020365758,0.0006222103,0.0002846363,0.00006453338,0.00015216664,0.000080162245,0.00009251614,0.00059601536,0.9954239],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009036418,0.000031986765,1.347671e-8,0.00004800446,0.00025167473,0.000118465934,0.00002073307,0.000009571834,0.00003335284,0.000098916586,0.0062231664,0.99226046],"study_design_scores_gemma":[0.0009689448,0.00045268063,0.0000032861487,0.00062180124,0.00026109634,0.00021460508,6.165801e-7,0.0000032987336,0.000043947763,0.00059208897,0.996239,0.0005986193],"about_ca_topic_score_codex":0.000012320731,"about_ca_topic_score_gemma":3.307386e-7,"teacher_disagreement_score":0.99166185,"about_ca_system_score_codex":0.0003025875,"about_ca_system_score_gemma":0.00018301109,"threshold_uncertainty_score":0.99962294},"labels":[],"label_agreement":null},{"id":"W4406638439","doi":"10.1016/b978-0-7506-3993-4.50303-4","title":"10.1016/b978-0-7506-3993-4.50303-4","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Materials science","score_opus":0.009908335549606401,"score_gpt":0.20531102729740855,"score_spread":0.19540269174780214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406638439","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[6.2706994e-7,0.0018683732,0.0000052836913,0.00055220386,0.000007911626,0.0007541568,0.0001399132,0.00036512106,0.9963064],"genre_scores_gemma":[0.0000012885369,4.6107556e-7,0.0004081284,0.00032613002,0.0011939774,0.00004733956,0.00020022922,0.00029436682,0.9975281],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997806,0.000013069283,0.00045245021,0.0006934833,0.0005433386,0.00049166905],"domain_scores_gemma":[0.9982402,0.00006288971,0.00015990506,0.00097525405,0.00015137454,0.0004104034],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0000953124,0.000646876,0.00092893594,0.00031147475,0.000076660865,0.000024699273,0.00027822403,0.0004137415,0.9985559],"category_scores_gemma":[0.000020515214,0.0006299462,0.00028875534,0.00006708722,0.00015251034,0.00008119477,0.00009360035,0.0006114255,0.9954944],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093632634,0.000032262018,1.4571554e-8,0.000047620004,0.00025352844,0.00011763241,0.000020633448,0.000011696808,0.00003399537,0.00007926434,0.00599889,0.9924681],"study_design_scores_gemma":[0.0009796664,0.00045491793,0.0000033767874,0.0006157986,0.000265509,0.00022464358,6.3574043e-7,0.0000040680557,0.0000473346,0.00056304433,0.9962348,0.0006062522],"about_ca_topic_score_codex":0.00001280208,"about_ca_topic_score_gemma":3.312091e-7,"teacher_disagreement_score":0.9918619,"about_ca_system_score_codex":0.0003045606,"about_ca_system_score_gemma":0.00018994778,"threshold_uncertainty_score":0.9996152},"labels":[],"label_agreement":null},{"id":"W4406638440","doi":"10.1016/b978-0-7506-3993-4.50320-4","title":"10.1016/b978-0-7506-3993-4.50320-4","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.009768182993261723,"score_gpt":0.2048960227545749,"score_spread":0.1951278397613132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406638440","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[2.8540728e-7,0.0014231735,0.0000033016245,0.00034493383,0.0000065703953,0.00045916616,0.00009371698,0.00036195552,0.9973069],"genre_scores_gemma":[5.3899026e-7,2.92192e-7,0.0003390658,0.00027375112,0.00092515105,0.000037724767,0.00017132799,0.00019784861,0.9980543],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99855715,0.0000069705634,0.0002861809,0.0004569132,0.00037540615,0.0003173526],"domain_scores_gemma":[0.9988541,0.000037296657,0.000099087054,0.00067628187,0.000095374366,0.00023788099],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000058840575,0.000411894,0.000607337,0.00022128531,0.000045788125,0.0000137221205,0.0001897898,0.00027242026,0.9971224],"category_scores_gemma":[0.000013866372,0.00038847,0.00018429321,0.0000437007,0.000088202876,0.00005168254,0.000055153443,0.00041638082,0.989664],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040683942,0.000014991026,6.2565833e-9,0.000024907611,0.0001208268,0.00006368256,0.000009432617,0.000004250233,0.000016907105,0.00007282017,0.01282112,0.98644423],"study_design_scores_gemma":[0.0005446654,0.00022665801,0.0000015093301,0.00030425095,0.00012435677,0.00012810611,2.8336277e-7,0.0000013914557,0.000027882881,0.00064627227,0.99761206,0.00038254526],"about_ca_topic_score_codex":0.0000074280383,"about_ca_topic_score_gemma":2.2703102e-7,"teacher_disagreement_score":0.9860617,"about_ca_system_score_codex":0.00017298826,"about_ca_system_score_gemma":0.00011324681,"threshold_uncertainty_score":0.9998567},"labels":[],"label_agreement":null},{"id":"W4406638442","doi":"10.1016/b978-0-7506-3993-4.50308-3","title":"10.1016/b978-0-7506-3993-4.50308-3","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.009918574652004197,"score_gpt":0.20536571253186714,"score_spread":0.19544713787986295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406638442","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[7.366655e-7,0.0018331271,0.000004179936,0.0005524689,0.000007815104,0.0007472992,0.00013811498,0.00036130458,0.99635494],"genre_scores_gemma":[0.0000013124302,4.5214117e-7,0.00041329348,0.00032033934,0.0011866743,0.000046815105,0.0001985608,0.00029115667,0.99754137],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99782825,0.000012880558,0.00044763213,0.0006866179,0.0005380731,0.00048653342],"domain_scores_gemma":[0.9982578,0.000061974184,0.0001580965,0.0009650297,0.000151316,0.00040577172],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009407464,0.00064035284,0.0009219736,0.00030637503,0.00007577992,0.000024342356,0.000274926,0.00040959663,0.99855155],"category_scores_gemma":[0.000020228721,0.0006232373,0.00028549388,0.00006612709,0.00015078782,0.00008006452,0.00009207462,0.00060547946,0.9955743],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093871844,0.000031952208,1.4633075e-8,0.000047148096,0.00025073465,0.00011884327,0.000021160859,0.000009810768,0.000033785705,0.00009709141,0.0058184094,0.9926323],"study_design_scores_gemma":[0.0009821872,0.0004530665,0.000003465717,0.00061377254,0.0002626361,0.00022306679,6.340499e-7,0.0000035050184,0.000045812176,0.00056566607,0.99624634,0.00059984473],"about_ca_topic_score_codex":0.000013331625,"about_ca_topic_score_gemma":3.435651e-7,"teacher_disagreement_score":0.99203247,"about_ca_system_score_codex":0.00030279317,"about_ca_system_score_gemma":0.0001892606,"threshold_uncertainty_score":0.99962187},"labels":[],"label_agreement":null},{"id":"W4406638444","doi":"10.1016/b978-0-7506-3993-4.50296-x","title":"10.1016/b978-0-7506-3993-4.50296-x","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.00969590450727235,"score_gpt":0.2048184744552951,"score_spread":0.19512256994802277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406638444","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[6.569236e-7,0.0018840571,0.000004390121,0.0005799765,0.000007711916,0.0007444401,0.00014523054,0.00036062713,0.9962729],"genre_scores_gemma":[0.0000012805672,4.7655712e-7,0.0004308643,0.00032700857,0.0012042803,0.00004653713,0.00019590717,0.00029425122,0.9974994],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978252,0.000013169365,0.00044762637,0.0006882347,0.00053847395,0.00048731646],"domain_scores_gemma":[0.99824977,0.00006437258,0.00015765172,0.00097010494,0.00015202245,0.0004060853],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009494911,0.00064057444,0.0009173166,0.0003080617,0.00007585053,0.00002470316,0.00027560783,0.00041007387,0.9985715],"category_scores_gemma":[0.00002168596,0.00062354753,0.00028574583,0.00006608768,0.00015096381,0.0000807307,0.00009097435,0.00061273284,0.99542034],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009272316,0.0000318359,1.4546076e-8,0.000047591722,0.00025116466,0.00011700326,0.000021142054,0.000010306645,0.000033023105,0.0000902901,0.0064578117,0.99201256],"study_design_scores_gemma":[0.00097034813,0.0004514727,0.0000034323143,0.0006114226,0.0002593525,0.00022211044,6.732258e-7,0.00000329695,0.00004401972,0.00056255265,0.9962712,0.0006001441],"about_ca_topic_score_codex":0.00001288382,"about_ca_topic_score_gemma":3.3996497e-7,"teacher_disagreement_score":0.99141246,"about_ca_system_score_codex":0.00030205012,"about_ca_system_score_gemma":0.00018920131,"threshold_uncertainty_score":0.99962157},"labels":[],"label_agreement":null},{"id":"W4406638469","doi":"10.1016/b978-0-7506-3993-4.50311-3","title":"10.1016/b978-0-7506-3993-4.50311-3","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.009754586290943784,"score_gpt":0.20483682293772146,"score_spread":0.19508223664677768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406638469","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[6.366975e-7,0.0018315633,0.0000043953214,0.00056601845,0.000008013631,0.00074563856,0.00014196456,0.00036139195,0.9963404],"genre_scores_gemma":[0.0000012852878,4.64558e-7,0.00041763546,0.000325906,0.0011934438,0.000046673937,0.00019989998,0.0002940647,0.9975206],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978267,0.000012951021,0.00044784334,0.00068700744,0.0005383467,0.0004871772],"domain_scores_gemma":[0.99826163,0.00006107738,0.00015842749,0.0009657616,0.00015159632,0.00040150568],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009472438,0.00064047636,0.0009169982,0.0003073536,0.00007593761,0.00002437907,0.00027527,0.00040956953,0.9985478],"category_scores_gemma":[0.000020596277,0.0006234185,0.00028551224,0.00006615116,0.00015092178,0.000080124046,0.00009283801,0.0006057988,0.99552625],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091806566,0.000031791766,1.3642981e-8,0.000046922356,0.00024696952,0.000119467884,0.000020320353,0.000009675141,0.00003333935,0.00009185775,0.006916362,0.9915652],"study_design_scores_gemma":[0.000976856,0.0004503353,0.0000033501626,0.00061183673,0.0002620103,0.00022243035,6.2714014e-7,0.0000034249597,0.000046591933,0.000566627,0.99625933,0.00059657055],"about_ca_topic_score_codex":0.000012500153,"about_ca_topic_score_gemma":3.2092e-7,"teacher_disagreement_score":0.99096864,"about_ca_system_score_codex":0.00030193824,"about_ca_system_score_gemma":0.0001860192,"threshold_uncertainty_score":0.9996217},"labels":[],"label_agreement":null},{"id":"W4406638553","doi":"10.1016/b978-0-7506-3993-4.50158-8","title":"10.1016/b978-0-7506-3993-4.50158-8","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Philosophy","score_opus":0.009933190577918253,"score_gpt":0.20555356407068867,"score_spread":0.19562037349277042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406638553","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[6.7366517e-7,0.0019116146,0.000004267372,0.0005733269,0.0000078052635,0.0007401979,0.00014777074,0.00036021083,0.99625415],"genre_scores_gemma":[0.0000012531704,4.7667453e-7,0.0004164509,0.00031646137,0.0011880778,0.000043282856,0.00020147295,0.00029317368,0.99753934],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99782664,0.0000129690725,0.0004470966,0.0006843335,0.00054362457,0.00048535338],"domain_scores_gemma":[0.9982528,0.000061438106,0.00015799496,0.000962106,0.00015528889,0.00041039116],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009587156,0.0006372339,0.00091687945,0.00030696447,0.000074127995,0.000024499626,0.0002745116,0.00040859455,0.9984954],"category_scores_gemma":[0.00002123628,0.0006221465,0.00028232922,0.000066495486,0.00015042117,0.00008031658,0.00009256503,0.000604048,0.9953951],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009340706,0.000031825388,1.4355004e-8,0.00004652612,0.0002494742,0.00011976297,0.000019894174,0.000010055049,0.000031553573,0.00009050383,0.0068839416,0.9915824],"study_design_scores_gemma":[0.0009796497,0.0004553068,0.0000033339434,0.00060565484,0.00026197737,0.00022298918,6.3219915e-7,0.000003487614,0.00004492212,0.00057801924,0.99624544,0.00059858436],"about_ca_topic_score_codex":0.0000126911,"about_ca_topic_score_gemma":3.3832836e-7,"teacher_disagreement_score":0.9909838,"about_ca_system_score_codex":0.000307296,"about_ca_system_score_gemma":0.00019197981,"threshold_uncertainty_score":0.999623},"labels":[],"label_agreement":null},{"id":"W4406643716","doi":"10.1016/b978-84-9113-504-3.00113-x","title":"10.1016/b978-84-9113-504-3.00113-x","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.009928572555935626,"score_gpt":0.20465386030195948,"score_spread":0.19472528774602385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406643716","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000001017843,0.0019883753,0.000004525458,0.0005846019,0.000009171529,0.00079941837,0.00015887256,0.00038158448,0.9960724],"genre_scores_gemma":[0.0000016417526,0.0000035289852,0.0004255133,0.0003390779,0.0012843937,0.00005177023,0.00021545819,0.00031393566,0.9973647],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99766123,0.00001437842,0.00048460148,0.00072761416,0.0005769865,0.0005351804],"domain_scores_gemma":[0.99813986,0.000065173605,0.00017393204,0.0010178662,0.0001633648,0.0004398302],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009948244,0.00069668004,0.0009880451,0.0003330067,0.000082011305,0.000026464637,0.00030378558,0.0004463998,0.9983779],"category_scores_gemma":[0.000021368023,0.00067678245,0.0003073159,0.00007318943,0.00016358528,0.000086998494,0.00010203016,0.0006571438,0.9941309],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010375995,0.000037972957,1.3482583e-8,0.00006514174,0.00028539402,0.00012954429,0.000026271511,0.000010268304,0.000045842717,0.000064860076,0.04020439,0.9580927],"study_design_scores_gemma":[0.001081877,0.0004994947,0.0000045062447,0.00067176024,0.00027558563,0.00022630763,8.1487207e-7,0.0000044727217,0.00004570107,0.0006991877,0.9958397,0.00065059215],"about_ca_topic_score_codex":0.000015955562,"about_ca_topic_score_gemma":3.664939e-7,"teacher_disagreement_score":0.9574421,"about_ca_system_score_codex":0.00032567084,"about_ca_system_score_gemma":0.00020396925,"threshold_uncertainty_score":0.99956834},"labels":[],"label_agreement":null},{"id":"W4406643717","doi":"10.1016/b978-84-9113-504-3.00144-x","title":"10.1016/b978-84-9113-504-3.00144-x","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Geology","score_opus":0.009613474358976217,"score_gpt":0.20470766325170212,"score_spread":0.1950941888927259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406643717","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[9.248539e-7,0.0018786807,0.00000573575,0.00059535255,0.000008831372,0.0007924992,0.00014978914,0.000369149,0.996199],"genre_scores_gemma":[0.000001875354,0.0000022892405,0.0003639175,0.0002659435,0.001284339,0.000050935036,0.00020950784,0.00030389312,0.9975173],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99772775,0.000014048154,0.00046981417,0.00070587476,0.00056426745,0.0005182647],"domain_scores_gemma":[0.9981938,0.000065092965,0.00016849196,0.0009898224,0.00015762844,0.00042518548],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009714529,0.00067476305,0.0009633062,0.00031963145,0.000079159836,0.000025864885,0.0002928804,0.0004322504,0.99831176],"category_scores_gemma":[0.000021173699,0.0006543521,0.00029703596,0.00007084537,0.000157765,0.00008301564,0.000097855365,0.0006406954,0.9940708],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009976715,0.000035862406,1.9527507e-8,0.00006368851,0.00027483635,0.00012275654,0.000022388967,0.000011220024,0.000045084085,0.00006544564,0.04547955,0.95288146],"study_design_scores_gemma":[0.0010736302,0.00049085217,0.000004113622,0.0006625436,0.0002648578,0.00021764578,6.297159e-7,0.0000042701618,0.0000492682,0.0006710811,0.9959323,0.00062884355],"about_ca_topic_score_codex":0.000012386919,"about_ca_topic_score_gemma":5.125204e-7,"teacher_disagreement_score":0.9522526,"about_ca_system_score_codex":0.00031699872,"about_ca_system_score_gemma":0.00019645014,"threshold_uncertainty_score":0.99959075},"labels":[],"label_agreement":null},{"id":"W4406643720","doi":"10.1016/b978-84-9113-504-3.00127-x","title":"10.1016/b978-84-9113-504-3.00127-x","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.009817848582310326,"score_gpt":0.20540923312747963,"score_spread":0.1955913845451693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406643720","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[9.465615e-7,0.0020602334,0.000005031292,0.00060574984,0.0000086439095,0.00075608405,0.0001521258,0.00036802844,0.99604315],"genre_scores_gemma":[0.0000020397854,0.0000033788735,0.00041833383,0.00033923742,0.0012965333,0.000046991823,0.0001700163,0.00030395968,0.99741954],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977413,0.000013061528,0.00046620396,0.00069661933,0.0005618445,0.00052098813],"domain_scores_gemma":[0.99822015,0.000062623636,0.00016729714,0.0009604852,0.00016063062,0.00042883723],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000095190175,0.0006730884,0.000954963,0.00031698158,0.00008000143,0.000025517296,0.0002905498,0.00043095363,0.99836993],"category_scores_gemma":[0.000021059408,0.0006533347,0.0002922639,0.00007361221,0.00015646197,0.000086671185,0.00009627837,0.00063418096,0.9939444],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009681072,0.00003589414,1.545313e-8,0.000065030996,0.0002667122,0.00011615183,0.000022578744,0.000009783701,0.00003862634,0.0000650358,0.047455907,0.95095617],"study_design_scores_gemma":[0.0010462546,0.00046674974,0.000004211949,0.00065219606,0.00026776508,0.00022184974,7.4470285e-7,0.000004145473,0.000049165326,0.00069755194,0.9959613,0.00062806014],"about_ca_topic_score_codex":0.0000115363055,"about_ca_topic_score_gemma":3.0704953e-7,"teacher_disagreement_score":0.9503281,"about_ca_system_score_codex":0.00031430088,"about_ca_system_score_gemma":0.00019811343,"threshold_uncertainty_score":0.99959177},"labels":[],"label_agreement":null},{"id":"W4406643723","doi":"10.1016/b978-84-9113-504-3.00107-4","title":"10.1016/b978-84-9113-504-3.00107-4","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.00977756171904481,"score_gpt":0.20470862192292993,"score_spread":0.19493106020388512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406643723","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[8.4821124e-7,0.0019324333,0.0000054754914,0.00059752085,0.000009205948,0.00077774003,0.00014622854,0.0003691438,0.9961614],"genre_scores_gemma":[0.0000014220057,0.000003547317,0.00044675087,0.00033253303,0.0013027602,0.000050043105,0.00020611334,0.00030395074,0.9973529],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99772614,0.0000136663175,0.0004703548,0.00070524774,0.00056732516,0.00051724055],"domain_scores_gemma":[0.9981859,0.00006462315,0.00016903906,0.0009946943,0.00016016887,0.00042561203],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009753538,0.00067359785,0.0009591425,0.00032402083,0.000080261576,0.000026737052,0.00029612635,0.00044019578,0.9983844],"category_scores_gemma":[0.000021781476,0.00065512833,0.0002967784,0.00007175374,0.00015857027,0.00008783068,0.00009914313,0.0006580517,0.9940694],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095789426,0.000035463505,1.5925288e-8,0.0000625035,0.00027139814,0.00012498787,0.000023511837,0.0000100347115,0.00004572024,0.00006164961,0.045030214,0.9533766],"study_design_scores_gemma":[0.0010352171,0.00048075037,0.000003745112,0.0006733497,0.00026695416,0.00022159776,7.334565e-7,0.0000046393648,0.000050629933,0.00071409787,0.99591905,0.0006292532],"about_ca_topic_score_codex":0.000014293884,"about_ca_topic_score_gemma":3.7684111e-7,"teacher_disagreement_score":0.95274734,"about_ca_system_score_codex":0.000317943,"about_ca_system_score_gemma":0.00020110414,"threshold_uncertainty_score":0.99959},"labels":[],"label_agreement":null},{"id":"W4406644229","doi":"10.1016/b978-84-9022-657-5.00127-1","title":"10.1016/b978-84-9022-657-5.00127-1","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.01014701913919605,"score_gpt":0.2062667392643327,"score_spread":0.19611972012513665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406644229","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[8.169939e-7,0.001988029,0.000005272365,0.00078891753,0.00000913427,0.0007804755,0.00016481709,0.00036584484,0.9958967],"genre_scores_gemma":[0.0000016886221,0.000003161085,0.0004215763,0.0004083827,0.0013195162,0.000052039744,0.00018748122,0.0003064767,0.9972997],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977225,0.000014305963,0.000471562,0.000698947,0.00056739734,0.0005252911],"domain_scores_gemma":[0.9981913,0.00006754255,0.00017048998,0.0009865097,0.00015503369,0.00042913077],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009851707,0.00067129545,0.000962098,0.0003215686,0.00008210821,0.000025088315,0.0002935695,0.00042841528,0.99841845],"category_scores_gemma":[0.000021587746,0.00065420946,0.0002965845,0.00007335044,0.00015677558,0.00008820202,0.000100071265,0.0006482991,0.99375236],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009967809,0.000036969563,1.3873579e-8,0.000061368744,0.00026806362,0.00011866909,0.000022936281,0.000010574344,0.00004196845,0.00006424461,0.07025568,0.92812276],"study_design_scores_gemma":[0.0010799365,0.0004641381,0.0000039818856,0.0006089793,0.00026825882,0.0002303213,7.14494e-7,0.0000041034905,0.00004889281,0.0005991375,0.99606156,0.0006299749],"about_ca_topic_score_codex":0.000013092612,"about_ca_topic_score_gemma":3.8261382e-7,"teacher_disagreement_score":0.92749274,"about_ca_system_score_codex":0.00032723902,"about_ca_system_score_gemma":0.00019294322,"threshold_uncertainty_score":0.99959093},"labels":[],"label_agreement":null},{"id":"W4406644417","doi":"10.1016/b978-84-9113-504-3.00112-8","title":"10.1016/b978-84-9113-504-3.00112-8","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.010049375397023214,"score_gpt":0.2045754626382155,"score_spread":0.19452608724119227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406644417","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000010979628,0.0018842696,0.0000051776833,0.00047010538,0.000008770649,0.0007705776,0.00015280554,0.00036870863,0.9963385],"genre_scores_gemma":[0.0000017151017,0.0000032160435,0.00043116673,0.0002689039,0.0012233275,0.00004947493,0.00020799418,0.00030360406,0.9975106],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99773484,0.000013621562,0.00046848998,0.00070744415,0.00055847014,0.0005171259],"domain_scores_gemma":[0.99819267,0.00006280045,0.00016785481,0.0009941567,0.0001574494,0.00042508912],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009593229,0.0006747644,0.0009589041,0.00031938282,0.000078653524,0.000025321591,0.0002926116,0.0004313604,0.9988398],"category_scores_gemma":[0.000020391835,0.0006549277,0.0002966652,0.000070088616,0.00015753723,0.00008388059,0.0000980816,0.00063326914,0.994288],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010314267,0.000037078888,2.4990998e-8,0.000063926025,0.00028187694,0.00012729368,0.000024456982,0.000010165793,0.000043842967,0.00006467764,0.02207972,0.9762355],"study_design_scores_gemma":[0.0010709161,0.00049259845,0.000004492515,0.0006539379,0.00026733015,0.00021757282,7.746181e-7,0.000004355775,0.00005064251,0.0005642,0.99604356,0.00062961876],"about_ca_topic_score_codex":0.000013440981,"about_ca_topic_score_gemma":3.7238374e-7,"teacher_disagreement_score":0.9756059,"about_ca_system_score_codex":0.00031471104,"about_ca_system_score_gemma":0.00019299542,"threshold_uncertainty_score":0.9995902},"labels":[],"label_agreement":null},{"id":"W4406644437","doi":"10.1016/b978-84-9022-657-5.00104-0","title":"10.1016/b978-84-9022-657-5.00104-0","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.00960715524878358,"score_gpt":0.2046695614027373,"score_spread":0.1950624061539537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406644437","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[8.218001e-7,0.0018599387,0.000004547559,0.00077844097,0.00000911957,0.0007807091,0.00016152588,0.0003674622,0.9960374],"genre_scores_gemma":[0.0000014418329,0.0000030877368,0.00043672553,0.0004118156,0.0012953734,0.000051639025,0.00022113982,0.0003069151,0.99727184],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99771655,0.000014121528,0.00047263436,0.00070801604,0.0005676363,0.00052102614],"domain_scores_gemma":[0.9981914,0.000068069414,0.00017094635,0.000986943,0.00015662861,0.0004259982],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0000987785,0.00067236956,0.0009641871,0.00032563228,0.000081541715,0.000025464895,0.00029563945,0.00043629913,0.99840754],"category_scores_gemma":[0.000022336902,0.0006554118,0.00029719487,0.000072813185,0.00015899526,0.0000855847,0.00010028665,0.0006679571,0.99381614],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010547179,0.000037308815,1.6283323e-8,0.00006197887,0.00027080363,0.00012468913,0.000022570046,0.000010258551,0.00004714979,0.00006378684,0.05723346,0.94107324],"study_design_scores_gemma":[0.0010844084,0.000499425,0.000003520071,0.0006146308,0.00026500595,0.00023310307,6.79936e-7,0.000004707823,0.000051794512,0.0006155895,0.99599653,0.0006306047],"about_ca_topic_score_codex":0.0000139589765,"about_ca_topic_score_gemma":4.192799e-7,"teacher_disagreement_score":0.9404427,"about_ca_system_score_codex":0.0003232437,"about_ca_system_score_gemma":0.00019699155,"threshold_uncertainty_score":0.99958974},"labels":[],"label_agreement":null},{"id":"W4406644835","doi":"10.1016/b978-84-9022-657-5.00144-1","title":"10.1016/b978-84-9022-657-5.00144-1","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.00955987355795017,"score_gpt":0.20442602095309084,"score_spread":0.19486614739514066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406644835","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[8.901164e-7,0.0018395184,0.000005335291,0.0007546286,0.000008998843,0.0007967085,0.00016082209,0.00036677447,0.99606633],"genre_scores_gemma":[0.0000017563386,0.000002185128,0.0003521735,0.0003238152,0.001287301,0.000052856147,0.00022829325,0.0003063961,0.9974452],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977194,0.00001451101,0.00047238567,0.0007060762,0.00056765473,0.0005199427],"domain_scores_gemma":[0.99819195,0.000068419904,0.00017115442,0.000990187,0.00015419199,0.0004240745],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009939167,0.00067103474,0.00096484,0.00032277722,0.00008081327,0.000025331377,0.00029435224,0.00042767022,0.99826694],"category_scores_gemma":[0.000021888407,0.0006536396,0.00029717616,0.00007129227,0.00015711946,0.00008476364,0.00009973816,0.00064989645,0.9935413],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010265276,0.000037034857,2.0591338e-8,0.00006306303,0.0002734086,0.0001231403,0.000022763437,0.000011672712,0.0000433065,0.00006262894,0.06682322,0.9315132],"study_design_scores_gemma":[0.0011049462,0.00048945466,0.000004030889,0.0006191149,0.000264343,0.00023000877,6.0775346e-7,0.0000042603333,0.00004811872,0.0005948863,0.9960115,0.00062874774],"about_ca_topic_score_codex":0.000013304301,"about_ca_topic_score_gemma":5.7833046e-7,"teacher_disagreement_score":0.9308845,"about_ca_system_score_codex":0.000325995,"about_ca_system_score_gemma":0.00019476979,"threshold_uncertainty_score":0.99959147},"labels":[],"label_agreement":null},{"id":"W4406644837","doi":"10.1016/b978-84-9022-657-5.00137-4","title":"10.1016/b978-84-9022-657-5.00137-4","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.009651969180761319,"score_gpt":0.20440560683347045,"score_spread":0.19475363765270914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406644837","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[7.463976e-7,0.0019189712,0.0000050485855,0.00080927846,0.000008916464,0.00079032074,0.00015902465,0.0003669063,0.9959408],"genre_scores_gemma":[0.0000013714298,0.000003305881,0.0004495334,0.00042303436,0.0012610281,0.000052982763,0.00022371818,0.00030680044,0.9972782],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997715,0.00001420539,0.00047321725,0.0007074395,0.00056793715,0.00052218727],"domain_scores_gemma":[0.99818647,0.00006700937,0.00017081741,0.0009917775,0.00015769506,0.00042625048],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000097259355,0.00067316426,0.0009653162,0.0003248135,0.00008095641,0.00002565289,0.00029547553,0.0004288992,0.9982974],"category_scores_gemma":[0.000021446775,0.00065550394,0.00029642627,0.00007287771,0.00015693053,0.00008680933,0.000098914774,0.00064903474,0.99360466],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009842785,0.0000370226,1.4743375e-8,0.000062360734,0.0002724751,0.00012127566,0.000022925153,0.0000114851055,0.0000421784,0.00006403083,0.066583134,0.9317988],"study_design_scores_gemma":[0.0010812782,0.00048449144,0.0000032397415,0.00062388997,0.00026298966,0.0002310113,7.053009e-7,0.0000050225094,0.000047980484,0.00068561506,0.99594307,0.00063072523],"about_ca_topic_score_codex":0.000014464402,"about_ca_topic_score_gemma":3.9991698e-7,"teacher_disagreement_score":0.9311681,"about_ca_system_score_codex":0.0003275273,"about_ca_system_score_gemma":0.00019441795,"threshold_uncertainty_score":0.9995896},"labels":[],"label_agreement":null},{"id":"W4406688928","doi":"10.1016/b978-0-08-051980-7.50084-6","title":"10.1016/b978-0-08-051980-7.50084-6","year":2000,"lang":"en","type":"book-chapter","venue":"Time to knit","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.009954322889676343,"score_gpt":0.20572887464292164,"score_spread":0.1957745517532453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406688928","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[6.902445e-7,0.001926151,0.000004578941,0.0005894383,0.000008076198,0.0007507954,0.0001480965,0.0003645997,0.9962076],"genre_scores_gemma":[0.0000011670683,0.000002600367,0.00044015326,0.00031216396,0.0011753009,0.000043456195,0.0002145063,0.00029484575,0.9975158],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978175,0.000012898424,0.00044515586,0.00068244484,0.00054627756,0.0004957276],"domain_scores_gemma":[0.9982569,0.00006033674,0.0001563018,0.0009566267,0.00015138798,0.0004184048],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00008856741,0.00065340527,0.0009392156,0.00030971036,0.00007759818,0.000024972946,0.0002749942,0.0004201316,0.998405],"category_scores_gemma":[0.000019945623,0.0006313003,0.00029266434,0.00006555726,0.00015054908,0.00008251902,0.00009480874,0.00060235115,0.99597967],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00097585877,0.000031990872,1.1754138e-8,0.00006110123,0.00025410738,0.00012018131,0.00002184777,0.000010903288,0.000040219464,0.00006867242,0.039477956,0.95893717],"study_design_scores_gemma":[0.0010315444,0.00043629363,0.0000025457925,0.00063715864,0.00025629744,0.00024111818,6.276247e-7,0.0000045467596,0.000051315877,0.0005479188,0.9961885,0.0006021233],"about_ca_topic_score_codex":0.000008912055,"about_ca_topic_score_gemma":2.631647e-7,"teacher_disagreement_score":0.95833504,"about_ca_system_score_codex":0.00031284738,"about_ca_system_score_gemma":0.000184114,"threshold_uncertainty_score":0.9996138},"labels":[],"label_agreement":null},{"id":"W4406743944","doi":"10.17615/2k59-eh95","title":"Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer","year":2025,"lang":"en","type":"article","venue":"UNC Libraries","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Placebo; Internal medicine; Alliance; Breast cancer; Medicine; Oncology; Gastroenterology; Cancer; Political science; Pathology","score_opus":0.006502200101560952,"score_gpt":0.2442641934197829,"score_spread":0.23776199331822195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406743944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96190727,0.0037004866,0.00026852623,0.024965994,0.00051485497,0.0021883629,0.00056045054,0.00029220487,0.0056018275],"genre_scores_gemma":[0.981924,0.00005057554,0.008046269,0.0051002563,0.00024481595,0.00035234116,0.0002182517,0.00009901603,0.003964498],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978064,0.000101556434,0.00043619555,0.0006413367,0.00043215483,0.0005823745],"domain_scores_gemma":[0.9985834,0.0002783229,0.00018783905,0.00050421304,0.0002904981,0.00015572795],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000078514204,0.0004307937,0.0006546574,0.00020305767,0.00013971479,0.000087250024,0.00026302668,0.00014022815,0.00035123213],"category_scores_gemma":[0.00007064802,0.00034777133,0.00006004907,0.00071571005,0.00047516995,0.0008056855,0.00013913304,0.00043591842,0.000023715857],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0150494175,0.0006624464,0.9491156,0.0002743315,0.00047590825,0.00007515244,0.0025610272,0.0001413261,0.00018934246,0.010645287,0.0037255494,0.017084613],"study_design_scores_gemma":[0.008837453,0.00035336206,0.976176,0.002253498,0.00010212015,0.000013814744,0.0008825122,0.0000080278705,0.0050356826,0.0032967788,0.0026390718,0.00040164244],"about_ca_topic_score_codex":0.00047516896,"about_ca_topic_score_gemma":0.0006050194,"teacher_disagreement_score":0.027060438,"about_ca_system_score_codex":0.0003459167,"about_ca_system_score_gemma":0.0012356002,"threshold_uncertainty_score":0.9998974},"labels":[],"label_agreement":null},{"id":"W4406778471","doi":"10.1007/s10549-024-07580-8","title":"A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancer","year":2025,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Novartis (Canada); Kingston Health Sciences Centre; McGill University Health Centre; Jewish General Hospital; Ottawa Hospital; Saskatchewan Cancer Agency; Ottawa Regional Cancer Foundation; Windsor Regional Hospital; Western University; Grand River Hospital; Centre hospitalier universitaire de Québec","funders":"Novartis Pharmaceuticals Canada","keywords":"Medicine; Observational study; Oncology; Targeted therapy; Survival analysis; Internal medicine; Prospective cohort study; Endocrine system; Cancer; Hormone","score_opus":0.08490122213785031,"score_gpt":0.4171629806915637,"score_spread":0.3322617585537134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406778471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96610373,0.0023938345,0.0000073533365,0.015440306,0.0000932547,0.014291837,0.0015332215,0.000042701467,0.00009377361],"genre_scores_gemma":[0.95485324,0.019991059,0.00010693063,0.00023198679,0.00013962697,0.022624794,0.00016375187,0.00006367232,0.0018249502],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99648744,0.0005747041,0.00049266464,0.00092671847,0.0005833772,0.00093510683],"domain_scores_gemma":[0.99722356,0.0007771224,0.0001835978,0.0005832365,0.0009763938,0.0002560744],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033834734,0.00066014647,0.0007546847,0.0003330201,0.0012998533,0.00023446724,0.00019529143,0.000059102647,0.000047207614],"category_scores_gemma":[0.000016151766,0.000278032,0.000121233155,0.0010204907,0.00076257566,0.00029155315,0.000027433747,0.00023222173,6.150283e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020574294,0.0060974085,0.8079804,0.000012224087,0.0020514978,0.000024908708,0.0035604776,0.00006744872,0.000048986567,0.00020674206,0.000010148993,0.15936543],"study_design_scores_gemma":[0.09159211,0.0041411095,0.89909506,0.00018497498,0.0001242882,0.000020782692,0.0018909486,0.00033067606,0.00028444204,0.00019044333,0.0019171963,0.00022799562],"about_ca_topic_score_codex":0.50685304,"about_ca_topic_score_gemma":0.6543381,"teacher_disagreement_score":0.15913744,"about_ca_system_score_codex":0.006997347,"about_ca_system_score_gemma":0.0020479034,"threshold_uncertainty_score":0.99996716},"labels":[],"label_agreement":null},{"id":"W4406915772","doi":"10.1016/b978-0-443-24838-2.00011-2","title":"Understanding of chemotherapeutic resistance: With special reference to breast cancer","year":2025,"lang":"en","type":"book-chapter","venue":"Elsevier eBooks","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Chemotherapeutic drugs; Breast cancer; Medicine; Oncology; Cancer; Internal medicine","score_opus":0.05015220519122143,"score_gpt":0.29138843349262933,"score_spread":0.2412362283014079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406915772","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026221069,0.0013425376,0.00018278252,0.00091265154,0.00019650183,0.0009567898,0.00028692337,0.00006375932,0.9960318],"genre_scores_gemma":[0.0037280032,0.00019159433,0.0011551338,0.001188006,0.0009032278,0.00006317305,0.000013944401,0.0001248624,0.99263203],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979822,0.000012850351,0.00046571853,0.0006062959,0.0005728513,0.00036008054],"domain_scores_gemma":[0.9984967,0.000052054547,0.00031348033,0.0006922854,0.00026803842,0.00017742044],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000094341114,0.00052165077,0.0010256604,0.0003005158,0.000080317324,0.00001550045,0.00021707483,0.00026331987,0.0009985775],"category_scores_gemma":[0.00000418134,0.00043518242,0.00014372483,0.00006397971,0.00030010162,0.000034166926,0.00006694586,0.0005136231,0.000015372398],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042414307,0.00002049404,0.00004968438,0.0011253379,0.000885613,0.00003828142,0.0005334424,0.0000024750648,0.00041089684,0.037585516,0.00028742306,0.9548194],"study_design_scores_gemma":[0.0015898974,0.0001499582,0.00024250487,0.01099133,0.00055480486,0.000050293358,0.00007763722,3.494526e-7,0.00036118273,0.009021046,0.97645736,0.00050364126],"about_ca_topic_score_codex":0.0000020039365,"about_ca_topic_score_gemma":0.0003087246,"teacher_disagreement_score":0.97616994,"about_ca_system_score_codex":0.0012655549,"about_ca_system_score_gemma":0.0008208544,"threshold_uncertainty_score":0.99991465},"labels":[],"label_agreement":null},{"id":"W4407266958","doi":"10.51731/cjht.2025.1072","title":"Abemaciclib (Verzenio)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Oncology; Breast cancer; Internal medicine; Disease; Adjuvant; Human Epidermal Growth Factor Receptor 2; Drug; Cancer; Family medicine; Oestrogen receptor; Gynecology; Pharmacology; Political science; Health care","score_opus":0.016496647619343496,"score_gpt":0.3269568899253435,"score_spread":0.310460242306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407266958","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12795791,0.4636574,0.0074591762,0.3940198,0.0017579932,0.00063973357,0.000022099617,0.00042678817,0.004059053],"genre_scores_gemma":[0.99405897,0.00037936613,0.002592132,0.0025298425,0.000011537714,0.0000039583256,7.704302e-7,0.000010542638,0.0004128648],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989321,0.000020942773,0.0004509282,0.00010388173,0.00010431762,0.00038778034],"domain_scores_gemma":[0.99920183,0.00003493607,0.00023344156,0.00025499234,0.0001905836,0.000084216066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030162235,0.000105336345,0.0003969745,0.0008340875,0.00014908667,0.000013367962,0.00021908205,0.00010872307,0.000033674838],"category_scores_gemma":[0.00036846515,0.0000875104,0.0000772673,0.00048945664,0.00024571596,0.00008319933,0.000013396245,0.00043436498,0.000006045503],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039032348,0.000009874781,0.008006866,0.00012666942,0.00006464873,0.00012047795,0.00009726664,0.0000060024977,0.00009741568,0.0035743373,0.0028943222,0.98496306],"study_design_scores_gemma":[0.0012163002,0.00035162878,0.022428978,0.0009090069,0.00002591852,0.00069807743,0.0028233496,0.000004327627,0.002162296,0.017970031,0.9513083,0.00010179685],"about_ca_topic_score_codex":0.0009394843,"about_ca_topic_score_gemma":0.0009095156,"teacher_disagreement_score":0.9848613,"about_ca_system_score_codex":0.0006645732,"about_ca_system_score_gemma":0.0049113138,"threshold_uncertainty_score":0.871246},"labels":[],"label_agreement":null},{"id":"W4407393534","doi":"10.1016/j.annonc.2025.01.009","title":"VP1-2025: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Final overall survival (OS) from the phase III TROPION-Breast01 trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis; Pfizer","keywords":"Medicine; Metastatic breast cancer; Chemotherapy; Oncology; Breast cancer; Internal medicine; Hormone receptor; Cancer; HER2 negative; Mammary gland","score_opus":0.0593424706167068,"score_gpt":0.39717629210244715,"score_spread":0.33783382148574037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407393534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9562943,0.003057479,0.0003345624,0.034593422,0.0005614388,0.0031345778,0.0011128363,0.000090726986,0.00082065235],"genre_scores_gemma":[0.9812277,0.006471612,0.0013372825,0.006195905,0.0005680977,0.0008319481,0.00039883278,0.000105160696,0.0028634844],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954457,0.0009889703,0.0012404973,0.0009207588,0.00048773768,0.00091629516],"domain_scores_gemma":[0.9962773,0.0014819285,0.00063178374,0.0007826153,0.0006002907,0.00022610032],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00065568753,0.00064858585,0.0020342658,0.0002749673,0.00018665279,0.000036358862,0.0005446753,0.00021324445,0.0028085562],"category_scores_gemma":[0.00025412597,0.0004574171,0.00029350907,0.001010145,0.0006332976,0.00033463322,0.00014367337,0.0007715566,0.000019980685],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6060981,0.00575943,0.0036125523,0.000115381445,0.0033433188,0.00030997305,0.0025945723,0.000106732106,0.0063042217,0.0003287418,0.011513049,0.35991395],"study_design_scores_gemma":[0.7029072,0.020715771,0.098038,0.0023997729,0.0015012175,0.0003500876,0.0037012915,0.0005402474,0.037069324,0.003379797,0.12777662,0.001620676],"about_ca_topic_score_codex":0.03199148,"about_ca_topic_score_gemma":0.0064133657,"teacher_disagreement_score":0.35829327,"about_ca_system_score_codex":0.00065398886,"about_ca_system_score_gemma":0.0021988736,"threshold_uncertainty_score":0.99978775},"labels":[],"label_agreement":null},{"id":"W4408028458","doi":"10.1158/1078-0432.ccr-24-1724","title":"Health-Related Quality of Life in Patients with HR+/HER2− Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Aromatase inhibitor; Breast cancer; Quality of life (healthcare); Hospital Anxiety and Depression Scale; Internal medicine; Oncology; Cancer; Clinical trial; Anxiety; Tamoxifen; Psychiatry","score_opus":0.11877911940044678,"score_gpt":0.47198029307840106,"score_spread":0.3532011736779543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408028458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97782195,0.0017716669,0.000008198162,0.012357678,0.00025346427,0.0031713853,0.004459212,0.000059491915,0.00009692985],"genre_scores_gemma":[0.9974611,0.00020017389,0.00008052467,0.00073536794,0.00036221455,0.0004711635,0.00033920328,0.000056659563,0.00029362613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99232477,0.0018652246,0.0023432795,0.0010399764,0.0015868428,0.0008399232],"domain_scores_gemma":[0.9937427,0.0030145242,0.0006827438,0.0012143259,0.0009054736,0.00044020853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035497549,0.0003464304,0.0015551362,0.00022976955,0.0002008537,0.00004306764,0.0004918992,0.00028911678,0.000115321396],"category_scores_gemma":[0.0010380044,0.00020688325,0.00015881406,0.0016926943,0.0016497703,0.00019559271,0.00021088263,0.0019656743,0.000010481474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4674968,0.0008300962,0.51529956,0.00009110942,0.0004292468,0.000011332225,0.00043244596,0.000037540703,0.00000989125,0.00001258451,0.0008103351,0.014539063],"study_design_scores_gemma":[0.19122727,0.0021981162,0.8036841,0.0019109849,0.000048843554,8.1271946e-7,0.00025728828,0.00002197571,0.000035981313,0.000051100917,0.0003878143,0.00017571115],"about_ca_topic_score_codex":0.10922929,"about_ca_topic_score_gemma":0.019960009,"teacher_disagreement_score":0.28838456,"about_ca_system_score_codex":0.0009235072,"about_ca_system_score_gemma":0.004840992,"threshold_uncertainty_score":0.9979232},"labels":[],"label_agreement":null},{"id":"W4408042402","doi":"10.1080/14796694.2025.2459548","title":"CAMBRIA-1 &amp; CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2– early breast cancer","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Endocrine system; Metastatic breast cancer; Cancer; Gynecology; Hormone","score_opus":0.04278605245297019,"score_gpt":0.4233400671943058,"score_spread":0.3805540147413356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408042402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9241165,0.017439604,0.0010003517,0.036373325,0.010738851,0.0029482192,0.0011843113,0.00030543967,0.0058933822],"genre_scores_gemma":[0.9710181,0.008103689,0.0026201913,0.0038113412,0.006975313,0.0011263125,0.00022730544,0.0001452662,0.0059724892],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99636656,0.00063330424,0.0010458226,0.0007424962,0.00038575404,0.0008260715],"domain_scores_gemma":[0.9977984,0.00065019017,0.0003586788,0.00065273116,0.00030835008,0.00023163689],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009913598,0.0005120931,0.0020524699,0.00042303148,0.000120037475,0.00002792011,0.00027332944,0.00038175224,0.0014414983],"category_scores_gemma":[0.00016684539,0.0004160871,0.00029868644,0.0007556111,0.0002560235,0.00015885063,0.00006106567,0.0008548122,0.000024123783],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24911979,0.00086931785,0.0017562557,0.00008435282,0.0010492832,0.00048329917,0.0011593836,0.00002423236,0.015002175,0.0012264473,0.00643661,0.7227889],"study_design_scores_gemma":[0.16797557,0.0024684311,0.018373948,0.00023890182,0.00030316124,0.00023192746,0.00080305245,0.0000089532905,0.0013482746,0.00016241096,0.8076933,0.0003920927],"about_ca_topic_score_codex":0.00303327,"about_ca_topic_score_gemma":0.007771135,"teacher_disagreement_score":0.80125666,"about_ca_system_score_codex":0.0017750175,"about_ca_system_score_gemma":0.0020919605,"threshold_uncertainty_score":0.9998291},"labels":[],"label_agreement":null},{"id":"W4408295760","doi":"10.3389/fonc.2025.1530391","title":"Real-world effectiveness of CDK4/6i in first-line treatment of HR+/HER2− advanced/metastatic breast cancer: updated systematic review","year":2025,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Palbociclib; Medicine; Metastatic breast cancer; Oncology; Internal medicine; Clinical trial; Progression-free survival; Breast cancer; Cancer; Overall survival","score_opus":0.023078108348173875,"score_gpt":0.3946680097727225,"score_spread":0.3715899014245486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408295760","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000017040757,0.9866224,0.00033992218,0.0001470202,0.0010483592,0.0108264955,0.0005681356,0.000036919286,0.00039368606],"genre_scores_gemma":[0.000041899126,0.9900947,0.0033197238,0.00005559066,0.000047749207,0.005303741,0.00036449046,0.00009259739,0.0006794709],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9935828,0.0018344177,0.0028965017,0.0008071465,0.00031834745,0.0005607798],"domain_scores_gemma":[0.995264,0.0013001428,0.0020338797,0.0010311621,0.00024887823,0.00012194048],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.00092171435,0.00085575326,0.014692274,0.0014710878,0.000025583775,0.000002744364,0.00039783499,0.00032403375,0.00007849355],"category_scores_gemma":[0.0002139021,0.0006536429,0.0007222381,0.002551504,0.00029298002,0.0000850494,0.000077349854,0.00042508266,0.0000033131919],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056847424,0.0007451184,0.00036914088,0.6314984,0.0010424107,0.00012581899,0.000047050034,0.000040947692,6.632499e-7,0.000020988831,0.0000915994,0.3654494],"study_design_scores_gemma":[0.004962783,0.0010809524,0.00021011852,0.9006593,0.0077946335,0.00013814174,0.000052660944,0.000014002758,0.000008543341,0.00012959748,0.08456596,0.00038327381],"about_ca_topic_score_codex":0.00070529245,"about_ca_topic_score_gemma":0.0010394137,"teacher_disagreement_score":0.36506614,"about_ca_system_score_codex":0.0073761665,"about_ca_system_score_gemma":0.0024442596,"threshold_uncertainty_score":0.9999356},"labels":[],"label_agreement":null},{"id":"W4408343784","doi":"10.3390/curroncol32030161","title":"Real-Life Efficacy of Palbociclib and Ribociclib in Advanced Breast Cancer","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Palbociclib; Fulvestrant; Medicine; Letrozole; Metastatic breast cancer; Internal medicine; Oncology; Progression-free survival; Breast cancer; Cancer; Population; Overall survival; Estrogen receptor; Tamoxifen","score_opus":0.05340340222968545,"score_gpt":0.4452551598341567,"score_spread":0.3918517576044713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408343784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98314714,0.010238964,0.00013725461,0.003770179,0.0007718526,0.00048938656,0.00003947681,0.000048593745,0.0013571635],"genre_scores_gemma":[0.99461293,0.004320359,0.0003626404,0.00028394524,0.00011984269,0.00011367168,0.0000124929775,0.000018000399,0.0001561421],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99875206,0.00007168866,0.00041996854,0.0003405587,0.00011776605,0.0002979462],"domain_scores_gemma":[0.99913764,0.00022485682,0.00015221335,0.00024351952,0.00012214448,0.000119612094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013745538,0.00017031239,0.0006207582,0.00021259788,0.000029366764,0.0000028116094,0.00009344061,0.000113423936,0.00010725524],"category_scores_gemma":[0.000103801794,0.00015437651,0.00006117939,0.00039991704,0.00026735372,0.00007012205,0.00008180184,0.00028944865,0.0000027784752],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021854572,0.0005928513,0.34157553,0.00033373374,0.00007065082,0.00000870849,0.00046131702,0.000031777497,0.004391369,0.0014372283,0.00017930499,0.64873207],"study_design_scores_gemma":[0.011706023,0.00018341023,0.94699305,0.0006643148,0.00008730658,0.000022760043,0.00030188588,0.00009956079,0.00053867593,0.00044300273,0.038826503,0.00013352439],"about_ca_topic_score_codex":0.000099237426,"about_ca_topic_score_gemma":0.00012880524,"teacher_disagreement_score":0.64859855,"about_ca_system_score_codex":0.0003371616,"about_ca_system_score_gemma":0.0005669882,"threshold_uncertainty_score":0.6295292},"labels":[],"label_agreement":null},{"id":"W4408531295","doi":"10.3390/curroncol32030169","title":"Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2− Metastatic Breast Cancer","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; Servier; Seagen; Clovis Oncology; Eisai; Jazz Pharmaceuticals; National Cancer Institute; Baxalta; F. Hoffmann-La Roche; Amgen; Ariad Pharmaceuticals; Gilead Sciences; Daiichi Sankyo Europe; Bayer HealthCare; Sanofi; Pfizer; Myriad Genetics; Eli Lilly and Company; AstraZeneca; Queen Mary University of London","keywords":"Medicine; Breast cancer; Internal medicine; Metastatic breast cancer; Twist; Cancer; Adverse effect; Oncology; Chemotherapy; Randomization; Population; Quality of life (healthcare); Clinical trial; Surgery","score_opus":0.028743316367622486,"score_gpt":0.3872256807176728,"score_spread":0.3584823643500503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408531295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944617,0.0021200008,0.00073545385,0.001028009,0.00019807754,0.0009342127,0.00019739704,0.000046608857,0.00027850468],"genre_scores_gemma":[0.99842334,0.0003127265,0.00032315202,0.00033666033,0.000028298433,0.00024350367,0.00016127163,0.000026801115,0.0001442254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983054,0.000116572955,0.000527078,0.00043652527,0.00023722538,0.00037721902],"domain_scores_gemma":[0.9987917,0.000098923636,0.00030178585,0.00038659925,0.00032225816,0.000098739794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012476495,0.00027190032,0.0012221191,0.0007689059,0.00003071925,0.0000057771094,0.00014745785,0.000077233904,0.00038588844],"category_scores_gemma":[0.00002168952,0.00020962936,0.0001533173,0.0023185858,0.0002507523,0.00007497844,0.000029441233,0.00024320428,0.0000020028233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039791744,0.0015744636,0.6928317,0.00019563593,0.001988556,0.0000062372605,0.0005130377,0.00016626563,0.00007881559,0.00005968297,0.000065906956,0.2985405],"study_design_scores_gemma":[0.012197401,0.0006529101,0.9719829,0.00041431907,0.0026151906,0.000004717856,0.000113104914,0.0003864038,0.0001968121,0.0000475948,0.011207828,0.00018082031],"about_ca_topic_score_codex":0.00048273656,"about_ca_topic_score_gemma":0.0016367885,"teacher_disagreement_score":0.2983597,"about_ca_system_score_codex":0.0012854327,"about_ca_system_score_gemma":0.0005126355,"threshold_uncertainty_score":0.85484374},"labels":[],"label_agreement":null},{"id":"W4408562453","doi":"10.1016/j.esmoop.2025.104497","title":"Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"AstraZeneca; Les Laboratories Pierre Fabre; Seagen; Gilead Sciences; Pfizer; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Palbociclib; Letrozole; Medicine; Gynecology; Internal medicine; Cancer; Breast cancer","score_opus":0.03697220638522724,"score_gpt":0.3806589555226792,"score_spread":0.34368674913745195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408562453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99126744,0.00039805242,0.000035780908,0.0012968378,0.00083464244,0.0033888437,0.000032843916,0.000023947247,0.0027216088],"genre_scores_gemma":[0.998422,0.00001025448,0.00008571924,0.00040611255,0.000023981585,0.00009675949,0.000022728798,0.000021055828,0.00091136695],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968249,0.00078476925,0.0013960908,0.0003024139,0.00046432283,0.0002274587],"domain_scores_gemma":[0.9969903,0.0005353067,0.0013107276,0.00092222996,0.00015790612,0.00008350274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013825761,0.00019760036,0.0012869876,0.0000923254,0.00006792599,0.000005691078,0.00037765072,0.00011320442,0.00012903023],"category_scores_gemma":[0.0012921138,0.000129504,0.00028252404,0.0005304447,0.00019707649,0.00006799877,0.00021733598,0.00024766446,0.000002026898],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7214604,0.0014862047,0.039184857,0.0021193316,0.003079347,0.000011285861,0.0035100586,0.00016717798,0.009352431,0.0031382015,0.0018105184,0.2146802],"study_design_scores_gemma":[0.41242823,0.012531812,0.38027483,0.002818799,0.00045857308,0.000007424655,0.0005975538,0.000052451454,0.18633817,0.0014804115,0.0026571758,0.0003545658],"about_ca_topic_score_codex":0.004503536,"about_ca_topic_score_gemma":0.00016310133,"teacher_disagreement_score":0.34108996,"about_ca_system_score_codex":0.000149929,"about_ca_system_score_gemma":0.0007553517,"threshold_uncertainty_score":0.68080294},"labels":[],"label_agreement":null},{"id":"W4408682588","doi":"10.1177/17588359251326710","title":"Clinician’s guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research; Novartis Pharmaceuticals Canada; Genentech; Astellas Pharma; Seagen; University of Toronto; Genomic Health; F. Hoffmann-La Roche; Purdue University; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Novartis; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Adverse effect; Discontinuation; Breast cancer; Adjuvant; Oncology; Clinical trial; Disease; Internal medicine; Cancer; Intensive care medicine; Quality of life (healthcare); Metastatic breast cancer","score_opus":0.05930661329680937,"score_gpt":0.42576301221026475,"score_spread":0.3664563989134554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408682588","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005392155,0.9938533,0.00007988824,0.0015961966,0.000977689,0.0024041072,0.00005455545,0.00003956714,0.0004555217],"genre_scores_gemma":[0.000687691,0.9916304,0.0002888541,0.0058110515,0.00035586715,0.0009114409,0.000031736952,0.00008998815,0.0001930071],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99452984,0.00094681873,0.0019262871,0.000813352,0.0011423,0.00064142357],"domain_scores_gemma":[0.9936411,0.0041940575,0.0009125696,0.0008340865,0.0002154743,0.00020275358],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004990231,0.0007259228,0.0036074363,0.0005865451,0.000053137246,0.000008199877,0.0006364249,0.0008811424,0.0003737802],"category_scores_gemma":[0.00037127014,0.0003882208,0.00029392185,0.0012620233,0.0011783872,0.00021616924,0.00014727538,0.0019451429,0.000009560161],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001577558,0.0009730632,0.002369007,0.0019310003,0.00024803422,0.000081761405,0.00035408436,0.000011029917,7.448667e-8,0.00033294817,0.00006504626,0.99205637],"study_design_scores_gemma":[0.0038256499,0.001179428,0.002106447,0.04917484,0.00025963358,0.00002052343,0.00006124278,0.0000048397987,9.0121745e-7,0.00016762664,0.9428617,0.0003372164],"about_ca_topic_score_codex":0.0001601554,"about_ca_topic_score_gemma":0.0005527445,"teacher_disagreement_score":0.9917192,"about_ca_system_score_codex":0.0013548278,"about_ca_system_score_gemma":0.0029006836,"threshold_uncertainty_score":0.99985695},"labels":[],"label_agreement":null},{"id":"W4408803504","doi":"10.1016/j.annonc.2025.03.010","title":"Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2− breast cancer and residual disease after neoadjuvant chemotherapy","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"Gilead Sciences; Novartis","keywords":"Medicine; Breast cancer; Chemotherapy; Oncology; Palbociclib; Internal medicine; Cancer; Placebo; Gynecology; Pathology; Metastatic breast cancer","score_opus":0.052464791902858084,"score_gpt":0.3622241662839321,"score_spread":0.30975937438107404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408803504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96250653,0.00065634283,0.00004191774,0.03239397,0.00054347346,0.0013862124,0.0023736833,0.000025889596,0.000071976065],"genre_scores_gemma":[0.99362606,0.00035833658,0.0015185653,0.002995033,0.00066831487,0.00040122194,0.00019816046,0.000036485148,0.0001978264],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99832517,0.00017251467,0.00045626203,0.00045008873,0.00025450022,0.00034148386],"domain_scores_gemma":[0.9970931,0.0016442505,0.00038012554,0.00035174756,0.00037253127,0.00015824389],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036704002,0.00024051231,0.0005562315,0.0000551279,0.00012896389,0.000014986124,0.00014413543,0.00011881427,0.000035772646],"category_scores_gemma":[0.00047347386,0.00015841884,0.00007716071,0.00015587609,0.0004536812,0.00009868414,0.000063122156,0.0002270214,9.0009684e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77822053,0.00031041657,0.0748503,0.000036988484,0.00054265367,0.000007338609,0.0006625138,0.000035981353,0.000025717432,0.000058470916,0.0014630076,0.14378606],"study_design_scores_gemma":[0.24615195,0.0034102874,0.73736936,0.0003013081,0.00031349063,7.1735724e-7,0.00022201258,0.00002575995,0.00017472552,0.0008961927,0.010956667,0.00017750001],"about_ca_topic_score_codex":0.0012526431,"about_ca_topic_score_gemma":0.00093088875,"teacher_disagreement_score":0.6625191,"about_ca_system_score_codex":0.000075225704,"about_ca_system_score_gemma":0.000763886,"threshold_uncertainty_score":0.6460133},"labels":[],"label_agreement":null},{"id":"W4408892266","doi":"10.2139/ssrn.5191139","title":"Association between Daily Timing of Everolimus Combined with Adjuvant Endocrine Therapy with Survival Outcomes in Patients with High-Risk Hormone Positive and Her2 Negative Early Breast Cancer: Results of a Sub-Study of the UCBG- UNIRAD Trial","year":2025,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Everolimus; Medicine; Oncology; Adjuvant; Breast cancer; Internal medicine; Endocrine system; Hormone; Hormone therapy; Cancer","score_opus":0.007154990175157891,"score_gpt":0.2498844247538465,"score_spread":0.24272943457868862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408892266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99503297,0.0005437088,0.000087206376,0.00046830295,0.000089398665,0.0028176557,0.000937612,0.000012074345,0.000011066876],"genre_scores_gemma":[0.9982745,0.0013497606,0.000073992516,0.000010470651,0.00007954775,0.00005735277,0.00003175258,0.00004892343,0.000073707546],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958086,0.00063710194,0.0009912646,0.00046729925,0.0011707412,0.00092497456],"domain_scores_gemma":[0.994843,0.00044521937,0.003154326,0.0004271923,0.0010580957,0.00007216767],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00094989565,0.0004968593,0.0018297596,0.00030501003,0.00010215908,0.0000148291765,0.00029547163,0.00014210599,0.0000012985322],"category_scores_gemma":[0.000076383134,0.00028401846,0.00011626445,0.00051814265,0.00017678071,0.00013592806,0.00012948707,0.0025803293,2.7084402e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24888013,0.0010150083,0.73494893,0.000030504643,0.0064173457,0.0000025826716,0.0020640218,0.0003506177,0.00002041971,0.000019147528,3.3735213e-7,0.0062509202],"study_design_scores_gemma":[0.18519606,0.020018568,0.79032344,0.0008230628,0.0011398597,0.000006642566,0.0012731205,0.000004659804,0.00037873004,0.00063074636,2.5905265e-7,0.0002048473],"about_ca_topic_score_codex":0.019421719,"about_ca_topic_score_gemma":0.015696574,"teacher_disagreement_score":0.06368408,"about_ca_system_score_codex":0.001838063,"about_ca_system_score_gemma":0.0030738646,"threshold_uncertainty_score":0.9999612},"labels":[],"label_agreement":null},{"id":"W4408905436","doi":"10.3390/curroncol32040192","title":"New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2−Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and III","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Adjuvant; Context (archaeology); Breast cancer; Stage (stratigraphy); Oncology; Cancer; Algorithm; Cancer treatment; Internal medicine; Bioinformatics; Gynecology; Computer science; Biology","score_opus":0.13264753656771128,"score_gpt":0.46895243524388086,"score_spread":0.3363048986761696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408905436","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034466042,0.98781466,0.00018110122,0.0009660399,0.00042301926,0.0089160735,0.0013055303,0.0000114508675,0.000037432972],"genre_scores_gemma":[0.00095756206,0.991987,0.0002431566,0.00007480175,0.00024404807,0.005739905,0.00016445034,0.00004326343,0.000545835],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997672,0.00024136243,0.0009719803,0.0005058976,0.00016149537,0.00044721543],"domain_scores_gemma":[0.99736226,0.0012494059,0.00067698053,0.0005206132,0.000117466916,0.000073262534],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031847093,0.00054112304,0.0029169898,0.00024924747,0.000084868065,0.000006995197,0.00028783188,0.00024639696,0.00003131644],"category_scores_gemma":[0.000021036094,0.00027055817,0.0005016856,0.00034580738,0.00021862928,0.000039578885,0.00005888062,0.00023328344,2.8040438e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008264423,0.0012204869,0.00035394076,0.0040587257,0.00064616837,0.0000025615504,0.0040788273,0.0000043561395,0.000004835974,0.0003865935,0.000038709866,0.98837835],"study_design_scores_gemma":[0.012849203,0.003847132,0.00032005948,0.007837155,0.0023727224,0.00003852118,0.0024695543,0.00009611263,0.000027935086,0.00024982123,0.9696863,0.00020545309],"about_ca_topic_score_codex":0.0012123282,"about_ca_topic_score_gemma":0.0030346946,"teacher_disagreement_score":0.9881729,"about_ca_system_score_codex":0.0016948949,"about_ca_system_score_gemma":0.003065432,"threshold_uncertainty_score":0.99997467},"labels":[],"label_agreement":null},{"id":"W4408921873","doi":"10.1007/s10549-025-07653-2","title":"Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer","year":2025,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Palbociclib; Medicine; Randomized controlled trial; Breast cancer; Adjuvant; Internal medicine; Cancer; Pill; Gynecology; Oncology; Metastatic breast cancer; Pharmacology","score_opus":0.03299598826769643,"score_gpt":0.40508378264795325,"score_spread":0.3720877943802568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408921873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813661,0.001668338,0.0000084290605,0.0018918416,0.00009009245,0.013358366,0.0012098517,0.000028282157,0.00037869444],"genre_scores_gemma":[0.98446804,0.0019247732,0.00008136338,0.00006271956,0.00013276604,0.012946372,0.000051252016,0.000036710844,0.00029599635],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953957,0.0009438562,0.00082636223,0.0008830991,0.0008916935,0.0010592785],"domain_scores_gemma":[0.9972871,0.0012055889,0.00020830991,0.00062239513,0.00034619487,0.00033044367],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062851986,0.00070544385,0.0024920518,0.000572995,0.00015805417,0.000075899865,0.0001946665,0.00009058476,0.00015313775],"category_scores_gemma":[0.00006656095,0.00032988968,0.00045435986,0.0012601955,0.0004939092,0.00012941309,0.000057350797,0.00021148498,0.0000044506314],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63557494,0.0032336551,0.2009373,0.000024635647,0.0014998721,0.00006223447,0.0009801368,0.00015583218,0.000009096873,0.00012701847,0.0000037936888,0.15739149],"study_design_scores_gemma":[0.649128,0.009217805,0.33992332,0.0009264195,0.0002608104,0.00001655012,0.00014154192,0.000026178763,0.00005705356,0.00010850692,0.000030624782,0.00016315369],"about_ca_topic_score_codex":0.11157919,"about_ca_topic_score_gemma":0.012950789,"teacher_disagreement_score":0.15722834,"about_ca_system_score_codex":0.008475923,"about_ca_system_score_gemma":0.0015845388,"threshold_uncertainty_score":0.9999153},"labels":[],"label_agreement":null},{"id":"W4409052291","doi":"10.1016/j.ejca.2025.115397","title":"Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre","funders":"Memorial Sloan-Kettering Cancer Center; Genentech Foundation","keywords":"Fulvestrant; Metastatic breast cancer; Letrozole; HER2 negative; Oncology; Medicine; Breast cancer; Internal medicine; Maximum tolerated dose; Cancer; Estrogen receptor; Aromatase","score_opus":0.03895608083333525,"score_gpt":0.3902829151311198,"score_spread":0.35132683429778455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409052291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884858,0.005826779,0.0011645337,0.0015461489,0.0004776749,0.0021309978,0.00016569169,0.00004066489,0.00016169046],"genre_scores_gemma":[0.98926157,0.002930547,0.005905657,0.0007144107,0.0002577132,0.00007285651,0.000014507064,0.00011502833,0.0007277378],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9958992,0.0009978906,0.0012920422,0.0006257738,0.00065362296,0.00053147366],"domain_scores_gemma":[0.99733233,0.0002157296,0.0008804614,0.00036906503,0.0008086516,0.00039376886],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00093545107,0.0005263833,0.0011186139,0.000478926,0.00019469946,0.00014042619,0.00042493726,0.00004690721,0.00025692707],"category_scores_gemma":[0.00015904556,0.00037149122,0.000060659222,0.0010753867,0.00021933201,0.0014877614,0.00016629942,0.00074936973,0.000004445503],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18596832,0.009060872,0.0031361326,0.00021001433,0.0012553068,0.0023019523,0.01297304,0.004803582,0.04534095,0.000009364003,0.00024547763,0.73469496],"study_design_scores_gemma":[0.42417368,0.021997212,0.50361973,0.008113428,0.0017603067,0.00076400704,0.026689027,0.004064446,0.0047521144,0.000040094797,0.002773617,0.0012523269],"about_ca_topic_score_codex":0.0007552356,"about_ca_topic_score_gemma":0.0015079551,"teacher_disagreement_score":0.73344266,"about_ca_system_score_codex":0.0010157404,"about_ca_system_score_gemma":0.0010587983,"threshold_uncertainty_score":0.9998737},"labels":[],"label_agreement":null},{"id":"W4409313677","doi":"10.2196/64697","title":"A Deep Learning–Enabled Workflow to Estimate Real-World Progression-Free Survival in Patients With Metastatic Breast Cancer: Study Using Deidentified Electronic Health Records","year":2025,"lang":"en","type":"article","venue":"JMIR Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Metastatic breast cancer; Progression-free survival; Palbociclib; Medicine; Workflow; Breast cancer; Artificial intelligence; Tumor progression; Cancer; Oncology; Internal medicine; Machine learning; Computer science; Database; Overall survival","score_opus":0.014850305271766921,"score_gpt":0.38214682053305904,"score_spread":0.36729651526129214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409313677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98949224,0.0012440898,0.0010760233,0.0019737536,0.0004636048,0.005417927,0.000031504227,0.00019413736,0.00010669446],"genre_scores_gemma":[0.9910917,0.000100162346,0.0036229857,0.0004924822,0.00012115427,0.002921036,0.000025234298,0.00011999397,0.0015052289],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963714,0.00026575383,0.00064111094,0.00083609496,0.0007512135,0.0011344597],"domain_scores_gemma":[0.99829245,0.00007358353,0.0003436486,0.00067559007,0.00034869357,0.00026601148],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045219058,0.00045314018,0.0009994395,0.0006240116,0.00023663875,0.00006032353,0.0002911763,0.000048445723,0.0001956638],"category_scores_gemma":[0.000038045106,0.00037215956,0.00007389661,0.0025035085,0.00007096487,0.00021957645,0.00015626088,0.00062731496,0.0000036796007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006591252,0.000841291,0.8003455,0.00026600139,0.00037507564,0.00001846767,0.0008282372,0.0075958306,0.00002537374,0.000019866138,0.00006927228,0.18302386],"study_design_scores_gemma":[0.0124582155,0.00089367596,0.9807292,0.002752379,0.00019290898,0.0000035740995,0.00037947952,0.0011669158,0.000024777977,0.00014226804,0.0008765467,0.0003800473],"about_ca_topic_score_codex":0.009662121,"about_ca_topic_score_gemma":0.10809686,"teacher_disagreement_score":0.1826438,"about_ca_system_score_codex":0.0039354814,"about_ca_system_score_gemma":0.0018173624,"threshold_uncertainty_score":0.99988824},"labels":[],"label_agreement":null},{"id":"W4409318045","doi":"10.1200/po-24-00742","title":"<i>BRCA1/2</i> and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2– Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Palbociclib; Oncology; Breast cancer; Medicine; Internal medicine; Hazard ratio; Cancer; Hormone receptor; Placebo; Metastatic breast cancer; Confidence interval; Pathology","score_opus":0.015640053231237825,"score_gpt":0.3257295918809627,"score_spread":0.3100895386497248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409318045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99283046,0.0020389033,0.0006103645,0.0011729349,0.00009108437,0.002497783,0.0003999043,0.00016668807,0.00019185779],"genre_scores_gemma":[0.99242705,0.0016457089,0.002707801,0.0007655887,0.00017912507,0.000993514,0.00009226718,0.00009702437,0.0010919345],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99649584,0.0006342471,0.00076518755,0.0011132532,0.0004306043,0.0005608685],"domain_scores_gemma":[0.99798703,0.00037655924,0.00046599747,0.00057598756,0.00037756035,0.00021684627],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003380465,0.0005889432,0.0016358204,0.00084259745,0.00023081999,0.000045065834,0.00021490935,0.00022703,0.001461564],"category_scores_gemma":[0.000026810998,0.00036185607,0.00010213034,0.0017271239,0.0003033245,0.0003151669,0.000096105396,0.000586172,0.0000056769836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043846257,0.0014101525,0.7721886,0.000030639254,0.0025536807,0.00006613446,0.0012979689,0.000056782694,0.0081623765,0.0000072517914,0.00012905835,0.17025113],"study_design_scores_gemma":[0.032236055,0.008115486,0.9486342,0.0001813952,0.0010936223,0.00010277757,0.0012267997,0.000060988554,0.0032061546,0.000033480974,0.00465283,0.0004562339],"about_ca_topic_score_codex":0.0050297333,"about_ca_topic_score_gemma":0.011300601,"teacher_disagreement_score":0.1764456,"about_ca_system_score_codex":0.00067025697,"about_ca_system_score_gemma":0.0004970844,"threshold_uncertainty_score":0.99988335},"labels":[],"label_agreement":null},{"id":"W4409344692","doi":"10.3389/or.2025.1564642","title":"Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action","year":2025,"lang":"en","type":"review","venue":"Oncology Reviews","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Fulvestrant; Tamoxifen; Breast cancer; Raloxifene; Selective estrogen receptor modulator; Anastrozole; Estrogen receptor; Toremifene; Aromatase; Cancer; Oncology; Pharmacology; Exemestane; Internal medicine; Cancer research","score_opus":0.05362469868518655,"score_gpt":0.42122606591513884,"score_spread":0.3676013672299523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409344692","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000021671208,0.9934832,0.000210117,0.000667095,0.00032649786,0.004599889,0.00033149924,0.000014076809,0.00036549446],"genre_scores_gemma":[0.0000032894318,0.99780935,0.00041317422,0.00041357538,0.00011470172,0.00095460593,0.000042815733,0.000034696397,0.00021380038],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99694765,0.0008657445,0.0013123127,0.00050898053,0.00013582858,0.0002294925],"domain_scores_gemma":[0.99664897,0.0003336648,0.0021613305,0.0005661627,0.00020605873,0.00008378805],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008102339,0.0005384196,0.005406543,0.000104959625,0.000073580886,0.00000370155,0.00019077685,0.00022937192,0.000043261825],"category_scores_gemma":[0.00016740213,0.00027712793,0.0006052368,0.0005228907,0.0002560592,0.000060161154,0.00019631912,0.0006173637,9.985301e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023466024,0.00005140229,0.000005797432,0.29742816,0.0001910915,5.5383515e-7,0.000057417707,1.2533519e-8,0.000020220967,0.00007180784,0.00008544044,0.70206463],"study_design_scores_gemma":[0.00029968118,0.000110950896,0.000027433342,0.38680577,0.0025806073,0.00027918039,0.000015822057,9.868625e-7,0.000017675295,0.00008706216,0.6096547,0.00012007796],"about_ca_topic_score_codex":0.000028715202,"about_ca_topic_score_gemma":0.000035686488,"teacher_disagreement_score":0.70194453,"about_ca_system_score_codex":0.0003777161,"about_ca_system_score_gemma":0.0010157031,"threshold_uncertainty_score":0.9999681},"labels":[],"label_agreement":null},{"id":"W4409548952","doi":"10.2139/ssrn.5218674","title":"Association between Daily Timing of Everolimus Combined with Adjuvant Endocrine Therapy with Survival Outcomes in Patients with High-Risk Hormone Positive and Her2 Negative Early Breast Cancer: Results of a Sub-Study of the Ucbg- Unirad Trial","year":2025,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Oncology; Everolimus; Breast cancer; Internal medicine; Medicine; Adjuvant; Endocrine system; Hormone; Association (psychology); Cancer; Gynecology; Psychology; Psychotherapist","score_opus":0.007154990175157891,"score_gpt":0.2498844247538465,"score_spread":0.24272943457868862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409548952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99503297,0.0005437088,0.000087206376,0.00046830295,0.000089398665,0.0028176557,0.000937612,0.000012074345,0.000011066876],"genre_scores_gemma":[0.9982745,0.0013497606,0.000073992516,0.000010470651,0.00007954775,0.00005735277,0.00003175258,0.00004892343,0.000073707546],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958086,0.00063710194,0.0009912646,0.00046729925,0.0011707412,0.00092497456],"domain_scores_gemma":[0.994843,0.00044521937,0.003154326,0.0004271923,0.0010580957,0.00007216767],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00094989565,0.0004968593,0.0018297596,0.00030501003,0.00010215908,0.0000148291765,0.00029547163,0.00014210599,0.0000012985322],"category_scores_gemma":[0.000076383134,0.00028401846,0.00011626445,0.00051814265,0.00017678071,0.00013592806,0.00012948707,0.0025803293,2.7084402e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24888013,0.0010150083,0.73494893,0.000030504643,0.0064173457,0.0000025826716,0.0020640218,0.0003506177,0.00002041971,0.000019147528,3.3735213e-7,0.0062509202],"study_design_scores_gemma":[0.18519606,0.020018568,0.79032344,0.0008230628,0.0011398597,0.000006642566,0.0012731205,0.000004659804,0.00037873004,0.00063074636,2.5905265e-7,0.0002048473],"about_ca_topic_score_codex":0.019421719,"about_ca_topic_score_gemma":0.015696574,"teacher_disagreement_score":0.06368408,"about_ca_system_score_codex":0.001838063,"about_ca_system_score_gemma":0.0030738646,"threshold_uncertainty_score":0.9999612},"labels":[],"label_agreement":null},{"id":"W4409613307","doi":"10.1016/j.ctrv.2025.102944","title":"Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty","year":2025,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Adjuvant; Oncology; Breast cancer; Palbociclib; Internal medicine; Clinical trial; Cancer; Metastatic breast cancer","score_opus":0.11247059329814481,"score_gpt":0.43692024393763434,"score_spread":0.32444965063948955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409613307","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000115237945,0.9842971,0.00007072248,0.0005832236,0.0011386846,0.013427589,0.00024494217,0.00009261592,0.00013359259],"genre_scores_gemma":[0.000015810732,0.977601,0.0004593344,0.0003312291,0.0009998523,0.019379742,0.000068325484,0.00011641094,0.001028303],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99421054,0.00091925927,0.0021989853,0.0015407035,0.00033950552,0.00079102017],"domain_scores_gemma":[0.99660826,0.0008196484,0.0011763,0.00095792493,0.00011374416,0.00032411772],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00073791674,0.0014908006,0.0073044137,0.00059764093,0.00011795988,0.0000652382,0.00030254363,0.00043712472,0.00032051333],"category_scores_gemma":[0.000175908,0.00096685265,0.0010992554,0.0011982131,0.0002142702,0.0002326882,0.00015053056,0.00063329353,0.00002409864],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040371004,0.00020204285,0.0001451429,0.031478386,0.00047587263,0.000058422713,0.00015580676,0.000011982785,0.0000010635416,0.0000049136847,0.0005042122,0.9629251],"study_design_scores_gemma":[0.008801113,0.0004381318,0.000008322205,0.31875223,0.0030988047,0.0000829039,0.000018028064,0.0000095564355,0.0000020165846,0.000011256748,0.66829497,0.000482651],"about_ca_topic_score_codex":0.0012878247,"about_ca_topic_score_gemma":0.00031058813,"teacher_disagreement_score":0.9624424,"about_ca_system_score_codex":0.006031201,"about_ca_system_score_gemma":0.0030845487,"threshold_uncertainty_score":0.9997841},"labels":[],"label_agreement":null},{"id":"W4409652574","doi":"10.1158/1538-7445.am2025-5341","title":"Abstract 5341: Duration of CDK4/6 inhibitor (CDKi) treatment in metastatic HR+ HER2- breast cancer (mHRBC) is associated with changes in AKT pathway protein expression","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Metastatic breast cancer; Medicine; Breast cancer; Oncology; Protein kinase B; Cancer; Internal medicine; Cancer research; Signal transduction; Biology","score_opus":0.06060826507613826,"score_gpt":0.4004901628861432,"score_spread":0.33988189781000494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409652574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882073,0.0027296757,0.000017374208,0.0059995344,0.00006189665,0.0024229265,0.0002579723,0.00003282067,0.00027053562],"genre_scores_gemma":[0.9937964,0.00038106323,0.00010948759,0.00010858322,0.00009127005,0.003640744,0.0000313184,0.000046529978,0.0017946089],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99736655,0.00022787835,0.00045020913,0.00054076366,0.00079050247,0.00062407146],"domain_scores_gemma":[0.9986994,0.000157103,0.00017786508,0.00038025205,0.00047030183,0.000115056006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060302543,0.00026692214,0.000605081,0.000709132,0.00007878182,0.000023511751,0.00014421555,0.00012194139,0.0006047533],"category_scores_gemma":[0.00008827206,0.00019887999,0.000052853877,0.0014743969,0.00022379367,0.00018032295,0.000054681543,0.00046397018,0.0000035349235],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005882645,0.0010962478,0.034269784,0.00077033084,0.00025243976,0.00014267725,0.0034578776,0.00016547987,0.8742103,0.000042662043,0.00013966869,0.07956986],"study_design_scores_gemma":[0.007541927,0.0005776873,0.15040532,0.007950994,0.000027452745,0.0000049688288,0.0013158638,0.000059548667,0.8305756,0.00020855464,0.0011177134,0.00021438171],"about_ca_topic_score_codex":0.007989992,"about_ca_topic_score_gemma":0.024277909,"teacher_disagreement_score":0.11613553,"about_ca_system_score_codex":0.0028341622,"about_ca_system_score_gemma":0.0015687984,"threshold_uncertainty_score":0.99861586},"labels":[],"label_agreement":null},{"id":"W4409821785","doi":"10.1158/1538-7445.am2025-ct239","title":"Abstract CT239: IND.241: A Canadian cancer trials group liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant ER+/HER2- metastatic breast cancer","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Society for Arts and Technology; Hamilton Health Sciences; Queen's University; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Ottawa Hospital; Princess Margaret Cancer Centre; Interior Health; Queen Elizabeth II Health Sciences Centre; Kingston Health Sciences Centre","funders":"","keywords":"Medicine; Metastatic breast cancer; Cancer; Oncology; Breast cancer; Internal medicine; Clinical trial; Randomized controlled trial","score_opus":0.16135548478936873,"score_gpt":0.4902675803125865,"score_spread":0.32891209552321776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409821785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9592164,0.0079683,0.000017439947,0.016628014,0.0016951375,0.009877412,0.002503922,0.00010703148,0.0019863546],"genre_scores_gemma":[0.96990067,0.0024284157,0.00031864803,0.0013206501,0.001646883,0.019870283,0.00010510678,0.00015981052,0.004249521],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99215406,0.00049018854,0.0018058826,0.0012726921,0.0018224829,0.0024547034],"domain_scores_gemma":[0.99508595,0.0010764954,0.00032100084,0.0010842432,0.0009958079,0.001436513],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0042483406,0.0007644504,0.0020467641,0.0025422713,0.00045162483,0.0001842815,0.0005914856,0.0003225236,0.005032357],"category_scores_gemma":[0.00097562256,0.0006122023,0.0003936133,0.0031498224,0.00037928356,0.0004385013,0.00015476052,0.0011036831,0.000076576835],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.5677115,0.0010674482,0.002247439,0.0013825512,0.002858492,0.00072696415,0.0051167514,0.00091640063,0.064392835,0.0005602077,0.0072813206,0.34573814],"study_design_scores_gemma":[0.35848483,0.008441543,0.12346696,0.016429702,0.0014804793,0.000100224905,0.007052876,0.0001819152,0.049148146,0.0017177602,0.43041417,0.0030813816],"about_ca_topic_score_codex":0.5559891,"about_ca_topic_score_gemma":0.7944316,"teacher_disagreement_score":0.42313287,"about_ca_system_score_codex":0.023042422,"about_ca_system_score_gemma":0.024699792,"threshold_uncertainty_score":0.99963295},"labels":[],"label_agreement":null},{"id":"W4409906388","doi":"10.2196/57256","title":"Prognostic Disclosure in Metastatic Breast Cancer: Protocol for a Scoping Review","year":2025,"lang":"en","type":"review","venue":"JMIR Research Protocols","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Systematic review; Protocol (science); Breast cancer; Health care; MEDLINE; Distress; Peer review; Alternative medicine; Cancer; Clinical psychology; Pathology","score_opus":0.4711755678525816,"score_gpt":0.6888431434261293,"score_spread":0.2176675755735477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409906388","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[5.8706573e-10,0.43785143,0.000026943142,0.0005387731,0.000004354905,0.5611806,0.00022325435,0.000066812776,0.00010784436],"genre_scores_gemma":[5.7297594e-10,0.38320273,0.00047501622,0.000100297635,0.00019239602,0.61497694,0.000053172414,0.0001267638,0.00087266846],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99222875,0.0014065235,0.0019353975,0.0014191888,0.0013992726,0.0016108524],"domain_scores_gemma":[0.9949582,0.001685551,0.0006235566,0.001373575,0.000998837,0.00036023077],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0029145537,0.00089671655,0.004682522,0.0010654313,0.00019819169,0.0001152893,0.0008599866,0.00031112682,0.00047455248],"category_scores_gemma":[0.0011506188,0.00063726003,0.00080572465,0.0030957337,0.00032878184,0.00023736584,0.00039685532,0.0020554778,0.000039778482],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038704305,0.0004165079,0.000026256996,0.52204704,0.00008917168,0.000039354247,0.000010582587,1.2126208e-7,2.0309733e-7,0.000032640182,0.0013778647,0.4755732],"study_design_scores_gemma":[0.0023776523,0.0003560351,0.000006519168,0.5085309,0.0000852678,0.00007958859,0.0000035543326,8.952016e-7,7.06706e-7,0.000075843906,0.4882266,0.0002564236],"about_ca_topic_score_codex":0.000021336331,"about_ca_topic_score_gemma":0.00006126632,"teacher_disagreement_score":0.48684874,"about_ca_system_score_codex":0.0013579219,"about_ca_system_score_gemma":0.013073459,"threshold_uncertainty_score":0.99960786},"labels":[],"label_agreement":null},{"id":"W4410080762","doi":"10.1016/s1470-2045(25)00140-8","title":"Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Ottawa Hospital; Jewish General Hospital","funders":"Jazz Pharmaceuticals; Pfizer","keywords":"Fulvestrant; Palbociclib; Metastatic breast cancer; Medicine; Oncology; Internal medicine; Cancer; Breast cancer; Hormone receptor; Gynecology; Estrogen receptor","score_opus":0.02242860463022142,"score_gpt":0.3244790213498309,"score_spread":0.3020504167196095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410080762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98631465,0.0021299457,0.000072030736,0.0040160036,0.00013915381,0.0037079486,0.0029900505,0.00009975814,0.0005304826],"genre_scores_gemma":[0.9951106,0.0005557733,0.0012276133,0.0014673963,0.00021510501,0.00031103916,0.0009075802,0.000050641913,0.00015425321],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9967597,0.00078032207,0.000671251,0.00080010196,0.00031235363,0.00067626877],"domain_scores_gemma":[0.99776965,0.000839629,0.00038788872,0.0006191241,0.00022956968,0.00015410985],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040378448,0.00044886043,0.0014171109,0.00014376733,0.00014253215,0.00003363887,0.000252929,0.00009254141,0.000041409185],"category_scores_gemma":[0.000071968214,0.00030081143,0.00005205585,0.0005338352,0.0004062729,0.00019974222,0.00013264838,0.00053576584,0.0000060013444],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43800777,0.024492078,0.119433515,0.00020434085,0.0044614137,0.0008529251,0.03194963,0.00030279718,0.0073544276,0.000047146685,0.00081122195,0.37208274],"study_design_scores_gemma":[0.2681205,0.010817356,0.7109787,0.0011635176,0.0017725353,0.000060832415,0.0030616361,0.00024017204,0.0005997138,0.00008482615,0.0025778422,0.00052237965],"about_ca_topic_score_codex":0.004085582,"about_ca_topic_score_gemma":0.0034332292,"teacher_disagreement_score":0.59154516,"about_ca_system_score_codex":0.0012461169,"about_ca_system_score_gemma":0.00043474342,"threshold_uncertainty_score":0.9999444},"labels":[],"label_agreement":null},{"id":"W4410236307","doi":"10.3390/cancers17101609","title":"Continuing Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Advanced Breast Cancer: A Meta-Analysis","year":2025,"lang":"en","type":"review","venue":"Cancers","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; St. Michael's Hospital; Lakeridge Health; Queen's University; Lakeshore General Hospital; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Health Sciences North; University of Toronto","funders":"","keywords":"Palbociclib; Medicine; Oncology; Internal medicine; Breast cancer; Cyclin-dependent kinase; Cyclin-dependent kinase 4; Metastatic breast cancer; Cancer; Cyclin-dependent kinase 2; Cell cycle","score_opus":0.03523666760996913,"score_gpt":0.3882565185404877,"score_spread":0.3530198509305186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410236307","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004445984,0.99415356,0.00006636461,0.00025256167,0.0007010735,0.0030631917,0.0010609264,0.0001686543,0.00048920413],"genre_scores_gemma":[0.0004496409,0.9904179,0.0006663119,0.00025103282,0.0003692845,0.004649797,0.00027283462,0.00015151905,0.0027716993],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99450356,0.00028988215,0.0017176523,0.0016823662,0.0008540595,0.0009524623],"domain_scores_gemma":[0.9966033,0.00028059317,0.0012270864,0.0012409609,0.00027883888,0.00036923614],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046568,0.0012448115,0.008928138,0.0017532363,0.000096010815,0.000054075677,0.0004727523,0.0005507846,0.00075917604],"category_scores_gemma":[0.00007936929,0.0009479768,0.0041653477,0.0038167855,0.00022100384,0.00023477314,0.00020258772,0.0012341716,0.000014168229],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023334016,0.000048014703,0.000068269444,0.012016905,0.055756867,0.00018967561,0.000139089,0.0006309691,0.000006327029,0.000013734786,0.000063632346,0.93083316],"study_design_scores_gemma":[0.0017751366,0.00007105829,0.00002565844,0.02067492,0.39447716,0.00006376133,0.00014885105,0.000019548112,0.000036826106,0.000026464051,0.581737,0.00094365317],"about_ca_topic_score_codex":0.00061833224,"about_ca_topic_score_gemma":0.0010076019,"teacher_disagreement_score":0.9298895,"about_ca_system_score_codex":0.0070300335,"about_ca_system_score_gemma":0.0034358425,"threshold_uncertainty_score":0.9992971},"labels":[],"label_agreement":null},{"id":"W4410312427","doi":"10.1093/oncolo/oyaf048","title":"Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician’s choice of chemotherapy in patients with HER2-low mBC","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Genentech; Astellas Pharma; Oncolytics Biotech; Eisai; Les Laboratories Pierre Fabre; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; F. Hoffmann-La Roche; Chugai Pharmaceutical; Seagen; Roche; GlaxoSmithKline; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Nausea; Internal medicine; Trastuzumab; Chemotherapy; Oncology; Hazard ratio; Adverse effect; Quality of life (healthcare); Cohort; Cancer; Breast cancer; Confidence interval","score_opus":0.016821581969634323,"score_gpt":0.3043310066982524,"score_spread":0.28750942472861807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410312427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99479496,0.0001397975,0.0001761159,0.0015559234,0.00025195957,0.000884835,0.000032925087,0.000077344346,0.0020861218],"genre_scores_gemma":[0.9972834,0.00000705525,0.0010964245,0.0012110752,0.000046488192,0.00009071434,0.00004018477,0.00003321217,0.00019146841],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845874,0.00006994264,0.00045362857,0.00035260618,0.00034039983,0.0003246525],"domain_scores_gemma":[0.9982929,0.00049728894,0.00036080964,0.0006161678,0.00017621607,0.00005659853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000091717,0.00027977265,0.0006376284,0.000095612646,0.00007064209,0.000009767025,0.00021148704,0.000092948954,0.000054257733],"category_scores_gemma":[0.000135174,0.00017519906,0.000092687216,0.0004751156,0.00043308386,0.0000780364,0.000048944137,0.0002675322,0.000004133114],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012563953,0.0017453864,0.7567856,0.000042043554,0.00064571254,0.000014090402,0.00077666447,0.00017282137,0.00060305285,0.00005434172,0.000050888542,0.22654548],"study_design_scores_gemma":[0.019326923,0.0011965652,0.97429246,0.0002607073,0.0001571186,7.407286e-7,0.000627681,0.00001736781,0.0025135311,0.00029577484,0.0011435203,0.0001676275],"about_ca_topic_score_codex":0.0017419835,"about_ca_topic_score_gemma":0.00076223747,"teacher_disagreement_score":0.22637786,"about_ca_system_score_codex":0.0005336049,"about_ca_system_score_gemma":0.00025269503,"threshold_uncertainty_score":0.71444106},"labels":[],"label_agreement":null},{"id":"W4410455776","doi":"10.1016/j.esmoop.2025.104922","title":"351P Real-world (RW) analysis of alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevation in patients (pts) with metastatic breast cancer (MBC) treated with ribociclib (RIB)","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Alanine aminotransferase; Metastatic breast cancer; Alanine; Medicine; Internal medicine; Breast cancer; Alanine transaminase; Gastroenterology; Cancer; Oncology; Biology; Biochemistry; Amino acid","score_opus":0.014352393836994859,"score_gpt":0.31418076628660285,"score_spread":0.29982837244960797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410455776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99366164,0.000053695225,0.0014083252,0.00095040485,0.0000337025,0.002048316,0.0006693928,0.000061868785,0.001112657],"genre_scores_gemma":[0.9947274,0.000103660896,0.0012406356,0.0004968721,0.000016459802,0.00044351528,0.0010064512,0.00006554167,0.0018995084],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972487,0.00016188437,0.0007939462,0.0007393084,0.00053711917,0.00051900436],"domain_scores_gemma":[0.99831206,0.0001229658,0.00022589536,0.0006773912,0.00048398823,0.00017770301],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025785845,0.00048296683,0.0014039307,0.0010198009,0.00009374943,0.000046141962,0.000343221,0.00006629339,0.00066688505],"category_scores_gemma":[0.000012733303,0.0003611821,0.00012581568,0.0045071905,0.00020676086,0.00050407666,0.0000453917,0.000287312,0.0000043318364],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01359677,0.0012258943,0.95840067,0.00021872319,0.0048854635,0.000074496165,0.000812578,0.0039077913,0.0007701544,0.00028789698,0.00003978239,0.015779775],"study_design_scores_gemma":[0.016351935,0.0006529697,0.9692259,0.00085529493,0.0046096244,0.0000044297917,0.00019409355,0.00075655535,0.0067555844,0.000028893764,0.00019509718,0.00036962933],"about_ca_topic_score_codex":0.039779663,"about_ca_topic_score_gemma":0.088595845,"teacher_disagreement_score":0.04881618,"about_ca_system_score_codex":0.00052345154,"about_ca_system_score_gemma":0.00039861846,"threshold_uncertainty_score":0.999884},"labels":[],"label_agreement":null},{"id":"W4410463538","doi":"10.1016/j.esmoop.2025.104671","title":"117P PIK3CA mutational status concordance between plasma and tumor in HER2+ advanced breast cancer (ABC) patients (pts) of ALPHABET (GEICAM/2017-01_IBCSG 62-20_BIG 18-04) trial","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Ipsen; Universitat de València; PharmaMar; Astellas Pharma; Seagen; Sociedad Española de Oncología Médica; BeiGene; Mersana Therapeutics; AstraZeneca España; Menarini Silicon Biosystems; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Carrick Therapeutics; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Dana-Farber Cancer Institute; McGill University; Merck KGaA; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Amgen; Pfizer","keywords":"Concordance; Breast cancer; Oncology; Internal medicine; Medicine; Alphabet; Cancer; HER2 negative; Metastatic breast cancer","score_opus":0.022531783675793643,"score_gpt":0.3512807230497896,"score_spread":0.32874893937399596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410463538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99163485,0.00035738904,0.00009135251,0.0010295048,0.00054840447,0.0024565107,0.0010146664,0.000036571848,0.0028307268],"genre_scores_gemma":[0.99503016,0.000089014626,0.002230906,0.00057813927,0.00018773187,0.0004716934,0.0002145196,0.000046469184,0.001151384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99744546,0.00011916093,0.000791996,0.0006538782,0.00045285645,0.0005366717],"domain_scores_gemma":[0.99840903,0.00026901104,0.00040194148,0.00042590292,0.0002916349,0.0002024897],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026742733,0.000348085,0.00097031024,0.00021725219,0.00010832958,0.000044031716,0.0003889852,0.00010676587,0.00042711975],"category_scores_gemma":[0.00016337913,0.00032960693,0.00007768698,0.0005087036,0.00032515408,0.0005205505,0.00029529998,0.00034227682,0.000010872719],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055960685,0.00077624846,0.757882,0.00027687065,0.00040585917,0.00004144455,0.00080781867,0.0001689115,0.0002845762,0.00042767604,0.00076246774,0.18220547],"study_design_scores_gemma":[0.0926513,0.00062862836,0.88980347,0.00082040374,0.000106040825,0.000011014947,0.0002494509,0.00006262449,0.0011543692,0.0007049475,0.013500264,0.00030746558],"about_ca_topic_score_codex":0.003176204,"about_ca_topic_score_gemma":0.0009846344,"teacher_disagreement_score":0.18189801,"about_ca_system_score_codex":0.00044301827,"about_ca_system_score_gemma":0.0009644635,"threshold_uncertainty_score":0.9999156},"labels":[],"label_agreement":null},{"id":"W4410463909","doi":"10.1016/j.esmoop.2025.104766","title":"212P Cost-effectiveness analysis of ribociclib plus endocrine therapy (ET) versus ET alone in the adjuvant treatment of stage II and III pre and postmenopausal women with HR+/HER2− early breast cancer (EBC): A Canadian payer perspective","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation; Novartis (Canada); Mount Sinai Hospital","funders":"Daiichi Sankyo Europe; Ipsen; Eisai; Pfizer; Ministero della Salute; Incyte; Teva Pharmaceutical Industries; Gilead Sciences; Amgen; Associazione Italiana per la Ricerca sul Cancro; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Stage (stratigraphy); Oncology; Internal medicine; Gynecology; Postmenopausal women; Adjuvant; Breast cancer; Cancer; Biology","score_opus":0.023663144756867982,"score_gpt":0.36959615737085977,"score_spread":0.3459330126139918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410463909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99144673,0.0020558308,0.000015246088,0.0024077282,0.000026322801,0.0026902948,0.00056785607,0.000008160675,0.00078185357],"genre_scores_gemma":[0.99721575,0.0009885372,0.00006694915,0.00030923763,0.000011345813,0.00097356143,0.000028551269,0.000022307066,0.00038376285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861413,0.00023448573,0.0002212619,0.00041010772,0.00019600704,0.00032398282],"domain_scores_gemma":[0.9989702,0.00022168548,0.00013096098,0.00036768956,0.0001824506,0.00012702677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027824778,0.00025914118,0.0008693758,0.0003281701,0.000092738126,0.000031039566,0.00016456204,0.000045649977,0.00009814999],"category_scores_gemma":[0.000009990086,0.0001620658,0.000038502458,0.00081492856,0.00021906034,0.00019596043,0.00007237988,0.00012821631,1.0325121e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1865342,0.0021000553,0.4451496,0.00019701937,0.026763711,0.00039168462,0.20842479,0.0017978807,0.0037522158,0.0064172987,0.000011623949,0.11845991],"study_design_scores_gemma":[0.023802739,0.0038875,0.96120864,0.00016216667,0.00058169744,0.000016761598,0.008717361,0.000046791214,0.00073365483,0.000053622007,0.00063720794,0.00015185797],"about_ca_topic_score_codex":0.6976329,"about_ca_topic_score_gemma":0.51655376,"teacher_disagreement_score":0.51605904,"about_ca_system_score_codex":0.0012677757,"about_ca_system_score_gemma":0.00088459876,"threshold_uncertainty_score":0.66088516},"labels":[],"label_agreement":null},{"id":"W4410642612","doi":"10.3390/curroncol32060299","title":"TreC_Metha: A Digital Application to Enhance Patient Agency, Therapy Compliance and Quality of Life in Metastatic Breast Cancer Patients","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Pfizer","keywords":"Medicine; Breast cancer; Metastatic breast cancer; Quality of life (healthcare); Agency (philosophy); Cancer; Compliance (psychology); Intensive care medicine; Oncology; Internal medicine; Nursing","score_opus":0.11292564531760778,"score_gpt":0.4745439486751349,"score_spread":0.3616183033575271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410642612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856833,0.0067364415,0.0048337583,0.0009814166,0.0003122292,0.0010830903,0.0001668076,0.000018871246,0.00018403516],"genre_scores_gemma":[0.9981202,0.0005247135,0.00045462232,0.00046243842,0.000026397776,0.00035180117,0.00002589654,0.000010405839,0.000023509532],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998613,0.00010351168,0.00055846147,0.00035282492,0.00016487911,0.0002073482],"domain_scores_gemma":[0.99904364,0.0001579385,0.00023863053,0.00022275436,0.00022757812,0.00010943742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013347597,0.00015559625,0.00057256187,0.00014344204,0.000024065983,0.0000051356396,0.00008673439,0.000041766514,0.000022891265],"category_scores_gemma":[0.000110942914,0.00013613181,0.0000458122,0.00040006748,0.00012079848,0.00008501286,0.000055479726,0.00014186309,0.0000037003526],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011236424,0.00097465055,0.24921608,0.00017088272,0.000034634257,2.5649575e-7,0.0007647472,0.000010924434,0.0011992303,0.0000835719,0.000025519812,0.7463959],"study_design_scores_gemma":[0.0034524046,0.0004709685,0.9739286,0.00035899595,0.000021806443,0.0000015945027,0.00018493274,0.00007143352,0.0010331968,0.00053519406,0.019783426,0.00015749723],"about_ca_topic_score_codex":0.000097981305,"about_ca_topic_score_gemma":0.00008225002,"teacher_disagreement_score":0.74623835,"about_ca_system_score_codex":0.0002951426,"about_ca_system_score_gemma":0.0002416232,"threshold_uncertainty_score":0.55512947},"labels":[],"label_agreement":null},{"id":"W4410802815","doi":"10.1200/jco.2025.43.16_suppl.e13102","title":"Association of rapid progression on CDK4/6 inhibitor (CDKi) for metastatic HR+HER2- breast cancer (mHRBC) with genomic, proteomic, and immune microenvironment alterations.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Collins Medical Trust; Conquer Cancer Foundation","keywords":"Medicine; Metastatic breast cancer; Immune system; Tumor microenvironment; Cancer; Breast cancer; Cancer research; Oncology; Internal medicine; Immunology","score_opus":0.03602998094487765,"score_gpt":0.4237871358077679,"score_spread":0.38775715486289025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410802815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9575008,0.0019510784,0.0020912357,0.03633559,0.0005875567,0.0013668414,0.00004773659,0.000007358772,0.00011176395],"genre_scores_gemma":[0.95624614,0.0014186652,0.038815953,0.0018968461,0.00074321654,0.00015372348,0.0000071050245,0.000033155025,0.000685181],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99751747,0.00024147169,0.0016014418,0.00019922407,0.0002513343,0.00018907251],"domain_scores_gemma":[0.9961601,0.00090651534,0.0023429058,0.00014185268,0.00033348045,0.00011517699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015819517,0.00015156371,0.0011671039,0.00012613833,0.000057873047,0.000008255874,0.000080014026,0.00015624992,0.00007048099],"category_scores_gemma":[0.0003677432,0.00010049394,0.00020017482,0.000081894825,0.00017093909,0.00009791274,0.000030385601,0.00044025917,0.0000010201609],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051026423,0.0033103677,0.06089735,0.0004138687,0.0028487758,0.00003077882,0.0002543124,0.00021598567,0.08535412,0.000129138,0.0012312115,0.7942877],"study_design_scores_gemma":[0.049462177,0.0317024,0.8111848,0.0025079646,0.0021345816,0.0002797965,0.00026430513,0.00023418387,0.034195766,0.0009161165,0.06683552,0.0002823738],"about_ca_topic_score_codex":0.0000076682045,"about_ca_topic_score_gemma":0.000014352965,"teacher_disagreement_score":0.7940053,"about_ca_system_score_codex":0.0005957677,"about_ca_system_score_gemma":0.0009031646,"threshold_uncertainty_score":0.40980238},"labels":[],"label_agreement":null},{"id":"W4410804826","doi":"10.1200/jco.2025.43.16_suppl.1003","title":"INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with <i>PIK3CA</i> -mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Fulvestrant; Palbociclib; Medicine; Placebo; Oncology; Internal medicine; Pharmacology; Gynecology; Cancer; Estrogen receptor; Metastatic breast cancer; Breast cancer; Pathology","score_opus":0.03850210338684483,"score_gpt":0.4100375686141059,"score_spread":0.37153546522726105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882278,0.00083851744,0.0008806533,0.005634335,0.0013595783,0.0017785153,0.00059051317,0.000032757387,0.0006573532],"genre_scores_gemma":[0.9933153,0.0021447132,0.0023745222,0.0008843008,0.00068882946,0.000108778164,0.00010238208,0.00007257259,0.00030861268],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98966813,0.0013062455,0.0058563007,0.0009216512,0.0013133931,0.00093428546],"domain_scores_gemma":[0.9868767,0.0042774347,0.0051400354,0.0006139542,0.0024670037,0.00062483916],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0022468697,0.00077910075,0.0059358855,0.0010834296,0.0001460086,0.000027339294,0.00057235785,0.00058169145,0.00040347624],"category_scores_gemma":[0.0017014344,0.00059297227,0.0012534563,0.002414412,0.001047031,0.00055570225,0.0001629992,0.002387712,0.0000033364388],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8505651,0.013503165,0.045055825,0.00010546305,0.008109291,0.00070519425,0.0006033184,0.0032053143,0.00044730998,0.00009518014,0.0003140072,0.07729088],"study_design_scores_gemma":[0.6486465,0.048143037,0.2878221,0.0014531557,0.006207226,0.00007549316,0.0007583991,0.00055824977,0.00058036775,0.00026506346,0.004835531,0.0006549372],"about_ca_topic_score_codex":0.0014222749,"about_ca_topic_score_gemma":0.004208294,"teacher_disagreement_score":0.24276626,"about_ca_system_score_codex":0.0015720673,"about_ca_system_score_gemma":0.0030183296,"threshold_uncertainty_score":0.9999138},"labels":[],"label_agreement":null},{"id":"W4410804831","doi":"10.1200/jco.2025.43.16_suppl.tps1138","title":"Update on phase III pivotal trial of Bria-IMT + CPI vs physician’s choice in advanced metastatic breast cancer (BRIA-ABC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Metastatic breast cancer; Breast cancer; Oncology; Cancer; Internal medicine; Gynecology; Family medicine","score_opus":0.0740530162583808,"score_gpt":0.5179718007567261,"score_spread":0.4439187844983453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97305816,0.0009205182,0.00049603666,0.018973334,0.004253125,0.00076856784,0.0000592253,0.000016309375,0.0014547443],"genre_scores_gemma":[0.98540497,0.0007118237,0.002013215,0.009258879,0.0020431099,0.000035968904,0.0000052322544,0.000034247274,0.00049257587],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944287,0.00061397697,0.0036460778,0.0003654953,0.00053652533,0.0004092167],"domain_scores_gemma":[0.99307513,0.0028323994,0.0028882741,0.000363811,0.000568472,0.0002719213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020733427,0.000286515,0.0032011997,0.00035752772,0.000039635506,0.0000073708657,0.0003194275,0.00024913053,0.0002459098],"category_scores_gemma":[0.0017399542,0.00022119223,0.00068192265,0.0005231378,0.0003804796,0.0002602668,0.0000660888,0.0014568288,0.0000097477905],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41748935,0.0065232757,0.0012155871,0.00006872417,0.0008615269,0.00022520551,0.00005204184,0.00034601268,0.0013876864,0.00025191956,0.0008502748,0.5707284],"study_design_scores_gemma":[0.7952765,0.03056102,0.065033756,0.0017062754,0.0015481652,0.00019384087,0.00023046027,0.0002582404,0.0012873139,0.002871267,0.100677505,0.0003556114],"about_ca_topic_score_codex":0.00008443749,"about_ca_topic_score_gemma":0.00019053879,"teacher_disagreement_score":0.57037276,"about_ca_system_score_codex":0.00048821978,"about_ca_system_score_gemma":0.0027142284,"threshold_uncertainty_score":0.9019957},"labels":[],"label_agreement":null},{"id":"W4410805181","doi":"10.1200/jco.2025.43.16_suppl.tps1121","title":"IND.241: A Canadian Cancer Trials Group liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant ER+/HER2- metastatic breast.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Queen's University; University Health Network; Ottawa Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; Kingston Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; Dalhousie University","funders":"","keywords":"Medicine; Metastatic breast cancer; Breast cancer; Oncology; Biopsy; Cancer; Internal medicine; Clinical trial; Gynecology","score_opus":0.20410881735378156,"score_gpt":0.5357717868143332,"score_spread":0.3316629694605517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9563384,0.0012658342,0.00015429755,0.032988977,0.004915352,0.0024876224,0.0001118514,0.000018636782,0.0017189978],"genre_scores_gemma":[0.9774991,0.000838713,0.007859341,0.008845035,0.0033175438,0.0003835981,0.0000149236585,0.000055320474,0.0011863812],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99130577,0.0009833917,0.005979748,0.00038981435,0.0006173035,0.00072399],"domain_scores_gemma":[0.9904537,0.0050601168,0.0022979076,0.00037940245,0.0006015721,0.0012072844],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009419998,0.00038363345,0.0042874166,0.0010157393,0.00007929989,0.000025867721,0.0002929624,0.00045642545,0.00056907284],"category_scores_gemma":[0.009553965,0.00025880983,0.0009110048,0.00071549235,0.00019646782,0.00023717535,0.000052621213,0.00094215554,0.000019513447],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.5895557,0.0016214153,0.0012471371,0.00006295146,0.0018339056,0.0010524997,0.0005148136,0.000092679846,0.0005044716,0.00024735287,0.0011995102,0.40206757],"study_design_scores_gemma":[0.40487635,0.07099414,0.055032004,0.0017149362,0.0024705299,0.00060912577,0.0011353752,0.00005192878,0.0003566326,0.0018423982,0.4604362,0.00048038177],"about_ca_topic_score_codex":0.01639823,"about_ca_topic_score_gemma":0.22639017,"teacher_disagreement_score":0.45923668,"about_ca_system_score_codex":0.005754888,"about_ca_system_score_gemma":0.026657702,"threshold_uncertainty_score":0.9999864},"labels":[],"label_agreement":null},{"id":"W4410805186","doi":"10.1200/jco.2025.43.16_suppl.1004","title":"Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy ± palbociclib (PALBO) in patients (pts) with <i>PIK3CA</i> -mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer (HR+, HER2– LA/mBC): Analysis of hyperglycemia (HG) in prediabetic/obese pts.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Roche (Canada)","funders":"","keywords":"Palbociclib; Medicine; Oncology; Metastatic breast cancer; Internal medicine; Endocrine system; Hormone receptor; Hormone; Cancer; Breast cancer","score_opus":0.020809135491573573,"score_gpt":0.39416071469548014,"score_spread":0.37335157920390655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410805186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960058,0.0011025805,0.00017409827,0.0011232977,0.00010198119,0.0013242933,0.000069459915,0.000007699936,0.00009080094],"genre_scores_gemma":[0.994792,0.0024770254,0.002232972,0.0003117186,0.000029867604,0.00007489803,0.000019096497,0.000036407622,0.000026020947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99412704,0.00122441,0.003079953,0.00049470545,0.00067877746,0.00039512542],"domain_scores_gemma":[0.9934455,0.002358609,0.0024485167,0.0002943601,0.001251801,0.0002011996],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013721243,0.00038054187,0.003385013,0.0011850377,0.000027576885,0.000009043097,0.00022589181,0.00019142666,0.00002981858],"category_scores_gemma":[0.0005477302,0.00027382394,0.00016911692,0.002734101,0.000673908,0.00038288784,0.00006970946,0.0011875666,2.1135257e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14444429,0.035084426,0.66829664,0.0000796342,0.0024050432,0.0003060143,0.0017607007,0.0031660588,0.00036980654,0.0000074665036,0.000009867814,0.14407006],"study_design_scores_gemma":[0.18206356,0.045857236,0.766918,0.0010648024,0.00096995523,0.00003121211,0.0019923283,0.0004226421,0.00034897673,0.00009556067,0.000049630693,0.00018608171],"about_ca_topic_score_codex":0.0009434153,"about_ca_topic_score_gemma":0.004932507,"teacher_disagreement_score":0.14388397,"about_ca_system_score_codex":0.00057233905,"about_ca_system_score_gemma":0.0010818959,"threshold_uncertainty_score":0.9999714},"labels":[],"label_agreement":null},{"id":"W4410808631","doi":"10.1200/jco.2025.43.16_suppl.526","title":"Treatment-related neutropenia as a predictor of response to adjuvant palbociclib in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Pfizer","keywords":"Palbociclib; Medicine; Adjuvant; Neutropenia; Oncology; Internal medicine; Chemotherapy; Cancer; Breast cancer; Metastatic breast cancer","score_opus":0.08376305800752132,"score_gpt":0.4768709556258369,"score_spread":0.3931078976183156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410808631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9523752,0.0009442445,0.000064109365,0.040535387,0.0030057258,0.0011613617,0.00001188802,0.000014259975,0.0018878566],"genre_scores_gemma":[0.99035984,0.00043604363,0.0008005174,0.005072827,0.00095968344,0.00004818131,0.0000022585778,0.000027399046,0.0022932636],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9925438,0.0023804693,0.0038198116,0.00033182846,0.00052904023,0.00039501066],"domain_scores_gemma":[0.9886496,0.008398791,0.0016589048,0.0005272331,0.00043381203,0.00033167188],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004819557,0.00027384126,0.0024959694,0.00037815204,0.000047940837,0.0000114859895,0.0004722619,0.00053647417,0.00021510465],"category_scores_gemma":[0.008958574,0.0001586886,0.00075721345,0.0006137121,0.00035403814,0.00009498972,0.00008597124,0.0011924108,0.000033670105],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8191609,0.003531198,0.014147364,0.000022285838,0.00092842325,0.0013682646,0.0012272244,0.00008471947,0.001724904,0.00019028936,0.0014276206,0.15618685],"study_design_scores_gemma":[0.4510752,0.07649139,0.2590991,0.00043114586,0.00091059395,0.00050411036,0.0008831719,0.000030977586,0.000246983,0.0017585837,0.2084016,0.00016714235],"about_ca_topic_score_codex":0.00004984402,"about_ca_topic_score_gemma":0.00020818878,"teacher_disagreement_score":0.36808565,"about_ca_system_score_codex":0.0004925836,"about_ca_system_score_gemma":0.004343558,"threshold_uncertainty_score":0.9993894},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4410810218","doi":"10.1200/jco.2025.43.16_suppl.e12598","title":"A phase 1 study of abemaciclib and niraparib as neoadjuvant therapy in hormone receptor positive and HER2 negative breast cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Oncology; Hormone receptor; Internal medicine; Cancer; Hormone therapy; Neoadjuvant therapy; Cancer research","score_opus":0.060797614044561125,"score_gpt":0.497628338165247,"score_spread":0.43683072412068585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410810218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98501796,0.005203504,0.00003556692,0.008544019,0.0003815434,0.0005415287,0.000019565863,0.0000051119678,0.0002511809],"genre_scores_gemma":[0.98974,0.0073883524,0.00072249933,0.001724763,0.00030636732,0.000015542822,6.3440757e-7,0.000013021603,0.00008879994],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99713373,0.0004959028,0.0017129134,0.00024191657,0.00022539592,0.00019011523],"domain_scores_gemma":[0.99618185,0.0018114372,0.0011949819,0.00013130091,0.00047543086,0.0002049775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012813574,0.00016978926,0.0017518079,0.00020697467,0.00003310256,0.0000060124266,0.00009655878,0.00020388355,0.000052469248],"category_scores_gemma":[0.0005750348,0.00012078592,0.00011950978,0.00028277704,0.0004246575,0.00014484623,0.000053689673,0.00080722134,5.293617e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06940435,0.009203378,0.0680658,0.000018406063,0.0009753554,0.00022028295,0.0024804063,0.00000531309,0.0025706994,0.00004746838,0.00017667779,0.84683186],"study_design_scores_gemma":[0.1009122,0.068703115,0.820272,0.00041974342,0.00024814214,0.0003463874,0.0049689407,0.000030185016,0.00052633655,0.00084385806,0.002608138,0.000120929944],"about_ca_topic_score_codex":0.00053790334,"about_ca_topic_score_gemma":0.00020148605,"teacher_disagreement_score":0.8467109,"about_ca_system_score_codex":0.0001515724,"about_ca_system_score_gemma":0.00088955206,"threshold_uncertainty_score":0.49255067},"labels":[],"label_agreement":null},{"id":"W4410820157","doi":"10.1200/jco.2025.43.16_suppl.tps617","title":"Adjuvant WIDER: A phase 3b trial of ribociclib (RIB) + endocrine therapy (ET) as adjuvant treatment (tx) in a close-to-clinical-practice patient (pt) population with HR+/HER2− early breast cancer (EBC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Adjuvant; Breast cancer; Cancer; Clinical Practice; Population; Oncology; Clinical trial; Internal medicine; Adjuvant therapy; Endocrine system; Gynecology; Surgery; Family medicine; Hormone","score_opus":0.08150653700977262,"score_gpt":0.5433641036047657,"score_spread":0.4618575665949931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410820157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9616377,0.0021865352,0.00020459495,0.03167271,0.0019339387,0.001759992,0.00004404662,0.000023090064,0.0005374395],"genre_scores_gemma":[0.97851944,0.005404249,0.006209035,0.008312237,0.0011509884,0.00011935444,0.000009271547,0.000053104828,0.00022231133],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99108803,0.0016225489,0.0054194774,0.00056974654,0.0008045612,0.0004956366],"domain_scores_gemma":[0.9886966,0.0050215623,0.004045788,0.0005376155,0.001162118,0.00053635874],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002823477,0.00042507687,0.0034938618,0.00040900486,0.000052249477,0.000016711634,0.0002492277,0.00036523977,0.00019607131],"category_scores_gemma":[0.0032581545,0.00027432738,0.0007527808,0.0005744186,0.00028270078,0.00039645375,0.00006809538,0.0012809803,0.00000891894],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3919838,0.012279833,0.044031084,0.000017325974,0.001080825,0.0006876497,0.00039438842,0.00008133502,0.000119302276,0.00011373245,0.000112197034,0.5490985],"study_design_scores_gemma":[0.3674637,0.14085068,0.39643937,0.0009019651,0.00097094104,0.0007096788,0.00047665244,0.000038676888,0.00023305336,0.0009233732,0.09071412,0.00027780051],"about_ca_topic_score_codex":0.002023423,"about_ca_topic_score_gemma":0.00082848174,"teacher_disagreement_score":0.54882073,"about_ca_system_score_codex":0.0010138022,"about_ca_system_score_gemma":0.0041859206,"threshold_uncertainty_score":0.9999709},"labels":[],"label_agreement":null},{"id":"W4410927250","doi":"10.1056/nejmoa2502929","title":"First-Line Camizestrant for Emerging <i>ESR1</i> -Mutated Advanced Breast Cancer","year":2025,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Agence Nationale de la Recherche; AstraZeneca","keywords":"Breast cancer; Line (geometry); Oncology; Cancer research; Cancer; Computational biology; Medicine; Biology; Internal medicine; Mathematics","score_opus":0.012929503962553057,"score_gpt":0.3241416641217435,"score_spread":0.31121216015919045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410927250","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36214072,0.0469549,0.18444623,0.39639574,0.0068159886,0.0017085003,0.00011785072,0.00015700451,0.0012630933],"genre_scores_gemma":[0.9792309,0.003302717,0.0050712284,0.0039401767,0.0060193306,0.000022957129,0.000015102304,0.000053519696,0.0023440656],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981717,0.000031856398,0.000816435,0.00021674957,0.00040348995,0.0003597662],"domain_scores_gemma":[0.9980793,0.00030566004,0.0004280418,0.00021434062,0.00066107727,0.00031158017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048804109,0.00026470993,0.0008890067,0.00032400564,0.00009963644,0.000006989854,0.00016461984,0.00007506627,0.00025839123],"category_scores_gemma":[0.0002493045,0.00017700413,0.00015023092,0.00042431764,0.00013292137,0.00014742881,0.00001733884,0.00039374683,9.227521e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016975958,0.00012114572,0.003564293,0.00040563906,0.00067189534,0.00017102293,0.0009442293,0.003614902,0.020821927,0.00020254157,0.0039417585,0.9485647],"study_design_scores_gemma":[0.37570482,0.0028608548,0.02042884,0.010987856,0.0019124293,0.004949161,0.00086673343,0.0011173504,0.0063044555,0.0059855743,0.5684262,0.00045575656],"about_ca_topic_score_codex":0.00016815863,"about_ca_topic_score_gemma":0.00012409565,"teacher_disagreement_score":0.9481089,"about_ca_system_score_codex":0.00021492876,"about_ca_system_score_gemma":0.0005351508,"threshold_uncertainty_score":0.7218019},"labels":[],"label_agreement":null},{"id":"W4411017560","doi":"10.1016/j.esmoop.2025.105120","title":"Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"National Cancer Institute; University of California, San Francisco; Eisai; Daiichi-Sankyo; Veracyte; Genentech; NSABP Foundation; Les Laboratories Pierre Fabre; Astex Pharmaceuticals; Regeneron Pharmaceuticals; Gilead Sciences; Amgen; Pfizer; Novartis Pharmaceuticals Corporation; AstraZeneca; Eli Lilly and Company; F. Hoffmann-La Roche; Seagen; Roche","keywords":"Palbociclib; Medicine; Oncology; Breast cancer; Quality of life (healthcare); Adjuvant; Randomized controlled trial; Internal medicine; Cancer; Adjuvant therapy; Endocrine system; Gynecology; Metastatic breast cancer; Hormone","score_opus":0.031208791184765088,"score_gpt":0.3602247273950173,"score_spread":0.3290159362102522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411017560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98691666,0.0013095954,0.000058081274,0.0052987286,0.000175776,0.0047985334,0.00007017308,0.000016941976,0.0013555109],"genre_scores_gemma":[0.99573296,0.0014788941,0.0003186206,0.0011443335,0.00009247881,0.00080741744,0.000012534168,0.000027196362,0.00038553734],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971234,0.00080968643,0.0009106075,0.00041491888,0.00042044497,0.00032095108],"domain_scores_gemma":[0.9979518,0.00088026177,0.00037118685,0.0005713505,0.0001501451,0.000075244556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014771136,0.00028568378,0.0016805197,0.00017828257,0.0000456623,0.000035653993,0.0004549298,0.00008668164,0.000117564465],"category_scores_gemma":[0.00019485819,0.00017071681,0.000116971234,0.0005900926,0.0004161309,0.00019477856,0.00014742235,0.00034962798,8.709343e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8317622,0.0004960517,0.12896518,0.00014349284,0.00039915307,0.0000146475695,0.0028924095,0.000015176631,0.00020267523,0.0006060751,0.000035714846,0.03446723],"study_design_scores_gemma":[0.62322897,0.00027602268,0.37373576,0.00047299947,0.000045407098,0.000010639224,0.00041844984,0.000016172951,0.00030206316,0.00057172705,0.0007787794,0.00014300579],"about_ca_topic_score_codex":0.026936466,"about_ca_topic_score_gemma":0.008341453,"teacher_disagreement_score":0.24477056,"about_ca_system_score_codex":0.000086234926,"about_ca_system_score_gemma":0.00058546726,"threshold_uncertainty_score":0.97954327},"labels":[],"label_agreement":null},{"id":"W4411026697","doi":"10.1200/jco.2025.43.17_suppl.lba1005","title":"A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Western University; Hôpital du Saint-Sacrement; Princess Margaret Cancer Centre; BC Cancer Agency; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal; Royal Victoria Regional Health Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Fulvestrant; Medicine; Estrogen receptor; HER2 negative; Metastatic breast cancer; Palbociclib; Placebo; Internal medicine; Double blind; Cyclin-dependent kinase; Breast cancer; Oncology; Estrogen; Cancer; Pathology; Cell cycle","score_opus":0.057816360904797394,"score_gpt":0.47860900126528566,"score_spread":0.42079264036048825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411026697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752631,0.0026445852,0.00010260786,0.009611108,0.0009805837,0.011129257,0.00022291853,0.000013113285,0.00003271627],"genre_scores_gemma":[0.9950883,0.0013178817,0.0011327869,0.00034452163,0.0009848318,0.00097272516,0.00002165425,0.000033330958,0.0001039749],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949916,0.00092035066,0.0028565796,0.0004989058,0.00040801123,0.00032453102],"domain_scores_gemma":[0.9865751,0.010058335,0.0023650131,0.00023945804,0.0004167291,0.00034531605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032825551,0.00044161692,0.0042245784,0.00020016152,0.00022136407,0.000029491572,0.00011074455,0.00029019167,0.000019193782],"category_scores_gemma":[0.0017431804,0.00023127541,0.0006678665,0.00015776849,0.00063766364,0.00018795917,0.000067639834,0.000569266,3.2105865e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8485302,0.0071479245,0.00038567753,0.00004722828,0.0041482677,0.00010916968,0.0007370357,0.000021341588,0.000507522,0.000029322668,0.000045953155,0.13829038],"study_design_scores_gemma":[0.92984176,0.05985537,0.0003809944,0.0011369603,0.0039607235,0.000098956494,0.0011519411,0.00010593274,0.0022273362,0.00017258812,0.00089341565,0.00017399772],"about_ca_topic_score_codex":0.0001094984,"about_ca_topic_score_gemma":0.00015920572,"teacher_disagreement_score":0.13811637,"about_ca_system_score_codex":0.00024651972,"about_ca_system_score_gemma":0.0012717148,"threshold_uncertainty_score":0.94311374},"labels":[],"label_agreement":null},{"id":"W4411028189","doi":"10.1200/jco.2025.43.17_suppl.lba4","title":"Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent <i>ESR1</i> mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Endocrine system; Disease; Oncology; First line treatment; Palbociclib; Internal medicine; Cancer; Hormone; Chemotherapy; Metastatic breast cancer; Breast cancer","score_opus":0.09887842059387833,"score_gpt":0.4985457819358709,"score_spread":0.39966736134199254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411028189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98146707,0.003271618,0.0004549769,0.010548888,0.00067539274,0.0034267176,0.00013409763,0.000010263394,0.00001096315],"genre_scores_gemma":[0.99211055,0.0052063116,0.001517151,0.00030442287,0.00034214035,0.00041331223,0.000023676817,0.00003421016,0.000048219765],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961034,0.0002290181,0.0026069311,0.0003348822,0.00041731994,0.00030846067],"domain_scores_gemma":[0.99490404,0.0014979318,0.0021192292,0.0003050925,0.0008910399,0.0002826672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005942985,0.00030663647,0.001623337,0.0002354002,0.00009371643,0.000008536925,0.00014644998,0.00013134569,0.000040154126],"category_scores_gemma":[0.00022970997,0.0001701576,0.0004078301,0.00032560385,0.0003854398,0.00017272161,0.000020241407,0.0003309872,1.2437314e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71810263,0.01658782,0.037297305,0.00020335993,0.00069695764,0.00004454927,0.00018599376,0.0025706014,0.00048538204,0.000012937138,0.000015779007,0.22379665],"study_design_scores_gemma":[0.84014994,0.041149866,0.10655394,0.0018481683,0.0008895208,0.00001797335,0.00014613436,0.00032466304,0.00445207,0.00008467402,0.0042015268,0.00018153845],"about_ca_topic_score_codex":0.0000751981,"about_ca_topic_score_gemma":0.00037203555,"teacher_disagreement_score":0.22361512,"about_ca_system_score_codex":0.00035199852,"about_ca_system_score_gemma":0.002354269,"threshold_uncertainty_score":0.6938825},"labels":[],"label_agreement":null},{"id":"W4411229260","doi":"10.1016/j.esmoop.2025.105303","title":"Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre","funders":"Genentech; Sun Pharma; Natera; Relay Therapeutics; Seagen; MacroGenics; Puma Biotechnology; Loxo Oncology; Ribon Therapeutics; BeiGene; Mersana Therapeutics; Les Laboratories Pierre Fabre; Astellas Pharma; Eisai; Jazz Pharmaceuticals; F. Hoffmann-La Roche; AstraZeneca; Invitae; Daiichi Sankyo Europe; National Cancer Institute; Servier; Gilead Sciences; Sanofi; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Amgen; Pfizer; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Breast cancer; Medicine; Oncology; HER2 negative; Internal medicine; Cancer; Metastatic breast cancer","score_opus":0.013185224983119479,"score_gpt":0.3310736711880635,"score_spread":0.31788844620494405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411229260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788796,0.007993111,0.00018418666,0.006883678,0.00008779468,0.002618002,0.00008361274,0.000020970525,0.0032490694],"genre_scores_gemma":[0.9839956,0.012756369,0.0019462114,0.00057364634,0.000006638006,0.00023253972,0.000020010275,0.000019363732,0.0004496069],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99884313,0.00009682016,0.0003509705,0.0003558354,0.00015145875,0.00020180213],"domain_scores_gemma":[0.99945104,0.00008930904,0.00012330747,0.00019874667,0.00009453245,0.000043049753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025301118,0.00019164519,0.0005208497,0.00018767637,0.000046842706,0.000022813343,0.00013681583,0.000057453355,0.00006453307],"category_scores_gemma":[0.000009823146,0.00017605825,0.000021430207,0.00056238944,0.00016808718,0.00037242193,0.0002512301,0.00015652791,6.2057717e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010601318,0.00076214486,0.18695818,0.001466775,0.0006078653,0.00009410978,0.005176598,0.00021790918,0.000550268,0.008537436,0.000035316287,0.7849921],"study_design_scores_gemma":[0.01346793,0.000100115976,0.9746002,0.0042046746,0.000050705556,0.000014221739,0.0017662788,0.000110122055,0.001196074,0.003681557,0.00065352395,0.00015457551],"about_ca_topic_score_codex":0.005068208,"about_ca_topic_score_gemma":0.0038035936,"teacher_disagreement_score":0.78764206,"about_ca_system_score_codex":0.00025067414,"about_ca_system_score_gemma":0.000065391134,"threshold_uncertainty_score":0.76616484},"labels":[],"label_agreement":null},{"id":"W4411241937","doi":"10.3390/cimb47060454","title":"Development of CDK4/6 Inhibitors in Gastrointestinal Cancers: Biomarkers to Move Forward","year":2025,"lang":"en","type":"review","venue":"Current Issues in Molecular Biology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University","funders":"","keywords":"Cyclin-dependent kinase 6; Cancer research; Cyclin-dependent kinase 4; PI3K/AKT/mTOR pathway; Cancer; Breast cancer; KRAS; Medicine; Cell cycle; Biology; Signal transduction; Cyclin-dependent kinase; Colorectal cancer; Internal medicine; Cyclin-dependent kinase 2; Cell biology","score_opus":0.030086009844851817,"score_gpt":0.4142944285178627,"score_spread":0.38420841867301087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411241937","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022572739,0.9917739,0.005728568,0.0000789342,0.0004690621,0.0015461219,0.000043421565,0.00002529644,0.0001089764],"genre_scores_gemma":[0.00006642935,0.93372893,0.064967245,0.0000718781,0.00010147425,0.0006287004,0.00033389754,0.00005872793,0.000042696156],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99714607,0.00018189366,0.0012240062,0.00072725234,0.00017240304,0.0005483532],"domain_scores_gemma":[0.99891657,0.00009234257,0.0003193836,0.00044922024,0.00009627872,0.00012618196],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028297887,0.000541249,0.0021833528,0.0011980658,0.000015751375,0.0000045784896,0.00032705517,0.00020500521,0.000027320239],"category_scores_gemma":[0.00031425114,0.00048112893,0.0002673639,0.0010433249,0.00016070073,0.000020585527,0.00026633672,0.00048079653,0.000012167558],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009516253,0.00010081714,0.00035530486,0.0135164615,0.000116696814,0.000048736336,0.00020389029,0.0000057439847,0.00019950011,0.00010929907,0.000043549648,0.9852048],"study_design_scores_gemma":[0.0006725233,0.00013613648,0.000043670727,0.11180676,0.00010797363,0.00004742632,0.000072802504,0.0000016451581,0.00043264517,0.00010348624,0.8862302,0.00034477175],"about_ca_topic_score_codex":0.000060724768,"about_ca_topic_score_gemma":0.00007069925,"teacher_disagreement_score":0.98486006,"about_ca_system_score_codex":0.0012222972,"about_ca_system_score_gemma":0.0016122698,"threshold_uncertainty_score":0.999764},"labels":[],"label_agreement":null},{"id":"W4411255039","doi":"10.1158/1557-3265.sabcs24-p2-08-26","title":"Abstract P2-08-26: FLEX: A Real-World Evidence, Full Transcriptome Study in 30,000 Patients with Early-Stage Breast Cancer","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"FLEX; Cancer; Medicine; Transcriptome; Breast cancer; Stage (stratigraphy); Oncology; Internal medicine; Biology; Gene; Genetics; Computer science; Gene expression; Telecommunications","score_opus":0.16654400283689585,"score_gpt":0.5251134407569966,"score_spread":0.35856943792010076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411255039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98816925,0.0016997986,0.000015130168,0.0040318402,0.0004887283,0.00349162,0.00022413173,0.00015683062,0.0017226656],"genre_scores_gemma":[0.99004406,0.0015710121,0.000069131645,0.0005963673,0.00048806242,0.0016395287,0.000007807997,0.00011901949,0.005464996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99313164,0.00061979465,0.0014188361,0.0014459589,0.0020016092,0.0013821849],"domain_scores_gemma":[0.99542326,0.0013364392,0.00020206273,0.0012065585,0.0012831715,0.0005484835],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029789568,0.0004607887,0.0012118142,0.00092550565,0.00022909968,0.00009750487,0.0007048785,0.0002301368,0.0038332408],"category_scores_gemma":[0.0002903738,0.00035978062,0.00019901978,0.0030087582,0.0009354896,0.00045754723,0.00019723746,0.002751371,0.00010210982],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021987302,0.0023538356,0.91777277,0.00039064913,0.00035927727,0.00014557707,0.000582917,0.00006311731,0.00016080975,0.000038679955,0.0005805668,0.055564497],"study_design_scores_gemma":[0.011617472,0.0014872742,0.97681844,0.003142289,0.00010142793,0.0000010697273,0.0004956095,0.000018731533,0.000042681007,0.00009118056,0.005850163,0.00033365694],"about_ca_topic_score_codex":0.024919841,"about_ca_topic_score_gemma":0.031951707,"teacher_disagreement_score":0.059045672,"about_ca_system_score_codex":0.0015456639,"about_ca_system_score_gemma":0.0022482472,"threshold_uncertainty_score":0.99988544},"labels":[],"label_agreement":null},{"id":"W4411286445","doi":"10.1158/1557-3265.sabcs24-p5-03-01","title":"Abstract P5-03-01: Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Metastatic breast cancer; Oncology; Breast cancer; Phases of clinical research; Cancer; Internal medicine; Open label; Randomized controlled trial; Clinical trial","score_opus":0.1548699941123187,"score_gpt":0.5548477553664776,"score_spread":0.39997776125415885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411286445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98260784,0.0017294541,0.0011211854,0.0016987909,0.00017470251,0.0122158695,0.00034450856,0.000029439272,0.000078187906],"genre_scores_gemma":[0.9923824,0.0008459184,0.0035434135,0.0002067593,0.00012242395,0.002279179,0.000023271929,0.000068634065,0.00052797707],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99503946,0.0009979182,0.0016992298,0.0008416774,0.00085456925,0.00056714047],"domain_scores_gemma":[0.9903127,0.00652063,0.00067480246,0.00080348615,0.0014343932,0.00025396657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00422214,0.00033765452,0.0018372993,0.0001883888,0.00029177286,0.00004922323,0.00058239186,0.000103818544,0.0001732644],"category_scores_gemma":[0.0020807544,0.00019330489,0.00011886498,0.00093690684,0.0013157545,0.00031427888,0.00027634483,0.0007022426,6.1588355e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.671713,0.005849095,0.0013975534,0.00077628094,0.001123715,0.000017420198,0.0007834056,0.0007627976,0.0013527836,0.000041120304,0.000017494853,0.31616533],"study_design_scores_gemma":[0.9468942,0.010079405,0.025384098,0.00384673,0.0010873245,0.000015925438,0.004240267,0.0056862715,0.0021054626,0.00013620865,0.00024159566,0.00028247043],"about_ca_topic_score_codex":0.002111387,"about_ca_topic_score_gemma":0.003974465,"teacher_disagreement_score":0.31588283,"about_ca_system_score_codex":0.00034546375,"about_ca_system_score_gemma":0.0017959576,"threshold_uncertainty_score":0.78827447},"labels":[],"label_agreement":null},{"id":"W4411287522","doi":"10.1158/1557-3265.sabcs24-p1-03-28","title":"Abstract P1-03-28: Agreement between the DESTINY-Breast04/06 VENTANA 4B5 HER2 IHC clinical trial assay and other comparator assays for HER2-low breast cancer: Overall results of a large-scale, multicenter global ring study","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Immunohistochemistry; Pathology; Cancer; Oncology; Internal medicine","score_opus":0.20641135838187216,"score_gpt":0.5548789198231137,"score_spread":0.34846756144124147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411287522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789103,0.0018414845,0.00026532996,0.0070142476,0.0009425103,0.0068205427,0.0032632484,0.00006656275,0.0008757326],"genre_scores_gemma":[0.99417454,0.0003002925,0.000433246,0.00075891986,0.0025971064,0.0010515428,0.000035800775,0.00006564462,0.00058288145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99144876,0.0014394373,0.002895816,0.0014432215,0.0015260924,0.0012466706],"domain_scores_gemma":[0.9908588,0.0056520915,0.00066148525,0.0012586783,0.000993929,0.00057500217],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.013848772,0.00048559872,0.0017111339,0.00014361972,0.00040252894,0.00009872869,0.0007953978,0.00038127482,0.00018007276],"category_scores_gemma":[0.001395684,0.00035030686,0.00055724557,0.00064171816,0.0012139961,0.00014365722,0.00056954124,0.0017449317,0.000018600902],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13562179,0.00402657,0.80333364,0.0003486061,0.0015693534,0.00001928314,0.0002779994,0.000042862262,0.000024242414,0.000067940695,0.003595871,0.051071856],"study_design_scores_gemma":[0.12734465,0.0019365328,0.8465815,0.0012841963,0.00045225094,0.0000047023973,0.0011197991,0.00054314313,0.00005271282,0.00025735865,0.020121641,0.00030151397],"about_ca_topic_score_codex":0.003494681,"about_ca_topic_score_gemma":0.0037025986,"teacher_disagreement_score":0.050770342,"about_ca_system_score_codex":0.00075425213,"about_ca_system_score_gemma":0.0012161974,"threshold_uncertainty_score":0.9998949},"labels":[],"label_agreement":null},{"id":"W4411289812","doi":"10.1158/1557-3265.sabcs24-p3-12-05","title":"Abstract P3-12-05: Real-world use of sacituzumab govitecan (SG) in the management of metastatic triple-negative breast cancer (mTNBC) through a Canadian Patient Support Program (PSP)","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Triple-negative breast cancer; Medicine; Metastatic breast cancer; Cancer; Oncology; Breast cancer; Internal medicine","score_opus":0.24053259445637507,"score_gpt":0.5369587132434502,"score_spread":0.29642611878707514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411289812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9392878,0.0019230564,0.000067615845,0.026219558,0.0010190808,0.01440798,0.0023461224,0.00013085362,0.014597931],"genre_scores_gemma":[0.990748,0.0025448846,0.0019198548,0.0010494086,0.000099197976,0.0022736492,0.000028772045,0.0000604348,0.0012758275],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99453354,0.0005884449,0.0016603458,0.0007688807,0.0013822084,0.0010665661],"domain_scores_gemma":[0.99602216,0.0013780617,0.00037753885,0.0010625613,0.00083459937,0.00032507197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021800355,0.00032874531,0.0010448466,0.000607973,0.000140678,0.00004391289,0.00058955513,0.0001299127,0.00082497456],"category_scores_gemma":[0.00022407877,0.00023887857,0.0002990438,0.0025276083,0.001351389,0.00024828114,0.00017743585,0.0013391414,0.000008001432],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009113545,0.002250945,0.07997325,0.00223486,0.0019558507,0.0004940005,0.0028813542,0.00020031277,0.000060725783,0.002823852,0.005834996,0.89217633],"study_design_scores_gemma":[0.007246279,0.0015117236,0.9202806,0.0031232198,0.00035822822,0.000012172062,0.004208406,0.0000942249,0.0004897611,0.0021645234,0.060183797,0.0003271171],"about_ca_topic_score_codex":0.5288675,"about_ca_topic_score_gemma":0.60551095,"teacher_disagreement_score":0.89184916,"about_ca_system_score_codex":0.001677496,"about_ca_system_score_gemma":0.003705343,"threshold_uncertainty_score":0.97411853},"labels":[],"label_agreement":null},{"id":"W4411291480","doi":"10.1158/1557-3265.sabcs24-p2-11-18","title":"Abstract P2-11-18: Patterns of Treatment in Older Patients with Early-Stage Triple Negative Breast Cancer","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Triple-negative breast cancer; Stage (stratigraphy); Medicine; Breast cancer; Cancer; Oncology; Internal medicine; Biology","score_opus":0.1123254802411527,"score_gpt":0.49916572405282017,"score_spread":0.3868402438116675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411291480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99444777,0.00048665292,0.000028144874,0.0017394077,0.00022746151,0.0017986762,0.0007114078,0.000027369106,0.0005331269],"genre_scores_gemma":[0.9936278,0.00077510154,0.00007207261,0.00023489766,0.0001866476,0.000807213,0.000022612756,0.000045176388,0.0042284643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968449,0.00023878425,0.0008101788,0.0006921019,0.0007331447,0.00068088225],"domain_scores_gemma":[0.9973109,0.00080083066,0.00018584296,0.0005980869,0.00086105725,0.00024328951],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006485529,0.00026386563,0.00080899446,0.00035121813,0.000079562735,0.000019992545,0.00024143205,0.00017852742,0.0022529901],"category_scores_gemma":[0.00015146061,0.00018711988,0.00015165222,0.00086590473,0.00051251985,0.00014969906,0.00010447987,0.00074617687,0.0000095426085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006494456,0.0013086441,0.90151817,0.00023098147,0.00025811547,0.000023707926,0.00040336256,0.000047160378,0.000046789886,0.000029565326,0.00014953541,0.0894895],"study_design_scores_gemma":[0.016286625,0.00086615613,0.97741073,0.0014137186,0.00004707636,5.080814e-7,0.00035733762,0.000014363583,0.000824286,0.000061636754,0.0025623362,0.00015519926],"about_ca_topic_score_codex":0.030981526,"about_ca_topic_score_gemma":0.011678985,"teacher_disagreement_score":0.0893343,"about_ca_system_score_codex":0.0013859438,"about_ca_system_score_gemma":0.001762115,"threshold_uncertainty_score":0.9986591},"labels":[],"label_agreement":null},{"id":"W4411339100","doi":"10.1007/s00520-025-09625-0","title":"Hepatotoxicity across CDK 4/6 inhibitors: a Narrative Review","year":2025,"lang":"en","type":"review","venue":"Supportive Care in Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Waterloo","funders":"","keywords":"Medicine; Pain medicine; Nursing research; Narrative; Pharmacology; Nursing; Pathology; Anesthesiology","score_opus":0.03889284046734905,"score_gpt":0.4618086979853515,"score_spread":0.4229158575180025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411339100","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012520126,0.9906712,0.000008529811,0.00042826912,0.00096767436,0.004912488,0.0015964336,0.00010966728,0.0012932112],"genre_scores_gemma":[0.0000306314,0.9899536,0.000084413965,0.0019020227,0.0005896708,0.005316647,0.00055429206,0.00011386847,0.0014548713],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99560356,0.00028613931,0.0015089416,0.0012129868,0.00053754344,0.0008508556],"domain_scores_gemma":[0.99708617,0.00023053012,0.00084313325,0.00083375286,0.0007834681,0.00022294813],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003095192,0.0009821593,0.0047875177,0.00026303306,0.00010308317,0.000020273144,0.00032471845,0.0005165581,0.0007912678],"category_scores_gemma":[0.0004039201,0.00079532294,0.0010984594,0.0015907558,0.0002992638,0.00020161446,0.00023166339,0.0013610901,0.000038815437],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056921202,0.000049332117,0.00011615738,0.23938401,0.0002632414,0.00018456792,0.0024375287,2.0532363e-7,3.1788062e-7,0.000005173494,0.002742452,0.7547601],"study_design_scores_gemma":[0.00046920404,0.00009959978,0.000016295746,0.37239936,0.00059980364,0.000037757574,0.0012313216,5.1594572e-8,0.0000158631,0.000009501195,0.6247138,0.0004074611],"about_ca_topic_score_codex":0.0002194223,"about_ca_topic_score_gemma":0.00083817384,"teacher_disagreement_score":0.7543526,"about_ca_system_score_codex":0.0041103996,"about_ca_system_score_gemma":0.005060276,"threshold_uncertainty_score":0.99971265},"labels":[],"label_agreement":null},{"id":"W4412431037","doi":"10.1016/j.ejca.2025.115629","title":"Paediatric strategy forum for medicinal product development of cyclin-dependent kinase inhibitors in children and adolescents ACCELERATE in collaboration with the European Medicines Agency With participation of the Food and Drug Administration","year":2025,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Agenzia Italiana del Farmaco, Ministero della Salute; Loxo Oncology; National Institutes of Health; Cambridge University Hospitals; Solving Kids' Cancer; College ter Beoordeling van Geneesmiddelen; G1 Therapeutics; Institut Gustave-Roussy; Amsterdam University Medical Centers; Deutsches Krebsforschungszentrum; B-IT Foundation; Uniwersytet Jagielloński Collegium Medicum; Bundesinstitut für Arzneimittel und Medizinprodukte; National Cancer Center Japan; Karolinska Institutet; University of Minnesota; Memorial Sloan-Kettering Cancer Center; Centre Léon Bérard; Eli Lilly and Company; AstraZeneca; University of Cambridge; Children's Hospital of Philadelphia; Royal Marsden NHS Foundation Trust; Children's Hospital Colorado; Hospital for Sick Children; Pfizer","keywords":"Food and drug administration; Agency (philosophy); Product (mathematics); Drug; Medicine; Business; Regulatory agency; Pharmacology; Political science","score_opus":0.018511681054757822,"score_gpt":0.3160960032715867,"score_spread":0.2975843222168289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412431037","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10141324,0.89585805,0.0001022249,0.00071737607,0.00010316126,0.0017414934,0.000024396066,0.0000029407872,0.00003714152],"genre_scores_gemma":[0.7157965,0.28369784,0.0001484336,0.000034350604,0.00023478804,0.000026611368,0.000008395994,0.000032682754,0.000020401143],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975616,0.0005930587,0.0010479436,0.00022464375,0.00041219115,0.00016056688],"domain_scores_gemma":[0.99779665,0.000055268472,0.0015651135,0.00016058929,0.0003608687,0.00006151405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001332319,0.0002514475,0.0007167674,0.00023550715,0.000052307172,0.000014962433,0.00014570194,0.000021872416,0.0000016364088],"category_scores_gemma":[0.000083734805,0.00012112658,0.000047222096,0.0005463928,0.00013644093,0.00011561653,0.000036344023,0.00030627698,4.4306066e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059023214,0.00008867286,0.010760467,0.0034059815,0.0001593818,0.000010311905,0.0012112135,0.00006527953,0.000023732146,0.0000023170533,0.00003469818,0.9836477],"study_design_scores_gemma":[0.018303378,0.004593009,0.7864893,0.15452182,0.003999596,0.00029991602,0.002372658,0.000006908388,0.0017417221,0.000017014985,0.026943127,0.00071153825],"about_ca_topic_score_codex":0.0000045115935,"about_ca_topic_score_gemma":0.00047224967,"teacher_disagreement_score":0.9829362,"about_ca_system_score_codex":0.00011047503,"about_ca_system_score_gemma":0.0013866782,"threshold_uncertainty_score":0.49393985},"labels":[],"label_agreement":null},{"id":"W4412699285","doi":"10.1038/s41571-025-01063-5","title":"Clarifying the role of SONIA: supporting academic evidence on CDK4/6 inhibitor timing","year":2025,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; MEDLINE; Internal medicine; Oncology","score_opus":0.24823529704736547,"score_gpt":0.5942362198508672,"score_spread":0.3460009228035017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412699285","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000002998051,0.99009746,0.000040487983,0.002254125,0.0016892784,0.0039466606,0.00001747857,0.00006139496,0.0018901395],"genre_scores_gemma":[0.00003059286,0.9884299,0.0020186575,0.0054813656,0.0029457563,0.00042780107,0.000029948134,0.00007873822,0.00055724266],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9893053,0.0027622108,0.0055809557,0.0011383856,0.0005369283,0.0006762009],"domain_scores_gemma":[0.9736441,0.01920831,0.00523229,0.0013926899,0.0002770946,0.00024556604],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0090224035,0.0007805129,0.009203607,0.00025047467,0.00013338895,0.000009346255,0.0010151706,0.005537551,0.00012317853],"category_scores_gemma":[0.03140457,0.0004302277,0.0027125436,0.00094799994,0.00048654518,0.00010179363,0.00040993094,0.017862253,0.000119587545],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014478162,0.00011902988,0.000072415976,0.027641615,0.0002592756,0.000025874768,0.000030852025,1.4607514e-7,0.0000032566843,0.0003456526,0.0011802389,0.9701769],"study_design_scores_gemma":[0.00039318908,0.0006190074,0.000014963137,0.18533225,0.0027654022,0.00008889385,0.000020899386,0.0000015401176,0.0000050067147,0.00027043946,0.810247,0.00024140326],"about_ca_topic_score_codex":0.0000026682906,"about_ca_topic_score_gemma":0.0000040101204,"teacher_disagreement_score":0.9699355,"about_ca_system_score_codex":0.00066598016,"about_ca_system_score_gemma":0.0033920233,"threshold_uncertainty_score":0.9998149},"labels":[],"label_agreement":null},{"id":"W4412708027","doi":"10.1016/j.esmoop.2025.105506","title":"Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb; Samsung; Genentech; Natera; Seagen; Puma Biotechnology; Pfizer; Incyte; BeiGene; Mersana Therapeutics; Menarini Silicon Biosystems; Astex Pharmaceuticals; Eisai; Jazz Pharmaceuticals; McGill University; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Exelixis; GlaxoSmithKline; Amgen; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Fulvestrant; Palbociclib; Metastatic breast cancer; Oncology; Internal medicine; Cancer research; Cancer; Breast cancer; Medicine; Biology; Estrogen receptor","score_opus":0.017361168536061036,"score_gpt":0.3840519532464865,"score_spread":0.3666907847104255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412708027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854577,0.00012041562,0.00056664896,0.008226336,0.00015119168,0.004530719,0.0004194619,0.000016197746,0.0005113301],"genre_scores_gemma":[0.99376607,0.0000028793631,0.0018365834,0.0012898128,0.00015212456,0.0026424578,0.000085832595,0.000021590375,0.00020266556],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99887365,0.00011811986,0.0002558282,0.00032824138,0.000213402,0.00021074327],"domain_scores_gemma":[0.9991726,0.00039137877,0.00013084835,0.00015315671,0.00010573139,0.000046279623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000349191,0.0001790284,0.0003161787,0.00009629208,0.0001763064,0.00006891066,0.0001208581,0.000033556422,0.00008163608],"category_scores_gemma":[0.00011218768,0.00011992655,0.000050637635,0.00024994276,0.00008971299,0.00019562167,0.0000885811,0.00017765113,8.4880804e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54921937,0.0055990093,0.012077272,0.0007260484,0.0011183843,0.0006298953,0.026676198,0.00031064806,0.0005956245,0.00477649,0.0008132534,0.3974578],"study_design_scores_gemma":[0.6247355,0.008687858,0.29345512,0.00965855,0.00092520006,0.0005825554,0.012899761,0.028028546,0.0034205744,0.014873724,0.0016032167,0.0011294086],"about_ca_topic_score_codex":0.00021964789,"about_ca_topic_score_gemma":0.00046244744,"teacher_disagreement_score":0.3963284,"about_ca_system_score_codex":0.00017690909,"about_ca_system_score_gemma":0.00028560506,"threshold_uncertainty_score":0.4890463},"labels":[],"label_agreement":null},{"id":"W4413122220","doi":"10.3390/curroncol32080444","title":"Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Calgary; Grand River Hospital; Ottawa Hospital; Dr. H. Bliss Murphy Cancer Centre; Jewish General Hospital; University of Toronto; Mount Sinai Hospital; Sunnybrook Health Science Centre","funders":"Daiichi Sankyo Europe; Eli Lilly Canada; Ipsen; Astellas Pharma; Eisai; Incyte; Allergan; Helsinn; Genomic Health; Seagen; Gilead Sciences; Amgen; Pfizer; Myriad Genetics; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Tolerability; Adverse effect; Breast cancer; Multidisciplinary approach; Quality of life (healthcare); Clinical trial; Oncology; Metastatic breast cancer; Intensive care medicine; Adjuvant; Advance care planning; Internal medicine; Cancer; Palliative care; Nursing","score_opus":0.03220749072323967,"score_gpt":0.4056603800270666,"score_spread":0.3734528893038269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413122220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98117626,0.0006786413,0.005130363,0.005482883,0.001400549,0.0044299792,0.0012344681,0.00004019012,0.00042668506],"genre_scores_gemma":[0.9915266,0.000018324634,0.006008442,0.00015536587,0.00019952211,0.0017838962,0.00006405696,0.000050387007,0.00019341231],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983242,0.00005866747,0.0004092884,0.000457057,0.00017359601,0.0005771978],"domain_scores_gemma":[0.99854016,0.0005049377,0.00025307835,0.00016075604,0.00043006174,0.000111012894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013029002,0.0002306368,0.00049272715,0.000118899865,0.00011409202,0.0000065358067,0.000080132646,0.00006215482,0.0000495303],"category_scores_gemma":[0.00011986472,0.00019322387,0.000055724027,0.00024359672,0.00010986838,0.00011634868,0.0000851716,0.00022279932,7.2356414e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047602057,0.0005866095,0.78370345,0.00025905087,0.00014311534,0.000009032868,0.00052279374,0.00001939401,0.000077050376,0.00018337957,0.0010416412,0.2086943],"study_design_scores_gemma":[0.013594944,0.0008085966,0.9590111,0.0010729347,0.0001406605,0.000007723948,0.0008180271,0.00037435218,0.0004761312,0.000215906,0.023242287,0.000237331],"about_ca_topic_score_codex":0.061747853,"about_ca_topic_score_gemma":0.55379176,"teacher_disagreement_score":0.4920439,"about_ca_system_score_codex":0.0026946443,"about_ca_system_score_gemma":0.0032134475,"threshold_uncertainty_score":0.9445},"labels":[],"label_agreement":null},{"id":"W4413187666","doi":"10.2139/ssrn.5387530","title":"Discovery and Chemical Biology of CDK8 Inhibitors Reveals Insights for Kinase Inhibitor Development","year":2025,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Kinase; Drug discovery; Computational biology; Chemical biology; Biology; Cell biology; Genetics; Bioinformatics","score_opus":0.010839455407165766,"score_gpt":0.28721542164810887,"score_spread":0.2763759662409431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413187666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9392197,0.041853048,0.016525023,0.0007720783,0.0006286894,0.0008535042,0.000040544564,0.000030616102,0.000076772005],"genre_scores_gemma":[0.9893572,0.004005609,0.0043199435,0.0001269233,0.0009346203,0.00010130372,0.00007905902,0.000040460214,0.001034925],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9971382,0.000057252444,0.0007978043,0.00048595158,0.00020718957,0.0013136233],"domain_scores_gemma":[0.99871665,0.00012673267,0.00051511964,0.00027183513,0.00025644086,0.00011320861],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00061483064,0.00038214467,0.00088097935,0.0003098754,0.00009015154,0.000022391414,0.00019371476,0.00039581305,0.0000028557458],"category_scores_gemma":[0.00016456387,0.00031475586,0.00022154892,0.0001185476,0.00018302357,0.00009501372,0.0003033372,0.0023186118,4.965296e-7],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063867057,0.0007627748,0.006164635,0.003206896,0.004676896,0.000017382583,0.0023314764,0.000031407304,0.3571755,0.07208653,0.00017370417,0.5469861],"study_design_scores_gemma":[0.008156277,0.0010816401,0.0006439232,0.00424654,0.00063362997,0.00062720577,0.0012432608,0.000017926672,0.31501466,0.64843595,0.018975109,0.0009238991],"about_ca_topic_score_codex":0.0000135021655,"about_ca_topic_score_gemma":0.000040080915,"teacher_disagreement_score":0.57634944,"about_ca_system_score_codex":0.0017152164,"about_ca_system_score_gemma":0.0076940153,"threshold_uncertainty_score":0.9999831},"labels":[],"label_agreement":null},{"id":"W4413273638","doi":"10.1200/po-24-00810","title":"Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving Palbociclib: Biomarker Results From POLARIS Study","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Palbociclib; Genotyping; Biomarker; Breast cancer; Medicine; Oncology; Cancer; Gene; Internal medicine; Cancer research; Biology; Metastatic breast cancer; Genotype; Genetics","score_opus":0.013986420986430633,"score_gpt":0.31583188916411026,"score_spread":0.3018454681776796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413273638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99647045,0.0005385356,0.0005261141,0.0006008797,0.00025975803,0.0012758245,0.00016458912,0.000042055104,0.000121804245],"genre_scores_gemma":[0.99305314,0.000030962918,0.006385458,0.00026746216,0.000055092733,0.000099600584,0.000047217964,0.000029420156,0.000031669595],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978585,0.00021495236,0.00079500675,0.0005993751,0.00025211618,0.00028001843],"domain_scores_gemma":[0.9981633,0.0006261477,0.00039266056,0.00041295076,0.00032240106,0.000082563216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032988362,0.0002202639,0.0006613622,0.00035392086,0.000109463406,0.000014534456,0.00011055534,0.00010704413,0.00004037368],"category_scores_gemma":[0.00032081467,0.00018540576,0.000037645354,0.0006062924,0.00010744381,0.00020898759,0.00015122397,0.00017774265,9.830518e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011045106,0.00060302234,0.45260474,0.000020171945,0.00017315288,0.00002324632,0.002216282,0.00013327504,0.018894477,0.000003468941,0.000008015046,0.514275],"study_design_scores_gemma":[0.01757826,0.00056725624,0.9786371,0.0006634992,0.0001014732,0.000010470767,0.0007173964,0.00023125536,0.0010776591,0.000101712205,0.00015950533,0.00015440189],"about_ca_topic_score_codex":0.0008055041,"about_ca_topic_score_gemma":0.0009347339,"teacher_disagreement_score":0.5260324,"about_ca_system_score_codex":0.0005116466,"about_ca_system_score_gemma":0.00033408558,"threshold_uncertainty_score":0.75606275},"labels":[],"label_agreement":null},{"id":"W4413307651","doi":"10.3389/fonc.2025.1609735","title":"Combined treatment with CDK4/6, CDK2, and CXCR1/2 inhibitors effectively halts the growth of BRAF wild-type melanoma tumors","year":2025,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"National Cancer Institute; U.S. Department of Veterans Affairs","keywords":"Cancer research; Melanoma; Medicine; Oncology; Cyclin-dependent kinase 2; Internal medicine; Cell cycle; Cancer","score_opus":0.006008888807331593,"score_gpt":0.2659323550839981,"score_spread":0.2599234662766665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413307651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98873174,0.0027682488,0.001025881,0.0034047307,0.0007535375,0.0010325129,0.000005999511,0.000036920836,0.0022404243],"genre_scores_gemma":[0.9944597,0.00016842173,0.0041752113,0.00044913558,0.000056439883,0.000100457284,0.0000074582504,0.000020690522,0.0005624777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989099,0.00015487478,0.00026611413,0.0002984431,0.00011546227,0.00025523483],"domain_scores_gemma":[0.99924,0.00023231877,0.00014058065,0.00023031293,0.00009735045,0.00005946234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015883072,0.00020538163,0.00068164006,0.00023298452,0.000060097896,0.0000042499187,0.00009486947,0.00011747602,0.000006121258],"category_scores_gemma":[0.00007003118,0.00012725285,0.000044316937,0.0004693668,0.0005433742,0.000053236752,0.000041738072,0.00018327351,8.8815807e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009870726,0.0005401753,0.8792559,0.00012801948,0.00060957397,0.00014117868,0.001882237,0.00001528309,0.0009423577,0.0007561072,0.0015874099,0.10427107],"study_design_scores_gemma":[0.03440812,0.025718663,0.8839708,0.00076380407,0.0005769593,0.00021020981,0.003334566,0.00027075657,0.019848164,0.00587045,0.024632221,0.00039531355],"about_ca_topic_score_codex":0.00024885315,"about_ca_topic_score_gemma":0.0001275299,"teacher_disagreement_score":0.10387575,"about_ca_system_score_codex":0.00064326695,"about_ca_system_score_gemma":0.00039291478,"threshold_uncertainty_score":0.51892203},"labels":[],"label_agreement":null},{"id":"W4413329945","doi":"10.3390/curroncol32080471","title":"Treatment Disparities, Heterogeneities, and Barriers to Access for Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A National Survey from Brazil","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Human Epidermal Growth Factor Receptor 2; Medicine; Breast cancer; Hormone receptor; Receptor; Metastatic breast cancer; Cancer research; Oncology; Cancer; Epidermal growth factor receptor; Internal medicine; Hormone","score_opus":0.06199026650173751,"score_gpt":0.4045101935267062,"score_spread":0.3425199270249687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413329945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95746845,0.0017435206,0.0012723497,0.0023689365,0.0006494283,0.0022773473,0.034120087,0.000055398334,0.000044486915],"genre_scores_gemma":[0.9918316,0.00035273022,0.0015056988,0.0008022314,0.00018472443,0.0018041104,0.0033528083,0.00004901544,0.000117081916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979603,0.00025162395,0.00040711535,0.0006476004,0.00029013577,0.0004431798],"domain_scores_gemma":[0.9975541,0.00080189726,0.00020793806,0.00016593807,0.00086486596,0.0004052654],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009932943,0.0003964136,0.00080150267,0.0002140734,0.00028793656,0.00004568612,0.00015443083,0.0000853267,0.0002337962],"category_scores_gemma":[0.00022942123,0.00031996603,0.00007937342,0.00027619267,0.0002987309,0.0002665246,0.000094265684,0.00015940367,0.0000027831543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01062327,0.0010341887,0.89249134,0.00012838515,0.0016357987,0.0000019982358,0.0010899382,0.000009599729,0.00036535627,0.00022708939,0.003118873,0.089274175],"study_design_scores_gemma":[0.01393677,0.002153936,0.97071844,0.00018312533,0.00024291017,0.0000036434012,0.00013670052,0.000017088641,0.0008705149,0.0003158186,0.011085374,0.00033570456],"about_ca_topic_score_codex":0.0017758968,"about_ca_topic_score_gemma":0.001609984,"teacher_disagreement_score":0.088938475,"about_ca_system_score_codex":0.002218263,"about_ca_system_score_gemma":0.0010376761,"threshold_uncertainty_score":0.99992526},"labels":[],"label_agreement":null},{"id":"W4413381395","doi":"10.3389/fonc.2025.1577075","title":"Real-world effectiveness and safety of CDK4/6i in elderly and BIPOC patients with HR+/HER2- advanced/metastatic breast cancer: an updated systematic literature review","year":2025,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Medicine; Palbociclib; Discontinuation; Metastatic breast cancer; Tolerability; Oncology; Breast cancer; Internal medicine; MEDLINE; Neutropenia; Meta-analysis; Cancer; Intensive care medicine; Adverse effect; Chemotherapy","score_opus":0.007872144586913443,"score_gpt":0.3346680337012885,"score_spread":0.32679588911437507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413381395","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025066294,0.9909788,0.00014121766,0.000078730285,0.00043213792,0.0074889585,0.0004959894,0.000029440567,0.000104100756],"genre_scores_gemma":[0.0000707633,0.99338764,0.0044483547,0.00011904781,0.000028173452,0.0012961363,0.00045839546,0.00007619066,0.000115276525],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99537635,0.0016740448,0.001391268,0.0008544598,0.00026210846,0.00044179667],"domain_scores_gemma":[0.997534,0.0004308634,0.0010092459,0.00059547334,0.00026936454,0.00016108419],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00072228286,0.0007042044,0.0069492212,0.0010313577,0.000040451425,0.000012400072,0.00022272923,0.00030838704,0.000015201985],"category_scores_gemma":[0.00009008491,0.00050573144,0.00012914196,0.0019423922,0.0003016406,0.00022726096,0.000080810874,0.00078317453,3.120788e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008285424,0.00017957523,0.004635775,0.47724277,0.00032513752,0.00006987243,0.00008226103,0.0000020324067,1.1989212e-7,0.000013130457,0.000055408666,0.5165654],"study_design_scores_gemma":[0.0055936654,0.0011129827,0.009796313,0.92964035,0.002594371,0.00018488581,0.00006488365,0.000005109944,2.494698e-7,0.000068224814,0.050496206,0.00044277072],"about_ca_topic_score_codex":0.00007856321,"about_ca_topic_score_gemma":0.0004197763,"teacher_disagreement_score":0.51612264,"about_ca_system_score_codex":0.0014163371,"about_ca_system_score_gemma":0.0008932273,"threshold_uncertainty_score":0.9997394},"labels":[],"label_agreement":null},{"id":"W4413920704","doi":"10.1200/po-25-00588","title":"Reply to: Germline and Somatic <i>BRCA1/2</i> Mutations in Breast Cancer Treatment Strategies","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Germline; Somatic cell; Germline mutation; Breast cancer; Oncology; Genetics; Medicine; Biology; Mutation; Cancer; Gene","score_opus":0.018202773317583652,"score_gpt":0.38088604077919874,"score_spread":0.3626832674616151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413920704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9179176,0.0023288196,0.0027590278,0.07042512,0.00048503885,0.0013122396,0.000060481478,0.000111178364,0.004600468],"genre_scores_gemma":[0.9837302,0.0005624221,0.0063672904,0.0061546625,0.00011842829,0.0006183797,0.000015614005,0.000021550219,0.002411455],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988276,0.00007217698,0.00038326267,0.00036417707,0.00011451582,0.0002383115],"domain_scores_gemma":[0.9990833,0.0003484425,0.00007691794,0.00028279665,0.000102533464,0.00010602152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012809255,0.00016863068,0.00046518512,0.00029173208,0.000060619368,0.000018298091,0.000065327666,0.000097920514,0.00019020122],"category_scores_gemma":[0.000050924635,0.000133197,0.000043854685,0.0003871729,0.00008935769,0.000114578535,0.000051649793,0.000121381476,0.00001639971],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015879391,0.0005501807,0.01422263,0.000064618966,0.000098596654,0.0000833911,0.0019335835,0.0008474781,0.011471858,0.00070400117,0.0006849124,0.9677508],"study_design_scores_gemma":[0.013397496,0.0017856462,0.6447515,0.0009822665,0.00024339936,0.0004962638,0.0035847316,0.00079950865,0.0028095522,0.013131383,0.3176637,0.00035453614],"about_ca_topic_score_codex":0.000539858,"about_ca_topic_score_gemma":0.00077447685,"teacher_disagreement_score":0.96739626,"about_ca_system_score_codex":0.00082361145,"about_ca_system_score_gemma":0.00071383733,"threshold_uncertainty_score":0.54316163},"labels":[],"label_agreement":null},{"id":"W4413931773","doi":"10.1111/jir.70030","title":"Abstracts for Presentation at the SSBP 27th International Research Symposium and Educational Day, Amsterdam, the Netherlands","year":2025,"lang":"en","type":"article","venue":"Journal of Intellectual Disability Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Services and Policy Research; Hospital for Sick Children; Holland Bloorview Kids Rehabilitation Hospital; Carleton University; University of Toronto","funders":"","keywords":"Presentation (obstetrics); Psychology; Medicine; Surgery","score_opus":0.09817265140670586,"score_gpt":0.48550087694054694,"score_spread":0.38732822553384105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413931773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8031442,0.0013173121,0.00053511956,0.1885749,0.00048893294,0.0010960762,0.00001924121,0.0000055460087,0.0048186607],"genre_scores_gemma":[0.9886332,0.00032685243,0.00016722913,0.00022532266,0.0008646708,0.00010802524,0.000012210317,0.000015358044,0.009647129],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9967636,0.0007203757,0.00056842656,0.00025200457,0.0013137222,0.00038185687],"domain_scores_gemma":[0.9798271,0.017030764,0.000118156706,0.00038419594,0.002520229,0.00011953267],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0083623445,0.00011578309,0.00021312798,0.00022296743,0.0006047273,0.00014302034,0.00050841377,0.00007823301,0.0005718284],"category_scores_gemma":[0.010883857,0.00006187802,0.0001304722,0.00053912355,0.0020121015,0.00017582526,0.00027869872,0.0011089762,0.000012581374],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048115123,0.003927519,0.1898659,0.0012230896,0.0026436946,0.000012290512,0.06174389,0.00090100913,0.067102045,0.0068275575,0.37212336,0.24551453],"study_design_scores_gemma":[0.006095608,0.0027427743,0.49311107,0.000970545,0.00014491916,0.00058236695,0.03045591,0.0019895362,0.023831794,0.068517976,0.37126958,0.00028790487],"about_ca_topic_score_codex":0.00006987263,"about_ca_topic_score_gemma":0.00014518152,"teacher_disagreement_score":0.3032452,"about_ca_system_score_codex":0.0008937563,"about_ca_system_score_gemma":0.00071532046,"threshold_uncertainty_score":0.9974479},"labels":[],"label_agreement":null},{"id":"W4414000156","doi":"10.21203/rs.3.rs-7488427/v1","title":"Tracing the evolutionary trajectory of CDK4/6 inhibitor resistance in oestrogen receptor positive breast cancer","year":2025,"lang":"en","type":"preprint","venue":"Research Square","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research; Department of Health and Social Care; Cancer Research UK; Royal Marsden NHS Foundation Trust; Pfizer","keywords":"Oestrogen receptor; Breast cancer; Tracing; Oncology; Cancer research; Resistance (ecology); Internal medicine; Cancer; Biology; Medicine; Computer science; Ecology","score_opus":0.03201981843941298,"score_gpt":0.3869663867890361,"score_spread":0.3549465683496231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414000156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80075634,0.13490793,0.00027218895,0.03199697,0.0011957423,0.008835812,0.01269768,0.00021101016,0.009126314],"genre_scores_gemma":[0.99169046,0.0013489638,0.0013220124,0.00009295419,0.00085864024,0.001189821,0.00016140289,0.000062761676,0.0032729849],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956903,0.00073474436,0.00061089126,0.0007936256,0.0014283509,0.0007420771],"domain_scores_gemma":[0.9966884,0.0006906825,0.00020122051,0.00093424344,0.0013300275,0.00015540714],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001102293,0.00035074088,0.00071870344,0.00065497303,0.00018689071,0.00002322963,0.0004850012,0.00036478386,0.00033593265],"category_scores_gemma":[0.0002444066,0.00027605807,0.0002682586,0.0010473476,0.0007022169,0.00010355953,0.0005221124,0.0026892954,0.00000831327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09746306,0.0069873645,0.38035867,0.078115955,0.0063411132,0.0009908859,0.06385113,0.011523891,0.087682046,0.009427435,0.03799977,0.21925868],"study_design_scores_gemma":[0.004241592,0.0003172353,0.898234,0.059589125,0.00014072788,0.000049371265,0.006463628,0.00019315117,0.016955901,0.0043950793,0.008633813,0.0007863946],"about_ca_topic_score_codex":0.0013032822,"about_ca_topic_score_gemma":0.0008513969,"teacher_disagreement_score":0.5178753,"about_ca_system_score_codex":0.0024634625,"about_ca_system_score_gemma":0.0033935634,"threshold_uncertainty_score":0.9999692},"labels":[],"label_agreement":null},{"id":"W4414011431","doi":"10.1177/16094069251376201","title":"Design of LONGEVITI (LIVinG with chrONIc cancEr Therapies): A Narrative Arts-Based Study of Living with Advanced Cancers Treated with Targeted Therapy","year":2025,"lang":"en","type":"article","venue":"International Journal of Qualitative Methods","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Alberta","funders":"Social Sciences and Humanities Research Council of Canada","keywords":"Medicine; Narrative; Narrative therapy; Cancer; The arts; Cancer therapy; Oncology; Internal medicine; Art; Visual arts","score_opus":0.19399369681579964,"score_gpt":0.5409394018545264,"score_spread":0.34694570503872674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414011431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5521183,0.0038715694,0.44289356,0.00034433583,0.00008842778,0.0006227852,0.000012121591,0.000013594933,0.00003531754],"genre_scores_gemma":[0.79218733,0.00012184541,0.20723906,0.00015271989,0.00005847179,0.00011920922,0.0000012741846,0.000042573345,0.00007750147],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9953601,0.0022377872,0.00087023573,0.0003229267,0.0009593873,0.00024959436],"domain_scores_gemma":[0.9899902,0.0043832324,0.0017595558,0.00023423684,0.0035473176,0.00008545778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021709872,0.0003746538,0.0010609153,0.00062266097,0.00006905213,0.000014448047,0.00032279894,0.00005441127,0.00017565388],"category_scores_gemma":[0.00037145478,0.0002279689,0.000108752865,0.00075535954,0.00041770804,0.00032638732,0.00002114734,0.00038123774,7.5878e-8],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05392602,0.0024534117,0.063247904,0.00024982833,0.024139069,0.00010991411,0.41112122,0.16696611,0.14640357,0.00017134273,0.000009632429,0.13120198],"study_design_scores_gemma":[0.039071433,0.06413301,0.19205822,0.038033124,0.0012998419,0.00014560255,0.49415627,0.0025188003,0.16695535,0.00034743894,0.00018350319,0.0010974136],"about_ca_topic_score_codex":0.00037888307,"about_ca_topic_score_gemma":0.00025148186,"teacher_disagreement_score":0.24006906,"about_ca_system_score_codex":0.0011160969,"about_ca_system_score_gemma":0.0020509188,"threshold_uncertainty_score":0.9296302},"labels":[],"label_agreement":null},{"id":"W4414098708","doi":"10.3390/curroncol32090503","title":"Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2− Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Exemestane; Everolimus; Metastatic breast cancer; Regimen; Aromatase inhibitor; Breast cancer; Targeted therapy; Clinical trial","score_opus":0.08547068337768098,"score_gpt":0.4293105904515208,"score_spread":0.3438399070738398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414098708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898232,0.0061770473,0.000039742343,0.0008539758,0.001372654,0.0011820191,0.000021175772,0.000038543007,0.0004916474],"genre_scores_gemma":[0.9984006,0.000606171,0.00018274727,0.00019789321,0.00012421234,0.00024977583,0.00000792989,0.00002654835,0.0002040737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982965,0.00018629723,0.0005399619,0.000412558,0.00021603491,0.00034866168],"domain_scores_gemma":[0.9992016,0.0001695619,0.00017213749,0.0002589689,0.00010954758,0.00008816079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022238468,0.00024098344,0.0008052419,0.00042675264,0.000042627515,0.000008029231,0.00010354194,0.000051881492,0.000076795346],"category_scores_gemma":[0.000022013526,0.0002060821,0.000082182836,0.0006013307,0.00012287998,0.00010544678,0.00007875391,0.0003004248,0.0000010609832],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024826308,0.0054595913,0.57086927,0.00014348276,0.00032921776,0.00006981983,0.0024771937,0.000007802432,0.0032595685,0.000035440386,0.00010004644,0.41476592],"study_design_scores_gemma":[0.05948105,0.0034141552,0.87802094,0.0018437435,0.00046384946,0.00009524603,0.00523002,0.00011285016,0.000816846,0.00040412392,0.04964585,0.0004713167],"about_ca_topic_score_codex":0.00028001392,"about_ca_topic_score_gemma":0.0023338892,"teacher_disagreement_score":0.4142946,"about_ca_system_score_codex":0.0006460264,"about_ca_system_score_gemma":0.00027249046,"threshold_uncertainty_score":0.8403784},"labels":[],"label_agreement":null},{"id":"W4414167802","doi":"10.1080/14796694.2025.2550930","title":"Plain language summary of a systematic review of palbociclib treatment for advanced/ metastatic breast cancer in older patients","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"Incyte; Seagen; Gilead Sciences; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Palbociclib; Metastatic breast cancer; Plain language; Breast cancer; MEDLINE","score_opus":0.010316438650245988,"score_gpt":0.35812746572584897,"score_spread":0.34781102707560296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414167802","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14082947,0.8168104,0.0007354042,0.012317286,0.001614736,0.022579245,0.0028095173,0.00008620677,0.0022177242],"genre_scores_gemma":[0.84221435,0.09343115,0.022550484,0.014199866,0.0006548684,0.018263375,0.0008667179,0.00023549408,0.0075837206],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99860334,0.00013344982,0.00069726823,0.00022173971,0.00013134256,0.00021287397],"domain_scores_gemma":[0.9988036,0.0002694925,0.00039144928,0.00031295902,0.00017861262,0.00004387495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017636875,0.00018422164,0.001467228,0.00015858912,0.000014834571,8.7012114e-7,0.00009666052,0.000074464675,0.00009583797],"category_scores_gemma":[0.000080825725,0.0001299451,0.0001643711,0.00030984337,0.000062488645,0.000042785636,0.000021563414,0.00008183874,7.0339064e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002436204,0.0019452837,0.0055968384,0.8829904,0.0009236957,0.00002737169,0.0020642902,0.000013605045,0.00126511,0.00048018614,0.00052425434,0.10173277],"study_design_scores_gemma":[0.05650252,0.004400621,0.042111833,0.8703033,0.0056053083,0.00008938016,0.0071134698,0.000057622277,0.0038483422,0.00039824547,0.00898556,0.0005838344],"about_ca_topic_score_codex":0.00005069191,"about_ca_topic_score_gemma":0.00022355655,"teacher_disagreement_score":0.72337925,"about_ca_system_score_codex":0.0005777945,"about_ca_system_score_gemma":0.00035054272,"threshold_uncertainty_score":0.5299007},"labels":[],"label_agreement":null},{"id":"W4414203572","doi":"10.3390/curroncol32090510","title":"Impact of Body Composition on Progression-Free Survival in Patients with Metastatic Breast Cancer Treated with Ribociclib","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Metastatic breast cancer; Overall survival; Breast cancer; Cancer; Proportional hazards model","score_opus":0.029893520340697498,"score_gpt":0.4138505576164836,"score_spread":0.3839570372757861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414203572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977026,0.0003203628,0.00013677754,0.00038436952,0.00014966307,0.000844087,0.00020071799,0.000033425316,0.00022801752],"genre_scores_gemma":[0.9993393,0.000021156342,0.00025142013,0.00003313703,0.00002873725,0.00014716321,0.00014360389,0.000019492409,0.000015981366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99882036,0.00011967421,0.00026339196,0.0002714406,0.0002641138,0.00026103106],"domain_scores_gemma":[0.99906886,0.00009737726,0.00019695616,0.00028640748,0.00027381832,0.000076572964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007775824,0.00020645789,0.00057144,0.000235458,0.000030832212,0.0000037046364,0.00009892803,0.000048462753,0.00007560219],"category_scores_gemma":[0.000012498826,0.0001236372,0.000054274613,0.00046593286,0.00018509454,0.00007042773,0.000030881045,0.00023202432,0.0000014361448],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019260982,0.0034144435,0.8747679,0.00012576392,0.0003060999,0.000011257598,0.00009593821,0.00012902432,0.00020771137,0.0000558977,0.00006057192,0.10156439],"study_design_scores_gemma":[0.020168904,0.004421319,0.9731678,0.0013746539,0.0002021648,0.000008497314,0.000029936256,0.00006498134,0.0002452793,0.0000444011,0.00015886406,0.00011324041],"about_ca_topic_score_codex":0.00011302586,"about_ca_topic_score_gemma":0.000086617896,"teacher_disagreement_score":0.10145115,"about_ca_system_score_codex":0.00089433603,"about_ca_system_score_gemma":0.0004487499,"threshold_uncertainty_score":0.50417787},"labels":[],"label_agreement":null},{"id":"W4414240310","doi":"10.51731/cjht.2025.1223","title":"Abemaciclib (Verzenio)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fulvestrant; Metastatic breast cancer; Breast cancer; Crizotinib; Cancer; Population; Drug; Chemotherapy","score_opus":0.016496647619343496,"score_gpt":0.3269568899253435,"score_spread":0.310460242306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414240310","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12795791,0.4636574,0.0074591762,0.3940198,0.0017579932,0.00063973357,0.000022099617,0.00042678817,0.004059053],"genre_scores_gemma":[0.99405897,0.00037936613,0.002592132,0.0025298425,0.000011537714,0.0000039583256,7.704302e-7,0.000010542638,0.0004128648],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989321,0.000020942773,0.0004509282,0.00010388173,0.00010431762,0.00038778034],"domain_scores_gemma":[0.99920183,0.00003493607,0.00023344156,0.00025499234,0.0001905836,0.000084216066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030162235,0.000105336345,0.0003969745,0.0008340875,0.00014908667,0.000013367962,0.00021908205,0.00010872307,0.000033674838],"category_scores_gemma":[0.00036846515,0.0000875104,0.0000772673,0.00048945664,0.00024571596,0.00008319933,0.000013396245,0.00043436498,0.000006045503],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039032348,0.000009874781,0.008006866,0.00012666942,0.00006464873,0.00012047795,0.00009726664,0.0000060024977,0.00009741568,0.0035743373,0.0028943222,0.98496306],"study_design_scores_gemma":[0.0012163002,0.00035162878,0.022428978,0.0009090069,0.00002591852,0.00069807743,0.0028233496,0.000004327627,0.002162296,0.017970031,0.9513083,0.00010179685],"about_ca_topic_score_codex":0.0009394843,"about_ca_topic_score_gemma":0.0009095156,"teacher_disagreement_score":0.9848613,"about_ca_system_score_codex":0.0006645732,"about_ca_system_score_gemma":0.0049113138,"threshold_uncertainty_score":0.871246},"labels":[],"label_agreement":null},{"id":"W4414282985","doi":"10.51731/cjht.2025.1226","title":"Abemaciclib (Verzenio)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Metastatic breast cancer; Breast cancer; Drug; Chemotherapy; Aromatase; Cancer","score_opus":0.016496647619343496,"score_gpt":0.3269568899253435,"score_spread":0.310460242306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414282985","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12795791,0.4636574,0.0074591762,0.3940198,0.0017579932,0.00063973357,0.000022099617,0.00042678817,0.004059053],"genre_scores_gemma":[0.99405897,0.00037936613,0.002592132,0.0025298425,0.000011537714,0.0000039583256,7.704302e-7,0.000010542638,0.0004128648],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989321,0.000020942773,0.0004509282,0.00010388173,0.00010431762,0.00038778034],"domain_scores_gemma":[0.99920183,0.00003493607,0.00023344156,0.00025499234,0.0001905836,0.000084216066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030162235,0.000105336345,0.0003969745,0.0008340875,0.00014908667,0.000013367962,0.00021908205,0.00010872307,0.000033674838],"category_scores_gemma":[0.00036846515,0.0000875104,0.0000772673,0.00048945664,0.00024571596,0.00008319933,0.000013396245,0.00043436498,0.000006045503],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039032348,0.000009874781,0.008006866,0.00012666942,0.00006464873,0.00012047795,0.00009726664,0.0000060024977,0.00009741568,0.0035743373,0.0028943222,0.98496306],"study_design_scores_gemma":[0.0012163002,0.00035162878,0.022428978,0.0009090069,0.00002591852,0.00069807743,0.0028233496,0.000004327627,0.002162296,0.017970031,0.9513083,0.00010179685],"about_ca_topic_score_codex":0.0009394843,"about_ca_topic_score_gemma":0.0009095156,"teacher_disagreement_score":0.9848613,"about_ca_system_score_codex":0.0006645732,"about_ca_system_score_gemma":0.0049113138,"threshold_uncertainty_score":0.871246},"labels":[],"label_agreement":null},{"id":"W4414294940","doi":"10.14740/jmc5163","title":"Acute Hepatitis in a Patient Treated With Ribociclib for Metastatic Breast Carcinoma","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Hepatocellular carcinoma; Discontinuation; Cirrhosis; Liver injury; Liver biopsy; Adverse effect; Liver disease; Hepatitis","score_opus":0.015122348738575314,"score_gpt":0.3164129143673272,"score_spread":0.3012905656287519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414294940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98639446,0.0016224555,0.0028843924,0.008565459,0.00010556369,0.00031404514,0.00005103123,0.000010388379,0.000052225103],"genre_scores_gemma":[0.9955598,0.00012543832,0.0027323237,0.0013460745,0.00009552801,0.000030448915,0.0000075150847,0.0000157385,0.00008713532],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984188,0.00005127003,0.00051574357,0.00012546228,0.000669388,0.00021931376],"domain_scores_gemma":[0.9988006,0.0003718755,0.00021689963,0.00011769829,0.00026488904,0.00022808938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023378387,0.00013842882,0.0005383468,0.0002505096,0.00003056615,0.000009956563,0.00009977454,0.00005790171,0.00014610527],"category_scores_gemma":[0.0003234731,0.000086654225,0.00011734747,0.0003086832,0.00011860334,0.00009598646,0.000019548896,0.00026997543,7.167307e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024658877,0.001928078,0.38596803,0.0006964633,0.0020597489,0.054325745,0.000925763,0.000037165923,0.000703064,0.00041063636,0.0036407865,0.5246456],"study_design_scores_gemma":[0.116259575,0.028581498,0.45651188,0.015986802,0.0058208206,0.3051636,0.0051403404,0.002960816,0.015764387,0.0020374374,0.044720486,0.0010523384],"about_ca_topic_score_codex":0.00017648125,"about_ca_topic_score_gemma":0.00014739842,"teacher_disagreement_score":0.5235933,"about_ca_system_score_codex":0.00020586101,"about_ca_system_score_gemma":0.00064160686,"threshold_uncertainty_score":0.35336566},"labels":[],"label_agreement":null},{"id":"W4414508430","doi":"10.1001/jamaoncol.2025.3700","title":"Ribociclib Plus Endocrine Therapy in Hormone Receptor–Positive/ <i>ERBB2</i> -Negative Early Breast Cancer","year":2025,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"BC Cancer Agency; College of Medicine, Seoul National University; University of California, Los Angeles; Instituto de Investigación Sanitaria Gregorio Marañón; Peter MacCallum Cancer Centre; Chinese Academy of Medical Sciences; Seoul National University Hospital; Universidad Complutense de Madrid; Seoul National University; Peking Union Medical College; University of Washington; University of Texas MD Anderson Cancer Center; Novartis Pharmaceuticals Corporation; Cancer Research Institute","keywords":"Endocrine system; Breast cancer; Hormone receptor; Cancer; Hormone therapy; Hormone","score_opus":0.012892989743431714,"score_gpt":0.33173204803363404,"score_spread":0.3188390582902023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414508430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91004145,0.006541041,0.0003411612,0.06434149,0.00078277645,0.0013554122,0.00021382562,0.00017897446,0.01620389],"genre_scores_gemma":[0.9768889,0.0030818658,0.0018078367,0.012771964,0.00058928656,0.000608802,0.000031079348,0.000054980886,0.00416531],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99793535,0.00021798031,0.00045998066,0.000549645,0.00022388317,0.0006131628],"domain_scores_gemma":[0.9986334,0.00040857415,0.00017176426,0.00035346634,0.00029273154,0.00014007262],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019986802,0.00032029382,0.00081894035,0.00029329,0.000085453175,0.000020061843,0.00020555758,0.00025036518,0.00045708372],"category_scores_gemma":[0.00007143111,0.00028315213,0.00012547382,0.00078893115,0.00034557405,0.00025110593,0.000097606404,0.00071558234,0.00005387746],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022445276,0.0007477313,0.032375738,0.000048666567,0.00057330047,0.0003187985,0.0032506578,0.000057025536,0.07367278,0.0014710256,0.0057382053,0.8593008],"study_design_scores_gemma":[0.033064425,0.001752863,0.7713318,0.00036204967,0.000074112824,0.00023281759,0.00078869925,0.000058701247,0.016406564,0.0017110651,0.17382136,0.0003955858],"about_ca_topic_score_codex":0.0025241338,"about_ca_topic_score_gemma":0.00054503646,"teacher_disagreement_score":0.8589052,"about_ca_system_score_codex":0.0021141279,"about_ca_system_score_gemma":0.0009458327,"threshold_uncertainty_score":0.9999621},"labels":[],"label_agreement":null},{"id":"W4414781849","doi":"10.3390/curroncol32100556","title":"Locoregional Treatment in De Novo Bone-Only Metastatic Breast Cancer: Prospective, Multi-Institutional Real-World Data, BOMETIN, Protocol MF14-1a","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Cohort; Breast cancer; Metastatic breast cancer; Systemic therapy; Overall survival; Cancer; Cohort study; Prospective cohort study","score_opus":0.14195975347552103,"score_gpt":0.4946694173711277,"score_spread":0.35270966389560665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414781849","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34573036,0.008558782,0.035797354,0.05387625,0.0076126214,0.5207504,0.007614043,0.0015050115,0.018555207],"genre_scores_gemma":[0.45288113,0.0008324586,0.034008387,0.0017855403,0.0017173314,0.50301814,0.0011866961,0.00014195198,0.0044283704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976004,0.00016213089,0.0005829225,0.0007921314,0.0002652409,0.00059717504],"domain_scores_gemma":[0.99860966,0.00016632503,0.00024011792,0.0005849889,0.00022012004,0.00017880384],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029432125,0.00038302114,0.0008479735,0.000540868,0.00012594498,0.000015280137,0.00027107337,0.00006994608,0.00017904487],"category_scores_gemma":[0.000056492438,0.00030507537,0.0001070902,0.00086822157,0.0005801232,0.00018778861,0.00016979597,0.0003972625,0.000022210277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.003984056,0.0046631335,0.5474853,0.00031892073,0.00027525853,0.00022756009,0.0002353052,0.00011740385,0.00015464368,0.0042844806,0.0005164055,0.43773755],"study_design_scores_gemma":[0.020657534,0.0005214015,0.5291469,0.0005309892,0.00022971808,0.00061985315,0.0001333385,0.0008375813,0.00010021249,0.00053048367,0.44642055,0.00027146132],"about_ca_topic_score_codex":0.0011234233,"about_ca_topic_score_gemma":0.017477171,"teacher_disagreement_score":0.44590414,"about_ca_system_score_codex":0.006036646,"about_ca_system_score_gemma":0.0058914702,"threshold_uncertainty_score":0.99994016},"labels":[],"label_agreement":null},{"id":"W4415279920","doi":"10.1016/j.annonc.2025.07.002","title":"Corrigendum to “Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3”","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham","funders":"","keywords":"Aromatase inhibitor; Nonsteroidal; Aromatase; Overall survival; Letrozole","score_opus":0.10947747122385279,"score_gpt":0.4493020162833795,"score_spread":0.33982454505952675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415279920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96722037,0.0013653834,0.0004285139,0.022736492,0.0016111229,0.0017648374,0.003176933,0.000055942433,0.0016403828],"genre_scores_gemma":[0.9899212,0.00050799735,0.0019243314,0.00499633,0.00044901166,0.00040633345,0.00017431905,0.000044951634,0.0015755191],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997564,0.00012765198,0.00088136486,0.0005338618,0.00033088643,0.00056222675],"domain_scores_gemma":[0.997794,0.00032780814,0.00040121685,0.00048195405,0.0007901809,0.00020484401],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040827476,0.0003081655,0.0011084528,0.00030616278,0.000071365874,0.000005861422,0.00026848607,0.00021990393,0.000095333155],"category_scores_gemma":[0.00017237927,0.00028559047,0.00023757407,0.00036293882,0.00029494776,0.000121124875,0.00010971771,0.0002351077,0.000008775626],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24876848,0.0015758375,0.0020202957,0.00040114365,0.00065414415,0.000091366026,0.001422191,0.0003132982,0.06000042,0.00077240105,0.01049848,0.67348194],"study_design_scores_gemma":[0.09166903,0.030778699,0.05571725,0.0017655157,0.00020854076,0.00031754255,0.001372352,0.000220042,0.3008392,0.0039555086,0.51224697,0.000909359],"about_ca_topic_score_codex":0.00068349554,"about_ca_topic_score_gemma":0.0002717424,"teacher_disagreement_score":0.6725726,"about_ca_system_score_codex":0.00015942293,"about_ca_system_score_gemma":0.0017066426,"threshold_uncertainty_score":0.99995965},"labels":[],"label_agreement":null},{"id":"W4415368586","doi":"10.1016/j.annonc.2025.10.006","title":"Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Takeda Oncology; Chugai Pharmaceutical; Weill Cornell Medical College; Daiichi Sankyo Company; Pfizer Japan; Unicancer; Ipsen; Eisai; Relay Therapeutics; Seagen; European Social Fund; Puma Biotechnology; Pfizer; Fondazione Internazionale Menarini; Genentech; Lilly Deutschland; Veracyte; Mersana Therapeutics; Helsinn; Les Laboratories Pierre Fabre; Menarini Silicon Biosystems; Friedrich-Alexander-Universität Erlangen-Nürnberg; Eisai Korea; Ipsen Biopharmaceuticals; F. Hoffmann-La Roche; Daiichi Sankyo Europe; Novartis Foundation; Gilead Sciences; Sanofi; Celgene; Universität Ulm; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Emory University","keywords":"Clinical trial; Disease; Breast cancer; Safety profile; MEDLINE","score_opus":0.02773852152055462,"score_gpt":0.35713053667040384,"score_spread":0.3293920151498492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415368586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899072,0.00040781003,0.000015866983,0.007776432,0.00016500063,0.0015871119,0.0000804707,0.000011726212,0.000048371985],"genre_scores_gemma":[0.99859726,0.0002897129,0.0001472525,0.00055804825,0.00002304235,0.00032785296,0.000025836203,0.000014919416,0.000016043212],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984225,0.00009177727,0.00072985596,0.00025351992,0.00024378113,0.00025855942],"domain_scores_gemma":[0.9988239,0.00020207331,0.00038470625,0.00025355094,0.00029256364,0.000043203538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012467256,0.00019005695,0.00067934976,0.0002779287,0.000038622686,0.0000025496097,0.000079950994,0.00006496008,0.000027610138],"category_scores_gemma":[0.00006705748,0.00012391225,0.00007060023,0.0004115408,0.00017272659,0.000077378994,0.000020953894,0.00017383312,1.0393381e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1909062,0.0039545074,0.687544,0.00023224649,0.00041774346,0.00007602242,0.0019760546,0.005445114,0.000921569,0.000028324477,0.000012905918,0.10848535],"study_design_scores_gemma":[0.14923157,0.0035294811,0.8419832,0.00031240954,0.000043778196,0.0000066272405,0.00039705128,0.00003689259,0.0039296965,0.00006715967,0.00034783324,0.000114320916],"about_ca_topic_score_codex":0.00057432987,"about_ca_topic_score_gemma":0.0012718571,"teacher_disagreement_score":0.15443923,"about_ca_system_score_codex":0.00010399493,"about_ca_system_score_gemma":0.00045934969,"threshold_uncertainty_score":0.50529945},"labels":[],"label_agreement":null},{"id":"W4415437777","doi":"10.1158/2767-9764.crc-25-0346","title":"Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer","year":2025,"lang":"en","type":"article","venue":"Cancer Research Communications","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre; University of Waterloo; Wilfrid Laurier University; Université Laval; Centre hospitalier de l'Université Laval; Kingston Health Sciences Centre; Interior Health; University Health Network; Ottawa Hospital; Centre hospitalier universitaire de Québec; BC Cancer Agency; Research Canada; University of Alberta; University of Toronto; Toronto Public Health; Cancer Care South East; Public Health Ontario; Ontario Institute for Cancer Research","funders":"Canadian Cancer Society; Pfizer Canada; Government of Ontario; Memorial Sloan-Kettering Cancer Center; Pfizer","keywords":"Palbociclib; Liquid biopsy; Dosing; Breast cancer; Profiling (computer programming); Clinical trial","score_opus":0.08343511337705574,"score_gpt":0.48942236705346986,"score_spread":0.40598725367641414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415437777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91802,0.06153948,0.000023035276,0.0175569,0.00005744568,0.0020410193,0.00025077592,0.000018663348,0.00049266923],"genre_scores_gemma":[0.9643489,0.032453563,0.0008229794,0.0000616696,0.000028116543,0.0021620756,0.000016483687,0.000017719345,0.00008850158],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983488,0.00041599644,0.0003482042,0.00026791534,0.00028220747,0.00033689576],"domain_scores_gemma":[0.9979497,0.0006513501,0.00007623749,0.00097340974,0.00028794407,0.00006131562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006484568,0.00015052831,0.0004201988,0.00030993778,0.0001612826,0.000024746447,0.00036373507,0.00006787025,0.000017988714],"category_scores_gemma":[0.00015857304,0.000114939234,0.000038150603,0.00074181025,0.00085408136,0.00010524604,0.00023749706,0.00040104365,2.7048884e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42493826,0.0015226954,0.022927614,0.00074748986,0.0008853575,0.000045673278,0.020487174,0.0002901012,0.10901184,0.012255815,0.000091198766,0.40679678],"study_design_scores_gemma":[0.521468,0.016383093,0.054778174,0.01059099,0.00063476193,0.00006893055,0.090961166,0.0012370679,0.19980764,0.006334464,0.096288204,0.0014475394],"about_ca_topic_score_codex":0.0016655738,"about_ca_topic_score_gemma":0.0037815247,"teacher_disagreement_score":0.40534925,"about_ca_system_score_codex":0.00056515617,"about_ca_system_score_gemma":0.0006562153,"threshold_uncertainty_score":0.4687086},"labels":[],"label_agreement":null},{"id":"W4415559897","doi":"10.3390/ijms262110366","title":"Navigating Treatment Sequencing in Advanced HR+/HER2− Breast Cancer After CDK4/6 Inhibitors: Biomarker-Driven Strategies and Emerging Therapies","year":2025,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Breast cancer; Metastatic breast cancer; Precision medicine; Cancer; Estrogen receptor; Personalized medicine; Targeted therapy; Clinical trial","score_opus":0.02745395676239146,"score_gpt":0.39727554851914,"score_spread":0.3698215917567485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415559897","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.037825357,0.960141,0.0002414183,0.00069813675,0.0006658124,0.0003106491,0.000039714956,0.000013221467,0.00006466249],"genre_scores_gemma":[0.06947214,0.9268481,0.0032101725,0.00011808816,0.00023430372,0.00007118874,0.000004759029,0.00002534045,0.000015876863],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99751115,0.00013297932,0.0009003625,0.0003972572,0.0007746849,0.000283594],"domain_scores_gemma":[0.99845266,0.0001443403,0.0008216115,0.00012967737,0.00035678138,0.00009490078],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033885034,0.00039867577,0.0010419493,0.00048915175,0.0000661826,0.00020700507,0.00039102614,0.00011333472,0.000037816917],"category_scores_gemma":[0.0000394316,0.0002785069,0.00034960711,0.00050926075,0.00032943205,0.0006645656,0.00009270188,0.00039950197,6.392358e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010079147,0.000030834544,0.00037410858,0.00072166737,0.0005449734,0.0006555379,0.0007701232,0.0004168948,0.00050184474,0.000042869317,5.9353994e-7,0.9958398],"study_design_scores_gemma":[0.009677686,0.0019045209,0.0031754614,0.7456667,0.0027442712,0.017259216,0.023650253,0.0007531564,0.0012406908,0.0024744333,0.18871623,0.0027373992],"about_ca_topic_score_codex":0.00019827882,"about_ca_topic_score_gemma":0.00006378637,"teacher_disagreement_score":0.9931024,"about_ca_system_score_codex":0.0016256694,"about_ca_system_score_gemma":0.0028241882,"threshold_uncertainty_score":0.9999667},"labels":[],"label_agreement":null},{"id":"W4415592687","doi":"10.1159/000549179","title":"Ribociclib-Induced Hepatitis: A Case Report of Possible Autoimmune Hepatotoxicity","year":2025,"lang":"en","type":"article","venue":"Case Reports in Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Liver enzyme; Kinase; Liver damage; Autoimmune disease; Enzyme; Elevated liver enzymes; Liver injury","score_opus":0.021952236381200252,"score_gpt":0.3644575798417199,"score_spread":0.34250534346051964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415592687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98680454,0.001105107,0.00041899565,0.00068598834,0.000932429,0.000799623,0.000006806307,0.00011078017,0.009135718],"genre_scores_gemma":[0.99506795,0.000039521063,0.0030009465,0.00037529945,0.00007020664,0.00017055093,0.000015506666,0.00002904495,0.0012309677],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9971844,0.00012750365,0.0015360995,0.000569255,0.0001856897,0.00039703585],"domain_scores_gemma":[0.9975618,0.00022597781,0.00076627784,0.0010234683,0.00030531385,0.00011715597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008957442,0.00023875164,0.0010221094,0.00040564805,0.00008426042,0.0000059202494,0.00004544587,0.00033297617,0.00013390808],"category_scores_gemma":[0.0009235356,0.00023405503,0.0001609615,0.00070337654,0.00024256452,0.00010495887,0.000121715275,0.00044965366,0.0000019239255],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022868066,0.00046702177,0.065111935,0.00016556875,0.00013253807,0.8911087,0.0003821923,0.000016828097,0.009100075,0.00013769304,0.00007894065,0.033069815],"study_design_scores_gemma":[0.0015549539,0.00038629674,0.011855124,0.00025838456,0.00011767931,0.9600187,0.00045913135,0.00011247309,0.017824458,0.001039187,0.0062106866,0.00016293292],"about_ca_topic_score_codex":0.0047794767,"about_ca_topic_score_gemma":0.0018981159,"teacher_disagreement_score":0.06890998,"about_ca_system_score_codex":0.0009918369,"about_ca_system_score_gemma":0.0016979083,"threshold_uncertainty_score":0.9544487},"labels":[],"label_agreement":null},{"id":"W4415790664","doi":"10.1161/circ.152.suppl_3.4365249","title":"Abstract 4365249: Treatment Modality and Cardiovascular Mortality in Breast Cancer: A SEER and Single-Center Analysis by Stage and Receptor Subtype","year":2025,"lang":"en","type":"article","venue":"Circulation","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Stage (stratigraphy); Breast cancer; Hazard ratio; Proportional hazards model; Chemotherapy; Cancer; Radiation therapy","score_opus":0.020632505869532407,"score_gpt":0.29050275532651887,"score_spread":0.26987024945698646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415790664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920508,0.006244573,0.0005646996,0.0004986133,0.000036638612,0.0003554944,0.00014603724,0.000023913803,0.000079190555],"genre_scores_gemma":[0.9991966,0.00047622577,0.00006011624,0.00006339436,0.00002501718,0.000039504608,0.00008711236,0.000009267035,0.000042801414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912405,0.00003946323,0.00019397071,0.000367524,0.0001379718,0.0001369999],"domain_scores_gemma":[0.9995719,0.000021764381,0.000052421263,0.00023161455,0.000053834687,0.00006846718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014470334,0.00014150278,0.00038909947,0.00013196484,0.000045255747,0.000024089226,0.000015894915,0.00007126141,0.00004123318],"category_scores_gemma":[0.000007448697,0.00012985595,0.00008064659,0.00030411858,0.00007550058,0.0001259394,0.000014603225,0.00006183683,2.7013886e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012591627,0.00010358035,0.9564583,0.00009914414,0.0015419101,0.0000030148126,0.0002041255,0.0003892578,0.005116751,0.000011966062,0.000003121537,0.035942968],"study_design_scores_gemma":[0.0020169045,0.0000125803335,0.99532175,0.000057515037,0.0007150621,0.0000052033547,0.00012283132,0.00084449793,0.00020977786,0.00004768031,0.0005465651,0.0000996253],"about_ca_topic_score_codex":0.0026210786,"about_ca_topic_score_gemma":0.00040164104,"teacher_disagreement_score":0.03886351,"about_ca_system_score_codex":0.00031065624,"about_ca_system_score_gemma":0.000042309046,"threshold_uncertainty_score":0.5295372},"labels":[],"label_agreement":null},{"id":"W4415900229","doi":"10.1136/jitc-2025-sitc2025.1235","title":"1235 Abemaciclib differentially reshapes the immunopeptidome of breast cancer subtypes","year":2025,"lang":"","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"Breast cancer; Cancer; Human breast; Clinical trial","score_opus":0.009399993672740354,"score_gpt":0.2676627313144038,"score_spread":0.25826273764166346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415900229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8751539,0.106463365,0.000141937,0.012709528,0.0021622907,0.0015539995,0.00046108972,0.000113881135,0.0012400178],"genre_scores_gemma":[0.9862212,0.006515345,0.00020880732,0.0012823861,0.0007413664,0.00014718107,0.00002554336,0.000095868214,0.004762326],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99572235,0.00024028686,0.0013931274,0.0009059727,0.000803404,0.00093483616],"domain_scores_gemma":[0.9967228,0.00025471626,0.0007572979,0.0011306475,0.00051644584,0.0006180622],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.00067972054,0.0008064484,0.0012996182,0.0002900256,0.0005001961,0.00016152515,0.00060401316,0.0004221396,0.00024848417],"category_scores_gemma":[0.00022375281,0.0005909158,0.00035401725,0.0007256997,0.002934543,0.0003757402,0.00029340445,0.0008676081,0.000017071743],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057429937,0.0011098281,0.16174278,0.0100425985,0.008796205,0.00018397604,0.005215791,0.00060124765,0.6160951,0.013414974,0.0032229843,0.17383151],"study_design_scores_gemma":[0.004458613,0.00020922557,0.8711308,0.006347006,0.0020133755,0.00031250538,0.0013074562,0.00013723118,0.07412088,0.0055682776,0.033575706,0.00081892096],"about_ca_topic_score_codex":0.0010501994,"about_ca_topic_score_gemma":0.00017749766,"teacher_disagreement_score":0.709388,"about_ca_system_score_codex":0.00024409313,"about_ca_system_score_gemma":0.0018425204,"threshold_uncertainty_score":0.9997789},"labels":[],"label_agreement":null},{"id":"W4415940075","doi":"10.1016/j.annonc.2025.08.971","title":"548P Phase I/Ib trial of inavolisib (INAVO) + pertuzumab (P) + trastuzumab (H) for PIK3CA-mutated (mut), HER2-positive advanced breast cancer (HER2+ aBC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Pertuzumab; Trastuzumab; Palbociclib; Fulvestrant; Chemotherapy; Cohort; Breast cancer; Clinical trial","score_opus":0.0452135782774123,"score_gpt":0.44670831638304226,"score_spread":0.40149473810562997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95557785,0.0036893848,0.0036287368,0.025109109,0.0014104482,0.0043164683,0.0017645381,0.00013081661,0.0043726717],"genre_scores_gemma":[0.9927827,0.0009302416,0.0017892807,0.0021138063,0.00037375843,0.0007449671,0.0001469196,0.00007288426,0.001045449],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99697024,0.00018577324,0.0011334502,0.0006539897,0.0003416054,0.0007149266],"domain_scores_gemma":[0.9963877,0.0006647699,0.0007335742,0.00053733133,0.0014823601,0.00019421647],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037028798,0.00044647753,0.0017557653,0.000402166,0.000119401506,0.00000792345,0.00031720012,0.00036866608,0.00024121249],"category_scores_gemma":[0.00027178245,0.00041189493,0.00046646313,0.00066024,0.00063225854,0.00023261523,0.00008318984,0.00035304733,0.0000034462464],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31497318,0.005267613,0.00010598406,0.00045969116,0.0012241396,0.000054130203,0.0013440818,0.00015675115,0.022743197,0.0009799962,0.001906768,0.6507845],"study_design_scores_gemma":[0.6013374,0.063949816,0.005891231,0.0023757091,0.0014881374,0.00041137348,0.003171988,0.0007841747,0.17305133,0.004720155,0.14172477,0.0010939531],"about_ca_topic_score_codex":0.00050005707,"about_ca_topic_score_gemma":0.0001560314,"teacher_disagreement_score":0.6496905,"about_ca_system_score_codex":0.0005085304,"about_ca_system_score_gemma":0.0018771644,"threshold_uncertainty_score":0.9998333},"labels":[],"label_agreement":null},{"id":"W4415941573","doi":"10.1016/j.annonc.2025.08.930","title":"507P Real-world outcomes of patients with advanced or metastatic HR+/HER2- breast cancer treated with CDK4/6 inhibitors","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; London Health Sciences Centre; Institute for Clinical Evaluative Sciences; Western University","funders":"Canadian Institutes of Health Research","keywords":"Palbociclib; Metastatic breast cancer; Breast cancer; Clinical trial; Randomized controlled trial; Endocrine system; Hormone receptor; Cancer","score_opus":0.032758316782611825,"score_gpt":0.3870564967107744,"score_spread":0.3542981799281626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910362,0.00027709175,0.000067298184,0.0047907443,0.00011009094,0.0008904539,0.0002400027,0.000055582877,0.002532557],"genre_scores_gemma":[0.9932923,0.00023539035,0.0023796994,0.0013840825,0.000026545376,0.00015591699,0.000040948165,0.000043841064,0.0024412978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827224,0.000088689594,0.0005787033,0.000360075,0.00031625893,0.00038404795],"domain_scores_gemma":[0.99779683,0.0002527196,0.0005342883,0.0003999389,0.00089923653,0.00011701139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116575495,0.00030348264,0.0012553321,0.00037312057,0.00004239985,0.0000029957155,0.0001371606,0.00007314287,0.000259493],"category_scores_gemma":[0.0000425792,0.00018039386,0.00009569879,0.0008901995,0.00043040857,0.00014717777,0.000041459716,0.00017254411,0.000001894077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024281241,0.0013534735,0.7940135,0.00031851232,0.0016976146,0.000041246323,0.00026360794,0.0001784971,0.00046086675,0.00017078266,0.00041830252,0.17680234],"study_design_scores_gemma":[0.011584634,0.0053642066,0.96296924,0.0006978676,0.0004919943,0.000011446971,0.00031631222,0.0000056010485,0.009034057,0.0000868932,0.009221453,0.0002162658],"about_ca_topic_score_codex":0.0010546471,"about_ca_topic_score_gemma":0.0028465237,"teacher_disagreement_score":0.17658608,"about_ca_system_score_codex":0.0001539892,"about_ca_system_score_gemma":0.00072441075,"threshold_uncertainty_score":0.73562485},"labels":[],"label_agreement":null},{"id":"W4415941623","doi":"10.1016/j.annonc.2025.08.942","title":"519P Real-world effectiveness of 1st line palbociclib + endocrine therapy and subsequent treatments in patients with HR+/HER2- advanced breast cancer: Interim results from the PERFORM study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Palbociclib; Interim; Second line; Endocrine system; Interim analysis; Line (geometry)","score_opus":0.0453364453890282,"score_gpt":0.3955320625878051,"score_spread":0.3501956171987769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945478,0.0008835594,0.0000035067592,0.0018794718,0.00012402193,0.0017815925,0.00035542663,0.000017807528,0.00040682688],"genre_scores_gemma":[0.99725515,0.0018725684,0.00009752494,0.000319532,0.00003803727,0.0002356827,0.00007407139,0.000024252402,0.000083174724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998189,0.0003178291,0.00056776893,0.00042662537,0.00021348405,0.00028532738],"domain_scores_gemma":[0.9980567,0.00070501235,0.00035020921,0.00044846846,0.00037885696,0.000060729835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003463984,0.0002615898,0.0008984289,0.0001675555,0.000045420038,0.0000041492317,0.00015958409,0.000056930232,0.00003426912],"category_scores_gemma":[0.000042984317,0.00016045345,0.00006097651,0.000431357,0.0002777802,0.00010032596,0.000077457385,0.00020126245,3.937901e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06314666,0.0024379718,0.661246,0.00004664003,0.0006557159,0.000014299445,0.00094496406,0.000041372637,0.0007202688,0.00001634898,0.000008143929,0.27072158],"study_design_scores_gemma":[0.035520654,0.008864855,0.9464706,0.00072332786,0.00009697179,0.0000024469055,0.00057404715,0.0000069423772,0.006947947,0.00011371406,0.00056805875,0.00011042717],"about_ca_topic_score_codex":0.006132513,"about_ca_topic_score_gemma":0.0042850813,"teacher_disagreement_score":0.2852246,"about_ca_system_score_codex":0.00021735068,"about_ca_system_score_gemma":0.00024300133,"threshold_uncertainty_score":0.92705655},"labels":[],"label_agreement":null},{"id":"W4415942060","doi":"10.1016/j.annonc.2025.08.797","title":"372P A NATALEE data–based machine learning (ML) model to predict distant recurrence (DR) and treatment (tx) effect in real-world (RW) patients (pts) with HR+/HER2– early breast cancer (EBC) without CDK4/6 inhibitor (CDK4/6i) tx","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Aromatase inhibitor; Breast cancer; Adjuvant; Aromatase; Cancer; Letrozole","score_opus":0.048406500609201604,"score_gpt":0.39043368077632307,"score_spread":0.34202718016712147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905254,0.0010377561,0.0005449462,0.0039411946,0.00017039187,0.0018603025,0.0011159447,0.00008393623,0.000720102],"genre_scores_gemma":[0.9960627,0.00046447737,0.0011526969,0.0008163023,0.00009127141,0.0004482715,0.0002683436,0.000056901317,0.000639055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99724865,0.00025913632,0.00060339714,0.0009167801,0.0003799486,0.0005920871],"domain_scores_gemma":[0.9980991,0.00029715008,0.0003300412,0.00071382156,0.0002970374,0.00026284938],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042460824,0.00046322637,0.0011174995,0.00046191155,0.00010168845,0.000017816796,0.0002742287,0.00014521331,0.00003321885],"category_scores_gemma":[0.00009980267,0.0003507585,0.00006750954,0.0006590261,0.00029374316,0.0002531003,0.00019566489,0.00042868534,0.000002930412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021304777,0.0010655669,0.7344514,0.00029818586,0.00036688783,0.00006844962,0.0008055411,0.002246943,0.00066228415,0.00003136734,0.00025815514,0.23844044],"study_design_scores_gemma":[0.038584106,0.032031767,0.8649472,0.0056333626,0.0006704915,0.000037278092,0.000163986,0.035688404,0.0043371343,0.00017148432,0.016753323,0.0009814353],"about_ca_topic_score_codex":0.0057699503,"about_ca_topic_score_gemma":0.01237186,"teacher_disagreement_score":0.237459,"about_ca_system_score_codex":0.0005730047,"about_ca_system_score_gemma":0.00077180495,"threshold_uncertainty_score":0.99989444},"labels":[],"label_agreement":null},{"id":"W4415942260","doi":"10.1016/j.annonc.2025.08.791","title":"366P Impact of neoadjuvant chemotherapy (NACT) response on clinical outcomes with ribociclib (RIB) in HR+/HER2− EBC: A subgroup analysis from the phase 3 NATALEE trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Subgroup analysis; Chemotherapy; Clinical trial; Population; Complete response; Phases of clinical research; Chinese population","score_opus":0.09594002647997328,"score_gpt":0.5289163602019209,"score_spread":0.4329763337219476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98331165,0.0005648226,0.00025379672,0.014471881,0.00014182391,0.00081594626,0.00017062193,0.000023650155,0.0002457909],"genre_scores_gemma":[0.99412805,0.00025918538,0.00040588982,0.004769334,0.0001100039,0.00004941011,0.00004302894,0.000024250096,0.00021082621],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99695116,0.0008253453,0.001107393,0.00044156634,0.00031479774,0.00035976127],"domain_scores_gemma":[0.99334586,0.004839475,0.000633256,0.0008324766,0.00024083011,0.00010809837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018353498,0.0002808887,0.001878953,0.00042537312,0.000036512058,0.000005892753,0.0003152323,0.0002642561,0.00027629174],"category_scores_gemma":[0.0009118224,0.0001625078,0.00081676367,0.001068331,0.0005321596,0.000072948846,0.000045019762,0.00047848484,0.0000030173153],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65278506,0.0035552725,0.24394979,0.000010905872,0.0062237214,0.00007888077,0.0007292552,0.000110294735,0.00081925176,0.000047598125,0.0006850239,0.09100495],"study_design_scores_gemma":[0.14656477,0.027678885,0.8174947,0.00013482328,0.00072526926,0.0000045717934,0.00034049677,0.00011804419,0.0015358613,0.00039651507,0.004844297,0.00016181362],"about_ca_topic_score_codex":0.0014136554,"about_ca_topic_score_gemma":0.00070096133,"teacher_disagreement_score":0.57354486,"about_ca_system_score_codex":0.00019209637,"about_ca_system_score_gemma":0.0010357358,"threshold_uncertainty_score":0.6626876},"labels":[],"label_agreement":null},{"id":"W4416003752","doi":"10.1038/s41698-025-01106-1","title":"Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterations","year":2025,"lang":"en","type":"article","venue":"npj Precision Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Instituto de Salud Carlos III; European Regional Development Fund; Bayer Canada; European Commission","keywords":"Fibroblast growth factor receptor; Breast cancer; Clinical trial; Acquired resistance; Endocrine system; Biomarker; Cancer","score_opus":0.028800045819358987,"score_gpt":0.4263399839146925,"score_spread":0.39753993809533356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416003752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9692249,0.004151049,0.0040629245,0.0129608605,0.0007768555,0.0019923688,0.00013269717,0.00007621737,0.006622154],"genre_scores_gemma":[0.9887955,0.0009361377,0.006476313,0.0016987377,0.0005121234,0.00031570983,0.000041821615,0.00002875851,0.0011948668],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99776465,0.00036931477,0.00073965755,0.0005649568,0.00023075727,0.00033065892],"domain_scores_gemma":[0.9979524,0.0011920575,0.00021072333,0.00026487844,0.00023802658,0.00014192137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077366846,0.00020968629,0.00071582856,0.00023054838,0.0001464802,0.000022200475,0.00010433463,0.00025649436,0.0001863162],"category_scores_gemma":[0.00031649828,0.00016230563,0.0000681398,0.0003582382,0.000316649,0.0001403023,0.000059629827,0.00055657054,0.000008777005],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40944064,0.0011737216,0.017080395,0.00004074723,0.00031231373,0.00023275585,0.0010356318,0.000096407246,0.012953494,0.00066040445,0.0045221066,0.5524514],"study_design_scores_gemma":[0.21604966,0.009533534,0.6396502,0.0011743823,0.00036254403,0.0002681703,0.0012358519,0.00054495555,0.0017570965,0.0019585907,0.12689419,0.0005708206],"about_ca_topic_score_codex":0.00018320646,"about_ca_topic_score_gemma":0.0006161681,"teacher_disagreement_score":0.6225698,"about_ca_system_score_codex":0.00050993444,"about_ca_system_score_gemma":0.00088202313,"threshold_uncertainty_score":0.66186315},"labels":[],"label_agreement":null},{"id":"W4416018018","doi":"10.1101/2025.11.06.686927","title":"Discovery and chemical biology of CDK8 inhibitors reveals insights for kinase inhibitor development","year":2025,"lang":"","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Institut National Du Cancer; National Cancer Institute; Ligue Contre le Cancer","keywords":"Kinase; Chemical biology; Mediator; Drug discovery; Cytotoxic T cell; DNA damage; Protein kinase A; Signal transduction; Toxicity","score_opus":0.013087089238106486,"score_gpt":0.2508270832582997,"score_spread":0.23773999402019325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416018018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9632984,0.021915412,0.0071526566,0.00031597252,0.002786143,0.0035075906,0.00083999423,0.00017711068,0.000006752328],"genre_scores_gemma":[0.96823865,0.0011154118,0.027518056,0.0002998099,0.0014805541,0.0011251225,0.000003510337,0.0001813539,0.000037545306],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99340844,0.00020246493,0.0023267674,0.002370915,0.0005033602,0.0011880415],"domain_scores_gemma":[0.9944791,0.000558555,0.001413125,0.0016365057,0.0013498577,0.00056285504],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.000792586,0.0014441162,0.0025361022,0.00079780736,0.0002635079,0.000103113045,0.0006074916,0.0014181451,0.000018612725],"category_scores_gemma":[0.00092313666,0.0014599855,0.0003731304,0.0008661093,0.0010270741,0.00037808646,0.0011594222,0.001041727,0.0000074311547],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012806519,0.00054043793,0.006710562,0.005816069,0.0010248092,0.000020314008,0.00014092437,0.0000057543702,0.9819134,0.0022625257,0.00005645019,0.00022811619],"study_design_scores_gemma":[0.004280097,0.00025797417,0.010519339,0.0068462105,0.0005219714,5.7766997e-8,0.000027896169,0.000030163286,0.94973385,0.000036247788,0.026478216,0.0012680023],"about_ca_topic_score_codex":0.000026635555,"about_ca_topic_score_gemma":0.0000018866434,"teacher_disagreement_score":0.03217956,"about_ca_system_score_codex":0.0010842356,"about_ca_system_score_gemma":0.003326289,"threshold_uncertainty_score":0.9998782},"labels":[],"label_agreement":null},{"id":"W4416084768","doi":"10.1158/1078-0432.ccr-25-1946","title":"Machine Learning–Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2− Early Breast Cancer Using Real-World and NATALEE Data","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"Astellas Pharma; Astex Pharmaceuticals; Seagen; Invitae; Gilead Sciences; BeiGene; Daiichi Sankyo Europe; Sanofi; Veracyte; Novartis Institutes for BioMedical Research; Amgen; Pfizer; Novartis Pharmaceuticals Corporation; AstraZeneca; Eli Lilly and Company","keywords":"Breast cancer; Cancer; MEDLINE; Risk assessment; Patient data","score_opus":0.1877959057952461,"score_gpt":0.5374822287604847,"score_spread":0.3496863229652386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416084768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98352385,0.012085273,0.00015728825,0.0009980759,0.00021440508,0.0010573047,0.0018283867,0.000037799033,0.00009763706],"genre_scores_gemma":[0.98116165,0.017784925,0.00024258671,0.000038261504,0.00018430926,0.00015982939,0.00008162204,0.000032205407,0.0003146288],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964767,0.0009569068,0.000688013,0.0009073028,0.00050655025,0.00046452356],"domain_scores_gemma":[0.99677587,0.0018448447,0.00018872991,0.00073261093,0.00023987518,0.00021809354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026747587,0.0002386507,0.00075845624,0.00036991274,0.00017136935,0.00003155093,0.00022300488,0.00013643959,0.00007791091],"category_scores_gemma":[0.0006071862,0.00018186422,0.000065290995,0.0009950801,0.00096974545,0.00018059883,0.00029562984,0.0011194973,7.460969e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005523681,0.00018088109,0.7397805,0.00027165608,0.00012484733,0.000016686665,0.00007938586,0.000078049976,0.00030676965,0.000013503214,0.000021125388,0.25360295],"study_design_scores_gemma":[0.007928707,0.0012609344,0.96265316,0.0020470966,0.00019406198,0.00000413701,0.000046381727,0.022184674,0.00047394854,0.00015711877,0.0029151768,0.00013458572],"about_ca_topic_score_codex":0.046362158,"about_ca_topic_score_gemma":0.0094217025,"teacher_disagreement_score":0.25346836,"about_ca_system_score_codex":0.0006862406,"about_ca_system_score_gemma":0.00080357597,"threshold_uncertainty_score":0.9599882},"labels":[],"label_agreement":null},{"id":"W4416103014","doi":"10.3389/fonc.2025.1734231","title":"Correction: Abemaciclib early access - an Italian experience","year":2025,"lang":"en","type":"erratum","venue":"Frontiers in Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"MEDLINE; Cancer; Clinical trial; Expanded access","score_opus":0.023743052512218282,"score_gpt":0.383242899830521,"score_spread":0.35949984731830276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416103014","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035619943,0.015161032,0.009384211,0.0028437697,0.65197885,0.001774272,0.00007217052,0.00045393073,0.31476977],"genre_scores_gemma":[0.0033153023,0.0018706978,0.010025947,0.004163623,0.0054031294,0.0008305917,0.0005599084,0.0001380166,0.9736928],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974758,0.00016947153,0.00055573724,0.0008826438,0.0003088609,0.00060750137],"domain_scores_gemma":[0.9985045,0.000059065398,0.0002918391,0.0007697472,0.00016059614,0.00021424776],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015289403,0.00044183605,0.0013028195,0.00055262947,0.0000974384,0.00004481741,0.0006697671,0.0011979647,0.0003548978],"category_scores_gemma":[0.0001725335,0.00045515277,0.00013977787,0.0006972558,0.00044475702,0.00041700908,0.0001738356,0.0018114019,0.000013212045],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008572832,0.00021398607,0.014232416,0.000115756964,0.000108959546,0.00035298098,0.002294108,0.000008244597,0.0000071242744,0.000010420627,0.81496686,0.16683187],"study_design_scores_gemma":[0.0016285279,0.00083566835,0.015380263,0.00054967153,0.000092443865,0.00012141846,0.0014334731,0.0002116891,0.0000466074,0.00039619766,0.97893673,0.00036732593],"about_ca_topic_score_codex":0.00027992312,"about_ca_topic_score_gemma":0.00029435017,"teacher_disagreement_score":0.65892303,"about_ca_system_score_codex":0.0020117238,"about_ca_system_score_gemma":0.0017175094,"threshold_uncertainty_score":0.99979},"labels":[],"label_agreement":null},{"id":"W4416239499","doi":"10.1158/1078-0432.ccr-25-3040","title":"Real-World Outcomes of Elacestrant in ER+, HER2−, <i>ESR1</i> -Mutant Metastatic Breast Cancer","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovative Research Group (Canada)","funders":"Menarini Group","keywords":"Metastatic breast cancer; Breast cancer; PI3K/AKT/mTOR pathway; Cancer; MEDLINE","score_opus":0.16887152885739296,"score_gpt":0.562525891090164,"score_spread":0.39365436223277106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416239499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9592206,0.0041377842,0.00006358597,0.03018938,0.0007248095,0.001505904,0.0003162346,0.000076799886,0.0037649148],"genre_scores_gemma":[0.9852497,0.0061862646,0.00053087284,0.0011294653,0.00021534043,0.00058618403,0.000008077089,0.000058357775,0.0060357293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950363,0.00060129055,0.0015282959,0.0007960628,0.0011058451,0.00093217357],"domain_scores_gemma":[0.9959619,0.0019242273,0.00020601379,0.00086434715,0.00073196215,0.00031154134],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030297458,0.000297262,0.0014393714,0.00070011953,0.00009163261,0.000022769855,0.00047499087,0.00013974319,0.0010852246],"category_scores_gemma":[0.00044544326,0.00023192025,0.0003101821,0.0024234685,0.0011122269,0.00014268537,0.00021880979,0.0015916007,0.000021668684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004630374,0.0009752816,0.83880466,0.00071089226,0.00062475476,0.00013055075,0.00017463403,0.000119107935,0.0021351862,0.0012712444,0.0008254746,0.14959785],"study_design_scores_gemma":[0.0067141317,0.00024376069,0.97582984,0.0016449075,0.00014903146,0.000008527478,0.00036218608,0.00013303536,0.0023999969,0.002247077,0.01004077,0.00022671871],"about_ca_topic_score_codex":0.01683873,"about_ca_topic_score_gemma":0.018472172,"teacher_disagreement_score":0.14937113,"about_ca_system_score_codex":0.00083883386,"about_ca_system_score_gemma":0.0026955435,"threshold_uncertainty_score":0.9998279},"labels":[],"label_agreement":null},{"id":"W4416391803","doi":"10.1016/j.annonc.2025.09.024","title":"LBA14 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 5-year outcomes","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Aromatase inhibitor; Adjuvant; Aromatase; Breast cancer; Nonsteroidal; Cancer","score_opus":0.019907205644584276,"score_gpt":0.3489278082874372,"score_spread":0.32902060264285293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98961663,0.0005789933,0.000042371143,0.006846926,0.00040695656,0.0007617522,0.00065475807,0.000059851645,0.0010317762],"genre_scores_gemma":[0.9950118,0.00009334379,0.0004649974,0.0034283737,0.00010163775,0.00013912964,0.00009128371,0.00004494971,0.0006244511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977515,0.00011102813,0.00065555633,0.00050926395,0.000380263,0.0005924259],"domain_scores_gemma":[0.99842924,0.00015644307,0.00032362094,0.00050064473,0.00041623675,0.00017383033],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021264039,0.00034576716,0.0011133797,0.0003748552,0.000055809778,0.000010940676,0.00023998936,0.00023674042,0.00015426868],"category_scores_gemma":[0.000059139937,0.0002761471,0.0001326995,0.00047209382,0.00039720576,0.0002519661,0.00013776672,0.0004023678,0.000028779039],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009716051,0.0012290265,0.89339614,0.00019763884,0.00044699284,0.00013176224,0.0006640401,0.000054562435,0.00036741397,0.00017049232,0.001852785,0.091773115],"study_design_scores_gemma":[0.016548451,0.002682672,0.9680874,0.00061670324,0.00009343669,0.000022250559,0.00029916715,0.000012319385,0.0014590377,0.00016227578,0.009748507,0.000267786],"about_ca_topic_score_codex":0.0008646026,"about_ca_topic_score_gemma":0.00077951455,"teacher_disagreement_score":0.091505334,"about_ca_system_score_codex":0.0003384932,"about_ca_system_score_gemma":0.00079871947,"threshold_uncertainty_score":0.99996907},"labels":[],"label_agreement":null},{"id":"W4416816908","doi":"10.64483/202412279","title":"Multidisciplinary Approaches to Breast Cancer: An Updated Review for Healthcare Providers.","year":2024,"lang":"","type":"article","venue":"Saudi Journal of Medicine and Public Health","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovation Cluster (Canada)","funders":"","keywords":"Multidisciplinary approach; Breast cancer; Health care; Disease; Cancer; Quality of life (healthcare); Stage (stratigraphy); MEDLINE; Systemic therapy","score_opus":0.2166034125734339,"score_gpt":0.42166912572618404,"score_spread":0.20506571315275013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416816908","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006164959,0.46257865,0.0040287157,0.5295754,0.0010670555,0.0018421271,0.0001870162,0.00004236131,0.00006214821],"genre_scores_gemma":[0.28402796,0.5948039,0.0076484443,0.0942567,0.016637199,0.00028803674,0.00021594191,0.0005093688,0.001612398],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994024,0.0005887153,0.002319013,0.0007898904,0.0009622959,0.0013161275],"domain_scores_gemma":[0.9935391,0.00023434607,0.0010690053,0.0005050318,0.0007932472,0.0038592985],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0059468998,0.0006209592,0.0023007526,0.00096139667,0.00033273295,0.000074317286,0.0003574459,0.00019152027,0.00093014917],"category_scores_gemma":[0.00028337966,0.00043138553,0.00021875286,0.0013851165,0.00046223146,0.000829835,0.00009059949,0.0010916614,0.0000063479165],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000729867,0.00024316562,0.00074977614,0.040722482,0.00056526886,0.000082731945,0.008092448,0.000003534156,0.00002815105,0.0010772127,0.06947986,0.8782255],"study_design_scores_gemma":[0.0060584755,0.011502366,0.0040877806,0.1106357,0.0006197283,0.0064721564,0.014024905,0.00064759,0.0000033621266,0.00073635345,0.84469163,0.0005199337],"about_ca_topic_score_codex":0.0006335047,"about_ca_topic_score_gemma":0.00023623138,"teacher_disagreement_score":0.8777056,"about_ca_system_score_codex":0.00089194614,"about_ca_system_score_gemma":0.007990751,"threshold_uncertainty_score":0.99998313},"labels":[],"label_agreement":null},{"id":"W4417076742","doi":"10.1177/17151635251386986","title":"AFPC CPERC 2025 Abstracts – Oral and Poster Presentations","year":2025,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"MEDLINE; Presentation (obstetrics); Telemedicine; Data collection; Public health","score_opus":0.031207779115766235,"score_gpt":0.32343007341446256,"score_spread":0.29222229429869634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417076742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97853357,0.004917573,0.00019367783,0.002581625,0.0024498177,0.00067583675,0.0003663852,0.00004789907,0.010233632],"genre_scores_gemma":[0.9826037,0.0020927829,0.00041977924,0.008896586,0.00036903506,0.000020046326,0.000028863644,0.00004012109,0.0055290516],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.99797416,0.00007066529,0.00050013553,0.0003572905,0.00029946706,0.0007982651],"domain_scores_gemma":[0.99726397,0.00008425627,0.00013774389,0.0002233003,0.00050432334,0.0017864241],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025164176,0.00031387212,0.00038106064,0.00039492897,0.0006350232,0.00014965,0.00024190097,0.00006169404,0.00076355773],"category_scores_gemma":[0.00013129316,0.0003221845,0.00009819263,0.00054929696,0.0002605722,0.00037580382,0.000037914557,0.0006539654,0.000008821087],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011881533,0.0001636545,0.037954606,0.0010252554,0.0016744686,0.11181288,0.0024730042,0.0012951173,0.02021327,0.00025957162,0.095887646,0.7260524],"study_design_scores_gemma":[0.0074608843,0.00007185131,0.004751678,0.00013052372,0.0006201229,0.5104008,0.00006948242,0.0006870262,0.008083255,0.0003820941,0.4666288,0.00071351044],"about_ca_topic_score_codex":0.02242156,"about_ca_topic_score_gemma":0.08772445,"teacher_disagreement_score":0.7253389,"about_ca_system_score_codex":0.0016142193,"about_ca_system_score_gemma":0.0051103244,"threshold_uncertainty_score":0.99992305},"labels":[],"label_agreement":null},{"id":"W4417290768","doi":"10.1016/j.celrep.2025.116676","title":"CDK4/6 inhibition reprograms the breast cancer immunopeptidome via Rb-dependent chromatin and transcriptomic remodeling","year":2025,"lang":"en","type":"article","venue":"Cell Reports","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Fonds de Recherche du Québec - Santé; Fonds de recherche du Québec; Canada Foundation for Innovation; Canadian Cancer Society","keywords":"Chromatin remodeling; Chromatin; Breast cancer; MHC class I; Transcriptome; Antigen; Antigen presentation; Cancer","score_opus":0.007067645185648071,"score_gpt":0.2582340218211176,"score_spread":0.25116637663546953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417290768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769281,0.011732719,0.0046739113,0.0026646059,0.00053239363,0.00088450627,0.000006860322,0.00017408351,0.002402832],"genre_scores_gemma":[0.99566936,0.0003938179,0.0005176999,0.00062419585,0.0001392526,0.00013705295,0.000016801232,0.00003454295,0.0024672963],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984315,0.000034709083,0.0005142914,0.00048403937,0.000254427,0.00028101302],"domain_scores_gemma":[0.99895036,0.000023965527,0.00021038759,0.00061595486,0.00012573444,0.00007359834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034705046,0.00020701444,0.00030848643,0.00007791978,0.00017750623,0.000040698906,0.000049070975,0.00009022307,0.00010049813],"category_scores_gemma":[0.0000124077615,0.00015083047,0.00009387608,0.00021012443,0.00014663847,0.00012320698,0.000042757805,0.0002702062,0.000003320985],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036798842,0.00013593506,0.005207573,0.00032959078,0.00011715151,0.0003330761,0.00092592236,0.00021532105,0.7240125,0.000019779178,0.00012887764,0.2682063],"study_design_scores_gemma":[0.012752898,0.00048463067,0.16004343,0.0071812514,0.0020189798,0.041532107,0.004455141,0.005481078,0.69364434,0.014484163,0.055869814,0.0020521795],"about_ca_topic_score_codex":0.0004660654,"about_ca_topic_score_gemma":0.000047893333,"teacher_disagreement_score":0.2661541,"about_ca_system_score_codex":0.00021539813,"about_ca_system_score_gemma":0.00015554747,"threshold_uncertainty_score":0.61506885},"labels":[],"label_agreement":null},{"id":"W4417329605","doi":"10.51731/cjht.2025.1306","title":"Inavolisib (Itovebi)","year":2025,"lang":"","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Metastatic breast cancer; Regimen; Reimbursement; Cancer; Fulvestrant; Palbociclib","score_opus":0.017625129350615592,"score_gpt":0.3259197549193014,"score_spread":0.3082946255686858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417329605","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016261518,0.776894,0.0037541003,0.19649626,0.004618406,0.0005828826,0.000049317845,0.00013408571,0.0012094465],"genre_scores_gemma":[0.9867579,0.006568175,0.0015138136,0.004066436,0.00007547603,0.000008833424,0.0000017546763,0.000039606002,0.0009680182],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959003,0.00013983536,0.0018440955,0.00034297357,0.00032382744,0.0014490165],"domain_scores_gemma":[0.99667674,0.00017762258,0.0012854123,0.00079672015,0.00076297985,0.00030053724],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012853859,0.0004223195,0.0014168737,0.0030250316,0.0006188756,0.0000753345,0.0009845877,0.0005255117,0.00014845062],"category_scores_gemma":[0.002015026,0.0003866177,0.00026036645,0.0017762247,0.0012449845,0.00028551396,0.00007185559,0.0019916615,0.000024555105],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001179815,0.000034522724,0.006299204,0.0006766989,0.00028120383,0.00035788555,0.00062344497,0.000028162187,0.000049999428,0.006166577,0.005790116,0.9795742],"study_design_scores_gemma":[0.0023088607,0.0010150464,0.016091213,0.006834184,0.00011721202,0.0006424751,0.0143849915,0.000013288385,0.0011409008,0.025367802,0.93180084,0.0002831865],"about_ca_topic_score_codex":0.0074909185,"about_ca_topic_score_gemma":0.004841347,"teacher_disagreement_score":0.979291,"about_ca_system_score_codex":0.0036039324,"about_ca_system_score_gemma":0.032450076,"threshold_uncertainty_score":0.99985856},"labels":[],"label_agreement":null},{"id":"W4417360319","doi":"10.3390/curroncol32120709","title":"Real-World Predictors of Survival in CDK4/6 Inhibitor-Treated Metastatic Breast Cancer: The Significance of ER Expression Level and Treatment Naivety","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Selçuk Üniversitesi","keywords":"Metastatic breast cancer; Expression (computer science); Selection (genetic algorithm); Breast cancer; Overall survival; Phenotype; Clinical significance","score_opus":0.08854907078104424,"score_gpt":0.4056418729579827,"score_spread":0.31709280217693847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417360319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930647,0.0033115789,0.00010994242,0.00097050995,0.0007104747,0.0010026855,0.0003167522,0.00002329564,0.00049008854],"genre_scores_gemma":[0.9972346,0.0018468508,0.00019039903,0.000019231176,0.00009252023,0.0002768765,0.000021307927,0.00001493877,0.0003033036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99854136,0.00023398225,0.0005035618,0.00030915195,0.000176135,0.00023584026],"domain_scores_gemma":[0.99882644,0.0003994144,0.00026969003,0.00028043,0.00015892879,0.00006508127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019374539,0.00020928532,0.00073747814,0.00021477017,0.000039678744,0.0000024906715,0.00009797401,0.000056186942,0.000052424886],"category_scores_gemma":[0.000032955646,0.00013294739,0.000072834315,0.00047374165,0.0004349834,0.000053214717,0.00006066266,0.0001748988,4.2817726e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026530004,0.00116577,0.7828977,0.0003615349,0.00026081194,0.000010491014,0.0012951693,0.00007011615,0.03473455,0.00027099097,0.00017895976,0.17610088],"study_design_scores_gemma":[0.0077728126,0.00055546383,0.9456116,0.0010726297,0.00031339386,0.000010342686,0.0008705858,0.00010285569,0.03254211,0.00018032115,0.010832592,0.00013528556],"about_ca_topic_score_codex":0.0011866931,"about_ca_topic_score_gemma":0.0013950602,"teacher_disagreement_score":0.17596559,"about_ca_system_score_codex":0.00064946816,"about_ca_system_score_gemma":0.00049636146,"threshold_uncertainty_score":0.5421437},"labels":[],"label_agreement":null},{"id":"W4417482291","doi":"10.1016/j.jval.2025.09.1373","title":"EPH244 The Incidence, Mortality, and Survival of Breast Cancer per HER2/HR Status in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2018-2022 Database Analysis","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Canada","funders":"","keywords":"Breast cancer; Survival analysis; Cancer; Overall survival","score_opus":0.07087840206212208,"score_gpt":0.4005935166910704,"score_spread":0.3297151146289483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417482291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9614565,0.013947981,0.0002459413,0.021083666,0.00013070052,0.0007441782,0.0023034348,0.000018112896,0.000069537025],"genre_scores_gemma":[0.96790445,0.028056346,0.00024042613,0.0032689993,0.000052987532,0.000073143194,0.00035051187,0.000014462278,0.000038676626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953239,0.0022990303,0.00095220556,0.0005245976,0.0003110265,0.0005892556],"domain_scores_gemma":[0.99517334,0.0034508854,0.00038082074,0.0007410559,0.0001215491,0.0001323537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0073586265,0.00022777182,0.00090022996,0.00061083713,0.00011586172,0.000010775849,0.00019800666,0.00007696581,0.000025557938],"category_scores_gemma":[0.00066350616,0.00014003087,0.00006010422,0.0026771063,0.0005855443,0.00008936197,0.00013919093,0.0005017574,3.3913446e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088445237,0.000094336065,0.9853114,0.00034979577,0.00028955095,0.00000969608,0.0022990452,0.006934594,0.000013616895,0.0007804826,0.0002797978,0.002753224],"study_design_scores_gemma":[0.001917859,0.00009231259,0.98327035,0.000323727,0.00009715179,0.000017265875,0.0028695045,0.007277101,0.0000019002445,0.0008747277,0.0031479315,0.00011014402],"about_ca_topic_score_codex":0.310498,"about_ca_topic_score_gemma":0.07365453,"teacher_disagreement_score":0.23684347,"about_ca_system_score_codex":0.0002770453,"about_ca_system_score_gemma":0.00062063645,"threshold_uncertainty_score":0.94324887},"labels":[],"label_agreement":null},{"id":"W6902098814","doi":"10.6084/m9.figshare.25963250","title":"Additional file 2 of Genome-wide in vivo CRISPR screen identifies TGFβ3 as actionable biomarker of palbociclib resistance in triple negative breast cancer","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Palbociclib; CRISPR; Biomarker; Triple-negative breast cancer; Breast cancer; In vivo","score_opus":0.02234132432658594,"score_gpt":0.2961428351085454,"score_spread":0.27380151078195947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902098814","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00050630857,0.0018131244,9.396201e-7,0.00033670838,0.00003756368,0.0003519117,0.9927813,0.000036582285,0.0041355994],"genre_scores_gemma":[0.09677931,0.00006285602,0.0009960089,0.00041209286,0.0003094951,0.0043547857,0.8606257,0.00011913918,0.03634061],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986857,0.00003754177,0.00038813704,0.00032372252,0.00032915833,0.00023570897],"domain_scores_gemma":[0.9983307,0.0010234466,0.00015174285,0.00020289198,0.00023104777,0.00006018206],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00003923282,0.00016558831,0.0003430259,0.00031428674,0.000025824722,0.000014249055,0.000118201606,0.00009074516,0.98060656],"category_scores_gemma":[0.00094785116,0.0001617387,0.00010176005,0.00082275004,0.000046650213,0.00031779465,0.000053474792,0.00019203396,0.00021333114],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056698645,0.000063876556,0.000093078816,0.00079438085,0.00009210188,0.000056178083,0.00030167337,0.00002210004,0.00072055496,0.0000070447904,0.99622875,0.0010532973],"study_design_scores_gemma":[0.0011042486,0.000035010107,0.24443556,0.022065386,0.000016944734,0.00002201318,0.00050683966,0.00007638895,0.0039573167,0.00075018284,0.72681266,0.00021742655],"about_ca_topic_score_codex":0.0003135439,"about_ca_topic_score_gemma":0.0018507165,"teacher_disagreement_score":0.98039323,"about_ca_system_score_codex":0.0002831755,"about_ca_system_score_gemma":0.00049506064,"threshold_uncertainty_score":0.6595513},"labels":[],"label_agreement":null},{"id":"W6902128620","doi":"10.6084/m9.figshare.24070298.v1","title":"Additional file 1 of Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Fulvestrant; Placebo; Adverse effect; Overall survival; Postmenopausal women; Cancer","score_opus":0.02565653570190988,"score_gpt":0.2702826857817846,"score_spread":0.24462615007987473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902128620","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.058852784,0.00010333908,3.3445232e-7,0.00086570653,0.00007224761,0.0007795979,0.939013,0.00013759987,0.00017540618],"genre_scores_gemma":[0.06769835,0.000017031598,0.0002093513,0.0003599943,0.0006846609,0.0041353935,0.9259577,0.00008675973,0.0008507933],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99794924,0.000067847686,0.0004184999,0.00045837485,0.00057854864,0.0005274912],"domain_scores_gemma":[0.9972401,0.0017315237,0.00027735278,0.00038317713,0.00022318879,0.00014465976],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000058034584,0.00030639034,0.0005395414,0.00009408813,0.00009497186,0.0000197426,0.00025036364,0.00011356577,0.9522986],"category_scores_gemma":[0.00050490955,0.00022058976,0.00006593675,0.000662937,0.000047478785,0.00022672758,0.00009441757,0.00037877314,0.00031671405],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05843445,0.00018955277,0.0000919425,0.00011718365,0.00032783582,0.00014345734,0.00075963093,0.0024039783,0.00021199243,0.0000016569259,0.92713416,0.010184187],"study_design_scores_gemma":[0.05690001,0.0012475275,0.40589872,0.01152522,0.000047387988,0.000060257058,0.0007929148,0.0006597065,0.00010263719,0.00018893117,0.5219378,0.0006388892],"about_ca_topic_score_codex":0.00021687479,"about_ca_topic_score_gemma":0.0009034132,"teacher_disagreement_score":0.9519819,"about_ca_system_score_codex":0.0004346702,"about_ca_system_score_gemma":0.0006127187,"threshold_uncertainty_score":0.89953893},"labels":[],"label_agreement":null},{"id":"W6908719269","doi":"10.3389/fmed.2024.1465753.s001","title":"Data_Sheet_1_Determinants for worsening in systemic autoimmune rheumatic disease-associated interstitial lung disease: a systematic review and meta-analysis of cohort studies.docx","year":2024,"lang":"en","type":"dataset","venue":"Figshare","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Interstitial lung disease; Cohort; Exacerbation; Cohort study; Lung; Risk factor","score_opus":0.07697763199471633,"score_gpt":0.3817473186727093,"score_spread":0.304769686677993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6908719269","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000027997435,0.43822265,7.7668733e-7,0.000048203525,0.000044680157,0.0038679694,0.5577803,0.000032297263,2.840939e-7],"genre_scores_gemma":[0.0007778141,0.0059505776,0.000012253255,0.00020188643,0.000020731342,0.009286722,0.9835309,0.00007276315,0.00014639624],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9959958,0.00024823702,0.0018837394,0.0008601567,0.0006029121,0.00040915885],"domain_scores_gemma":[0.99591535,0.0007579296,0.0013501098,0.0013893064,0.00036060193,0.00022668038],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047871005,0.00069984264,0.0077694072,0.00075105426,0.000057082412,0.000049722075,0.00041123328,0.0001488394,0.00893139],"category_scores_gemma":[0.006891845,0.0005238104,0.0013369349,0.0011173557,0.000039416638,0.00016097045,0.0003740114,0.00037797858,0.00009735099],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005265654,0.000035052173,0.000003416917,0.49278703,0.15420197,0.00012973534,0.00003518103,0.0000073186297,1.0435757e-7,1.4574208e-7,0.35274395,0.0000034183852],"study_design_scores_gemma":[0.00029203118,0.000023171648,0.0001181521,0.41118068,0.58503276,0.000017514873,0.000049141523,0.000596093,8.389136e-8,0.0000023143775,0.002408853,0.00027921674],"about_ca_topic_score_codex":0.000017143138,"about_ca_topic_score_gemma":0.000066443004,"teacher_disagreement_score":0.43227205,"about_ca_system_score_codex":0.0005660039,"about_ca_system_score_gemma":0.00028816378,"threshold_uncertainty_score":0.99972135},"labels":[],"label_agreement":null},{"id":"W6911548817","doi":"10.5281/zenodo.11854340","title":"Marie louise von franz pdf","year":2024,"lang":"de","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Interpretation (philosophy); Gloom; Staring; Circumstantial evidence; Subject (documents); Pretext","score_opus":0.022300329269950698,"score_gpt":0.26067136389522116,"score_spread":0.23837103462527046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6911548817","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008121409,0.030638484,0.0034652129,0.0020694092,0.00157801,0.0015779571,0.0010311895,0.0020357652,0.95752275],"genre_scores_gemma":[0.0053222785,0.003471245,0.0004936143,0.00080471754,0.00444008,2.1560663e-7,0.0060031503,0.027030807,0.9524339],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955642,0.00043692085,0.00061672105,0.0013608196,0.0010180117,0.0010033292],"domain_scores_gemma":[0.9969988,0.00004850487,0.00030574694,0.0013756668,0.00068884174,0.000582444],"candidate_categories":["metaepi_narrow","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00069702015,0.000675958,0.00070410955,0.0008232758,0.001176293,0.0010376493,0.0014224313,0.00043808075,0.6364123],"category_scores_gemma":[0.00081611413,0.0006913242,0.00024292576,0.0011108794,0.0006519127,0.00018265778,0.0018222968,0.0014550496,0.77274716],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004410248,0.00024320229,0.0000016157189,0.0012493063,0.00089119235,0.000337089,0.001470426,0.000015203341,0.0009920447,0.0017979748,0.70900625,0.28355467],"study_design_scores_gemma":[0.001531513,0.0005430337,0.00004700122,0.0013617076,0.0003988986,0.00017973973,0.0003980512,0.000100108606,0.00014505631,0.00070996344,0.9939593,0.00062560884],"about_ca_topic_score_codex":0.00003623959,"about_ca_topic_score_gemma":5.810004e-7,"teacher_disagreement_score":0.2849531,"about_ca_system_score_codex":0.00073409546,"about_ca_system_score_gemma":0.000023826698,"threshold_uncertainty_score":0.99999934},"labels":[],"label_agreement":null},{"id":"W6912438245","doi":"10.5281/zenodo.3541269","title":"NPA_ref6302","year":2019,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"","keywords":"Context (archaeology); Stage (stratigraphy); Ideal (ethics)","score_opus":0.02424088186876655,"score_gpt":0.26031853380632936,"score_spread":0.2360776519375628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6912438245","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26393738,0.0003784827,0.003577852,0.0030224929,0.00026740323,0.0012010776,0.000103197,0.0020371675,0.72547495],"genre_scores_gemma":[0.9913351,0.000037731395,0.0005516536,0.00051447714,0.00017211222,2.1206374e-8,0.0005009864,0.0014182815,0.0054696715],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99890333,0.000073140785,0.00014844137,0.00029941398,0.00029477483,0.0002809093],"domain_scores_gemma":[0.9989962,0.00001068332,0.000054797765,0.0004533536,0.00033350923,0.00015147074],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00021382296,0.00010564176,0.00015202776,0.00013672383,0.00048543277,0.00013093709,0.00032444057,0.00004465459,0.038742486],"category_scores_gemma":[0.00013065555,0.000101290636,0.0000501595,0.00032605525,0.00008602104,0.0001591034,0.0003507259,0.00020962209,0.03064248],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008066366,0.0003105572,0.00012573614,0.00027093038,0.00017805348,0.00004671516,0.0014813553,0.00006835793,0.10189027,0.013817227,0.03805825,0.8429459],"study_design_scores_gemma":[0.0011259735,0.00029483341,0.0024776976,0.00004407379,0.000012180564,0.0003274887,0.0002121444,0.00008499303,0.0015531132,0.00021068024,0.9935459,0.00011095041],"about_ca_topic_score_codex":0.0000035050539,"about_ca_topic_score_gemma":2.7302304e-8,"teacher_disagreement_score":0.9554876,"about_ca_system_score_codex":0.00015769312,"about_ca_system_score_gemma":0.000003516671,"threshold_uncertainty_score":0.97011226},"labels":[],"label_agreement":null},{"id":"W6920457922","doi":"10.60692/y0b4j-5mz07","title":"Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population","year":2021,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Letrozole; Adverse effect; Metastatic breast cancer; Neutropenia; Population; Breast cancer; Hazard ratio; Quality of life (healthcare)","score_opus":0.08972826809251612,"score_gpt":0.35880974472505195,"score_spread":0.26908147663253584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920457922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99041104,0.000053232874,0.0033528344,0.0001329176,0.00022216608,0.0023940597,0.0033672226,0.000056215104,0.000010298138],"genre_scores_gemma":[0.99721086,0.0000021469439,0.00030868337,0.0001060624,0.00013595655,0.00033492717,0.0018686148,0.000022088687,0.000010666207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764425,0.00009423695,0.0013555003,0.00022704883,0.00045105533,0.0002279173],"domain_scores_gemma":[0.99779445,0.000046660032,0.0010051776,0.00054555584,0.0005296857,0.00007849602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003074919,0.00022841716,0.0005855287,0.00016474363,0.000106026266,0.000025761772,0.00011602997,0.000078657686,0.00003072324],"category_scores_gemma":[0.00003799034,0.00017007529,0.00008896862,0.00037515527,0.000025140522,0.0007866376,0.000027566803,0.000093362316,0.0000020793532],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.095336385,0.0008597216,0.5653108,0.00060634635,0.00044584947,0.0000059883873,0.27383602,0.014216513,0.0011145093,0.00005034973,0.000010000808,0.048207544],"study_design_scores_gemma":[0.17862754,0.0028941701,0.6817159,0.0011917381,0.00017668499,0.000050101196,0.10982796,0.021916935,0.0031655806,0.000013283447,0.00006596997,0.00035415427],"about_ca_topic_score_codex":0.00083868153,"about_ca_topic_score_gemma":0.00016347917,"teacher_disagreement_score":0.16400805,"about_ca_system_score_codex":0.00033151355,"about_ca_system_score_gemma":0.00007299213,"threshold_uncertainty_score":0.6935469},"labels":[],"label_agreement":null},{"id":"W6920972336","doi":"10.6084/m9.figshare.25963049.v1","title":"Additional file 1 of Genome-wide in vivo CRISPR screen identifies TGFβ3 as actionable biomarker of palbociclib resistance in triple negative breast cancer","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Palbociclib; CRISPR; Biomarker; Triple-negative breast cancer; Breast cancer; In vivo","score_opus":0.023108480074749922,"score_gpt":0.2967138263353508,"score_spread":0.2736053462606009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920972336","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00050964224,0.0017851876,9.597352e-7,0.00033840133,0.000037348836,0.0003525071,0.9928937,0.000036589066,0.004045664],"genre_scores_gemma":[0.09841068,0.00006134749,0.0010190832,0.00041255789,0.00030543742,0.004443165,0.85896057,0.0001194434,0.036267735],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986855,0.00003755421,0.00038796687,0.0003239599,0.00032923877,0.00023579388],"domain_scores_gemma":[0.99831563,0.0010378098,0.0001515398,0.00020327947,0.00023155789,0.0000601924],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000039443436,0.00016563982,0.0003429438,0.00031448805,0.000025822872,0.000014218874,0.00011826598,0.000090744645,0.9809572],"category_scores_gemma":[0.0009591648,0.00016179042,0.0001017793,0.00082337554,0.000046650843,0.00031758187,0.000053482152,0.0001920772,0.00021558041],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005694246,0.00006383017,0.00009595842,0.00078658375,0.00009200479,0.000054656903,0.00030110966,0.000021973665,0.00074502523,0.0000069183825,0.9962383,0.0010242324],"study_design_scores_gemma":[0.0011083867,0.00003537067,0.25039387,0.022565363,0.000017182918,0.000022195385,0.0005173071,0.00007769631,0.004023161,0.0007521803,0.7202671,0.00022015382],"about_ca_topic_score_codex":0.00031048505,"about_ca_topic_score_gemma":0.0018400856,"teacher_disagreement_score":0.9807416,"about_ca_system_score_codex":0.00028309622,"about_ca_system_score_gemma":0.00049722387,"threshold_uncertainty_score":0.6597622},"labels":[],"label_agreement":null},{"id":"W6921018294","doi":"10.6084/m9.figshare.25893879","title":"Additional file 2 of Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Systematic review; MEDLINE; Medical literature; Meta-analysis; Systematic error","score_opus":0.05918774563679358,"score_gpt":0.34451355176803916,"score_spread":0.2853258061312456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921018294","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026352962,0.14023161,0.0000011193939,0.00019107155,0.0000166404,0.002049105,0.85724115,0.000036326186,0.00020660275],"genre_scores_gemma":[0.0023878831,0.0042364867,0.0021708207,0.00034523915,0.00023163452,0.027434057,0.9480457,0.0000784101,0.015069785],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9985572,0.00003990322,0.00056748395,0.00035687233,0.00027418954,0.00020434817],"domain_scores_gemma":[0.99722517,0.0017431397,0.00023989454,0.00040720194,0.00030665274,0.000077941775],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000039572755,0.00028459638,0.0008222987,0.0001770207,0.00001794379,0.000014131597,0.00009121803,0.00006637852,0.86726516],"category_scores_gemma":[0.00060056866,0.0001842899,0.0002001269,0.00058845984,0.000016652883,0.00019866644,0.000021912865,0.00010148243,0.00012262476],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005283519,0.00016522974,0.0000131992765,0.5217015,0.00029116185,0.0001875159,0.00020123096,0.000003603786,0.000008276168,0.0000022065954,0.4752031,0.0016945979],"study_design_scores_gemma":[0.00075802905,0.0010365336,0.0006681404,0.82808197,0.00018539236,0.00006994519,0.000011073917,0.00006414099,0.00021990745,0.000013396836,0.16876389,0.00012755749],"about_ca_topic_score_codex":0.0000061072133,"about_ca_topic_score_gemma":0.00038096285,"teacher_disagreement_score":0.86714256,"about_ca_system_score_codex":0.00037445102,"about_ca_system_score_gemma":0.0002537371,"threshold_uncertainty_score":0.75151235},"labels":[],"label_agreement":null},{"id":"W6921086538","doi":"10.6084/m9.figshare.25963049","title":"Additional file 1 of Genome-wide in vivo CRISPR screen identifies TGFβ3 as actionable biomarker of palbociclib resistance in triple negative breast cancer","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Palbociclib; CRISPR; Biomarker; Triple-negative breast cancer; Breast cancer; In vivo","score_opus":0.023108480074749922,"score_gpt":0.2967138263353508,"score_spread":0.2736053462606009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921086538","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00050964224,0.0017851876,9.597352e-7,0.00033840133,0.000037348836,0.0003525071,0.9928937,0.000036589066,0.004045664],"genre_scores_gemma":[0.09841068,0.00006134749,0.0010190832,0.00041255789,0.00030543742,0.004443165,0.85896057,0.0001194434,0.036267735],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986855,0.00003755421,0.00038796687,0.0003239599,0.00032923877,0.00023579388],"domain_scores_gemma":[0.99831563,0.0010378098,0.0001515398,0.00020327947,0.00023155789,0.0000601924],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000039443436,0.00016563982,0.0003429438,0.00031448805,0.000025822872,0.000014218874,0.00011826598,0.000090744645,0.9809572],"category_scores_gemma":[0.0009591648,0.00016179042,0.0001017793,0.00082337554,0.000046650843,0.00031758187,0.000053482152,0.0001920772,0.00021558041],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005694246,0.00006383017,0.00009595842,0.00078658375,0.00009200479,0.000054656903,0.00030110966,0.000021973665,0.00074502523,0.0000069183825,0.9962383,0.0010242324],"study_design_scores_gemma":[0.0011083867,0.00003537067,0.25039387,0.022565363,0.000017182918,0.000022195385,0.0005173071,0.00007769631,0.004023161,0.0007521803,0.7202671,0.00022015382],"about_ca_topic_score_codex":0.00031048505,"about_ca_topic_score_gemma":0.0018400856,"teacher_disagreement_score":0.9807416,"about_ca_system_score_codex":0.00028309622,"about_ca_system_score_gemma":0.00049722387,"threshold_uncertainty_score":0.6597622},"labels":[],"label_agreement":null},{"id":"W6921152763","doi":"10.6084/m9.figshare.25893879.v1","title":"Additional file 2 of Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Systematic review; MEDLINE; Medical literature; Meta-analysis; Systematic error","score_opus":0.05918774563679358,"score_gpt":0.34451355176803916,"score_spread":0.2853258061312456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921152763","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026352962,0.14023161,0.0000011193939,0.00019107155,0.0000166404,0.002049105,0.85724115,0.000036326186,0.00020660275],"genre_scores_gemma":[0.0023878831,0.0042364867,0.0021708207,0.00034523915,0.00023163452,0.027434057,0.9480457,0.0000784101,0.015069785],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9985572,0.00003990322,0.00056748395,0.00035687233,0.00027418954,0.00020434817],"domain_scores_gemma":[0.99722517,0.0017431397,0.00023989454,0.00040720194,0.00030665274,0.000077941775],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000039572755,0.00028459638,0.0008222987,0.0001770207,0.00001794379,0.000014131597,0.00009121803,0.00006637852,0.86726516],"category_scores_gemma":[0.00060056866,0.0001842899,0.0002001269,0.00058845984,0.000016652883,0.00019866644,0.000021912865,0.00010148243,0.00012262476],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005283519,0.00016522974,0.0000131992765,0.5217015,0.00029116185,0.0001875159,0.00020123096,0.000003603786,0.000008276168,0.0000022065954,0.4752031,0.0016945979],"study_design_scores_gemma":[0.00075802905,0.0010365336,0.0006681404,0.82808197,0.00018539236,0.00006994519,0.000011073917,0.00006414099,0.00021990745,0.000013396836,0.16876389,0.00012755749],"about_ca_topic_score_codex":0.0000061072133,"about_ca_topic_score_gemma":0.00038096285,"teacher_disagreement_score":0.86714256,"about_ca_system_score_codex":0.00037445102,"about_ca_system_score_gemma":0.0002537371,"threshold_uncertainty_score":0.75151235},"labels":[],"label_agreement":null},{"id":"W6923397333","doi":"10.14288/1.0443030","title":"The Canadian Breast Cancer Symposium 2023 Meeting Report","year":2024,"lang":"en","type":"article","venue":"Open Collections","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Multidisciplinary approach; Health professionals; Cancer; Health care; Alternative medicine","score_opus":0.015689759989998917,"score_gpt":0.31622979232991427,"score_spread":0.30054003233991533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6923397333","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020415006,0.0022480746,0.000065607535,0.068559356,0.0024596476,0.0010565468,0.00020442334,0.0001372289,0.925065],"genre_scores_gemma":[0.048976347,0.00020330017,0.00023893565,0.0004844995,0.0006400551,0.0007205085,0.000013718016,0.000045445566,0.9486772],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990463,0.000023541725,0.00019091868,0.00027218316,0.0001613961,0.000305615],"domain_scores_gemma":[0.99922013,0.00007672943,0.00003416153,0.00030680298,0.00015937675,0.00020277733],"candidate_categories":["sts","scholarly_communication","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000251337,0.00010774298,0.00013492744,0.00007045521,0.0038387356,0.0013305967,0.00016312404,0.000049749957,0.001019922],"category_scores_gemma":[0.000031280775,0.00007777864,0.000060158745,0.0012142712,0.00008159185,0.00014803471,0.00005759311,0.00023083347,0.00003337649],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010013148,0.000030192492,0.00083390274,0.000042263746,0.000581123,0.0008020663,0.0003554966,0.0002733455,0.0007026705,0.00034197615,0.9772582,0.018678654],"study_design_scores_gemma":[0.00021605233,0.000020868702,0.0014539098,0.00024285217,0.00008201556,0.003917096,0.00020933556,0.00033946856,0.00011760537,0.00039094343,0.9929039,0.00010595057],"about_ca_topic_score_codex":0.8483011,"about_ca_topic_score_gemma":0.9393197,"teacher_disagreement_score":0.09101856,"about_ca_system_score_codex":0.0011087934,"about_ca_system_score_gemma":0.0029544306,"threshold_uncertainty_score":0.9998933},"labels":[],"label_agreement":null},{"id":"W6949684207","doi":"10.5281/zenodo.16575676","title":"Perspectives and Insights on Antineoplastic Agents with Diverse Mechanisms of Action (L01XX): From Development to New Drug Application (NDA) Submission for FDA","year":2025,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Action (physics); Drug approval; Drug delivery; Antineoplastic Drugs; Cancer drugs; Cancer; Site of action","score_opus":0.02759747095780769,"score_gpt":0.2807595226296699,"score_spread":0.25316205167186223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6949684207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5227701,0.00009495449,0.47150403,0.0012775034,0.00006243419,0.0015490943,0.00006355871,0.0002762628,0.0024020781],"genre_scores_gemma":[0.9899836,0.000023154287,0.008232778,0.00012679982,0.000039088573,3.646585e-7,0.00034559393,0.0002534155,0.000995175],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991023,0.00004043062,0.0001432279,0.00034336845,0.00023309625,0.0001376105],"domain_scores_gemma":[0.9992217,0.000028502516,0.00007805528,0.0001979694,0.00034698602,0.00012680133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009104273,0.000111951376,0.00014741533,0.00021752401,0.0004946841,0.000054143748,0.00014395,0.000031493204,0.00039589318],"category_scores_gemma":[0.00013288516,0.00009841292,0.000017443102,0.00031495182,0.000045791883,0.000096211596,0.00017060417,0.00008719621,0.00010650293],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063946974,0.0004614448,0.00003455184,0.000305149,0.0002959018,0.0000053845642,0.024640357,0.00019771142,0.2163691,0.007009683,0.010085111,0.7342009],"study_design_scores_gemma":[0.0052681467,0.0010952207,0.016125534,0.00065360445,0.00011005997,0.000021043132,0.009996867,0.0005834068,0.13330851,0.0020650239,0.8304667,0.0003058665],"about_ca_topic_score_codex":0.000021587886,"about_ca_topic_score_gemma":0.0000014742989,"teacher_disagreement_score":0.8203816,"about_ca_system_score_codex":0.00017896332,"about_ca_system_score_gemma":0.000017652717,"threshold_uncertainty_score":0.43347526},"labels":[],"label_agreement":null},{"id":"W6950436998","doi":"10.5281/zenodo.3541270","title":"NPA_ref6302","year":2019,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"","keywords":"Context (archaeology); Stage (stratigraphy); Ideal (ethics)","score_opus":0.02424088186876655,"score_gpt":0.26031853380632936,"score_spread":0.2360776519375628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6950436998","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26393738,0.0003784827,0.003577852,0.0030224929,0.00026740323,0.0012010776,0.000103197,0.0020371675,0.72547495],"genre_scores_gemma":[0.9913351,0.000037731395,0.0005516536,0.00051447714,0.00017211222,2.1206374e-8,0.0005009864,0.0014182815,0.0054696715],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99890333,0.000073140785,0.00014844137,0.00029941398,0.00029477483,0.0002809093],"domain_scores_gemma":[0.9989962,0.00001068332,0.000054797765,0.0004533536,0.00033350923,0.00015147074],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00021382296,0.00010564176,0.00015202776,0.00013672383,0.00048543277,0.00013093709,0.00032444057,0.00004465459,0.038742486],"category_scores_gemma":[0.00013065555,0.000101290636,0.0000501595,0.00032605525,0.00008602104,0.0001591034,0.0003507259,0.00020962209,0.03064248],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008066366,0.0003105572,0.00012573614,0.00027093038,0.00017805348,0.00004671516,0.0014813553,0.00006835793,0.10189027,0.013817227,0.03805825,0.8429459],"study_design_scores_gemma":[0.0011259735,0.00029483341,0.0024776976,0.00004407379,0.000012180564,0.0003274887,0.0002121444,0.00008499303,0.0015531132,0.00021068024,0.9935459,0.00011095041],"about_ca_topic_score_codex":0.0000035050539,"about_ca_topic_score_gemma":2.7302304e-8,"teacher_disagreement_score":0.9554876,"about_ca_system_score_codex":0.00015769312,"about_ca_system_score_gemma":0.000003516671,"threshold_uncertainty_score":0.97011226},"labels":[],"label_agreement":null},{"id":"W6957978381","doi":"10.60692/853mx-qvt30","title":"Thrombotic risk in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with CDK 4/6 inhibitors: a meta-analysis","year":2023,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Odds ratio; Randomized controlled trial; Incidence (geometry); Thrombosis; Risk factor; Meta-analysis; Venous thrombosis; Confidence interval","score_opus":0.029473503207622227,"score_gpt":0.24551623945945017,"score_spread":0.21604273625182793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6957978381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929264,0.000013498056,0.00079256,0.00016334876,0.000051969426,0.0016663428,0.0038122816,0.0004241915,0.0001493653],"genre_scores_gemma":[0.9981266,0.0000012475734,0.0003599444,0.00009527037,0.000074876516,0.0005859414,0.00056388025,0.00005924034,0.0001329736],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996747,0.00024796725,0.0010306379,0.00047906168,0.00090685365,0.0005884657],"domain_scores_gemma":[0.9973011,0.000037962316,0.0009811957,0.0005202485,0.0009232307,0.00023628473],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002637652,0.00059011375,0.0016234261,0.0012614365,0.00023644883,0.00010292084,0.00015167631,0.00016524091,0.00028980355],"category_scores_gemma":[0.000018541237,0.0003684027,0.000364977,0.0031482114,0.00014689466,0.0013678604,0.000051973537,0.000321548,0.0002725223],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021944416,0.00002504396,0.9358182,0.00018944677,0.031223694,0.000006812589,0.029589312,0.0006823417,0.000007255262,0.0000065409677,0.000039809107,0.00021709125],"study_design_scores_gemma":[0.0066719833,0.0004274327,0.9705257,0.00016444706,0.015637754,0.000009968673,0.0053419485,0.00014681942,0.0006152743,4.773876e-7,0.0000067937053,0.00045141167],"about_ca_topic_score_codex":0.0007724748,"about_ca_topic_score_gemma":0.0000225629,"teacher_disagreement_score":0.03470748,"about_ca_system_score_codex":0.00076384534,"about_ca_system_score_gemma":0.00008636333,"threshold_uncertainty_score":0.9998768},"labels":[],"label_agreement":null},{"id":"W6958544899","doi":"10.6084/m9.figshare.25893807.v1","title":"Additional file 1 of Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Systematic review; MEDLINE; Medical literature; Systematic error; Meta-analysis","score_opus":0.061284668874714426,"score_gpt":0.345181056771748,"score_spread":0.28389638789703353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958544899","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002656212,0.13863765,0.0000011445953,0.00019229502,0.000016570993,0.0020554925,0.85883147,0.000036385714,0.00020246589],"genre_scores_gemma":[0.0024286655,0.0041371672,0.0022203368,0.00034564862,0.00022866868,0.02797481,0.9475449,0.000078612866,0.015041193],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99855703,0.000039916227,0.00056723977,0.0003571295,0.00027425546,0.00020442055],"domain_scores_gemma":[0.9972001,0.0017671094,0.00023957354,0.00040795605,0.00030731046,0.000077953075],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00003978144,0.0002846833,0.00082210544,0.00017713211,0.000017942528,0.000014102191,0.00009126683,0.000066378154,0.869355],"category_scores_gemma":[0.0006076125,0.00018434778,0.0002001641,0.0005888995,0.000016653104,0.00019853575,0.000021915826,0.000101504884,0.00012389488],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053011696,0.00016496646,0.000013588378,0.5179392,0.00029060422,0.0001823664,0.00020068469,0.000003580385,0.000008544858,0.0000021657843,0.47901693,0.0016472138],"study_design_scores_gemma":[0.00075527566,0.0010393909,0.0006806147,0.83243936,0.00018658218,0.00006999999,0.000011216231,0.000064743894,0.00022187468,0.000013333928,0.16438945,0.00012818801],"about_ca_topic_score_codex":0.0000060486605,"about_ca_topic_score_gemma":0.00037880984,"teacher_disagreement_score":0.8692311,"about_ca_system_score_codex":0.00037434802,"about_ca_system_score_gemma":0.0002548265,"threshold_uncertainty_score":0.75174844},"labels":[],"label_agreement":null},{"id":"W6976353947","doi":"10.60692/04tvx-65s90","title":"Thrombotic risk in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with CDK 4/6 inhibitors: a meta-analysis","year":2023,"lang":"en","type":"article","venue":"Greater South Information System","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Odds ratio; Randomized controlled trial; Incidence (geometry); Thrombosis; Risk factor; Meta-analysis; Venous thrombosis; Confidence interval","score_opus":0.029473503207622227,"score_gpt":0.24551623945945017,"score_spread":0.21604273625182793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976353947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929264,0.000013498056,0.00079256,0.00016334876,0.000051969426,0.0016663428,0.0038122816,0.0004241915,0.0001493653],"genre_scores_gemma":[0.9981266,0.0000012475734,0.0003599444,0.00009527037,0.000074876516,0.0005859414,0.00056388025,0.00005924034,0.0001329736],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996747,0.00024796725,0.0010306379,0.00047906168,0.00090685365,0.0005884657],"domain_scores_gemma":[0.9973011,0.000037962316,0.0009811957,0.0005202485,0.0009232307,0.00023628473],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002637652,0.00059011375,0.0016234261,0.0012614365,0.00023644883,0.00010292084,0.00015167631,0.00016524091,0.00028980355],"category_scores_gemma":[0.000018541237,0.0003684027,0.000364977,0.0031482114,0.00014689466,0.0013678604,0.000051973537,0.000321548,0.0002725223],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021944416,0.00002504396,0.9358182,0.00018944677,0.031223694,0.000006812589,0.029589312,0.0006823417,0.000007255262,0.0000065409677,0.000039809107,0.00021709125],"study_design_scores_gemma":[0.0066719833,0.0004274327,0.9705257,0.00016444706,0.015637754,0.000009968673,0.0053419485,0.00014681942,0.0006152743,4.773876e-7,0.0000067937053,0.00045141167],"about_ca_topic_score_codex":0.0007724748,"about_ca_topic_score_gemma":0.0000225629,"teacher_disagreement_score":0.03470748,"about_ca_system_score_codex":0.00076384534,"about_ca_system_score_gemma":0.00008636333,"threshold_uncertainty_score":0.9998768},"labels":[],"label_agreement":null},{"id":"W6977161993","doi":"10.6084/m9.figshare.24070298","title":"Additional file 1 of Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Fulvestrant; Placebo; Adverse effect; Overall survival; Postmenopausal women; Cancer","score_opus":0.02565653570190988,"score_gpt":0.2702826857817846,"score_spread":0.24462615007987473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977161993","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.058852784,0.00010333908,3.3445232e-7,0.00086570653,0.00007224761,0.0007795979,0.939013,0.00013759987,0.00017540618],"genre_scores_gemma":[0.06769835,0.000017031598,0.0002093513,0.0003599943,0.0006846609,0.0041353935,0.9259577,0.00008675973,0.0008507933],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99794924,0.000067847686,0.0004184999,0.00045837485,0.00057854864,0.0005274912],"domain_scores_gemma":[0.9972401,0.0017315237,0.00027735278,0.00038317713,0.00022318879,0.00014465976],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000058034584,0.00030639034,0.0005395414,0.00009408813,0.00009497186,0.0000197426,0.00025036364,0.00011356577,0.9522986],"category_scores_gemma":[0.00050490955,0.00022058976,0.00006593675,0.000662937,0.000047478785,0.00022672758,0.00009441757,0.00037877314,0.00031671405],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05843445,0.00018955277,0.0000919425,0.00011718365,0.00032783582,0.00014345734,0.00075963093,0.0024039783,0.00021199243,0.0000016569259,0.92713416,0.010184187],"study_design_scores_gemma":[0.05690001,0.0012475275,0.40589872,0.01152522,0.000047387988,0.000060257058,0.0007929148,0.0006597065,0.00010263719,0.00018893117,0.5219378,0.0006388892],"about_ca_topic_score_codex":0.00021687479,"about_ca_topic_score_gemma":0.0009034132,"teacher_disagreement_score":0.9519819,"about_ca_system_score_codex":0.0004346702,"about_ca_system_score_gemma":0.0006127187,"threshold_uncertainty_score":0.89953893},"labels":[],"label_agreement":null},{"id":"W6995585756","doi":"","title":"Perspectives Of Beginning Teachers From Generation Z: A Narrative Study","year":2021,"lang":"en","type":"article","venue":"UND Scholarly Commons (University of North Dakota)","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Narrative; Context (archaeology); Point (geometry); Field (mathematics); Teacher education; Narrative inquiry; Work (physics); Order (exchange)","score_opus":0.031929974121356626,"score_gpt":0.27277112281560967,"score_spread":0.24084114869425305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6995585756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99412423,0.0013605533,0.0027344753,0.00083272555,0.000048059435,0.00024299751,0.000059294252,0.000034772165,0.0005629157],"genre_scores_gemma":[0.99077326,0.000022033757,0.008517809,0.000026202171,0.000050149087,4.893912e-7,0.000075799995,0.0000134996435,0.0005207605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888134,0.00017930703,0.00014587962,0.00032182562,0.00033324692,0.00013837915],"domain_scores_gemma":[0.99860257,0.000067211375,0.0001830064,0.0004394036,0.0006102899,0.0000975073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011213952,0.00013570773,0.00039233742,0.00016023351,0.00025145386,0.000023181601,0.00016883382,0.000055167235,0.00023377054],"category_scores_gemma":[0.000087412714,0.00016586766,0.000115682495,0.0004793221,0.00020655687,0.0008663553,0.00011579788,0.00037663756,0.000004322626],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029409514,0.0009397923,0.78555906,0.000012035145,0.0010423742,0.0001599719,0.18797214,0.00011181718,0.011712016,0.000098475684,0.00007498072,0.012023207],"study_design_scores_gemma":[0.002345784,0.00032848082,0.76087123,0.000049555176,0.0002773835,0.0000064143537,0.234638,0.000106014166,0.00040980036,0.000042066396,0.00080245966,0.00012281774],"about_ca_topic_score_codex":0.0009294193,"about_ca_topic_score_gemma":0.0069854776,"teacher_disagreement_score":0.04666585,"about_ca_system_score_codex":0.00016921267,"about_ca_system_score_gemma":0.0002327027,"threshold_uncertainty_score":0.6763887},"labels":[],"label_agreement":null},{"id":"W7009884254","doi":"","title":"GCC Reports Fourth Quarter and Full Year 2019 Results","year":2020,"lang":"en","type":"other","venue":"","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Government (linguistics); Period (music); China; Work (physics)","score_opus":0.009226099576907919,"score_gpt":0.25635162859328936,"score_spread":0.24712552901638143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7009884254","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000028773335,0.002300715,0.0006885971,0.0047946107,0.00040105358,0.0004985401,0.000071073344,0.00041079344,0.99080586],"genre_scores_gemma":[0.0006255787,0.0002199199,0.011611566,0.0011698153,0.0012058315,0.000010821733,0.00011218086,0.0003725372,0.9846718],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99888754,0.000012533673,0.0002455521,0.0004654986,0.00020983296,0.00017907337],"domain_scores_gemma":[0.9991545,0.00001555188,0.00019314086,0.00045909084,0.00002030643,0.00015737471],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00005165937,0.00022795062,0.0004230579,0.00009117802,0.000011669907,0.000010460331,0.00003739492,0.00018268045,0.003065678],"category_scores_gemma":[0.00003075499,0.00017689502,0.000057747046,0.00006830002,0.00006402981,0.00002245518,0.0000327938,0.00020071967,0.0002266593],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004060345,0.000018075008,0.00009740616,0.0000970321,0.00014304873,0.00040766058,0.00011803662,1.0109274e-7,0.0001661343,0.00004701298,0.99181557,0.0066839173],"study_design_scores_gemma":[0.0013381933,0.00021671182,0.000436832,0.0002657104,0.00006667263,0.00039928386,0.00008614961,0.0000020437149,0.000031507814,0.000092853144,0.9968703,0.0001937825],"about_ca_topic_score_codex":0.00013752442,"about_ca_topic_score_gemma":0.00008881429,"teacher_disagreement_score":0.010922969,"about_ca_system_score_codex":0.000025495034,"about_ca_system_score_gemma":0.00006234971,"threshold_uncertainty_score":0.99784565},"labels":[],"label_agreement":null},{"id":"W7009984660","doi":"","title":"GCC Reports Fourth Quarter and Full Year 2019 Results","year":2020,"lang":"en","type":"other","venue":"","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Government (linguistics); Period (music); China; Work (physics)","score_opus":0.009226099576907919,"score_gpt":0.25635162859328936,"score_spread":0.24712552901638143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7009984660","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000028773335,0.002300715,0.0006885971,0.0047946107,0.00040105358,0.0004985401,0.000071073344,0.00041079344,0.99080586],"genre_scores_gemma":[0.0006255787,0.0002199199,0.011611566,0.0011698153,0.0012058315,0.000010821733,0.00011218086,0.0003725372,0.9846718],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99888754,0.000012533673,0.0002455521,0.0004654986,0.00020983296,0.00017907337],"domain_scores_gemma":[0.9991545,0.00001555188,0.00019314086,0.00045909084,0.00002030643,0.00015737471],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00005165937,0.00022795062,0.0004230579,0.00009117802,0.000011669907,0.000010460331,0.00003739492,0.00018268045,0.003065678],"category_scores_gemma":[0.00003075499,0.00017689502,0.000057747046,0.00006830002,0.00006402981,0.00002245518,0.0000327938,0.00020071967,0.0002266593],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004060345,0.000018075008,0.00009740616,0.0000970321,0.00014304873,0.00040766058,0.00011803662,1.0109274e-7,0.0001661343,0.00004701298,0.99181557,0.0066839173],"study_design_scores_gemma":[0.0013381933,0.00021671182,0.000436832,0.0002657104,0.00006667263,0.00039928386,0.00008614961,0.0000020437149,0.000031507814,0.000092853144,0.9968703,0.0001937825],"about_ca_topic_score_codex":0.00013752442,"about_ca_topic_score_gemma":0.00008881429,"teacher_disagreement_score":0.010922969,"about_ca_system_score_codex":0.000025495034,"about_ca_system_score_gemma":0.00006234971,"threshold_uncertainty_score":0.99784565},"labels":[],"label_agreement":null},{"id":"W7019314947","doi":"","title":"GCC Reports Second Quarter and Six Month 2019 Results","year":2019,"lang":"en","type":"other","venue":"","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Period (music); Government (linguistics); Work (physics)","score_opus":0.0066772109304854615,"score_gpt":0.2540735297796291,"score_spread":0.24739631884914365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7019314947","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018189012,0.005227805,0.00008049181,0.0008244778,0.0006513405,0.00074839854,0.00010210192,0.0002427594,0.99194074],"genre_scores_gemma":[0.0014880553,0.000108273016,0.001634751,0.0007777259,0.0006074304,0.000014433338,0.00011346964,0.0003838723,0.994872],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99861395,0.00001460727,0.00032208025,0.0005815199,0.00022004377,0.00024781076],"domain_scores_gemma":[0.9986518,0.000030827956,0.0002907954,0.000866,0.000036288435,0.00012427775],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000092063034,0.0003051301,0.0005743809,0.0001607278,0.000013383616,0.000013717898,0.00004599985,0.0002949102,0.006072871],"category_scores_gemma":[0.00001891657,0.00023121931,0.000068507354,0.00005573741,0.000074113465,0.000043815395,0.000033645403,0.00022386869,0.00031363004],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002584492,0.0000312681,0.00024514354,0.0001826114,0.00017945205,0.00018780277,0.000111292495,1.7895854e-7,0.00014907324,0.000034279423,0.9920162,0.006604269],"study_design_scores_gemma":[0.002023051,0.0001819335,0.001327704,0.00039210042,0.000060732735,0.0005140049,0.00008400404,0.0000020904322,0.00009073296,0.000059511254,0.99499893,0.0002652073],"about_ca_topic_score_codex":0.00030519717,"about_ca_topic_score_gemma":0.00034880126,"teacher_disagreement_score":0.006339062,"about_ca_system_score_codex":0.000044580822,"about_ca_system_score_gemma":0.00008295308,"threshold_uncertainty_score":0.99483573},"labels":[],"label_agreement":null},{"id":"W7083849002","doi":"","title":"Carlsbad Caverns 500K bats face threat of deadly syndrome","year":2018,"lang":"en","type":"other","venue":"Internet Archive (Internet Archive)","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"National park; Hibernation (computing); Nose; Face (sociological concept); White (mutation); Tourism","score_opus":0.014556795260907314,"score_gpt":0.2699593117027074,"score_spread":0.2554025164418001,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7083849002","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012182193,0.0017639535,0.029092778,0.00015990916,0.0014781766,0.001982653,0.0020264194,0.0006281402,0.9506858],"genre_scores_gemma":[0.10110105,0.00022205526,0.0069869156,0.00027886816,0.00082975486,0.00012080269,0.0007185316,0.0012070481,0.88853496],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99524903,0.00023311088,0.0010348165,0.0015124214,0.00089900655,0.001071583],"domain_scores_gemma":[0.9965678,0.00028384657,0.0009039827,0.001581138,0.00010939018,0.0005538577],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.00015651545,0.0012767606,0.0020727003,0.0010551438,0.00002673497,0.000042011266,0.0012624603,0.00036167112,0.020909406],"category_scores_gemma":[0.00008616644,0.0011409811,0.0008072768,0.00019315089,0.0015489035,0.000099560835,0.0008790693,0.00095279946,0.0034345302],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017385854,0.00038501446,0.00491599,0.0010919344,0.0028985587,0.0009842383,0.0042509674,0.0000049163923,0.0017176579,0.0009347366,0.97878164,0.002295788],"study_design_scores_gemma":[0.0031564997,0.0022101768,0.005953133,0.008130435,0.0005753082,0.0022074825,0.00019486176,0.0002688155,0.0028246057,0.001305135,0.9720274,0.0011461383],"about_ca_topic_score_codex":0.015513228,"about_ca_topic_score_gemma":0.01008419,"teacher_disagreement_score":0.08891885,"about_ca_system_score_codex":0.00019720102,"about_ca_system_score_gemma":0.000262013,"threshold_uncertainty_score":0.99999845},"labels":[],"label_agreement":null},{"id":"W7108217975","doi":"10.2139/ssrn.5801208","title":"Patterns of disease progression in advanced breast cancer patients treated with Cyclin D kinase 4/6 inhibitors: Prognostic and therapeutic implications","year":2025,"lang":"","type":"preprint","venue":"SSRN Electronic Journal","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Palbociclib; Breast cancer; Disease; Hormonal therapy; Overall survival; Metastatic breast cancer; Progression-free survival; Progressive disease; Family history","score_opus":0.006681315972447274,"score_gpt":0.29107749360641855,"score_spread":0.2843961776339713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108217975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9503535,0.04168788,0.0010207342,0.0022284952,0.00022100072,0.003635119,0.0007914106,0.000047888716,0.000013951305],"genre_scores_gemma":[0.9648147,0.03331818,0.00007477501,0.000097841206,0.00028461337,0.0009489233,0.00014382515,0.00011873253,0.00019837091],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9929042,0.00037709615,0.0015626949,0.0012347143,0.0007631819,0.0031581465],"domain_scores_gemma":[0.99584824,0.0001872151,0.0016873557,0.0007541069,0.000992266,0.0005308159],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00063813134,0.0010452147,0.0013453481,0.000784387,0.00028240326,0.00005982464,0.00047682712,0.00033281432,0.00004351198],"category_scores_gemma":[0.00007565473,0.0008214048,0.00024971532,0.0007879417,0.00029696556,0.00028080016,0.000268268,0.0046634655,0.0000011728374],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0071952557,0.0014870327,0.61335707,0.000651865,0.00070840435,0.000008366121,0.00030238542,0.0003755803,0.0002764593,0.00035490983,2.5158064e-7,0.3752824],"study_design_scores_gemma":[0.01292949,0.0019397195,0.95077056,0.021400148,0.0015803854,0.00014735988,0.0009110774,0.00013603979,0.00028013642,0.009059437,0.00005332248,0.0007923103],"about_ca_topic_score_codex":0.00035554334,"about_ca_topic_score_gemma":0.0013184713,"teacher_disagreement_score":0.37449008,"about_ca_system_score_codex":0.0041011106,"about_ca_system_score_gemma":0.010601016,"threshold_uncertainty_score":0.99972194},"labels":[],"label_agreement":null},{"id":"W7116080493","doi":"10.51731/cjht.2025.1312","title":"Abemaciclib (Verzenio)","year":2025,"lang":"","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fulvestrant; Reimbursement; Disease; Drug; Breast cancer; Metastatic breast cancer; Cancer","score_opus":0.018015218389356564,"score_gpt":0.32893630027680315,"score_spread":0.3109210818874466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116080493","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01158076,0.7765502,0.003941523,0.20141459,0.0041528237,0.000598984,0.000051040115,0.00015448974,0.0015556463],"genre_scores_gemma":[0.98604816,0.0070509017,0.0016573342,0.003879658,0.00005865959,0.000009154208,0.000001857946,0.000041605424,0.0012526512],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99579763,0.00014016494,0.0018929355,0.00035416443,0.00032702892,0.0014880685],"domain_scores_gemma":[0.99674946,0.00016908342,0.0012930189,0.00079068815,0.0006905805,0.00030719658],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012765208,0.00042959722,0.0014348273,0.0028143153,0.00062078383,0.00007338253,0.0009654376,0.0005050949,0.00021450236],"category_scores_gemma":[0.0015442912,0.000397878,0.00028346703,0.001702258,0.0012668596,0.000282018,0.00006352726,0.0018396684,0.0000336739],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001226485,0.000035526056,0.005875684,0.000721014,0.00035399653,0.00039827486,0.0004538256,0.000027077025,0.000059506496,0.005756513,0.005193824,0.9810021],"study_design_scores_gemma":[0.0026014878,0.0009914611,0.0101541085,0.0059105246,0.00014152692,0.0007857034,0.013906201,0.000015994094,0.0015146928,0.022964517,0.9407075,0.0003062776],"about_ca_topic_score_codex":0.004216227,"about_ca_topic_score_gemma":0.0033333052,"teacher_disagreement_score":0.98069584,"about_ca_system_score_codex":0.003235739,"about_ca_system_score_gemma":0.029728003,"threshold_uncertainty_score":0.9998473},"labels":[],"label_agreement":null},{"id":"W7116849294","doi":"10.51731/cjht.2025.1315","title":"Abemaciclib (Verzenio)","year":2025,"lang":"","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fulvestrant; Breast cancer; Metastatic breast cancer; Chemotherapy; Reimbursement; Regimen; Cancer; Aromatase","score_opus":0.018015218389356564,"score_gpt":0.32893630027680315,"score_spread":0.3109210818874466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116849294","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01158076,0.7765502,0.003941523,0.20141459,0.0041528237,0.000598984,0.000051040115,0.00015448974,0.0015556463],"genre_scores_gemma":[0.98604816,0.0070509017,0.0016573342,0.003879658,0.00005865959,0.000009154208,0.000001857946,0.000041605424,0.0012526512],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99579763,0.00014016494,0.0018929355,0.00035416443,0.00032702892,0.0014880685],"domain_scores_gemma":[0.99674946,0.00016908342,0.0012930189,0.00079068815,0.0006905805,0.00030719658],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012765208,0.00042959722,0.0014348273,0.0028143153,0.00062078383,0.00007338253,0.0009654376,0.0005050949,0.00021450236],"category_scores_gemma":[0.0015442912,0.000397878,0.00028346703,0.001702258,0.0012668596,0.000282018,0.00006352726,0.0018396684,0.0000336739],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001226485,0.000035526056,0.005875684,0.000721014,0.00035399653,0.00039827486,0.0004538256,0.000027077025,0.000059506496,0.005756513,0.005193824,0.9810021],"study_design_scores_gemma":[0.0026014878,0.0009914611,0.0101541085,0.0059105246,0.00014152692,0.0007857034,0.013906201,0.000015994094,0.0015146928,0.022964517,0.9407075,0.0003062776],"about_ca_topic_score_codex":0.004216227,"about_ca_topic_score_gemma":0.0033333052,"teacher_disagreement_score":0.98069584,"about_ca_system_score_codex":0.003235739,"about_ca_system_score_gemma":0.029728003,"threshold_uncertainty_score":0.9998473},"labels":[],"label_agreement":null},{"id":"W7117517914","doi":"10.3390/curroncol33010015","title":"The Canadian Breast Cancer Symposium 2025: Meeting Report","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre; University of Calgary; University of Toronto; Sunnybrook Health Science Centre; Mount Sinai Hospital","funders":"University of Toronto; Hologic; Merck KGaA; Exact Sciences Corporation; Pfizer; Stryker; Novartis Pharmaceuticals Corporation; Merit Medical Systems; F. Hoffmann-La Roche","keywords":"Breast cancer; Survivorship curve; Systemic therapy; Radiation therapy; Radiation oncology; Cancer survivorship; Alternative medicine; Clinical Practice","score_opus":0.04691640394276307,"score_gpt":0.4207245494578253,"score_spread":0.3738081455150622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117517914","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.081752494,0.07963034,0.0005111464,0.5508571,0.03562641,0.0026527902,0.00016453548,0.0004248435,0.24838029],"genre_scores_gemma":[0.97960585,0.001927852,0.00021528239,0.002693872,0.0016362034,0.0005513463,0.00004519967,0.000042984608,0.013281393],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99871343,0.00005971503,0.00031253343,0.00029473266,0.00014606718,0.00047351373],"domain_scores_gemma":[0.9988972,0.00012654209,0.00012252528,0.00036793688,0.00028637925,0.00019940581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003133251,0.00014568465,0.00027176313,0.000117926385,0.00043696462,0.00002089889,0.00015485211,0.0001025928,0.00011280822],"category_scores_gemma":[0.00008453035,0.00010457833,0.00007558321,0.0002844791,0.0002307597,0.000039076738,0.000054501565,0.00037639352,0.000021055117],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023205348,0.00011080785,0.18841779,0.000104879226,0.00023466181,0.00026292948,0.0003121731,0.000039171693,0.0005916994,0.001528309,0.026709603,0.78145593],"study_design_scores_gemma":[0.0007743304,0.00003220121,0.0607992,0.0002166916,0.00009592399,0.00051677035,0.000117946765,0.000073420706,0.00010159145,0.0003241066,0.9368576,0.000090243266],"about_ca_topic_score_codex":0.03182798,"about_ca_topic_score_gemma":0.30521294,"teacher_disagreement_score":0.91014796,"about_ca_system_score_codex":0.0020584508,"about_ca_system_score_gemma":0.0036563019,"threshold_uncertainty_score":0.97461915},"labels":[],"label_agreement":null},{"id":"W7132871786","doi":"","title":"Development of CDK4/6 Inhibitor Resistant ER-positive HER2-negative Breast Cancer Cell Lines to Elucidate Novel Mechanisms of Resistance","year":2023,"lang":"","type":"dissertation","venue":"TSpace","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"George Mason University","keywords":"Palbociclib; Acquired resistance; Downregulation and upregulation; Breast cancer; Cell culture; Disease; Cancer; Cell cycle","score_opus":0.01879061660475601,"score_gpt":0.33171517628327846,"score_spread":0.31292455967852245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7132871786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93042517,0.006646973,0.033037923,0.0034057165,0.0057410807,0.009152198,0.0071460498,0.0003914783,0.004053424],"genre_scores_gemma":[0.81247306,0.0009361425,0.108155936,0.00025980783,0.0007812066,0.0011852073,0.00079565926,0.00071733753,0.07469564],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99281836,0.00014306042,0.0023156519,0.0016865887,0.0018882869,0.0011480544],"domain_scores_gemma":[0.9919613,0.00043750598,0.0027638038,0.0010421351,0.0032494557,0.0005458262],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00063953083,0.0013974025,0.0024895626,0.00057511247,0.00031432798,0.000030289786,0.0006485278,0.00061853544,0.0006298776],"category_scores_gemma":[0.00020247162,0.0014227747,0.00037299105,0.0018842352,0.00027947917,0.00022759411,0.00022900934,0.0006900587,0.000067346315],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023282124,0.00063609524,0.000015596654,0.0046171383,0.0010890161,0.000028819137,0.12366959,0.00017848883,0.84157073,0.00037391722,0.0001378012,0.0044006803],"study_design_scores_gemma":[0.0034535194,0.0003732642,0.014970299,0.018055024,0.00052183046,0.0000042748293,0.12567875,0.000016410988,0.8349733,0.00020452119,0.0006757548,0.0010730928],"about_ca_topic_score_codex":0.0041363332,"about_ca_topic_score_gemma":0.026966525,"teacher_disagreement_score":0.11795209,"about_ca_system_score_codex":0.0018378393,"about_ca_system_score_gemma":0.0031648956,"threshold_uncertainty_score":0.99987763},"labels":[],"label_agreement":null},{"id":"W755048376","doi":"10.1158/1538-7445.sabcs14-p4-01-01","title":"Abstract P4-01-01: Circulating tumor cell (CTC) enumeration and HER2 assessment as predictors of breast cancer outcomes in the ALTTO (BIG 2-06, Alliance N063D) Trial","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lapatinib; Trastuzumab; Breast cancer; Internal medicine; Oncology; Circulating tumor cell; Metastatic breast cancer; Cancer; Clinical endpoint; Stage (stratigraphy); Clinical trial; Metastasis","score_opus":0.12213865768116128,"score_gpt":0.4484369535614017,"score_spread":0.3262982958802404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W755048376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887031,0.0029328982,0.000028405218,0.0042633284,0.00039297526,0.0018195767,0.00010615391,0.000030021012,0.0017235933],"genre_scores_gemma":[0.9967833,0.00045509456,0.00020895142,0.00030636805,0.00091772137,0.00089641917,0.000018367637,0.000051262607,0.0003625185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963953,0.00029813783,0.0005678512,0.0005179885,0.0015900977,0.0006306591],"domain_scores_gemma":[0.99814266,0.00042144218,0.00022392998,0.00050653727,0.00045039022,0.00025501882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018823276,0.00025493564,0.0005384996,0.00017070904,0.00013323697,0.00006654588,0.00029767375,0.00010266365,0.00020105127],"category_scores_gemma":[0.00019852081,0.00018412762,0.00008155842,0.0005256188,0.00033145884,0.0002475587,0.00009144467,0.0008169822,0.000008620643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0329174,0.0017541432,0.7615175,0.0018684227,0.0005888428,0.00031320518,0.014821401,0.002225946,0.1113717,0.0006486604,0.0020716158,0.06990112],"study_design_scores_gemma":[0.05057091,0.0009141768,0.92505014,0.0010562845,0.00008959646,0.000075058095,0.0063462355,0.00023935197,0.007185257,0.00074817496,0.007273272,0.00045154174],"about_ca_topic_score_codex":0.007115058,"about_ca_topic_score_gemma":0.0016135131,"teacher_disagreement_score":0.16353261,"about_ca_system_score_codex":0.00096409826,"about_ca_system_score_gemma":0.0021351469,"threshold_uncertainty_score":0.99949664},"labels":[],"label_agreement":null},{"id":"W88453891","doi":"","title":"CCI-779 Wyeth.","year":2002,"lang":"en","type":"article","venue":"PubMed","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Regional Laboratory Medicine Program","funders":"","keywords":"Medicine; Internal medicine; Oncology; Renal cell carcinoma","score_opus":0.043699589967156414,"score_gpt":0.22996376326831122,"score_spread":0.1862641733011548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W88453891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.54099333,0.016124839,0.0020958632,0.039745186,0.0019655772,0.003979386,0.000026444068,0.0014406838,0.3936287],"genre_scores_gemma":[0.9782699,0.000055121633,0.00059439096,0.0018467837,0.0003845441,0.00074692816,0.000002779368,0.000024181223,0.018075375],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99926096,0.0000101522655,0.00010652902,0.00015783396,0.00015631365,0.00030821178],"domain_scores_gemma":[0.9995305,0.000021898602,0.000030590392,0.00023812617,0.000032534594,0.0001463764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000062964165,0.0000862317,0.0001444722,0.000048809194,0.000029596957,0.0000072741013,0.000056687255,0.00003782851,0.0006938333],"category_scores_gemma":[0.00005469889,0.000073336545,0.000049750066,0.0001307104,0.00005020982,0.00007143297,0.000016600285,0.00010629996,0.00024778035],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047156293,0.000064891865,0.0038612294,0.000016053744,0.000037390906,0.000023428533,0.0001278154,0.0000018836944,0.00009701754,0.00017814578,0.0014741919,0.99407077],"study_design_scores_gemma":[0.0019101349,0.00002691617,0.44843012,0.000011166753,0.000037216632,0.00013303444,0.00004752325,0.000041815452,0.0018361869,0.00046440132,0.5469233,0.00013822466],"about_ca_topic_score_codex":0.0000049253163,"about_ca_topic_score_gemma":0.0000016986631,"teacher_disagreement_score":0.99393255,"about_ca_system_score_codex":0.000076622215,"about_ca_system_score_gemma":0.000004373008,"threshold_uncertainty_score":0.7596988},"labels":[],"label_agreement":null},{"id":"W899967719","doi":"10.1158/1538-7445.sabcs14-p6-08-40","title":"Abstract P6-08-40: Survival of metastatic hormone receptor (HR) positive/HER2 negative; HER2+; and triple negative (TN) breast cancer based on initial presentation","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Metastatic breast cancer; Trastuzumab; Oncology; Cohort; Cancer; Biomarker; Hazard ratio; Confidence interval","score_opus":0.10831332894221743,"score_gpt":0.43870156604621263,"score_spread":0.33038823710399523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W899967719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98524326,0.0021194366,0.0003447869,0.005983413,0.00042284516,0.002189242,0.0017829847,0.00006996557,0.001844064],"genre_scores_gemma":[0.9966644,0.00039915094,0.00080102606,0.00021581585,0.000555638,0.0006096775,0.000080493875,0.00009104041,0.00058274466],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99590844,0.00056427426,0.00048601703,0.0006543937,0.0016844504,0.00070243335],"domain_scores_gemma":[0.9960924,0.00092309806,0.00024171399,0.00041144234,0.0017971974,0.0005341542],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011115462,0.0003399308,0.00068286783,0.0004186509,0.0001664257,0.00005216969,0.00021062445,0.00011465615,0.00092301134],"category_scores_gemma":[0.00049346435,0.0002959651,0.00010003801,0.0009350609,0.00089806865,0.000417592,0.00008560922,0.0007767023,0.000031630818],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20899688,0.0034868827,0.016441114,0.0019521393,0.0033165128,0.00037396714,0.030569823,0.004279064,0.32574022,0.00050654734,0.013637101,0.39069974],"study_design_scores_gemma":[0.045142114,0.0049005304,0.6599584,0.0023300252,0.00035760665,0.00005733978,0.011615815,0.0021151328,0.2673101,0.0027383324,0.0022997872,0.0011747527],"about_ca_topic_score_codex":0.010750412,"about_ca_topic_score_gemma":0.00074309873,"teacher_disagreement_score":0.6435173,"about_ca_system_score_codex":0.0010186047,"about_ca_system_score_gemma":0.001678551,"threshold_uncertainty_score":0.9999903},"labels":[],"label_agreement":null}]}